<SEC-DOCUMENT>0001144204-14-021277.txt : 20140408
<SEC-HEADER>0001144204-14-021277.hdr.sgml : 20140408
<ACCEPTANCE-DATETIME>20140407204812
ACCESSION NUMBER:		0001144204-14-021277
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20140408
DATE AS OF CHANGE:		20140407

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO BLAST PHARMA LTD.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-193824
		FILM NUMBER:		14749790

	BUSINESS ADDRESS:	
		STREET 1:		35 AHAD HA'AM ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			65202
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		35 AHAD HA'AM ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			65202
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>v374074_f1a.htm
<DESCRIPTION>FORM F-1/A
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY><DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 177mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 177mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>As filed with the Securities and Exchange Commission on April 7, 2014</B> </P>



<H2 STYLE="text-indent:0pt; text-align: right; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Registration No. 333-193824</B> </H2>

<DIV  STYLE="width: 100%; display: inline; vertical-align: middle; border-top: 4pt black double">&nbsp;</DIV></DIV><DIV STYLE="width: 177mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">UNITED STATES<BR> SECURITIES AND EXCHANGE COMMISSION<BR> Washington, DC 20549 </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>



<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Amendment No. 2<BR> to<BR> Form F-1 </H1>



<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 18pt; line-height: 20pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Bio Blast Pharma Ltd. </H1>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 8pt; line-height: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>(Exact name of registrant as specified in its charter)</I> </P>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="672" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="216"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="208"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="216"></TD>

</TR>

<TR STYLE="vertical-align: top; text-align: center">

          <TD STYLE="line-height: 12pt; vertical-align: text-bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>State of Israel</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: 12pt; vertical-align: text-bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: 12pt; vertical-align: text-bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>Not Applicable</TD>

</TR>

<TR STYLE="vertical-align: top; text-align: center">

          <TD STYLE="padding-left: 0pt; text-indent: 0pt; font-style: italic" ROWSPAN=1 COLSPAN=1>(State or other jurisdiction of<BR> incorporation or organization)</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"><I>(Primary Standard Industrial<BR> Classification Code Number)</I></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"><I>(I.R.S. Employer<BR> Identification Number)</I></TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="672" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="328"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="328"></TD>

</TR>

<TR STYLE="vertical-align: top; text-align: center">

          <TD STYLE="line-height: 12pt; vertical-align: text-bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>Dalia Megiddo MD, MBA<BR> Bio Blast Pharma Ltd.<BR> 35 Ahad Ha&#146;am St.<BR> Tel-Aviv 6520206 Israel<BR> Tel: +972 (0)3 7326616</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: 12pt; vertical-align: text-bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>Zysman, Aharoni, Gayer and<BR> Sullivan &amp; Worcester LLP<BR> 1633 Broadway<BR> New York, NY 10019<BR> Tel: 212.660.5000</TD>

</TR>

<TR STYLE="vertical-align: top; text-align: center">

          <TD STYLE="padding-left: 0pt; text-indent: 0pt; font-style: italic" ROWSPAN=1 COLSPAN=1>(Address, including zip code, and telephone number,<BR> including area code, of registrant&#146;s principal executive offices)</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"><I>(Name, address, including zip code, and telephone<BR> number, including area code, of agent for service)</I></TD>

</TR>

</TABLE></DIV>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B><I>Copies to:</I></B> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="672" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="160"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="152"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="152"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="160"></TD>

</TR>

<TR STYLE="vertical-align: top; text-align: center">

          <TD STYLE="line-height: 12pt; vertical-align: text-bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>Edwin L. Miller Jr., Esq.<BR> Oded Har-Even, Esq.<BR> Shy S. Baranov, Esq.<BR> Zysman, Aharoni,<BR> Gayer and<BR> Sullivan &amp; Worcester LLP<BR> 1633 Broadway<BR> New York, NY 10019<BR> Tel: 212.660.5000</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: 12pt; vertical-align: text-bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>Mor Limanovich, Adv.<BR> Zysman, Aharoni,<BR> Gayer &amp; Co.<BR> 41-45 Rothschild Blvd.<BR> Beit Zion<BR> Tel-Aviv, Israel 65784<BR> Tel: +972.3.795.5555<BR> &nbsp;&nbsp;<BR>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: 12pt; vertical-align: text-bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>Henry I. Rothman, Esq.<BR> Joseph Walsh, Esq.<BR> Troutman Sanders LLP<BR> The Chrysler Building<BR> 405 Lexington Avenue<BR> New York, NY 10174<BR> Tel: 212.704.6000<BR> &nbsp;&nbsp;<BR>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: 12pt; vertical-align: text-bottom; font-weight: bold; font-size: 10pt; text-align: center" ROWSPAN=1 COLSPAN=1>Barry Levenfeld<BR> Eric Spindel<BR> Yigal Arnon &amp; Co.<BR> 1 Azrieli Center<BR> Tel-Aviv, Israel 67021<BR> Tel: +972.3.608.7777<BR>&nbsp;&nbsp;<BR>&nbsp;&nbsp;<BR>&nbsp;&nbsp;</TD>

</TR>

</TABLE></DIV>




<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date hereof. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box. <FONT STYLE="font-family: wingdings">o</font> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: wingdings">o</font> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: wingdings">o</font> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: wingdings">o</font> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.</B> </P>

</DIV><DIV STYLE="width: 177mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><DIV  STYLE="width: 100%; display: inline; vertical-align: middle; border-top: 4pt black double">&nbsp;</DIV></P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 4mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

</DIV><DIV STYLE="width: 174mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><FONT COLOR="RED">The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</FONT> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="657" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="211"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="203"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="211"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; font-weight: bold" ROWSPAN=1 COLSPAN=1><FONT COLOR="RED">PRELIMINARY PROSPECTUS</FONT></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center"><B><FONT COLOR="RED">SUBJECT TO COMPLETION</FONT></B></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: right"><B><FONT COLOR="RED">DATED APRIL 7, 2014</FONT></B></TD>

</TR>

</TABLE></DIV>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 16pt; line-height: 18pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Ordinary Shares</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_tlogo.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Bio Blast Pharma Ltd. is offering its ordinary shares in an initial public offering. No public market currently exists for our ordinary shares. The estimated initial public offering price is between $&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have applied to list our ordinary shares on The NASDAQ Capital Market under the symbol &#147;ORPN&#148;. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) and will be subject to reduced public company reporting requirements. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 14pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Investing in our ordinary shares involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page <a href="#tRF">9</a> of this prospectus for a discussion of information that should be considered in connection with an investment in our ordinary shares.</B> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 14pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="657" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="489"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 9pt">Per Share</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-size: 9pt">Total</FONT></TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Initial public offering price</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Underwriting discounts and commissions</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds to us (before expenses)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters will receive compensation in addition to the underwriting discounts and commissions. See &#147;Underwriting&#148; for a description of compensation payable to the underwriters. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have granted a 45-day option to the underwriters to purchase up to &nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares solely to cover over-allotments, if any. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters expect to deliver the shares to purchasers in the offering on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 18pt; line-height: 20pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aegis Capital Corp </H1>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 11pt; line-height: 13pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;, 2014. </P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="TOC"></a>TABLE OF CONTENTS </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="552"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="40"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Page</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSUM">Summary</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSUM">1</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tRF">Risk Factors</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tRF">9</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tFLS">Cautionary Note Regarding Forward-Looking Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tFLS">44</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tUP">Use of Proceeds</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tUP">45</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tDP">Dividend Policy</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tDP">46</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tCAP">Capitalization</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tCAP">47</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tDIL">Dilution</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tDIL">48</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSFD">Selected Financial Data</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSFD">49</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tMDA">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tMDA">50</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tBUS">Business</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tBUS">56</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tMAN">Management</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tMAN">91</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tPSH">Principal Shareholders</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tPSH">110</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tDSC">Description of Share Capital</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tDSC">112</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tSEFS">Shares Eligible for Future Sale</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tSEFS">119</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tTAX">Taxation</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tTAX">120</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tUND">Underwriting</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tUND">127</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tEXP">Expenses</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tEXP">133</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tLM">Legal Matters</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tLM">133</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tEXP">Experts</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tEXP">133</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tECL">Enforceability of Civil Liabilities</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tECL">133</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tWYC">Where You Can Find Additional Information</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tWYC">134</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><a href="#tIFS">Index of Financial Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1><a href="#tIFS">F-1</a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred you. We have not authorized anyone to provide you with information that is different. We are offering to sell our ordinary shares, and seeking offers to buy our ordinary shares, only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our ordinary shares. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Until and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 25 days after the date of this prospectus, all dealers that buy, sell or trade our ordinary shares, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to unsold allotments or subscriptions. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In this prospectus, &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; the &#147;Company&#148; and &#147;BioBlast&#148; refer to Bio Blast Pharma Ltd. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our reporting currency and functional currency is the U.S. dollar. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">i</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

</DIV><DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSUM"></a>PROSPECTUS SUMMARY </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>The items in the following summary are described in more detail later in this prospectus. This summary provides an overview of selected information and does not contain all of the information you should consider before buying our ordinary shares. Therefore, you should read the entire prospectus carefully, especially the &#147;Risk Factors&#148; section beginning on page <a href="#tRF">9</a> and our financial statements and the related notes appearing at the end of this prospectus, before deciding to invest in our ordinary shares.</I> </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Overview </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a development-stage biopharmaceutical company focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. We seek to identify therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. We focus on rare diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood and for which there is no satisfactory treatment. Since our
inception in 2012, we have developed and in-licensed potential treatments for six diseases, one of which is in Phase 2 clinical studies and three of which we expect will be in Phase 2 clinical studies by late 2014 or early 2015. Our current drug candidate pipeline has been either in-licensed from academic institutions or developed internally. Our strategy is based on risk diversification through multiple therapeutic platforms, diversified clinical and pre-clinical stages of our programs, and diversified diseases addressed. We use strict selection criteria of our pipeline platforms and cost-efficient drug development. This allows us to pursue multiple programs in parallel with the goal of promptly delivering safe and effective therapies to patients in dire need. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our current pipeline is based on three platforms: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Cabaletta </I>is a mutant protein stabilizing platform based on a small repurposed molecule, Trehalose, which is currently used as an excipient for intravenous protein drugs. We are currently conducting a Phase 2 clinical trial to assess its efficacy in treating Oculopharyngeal Muscular Dystropy, or OPMD. Subject to regulatory approval, we plan to begin conduct two additional Phase 2 studies, one in late 2014, aimed at Machado Joseph disease, or SCA3, and one in 2015 aimed at Kennedy&#146;s disease, or SBMA. Mutant unstable cellular proteins are the cause of several genetic diseases known as PolyA/Poly Q, including OPMD, SBMA and SCA3. These proteins aggregate within cells, eventually leading to cell death. Our data to date from preclinical studies from both cells and animal models indicates that our Cabaletta platform has the potential to prevent mutant protein aggregation in humans. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>mPRT </I>is a mitochondrial protein replacement platform that is based on biological components that we synthesize in bacteria. Mitochondria are cell components that supply chemical energy for normal cell functioning. This platform is currently in preclinical development for two diseases: Friedrich&#146;s Ataxia and Ornithine Transcarbamylase Deficiency. These diseases are among over 100 genetic diseases that are caused by a missing or mutant protein that has critical role in the normal mitochondrial function. While lysosomal protein replacement platforms have been successful in replacing a missing protein in lysosomes, we believe that our mPRT platform is the first one to be successful in replacing mitochondrial proteins. Our product candidates are new &#147;fusion proteins&#148; that are a combination of the replaced protein fused with two additional sequences that facilitate its transport through biological membranes. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>BBrm</I> is our read-through platform based on a small repurposed molecules. The platform enables the read-through (or bypassing) of genetic defects called nonsense mutations or stop codons that interfere with normal protein formation and cause disease. Based on our preclinical data, we believe that this drug platform has the potential to treat six different diseases caused by nonsense mutation. Subject to regulatory approval, we plan to conduct Phase 2 clinical studies in late 2014 for our lead indication in Spinal Muscular Atrophy (SMA). </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 1mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">1</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

</DIV><DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table summarizes our product candidate pipeline: </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_chrt-shade.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Product Candidates </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The diseases which we are addressing have devastating consequences on the patient&#146;s health, quality of life and life expectancy. In addition these diseases create significant burden on the patient&#146;s family and care takers as well as on the public health resources. In all the diseases we are addressing patients cannot be offered an alternative therapy or the current solutions are inadequate in their abilities to change the course of the disease. We believe that prompt and efficient drug development can be of substantial benefit to the patients who are suffering from these incurable diseases. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cabaletta for the treatment of OPMD </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cabaletta is our proprietary intravenous (IV) solution of Trehalose for the treatment of OPMD. OPMD is an inherited myopathy, which is a muscle disease caused by a primary defect in muscle cells, characterized by dysphagia (difficulty in swallowing) and the loss of muscular strength and weakness in multiple parts of the body. As the dysphagia becomes more severe, patients become malnourished, lose significant weight, become dehydrated and suffer from repeated incidents of aspiration pneumonia. These last two are often the cause of death. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Trehalose is naturally occurring and is well known for its protein-stabilizing properties. It is used in several biological systems, such as freeze drying of red blood cells and the preservation of organs for donation and as a protein stabilizer in IV pharmaceutical products. Trehalose is approved by the U.S. Food and Drug Administration, or FDA, as a GRAS (Generally Recognized As Safe) food ingredient and is listed in the U.S. National Formulary, which is a compendium of public pharmacopeial standards, which are directions for the identification of compound medicines, as well as in Europe and Japan. It is a disaccharide
chemical chaperone, which is a chemical molecule comprised of two sugar components that stabilizes the folding of proteins and buffer abnormal protein aggregation, that protects against pathological processes in cells. It has been shown to prevent pathological aggregation of proteins within cells in several diseases associated with abnormal cellular-protein aggregation as well as acting as an autophagy enhancer. Autophagy is the basic catabolic mechanism that involves cell degradation of unnecessary or dysfunctional cellular components. Autophagy, if regulated, ensures the synthesis, degradation and recycling of cellular components. Trehalose has been documented as demonstrating significant efficacy in preclinical animal models of OPMD and other PolyA/PolyQ diseases. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Trehalose is not effective when given orally since it is almost completely metabolized in the small intestine into glucose and often causes diarrhea and flatulence after ingestion of more than 50g. We have developed a proprietary IV solution of Trehalose, which we call Cabaletta<sup>TM</sup> to circumvent the breakdown of Trehalose in the gastrointestinal tract, and to enable therapeutic doses of Trehalose to reach the muscles. </P>

</DIV><DIV STYLE="width: 1mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

</DIV><DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have recently started our Phase 2 clinical trial of Cabaletta to treat OPMD in Israel, and, if successful and subject to regulatory approval, are planning to expand the study to the United States and Canada later in 2014. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cabaletta for the treatment of spinocerebellar ataxia type 3 (SCA3&nbsp;&#151;&nbsp;Machado Joseph disease) </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SCA3, also known as Machado Joseph disease, is the most common disease among the cerebellar ataxias, which are a group of genetic diseases that are characterized by memory deficits, spasticity, difficulty with speech and swallowing, weakness in arms and other muscular disorders. Symptoms can begin in early adolescence and get worse over time. Eventually SCA3 leads to paralysis, and severe cases can lead to an early death in the fourth decade of life. SCA3 is incurable, and there is currently no approved treatment for the disease. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SCA3 is caused by a mutation in the DNA that leads to the creation of a pathological protein&nbsp;&#151;&nbsp; Ataxin 3. Ataxin 3 is unstable, meaning that it aggregates within the cells and eventually leads to cell death. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Multiple reported studies in cell models have shown that Trehalose, both as an anti-mutant protein aggregator and as an autophagy enhancer, is able to reduce protein aggregates and improve cell survival in several spiocerebellar ataxias including SCA3 cells. Additional animal studies show that activation of autophagy may be beneficial in alleviating disease symptoms. We are now conducting more advanced proof-of-concept preclinical studies of this process and, if successful and subject to regulatory approval, expect to start a Phase 2 study late in 2014. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cabaletta for the treatment of Spino Bulbar Cerebellar Ataxia (SBMA&nbsp;&#151;&nbsp;Kennedy&#146;s disease) </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SBMA, also known as Kennedy&#146;s disease, is characterized by the degeneration and loss of lower motor neurons in the brainstem and spinal cord. Patients present with weakness in muscle function, including severe difficulty in swallowing and aspiration, and other disorders. SBMA is caused by an abnormal androgen receptor (AR) protein. Like other PolyA/PolyQ diseases, the abnormal protein is unstable and aggregates within cells, eventually leading to cell death. Patients suffering from SBMA suffer from progressive neuromuscular deterioration that can end up in extreme disability and repeated aspiration pneumonia. There is
currently no approved therapy for SBMA. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Studies in cell models have shown that Trehalose in its capacity both as an anti-mutant protein aggregation and as an autophagy enhancer is able to reduce protein aggregates and improve cell survival in SBMA cells. Additional studies show that activation of autophagy may be beneficial in alleviating disease symptoms in animal models. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have signed an agreement with MINDS (a group within the U.S. National Institutes of Health, or NIH) pursuant to which MINDS will conduct animal studies on SBMA mouse models to validate explore the potential efficacy of Cabaletta. MINDS will conduct the study using its own resources, and we will supply the research material. We have retained all intellectual property and commercialization rights for this indication, and if the animal studies are successful and subject to regulatory approval, we will commence Phase 2/3 clinical trials. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Mitochondrial protein replacement platform (mPRT) </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Mitochondrial disorders are diseases, for which no cure has been found, that stem from a missing or mutated critical enzyme or protein in the cell. Our fusion proteins, comprised of TAT-MTS (het)-replacement proteins, help move proteins across biological membranes to facilitate the creation of mature proteins inside the mitochondria. Our replacement proteins are able to enter human cells and mitochondria and replace the damaged or missing proteins in the mitochondria. Our breakthrough platform technology demonstrated efficacy in several mitochondrial protein deficiencies in cells and animal models. Currently, Frataxin for
Friedrich&#146;s Ataxia (BB-FA) is our most advanced mPRT preclinical program, followed by Ornithine Transcarbamylase (BB-OTC) for Ornithine Transcarbamylase Deficiency (OTCD). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our preclinical studies demonstrated the superiority of our proprietary approach of using a heterologous (none native) mitochondrial targeting sequence (MTS) as part of our fusion proteins in four different aspects: expression by bacteria, cell penetration, mitochondrial processing and anchorage of target proteins, and rescue of cells in oxidative stress. </P>

</DIV><DIV STYLE="width: 1mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">3</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

</DIV><DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have an exclusive worldwide and royalty-bearing license to the technology, including certain patent applications, from the Hebrew University in Jerusalem. These patent applications cover our unique approach of using homologous and heterologous MTS in the fusion proteins. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BB-FA for the treatment of Friedrich&#146;s Ataxia </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Friedreich&#146;s Ataxia is an inherited disease characterized by progressive deterioration of the muscular and nervous system, resulting in gait disturbance (Ataxia), cognitive impairment, progressive heart disease and diabetes. Patients are typically diagnosed in the first or second decade of life, and are wheelchair-bound within 15 years of diagnosis. Most patients do not survive beyond the fourth decade of life. In many cases the cause of death is myopathic heart disease. The underlying causes of Friedrich&#146;s Ataxia are reduced levels of Frataxin&nbsp;&#151;&nbsp;a protein responsible for iron-sulphor clusters in the
mitochondria that are critical for the mitochondria activity. Our preclinical data demonstrated successful placement of Frataxin into the mitochondria and in the treatment of oxidative stress in Friedreich&#146;s Ataxia patients&#146; cells. We are advancing the Friedreich&#146;s Ataxia program through its preclinical development through 2014. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BB-OTC for the treatment of ornithine transcarbamylase deficiency (OTCD) </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">OTCD is the most common disorder among urea cycle disorders&nbsp;&#151;&nbsp;a group of rare genetic diseases characterized by body&#146;s inability to detoxify ammonia. Ammonia is a toxic breakdown product of proteins. OTCD is caused by a mutated and ineffective form of the enzyme, ornithine transcarbamylase. As a result, ammonia accumulates in the blood causing hyperammonemia. Newborn males affected with OTCD may suffer devastating hepatic coma in the first few days after birth, and survivors typically suffer from severe cognitive, mental and metabolic disorders and growth retardation. Many do not survive the first decade of
life. Ornithine transcarbamylase is part of the urea cycle complex in the mitochondria. We are using our mitochondrial protein replacement platform to replace this enzyme in the mitochondria. Our preclinical data indicates that our OTC fusion protein is well able to be transferred into the mitochondria and processed in it. We are advancing the OTC program through its preclinical development through 2014. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BBrm&nbsp;&#151;&nbsp;our read-through platform </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BBrm is our family of small molecule non-glycosides repurposed drugs for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation (stop codon). The platform enables the read-through (deactivation) of the genetic defects that stop synthesis of proteins called stop codons. Deactivation of disease-causing nonsense mutation can alleviate the symptoms of genetic diseases caused by these nonsense mutations. Our BBrm family of repurposed drugs is able to induce translational readthrough, restoring full-length functional proteins in diseases where the nonsense mutation
results in truncated ineffective proteins. We licensed the exclusive worldwide rights for our BBrm technology from the Tel-Aviv University in January 2014. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BBrm1 for the treatment of Spinal Muscular Atrophy (SMA) </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Using our BBrm platform, we developed a unique therapeutic candidate for SMA. SMA is the leading genetic cause of infantile death and is caused by the loss of a functional Survival Motor Neuron 1 (SMN1). The disease is manifested by loss of muscle mass and mobility as well as severe compromise of vital functions such as respiration. Another protein called SMN2 is a nearly identical copy of SMN1, differentiated only by a silent, single-nucleotide mutation within the DNA. SMN2 partially compensates for the dysfunction of SMN1, however, the small amount of the functional protein that is produced from the SMN2 gene is not able to
fully compensate for the loss of SMN1. Prior independent studies proposed that read-through agents, such as aminoglycosides, can induce the read-through of the stop codon located in the SMN2-protein, thus elongating the SMN2 and creating a full length functional protein that can compensate for the non-functioning SMN1 and alleviate the disease. This approach was also successfully tested in SMA animal models. Nonetheless, chronic administration of aminoglycosides was found to be associated with prohibitive toxicity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Nevertheless, drug-induced read-through of premature stop codons remains a promising approach to elevate active protein expression from the SMN2 gene which is an ideal therapeutic target as it is found in all SMA patients. Our family of repurposed FDA-approved non-glycosides molecules (BBrm) induce significantly higher levels of full length functional SMN2 protein. These molecules are ineffective if administered orally or intravenously since they do not penetrate into the brain to create high enough therapeutic levels within nerve cells. Our BBrm1 product can be injected directly into the central nervous system (CNS), creating
adequate </P>

</DIV><DIV STYLE="width: 1mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">4</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

</DIV><DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">drug concentration. This method of administration has the added benefit of further protection against off label use. We plan to continue our preclinical development of BBrm1 for SMA through 2014, and, if successful and subject to regulatory approval, expect to start a Phase 2 study late in 2014 or early in 2015. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Strategy </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our strategy is to identify, acquire, license, develop, and commercialize novel products for the treatment of rare and ultra-rare diseases in the United States, the European Union, and select international markets, with the goal of becoming a leading rare disease biotechnology company. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The critical components of our business strategy include the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Focus on rare and ultra-rare diseases with significant unmet medical need; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Focus on diseases and therapies with clear mechanisms of action; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Leverage our experience and relationships to in-license promising product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Develop and commercialize multiple product candidates in parallel; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Focus on excellent and rapid clinical and regulatory execution; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Seek to retain global commercialization rights to product candidates. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Recent Developments </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On February 6, 2014, we closed a private placement, pursuant to which we sold to accredited investors an aggregate of 782,537 of our ordinary shares at a price of $6.07 per share for a total consideration of $4,368,000 net of expenses. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Associated with Our Business </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our ability to implement our business strategy is subject to numerous risks that you should be aware of before making an investment decision. These risks are described more fully in the section entitled &#147;Risk Factors&#148; immediately following this prospectus summary. These are not the only risks we face. These risks include, among others: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">We are a development-stage biopharmaceutical company and have a limited operating history on which to assess our business, have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Even if this offering is successful, we expect that we will need to raise additional funding before we can expect to become profitable from sales of our products; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">We are heavily dependent upon the success of our product candidates, which are in the early stages of clinical development, and we cannot provide any assurance that any of our product candidates will receive regulatory approval; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Because the target patient populations of our product candidates are small, we must be able to successfully identify patients and achieve a significant market share to maintain profitability and growth; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">We have not completed preclinical development of several product candidates and do not have any products approved for sale by the FDA or any other regulatory bodies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The insurance coverage and reimbursement status of newly-approved orphan products is uncertain and failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to market those products and decrease our ability to generate revenue; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">If we are unable to obtain and maintain effective intellectual property rights for our technologies, product candidates, or any future product candidates, we may not be able to compete effectively in our markets; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Our future success depends in part upon our ability to retain our executive team, particularly Dr. Dalia Megiddo and Mr. Udi Gilboa, and to attract, retain, and motivate other qualified personnel. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 1mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">5</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

</DIV><DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Corporate Information </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are an Israeli corporation based in Tel Aviv and were incorporated on January 22, 2012. Our principal executive offices are located at 35 Ahad Ha&#146;am St. Tel Aviv 6520206, Israel, and our telephone number is: +972 722409060. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Implications of being an Emerging Growth Company </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are an &#147;emerging growth company,&#148; as defined in Section 2(a) of the Securities Act of 1933, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not &#147;emerging growth companies&#148; including, but not limited to: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">only two years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to take advantage of these and other exemptions available to &#147;emerging growth companies.&#148; We could remain an &#147;emerging growth company&#148; for up to five years, or until the earliest of (a) the last day of the first fiscal year in which our annual gross revenue exceeds $1 billion, (b) the date that we become a &#147;large accelerated filer&#148; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (c) the date
on which we have issued more than $1 billion in nonconvertible debt during the preceding three-year period. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The JOBS Act permits an &#147;emerging growth company&#148; like us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. This means that an &#147;emerging growth company&#148; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are electing to delay such adoption of new or revised accounting standards. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Implications of being a Foreign Private Issuer </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our status as a foreign private issuer also exempts us from compliance with certain laws and regulations of the Securities and Exchange Commission (the &#147;SEC&#148;) and certain regulations of The NASDAQ Stock Market, including the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent director oversight of the nomination of directors and executive compensation. In addition, we will not be required to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as registered United States companies. </P>

</DIV><DIV STYLE="width: 1mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">6</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

</DIV><DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">THE OFFERING </H1>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Ordinary shares offered by us </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Ordinary shares to be outstanding after this offering </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Over-allotment option </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">The underwriters have an option for a period of 45 days to purchase up to additional ordinary shares to cover over-allotments, if any. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Use of proceeds </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">We expect to receive approximately $&nbsp;&nbsp;&nbsp;&nbsp; million in net proceeds from the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares offered by us in this offering (approximately $&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their over-allotment option in full), after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, assuming the shares are offered at $&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover of this prospectus. We currently expect to use the net proceeds from this offering for: </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">completing our Phase 3 clinical program for OPMD, estimated at $4,000,000; </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">completing our pivotal study/adaptive design clinical program for SCA3, estimated at $2,400,000; </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">completing our Phase 2 clinical program for SBMA, estimated at $3,200,000; </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">completing our pre-clinical program for BB-FA, estimated at $2,400,000; </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">completing our pre-clinical program for BB-OTC, estimated at $2,400,000; </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">completing our Phase 2 clinical program for SMA, estimated at $1,600,000; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">the remainder for personnel-related costs, preclinical research, working capital, and other general corporate purposes. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Risk factors </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">You should read the &#147;Risk Factors&#148; section starting on page <a href="#tRF">9</a> of this prospectus for a discussion of factors to consider carefully before deciding to invest in ordinary shares. </TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width: 35%; padding-left: 10pt; text-indent: -10pt">Proposed NASDAQ Capital Market Symbol </TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&nbsp;</TD>

</TR>

</TABLE><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 0pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -15pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="vertical-align: top">

          <TD STYLE="width:35%"><!--sum1-->&nbsp;</TD>

          <TD STYLE="width: 5%"><!--Summary Gutter-->&nbsp;</TD>

          <TD STYLE="width: 60%; text-align: left; padding-left: 0pt">&#147;ORPN&#148;</TD>

</TR>

</TABLE><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The number of our ordinary shares to be outstanding immediately after this offering is based on 11,030,480 ordinary shares outstanding as of the date of this prospectus. This number excludes: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">403,110 shares issuable upon the exercise of share options outstanding as of January 1, 2014; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">53,789 shares reserved as of January 26, 2014 for future grants under our equity incentive plan. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Unless otherwise indicated, all information in this prospectus assumes or gives effect to: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the filing of our amended and restated articles of association, which will occur immediately prior to the completion of this offering; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">no exercise of the underwriters&#146; over-allotment option. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 1mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">7</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

</DIV><DIV STYLE="width: 708px; border-top: 1pt black solid; border-bottom: 1pt black solid; border-right: 1pt black solid; border-left: 1pt black solid; padding-top: 9pt; padding-bottom: 9pt; padding-right: 3pt; padding-left:6pt; margin-top:6pt; margin-right: 0pt; margin-left:0pt; margin-bottom:6pt" ALIGN="CENTER">

<DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SUMMARY FINANCIAL DATA </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table summarizes our financial data. We have derived the following statements of operations data for the years ended December 31, 2013 and 2012 and the balance sheet data as of December 31, 2013 from our audited financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in the future. The following summary financial data should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes included elsewhere in
this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="432"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="76"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black"  ROWSPAN=1 COLSPAN=1>(in thousands of U.S. dollars, except share and per share amounts)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Statements of Operations Data:<BR></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>732</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>140</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>General and administrative expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>416</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>86</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Financial expense (income), net</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deemed dividend</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Loss attributable to holders of ordinary shares</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,171</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Weighted average number of ordinary shares used in computing basic and diluted net loss per share</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,423,018</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,551,427</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="348"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="68"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="76"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=11>As of December 31, 2013</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black"  ROWSPAN=1 COLSPAN=1>(in U.S. dollars)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Actual</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Pro forma (unaudited)<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>As Adjusted (unaudited)<sup>&#040;2&#041;</sup></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Balance Sheet Data:<BR></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total long-term assets</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total current liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>131</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>131</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shareholders equity</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>175</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,555</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Effect to the sale of 1,065,076 ordinary shares on January 1, 2014 at the price of $0.95 per share and to the sale of 782,537 ordinary shares on February 6, 2014 at the price of $6.07 per share, as if the sale of the shares in each case had occurred on December 31, 2013. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">The unaudited as adjusted column in the balance sheet data above gives effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the estimated price range on the cover page of this prospectus), after deducting underwriting discounts and commissions and estimated offering expenses payable by us, as if the sale had occurred on December 31, 2013. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 1mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">8</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tRF"></a><a name="tRF"></a>RISK FACTORS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>An investment in shares of our ordinary shares involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this prospectus, including our financial statements and related notes thereto, before deciding to invest in our ordinary shares. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects. In these circumstances, the market price of our ordinary shares could decline, and you may lose all or part of your
investment.</I> </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to Our Financial Condition and Capital Requirements </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a development-stage company and have a limited operating history on which to assess our business, have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a development-stage biopharmaceutical company with a limited operating history. We have incurred net losses since our inception in January 2012, including net losses of $1.1 million for the year ended December 31, 2013. As of December 31, 2013, we had an accumulated deficit of $1.4 million. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have devoted substantially all of our financial resources to identify, acquire, license, and develop our product candidates, including conducting preclinical and clinical studies and providing general and administrative support for these operations. To date, we have financed our operations primarily through the sale of equity securities. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a
substantial degree of risk. We are in the early stages of clinical development for our product candidates, we have not yet commenced pivotal clinical studies for any product candidate and it may be several years, if ever, before we complete pivotal clinical studies and have a product candidate approved for commercialization. Even if we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors, and adequate market share for our product candidates in those markets. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">continue our research and preclinical and clinical development of our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">expand the scope of our current clinical studies for our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">advance our programs into more expensive clinical studies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">initiate additional preclinical, clinical, or other studies for our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">change or add additional manufacturers or suppliers; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">seek regulatory and marketing approvals for our product candidates that successfully complete clinical studies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">seek to identify, assess, acquire, license, and/or develop other product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">make milestone or other payments under any license agreements; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">seek to maintain, protect, and expand our intellectual property portfolio; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">seek to attract and retain skilled personnel; </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">9</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">experience any delays or encounter issues with any of the above, including but not limited to failed studies, complex results, safety issues, or other regulatory challenges that require longer follow-up of existing studies, additional major studies, or additional supportive studies in order to pursue marketing approval. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have never generated any revenue from product sales and may never be profitable. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have no products approved for commercialization and have never generated any revenue. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">completing research and preclinical and clinical development of our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtaining regulatory and marketing approvals for product candidates for which we complete clinical studies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">developing a sustainable and scalable manufacturing process for any approved product candidates and establishing and maintaining supply and manufacturing relationships with third parties that can conduct the process and provide adequate (in amount and quality) products to support clinical development and the market demand for our product candidates, if approved; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">launching and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtaining market acceptance of our product candidates as viable treatment options; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">addressing any competing technological and market developments; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">identifying, assessing, acquiring and/or developing new product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">attracting, hiring, and retaining qualified personnel. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies, domestic or foreign, to change our manufacturing processes or assays, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining regulatory approvals to market one or more of our
product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to get reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable rare disease patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Additionally, if we are not able to generate revenue from the sale of any approved products, we may never become profitable. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">10</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if this offering is successful, we expect that we will need to raise substantial additional funding before we can expect to become profitable from sales of our products. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit, or terminate our product development efforts or other operations. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are currently advancing our Cabaletta platform product candidates through clinical development and our other product candidate, BB-FA, BB-OTC, and BBrm1 as well as our other early stage research projects, through preclinical development. Developing our product candidates is expensive, and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance our product candidates through clinical studies. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2013, our cash and cash equivalents were $0.3 million. This amount does not reflect $5.3 million that we received in connection with sales of our ordinary shares in 2014. Upon the completion of this offering, based upon our currently expected level of operating expenditures, we expect that our existing cash, cash equivalents and marketable securities will be sufficient to fund our current operations for at least the next 12 months; however, we expect that we will require substantial additional capital to obtain regulatory approval for, and to commercialize, our product candidates. In addition, our operating
plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors, including but not limited to: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the scope, rate of progress, results and cost of our clinical studies, preclinical testing, and other related activities; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates and any products that we may develop; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the number and characteristics of product candidates that we pursue; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the cost, timing, and outcomes of regulatory approvals; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the cost and timing of establishing sales, marketing, and distribution capabilities; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the terms and timing of any collaborative, licensing, and other arrangements that we may establish, including any required milestone and royalty payments thereunder. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The incurrence of indebtedness could
result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights, and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results, and prospects. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay, or discontinue one or more of our research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition, and results of operations. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">11</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Raising additional capital would cause dilution to our existing shareholders, and may restrict our operations or require us to relinquish rights. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may seek additional capital through a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions such as
incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through collaboration, strategic alliance and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that are not favorable to us. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to the Discovery and Development of Our Product Candidates. </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are heavily dependent on the success of our product candidates, which are in the early stages of preclinical or clinical development. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To date, we have invested substantially all of our efforts and financial resources to identify, acquire, license, and develop our product candidates, including conducting preclinical and clinical studies and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize one or more product candidates. We currently generate no revenue from sales of any drugs, and we may never be able to develop or commercialize a marketable drug. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Each of our product candidates is in the early stages of development and will require additional clinical development (and in some cases additional preclinical development), management of nonclinical, clinical, and manufacturing activities, regulatory approval, obtaining adequate manufacturing supply, building of a commercial organization, and significant marketing efforts before we generate any revenue from product sales. We currently have one product candidate in Phase 2 clinical studies. None of our product candidates have advanced into a pivotal study and it may be years before such study is initiated, if at all. We are
not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We as a company have never submitted marketing applications to the FDA or comparable foreign regulatory authorities. We cannot be certain that any of our product candidates will be successful in clinical studies or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical studies. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We generally plan to seek regulatory approval to commercialize our product candidates in the United States, the European Union, or EU, and in additional foreign countries where we have commercial rights. To obtain regulatory approval in other countries, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical studies, commercial sales, pricing, and distribution of our product candidates. Even if we are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other
jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical studies, and depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">12</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. We have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product candidate&#146;s safety-benefit ratio for its proposed indication is acceptable; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical studies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of a new drug application, or NDA, or biologics license application, or BLA, or other submission or to obtain regulatory approval in the United States or elsewhere; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">This lengthy approval process, as well as the unpredictability of the results of clinical studies, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer significant setbacks in subsequent registration clinical studies. For example, the safety or efficacy results generated to date in preclinical and clinical studies for Cabaletta and BBrm1 or BB-FA, and
BB-OTC do not ensure that later clinical studies will demonstrate similar results. There is a high failure rate for drugs and biologics proceeding through clinical studies, and product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical studies. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier studies. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase 2, Phase 3, or other clinical studies we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain regulatory approval to market our drug candidates. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">13</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may find it difficult to enroll patients in our clinical studies given the limited number of patients who have the diseases for which our product candidates are being studied. Difficulty in enrolling patients could delay or prevent clinical studies of our product candidates. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Identifying and qualifying patients to participate in clinical studies of our product candidates is critical to our success. The timing of our clinical studies depends in part on the speed at which we can recruit patients to participate in testing our product candidates, and, although we have not yet experienced difficulty enrolling patients in clinical studies in the past, we may experience delays in our clinical studies if we encounter difficulties in enrollment in the future. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Each of the conditions for which we plan to evaluate our current product candidates is a rare genetic disease. Accordingly, there are limited patient pools from which to draw for clinical studies. For our current product candidates: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we estimate that several thousand patients in the United States suffer from OPMD for which Cabaletta is being studied; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we estimate that a few thousand patients in the United States suffer from SCA3 for which Cabaletta is being studied; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we estimate a few thousand patients in the United States suffer from SBMA for which Cabaletta is being studied; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we estimate that several thousand patients in the United States suffer from Friedrich&#146;s Ataxia for which BB-FA is being studied; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we estimate that a few thousand patients in the United States suffer from OTC deficiency for which BB-OTC is being studied; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we estimate that several thousand patients in the United States suffer from SMA deficiency for which BBrm1 is being studied; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we estimate that the prevalence of the diseases we aim at is similar and sometimes higher than the total number of patients in the US. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to the rarity of these diseases, the eligibility criteria of our clinical studies will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure or to assure their disease is either severe enough or not too advanced to include them in a study. Additionally, the process of finding and diagnosing patients may prove costly. We also may not be able to identify, recruit, and enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidate under study, the
availability and efficacy of competing therapies and clinical studies, the proximity and availability of clinical study sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies, and obtaining regulatory approval of potential products may be delayed. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we experience delays in the completion of, or termination of, any clinical study of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition, any delays in completing our clinical studies will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may harm our business, financial condition, and prospects significantly. In addition, many of
the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may encounter substantial delays in our clinical studies, or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time consuming, and uncertain as to outcome. We cannot guarantee that </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">14</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include but are not limited to: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">inability to generate sufficient preclinical, toxicology, or other <I>in vivo</I> or <I>in vitro</I> data to support the initiation of human clinical studies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in reaching a consensus with regulatory agencies on study design; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in obtaining required Institutional Review Board, or IRB, approval at each clinical study site; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">imposition of a clinical hold by regulatory agencies, after review of an investigational new drug, or IND, application, or equivalent application, or an inspection of our clinical study operations or study sites; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in recruiting suitable patients to participate in our clinical studies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">difficulty collaborating with patient groups and investigators; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure by our CROs, other third parties, or us to adhere to clinical study requirements; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure to perform in accordance with the FDA&#146;s good clinical practices requirements, or applicable regulatory guidelines in other countries; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in having patients complete participation in a study or return for post-treatment follow-up; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">patients dropping out of a study; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the cost of clinical studies of our drug candidates being greater than we anticipate; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">clinical studies of our drug candidates producing negative or inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon drug development programs; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, we may need to conduct additional studies to bridge our repurposed product candidates to generic products in the market. We may also be required to conduct additional safety, efficacy and comparability studies before we will be allowed to start clinical studies with our repurposed drugs. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do,
which could impair our ability to obtain orphan exclusivity and to successfully commercialize our product candidates and may harm our business and results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. While our own clinical study Safety </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">15</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Tolerability and Efficacy Study of Cabaletta to Treat OPMD Patients, or HOPEMD, for OPMD, enrolled patients there may be side effects associated with the use of Cabaletta that we discover. Other enzyme replacement therapies have been associated with infusion-associated reactions due to a developing allergy to the product, which can cause rashes, pain, significant clinical disease, or even death. Our BB-FA and BB-OTC product candidates may also cause these or similar side effects. Results of our studies could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our studies
could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny or withdraw approval of our product candidates for any or all targeted indications. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The drug-related side effects could affect patient recruitment, the ability of enrolled patients to complete the study, or result in potential product liability claims. We do not currently hold product liability insurance and do not anticipate obtaining product liability insurance until such time as we have received FDA or other comparable foreign authority approval for a product and there is a product that is being provided to third parties outside of clinical trials. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including but not limited to: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">regulatory authorities may withdraw approvals of such product; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">regulatory authorities may require additional warnings on the label; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may be required to create a Risk Evaluation and Mitigation Strategy, or REMS, plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we could be sued and held liable for harm caused to patients; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our reputation may suffer. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations, and prospects. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States. In addition, manufacturers and manufacturers&#146; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices, or cGMP, regulations. As
such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA or BLA. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to
prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#146;s approved label. As such, we may not promote our products for indications or uses for which they do not have FDA approval. The holder of an approved NDA or BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical studies to </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">16</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">verify the safety and efficacy of our products in general or in specific patient subsets. If original marketing approval were obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical study to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. Furthermore, any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. Foreign regulatory authorities impose
similar requirements. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">issue warning letters; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">impose civil or criminal penalties; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">suspend or withdraw regulatory approval; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">suspend any of our ongoing clinical studies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">refuse to approve pending applications or supplements to approved applications submitted by us; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">impose restrictions on our operations, including closing our contract manufacturers&#146; facilities; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">seize or detain products, or require a product recall. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our recurring operating losses have raised substantial doubt regarding our ability to continue as a going concern. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2013, we had an accumulated deficit of $1.4 million. Our recurring operating losses raise substantial doubt about our ability to continue as a going concern. Our financial statements include a note describing the conditions which raise this substantial doubt. As a result, our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of and for the year ended December 31, 2013 with respect to this uncertainty. We have no current source of revenue to sustain our present activities, and we do not expect to generate revenue until, and unless, the
FDA or other regulatory authorities approve our product candidates and we successfully commercialize our product candidates. Accordingly, our ability to continue as a going concern will require us to obtain additional financing to fund our operations. The perception of our ability to continue as a going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the loss of confidence by investors, suppliers and employees. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to our Reliance on Third Parties </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We rely on third parties to conduct our preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical and clinical studies, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">17</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with cGMP, current good clinical practices, or cGCP, and Good Laboratory Practices, or GLP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these regulations through periodic inspections of study sponsors, principal investigators, study
sites, and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, the clinical data generated in our clinical studies may be deemed unreliable and the FDA, EMA, or comparable foreign regulatory authorities may require us to perform additional clinical studies before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical studies comply with cGCP regulations. In addition, our clinical studies must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical studies, which would delay the regulatory approval process. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical, and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they
obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical studies may be extended, delayed, or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We rely completely on third parties to manufacture our preclinical and clinical drug supplies. Our business could be harmed if those third parties fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture our preclinical and clinical drug supplies for use in the conduct of our clinical studies, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical studies. There are a limited number of suppliers for raw materials that we use to manufacture our drugs, and there may be a need to identify alternate suppliers to
prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical studies, and, if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Although we generally do not begin a clinical study unless we believe we have a sufficient supply of a product candidate to complete such study, any significant delay or discontinuity in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical study due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies, product testing, and potential regulatory approval of our product candidates, which could harm our business and results of operations. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">18</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The process of manufacturing our product candidates is complex, highly regulated, and subject to several risks, including but not limited to: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the process of manufacturing biologics, such as BB-FA and BB-OTC is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or vendor or operator error. Even minor deviations from normal manufacturing processes for any of our product candidates could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures, and numerous other factors. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures, withdrawals or recalls, or other interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for product candidates that fail to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The drug substance and drug product for our product candidates are currently acquired from single-source suppliers. The loss of these suppliers, or their failure to supply us with the drug substance or drug product, could materially and adversely affect our business. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The pharmaceutical-grade drug substance for our Cabaletta is acquired from third party drug products suppliers and manufacturers under a development and clinical supply agreements and accompanying purchase orders. In several cases, the Company relies on a sole provider, and it is possible that the Company will be required to switch providers in the unforeseen future. In such case, the process of switching suppliers may be costly and/or time consuming for us, and that may include the temporary or permanent suspension of a clinical study or commercial sales of our candidate products. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We do not currently have any other suppliers for the drug substance or drug product of our product candidates and, although we believe that there are alternate sources of supply that could satisfy our clinical and commercial requirements, we cannot assure you that identifying alternate sources and establishing relationships with such sources would not result in significant delay in the development of our product candidates. Additionally, we may not be able to enter into supply arrangements with alternative suppliers on commercially reasonable terms, or at all. A delay in the development of our product candidates or having to
enter into a new agreement with a different third party on less favorable terms than we have with our current suppliers could have a material adverse impact upon on our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We and our collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of
production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We, our collaborators, or our contract manufacturers must supply all necessary documentation in support of an NDA, BLA, or Marketing Authorization Application, or MAA, on a timely basis and must adhere to GLP and cGMP regulations enforced by the FDA and other regulatory agencies through their facilities inspection program. Some of our </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">19</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">contract manufacturers have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some or all of our collaborators and third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other
potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our collaborators and third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial
sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we, our collaborators, or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, withdrawal of an approval, or suspension of production. As a result, our business, financial condition, and results of operations may be materially harmed. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA or BLA supplement or MAA amendment, or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These factors could cause us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed or we could lose potential revenue. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Because we rely on third parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees, and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets.
Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">20</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to Commercialization of Our Product Candidates </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Because the target patient populations of our product candidates are small, we must be able to successfully identify patients and achieve a significant market share to maintain profitability and growth. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We focus our research and product development on treatments for rare and ultra-rare genetic diseases. Given the small number of patients who have the diseases that we are targeting, it is critical to our ability to grow and become profitable that we continue to successfully identify patients with these rare and ultra-rare genetic diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of
sources, including the scientific literature, surveys of clinics, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to rely on third-party manufacturers to produce our product candidates, but we have not entered into binding agreements with any such manufacturers to support commercialization. Additionally, these manufacturers do not have experience producing our product candidates at commercial levels and may not achieve the necessary regulatory approvals or produce our product candidates at the quality, quantities, locations, and timing needed to support commercialization. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have not yet secured manufacturing capabilities for commercial quantities of our product candidates. Although we intend to rely on third-party manufacturers for commercialization, we have only entered into agreements with such manufacturers to support our clinical studies. We may be unable to negotiate binding agreements with the manufacturers to support our commercialization activities at commercially reasonable terms. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Manufacturers may not have the experience or ability to produce our product candidates at commercial levels. We may run into technical or scientific issues related to manufacturing or development that we may be unable to resolve in a timely manner or with available funds. We also have not completed all of the characterization and validation activities necessary for commercialization and regulatory approvals. If our manufacturing partners do not conduct all such necessary activities, our commercialization efforts will be harmed. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we timely develop a manufacturing process and successfully transfer it to the third-party product manufacturers, if such third-party manufacturers are unable to produce the necessary quantities of our product candidates, or in compliance with cGMP or other pertinent regulatory requirements, and within our planned timeframe and cost parameters, the development and sales of our products, if approved, may be materially harmed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We are currently aware of various existing therapies in the market and in development that may in the future compete with our product candidates. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Gene therapy, cell therapy, bone marrow transplantation and other approaches may also emerge for the treatment of any of the disease areas in which we focus. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">21</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies. Some of the pharmaceutical and biotechnology companies we expect to compete with include Shire, Sanofi, BioMarin, Alexion, and Roche, other smaller companies or biotechnology startups, as well as other large multinational pharmaceutical companies. Many of our competitors have substantially greater financial,
technical, and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop, or achieve
earlier patent protection, regulatory approval, product commercialization, and market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently have no marketing and sales organization. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although our employees may have sold other similar products in the past while employed at other companies, we as a company have no experience selling and marketing our product candidates and we currently have no marketing or sales organization. To successfully commercialize any products that may result from our development programs, we will need to develop these capabilities, either on our own or with others. If our product candidates receive regulatory approval, we intend to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in
major markets, which will be expensive, difficult, and time consuming. Any failure or delay in the development of our internal sales, marketing, and distribution capabilities would adversely impact the commercialization of our products. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, given our lack of prior experience in marketing and selling biopharmaceutical products, our initial estimate of the size of the required sales force may be materially more or less than the size of the sales force actually required to effectively commercialize our product candidates. As such, we may be required to hire substantially more sales representatives to adequately support the commercialization of our product candidates or we may incur excess costs as a result of hiring more sales representatives than necessary. With respect to certain geographical markets, we may enter into collaborations with other entities
to utilize their local marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If our future collaborators do not commit sufficient resources to commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We may be competing with companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">22</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The commercial success of any current or future product candidate will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even with the requisite approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our product candidates will depend in part on the medical community, patients, and third-party payors accepting our product candidates as medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors, and others in the medical community. The degree of market acceptance of any of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the efficacy of the product as demonstrated in clinical studies and potential advantages over competing treatments; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#146;s approved labeling; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the clinical indications for which approval is granted; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">relative convenience and ease of administration; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the cost of treatment, particularly in relation to competing treatments; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the strength of marketing and distribution support and timing of market introduction of competitive products; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">publicity concerning our products or competing products and treatments; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">sufficient third-party insurance coverage and reimbursement. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if a potential product displays a favorable efficacy and safety profile in preclinical and clinical studies, market acceptance of the product will not be fully known until after it is launched. Our efforts to educate the medical community and third-party payors on the benefits of the product candidates may require significant resources and may never be successful. If our product candidates are approved but fail to achieve an adequate level of acceptance by physicians, patients, third-party payors, and others in the medical community, we will not be able to generate sufficient revenue to become or remain profitable. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our target patient populations are small, and accordingly the pricing, coverage, and reimbursement of our product candidates, if approved, must be adequate to support our commercial infrastructure. Our per-patient prices must be sufficient to recover our development and manufacturing costs and potentially achieve profitability. Accordingly, the availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford expensive treatments such as ours, assuming approval. Sales of our product candidates will depend substantially, both domestically and abroad,
on the extent to which the costs of our product candidates will be paid for by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities, private health insurers, and other third-party payors. If coverage and reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">23</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as ours. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own
prices for medicinal products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general,
particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the Health Care Reform Law, was passed, which substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The Health Care Reform Law, among other things, subjects biologic products to potential competition by lower-cost biosimilars, addresses a new methodology by which
rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and promotes a new Medicare Part D coverage gap discount program. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, other legislative changes have been proposed and adopted in the United States since the Health Care Reform Law was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per
fiscal year. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which, among other things, delayed for another two months the budget cuts mandated by these sequestration provisions of the Budget Control Act of 2011. On March 1, 2013, the President signed an executive order implementing sequestration, and on April 1, 2013, the 2% Medicare payment reductions went into effect. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">24</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to Our Intellectual Property </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are unable to obtain and maintain effective patent rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. Our success depends in large part on our and our licensors&#146; ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and products. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and products that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully
issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We, independently or together with our licensors, have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory
approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although we have a number of patents/patents applications covering methods of use and certain compositions of matter, we do not have complete patent protection for our product candidates. For example: We do not have a patent covering the composition of matter of Trehalose, and our patents cover only the route of administration (IV) and use in several orphan diseases associated with trinucleotide repeat expansion (PolyA/PolyQ) diseases. With regards to our mitochondrial protein replacement therapy we do not have a patent covering the concept of attaching TAT to a protein. With our read-through patents we do not have a
composition of matter protection. Instead, we have filed a use patent application of a generic family of molecules in a non-systemic route of administration for genetic neuro degenerative and neuro developmental diseases and new route of administration through direct injection to the central nervous system. In addition, our patent applications have not resulted in issued patents. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we cannot obtain and maintain effective patent rights for our product candidates, we may not be able to compete effectively and our business and results of operations would be harmed. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may not have sufficient patent terms to effectively protect our products and business. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">25</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">While patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent exclusivity term for Cabaletta, BB-FA and BB-OTC as well as the BBrm family of molecules we cannot provide any assurances that any such patent term extension will be obtained and, if so, for how long. In addition, upon issuance in the United States any patent term can be adjusted based on certain delays caused by the applicant(s) or
USPTO. For example, a patent term can be reduced based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely affected. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore cannot be certain that we or our licensors were the first to
make the invention claimed in our owned and licensed patents or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming the other requirements for patentability are met, in the United States prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on September 16, 2011, the United States has moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. The effects of these changes are currently unclear as the United States Patent and Trademark office, or USPTO, must still implement various regulations, the courts have yet to address any of these provisions and
the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. In general, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants,
scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized
disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">26</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the
biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. We have conducted freedom to operate analyses with respect to only certain of our product candidates, and therefore we do not know whether there are any third-party patents that would impair our ability to commercialize these product candidates. We also cannot guarantee that any of our analyses are complete and thorough, nor
can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture, or methods of use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses
from third parties, which may be impossible or require substantial time and monetary expenditure. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license, or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other
third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">27</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are
unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, we may have to abandon development of that program and our business and financial condition could suffer. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may face competition from biosimilars, which may have a material adverse impact on the future commercial prospects of our mitochondrial protein replacment platform. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if we are successful in achieving regulatory approval to commercialize a product candidate faster than our competitors, we may face competition from biosimilars with respect to BB-FA and BB-OTC and future product candidates based on our protein replacement platform. In the United States, the Biologics Price Competition and Innovation Act of 2009 created an abbreviated approval pathway for biological products that are demonstrated to be &#147;highly similar,&#148; or biosimilar, to or &#147;interchangeable&#148; with an FDA-approved biological product. This new pathway could allow competitors to reference data from
innovative biological products 12 years after the time of approval of the innovative biological product. This data exclusivity does not prevent another company from developing a product that is highly similar to the innovative product, generating its own data, and seeking approval. Data exclusivity only assures that another company cannot rely upon the data within the innovator&#146;s application to support the biosimilar product&#146;s approval. In his proposed budget for fiscal year 2014, President Obama proposed to cut this 12-year period of exclusivity down to seven years. He also proposed to prohibit additional periods of exclusivity due to minor changes in product formulations, a practice often referred to as &#147;evergreening.&#148; It is possible that Congress may take these or other measures to reduce or eliminate periods of exclusivity. The Biologics Price Competition and Innovation Act of 2009 is complex and only beginning to be interpreted and implemented by the FDA. As a
result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when any such processes may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for BB-FA and BB-OTC. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In Europe, the European Commission has granted marketing authorizations for several biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological product, but will not be able to get on the market until 10 years after the time of approval of the innovative product. This 10-year marketing exclusivity period will be extended to 11 years if, during the first eight of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic
indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilars in other countries that could compete with our products. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The patent protection and patent prosecution for some of our product candidates is dependent on third parties. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">While we normally seek and gain the right to fully prosecute the patents relating to our product candidates, there may be times when patents relating to our product candidates are controlled by our licensors. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, even where we now have the right to control patent prosecution of patents and patent applications we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to us assuming control over patent prosecution. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">28</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we fail to comply with our obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty, and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, we may be required to make certain payments to the licensor, we may lose the exclusivity of our license, or the licensor may have the right to terminate the license, in which event we
would not be able to develop or market products covered by the license. Additionally, the milestone and other payments associated with these licenses will make it less profitable for us to develop our drug candidates. See &#147;Business&nbsp;&#151;&nbsp;License Agreements&#148; for a description of our license agreements with the Hebrew University in Jerusalem and the Tel-Aviv University. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues. Disputes may arise regarding intellectual property subject to a licensing agreement, including but not limited to: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the scope of rights granted under the license agreement and other interpretation-related issues; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the sublicensing of patent and other rights; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the priority of invention of patented technology. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Competitors may infringe our patents or the patents of our licensors. If we or one of our licensing partners were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management
and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">29</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our ordinary shares. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#146;s former employer or other third
parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may be subject to claims challenging the inventorship of our patents and other intellectual property. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable
intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. In addition, the Israeli Supreme Court ruled in 2012 that an employee who receives a patent or contributes to an invention during his employment may be allowed to seek compensation for it from his employer, even if the employee&#146;s contract of employment specifically states otherwise and the employee has transferred all intellectual property rights to the employer. The Israeli Supreme Court ruled that the fact that a contract revokes the employee&#146;s right for royalties and compensation, does not rule out the right of the employee to claim his right for royalties. As a result, it is unclear if, and to what extent, our employees may be able to claim compensation with respect to our future revenue. Therefore, we may receive less
revenue from future products if such claims are successful which in turn could impact our future profitability. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity. Therefore, obtaining and enforcing biotechnology patents is costly, time consuming, and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners
in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">30</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may not be able to protect our intellectual property rights throughout the world. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Among these countries is China where we intend to protect our intellectual property rights to the extent possible. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful,
could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to Our Business Operations </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our future success depends in part on our ability to retain our Chief Executive Officer and our Chief Financial Officer and to attract, retain, and motivate other qualified personnel. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are highly dependent on Dalia Megiddo, M.D, our Founder, and Chief Executive Officer, and Udi Gilboa, our Chief Financial Officer, the loss of their services without a proper replacement may adversely impact the achievement of our objectives. Dr. Megiddo and Mr. Gilboa may leave our employment at any time (subject, in each case, to a 60 days prior notice, under the terms of their consultancy agreements), as each one is an &#147;at will&#148; independent contractor. Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical personnel, will also be
critical to our success. There is currently a shortage of skilled personnel in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in preclinical or clinical studies may make it more challenging to recruit and retain qualified personnel. The inability to recruit and retain qualified personnel, or the loss of the services of Dr. Megiddo or Mr. Gilboa without proper replacement, may impede the progress of our research, development, and commercialization objectives. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we fail to obtain or maintain orphan drug exclusivity for our products, our competitors may sell products to treat the same conditions and our revenue will be reduced. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our business strategy focuses on the development of drugs that are eligible for FDA and EU orphan drug designation. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the EMA&#146;s Committee for Orphan Medicinal Products, or COMP, grants orphan drug
designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">31</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Community. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the
manufacturer is unable to assure sufficient product quantity. In the European Union, orphan drug designation also entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity is granted following drug or biological product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Because the extent and scope of patent protection for our products may in some cases be limited, orphan drug designation is especially important for our products for which orphan drug designation may be available. For eligible drugs, we plan to rely on the exclusivity period under the Orphan Drug Act to maintain a competitive position. If we do not obtain orphan drug exclusivity for our drug products and biologic products that do not have broad patent protection, our competitors may then sell the same drug to treat the same condition sooner than if we had obtained orphan drug exclusivity and our revenue will be reduced. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even though we have obtained orphan drug designation for OPMD in the United States, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Although we have orphan drug exclusivity and certain intellectual property covering the use of Trehalose IV, if a third party were to prepare or
market a Trehalose IV preparation, we may need to initiate litigation, which may be costly, to enforce our rights against such party. Even after an orphan drug is approved, the FDA can subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial, legal, and other resources. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our
expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">32</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may not be successful in our efforts to identify, license, or discover additional product candidates. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although a substantial amount of our effort will focus on the continued clinical testing, potential approval, and commercialization of our existing product candidates, the success of our business also depends upon our ability to identify, license, or discover additional product candidates. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development for a number of reasons, including but not limited to the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our product candidates may not succeed in preclinical or clinical testing; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">competitors may develop alternatives that render our product candidates obsolete or less attractive; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">product candidates we develop may be covered by third parties&#146; patents or other exclusive rights; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the market for a product candidate may change during our program so that such a product may become unreasonable to continue to develop; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license, or discover additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a public company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and The NASDAQ Global Market has imposed various requirements on public companies. In July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#147;say on pay&#148;
and pay parity. Recent legislation permits smaller &#147;emerging growth companies&#148; to implement many of these requirements over a longer period and up to five years from the pricing of this offering. We intend to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more
time consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such coverage. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">33</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we will be required to perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report, commencing in our annual report on Form 20-F for the year ending December 31, 2014, on the effectiveness of our internal controls over financial reporting, if then required by
Section 404 of the Sarbanes-Oxley Act. Our testing may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses. Our compliance with Section 404 will require that we incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge. Moreover, if we are not able to comply with the requirements of Section 404 in a timely manner or if we identify or our independent registered public accounting firm identifies deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by NASDAQ, the SEC, or other regulatory authorities, which would require additional financial and management resources.
</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">New laws and regulations as well as changes to existing laws and regulations affecting public companies, including the provisions of the Sarbanes-Oxley Act and rules adopted by the SEC and by NASDAQ, would likely result in increased costs to us as we respond to their requirements. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and physician sunshine laws and regulations. These laws may impact, among other things, our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The
laws that may affect our ability to operate include: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security, and transmission of individually identifiable health information; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the federal physician sunshine requirements under the Health Care Reform Laws requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">34</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px; text-align: left"></TD>

          <TD STYLE="width: 24px; text-align: left"></TD>

          <TD STYLE="text-align: left">industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the Health Care Reform Law, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the Health Care Reform Law provides that the
government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States or Israel. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Other than our headquarters and other operations which are located in Israel (as further described below), we currently have limited international operations, but our business strategy incorporates potentially significant international expansion, particularly in anticipation of approval of our product candidates. We plan to maintain sales representatives and conduct physician and patient association outreach activities, as well as clinical trials, outside of the United States and Israel. Doing business internationally involves a number of risks, including but not limited to: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">multiple, conflicting, and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">failure by us to obtain regulatory approvals for the use of our products in various countries; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">additional potentially relevant third-party patent rights; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">complexities and difficulties in obtaining protection and enforcing our intellectual property; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">difficulties in staffing and managing foreign operations; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">limits in our ability to penetrate international markets; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">certain expenses including, among others, expenses for travel, translation, and insurance; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, or FCPA, its books and records provisions, or its anti-bribery provisions. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">35</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our research and development activities and our third-party manufacturers&#146; and suppliers&#146; activities involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#146; facilities pending their use and disposal. We cannot eliminate the
risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex,
change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to this Offering and Ownership of Our Ordinary Shares </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may be a &#147;passive foreign investment company&#148;, or PFIC, for U.S. federal income tax purposes in the current taxable year or may become one in any subsequent taxable year. There generally would be negative tax consequences for U.S. taxpayers that are holders of our Ordinary Shares if we are or were to become a PFIC. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We would be treated as a PFIC for U.S. federal income tax purposes in any taxable year in which either (1) at least 75% of our gross income is &#147;passive income&#148; or (2) on average at least 50% of our assets by value produce passive income or are held for the production of passive income. Passive income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment of
funds, including those raised in a public offering. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. We cannot rule out that we will not be a PFIC for our current taxable year or in the future. The tests for determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets which are relevant to this determination. In addition, our PFIC status may depend in part on the market value of our Ordinary Shares. Accordingly, there can be no assurance that we currently are not or will not become a PFIC in the future. If we are a PFIC in any taxable year during which a U.S. taxpayer holds our Ordinary Shares, such U.S. taxpayer would be subject to certain adverse U.S. federal income tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as
a &#147;qualified electing fund,&#148; or QEF, or make a &#147;mark-to-market&#148; election, then &#147;excess distributions&#148; to the U.S. taxpayer, and any gain realized on the sale or other disposition of our Ordinary Shares by the U.S. taxpayer: (1) would be allocated ratably over the U.S. taxpayer&#146;s holding period for the Ordinary Shares; (2) the amount allocated to the current taxable year and any period prior to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year. In addition, if the IRS determines that we are a PFIC for a year with respect to which we have determined that we were not a PFIC, it may be
too late for a U.S. taxpayer to make a timely QEF or mark-to-market election. U.S. taxpayers that </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">36</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">have held our Ordinary Shares during a period when we were a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto. We do not intend to notify U.S. taxpayers that hold our Ordinary Shares if we believe we will be treated as a PFIC for any taxable year in order to enable U.S. taxpayers to consider whether to make a QEF election. In addition, we do not
intend to furnish such U.S. taxpayers annually with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election for any year in which we or any of our subsidiaries are a PFIC. U.S. taxpayers that hold our Ordinary Shares are strongly urged to consult their tax advisors about the PFIC rules, including tax return filing requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market election with respect to our Ordinary Shares in the event that we are a PFIC. See &#147;Taxation&nbsp;&#151;&nbsp;U.S. Federal Income Tax Consequences&nbsp;&#151;&nbsp;Passive foreign investment company consequences&#148; for additional information. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The market price of our ordinary shares may be highly volatile, and you may not be able to resell your shares at or above the initial public offering price. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to this offering, there has not been a public market for our ordinary shares. If an active trading market for our ordinary shares does not develop following this offering, you may not be able to sell your shares quickly or at the market price. The initial public offering price for the shares will be determined by negotiations between us and representatives of the underwriters and may not be indicative of prices that will prevail in the trading market. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The trading price of our ordinary shares is likely to be volatile. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our ordinary shares: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">inability to obtain the approvals necessary to commence further clinical trials; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">unsatisfactory results of clinical trials; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">announcements of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">announcements of therapeutic innovations or new products by us or our competitors; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">changes or developments in laws or regulations applicable to any candidate product of our in each of our platforms; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any adverse changes to our relationship with manufacturers or suppliers; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any intellectual property infringement actions in which we may become involved; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">announcements concerning our competitors or the pharmaceutical industry in general; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">achievement of expected product sales and profitability or our failure to meet expectations; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our commencement of, or involvement in, litigation; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any major changes in our board of directors or management; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">legislation in the United States relating to the sale or pricing of pharmaceuticals. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, the stock market in general, and The NASDAQ Stock Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of small companies. Broad market and industry factors may negatively affect the market price of our ordinary shares, regardless of our actual operating performance. Further, a systemic decline in the financial markets and related factors beyond our control may cause our share price to decline rapidly and unexpectedly. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">37</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may be subject to securities litigation, which is expensive and could divert management attention. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the past companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#146;s attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us to significant liabilities. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our principal shareholders, chief executive officer and directors currently own over 85% of our outstanding ordinary shares and will own approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our ordinary shares upon the closing of this offering. They will therefore be able to exert significant control over matters submitted to our shareholders for approval. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After this offering, our chief executive officer and directors, and shareholders who own more than 5% of our outstanding ordinary shares before this offering will, in the aggregate, beneficially own approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our ordinary shares (assuming no exercise of the underwriters&#146; over-allotment option and no exercise of outstanding options). This significant concentration of share ownership may adversely affect the trading price for our ordinary shares because investors often perceive disadvantages in owning stock in companies with controlling shareholders. As a result, these shareholders, if
they acted together, could significantly influence or even unilaterally approve matters requiring approval by our shareholders, including the election of directors and the approval of mergers or other business combination transactions. The interests of these shareholders may not always coincide with our interests or the interests of other shareholders. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If you purchase our ordinary shares in this offering, you will incur immediate and substantial dilution in the book value of your shares. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The initial public offering price is substantially higher than the net tangible book value per share of our ordinary shares. Investors purchasing ordinary shares in this offering will pay a price per share that substantially exceeds the net tangible book value of our ordinary shares. As a result, investors purchasing ordinary shares in this offering will incur immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp; per share, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the range on the cover page of this prospectus, and our pro forma net tangible book value as of December
31, 2013. In addition, as of the date of this prospectus, options to purchase 403,110 of our ordinary shares at a weighted average exercise price of $0.0004 per share were outstanding. The exercise of these options would result in additional dilution. As a result of this dilution, investors purchasing shares in this offering may receive significantly less than the purchase price paid in this offering in the event of liquidation. For more information, please refer to the section of this prospectus entitled &#147;Dilution.&#148; </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sales of a substantial number of shares of our ordinary shares in the public market by our existing shareholders could cause our share price to fall. </H3>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sales of a substantial number of shares of our ordinary shares in the public market or the perception that these sales might occur, could depress the market price of our ordinary shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our ordinary shares. Substantially all of the shares owned by our existing shareholders and option holders are subject to lock-up agreements with the underwriters of this offering that restrict the shareholders&#146; ability to transfer our ordinary shares for
at least six or 18 months, as applicable, from the date of this prospectus. Substantially all of our outstanding shares will become eligible for unrestricted sale upon expiration of the lockup period, as described in the section of this prospectus entitled &#147;Shares Eligible for Future Sale.&#148; In addition, shares issued or issuable upon exercise of options and warrants vested as of the expiration of the lock-up period will be eligible for sale at that time. Sales of shares by these shareholders could have a material adverse effect on the trading price of our ordinary shares. </P>



</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">38</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our management will have broad discretion in the use of the net proceeds from this offering and may allocate the net proceeds from this offering in ways that you and other shareholders may not approve. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our management will have broad discretion in the use of the net proceeds, including for any of the purposes described in the section entitled &#147;Use of Proceeds,&#148; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. The failure of our management to use these funds effectively could harm our business. Pending their use, we may invest the net
proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our shareholders. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations or publish negative reports regarding our business or our shares, our share price and trading volume could decline. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The trading market for our ordinary shares will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our shares, or provide more favorable relative recommendations about our competitors, our share price would likely decline. If any analyst who may cover us were to cease coverage of our company or fail to
regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Because we do not intend to declare cash dividends on our ordinary shares in the foreseeable future, shareholders must rely on appreciation of the value of our ordinary shares for any return on their investment. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have never declared or paid cash dividends on our ordinary shares. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. As a result, only appreciation of the price of our ordinary shares, if any, will provide a return to investors in this offering. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The requirements associated with being a public company will require significant company resources and management attention. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Following this offering, we will become subject to the reporting requirements of the Securities Exchange Act of 1934, the Sarbanes-Oxley Act, the listing requirements of the securities exchange on which our ordinary shares is traded, and other applicable securities rules and regulations. The Securities Exchange Act of 1934 requires that we file periodic reports with respect to our business and financial condition and maintain effective disclosure controls and procedures and internal control over financial reporting. In addition, subsequent rules implemented by the SEC and The NASDAQ Stock Market may also impose various
additional requirements on public companies. As a result, we will incur additional legal, accounting and other expenses that we did not incur as a nonpublic company, particularly after we are no longer an &#147;emerging growth company&#148; as defined in the JOBS Act. Further, the need to establish the corporate infrastructure demanded of a public company may divert management&#146;s attention from implementing our development plans. We have made changes to our corporate governance standards, disclosure controls and financial reporting and accounting systems to meet our reporting obligations. The measures we take, however, may not be sufficient to satisfy our obligations as a public company, which could subject us to delisting of our ordinary shares, fines, sanctions and other regulatory action and potentially civil litigation. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">39</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The JOBS Act and our status as a foreign private issuer will allow us to postpone the date by which we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information we provide in our reports filed with the SEC, which could undermine investor confidence in our company and adversely affect the market price of our ordinary shares. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For so long as we remain an &#147;emerging growth company&#148; as defined in the JOBS Act, we intend to take advantage of certain exemptions from various requirements that are applicable to public companies that are not &#147;emerging growth companies&#148; including: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the provisions of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the &#147;say on pay&#148; provisions requiring a non-binding shareholder vote to approve compensation of certain executive officers and the &#147;say on golden parachute&#148; provisions requiring a non-binding shareholder vote to approve golden parachute arrangements for certain executive officers in connection with mergers and certain other business combinations of the Dodd-Frank Act and some of the disclosure requirements of the Dodd-Frank Act relating to compensation of our chief executive officer; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Section 107 of the JOBS Act provides that an &#147;emerging growth company&#148; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This means that an &#147;emerging growth company&#148; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are electing to delay such adoption of new or revised accounting standards. As a result, our financial statements may not be comparable to companies that comply with the public company effective date. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the requirement to provide detailed compensation discussion and analysis in proxy statements and reports filed under the Securities Exchange Act of 1934, and instead provide a reduced level of disclosure concerning executive compensation; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability not to comply with new accounting principles that do not apply to public companies until such accounting principles become applicable to private companies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor&#146;s report on the financial statements; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to furnish two rather than three years of income statements and statements of cash flows in various required filings. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to take advantage of these exemptions until we are no longer an &#147;emerging growth company.&#148; We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.0 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the prior June 30<sup>th</sup>, and (2) the date on which we have issued more than $1.0 billion in
non-convertible debt during the prior three-year period. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our status as a foreign private issuer also exempts us from compliance with certain SEC laws and regulations and certain regulations of The NASDAQ Stock Market, including the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent director oversight of the nomination of directors and executive compensation. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We cannot predict if investors will find our ordinary shares less attractive because we may rely on these exemptions. If some investors find our ordinary shares less attractive as a result, there may be a less active trading market for our ordinary shares, and our share price may be more volatile and may decline. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">40</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risks Related to Israeli Law and Our Operations in Israel </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our headquarters and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our executive offices are located in Tel-Aviv, Israel. In addition, the majority of our officers and directors are residents of Israel. Accordingly, political, economic and military conditions in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations. During November 2012, Israel was engaged in an armed conflict with a
militia group and political party which controls the Gaza Strip, and during the summer of 2006, Israel was engaged in an armed conflict with Hezbollah, a Lebanese Islamist Shiite militia group and political party. These conflicts involved missile strikes against civilian targets in various parts of Israel, including areas in which our employees and some of our consultants are located, and negatively affected business conditions in Israel. Any armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions and could harm our results of operations and could make it more difficult for us to raise capital. Parties with whom we do business may sometimes decline to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary in order to meet our business partners face to face. In addition, the political and security situation in Israel may result in parties with whom we have
agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government has in the past covered the reinstatement value of certain damages that were caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect
business conditions generally and could harm our results of operations. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial conditions or the expansion of our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our operations may be disrupted as a result of the obligation of management or key personnel to perform military service. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our male employees and consultants in Israel, including members of our senior management, may be obligated to perform one month, and in some cases longer periods, of annual military reserve duty until they reach the age of 40 (or older, for citizens who hold certain positions in the Israeli armed forces reserves), and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be similar large-scale military reserve duty call-ups in the future. Our operations could be
disrupted by the absence of a significant number of our officers, directors, employees and consultants. Such disruption could materially adversely affect our business and operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Exchange rate fluctuations between the U.S. dollar and the New Israeli Shekel currencies may negatively affect our earnings. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We incur expenses both in U.S. dollars and New Israeli Shekels, but our financial statements are denominated in U.S. dollars. As a result, we are exposed to the risks that the New Israeli Shekel may appreciate relative to the U.S. dollar, or, if the New Israeli Shekel instead devalues relative to the U.S. dollar, that the inflation rate in Israel may exceed such rate of devaluation of the New Israeli Shekel, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the U.S. dollar cost of our operations in Israel would increase and our U.S. dollar-denominated results of operations would be
adversely </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">41</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the New Israeli Shekel against the U.S. dollar. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Provisions of Israeli law and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, our company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date on which a merger proposal is filed by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the date on which the shareholders of both merging companies have approved the merger. In addition, a
majority of each class of securities of the target company must approve a merger. Moreover, a tender offer for all of a company&#146;s issued and outstanding shares can only be completed if the acquirer receives positive responses from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless, following consummation of the tender offer, the acquirer would hold at least 98% of the Company&#146;s outstanding shares. Furthermore, the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition an Israeli court to alter the consideration for the acquisition, unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. See &#147;Taxation&nbsp;&#151;&nbsp;Israeli Tax Considerations&#148; for additional information. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our amended and restated articles of association that will be in effect immediately prior to the consummation of this offering will also contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions will include the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the exclusive right of our Board of Directors to elect a director to fill a vacancy created by the expansion of the Board of Directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">It may be difficult to enforce a judgment of a United States court against us and our officers and directors and the Israeli experts named in this prospectus in Israel or the United States, to assert United States securities laws claims in Israel or to serve process on our officers and directors and these experts. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We were incorporated in Israel. Substantially all of our executive officers and directors reside outside of the United States, and all of our assets and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against us, or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not necessarily be enforced by an Israeli court. It also may be difficult for you to affect service of process on these persons in the United States or to assert U.S. securities law
claims in original actions instituted in Israel. Additionally, it may be difficult for an investor, or any other person or entity, to initiate an action with respect to United States securities laws in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of United States securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not United States law is applicable to the claim. If United States law is found to be applicable, the content of applicable United States law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be
able to collect any </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">42</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">damages awarded by either a United States or foreign court. See &#147;Enforceability of Civil Liabilities&#148; for additional information on your ability to enforce a civil claim against us and our executive officers or directors named in this prospectus. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Your rights and responsibilities as a shareholder will be governed by Israeli law which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The rights and responsibilities of the holders of our ordinary shares are governed by our amended and restated articles of association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in typical U.S.-based corporations. In particular, a shareholder of an Israeli company has certain duties to act in good faith and fairness towards the Company and other shareholders, and to refrain from abusing its power in the Company. See &#147;Management&nbsp;&#151;&nbsp;Approval of Related Party Transactions under Israeli
Law&nbsp;&#151;&nbsp;Shareholder Duties&#148; for additional information. There is limited case law available to assist us in understanding the nature of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">43</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tCNR"></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tFLS"></a>Some of the statements made under &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Use of Proceeds,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; &#147;Business&#148; and elsewhere in this prospectus constitute forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148;
&#147;intends&#148; or &#147;continue,&#148; or the negative of these terms or other comparable terminology. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Forward-looking statements include, but are not limited to, statements about: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our expectations regarding expansion of the OPMD clinical study; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our expectations regarding the timing of commencing clinical studies with SCA3, SBMA, BB-FA, BB-OTC and BBrm1; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the likelihood of regulatory approvals for our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the commercial launch and future sales of our product candidates or any other future products or product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our ability to achieve favorable pricing for our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the potential for our drug candidate product to receive designation as an orphan drug and implications if it does not receive such designation; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our expectations regarding the commercial supply of our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">third-party payor reimbursement for our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our estimates regarding anticipated expenses, capital requirements and our needs for substantial additional financing; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the ultra-rare diseases patient market size and market adoption of our candidate products by physicians and patients; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the timing, cost or other aspects of the commercial launch of our product candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the timing of commencement, duration and cost of clinical trials for our candidate products or whether such trials will be conducted at all; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">completion and receiving favorable results of clinical trials for our candidate products; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">issuance of patents to us by the U.S. PTO and other governmental patent agencies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the development and approval of the use of our candidate products for additional indications other than ultra-rare diseases; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our expectations regarding licensing, acquisitions and strategic operations. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&#146;s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading &#147;Risk Factors&#148; and elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions of future events. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this prospectus. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">44</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tUP"></a>USE OF PROCEEDS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect to receive approximately $&nbsp;&nbsp;&nbsp;&nbsp; million in net proceeds from the sale of ordinary shares offered by us in this offering (approximately $&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their over-allotment option in full), after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently expect to use the net proceeds from this offering for: </P>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">completing our Phase 3 clinical program for OPMD, estimated at $4,000,000; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">completing our pivotal study/adaptive design clinical program for SCA3, estimated at $2,400,000; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">completing our Phase 2 clinical program for SBMA, estimated at $3,200,000; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">completing our pre-clinical program for BB-FA, estimated at $2,400,000; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">completing our pre-clinical program for BB-OTC, estimated at $2,400,000; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">completing our Phase 2 clinical program for SMA, estimated at $1,600,000; and </TD>

</TR>

</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the remainder for personnel-related costs, preclinical research, working capital, and other general corporate purposes. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The amounts and timing of our actual expenditures will depend upon numerous factors, including the progress of our development and commercialization efforts, the status of and results from our clinical trials, whether or not we enter into strategic collaborations or partnerships, and our operating costs and expenditures. Accordingly, our management will have significant flexibility in applying the net proceeds of this offering. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have no current understandings, commitments or agreements with respect to any material acquisition of or investment in any technologies, products or companies. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">45</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tDP"></a>DIVIDEND POLICY </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have never declared or paid any cash dividends on our ordinary shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Israeli Companies Law imposes further restrictions on our ability to declare and pay dividends. See &#147;Description of Share Capital&nbsp;&#151;&nbsp;Dividend and Liquidation Rights&#148; for additional information. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Payment of dividends may be subject to Israeli withholding taxes. See &#147;Taxation&nbsp;&#151;&nbsp;Israeli Tax Considerations&#148; for additional information. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">46</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tCAP"></a>CAPITALIZATION </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth our cash and cash equivalents and our capitalization as of December 31, 2013: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">on an actual basis; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">on a pro forma basis to also give effect to the sale of 1,065,076 ordinary shares on January 1, 2014 at the price of $0.95 per share and to the sale of 782,537 ordinary shares on February 6, 2014 at the price of $6.07 per share, as if the sale of the shares in each case had occurred on December 31, 2013. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">on a pro forma, as adjusted, basis to also give effect to the sale of &nbsp;&nbsp; ordinary shares in this offering at the initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the range set forth on the cover page of this prospectus), after deducting underwriting discounts and commissions and estimated offering expenses payable by us, at the closing of the offering, as if the sale of the shares in each case had occurred on December 31, 2013. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You should read this table in conjunction with the sections titled &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes included elsewhere in this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="376"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=11>December 31, 2013</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black"  ROWSPAN=1 COLSPAN=1>(in thousands, except share and per share data)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Actual</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Pro forma (unaudited)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Pro Forma<BR> as adjusted (unaudited)</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ordinary shares of NIS 0.01 par value&nbsp;&#150;&nbsp;16,613,139 and 15,102,854 shares authorized at December 31, 2013 and 2012, respectively; 9,182,867 and 7,551,427 issued and outstanding shares at December 31, 2013 and 2012 respectively; 11,030,480 shares pro forma as of December 31, 2013 (unaudited)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>24</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>29</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Additional paid-in capital</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,551</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,926</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deficit accumulated during the development stage</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,400</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,400</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total shareholders&#146; equity</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>175</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,555</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total capitalization</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>175</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,555</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The outstanding share information above excludes: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">403,110 shares issuable upon the exercise of share options outstanding as of December 31, 2013; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">53,789 shares reserved as of January 26, 2014 for future grants under our equity incentive plan. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">47</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tDIL"></a>DILUTION </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If you invest in our ordinary shares, you will experience immediate and substantial dilution to the extent of the difference between the initial public offering price of our ordinary shares and the pro forma as adjusted net tangible book value (deficit) per share of our ordinary shares immediately after the offering. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our historical net tangible book value (deficit) per share is determined by dividing our total tangible assets, less total liabilities, by the actual number of outstanding ordinary shares. The historical net tangible book value (deficit) of our ordinary shares as of December 31, 2013 was $175, or $0.02 per share. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The pro forma as adjusted net tangible book value (deficit) of our ordinary shares as of December 31, 2013 was $&nbsp;&nbsp;&nbsp;&nbsp;, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. The pro forma as adjusted net tangible book value (deficit) gives effect to the sale of ordinary shares in this offering at the initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per share (the midpoint of the range set forth on the cover page of this prospectus), after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The difference between the initial public offering price and the pro forma
as adjusted net tangible book value (deficit) per share represents an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors purchasing ordinary shares in this offering. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table illustrates this dilution on a per share basis to new investors: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="405"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="62"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Assumed initial public offering price per share</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Historical net tangible book value per share before this offering, as of December 31, 2013<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Increase in net tangible book value per share attributable to new investors in this offering</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Pro forma net tangible book value per share after offering<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dilution in pro forma tangible book value per share to new investors<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If the underwriters&#146; over-allotment option to purchase additional shares from us is exercised in full, and based on the initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per share, the pro forma as adjusted net tangible book value (deficit) per share after this offering would be approximately $&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase in the pro forma net tangible book value (deficit) per share attributable to new investors would be approximately $&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution to new investors purchasing shares in this offering would be approximately $&nbsp;&nbsp;&nbsp;&nbsp; per
share. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The table below summarizes as of December 31, 2013, on the pro forma as adjusted basis described above, the number of ordinary shares we issued and sold, the total consideration we received and the average price per share (1) paid by our existing shareholders and (2) to be paid by new investors purchasing our ordinary shares in this offering at the initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per share, before deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="246"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="62"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Shares Purchased</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Total Consideration</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Average Price<BR> Per Share</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Percent</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Percent</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Existing shareholders</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>%</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>%</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>New investors</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>%</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>100</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>100</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The number of ordinary shares outstanding immediately after this offering is based on 9,182,867 ordinary shares outstanding as of December 31, 2013 and gives effect to the pro forma transactions of the sale of 1,065,076 ordinary shares on January 1, 2014 at the price of $0.95 per share and to the sale of 782,537 ordinary shares on February 6, 2014 at the price of $6.07 per share, as if the sale of the shares in each case had occurred on December 31, 2013. This number excludes: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">403,110 shares issuable upon the exercise of share options outstanding as of December 31, 2013; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">53,789 shares reserved as of January 26, 2014 for future grants under our equity incentive plan. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To the extent that new options are granted under our equity benefit plans, there will be further dilution to investors purchasing ordinary shares in this offering. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">48</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSFD"></a>SELECTED FINANCIAL DATA </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table summarizes our financial data. We have derived the following statements of operations data for the years ended December 31, 2013 and 2012 and the balance sheet data as of December 31, 2013 from our audited financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that may be expected in the future. The following summary financial data should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes included elsewhere in
this prospectus. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="440"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black"  ROWSPAN=1 COLSPAN=1>(in thousands of U.S. dollars, except share and per share amounts)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Statements of Operations Data:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>732</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>140</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>General and administrative expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>416</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>86</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Financial expense (income), net</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deemed dividend</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Loss attributable to holders of ordinary shares</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,171</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Weighted average number of ordinary shares used in computing basic and diluted net loss per share</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8,423,018</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,551,427</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="356"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="70"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="78"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=11>Year Ended December 31, 2013</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black"  ROWSPAN=1 COLSPAN=1>(in thousands of U.S. dollars)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Actual</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Pro forma (unaudited)<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Pro forma,<BR> as adjusted (unaudited)<sup>&#040;2&#041;</sup></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Balance Sheet Data:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total long-term assets</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total current liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>131</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>131</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Shareholders equity</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>175</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,555</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Gives effect to the sale of 1,065,076 ordinary shares on January 1, 2014 at the price of $0.95 per share and to the sale of 782,537 ordinary shares on February 6, 2014 at the price of $6.07 per share, as if the sale of the shares in each case had occurred on December 31, 2013. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Gives effect to the sale of &nbsp;&nbsp; ordinary shares in this offering at the initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, as if the sale had occurred on December 31, 2013. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">49</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tMDA"></a>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF<BR> FINANCIAL CONDITION AND RESULTS OF OPERATIONS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this prospectus. This discussion and other parts of the prospectus contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under &#147;Risk Factors&#148; and elsewhere in this prospectus.</I> </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Introduction </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a development-stage biopharmaceutical company focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. We seek to identify therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism. We focus on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood and for which there is no satisfactory treatment. Since our inception in 2012, we have developed and in-licensed potential treatments for
six diseases, one of which is in Phase 2 clinical studies and three of which we expect will be in Phase 2 clinical studies by late 2014 or early 2015. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our current drug candidate pipeline has been either in-licensed from academic institutions or developed internally. Our strategy is based on risk diversification through multiple therapeutic platforms, diversified clinical and pre-clinical stages of our programs, and diversified diseases addressed. We use strict selection criteria of our pipeline platforms and cost-efficient drug development. This allows us to pursue multiple programs in parallel with the goal of promptly delivering safe and effective therapies to patients in dire need. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To date, we have not generated revenue from the sale of any product, and we do not expect to generate significant revenue unless and until we obtain marketing approval of, and commercialize our product candidates. As of December 31, 2013, we had an accumulated deficit of $1.4 million. Our financing activities are described below under &#147;Liquidity and Capital Resources.&#148; </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Financial Overview </H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Operating Expenses </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our current operating expenses consist of two components&nbsp;&#151;&nbsp;research and development expenses, and general and administrative expenses. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and Development Expenses </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our research and development expenses consist primarily of cost of third party clinical consultants and expenses related to conducting clinical and preclinical trials, salaries and related personnel expenses, share-based compensation expenses, travel expenses and other research and development expenses. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect that our research and development expenses will materially increase as we plan to initiate clinical activity and prepare to conduct clinical trials in the near future. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and Administrative Expenses </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and administrative expenses consist primarily of salaries, share-based compensation expense, professional service fees for accounting, legal, bookkeeping and facilities, travel expenses and other general and administrative expenses. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect our general and administrative expenses, such as accounting and legal fees, to increase after we become a U.S. public company, and we expect increases in the number of our executive, accounting and administrative personnel due to the anticipated growth of our company. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Financial Expense and Income </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Financial expense and income consist of bank fees and other transactional costs and exchange rate differences. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">50</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Critical Accounting Policies and Estimate </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We describe our significant accounting policies more fully in Note 2 to our financial statements for the year ended December 31, 2013. We believe that the accounting policies below are critical in order to fully understand and evaluate our financial condition and results of operations. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We prepare our financial statements in accordance with accounting principles generally accepted in the United States (&#147;U.S. GAAP&#148;). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. Our management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">JOBS Act </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">On April 5, 2012, the U.S. Congress enacted the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Section 107 of the JOBS Act provides that an &#147;emerging growth company&#148; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This means that an &#147;emerging growth company&#148; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are electing to delay such adoption of new or revised accounting standards. As a result, our financial
statements may not be comparable to companies that comply with the public company effective date. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Subject to certain conditions set forth in the JOBS Act, as an &#147;emerging growth company&#148;, we intend to rely on other exemptions, including without limitation, (i) providing an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section 404 and (ii) complying with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (auditor discussion and analysis). These exemptions will apply for a period of five years
following the completion of our initial public offering or until we are no longer an &#147;emerging growth company.&#148; </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Stock-Based Compensation and Fair Value of Ordinary Shares </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We account for stock-based compensation in accordance with ASC 718, &#147;Compensation&nbsp;&#151;&nbsp;Stock Compensation,&#148; which requires companies to estimate the fair values of equity-based payments awards on the date of grant using an option-pricing model. The value of the stock options is recognized as an expense over the requisite service periods in our statement of operations. We recognize compensation expenses for the value of our awards granted based on the accelerated method over the requisite service period of each of the awards. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The fair value of the ordinary shares was based on the application of Option-Pricing Method (&#147;OPM&#148;). The first step in performing a valuation using OPM involves estimating the fair value of the total shareholders&#146; equity (capital instruments). As part of our analysis, we used recent investment rounds, respectively to the option valuation dates, in our shares in order to evaluate the fair value of our total shareholders&#146; equity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the option-pricing method, we estimated the fair value of the ordinary shares as the net value of a series of call options, representing the present value of the expected future returns to the ordinary shareholders. Essentially, the rights of the ordinary shareholders are equivalent to a call option on any value of the Company above the respective preferred shareholders&#146; liquidation preferences, with adjustment to account for the rights retained by the preferred shareholders related to their share in any value above the values at which they would convert to ordinary shares. Thus, the ordinary shares were valued by
estimating the value of its share in each of these call option rights. As all options were granted at par value and the exercise price is negligible, the fair value of the options is equal to the share price. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">51</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Results of Operations </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="440"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=7><FONT STYLE="font-weight: normal">(in thousands US$)</FONT></TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>732</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>140</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>General and administrative expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>416</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>86</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Operating loss</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,148</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>226</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Financial Expense (income), net</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Loss</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,145</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deemed dividend</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Loss attributable to holders of ordinary shares</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,171</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Comparison of the Year Ended December 31, 2013 to the Year Ended December 31, 2012 </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development expenses </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table discloses the breakdown of research and development expenses for the last two fiscal years. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="458"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="54"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="62"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=7><FONT STYLE="font-weight: normal">(in thousands US$)</FONT></TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cost to third-party clinical consultants and expenses related to conducting clinical and preclinical trials</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>470</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>75</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Salaries and related personnel</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>171</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>34</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Share-based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>44</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Travel</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>31</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>8</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Other</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>16</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>23</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>732</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>140</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our research and development expenses for the year ended December 31, 2013 amounted to $732,000, representing an increase of $592,000, or 423%, compared to $140,000 for the year ended December 31, 2012. The increase was primarily attributable to an increase of expenses related to third party preclinical consultants and other expenses related to conducting preclinical trials in an amount of $395,000 and to an increase of salaries and related personnel expenses in an amount of $137,000 reflecting an increase in the number of employees engaged in research and development related activities from one to three, in addition an
increase of stock based compensation expenses of $44,000 in 2013 from $0 in 2012. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Project expenses by project </H3>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="360"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Change<BR> %</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=7><FONT STYLE="font-weight: normal">(in thousands US$)</FONT></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cabaletta projects:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>OPMD</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>407</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>100</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>SCA3</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>39</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>100</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>SBMA</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>22</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>100</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>mPRT projects:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Freiedrich&#146;s A taxia</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>75</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>64</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>17</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>OTC def</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>94</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>64</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>47</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Read-through project:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>SMA</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>48</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>12</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>300</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Other costs</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>47</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>100</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>732</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>140</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">52</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our research and development expense is highly dependent on the development phases of our projects and therefore fluctuates highly from year to year. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The variances in expense between the year ended December 31, 2013 and the corresponding period in 2012 are mainly due to the following projects: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Cabaleta projects</I>.&nbsp;&nbsp;Our expenses related to OPMD, SCA3 and SBMA for the year ended December 31, 2013 amounted to $407,000, $39,000 and $22,000, respectively. These projects were initiated in 2013; therefore, there were no expenses in 2012. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>mPRT projects</I>.&nbsp;&nbsp;Our expenses related to Freiedrich&#146;s Ataxia and OTC def for the year ended December 31, 2013 amounted to $75,000 and $94,000, respectively, representing an increase of $11,000 and $30,000, or 17% and 47%, respectively, compared to $64,000 for the year ended December 31, 2012. The increase was primarily attributable to an increase in the number of employees involved in this project from one to two and to an increase in the activity. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Read-through project</I>.&nbsp;&nbsp;Our expenses related to SMA for the year ended December 31, 2013 amounted to $48,000, representing an increase of $36,000, or 300%, compared to $12,000 for the year ended December 31, 2012. The increase was primarily attributable to an increase in the number of employees involved in this project from one to two and to the initiation of pre-clinical trials. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Other costs</I>.&nbsp;&nbsp;We incurred costs associated with our research and development that are allocated to projects that were terminated. </TD>

</TR>

</TABLE>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General and administrative expenses </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our general and administrative expenses totaled $416,000 for the year ended December 31, 2013, an increase of $330,000, or 384%, compared to $86,000 for the year ended December 31, 2012. The increase resulted primarily from an increase of $201,000 in share-based compensation expenses, an increase of payroll in an amount of $48,000 reflecting an increase of payroll to our employees, and an increase of $43,000 in professional services. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Operating loss </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a result of the foregoing, our operating loss for the year ended December 31, 2013 was $1,148,000, as compared to an operating loss of $226,000 for the year ended December 31, 2012, an increase of $922,000, or 408%. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Financial expense and income </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We recognized financial income of $3,000 for the year ended December 31, 2013, compared to financial expenses of $3,000 for the year ended December 31, 2012. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Loss </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As a result of the foregoing, our loss for the year ended December 31, 2013 was $1,145,000, as compared to $229,000 for the year ended December 31, 2012, an increase of $916,000 or 400%. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Liquidity and Capital Resources </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Overview </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Since our inception through December 31, 2013, we have funded our operations principally with $1.3 million from the issuance of ordinary and preferred shares. As of December 31, 2013, we had $270,000 in cash and cash equivalents. Subsequent to the year end, on January 1, 2014 in connection with the share purchase agreement dated June 2013, we issued 1,065,076 ordinary shares for a total consideration of $1,012,000. In addition, on February 6, 2014 we issued 782,537 ordinary shares to investors for a total consideration of $4,368,000, net. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">53</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The table below presents our cash flows for the years 2013 and 2012: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="386"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Years Ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=7><FONT STYLE="font-weight: normal">(in thousands US$)</FONT></TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Operating activities</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(865</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(149</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Investing activities</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Financing activities</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>991</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>295</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net increase in cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>124</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>146</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Operating Activities </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash used in operating activities of $0.9 million during the year ended December 31, 2013 was primarily used for payment of $0.6 million for clinical trials and other third party expenses and an aggregate of $0.2 million in salaries and related personnel expenses. The remaining amount of $0.1 was for travel, patent, rent and other miscellaneous expenses. Net cash used in operating activities of $0.1 million during the year ended December 31, 2012 was primarily used for salary payments and for clinical trials and other third party expenses. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Investing Activities </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash used in investing activities during 2013 primarily reflected an increase in property and equipment. In 2012, we had no investment activity. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Financing Activities </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Net cash provided by financing activities in the year ended December 31, 2013 consisted of approximately $1 million of net proceeds from issuance of ordinary shares. Net cash provided by financing activities in the year ended December 31, 2012 consisted of approximately $0.3 million of net proceeds from issuance of shares. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Current Outlook </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have financed our operations to date primarily through proceeds from sales of our shares. We have incurred losses and generated negative cash flows from operations since inception. To date, we have not generated any revenue from the sale of products and we do not expect to generate revenues from sale of our products in the next few years. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our independent registered public accounting firm&#146;s report to our financial reports for the fiscal year ended December 31, 2013, states that there is a substantial doubt that we will be able to continue as a going concern. Furthermore, according to our estimates, based on our budget, if we are not successful in obtaining additional capital resources, there is a substantial doubt that we will be able to continue our activities after December 31, 2014. Even if we are able to raise funds in the offering contemplated herein, we believe that we will need to raise additional funds before we generate positive cash flow from
operations. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2013, our cash, cash equivalents totaled $0.3 million. On January 1, 2014 we issued 1,065,076 ordinary shares for a total consideration of $1,012,000. In addition, on February 6, 2014 we issued 782,537 ordinary shares to investors for a total consideration of $4,368,000, net. We believe that our existing cash resources and the net proceeds from the current offering will be sufficient to fund our projected cash requirements approximately through the conclusion of 2015. Nevertheless, we will require significant additional financing in the future to fund our operations if and when we obtain regulatory approval
and commercialize our drugs. We currently anticipate that, assuming consummation of the current offering, we will utilize approximately $&nbsp;&nbsp;&nbsp;&nbsp; million for clinical trial activities over the course of the next 30 months. We also anticipate utilizing approximately between $1 million to $3 million for capital expenditures over such 30-month period, which consists primarily of expenditures for the manufacture of our drug candidate for use in clinical trials and supporting preclinical studies required for obtaining approval to conduct such clinical studies. Our future capital requirements will depend on many factors, including: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the progress and costs of our preclinical studies, clinical trials and other research and development activities; </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">54</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the scope, prioritization and number of our clinical trials and other research and development programs; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs and timing of obtaining regulatory approval for our drug candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs of, and timing for, strengthening our manufacturing agreements for production of sufficient clinical and commercial quantities of our drug candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the costs of acquiring or undertaking the development and commercialization efforts for additional, future therapeutic applications of our drug candidates; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the magnitude of our general and administrative expenses; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">any cost that we may incur under current and future in- and out-licensing arrangements relating to our drug candidates. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through the net proceeds from the current offering, debt or equity financings, or by out-licensing applications of our drug candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to, one or more applications of our drug candidates. This may raise substantial doubts about the Company&#146;s ability to continue
as a going concern. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Contractual Obligations </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table summarizes our significant contractual obligations at December 31, 2013: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="200"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Less than<BR> 1 year</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>1&nbsp;&#150;&nbsp;3 years</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>4&nbsp;&#150;&nbsp;5 years</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>More than<BR> 5 years</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=19><FONT STYLE="font-weight: normal">(in thousands US$)</FONT></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Operating leases:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Facility</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Motor Vehicles</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>39</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>39</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">During the year ended December 31, 2013, we engaged with few service providers and vendors. However, we do not deem such engagements as significant compared with our current financial resources. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Off-Balance Sheet Arrangements </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently do not have any off-balance sheet arrangements. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Quantitative and Qualitative Disclosure About Market Risk </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of foreign currency exchange rates. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Foreign Currency Exchange Risk </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our results of operations and cash flow are subject to fluctuations due to changes in foreign currency exchange rates. Certain of our expenses are denominated in New Israeli Shekels. Our results of operations and cash flow are, therefore, subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. Approximately 40% of our expenses are denominated in New Israeli Shekel. Changes of 5% and 10% in the USD/NIS exchange rate will increase/decrease the operation expenses by 2% and 4%, respectively. We do not hedge our foreign currency
exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">55</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tBUS"></a>BUSINESS </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Overview </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are a development-stage biopharmaceutical company focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. We seek to identify therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. We focus on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood and for which there is no satisfactory treatment. Since
our inception in 2012, we have developed and in-licensed potential treatments for six diseases, one of which is in Phase 2 clinical studies and three of which we expect will be in Phase 2 clinical studies by late 2014 or early 2015. We have not yet submitted any investigational new drug applications for our products to the FDA. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our current drug candidate pipeline has been either in-licensed from academic institutions or developed internally. Our strategy is based on risk diversification through multiple therapeutic platforms, diversified clinical and pre-clinical stages of our programs, and diversified diseases addressed. We use strict selection criteria of our pipeline platforms and cost-efficient drug development. This allows us to pursue multiple programs in parallel with the goal of promptly delivering safe and effective therapies to patients in dire need. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In order to implement our strategy we are following three principles: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Strict selection criteria of our platforms and clinical programs; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Risk diversification through multiple platforms, clinical programs and stages of development; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Variable lean cost structure. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe that our strategy and special business operation model is especially suitable for commercializing effective and safe products in a timely and cost efficient manner. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Strict selection criteria of our platforms and clinical program. </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We target rare and ultra-rare diseases that: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">cause severely shortened life expectancy or severe debilitation; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">do not have an approved and effective therapy currently available; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">have a drug candidate that we believe will either be lifesaving or significantly ameliorate the disease course; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">have tangible and validated tests where initial efficacy can be demonstrated in a reasonable time frame to show initial efficacy; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">preferably have validated biomarkers and where there is availability of a natural history study. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As part of this selection process, we: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">estimate the scope and availability of research tools for the preclinical studies required; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">limit the diseases selected to those in which the full pre-clinical tool kit is available or can be obtained through collaboration with patients organizations; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">estimate the size and structure of the clinical studies that will be required and confine our selections to fit what we believe will be a cost effective program that will not require unreasonable financial resources; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">select diseases in which the regulatory path to approval is clear and well defined; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">strictly evaluate the strength of the intellectual property that we license for further development; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">estimate the required chemistry, manufacturing and control, or CMC, development program; </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">56</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">exclude drug candidates that are known to have any safety issues and prefer, when possible and feasible to repurposed drugs; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">part of our screening and selection criteria involves the key opinion leaders and the advocacy group for the specific disease we are considering, and our decision to move forward is often taken in consensus with them. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Because these diseases are rare or ultra-rare, no prenatal diagnosis is widely offered that might reduce the incidence of the diseases. Optimally, our target diseases have geographic clusters around a small number of clinics with sufficient number of patients to avoid large multicenter studies. Due to our location in Israel we focus on such diseases for which we can find a disease cluster in Israel where we can start a proof of concept study promptly. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risk diversification through multiple platforms, clinical programs and stages of development. </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Drug development is a complex and unpredictable process with multiple risks. We believe that a biopharmaceutical company such as ours should diversify the inherent risk associated with drug development. Drug development occurs in preclinical and clinical stages, each of which must satisfy separate criteria with different risks, including safety and efficacy. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have begun to diversify risk by initially focusing on three therapeutic platforms, each of them can be applied to several diseases. In each case, we have identified a lead program, but we believe we have the opportunity to benefit from the shorter and less expansive route to additional indications based on the same platform. In addition there are different risks associated with the development of a small molecule drug, a biological drug, or a repurposed drug. Our portfolio is comprised of all three therefore balancing the systematic risk associated with it. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Variable lean cost structure. </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe in keeping a small, select and highly professional core team at our Company while relying on experienced service providers and CRO&#146;s to result in an efficient and time&nbsp;&#150;&nbsp;saving development process. We carefully screen our service providers and CRO&#146;s for their expertise in the specific project required and work with them closely to complete the task assigned to them efficiently and professionally. This business operation model enables us to develop multiple programs while avoiding the exorbitant costs associated with learning curve, setup times, and high fixed costs associated with in-house
development. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our current pipeline is based on three platforms: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Cabaletta </I>is a mutant protein stabilizing platform based on a small repurposed molecules, Trehalose, which is currently used as an excipient for IV protein drugs. We are currently conducting a Phase 2 clinical trial to assess its efficacy in treating Oculopharyngeal Muscular Dystropy (OPMD). Subject to regulatory approval, we plan to begin conduct two additional Phase 2 studies, one in late 2014, aimed at Machado Joseph disease, or SCA3 and one in 2015 aimed at Kennedy&#146;s disease, or SBMA. Mutant unstable cellular proteins are the cause of several genetic diseases known as PolyA/PolyQ, including OPMD, SBMA and SCA3. These pathological proteins aggregate within cells, eventually leading to cell death. Our data to date from preclinical studies from both cells and animal models, indicates that our Cabaletta platform has the potential to prevent mutant protein aggregation in humans. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>mPRT </I>is a mitochondrial protein replacement platform that is based on biological components that we synthesize in bacteria. Mitochondria are cell components that supply chemical energy for normal cell functioning. This platform is currently in preclinical development for two diseases: Friedrich&#146;s Ataxia and Ornithine Transcarbamylase Deficiency. These diseases are among over 100 genetic diseases that are caused by a missing or mutant protein that has critical role in the normal mitochondrial function. While lysosomal protein replacement platforms have been successful in replacing a missing protein in lysosomes, we believe that our mPRT platform is the first one to be successful in replacing mitochondrial proteins. Our product candidates are new &#147;fusion proteins&#148; that are a combination of the replaced protein fused with two additional sequences that facilitate its transport through biological membranes. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">57</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>BBrm </I>is our read-through platform based on a small repurposed molecule. The platform enables the read-through (or bypassing) of genetic defects called nonsense mutations or stop codons that interfere with normal protein formation and cause disease. Based on our preclinical data, we believe that this drug platform has the potential to treat six different diseases caused by nonsense mutation. Subject to regulatory approval, we plan to conduct Phase 2 clinical studies in late 2014 for our lead indication in Spinal Muscular Atrophy (SMA). </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table summarizes our product candidate pipeline: </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_chrt-shade.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Product Candidates&nbsp;&#151;&nbsp;Overview </H2>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cabaletta for the treatment of Oculopharyngeal Muscular Dystropy (OPMD) </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cabaletta is our proprietary intravenous (IV) solution of Trehalose for the treatment of OPMD. OPMD is an inherited myopathy, which is a muscle disease caused by a primary defect in muscle cells, characterized by dysphagia (difficulty in swallowing), the loss of muscular strength and weakness in multiple parts of the body. As the dysphagia becomes more severe, patients become malnourished, lose significant weight, become dehydrated and suffer from repeated incidents of aspiration pneumonia. These last two are often the cause of death. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Trehalose is naturally occurring and is well known for its protein-stabilizing properties. It is used in several biological systems, such as freeze drying of red blood cells and the preservation of organs for donation and as a protein stabilizer in IV pharmaceutical products. Trehalose is approved by the FDA as a GRAS (Generally Recognized As Safe) food ingredient and is listed in the U.S. National Formulary, which is a compendium of public pharmacopeial standards, which are directions for the identification of compound medicines, as well as in Europe and Japan. It is a disaccharide chemical chaperone, which is a chemical
molecule comprised of two sugar components that stabilizes the folding of proteins and buffer abnormal protein aggregation, that protects against pathological processes in cells. It has been shown to prevent pathological aggregation of proteins within cells in several diseases associated with abnormal cellular-protein aggregation as well as acting as an autophagy enhancer. Autophagy is the basic catabolic mechanism that involves cell degradation of unnecessary or dysfunctional cellular components. Autophagy, if regulated, ensures the synthesis, degradation and recycling of cellular components. Trehalose has been documented as demonstrating significant efficacy in preclinical animal models of OPMD and other PolyA/PolyQ diseases. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Trehalose is not effective when given orally since it is almost completely metabolized in the small intestine into glucose and often causes diarrhea and flatulence after ingestion of more than 50g. We have </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">58</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">developed a proprietary IV solution of Trehalose, which we call Cabaletta<sup>TM</sup> to circumvent the breakdown of Trehalose in the gastrointestinal tract, and to enable therapeutic doses of Trehalose to reach the muscles. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have recently started our Phase 2 clinical trial of Cabaletta to treat OPMD in Israel, and, if successful and subject to regulatory approval, are planning to expand the study to the United States and Canada later in 2014. The study is an adaptive design study that will include 35&nbsp;&#150;&nbsp;40 patients in two dosage arms (weekly IV of 15&nbsp;&#150;&nbsp;30g Cabaletta respectively). Patients will be followed up to 18 months for safety tolerability and efficacy. Clinical endpoint will be focused on effect of dysphagia parameters and muscle weakness as well as patients&#146; reported quality of life. The HOPEMD study
will be a multicenter study with one center in Israel and two centers in North America. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cabaletta for the treatment of spinocerebellar ataxia type 3 (SCA3) (Machado Joseph disease) </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SCA3, also known as Machado Joseph disease, is the most common disease among the cerebellar ataxias, which are a group of genetic diseases that are characterized by memory deficits, spasticity, difficulty with speech and swallowing, weakness in arms and other muscular disorders. Symptoms can begin in early adolescence and get worse over time. Eventually SCA3 leads to paralysis, and severe cases can lead to an early death in the fourth decade of life. SCA3 is incurable, and there is currently no approved treatment for the disease. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SCA3 is caused by a mutation in the DNA that leads to the creation of a pathological protein&nbsp;&#151;&nbsp; Ataxin 3. Ataxin 3 is unstable, meaning that it aggregates within the cells and eventually leads to cell death. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Multiple reported studies in cell models have shown that Trehalose, both as an anti-mutant protein aggregation agent and as an autophagy enhancer, is able to reduce protein aggregates and improve cell survival in several spinocerebellar ataxias including SCA3 cells. Additional animal studies show that activation of autophagy may be beneficial in alleviating disease symptoms. We are now conducting more advanced proof-of-concept preclinical studies of this process and, if successful and subject to regulatory approval, expect to start a Phase 2 study late in 2014. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cabaletta for the treatment of Spino Bulbar Cerebellar Ataxia (SBMA&nbsp;&#151;&nbsp;<I>Kennedy&#146;s disease) </I></H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SBMA, also known as Kennedy&#146;s disease, is characterized by the degeneration and loss of lower motor neurons in the brainstem and spinal cord. Patients present with weakness in muscle function, including severe difficulty in swallowing and suffer from repeated aspiration pneumonia, and other symptoms. SBMA is caused by an abnormal androgen receptor (AR) protein. Like other PolyA/PolyQ diseases, the abnormal protein is unstable and aggregates within cells, eventually leading to cell death. Patients suffering from SBMA suffer from progressive neuromuscular deterioration that can end up in extreme disability and repeated
aspiration pneumonia. There is currently no approved therapy for SBMA. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Studies in cell models have shown that Trehalose in its capacity both as an anti-mutant protein aggregation and as an autophagy enhancer is able to reduce protein aggregates and improve cell survival in SBMA cells. Additional studies show that activation of autophagy may be beneficial in alleviating disease symptoms in animal models. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have signed an agreement with MINDS (a group within the U.S. National Institutes of Health, or NIH) pursuant to which MINDS will conduct animal studies on SBMA mouse models to validate the potential efficacy of Cabaletta. MINDS will conduct the study using its own resources, and we will supply the research material. We have retained all intellectual property and commercialization rights for this indication, and if the animal studies are successful and subject to regulatory approval, we will commence Phase 2/3 clinical trials. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Mitochondrial protein replacement platform (mPRT) </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Mitochondrial disorders are diseases, for which no cure has been found, that stem from a missing or mutated critical enzyme or protein in the cell organelle called mitochondria. Our fusion proteins, comprised of TAT-MTS(het)-replacement proteins, help move proteins across biological membranes to facilitate the creation of mature proteins inside the mitochondria. Our replacement proteins are able to enter human cells and mitochondria and replace the damaged or missing proteins in the mitochondria. Our breakthrough platform technology demonstrated efficacy in several mitochondrial protein deficiencies in cells and animal models.
</P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">59</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Currently, Frataxin for Friedrich&#146;s Ataxia (BB-FA) is our most advanced mPRT preclinical program, followed by Ornithine Transcarbamylase (BB-OTC) for Ornithine Transcarbamylase Deficiency (OTCD). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our studies demonstrated the superiority of our proprietary approach of using a heterologous (none native) mitochondrial targeting sequence (MTS) as part of our fusion proteins in four different aspects: expression by bacteria, cell penetration, mitochondrial processing and anchorage of target proteins, and rescue of cells in oxidative stress. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have an exclusive worldwide and royalty-bearing license to the technology, including certain patent applications, from the Hebrew University in Jerusalem. These patent applications cover our unique approach of using homologous and heterologous MTS in the fusion proteins. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BB-FA for the treatment of Friedrich&#146;s Ataxia </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Friedreich&#146;s Ataxia is an inherited disease characterized by progressive deterioration of muscles and nerves, resulting in gait disturbance (Ataxia), cognitive impairment, progressive heart disease and diabetes. Patients are typically diagnosed in the first or second decade of life, and are wheelchair-bound within 15 years of diagnosis. Most do not survive beyond the fourth decade of life. In many cases the cause of death is myopathic heart disease. The underlying causes of Friedrich&#146;s Ataxia are reduced levels of Frataxin&nbsp;&#151;&nbsp;a protein responsible for iron-sulphor clusters in the mitochondria that are
critical for the mitochondria activity. Our preclinical data demonstrated successful placement of Frataxin into the mitochondria and in the treatment of oxidative stress in Friedreich&#146;s Ataxia patients&#146; cells. We are advancing the Friedreich&#146;s Ataxia program through its preclinical development during 2014. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BB-OTC for the treatment of ornithine transcarbamylase deficiency (OTCD) </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">OTCD is the most common disorder among urea cycle disorders&nbsp;&#151;&nbsp;a group of rare genetic diseases characterized by body&#146;s inability to detoxify ammonia. Ammonia is a toxic breakdown product of proteins. OTCD is caused by a mutated and ineffective form of the enzyme, ornithine transcarbamylase that is part of the urea cycle complex in the mitochondria. As a result, the normal breakdown of ammonia is disrupted and toxic ammonia accumulates in the blood causing severe damage to the brain and other vital organs. Newborn males affected with OTCD may suffer devastating hepatic coma in the first few days after birth,
and survivors typically suffer from severe cognitive, mental and metabolic disorders and growth retardation. Many do not survive the first decade of life. We are using our mitochondrial protein replacement platform to replace this enzyme in the mitochondria. Our preclinical data indicates that our OTC fusion protein is well able to be transferred into the mitochondria and be processed in it. We are advancing the OTC program through its preclinical development during 2014. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BBrm&nbsp;&#151;&nbsp;our read-through platform </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BBrm is our family of small molecule non-glycosides repurposed drugs for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation (stop codon). The platform enables the read-through (deactivation) of the genetic defects that stop synthesis of normal full length proteins. Deactivation of disease-causing nonsense mutation can alleviate the symptoms of genetic diseases caused by these mutations. Our BBrm family of repurposed drugs is able to induce translational readthrough, restoring full-length functional proteins in diseases where the nonsense mutation results in
truncated ineffective proteins. We licensed the exclusive worldwide rights for our BBrm technology from the Tel Aviv University in January 2014. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BBrm1 for the treatment of Spinal Muscular Atrophy (SMA) </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Using our BBrm platform, we developed a unique therapeutic candidate for SMA. SMA is the leading genetic cause of infantile death and is caused by the loss of a functional Survival Motor Neuron 1 (SMN1). The disease is manifested by loss of muscle mass and mobility as well as severe compromise of vital functions such as respiration. Another protein called SMN2 is a nearly identical copy of SMN1, differentiated only by a silent, single-nucleotide mutation within the DNA. SMN2 partially compensates for the dysfunction of SMN1, however the small amount of the functional protein that is produced from the SMN2 gene is not able to
fully compensate for the loss of SMN1. Prior independent studies proposed that read-through agents, such as aminoglycosides, can induce the read-through of the stop codon located in the SMN2- protein, thus elongating the SMN2 and creating a full length functional protein, that can compensate for the </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">60</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">non-functioning SMN1 and alleviate the disease. This approach was also successfully tested in SMA animal models. Nonetheless, chronic administration of aminoglycosides was found to be associated with prohibitive toxicity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Nevertheless, drug-induced read-through of premature stop codons remains a promising approach to elevate active protein expression from the SMN2 gene which is an ideal therapeutic target as it is found in all SMA patients. Our family of repurposed FDA-approved non-glycosides molecules (BBrm) induced significantly higher levels of full length functional SMN2 protein. These molecules are ineffective if administered orally or intravenously since they do not penetrate into the brain to create high enough therapeutic levels within nerve cells. Our BBrm1 product can be injected directly into the central nervous system (CNS),
creating adequate drug concentration. This method of administration has the added benefit of further protection against off label use. We plan to continue our preclinical development of BBrm1 for SMA through 2014, and, if successful and subject to regulatory approval, expect to start a Phase 2 study late in 2014 or early in 2015. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our current product candidate pipeline has been either in-licensed from academic institutions or developed internally. Where possible, our strategy is to acquire and retain global commercialization rights to our products to maximize long-term value. Over time, we intend to build our own commercial organization, which we believe will be of modest size due to the relatively small number of specialists who treat patients with rare and ultra-rare diseases. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The diseases which we are addressing have devastating consequences on the patient&#146;s health, quality of life and life expectancy. In addition these diseases create significant burden on the patient&#146;s family and care takers as well as on the public health resources. In all the diseases we are addressing patients cannot be offered an alternative therapy or the current solutions are inadequate in their abilities to change the course of the disease. We believe that prompt and efficient drug development can be of substantial benefit to the patients who are suffering from these incurable diseases. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have assembled an experienced team, of employees, consultants, service providers and board with extensive drug development and commercialization capabilities, particularly in the orphan drug area. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Strategy </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our strategy is to identify, acquire, license, develop, and commercialize novel products for the treatment of rare and ultra-rare diseases in the United States, the European Union, and select international markets, with the goal of becoming a leading rare disease biotechnology company. Our current product candidate pipeline has been either in-licensed from academic institutions or developed internally. Where possible, our strategy is to acquire, license and retain global commercialization rights to our products to maximize long-term value. Over time, we intend to build our own commercial organization, which we believe will be
of modest size due to the relatively small number of specialists who treat patients with rare and ultra-rare diseases. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The patients we seek to treat have diseases with limited or no treatment options, and their lives and well-being are highly dependent upon our efforts to develop new therapies. We strive to build a company that is faster, better and smarter about advancing multiple product candidates through approval. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The critical components of our business strategy include the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Focus on rare and ultra-rare diseases with significant unmet medical need</I>.&nbsp;&nbsp;There are numerous rare and ultra-rare metabolic genetic diseases that currently have no approved drug therapy and for which no therapies, to our knowledge, are currently in development. Patients suffering from these diseases often have a high unmet medical need with significant morbidity and/or mortality. We are focused on developing and commercializing therapies for multiple such indications. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Focus on diseases and therapies with clear mechanisms of action</I>.&nbsp;&nbsp;We also focus on diseases that have biology and root causes that are well understood. For example, several of our product candidates are replacement therapies for a single deficient enzyme or substrate in the body. We believe that developing drugs that directly impact known disease pathways will increase the probability of success of our development programs. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">61</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Leverage our experience and relationships to in-license promising product candidates</I>.&nbsp;&nbsp;Our management and board has strong relationships with key opinion leaders in the metabolic genetic field, as well as a history of success in the development and commercialization of therapies for rare and ultra-rare genetic diseases. Accordingly, we enjoy excellent access to many in-licensing opportunities. Most of our current product candidates are in-licensed from academic institutions. We believe these parties have agreed to license product candidates to us because they are confident in our drug development capabilities and experience in bringing rare disease therapies to market. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Develop and commercialize multiple product candidates in parallel</I>.&nbsp;&nbsp;Clinical studies for rare and ultra-rare diseases can often be smaller, fewer in number, and less expensive than those for larger market indications. Development of multiple programs in the metabolic genetics field also generates organizational efficiencies and economies of scale. As a result of these efficiencies, we can feasibly develop multiple clinical-stage product candidates in parallel, resulting in a more diversified portfolio that provides multiple opportunities to create value. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Focus on excellent and rapid clinical and regulatory execution</I>.&nbsp;&nbsp; We believe that building a successful and sustainable rare disease-focused company requires very specific expertise in the areas of patient identification, clinical study design and conduct, and regulatory strategy. We have assembled a team with a successful track record in managing global clinical development activities in an efficient manner, and with multinational experience in obtaining regulatory approvals for rare disease products. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Seek to retain global commercialization rights to product candidates</I>.&nbsp;&nbsp; We intend to seek and retain global commercialization rights to our product candidates whenever possible to maximize the potential value of our product portfolio. Our plan is to establish our own commercial organization in major pharmaceutical markets and develop a network of third-party distributors in smaller markets. We believe this commercial organization can be modest and targeted due to the relatively small number of specialists who typically treat patients with the diseases to be addressed by our product candidates. As a result, we do not expect that we will require pharmaceutical partners for commercialization of our product candidates, although we may consider partnering for certain territories or indications or for other strategic purposes. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Product Candidates&nbsp;&#151;&nbsp;Disease background, rationale for treatment, development plan and market potential </H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Oculopharyngeal Muscular Dystropy (OPMD): </H2>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Disease background: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">OPMD is a rare inherited myopathy characterized by dysphagia (difficulty in swallowing), the loss of muscular strength and weakness in multiple parts of the body. Patients typically suffer from severe dysphagia, ptosis (eye lid drooping), tongue atrophy, lower limb proximal weakness, dysphonia (altered and weak voice), limitation in looking upward, facial muscle weakness and upper limb proximal weakness. The disease is most often diagnosed in the fifth-sixth decade of life and progresses throughout the patient&#146;s life. As the dysphagia becomes more severe, patients become malnourished, lose significant weight, become
dehydrated and suffer from repeated incidents of aspiration pneumonia. These last two are often the cause of death. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">OPMD is one of a larger group of diseases called tri-nucleotide repeat disease that are associated with the presence of an abnormal cellular protein, that aggregates in the cells eventually causing cell death. In OPMD the mutant protein PABPN1 was found to be correlated with disease severity in animal models and was identified within the typical cellular protein aggregates-the intranuclear inclusion body (INI) that are the diagnostic hallmark of the disease. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There is no medical treatment or, to our knowledge, potential cure for OPMD. Current therapeutic strategies are confined to surgical interventions that have limited efficacy and need to repeated often while the progressive loss of muscle&#146;s contractility continue relentlessly. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Rationale for treatment: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The naturally occurring disaccharide Trehalose is well known for its protein-stabilizing properties. It is used extensively in many applications as a stabilizer of frozen food, in freeze drying of biological systems and </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">62</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">cells, as a stabilizer of therapeutic parenteral proteins and as an excipient in tablets and intravenous (IV) solutions. Trehalose has been shown to prevent pathological aggregation of proteins within cells in several diseases associated with mutant cellular-protein aggregation such as PolyA/PolyQ and taupathy diseases (for example OPMD, Huntington&#146;s disease, Spinocerebellar ataxia, Parkinson and Alzheimer disease and more). Recent studies demonstrated that Trehalose enhances autophagy&nbsp;&#151;&nbsp;a natural mechanism of debris-clearance within cells.</P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_tpg61.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Trehalose was found to be effective in cell studies and in a mouse model of OPMD. In this disease there are characteristic intracellular aggregations of the abnormal protein PABPN1 (INI). Animal studies showed a direct correlation between reduction of mutant PABPN1 aggregates (INI) in cells and reduced cell death. Trehalose effectively reduced the aggregation and toxicity of mutant PABPN1 proteins in OPMD cell models. Furthermore, treatment of an OPMD mouse model with Trehalose resulted in the attenuation of muscle weakness, decreased aggregate formation and a reduced number of TUNEL-positive nuclei in skeletal muscle fibers.
</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Like all disaccharides, Trehalose is metabolized at the epithelial brush border of the intestine into two D-glucose molecules. Less than 0.5% of ingested Trehalose is absorbed into the blood stream where it is further metabolized by the liver and kidney. Oral Trehalose in amounts exceeding 40&nbsp;&#150;&nbsp;50 g per day causes diarrhea, bloating and abdominal pain. To achieve therapeutic amounts of Trehalose in the muscle cells, it is necessary to circumvent the massive metabolism in the gastrointestinal (GI) tract. Cabaletta is our proprietary IV formulation of Trehalose developed for the treatment of diseases characterized
by unstable mutant protein aggregates causing cellular damage and eventually cell death. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Trehalose was approved by the FDA EMEA and several other authorities as GRAS food ingredient and is also registered on the US National Formulary, as well as in Europe and Japan. Its safety in preclinical studies was extensively researched and validated. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Clinical development plan: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our ongoing clinical plan will include eventually three centers in an adaptive design study that will look at the safety and efficacy of Trehalose in OPMD patients across centers in Israel and North America. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">63</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The study is an adaptive design study that will include 35 to 40 patients in two dosage arms (weekly IV of 15&nbsp;&#150;&nbsp;30g Cabaletta respectively). Patients will be followed up to 18 months for safety tolerability and efficacy. Clinical endpoint will be focused on effect of dysphagia parameters and muscle weakness as well as patients&#146; reported quality of life. The HOPEMD study will be a multicenter study with one center in Israel, one center in the United States and one center in Canada.
</P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The market potential for OPMD: </H4>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The prevalence of OPMD is estimated at 1:100,000. The disease is more prevalent among people of French Canadian origin residing in Canada and in the U.S., and among Hispanics in New Mexico, Arizona and the other south western states of the U.S. and in Israel. The prevalence of OPMD among French Canadians in the Montreal, Canada area is 1:1,000. There are estimated 4,000&nbsp;&#150;&nbsp;5,000 patients in Canada. In Israel, the prevalence of OPMD among Bukharean Jews is 1:700. There are estimated 1,200&nbsp;&#150;&nbsp;1,500 patients in Israel. It has been reported to occur in 33 countries in the world. In the United States,
the estimated number of patients is less than 6,000. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Spinocerebellar Ataxia type 3 ( Machado Joseph disease) </H2>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Disease background: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Spinocerebellar ataxia Type 3 (SCA3), also known as Machado-Joseph disease, is a dominantly inherited ataxia, and is the most common disease among the cerebellar ataxias. SCA3 is characterized by memory deficits, clumsiness in movements in the arms and legs, unstable gait, difficulty with speech and swallowing, impaired eye movements that may be accompanied by double vision or bulging eyes, and lower limb spasticity. In most individuals with SCA3, symptoms typically begin in the third to fifth decade of life but can start as early as young childhood or as late as 70 years of age. The cause of death is often aspiration
pneumonia. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SCA3 is a caused by a repeat expansion in the DNA code causing the creation of an abnormal and unstable cellular protein Ataxin 3. Typically the longer the expansion, the more severe the disease which may manifest earlier in life and exert a broader range of neurological symptoms. Cellular aggregations of Ataxin 3 inclusion bodies are found in SCA3 patients&#146; brain and nerve cells. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There is no medical treatment for SCA3 and current approaches are focused on alleviating disease symptoms and supportive care. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Rationale for treatment and development plan: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">It has been established that enhancement of autophagy in SCA3 is an effective approach that reduces intracellular aggregates and increase cell survivals. Trehalose was found to be effective in SCA3 cells as a stabilizer of the mutant Ataxin 3 and as an enhancer of autophagy. Animal studies to further prove the concept are now ongoing. We plan to continue our preclinical development and expect to continue to Phase II studies by the end of 2014 in Israel to be expanded later in 2015 to the United States, Europe and South America. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Market potential: </H4>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The prevalence of SCA3 is estimated as 1&nbsp;&#150;&nbsp;2 cases per 100,000 people. The prevalence of the disease is highest among people of Portuguese/Azorean descent. For example, among immigrants of Portuguese ancestry in New England, the prevalence is around one in 4,000, and the highest prevalence in the world, about one in 140, occurs on the small Azorean island of Flores. There are an estimated 4,000 to 6,000 patients in the United States, and an estimated 2,000 patients in each of Portugal and Brazil. SCA3 has been reported in over a dozen European countries with a few effected families mentioned in each of the
reported case studies. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Spino Bulabr muscular atrophy (SBMA) </H2>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Disease background: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SBMA, also known as Kennedy&#146;s disease, is a rare inherited X linked disease, characterized by the degeneration and loss of lower motor neurons in the brainstem and spinal cord resulting in progressive muscle weakness, atrophy, and fasciculation. The disease is typically manifested in the fourth or fifth decade of life. Affected patients also have signs of androgen insensitivity such as gynecomastia (large male breasts), reduced fertility, and testicular atrophy. As the disease progresses, disability is increased until the patient is wheelchair </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">64</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">bound. Involvement of the bulbar musculature may be expressed as difficulty in chewing, swallowing, and speaking. Postural tremor and tremor in the upper extremities usually begins late in the course of the illness. Patient may also suffer from sensory disorders as well as symptoms related to endocrinopathy, particularly diabetes. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Rationale for treatment and development plan: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SBMA is caused by an expansion of the CAG trinucleotide repeat in exon 1 of the human androgen receptor (<I>AR</I>) gene. A disease causing protein&nbsp;&#151;&nbsp;a mutant AR (androgen receptor) have been identified in patient&#146;s cells, where it aggregates both in the cytoplasm and in the nucleus. Several studies demonstrated the ability of Trehalose as a protein stabilizer and an autophagy enhancer to protect SBMA cells from the toxic effects of the mutant AR protein. We are now conducting an a study in animal models, in collaboration with the NIH. We plan to continue our preclinical development and if successful,
expect to be in Phase II study in 2015 in the United States. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Market potential: </H4>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The estimated incidence of SBMA in the U.S. is approximately 1 case in 40,000 men, or approximately 3,775 patients. There is a general impression that SBMA may be under-diagnosed, owing in part to misdiagnosis and to the mild symptoms exhibited by some patients. The estimated prevalence in the rest of the world (Europe, Japan, Australia) is similar. Some regions, such as western Finland and Japan, may have a higher prevalence. There are an estimated 10,000 patients in Europe, 1,500 patients in Japan and 300 patients in Australia. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Friedrich&#146;s Ataxia: </H2>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Disease background: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Friedreich&#146;s ataxia is a rare inherited disease that causes muscle and nerve damage. It usually begins in childhood and is caused by progressive degeneration of the spinal cord and peripheral nerves. The cerebellum&nbsp;&#151;&nbsp;the part of the brain that coordinates balance and movement, also degenerates. This damage results in clumsy, unsteady movements and gait and impaired sensory functions. The disease also causes severe heart disease, spinal deformity and diabetes. Typically patients are diagnosed within the first two decades of life and may become wheelchair bound within 15 years of diagnosis. Life expectancy is
severely shortened and most patients do live beyond the fourth decade of life. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Friedreich&#146;s ataxia is caused by a defect (mutation) in a gene labeled FXN. As a result a protein called Frataxin is mutated and dysfunctional. Fratxin plays a pivotal role in the normal mitochondrial metabolism: Without a normal level of Frataxin, certain cells in the body (especially peripheral nerve, spinal cord, brain and heart muscle cells) cannot effectively produce energy, and buildup toxic byproducts leading to what is called &#147;oxidative stress.&#148; Frataxin deficiency may also lead to increased levels of iron in the mitochondria. When the excess iron reacts with oxygen, free radicals can be produced.
Although free radicals are essential molecules in the body&#146;s metabolism, they can also destroy cells and harm the body. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Rationale for treatment and development plan: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Unlike successful lysosomal Enzyme-Protein Replacement Therapy (ERT)- mitochondrial ERT has yet to be established. We have developed a successful mitochondrial PRT platform based on a recombinant protein containing targeting signals (TAT-MTS-protein). Our novel platform was the first proven approach towards correction of mitochondrial protein deficiency diseases. Based on our approach, PRT therapy has been studied in FA mouse model with some success, using the native mitochondrial targeting sequence (MTS) of Frataxin (MTSfa). We have made a scientific leap by replacing the native MTS with a heterologous MTS (one that is native
to another protein). Our approach was tested in preclinical studies and was found to be highly superior in four major parameters: The expression of the fusion protein by bacterial cells, the penetration of the protein into FA patient&#146;s cells, the breakout of the fusion protein into its components leaving the Frataxin protein in the mitochondria, and finally, the correction of the pathological &#147;oxidative stress&#148; of the cells. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">65</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Better expression by bacteria </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="376"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="96"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="104"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Protein</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Final concentration (mg)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount purified from 0.5 bacterial culture (mg)</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>TAT-MTSfra-FRA</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: center" ROWSPAN=1 COLSPAN=1>0.6&nbsp;-&nbsp;0.7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>TAT-MTScs-FRA</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: center" ROWSPAN=1 COLSPAN=1>3&nbsp;-&nbsp;4</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>TAT-MTSorf-FRA</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: center" ROWSPAN=1 COLSPAN=1>3&nbsp;-&nbsp;4</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>TAT-MTSlad-FRA</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.8</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: center" ROWSPAN=1 COLSPAN=1>2.4&nbsp;-&nbsp;3.2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Higher efficiency in cell rescue </P>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_chrt-bar.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We continue our preclinical development of our BB-FA candidate and will advance into full preclinical regulatory route later in 2014. We expect to start clinical studies late in 2015 in the United States and Europe. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Market potential for BB-FA: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although rare, Friedreich&#146;s ataxia is the most common form of hereditary ataxia, affecting about 1 in every 50,000 people in the United States. It is estimated that the number of Friedreich&#146;s ataxia patients in the U.S. is about 6,000, with approximately 15,000 patients worldwide. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Ornithine transcarbamylase deficiency </H2>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Disease background: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Ornithine transcarbamylase deficiency (OTCD) is the most common urea cycle disorder, a group of rare genetic metabolic disorders characterized by the body&#146;s inability to detoxify ammonia. OTCD is caused by a mutated and ineffective form of the enzyme ornithine transcarbamylase (OTC). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">OTC is one of the critical enzymes that participate in the &#147;Urea cycle&#148;&nbsp;&#151;&nbsp;a metabolic process that helps the body get rid of ammonia, the toxic breakdown product of proteins. As a result, the normal breakdown of ammonia is disrupted and toxic ammonia accumulates in the blood causing severe damage to the brain and other vital organs, especially in the highly vulnerable nervous system. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Ornithine transcarbamylase deficiency often becomes evident in the first few days of life, however it can present at middle age. The typical initial symptoms of a child with hyperammonemia are failure to feed, loss of thermoregulation with a low core temperature, and somnolence. Symptoms progress from somnolence to lethargy and coma. Abnormal posturing and encephalopathy are often related to the degree of central nervous system swelling and pressure upon the brain stem. In cases where OTC enzyme production is low or non-existent, death can occur within the first days of life. Complications from ornithine transcarbamylase
deficiency may include developmental delay and mental retardation. Progressive liver damage, skin lesions, and brittle hair may also be seen. Other symptoms include irrational behavior (caused by encephalitis), mood </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">66</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">swings, and poor performance in school. In milder (or partial) urea cycle enzyme deficiencies, ammonia accumulation may be triggered by illness or stress at almost any time of life, resulting in multiple mild elevations of plasma ammonia concentration.</P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Rationale for treatment and development plan: </H4>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_tpg65.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Loss of OTC blocks the normal metabolism of ammonia into the less toxic urea that can be cleared from the blood by the kidneys. Replacement of the missing or mutated protein can restore the normal function of the urea cycle and prevent the toxic accumulation of ammonia. Based on our PRT platform, we have developed a fusion protein that is comprised of TAT-MTS (het)-OTC. We are developing it towards proof of concept in human cells and in animal models. We continue our preclinical development and expect to start a full preclinical regulatory phase in mid 2014. We expect to start Phase I study late in 2015 in the United States
and Europe. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Market potential for BB-OTC: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The incidence of OTCD is 1 in 70,000, with approximately 4,000 patients in the United States, of which 2,000 males suffer from the severe lethal form. This incidence may be an underestimation due to under diagnosis. In some affected individuals, signs and symptoms of ornithine transcarbamylase may be less severe, and may not appear until later in life. Some female carriers become symptomatic later in life in times of metabolic stress. Despite milder presentations in adulthood, hyperammonemia, encephalopathy, cerebral edema, and death can occur. On February 1, 2013, the FDA approved RAVICTI&reg; (glycerol phenylbutyrate) Oral
Liquid for use as a nitrogen-binding agent for chronic management of adult and pediatric patients 2 years of age or older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. In clinical studies, RAVICTI was shown to be noninferior to sodium phenylbutyrate, and kept ammonia at safe levels throughout the day and night and over the long-term (1 year). Despite RAVCITI&#146;s effectiveness in lowering blood ammonia levels it has some significant limitations in that it is not approved for patients suffering from liver or kidney disease and many OTCD patients have some disturbance in liver or kidney functions. In addition, over 10% of RAVCITI users suffer from diarrhea, bloating, and abdominal pain. There exists a place for a therapy that will prevent the accumulation of ammonia in the first place. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">67</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Spinal Muscular atrophy </H2>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Disease background: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Spinal Muscular Atrophy (SMA) is a neuromuscular disorder for which there is no available therapy. SMA is the number one autosomal recessive cause of infantile death. SMA is caused by loss or mutation of the survival motor neuron 1 gene, SMN1, while the nearly identical copy gene, SMN2 is retained. In contrast to SMN1, most SMN2 transcripts lack exon 7. This alternatively spliced transcript, |gD7-SMN, translates into a prematurely terminated (truncated) protein that is rapidly degraded. It has been established that read-through of the stop codon in Axon 8 of the |gD7-SMN2 protein increases the amount of full-length
SMN2&nbsp;&#151;&nbsp;a protein that can significantly attenuate disease severity in SMA patients. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Rational for therapy and development plan: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Drug-induced read-through of the premature termination codon enables full-length translation of SMN, thus serving as an ideal therapeutic target as it is found in all SMA patients. This approach was successfully tested in SMA cells and animal models using a known family of antibiotics called aminoglycosides. Unfortunately, chronic administration of aminoglycosides is impossible due to their well-known prohibitive toxicity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our family of FDA-approved molecules (BBrm) are non-glycosides that were found to be highly superior to aminoglycosides in enabling read-through and enabling the expression of full length functional SMN2 and rescue of cells. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_chrt-barcells.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">68</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_chrt-barcells1.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We continue our preclinical development of our BBrm program and expect to start Phase II clinical study by the end of 2014 in Israel to be expanded to the United States and Europe in 2015. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Market potential for SMA: </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SMA has a carrier frequency of one in every 35 people, affecting every one in 6,000 live births. It is estimated that some 30,000 children suffer from SMA in the U.S. and in similar numbers in Europe. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There are several drugs in development for SMA; however, there is no approved therapy for this disease. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Competition </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The commercialization of new drugs is competitive, and we may face worldwide competition from individual investigators, major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, nutraceutical companies, and ultimately biosimilar and generic companies. Our competitors may develop or market therapies that are more effective, safer, or less costly than any that may be commercialized by us, or may obtain regulatory approval for their therapies more rapidly than we may obtain approval for ours. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The acquisition or licensing of pharmaceutical products is also very competitive, and a number of more established companies, which have acknowledged strategies to license or acquire products, may have competitive advantages as may other emerging companies taking similar or different approaches to product acquisitions. These established companies may have a competitive advantage over us due to their size, cash flows, and institutional experience. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With respect to our programs in Cabaletta for OPMD, although we are not aware of any other products currently in clinical development for the treatment of OPMD, it is possible that competitors may produce, develop, and commercialize therapeutics, or utilize other approaches such as gene therapy, to treat OPMD. An academic based study testing the use of injected myoblasts has completed Phase 2 study. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With respect to our programs in Cabaletta for SCA3, although we are not aware of any other products currently in clinical development for the treatment of SCA3, it is possible that competitors may produce, develop, and commercialize therapeutics, or utilize other approaches such as gene therapy, to treat SCA3. Note that in the last few years several academic researches where conducted to explore the efficacy of approved drugs such as Lithium, Varenicline (Chantix), riluzol, Dalfampridine. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">69</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With respect to our programs in Cabaletta for SBMA, Novartis is planning to conduct a Phase 2 study for its insulin resistance drug candidate BVS857 in SBMA patients. This will be a 2 years study that will look at the size of patients muscle as an endpoint. Although we are not aware of any other products currently in clinical development for the treatment of SBMA, it is possible that competitors may produce, develop, and commercialize therapeutics, or utilize other approaches such as gene therapy to
treat SBMA. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Although we believe that Cabaletta should be considered a drug and that only insignificant amounts of Trehalose can be absorbed through an oral administration&nbsp;&#151;&nbsp;it is possible that other companies or individuals may attempt to use food grade Trehalose as a substitute, and others may attempt to sell the product via a nutraceutical or food pathway. We believe that following the approval of our patent applications, if approved, we will be well protected in our IP from the use of Trehalose as an IV product. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With respect to our programs in protein replacement platform although we are not aware of any other similar products currently in clinical development for the treatment of Friedrich&#146;s Ataxia, there are a number of competitors trying to develop and commercialize therapeutics, or utilize other approaches such as mitochondria protecting agents, anti-oxidants, HDAC inhibitors, cell therapy or gene therapy, to treat Friedrich&#146;s Ataxia. The table below described, to our knowledge, the current therapeutic approaches in different stages of development and please note that as of December 2013 Idebenon is not approved by
either in the US or Europe. </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_tpg68.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With respect to the table above, BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced on January 20, 2014 that it has entered into an agreement to purchase Repligen Corporation&#146;s histone deacetylase inhibitor (HDACi) library and related intellectual property. Potential applications of the HDACi portfolio include Friedreich&#146;s ataxia and other neurological disorders. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With respect to our programs in protein replacement platform although we are not aware of any other similar products currently in clinical development for the treatment of Ornithine transcarbamylase deficiency, </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">70</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">there are a number of clinical approaches currently used to treat OTCD patients in emergency situation: Intravenous administration of sodium benzoate, arginine, and sodium phenylacetate might be beneficial for patients in hepatic coma; however, they can only be administered in a large medical facility setting with close laboratory monitoring available. Intravenous sodium benzoate and phenylacetate (Ammonul) was approved in the United States in February 2005. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Glycerol phenylbutyrate (Ravicti) is a pre-prodrug that undergoes metabolism to form phenylacetate. Results of a Phase III study comparing ammonia control in adults showed glycerol phenylbutyrate was non-inferior to sodium phenylbutyrate. In a separate study involving young children ages 2 months through 5 years, glycerol phenylbutyrate resulted in a more evenly distributed urinary output of PAGN over 24 hours and accounted for fewer symptoms from accumulation of phenylacetate. Ravicti was approved by the FDA early in 2013 (Hyperion). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">With respect to our program in BBrm- read through platform there are a number of competitors developing read through molecules, both small molecules (PTC) and exon- skipping RNA based platform (ISIS, Prosensa, Sarepta). Although not all have focused so far on SMA it is possible that they will develop in the future programs that will attempt to utilize their technology for SMA. In addition it is possible that competitors may produce, develop, and commercialize therapeutics, or utilize other approaches such as gene </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">71</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">therapy, cell therapy or bone marrow transplantation to treat SCA3. The table below outlines, to our knowledge, the different approaches for developing drugs for SMA. </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_tpg69.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_tpg69a.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We believe that our read-through platform could be synergistic to most technologies outlined above since most are focused on either generally enhancing the total production of SMN2 through exon skipping, or focused on the downstream effects of lack of SMN1. Many of our competitors have substantially greater financial, technical, and human resources than we have. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances made in the commercial applicability of technologies and greater </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">72</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">availability of capital for investment in these fields. Our success will be based in part on our ability to build and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient therapy. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">License Agreements </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have entered into two license agreements with respect to two of our three platform technologies. On December 19, 2011, we entered into a Research and Exclusive License Agreement with Yissum Research Development Company of the Hebrew University in Jerusalem Ltd., whereby we licensed exclusively two patent applications covering our mitochondrial protein replacement platform. One patent application covers the use of TAT-MTS-Protein for protein replacement in mitochondrial diseases. The second patent application covers the use of heterologous MTS in a fusion protein for treatment of mitochondrial protein deficiency diseases.
These patent applications, if issued, will expire in 2029 and 2033, respectively. In addition, on January 1, 2014 we entered into an Exclusive License Agreement with Ramot at Tel Aviv University Ltd., for the use, development and commercialization of our-read through platform. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Intellectual Property and Patents and Proprietary Rights </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The proprietary nature of, and protection for, our product candidates, processes, and know-how are important to our business. Our success depends in part on our ability to protect the proprietary nature of our product candidates, technology, and know-how, to operate without infringing on the proprietary rights of others, and to prevent others from infringing our proprietary rights. We seek patent protection in the United States and internationally for our product candidates and other technology. Our policy is to patent or in-license the technology, inventions and improvements that we consider important to the development of
our business. In addition to patent protection, we intend to use other means to protect our proprietary rights, including pursuing marketing or data exclusivity periods, orphan drug status, and similar rights that are available under regulatory provisions in certain countries, including the United States, Europe, Japan, and China. See &#147;U.S. Government Regulation&nbsp;&#151;&nbsp;Orphan Designation and Exclusivity,&#148; &#147;U.S. Government Regulation&nbsp;&#151;&nbsp;Pediatric Studies and Exclusivity,&#148; &#147;U.S. Government Regulation&nbsp;&#151;&nbsp;Patent Term Restoration,&#148; &#147;U.S. Government Regulation&nbsp;&#151;&nbsp;Biosimilars and Exclusivity,&#148; &#147;U.S. Government Regulation&nbsp;&#151;&nbsp;Abbreviated New Drug Applications for Generic Drugs,&#148; &#147;U.S. Government Regulation&nbsp;&#151;&nbsp;Hatch-Waxman Patent Certification and the 30-Month Stay,&#148; and &#147;European Union/Rest of World Government Regulation&nbsp;&#151;&nbsp;Orphan
Designation and Exclusivity&#148; below for additional information. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We also rely on trade secrets, know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We seek regulatory approval for our products in disease areas with high unmet medical need, great market potential, and where we have a proprietary position through patents covering various aspects of our products, such as composition, dosage, formulation, use, and manufacturing process, among others. Our success depends on an intellectual property portfolio that supports our future revenue streams and erects barriers to our competitors. We are maintaining and building our patent portfolio through filing new patent applications, prosecuting existing applications, and licensing and acquiring new patents and patent applications.
</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Despite these measures, any of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated, or such intellectual property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide competitive advantages. For more information, please see &#147;Risks Related to our Intellectual Property.&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of January 2014, we own and/or are the exclusive licensee of 5 pending U.S. patent applications and corresponding patents and patent applications internationally. With respect to our issued patents in the United States and Europe, we may also be entitled to obtain a patent term extension to extend the patent expiration date. For example, in the United States, we can apply for a patent term extension of up to five years for one of the patents covering a product once the product is approved by the FDA. The exact duration of the </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">73</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">extension depends on the time we spend in clinical studies as well as getting a new drug application approval from the FDA. The patent portfolios for our three leading platform and product candidates as of January 2014 are summarized below. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cabaletta </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have a patent application covering the use of Trehalose for the treatment of PolyA/PolyQ diseases and Taupathies. The patent application covers a novel therapeutic regime using parenteral administration of trehalose, thereby achieving higher bioavailability and therapeutic efficacy in the treatment of myopathic and neurodegenerative diseases associated with abnormal protein aggregation, specifically polyalanine or polyglutamine expansion protein and tauopathies disorders such as OPMD, SCA, SBMA, Huntington and more. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The expiring patent terms for such pending patents applications in the United States would be 2033. We intend to pursue marketing and orphan drug exclusivity periods that are available to us under regulatory provisions in certain countries. We intend to submit a Track One Priority Examination patent application on related future patent applications. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition we have received orphan drug designation for the use of Trehalose in OPMD patients. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">mPRT </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have licensed exclusively two patent applications covering our mitochondrial protein replacement platform from the Hebrew University in Israel. One patent application covers the use of TAT-MTS-Protein for protein replacement in mitochondrial diseases (See &#147;License Agreements&#148;). The second patent application covers the use of heterologous MTS in a fusion protein for treatment of mitochondrial protein deficiency diseases. These patent applications, if issued, will expire in 2029 and 2033 respectively. In addition, we have applied for a Track One Priority Examination approval for our FA and OTC program, based on our
heterologous MTS patent application. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Read-through </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are the exclusive licensee of one patent and one patent application covering our-read through platform that we licensed from Tel Aviv University (See &#147;License Agreements&#148; section above). One patent covers a method for treating cancer through read through of nonsense mutation. This patent is already granted in Europe. The patent application covers a method of treatment for orphan genetic neurodegenerative and neurodevelopmental diseases through non-systemic administration. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The expiration dates on these patents are 2029 and 2033 respectively. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Trademarks </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have filed with the United States Trademark Office an intent to use application for the trademark CABALETTA in International Class 5 for certain pharmaceutical preparations. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Other </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We rely upon unpatented trade secrets, know-how, and continuing technological innovation to develop and maintain our competitive position. We seek to protect our ownership of know-how and trade secrets through an active program of legal mechanism including assignments, confidentiality agreements, material transfer agreements, research collaborations, and licenses. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Manufacturing </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We currently contract with third parties for the manufacturing and testing of our product candidates for preclinical studies and clinical studies and intend to do so in the future. We do not own or operate manufacturing facilities for the production of clinical quantities of our product candidates. We currently have no plans to build our own clinical or commercial scale manufacturing capabilities. The use of contracted manufacturing and reliance on collaboration partners is relatively cost-efficient and has eliminated the need for our direct investment in manufacturing facilities and additional staff early in development.
Although we rely on contract manufacturers, we have personnel with extensive manufacturing experience to oversee our contract manufacturers. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">74</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To date, our third-party manufacturers have met our manufacturing requirements. We expect third-party manufacturers to be capable of providing sufficient quantities of our product candidates to meet anticipated full scale commercial demands. To meet our projected needs for commercial manufacturing, third parties with whom we currently work might need to increase their scale of production or we will need to secure alternate suppliers. We believe that there are alternate sources of supply that can
satisfy our clinical and commercial requirements, although we cannot be certain that identifying and establishing relationships with such sources, if necessary, would not result in significant delay or material additional costs. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Cabaletta:</I>&nbsp;&nbsp;The drug substance for Cabaletta is purchased from a third party supplier and drug product for Cabaletta is manufactured by a third party manufacturer. There are other suppliers for pharmaceutical grade Trehalose in the market. We have not yet started the development of our clinical trial material for our pre-clinical programs in mPRT and Read through platform. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sales and Marketing </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to build the commercial infrastructure in the United States and Europe necessary to effectively support the commercialization of all of our product candidates, if and when we believe a regulatory approval of the first of such product candidates in a particular geographic market appears imminent. The commercial infrastructure for orphan products typically consists of a targeted, specialty sales force that calls on a limited and focused group of physicians supported by sales management, medical liaisons, internal sales support, an internal marketing group, and distribution support. One challenge unique to
commercializing therapies for rare diseases is the difficulty in identifying eligible patients due to the very small and sometimes heterogeneous disease populations. Our management team is experienced in maximizing patient identification for both clinical development and commercialization purposes in rare diseases. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Additional capabilities important to the orphan marketplace include the management of key accounts such as managed care organizations, group-purchasing organizations, specialty pharmacies, and government accounts. To develop the appropriate commercial infrastructure, we will have to invest significant amounts of financial and management resources, some of which will be committed prior to any confirmation that any of our product candidates will be approved. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Outside of the United States and Europe, where appropriate, we may elect in the future to utilize strategic partners, distributors, or contract sales forces to assist in the commercialization of our products. In certain instances we may consider building our own commercial infrastructure. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Government Regulation </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Clinical trials, the drug approval process, and the marketing of drugs are intensively regulated in the United States and in all major foreign countries. Government authorities in the United States (including federal, state, and local authorities) and in other countries, extensively regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution, post-approval monitoring and reporting, advertising and promotion, pricing, and export and import of pharmaceutical products, such as those we are developing. The process of obtaining regulatory approvals and
the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">U.S. Government Regulation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and related regulations, and biologics under the FDCA and the Public Health Service Act, or PHSA, and its implementing regulations. FDA approval is required before any new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States. Drugs and biologics are also subject to other federal, state and local statutes and regulations. Failure to comply with the applicable United States regulatory requirements at any time during the product development process, approval
process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the imposition by the FDA or an Institutional Review Board, or IRB, of a clinical hold on trials, the FDA&#146;s refusal to approve pending applications or supplements, license suspension or revocation, withdrawal of an approval, warning letters, product recalls, product seizures, total or partial suspension of production or </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">75</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">distribution, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, distribution, record keeping, approval, advertising and promotion of our products. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA&#146;s policies may change and additional government regulations may be enacted that could prevent or delay regulatory approval of our platforms and candidate products or any future product candidates or approval of new disease indications or label changes. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the United States or abroad. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Marketing Approval </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The process required by the FDA before product candidates may be marketed in the United States generally involves the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the Good Laboratory Practices, or GLP, regulations; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical studies may begin and must be updated annually; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">approval by an independent institutional review board, or IRB, or ethics committee representing each clinical site before each clinical study may be initiated; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">performance of adequate and well-controlled human clinical studies to establish the safety and efficacy of the product candidate for each proposed indication; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">preparation of and submission to the FDA of a new drug application, or NDA, or biologics license application, or BLA, after completion of all pivotal clinical studies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">potential review of the product application by an FDA advisory committee, where appropriate and if applicable; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities where the proposed product drug substance is produced to assess compliance with current Good Manufacturing Practices, or cGMP; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">FDA review and approval of an NDA or BLA prior to any commercial marketing or sale of the drug in the United States. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The testing and approval process requires substantial time and financial resources, and we cannot be certain that any approvals for our candidate products will be granted on a timely basis, if at all. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human studies. The IND also includes results of animal and <I>in vitro</I> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational new drug. An IND must become effective before human clinical trials may begin. An IND will
automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the proposed clinical studies. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before clinical studies can begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical studies to commence. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">76</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We will need to successfully complete extensive additional clinical trials in order to be in a position to submit a new drug application to the FDA. Our planned future clinical trials for our candidate products may not begin or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays in: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtaining regulatory approval to commence a study; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reaching agreement with third-party clinical trial sites and their subsequent performance in conducting accurate and reliable studies on a timely basis; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">obtaining institutional review board approval to conduct a study at a prospective site; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">recruiting patients to participate in a study; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">supply of the drug. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We must reach agreement with the FDA on the proposed protocols for our future clinical trials in the United States. A separate submission apart from any IND application we submit must be made for each successive clinical trial to be conducted during product development. Further, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that site. Informed consent must also be obtained from each study subject. Regulatory authorities, an IRB, a data safety monitoring board or the sponsor, may suspend or terminate a clinical trial at any
time on various grounds, including a finding that the participants are being exposed to an unacceptable health risk. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Clinical Studies </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Clinical studies involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with current Good Clinical Practices, or cGCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety, and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted to
the FDA as part of the IND. Additionally, approval must also be obtained from each clinical study site&#146;s institutional review board, or IRB, before the studies may be initiated, and the IRB must monitor the study until completed. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our objective is to conduct additional clinical trials for our candidate products and, if those trials are successful, seek marketing approval from the FDA and other worldwide regulatory bodies. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For purposes of NDA approval, human clinical trials are typically conducted in phases that may overlap. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Phase I</I>.&nbsp;&nbsp;The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Phase II</I>.&nbsp;&nbsp;This phase involves trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Phase III</I>.&nbsp;&nbsp;This phase involves trials undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population, often at geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Phase IV</I>.&nbsp;&nbsp;In some cases, the FDA may condition approval of an NDA or BLA for a product candidate on the sponsor&#146;s agreement to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after approval to gain more information about the drug. Such post-approval studies are typically referred to as Phase 4 clinical studies. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">77</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A pivotal study is a clinical study that adequately meets regulatory agency requirements for the evaluation of a drug candidate&#146;s efficacy and safety such that it can be used to justify the approval of the product. Generally, pivotal studies are Phase 3 studies, but the FDA may accept results from Phase 2 studies if the study design provides a well-controlled and reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need and the results are
sufficiently robust. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA, the IRB, or the clinical study sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Additionally, some clinical studies are overseen by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study. We may also suspend or terminate a clinical study based on evolving business objectives and/or competitive climate. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">All of these trials must be conducted in accordance with good clinical practice requirements in order for the data to be considered reliable for regulatory purposes. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The clinical study process can take three to ten years or more to complete, and there can be no assurance that the data collected will support FDA approval or licensure of the product. Government regulation may delay or prevent marketing of product candidates or new drugs for a considerable period of time and impose costly procedures upon our activities. We cannot be certain that the FDA or any other regulatory agency will grant approvals for our candidate products or any future product candidates on a timely basis, if at all. Success in early stage clinical trials does not ensure success in later stage clinical trials. Data
obtained from clinical activities is not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The NDA Approval Process </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational new drug product information is submitted to the FDA in the form of an NDA or BLA requesting approval to market the product for one or more indications. Under federal law, the submission of most NDAs and BLAs is subject to an application user fee. For fiscal year 2014, the application user fee exceeds $2.1 million, and the sponsor of an approved NDA or BLA is also subject to annual product and establishment user fees, set at $104,060 per product and $554,600 per establishment. These fees
are typically increased annually. Applications for orphan drug products are exempted from the NDA and BLA user fees and may be exempted from product and establishment user fees, unless the application includes an indication for other than a rare disease or condition. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An NDA or BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish
the safety and effectiveness of the investigational new drug product to the satisfaction of the FDA. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA will initially review the NDA for completeness before it accepts it for filing. The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#146;s threshold determination that the application is sufficiently complete to permit substantive review. After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#146;s identity,
strength, quality and purity. The FDA may refer applications for novel drug products or drug products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">78</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Based on pivotal Phase III trial results submitted in an NDA, upon the request of an applicant, the FDA may grant a priority review designation to a product, which sets the target date for FDA action on the application at six months, rather than the standard ten months. Priority review is given where preliminary estimates indicate that a product, if approved, has the potential to provide a significant improvement compared to marketed products or offers a therapy where no satisfactory alternative therapy exists. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence
necessary to support approval. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After the FDA completes its initial review of an NDA, it will communicate to the sponsor that the drug will either be approved, or it will issue a complete response letter to communicate that the NDA will not be approved in its current form and inform the sponsor of changes that must be made or additional clinical, nonclinical or manufacturing data that must be received before the application can be approved, with no implication regarding the ultimate approvability of the application. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Before approving an NDA o rBLA, the FDA will typically inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Additionally, before approving an NDA, the FDA may inspect one or more clinical sites to assure compliance with good clinical practices (GCPs). If the FDA determines the application, manufacturing process or manufacturing facilities are not acceptable, it typically will outline the deficiencies and often will request additional testing or information. This may significantly delay further review of the application. If the FDA finds that a clinical site did not conduct the clinical trial in accordance with GCP, the FDA may determine the data generated by the clinical site should be excluded from the primary efficacy analyses
provided in the NDA. Additionally, notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The testing and approval process for a drug requires substantial time, effort and financial resources, and this process may take several years to complete. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us from marketing our products. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase IV studies may be made a condition to be satisfied for continuing drug approval. The results of Phase IV studies can confirm the effectiveness of a product candidate and can provide important safety information. In addition, the FDA now has express statutory authority to require sponsors to conduct post-market studies to specifically address safety issues identified by the agency. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any approvals that we may ultimately receive could be withdrawn if required post-marketing trials or analyses do not meet the FDA requirements, which could materially harm the commercial prospects for our candidate products. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA also has authority to require a Risk Evaluation and Mitigation Strategy, or REMS, from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks. A sponsor may also voluntarily propose a REMS as part of the NDA submission. The need for a REMS is determined as part of the review of the NDA. Based on statutory standards, elements of a REMS may include &#147;dear doctor letters,&#148; a medication guide, more elaborate targeted educational programs, and in some cases restrictions on distribution. These elements are negotiated as part of the NDA approval, and in some cases if consensus is
not obtained until after the PDUFA review cycle, the approval date may be delayed. Once adopted, REMS are subject to periodic assessment and modification. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">79</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Even if a product candidate receives regulatory approval, the approval may be limited to specific disease states, patient populations and dosages, or might contain significant limitations on use in the form of warnings, precautions or contraindications, or in the form of onerous risk management plans, restrictions on distribution, or post-marketing study requirements. Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in
restrictions on the product or even complete withdrawal of the product from the market. Delay in obtaining, or failure to obtain, regulatory approval for our candidate products, or obtaining approval but for significantly limited use, would harm our business. In addition, we cannot predict what adverse governmental regulations may arise from future U.S. or foreign governmental action. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Expedited Review and Accelerated Approval Programs </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#146;s review and approval of NDAs and BLAs. For example, Fast Track Designation may be granted to a drug intended for treatment of a serious or life-threatening disease or condition that has potential to address unmet medical needs for the disease or condition. The key benefits of fast track designation are the eligibility for priority review, rolling review (submission of portions of an application before the complete marketing application is submitted), and accelerated approval, if relevant criteria are met. Based on results of
the Phase 3 clinical study(ies) submitted in an NDA or BLA, upon the request of an applicant, the FDA may grant the NDA or BLA a priority review designation, which sets the target date for FDA action on the application at six months after the FDA accepts the application for filing. Priority review is granted where there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. If criteria are not met for priority review, the application is subject to the standard FDA review period of ten months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the accelerated approval program, the FDA may approve an NDA or BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the
drug&#146;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the Food and Drug Administration Safety and Innovation Act, or FDASIA, which was enacted and signed into law in 2012, established the new Breakthrough Therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">FDA Post-Approval Requirements </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as
well as new application fees for supplemental applications with clinical data. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Drug manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">80</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We rely, and expect to continue to rely, on third parties for the production of clinical quantities of our product candidates, and expect to rely in the future on third parties for the production of commercial quantities. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer or holder of
an approved NDA or BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#146;s policies may change, which could delay or prevent regulatory approval of our products under development. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other
potential consequences include, among other things: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">fines, warning letters or holds on post-approval clinical studies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">injunctions or the imposition of civil or criminal penalties; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">product seizure or detention, or refusal to permit the import or export of products. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Orphan Designation and Exclusivity </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making the drug for this type of disease or condition will be recovered from sales in the United States. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical study costs, tax advantages, and user-fee waivers. In addition, if a product receives FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pediatric Studies and Exclusivity </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NDAs and BLAs must contain data (or a proposal for post-marketing activity) to assess the safety and effectiveness of an investigational new drug product for the claimed indications in all relevant pediatric populations in order to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">81</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">waivers if certain criteria are met. Discussions about pediatric development plans can be discussed with the FDA at any time, but usually occur any time between the end-of-Phase II meeting and submission of the NDA or BLA. The requirements for pediatric data do not apply to any drug for an indication for which orphan designation has been granted. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pediatric exclusivity is another type of non-patent exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the five-year and three-year non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA or BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical study is deemed to fairly respond to the
FDA&#146;s request, the additional protection is granted. If reports of FDA-requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot accept or approve another application relying on the NDA or BLA sponsor&#146;s data. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patent Term Restoration </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Depending upon the timing, duration, and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Amendments.&nbsp;&nbsp;The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA or BLA, plus the time between the submission date and the approval of that application. Only one patent applicable to an approved product is
eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical studies and other factors involved in the filing of the relevant NDA or BLA. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Biosimilars and Exclusivity </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Patient Protection and Affordable Care Act, or Affordable Care Act, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCI Act, which created an abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-licensed reference biological product. This amendment to the PHSA attempts to minimize duplicative testing. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown
through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structure of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A reference biologic is granted twelve years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitting under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing, (ii) eighteen months after approval if there is no legal challenge, (iii) eighteen months after the resolution in </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">82</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">the applicant&#146;s favor of a lawsuit challenging the biologics&#146; patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Abbreviated New Drug Applications for Generic Drugs </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In 1984, with passage of the Hatch-Waxman Act, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference listed drug, or RLD. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is &#147;bioequivalent&#148; to the innovator drug. Under the statute, a generic drug is bioequivalent to an RLD if &#147;the rate and extent of absorption of the generic drug do not show a significant difference from the rate and extent of absorption of the listed drug. . . .&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Upon approval of an ANDA, the FDA indicates that the generic product is &#147;therapeutically equivalent&#148; to the RLD and it assigns a therapeutic equivalence rating to the approved generic drug in its publication &#147;Approved Drug Products with Therapeutic Equivalence Evaluations,&#148; also referred to as the &#147;Orange Book.&#148; Physicians and pharmacists consider an &#147;AB&#148; therapeutic equivalence rating to mean that a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#146;s designation of an &#147;AB&#148;
rating often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDCA provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval. The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or
for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Hatch-Waxman Patent Certification and the 30-Month Stay </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#146;s product or a method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Specifically, the applicant must certify with respect to each patent that: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the required patent information has not been filed; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the listed patent has expired; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the listed patent is invalid, unenforceable or will not be infringed by the new product. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A certification that the new product will not infringe the already approved product&#146;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">83</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA
from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA applicant. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">European Union/Rest of World Government Regulation </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial sales and distribution of our products. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. In the European Union, for example, a clinical study application, or CTA, must be submitted for each clinical protocol to each country&#146;s national health authority and an independent ethics
committee, much like the FDA and IRB, respectively. Once the CTA is accepted in accordance with a country&#146;s requirements, the clinical study may proceed. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The requirements and process governing the conduct of clinical studies vary from country to country. In all cases, the clinical studies are conducted in accordance with cGCP, the applicable regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">To obtain regulatory approval of an investigational medicinal product under European Union regulatory systems, we must submit a marketing authorization application. The content of the NDA or BLA filed in the United States is similar to that required in the European Union, with the exception of, among other things, country-specific document requirements. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing product licensing, pricing, and reimbursement vary from country to country. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Countries that are part of the European Union, as well as countries outside of the European Union, have their own governing bodies, requirements, and processes with respect to the approval of pharmaceutical products. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Authorization Procedures in the European Union </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Medicines can be authorized in the European Union by using either the centralized authorization procedure or national authorization procedures. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Centralized procedure.</I>&nbsp;&nbsp;The EMA implemented the centralized procedure for the approval of human medicines to facilitate marketing authorizations that are valid throughout the European Economic Area, or EEA, which is comprised of the 28 member states of the European Union plus Norway, Iceland, and Lichtenstein. This procedure results in a single marketing authorization issued by the EMA that is valid across the EEA. The centralized procedure is compulsory for human medicines that are: derived from biotechnology processes, such as genetic engineering, contain a new active substance indicated for the treatment of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions, and officially designated orphan medicines. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">For medicines that do not fall within these categories, an applicant has the option of submitting an application for a centralized marketing authorization to the European Commission following a favorable opinion by the EMA, as long as the medicine concerned is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public health. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">84</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">National authorization procedures.&nbsp;&nbsp;There are also two other possible routes to authorize medicinal products in several European Union countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure: </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Decentralized procedure.&nbsp;&nbsp;Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one European Union country of medicinal products that have not yet been authorized in any European Union country and that do not fall within the mandatory scope of the centralized procedure. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Mutual recognition procedure.</I>&nbsp;&nbsp;In the mutual recognition procedure, a medicine is first authorized in one European Union Member State, in accordance with the national procedures of that country. Following this, further marketing authorizations can be sought from other European Union countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In some cases, a Pediatric Investigation Plan, and/or a request for waiver or deferral, is required for submission prior to submitting a marketing authorization application. A PIP describes, among other things, proposed pediatric studies and their timing relative to clinical studies in adults. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">New Chemical Entity Exclusivity </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the European Union, new chemical entities, sometimes referred to as new active substances, qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#146;s data to assess a generic (abbreviated) application for eight years, after which generic marketing authorization can be submitted, and the innovator&#146;s data may be referenced, but not approved for two years. The overall ten-year period will be extended to a maximum of eleven years if,
during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Orphan Designation and Exclusivity </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the European Union, the EMA&#146;s Committee for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the European Union Community and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a
life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the medicinal product. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and 10 years of market exclusivity is granted following medicinal product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Exceptional Circumstances/Conditional Approval </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Orphan drugs or drugs with unmet medical needs may be eligible for EU approval under exceptional circumstances or with conditional approval. Approval under exceptional circumstances is applicable to orphan products and is used when an applicant is unable to provide comprehensive data on the efficacy and safety under normal conditions of use because the indication for which the product is intended is encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, when the present state of scientific knowledge does not allow comprehensive information to be provided, or when it is </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">85</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">medically unethical to collect such information. Conditional marketing authorization is applicable to orphan medicinal products, medicinal products for seriously debilitating or life-threatening diseases, or medicinal products to be used in emergency situations in response to recognized public threats. Conditional marketing authorization can be granted on the basis of less complete data than is normally required in order to meet unmet medical needs and in the interest of public health, provided the risk-benefit balance is positive, it is likely that the applicant will be able to provide the comprehensive clinical data, and
unmet medical needs will be fulfilled. Conditional marketing authorization is subject to certain specific obligations to be reviewed annually. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Accelerated Review </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Centralized Procedure in the European Union, the maximum timeframe for the evaluation of a marketing authorization application is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the EMA&#146;s Committee for Medicinal Products for Human Use, or CHMP). Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. In this circumstance, EMA ensures that the opinion of the
CHMP is given within 150 days, excluding clock stops. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pharmaceutical Coverage, Pricing and Reimbursement </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the
reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a payor&#146;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payors do not consider a product to
be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. By way of example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the Healthcare Reform Law, contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs
sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#146; share of sales to federal health care programs. Adoption of government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the European Community, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. To obtain </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">86</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">reimbursement or pricing approval, some of these countries may require the completion of clinical studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on
pricing within a country. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on cost containment measures in the United States and other countries has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage
policies and reimbursement rates may be implemented in the future. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Other Healthcare Laws and Compliance Requirements </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we obtain regulatory approval for any of our product candidates, we may be subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the federal transparency laws, including the federal Physician Payment Sunshine Act, that requires drug manufacturers to disclose payments and other transfers of value provided to physicians and teaching hospitals; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Healthcare Reform Law broadened the reach of the fraud and abuse laws by, among other things, amending the intent requirement of the federal Anti-Kickback Statute and the applicable criminal healthcare fraud statutes contained within 42 U.S.C. &sect;1320a-7b, effective March 23, 2010. Pursuant to the statutory amendment, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the Healthcare Reform Law provides that the government may assert that a claim including items or services resulting from a violation of the
federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below) or the civil monetary penalties statute. Many states have adopted laws similar to the federal </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">87</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Anti-Kickback Statute, some of which apply to the referral of patients for healthcare items or services reimbursed by any source, not only the Medicare and Medicaid programs. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are also subject to the Foreign Corrupt Practices Act, or FCPA, which prohibits improper payments or offers of payments to foreign governments and their officials for the purpose of obtaining or retaining business. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Safeguards we implement to discourage improper payments or offers of payments by our employees, consultants, and others may be ineffective, and violations of the FCPA and similar laws may result in severe criminal or civil sanctions, or other liabilities or proceedings against us, any of which would likely harm our reputation, business, financial condition and result of operations. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid and imprisonment, damages, fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Labeling, Marketing and Promotion </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The FDA closely regulates the labeling, marketing and promotion of drugs. While doctors are free to prescribe any drug approved by the FDA for any use, a company can only make claims relating to safety and efficacy of a drug that are consistent with FDA approval, and the Company is allowed to actively market a drug only for the particular use and treatment approved by the FDA. In addition, any claims we make for our products in advertising or promotion must be appropriately balanced with important safety information and otherwise be adequately substantiated. Failure to comply with these requirements can result in adverse
publicity, warning letters, corrective advertising, injunctions and potential civil and criminal penalties. Government regulators recently have increased their scrutiny of the promotion and marketing of drugs. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pediatric Research Equity Act </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Pediatric Research Equity Act, or PREA, amended the FDCA to authorize the FDA to require certain research into drugs used in pediatric patients. The intent of PREA is to compel sponsors whose drugs have pediatric applicability to study those drugs in pediatric populations, rather than ignoring pediatric indications for adult indications that could be more economically desirable. The Secretary of Health and Human Services may defer or waive these requirements under specified circumstances. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Anti-Kickback and False Claims Laws </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States, the research, manufacturing, distribution, sale and promotion of drug products and medical devices are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare &amp; Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, state Attorneys General, and other state and local government agencies. For example, sales, marketing and scientific/educational grant programs must comply with the Medicare-Medicaid Anti-Fraud and
Abuse Act, as amended (the &#147;Anti-Kickback Statute&#148;), the False Claims Act, as amended, the privacy regulations promulgated under the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus Budget Reconciliation Act of 1990, as amended, and the Veterans Health Care Act of 1992, as amended. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition laws. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the United States, we are subject to complex laws and regulations pertaining to healthcare &#147;fraud and abuse,&#148; including, but not limited to, the Anti-Kickback Statute, the federal False Claims Act, and other state and federal laws and regulations. The Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, or prescription of a particular drug, for which payment may be made under a
federal healthcare program, such as Medicare or Medicaid. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">88</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The federal False Claims Act prohibits anyone from knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information. Many of these laws contain ambiguities as to what is required to comply with the laws. In addition, as discussed below, beginning in 2013, a similar federal requirement will require manufacturers to track and report to the federal government certain payments made to physicians and teaching hospitals made in the previous calendar year. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the
lack of clarity with respect to these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state, and soon federal, authorities. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Patient Protection and Affordable Health Care Act </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In March 2010, the Patient Protection and Affordable Health Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively PPACA, was enacted, which includes measures that have or will significantly change the way health care is financed by both governmental and private insurers. The fees, discounts and other provisions of this law are expected to have a significant negative effect on the profitability of pharmaceuticals. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Many of the details regarding the implementation of PPACA are yet to be determined, and at this time, it remains unclear the full effect that PPACA would have on our business. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Other Regulations </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with such laws and regulations now or in the future. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Israel </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Clinical Testing in Israel </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In order to conduct clinical testing on humans in the State of Israel, special authorization must first be obtained from the ethics committee and general manager of the institution in which the clinical studies are scheduled to be conducted, as required under the Guidelines for Clinical Trials in Human Subjects implemented pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects), as amended from time to time, and other applicable legislation. These regulations require authorization by the institutional ethics committee and general manager as well as from the Israeli Ministry of Health, except in
certain circumstances, and in the case of genetic trials, special fertility trials and complex clinical trials, an additional authorization of the Ministry of Health&#146;s overseeing ethics committee. The institutional ethics committee must, among other things, evaluate the anticipated benefits that are likely to be derived from the project to determine if it justifies the risks and inconvenience to be inflicted on the human subjects, and the committee must ensure that adequate protection exists for the rights and safety of the participants as well as the accuracy of the information gathered in the course of the clinical testing. Since we perform a portion of the clinical studies on certain of our therapeutic candidates in Israel, we are required to obtain authorization from the ethics committee and general manager of each institution in which we intend to conduct our clinical trials, and in most cases, from the Israeli Ministry of Health. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Employees </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2013, we had three full time and one part time employees. All of our employees are based in Israel. None of our employees is represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. Our company uses a cost-effective business model, only retaining top management as company employees or dedicated consultants, and drawing upon other consultants globally to advance our development programs. As of December 31, 2013, our management consisted of our chief executive officer and our chief financial officer. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">89</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and Development </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We invested $0.1 million and $0.7 million in research and development in the years ended December 31, 2012 and December 31, 2013, respectively. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and Facilities </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our headquarters is currently located in Tel Aviv, Israel and consists of approximately 1600 square feet of leased office space under a lease for an indefinite period of time, subject to each party&#146;s right to terminate it within 30 days. We may require additional space and facilities as our business expands. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Legal Proceedings </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are not currently subject to any material legal proceedings.</P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">90</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tMAN"></a>MANAGEMENT </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Executive Officers, Key Employees and Directors </H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Executive Officers and Directors </H2>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth information regarding our executive officers and directors as of April 1, 2014: </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="136"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="338"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Name</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Age</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Position</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Fredric Price</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">68</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chairman of the Board of Directors</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Dr. Dalia Megiddo</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">62</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Executive Officer, Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Ehud (Udi) Gilboa</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">47</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Financial Officer, Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Dr. Yaron Daniely<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">38</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Ran Nusbaum</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">40</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>Marlene Haffner</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">72</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Dr. Daniely will resign from our board of directors immediately prior to the declaration of effectiveness of the registration statement of which this prospectus forms a part. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company intends to add additional members to its Board of Directors prior to the closing of this offering. These directors will be &#147;independent directors&#148; and nominees for the purposes of election as &#147;external directors&#148; as contemplated by the NASDAQ Stock Market rules and Israeli law. The Company will also establish an Audit Committee and a Compensation Committee. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Fredric Price</I> became the Chairman of our Board of Directors on April 24, 2012. Mr. Price is Executive Chairman of the Board of Directors of Chiasma, having served as its Executive Chairman and CEO from 2008 to 2013, stepping down as its Chief Executive Officer after completing a strategic collaboration for its Phase III oral drug candidate in acromegaly with Roche. Previously, he was Executive Chairman of the Board of Directors of Omrix Biopharmaceuticals (2004&nbsp;&#150;&nbsp;2008), a member of the Board of Directors of Enobia Pharma (2006&nbsp;&#150;&nbsp;2012), a member of the Board of Directors of Pharmasset
(2007&nbsp;&#150;&nbsp;2010), Executive Chairman of the Board of Directors of Peptimmune (2007&nbsp;&#150;&nbsp;2011), Chairman of the Board of Directors and CEO of BioMarin Pharmaceutical (2000&nbsp;&#150;&nbsp;2004) and CEO and a member of the Board of Directors of Applied Microbiology (1994&nbsp;&#150;&nbsp;2000). Mr. Price is also currently serving as a member of the Advisory Board of FDNA. His earlier experience includes having been Vice President of Finance and Administration and Chief Financial Officer of Regeneron Pharmaceuticals (1991&nbsp;&#150;&nbsp;1994), the founder of the strategy consulting firm RxFDP (1986&nbsp;&#150;&nbsp;1991), and Vice President of Pfizer Pharmaceuticals with both line and staff responsibilities (1973&nbsp;&#150;&nbsp;1986). He received a BA from Dartmouth College and an MBA from the Wharton School of the University of Pennsylvania. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Dr. Dalia Megiddo</I> has been a director and Chief Executive Officer of the Company since its inception. Dr. Megiddo co-founded Alcobra Ltd., a NASDAQ traded company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder in February 2008 and became a Director at that time. She is an entrepreneur and a medical doctor in family medicine. Since 2000, she has been a manager of InnoMed Ventures, an Israeli venture capital fund focused on life sciences. From 2006 to 2010, she was also a manager of 7 Health Ventures, a Israeli venture capital
fund. She is also the founder of a number of life science companies. Dr. Megiddo received her M.D. degree from Hebrew University Hadassah Medical School and holds a specialist degree in Family Medicine, and also holds an M.B.A. from the Kellogg-Recanati School of Business. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Udi Gilboa</I> has been a director and Chief Financial Officer of our Company since its inception. In addition, Mr. Gilboa co-founded Alcobra Ltd. in February 2008, became a director at that time and has served as its Chief Financial Officer and Chief Accounting Officer since that time. Mr. Gilboa is the founder and managing partner of Top Notch Capital, a prominent Israeli life sciences investment bank. He is also the founder of a number of medical device and pharmaceutical companies. Mr. Gilboa holds a Bachelor&#146;s degree and M.B.A. from Tel Aviv University. Mr. Gilboa serves a director of Insuline Medical Ltd., a
public company whose shares are listed for trading on the Tel Aviv Stock Exchange. In addition, he is a director of Samson Neurosciences Ltd. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">91</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Dr. Yaron Daniely</I> has been a director in our company since its inception. In addition, Dr. Daniely serves as the President and Chief Executive Officer and Director of Alcobra Ltd. Prior to joining us and since 2007, Dr. Daniely was the President and Chief Executive Officer of NanoCyte, Inc., a company that develops transdermal delivery technologies based in Caesarea, Israel. Before NanoCyte and from 2004, Dr. Daniely was a/the General Manager of Gamida Cell&nbsp;&#151;&nbsp;Teva Joint Venture
Ltd., a joint venture company that acquired an exclusive license to develop and commercialize a Phase III-stage cell therapy product for treatment of Leukemia and Lymphoma based in Jerusalem, Israel. From 2003&nbsp;&#150;&nbsp;2007, Dr. Daniely also served as the Vice President of Business Development of Gamida Cell Ltd., and engaged in several licensing and financial transactions for the Company. Dr. Daniely holds a B.Sc. degree in Biological Sciences from Florida International University, and holds a Ph.D. from the Sackler Institute of Graduate Biomedical Sciences at the New York University School of Medicine. Following his doctoral program, Dr. Daniely served as an NIH Visiting Fellow in its Cell Biology section and a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. Subsequently, he received an Executive M.B.A. from the Technion, Israel Institute of Technology. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Ran Nusbaum</I> is a director in our company since July 1, 2013. Mr. Nusbaum is a managing partner and the co-founder of The Pontifax Group, which established three funds with over $220 million under management and over 30 portfolio companies. Over the past 10 years, Mr. Nusbaum has been co-managing The Pontifax Group. From 2006 to 2008 he also served as CEO of Biomedix Ltd. and Spearhead Ltd., as well as Chairman of the Board of Nasvax Ltd. Mr. Nusbaum&#146;s experience in the life sciences arena coupled with a 10-year experience in the business intelligence field create a unique blend of skills, enabling him to support
companies from inception to commercialization. Mr. Nusbaum also serves on the Board of Directors of many of The Pontifax Group&#146;s portfolio companies including, Kite pharma Inc., c-CAM Ltd., Insuline Ltd. (public co.), Eloxx, Theracaot, CollPlant (public), Protab, Quiet, Fusimab Ltd and as chairman of the board of Ocon. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Dr. Marlene Haffner </I>is a director in our company since July 1, 2013. Dr. Haffner is a former Director of the Office of Orphan Products Development (OOPD) of the US Food and Drug Administration (FDA). As OOPD Director she was responsible for the leadership and management of the FDA orphan products development program, the first Orphan Products program in the world. After leaving the FDA, she served as Executive Director, Global Regulatory Policy and Intelligence at Amgen, Inc, and now holds position of CEO at Orphan Solutions and Haffner Associates, services companies for the Orphan Drugs industry. In addition to her
consulting activities, Dr Haffner is Adjunct Professor, Department of Preventive Medicine and Biometrics, and Clinical Professor, Department of Medicine, at the F Edward H&eacute;bert School of Medicine, Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland. For 36 years she served in the United States Public Health Service beginning her career with the Indian Health Service in Gallup, New Mexico. She received her MD from the George Washington University School of Medicine where she then interned in Internal Medicine. She received further training in internal medicine, dermatology and hematology at the Presbyterian Hospital, New York and at the Albert Einstein College of Medicine, New York. She received an MPH from the Johns Hopkins University Bloomberg School of Public Health. During her Public Health career, she rose to the rank of Rear Admiral in the USPHS. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Arrangements Concerning Election of Director; Family Relationships </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our directors or members of senior management were selected as such. In addition, there are no family relationships among our executive officers and directors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Corporate Governance Practices </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As an Israeli company we are subject to various corporate governance requirements under Israeli law relating to such matters as the election of external directors, the appointment of the audit committee, the compensation committee and an internal auditor. These requirements are in addition to the corporate governance requirements imposed by the Listing Rules of the NASDAQ Stock Market and other applicable provisions of U.S. securities laws to which we will become subject upon consummation of this offering and the listing of our ordinary shares on the NASDAQ Capital Market. Under the Listing Rules of the NASDAQ Stock Market, a
foreign private issuer may generally follow its home country rules of corporate governance in lieu of the comparable requirements of the Listing Rules of the NASDAQ Stock Market, except for certain </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">92</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">matters, including (among others) the composition and responsibilities of the audit committee and the independence of its members within the meaning of the rules and regulations of the SEC. For further information, see &#147;Risk factors&#148; and &#147;NASDAQ Listing Rules and Home Country Practices.&#148; </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Board Practices </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Board of Directors </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, setting up the Company&#146;s policy and oversight over our business is vested in our Board of Directors. Our Board of Directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our Board of Directors. Our Chief Executive Officer is appointed by, and serves at the discretion of, our Board of Directors, subject to the service agreement that we have entered into with her. All other executive officers are
appointed by our Chief Executive Officer, and are subject to the terms of any applicable employment agreements that we may enter into with them. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under our amended and restated articles of association, which will be effective upon the consummation of this offering, our Board of Directors must consist of at least &nbsp;&nbsp;&nbsp;&nbsp; and not more &nbsp;&nbsp;&nbsp;&nbsp; than directors, including at least &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; external directors required to be appointed under the Israeli Companies Law. Accordingly, at any time, the minimum number of directors (other than the external directors) may not fall below. Our Board of Directors will consist of directors upon the consummation of this offering, which will include new directors and nominees as external
directors whose service as directors will commence upon the consummation of this offering and, in the case of the external directors, their appointment as external directors shall be subject to ratification at a meeting of our shareholders to be held no later than three months following the completion of this offering. Dr. Yaron Daniely, currently a member of our board of directors, has indicated to us his intention to resign from our board of directors immediately prior to the declaration of effectiveness of the registration statement of which this prospectus forms a part. We have only one class of directors. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Other than external directors, for whom special election requirements apply under the Israeli Companies Law as detailed below, our directors are each elected at a general meeting of our shareholders and serve for a term of one year. Directors (other than external directors) shall nevertheless be removed prior to the end of their term by the majority of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events, all in accordance with the Israeli Companies Law and our amended and restated articles of association. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, our amended and restated articles of association allow our Board of Directors to appoint directors, other than external directors, to fill vacancies on our Board of Directors, for a term of office equal to the remaining period of the term of office of the director(s) whose office(s) have been vacated. External directors are elected for an initial term of three years and may be elected for additional three-year terms under the circumstances described below. External directors may be removed from office only under the limited circumstances set forth in the Israeli Companies Law. See &#147;&#151;&nbsp;External
directors.&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In accordance with the exemption available to foreign private issuers under NASDAQ rules, we do not intend to follow the requirements of the NASDAQ rules with regard to the process of nominating directors, and instead, will follow Israeli law and practice, in accordance with which our Board of Directors (or a committee thereof, or a certain number of directors serving thereon) is authorized to recommend to our shareholders director nominees for election. Under the Israeli Companies Law and our amended and restated articles of association, nominations for directors may also be added to the agenda of future general meetings,
which has yet to have been summoned, upon the request of any one or more shareholders holding at least one percent (1%) of our outstanding voting power. Furthermore, under the Israeli Companies Law, one or more shareholders holding, in the aggregate, either (i) 5% of our outstanding shares and 1% of our outstanding voting power; or (ii) 5% of our outstanding voting power, may request the Board of Directors to call a general meeting in order to nominate one or more persons for election as directors at a special meeting. However, any such shareholders may make such a nomination only if a written notice of such shareholder&#146;s intent to make such nomination has been given to our chairman of the board (or, if we have no chairman of the board, our chief executive officer). Any such notice must include certain information we are required under the Israeli Companies Law to provide to our shareholders, the consent of the proposed director nominee(s) to serve as </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">93</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">our director(s) if elected and a declaration signed by the nominee(s) declaring that there is no limitation under the Israeli Companies Law preventing their election and that all of the information that is required under the Israeli Companies Law to be provided to us in connection with such election has been provided. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition to its role in making director nominations, under the Israeli Companies Law, our Board of Directors must determine the minimum number of directors who are required to have accounting and financial expertise. Under applicable regulations, a director with accounting and financial expertise is a director who, by reason of his or her education, professional experience and skill, has a high level of proficiency in and understanding of business accounting matters and financial statements, sufficient to be able to thoroughly comprehend the financial statements of the Company and initiate debate regarding the manner in
which financial information is presented. In determining the number of directors required to have such expertise, our Board of Directors must consider, among other things, the type and size of our company and the scope and complexity of its operations. Our Board of Directors has determined that our company requires one director with such expertise. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">External Directors </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, the boards of directors of companies whose shares are publicly traded, including companies with shares listed on the NASDAQ Capital Market, are required to include at least two members elected to serve as external directors. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;agreed to serve as our external directors following the consummation of this offering, subject to ratification at a meeting of our shareholders to be held no later than three months following the completion of this offering. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The definitions of an external director under the Israeli Companies Law and independent director under NASDAQ listing rules are similar such that it would generally be expected that our two external directors will also comply with the independence requirement under the NASDAQ Stock Market rules. The definition of an external director includes a set of statutory criteria (which are described below) that must be satisfied and for which the candidates must attest to the company, while the definition of an independent director requires the board to consider any factor which would impair the ability of a director to exercise
independent judgment. In addition, while external directors serve for a period of three years pursuant to the requirements of Israeli law, independent directors serve for one year pursuant to the provisions of our amended and restated articles of association. External directors must be elected by a special majority of shareholders who are not controlling shareholders, while independent directors are elected by an ordinary majority. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Israeli Companies Law provides that external directors must be elected by a majority vote of the shares present and voting at a shareholders meeting, provided that either: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the majority voted in favor of election includes a majority of the shares held by non-controlling shareholders who do not have a personal interest in the election of the external director (other than a personal interest not deriving from a relationship with a controlling shareholder) that are voted at the meeting, excluding for such purpose any abstentions, which we refer to as a disinterested majority; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the total number of shares held by non-controlling disinterested shareholders (as described in the previous bullet-point) that voted against the election of the director does not exceed two percent (2%) of the aggregate voting rights in the Company. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The term controlling shareholder is defined in the Israeli Companies Law as a shareholder with the ability to direct the activities of the Company, other than by virtue of being an office holder. A shareholder is in any case deemed to be a controlling shareholder if the shareholder holds 50% or more of the means of control, which include the right to vote at a shareholders meeting and the right to appoint the directors of the Company or its general manager. In connection with approval of certain extraordinary and interested party transactions as well as corporate approval of executive compensation, by shareholders, any
shareholder (or group of shareholders having interest in the same matter being brought for approval) who hold(s) in the aggregate 25% or more of the means of control if no other shareholder holds more than 50% of the voting rights, would be deemed a controlling shareholder. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">After an initial term of three years, external directors may be reelected to serve in that capacity for up to two additional three year terms, provided that either (i) (1) his or her service for each such additional term is </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">94</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">recommended by one or more shareholders holding in aggregate at least one percent (1%) of the Company&#146;s voting rights and is approved at a shareholders meeting by a majority of the shares held by non-controlling shareholders who do not have a personal interest in the election of the external director (other than a personal interest not deriving from a relationship with a controlling shareholder) that are voted at the meeting, excluding for such purpose any abstentions, where the total number of shares held by non-controlling, disinterested shareholders voting for such reelection exceeds two percent (2%) of the aggregate
voting rights in the Company, and (2) the external director who has been nominated in such fashion by the shareholders is not a linked or competing shareholder, and does not have or has not had, on or within the two years preceding the date of such person&#146;s appointment to serve as another term as external director, any affiliation with a linked or competing shareholder. The term &#147;linked or competing shareholder&#148; means the shareholder(s) who nominated the external director for reappointment or a material shareholder of the company holding more than 5% of the shares in the company, provided that at the time of the reappointment, such shareholder(s) of the company, the controlling shareholder of such shareholder(s) of the company, or a company under such shareholder(s) of the company&#146;s control, has a business relationship with the company or are competitors of the company; the Israeli Minister of Justice, in consultation with the Israeli Securities Authority, may
determine that certain matters will not constitute a business relationship or competition with the company; or (ii) his or her service for each such additional term is recommended by the board of directors and is approved at a shareholders meeting by the same disinterested majority required for the initial election of an external director (as described above). The term of office for external directors for Israeli companies traded on certain foreign stock exchanges, including the NASDAQ Capital Market, may be further extended, indefinitely, in increments of additional three-year terms, in each case provided that, in addition to reelection in such manner described above, (i) the audit committee and subsequently the board of directors of the Company confirm that, in light of the external director&#146;s expertise and special contribution to the work of the board of directors and its committees, the reelection for such additional period is beneficial to the Company, and (ii) prior to the
approval of the reelection of the external director, the Company&#146;s shareholders have been informed of the term previously served by such nominee and of the reasons why the board of directors and audit committee recommended the extension of such nominee&#146;s term. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If an external directorship becomes vacant and there are less than two external directors on the board of directors at the time, then the board of directors is required under the Israeli Companies Law to call a shareholders&#146; meeting as soon as possible to appoint a replacement external director. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Each committee of the board of directors that is authorized to exercise the powers of the board of directors must include at least one external director, except that the audit committee and compensation committee must each include all external directors then serving on the board of directors. Under the Israeli Companies Law, external directors of a company are prohibited from receiving, directly or indirectly, any compensation for their services as external directors, other than compensation and reimbursement of expenses pursuant to applicable regulations promulgated under the Companies Law. Compensation of an external
director is determined prior to his or her appointment and may not be changed during his or her term subject to certain exceptions. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Israeli Companies Law provides that a person is not qualified to serve as an external director if (i) the person is a relative of the controlling shareholder of the Company, or (ii) if that person or his or her relative, partner, employer, another person to whom he or she was directly or indirectly subject, or any entity under the person&#146;s control, has or had, during the two years preceding the date of appointment as an external director: (a) any affiliation or other prohibited relationship with the Company, with any person or entity who is a controlling shareholder of the Company at the date of appointment or a
relative of such person, or with any entity controlled, during the two years preceding the date of appointment as an external director, by the Company or a controlling shareholder of the Company; or (b) in the case of a company with no controlling shareholder, any affiliation or other prohibited relationship with a person serving, at the date of appointment as external director, as chairman of the board, chief executive officer, a substantial shareholder or the most senior office holder in the Company&#146;s finance department. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">95</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The term relative is defined as a spouse, sibling, parent, grandparent or descendant; spouse&#146;s sibling, parent or descendant; and the spouse of each of the foregoing persons. The term affiliation and the similar types of prohibited relationships include (subject to certain exemptions): </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an employment relationship; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a business or professional relationship even if not maintained on a regular basis (excluding insignificant relationships); </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">control; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">service as an office holder, excluding service as a director in a private company prior to the first offering of its shares to the public if such director was appointed as a director of the private company in order to be nominated to serve as an external director following the initial public offering. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The term office holder is defined under the Israeli Companies Law as the general manager (chief executive officer), chief business manager, deputy general manager, vice general manager, any other person assuming the responsibilities of any of these positions regardless of that person&#146;s title, a director, or a manager directly subordinate to the general manager. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, no person may serve as an external director if that person&#146;s position or professional or other activities create, or may create, a conflict of interest with that person&#146;s responsibilities as a director or otherwise interfere with that person&#146;s ability to serve as an external director or if the person is an employee of the Israel Securities Authority or of an Israeli stock exchange. A person may furthermore not continue to serve as an external director if he or she received direct or indirect compensation for his or her role as a director, other than compensation paid or given in accordance with
Israeli Companies Law regulations or amounts paid pursuant to indemnification and/or exculpation contracts or commitments and insurance coverage. Following the termination of an external director&#146;s service on a board of directors, such former external director and his or her spouse and children may not be provided with direct or indirect benefit by the Company, its controlling shareholder or any entity under its controlling shareholder&#146;s control. This includes appointment as an office holder of the Company or a company controlled by its controlling shareholder, employment as an employee, or receipt of professional services for consideration, either directly or indirectly, including through a corporation in his or her control. These restrictions extend for a period of two years with regard to the former external director and his or her spouse or child, and for one year with respect to other relatives of the former external director. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If at the time at which an external director is appointed all members of the board of directors, who are not controlling shareholders or relatives thereof, are of the same gender, the external director must be of the other gender. A director of one company may not be appointed as an external director of another company if a director of the other company is acting as an external director of the first company at such time. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">According to the Israeli Companies Law, a person may be appointed as an external director only if he or she has professional qualifications or if he or she has accounting and financial expertise (each, as defined below). In addition, at least one of the external directors must be determined by our Board of Directors to have accounting and financial expertise. However, if at least one of our other directors (i) meets the independence requirements under the Exchange Act, (ii) meets the standards of the NASDAQ Listing Rules for membership on the audit committee, and (iii) has accounting and financial expertise as defined under
Israeli law, then neither of our external directors is required to possess accounting and financial expertise as long as both possess other requisite professional qualifications. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A director with accounting and financial expertise is a director who, due to his or her education, experience and skills, possesses an expertise in, and an understanding of, financial and accounting matters and financial statements, in such a manner which allows him or her to understand the financial statements of the Company and initiate a discussion about the presentation of financial data. A director is deemed to have professional qualifications if he or she has any of (i) an academic degree in economics, business management, accounting, law or public service, (ii) an academic degree or has completed other higher education,
in the main field of business of the Company or a field relevant for the position, or (iii) at least five years of </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">96</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">experience as one of the following, or at least five years accumulated experience as two or more of the following&nbsp;&#151;&nbsp;(a) a senior officer in the business management of a company with a significant volume of business, (b) a senior public officer or senior position in the public service, and (c) a senior position in the Company&#146;s main line of business. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Board of Directors has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has accounting and financial expertise and possesses professional qualifications as required under the Israeli Companies Law. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Leadership Structure of the Board </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In accordance with the Israeli Companies Law and our amended and restated articles of association, our board of directors is required to appoint one of its members to serve as Chairman of the Board of Directors. Our board of directors has appointed Fredric Price to serve as Chairman of the Board of Directors. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Role of Board in Risk Oversight Process </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Risk assessment and oversight are an integral part of our governance and management processes. Our board of directors encourages management to promote a culture that incorporates risk management into our corporate strategy and day-to-day business operations. Management discusses strategic and operational risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing us. Throughout the year, senior management reviews these risks with the board of directors at regular board meetings as part of management
presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Board Committees </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Audit Committee </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, the board of directors of a public company must appoint an audit committee. The audit committee must be comprised of at least three directors, including all of the external directors, one of whom must serve as chairman of the committee. The audit committee may not include the chairman of the board, any director employed by or otherwise providing services on a regular basis to the Company, to a controlling shareholder or to any entity controlled by a controlling shareholder, any director whose main livelihood is dependent on a controlling shareholder, nor a controlling shareholder or a relative
thereof. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, the audit committee of a publicly traded company must consist of a majority of unaffiliated directors. An &#147;unaffiliated director&#148; is defined as either an external director or as a director, classified as an &#147;unaffiliated director&#148; by the Company, who meets the following criteria: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">he or she meets the qualifications for being appointed as an external director, except for (i) the requirement that the director be an Israeli resident (which requirement does not, in any event, apply to external directors at public companies such as ours whose securities have been offered outside of Israel or are listed outside of Israel) and (ii) the requirement for accounting and financial expertise or professional qualifications with respect to the proposed unaffiliated director; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">he or she has not served as a director of the Company for a period exceeding nine consecutive years. For this purpose, a break of less than two years in the service shall not be deemed to interrupt the continuation of the service. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Board of Directors intends to adopt an audit committee charter that will set forth the responsibilities of the Audit Committee consistent with the rules of the SEC and the Listing Rules of the NASDAQ Stock Market, as well as subjecting the audit committee charter to the requirements under the Israeli Companies Law, as described below. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Audit Committee provides assistance to our Board of Directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">97</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Audit Committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the accountants are independent of management. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, our Audit Committee is responsible for (i) determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the Board of Directors to improve such practices and amend such deficiencies, (ii) determining whether certain related party transactions (including transactions in which an office holder has a personal interest) should be deemed as material or extraordinary, and to approve such transactions (which may be approved according to certain criteria set
out by our Audit Committee on an annual basis) (see &#147;&#151;&nbsp;Approval of related party transactions under Israeli Law&#148;), (iii) to establish procedures to be followed in respect of related party transactions with a controlling shareholder (where such are not extraordinary transactions), which may include, where applicable, the establishment of a competitive process for such transaction, under the supervision of the audit committee, or individual, or other committee or body selected by the audit committee, in accordance with criteria determined by the audit committee; (iv) to determine procedures for approving certain related party transactions with a controlling shareholder, which having been determined by the audit committee not to be extraordinary transactions, were also determined by the audit committee not to be negligible transactions; (v) where the Board of Directors approves the working plan of the internal auditor, to examine such working plan before its submission
to the Board and propose amendments thereto, (iv) examining our internal controls and internal auditor&#146;s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities, (v) examining the scope of our auditor&#146;s work and compensation and submitting a recommendation with respect thereto to our Board of Directors or shareholders, depending on which of them is considering the appointment of our auditor, and (vi) establishing procedures for the handling of employees&#146; complaints as to the management of our business and the protection to be provided to such employees. Our Audit Committee may not approve an action or a related party transaction, or take any other action required under the Israeli Companies Law, unless at the time of approval a majority of the committee&#146;s members are present, which majority consists of unaffiliated directors including at least one external director, and it further complies with the
committee composition set forth above. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NASDAQ requirements </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Nasdaq Marketplace Rules, we are required to maintain an Audit Committee consisting of at least three independent directors, all of whom are financially literate and one of whom has accounting or related financial management expertise. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Compensation Committee </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We intend to rely upon the exemption available to foreign private issuers under the Listing Rules of the NASDAQ Stock Market with respect to the determination of the compensation of our Chief Executive Officer and other executive officers in lieu of forming a compensation committee consisting entirely of independent directors (or the determination of such compensation solely by the independent members of our Board of Directors), and rather form a compensation committee in compliance with the Israeli Companies Law. See &#147;&#151;&nbsp;NASDAQ Listing Rules and home country practices.&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, the board of directors of a public company must appoint a compensation committee. The compensation committee must be comprised of at least three directors, including all of the external directors, which shall be a majority of the members of the compensation committee and one of whom must serve as chairman of the committee. However, subject to certain exceptions, Israeli companies whose securities are traded on stock exchanges such as NASDAQ, and who do not have a controlling party, do not have to meet this majority requirement; provided, however, that the compensation committee meets other
Companies Law composition requirements, as well as the requirements of the non-Israeli jurisdiction where the company&#146;s securities are traded. Other than the external directors, the rest of the members of the compensation committee shall be directors who will receive compensation for their role as directors only in accordance with Israeli Companies Law regulations or amounts paid pursuant to indemnification and/or exculpation contracts or commitments and insurance coverage. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The compensation committee may not include the chairman of the board, any director employed by or otherwise providing services on a regular basis to the Company, to a controlling shareholder or to any entity </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">98</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">controlled by a controlling shareholder, any director whose main livelihood is dependent on a controlling shareholder, nor a controlling shareholder or a relative thereof. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The members of our compensation committee, which will be formed prior to the consummation of this offering, will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , along with our two external director nominees, Messrs.&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, our compensation committee is responsible for (i) proposing an office holder compensation policy to the Board of Directors, (ii) propose necessary revisions to the compensation policy and examine its implementation, (iii) determining whether to approve transactions with respect to the terms of office and employment of office holders, and (iv) determining, in accordance with our office holder compensation policy, whether to exempt an engagement with an unaffiliated nominee for the position of chief executive officer from requiring shareholders&#146; approval. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, our compensation policy must generally serve as the basis for corporate approvals with respect to the financial terms of employment or engagement of office holders, including exemption, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain factors, including advancement of the company&#146;s objective, the company&#146;s business plan and its long term strategy, and creation of appropriate incentives for office holders. It must also consider, among other things, the company&#146;s risk
management, size and nature of its operations. The compensation policy must furthermore consider the following additional factors: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The knowledge, skills, expertise, and accomplishments of the relevant office holder; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The office holder&#146;s roles and responsibilities and prior compensation agreements with him or her; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The relationship between the terms offered and the average compensation of the other employees of the company, including those employed through manpower companies; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The impact of disparities in salary upon work relationships in the company; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">The possibility of reducing variable compensation at the discretion of the board of directors; the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">As to severance compensation, the period of service of the office holder, the terms of his or her compensation during such service period, the company&#146;s performance during that period of service, the person&#146;s contributions towards the company&#146;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The compensation policy must also include the following principles: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the link between variable compensation and the long term performance and measurable criteria; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company&#146;s financial statements; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the minimum holding or vesting period for variable, equity-based compensation; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">maximum limits for severance compensation. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the amendment to the Israeli Companies Law, we are required to adopt an office holder compensation policy no later than. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Compensation Committee&nbsp;&#151;&nbsp;<I>Charter </I></H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our board of directors intends to adopt a compensation committee charter setting forth the responsibilities of the committee, subjecting the compensation committee charter to the requirements under the Israeli Companies Law, as described above. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">99</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Compensation Committee&nbsp;&#151;&nbsp;<I>NASDAQ Requirements </I></H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are independent under the listing standards of the NASDAQ Capital Market. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Nominating Committee </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our Board of Directors does not currently have a nominating committee, as director nominees are presented by our Board of Directors to our shareholders based upon the nominations made by the Board of Directors itself. We intend to rely upon the exemption available to foreign private issuers under the Listing Rules of the NASDAQ Stock Market from the NASDAQ listing requirements related to independent director oversight of nominations to our Board of Directors and the adoption of a formal written charter or board resolution addressing the nominations process. See &#147;&#151;&nbsp;NASDAQ Listing Rules and home country
practices.&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Other than with Dr. Yaron Daniely, we have service contracts with our directors, Ehud Gilboa, Dr. Dalia Megiddo, Fredric Price, Marlene Haffner and with Pontifax (Cayman) III Limited Partnership and Pontifax (Israel) III Limited Partnership, who are affiliated with our Director, Ran Nusbaum. All of the foregoing service contracts have been approved by our shareholders. Please see &#147;Certain Relationships and Related Party Transactions&nbsp;&#151;&nbsp;Agreements and Arrangements with, and Compensation of, Directors and Executive Officers&#148; for a summary of these agreements. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Internal auditor </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee and nominated by the board of directors. An internal auditor may not be: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a person (or a relative of a person) who holds more than 5% of the Company&#146;s outstanding shares or voting rights; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a person (or a relative of a person) who has the power to appoint a director or the general manager of the Company; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an office holder (including a director) of the Company (or a relative thereof); or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a member of the Company&#146;s independent accounting firm, or anyone on his or her behalf. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The role of the internal auditor is to examine, among other things, our compliance with applicable law and orderly business procedures. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NASDAQ Listing Rules and Home Country Practices </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Sarbanes-Oxley Act, as well as related rules subsequently implemented by the SEC, requires foreign private issuers, such as us, to comply with various corporate governance practices. In addition, upon the contemplated listing of our ordinary shares on the NASDAQ Capital Market, we will need to comply with the Listing Rules of the NASDAQ Stock Market. Under those Listing Rules, we may elect to follow certain corporate governance practices permitted under the Israeli Companies Law in lieu of compliance with corresponding corporate governance requirements otherwise imposed by the Listing Rules of the NASDAQ Stock Market for
U.S. domestic issuers. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In accordance with Israeli law and practice and subject to the exemption set forth in Rule 5615 of the Listing Rules of the NASDAQ Stock Market, if we list on the NASDAQ Capital Market we intend to follow the provisions of the Israeli Companies Law, rather than the Listing Rules of the NASDAQ Stock Market, with respect to the following requirements: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Distribution of periodic reports to shareholders; proxy solicitation.</I>&nbsp;&nbsp;As opposed to the Listing Rules of the NASDAQ Stock Market, which require listed issuers to make such reports available to shareholders in one of a number of specific manners, Israeli law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">100</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px; text-align: left"></TD>

          <TD STYLE="width: 24px; text-align: left"></TD>

          <TD STYLE="text-align: left">website. In addition to making such reports available on a public website, we plan to make our audited financial statements available to our shareholders at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt from the SEC&#146;s proxy solicitation rules. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Nomination of our directors.</I>&nbsp;&nbsp;With the exception of our external directors and directors elected by our Board of Directors due to vacancy, our directors are elected by an annual meeting of our shareholders to hold office until the next annual meeting following one year from his or her election. See &#147;Management&nbsp;&#151;&nbsp;Board Practices&nbsp;&#151;&nbsp;Board of Directors.&#148; The nominations for directors, which are presented to our shareholders by our Board of Directors, are generally made by the Board of Directors itself, in accordance with the provisions of our amended and restated articles of association and the Israeli Companies Law. Nominations need not be made by a nominating committee of our Board of Directors consisting solely of independent directors, as required under the Listing Rules of the NASDAQ Stock Market. Nominations may also be made by one or more of our shareholders, as provided in our
Articles of Association, or under the Israeli Companies Law. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Compensation of officers.</I>&nbsp;&nbsp;Israeli law and our amended and restated articles of association do not require that the independent members of our Board of Directors (or a compensation committee composed solely of independent members of our Board of Directors) determine an executive officer&#146;s compensation, as is generally required under the Listing Rules of the NASDAQ Stock Market with respect to the Chief Executive Officer and all other executive officers. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Instead, compensation of executive officers is determined and approved by our Board of Directors and our Compensation Committee, either in consistency with our office holder compensation policy or, in special circumstances, taking into account certain considerations stated in the Israeli Companies Law. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Shareholder approval shall be further required in the event (i) approval by our Board of Directors and our Compensation Committee is not consistent with our office holders compensation policy, or (ii) compensation required to be approved is that of our chief executive officer or an executive officer who is also the controlling shareholder of our company (including an affiliate thereof). Such shareholder approval shall require a majority vote of the shares present and voting at a shareholders meeting, provided either (i) such majority includes a majority of the shares held by non-controlling shareholders who do not have a
personal interest in the compensation arrangement that are voted at the meeting, excluding for such purpose any abstentions disinterested majority, or (ii) the total shares held by non-controlling disinterested shareholders voted against the arrangement does not exceed two percent (2%) of the voting rights in our company. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Additionally, approval of the compensation of an executive officer, who is also a director, shall require a simple majority vote of the shares present and voting at a shareholders meeting, if consistent with our office holders compensation policy or a special majority as set forth above if the proposed compensation for the director is not consistent with our office holders compensation policy. Our Compensation Committee may, in special circumstances, approve the compensation of an executive officer (other than a director or a controlling shareholder) despite shareholders objection, based on specified arguments and taking
shareholders&#146; objection into account. Our Compensation Committee may exempt an engagement with a nominee for the position of chief executive officer, who meets the non-affiliation requirements set forth for an external director, from requiring shareholders&#146; approval, if such engagement is consistent with our office holders compensation policy and our Compensation Committee determines based on specified arguments that presentation of such engagement to shareholders&#146; approval is likely to prevent such engagement. To the extent that any such transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every three years. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">101</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A director or executive officer may not be present when the compensation committee or board of directors of a company discusses or votes upon the terms of his or her compensation, unless the chairman of the compensation committee or board of directors (as applicable) determines that he or she should be present to present the transaction that is subject to approval. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Independent directors.</I>&nbsp;&nbsp;Israeli law does not require that a majority of the directors serving on our Board of Directors be &#147;independent,&#148; as defined under NASDAQ Listing Rule 5605(a)(2), and rather requires we have at least two external directors who meet the requirements of the Israeli Companies Law, as described above under &#147;Management&nbsp;&#151;&nbsp;Board Practices&nbsp;&#151;&nbsp;External Directors.&#148; We are required, however, to ensure that all members of our Audit Committee are &#147;independent&#148; under the applicable NASDAQ and SEC criteria for independence (as we cannot exempt ourselves from compliance with that SEC independence requirement, despite our status as a foreign private issuer), and we must also ensure that a majority of the members of our Audit Committee are &#147;unaffiliated directors&#148; as defined in the Israeli Companies Law. Furthermore, Israeli law does not require, nor do
our independent directors conduct, regularly scheduled meetings at which only they are present, which the NASDAQ Listing Rules otherwise require. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Shareholder approval.</I>&nbsp;&nbsp;We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Israeli Companies Law, rather than seeking approval for corporation actions in accordance with NASDAQ Listing Rule 5635. In particular, under this NASDAQ rule, shareholder approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer&#146;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment of equity compensation arrangements; and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales
by directors/officers/5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares. By contrast, under the Israeli Companies Law, shareholder approval is required for, among other things: (i) transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders are all required, (ii) extraordinary transactions with controlling shareholders of publicly held companies, which require the special approval described below under &#147;Approval of related party transactions under Israeli Law&nbsp;&#151;&nbsp;Disclosure of personal interests of controlling shareholders&#148;, and (iii) terms of employment or other engagement of the controlling shareholder of the Company or such controlling shareholder&#146;s relative, which require the
special approval described below under &#147;Approval of related party transactions under Israeli Law&nbsp;&#151;&nbsp;Disclosure of personal interests of controlling shareholders&#148;. In addition, under the Israeli Companies Law, a merger requires approval of the shareholders of each of the merging companies. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Approval of Related Party Transactions under Israeli Law </H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Fiduciary duties of directors and executive officers </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Israeli Companies Law codifies the fiduciary duties that office holders owe to a company. Each person listed in the table under &#147;Management&nbsp;&#151;&nbsp;Executive officers and directors&#148; is an office holder under the Israeli Companies Law. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">102</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An office holder&#146;s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same circumstances. The duty of loyalty requires that an office holder act in good faith and in the best interests of the Company. The duty of care includes a duty to use reasonable means to obtain: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">all other important information pertaining to these actions. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The duty of loyalty requires an office holder to act in good faith and for the benefit of the Company, and includes a duty to: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">refrain from any conflict of interest between the performance of his or her duties to the Company and his or her other duties or personal affairs; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">refrain from any activity that is competitive with the Company; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">refrain from exploiting any business opportunity of the Company to receive a personal gain for himself or herself or others; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">disclose to the Company any information or documents relating to the Company&#146;s affairs which the office holder received as a result of his or her position as an office holder. </TD>

</TR>

</TABLE>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Disclosure of Personal Interests of an Office Holder </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Israeli Companies Law requires that an office holder promptly disclose to the board of directors any personal interest that he or she may have concerning any existing or proposed transaction with the Company, as well as any substantial information or document with respect thereof. An interested office holder&#146;s disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is considered. A personal interest includes an interest of any person in an act or transaction of a company, including a personal interest of one&#146;s relative or of a corporate
body in which such person or a relative of such person is a 5% or greater shareholder, director or general manager or in which he or she has the right to appoint at least one director or the general manager, but excluding a personal interest stemming from one&#146;s ownership of shares in the Company. A personal interest furthermore includes the personal interest of a person for whom the office holder holds a voting proxy or the interest of the office holder with respect to his or her vote on behalf of the shareholder for whom he or she holds a proxy even if such shareholder itself has no personal interest in the approval of the matter. An office holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of a relative of such office holder in a transaction that is not considered an extraordinary transaction. Under the Israeli Companies Law, an extraordinary transaction is defined as any of the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a transaction other than in the ordinary course of business; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a transaction that is not on market terms; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a transaction that may have a material impact on a company&#146;s profitability, assets or liabilities. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If it is determined that an office holder has a personal interest in a transaction which is not an extraordinary transaction, approval by the board of directors is required for the transaction, unless the Company&#146;s articles of association provide for a different method of approval. Further, so long as an office holder has disclosed his or her personal interest in a transaction, the board of directors may approve an action by the office holder that would otherwise be deemed a breach of duty of loyalty. However, a company may not approve a transaction or action that is adverse to the Company&#146;s interest or that is not
performed by the office holder in good faith. Approval first by the Company&#146;s audit committee and subsequently by the board of directors is required for an extraordinary transaction in which an office holder has a personal interest. Arrangements regarding the compensation, indemnification or insurance of an office holder require the approval of the compensation committee, board of directors and, in certain circumstances, the shareholders, in </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">103</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">that order, as described above under &#147;&#151;&nbsp;NASDAQ Listing Rules and home country practices&nbsp;&#151;&nbsp; Compensation of officers&#148; and &#147;&#151;&nbsp;NASDAQ Listing Rules and home country practices&nbsp;&#151;&nbsp;Shareholder approval.&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Generally, except with respect to non-extraordinary transactions, a person who has a personal interest in a matter which is considered at a meeting of the board of directors or the audit committee may not be present at such a meeting or vote on that matter unless a majority of the directors or members of the audit committee have a personal interest in the matter, or unless the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present in order to present the transaction that is subject to approval. Generally, if a majority of the members of the audit committee and/or the
board of directors has a personal interest in the approval of a transaction, then all directors may participate in discussions of the audit committee and/or the board of directors on such transaction and the voting on approval thereof, but shareholder approval is also required for such transaction. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Disclosure of a personal interest is also required of a person who is an interested party with respect to (i) a private placement submitted for approval whereby 20% or more of the company&#146;s outstanding share capital prior to the placement is offered, and the payment for which is not only in cash or in tradable securities registered in a stock exchange, or that is not at market terms, and which will result in an increase of the holdings of a shareholder that already holds 5% or more of the company&#146;s outstanding share capital or voting rights or will cause any person to become, as a result of the issuance, a holder of
more than 5% of the company&#146;s outstanding share capital or voting rights, or (ii) that as a result of a private placement submitted for approval will become a controlling shareholder. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Disclosure of Personal Interests of Controlling Shareholders </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The disclosure requirements regarding personal interests that apply to directors and executive officers also apply to controlling shareholders, as defined below. The Israeli Companies Law requires a special approval procedure for (1) extraordinary transactions with controlling shareholders, (2) extraordinary transactions with a third party where a controlling shareholder has a personal interest in the transaction, and (3) any transaction with the controlling shareholder or the controlling shareholder&#146;s relative regarding terms of service provided directly or indirectly (including through a company controlled by the
controlling shareholder) and terms of employment (for a controlling shareholder who is not an office holder). A &#147;relative&#148; is defined in the Companies Law as spouse, sibling, parent, grandparent, descendant, spouse&#146;s descendant, sibling, parent, or the spouse of any of the foregoing. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Such extraordinary transactions with controlling shareholders require the approval of the audit committee or the compensation committee, as applicable, the board of directors and the majority of the voting power of the shareholders present and voting at the general meeting of the company (not including abstentions), provided that either: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the majority of the shares of shareholders who have no personal interest in the transaction and who are present and voting, vote in favor; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">shareholders who have no personal interest in the transaction who vote against the transaction do not represent more than two percent of the aggregate voting rights in the company. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any shareholder participating in the vote on approval of an extraordinary transaction with a controlling shareholder must inform the company prior to the voting whether or not he or she has a personal interest in the approval of the transaction, and if he or she fails to do so, his or her vote will be disregarded. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further, extraordinary transactions with controlling shareholders, extraordinary transactions with a third party where a controlling shareholder has a personal interest in the transaction, or transactions with a controlling shareholder or his or her relative concerning terms of service or employment need to be re-approved once every three years, provided, however, that with respect to extraordinary transactions with controlling shareholders or extraordinary transaction with a third party where a controlling shareholder has a personal interest in the transaction, the audit committee may determine that the duration of the
transaction in excess of three years is reasonable given the circumstances related thereto. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">104</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In accordance with regulations promulgated under the Israeli Companies Law, certain defined types of extraordinary transactions between a public company and its controlling shareholder or controlling shareholders are exempt from the shareholder approval requirements if the audit committee and the board of directors determine that the transaction meets the conditions for such type of transaction which are set forth in the regulations. Examples of such transactions are stipulated in the regulations and
include transactions being entered in pursuant to a framework arrangement whose terms and conditions and length of validity were established beforehand and was approved as such a framework by the shareholders; an extension of a transaction which was previously approved by the shareholders without any significant change to the terms and conditions; or transactions that can only benefit the company. However, such exemptions will not apply if one or more shareholders holding at least 1% of the issued and outstanding shares or voting rights, objects to the use of these exemptions in writing not later than 14 days from the date the company notifies its shareholders of the adoption by the relevant corporate bodies of the resolution regarding the transaction without shareholder approval in reliance upon such exemption. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, the approval of the audit committee, followed by the approval of the board of directors and the shareholders, is required in order to effect a private placement of securities, in which either (i) 20% or more of the company&#146;s outstanding share capital prior to the placement is offered, and the payment for which is not only in cash or in tradable securities registered in a stock exchange, or that is not at market terms, and which will result in an increase of the holdings of a shareholder that already holds 5% or more of the company&#146;s outstanding share capital or voting rights or will cause any person to
become, as a result of the issuance, a holder of more than 5% of the company&#146;s outstanding share capital or voting rights or (ii) a person will become a controlling party in the company. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A &#147;controlling shareholder&#148; is defined in the Israeli Companies Law for purposes of the provisions governing related party transactions and office holder compensation as a person with the ability to direct the actions of a company, or a person who holds 25% or more of the voting power in a public company if no other shareholder owns more than 50% of the voting power in the company, but excluding a person whose power derives solely from his or her position as a director of the company or any other position with the company. Any two or more persons holding voting rights in the company, who each have a personal interest
in the approval of the same such transaction, shall be deemed to be one holder with respect thereto. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Arrangements regarding the terms of engagement and compensation of a controlling shareholder who is an office holder, and the terms of employment of a controlling shareholder who is an employee of the Company, require the approval of the compensation committee, board of directors and, generally, the shareholders, in that order, as described above under &#147;NASDAQ Listing Rules and home country practices&nbsp;&#151;&nbsp;Compensation of officers&#148;. </P>

<H4 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Shareholder Duties </H4>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the Israeli Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward the Company and other shareholders and to refrain from abusing his or her power in the Company, including, among other things, in voting at the general meeting of shareholders and at class shareholder meetings with respect to the following matters: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an amendment to the Company&#146;s articles of association; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an increase of the Company&#146;s authorized share capital; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a merger; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">approval of interested party transactions and acts of office holders that require shareholder approval. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, a shareholder also has a general duty to refrain from discriminating against other shareholders. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Certain shareholders have a further duty of fairness toward the Company. These shareholders include any controlling shareholder, any shareholder who knows that it has the power to determine the outcome of a shareholder vote or a shareholder class vote and any shareholder who has the power to appoint or to prevent the appointment of an office holder of the Company or other power towards the Company. The Israeli </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">105</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Companies Law does not define the substance of this duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Exculpation, Insurance and Indemnification of Directors and Officers </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the Company, in whole or in part, for damages caused to the Company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association include such a provision. The company may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law and the Israeli Securities Law, a company may indemnify, or undertake in advance to indemnify, an office holder for the following liabilities and expenses, imposed on office holder or incurred by office holder due to acts performed by him or her as an office holder, provided its articles of association include a provision authorizing such indemnification: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">financial liability incurred by or imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#146;s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the Company&#146;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent or as a monetary sanction (the items (i) and (ii) above shall have the meanings ascribed to them in section 260(a)(1a) of the Companies Law); </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the Company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments required to be made to an injured party, pursuant to certain provisions of the Securities Law. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the Company&#146;s articles of association: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a breach of the duty of loyalty to the Company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the Company; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a breach of duty of care to the Company or to a third party; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a financial liability imposed on the office holder in favor of a third party. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Without derogating from the aforementioned, subject to the provisions of the Companies Law and the Securities Law, we may also enter into a contract to insure an office holder, in respect of </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">106</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px; text-align: left"></TD>

          <TD STYLE="width: 24px; text-align: left"></TD>

          <TD STYLE="text-align: left">expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder or payment required to be made to an injured party, pursuant to certain provisions of the Securities Law. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Nevertheless, under the Israeli Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following: </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a breach of fiduciary duty, except for indemnification and insurance for a breach of the duty of loyalty to the Company in the event office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the Company; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an act or omission committed with intent to derive unlawful personal benefit; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a fine, monetary sanction, penalty or forfeit levied against the office holder. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, exculpation, indemnification and insurance of office holders require the approval of the compensation committee, board of directors and, in certain circumstances, the shareholders, as described above under &#147;&#151;&nbsp;NASDAQ Listing Rules and home country practices&nbsp;&#151;&nbsp;Compensation of officers&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted by the Israeli Companies Law and Israeli Securities Law. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have obtained directors&#146; and officers&#146; liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies Law and Israeli Securities Law. In addition, we have entered into agreements with each of our office holders undertaking to indemnify them to the fullest extent permitted by Israeli law, including with respect to liabilities resulting from this offering to the extent that these liabilities are not covered by insurance. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Code of Business Conduct and Ethics </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have adopted, effective upon the consummation of this offering, a Code of Business Conduct and Ethics applicable to all of our directors and employees, including our Chief Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions, which is a &#147;code of ethics&#148; as defined in Item 16B of Form 20-F promulgated by the SEC. Upon the effectiveness of the registration statement of which this prospectus forms a part, the full text of the Code of Business Conduct and Ethics will be posted on our website at <I>www.bioblast-pharma.com</I>. If we make
any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the code of ethics, we will disclose the nature of such amendment or waiver to the extent required by the rules and regulations of the SEC. Under Item 16B of the SEC&#146;s Form 20-F, if a waiver or amendment of the Code of Business Conduct and Ethics applies to our principal executive officer, principal financial officer, principal accounting officer or controller and relates to standards promoting any of the values described in Item 16B(b) of such Form 20-F, we will disclose such waiver or amendment in accordance with the requirements of Instruction 4 to such Item 16B. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Compensation of Executive Officers and Directors </H2>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The aggregate compensation, including share-based compensation, paid by us to our directors and executive officers with respect to the year ended December 31, 2013 was approximately $0.5 million. This amount does not include business travel, relocation, professional and business association due and expenses reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in our industry. Our current directors and executive officers are not eligible for pension, retirements or similar benefits. Upon the consummation of this offering, each of our board members, other than our Chairman of the Board,
executive officers and external directors, shall be entitled to an annual service fee of $25,000 plus Value Added Tax (currently at 18%), if applicable, to be paid quarterly in arrears. </P>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of January 1, 2014, options to purchase 83,579 ordinary shares were issued to Mrs. Marlene Haffner, a director in our Company. Of such outstanding options, options to purchase 27,860 ordinary shares were </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">107</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">vested as of January 1, 2014, with an exercise price of $0.0004 per share. The expiration date of all of these options is May 13, 2023. 27,860 additional options shall vest on May 13, 2014, and the remaining 27,859 options shall vest on May 13, 2015. </P>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of January 1, 2014, options to purchase 319,531 ordinary shares were issued to Mr. Fredric Price, the Chairman of our Board of Directors. Of such outstanding options, options to purchase 106,510 ordinary shares were vested as of January 1, 2014, with an exercise price of $0.0004 per share. The expiration date of all of these options is April 24, 2022. 106,510 additional options shall vest on April 24, 2014, and the remaining 106,511 options shall vest on April 24, 2015. In addition, upon the consummation of this offering, options to purchase 206,702 ordinary shares will be issued to Mr. Price at an exercise price equal to
the offering price per share of this offering. These options shall vest in accordance with the 2013 Incentive Option Plan. Also upon the consummation of this offering, the annual compensation of Mr. Price shall be $120,000. </P>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We do not have written agreements with any director providing for benefits upon the termination of their employment with our company. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Employment or Service Agreements with Executive Officers; Consulting and Directorship Services Provided by Directors </H2>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have entered into an amended and restated written service agreement with our chief executive officer, Dr. Dalia Megiddo through her wholly-owned company, DM Medica Ltd. This agreement contains provisions standard for a company in our industry regarding non-competition, confidentiality of information and assignment of inventions. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have entered into an amended and restated written service agreement with our chief financial officer, Mr. Udi Gilboa, through his wholly owned company Top Notch Consultancy (2009) Ltd. This agreement contains provisions standard for a company in our industry regarding non-competition, confidentiality of information and assignment of inventions. </P>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under current applicable Israeli employment laws, we may not be able to enforce (either in whole or in part) covenants not to compete and therefore may be unable to prevent our competitors from benefiting from the expertise of some of our former employees. Please see &#147;Risk factors&nbsp;&#151;&nbsp;Risks Relating to Our Business and Industry.&#148; for a further description of the enforceability of non-competition clauses. See &#147;Certain Relationships and Related Party Transactions&nbsp;&#151;&nbsp;Agreements and Arrangements with, and Compensation of, Directors and Executive Officers&#148; for additional information.
</P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">2013 Incentive Option Plan </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We maintain one equity incentive plan&nbsp;&#151;&nbsp;our 2013 Incentive Option Plan, or our 2013 Plan. As of January 26, 2014, a total of 53,789 shares were reserved for issuance under our 2013 Plan. In addition, options to purchase 403,110 ordinary shares were issued and outstanding. Of such outstanding options, options to purchase 134,370 ordinary shares were vested as of that date, with a weighted average exercise price of $0.0004 per share. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our 2013 Plan, which was adopted by our Board of Directors on November 13, 2013, provides for the grant of options to our and our affiliates&#146; respective directors, employees, office holders, service providers and consultants. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The 2013 Plan is administered by our Board of Directors, which shall determine, subject to Israeli law, the grantees of awards and various terms of the grant. The 2013 Plan provides for granting options in compliance with Section 102 of the Israeli Income Tax Ordinance, 1961, or the Ordinance. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Section 102 of the Ordinance allows employees, directors and officers, who are not controlling shareholders and are considered Israeli residents, to receive favorable tax treatment for compensation in the form of shares or options. Our Israeli non-employee service providers and controlling shareholders may only be granted options under Section 3(9) of the Ordinance, which does not provide for similar tax benefits. Section 102 of the Ordinance includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the
issuance of options or shares directly to the grantee. Section 102(b)(2) of the Ordinance, the most favorable tax treatment for grantees, permits the issuance to a trustee under the &#147;capital gains track.&#148; However, under this track we </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">108</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">are not allowed to deduct an expense with respect to the issuance of the options or shares. In order to comply with the terms of the capital gains track, all options granted under the 2013 Plan pursuant and subject to the provisions of Section 102 of the Ordinance, as well as the ordinary shares issued upon exercise of these options and other shares received subsequently following any realization of rights with respect to such options, such as share dividends and share splits, must be granted to a trustee for the benefit of the relevant employee, director or officer and should be held by the trustee for at least two years after
the date of the grant. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Options granted under the 2013 Plan will generally vest over four years commencing on the date of grant such that 25% vest after one year and an additional 6.25% vest at the end of each subsequent three-month period thereafter for 36 months. Options that are not exercised within ten years from the grant date expire, unless otherwise determined by the Board or its designated committee, as applicable. In case of termination for reasons of disability or death, the grantee or his legal successor may exercise options that have vested prior to termination within a period of six months from the date of disability or death. If we
terminate a grantee&#146;s employment or service for cause, all of the grantee&#146;s vested and unvested options will expire on the date of termination. If a grantee&#146;s employment or service is terminated for any other reason, the grantee may exercise his or her vested options within 30 days of the date of termination. Any expired or unvested options return to the pool for reissuance. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the event of a merger or consolidation of our company subsequent to which we shall no longer exist as a legal entity, or a sale of all, or substantially all, of our shares or assets or other transaction having a similar effect on us, then any outstanding option shall be assumed, or an equivalent option shall be substituted, by such successor corporation or an affiliate thereof or, in case the successor corporation refuses to assume or substitute the option, our board of directors or its designated committee may (a) provide the grantee with the opportunity to exercise the option as to all or part of the shares, vested or
otherwise, and (b) specify a period of time, no less than 7 days, following which all outstanding options shall terminate. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Certain relationships and related party transactions </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following is a description of the material terms of those transactions with related parties to which we, or our subsidiaries, are party and which we are required to disclose pursuant to the disclosure rules of the SEC. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We entered into a service agreement, dated July 1, 2013, with Pontifax (Cayman) III Limited Partnership and Pontifax (Israel) III Limited Partnership (together, &#147;Pontifax&#148;). Under the terms of the service agreement, Pontifax is entitled to a gross monthly consideration of $1,000 plus Value Added Tax (currently at 18%). Pontifax&#146;s service engagement is automatically terminated on the second anniversary date of this agreement, and if extended thereafter, terminable by either party upon thirty days prior written notice. The service agreement further contains a customary provision regarding confidentiality of
information and explicitly state that all work products shall belong to the Company. Our Director, Ran Nusbaum, is a managing partner of The Pontifax Group, which operates the Pontifax limited partnerships, which invest pro rata in Israeli and Israeli-related high growth pharmaceutical, biotechnology and medical devise companies. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Agreements and Arrangements With, and Compensation of, Directors and Executive Officers </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Service Agreement with DM Medica Ltd </H3>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have entered into an amended and restated service agreement, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with our Chief Executive Officer, Dr. Dalia Megiddo, through her wholly owned service providing company, DM Medica Ltd. Subject to the consummation of this offering, under the terms of her service agreement, Dr. Megiddo is entitled to a gross monthly fee of $19,287 plus Value Added Tax (currently at 18%). Dr. Megiddo&#146;s service engagement is terminable by either party upon 60 days prior written notice, and contains customary provisions regarding noncompetition, confidentiality of information and assignment of
inventions. DM Medica Ltd. is also entitled to a one-time bonus of $90,000 plus Value Added Tax upon consummation of this offering. </P>



<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Services Agreement with Top Notch Consultancy (2009) Ltd. </H3>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have entered into an amended and restated service agreement, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, with our chief financial officer, Mr. Udi Gilboa, through his wholly-owned company Top Notch Consultancy (2009) Ltd. for part time </P>



</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">109</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV>

<DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">CFO services, effective as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and terminable by either party upon 60 days prior written notice, and contains provisions standard for a company in our industry regarding non-competition, confidentiality of information and assignment of inventions. Subject to the consummation of this offering, the monthly amount payable under the agreement is NIS 57,861 plus Value Added Tax (currently at 18%). Top Notch Consultancy (2009) Ltd. is also entitled to a one-time bonus of $80,000 plus Value Added Tax upon consummation of this offering. In addition, effective as of September 10, 2013, we entered into
an agreement with Top Notch Consultancy (2009) Ltd. for providing the Company with office space and services for a monthly fee of NIS 14,832 (approximately $4,250), plus Value Added Tax (currently at 18%). Either party may terminate the agreement on 30-days notice. </P>



<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Engagement Letter with Fredric Price </H3>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Fredric Price, our Chairman of the Board of Directors, has been appointed by the Company to its Board of Directors pursuant to an engagement letter agreement, effective April 24, 2012 and terminable by either party upon 30 days prior written notice. We granted Mr. Price an aggregate of 319,531 options to purchase our ordinary shares, of which 106,510 have vested as of January 1, 2014. In addition, contingent upon the consummation of this offering, we granted Mr. Price 206,702 options to purchase our ordinary shares at an exercise price equal to the offering price per share of the offering, which options shall vest in
accordance with the 2013 Plan. </P>



<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Engagement Letter with Marlene Haffner </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Marlene Haffner, a Director in our Company, has been appointed by the Company to its Board of Directors pursuant to an engagement letter agreement, effective May 13,2013 and terminable by either party upon 30 days prior written notice. We granted Mrs. Haffner an aggregate of 83,579 options to purchase our ordinary shares, of which 27,860, have vested as of January 1, 2014. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Indemnification Agreements </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our amended and restated articles of association permit us to exculpate, indemnify and insure each of our directors and office holders to the fullest extent permitted by the Israeli Companies Law and the Israeli Securities Law. We have also obtained Directors &amp; Officers insurance for each of our officers and directors. For further information, see &#147;Management&nbsp;&#151;&nbsp;Exculpation, insurance and indemnification of directors and officers.&#148; </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tPSH"></a>PRINCIPAL SHAREHOLDERS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following table sets forth information regarding beneficial ownership of our ordinary shares as of the date of this prospectus by: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">each person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our outstanding ordinary shares; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">each of our directors and executive officers; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">all of our directors and executive officers as a group. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Beneficial ownership is determined in accordance with the rules of the SEC, and includes voting or investment power with respect to ordinary shares. Ordinary shares issuable under share options or warrants that are exercisable within 60 days after the date of this prospectus are deemed outstanding for the purpose of computing the percentage ownership of the person holding the options or warrants but are not deemed outstanding for the purpose of computing the percentage ownership of any other person. Percentage of shares beneficially owned before this offering is based on 11,030,480 shares outstanding on the date of this
prospectus. The number of ordinary shares deemed outstanding after this offering includes the ordinary shares being offered for sale in this offering but assumes no exercise of the underwriter&#146;s over-allotment option. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of the date of this prospectus, there thirty record holders of our ordinary shares. None of our shareholders has different voting rights from other shareholders. To the best of our knowledge, we are not owned or controlled, directly or indirectly, by another corporation or by any foreign government. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">110</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Except as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all shares shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise noted below, each shareholder&#146;s address is: c/o Bio Blast Pharma Ltd., 35 Ahad Ha&#146;am St., Tel Aviv 6520206, Israel. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="289"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="128"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="86"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>No. of Shares<BR> Beneficially Owned<BR> Prior to this Offering</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Percentage<BR> Owned Before this Offering</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Percentage Owned After this Offering</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Holders of more than 5% of our voting securities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Udi Gilboa</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,288,694</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>29.8</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dr. Dalia Megiddo</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3,288,694</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>29.8</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Pontifax<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2,229,008</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20.2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>Directors and executive officers who are not 5% holders:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Dr. Yaron Daniely</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>163,024</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1.5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Fredric Price<sup>&#040;2&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>227,265</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2.0</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Marlene Haffner<sup>&#040;3&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>27,857</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1>All directors and executive officers as a group<BR> (5 persons)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,995,534</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>62.7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">%<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">Comprised of Pontifax (Cayman) III Limited Partnership that holds 709,431 Ordinary Shares of the Company and Pontifax (Israel) III Limited Partnership who holds 1,519,577 Ordinary Shares of the Company. These two entities are under common control of and are affiliated with our Director, Ran Nusbaum. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(2)</TD>

          <TD STYLE="text-align: left">Comprised of 120,752 ordinary shares and 106,513 ordinary shares issuable upon the exercise of outstanding options that are vested within 60 days of the date hereof. The exercise price of these options is $0.0004 per share and the options expire on April 24, 2022. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(3)</TD>

          <TD STYLE="text-align: left">Comprised of 27,860 ordinary shares issuable upon the exercise of outstanding options that are vested within 60 days of the day hereof. The exercise price of these options is $0.0004 per share and the options expire on May 13, 2023. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Record Holders </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of the date of this prospectus, there were 32 holders of record of our Ordinary Shares, of which 17 record holders holding approximately 7.26% of our outstanding shares had registered addresses in the United States.</P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">111</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tDSC"></a>DESCRIPTION OF SHARE CAPITAL </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following description of our share capital and provisions of our amended and restated articles of association which will be adopted immediately prior to the consummation of this offering are summaries and do not purport to be complete. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Ordinary Shares </H3>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Immediately prior to the consummation of this offering, effective upon the adoption of our amended and restated articles of association, our authorized share capital will consist of 50,000,000 ordinary shares, par value NIS 0.01 per share, of which shares will be issued and outstanding. </P>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">All of our outstanding ordinary shares are validly issued, fully paid and non-assessable. They are not redeemable and do not have any preemptive rights. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Options </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of January 1, 2014, we had the following options outstanding: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Options issued to the Chairman of the Board.</I>&nbsp;&nbsp;We issued to Mr. Fredric Price, our Chairman of the Board, options to purchase up to 319,531 ordinary shares at an exercise price of $0.0004 per share. These options shall expire on April 24, 2022. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left"><I>Options issued to one of our board members.</I>&nbsp;&nbsp;We issued to Mrs. Marlene Haffner, a Director in our company, options to purchase up to 83,579 ordinary shares at an exercise price of $0.0004 per share. These options shall expire on May 13, 2023. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Share History </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following is a summary of the history of our share capital since the Company&#146;s inception. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>February 2012 Subscription Agreement</I>.&nbsp;&nbsp;On February 13, 2012, we closed the February 2012 Subscription Agreement, pursuant to which we sold an aggregate of 471,964 series A preferred shares, at a price of $0.53 per share. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>August 2012 Joinder to a Subscription Agreement</I>.&nbsp;&nbsp;On August 6, 2012, we closed the August 2012 Joinder to a Subscription Agreement, pursuant to which we sold an aggregate of 94,393 series A preferred shares, at a price of $0.53 per share. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>June 2013 Share Purchase Agreement.</I>&nbsp;&nbsp;On July 1, 2013, we closed the first closing of the June 2013 Share Purchase Agreement, with the second closing occurred on January 1<sup>st</sup>, 2014, pursuant to which we sold an aggregate of 2,130,159 of our ordinary shares at a price of $0.95 per share. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Conversion of Preferred Shares to Ordinary Shares</I>.&nbsp;&nbsp;In connection with the June 2013 Share Purchase Agreement, on June 19, 2013, all classes of preferred shares in the Company&#146;s share capital, including all preferred shares issued and outstanding, were converted to ordinary shares on a one for one basis, resulting in a one-class capital structure consisting solely of ordinary shares. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>February 2014 Private Placement.</I>&nbsp;&nbsp;On February 6, 2014, we closed a private placement, pursuant to which we sold an aggregate of 782,537 of our ordinary shares at a price of $6.07 per share. </P>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Share Options.</I>&nbsp;&nbsp;Since the Company&#146;s inception, we have granted options to purchase a total of 411,630 ordinary shares upon the exercise of such share options. None of such options were exercised up to date, and all of the options are still outstanding. In addition, contingent upon consummation of this offering, we have granted options to purchase a total of 206,702 ordinary shares. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Voting Rights </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general meeting. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">112</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Transfer of Shares </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our ordinary shares that are fully paid for are issued in registered form and may be freely transferred under our amended and restated articles of association, unless the transfer is restricted or prohibited by applicable law or the rules of a stock exchange on which the shares are traded. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended and restated articles of association or the laws of the State of Israel, except under certain circumstances for ownership by nationals of some countries that are, or have been, in a state of war with Israel. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Election of Directors </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our ordinary shares do not have cumulative voting rights in the election of directors. As a result, the holders of a majority of the voting power represented at a shareholders meeting have the power to elect all of our directors, subject to the special approval requirements for external directors in accordance with Israeli Companies Law which are described under &#147;Management&nbsp;&#151;&nbsp;External directors.&#148; </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our directors hold office for their scheduled term unless they are removed from office upon the occurrence of certain events, in accordance with the Israeli Companies Law and our amended and restated articles of association. In addition, our amended and restated articles of association allow our Board of Directors to appoint directors to fill vacancies on the Board of Directors to serve for a term of office equal to the remaining period of the term of office of the directors(s) whose office(s) have been vacated. External directors are elected for an initial term of three years, may be elected for additional terms of three
years each under certain circumstances, and may be removed from office pursuant to the terms of the Israeli Companies Law. See &#147;Management&nbsp;&#151;&nbsp;Board practices&nbsp;&#151;&nbsp;External directors.&#148; </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Dividend and Liquidation Rights </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Israeli Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the Company&#146;s articles of association provide otherwise. Our amended and restated articles of association do not require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our Board of Directors. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the Israeli Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, as such are defined in the Companies Law, according to our then last reviewed or audited financial reports, provided that the date of the financial reports is not more than six months prior to the date of distribution, or we may distribute dividends that do not meet such criteria only with court approval. In each case, we are only permitted to pay a dividend if our Board of Directors or the court, as applicable, determined that there is no reasonable concern that
payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Exchange Controls </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to non-residents of Israel, except under certain circumstances for shareholders who are subjects of countries that are, or have been, in a state of war with Israel. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Shareholder Meetings </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be no later than 15 months after the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to as special meetings. Our Board of Directors may call special meetings whenever it sees fit, at such time and place, within or outside of Israel, </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">113</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">as it may determine. In addition, the Israeli Companies Law provides that our Board of Directors is required to convene a special meeting upon the written request of (i) any two of our directors or one-quarter of our Board of Directors, or (ii) one or more shareholders holding, in the aggregate, either (a) 5% of our outstanding issued shares and 1% of our outstanding voting power, or (b) 5% of our outstanding voting power. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Subject to the provisions of the Israeli Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record on a date to be decided by the board of directors, which may generally be between four and 40 days prior to the date of the meeting. Furthermore, the Israeli Companies Law requires that resolutions regarding the following matters must be passed at a general meeting of our shareholders: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">amendments to our amended and restated articles of association; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the exercise of our Board of Director&#146;s powers by a general meeting, if our Board of Directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">appointment or termination of our auditors; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">appointment of external directors; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">approval of acts and transactions involving related parties, as defined by the Israeli Companies Law; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">increases or reductions of our authorized share capital; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a merger. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Israeli Companies Law and our amended and restated articles of association require that a notice of any annual general meeting or special shareholders meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes matters upon which shareholders may vote by means of a voting deed, including the appointment or removal of directors, the approval of a compensation policy with respect to office holders, the approval of transactions with office holders or interested or related parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting.
</P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law and our amended and restated articles of association, shareholders are not permitted to take action via written consent in lieu of a meeting. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Voting Rights </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Quorum Requirements </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The quorum required for our general meetings of shareholders consists of at least two shareholders present in person, by proxy or written ballot who hold or represent between them at least one-third of the total outstanding voting rights. A meeting adjourned for lack of a quorum is generally adjourned to the same day in the following week at the same time and place or to a later time/date if so specified in the summons or notice of the meeting. At the reconvened meeting, any two or more shareholders present in person or by proxy shall constitute a lawful quorum. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Vote Requirements </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Israeli Companies Law or by our amended and restated articles of association. Under the Israeli Companies Law certain actions require a special majority, which may include (i) appointment of external directors, requiring the approval of certain transactions described above under &#147;Management&nbsp;&#151;&nbsp;Board Practices&nbsp;&#151;&nbsp;External Directors&#148;, (ii) approval of an extraordinary transaction with a controlling shareholder and the terms of
employment or other engagement of the controlling shareholder of the Company or such controlling shareholder&#146;s relative (even if not extraordinary), requiring the approval described above under &#147;Approval of Related Party Transactions under Israeli Law&nbsp;&#151;&nbsp;Disclosure of Personal Interests of Controlling Shareholders.&#148;, (iii) approval of executive officer&#146; compensation inconsistent with our office holder compensation policy, compensation of our chief executive officer, or the compensation of an executive officer who is also the controlling shareholder of our company (including an </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">114</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">affiliate thereof), all of which require the approval described above under &#147;Management&nbsp;&#151;&nbsp;NASDAQ Listing Rules and Home Country Practices&nbsp;&#151;&nbsp;Compensation of Officers.&#148;; (iv) approving the authorization of the chairman of the board or a relative thereof to assume the role or responsibilities of the chief executive officer, or the authorization of the chief executive officer or a relative thereof to assume the role or responsibilities of the chairman of the board, for periods of no longer than three years each and subject to receipt of the approval of a majority of the shares voting on the
matter, providing that either (1) included in such majority are at least two-thirds of the shares of shareholders who are non-controlling parties and do not have a personal interest in the said resolution (excluding for such purpose any abstentions); or (2) the total number of shares of shareholders specified in clause (3) who voted against the resolution does not exceed two percent (2%) of the voting rights in the company; and (v) mergers, certain private placements that will increase certain types of shareholders&#146; relative holdings in the company, or certain special tender offers or forced bring along share purchase transactions, all of which require the approval described below under &#147;Acquisitions under Israeli Law&#148;. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under our amended and restated articles of association, the alteration of the rights, privileges, preferences or obligations of any class of our share capital requires a simple majority of the class so affected (or such other percentage of the relevant class that may be set forth in the governing documents relevant to such class), in addition to the ordinary majority vote of all classes of shares voting together as a single class at a shareholder meeting. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Further exceptions to the simple majority vote requirement are a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the Company pursuant to Section 350 of the Israeli Companies Law, which requires the approval of the majority of the shareholders in each class of shareholders present at the meeting and who are together the holders of 75% of the voting rights represented at the meeting, in person, by proxy or by voting deed and voting on the resolution. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Israeli law provides that a shareholder of a public company may vote in a meeting and in a class meeting by means of a voting deed in which the shareholder indicates how he or she votes on resolutions relating to the following matters: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">appointment or removal of directors; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">approval of transactions with office holders or interested or related parties; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">approval of a merger; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">authorization of the chairman of the board or a relative thereof to assume the role or responsibilities of our chief executive officer, and authorization of our chief executive officer or a relative thereof to assume the role or responsibilities of the chairman of the board; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">approval of an arrangement or reorganization of the Company pursuant to Section 350 of the Israeli Companies Law; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">approval of the compensation policy with respect to the terms of office and employment of office holders; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">other matters in respect of which there is a provision in the articles of association providing that decisions of the general meeting may also be passed by voting deed or which may be prescribed by Israel&#146;s Minister of Justice. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The provision allowing the vote by voting deed does not apply if, to the best knowledge of the Company at the time of calling the general shareholders meeting, a controlling shareholder will hold on the record date for such shareholders meeting, voting power sufficient to determine the outcome of the vote. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Israeli Companies Law provides that a shareholder, in exercising his or her rights and performing his or her obligations toward the Company and its other shareholders, including voting at general meetings, must act in good faith and in a customary manner, and avoid abusing his or her power. See &#147;Approval of Related Party Transactions under Israeli Law&nbsp;&#151;&nbsp;Shareholder Duties&#148; above for further detail. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">115</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Access to Corporate Records </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law and our amended and restated articles of association, shareholders are provided access to the following corporate records: minutes of our general meetings; our shareholders register and principal shareholders register, articles of association and financial statements; and any document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may submit a reasoned request to be provided with any document related to an action or transaction requiring shareholder approval under the approval of related party
transaction provisions of the Companies Law. We may deny this request if we believe it has not been submitted in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Modification of Class Rights </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The rights attached to any class of shares, such as voting, liquidation and dividend rights, may be amended by adoption of a resolution by the holders of a majority (or a special majority, as may be applicable to the particular matter) of the shares of that class present at a separate class meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in our amended and restated articles of association. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Acquisitions under Israeli Law </H2>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Full Tender Offer </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A person wishing to acquire shares of a public Israeli company and who could as a result hold over 90% of the target company&#146;s issued and outstanding share capital or voting rights is required by the Israeli Companies Law to make a tender offer to all of the company&#146;s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who could as a result hold over 90% of the issued and outstanding share capital or voting rights of a certain class of shares is required to make a tender offer to all of the shareholders who hold
shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital and voting rights of the company or of the applicable class, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law (provided that a majority of the offerees that do not have a personal interest in such tender offer shall have approved it, which condition shall not apply if, following consummation of the tender offer, the acquirer would hold at least 98% of all of the company&#146;s outstanding shares and voting rights (or shares and voting rights of the relevant class)). However, shareholders may, at any time within six months following the completion of the tender offer, petition the court to alter the consideration for the acquisition. Even shareholders who indicated their acceptance of the tender offer may so
petition the court, unless the acquirer stipulated that a shareholder that accepts the offer may not seek appraisal rights. If the shareholders who did not accept the tender offer hold 5% or more of the issued and outstanding share capital or voting rights of the company or of the applicable class, the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#146;s issued and outstanding share capital or voting rights or 90% of the shares or voting rights of the applicable class, from shareholders who accepted the tender offer. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Special Tender Offer </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Israeli Companies Law provides that an acquisition of a control bloc of shares in a public Israeli company must be made by means of a special tender offer if as a result of the transaction the shareholder could become a holder of 25% or more of the voting rights in the company, unless one of the exemptions in the Israeli Companies Law (as described below) is met. This rule does not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Israeli Companies Law provides that an acquisition of shares in a public company must be made by means of a tender offer if as a result
of the acquisition the purchaser could become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company, unless one of the exemptions in the Israeli Companies Law is met. Such exemptions include (a) acquisition of shares issued in the course of a private placement approved by the general meeting of the company as a private placement intended to provide purchaser with holdings of 25% or more of the voting rights in the </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">116</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">company, if there is no other shareholder of the company who holds more than 25% of the voting rights in the company, or as a private placement intended to provide purchaser with holdings of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company, (b) acquisition of shares from a holder of 25% or more of the voting rights in the company following which purchaser shall hold 25% or more of the voting rights in the company, or (c) acquisition of shares from a holder of 45% or more of the voting rights in the company following
which purchaser shall hold 45% or more of the voting rights in the company. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A special tender offer must be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting power attached to the company&#146;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company&#146;s outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (disregarding holders who control the offeror and who have a
personal interest in the acceptance of the offer or the holder of 25% or more of the voting rights of the company, any of their relatives, or corporations controlled by any of the above). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Merger </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Israeli Companies Law permits merger transactions between Israeli companies if approved by each party&#146;s board of directors and, unless certain requirements described under the Israeli Companies Law are met, by a majority vote of each party&#146;s shares, and, in the case of the target company, a majority vote of each class of its shares, voted on the proposed merger at a shareholders meeting called with at least 35 days&#146; prior notice. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of shares represented at the shareholders meeting (disregarding abstentions) that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party, vote against the merger, or anyone on such parties&#146; behalf, including relatives of such parties and corporations controlled them, vote against the
merger. If, however, the merger involves a merger with a company&#146;s own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority approval that governs all extraordinary transactions with controlling shareholders (as described above in this prospectus under &#147;Management&nbsp;&#151;&nbsp;NASDAQ Listing Rules and Home Country Practices&nbsp;&#151;&nbsp;Shareholder Approval.&#148;) </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value of the parties to the merger and the consideration offered to the shareholders of the company that have petitioned the court to approve the merger. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of any of the parties to the merger, and may further give instructions to secure the rights of creditors. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">117</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Anti-takeover Measures under Israeli Law </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Israeli Companies Law allow us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights, distributions or other matters and shares having preemptive rights. As of the closing of this offering, no preferred shares will be authorized under our amended and restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent
our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended and restated articles of association, which requires the prior approval of the holders of a majority of the voting power attaching to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Israeli Companies Law as described above in &#147;&#151;&nbsp;Voting Rights.&#148; </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Borrowing Powers </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the Israeli Companies Law and our amended and restated articles of association, our Board of Directors may exercise all powers and take all actions that are not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders or other corporate bodies, including the power to borrow money for company purposes. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Changes in Capital </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies Law and must be approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits and, in certain circumstances, an issuance of shares for less than their nominal value, require the approval of both our Board of Directors and an
Israeli court. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Transfer Agent </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Our transfer agent in the United States will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">118</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tSEFS"></a>SHARES ELIGIBLE FOR FUTURE SALE </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to this offering, no public market existed for our ordinary shares. Sales of substantial amounts of our ordinary shares following this offering, or the perception that these sales could occur, could adversely affect prevailing market prices of our ordinary shares and could impair our future ability to obtain capital, especially through an offering of equity securities. Assuming that the underwriters do not exercise their over-allotment option with respect to this offering and assuming no exercise of options outstanding following the offering, we will have an aggregate of ordinary shares outstanding upon completion of
this offering. Of these shares, the ordinary shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless purchased by &#147;affiliates&#148; (as that term is defined under Rule 144 of the Securities Act), who may sell only the volume of shares described below and whose sales would be subject to additional restrictions described below. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The remaining ordinary shares will be held by our existing shareholders. Because substantially all of these shares were sold outside the United States to persons residing outside the United States at the time, they also will be freely tradable without restriction or further registration, except that shares held by affiliates must be sold under Rule 144, and except for the lock-up restrictions described below. Further, substantially all of our outstanding shares are subject to the lock-up agreements. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Lock-up agreements </H2>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We, all of our directors and executive officers and holders of all of our outstanding ordinary shares have signed lock-up agreements pursuant to which, subject to certain exceptions, they have agreed not to sell or otherwise dispose of their ordinary shares or any securities convertible into or exchangeable for ordinary shares for a period of 180 days or 18 months, as applicable, after the date of this prospectus without the prior written consent of Aegis Capital Corp. In addition, certain holders of options to purchase our shares have entered into similar lock-up agreements. </P>



<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Rule 144 </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In general, under Rule 144, beginning 90 days after the date of this prospectus, any person who is not our affiliate and has held their shares for at least six months, including the holding period of any prior owner other than one of our affiliates, and so long as we have filed all reports required by the Exchange Act during the previous 12 months (or such shorter period that were required to file such reports) may sell shares without restriction. In addition, under Rule 144, any person who is not an affiliate of ours and has held their shares for at least one year, including the holding period of any prior owner other than
one of our affiliates, would be entitled to sell an unlimited number of shares immediately upon the closing of this offering without regard to whether current public information about us is available. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Beginning 90 days after the date of this prospectus, a person who is our affiliate or who was our affiliate at any time during the preceding three months and who has beneficially owned restricted securities for at least six months, including the holding period of any prior owner other than one of our affiliates, is entitled to sell a number of shares within any three-month period that does not exceed the greater of: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">one percent of the number of ordinary shares then outstanding, which will equal shares; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the average weekly trading volume of our ordinary shares on the NASDAQ Capital Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If an affiliate acquires &#147;restricted securities,&#148; those securities will also be subject to holding period requirements. </P>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Upon expiration of the applicable lock-up period described above, substantially all of our outstanding ordinary shares will either be unrestricted or will be eligible for sale under Rule 144. We cannot estimate the number of our ordinary shares that our existing stockholders will elect to sell. </P>



</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">119</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Form S-8 Registration Statements </H2>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Following the completion of this offering, we intend to file one or more registration statements on Form S-8 under the Securities Act to register up the ordinary shares issued or reserved for issuance under our 2013 Plan. The registration statement on Form S-8 will become effective automatically upon filing. Ordinary shares issued to individuals upon exercise of a share option and registered under the Form S-8 registration statement will, subject to vesting and lock-up provisions and Rule 144 volume limitations applicable to our affiliates, be available for sale in the open market immediately unless they are subject to the
180-day or 18-month lock-up, as applicable, or, if subject to the lock-up, immediately after the applicable lock-up period expires. </P>



<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tTAX"></a>TAXATION </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>The following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition of our ordinary shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign, including Israeli, or other taxing jurisdiction.</I> </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ISRAELI TAX CONSIDERATIONS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The following is a summary of the material Israeli income tax laws applicable to us. This section also contains a discussion of material Israeli income tax consequences concerning the ownership and disposition of our ordinary shares. This summary does not discuss all the aspects of Israeli income tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of this kind of investor include residents of Israel or traders in securities who are subject to special tax regimes not covered in this
discussion. To the extent that the discussion is based on new tax legislation that has not yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. This summary is based on laws and regulations in effect as of the date of this prospectus and does not take into account possible future amendments which may be under consideration. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">General corporate tax structure in Israel </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Israeli resident companies, such as the Company, are generally subject to corporate tax at the rate of 26.5% as of 2014. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Capital gains derived by an Israeli resident company are generally subject to tax at the same rate as the corporate tax rate. Under Israeli tax legislation, a corporation will be considered as an &#147;Israeli Resident&#148; if it meets one of the following: (a) it was incorporated in Israel; or (b) the control and management of its business are exercised in Israel. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Taxation of our Israeli individual shareholders on receipt of dividends </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Israeli residents who are individuals are generally subject to Israeli income tax for dividends paid on our ordinary shares (other than bonus shares or share dividends) at a rate of 25%, or 30% if the recipient of such dividend is a &#147;substantial shareholder&#148; (as defined below) at the time of distribution or at any time during the preceding 12-month period. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of January 1, 2013, an additional income tax at a rate of 2% is imposed on high earners whose annual income or gain exceeds NIS 811,560. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A &#147;substantial Shareholder&#148; is generally a person who alone, or together with his relative or another person who collaborates with him on a regular basis, holds, directly or indirectly, at least 10% of any of the &#147;means of control&#148; of the corporation. &#147;Means of control&#148; generally include the right to vote, receive profits, nominate a director or an officer, receive assets upon liquidation, or instruct someone who holds any of the aforesaid rights regarding the manner in which he or she is to exercise such right(s), and all regardless of the source of such right. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The term &#147;Israeli Resident&#148; is generally defined under Israeli tax legislation with respect to individuals as a person whose center of life is in Israel. The Israeli Tax Ordinance New Version, 1961 (the &#147;Israeli Tax </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">120</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Ordinance&#148;) provides that in order to determine the center of life of an individual, account will be taken of the individual&#146;s family, economic and social connections, including: (a) place of permanent home; (b) place of residential dwelling of the individual and the individual&#146;s immediate family; (c) place of the individual&#146;s regular or permanent occupation or the place of his permanent employment; (d) place of the individual&#146;s active and substantial economic interests; (e) place of the individual&#146;s activities in organizations, associations and other institutions. The center of life of an
individual will be presumed to be in Israel if: (a) the individual was present in Israel for 183 days or more in the tax year; or (b) the individual was present in Israel for 30 days or more in the tax year, and the total period of the individual&#146;s presence in Israel in that tax year and the two previous tax years is 425 days or more. The presumption in this paragraph may be rebutted either by the individual or by the assessing officer. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Taxation of Israeli Resident Corporations on Receipt of Dividends </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Israeli resident corporations are generally exempt from Israeli corporate income tax with respect to dividends paid on our ordinary shares. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Capital Gains Taxes Applicable to Israeli Resident Shareholders </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The income tax rate applicable to Real Capital Gain derived by an Israeli individual from the sale of shares which had been purchased after January 1, 2012, whether listed on a stock exchange or not, is 25%. However, if such shareholder is considered a &#147;Substantial Shareholder&#148; (as defined above) at the time of sale or at any time during the preceding 12-month period, such gain will be taxed at the rate of 30%. As of January 1, 2013, an additional tax at a rate of 2% is imposed on high earners whose annual income or gains exceed NIS 811,560. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Moreover, capital gains derived by a shareholder who is a dealer or trader in securities, or to whom such income is otherwise taxable as ordinary business income, are taxed in Israel at ordinary income rates (26.5 as of 2014 for corporations and up to 50% for individuals). </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Taxation of Non-Israeli Shareholders on Receipt of Dividends </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Non-Israeli residents are generally subject to Israeli income tax on the receipt of dividends paid on our Shares at the rate of 25% or 30% if such recipient is a &#147;substantial shareholder&#148; at the time receiving the dividend or on any date in the 12 months preceding such date. If the shares are held by a nominee company, the nominee company or the financial institution will withhold at the source a tax of 25% whether the recipient is a substantial shareholder or not. Otherwise, the withholding at the source will be 25% or 30% in accordance with the above, unless a lower tax rate is provided in a tax treaty between
Israel and the shareholder&#146;s country of residence. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A non-Israeli resident who receives dividends from which tax was withheld is generally exempt from the duty to file returns in Israel in respect of such income; provided such income was not derived from a business conducted in Israel by the taxpayer, and the taxpayer has no other taxable sources of income in Israel. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For example, under the Convention Between the Government of the United States of America and the Government of Israel with Respect to Taxes on Income, as amended (the &#147;U.S.-Israel Tax Treaty&#148;), Israeli withholding tax on dividends paid to a U.S. resident for treaty purposes may not, in general, exceed 25%, or 15% in the case of dividends paid out of the profits of a Benefited Enterprise, subject to certain conditions. Where the recipient is a U.S. corporation owning 10% or more of the voting shares of the paying corporation during the part of the paying corporation&#146;s taxable year which precedes the date of
payment of the dividend and during the whole of its prior taxable year (if any) and the dividend is not paid from the profits of a Benefited Enterprise, the Israeli tax withheld may not exceed 12.5%, subject to certain conditions. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Capital gains income taxes applicable to non-Israeli shareholders. </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Non-Israeli resident shareholders are generally exempt from Israeli capital gains tax on any gains derived from the sale, exchange or disposition of our ordinary shares, provided that such gains were not derived from a permanent establishment or business activity of such shareholders in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemptions if an Israeli resident (i) has a controlling interest of more than 25% in such non-Israeli corporation or (ii) is the beneficiary of or is entitled to 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.
</P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">121</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Regardless of whether shareholders may be liable for Israeli income tax on the sale of our ordinary shares, the payment of the consideration may be subject to withholding of Israeli tax at the source. Accordingly, shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Estate and gift tax </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Israeli law presently does not impose estate or gift taxes. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE PARTICULAR ISRAELI TAX CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF OUR ORDINARY SHARES, INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE LAWS.</B> </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">U.S. FEDERAL INCOME TAX CONSEQUENCES </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Except as specifically set forth below, the following discussion is limited to the material U.S. federal income tax consequences relating to the purchase, ownership and disposition of our ordinary shares by U.S. Holders (as defined below) that purchase ordinary shares pursuant to the offering and hold such ordinary shares as capital assets. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, U.S. Treasury regulations promulgated thereunder and administrative and judicial interpretations thereof, all as in effect on the date hereof and all of which are subject to change, possibly with
retroactive effect. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as certain financial institutions, insurance companies, broker-dealers and traders in securities or other persons that generally mark their securities to market for U.S. federal income tax purposes, tax-exempt entities, retirement plans, regulated investment companies, real estate investment trusts, certain former citizens or residents of the United States, persons who hold ordinary shares as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148; &#147;synthetic security&#148; or integrated investment, persons that have a &#147;functional currency&#148; other than the U.S. dollar, persons that own (or are deemed to own) 10% or more (by voting power or value) of our shares,
corporations that accumulate earnings to avoid U.S. federal income tax, partnerships and other pass-through entities, and investors in such pass-through entities). Except as expressly set forth herein, this discussion does not address any U.S. state or local or non-U.S. tax consequences or any U.S. federal estate, gift or alternative minimum tax consequences. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As used in this discussion, the term &#147;U.S. Holder&#148; means a beneficial owner of ordinary shares that is, for U.S. federal income tax purposes, (i) an individual who is a citizen or resident of the United States, (ii) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income tax regardless of its source or (iv) a trust (x) with respect to which a court within the United States is able to exercise primary
supervision over its administration and one or more United States persons have the authority to control all of its substantial decisions or (y) that has elected under applicable U.S. Treasury regulations to be treated as a domestic trust for U.S. federal income tax purposes. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If an entity treated as a partnership for U.S. federal income tax purposes holds the ordinary shares, the U.S. federal income tax consequences relating to an investment in the ordinary shares will depend in part upon the status and activities of such entity and the particular partner. Any such entity should consult its own tax advisor regarding the U.S. federal income tax consequences applicable to it and its partners of the purchase, ownership and disposition of the ordinary shares. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>Persons considering an investment in the ordinary shares should consult their own tax advisors as to the particular tax consequences applicable to them relating to the purchase, ownership and disposition of the ordinary shares, including the applicability of U.S. federal, state and local tax laws and non-U.S. tax laws.</B> </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">122</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Distributions </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Subject to the discussion below under &#147;Passive foreign investment company consequences,&#148; a U.S. Holder that receives a distribution with respect to an ordinary share generally will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Israeli tax withheld from such distribution) when actually or constructively received to the extent of the U.S. Holder&#146;s pro rata share of our current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend
because it exceeds the U.S. Holder&#146;s pro rata share of our current and accumulated earnings and profits, it will be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&#146;s ordinary shares. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&#146;s shares, the remainder will be taxed as capital gain. Because we do not account for our income in accordance with U.S. federal income tax purposes, U.S. Holders should expect all distributions to be reported to them as dividends. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The U.S. dollar value of any distribution on the ordinary shares made in NIS generally should be calculated by reference to the exchange rate between the U.S. dollar and the NIS in effect on the date of receipt of such distribution by the U.S. Holder regardless of whether the NIS so received is in fact converted into U.S. dollars at that time. If the NIS so received is converted into U.S. dollars on the date of receipt, such U.S. Holder generally should not recognize currency gain or loss on such conversion. If the NIS so received is not converted into U.S. dollars on the date of receipt, such U.S. Holder generally will have a
basis in such NIS equal to the U.S. dollar value of such NIS on the date of receipt. Any gain or loss on a subsequent conversion or other disposition of such NIS by such U.S. Holder generally will be treated as ordinary income or loss and generally will be income or loss from sources within the United States for U.S. foreign tax credit purposes. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Distributions on the ordinary shares that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit purposes. Such dividends will not be eligible for the &#147;dividends received&#148; deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations. Distributions treated as dividends that are received by non-corporate U.S. Holders are expected to qualify for the 20% reduced maximum tax rate available for dividends received from &#147;qualified foreign corporation&#148; provided certain holding periods and other
requirements are met. We will not be treated as a qualifying foreign corporation, and therefore the reduced maximum tax rate in effect for 2014 described above will not apply, if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable year (see &#147;Passive foreign investment company consequences,&#148; below). </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Distributions may be subject to Israeli withholding tax&nbsp;&#151;&nbsp;see&nbsp;&#151;&nbsp;&#147;Taxation&nbsp;&#151;&nbsp;Israeli tax considerations&nbsp;&#151;&nbsp;Taxation of our shareholders&nbsp;&#151;&nbsp;Taxation of non-Israeli shareholders on receipt of dividends.&#148; Subject to certain conditions and limitations, Israeli taxes withheld from distributions by us may be credited against a U.S. Holder&#146;s U.S. federal income tax liability or, alternatively, deducted to determine the U.S. Holder&#146;s taxable income. This election to deduct foreign income taxes is made on a year-by-year basis and applies to all
foreign taxes paid by a U.S. Holder that year. Dividends paid on the ordinary shares generally will constitute income from sources outside the United States and be categorized as &#147;passive category income&#148; for U.S. foreign tax credit purposes. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Sale, exchange or other disposition of the ordinary shares </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Subject to the discussion below under &#147;Passive foreign investment company consequences,&#148; a U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of a ordinary share in an amount equal to the difference, if any, between the amount realized (i.e., the amount of cash plus the fair market value of any property received) on the sale, exchange or other disposition and such U.S. Holder&#146;s adjusted tax basis in the ordinary share, both amounts determined in U.S. dollars. Such capital gain or loss generally will be long-term capital gain
taxable at a reduced rate for non-corporate U.S. Holders (currently a maximum of 20%) or loss if, on the date of sale, exchange or other disposition, the ordinary share was held by the U.S. Holder for more than one year. Any capital gain of a non-corporate U.S. Holder that is not long-term capital gain is taxed at ordinary income </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">123</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized from the sale or other disposition of our ordinary shares will generally be gain or loss from sources within the United States for U.S. foreign tax credit purposes. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A U.S. Holder that receives NIS from the sale, exchange or other disposition of ordinary shares will generally realize an amount equal to the U.S. dollar value of the NIS received at the spot rate on the date of sale (or, in the case of cash basis and electing accrual basis U.S. Holders, the settlement date). A U.S. Holder will recognize foreign currency gain or loss to the extent the U.S. dollar value of the amount received at the spot exchange rate on the settlement date differs from the amount realized. A U.S. Holder will have a tax basis in the NIS received equal to its U.S. dollar value on the settlement date. Any gain or
loss on a subsequent conversion or other disposition of the NIS will be U.S. source ordinary income or loss. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Passive foreign investment company consequences </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In general, a corporation organized outside the United States will be treated as a PFIC in any taxable year in which either (i) at least 75% of its gross income is &#147;passive income&#148; or (ii) on average at least 50% of its assets is attributable to assets that produce passive income or are held for the production of passive income. Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from commodities transactions and from the sale or exchange of property that gives rise to passive income. Assets that produce or are held for the production of passive
income include cash, even if held as working capital or raised in a public offering, marketable securities and other assets that may produce passive income. The average percentage of a corporation&#146;s assets that produce or are held for the production of passive income generally is determined on the basis of the fair market value of the corporation&#146;s assets at the end of each quarter. This determination is based on the adjusted tax basis of the corporation&#146;s assets however, if the corporation is a &#147;controlled foreign corporation&#148;, that is not a publicly traded corporation for the taxable year. In determining whether a foreign corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Based on the nature of our business, the projected composition of our income and the projected composition and estimated fair market values of our assets, we cannot rule out that we will be a passive foreign investment company within the meaning of Section 1297 of the United States Internal Revenue Code of 1986, as amended or the regulations promulgated thereunder in 2013, 2014 or a subsequent year. Nevertheless, because this determination is made annually after the close of each taxable year, because we hold and expect to continue to hold following this offering a substantial amount of cash and cash equivalents, and because
the calculation of the value of our assets may be based in part on the value of our ordinary shares, which may fluctuate after this offering and may fluctuate considerably given that market prices of technology companies historically often have been volatile, it is difficult to predict whether we will be a PFIC in any taxable year. Even if we determine that we are not a PFIC after the close of our taxable year, there can be no assurance that the Internal Revenue Service, or the IRS, will agree with our conclusion. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are a PFIC in any taxable year during which a U.S. Holder owns ordinary shares, such U.S. Holder could be liable for additional taxes and interest charges upon (i) certain distributions by us (generally any distribution paid during a taxable year that is greater than 125 percent of the average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder&#146;s holding period for our ordinary shares), and (ii) any gain recognized on a sale, exchange or other disposition, including a pledge, of the ordinary shares, whether or not we continue to be a PFIC. In these circumstances, the tax
will be determined by allocating such distributions or gain ratably over the U.S. Holder&#146;s holding period for the ordinary shares. The amount allocated to the current taxable year (i.e., the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations as appropriate applicable to ordinary income for each such taxable year, and an interest charge, generally that applicable to underpayments of tax, will be added to the tax. If we are a PFIC for any year during which a U.S. Holder holds our ordinary shares, we will generally continue to be treated as a PFIC with respect to the holder for all succeeding years during which the U.S. Holder holds ordinary shares even if we cease to meet the requirements for PFIC status.
</P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">124</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The tax consequences that would apply if we were a PFIC would be different from those described above if a timely and valid &#147;mark-to-market&#148; election is made by a U.S. Holder for our ordinary shares. An electing U.S. Holder generally would take into account as ordinary income each year, the excess of the fair market value of our ordinary shares held at the end of the taxable year over the adjusted tax basis of such ordinary shares. The U.S. Holder would also take into account, as an ordinary
loss each year, the excess of the adjusted tax basis of such ordinary shares over their fair market value at the end of the taxable year, but only to the extent of the amount previously included in income as a result of the mark-to-market election. The U.S. Holder&#146;s tax basis in our ordinary shares would be adjusted to reflect any income or loss resulting from the mark-to-market election. Any gain from a sale, exchange or other disposition of the ordinary shares in any taxable year in which we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously included in income) and thereafter as capital loss. If, after having been a PFIC for a taxable year, we cease to be classified as a PFIC, the U.S. Holder would not be required to take into account any latent gain or loss in the manner described above and any realized gain or loss would be
classified as a capital gain or loss. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A mark-to-market election is available to a U.S. Holder only if the ordinary shares are considered &#147;marketable stock&#148;. Generally, stock will be considered marketable stock if it is &#147;regularly traded&#148; on a &#147;qualified exchange&#148; within the meaning of applicable U.S. Treasury regulations. A class of stock is regularly traded during any calendar year during which such class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Our ordinary shares will be marketable stock as long as they remain listed on the NASDAQ Global Market and are regularly
traded. A mark-to-market election will not apply to our ordinary shares for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply to any subsidiary that we own. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The tax consequences that would apply if we were a PFIC would also be different from those described above if a U.S. Holder were able to make a valid &#147;qualified electing fund&#148; (&#147;QEF&#148;) election. As we do not expect to provide U.S. Holders with the information required in order to permit a QEF election, prospective investors should assume that a QEF election will not be available. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If we are a PFIC in any taxable year during which a U.S. Holder owns the ordinary shares, such U.S. Holder may also suffer adverse tax consequences under the PFIC rules described above with respect to any lower-tier PFIC in which we have a direct or indirect equity interest. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Each U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain information. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>The U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urged to consult their own tax advisers with respect to the purchase, ownership and disposition of ordinary shares, the consequences to them of an investment in a PFIC, any elections available with respect to our ordinary shares and the IRS information reporting obligations with respect to the purchase, ownership and disposition of ordinary shares.</B> </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Certain reporting requirements with respect to payments of Offer Price </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">U.S. Holders paying more than U.S. $100,000 for ordinary shares generally will be required to file IRS Form 926 reporting the payment of the Offer Price for an ordinary share to us. Substantial penalties may be imposed upon a U.S. Holder that fails to comply. Each U.S. Holder should consult its own tax advisor as to the possible obligation to file IRS Form 926. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Information reporting and backup withholding </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Dividends on and proceeds from the sale or other disposition of the ordinary shares may be reported to the IRS unless the U.S. Holder establishes a basis for exemption. Backup withholding may apply to amounts subject to reporting if (i) the holder fails to provide an accurate taxpayer identification number or otherwise establish a basis for exemption, or (ii) is described in certain other categories of persons. Backup withholding is not an additional tax. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">125</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Any amounts withheld under the backup withholding rules generally will be allowed as a refund or a credit against a U.S. Holder&#146;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to the IRS. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Certain U.S. Holders who are individuals must report information relating to stock of a non-U.S. person, subject to certain exceptions (including an exception for stock held in custodial accounts maintained by a U.S. financial institution). U.S. Holders are urged to consult their tax advisers regarding the effect, if any, of this legislation on their ownership and disposition of ordinary shares. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><B>THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A PROSPECTIVE INVESTOR. EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN ORDINARY SHARES IN LIGHT OF THE INVESTOR&#146;S OWN CIRCUMSTANCES.</B> </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">126</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tUND"></a>UNDERWRITING </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aegis Capital Corp. is acting as the representative of the underwriters of this offering (the &#147;Representative&#148;). We have entered into an underwriting agreement dated the date of this prospectus with the Representative. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named below and each underwriter named below has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of our ordinary shares next to its name in the following table: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="464"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Underwriter</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of Shares</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Aegis Capital Corp<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Total<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters are committed to purchase all the shares offered by us if any shares are purchased, other than those covered by the option to purchase additional shares described below. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may be increased or the offering may be terminated. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters propose to offer the shares offered by us to the public at the public offering price set forth on the cover of this prospectus. In addition, the underwriters may offer some of the shares to other securities dealers at such price less a concession of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. If all of the shares offered by us are not sold at the public offering price, the underwriters may change the offering price and other selling terms by means of a supplement to this prospectus. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriters&#146; obligations are subject to customary conditions, representations and warranties, such as receipt by the underwriters of officers&#146; certificates and legal opinions. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act of 1933, and to contribute to payments the underwriters may be required to make in respect thereof. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have granted the underwriters an over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus, permits the underwriters to purchase a maximum of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares from us to cover over-allotments. If the underwriters exercise all or part of this option, they will purchase shares covered by the option at the public offering price less the underwriting discounts and commissions that appear on the cover page of this prospectus. If this option is exercised in full, the total price to the public will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , and the total
proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">127</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Underwriting Discounts and Commissions.</I>&nbsp;&nbsp;We have agreed to pay underwriting discounts and commissions of 7% of the gross proceeds of the offering (equivalent to 7% of the per share public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ). The following table shows the public offering price, underwriting discounts and commissions and expenses to be paid by us to the underwriters and the proceeds of the public offering, before expenses, to us. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="424"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Without<BR> over-allotment<BR> exercise</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>With full<BR> over-allotment<BR> exercise</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Public offering price</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Underwriting discounts and commissions paid by us (per ordinary share)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Underwriting discounts and commissions paid by us (total)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Proceeds before other expenses<sup>&#040;1&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">(1)</TD>

          <TD STYLE="text-align: left">We have agreed to pay the underwriters a non-accountable expense allowance in the amount of 1% of the total public offering price of the shares sold (excluding the over-allotment option). We have paid a $25,000 advance to the underwriters and are required to pay an additional $25,000 within five days after the filing of this registration statement, such amounts to be applied against the underwriters&#146; out-of-pocket accountable expenses actually incurred by the underwriters in connection with this offering. We will also pay or reimburse the underwriters over and above the underwriting discount, to cover certain out of pocket items of expenses they incur in connection with this offering, including (i) expenses relating to background checks of our officers and directors not to exceed an aggregate of $30,000, (ii) $21,775 for costs associated with the use of Ipreo&#146;s book-building, prospectus tracking and compliance software; (iii) up to
$20,000 for the underwriters&#146; actual accountable &#147;road show&#148; expenses, and (iv) up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for commemorative mementos and Lucite tombstones. Excluding the underwriting discounts and commissions, total expenses attributable to this offering are estimated to be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Right of First Refusal</I>.&nbsp;&nbsp;We have agreed to grant to the Representative the right of first refusal to act as exclusive financial advisor, lead managing underwriter and/or book runner and investment banker for each and every future public and private equity and public debt offerings during such six (6) month period of the Company, or any successor to or any subsidiary of the Company that takes place within a period of six (6) months from the effective date of this registration statement. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Representative&#146;s Warrants.</I>&nbsp;&nbsp;We have also agreed to issue to the Representative or its designees, at the closing of this offering, warrants (the &#147;Representative&#146;s Warrants&#148;) to purchase that number of our ordinary shares equal to 5% of the aggregate number of shares sold in the offering (excluding the over-allotment option). The Representative&#146;s Warrants will be exercisable at any time and from time to time, in whole or in part, during a period commencing one year from the date of effectiveness of this registration statement (the &#147;First Anniversary&#148;), as follows: &nbsp;1/3 of
the Representative&#146;s Warrants will have an exercise period of 12 months beginning on the First Anniversary, at a price per share equal to 150.0% of the public offering price per share of ordinary shares at the offering; &nbsp;1/3 of the Representative&#146;s Warrants will have an exercise period of 18 months beginning on the First Anniversary, at a price per share equal to 200.0% of the public offering price per share of ordinary shares at the offering; and &nbsp;1/3 of the Representative&#146;s Warrants will have an exercise period of 24 months beginning on the First Anniversary, at a price per share equal to 250.0% of the public offering price per share of ordinary shares at the offering. The Representative&#146;s Warrants and the ordinary shares underlying the Representative&#146;s Warrants have been deemed compensation by FINRA and are, therefore, subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA. The Representative (or permitted assignees under the Rule) will
not sell, transfer, assign, pledge or hypothecate the Representative&#146;s Warrants or the ordinary share underlying the Representative&#146;s Warrants, nor will it engage in any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the Representative&#146;s Warrants or the ordinary shares underlying the Representative&#146;s Warrants for a period of 180 days after the effective date of the registration statement. The Representative&#146;s Warrants will provide for one demand registration right (with a duration of not more than five years from the date of effectiveness of this registration statement) and customary anti-dilution provisions (for share dividends and splits and recapitalizations) consistent with FINRA Rule 5110, and further, the number of shares underlying the Representative&#146;s Warrants shall be reduced if necessary to comply with FINRA rules or regulations. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">128</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Discretionary Accounts.</I>&nbsp;&nbsp;The underwriters do not intend to confirm sales of the shares offered hereby to any accounts over which they have discretionary authority. </P>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Lock-Up Agreements.</I>&nbsp;&nbsp;We, our officers and directors and holders of all of our outstanding ordinary shares have entered into lock-up agreements with the underwriters. Under these agreements, we and these other individuals have agreed, subject to specified exceptions, not to sell or transfer any ordinary shares or securities convertible into, or exchangeable or exercisable for, our ordinary shares, during a period ending 180 days or, with respect to Dr. Dalia Megiddo and Mr. Udi Gilboa, 18 months after the date of this prospectus, without first obtaining the written consent of the Representative. Specifically,
we and these other individuals have agreed not to: </P>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any ordinary shares, or any options or warrants to purchase any shares of our ordinary shares, or any securities convertible into, exchangeable for or that represent the right to receive ordinary shares; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">engage in any hedging or other transactions, including, without limitation, any short sale or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to any of the ordinary shares or with respect to any security that includes, relates to, or derives any significant part of its value from the individual&#146;s ordinary shares; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">whether any such transaction described above is to be settled by delivery of ordinary shares or other securities, in cash or otherwise. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The restrictions described above, applicable to us, do not apply to: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the sale of shares of ordinary shares to the underwriters pursuant to the underwriting agreement; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the issuance by us of shares of our ordinary shares upon the exercise of an option or warrant or the conversion of a security outstanding on the date of this prospectus of which the underwriters have been advised in writing or that is described in this prospectus; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the grant by us of stock options or other stock-based awards, or the issuance of shares of our ordinary shares upon exercise thereof, to eligible participants pursuant to employee benefit or equity incentive plans described in this prospectus, provided that, prior to the grant of any such stock options or other stock-based awards that vest within the restricted period, each recipient of such grant shall sign and deliver a lock-up agreement agreeing to be subject to the restrictions on transfer described above; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the filing by us of a registration statement on Form S-8 or any successor form thereto with respect to the registration of securities to be offered under any employee benefit or equity incentive plans described in this prospectus. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If the Representative agrees to release any party from the restrictions set forth in the lock-up agreement with such party prior to the expiration of the restricted period, all other parties subject to the lock-up agreement shall be entitled to a proportionate release of their ordinary shares from the lock-up agreement restrictions. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Electronic Offer, Sale and Distribution of Shares.</I>&nbsp;&nbsp;A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The Representative may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet
distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon by investors. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">129</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Other Relationships.</I>&nbsp;&nbsp;Certain of the underwriters and their affiliates have provided, and may in the future provide, various investment banking, commercial banking and other financial services for us and our affiliates for which they have received, and may in the future receive, customary fee; however, except as disclosed in this prospectus, we have no present arrangements with any of the underwriters for any further services. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><I>Stabilization.</I>&nbsp;&nbsp;In connection with this offering, the underwriters may engage in stabilizing transactions, overallotment transactions, syndicate covering transactions, penalty bids and purchases to cover positions created by short sales. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Stabilizing transactions permit bids to purchase shares so long as the stabilizing bids do not exceed a specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the shares while the offering is in progress. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Overallotment transactions involve sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the overallotment option. In a naked short position, the number of shares involved is greater than the number of shares in the overallotment option. The underwriters may close out any short position by exercising their overallotment option and/or purchasing shares in the open market. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Syndicate covering transactions involve purchases of shares in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise of the overallotment option. If the underwriters sell more shares than could be covered by exercise of the overallotment option and, therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the open market that could adversely affect investors who purchase in the offering. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">Penalty bids permit the representative to reclaim a selling concession from a syndicate member when the shares originally sold by that syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our ordinary shares or preventing or retarding a decline in the market price of our ordinary shares. As a result, the price of our ordinary shares in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our ordinary shares. These transactions may be effected on Nasdaq, in the over-the-counter
market or otherwise and, if commenced, may be discontinued at any time. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Initial public offering of ordinary shares </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to this offering, there has been no public market for our ordinary shares. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the information set forth in this prospectus and otherwise available to the representative; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our prospects and the history and prospects for the industry in which we compete; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an assessment of our management; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">our prospects for future earnings; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the general condition of the securities markets at the time of this offering; </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">130</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the recent market prices of, and demand for, publicly traded ordinary shares of generally comparable companies; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">other factors deemed relevant by the underwriters and us. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Neither we nor the underwriters can assure investors that an active trading market will develop for our ordinary shares, or that the shares will trade in the public market at or above the initial public offering price. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Offering Restrictions Outside the United States </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the shares offered by this prospectus in any jurisdiction where action for that purpose is required. The shares offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such shares be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose
possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any shares offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">European economic area </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &#147;Relevant Member State&#148;) an offer to the public of any shares which are the subject of the offering contemplated by this Prospectus (the &#147;Shares&#148;) may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any Shares may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representative for any such offer; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of Shares shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article 3 of the Prospectus Directive. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any Shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide to purchase any Shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the
Relevant Member State), and includes any relevant implementing measure in the Relevant Member State, and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>

<H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">United Kingdom </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Each underwriter has represented and agreed that: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the FSMA) received by it in connection with the issue or sale of the Shares in circumstances in which Section 21(1) of the FSMA does not apply to us; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the Shares in, from or otherwise involving the United Kingdom. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">131</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Israel </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In the State of Israel, the securities offered hereby may not be offered to any person or entity other than the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a fund for joint investments in trust (i.e., mutual fund), as such term is defined in the Law for Joint Investments in Trust, 5754 1994, or a management company of such a fund; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a provident fund as defined in the Control of the Financial Services (Provident Funds) Law 5765-2005, or a management company of such a fund; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an insurer, as defined in the Law for Oversight of Insurance Transactions, 5741-1981; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a banking entity or satellite entity, as such terms are defined in the Banking Law (Licensing), 5741-1981, other than a joint services company, acting for its own account or for the account of investors of the type listed in Section 15A(b) of the Securities Law, 1968; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a company that is licensed as a portfolio manager, as such term is defined in Section 8(b) of the Law for the Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account or for the account of investors of the type listed in Section 15A(b) of the Securities Law, 1968; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an investment advisor or investment distributer, as such term is defined in Section 7(c) of the Law for the Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a member of the Tel Aviv Stock Exchange, acting on its own account or for the account of investors of the type listed in Section 15A(b) of the Securities Law, 1968; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an underwriter fulfilling the conditions of Section 56(c) of the Securities Law, 5728-1968, acting on its own account; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a venture capital fund (defined as an entity primarily involved in investments in companies which, at the time of investment, (i) are primarily engaged in research and development or manufacture of new technological products or processes and (ii) involve above-average risk); </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an entity fully owned by investors of the type listed in Section 15A(b) of the Securities Law, 1968; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an entity, other than an entity formed for the purpose of purchasing securities in this offering, in which the shareholders&#146; equity is in excess of NIS 50 million; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an individual fulfilling the conditions of Section 9 to the supplement to the Law for the Regulation of Investment Advisors and Portfolio Managers, 5755-1995, acting on its own account (for this matter, Section 9 to the supplement shall be referred to as &#147;as an investor for the meaning of Section 15A(b)(1) of the Securities Law 1968&#148; instead of &#147;as an eligible client for the meaning of this law&#148;). </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Offerees of the securities offered hereby (&#147;Investors&#148;) in the State of Israel shall be required to submit written confirmation that they fall within the scope of one of the above criteria, that they are fully aware of the significance of being an Investor pursuant to such criteria and that they have given their consent (the &#147;Consent&#148;). An appeal to an Investor for the Consent shall not be considered a public offering. This prospectus supplement will not be distributed or directed to investors in the State of Israel who do not fall within one of the above criteria. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, if a purchase of securities is made within an institutional trading system, as that term is defined in the Tel Aviv Stock Exchange regulations, a person giving a stock exchange member his prior Consent before submitting a purchase order to the institutional trading system for the first time will be seen as acting within the provisions the above criteria with respect to the Consent, provided that if such person is an investor pursuant to the sixth, tenth, eleventh or twelfth bullet points specified above, such person committed in advance that, until the last business day of the third month in each year, he will
renew his Consent, and that if he withdraws his Consent, he will notify the stock exchange member immediately and will cease to give purchase orders in such institutional trading institution. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">132</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H3 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: italic; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Canada </H3>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Shares sold in this offering have not been and will not be qualified for distribution under applicable Canadian securities laws. Shares may be offered to residents of Canada pursuant to exemptions from the prospectus requirements of such laws. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The address of Aegis Capital Corp. is 810 Seventh Avenue, 18<sup>th</sup> Floor, New York, New York 10019. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tEXP"></a>EXPENSES </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We estimate that the total expenses of this offering payable by us, excluding the underwriting discounts and commissions and expenses, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="464"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="74"></TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>SEC filing fee</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>4,830.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>FINRA filing fee</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,675.00</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Nasdaq listing fee</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Transfer agent fees and expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Printer fees and expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Legal fees and expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accounting fees and expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Miscellaneous</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Total</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>




<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">*</TD>

          <TD STYLE="text-align: left">To be completed by amendment </TD>

</TR>

</TABLE>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tLM"></a>LEGAL MATTERS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Certain legal matters concerning this offering will be passed upon for us by Zysman, Aharoni, Gayer and Sullivan &amp; Worcester LLP, New York, New York. Certain legal matters with respect to the legality of the issuance of the securities offered by this prospectus will be passed upon for us by Zysman, Aharoni, Gayer &amp; Co., Tel Aviv, Israel. As of the date of this prospectus, certain partners with Zysman Aharoni Gayer &amp; Co. Law Offices beneficially own 537,585 ordinary shares. Certain legal matters related to the offering will be passed upon for the underwriters by Troutman Sanders LLP, New York, New York and Yigal
Arnon &amp; Co., Tel Aviv, Israel. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tEXP"></a>EXPERTS </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The financial statements of Bio Blast Pharma Ltd. for its fiscal years ended December 31, 2013 and December 31, 2012 included herein have been audited by Kost Forer Gabbay &amp; Kasierer (a Member of Ernst &amp; Young Global), independent registered public accounting firm, as set forth in their report thereon, which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company&#146;s ability to continue as a going concern as described in Note 1(c) to the financial statements included herein. Such financial statements are included herein in reliance upon such report given on the
authority of such firm as experts in accounting and auditing. The address of Kost Forer Gabbay &amp; Kasierer is 3 Aminadav St., Tel-Aviv, Israel 67067. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tECL"></a>ENFORCEABILITY OF CIVIL LIABILITIES </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this registration statement, substantially all of whom reside outside of the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located outside of the United States, any judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have been informed by our legal counsel in Israel, Zysman, Aharoni, Gayer &amp; Co., that it may be difficult to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws because Israel is not the most appropriate forum to </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">133</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Subject to specified time limitations and legal procedures, Israeli courts may enforce a United States judgment in a civil matter which, subject to certain exceptions, is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that among other things: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the judgment is obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law currently prevailing in Israel; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the judgment is final and is not subject to any right of appeal; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the prevailing law of the foreign state in which the judgment was rendered allows for the enforcement of judgments of Israeli courts; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the liabilities under the judgment are enforceable according to the laws of the State of Israel and the judgment and the enforcement of the civil liabilities set forth in the judgment is not contrary to the law or public policy in Israel nor likely to impair the security or sovereignty of Israel; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the judgment was not obtained by fraud and do not conflict with any other valid judgments in the same matter between the same parties; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">the judgment is enforceable according to the law of the foreign state in which the relief was granted. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the
Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates. </P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tWYC"></a>WHERE YOU CAN FIND ADDITIONAL INFORMATION </H1>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to this offering of our ordinary shares. This prospectus does not contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is included in the registration statement. Statements made in this prospectus concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents. If we
filed any of these documents as an exhibit to the registration statement, you may read the document itself for a complete description of its terms. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">You may read and copy the registration statement, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC&#146;s public reference room at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, DC 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">134</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SEC also maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC&#146;s website at <I>http://www.sec.gov.</I> </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Upon completion of this offering, we will be subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements will file reports with the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of
the Exchange Act. In addition, we will not be required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However, we will file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and will submit to the SEC, on Form 6-K, unaudited quarterly financial information. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We expect to maintain a corporate website at <I>www.bioblast-pharma.com.</I> Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus, and we have included our website address in this prospectus solely as an inactive textual reference. We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and regulations, including, posting any XBRL interactive financial data required to be filed with the SEC, and any notices of general meetings of our shareholders. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">135</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tIFS"></a>BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> FINANCIAL STATEMENTS<BR> AS OF DECEMBER 31, 2013<BR> U.S. DOLLARS IN THOUSANDS<BR>&nbsp;&nbsp;<BR> INDEX </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="520"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="72"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Page</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1><a href="#tFRIR">Report of Independent Registered Public Accounting Firm</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: center" ROWSPAN=1 COLSPAN=1><a href="#tFRIR"><B>F-2</B></a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1><a href="#tFBAS">Balance Sheets</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: center" ROWSPAN=1 COLSPAN=1><a href="#tFBAS"><B>F-3</B></a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1><a href="#tFSOO">Statements of Operations</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: center" ROWSPAN=1 COLSPAN=1><a href="#tFSOO"><B>F-4</B></a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1><a href="#tFSSE">Statements of Changes in Shareholders&#146; Equity</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: center" ROWSPAN=1 COLSPAN=1><a href="#tFSSE"><B>F-5</B></a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1><a href="#tFSCF">Statements of Cash Flows</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: center" ROWSPAN=1 COLSPAN=1><a href="#tFSCF"><B>F-6</B></a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white"><TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; font-weight: bold" ROWSPAN=1 COLSPAN=1><a href="#tFNFS1">Notes to Financial Statements</a></TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

<TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

<TD STYLE="vertical-align: text-bottom; text-align: center" ROWSPAN=1 COLSPAN=1><a href="#tFNFS1"><B>F-7&nbsp;&#150;&nbsp;F-15</B></a></TD>

<TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-1</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="120"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="192"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="120"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="128"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1><IMG SRC="v371611_tlogo1.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left"><B>Kost Forer Gabbay &amp; Kasierer</B><BR>3 Aminadav St.<BR> Tel-Aviv 6706703, Israel</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Tel: +972-3-6232525<BR>Fax: +972-3-5622555<BR>ey.com</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>

</TR>

</TABLE></DIV>



<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tFRIR"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM<BR> &nbsp;&nbsp;<BR>To the Shareholders and Board of Directors of<BR> BIO BLAST PHARMA LTD.<BR> (A development stage company) </H1>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We have audited the accompanying balance sheets of BIO BLAST PHARMA Ltd. (a development stage company) (&#147;the Company&#148;) as of December 31, 2013 and 2012, and the related statements of operations, changes in shareholders&#146; equity and cash flow for the year ended December 31, 2013, for the period from January 22, 2012 (date of inception) to December 31, 2012 and for the period from January 22, 2012 (date of inception) to December 31, 2013. These financial statements are the responsibility of the Company&#146;s board of directors and management. Our responsibility is to express an opinion on these financial
statements based on our audits. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company&#146;s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of the
Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by the board of directors and management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In our opinion, based on our audits, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2013 and 2012, and its results of operations and cash flows for the year ended December 31, 2013, for the period from January 22, 2012 (date of inception) to December 31, 2012 and for the period from January 22, 2012 (date of inception) to December 31, 2013, in conformity with generally accepted accounting principles in the United States. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1c, the Company has incurred losses in the amount of $1,145 thousand during the year ended December 31, 2013, and has a deficit accumulated during the development stage of $1,400 thousand as of December 31, 2013. Its ability to continue to operate is dependent upon obtaining additional financial support. These conditions, among other matters described in Note 1c, raise substantial doubt about the Company&#146;s ability to continue as a going concern. The financial statements do
not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="296"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="296"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt; font-weight: bold" ROWSPAN=1 COLSPAN=1>Tel-Aviv, Israel<BR> April 7, 2014</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: center">/s/ KOST FORER GABBAY &amp; KASIERER<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt">KOST FORER GABBAY &amp; KASIERER<BR> A Member of EY Global</TD>

</TR>

</TABLE></DIV>



</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-2</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> <a name="tFBAS"></a>BALANCE SHEETS<BR> U.S. dollars in thousands </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="352"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Pro Forma financial information as of December 31, 2013*</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center" ROWSPAN=1 COLSPAN=3><FONT STYLE="font-weight: normal">(Unaudited)</FONT></TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>ASSETS<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>CURRENT ASSETS:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>270</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>146</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5,550</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Receivables and prepaid expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>29</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>10</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>129</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><U>Total</U> current assets</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>299</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>156</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>5,679</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>LONG-TERM ASSETS:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Long-term deposit</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Property and equipment, net</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><U>Total</U> long-term assets</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>TOTAL ASSETS</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>306</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>156</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>5,686</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="text-align: center; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>LIABILITIES AND SHAREHOLDERS&#146; EQUITY<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>CURRENT LIABILITIES:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Trade payables</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>46</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>74</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>46</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Other accounts payable</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>85</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>85</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><U>Total</U> current liabilities</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>131</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>81</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>131</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>SHAREHOLDERS&#146; EQUITY:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Ordinary shares of NIS 0.01 par value&nbsp;&#150;&nbsp;16,613,139 and 15,102,854 shares authorized at December 31, 2013 and 2012, respectively; 9,182,867 and 7,551,427 issued and outstanding shares at December 31, 2013 and 2012, respectively; 11,030,480 shares pro forma as of December 31, 2013 (Unaudited).</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>24</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>29</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Preferred shares of NIS 0.01 par value&nbsp;&#150;&nbsp;Nil neither authorized nor outstanding as of December 31, 2013. 1,510,285 shares authorized at December 31, 2012; 566,357 issued and outstanding preferred shares at December 31, 2012.</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Additional paid- in capital</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,551</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>283</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>6,926</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deficit accumulated during the development stage</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,400</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,400</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1><U>Total</U> shareholders&#146; equity</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>175</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>75</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>5,555</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>TOTAL LIABILITIES AND SHAREHOLDERS&#146; EQUITY</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>306</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>156</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>5,686</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">*</TD>

          <TD STYLE="text-align: left">See Note 2.b. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of the financial statements. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-3</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> <a name="tFSOO"></a>STATEMENTS OF OPERATIONS<BR> U.S. dollars in thousands, (except share and per share data) </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="352"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year ended December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Period from January 22,<BR> 2012 (date of inception) to December 31, 2013</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>732</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>140</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>872</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>General and administrative expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>416</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>86</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>502</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Operating loss</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,148</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>226</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,374</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Financial expenses (income), net</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Loss</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,145</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,374</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Deemed dividend</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Loss attributable to holders of Ordinary shares</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,171</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,400</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Basic and diluted loss per share</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.14</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.03</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Weighted average number of Ordinary shares used in computing basic and diluted loss per share</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>8,423,018</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>7,551,427</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of the financial statements. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-4</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> <a name="tFSSE"></a>STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; EQUITY<BR> U.S. dollars in thousands, except share data </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="184"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="42"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="42"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Ordinary shares</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Preferred A shares</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Additional paid-in capital</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Deficit accumulated during the development stage</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Total shareholders&#146; equity</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Amount</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Balance as of January 22, 2012 (date of inception)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of Ordinary shares to founders</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,551,427</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of Preferred A shares, net ($0.53 per share)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>566,357</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>294</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>295</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Share based compensation related</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Loss</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Balance as of December 31, 2012</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>7,551,427</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>20</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>566,357</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>283</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>75</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Conversion of Preferred<BR> A shares into Ordinary shares</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>566,357</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(566,357</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Deemed Dividend</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Issuance of Ordinary shares, net ($0.95 per share)</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>1,065,083</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>988</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>991</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Share based compensation related</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>254</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>254</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Loss</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,145</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,145</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Balance as of December 31, 2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>9,182,867</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>24</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>1,551</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(1,400</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>175</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of the financial statements. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-5</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> <a name="tFSCF"></a>STATEMENTS OF CASH FLOWS<BR> U.S. dollars in thousands, except share data </H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="352"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="80"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year ended December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Period from January 22,<BR> 2012 (date of inception) to December 31, 2013</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><U>Cash flows from operating activities</U><BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Loss</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,145</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(1,374</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Adjustments to reconcile loss to net cash used in operating activities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Depreciation</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;*)</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;*)</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Stock based compensation</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>254</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>9</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>263</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Change in operating assets and liabilities:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Receivables and prepaid expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(19</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(10</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(29</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Long-term deposit</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Trade payables</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>(28</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>74</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>46</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Other accounts payables</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>78</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>85</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash used in operating activities</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(865</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(149</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,014</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><U>Cash flows from investing activities</U><BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Purchase of property and equipment</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash used in investing activities</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1><U>Cash flows from financing activities</U><BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Issuance of shares, net</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>991</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>295</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,286</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net cash provided by financing activities</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>991</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>295</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1,286</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Increase in cash and cash equivalents</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>124</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>146</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>270</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents at the beginning of the period</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>146</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Cash and cash equivalents at the end of the period</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>270</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>146</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>270</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">*)</TD>

          <TD STYLE="text-align: left">Represents an amount lower than $1. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The accompanying notes are an integral part of the financial statements. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-6</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> NOTES TO FINANCIAL STATEMENTS<BR> U.S. dollars in thousands, except share data </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 1:- GENERAL </H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left"><a name="tFNFS"></a>a.</TD>

          <TD STYLE="text-align: left">Bio Blast Pharma Ltd. (the &#147;Company&#148;) was incorporated in Israel and commenced its operation on January 22, 2012. The Company is an emerging biopharmaceutical company primarily focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. The Company seeks to identify therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism. The Company&#146;s objective is to conduct additional clinical trials for its drugs (the &#147;Drugs&#148;) and, if those trials are successful, seek marketing approval from the U.S. Food and Drug Administration (the &#147;FDA&#148;) and other worldwide regulatory bodies. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">b.</TD>

          <TD STYLE="text-align: left">The Company is engaged in the research and development of products in the biopharmaceutical filed, has not generated revenue from the sale of any product, and does not expect to generate significant revenue unless and until the obtaining of marketing approval, and commercialize its Drugs. Accordingly, the Company is considered to be in the development stage as defined in ASC 915, &#147;Development stage entities&#148;. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">c.</TD>

          <TD STYLE="text-align: left">The Company has incurred losses in the amount of $1,145 during the year ended December 31, 2013. The Company has deficit accumulated during the development stage in the amount of $1,400 as of December 31, 2013 and as of that date the accumulated negative cash flow from operating activity is in the amount of $1,014. These conditions raise substantial doubts about the Company&#146;s ability to continue as a going concern. The Company&#146;s ability to continue to operate is dependent upon raising additional funds to finance its activities. According to the management&#146;s estimates, based on the Company&#146;s budget, if the Company is not successful in obtaining additional capital resources to maintain its operational activities, there is substantial doubt that the Company will be able to continue its activity until December 31, 2014. The Company is in the process of listing its securities on the NASDAQ Stock Market (the &#147;NASDAQ&#148;),
for the purpose of raising capital to finance its operations. There are no assurances, however, that the Company will be successful in obtaining an adequate level of financing needed for the long-term development and commercialization of its products. The financial statements do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might be necessary should the Company be unable to continue as a going concern. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#147;U.S. GAAP&#148;). </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">a.</TD>

          <TD STYLE="text-align: left">Use of estimates: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#146;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">b.</TD>

          <TD STYLE="text-align: left">Unaudited pro forma information: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Unaudited pro forma information as of December 31, 2013 as adjusted for the assumed two significant transactions of issuance of shares by the Company on January 1, 2014 and on February 6, 2014 of 1,065,076 Ordinary shares in an amount of $1,012 and 782,537 Ordinary shares in an </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-7</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> NOTES TO FINANCIAL STATEMENTS<BR> U.S. dollars in thousands, except share data</H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES&nbsp;-&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">amount of $4,368 net, respectively. No pro forma basic and diluted loss per share has been presented, as these transactions are assumed to occur on December 31, 2013, (see Note 12.4 and Note 12.7). </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">c.</TD>

          <TD STYLE="text-align: left">Financial statements in U.S. dollars: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company finances its operation in U.S. dollars. The majority of the Company&#146;s operations are currently conducted in Israel, a significant part of the Company&#146;s expenses are denominated and determined in U.S. dollars. The Company&#146;s management believes that the dollar is the currency of the primary economic environment in which the Company operates and expects to continue to operate in the foreseeable future. Thus, the functional and reporting currency of the Company is the U.S. dollar. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Non-dollar transactions and balances have been remeasured to U.S. dollars in accordance with ASC 830, &#147;Foreign Currency Matters&#148;, of the Financial Accounting Standards Board (&#147;FASB&#148;). All transaction gains and losses from remeasurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements of operations as financial income or expenses, as appropriate. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">d.</TD>

          <TD STYLE="text-align: left">Cash equivalents: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">e.</TD>

          <TD STYLE="text-align: left">Property and equipment, net: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following rates: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="482"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>%</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Computers and electronic equipment</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>33</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company&#146;s property and equipment are reviewed for impairment in accordance with ASC 360, &#147;Property, Plant, and Equipment,&#148; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Assets
to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. In 2013 and 2012, no impairment losses have been identified. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">f.</TD>

          <TD STYLE="text-align: left">Long-term deposits: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Long-term deposits include long-term deposits for motor vehicles under operating leases, presented at their cost. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">g.</TD>

          <TD STYLE="text-align: left">Research and development costs: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Research and development costs are expensed as incurred. Those expenses includes payments to third party clinical consultants, expenses related to conducting clinical trials, salaries and related personnel expenses, travel expenses, and share based compensations expenses to research and development employees. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-8</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> NOTES TO FINANCIAL STATEMENTS<BR> U.S. dollars in thousands, except share data</H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES&nbsp;-&nbsp;(continued)</H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">h.</TD>

          <TD STYLE="text-align: left">Income taxes: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company account for income taxes in accordance with ASC 740, &#147;Income Taxes&#148;. This topic prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, to reduce deferred tax assets to the amount that is more likely than not to be realized. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company implements a two-step approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% (cumulative basis) likely to be realized upon ultimate settlement. As of December 31, 2013 and 2012 the
Company has not recorded a liability for uncertain tax positions. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">i.</TD>

          <TD STYLE="text-align: left">Concentrations of credit risk: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Cash and cash equivalents are invested in major banks in Israel. Management believes that the financial institutions that hold the Company&#146;s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">j.</TD>

          <TD STYLE="text-align: left">Fair value of financial instruments: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has no financial instruments that are measured at fair value. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The carrying amounts of cash and cash equivalents, accounts receivable and accounts payable, approximate their fair value due to the short-term maturities of such instruments. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">k.</TD>

          <TD STYLE="text-align: left">Basic and diluted loss per share: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Basic loss per share is computed based on the weighted average number of Ordinary shares outstanding during each year. Diluted loss per share is computed based on the weighted average number of Ordinary shares outstanding during each year plus dilutive potential equivalent Ordinary shares considered outstanding during the year, in accordance with ASC 260, &#147;Earnings per Share.&#148; </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">All outstanding stock options have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods presented. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">l.</TD>

          <TD STYLE="text-align: left">Accounting for stock-based compensation: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company accounts for stock-based compensation in accordance with ASC 718, &#147;Compensation&nbsp;&#151;&nbsp;Stock Compensation&#148; that requires the measurement and recognition of compensation expense based on estimated fair values for all share-based payment awards made to employees, directors. ASC 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the option award </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-9</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> NOTES TO FINANCIAL STATEMENTS<BR> U.S. dollars in thousands, except share data</H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES&nbsp;-&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">is recognized as an expense over the requisite service periods in the Company&#146;s statement of operations based on the accelerated method. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As all options were granted at par value and the exercise price is negligible, the fair value of the options is equal to the share price. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 3:- RECEIVABLES AND PREPAID EXPENSES </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="472"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Government authorities</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>10</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Prepaid expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>29</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>10</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 4:- PROPERTY AND EQUIPMENT, NET </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="472"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Cost:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Computers and electronic equipment</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Accumulated depreciation:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Computers and electronic equipment</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;*)</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;*)</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Depreciated cost</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">*)</TD>

          <TD STYLE="text-align: left">Represents an amount lower than $1. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Depreciation expenses for the year ended December 31, 2013 were less than $1. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 5:- OTHER ACCOUNTS PAYABLE </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="472"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Employees and payroll accruals</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Accrued expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>59</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>85</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>7</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 6:- INCOME TAXES </H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">a.</TD>

          <TD STYLE="text-align: left">Tax rates applicable to the Company: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company is incorporated in Israel. Taxable income of Israeli companies is subject to tax at the rate of 25% in 2012 and 2013 and 26.5% in 2014 and onward. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">b.</TD>

          <TD STYLE="text-align: left">Net operating losses carry forward: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company has accumulated losses for tax purposes as of December 31, 2013 in the amount of approximately $600 which may be carried forward and offset against taxable income in the future for an indefinite period. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-10</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> NOTES TO FINANCIAL STATEMENTS<BR> U.S. dollars in thousands, except share data</H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 6:- INCOME TAXES&nbsp;-&nbsp;(continued)</H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">c.</TD>

          <TD STYLE="text-align: left">Deferred income taxes: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#146;s deferred tax assets are as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="418"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Operating loss carry forward</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>166</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>26</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Research and Development expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>146</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>29</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Net deferred tax asset before valuation allowance</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>312</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>55</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Valuation allowance</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(312</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(55</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 30pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net deferred tax asset</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Management currently believes that since the Company has a history of losses it is more likely than not that the deferred tax regarding the loss carry forward and other temporary differences will not be realized in the foreseeable future. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">d.</TD>

          <TD STYLE="text-align: left">No liability for uncertain tax positions was recorded as a result of implementation of ASC 740. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">e.</TD>

          <TD STYLE="text-align: left">The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowances in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 7:- CONTINGENT LIABILITIES AND COMMITMENTS </H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">a.</TD>

          <TD STYLE="text-align: left">The Company is engaged in an operating lease agreement for its office facilities. Future minimum non-cancelable rental payments under the operating lease are $4. The rent expenses for the year ended December 31, 2013 amounted to $14. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">b.</TD>

          <TD STYLE="text-align: left">On June 2013 the Company entered into an operating lease agreement for its vehicles until 2016. The rent expenses for the year ended December 31, 2013 amounted to $11. Future minimum payments under the lease are as follows: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="501" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="429"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Year ended December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Total</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2014</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>15</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>2015</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>15</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>2016</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>9</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>39</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">c.</TD>

          <TD STYLE="text-align: left">License agreement: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company entered into a Research and Exclusive License Agreement with Yissum Research Development Company of the Hebrew University in Jerusalem Ltd., for the use, development and commercialization of the TAT-MTS-Protein for protein replacement in mitochondrial diseases. The consideration to Yissum is composed of tiered low single digit royalties on net sales and a sublicense fee that will not exceed double-digits in the mid to high ten percent range of the sublicense consideration, but, if the sublicense arises from the sales of a product, the sublicense fee shall not be less than a low single digit percent of the gross
sales of such product. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-11</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> NOTES TO FINANCIAL STATEMENTS<BR> U.S. dollars in thousands, except share data</H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 8:- SHAREHOLDERS&#146; EQUITY </H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">a.</TD>

          <TD STYLE="text-align: left">General: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">All Ordinary shares, options, per share data and exercise price included in these financial statements for all periods presented have been retroactively adjusted to reflect the issuance on January 26, 2014 of 6.55-to-one bonus shares (equivalent to a 7.55-for-1 stock split), (see Note 12.2). </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">b.</TD>

          <TD STYLE="text-align: left">Share capital: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Ordinary shares confer upon their holders the right to participate and vote in general shareholders meetings of the Company and to share in the distribution of dividends, if any declared by the Company. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">c.</TD>

          <TD STYLE="text-align: left">Issuances of share: </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">1.</TD>

          <TD STYLE="text-align: left">On January 22, 2012, (inception day) the Company issued 7,551,427 Ordinary shares in consideration of their par value. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">2.</TD>

          <TD STYLE="text-align: left">In February 2012, the Company entered into an investment agreement, according to which, the Company issued 471,964 Preferred A shares in consideration of $250. In addition, in August 2012, the Company issued 94,393 Preferred A shares in consideration of $50. The issuance expenses amounted to $5. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">3.</TD>

          <TD STYLE="text-align: left">In June 2013, the Company entered into a share purchase agreement according to which, the Company shall issue a total of 2,130,159 Ordinary shares in consideration of $2,024, in two equal installments. As of December 31, 2013, the Company issued 1,065,083 Ordinary shares in consideration of $991, net of issuance expenses. Subsequent to the balance sheet date, on January 1, 2014, the Company issued 1,065,076 Ordinary shares in consideration for $1,012. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 64px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Prior to the closing of the share purchase agreement above and as a condition to it, the Company affected an equity restructuring, under which, all of the Company&#146;s Preferred shares (566,357 Preferred A shares) were converted into Ordinary shares at 1:1 ratio. As a result and in accordance with ASC 718-20-35-6, the Company recorded compensation expense in the amount of $183 and a deemed dividend in the amount of $26 in the year ended December 31, 2013. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">d.</TD>

          <TD STYLE="text-align: left">2013 incentive option plan: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In December 2013, the Company authorized through its 2013 incentive option plan (the &#147;2013 Plan&#148;) the grant of options to officers, directors, advisors, management and other key employees. The options granted have a graded vesting schedule of generally four years and expire ten years after the grant date (see Note 12.5). </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-12</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> NOTES TO FINANCIAL STATEMENTS<BR> U.S. dollars in thousands, except share data</H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 8:- SHAREHOLDERS&#146; EQUITY&nbsp;-&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">A summary of the Company&#146;s options activity (for employees and directors) under the 2013 Plan is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="322"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="53"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="61"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=15>Year ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>2012</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of options</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted average exercise price</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Number of options</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>Weighted average exercise price</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Outstanding at beginning of year</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>319,531</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>0.0004</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Granted</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>83,579</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>0.0004</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>319,531</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>0.0004</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Outstanding at end of year</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>403,110</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>0.0004</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>319,531</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>0.0004</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Vested and expected to vest</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>403,110</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>0.0004</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Options exercisable at the end of the period</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>134,370</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>0.0004</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">As of December 31, 2013, the weighted-average remaining contractual term of the outstanding and exercisable options is 8.53 years; the aggregated intrinsic value of the outstanding and exercisable options is $383 and $128. As of December 31, 2013, the unrecognized compensation cost is $20 and $5 to be recognized in 2014 and 2015, respectively. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">e.</TD>

          <TD STYLE="text-align: left">Options granted to consultants: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Company did not grant any options to consultants. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">f.</TD>

          <TD STYLE="text-align: left">Share-based payment: </TD>

</TR>

</TABLE>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 44px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The share based expense recognized in the financial statements is as follows: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="384"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year ended December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Period from January 22, 2012 (date of inception) to December 31, 2013</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Research and development</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>44</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>44</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>General and administrative expenses</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>210</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>9</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>219</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>254</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>9</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>263</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 9:- RELATED PARTY BALANCES AND TRANSACTIONS </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Balances with related parties: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="472"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="48"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Trade payable<sup>&#040;d&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>1</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Other accounts payable<sup>&#040;a&#041;</sup><sup>&#040;b&#041;</sup><sup>&#040;c&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>36</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>8</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-13</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> NOTES TO FINANCIAL STATEMENTS<BR> U.S. dollars in thousands, except share data</H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 9:- RELATED PARTY BALANCES AND TRANSACTIONS&nbsp;-&nbsp;(continued)</H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Related parties&#146; expenses: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="384"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year ended December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Period from January 22, 2012 (date of inception) to December 31, 2013</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Amounts charged to:*)<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>General and administrative expense<sup>&#040;a&#041;</sup><sup>&#040;b&#041;</sup><sup>&#040;c&#041;</sup><sup>&#040;d&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>257</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>55</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>312</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Research and Development expense<sup>&#040;c&#041;</sup></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>99</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>34</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>133</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">*)</TD>

          <TD STYLE="text-align: left">Including share based compensation expenses for the year ended December 31, 2013 in the amounts of $176. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">a.</TD>

          <TD STYLE="text-align: left">In August, 2012, the Company signed an agreement with a consultant, who is also one of the Company&#146;s shareholders and a director, as a contractor to render management, finance and operation services. The Company pays the consultant an amount of $6 per month. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">b.</TD>

          <TD STYLE="text-align: left">The Company signed an agreement with a company owned by one of its related parties. Under the agreement, the related company renders the Company with office services and office lease for a monthly fee in the amount of approximately $4 since September 10, 2013. Each party may terminate the agreement with 30-days&#146; notice. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">c.</TD>

          <TD STYLE="text-align: left">An agreement was signed on August 20, 2013 between the Company and one its shareholders, as a contractor to render services related to pre-clinical, clinical, regulatory and intellectual property issues, for an amount of approximately $15 per month. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 20px; text-align: left">d.</TD>

          <TD STYLE="text-align: left">On July 1, 2013 the Company signed an agreement with a consultant, who is also one of the Company&#146;s shareholders. The consultant shall provide advisory services. The Company pays the consultant an amount of $1 per month. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 10:- FINANCIAL EXPENSES (INCOME), NET </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="384"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="64"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year ended December 31,</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=2><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=2 COLSPAN=3>Period from January 22, 2012 (date of inception) to December 31, 2013</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Financial expenses:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Interest expense</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&#151;)*</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Exchange rate</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>2</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom" ROWSPAN=1 COLSPAN=1>Financial income:<BR></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 20pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Exchange rate</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>5</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>3</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>&#151;</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white"><!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>


<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">*)</TD>

          <TD STYLE="text-align: left">Represents an amount lower than $1. </TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-14</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> NOTES TO FINANCIAL STATEMENTS<BR> U.S. dollars in thousands, except share data</H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 11:- BASIC AND DILUTED NET LOSS PER SHARE </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><a name="tFNFS1"></a>The following table sets forth the computation of the Company&#146;s basic and diluted loss per Ordinary share: </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="554" STYLE="vertical-align: text-bottom; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="397"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="58"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD COLSPAN="3"><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="66"></TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left" ROWSPAN=1 COLSPAN=1></TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=7>Year ended December 31,</TD>

</TR>

<TR>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left"  ROWSPAN=1 COLSPAN=1>&nbsp;&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2013</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=3>2012</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Net loss attributable to Ordinary shares as reported</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(1,171</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>(229</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: #CCFFCC">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 1pt solid white" ROWSPAN=1 COLSPAN=1>Shares used in computing net loss per share of Ordinary shares, basic and diluted</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>8,423,018</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 1pt solid white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1><!-- $ -->&nbsp;</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>7,551,427</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 1pt solid white"><!-- PERCENT -->&nbsp;</TD>

</TR>

<TR STYLE="background-color: white">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt; vertical-align: text-bottom; border-bottom: 3pt double white" ROWSPAN=1 COLSPAN=1>Net loss per share of Ordinary share, basic and diluted</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.14</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: center; border-bottom: 3pt double white" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="width: 6px; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double black" ROWSPAN=1><!-- $ -->$</TD>

          <TD STYLE="vertical-align: text-bottom; text-align: right; border-bottom: 3pt double black" ROWSPAN=1 COLSPAN=1>(0.03</TD>

          <TD STYLE="white-space: nowrap; vertical-align: text-bottom; text-align: left; border-bottom: 3pt double white">)<!-- PERCENT -->&nbsp;</TD>

</TR>

</TABLE></DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">For the years ended December 31, 2013 and 2012, all outstanding options have been excluded from the calculation of the diluted net loss per share since their effect was anti-dilutive. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 12:- SUBSEQUENT EVENTS </H2>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">1.</TD>

          <TD STYLE="text-align: left">The Company evaluates events or transactions that occur after the balance sheet date but prior to the issuance of financial statements to identify matters that require additional disclosure. For its financial statements as of December 31, 2013 and for the year then ended, the Company evaluated subsequent events through April 7, 2014, the date that the financial statements were issued. Except as described below, the Company has concluded that no subsequent event has occurred that requires disclosure. </TD>

</TR>

</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">2.</TD>

          <TD STYLE="text-align: left">On January 26, 2014, the Company&#146;s shareholders resolved to issue bonus shares of 6.55-to-one bonus shares (equivalent to a 7.55-for-1 stock split) to all of its Ordinary shares and options holders. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">3.</TD>

          <TD STYLE="text-align: left">During January 2014, the Company&#146;s shareholders resolved to increase the Company&#146;s authorized shares to 17,000,000 Ordinary shares. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">4.</TD>

          <TD STYLE="text-align: left">On January 1, 2014 and in connection to the share purchase agreement dated June 2013 (see Note 8.c.3), the Company issued 1,065,076 Ordinary shares in consideration of $1,012. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">5.</TD>

          <TD STYLE="text-align: left">During January 2014, the Company&#146;s board of directors resolved to increase the Company&#146;s options pool reserved for future grant to a total of 456,899. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">6.</TD>

          <TD STYLE="text-align: left">During January 2014, the Company entered into an Exclusive License Agreement with Ramot At Tel Aviv University, for the use, development and commercialization of our-read through platform. </TD>

</TR>

</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">7.</TD>

          <TD STYLE="text-align: left">On February 6, 2014, the Company issued 782,537 Ordinary shares to private placement investors in consideration of $4,368, net. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">8.</TD>

          <TD STYLE="text-align: left">On April 1, 2014, the Company's board of directors resolved to approve the grant of options to purchase 8,520 ordinary shares of the Company to an employee. The exercise price shall be $0.95 per share. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 41px"></TD>

          <TD STYLE="width: 20px; text-align: left">9.</TD>

          <TD STYLE="text-align: left">On April 1, 2014, the Company&#146;s board of directors resolved the following resolutions, subject to the approval of the general meeting and to the closing of an Initial Public Offering (the&#147;IPO&#148;):</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 61px"></TD>

          <TD STYLE="width: 20px; text-align: left">(i)</TD>

          <TD STYLE="text-align: left">To issue the chairman of the board 206,702 options to ordinary shares and to pay him an annual compensation fee in an amount of $120.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 61px"></TD>

          <TD STYLE="width: 20px; text-align: left">(ii)</TD>

          <TD STYLE="text-align: left">To increase the monthly fee of two related party consultants to approximately $17 and $19 </TD>

</TR>

</TABLE>



</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-15</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD.<BR> (A development stage company)<BR>&nbsp;<BR> NOTES TO FINANCIAL STATEMENTS<BR> U.S. dollars in thousands, except share data</H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">NOTE 12:- SUBSEQUENT EVENTS&nbsp;-&nbsp;(continued)</H2>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 61px; text-align: left"></TD>

          <TD STYLE="width: 20px; text-align: left"></TD>

          <TD STYLE="text-align: left">per month, respectively. In addition, it was resolved to grant the consultants a one-time bonus of $80 and $90, respectively, upon the closing of the IPO (See Note 9.a and 9.c).</TD>

</TR>

</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 61px"></TD>

          <TD STYLE="width: 20px; text-align: left">(iii)</TD>

          <TD STYLE="text-align: left">To approve an annual service fee of US$25 to each of the Company&#146;s board members, excluding the chairman of the board, any executive of the Company and the external directors.</TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 61px"></TD>

          <TD STYLE="width: 20px; text-align: left">(iv)</TD>

          <TD STYLE="text-align: left">To increase the Company&#146;s authorized shares to 50,000,000 ordinary shares.</TD>

</TR>

</TABLE>



</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">F-16</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 177mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 177mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;</P>

<H2 STYLE="text-indent:0pt; text-align: right; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;</H2>

<DIV  STYLE="width: 100%; display: inline; vertical-align: middle; border-top: 4pt black double">&nbsp;</DIV></DIV><DIV STYLE="width: 177mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 16pt; line-height: 18pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Ordinary Shares</H1>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR> </P>

<P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><IMG SRC="v371611_tlogo.jpg" ALIGN="MIDDLE" ALT="[GRAPHIC MISSING]"> &nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR> </P>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 12pt; line-height: 14pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">PROSPECTUS </H1>


<DIV ALIGN="CENTER"><BR><IMG SRC="line.gif" ALIGN="MIDDLE" STYLE="width: 180px; height: 1pt; text-align: center"><BR>&nbsp;</DIV>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR> &nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR>&nbsp;<BR> &nbsp;<BR></P>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 18pt; line-height: 20pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Aegis Capital Corp </H1>

</DIV><DIV STYLE="width: 177mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"><DIV  STYLE="width: 100%; display: inline; vertical-align: middle; border-top: 4pt black double">&nbsp;</DIV></P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">PART II </H1>

<H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">INFORMATION NOT REQUIRED IN PROSPECTUS </H1>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Item 6. Indemnification of Directors, Officers and Employees </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An Israeli company may indemnify an office holder in respect of certain liabilities either in advance of an event or following an event provided that a provision authorizing such indemnification is inserted in its articles of association. Our amended and restated articles of association contain such a provision. An undertaking provided in advance by an Israeli company to indemnify an office holder with respect to a financial liability imposed on him or her in favor of another person pursuant to a judgment, settlement or arbitrator&#146;s award approved by a court must be limited to events which in the opinion of the board of
directors can be foreseen based on the Company&#146;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking must detail the abovementioned events and amount or criteria. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">In addition, a company may indemnify an office holder against the following liabilities incurred for acts performed as an office holder: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability, such as a criminal penalty, was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent or as a monetary sanction; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the Company, on its behalf or by a third party or in connection with criminal proceedings in which the office holder was acquitted or as a result of a conviction for a crime that does not require proof of criminal intent. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An Israeli company may insure a director or officer against the following liabilities incurred for acts performed as a director or officer: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a breach of duty of care to the Company or to a third party, including a breach arising out of the negligent conduct of an office holder; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a breach of duty of loyalty to the Company, provided the director or officer acted in good faith and had a reasonable basis to believe that the act would not prejudice the interests of the Company; and </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">financial liabilities imposed on the office holder for the benefit of a third party. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">An Israeli company may not, however, indemnify or insure an office holder against any of the following: </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a breach of duty of loyalty, except to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the Company; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">an act or omission committed with intent to derive unlawful personal benefit; or </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">a fine, monetary sanction, penalty or forfeit levied against the office holder. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">The Israeli Securities Law, provides that a company cannot obtain insurance against or indemnify a third party (including its officers and/or employees) for any administrative procedure conducted by the Israeli Securities Authority and/or monetary fine (other than for certain legal expenses and payments of damages to an injured party). The Israeli Securities Law permits insurance coverage and/or indemnification for certain liabilities incurred in connection with an administrative procedure, such as reasonable legal fees and certain </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-1</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm">

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">compensation payable to injured parties for damages suffered by them, provided that such insurance and/or indemnification is permitted under the company&#146;s articles of association. Our articles of association contain such a provision. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Under the Israeli Companies Law, indemnification and insurance of office holders must be approved by our compensation committee, our Board of Directors and, in certain circumstances, by our shareholders. We have obtained directors&#146; and officers&#146; liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies Law, Securities Law, and our articles of association. In addition, we have entered into indemnification agreements with each of our directors and officers providing them with
indemnification for liabilities or expenses incurred as a result of acts performed by them in their capacity as our, or our subsidiaries&#146;, directors and officers. This indemnification is limited both in terms of amount and coverage. In the opinion of the SEC, however, indemnification of directors and office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">It is our intention to include in our office holders compensation policy to be brought for approval of the shareholders following the initial issuance of the securities hereunder (and as required under the Companies Law) applicable provisions with respect to directors&#146; and officers&#146; liability insurance for the benefit of our office holders, as well as with respect to indemnification of office holders. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Item 7. Recent Sales of Unregistered Securities </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Set forth below are the sales of all securities by the Company since the date of the Company&#146;s inception on January 22, 2012. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On February 13, 2012, we sold an aggregate of 471,964 of our series A preferred shares in a private placement, at a price of $0.53 per share, for an aggregate consideration of $250,000. These series A preferred shares were later converted to ordinary shares of the Company. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On August 6, 2012, we sold an aggregate of 94,393 of our series A preferred shares in a private placement, at a price of $0.53 per share, for an aggregate consideration of $50,000. These series A preferred shares were later converted to ordinary shares of the Company. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On June 26, 2013, we sold an aggregate of 2,130,159 of our ordinary shares in a private placement at a price of $0.95 per share, for an aggregate consideration of $2,024,000. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 21px"></TD>

          <TD STYLE="width: 24px; text-align: left">&#149;</TD>

          <TD STYLE="text-align: left">On February 6, 2014, we sold an aggregate of 782,537 of our ordinary shares in a private placement at a price of $6.07 per share, for an aggregate consideration of $4,368,000, net. </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">We claimed exemption from registration under the Securities Act for the foregoing transactions under Regulation S under the Securities Act and/or Section 4(a)(2) under the Securities Act. No underwriters were employed in connection with the securities issuances set forth in this Item 7. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-2</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Item 8. Exhibits and Financial Statement Schedules </H2>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Exhibits: </H2>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="56"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="536"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Exhibit Number</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Exhibit Description</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&nbsp;1.1*</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Underwriting Agreement by and among the Company and the underwriters named therein.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&nbsp;3.1**</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Amended and Restated Articles of Association of the Company, as currently in effect.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&nbsp;3.2</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Articles of Association of the Company, to be in effect upon completion of this offering.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&nbsp;4.1*</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Representative&#146;s Warrant.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>&nbsp;5.1*</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Opinion of Zysman, Aharoni, Gayer &amp; Co., Israeli counsel to the Company, as to the validity of the ordinary shares being offered (including consent).</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>10.1*</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Amended and Restated Service Agreement between the Company and Dr. Dalia Megiddo through DM Medica Ltd., dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>10.2*</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Amended and Restated Services Agreement between the Company and Top-Notch Consulting 2009, dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>10.3**</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Bio Blast Pharma Ltd. 2013 Incentive Option Plan.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>10.4</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Form of Indemnification Agreement.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>10.5**</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Services Agreement between the Company and Top-Notch Consulting 2009 Ltd., dated November 2013.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>10.6*</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Engagement Letter between the Company and Frederic Price dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>10.7**</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Engagement Letter between the Company and Marlene Haffner dated May 13, 2013.</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>23.1</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Consent of Kost Forer Gabbay &amp; Kasierer (a Member of Ernst &amp; Young Global).</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>23.2*</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Consent of Zysman, Aharoni, Gayer, &amp; Co. (included in Exhibit 5.1).</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 10pt; text-indent: -10pt" ROWSPAN=1 COLSPAN=1>24.1**</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Power of Attorney (included on the signature page of the Registration Statement).</TD>

</TR>

</TABLE></DIV>




<P STYLE="text-align: left; text-indent: 1px"><IMG SRC="line.gif" STYLE="width: 72px; height: 1pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">*</TD>

          <TD STYLE="text-align: left">To be filed by amendment. </TD>

</TR>

</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 1px"></TD>

          <TD STYLE="width: 20px; text-align: left">**</TD>

          <TD STYLE="text-align: left">Previously filed. </TD>

</TR>

</TABLE>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Financial Statement Schedules: </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">All financial statement schedules have been omitted because either they are not required, are not applicable or the information required therein is otherwise set forth in the Company&#146;s financial statements and related notes thereto. </P>

<H2 STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 5pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Item 9. Undertakings </H2>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(a) The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(b) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described in Item 6 hereof, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-3</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(c) The undersigned registrant hereby undertakes that: </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(1) That for purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </P>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 24px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">(2) That for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial<I> bona fide</I> offering thereof. </P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-4</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SIGNATURES </H1>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this amendment to the registration statement on Form F-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York on April 7, 2014. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 224px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">BIO BLAST PHARMA LTD. </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 221px"></TD>

          <TD STYLE="width: 20px; text-align: left">By:</TD>

          <TD STYLE="text-align: left">/s/ Dr. Dalia Megiddo<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt">Dalia Megiddo<BR> Chief Executive Officer and President </TD>

</TR>

</TABLE>

<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the requirements of the Securities Act of 1933, this amendment to the registration statement on Form F-1 has been signed by the following persons in the capacities and on the dates indicated. </P>

<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>



<DIV style="text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="608" STYLE="vertical-align: text-top; text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: -24pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="200"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="184"></TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none"><!-- GUTTER -->&nbsp;</TD>

          <TD><IMG HEIGHT="1" SRC="spacer.gif" WIDTH="192"></TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: left; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Signature</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Title</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD STYLE="line-height: normal; vertical-align: text-bottom; font-weight: bold; font-size: 8pt; text-align: center; border-bottom: 1pt solid black" ROWSPAN=1 COLSPAN=1>Date</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ Fredric Price*<BR> <IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Fredric Price</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chairman of the Board</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">April 7, 2014</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ Dr. Dalia Megiddo<BR> <IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Dr. Dalia Megiddo</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Executive Officer and Director</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">April 7, 2014</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ Udi Gilboa*<BR> <IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Udi Gilboa</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Chief Financial Officer and Director</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">April 7, 2014</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ Dr. Yaron Daniely*<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Dr. Yaron Daniely</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">April 7, 2014</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ Ran Nusbaum*<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Ran Nusbaum</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">April 7, 2014</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1>/s/ Marlene Haffner*<BR> <IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"><BR>Marlene Haffner</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">Director</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">April 7, 2014</TD>

</TR>

<TR STYLE="vertical-align: top">

          <TD STYLE="padding-left: 0pt; text-indent: -0pt" ROWSPAN=1 COLSPAN=1><P STYLE="padding-left: 25pt; text-indent: -25pt; margin-bottom: -12pt">*By:</P><P STYLE="margin-top: 0pt; padding-left: 25pt">/s/ Dr. Dalia Megiddo<BR> <IMG SRC="line.gif" STYLE="width: 100%; height: 1pt">Dr. Dalia Megiddo, Attorney-in-fact</P></TD>          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">&nbsp;&nbsp;</TD>

          <TD STYLE="width: 12px; vertical-align: text-bottom; text-align: center; border-bottom: none" ROWSPAN=1><!-- GUTTER -->&nbsp;</TD>

          <TD ROWSPAN=1 COLSPAN=1 STYLE="text-align: left">&nbsp;&nbsp;</TD>

</TR>

</TABLE></DIV>



</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-5</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">

<div id="PN" style="PAGE-BREAK-AFTER: always">&nbsp;</div>

<div id="HDR">&nbsp;</div>

</DIV><P STYLE="text-align: left; font-family: Times New Roman, Times, Serif; font-size: 8pt; font-style: normal; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></P>

<DIV STYLE="width: 216mm; text-align: center"><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><H1 STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: bold; text-transform: none; padding-top: 9pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES </H1>



<P STYLE="text-indent:20px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">Pursuant to the Securities Act of 1933, as amended, the undersigned, Zysman, Aharoni, Gayer and Sullivan &amp; Worcester LLP, the duly authorized representative in the United States of Bio Blast Pharma Ltd., has signed this registration statement on April 7, 2014. </P>



<P STYLE="text-indent:0pt; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 224px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">ZYSMAN, AHARONI, GAYER AND<BR> SULLIVAN &amp; WORCESTER LLP </P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" STYLE="text-indent:0px; text-align: left; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 0pt; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">

<TR STYLE="font-weight: normal; font-style: normal; line-height: 12pt; font-size: 10pt; vertical-align: top; text-align: left">

          <TD STYLE="width: 221px"></TD>

          <TD STYLE="width: 20px; text-align: left">By:</TD>

          <TD STYLE="text-align: left">/s/ Edwin L. Miller Jr.<BR><IMG SRC="line.gif" STYLE="width: 100%; height: 1pt"></TD>

</TR>

</TABLE>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt"></P>

</DIV><DIV STYLE="width: 161mm; display: inline; vertical-align: top; margin-left: 0mm; padding-left: 0mm; padding-right: 0mm"><P STYLE="text-indent:0pt; text-align: center; font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 12pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; padding-top: 3pt; padding-right: 0pt; padding-left: 4px; padding-bottom: 3pt; margin-top: 0pt; margin-right: 0pt; margin-left: 0pt; margin-bottom: 0pt">II-6</P>

</DIV>

<HR STYLE="width: 708px; height: 2px; text-align: center">




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>v374074_ex3-2.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Articles
of Association of </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Bioblast
Pharma Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">A
Company Limited by Shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Under
The Companies Law, 5759-1999</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="width: 90%">Chapter 1 General</TD>
    <TD STYLE="width: 10%; text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Chapter 2 Shares and Share Capital</TD>
    <TD STYLE="text-align: right">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Chapter 3 General Meetings</TD>
    <TD STYLE="text-align: right">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Chapter 4 The Board of Directors</TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Chapter 5 Committees of the Board of Directors</TD>
    <TD STYLE="text-align: right">14</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Chapter 6 General Manager</TD>
    <TD STYLE="text-align: right">15</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Chapter 7 Exemption, Insurance, and Indemnification</TD>
    <TD STYLE="text-align: right">15</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Chapter 8 Internal Auditor</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Chapter 9 Auditing Accountant</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Chapter 10 Signing in the Company&rsquo;s Name</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Chapter 11 Dividend and Benefit Shares</TD>
    <TD STYLE="text-align: right">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Chapter 12 Accounts</TD>
    <TD STYLE="text-align: right">18</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Chapter 13 Notifications</TD>
    <TD STYLE="text-align: right">18</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 1 General</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">1.1</TD><TD STYLE="text-align: justify"><U>Name of Company</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">The name of the Company
is <FONT STYLE="font-variant: small-caps">Bioblast Pharma</FONT> Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">1.2</TD><TD STYLE="text-align: justify"><U>Goals of the Company</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">The goal of the Company
is to engage in any lawful business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">1.3</TD><TD STYLE="text-align: justify"><U>Interpretation</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">1.3.1</TD><TD STYLE="text-align: justify">Any statement in the singular shall also include the plural and vice versa; any statement in the
masculine shall also include the feminine and vice versa.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">1.3.2</TD><TD STYLE="text-align: justify">Except insofar as these Articles include special definitions of certain terms, any word and expression
in these Articles shall have the meaning attributed thereto in the Companies Law, 5759-1999 (the &ldquo;<B>Companies Law</B>&rdquo;)
unless this contradicts the written matter or the content thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">1.3.3</TD><TD STYLE="text-align: justify">To prevent doubt it is clarified that regarding matters regulated in the Companies Law in such
manner that the arrangements in these matters may be conditioned in the Articles, and in cases in which these Articles do not include
different provisions from those in the Companies Law, the provisions of the Companies Law shall apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">1.3.4</TD><TD STYLE="text-align: justify">For the avoidance of doubt, the provisions of the Articles of Association of the Company as detailed
below are in any event subject to the provisions of the Companies Law, the Securities Law, 5728-1968 (the &ldquo;<B>Securities
Law</B>&rdquo;) and any other applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">1.4</TD><TD STYLE="text-align: justify"><U>Limited Liability</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The liability of the shareholders
for the Company&rsquo;s debts shall be limited to the full amount (nominal value with the addition of premium) required to be paid
to the Company for the shares and which has not yet been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">1.5</TD><TD STYLE="text-align: justify"><U>Donations</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Company is entitled to
donate a reasonable sum of money for a fit purpose. The Board of Directors of the Company is entitled to determine, at its discretion,
rules for the making of donations by the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 2 Shares
and Share Capital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.1</TD><TD STYLE="text-align: justify"><U>Share Capital and Rights Attached to Shares</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.1.1</TD><TD STYLE="text-align: justify">The registered capital of the Company is NIS 500,000 divided into 50,000,000 ordinary shares with
a nominal value of NIS 0.01 each.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.1.2</TD><TD STYLE="text-align: justify">The ordinary shares shall entitle their owners to &ndash;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">2.1.2.1</TD><TD STYLE="text-align: justify">An equal right to participate in and vote at the General Meetings of the Company, whether Annual
Meetings or Extraordinary Meetings. Each of the shares in the Company shall entitle its owner present at the meeting and participating
in the vote in person, by proxy, or by means of a voting deed, to one vote;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">2.1.2.2</TD><TD STYLE="text-align: justify">An equal right to participate in the distribution of dividends, whether in cash or assets, benefit
shares, or any other distribution, according to the proportionate nominal value of the shares held thereby;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">2.1.2.3</TD><TD STYLE="text-align: justify">An equal right to participate in the distribution of the surplus assets of the Company in the event
of its liquidation in accordance with the proportionate nominal value of the shares held thereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.1.3</TD><TD STYLE="text-align: justify">The Board of Directors is entitled to issue shares and other convertible securities or securities
that may be realized as shares up to the limit of the Company&rsquo;s registered capital. For the purpose of calculating the limit
of the registered capital, convertible securities or securities that may be realized as shares shall be considered to have been
converted or realized as of their date of issue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.2</TD><TD STYLE="text-align: justify"><U>Share Certificates</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.2.1</TD><TD STYLE="text-align: justify">The owner of a share registered in the registry of shareholders is entitled to receive from the
Company, without payment and within a period of three months following the allocation or the registration of transfer, one share
certificate stamped with the Company&rsquo;s stamp regarding all the shares registered in his name, which certificate shall detail
the number of shares. In the event of a jointly owned share, the Company shall issue one share certificate for all the joint owners
of the share, and the delivery of such a certificate to one of the partners shall be considered delivery to them all.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">Each share certificate shall
bear the signature of at least one Director, together with the Company stamp or its printed name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.2.2</TD><TD STYLE="text-align: justify">A share certificate that has been defaced, destroyed, or lost may be renewed on the basis of such
proof and guarantees as shall be required by the Company from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.2.3</TD><TD STYLE="text-align: justify">Shares of the Company may be certificated or uncertificated, subject to the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.3</TD><TD STYLE="text-align: justify"><U>Reliefs relating to Shares that Have Not Been Fully Paid</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.3.1</TD><TD STYLE="text-align: justify">If any or all of the remuneration the shareholder undertook to pay the Company in return for his
shares has not been paid by such date and on such conditions as established in the conditions for the allocation of his shares
and/or in the payment request as stated in Article &lrm;2.3.2 below, the Company is entitled, by way of a decision of the Board
of Directors, to forfeit the shares whose remuneration has not been fully paid. The forfeiture of shares shall take place provided
that the Company has sent the shareholder written warning of its intention to forfeit the shares after at least 7 days from the
date of receipt of the warning, insofar as payment shall not be made during the period determined in the letter of warning.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">The Board of Directors is entitled,
at any time prior to the date on which the forfeited share is sold, reallocated, or otherwise transferred, to nullify the forfeiture
on such conditions as it shall see fit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.3.2</TD><TD STYLE="text-align: justify">If, in accordance with the conditions of allocation of the shares, there is no fixed date for the
payment of any part of the price to be paid on account thereof, the Board of Directors is entitled, from time to time, to present
payment requests to the shareholders on account of monies not yet removed for the shares they hold, and each shareholder shall
be obliged to pay the Company the amount requested on the date determined as stated, provided that he shall receive prior notice
of 14 days of the date and place of payment (a &ldquo;<B>Payment Request</B>&rdquo;). The notification shall specify that non-payment
by or before the determined date and in the specified place may lead to the forfeiture of the shares regarding which payment is
requested. A Payment Request may be nullified or postponed to another date, all as shall be decided by the Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.3.3</TD><TD STYLE="text-align: justify">Unless otherwise determined in the conditions of allocations of the shares, a shareholder shall
not be entitled to receive a dividend or to exercise any right as a shareholder on account of shares that have not yet been fully
paid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.3.4</TD><TD STYLE="text-align: justify">Persons who are the joint owners of a share shall be liable jointly and severally for payment of
the amounts due to the Company on account of the share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.3.5</TD><TD STYLE="text-align: justify">The content of this section shall not derogate from any other relief of the Company vis-&agrave;-vis
a shareholder who fails to pay his debt to the Company on account of his shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.4</TD><TD STYLE="text-align: justify"><U>Transfer of Shares</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.4.1</TD><TD STYLE="text-align: justify">The Company&rsquo;s shares are transferable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.4.2</TD><TD STYLE="text-align: justify">The transfer of shares must be made in writing, and it shall be recorded only if &ndash;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">2.4.2.1</TD><TD STYLE="text-align: justify">A proper certificate for the transfer of shares, together with the certificates of the share intended
for transfer, if such were issued, are delivered to the Company at its registered office. The certificate of transfer shall be
drafted in such form approved by the Board of Directors and signed by the transferor and by a witness confirming the signature
of the transferor. In the event of the transfer of shares that are not fully paid as of the date of transfer, the certificate of
transfer shall also be signed by the recipient of the share and by a witness testifying to the signature of the recipient; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">2.4.2.2</TD><TD STYLE="text-align: justify">A court order for the amendment of the registration shall be delivered to the Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">2.4.2.3</TD><TD STYLE="text-align: justify">It shall be proved to the Company that lawful conditions pertain for the transfer of the right
to the share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.4.3</TD><TD STYLE="text-align: justify">The transfer of shares that have not been fully paid requires the authorization of the Board of
Directors, which is entitled to refuse to grant its authorization at its absolute discretion and without stating grounds therefore.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.4.4</TD><TD STYLE="text-align: justify">The recipient of the transfer shall be considered the shareholder regarding the transferred shares
from the moment of the registration of his name in the registry of shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.5</TD><TD STYLE="text-align: justify"><U>Changes in Capital</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.5.1</TD><TD STYLE="text-align: justify">The General Meeting is entitled to increase the Company&rsquo;s registered share capital by creating
new shares of an existing class or a new class, all as shall be determined in the decision of the General Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.5.2</TD><TD STYLE="text-align: justify">Subject to the provisions of the Companies Law, the General Meeting is entitled to decrease the
Company&rsquo;s registered share capital or nullify registered share capital that has not yet been allocated (provided that there
is no commitment, including a conditioned commitment, by the Company to allocate the shares).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.5.3</TD><TD STYLE="text-align: justify">The General Meeting shall be entitled, subject to the provisions of any law:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">2.5.3.1</TD><TD STYLE="text-align: justify">To unify and redivide its share capital, or any part thereof, into shares of a nominal value greater
than the nominal value of the existing shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">2.5.3.2</TD><TD STYLE="text-align: justify">To divide, by way of the redivision of any or all of the existing shares, its share capital into
shares of a nominal value smaller than the nominal value of the existing shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">2.5.3.3</TD><TD STYLE="text-align: justify">To reduce its share capital and any reserved fund for the repayment of capital in such manner and
on such conditions and with the receipt of such authorization as shall be required by the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.6</TD><TD STYLE="text-align: justify"><U>Changes in the Rights of Share Classes</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.6.1</TD><TD STYLE="text-align: justify">Unless otherwise stated in the conditions of issue of the shares, and subject to the provisions
of any law, the rights of any share class may be changed following a decision of the Company&rsquo;s Board of Directors, and with
the authorization of the General Meeting of shareholders of that class, or with the written consent of all the shareholders of
that class. The provisions of the Company&rsquo;s Articles of Association regarding General Meetings shall apply, <I>mutatis mutandis</I>,
to a class meeting of class shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">2.6.2</TD><TD STYLE="text-align: justify">The rights granted to the holders of shares of a specific class issued with special rights shall
not be considered to have been changed by virtue of the creation or issue of additional shares of equal grade, unless otherwise
conditioned in the conditions of issue of the said shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">2.7</TD><TD STYLE="text-align: justify"><U>Redeemable Securities</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Company is entitled, subject
to any law, to issue redeemable securities on such conditions as shall be determined by the Board of Directors, provided that the
General Meeting shall approve the recommendation of the Board of Directors and the conditions established thereby.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 3 General
Meetings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">3.1</TD><TD STYLE="text-align: justify"><U>Authorities of General Meeting</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.1.1</TD><TD STYLE="text-align: justify">Company decisions on the following matters shall be taken at the General Meeting &ndash;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">3.1.1.1</TD><TD STYLE="text-align: justify">Changes to the Articles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">3.1.1.2</TD><TD STYLE="text-align: justify">Exercising vital authorities of the Board of Directors in the event that the Board of Directors
is unable to perform its function;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">3.1.1.3</TD><TD STYLE="text-align: justify">Appointment of the auditing accountant of the Company and the cessation of employment thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">3.1.1.4</TD><TD STYLE="text-align: justify">Appointment of Directors, including External Directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">3.1.1.5</TD><TD STYLE="text-align: justify">Authorization of actions and transactions requiring the authorization of the General Meeting in
accordance with the provisions of the Companies Law and any other law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">3.1.1.6</TD><TD STYLE="text-align: justify">Increasing and decreasing the registered share capital;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">3.1.1.7</TD><TD STYLE="text-align: justify">Merger as defined in the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.1.2</TD><TD STYLE="text-align: justify">Subject to the provisions of the law, the General Meeting is entitled to assume authorities granted
to another organ in the Company, including the Board of Directors, for a particular matter or for a given period of time required
under the circumstances.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">If the General Meeting has
assumed authorities granted to the Board of Directors in accordance with the Companies Law, the shareholders shall bear the same
rights, obligations, and liability as apply to the Board of Directors regarding the exercising of those same authorities, as detailed
in section 50 of the Companies Law, as this shall be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">3.2</TD><TD STYLE="text-align: justify"><U>Convening of General Meetings</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.2.1</TD><TD STYLE="text-align: justify">General meetings shall be convened at least once a year at such a venue and on such a date as shall
be determined by the Board of Directors, and subject to the provisions of the law, but not later than 15 months after the previous
General Meeting. These General Meetings shall be called &ldquo;Annual Meetings.&rdquo; The remaining meetings of the Company shall
be called &ldquo;Extraordinary Meetings.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.2.2</TD><TD STYLE="text-align: justify">The agenda at the Annual Meeting shall include discussion of the report of the Board of Directors
and financial statements as required by law. The Annual Meeting shall appoint an auditing accountant; shall appoint the Directors
in accordance with these Articles; and shall discuss all other matters to be discussed at the Annual Meeting of the Company in
accordance with these Articles or in accordance with the Companies Law, as well as any other matter as shall be determined by the
Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.2.3</TD><TD STYLE="text-align: justify">The Board of Directors is entitled to convene an Extraordinary Meeting in accordance with its decision,
and must convene a General Meeting if a written request is received from any of the following (a &ldquo;<B>Request to Convene</B>&rdquo;):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">3.2.3.1</TD><TD STYLE="text-align: justify">Two Directors or one-fourth of the incumbent Directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">3.2.3.2</TD><TD STYLE="text-align: justify">One or more shareholders holding at least five percent of the issued capital and at least one percent
of the voting rights in the Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">3.2.3.3</TD><TD STYLE="text-align: justify">One or more shareholders holding at least five percent of the voting rights in the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.2.4</TD><TD STYLE="text-align: justify">Any Request to Convene must specify the goals for whose purpose the meeting is to be convened,
and shall be signed by those requesting the convening and delivered at the Company&rsquo;s registered office. The request may consist
of a number of documents of identical format, each signed by one or more individuals making the request.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.2.5</TD><TD STYLE="text-align: justify">A Board of Directors required to convene an Extraordinary Meeting shall proceed to convene such
meeting within twenty-one days from the date on which the Request to Convene was submitted thereto, for a date determined in an
invitation in accordance with Article &lrm;&lrm;3.2.6 below and subject to any law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.2.6</TD><TD STYLE="text-align: justify">Notification of the members of the Company regarding the convening of a General Meeting shall be
published or delivered to all the shareholders registered in the registry of shareholders in the Company in accordance with the
requirements of the law. The notification shall include the agenda, the proposed decisions, and arrangements regarding voting in
writing.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">3.3</TD><TD STYLE="text-align: justify"><U>Discussion at General Meetings</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.3.1</TD><TD STYLE="text-align: justify">The discussion at the General Meeting shall be opened only if a legal quorum is present at the
time the discussion begins. A legal quorum is the presence of at least two shareholders holding at least one-third of the voting
rights (including presence by means of proxy or through a voting deed) within an hour from the time specified for the opening of
the meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.3.2</TD><TD STYLE="text-align: justify">If, at the end of one hour from the time specified for the opening of the meeting, no legal quorum
is present, the meeting shall be postponed by one week, to the same day, the same hour, and the same venue, or to a later date,
if specified in the invitation to the meeting or in the notification of the meeting (the &ldquo;<B>Postponed Meeting</B>&rdquo;).
Notification of a Postponed Meeting shall be made as stated in Article &lrm;3.2.6, <I>mutatis mutandis</I>, provided that notification
and invitation regarding a Postponed Meeting postponed for a period of not more than 21 days shall be made not later than seventy-two
hours prior to the Postponed Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.3.3</TD><TD STYLE="text-align: justify">The legal quorum for commencing a Postponed Meeting shall be the presence of any two shareholders
(including presence by means of proxy or through a voting deed).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.3.4</TD><TD STYLE="text-align: justify">The chairperson of the Board of Directors shall serve as the chairperson of the General Meeting.
If the chairperson of the Board of Directors is absent from the meeting after 15 minutes from the time specified for the meeting,
or if he refuses to serve as the chairperson of the meeting, the chairperson shall be elected by the General Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.3.5</TD><TD STYLE="text-align: justify">A General Meeting with a legal quorum is entitled to decide on the postponement of the meeting
to another date and to such venue as shall be determined and, in this case, notifications and invitations to the Postponed Meeting
shall be made as stated in Article &lrm;3.3.2 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">3.4</TD><TD STYLE="text-align: justify"><U>Voting at a General Meeting</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.1</TD><TD STYLE="text-align: justify">A shareholder in the Company shall be entitled to vote at General Meetings in person or by means
of a proxy or a voting deed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">Shareholders entitled to participate
in and vote at the General Meeting are the shareholders as of such date as shall be determined by the Board of Directors in the
decision to convene the General Meeting, and subject to any law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.2</TD><TD STYLE="text-align: justify">In any vote, each shareholder shall have a number of votes equivalent to the number of shares in
their possession entitling the holder to a vote.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.3</TD><TD STYLE="text-align: justify">A decision at the General Meeting shall be taken by an ordinary majority unless another majority
is determined in the Companies Law or in these Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.4</TD><TD STYLE="text-align: justify">The declaration by the chairperson of the meeting that a decision has been adopted unanimously
or by a given majority, or rejected or not adopted by a given majority, shall constitute prima facie evidence of the content thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.5</TD><TD STYLE="text-align: justify">If the votes at the meeting are equally divided, the chairperson of the meeting shall not have
an additional or casting opinion and the decision presented for voting shall be rejected.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.6</TD><TD STYLE="text-align: justify">To the extent required by the Companies Law or otherwise resolved by the Board of Directors in
its decision to convene the General Meeting, shareholders in the Company shall be entitled to vote on certain matters on the agenda
of a General Meeting (including class meetings) by means of a voting deed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.7</TD><TD STYLE="text-align: justify">In order to be considered tantamount to presence at the meeting, including for the matter of the
presence of the legal quorum, a voting deed, stating the manner of voting as set forth in the Companies Law, must be delivered
to the Company by such date prescribed by the Board of Directors, or, if no such date has been prescribed, up to 72 hours prior
to the time of commencement of the meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.8</TD><TD STYLE="text-align: justify">Appointment of a proxy shall be in writing, signed by the appointer (&ldquo;<B>Power of Attorney</B>&rdquo;).
A corporation shall vote by means of its representatives, who shall be appointed in a document signed properly by the corporation
(&ldquo;<B>Letter of Appointment</B>.&rdquo;)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.9</TD><TD STYLE="text-align: justify">A vote in accordance with the conditions of a Power of Attorney shall be lawful even if the appointer
dies before the voting, or becomes legally incompetent, is liquidated, becomes bankrupt, nullifies the Letter of Appointment, or
transfers the share regarding which it was given, unless written notification is received at the Company&rsquo;s office prior to
the meeting that the shareholder has died, become legally incompetent, been liquidated, become bankrupt, or has nullified the Letter
of Appointment or transferred the shares as stated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.10</TD><TD STYLE="text-align: justify">The Letter of Appointment and the Power of Attorney, or a copy authorized by an attorney, shall
be deposited at the Company&rsquo;s registered offices at least 72 hours prior to the time determined for the meeting or for the
Postponed Meeting at which the person mentioned in the document intends to vote in accordance therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.11</TD><TD STYLE="text-align: justify">A shareholder in the Company shall be entitled to vote at the Company&rsquo;s meetings by means
of several proxies appointed thereby, provided that each proxy shall be appointed on account of different sections of the shares
held by the said shareholder. There shall be no impediment to each proxy as stated voting in a different manner in the Company&rsquo;s
meetings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.12</TD><TD STYLE="text-align: justify">If a shareholder is legally incompetent, he is entitled to vote by means of his trustees, the recipient
of his assets, his natural guardian or other legal guardian, and these are entitled to vote in person or by proxy or a voting deed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">3.4.13</TD><TD STYLE="text-align: justify">When two or more persons are the joint owners of a share, in a vote on any matter the vote of the
person whose name is registered first in the registry of shareholders as the owner of that share shall be accepted, whether in
person or by proxy, and he is entitled to deliver voting deeds to the Company.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 4 The Board
of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">4.1</TD><TD STYLE="text-align: justify"><U>Authorities of the Board of Directors</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">The Board of Directors shall
set the Company&rsquo;s policy, supervise the execution of the functions and actions of the General Manager, and, within this,
shall act and shall enjoy all the authorities detailed in section 92 of the Companies Law. In addition, any authority not granted
in the Companies Law or in these Articles to another organ may be exercised by the Board of Directors, in addition to the authorities
and functions of the Board of Directors in accordance with the content of any law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">4.2</TD><TD STYLE="text-align: justify"><U>Appointment of Board of Directors and Cessation of Office Thereof</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.1</TD><TD STYLE="text-align: justify">The number of Directors in the Company shall be determined from time to time by the Annual Meeting,
provided that this shall not be fewer than 5 and not more than 11 Directors, including External Directors. The number of External
Directors in the Company shall not be less than the number determined in the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.2</TD><TD STYLE="text-align: justify">Other than External Directors (who shall be elected and serve in office in strict accordance with
the provisions of the Companies Law), the Directors in the Company shall be elected at an Annual Meeting and shall serve in their
office until the next Annual Meeting following one year from their election, or until they cease to serve in their office in accordance
with the provisions of the Articles or any law, whichever is the earlier.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.3</TD><TD STYLE="text-align: justify">In addition to the content of Article &lrm;4.2.2 above, the Board of Directors is entitled to appoint
a Director in place of a Director, other than an External Director, whose position has become vacant, or appoint new additions
to the Board of Directors up to the maximum number of Directors set forth in Article &lrm;4.2.1 above. The appointment of a Director
by the Board of Directors shall remain valid through the next Annual Meeting or until the Director shall cease to serve in their
office in accordance with the provisions of these Articles or of any law, whichever is the earlier.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.4</TD><TD STYLE="text-align: justify">A Director whose period of office has expired may be reelected; an External Director may be reelected
for additional periods of office in strict accordance with the provisions of the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.5</TD><TD STYLE="text-align: justify">The office of a Director shall commence on the date of appointment or on a later date if so determined
in the decision of appointment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.6</TD><TD STYLE="text-align: justify">The Board of Directors shall elect one of its members as the chairperson of the Board of Directors.
The elected chairperson shall run the meetings of the Board of Directors and shall sign the minutes of the discussion. If no chairperson
is elected, or if the chairperson of the Board of Directors is not present after 15 minutes from the time set for the meeting,
the Directors present shall choose one of their number to serve as the chairperson at that meeting, and the chosen member shall
run the meeting and sign the minutes of the discussion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.7</TD><TD STYLE="text-align: justify">The chairperson of the Board of Directors shall not be the General Manager of the Company or a
relative thereof unless the conditions stipulated in section 121(C) of the Companies Law apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.8</TD><TD STYLE="text-align: justify">The General Meeting is entitled to transfer any Director (other than an External Director) from
their office prior to the end of the period of their office, whether the Director was appointed thereby in accordance with Article
&lrm;4.2.2 above or was appointed by the Board of Directors in accordance with Article &lrm;4.2.3 above, provided that the Director
shall be given a reasonable opportunity to state their case before the General Meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.9</TD><TD STYLE="text-align: justify">Any Director is entitled, with the agreement of the Board of Directors and subject to the provisions
of the Companies Law, to appoint a substitute for themselves (a &ldquo;<B>Substitute Director</B>&rdquo;), provided that a person
who is not competent shall not be appointed to serve as a Substitute Director, nor a person who has been appointed as a Substitute
Director for another Director and/or a person who is already serving as a Director in the Company, and further provided that a
Substitute Director must posses the same qualifications as required of the appointing Director.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">The appointment or cessation
of office of a Substitute Director shall be made in a written document signed by the Director who appointed him; in any case, however,
the office of a Substitute Director shall be terminated if one of the cases stipulated in the paragraphs in Article &lrm;4.2.10
below shall apply, or if the office of the member of the Board of Directors for whom he serves as a substitute shall become vacant
for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">A Substitute Director is considered
tantamount to a Director and all the legal provisions and the provisions of these Articles shall apply, with the exception of the
provisions regarding the appointment and/or dismissal of a Director as established in these Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.10</TD><TD STYLE="text-align: justify">The office of a Director shall become vacant in any of the following cases:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">4.2.10.1</TD><TD STYLE="text-align: justify">He resigns from his office by means of a letter signed in his hand, submitted to the Company and
detailing the reasons for his resignation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">4.2.10.2</TD><TD STYLE="text-align: justify">He is removed from his office by the General Meeting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">4.2.10.3</TD><TD STYLE="text-align: justify">He is convicted of an offense as stated in section 232 of the Companies Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">4.2.10.4</TD><TD STYLE="text-align: justify">In accordance with the decision of the administrative enforcement committee, as stated in section
232A of the Companies Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">4.2.10.5</TD><TD STYLE="text-align: justify">In accordance with a court decision as stated in section 233 of the Companies Law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">4.2.10.6</TD><TD STYLE="text-align: justify">He is declared legally incompetent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">4.2.10.7</TD><TD STYLE="text-align: justify">He is declared bankrupt and, if the Director is a corporation &ndash; it opted for voluntary liquidation
or a liquidation order was issued against it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.11</TD><TD STYLE="text-align: justify">In the event that the position of a Director becomes vacant, the remaining Directors shall be entitled
to continue to act, provided the number of Directors remaining shall not be less than the minimum number of Directors as stated
above. If the number of Directors falls below the above-mentioned minimum number, the remaining Directors shall be entitled to
act solely in order to fill the place of the Director that has become vacant as stated in Article &lrm;4.2.3 above, or in order
to convene a General Meeting of the Company, and pending the convening of the General Meeting of the Company as stated they may
act to manage the Company&rsquo;s affairs solely in matters that cannot be delayed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.2.12</TD><TD STYLE="text-align: justify">The conditions of office of the members of the Board of Directors shall be authorized in accordance
with the provisions of the Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">4.3</TD><TD STYLE="text-align: justify"><U>Meetings of the Board of Directors</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.3.1</TD><TD STYLE="text-align: justify">The Board of Directors shall convene for a meeting in accordance with the needs of the Company,
and at least once every three months.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.3.2</TD><TD STYLE="text-align: justify">The chairperson of the Board of Directors is entitled to convene the Board at any time. In addition,
the Board of Directors shall hold a meeting on such subject as shall be specified in the following cases:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">4.3.2.1</TD><TD STYLE="text-align: justify">In accordance with the request of two Directors; however, if at the time the Board of Directors
comprises five Directors or less &ndash; in accordance with the request of one Director;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">4.3.2.2</TD><TD STYLE="text-align: justify">In accordance with the request of one Director if, in his request to convene the Board, he states
that he has learned of a matter in the Company ostensibly entailing a violation of the law or infringement of proper business practice;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">4.3.2.3</TD><TD STYLE="text-align: justify">If a notification or report by the General Manager require an action on the part of the Board of
Directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 127.6pt; text-align: justify; text-indent: -49.65pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 77.95pt"></TD><TD STYLE="width: 49.65pt">4.3.2.4</TD><TD STYLE="text-align: justify">If the auditing accountant has informed the chairperson of the Board of Directors &ndash; or, in
the event that no chairperson was appointed for the Board of Directors, has informed the Board of Directors &ndash; of substantial
defects in the accounting control of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.3.3</TD><TD STYLE="text-align: justify">Notification of the meeting of the Board of Directors shall be delivered to all members of the
Board a reasonable period of time (taking into account the circumstances and urgency of the matter) prior to the date of convening
of the Board. Notification shall be delivered to the address of the Director as forwarded to the Company in advance, and shall
stipulate the time of the meeting and the venue at which it shall convene, as well as reasonable detail of all subjects on the
agenda.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify">Notwithstanding the above,
the Board of Directors is entitled to convene a meeting without notification, in urgent matters, with the consent of the majority
of the Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.3.4</TD><TD STYLE="text-align: justify">The agenda of the meetings of the Board of Directors shall be determined by the chairperson of
the Board, or if no chairperson has been appointed the Directors convening the meeting, and shall include: Subjects determined
by the chairperson of the Board; subjects deriving from the report of the General Manager and/or the auditing accountant; or any
subject a Director or the General Manager have requested to be included on the agenda a reasonable period of time prior to the
convening of the meeting of the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.3.5</TD><TD STYLE="text-align: justify">The legal quorum for the commencement of a meeting of the Board of Directors shall be a majority
of the members of the Board of Directors. If, within half an hour from the time set for the commencement of the meeting, no quorum
is present, the meeting shall be postponed to another date as decided by the chairperson of the Board, or, in his absence, by the
Directors present at the convened meeting, provided that reasonable prior notification be given to all Directors regarding the
date of the Postponed Meeting. The legal quorum for the opening of a Postponed Meeting shall be any two Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.3.6</TD><TD STYLE="text-align: justify">The Board of Directors is entitled to hold meetings by use of any means of communication, providing
that all the participating Directors can hear each other simultaneously.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.3.7</TD><TD STYLE="text-align: justify">The Board of Directors is entitled to take decisions without actually convening, provided that
all the Directors entitled to participate in the discussion and to vote on the subject brought for decision agree thereto. If decisions
are made as stated in this section, the chairperson of the Board of Directors shall record minutes of the decisions stating the
manner of voting of each Director on the subjects brought for decision, as well as the fact that all the Directors agreed to take
the decision without convening.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">4.4</TD><TD STYLE="text-align: justify"><U>Voting on the Board of Directors</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.4.1</TD><TD STYLE="text-align: justify">Each Director shall have one vote when voting on the Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">4.4.2</TD><TD STYLE="text-align: justify">Decisions of the Board of Directors shall be taken by a majority vote. The chairperson of the Board
of Directors shall not have any additional or casting opinion, and in the event of a tie vote, the decision brought for voting
shall be rejected.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 5 Committees
of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.1</TD><TD STYLE="text-align: justify">The Board of Directors is entitled to establish committees and to appoint members thereto (&ldquo;<B>Board&rsquo;
Committee</B>&rdquo;). If Board&rsquo; Committees are established, the Board of Directors shall determine, in the conditions of
empowerment thereof, whether specific authorities of the Board of Directors shall be delegated to the Board&rsquo; Committees,
in such manner that the decision of the Board&rsquo; Committee shall be considered tantamount to a decision of the Board of Directors,
or whether the decision of the Board&rsquo; Committee shall merely constitute a recommendation, subject to the authorization of
the Board of Directors; provided that authorities to make decisions in the matters stated in Article 112 of the Companies Law shall
not be delegated to a committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.2</TD><TD STYLE="text-align: justify">A person who is not a Director shall not serve in a Board&rsquo; Committee to which the Board of
Directors has delegated authorities. Persons who are not members of the Board of Directors may serve in a Board&rsquo; Committee
whose function is merely to advise or submit recommendations to the Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">5.3</TD><TD STYLE="text-align: justify">The provisions included in these Articles relating to the meetings of the Board of Directors and
voting therein shall apply, <I>mutatis mutandis </I>and subject to the decisions of the Board of Directors regarding the procedures
for the meetings (if any) of any Board&rsquo; Committee comprising two or more members.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 6 General
Manager</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">6.1</TD><TD STYLE="text-align: justify">The Board of Directors of the Company shall appoint one or more General Managers. The General Manager
shall be responsible for the routine management of the Company&rsquo;s affairs within the framework of the policy set by the Board
of Directors and subject to its&nbsp;guidelines.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 7 Exemption,
Insurance, and Indemnification</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">7.1</TD><TD STYLE="text-align: justify"><U>Exemption</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Subject to the provisions of
the Companies Law and the Securities Law, the Company hereby releases, in advance, its Office Holders from liability to the Company
for damage that arises from the breach of the Office Holder&rsquo;s duty of care to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">7.2</TD><TD STYLE="text-align: justify"><U>Insurance</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Subject to the provisions of
the Companies Law and the Securities Law, the Company may enter into a contract for the insurance of the liability, in whole or
in part, of an Office Holder, with respect to an obligation imposed on such Office Holder due to an act performed by him in his
capacity as such, arising from any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">7.2.1</TD><TD STYLE="text-align: justify">a breach of duty of care to the Company or to any other person;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">7.2.2</TD><TD STYLE="text-align: justify">a breach of the duty of loyalty to the Company provided that the Office Holder acted in good faith
and had reasonable grounds to assume that the act would not harm the interests of the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">7.2.3</TD><TD STYLE="text-align: justify">a financial liability imposed on such Office Holder in favor of any other person, including in
favor of an injured party as set forth in section 52LIV(a)(1)(a) of the Securities Law, as well as expenses, including reasonable
litigation expenses and attorney&rsquo;s fees, expended by an Office Holder or which were imposed on an Office Holder by a court
in proceedings filed against the Office Holder under Chapters VIII&rsquo;3, VIII&rsquo;4 or IX&rsquo;1 of the Securities Law; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">7.2.4</TD><TD STYLE="text-align: justify">any other incident for which it is or shall be permitted to insure the liability of an officer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">7.3</TD><TD STYLE="text-align: justify"><U>Indemnification</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">Subject to the provisions of
the Companies Law and the Securities Law, the Company may undertake in advance to indemnify, or may indemnify retroactively, an
Office Holder of the Company with respect to any of the following liabilities or expenses that arise from an act performed by the
Office Holder by virtue of being an Office Holder of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">7.3.1</TD><TD STYLE="text-align: justify">a financial liability imposed on an Office Holder in favor of another person by any judgment, including
a judgment given as a result of a settlement or an arbitrator&rsquo;s award which has been confirmed by a court, provided however
that an undertaking to indemnify the Office Holder for such liabilities shall be restricted to those events that the Board may
deem foreseeable in light of the Company&rsquo;s actual activities, at the time of giving of such undertaking, and to a specific
sum or a reasonable criterion under such circumstances as determined by the Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">7.3.2</TD><TD STYLE="text-align: justify">reasonable litigation expenses, including attorney&rsquo;s fees, incurred by him as a result of
an investigation or proceeding instituted against him by an authority empowered to conduct an investigation or proceedings, which
are concluded without the filing of an indictment against the Office Holder and without the levying of a monetary obligation in
lieu of criminal proceedings upon the Office Holder, or which are concluded without the filing of an indictment against the Office
Holder but with levying a monetary obligation in substitute of such criminal proceedings upon the Office Holder for a crime that
does not require proof of criminal intent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">7.3.3</TD><TD STYLE="text-align: justify">reasonable litigation expenses, including attorney&rsquo;s fees, expended by an Office Holder or
which were imposed on an Office Holder by a court in proceedings filed against the Office Holder by the Company or in its name
or by any other person or in a criminal charge on which the Office Holder was acquitted or in a criminal charge on which the Office
Holder was convicted for an offense which did not require proof of criminal intent;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">7.3.4</TD><TD STYLE="text-align: justify">a financial liability imposed on an Office Holder in favor of an injured party as set forth in
section 52LIV(a)(1)(a) of the Securities Law, as well as expenses, including reasonable litigation expenses and attorney&rsquo;s
fees, expended by an Office Holder or which were imposed on an Office Holder by a court in proceedings filed against the Office
Holder under Chapters VIII&rsquo;3, VIII&rsquo;4 or IX&rsquo;1 of the Securities Law; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-align: justify; text-indent: -42.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.45pt"></TD><TD STYLE="width: 42.5pt">7.3.5</TD><TD STYLE="text-align: justify">any other obligation or expense for which it is or shall be permitted to indemnify an officer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">7.4</TD><TD STYLE="text-align: justify">The provisions of this &lrm;Chapter 7 are not intended, and shall not be interpreted, to restrict
the Company in any manner in respect of the procurement of insurance or in respect of indemnification (i) in connection with any
person who is not an Office Holder, including, without limitation, any employee, agent, consultant or contractor of the Company
who is not an Office Holder, or (ii) in connection with any Office Holder to the extent that such insurance and/or indemnification
is not specifically prohibited under the Companies Law; provided that the procurement of any such insurance or the provision of
any such indemnification shall be approved by the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">7.5</TD><TD STYLE="text-align: justify">Any modification of the provisions of this &lrm;Chapter 7, and any amendment to the Companies Law,
the Securities Law or any other applicable law, shall be prospective in effect and shall not affect the Company&rsquo;s obligation
or ability to indemnify an Office Holder for any act or omission occurring prior to such modification or amendment, unless otherwise
provided by the Companies Law, the Securities Law or such applicable law.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 8 Internal
Auditor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.1</TD><TD STYLE="text-align: justify">The Board of Directors of the Company shall appoint an internal auditor in accordance with the
proposal of the audit committee. A person who is an interested party in the Company, an office holder therein, or the relative
or either of the above, as well as the auditing accountant or any person on his behalf, shall not serve as an internal auditor
in the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.2</TD><TD STYLE="text-align: justify">The Board of Directors shall determine which office holder shall be organizationally accountable
for the internal auditor and, in the absence of such determination; this shall be the chairperson of the Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">8.3</TD><TD STYLE="text-align: justify">The internal audit plan prepared by the auditor shall be submitted to the audit committee for authorization;
however, the Board of Directors is permitted to determine that the plan shall be examined by the audit committee and submitted
to the Board of Directors for authorization.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 9 Auditing
Accountant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">9.1</TD><TD STYLE="text-align: justify">The General Meeting shall appoint an auditing accountant for the Company. The auditing accountant
shall serve in office through the end of the following Annual Meeting, or for a longer period as determined by the Annual Meeting,
provided that the period of office shall not be extended beyond the end of the third Annual Meeting following that at which the
auditing accountant was appointed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">9.2</TD><TD STYLE="text-align: justify">The fee of the auditing accountant for the auditing operations shall be determined by the Board
of Directors. The Board of Directors shall report to the Annual Meeting on the fee of the auditing accountant.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 10 Signing
in the Company&rsquo;s Name</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">10.1</TD><TD STYLE="text-align: justify">The rights to sign in the Company&rsquo;s name shall be determined from time to time by the Board
of Directors of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">10.2</TD><TD STYLE="text-align: justify">The Company&rsquo;s authorized signatory shall do so together with the Company&rsquo;s stamp, or
alongside its printed name.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 11 Dividend
and Benefit Shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">11.1</TD><TD STYLE="text-align: justify">The decision by the Company to allocate a dividend and/or to allocate benefit shares shall be taken
by the Company&rsquo;s Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">11.2</TD><TD STYLE="text-align: justify">Unless determined otherwise by the Board of Directors, it shall be permitted to pay any dividend
by way of check or payment order to be sent by mail in accordance with the registered address of the shareholder or the personal
eligible thereto or, in the case of joint registered owners of the same share, to that shareholder whose name is mentioned first
in the registry of shareholders with regard to the joint ownership. Any such check shall be made out to order of the person to
whom it is sent. A receipt from a person whose name, as of the date of declaration of the dividend, is registered in the registry
of shareholders as the owner of any share or, in the case of joint owners, of one of the joint owners, shall serve as authorization
regarding all payments made in connection with that share and regarding which the receipt was received.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">11.3</TD><TD STYLE="text-align: justify">For the purpose of executing any decision in accordance with the provisions of this section, the
Board of Directors is entitled to resolve as it sees fit any difficulty that emerges regarding distribution of the dividend and/or
the benefit shares, including determining the value for the purpose of the said division of certain assets, and to determine that
payments in cash shall be made to members on the basis of the value so determined; to determine provisions regarding fractions
of shares; or to determine that sums of less than NIS 50 shall not be paid to a shareholder.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 12 Accounts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.1</TD><TD STYLE="text-align: justify">The Company shall maintain accounts and shall prepare financial statements in accordance with the
Companies Law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">12.2</TD><TD STYLE="text-align: justify">The account ledgers shall be held at the Company&rsquo;s registered offices or in any other place
as the Directors shall see fit, and shall always be open for inspection by the Directors.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Chapter 13 Notifications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.1</TD><TD STYLE="text-align: justify">Subject to any law, a notification or any other document that shall be delivered by the Company,
and which it is entitled or required to issue in accordance with the provisions of the Articles or any law, shall be delivered
by the Company to any person in one of the following manners as decided by the Company in each individual case: (A) By dispatch
by registered mail in a letter addressed in accordance with the registered address of that shareholder in the registry of shareholders,
or in accordance with such address as stated by the shareholder in a letter to the Company as the letter for the delivery of notifications
or other documents; (B) By dispatch by facsimile or other electronic form, in accordance with the number or address stated by the
shareholder for the delivery of such notifications; or (C) By way of publication in applicable distribution site.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.2</TD><TD STYLE="text-align: justify">Any notification to be made to shareholders shall be made, regarding jointly owned shares, to that
person whose name is mentioned first in the registry of shareholders as the holder of that share, and any notification made in
this manner shall be sufficient notification for the holders of that share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.3</TD><TD STYLE="text-align: justify">Any notification or other document sent in accordance with the provisions of Article &lrm;13.1
above shall be considered to have reached its destination: (A) Within 3 business days &ndash; if sent by registered mail in Israel;
(B) On the first business day after its dispatch, if delivered by hand or sent by facsimile or other electronic method; or (C)
On the date of publication on applicable distribution site.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In proving delivery, it shall
be sufficient to prove that the letter sent by mail included the notification and that the document was addressed properly and
was delivered to the post office as a letter bearing stamps, or as a registered letter bearing stamps, and, regarding a facsimile
or other electronic method, it shall be sufficient to produce a dispatch confirmation sheet from the dispatching machine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.4</TD><TD STYLE="text-align: justify">Any record made in an ordinary manner in the company&rsquo;s registry shall be considered prima
facie evidence of dispatch as recorded in that registry.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 35.45pt">13.5</TD><TD STYLE="text-align: justify">When it is necessary to provide prior notification of a certain number of days, or when notification
is valid for a certain period, the date of delivery shall be included in reckoning the number of days or the period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">**************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>v374074_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Indemnification Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Indemnification Agreement (this &quot;<B>Agreement</B>&quot;)
is made as of ___________, 2014, by and between Bioblast Pharma Ltd., a company organized and existing under the laws of Israel
(the &quot;<B>Company</B>&quot;) and ____________ I.D. No / Passport No ____________ (&quot;<B>Indemnitee</B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, the Company desires to attract
and retain qualified directors and officers and to provide them with protection against liability and expenses incurred while acting
in that capacity; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, Indemnitee is director or officer
of the Company; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WHEREAS, in order to induce Indemnitee
to serve as a director or officer of the Company, the Company agrees to indemnify Indemnitee upon certain occurrences, all under
the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Now, therefore, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><U>Indemnity</U>. The Company hereby agrees, subject to the limitations set forth in this Agreement
and to applicable law:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To indemnify Indemnitee to the greatest
extent possible under applicable law against any liability or expense in respect of any acts or omissions of Indemnitee in his
capacity as a director or officer of the Company, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) a financial obligation imposed on Indemnitee
in favor of another person by a court judgment, including a compromise judgment or an arbitrator's award approved by court;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) reasonable litigation expenses, including
attorneys' fees, expended by Indemnitee or charged to him by a court, in a proceeding instituted against him by the Company or
on its behalf or by another person, or in a criminal charge from which he was acquitted or in any criminal proceeding of a crime
which does not require proof of mens rea (criminal intent) in which the Indemnitee is convicted, or due to an investigation or
a proceeding conducted against him by an authority authorized to conduct an investigation or a proceeding, pursuant to which no
indictment was filed against him and no monetary liability was imposed on him as an alternative to a criminal proceeding, or due
to an investigation or a proceeding conducted against him by an authority authorized to conduct an investigation or a proceeding,
pursuant to which no indictment was filed against him but a monetary liability was imposed on him as an alternative to a criminal
proceeding, for a crime which does not require a finding of mens rea (criminal intent) (collectively referred to hereinafter as
a &quot;<B>Claim</B>&quot;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii) a payment which Indemnitee is obligated
to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israeli Securities Law, 1968, as amended (the &quot;<B>Securities
Law</B>&quot;), if applicable, and expenses that Indemnitee incurs in connection with a proceeding under Chapters H'3, H'4 or I'1
of the Securities Law, if applicable, including reasonable legal expenses, which term includes attorney fees; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iv) any other obligation or expense in
respect of which it is permitted or will be permitted under the Companies Law, 5759-1999, to indemnify an officer or director,
subject to and in accordance with all applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The above indemnification will also apply
to any action taken by the Indemnitee in his capacity as a director and/or officer of any other company controlled, directly or
indirectly, by the Company (a &ldquo;<B>Subsidiary</B>&rdquo;) or in his capacity as a director, officer or observer at board of
directors&rsquo; meetings, of a company not controlled by the Company but where his appointment as a director, officer or observer
results from the Company&rsquo;s holdings in such company (&ldquo;<B>Affiliate</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify"><U>General Limitations on Indemnity.</U> If, when and
to the extent that a final judicial determination is made, as to which all rights of appeal therefrom have been exhausted or lapsed,
the Indemnitee would not be permitted to be so indemnified as provided under this Agreement, the Company shall be entitled to
be reimbursed by Indemnitee (who hereby agrees to reimburse the Company) for all such amounts theretofore paid. Indemnitee&rsquo;s
obligation to reimburse the Company for any advance expenses or other sums paid hereunder shall be unsecured and no interest shall
be charged thereon.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify"><U>Limitations on Indemnity.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company
undertakes to indemnify Indemnitee, with respect to Section 1(i) above, and in accordance with the terms of this Agreement up to
a total amount of US$5,000,000 (Five Million United States Dollars) in the aggregate, under the circumstances of indemnification
of Indemnitee as set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnitee
shall not be entitled to indemnification under Section 1, for financial obligations imposed arising from any of the following:
(i) a breach of the duty of fiduciary by Indemnitee, except, to the extent permitted by law, for a breach of the duty of fiduciary
by the Indemnitee to the Company, a Subsidiary or an Affiliate while acting in good faith and having reasonable cause to assume
that such act would not prejudice the interests of the Company, Subsidiary or Affiliate, as applicable; or (ii) a violation of
the Indemnitee&rsquo;s duty of care towards the Company, which was committed intentionally or recklessly, except if it was done
in negligence only; or (iii) an act committed with the intention to realize a personal unlawful profit; or (iv) a fine or monetary
penalty imposed on Indemnitee (excluding a fine or monetary penalty imposed pursuant to the conviction of a crime which requires
proof of mens rea (criminal intent)); or (v) a counterclaim made by the Company or in its name in connection with a claim against
the Company filed by Indemnitee, other than (a) by way of defense or by way of third party notice in connection with claim brought
against the Indemnitee, or (b) in specific cases in which the Company&rsquo;s Board of Directors has approved the initiation or
bringing of such suit by Indemnitee, which approval shall not be unreasonably withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The indemnification
amount actually paid shall be limited to those amounts not covered by the Company&rsquo;s directors and officers insurance policy
(the &ldquo;<B>D&amp;O Policy</B>&rdquo;), such that Indemnitee will not be entitled to payment from the Company for amounts which
Indemnitee has actually obtained under the D&amp;O Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to
the provisions of this Section 3, the indemnification hereunder will, in each case, cover all sums of money that the Indemnitee
will be obligated to pay, in those circumstances for which indemnification is permitted under the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company
will be entitled to reimbursement of amounts collected from a third party in connection with liabilities indemnified hereunder.
Such reimbursement shall not exceed the amount the Company has paid to the Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><U>Limitation of Categories of Claims. </U>The indemnification pursuant to Section 1(i) above,
shall only relate to liabilities arising in connection with acts or omissions of Indemnitee in respect of the following events
and circumstances which are deemed by the Company's Board of Directors to be foreseeable at the date hereof:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The offering
of securities by the Company and/or by a shareholder thereof to the public and/or to private investors or the offer by the Company
to purchase securities from the public and/or from private investors or other holders pursuant to a prospectus, agreements, notices,
reports, tenders and/or other proceedings;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Occurrences
in connection with investments in or by the Company and/or Subsidiary and/or Affiliate in other corporations whether before and/or
after the investment is made, entering into the transaction, the execution, development and monitoring thereof, including actions
taken by the Indemnitee in the name of the Company and/or Subsidiary and/or Affiliate as a director, officer, employee and/or board
observer of the corporation which is the subject of the transaction and the like;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The sale, purchase
and holding of negotiable securities or other investments for or in the name of the Company and/or Subsidiary and/or Affiliate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actions in
connection with the merger of the Company and/or any Subsidiary and/or any Affiliate with or into another entity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actions in
connection with the sale of the operations, assets and/or business, or part thereof, of the Company and/or Subsidiary and/or Affiliate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without derogating
from the generality of the above, actions in connection with the purchase or sale of companies, legal entities or assets, licensing
or acquisition of rights in products, assets or technologies of other persons or legal entities, and the sale, licensing or grant
of license in the same to other persons or legal entities, and the division or consolidation thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actions taken
in connection with labor relations and/or employment matters (including employment-related benefits) in the Company and/or Subsidiary
and/or Affiliate and trade relations of the Company and/or Subsidiary and/or Affiliate, including with employees, independent contractors,
customers, suppliers and various service providers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actions in
connection with the developing, testing and manufacturing of products (including a third party&rsquo;s products, solutions and
technologies) by the Company and/or Subsidiary and/or Affiliate or in connection with the distribution, sale, license or use of
such products, solutions or technologies, and management of projects whether of the Company and/or Subsidiary and/or affiliate
and/or any third party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actions relating
to the promotion, offering and/or support of the products, solutions and technologies in the fields of operation of the Company,
any of its Subsidiaries or Affiliates as shall exist from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actions taken
in connection with the intellectual property of the Company and/or Subsidiary and/or Affiliate and its protection, including the
registration or assertion of rights to intellectual property and the defense of claims related to intellectual property or any
claim or demand made for actual or alleged infringement, misappropriation, or misuse of any third party's intellectual property
rights by the Company, its Subsidiaries or Affiliates, including without limitation confidential information, patents, copyrights,
design rights, service marks, trade secrets, copyrights, and misappropriation of ideas by the Company, its Subsidiaries or Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Actions taken
pursuant to or in accordance with the policies and procedures of the Company and/or Subsidiary and/or Affiliate, that have been
decided upon, whether such policies and procedures are published or not, and actions relating to the operations and management
of the Company and/or of any Subsidiaries and/or Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Occurrences
resulting from the Company&rsquo;s and/or Subsidiary&rsquo;s and/or Affiliate&rsquo;s status as a public company, and/or from the
fact that the Company&rsquo;s securities were offered to the public and/or are traded on a stock exchange, whether in the U.S.
or elsewhere;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any claim
or demand made by any lenders or other creditors or for monies borrowed by, or other indebtedness of, the Company and\or Subsidiary
and/or any Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any claim
or demand made by any third party suffering any personal injury or damage to business or personal property through any act or omission
attributed to the Company or its Subsidiaries or its Affiliates, or their respective employees, agents or other persons acting
or allegedly acting on their behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any claim
or demand made by suppliers, contractors or other third parties transacting any form of business with the Company in the ordinary
course of their respective businesses, relating to the negotiations or performance of such transactions, representations or inducements
provided in connection thereto or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any claim
or demand made in connection with any transaction not in the ordinary course of business of either the Company or the party making
such claim (including any transaction with directors or officers of the Company or any controlling shareholder of the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any claim
or demand made directly or indirectly in connection with complete or partial failure, by the Company and\or Subsidiary and/or Affiliate,
or their respective directors, officers and employees, to pay, report, keep applicable records or otherwise, any federal, state,
municipal or foreign taxes or other mandatory payments of any nature whatsoever, including, without limitation, income, sales,
use, transfer, excise, value added, registration, severance, stamp, occupation, customs, duties, real property, personal property,
capital stock, social security, unemployment, disability, payroll or employee withholding or other withholding, including any interest,
penalty or addition thereto, whether disputed or not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any actions
or decisions relating to insurance matters and/or risk management of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The filing
of a report and/or announcement required by the Companies Law and/or any securities law which is applicable or may be applicable
to the Company from time to time, including the U.S. Securities Laws, including the regulations pertaining to these laws, the Israeli
Securities Law - 1968, and/or according to rules and/or regulations adopted by the NASDAQ or any other stock exchange and/or securities
market and/or any law of any other country pertaining to these issues and/or the failure to file such a report and/or announcement,
and/or actions relating to tender offers of the Company, including actions relating to delivery of opinions in relation thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any decision
regarding a distribution, as defined in the Companies Law, including a distribution pursuant to a court order, and/or repurchase
of shares or returns of capital or loans of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any actions
in connection with the change in the Company's structure and/or a reorganization of the Company, including any arrangement between
the Company and its shareholders and/or creditors according to the Companies Law, and/or any decision relating to these issues
including, but not limited to, a change in the Company's capital, the establishment of subsidiaries and/or their liquidation or
sale, and/or all allotments or distributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approval of
corporate actions, including the approval of acts of the Company's management, its guidance and its supervision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any claim
or demand made in connection with any expression of opinion or saying made in good faith during the course of performance of duties
and in connection with the performance of duties, including during meetings of the board of directors or committees of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any administrative,
regulatory or judicial actions, orders, decrees, suits, demands, demand letters, directives, claims, liens, investigations, proceedings
or notices of noncompliance or violation by any governmental entity (in Israel or abroad), including the Office of the Chief Scientist
or the Investment Center of the Israeli Ministry of Industry and Commerce, the Israeli Antitrust Authority or the Israel Securities
Authority, or other person alleging the failure to comply with any statute, law, ordinance, rule, regulation, order or decree of
any governmental entity applicable to the Company and/or Subsidiary, or any of their respective businesses or operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any claim
or demand made by purchasers, holders, lessors or other users of products of the Company, for damages, losses or personal injuries
related to such products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.26.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any claim
or demand made in connection with any preparation or formulation of work plans, including pricing, marketing, distribution, instructions
to employees, customers and suppliers, and collaboration with competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any acts in
regard of invasion of privacy, participation and/or non-participation at Board meetings and/or voting and/or abstention from voting
at Board meetings, approval of corporate actions, claims of failure to exercise business judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.28.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims of
failure to exercise business judgment and a reasonable level of proficiency, expertise and care in regard of the Company's business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.29.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Violations
of laws requiring the Company to obtain regulatory and governmental licenses, permits and authorizations in any jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.30.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decisions
and/or actions relating to environmental compliance, including pollution, contamination and hazardous materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.31.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granting of
liens on Company assets and granting guarantees on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.32.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims in
connection with publishing or providing any information, including any filings with governmental authorities in the U.S., Israel
and elsewhere, on behalf of the Company, in the circumstances required under applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.33.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims in
connection with the preparation, approval or providing of any annual or quarterly financial statements, profit and loss statements,
balance sheets and similar financial information or forecasts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.34.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any of the
forgoing actions or decisions relating or otherwise applicable to any Subsidiary or Affiliate of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.35.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any claim
or demand, not covered by any of the categories of events described above, which, pursuant to any applicable law, a director or
officer of the Company may be held liable to any government or agency thereof, or any person or entity, in connection with actions
taken by such director or officer in such capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD><U>Expenses; Indemnification Procedure.</U> The Company shall advance Indemnitee all expenses incurred by Indemnitee in connection
with a Claim on the date on which such amounts are first payable (&ldquo;<B>Time of Indebtedness</B>&rdquo;), and with respect
to items mentioned in Section 1(ii) above, even prior to a court decision, but has no duty to advance payments in less than twenty
(20) days (but in any event not later than thirty (30) days) following delivery of a written request therefor by Indemnitee to
the Company. Advances given to cover legal expenses in criminal proceedings will be repaid by Indemnitee to the Company, if such
proceedings are concluded in such manner that would not have entitled the Indemnitee to indemnification under Section &lrm;1 above.
Additionally, the Company shall make available to Indemnitee any securities and/or guarantees which Indemnitee will be required
to provide in the framework of any action or proceeding and/or according to any interim decision, including arbitration proceedings,
and including with respect to the exchange of any attachments imposed on Indemnitee's assets.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><U>Notification and Defense of Claim</U>. If any Claim is brought against Indemnitee in respect
of which indemnity may be sought under this Agreement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Indemnitee
shall promptly notify the Company of any legal proceedings initiated and of all possible or threatened legal proceedings without
delay following first becoming aware thereof, and the Indemnitee shall deliver to the Company, or to such person as it shall advise,
without delay all documents received in connection with these proceedings. Similarly, the Indemnitee must advise the Company on
an ongoing and current basis concerning all events which the Indemnitee suspects may give rise to the initiation of legal proceedings
against the Indemnitee. Notice to the Company shall be directed to the Chief Executive Officer with a copy to the General Counsel
and the Chief Financial Officer of the Company as per Section 19 hereof, or if the Indemnitee is then the Chief Executive Officer
of the Company, such notice shall be directed to the Chairman of the Board and the other addressees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company
will be entitled to participate therein at its own expense or to assume the defense thereof and to employ counsel reasonably satisfactory
to Indemnitee. Indemnitee shall have the right to employ its own counsel in connection with any such Claim and to participate in
the defense thereof, but the fees and expenses of such counsel shall be at the expense of Indemnitee unless: (i) the Company shall
not have assumed the defense of the Claim, or (ii) the named parties to any such action (including any impleaded parties) include
both Indemnitee and the Company, and Indemnitee shall have reasonably concluded that joint representation is inappropriate under
applicable standards of professional conduct due to a conflict of interest between Indemnitee and the Company, in either of which
events reasonable fees and expenses of such counsel to Indemnitee shall be borne by the Company. However, in no event will the
Company be obligated to pay the fees or expenses of more than one firm of attorneys representing Indemnitee in connection with
any one Claim or separate but substantially similar or related Claims in the same jurisdiction arising out of the same general
allegations or circumstances. For the avoidance of doubt, in the case of criminal proceedings the Company and/or the attorneys
as aforesaid will not have the right to plead guilty in Indemnitee&rsquo;s name or to agree to a plea-bargain in his name without
his prior written consent. Furthermore, in a civil proceeding (whether before a court or as a part of a compromise arrangement),
the Company and/or its attorneys will not have the right to admit to any occurrences that are not indemnifiable pursuant to this
Agreement and/or pursuant to law, without Indemnitee&rsquo;s prior written consent. However, the aforesaid will not prevent the
Company and/or its attorneys as aforesaid, with the approval of the Company, to come to a financial arrangement with a plaintiff
in a civil proceeding without Indemnitee&rsquo;s consent so long as such arrangement will not be an admittance of an occurrence
not fully indemnifiable pursuant to this Agreement and/or pursuant to law and further provided that any such settlement or arrangement
does not impose on Indemnitee any liability or limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company
shall not be liable to indemnify Indemnitee for any amounts paid in settlement of any Claim effected without the Company's written
consent. Indemnitee shall give the Company such information and cooperation as may be required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Indemnitee
will fully cooperate with the Company and/or any attorney as aforesaid in every reasonable way as may be required within the context
of their conduct of such legal proceedings, including but not limited to the execution of power(s) of attorney and other documents,
provided that the Company shall cover all costs incidental thereto such that the Indemnitee will not be required to pay the same
or to finance the same himself.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify"><U>Subrogation.</U> In the event of payment under this Agreement from Company to Indemnitee, the
Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all
documents reasonably required and shall do everything that may be reasonably necessary to secure such rights, including the execution
of such documents necessary to enable the Company effectively to bring suit to enforce such rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify"><U>Primacy of Indemnification</U>. The Company hereby acknowledges that Indemnitee has or may have
certain rights to indemnification, advancement of expenses and/or insurance provided by the Indemnitee or by the party or parties
who appointed the Indemnitee and certain of such party's affiliates (collectively, the &ldquo;<B>Appointing Party</B>&rdquo;).
The Company hereby agrees, with respect to Indemnitee's right to indemnification pursuant hereto: (i) that the Company is the indemnitor
of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Appointing Party or its (or the Indemnitee's)
insurer to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary),
(ii) that, subject to the provisions hereof, the Company shall be required to advance the full amount of expenses incurred by Indemnitee
and indemnifiable hereunder and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid
in settlement to the extent legally permitted and as required by the Company&rsquo;s Articles Association (or any agreement between
the Company and Indemnitee) all subject to the provisions hereof, without regard to any rights Indemnitee may have against the
Appointing Party or its (or the Indemnitee's) insurer, and, (iii) that the Company irrevocably waives, relinquishes and releases
the Appointing Party or its (or the Indemnitee's) insurer from any and all claims against the Appointing Party or its (or the Indemnitee's)
insurer for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no
advancement or payment by the Appointing Party or its (or the Indemnitee's) insurer on behalf of an Indemnitee with respect to
any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Appointing Party
or its (or the Indemnitee's) insurer shall have a right of contribution and/or be subrogated to the extent of such advancement
or payment to all of the rights of recovery of Indemnitee against the Company. The Company and the Indemnitee agree that the Appointing
Party or its (or the Indemnitee's) insurer are express third party beneficiaries of the terms hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify"><U>Partial Indemnification</U>. If Indemnitee is entitled under any provision of this Agreement
to indemnification by the Company for some or a portion of the expenses actually or reasonably incurred by Indemnitee in connection
with a Claim or Claims, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for
the portion of such expenses to which Indemnitee is entitled.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">10.</TD><TD STYLE="text-align: justify"><U>Other Indemnification. </U>Except to the extent provided in Section 8 above, the Company will
not indemnify Indemnitee for any liability with respect to which Indemnitee has received payment by virtue of an insurance policy
or other indemnification agreement, other than for amounts, which are in excess of the amount paid to Indemnitee pursuant to such
policy or agreement and other than a deductible payable by the Indemnitee under an insurance policy or indemnification agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">11.</TD><TD STYLE="text-align: justify"><U>Collection from a Third Party.</U> The Company will be entitled to any amount collected from
a third party in connection with a Claim or Claims actually indemnified hereunder by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">12.</TD><TD STYLE="text-align: justify"><U>Non-Exclusivity</U>. The rights of the Indemnitee hereunder shall not be deemed exclusive of
any other rights he may have under the Company&rsquo;s Articles of Association or applicable law or otherwise, and to the extent
that during the indemnification period hereunder the rights of the then existing directors and officers are more favorable to such
directors or officers than the rights currently provided thereunder or under this Agreement to Indemnitee, Indemnitee shall be
entitled to the full benefits of such more favorable rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">13.</TD><TD STYLE="text-align: justify"><U>Exemption. </U>The Company hereby exempts Indemnitee, to the fullest extent permitted by law,
from any liability, or any part of liability, for damages caused as a result of a breach of his duty of care to the Company, provided
that in no event shall he be exempt with respect to any actions listed in Section &lrm;3.2 above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">14.</TD><TD STYLE="text-align: justify"><U>Post Factum Indemnification.</U> It is hereby clarified that nothing in here shall limit the
Company&rsquo;s right to indemnify the Indemnitee post factum, for any and all amounts or events, without limitation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">15.</TD><TD STYLE="text-align: justify"><U>Severability.</U> Each of the provisions of this Agreement is a separate and distinct agreement
and independent of the others, so that if any provision hereof shall be held to be invalid or unenforceable for any reason, such
invalidity or unenforceability shall not affect the validity or enforceability of the other provisions hereof. If such invalid
or unenforceable undertaking may be modified or amended so as to be valid and enforceable as a matter of law, such undertaking
will be deemed to have been modified or amended, and any competent court or arbitrator are hereby authorized to modify or amend
such undertaking, so as to be valid and enforceable to the maximum extent permitted by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">16.</TD><TD STYLE="text-align: justify"><U>Termination of Services.</U> For the avoidance of doubt, the Company will indemnify Indemnitee
even if at the relevant Time of Indebtedness Indemnitee is no longer a director or officer of the Company or of a Subsidiary or
a director, officer and/or board observer of an Affiliate, as applicable, provided, that the obligations are in respect of actions
taken by the Indemnitee while serving as a director, officer and/or board observer, as aforesaid, and in such capacity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">17.</TD><TD STYLE="text-align: justify"><U>Attorneys' Fees</U>. In the event of any litigation or other action or proceeding to enforce
or interpret this Agreement, the prevailing party as determined by the court shall be entitled to an award of its reasonable attorneys'
fees and other costs, in addition to such relief as may be awarded by a court or other tribunal.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">18.</TD><TD STYLE="text-align: justify"><U>Further Assurances. </U>The parties will do, execute and deliver, or will cause to be done,
executed and delivered, all such further acts, documents and things as may be reasonably required for the purpose of giving effect
to this Agreement and the transactions contemplated hereby. Notwithstanding anything to the contrary, if for the validation of
any of the undertakings in this Agreement any act, resolution, approval or other procedure is required, the Company undertakes
to cause them to be done or adopted in a manner which will enable the Company to fulfill all its undertakings as aforesaid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">19.</TD><TD STYLE="text-align: justify"><U>Notice</U>. All notices, requests, demands and other communications under this Agreement shall
be in writing and shall be deemed duly given (i) if delivered by hand or by fax or other means of electronic communication and
receipted for by the party addressee, on the date of such receipt, or (ii) if mailed by certified or registered mail with postage
prepaid, on the third business day after the date postmarked.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">20.</TD><TD STYLE="text-align: justify"><U>Entire Agreement; Amendments.</U> This Agreement constitutes the entire agreement between the
parties with respect to its subject matter, and supersedes and cancels all prior agreements, proposals, representations and communications
between the parties regarding the subject matter hereof. No amendment, modification, termination or cancellation of this Agreement
shall be effective unless it is in writing and signed by the parties hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">21.</TD><TD STYLE="text-align: justify"><U>Binding Effect; No Assignment.</U> This Agreement shall be binding upon Indemnitee and the Company,
their successors and assignees, and shall inure to the benefit of Indemnitee, his heirs, personal representatives and assignees
and to the benefit of the Company, its successors and assignees. Indemnitee shall not assign or otherwise transfer his rights under
this Agreement and any attempt to assign or transfer such rights shall be deemed null and void.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">22.</TD><TD STYLE="text-align: justify"><U>Governing Law; Jurisdiction.</U> This Agreement shall be interpreted and enforced in accordance
with the laws of the State of Israel, without regard to their rules of conflict of laws, and any dispute arising from or in connection
with this Agreement is hereby submitted to the sole and exclusive jurisdiction of the competent courts in Tel Aviv, Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">23.</TD><TD STYLE="text-align: justify"><U>Construction. </U>The undertakings of the parties pursuant to this Agreement shall be widely
construed and in a manner designated to give them effect, to the fullest extent permissible under law. In the event of any contradiction
between the provisions of this Agreement and any provision of law that is not dispositive or which cannot be amended, the provision
of law shall prevail but the same shall not impair or derogate from the validity of the other provisions hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">24.</TD><TD STYLE="text-align: justify"><U>Counterpart Signatures.</U> This Agreement may be executed in counterparts, both of which when
taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by
each party and delivered to the other party, it being understood that two parties need not sign the same counterpart. In the event
that any signature is delivered by facsimile or PDF transmission, such signature shall create a valid and binding obligation of
the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile
or PDF signature page were an original thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bioblast Pharma Ltd.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify">Name:</TD>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>v374074_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the reference to our firm
under the caption &quot;Experts&quot; and to the use of our report dated April 7, 2014 with respect to the financial statements
of BioBlast Pharma Ltd. included in the Registration Statement on Form F-1 and related Prospectus of BioBlast Pharma Ltd., dated
April 7, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ KOST, FORER, GABBAY &amp; KASIERER</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tel Aviv, Israel</FONT></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">KOST, FORER, GABBAY &amp; KASIERER</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 7, 2014</FONT></TD>
    <TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">A Member of Ernst &amp; Young Global</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>line.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 line.gif
K1TE&.#EA`0`!`(```````/___R'Y!```````+``````!``$```("1`$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>spacer.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 spacer.gif
K1TE&.#EA`0`!`(```````````"'Y!`$`````+``````!``$```("1`$`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>v371611_tlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v371611_tlogo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4`$``P$1``(1`0,1`?_$`,@``0`!`P4!````````
M```````'`08(`@,$!0D*`0$``04!`0``````````````!@$"!`4'`P@0```&
M`0,"!`0"!@@""P$```$"`P0%!@<`$0@A$C$3%`E!42(5,B-A<9$D%A>Q4C.4
MUAA8&:%"@<'1X9*5M=5V1U<Y$0`!`@4#`@,%`@D%#0D!```!`@,`$00%!B$2
M!Q,(,4$B46%Q,A0C%8&AL9(STQ96&)'!0B074F*"LD-C<Y,T5;4F-O%RLW2T
MQ-0E-SC_V@`,`P$``A$#$0`_`/OPTA'G#[@,EE_%>-YW,>-\\7ZG+1*+9LA3
M(Z)HCRLK**.R@=TLK+U9_-@L":X%`"N0)L4.F^^_QEW/7CD+CFW,99BV2W)A
M-;<4,_2]*C4PR@MJ4>F54Q=)FF?K<5XGW1]4=MM%A&9Y(UA648[;JQ*DJ6:I
M3E6E_0:"3=0EJ6G]Q/WQIQAC#/F0L(U7)0\QLTL[%8J<G8ACBP&(/LR+XZ"J
MWIB@;'"K[TG<GMU4$_7QU/[KQ[R6UC+MULV<WM5V13=5"7V;<&24C<I*^G0[
MY%(4!(SG*9E.,3(<PXZL.=U6,+PBQ+ME/7%C?UKEU2B8&[_;0C=K/Y0/='(]
MOWDUD'-L'<:+E@6#V_XM>)Q,G/LDA1/8&Y2MD224@F44FI)!=R*O>"""*(`!
M>TH==9';#RU=.8N+DY'D3*6,@8K5TZPD2"VT-,J2XYZE`/*6M86$$-R"=H&L
M>?<IQ1CO'=^I;KB!<3C5U;+K;2S/HJ)42V@ZJ+:4A.TK4I<R9DQD"MQQC5.1
M;3D0?(]Q)/-X%2N)T_MK05I:,\F8312$#0_WHPM?O*ABB5SN(E+W;AOO,\?X
MRIK!R7<N1T72NJ+C=&$LNTSG0Z(9;4ZMEM.QI+NUA;JE()7N)`WE0TCG:^3Z
MIWC#^S(6NB%N34]<5(Z_7#A+6]7Z7I>L-)2H;)2)V@&,E#J)I%$ZJA$B!MN9
M0Y2%#<=@W,<0#J.NHJ6A`FL@#WF4<L2E2SM0"5>X3C2DN@L(^2N@MV[=P)+)
MJ"&_AN!#&VWVU1#C;D^FH*EXR,_R15;3C?SI4F?M!$>3ON%6K.F"X^$O^.N0
MV0X9&TVB)@AJ'V;'KFOQ+9TX2;++1Z[JHKS)ES`H)OSG"A=P#X=-?$?.-TY(
MP;.<>M=DRN[)H,@N2FW$%JA(IT*?80$L'Z69V)>('4*SZ4S)UC[*[<+/Q[R"
M*NR9)C-L==H*-;HJ`[6I==4E*E`.!-2&Y>G^@A/B8D>WXIY$QN#)/)-8YAYC
M=VMMCP+@QB9B!Q&$&XD30!94K%;T6.$WY6IW)P(':IW@7_FWZZF/)^-\HX)@
M%QSBPYE>*VKM5(Y5J8J&;>$/-LMJ<6V.E1H5O7()3ZTC4S4/&(KC.7\97/D&
MGQ2\859&[0[<_I5.-/7'JI3UNGO&^M*)@:F:93\O*+WX:<@;5RFP?-.+$Z"I
MWR#6=5.8G:PDD=1M(E4D&K>:8)3!)%H9\*+,JIBJ(BCYIA`"=NP:Z+QAE]SY
MGX4H\@4^Y9\EN5*^VX[2A!53.)=<:;=8#X>05[$)60ZE:.H3Z2F0B,\U<=VG
MB#D=NEH4?7XZX4U#3502`XV0A2FG"T6U;`5%`*5!6T#U;IF,2>/<E>2>Y/E.
ME77(ECR7_+['9X6"G[2TK[.6+'2JU!L"[99.MQ$+'&*F\D3%*((@;L(7<=]]
M^(=M%?>ZWF'+VK]7/W*MIZ0MA]Y+:7%I'TDBH-(0V#*0]*0-([5RU1V!/:WC
M]\L-MIK6FZ78//,L*>4WU&_K6`4E]QUS5*`3-1U)\I1[-*+H([><LBEOX>:J
MFGO^KO,7?7VHMUI!DM20?>0(^&T-N.?(E2O@"8U$435+W)*)JE_K)G*H7_Q$
M$0U>E25#<D@I/F(HI*D':L$'WZ1MBY;%,)#.6Y3AT$AETBG`?TE$X&#5G69F
M4[TS'O$7!EXIW!"MOMD8A//W(*C\=:*>]7,'T@V,^C8^/AH06*DQ+.)&381W
M[@1\[9M#D:`^!943JD`$B&[=S;%'F/)W+>,\54]`[?TO.OW*K13L-M;"M2U*
M2DF2UH&U(5N49_*#($Z1T#C;C/(.3[\;%8RVTI#3CCCKN\--I0VM?K*$K5-9
M1L3))]2A.0F1*54LK"X5N#LT:!TVD]$L)=NW74;F=-T)!LFY22=%;*K)%7(5
M38P%,8`,`[".NI';N*4J2J1E,&8_%$*N=N?M->];ZG5UEU2"0#(E)()$P#+3
M28$=#DVGV"]4Z2K=8R-:L4S#TR!FUUIC6MO)^-!%0%#D:(6N%L$*8KDH=I_-
M:J"!?#8>NM=<V:ERG*Z5Y;+C?KT"2%;==JMP/I,I';(R)D0=8LHJAFG=*GF4
M/(4A29**@`5`@+&TI.Y).Y,YB8$P1I'SW<2+3S,S]ROY'\>[CSOSC"P&&)Y_
M'5V<K-4P<$S,,4)BS1[56<&5Q6\8E>&;0B9E/3HID\PYMNFVVUQ'9DF%UN3/
MS;K*2J:9V)^0E9=2LZS5(%L;-1H3/72,3+Q^SF6VW'J7[2EK;=]0I:_G2KI-
M+VIVR3MFX1J"9`:Q>V3.0G+?A/S$H/'_`"?GBVYJPSR57BZ=1\@V2%HS/(V/
M):14@(*2L#!&MU6JU9=:+DK45=(KEJ^3$6Q`,F8!,4WGA:TY;77?"KE*EO+#
M0<9J6?'<4+4PV@.;TR7Z0^5-S"@.F93ADS#M@M5#FUN4*BWL%PU5*[\BD(4D
MJ!*`E>\I2KH[5A.IZA&D7W[<LU=G?-[F/'W_`"78\I/J^>IM&EQN#2MQLRYC
M5*K'*-$G:-8B(*&3(S9II)$$B!1[$P$PB;<1]..WD5O%-TNCK3;5>[?D-NE)
M4=ZJ<U3"5'<3ZE!$U2D)DR$I",/-M[/(]IMS*UKMK=D==90H)^S%4::H6@;1
MJ`I<A,DR`U,>[22Z"Y1,@LBN4!V$R*J:I0'Y"*9C``ZLD1KY&,J8G+S$:%7C
M-`W8N[:HGVW[%G"*1MOGVG.4=M6S!T'B(K(CQC>*<AR@<AR'(8-RG(8IB"'S
M`Q1$HAJI!3HK2*`@B8\(V#/61``QGC0I3#VE,9R@`&-\@$5``1T&I`'B1,?#
MVQ7^8R_#&Z*J)3=AEDBG[>[L,J0INWK]7:)@'MZ#U\.FDQK[O'W?&'L]_A[X
MT)NFJP&,BZ;*E(&YS)+I*`0/F<2'$"A^O0Z#<?EAY[?Z7L@BZ:N!$&[ILN)=
MA,"*Z2HE`=]A$$SF$`';21E/RAX&1\8U*KHH%[UUD4";[=RRI$B[_+N4,4-^
MNJ3$Y>9A(^/E%$G#=P`B@N@N!=@,**J:H%WWVW%,Q@#?;5TC*?E%)B<O.-[5
M(K#2$-(0TA'GA[G^_P#E0N6VV_FM-M_#?U3;;?\`1OKXQ[V]W]GMKVRW??*)
M3\)]%V4_=/QCZB[1?_UQB?AT5?SQ#]#4YUQ_$JJO<>_R#FX,E`C0@X6+B[VA
MD=>(55326*@^DYYM52RZ#)10YC&*5(2D$"@)A#?:YX>YACCNH5;OV>J6S3H!
M3;T53=;T=R.J65U3OTX6&MT]XU3N"05$1)[BCMYJ>8ZIC(CD-/7&Y.=5UY=*
MJA#H!*=R&F34=,K"0`"5`D3($X[#VQ9;"CND9!JM*"Y1&749%9QDL]V6B5[8
M5=ZU9M4'\<O#LTX<D,F^04,U34`[@JQ5!4`2"36W[6*KBVY\0_=7$GU=%:4N
M+2M+Q0:Q#BFFT_4+(1TMY&W;),MR-4RT.)W84?(%+E=NO.5?0OXNME*:/Z4.
M"E.Q2UJ;4'%%WJ[%)ZA!""@I"#N"HC!^VN54]SK%-`F\I7S(\(RHTY9HPUW<
MPJKB+=34'<6CEHS^PPT(W%DFE&D[`43.<!$VYAZ;<XXE8O5K[K'\?O%WN-Y-
M%:G6T/UBFB\I*6JL`*Z+;+9UF9AL:DGV`3*K<L=X[1+KE%OM%NM5<]=6F%II
M$NA"TM/4BDJ/6==5N)<,Y*`D!(#6+[RM,O>6/,4W&.9L<O$85I3%I.W*LQBS
M=JI=IJ*4?R;:/?K*-W9QB4).M$\PJ8H*&25,`'W$!+M;46.X3F7(K'D3SR\`
MQ=3+(MY(#;]3U*AIUQS:-Q2%,H4@!:2-9SG&AQNF9X3X29Y.M=*R[R'=%N-T
M]2L%0I6'4MH*D`*3]J6WU;20M(4$S$ISCGE#23<$,GXRRWQZ4-2:%<Y^(@LC
MT-HHLO`O6<?)0[-%9)-T*SM-RY;RSL3#ZCM[A#8`U%<M3<.VGG"PC`R&>/LP
MK&::KH)J4PU].MIHO>H[P[*K<6P0M20L'J)*?29+Q9>&^XC!;OBG(Z?KLIM5
M.X]15B@`\%.(=44J*9(*06FQ\@,O.+Q]TJ:-9<`8=L3$J21Y^Q4V::%6*<4$
MS2OV]\B54I#>8*1/4``@`[[!XZW?=M]6K/,%^Y%-"M-R5T"\%%O>:BDZ9=")
M**)RWA!"I3EK&F[1*1-NS'(+?5;BFGIGVU[93^S#B5;9Z3T,IZ1W68S<Z6?&
M1/Z,,3])>4B)93S7%L=<6&2&5'7K!PD)!L[M\V>N&=M(XH>8`)'$RP@)""7<
M->W/)YR9XXJ$YDFU57'JD_\`VPLR7VJT6SI+^K*36N+:*2U.82A2R=NU,IQK
M^.D\`/\`*A^F5>Z;)45KBJ95Q73KHE5H?'304TK0>`4Y\I*@`D'<J<C$U>W'
M/8*D\&!%X81G6CN$DW#>_,[<HS7MZ5B<OY1R4\ZXBF[>'7%1-0YF_I@$"MA(
M53\P#:[[P+<<$N'%UK''*5-XRTVI*&E?I&B7%DAV0"=ZU;E^G37\$<Z[F[;R
M!1<CN5.>%A9J6TJI5TX4*93*4-I/12LJ=`!D%]34N;BGTRC&?"7_`/5[D9_\
M1C__`$C&.N`]LO\`^UYO_HE?^TCKW*'_`/'N&_\`GE_^-<(F+-V`FTEE^WYJ
MY9Y*HDWQLK,0+FL8]D"V--S6P`S1$9!\C&($7>F!5=T4`0,J/YQ?IZ#MM[_Q
MK8K?G5[Y)[BKE;KGBCU"6+;2J^H_J"RXTM.QMM*5E$D/%6KJM[I,P!(0W!N1
M:E.$VSC[A*UW&FY/J:B555HZ!34F2SL0IPE*/2&SZPGY#KK$6^W)=U'LOR0I
M>/YE>2QM79!W(8W9=KDB+%-2,KZ*0,B2*2#U)/SCGV!8`-N._AMK4]L.1957
M\$WVDM;[M95VRY.4]OWRW-L!AEP-()V^D*<<6-WJF?'RB2]T%@IZ:IQJ]7UA
M#.05;"!7*$CO5U7IE6PE),@`=NDA&-''ZG8ZSXQR70\RV)[3.;,O=7SEA:+,
MLZ0F$F[9G"NGB#!9@V7@1CG"#1^F("!CF\PX%'<2[<NXKQ##.6N/GZ&EK54/
M/B;@W45SU65AZJ2A=.I;B]B>F:=<EI:0C:\'TDK^S(GUSE#(,FXWO-NOV'TJ
M*_M]8MZ6_IZ<)+4U*=2@J"U![J)4II1,]L@F?G$I^X1@"%I&`L0REA7)8+G5
MX:D8W4?(JK_9R(0\HQ(Y>QB*I4G0*2!)-5,YEA,(I;;`4P;ZW'>3A5EI;_B6
M1NMER]U]R;H7W%$^JE;4E:&)"0"$J=<(TW>LS4=)0[MDY#N%[S._T%N'T]C?
M=JJ]*2!U-[J%22LB:2$=-*@$@>J>I&D>G'%S#6+\7XSJLKC^FQ=7D+;4*R^L
M;F/4?'/*N_MY'`KN/6/'10.*[@Y_H`H;F'X;!K[TQK"\6P6C79\1HFJ"UEY2
M^FV5E.Y4IGUJ49F0\X^1>4<XRS,,CJ&<FKG:QNDJGDLA80-B=Q$AM2G20`UG
MX1DP/@/ZAUNZG_9G/]&K\ACFH\1\8^6'B7E:_8J]QGFS(T+CYDCD`[?VZ52>
M16.9BA1#N$32LMX!-P_4OEFK+15-T"QNP$53F#RQW#P`;.,:AYOC.Z4R65J8
M<NJ"IP%.U!2X_)*@2%$KF=NT$`).Z4P8S.3*=E?(5DJ%/(2\BQH"6R%;G`JG
M8F4D#:`B0W;B"=PE/6,PH[B)R4YI\Q\><K.1]1'`F-<)3<?*XZP_,O(N1R"X
MDXV0A'J#R0D:Y*6VJ'CW3JK)*."D<)*B5<H$[1`W;M,)IF\0J*_*ZQ]NIR*[
MLN,EIH*#=,VV%-,J5O`)6MM042E:D[@=`"!&JRZK?R6WM8K;F5TUGHRF;KI2
M55"7P%524["9!*AL1N0G0B95J8PVP]@V^<@_<;Y78UCLF/*/B%_(0"N8*S%#
MY,GD*M)P44R>U47*D;(((Q<I$O%45]A15W[1(H78=1WBNT4USXEK:J[E2[4W
M=:D(;3(*37*?J54U3,B6UD!8(G,E0])C:\AW%RT\ET-)9T(1=_NMB3RIG;2(
M9IDO-)`/Z19Z922"GTF<9`>U_%S_`!LYU<I>&T5;IRQ8RK48:X5]K,KHNO2.
MW#6CO&Y5%2MFB@BU1LZJ0`4H!V@&^XAOJ58S=;CE/#;ERJ@R;W0W/Z>G40KI
MMM?U@E$@=TEK2%KF2=T]I`D(CN36IC'.0:9R@4L6NZ4)<<29;UO@M)#BS+;Z
M4A2$[9>DB8)F8KF3BMCO&SC,>;O=`S3C#*TG='1ZMA$K1&^"\HRJ[)M(1\0P
MBXAB5X#T6D&X5\PZ2J(=PAW!N4-<XKD,V3`ZZRV7J.\DU3OU`JP1U'$H3TPD
MDR;3MFA*9I2-J!,DS)Z-3A5]SVGNCH#?'='1[5TJ_E;25H*W=/4H%95,)4I4
MUZ#V5]ORPYASE[:=N199VR-CN;QC:I5I3[93%X!.7-7T(TCI"!D%)ZO3J2L4
MHK+G5'L237`Y2?6``)1G?--35T>(6S,=Y7=G+2EVH"I;*EPU#C)+P3(_($C[
M-2/E'OG`N)*>DJLHNF*K0!:$W$L,2GNID=%MX%DDRGOW?.%Z+5I.4L3?;N]N
MB?YU8+:Y$Y"<@\N,:="VU9?'-;HTS!Q[N/DVS"-5+./59BJS":H'1>K)`4IP
M^HH")=O'?U%H8QFCLUYIEK3D'W:E-,M$MC%`5NE-/)0F5AXN+).X;5@`S\,"
MCOU=?+I=Z5>W[M%P6JHW?I'J[IMI6_,':$*8Z:```=R292B0LF8(SVK[HV-N
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M;<ALP`R*Y,M,K?<U)4THK<6H)D-4N'9).B]5:1)6!L.L>$OO'QF"L.V2QI8M
MRGC*8M\W6IA\F]00,2(NDA%0[42M41)&03A$/3`(F5`/QG/K/X\N#]WQO(K;
M<`E;=#4-AHRU`#JA/_O*``5Y>P"/+D"WHH[+9LO84K[Q55EA4Y>HJZ277%2`
MU6%STD)CPE&?_-+BE>\W9HKU\S/F;'K#A+CZ%-8[?AN>_B)K(S3N":HRDQ*O
M'$:@4KEHA]L*J5-!8%1+N&PB(!J*VA%IM&0NY)F6VJ:%.ZS2MB>VG6\A3:'$
M)^8N+44%R94GT)VI&L]Y=5W&YXW38[BQ7371RN;54N:;7VTNH4AHDSE(;TCY
M1Z]3[,%O;5RACMG[B.;L5\7;$D?BY8*DTL<)7XQ&:0@2S$7&23@RT<A96R$T
MFFBZD5!`3_2<!`0$0ZZF&#"[UW%=T<R8K=K:&[@4I7MFTQ4//JDG;Y+0AO14
MU`)$Y&<17,T4%MY-M]-9$I9:JK:L5:43DX_3-LH]4YC<VM3@FB225&4Q*/I.
MUIHW$-(0TA#2$>5GN=96I2^&[)B!J[FWV0Y!)J^9P$=4+=(D6;%>ID,?[NQ@
MUX0@@9`WTF<`;IOML(;_``7WB9A8[W9:7#[2JIJ,AH;JAQ]I%+4D(0&ES5U.
MCTE#U)^1:O'W&/L?M,Q"^TV9LYI4HIVL;"%(+RZFF0=Q$Y=-3H=\_'9+WQW^
M`^:7'NB8$QU5;%9[(UL]=I36/DH3^6&4EE22+=%7N8^J0IBK(QSG$"]Q5!)U
M\==H<[B^*J?'E--5E6[6)I2D-B@N`*E;9;9FE"1,^9,HCN=<#\F7WD"Y76@I
M*4VNIKU+0[]?0`;%$>O::H*T&LI3]T07P#IUMLF=^07+&5KTK1L<W"2?NXB-
MDVYB/U_**O(.VZD>0II$Q6+-^10!\@H'-N4O<8!`.7]I.,7G$[?DG*N54Z[=
M:K[3M%FG(*G&VF7.OU5);WJ*2%%*4`=0%)FG43Z-W+WVRTV&8QPY;:EFXY);
M6DH==0?029-I4%F2`5J20?49#4R&L1Q<LY8YF/<EH&9(Y[97.-HJ@A6']G#'
MU_3;MYQ9I;VB;$S):LIR9^YQ+-R^85$4@\S<3;`80A6!<C8I_%%49P7*L8M7
M4ZF6'S1U@"W'A4(;24FGZB-RG4#<M"4C=-1`!(E=+Q_D]'VH5^`5+=(G+E74
MU`I_K*,DLI52J*]X?+?@TX=N_<=N@F1.\<O-I_CGS?IW*AO"2DUAC(T(+9Y*
M1,7(/'#9689N4GC]]#,T5IU(&1+$1;M,U*<VP@`"8!`-E2NUW;UW*5URRBG=
M3QQE/U+YJV6G'R:A`>=Z6Q@.N(+2WV^HIQL)="OLB2E<M'C"[=RUV]57%B*A
MEG/;2^DI;<<0@%#2TE"4.+*6CU.BI&CA`T)D"";WY19&JG-2PX<PCA$DY;$7
M5P:V6ZSKRJVFJQ];KU;FJ](O#*JW"%@".UGC`'/ED1%4^Z.W:(B4!DN:5=)W
M!\H8M2X1U7,;L%:*RNJ76'F4E(=IW4LMI?0TLK<##B`H)4E)(*I#QT'%6.W;
M@C'LASC/2Q1U)HOIZ1E#[%0MYY]I]M,OIG'MH0LHW%>T25XZ$BP?<FO5&<T+
M'>%ZFXGYNU8YF:>E*QC"EW)=)K%0Y&2`.@E"0`1#K9NT$PE16.;X;;]-1/N1
MSK&+YR3BJ[(JJ=IK'=E&KE25<F$(J:<G7H`.22TO5K>#MT\1.2=K>-9!27&[
M9A>DTU/;;K3/%I:JJF!6XX%F6SK=1/J4/G2/&,M&_/+CM6\1,6K>9M%ALL)0
M8YJ2J-\9Y.;.)67CX)NB:&3?/*:E&(JKND12!0ZH)`([B;MZZZ_R!W$<:O8'
M<J2RNU=PNSE`ZANG%#7(ZJRV0$;W*9"$@G0E2@-?'SCB[';MR9<<T+E2S24E
MJ?N2U&I574*DM-+>)ZI0BI+A"4G=M"2H^$IQ`OMH8VM.+JIF3.^1&3^HU*[3
M4O9XF,<-5G3[[*D[D#.GJT6P(\E/.9'1%,J?D@J<!W*0P"`ZUO;/CE;PKQ'?
M,GY`W4=+<*A-R6V$*=73,,MN@A2&`ZMQ2D*2M*6DJ5+TE)5H.@]U64VG.LIL
M>!XHINLN]!3-TJUA00@O*2WM2''"AL!7B5%6T'Q(B%<1YMQY$^XMF;+LB[LS
M7'=Q@F<36[*?']^%O)2"4?16RC<&A*T:1;`5:%<E[UD4R#Y6^^QB[\O[<<UQ
M^W<R9#55RJIJFO8Z=$I5)5!+RU"G(!/1DW,-KU=V#34ZB<_Y$P3)*_MDQO#:
M-%*O);;4K<J6!64FYM!<K%!6XO[%:.MF2%*/J\-#+3)WRA6/G!F1SS$K$O.X
M]K$&2(Q='S=,M=J@H9^HI791JG&$KL/*"0RB#MXIW]W84RI@$0'IK281F6++
MY*R#+>;J2I=R9@J1;NK2U+Z6$`M%+-,66G`V22XO<I6T!2]02(]E8_DMLX$Q
MZFX,JV*>]5=3U;@MFJIZ=UY`#[:E.==UOP4EM.V6XA((!&L=[PGS-$4[/O(<
M]F@;/497(3QR\I4=*U>R/FSQTRBXA8D<K(140M'H"#6(44[U%DB"``0#=X@`
M[3MNSYS",1OV+UE-44V?U=V<J*6E>IWUH6!3,B2GFT=$>EM9]3R/``:D`ZCN
M!P6IO6%8V_9ZBDK;1;F$(J7&GV4*2E3K@*PVXX'#ZG`F00H@^HC;K%H9<S!@
MWE/@E&XY5@'U'Y9P;2+:P+FMXTR(5SYT?)M9!)HTDU:]-M$(H%WCHR9%'8'(
MKN83;#UC'*V3X+R)QU;LVLB'J'N+:13.%#%#6-I<JE/);=8<<6PI)92TM;B/
MZP).`$N*$P9-A6%Y[Q#R._C.,U#=?PB\\Z7`_741&U313O4A+S:BZ0A"5$-2
M*=-LQI(O)5EF"V>WWAN?O[&9G;8Q/4):QN/3+OISTB[FK;.Y)HW\]VX?G<^;
MYH)I[AMOV@&IQW.T655N`<<7>_L/.7ZDJ6'KIL27%-/;&NL5!O>524-2C<"?
M"<0[AY_#+1W!9+:L<<8I[.ZFI:ID[@AKTA^2&U*VI2@)EMW*_"3'H_Q<SCC3
M)E$K55ITU)OYZFTVLM;$QD*E;Z]Z!?T/I13*YL,%%LWIBKLU"CY"BNW;N/00
MW^T<3Y`Q3D!%15XG4.5%.PH;RMBH8EN)`D*AIHJG(_*#+SCY7Y2P#*L0O3UR
MO[#35'75;Q94BHIWMX"MTY,.N*3HI)]83.<AX&)CRCE*D8:IDG?\ARCN'JT2
M9`CY^R@I^QN$CNE`10*2*K,9+RZ_>H.PBF@<"^([!K=W6N8HJ4];=O<!0@`$
ME2U"24Z`@3)`FJ0$YD@:QSBAH:FO>+5*D*6E"EF:DIDE`*E'U$`R`)D-3X`$
MZ1\R'M_\G<9TGW`^35^N*%[KE+S/<G;/'5B>XRR2LTG#O+-:@B%#H-*@N[C$
MI9.:;G*9VFW*B!_S1+L;;?<<TJ[?@E=C-20F^5UQIUM-'SFXZ2DKGTQL*T@E
M2@#XC2-=R-4LUV96O(:0]2ST-F4V^X`?0M+#((V2WJ,T*^5)\-/*/J2EK1"0
M58?W*4=*H5V+A5[$]>D8OW2R40V9FD%G)8UHU7DUU"M"B8$4T3+&'Z0()NFM
M?<GF[2EU=>=B65%*Y`KD4D@_(%3U!U$P?*,BWMKNBV6Z'UJJ-NR<DSWRVSW[
M=LYCYI2\Y1\TW![D;C2L^XKR:N\V:YQ]'R(T3&J6MSC3)"3"17C64)&K-?3#
M4A?-SF<D4`IE4TRB!!'?80'5_&Z39N&;I;[G]E7,U[EP4@ZGZ-"JEQ3HVSW$
M)=;/23-T[I!!(('CG\[GRU;JZA^THW*)-`E8T'U:Q3H2T9RV@J;6.HJ30VS*
MP"">+QEY&T0GNN<B\HMVUS2K63ZZG3<9R;W'&0VS*TVLC''<>E&^<O5T`B$E
M'==>%]0]],W`$MQ4V,438>*N7&V<'W.V4B/^:%UBJME@D`J;D]M5NF$"8<0=
MI4%#=J)@R]\T515.:6RKJ'-M@H*?IU%0`I01JDK(0`7%;""GTI5N(FF8(B!N
M*V9L5R]EY+97Y@XZMM]Y6J7E=;`KJ?QQ>)*P`UCXEG$,H^KV9M6W->@C%3:&
M[5'KE),"EVWZAOBW>W,IXK<LN)E7[3W)A;=8H^EQXJ7NFXM02DH0$I3*<YI!
MU$;RJKUHY,IG\C'1PBCIP`U,.,M;E(7HALK62X%%9E.16H&2M!*/MO\`*_#V
M">'68L1Y><7FD7Z=M<R]A()QB?*LP:2:.XR-3162>P%*DXU$//2.GLJL0=R;
M^`AK;<JJ&3<;V^RV3[>Z,VI+*T?*0X*I3A$U[4_*9SG+WSC0<?4SF+<A5UPO
M`#5O>N)?2N84`@TZ&P))*E3F/9YQF1[*.=\:PW'F"P-,OK-#Y59OI"9<UB6Q
M[D&,(E'$C6O<O]]>UA"NF'=FH'8#L5!$O0H[AO-,AJ6+C9+?442@MJU69M-5
MY%L]=P2`,BX9N(T;"_&?@#*&V-IRU7:O;KP4+N5W6:?^EU`66Y&:9A`]"OTA
M3X2\Q."++R?PY*^[MC[,["5N"^,H7&W\&R=K_E3E1-FULA2Y(*,<+=6FD?J`
M`SS3\XB)D?S?Q_2;:)<3)*;7E;*_2[=REVD"O3U4-NM/+.LMDFVUJDYM49;0
M"H@&8<B-.(>QU@B;MJK'Q5`$*Z74IU,HU3,+FXI*9H*@)S)"03'7WGD7C4?>
M:H656IKF]QS7J!(8_L-M1QKD8L=$VM%GDEK]M.FI5`=O"'=3S0@+H)J-_P`[
M?O[2F$+>)5)-DR8*](NKGU--N]/49:4'E*D9%)Z:%$(7M62)!)40#3D5/5ME
MH:8^TK*"H"'6T^(+A0V)*^4R)F2"1('7SCBY'Y'XH4]YO'^9TW]P4QC5,<R&
M-IZVIXMR@=@QN9X^UPA8CR2T\7SD@R4F@GZE%)1I]?=YG8`F"WBUUM%MO@6=
MIO#S*J3<".JE3A(.OZ/10,G-A$]9:Q[\B*2_A-#:F3NN%#<EO/H&NQM)9)5/
MP5HVO1!43+0&8GQN9V6*W=/<MH%?Y6UJS6;A;`XU:V6)AGU&N-NIBTI;($'+
M&:<PU;@Y:4([=.8]HJ=(R1%DC%`%"E$-M86#(I:>OO-SR-.S+*.K=9I-PW!G
MH+<3N:4D*3O=DF2@HIF`=!&3EK]>O#;8UBBE&WUKK+KSB"$*?3N;6IMQ*RE8
M2PE1D%)23O4$DF<K.XQYXQ;0_=,L^0E:?<\<X7M5%A<=8Q>!CR\NH@[1K#MZ
M[3T6[2+K3MY$1\JT,AY!'::(M$MBN!()3;;WCHU;&$7?'+LHC)KG>T5#:%$$
MK#C[ZQ-P?9@_:IF5*$IZRUE'\XIJ)636O*K/M5CU';7FW5)24D.!MD.G89+.
MU:%3(2=YU1,1]4S5RB]:MGC8PG;.VZ+IN<Q%$C'0<)E62.9)4I%4Q,F<!$I@
M`P>`@`ZPGFG*=Y;#HDZA12H3!D4F1$Q,'4>()!\HSF7FZAE#[1FTM(4DR(F"
M)@R,B-#X$`CSC?UYQZ0TA#2$5`PA\=(17N-\](I**"(CUWTBL5[C?/2$4`1#
MXZ0@)A'Q'2$.X?GI"45[C?/2*2BFX^._72*Q7N-\](2BG</STBDH=QOF.D5B
MO<;YZ1244W'QW'2*P$1'Q'2$`$0\-(17N-\_Z-(13KX]?^.D4F(KN?\`3^S2
M*S$-S_I_9_W:128AW&_3^S2*P[S?/_@'_9I"'<8?C_U:0AW&^?\`1I"'<;YZ
M0AW&^?\`1I"*`80^.D(KW&^>D(TZ0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:
M0AI"&D(:0AI"&D(:0AI"*AXA^O2$>5]SXM\W)NV627KW*Z4@H*1FY1[$0Y$)
MLQ(V-<OG"S%D44KRV3$K9JH0@;)D#8O@'AKX^OO$//\`7WFJK+9F3U/;W:AQ
M3;0#I"$*6HH0)5:1Z4D#P'AX"/KZQ\N<!4-FI:.YX<S47!JG;2XZ2U-:TH2%
MJUI%'U*!.I/CXF.B:<4.>S1RBY#E\^7%%0J@(NV,ZX;J=I@'M61-D``43-ML
M(?$-:YGAON-9=2Z,V=44D&2D.E)EY$?6:CW1L'N8NW1YI37[%-IW`B:5-!0^
M!^CT,;3C"'N3)K*)M\Y0CE$IA!-?T[A'S"_UO*/?!,3]0CJCG'_=0E92WD#"
MD`Z&2A/WR^KTBK>?]K:D!3E@J$KEJ)@R_#])K'(5B?=@A%UUHE]B:Q@U3`K0
MDBWC$47X@0@#YJ;B\F%$^XB`F,/B&_QU>NC[R;>XI=&Y9JK8/2%A`"]/,*J]
M/B?C%B*SLZKVTHK&[Q2[SZB@K)1J?`BEU^`CAAD3W:H!OYUCQ+AZ3\Y?RT!A
MY2`*9,.SNV511L[Y3;Z#?6.P=0#QUX?M/WG6UO?=++9'MRI#I.,Z:>8#ZSY'
M701[G&>S6XN;+7>;VUM3,]5M[77R)82/9IK[8VU.8W-FF"H2[\65ITZ(`W4&
MKR1#E,Y((**+)BSBY8#H&1^D`#<.[XCX:HKG'GRQ$IR#$%5!3Z3].Y_2&I(V
MMN:2T'O\XN3PAP+?0%6#+DTZ5'<.NB7I\`#N<;UGK\/+SCFQ_NCS*1Q);^(V
M8ZD!53)F571L<@EY9"`85B'1QZ@0Y1'IL`]-M]>]/W=UZ%2O6%7RB`,ID/K$
MO;I1"<8U3VCT*T[K+FECK)B<@6$&?L,ZPQ(,5[J'&GZ"W+^-:,LH8A2DDJ7;
MW1/S!`A!,J6O-2E(90>WNVVZ:DM'W@\5:)O@K[>LRT72U*O'PUZ*=)Z3B-UG
M:%RGJ;']!<$#S154R?#QTZRM9:RC(.G<UN,MY%(L+E2`1%90$R_?%R5\`,.W
M4XS!V8$+U\1V#72K'SYQ/D!2*"\4R=QD.J>CK[^KME\3'-KWP-RMCX)KK14J
MVB?V0ZW\G2W3_!$_Q%YI-@$A8&XU2;,IMY81%BAY(5.[\/8#-XL)^[X;>.NE
M460X_<B!;:ZCJ"?#IO-KG\-JC'-ZW'K_`&T$W&AK*<#QZC+B)?'<D1=6P_(?
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MH^2;^%RLJ\)2]0[DQCF"?8IU_$'77,;[VR\.9`"*FU-L33+^K[6?Y-B!(^^.
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M=XXYK!-&L9`C8B4-^6,+<5VE4E#.RJ^G49MV4RZ;.G2X+@(%`A!$P=0#7<,'
MY_XNST!NTW)IBL.G2J2FG<W`R*4I=4E2C/P`$SX@1Q'-^`N4,")7=K:Z_2#7
MJTP54-[93"E*:2I*1+Q),AX3C+,H@8I3E$#$.4#$,40$IBF#<#%,'0Q1`>@A
MKLX(4`I)!2?..-$%)*5"2AY1758I#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA
M#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$<.0CH^6;'92K!E)LE
M?[5G(M4'K53H)?S&[E-5(_TF$.H>`Z\*FEI:UDT]8VVZP?%*TA23\0H$&/>F
MJJFC=%11N.-/I\%(44J'P*2"(PDSA[?6!,Q">6C84F-+HCNI%VBD(#"%CW78
M`%=&B(->%;.U2JE*?<QRF$P#UZCK@'(';3QSFY-;2,"U7X:MOTHZ6Q4OFZ;2
MFDJ(,CJ09^>L=\P'N3Y%PF5'5/FZV)6CC%4>KO3/Y>HZ'5)$IC0$2\M(P^J>
M4N1/`[)%6QMGJ8<9.P;<)!.*KN05UEUI.%.X7*8JLL_=$D5O5-RIN029J/0\
MQ(H&`P`7;7#[-E_)W;IE5)BW(KZ[MQ]6NAMFL))<:W$:N+4%G<)+VM*=U2)@
M@".W7G$>,NXC%JO*>.V$6G/Z)LN/48`"'9`Z-H24#:9HW.I:]*C*1)CVHU][
M1\'0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0
MTA#2$-(0TA#2$5V'Y#^P=(1'MDRSC"G>;_%=_J-<\@XD6^\SK".\HY1$!(IZ
ME9/L,`AX#J,W7-,1L>[[YN5%2[3(]5Y")?'<1*)-:L,RV^2^Y[;6U6X3'2:6
MN?PV@QC5>/<+XF48%O/RM`V<Z!3"=*F2D)/J"8I0,*1"DET.Y4!^G;^L`AKE
M.0]S/#6/!74O%/5J3Y4KC3Q^&C@U\OC'4[!VT<R9`4[+/44B5>!JFW61\=6S
MIY_",8I;W.9N_P#FL>,O'S(F4'*XJ-VT@\BGC%)N?JB#H48IO8DUB)./@(@`
MAX_+7):WNTN&23I^)L:N=W=5,)6IM2`D^&Z3:7@9'R/C'6*+M/M^.2J.5\EM
MEH:3(J0EQ*RH>.V;BF2)C\(CIH7BURDY6W.J7OEM8XVLT2L/T9:!QM#,DDY)
M4J2GUQ\V"$96G+554RBP@X,*RQ"&``Z#TP+?Q!R]S'?J/(>:*IJDQZD<#C5$
MVD!9D=4.R;8*29J]9*E`$`:&,^OY=XBX=L59CW#-*[5Y!5MEMVM<62@3&BVI
MN/I4!)/H&U)().HCV,U]RQ\/PTA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#
M2$5V'Y#I**3$.T?EI%9Q7M-\M(I.+8=W&JL/4>MGXQMZ3S1<^<Y*3R/)W\WS
M=P^GR^T=_EMK4O7VS4^[KU+2-D]TU2E+QG\(VS-CO%1MZ%,ZO?+;),YS\)?&
M+(?Y\PM%H&=2.3J>S;E."9EG$N@F0IQ[MBB8?`1[1_9J/U/)&!T;?5JKM1-M
M@RFIP`3]GXHD%-QQG=8X&:6TUKCI$Y!LDRBP)/F?Q2AE3H26?<9M'"9.\6ZM
MD:`N(=H&`"I_B$1`P;?KU&ZOG?ARA46ZK([4AP">TOIG_)$CI."N8:Y(<I<<
MNJVR9;@PJ7\L1M+>XWQ$B@((95BI3O.).V)7CW1B;=WU'`\@CL0>WQ_2&HO6
M=T7"E(`1>&7IG_)E"OY9K$2BC[8.::LD&SO-2'^4"TS^$D&(NFO=IXDPX*"1
MU?Y@4U02`L)7X1Z97<O=WI`>SM^Y/?IOTZZB%?WG\,4(,EW)^1E]DRTJ?O$Z
MA.D2VA[-.9JTB:;:Q,3^U>=3+W&3!UBVEO=/ILP+D*%AS+-A'8%6(.ZVR;"L
MV$Q"@JX]+8G7E;F$P?3W!N`:U*^\"QUQ6,<L=YJ3XHW,)3-/A,[7E2\_"<;9
M':%?*'8<CO=FIAX+VOJ5)6NB=S*9Z2\91UBW//E7.`<^/.$]RL21RD7:JOB2
MS,BC14X%(X5%H5YY93!OX;AN&L5SN+YAN`*L9P*OJ4&125AQ(*2="=H5*,QO
MMVX?M\ADV>4-*H3"@@MJ(4!JD;BF?E&R?./N6W#O^T\>82@]YP.3[F]E5/*(
MY$")I?OE8>`;TFW<81Z[?/7DKD'NKO<_HL9I[;,S'44X9!6@'J85\OB8O''_
M`&K627UF2OW&0D>FEL3*=2?2^GYO`1LGQG[K%Y[BR^8,:4N#7-V+1[).,7DB
MBB;O(H0ZV-DU03.?;P6#<`'IKS5B?>+D&E;>[306]1D4(#9<TU!!-"#(G^^\
MHO3E?9]C^M%9+K77!.H6HK#>NDI"N(F!_>^<;`^W5G6][!E/E9=&Q53&6<DJ
M23,GYQA[S%(9!.&$$Q4#;IML'P^&K/X8>0\B_P"K\QKT`ZGZ<)&OCI(-:3_[
M(]!W-\>X[_TAA]`LIT3]05'3PUF7=9?C\XD.M^U;A!D*`W2U7S(O8'[R$Y/V
M!GZPW3<ZOH+$7L$=A_#\]2>U=GV`4Y3]_5EQN@'S=5YY.[X['A^*(S=>[[/J
M@*^X:.WVR?R])EE6WX;V3^.,DZ3PEXP8]\D:QBF);F1."A32#^9FQ,H!Q4$Y
M_O4C(`;N.(B(#N'P\-=4L/`/$F-;?NFSLI*3,;UNNZSGKU5KGK'++]SWRUDF
M[[UO#R@H2]"&FM/"0Z2$>49'Q=:KD(!2PT!"1($`"E^VQ3!CV@'@`"U;I#XA
MKJ5):;7;P!04U.R!_<-H1_B@1RZKNMTN!)KJE]Z?]VXM?^,3'=ZV$8$>4#[W
M3*ZR=K-1PGE)043%*)R1$0)3;D*;Z1&S@.WU?+7QL_W?6QAU31L-W)2?$--2
M_P#41]C,=HES?92Z+]:`%>1<<_41Q/\`=6KG_P"'Y5_\GA_\4:\?XP[7_N"\
M?ZIK_P"1'K_!_<_]_P!G_P!8Y^HC;/[F]@EQ\ZG\=<A2;),.Q=5['L4E".0$
M1,0I4+*8HD`ABCN/7<=6*[L;G6G?8\8N;S`T)4A`(5[-'SI*47CM1MM"-E[R
M:V-/DS`2M9!3[=6/;.-/^Y!D[_3%=O[HW_Q'JG\4F7?NE</S4_KH?POXE^]E
M!^<K]3#_`'(,G?Z8KM_=&_\`B/3^*3+OW2N'YJ?UT/X7\2_>R@_.5^IA_N09
M._TQ7;^Z-_\`$>G\4F7?NE</S4_KH?POXE^]E!^<K]3%!]P'D;,;'IW$>T2J
M*/1X=VGY0I&-T2`@(6`P#W"4V^_RU:>Y/E&N]5CPNL>0GYMPE+V2D][C%Z>V
M_C"BTOF9TC*U?+M,YR\9S9'NC3_GHY@?Z,IS]J__`+[JG\0G-_[B5'X_UL7?
MP^<)_OS3_B_51QUN9GN`2(E6JO!I9^R#<JJK]X_;J`ITV*0J4T8I@W`V_P#T
M:H><^Y&K]=IP`K8'B5J6#/W2=B]'!G;?2_9W?D!+;_D$)01+WS:^$;1>6_N4
MKF!$."31L*OT`X4DY3L1$W0%3;2XCL3Q\!U:>9NZ98V)X^;2HZ3WN:>_])Y1
M<>&.UEL;SR$M0&L@VWK[OT?G&[_//W.3?5_EMKY>[ZNWUS_Z=^O;UW'Z=]M4
M_M"[LCK^RM,/\-<6_P!GO:@-/VIJ?S$1I'('NC3P^L;XSJM6(3\H8]9PX4,H
M/XO/W5BWAMMA[?Q?#PU0Y+W<W+[=JTT=&!IL*B9^_5M7P\8N&-]I-M^P<NM9
M6*.N\)`E[M'$_'PC3M[J]B'L;NZ14?3AWF4<"4Y7>X]O87S:B]V$.[?P#PU;
M+O#NAVMKM]%M\S([O=K3+_F\(K/M`M@W.(N%;N\A,;??I4I]GXXT'QQ[L\^`
M-4,UXXJADQ\P7RJ#-4JH#T\G93&KT`VVWZ%`?TZH<6[S+C]BW?K71D:[RE)!
M]VM"K\D53E'9O;OMG+%<ZP'38%*$O?I7)_+%"<=/=/EQ])9^5U"^W#]1OM;.
M-*X[PZE_^JFVX=Q0_P";PWU0<7]W]<>C=LQMOTO^;2@*_P"'I_+%3R=VB40Z
MUJP^X_5?YQ:RG_B"OR1J-PIYL6`2IW#E4F=%KN=C]J1C"G!14.U?SMZ,T`2B
M4A=NIOCX:N_L%Y[N1VWO,`4(U1TPW.9\9_U1/L$O&+?[>>!;<-UDQ`AQ>B^H
M7)2'A+^MJ]I]D5#VW,O3@>=;N4=T.Z2^E#[42(!($_`>_>":CW;`'P'3^%G-
MK@>I>LNKR\-!T^G*7O\`LD_DA_%)A5O^SLV(T(9.IZG4G/W?:JC:-[1\-+'!
M_8N2V9UI0_:5<62T2DV,FF.R12E*BD/X/$=@'<=4/9=15A^HNF57Q56?':6P
M)#P\AY>Z+AWG5M&GZ>V8K8DT@\-X<*IGQ\SY^$7>P]IK#K95`[W(^3)8B92`
MNB[DSD*[$`*!S+&0>)G`5=AW[1`.NMS3]F>$-+2JHNEU>2`)A3ADKVSDH>/G
M+VQI:CO)S9U"DL6NU,J),BEL';[)32?#RG[(O>,]KGC*T,I]QCIV<3.'THOY
MV?3(F.VW<7TLVD)A_7OXZD%+VB\4,D_5-5%0D^2WG@!^:Z/QQH*ONWY6>`^E
M=IZ=0\T-,DG\YHQ(<3[<W#6*,T<?R6BWD@T-WED'5CNRBQS@83%.=(;.9N/:
M&P;=NVP>&I/1]KW!E(4._<+*ZE&N]3]423[2.O+\41FL[GN<:P+;^_7FZ98E
ML2Q2@`>P'H;OQQ)<3Q!XUP:2J,7B6`;)KJ%65*+N;<=RA2]A3=SF56,78H>`
M"`:E='PEQ7;T*126:F0E1F?4Z=?#^DX8BE9S5RG<%I75WFI6I(D/2TG0Z_T6
MQ$KQ6,<>09C'BJ976AC)`B8P1C9813`2F`O[P17XD#KX]-3&CQ'&+>HJHZ"E
M0HB7Z-)T_"#$/K,LR:X`)K*^J6`9_.1K^"47,G!0:/\`8PL2ETV_+C61.GR^
ME`.FMLFW6]'R,,CX(2/YHU2KC<%_.^\?BM1_GCGI(((@`(HHH@````DDFF``
M'@`=A2[`&LE#;;?Z-*4_``1C+<<<_2*4KXDG\L;NKXLAI"&D(:0AI"&D(:0C
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>v371611_chrt-shade.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v371611_chrt-shade.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!.`)3`P$1``(1`0,1`?_$`*4``0$``@,!`0$!`0``
M```````)!P@%!@H+!`(#`0$!`0$!``````````````````(!`Q````4$`0`"
M"!,&`P4'`P4``P0%!@<``0(("1E9$1(3%!77.0HAM1:6MM87=Y?G.%AXF*BX
M:9D:,7$B1XC(L1AYT2,S=39!43(D-#5V8275H4(F-R@1`0`#`0$``P$!````
M```````1,0(!$B%!<6&!_]H`#`,!``(1`Q$`/P"3O&"M^<4<MEIOOJQR62^G
M_P"7_P!S6SZ]U?:*4FCW;W5?5_ZF/`/@9$=?A#N?N;J'?7=.]^Y=L#VO;]OE
MV@5>Z(CSN#K/OMJ3;XM:!T1'G<'6??;4FWQ:T#HB/.X.L^^VI-OBUH'1$>=P
M=9]]M2;?%K0.B(\[@ZS[[:DV^+6@=$1YW!UGWVU)M\6M`Z(CSN#K/OMJ3;XM
M:!T1'G<'6??;4FWQ:T#HB/.X.L^^VI-OBUH,'1KH5YU'*LH;`1&V.3I>#=>M
MKI9;0D+-4W#F8HE&%1]L1)D1%$;AP%AFA5(F&@+(.(^8P1;(,QVV&..>-NWN
M&<>B(\[@ZS[[:DV^+6@=$1YW!UGWVU)M\6M`Z(CSN#K/OMJ3;XM:!T1'G<'6
M??;4FWQ:T#HB/.X.L^^VI-OBUH'1$>=P=9]]M2;?%K0.B(\[@ZS[[:DV^+6@
M=$1YW!UGWVU)M\6M`Z(CSN#K/OMJ3;XM:!T1'G<'6??;4FWQ:T#HB/.X.L^^
MVI-OBUH'1$>=P=9]]M2;?%K08,:VAGG4+PV"F#6I(Y.EZTB0BPHAD5Y#F]PY
MF!;8R#-9E_E6@"B*>+"%-GE(`:-E'OT,0L!@#;N5\,Q>WOVH9SZ(CSN#K/OM
MJ3;XM:!T1'G<'6??;4FWQ:T#HB/.X.L^^VI-OBUH'1$>=P=9]]M2;?%K0.B(
M\[@ZS[[:DV^+6@=$1YW!UGWVU)M\6M`Z(CSN#K/OMJ3;XM:!T1'G<'6??;4F
MWQ:T&"CNA_G4!#9=OZI#<G:]E*#DA%QSZ1'#W"F?)K!,AKO=#8"B6-*V3"Q-
MAN#-;<1;((#`KF#D7OEE<;'+'M*#.O1$>=P=9]]M2;?%K0.B(\[@ZS[[:DV^
M+6@=$1YW!UGWVU)M\6M`Z(CSN#K/OMJ3;XM:!T1'G<'6??;4FWQ:T#HB/.X.
ML^^VI-OBUH'1$>=P=9]]M2;?%K0.B(\[@ZS[[:DV^+6@P6\M#_.H&+/<(:Y+
MG)VO>Z!/[<EMT,4<GN%,YAN@I\,)S:4W:$O*.3""-)YLP`["F)+$(L8P&SOG
M;/(*V/9N&=.B(\[@ZS[[:DV^+6@=$1YW!UGWVU)M\6M`Z(CSN#K/OMJ3;XM:
M!T1'G<'6??;4FWQ:T#HB/.X.L^^VI-OBUH'1$>=P=9]]M2;?%K0.B(\[@ZS[
M[:DV^+6@=$1YW!UGWVU)M\6M`Z(CSN#K/OMJ3;XM:!T1'G<'6??;4FWQ:T&#
M)3T-\ZAA^08!C1V\G:]FX]D'XNQW'^23N',YQ.++K>9JP^CPSD-"L(J(G)N:
M*ACV#$!#,B9#VQQOAC:_;4&<^B(\[@ZS[[:DV^+6@=$1YW!UGWVU)M\6M`Z(
MCSN#K/OMJ3;XM:!T1'G<'6??;4FWQ:T#HB/.X.L^^VI-OBUH'1$>=P=9]]M2
M;?%K0.B(\[@ZS[[:DV^+6@=$1YW!UGWVU)M\6M`Z(CSN#K/OMJ3;XM:!T1'G
M<'6??;4FWQ:T&#FGH5YU&\YYF+71'Y.EZS_@YJQ:\'H.;W#F8!O"I<O`.<PU
M0T11Q80IH\=!P:1NQS`0N!@#?M.TR$[:][!G'HB/.X.L^^VI-OBUH'1$>=P=
M9]]M2;?%K0.B(\[@ZS[[:DV^+6@=$1YW!UGWVU)M\6M`Z(CSN#K/OMJ3;XM:
M!T1'G<'6??;4FWQ:T#HB/.X.L^^VI-OBUH'1$>=P=9]]M2;?%K0.B(\[@ZS[
M[:DV^+6@PELEH+YU-JO`,P[(2;R<+P\>PA'KGDMY@M?<69%5Q"MUII@ZLJ8(
MJ:;8:65/*614OEW((0P#AGGV+7SQ_;00;Z9+E9]0O?\`TA&V??GN)^&^^O=I
M>?=O"_\`F-]3GA+NGA/MN_/`/_D^Z?\`B[W_`(/V>A0>E+S&/]G*)^_2?_#;
M>@]_=`H%`H%`H%`H%!+/2CY=G+C[^FM7W5(]H*F4"@4"@4"@4"@4"@4"@E9`
MGE>^1?Z*G'IZ>;>4%4Z!0*!0*!0*!02D<?EN(I_TQIC^\Y$E!5N@4"@4"@4"
M@4$I=EO*R<7OO/\`(#[$X,H*M4"@4"@4"@4"@4"@E5OK\L#B6^E3*7W;I+H*
MJT"@4"@4"@4"@4"@EGKWY6#D>]XG13TMG6@J90*!0*!0*!0*!03"YJO)(\C/
MT0)P]A"I0?'$_EU_3_\`W3T'M]\QC_9RB?OTG_PVWH/?W0*!0*!0*!0*!02S
MTH^79RX^_IK5]U2/:"IE`H%`H%`H%`H%`H%`H)60)Y7OD7^BIQZ>GFWE!5.@
M4"@4"@4"@4$I''Y;B*?],:8_O.1)05;H%`H%`H%`H%!*79;RLG%[[S_(#[$X
M,H*M4"@4"@4"@4"@4"@E5OK\L#B6^E3*7W;I+H*JT'F+YI&<IR+R:\047MUO
ML!T+4KMW?5DY-R2E4^BL=8,&8`QP;!]VF$=M.U4.%F4LGLU9/"#("#8'0.R7
M&*"Y=]!A-IQ2!M+Q$;,SEDESR@;#29KCH1QELR37#,R`Z7`%+I=Z[)N",'`"
MECAR0DK3:4$ANKU\""LH"+9[(L2*=WPRQQ$QS"D#SYH9\+;G.J`XU6M3'<TC
MU]\&,R51</NII,]KR=K8PV>YXJ39'D-P+2.H%CPC@<V::]LP4FS8P[GVZ4M9
M`@CFK!T4AS1;ONJ58BUZ:<21XS)G7X]E.27.D;(H2/#R,>=</[&MF+WSKOZM
MQYL'8QM40XF!6G$5=K4,N7-P#'D4T$@II'%1+XALKYP%;51Q0/"[/G+8H#6F
M>)"D!L`:S2:I;%N:&VS!ZN@.)N.F4YX-%$)WMA&>1UE,,H,03N_2"N.*K*1$
MH3P(XG39X`-T-ZMQ))UX8^F)"%[H9@+:&9D.)%"=9%;2NK->.&W>&I`E`L[5
MAKC+C+,F5YYBL0,F3"/'B@0??(PF=LQ,`P\@T"U<Y3=X=RYPU%A9EMK72$AI
M^XU(^WN=9Y\L"27>L%%XEM:%%#^;C6#)2JW2@3#D**DHVHMX8R5,G4PV>*YC
M#&PLLNYAZ2K=GL6[;L7OV+=F]K=BU[_]O8M>][VMV?\`ZWH/^T$L]>_*P<CW
MO$Z*>ELZT%3*"!7G,AO-,XB9N5BH^!-539*UQ$2E"QFY$R3'-3S'Z><N54`[
M7,DN^THV8`'S#_BR*BBXY6RPRRQN$TMBM7M@-/MH]%G=G,K):QO8/DFV-F6'
M(>;15T/&"M8V8:TU>?:L-M)RFHQ>><2<NJR!@JJA4D6;B+BJB!Y@DK=KG<<.
MSR9YP'L6V-(]8MB$C'6?*8GKJ%'&S\GQ`&C/<944,5G=N*]5UU7+@JSJ2T9H
MQ&N)+E7+$+$UE>=P+D+!WN0$1R*@;N&=9HYI]F80,3*&]H^8Q5(3MBX-8##D
M-M())V0JG:V3?M&[HBPV12YEM*R0U%I28+$;."*OM=WX,D5OR/G<0V;&23'>
M"<%8VG.^*AHFSWIR+K^M$6.QYJ0\6/TT$]RBQK>M2&-(2RQ&20.J0;K,IAEO
MOT^ED\U)O&5HT6!%-&$D<V8Q#S%S"=G&+-DP:M<*^Q[_`%:*#;]=>EROO6)&
MP2"_',^(ZV52X;=,@.Q!>4(.%:)B+Q.`7,N!F$IMX%[*%PD1.Q$*Y&NV#MF&
M%4KF=W*P7XNC8%OZZN94=W(1QLZG*,RFF"^RC$76/OEI*!M$^,FDVD29,L@)
M%@IW#8D0+"*YLHHHY]/`-!`',A3X@>E^)R4GIL9L-/FI?9SIEPDU44M([DCY
M`5&LR%QX@D00UY4:S<6UAP*R,B'%#'/,`N8.&!`\+VM?+_LL&@?-5Y)'D9^B
M!.'L(5*#XXG\NOZ?_P"Z>@]OOF,?[.43]^D_^&V]!Z*M].99;TAV>F^`!M;F
MD_6Y!7'B!R)N"15C8LQ'!Y<8H.P1"`%6,6^SAH,=R>-(PZP;N81L!ET$HKCY
M`$\A"HH_;X!F76KEMBB:5C9T.46>+KJW8%E"&HT:)EX.-1<#YE11FG7]#V'1
M$K&,DYD)[B;LB(3353(:BW"&;A,`62CICN]P"XF6(<O.W,;I7#*:Y!T5]Y3"
MI)6B<K\@J`%&(=UUN.Z$8U';Y!)Q2GJ#@(W[+4D*R[F`DXV$$!!LG&LSV96U
MB]C`=GU8Y%6C)[#AH]LDI0I`<K;!HD=/J(XT0)://P5:CV841M#1>HN-16&0
MQKLER/!]JJDUDE//AXV<"HD7LFBCCF+DBP9+7^2[0)JY.;%Q[<P:BV9)A_$W
MJ(HOA,+`,T_%CT9,<R(G.XP)G8!LJ3/?<CH:2>+'L@!P3JD$'VG;=MVH<ZS>
M072N07X@Q@S=D8Q7W^YI&>,1(C5*+(F*J<D]A(5W0YF+D$8+`8$W*7;5KJ!4
MJ/D&(I$;7')V,!6OE0;C4"@4$L]*/EV<N/OZ:U?=4CV@IPMGC*8C*RD3+`'3
M:>F'CI8F9-B$"YLP5*BC@EASP1-0%)@CB!VQR%Q`&R#M?MK89]CM;A`K6WG6
MSE6-]#IKFC5TK"\/[^3T]-7H]=K2G466S\?3BA.MUM9HH<D(JO#$1ER;5D$=
MF'LBJJGG3PA//''$P4Q#[<;`*O&-XM2"SBD=I9S['@KGB?OG%\H)15$/JJ>9
M(N!`:"FG)),D7,#.U81WB[$I%/$D>Q\V16E0F0,!AG#0`(@?V=W?U+352,T-
M3GI@):W+XV9>/D944ADU561L'\6BCN9U./%@#C;N+*IT!K!^%,"5A7*.$EX=
ML?$P+Y!KU)G*+JX0!;"3",]ZQ28_%J1&>V5%M.N<R[`3TUKF9M:D)R,I8KY%
MJ//&[R9[G=`:>501RY<RI+F8*?;,,86U!F"W(?I$(ON=IE=FHH/NIG"S`3<;
M:3G&$?74]9@%/"5YE:]TPH&*:,/*/$D7OM21@L<U0$I@(-WO<((7/`,,09R=
MPAL&Y&6OLIV14BP&[M5GAM!=XR!)N#)EM):K<?B4V";C5(>6VX7!3XH-H`YE
M1,.05<Q[P&L`5,E`11?0#,N?(EI`"WFVZ#.S$6D4MWN!1:+:"45L1-6UAX)C
M437X.SBC8/EBSFN[S+%6R*V32LBF*@?1SQ8Z6!&+&`1<PV4C"3X\FJ/&=+,3
M/)OR%&L@H">Z66]6JH@*S?<:`J`XCDE%-/%LL@Q0A,+]KEC?M1`A,<@Q,<<\
M<L;!WN@4"@E9`GE>^1?Z*G'IZ>;>4&UFZVWL5Z(:QRQM1,MU4=D14W_"@J(W
MPB8[E=JZ>-`)389C8+J!L@1'<3K7SI<B4Q&'""[L-:^>>.-KWH,8,O9?8`DR
M(CF*?X?A>)(7?+(6I'EMX`S\HFQ=:6WBR17<TRSRN[(L922^!E8;(%/5#9,R
MF!I*@+W,(%0`Q[\N':ND.TEQ0TYPF]DXT2B"J_UB*")==53#?7!9006^"[5.
M.1&PMDT]REGS@UC(:D$DBE,#QD@)B."$(%E;*X:V;C\O.LNM6IBGLY%[KC_9
M$^H1$'.$71RUY#$0,Y.C:SM2&8:=95U)C/?F#70`5Y6L1#.*"?B`.JX]X6O8
MU?M,0RDT>0>,\UB=,92=<(L5!BYWP<P6V4;\NG7W)*H^YMCPD]4*/G_&Q-A)
M*VQI`4#ARX*.DDKKIA8(!Y'<.YXVR"P#$.JW+_KI-FLK0V+G%696L-GF\I@;
MR8TEN0AGX`&VHDE(]%AV2#SE*LMJ>"6&>5@REQU4^0)I2<.?!+"F\A,L<LPS
MLG<ENGIV0MGH\.2B603>HZ_%[1EE?7$\\2;N;REQ".N)IL]E&;`BGGPY!TTI
MA?O5-+F,S&8^&);N]["=H&XK`D!D2JS&Y(D;NM">[%=R8"L-IUMI1+*R(LIP
M]\L<3!(\5S$"$[F*'D&)A>]A`1L,@\\<<\<L;!-1Q^6XBG_3&F/[SD24%+)!
M<QEE,)[/(FF@+)MI-)QN8LD&5$1(+J@Z$CG%0).'50DY7$30CN96P>0^)4S<
M*V7;6"$[':W"5FIW,MK1-&GD$;4['N6,M0E:>HXD27&U$CGEB[X6L8[C%RG6
MV[7(FJHC&8:BYRR$(3L,H=Y)&6)(,2U\\LK8YY8AVS=7EAA#55NQD:8.32V'
M>LARYJNQ#+$;$B70S3;86UKL!;C'E,XMIK/?*=<L93Q;J:8F&K$1%PGAEF"8
M##MW6@RBV>1""4AI2.])ZE?7^,T)J[)2I`;7.M68+2,"L^YJ;)`&QG,&"U6^
MH-%Z))8SD8<:1<N:+-L#M!#)[('.PM!EQ0W@U*2WV=C0W/<?>K8@E.=6$12J
MH*H6-ALMKEWN[4Q(4T\L:1UUT-MG&P50ZC$C!A6+IXP8^9:P6>.5PU?A+E1@
MO8!2AYX,=T16W=?Y6UHD_9.[LE:3O<WF!':,:/(5K*+E+PXL-84HI1:5+DC)
MA4<8B^4P21+!`BE\LQ,NYAL(-R"Z5%6RW'>H;*1:DH3M=ZO'S='6U[P&?4W\
MAMK%Y*#'"1%<`DN!._U)"!J8"8(6P.FR`P0X`8@8H>60;`Q-+4:SO&[/E^'G
MH@R)&3_1PE]FO5LG,3Z&X$@804'$X0,VQQOEC@.!F&)AECB($+AEAGCCGC>U
M@G3LMY63B]]Y_D!]B<&4%6J#%4[20;AN$I?ETB@%W6;BR,7W(P+9-K0K<+N"
M[):ZHY<D85?!17$(C64L$RX-C-B!ON-\[9=RS[':W",^J/.S'4S*K%"V%BUK
MZR-%]Z-,??`>3`)PPDZ/HHCIYO09AEVQ/K@5HMB4.*G&=7+!71AA,3Q%;`&M
M<,4$2U@\@I(4Y"](E!91F^0V=B,ZKKSX.QPFE"CH+F;7>)%;P;&:6>,@XYE4
MD`XYA,4PD<-Y@$5!1O8J6&&'OW.@UMW)Y:('UJC9\.F*C[$V0D&,I<B",'_%
M"))^#-5D(M)\QD8457(56<&<]2ZY9B.X<P4/ERI?,$-3)#)YDT3,XY8XAD1H
M<DNOA(!^#SK,.NT8W29NFJ*X]+-Z9;OE2>9&&$T!PN(%5216@V5!O2FAM@;O
MY::9;!4/)9?M<\Q,K9VM8.?([_PJI2=B7)RKKJ+KT-J:A[5E9>SF\D`YS307
M'8=0RCE*QZ*V^\343&4W`MD$YK+>.&:F-<A8KD-:@[.H\B>D22QF])*ELG&Q
M-D.3PKF47QU$YB`DE4!X)L>N-3>1;O&Y^/T1L/M8*(RH>70DTFF*AD(L:%"&
M$QPN'"Z?[J9;62EN_&N4:A,2VG&RPVO8*\`][N\&32GJ":;\)OC`E=HMCU(]
M]%77@#=.L.JXXW"[?$WG;.UK!O702JWU^6!Q+?2IE+[MTET%5:#6:8ISU0BJ
M08^;DW/B*&M)#S,IA5A%GEBDY.#+OYQ$6XA'+'C!0P*VDE2>2N52R)TX*4)F
M5@V"3!%R-C!A9!C=2VTT#7@ID<:U*<&*X<)B.),GM:5RJ4<]S`PP3*4FNA+E
M`^>2Q,FL;:)A9*!'"RED"(3[MCV^.-OV!J!LER)Z;QLG0HZX0CV!]J3DI[\P
MKJ6_+M5>:Z&K1:\]ID!2,>ZNI9X1\[S;B.KC10RHP>%[$,'*F#!9A*5P,,;W
M#:R^R?'*FICI`R?^M:<A:IDUY[*^69!J$D"'DIONM08;N>S:,9I824FHS8?:
M6<1%A61LLRR8LE#!(V,$:!%"Q#\+TWRXWCB>K.-[3YKXX$QH**N@N%941TEU
ME6@`AG682<:PX3H:<J8-EA-Y2DE`!4W`;R+M]/'6R6!DV'F9"MF']*V]^D;Y
M?6S&OKU=C642FM($8D)N!?;;P-1YBO2>8316&QTO%9(&"3W=*H>4T<,B0(ES
M8AY14RA4E8P<OD%@'-.'>OCZ8J"T99<NPL`-='=C`>CK9;Q4UM"3#2PPXQ&"
M)2)9&,B@AJN84>G,<2RTFX6L:23&/<3(`0F/:6#+T6[::W3:=NFQ),3-D(]@
MZW<Q#)5KGAE,5/>C!((JD]FHK6!+W\$.!J$W&0R/E#7<1BMS@6(F..>=L;AL
M102SU[\K!R/>\3HIZ6SK05,H,(SY*&OL1,Y,=.R3KC=EL,Z[6^TTU<E(9'*M
MF[R=!@1,;23@<70\T\LJK1K.Y<MVU\+BB9V#QOVV=K7#3E:WQU-<#WAHHWWS
MJJ[X-4(VV5>+D?3BDE+27;&H>NQAKICP)-.+SK)415--:>%E7%Y9#'D41I@I
M8.9L*^(H>-PRVJ37H6:8B0_%-9@U58+B8,<FFHM>I))6DMY1_L`[10HE3&0"
M`@'!'HF32^$_/U/IB4&<S<*F!>Y0`P-A>]@Q.!NIQO92@BP(BKT,*H.P&M,@
M;<N!S(K9:HT-+$'1BL-EKJCODUZXD@VF.7$\*F\@[GQ!L211!/7.Y%+8%\1P
MZ!/')QKG':+K"U(7;+`V":<T;R0+H$\VBGN*[!S@HW,3$<K^:+G5H_5X\63"
MDDE&DUBIQ,2ABZ.65$\\7,E#O<+8Y7"M@(()8$(N7""`+@!X`@``AXA`@@A8
MVP#"""PMC@&&'AC:V.-K6M:UNQ:@Z:F1I'"*F)Z(CQ^R4E&25,RMI20F-1"(
M)B8LG369XXKIY`J0"*DE,V=$R&%,!X8BB"Y7SRROE?LT'=J"87-5Y)'D9^B!
M.'L(5*#XXG\NOZ?_`.Z>@]OOF,?[.43]^D_^&V]!ZR'!QRIKMY4D[DJ=KY93
MI3473$CJ(A02X87`6AT0PF329FTA+R5*"G(!HN0=I);.C$00@6R'D$0%RMB8
ML)EEG<-7)&X?Y/=,N[#2,V=L&P@M[9C=F(]JGXSCNO@QT^FLZ,(*5H7'BM(>
MX$Q`+X"FX+"$3PB\F60A<@`S::8+F4\^8+YA@9B<![Z9\8->.?\`-BTA!0^'
M[8'B6>2[[@JP:#,-R7Y`,OENS`V4?W:4_(HMMH0W8$ZFFC@P![$#_="%KC]D
MN&4W7P;@N5R,`<38H3%KWC/C=8$V%\8]4"B\ZC?&R\;O%DK<6G0Y$,%HU+RO
MG>Q15*&\5S))QQ[X+#CC9YVH.>??"H;?.BF_VF8VR2(F*N]6Y$P;9&9<+P&(
M+G&8,PS+'TOJ\=ALS*9PC#QNG#L()/P5LEM,Q&#R!%S(]DM8,0/]$GAC<I#9
MLAL6:VD0C6!7DT</(V89I?7\^3R,&'%"5H1,1`"XQ)X.V+`ETBW?N"]D0%RN
M9_ANG]IZ%!=J@4"@EGI1\NSEQ]_36K[JD>T%.%LB94T96329D`D;4$P\2+'#
M)00^7*&#144`$R.1".)XIP$`02V606(X.0EK=K;/#L]M8(%:U<%0T4QKHE",
MU[1D)JAS0:?GEM'';2:4"B1&HO\`FY<<[L<[069)7EF:9?".M:/C+V4+%TI.
M)I^1[+,.YDSEACD$('_6?P8MMMM/:%@NE:UYF9LS3+TNOYAKDKP"Y5*4VQ'N
MP4F(\H2W"[DDQ"F-$6\$<9:(#B(Z\V\4%>(*=R2E<?,5/P`'#+<$\4LF0#LA
M$$_(^T1>5,&]JMCJE+:!/T;*<G*SM:K0V#=>P<*NYJ/`&1&RK$)`B\VY`6_9
M56;+`JB232RB+CBHVSSS#HQ?A14R^FJ-JAALR@>%$G?L;>/.4?\`+Z8MF:P'
MV")[`BQ9=J6F^Q@+$97(`)PBU=8SMF6`"SN0[</&U!J+J-Q3S#,S[G!WST;<
M$$M"/N5GDCV8BYH*4?J.#ODI+V+B]*B2.GT`[#CG*H]X[[Q55(_<G9(L=-"D
M0@\A@@C';X!F%M<`BB9BYIQ=)>U9%60V]Q;/#C*,V8\*J#753:2X'H4>*5,(
M"XJS$XBP:BF#I14,PA"IHI4WCW7&YG#'.W:AW%#X/G8'.+,V07-HVZ#)B=L0
MESV^4=*@Y9-L5>NU].2.G+8:K3*'IL*JS1M9O`FEX^?,#*PADZ9"*8A8`E+#
M#A47CXU+%T3TQU]U%&D(.5LX)9.3,M(830R86+I"Q6U=5`/W:.;I>MT43`!3
MQ!S#\*&[9YAW$MEC;.P>`;DT"@4$K($\KWR+_14X]/3S;R@V<WHTWC'?S5F6
M-4Y<-+*6T9012Y4-QMP8(%PM!R(Z@56VH\$/OC$0F,J-EPIY<V$$/AF`+<+M
M,\;XY>@&$W;JUML]],'-JPK[(0^G.\Q!@L.(<Q$-?32[BL*A=)*-]*D!W1X^
MI(=*!@/X(*]L=2@1C(8ZCG<R";+AVQ*6">D;<$KU8[]:;P,[8MLV39>[..YQ
M%.]PMT*:BMK!W5W#7)=9RLOKFP)L^&$<,9BK0:B)W\8MG?N(F(G9[IB&'\O-
MS7BB0`D0,SMS6]@&KZ#WT)D]X.;7=74,%-J(VQROL>SY#8;/3Y\(!-5QE5I:
M&2E(F;5%(L=+=H8PS!$P[E<-D')PFNX:9GWL*U]HT$&2E;<W4/<QAI*S"*M9
MD(#EU<@D]`9YDO`H0F>ZJ\D%_M]5,G@C(`R4.C'.YVMB<MC?+(-?'?YOC+SD
MUI2=8<=V69ZBTYG[4%!C/^6<ZF&C;ZV+F(C+*0OYF2$XBN$9O,40$4GDCFU,
MXEG\\@SG>P)L+`;$,M2_P:/B15[9%WH^S;32'',6R6E6V3-+*\.+:LVF_*.J
M$86BA>:KU2RDK)@[LC.26UD+<($`8DI)!D>PO?)JP?<Q`N+`4/-N`XD9\4-)
MOL5J(#5*'`R;;C%HXL2/T@934CBRI%VHT_"2T.D)@JHH##=J,=-CB"BYB""Y
M99WM8-!G'Y;B*?\`3&F/[SD24%+)!;)EZL)[,TFI`(QMVM)QMDLKF4X17+I8
MZZCG$L)1'2@E%($4@B69JPF0&)HM<6V/:V%#[/;6#SMM?S?5QMF$=9X:#W*1
M#=M;M(]T=,"#CSUG/!7=:=N&;',&Y`.)&.Q>=DHZP0S%\0T[`R.&I7M;+(P6
M_P##0<DL<"[WRQQ;S<VW;A1FKSKXYY'?GAV!5A8<!Q^\>X0*8DYLW,M.":1;
M33E!%+XV,$37A,5),=G((<QC>]J#OC?X4'_'TSL>?V)M0SSS_:FZ.U>RI]">
MVOJ@J1HXHOVZ32R:^X;6FJ!-5SYU<;UB0(I)Q!GRV!JV%PA$\+&_;6#G5_AZ
MEEX[GI.V+NVD9)XDAS'-KR1F$C0(9;0:1&<PZ^^XEZA2)E(E,!`R<#>.9Y*5
METPE#GU##'`$Z(9OA@+B&"D+S>8R>AV(H?D3;`N?1(MX[9UX]\Q69"QQ!4UM
M!E634V26S)UEE1EU6P3U9IFT$D`?2[$A`%8/N^(9@E83&^`9@2>$IR6DEBS4
MK[-H1:2$3<@KMV[R2;"RJ>9*\>0-6\=66HQ6ZGFYB(*K8+%D#&ZNH*(IA0S.
MF\[`8%P,,+"Y!2CCPU$-Z(:?0[JD<D@M+8D2)BXEAO\`+,D6/,%X%8<ZRY,!
M,VF*\7YDFBE;K%P;]A3'L)W.V78P[/:V#7K9;RLG%[[S_(#[$X,H*M4&*IVC
M<W,D)2_$1%?+M0W*<8ON.07,;117&7;]WLUU1M9+(J`"M-T19LFX*=QK%K'R
MG=KX6Q[KAV>VL$HQ.&]$#X=ECBD1I>:+;6'%$#<BAQ;*M^!"B6;<6;<=*4O@
MN]P1B5DX,TLKALDEV*B=W=.5^W$N+;/M;=QN'.25Q,)CZW.AO:@T[8J>C8:\
M"1S!LL0W,<,'7XUW.;B%X)[ZCN5([L6D1#*,MZ(BZ4SN&$H@+94+.X0_^\$!
MMCF&`BG""]RNH4BZ4%]I&6#&!O:M)V$B%^JVO2DY9@:S0*S\%L6HQ4_'"#-S
M72'F6$>.9@N4.E":5@7"'S'R+"B96#P#^,."]S^Z4C2,+MN@YC(NV6\^U`22
M'KBH!!#'=V8""@U198AO+807*Q6/+!65`3U@^W4O_39`%O\`CT&.'!YO*H.*
M&F_$9_<:P8;0XV8_T$;B^AP*,AJ."_%LTDYQ9LTG[&YL<1(P2NXR.!8\V<B^
M>`Y?L9X*(8F-J#,6[_$'L)O%%9*-7CM3#C!)G=8'7#SQ*L#6-21DI;EQQ2Y'
MLF82\$;`F@)X&2`A-@X$CR$IJJBEFCIH92L`&9RPL$&^>C^CZWJ&^]QGXN2T
ME2:<VXG=+G,PF)4<&V"6C\X0C5HQR,V@31R0WV*Z2PP#1"-8F\L$[+',7/"X
M5[=B]@H/02JWU^6!Q+?2IE+[MTET%5:"2&U7%RG;*;S1EMXHNJ.%MI)D$EM?
M97@R9(I-2@U7(WV_*.<OLA^L88)[M<LVI$:CI'&L7NH%55)MEF$:S*"#@6Q$
M#13?'BIG5(8?+#/D+R>3DAR;VZG+D>/S52/]?AD/U?R\W1SR1$;]93D"EI;$
M;SM)L=0"1UZXR8<#<)@/-3,BEKVQ#!#G&7PL/B3#+$V"?<^DF#+"OL9QE;.K
MC2PA%:,HB0WN/*&CD=-*(CB&KRTEJZ8\7R*XSYE:7<S`P)`6P1<%-&Q!R%&#
M\8?F^``4;2M%!':(1-;RMJ)LYIQ#*T:BLZX5QHLC:;94_L<[G;)8(LGHQ>1'
M2V#)D!$3L"0J&`+@7R/"WMD/WF"&:=\>'B2MQX?9<&(NS3+C9@-C35V:V*A(
M.!13!Q?D%65HL/H\HXJR%)[><!9NEB4;6+B-8\>5DC`0?`Y<,P<+E1RX?[O;
MAN<KUDG8F23FPJ$"H2_._'QM,TTXM&"N6)MJ:M#$UF)I1+<.5I)&S<$7R84:
MI@,0EA8!12A%`,?$V9R)6P,AR>OW#/[BDO:;R^>GY-=9O6AQ[S/M]-4U$9JZ
M9)SRWJ=YIY/&S643LI',8T:[&-&+$R!,4BO#GB?=>^!["C99XAEK1#5DJA;3
M[F[L"QA,,#WV0>::"3@F61VJ#@W'PVDA*:4OS*V4ICNQVH6(4^&&:A##FQC6
M8YT)#`,!XA@C6MF%;:"6>O?E8.1[WB=%/2V=:"IE!'[FSAR7)QU2BEHPJR'"
M_'BC[KZ>2`936ZWSKF'1VI'DSH+N=CK4DE/,D3)E%;*&E"FC(>)@`0?'"P(6
M=AA0[7#$$`<+0T5[6LK;1VST@O%6$E?D#F68HJRAPSDSGNO;^+#?.+[6;"HL
M2:?&:K-CY#::<G][J":MB+N7?8PMREC.`!<.087"LAQ;JY!4`L^=G(K+VK6\
M[5W$@=U/U./N--3&I$TB/M4A;7%SDPG`07#L=,V*7P.B6$+'P<`%L098+E,,
M1,D_(,:Q7P=O:`L6,>A[:ANEW(WN/7<'2E<6'[`Q1[IAUU[43TL[*6E5$:2O
M(!AOA(35DMQ&`+MI9#7"9I"!P*""YY"9C8!U%@\";^;+W;+N6MO6THXM[=_1
M3=XZ$'`SG/J;D=6GVNRO!#B9IE76]@C9E.(RB,MC*H2CGW^*DB6L'<N:QOV,
M0])%`H%!,+FJ\DCR,_1`G#V$*E!\<3^77]/_`/=/0>G[S4K?K_(Y;?/_`/Q7
MO_N![I]]7?D,:X_Y@/<\]17^8G_^T?\`^9-+U)>JWU6__9/_`%'?_@P__P"#
MO?\`C#U^=/I^"OS_`'Y<GQQT#I]/P5^?[\N3XXZ!T^GX*_/]^7)\<=`Z?3\%
M?G^_+D^..@=/I^"OS_?ER?''0.GT_!7Y_ORY/CCH'3Z?@K\_WY<GQQT#I]/P
M5^?[\N3XXZ!T^GX*_/\`?ER?''0:#:O<T?J*VQY%7UT3G-6[?=:E>#USU',G
M1+P\^XR]36OS-:O@>7&][J97U&+J_P"#_"287[L9[Z2AP3';8]OVE@WYZ?3\
M%?G^_+D^..@=/I^"OS_?ER?''0.GT_!7Y_ORY/CCH'3Z?@K\_P!^7)\<=`Z?
M3\%?G^_+D^..@=/I^"OS_?ER?''0.GT_!7Y_ORY/CCH'3Z?@K\_WY<GQQT#I
M]/P5^?[\N3XXZ!T^GX*_/]^7)\<=`Z?3\%?G^_+D^..@=/I^"OS_`'Y<GQQT
M&@,1\T/@'D<W1EWHG>:E:]T37_3=J^Y@@:)^$9?8ON?*NQH_JDD9E>ZF#ZF&
MH]_5=VC>.=\C^$Q$M0MV@?>W\8;_`'3Z?@K\_P!^7)\<=`Z?3\%?G^_+D^..
M@=/I^"OS_?ER?''0.GT_!7Y_ORY/CCH'3Z?@K\_WY<GQQT#I]/P5^?[\N3XX
MZ!T^GX*_/]^7)\<=`Z?3\%?G^_+D^..@GVM\S_?/*5'TV=$_S3@>"M%)*C+W
M(S.BG<IN4O#$ZQVYO=!26%[J67?D8I7@GP><5N^\>X*ADN!W++NG;V"@G3Z?
M@K\_WY<GQQT#I]/P5^?[\N3XXZ!T^GX*_/\`?ER?''0.GT_!7Y_ORY/CCH'3
MZ?@K\_WY<GQQT#I]/P5^?[\N3XXZ!T^GX*_/]^7)\<=`Z?3\%?G^_+D^..@G
MQ//-($M<@&BDS&N*/FD:Y&)XYV]13#"=NBV*))S[RD-N1:7#4HU:PDIB@NA)
M9N#<S&7ALC1;P<`9+YVQ$[I>V(;R_J)&EU/_`#N?E_IGCMK8ZR>'ZB1I=3_S
MN?E_IGCMI'2>'ZB1I=3_`,[GY?Z9X[:1TGA^HD:74_\`.Y^7^F>.VD=)X?J)
M&EU/_.Y^7^F>.VD=)X?J)&EU/_.Y^7^F>.VD=)X?J)&EU/\`SN?E_IGCMI'2
M>'ZB1I=3_P`[GY?Z9X[:1TGA^HD:74_\[GY?Z9X[:1TGA^HD:74_\[GY?Z9X
M[:1TGC0?;/G%;LA[&<>CU!XO.8]I`Q#/S]=0K<?&DY%!=DC>%84>C8LW(I2,
M):.XN]U)^:OB>-$[BENY)P(HW;W[2V&2.D\;\?J)&EU/_.Y^7^F>.VD=)X_[
M;SB)J96SO;A^YW;V#"&'$O;C^3;VP!+A9CCC9]B;/X0@00\L\\K^ACCC>]^Q
M:UZ1TGCL/3Z?@K\_WY<GQQUC3I]/P5^?[\N3XXZ!T^GX*_/]^7)\<=`Z?3\%
M?G^_+D^..@=/I^"OS_?ER?''0.GT_!7Y_ORY/CCH'3Z?@K\_WY<GQQT#I]/P
M5^?[\N3XXZ#0:'.:/U/\A&ZTK=$YS5KGNC1-J>A>YLWM$O"4L,3U"DI8#\,R
M.SO=3!]2Z"\?#O;(1COD?PAB3-7[4/N7\0;\]/I^"OS_`'Y<GQQT#I]/P5^?
M[\N3XXZ!T^GX*_/]^7)\<=`Z?3\%?G^_+D^..@=/I^"OS_?ER?''0.GT_!7Y
M_ORY/CCH'3Z?@K\_WY<GQQT#I]/P5^?[\N3XXZ!T^GX*_/\`?ER?''0:(\H'
M--[M/';NG$O1,\U\3>Z+KA*C0]TR:]$/4)$C%\.-8^1]5$C//W5%7U,,]([K
MW8\=[V'[W`QRS[3+L=B@^;G_`"Z_I_\`[IZ#V^^8Q_LY1/WZ3_X;;T'O[H%`
MH%`H%`H%`H)9Z4?+LY<??TUJ^ZI'M!4R@4"@4"@4"@4"@4"@4$K($\KWR+_1
M4X]/3S;R@JG0*!0*!0*!0*"4CC\MQ%/^F-,?WG(DH*MT"@4"@4"@4"@D3NKY
M0[CP]ZS>?V!1G59M.J9EJT%`H%`H%`H%`H%!.O<[Y3W%M]*:3ON_N^GV**4'
MZBW_``E?_P",NSV,*].TWEJ#UR="@4"@4"@4"@EGKWY6#D>]XG13TMG6@J90
M*!0*!0*!0*!03"YJO)(\C/T0)P]A"I0?'$_EU_3_`/W3T'M]\QC_`&<HG[])
M_P##;>@]1S0[O/W)YNS$NP(1A19,#0/J:HZPQLI*JFG-\=`E@*6U"6=@D%$+
M*!8!5D$.1&N5;)=QX8Y*34#0`\$\8AFJ&LSP:_;+[8NB*TT?4IGGV9*L*&F9
M(NHYB0,U]?=<I-EXM#C`EW<-MNN29)45THD+4B.I#C$I;-!((RH)=,6RB^>7
M"0QT@E'0Y^(]R]BX]9K#@):*0@?>XD%Z%NJ&W:42W\IW7TG8-$E1'4HH5(_'
M=J<9>DUMXK`2HH)QWU2M="5TH<TIG[HA5&-]\!B:&-\EX5XS+N"H,Y.)+$P:
M!\(JNHL-+7$T1J->0MFMKM\8;4W-<PXG*T$(P20;+J::,B'EA+[Z2D@N7'4P
M`@@S80?AV:WMY"6&TMC%+)2A.&GA`W'AR"3R::&#$3)*'5Y`UZ>;`M&#O-'6
MU/KJ2&*KKL<NE/.7;8YU<P;Q\Z>".B+861(4N&^*-NI*A?=)E:XJH,0OF/W/
M*3]@M3>4?)[F2E%L2%'FKC?V(5!5\XON]3*%G(</F#R<,TD\@KETA+$3SQIS
M7/F1$4$*BT"@4$L]*/EV<N/OZ:U?=4CV@I<ZB)-3;#B3E`N&;(GD-5*'"HMN
MR&8+&"(X0P6?8[%^US#RO;T/1M_V4'E/+3?L#&7'=MKHDL2W+!^7V#JQGM-$
MFP"NXW(<D4_I?*$,*4K*:CE)9I9%<Y]Z,69DA=C`)0"4<%I%**[=4+6SQMEE
M04@8^\L@,9MLN+DI"8&8J#*_'Y`:<JK`:X:459/VLBI"6EMRGR83B)"*#G;*
MV:'4+Y8B6P4BP0N(F(0E\C6(8N87)'LJW(>UG=+O/PI+;C?:I&)R:$Y!:;C:
MKD;B!/.V($#M0]D6N_C+>CMNH9,P;LCC#".98<ADIB6Q3002:@KT&/9=Y1]N
M2FMLS/%$`@]IO(71C>?9R+7&ALQW+8317]*]FFI`Y\DNIR\_Q2#J`D]`?!12
M(WPQ)X-T\4$Q&LL@BXXAA4[:.>IQB=[Z?11&IB(3CLV8?TLQ>M/!\M1W&6RU
MEE@:Q3-.A!V)S609"2U$XG778GQ)&4<97Q%$*G,NU401`NWS#0KI4)]!83ZE
MQ9CF*&TSXBUDC"8G\VE$B^S:JH/20Y*F^#[^"WF"NE2+;APB\HM*N?%?,HB@
M9R:1N^/>MQA,#009`>^YVU*+L"R8*4#\5(8C&V?"8,FO="CEPFFO,\9*VJ<F
M[!H8342U*4E`]$[S15Z.ATM:(#*KASQ+#IYZPH89VY.P<`W=^)JDPEKD[WS!
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MQT]1%'=Q-+-F[$\,5(#+OW,/T[T[T23+L`;>1J.E,DG'ZKJ[(LR1:^&:&XDY
MPMA>B6;X;89MGGG$L.'$9SO5$57B.&L&DY#12"&L$\B!0VJB!F10`W)G+?'9
M4):V3)0HP8_26-!3AEJ''*_GV;:9TZU9&;T,)LCQZ]4Y"QF]MNY]$W(N+02?
M=KX-<B+<`(4\"KF,`\BN085B'>C;[!8?Z,\Y)@IUJ&<<\;!>-BBK%#J0CBF_
M-JX]?;F>UF^A-V1Q\Y%>IWU*W&(H8JDV4LR)AEGFII!4,3*X5CTRGI9V=UCB
M6<W&VR#1<#[15,9<;J6>LHIZ8L(+D6FLI!DS-ASF'<!SB'F+B'B8-X`=T[GB
M9,XX6'$#9Z@E(X_+<13_`*8TQ_><B2@VBWZD"78ITHVFDF!"!I2F1CP=(;EC
MLN13L%@\$Y$ING3110(I(@8X:D>2<,,C0(&08N(H@..-PQ+7[3()2'+X1Z<X
M:W-KPZ%QWN7:=;1FYL<8..U:=AC8N%%N"%5\RY)TM!K!X]D[7&Q'%<JH%UHS
M;$\A=W[P`$`)=@G8-+M<(%V:F[1Z*9E.S6_8\A-PZGSU'4GKJ7.<FK,G23,C
MTV+5FS$<JHR,(*`1CQUP,DD;G";D**?ADT'D$DWQN1PO?$,DRGLO/$FZX0+"
MKT?#Q;DO:?;Z:\Z[[BJ":=5FX-+:T5E()L,4F<42"D5-KS1E>-S2:[5'L9G4
MI7P'&)F@[7M;&X?CD!>7F!I#R13\QY9DYA;&0QR;[$-#5PZVI)>X8[@<2'+K
M008NUP*1T"LF4"18]<P)H5+#9PB:;)8EQA1RX`(H7?`8>H5GGEY3:364G4F@
MH[G4&XB'G&D%^WN72EXVF%1UA-`N(*8$[B14!!`L>V$SOVN-NSE?]M!V.@4$
MB=U?*'<>'O6;S^P*,ZK-IU3,M6@H%`H%`H%`H%`H)U[G?*>XMOI32=]W]WT^
MQ12@_46_X2O_`/&79[&%>G:;RU!ZY.A0*!0*!0*!02SU[\K!R/>\3HIZ6SK0
M5,H%`H%`H%`H%`H)A<U7DD>1GZ($X>PA4H/CB?RZ_I__`+IZ#V^^8Q_LY1/W
MZ3_X;;T'NO?$+0Y)JTUW)),31G(+B9&9X5EK[X8;6=BTT!%.P&*D(UU5>2CY
MY`S4,2P=A[E!`;BV#Q[;L]K;L!U=8U>UH<+ZQE!P:[P6N27@H-U7PD18B1@*
M;ZP56>A*S6:2GB[3K?'7\5!KME>/)R<-8QW0D0.CEP<L`AA,,@_/CJGJ[@R<
M(TPUM@/&.`W"@.T./\8>CS%DX.MJB%16NYL&I9NV0L7"VQ2(.1`[8#ODGD#A
M<'/"^&/8#^DG575]`:[E9"%K?`B*RWFTKL%X-%)A^/4YKNMBW.*ZA=E.5`)M
MT%*76E<^X3X_@TT$*3[L>,9]S[882^0?R7U3U=*-]M-,KK;`99JLN/GE$K.;
M)>'H\!;[3BJ102Q>08S;2,&W<4Y"CY]@$P<%E&*AA)JI@%A8R"+;'&U@_P")
M.J.K:`[TF0D+6R`D5_(!EO'4)\),.QVFN]%.-%FB1RU#:2Y2;<!6DXRV(]&S
M04\0$?#,DC9W)`WP+7N%09]H%`H)9Z4?+LY<??TUJ^ZI'M!3Q6*I1U+4B:Z7
M3S:*:(FP%<JK!%ATLPF"@9X'@5(`YCF4%(B%KY6%Q%M<.X=[VR]#LT&FXDM\
M?2_:.(&+NW5=W)\M)#AC..XQ11XP=K:<[8::6GNEPLP@W4JRD@V:J45$3Q1"
M68>)*Q@R2PMA<4<OCF&!I2E3CQ8$EZQO&T9:=NY"E9_+4(7V13K0?FF0@)KM
M!,K[4L\NM/;P*<)IC=9J;'QT1.+^%R%T`XJ@&P`K8BYYV#\>Q:%HS%3*7WOG
MIWIE+:"PDZ-#*(E([5AD^Y@TC8B7\%1650T"T;K(;<:R^\1BKF".X#B`.95[
ML8O;`<#O@0-@C"+I`AH#I3Y$96EC+91,](FOI,%0&AS-NJ[1<`9!QR3&"^25
MD!"2T,5PK9LP,XFAE<X"-D%@:-=UR&[`8=2FZ(=/IW>FK@#KD*"Q&YJM=S3P
MT(4-#18M,I=8*I"STA$)>5F@IF12A.+FDS)',F$\Z4+!$2AX(F)W6X`5P!0V
M18S=UCDA/6W?&J%!#]2E]M%HF<CH8R9'SI3UIGMP"X12,UM;0`#Q91;2"54+
MXAHPXN94J&/V,0<;9^B'()VN.O*.@-)JI,#0PEM=@NU.?S$;:=%S')(#*?20
M#@727HTD<LAA)S<=J8`'C@74B88)P'#&UL!,;6M:@XALZHZMLL)4!9VM<`M,
M%;D7&8%H)LPY':"$KRUA<U?"450-+;A7$_(N-SPU[+8MLU.W=L_]]_'EV0[B
MU84AIBJ",KLB)(R9RJW$-6;#>4VJPFJWE!!;2^L6<2ZWD8ZD)1,REH:TX+=_
M&R@&6!<R<_WPF&0G\5!DV@4$K($\KWR+_14X]/3S;R@J2>(DE0D<35,F544Y
M0*F")]//%P39(\2-!9@&BAPJ8P$`,E3(`F6`@>>.6&>&5[7M>UZ#!X&JNKY6
M/3D1E=;X%+12HFTX^H1B!#\>@QZ>/(Z@&K)!TXRPV[BVS1M+50L3)83,MEF`
M8QL)A?'.UKT'\)NJ6KB-FV!$?6V`DH1E*:\M,T1-AV/".;2672LX.-SJS8R*
MMT+)!4W&X0L3Y\<KW(4X<QL.+EF+:V5!QIW3G4527E]U*.J^N!]SNL\N*;I<
M9V#XR-+SE4G/<G=RJ"^L#M@106#SANG%^_A3`@@AON`?=;Y]ICV`[0<UQUY4
M9$6)>4(&A@]+#B9`D9N"4#D7,<U(BY'`Q;(F-'ZP]1T/-RJ;(%*9Y!9)0YG,
MAD'>^-PNUOV*#KAO4#4L^GA))[5W74ZE`-MB,X!,-PG&AE/!:,7*.:Q&;5")
M#-G,L&VXZ5Q,C2$1MC8JD&<KBE,`L[WRH,LL..X_BMLDV5&#%9T<,U.,*)M/
M:3#;*(SVR1-*Z@95E8R306\13DHJ85%4Z,9,9X!8Y#F!<Q,[Y9Y97N'<:"4C
MC\MQ%/\`IC3']YR)*"K=!B!J:]P&PU-P+;&@^(&8LNPJHD72KM2-&8W5-RDE
M<V(?5B;@/HZ*3-+)54/"Y#&`S.8F`XV5\\[997O>@Y`G",+IS!M%*?$48$(N
MQ%[OC&Q-@M0JP<1^_P"RKW:S.`2<&[87PI:QGMN]NSWQ;NG_`(_1H/UNR((F
M?A7`D^8OCMYD@UI'<@91V,EM.(J&XF\#8L@+V!=83#@6"TAE[6#)FK6[N6PM
MVH>6-O0H.KM[6G7)HNG%\M2`(3;#UP53Z[@\&]%3$173@MJH7<%19Q<":@EE
M;%54@;]H8,6&[L-CZ&>5[4&;*!0*"1.ZOE#N/#WK-Y_8%&=5FTZIF6K04"@4
M"@4"@4"@4$Z]SOE/<6WTII.^[^[Z?8HI0?J+?\)7_P#C+L]C"O3M-Y:@]<G0
MH%`H%`H%`H)9Z]^5@Y'O>)T4]+9UH*F4"@4"@4"@4"@4$PN:KR2/(S]$"</8
M0J4'QQ/Y=?T__P!T]![??,8_V<HG[])_\-MZ#W]T"@4"@4"@4"@4$L]*/EV<
MN/OZ:U?=4CV@H?*;8,O6-7\SR:6@K9IT,]Q(!9'=)]92FVJ#*R4:(AD%U4;N
M`J^FI)O,>V`Y@ECD;!#ROF%:^=L;4$EV3HAMBSG3&#CQ>,2.4JP5'8A*24R5
M7TYY776PQI6@%CQZS";BD$*#([7=CS;;>#*#)#W=9<@N"-C(*QI?4QBP1:P8
M<B;C7VX9$BQ/*B^DZO**A'$L1A*9U@XS1**PVE8TA:(S;IF[41'6C6LR*09[
M?0SDGE%QNIB8W"R2$GE+I()5*#!","!VI/XM)K:4=/.-VFZ8E-I2[!NL$=((
MJFX'>C%T);A_9Z5-@':B$4HA'JN$F1TC)$I706H&$,*.$12"H0X(&&5\@PRB
M]](]H%U/FEBIQN%AHMV'W%D6;YC3`I4D=D/AU0*OL..4$C!Z4]4:&'`;9]Y%
M<$?@X/`R4#S%LW\A2:>8Q-CX'R8=73>/:=S<@RFM.QH:XF4M7-2)(<+.E(G7
M8\N:B%VR%K<3UU%A]$@S!E$89(LQ&:Q2Z9@]0+W-CMT2Y'%J@"8AF<`J+K-%
MI^$==8(AY7L@Y+<6PW%\=+AAL6&N@'5ABL5`:9XZDYFD]*-BIQ@9'[)?(8L`
M+W'M+988WMVM@SA0*!0*!02L@3RO?(O]%3CT]/-O*"J=`H%`H%`H%`H)2./R
MW$4_Z8TQ_><B2@JW0*!0*!0*!0*"1.ZOE#N/#WK-Y_8%&=5FTZIF6K04"@4"
M@4"@4"@4$Z]SOE/<6WTII.^[^[Z?8HI0?J+?\)7_`/C+L]C"O3M-Y:@]<G0H
M%`H%`H%`H)9Z]^5@Y'O>)T4]+9UH*F4"@4"@4"@4"@4$PN:KR2/(S]$"</80
MJ4'QQ/Y=?T__`-T]![??,8_V<HG[])_\-MZ#W]T"@4"@4"@4"@4$L]*/EV<N
M/OZ:U?=4CV@J90*!0*!0*!0*!0*!0*"5D">5[Y%_HJ<>GIYMY053H%`H%`H%
M`H%!*1Q^6XBG_3&F/[SD24%6Z!0*!0*!0*!02)W5\H=QX>]9O/[`HSJLVG5,
MRU:"@4"@4"@4"@4"@G7N=\I[BV^E-)WW?W?3[%%*#]1;_A*__P`9=GL85Z=I
MO+4'KDZ%`H%`H%`H%!+/7ORL'(][Q.BGI;.M!4R@4"@4"@4"@4"@F%S5>21Y
M&?H@3A["%2@^.)_+K^G_`/NGH/6]YGGK2H[$6Y$>\-EMG]=_4??4GNO^6]_-
M9C>K#U06V:[GZL_5*P7QX4]3_@3+P=W#O7N'?IGM^Z=TQ[F'M;Z-)Q=99R?_
M``^Q;X@Z!T:3BZRSD_\`A]BWQ!T#HTG%UEG)_P##[%OB#H'1I.+K+.3_`.'V
M+?$'0.C2<766<G_P^Q;X@Z!T:3BZRSD_^'V+?$'0.C2<766<G_P^Q;X@Z!T:
M3BZRSD_^'V+?$'0.C2<766<G_P`/L6^(.@G1J5H*NN#<;DX;8>_?(4WQ&3,<
M`IXSC;LSQR2<SVR5=;F0LX*#Y4#,+G2RLHI.!OO(IF7`*8!D@@\,L<\L;B7"
MB_1I.+K+.3_X?8M\0=`Z-)Q=99R?_#[%OB#H'1I.+K+.3_X?8M\0=`Z-)Q=9
M9R?_``^Q;X@Z!T:3BZRSD_\`A]BWQ!T#HTG%UEG)_P##[%OB#H'1I.+K+.3_
M`.'V+?$'0.C2<766<G_P^Q;X@Z!T:3BZRSD_^'V+?$'0.C2<766<G_P^Q;X@
MZ!T:3BZRSD_^'V+?$'0.C2<766<G_P`/L6^(.@G'#&@RZI\H&]C'QWYY"$P9
MKZVZ.+`KX2YGCHN^W3@Y5?9T()'=:N+"XY!11FSX"ODEA`E"P@&9XU<3,;NF
M/<PHYT:3BZRSD_\`A]BWQ!T#HTG%UEG)_P##[%OB#H'1I.+K+.3_`.'V+?$'
M0.C2<766<G_P^Q;X@Z!T:3BZRSD_^'V+?$'0.C2<766<G_P^Q;X@Z!T:3BZR
MSD_^'V+?$'0.C2<766<G_P`/L6^(.@FZOZ$KH7+E&D>WWWY!A1S7'K*KLQD$
M698ZRD8H"2V&C5*R:11<QAC%.P:![-0L;'+9$LQ\S9<'.PV..%\,@I%T:3BZ
MRSD_^'V+?$'0.C2<766<G_P^Q;X@Z!T:3BZRSD_^'V+?$'0.C2<766<G_P`/
ML6^(.@=&DXNLLY/_`(?8M\0=`Z-)Q=99R?\`P^Q;X@Z!T:3BZRSD_P#A]BWQ
M!T#HTG%UEG)_\/L6^(.@F+MIH4N(&\>C37SWUY!%\5SQSN&<"=#AF6.SKK;%
MFZS&`:$)M91+PR3*)Y-Q6.6"4L12YC(<($.V&05\;WO6;9JF5.C[7NL$Y%/A
MKC;Q)U<(.C[7NL$Y%/AKC;Q)T@.C[7NL$Y%/AKC;Q)T@.C[7NL$Y%/AKC;Q)
MT@.C[7NL$Y%/AKC;Q)T@.C[7NL$Y%/AKC;Q)T@.C[7NL$Y%/AKC;Q)T@.C[7
MNL$Y%/AKC;Q)T@.C[7NL$Y%/AKC;Q)T@.C[7NL$Y%/AKC;Q)T@:CSCH.<&VJ
MXXVDJ;N[X+@#TG>9BH:RL2\P#"\SS#;UN?SL+JS+.`Q`7+):L?'2,"9H0<$U
MCF1%$PPQPSOB)C/?AO/GL*V=$@F=81R6_#S&'B'J9ZJ./[PXE$X.^=\.0KDM
MMW0$<N):\[Q=ECF`:`$+&`L\<H%OCD&,`+EAE:]O1QRO2>D<=POQIN*][WZ2
MSD^]&_9]"?(LM;T?^ZUH#M:UJQK_`)T:3BZRSD_^'V+?$'0.C2<766<G_P`/
ML6^(.@=&DXNLLY/_`(?8M\0=`Z-)Q=99R?\`P^Q;X@Z!T:3BZRSD_P#A]BWQ
M!T#HTG%UEG)_\/L6^(.@=&DXNLLY/_A]BWQ!T$Z(0T%757DIWQ9>._7(4EC-
M6&M-U`5Z),SQT6>[JQ<*?,60:<[546%S!%23F[X-O9-P!*%LP+&1NWR%[;'M
M0HOT:3BZRSD_^'V+?$'0.C2<766<G_P^Q;X@Z!T:3BZRSD_^'V+?$'0.C2<7
M66<G_P`/L6^(.@=&DXNLLY/_`(?8M\0=`Z-)Q=99R?\`P^Q;X@Z!T:3BZRSD
M_P#A]BWQ!T#HTG%UEG)_\/L6^(.@=&DXNLLY/_A]BWQ!T$].6C0%=8'&5O:]
MA]_N0U_@M;5Z7UP5DR'-,<K;&=.">T%$QDANQ(3H613RB@J%L.YF003983,.
M][8B8W]&@^6C_+K^G_\`NGH/;[YC'^SE$_?I/_AMO0>_N@4"@4"@4"@4"@EG
MI1\NSEQ]_36K[JD>T%.%M2$1D965PDP^LB)::=4,$A*R3L%-4S)EA#&*>GYJ
MZ@DI6)TY</N85S)HN!;/*W=!<,>SE8)U-GE1UL=&A#RY"P$:5$R+X_(NS!WQ
M<KMQM%YX0WHU%>Z'[EQYHEGF<:9=_.0^8(W20\U[%,.%54D:[]P*&,1[!NRQ
MY>93X8[1?0:B6;11X(K>62J(YU=M%E])S<K>`=*<B+0*2NK*6`O60S%A\P`#
M9BW<[7SQRRPMVU!QS*V#@Z14=F+[*EE@KZ5(QUP)T?&BKF2PLGR;:RB92E_!
MH%C9@N;<F"<<*Y=L(3#&#S!O@-AED"(&)D'\/78>"H[9S[D!YRW'Z(SXQ;F;
MND!;$<Z4;`:3:P-'B%EE:`3S!LX4)#*"89+!97#O<8R`($';(3#+&P=Z77TR
M6LF!+3F>+5;B..5.G@%9=<*2D)@Q)-3QU=1.!'U`V7*B%2"45%-#B6SO@$7#
MR$RO;#&^5@_S%D!A`**8D#O=H@JRT2LIHZ6*Y$8-15D[)-/K.*@F$LSMC)\E
M=(2C1NPH6.8?>Q847L]H'GE8.F'=@X.(!1L8&EE@C%IB<P[-BPXG.=*5B3_<
MY0HHGSB,UCJ48.%5<V1)))H4QW+/+$#`#.XE\>UO0<T>DQNB=H&U5AI.PR5?
MJ0P'$6)/9NEA&XKGS((9\B>[<T-?)R)A0:PUDCL8'C%NQCACV<K4'/HCW9;F
M/GDIN.]KN!43"Q<ZI)J(OI*J?3R9PR=)%#9XF0-CF"A8T<33(08@F...8I<3
M'&]\L,K6#M%`H)60)Y7OD7^BIQZ>GFWE!O=L'/<9ZP0X^YUE]9%0V!'J/=66
MC),F,IJIP04P"12T5"2BW_F59?754T"3)%0^QD,9&PQ[.-KWRL'3FOL0?&5Q
MTV6(<?T")A:-AI2./61UN-!H^148!32DPRV'.\6J^5]*;S^2;JF(ITF+EDG6
M!#SS*'SF&`F6`?B_S8QSAL4F:^FA2A+-P0RD3(TY%-.5L8,MWD5Y[)[(26VV
MAK*>1M56U`\I@"E^TQ[F:P$QL!<2][]@/\-F=N8SULAF;9=-&"DBF8$14M=?
ML=LIRMD9[I1)54TP@!X133BF%DC9W+J=C.&)NP60P(=^YVRROC:X9L=DJQFQ
M<'!D\7^SVT(U&@I/]R%5AQ)1)0160CXYY*CL4$T4UBH`-\E?"^(ANX7<;9_P
M]MVU[6H,>M3:O6][`.@VVIJCP\39+.8$@/`Z.XR241;#,E))-+K`<2\=5\R!
M5+3G,DDA1@,AL\,L<<.P);#*]K7#.Y(Z34B9113C98^GGRP!TB>)#A&B9TF:
M"P'+&RAD#,0`R6,@"8YAB897PSPO:]KWM>@_302D<?EN(I_TQIC^\Y$E!1F6
M9/:<*QB_I<?9HP29L;M-<>;F-%0<3!D)&;Y`=1/9`!""@`7%N"!>V-Q1`@<+
MW[800,.V6>(:C*/(*P&?"ZS/$H1K)+"C\!KQ:YF0JA&8[?1:8Q9H,DR4>-2)
M3C#?2\4<3P45-3*DC!8UFGE@3(_=`C(Y'`0[B&P+&F=P+SG4VF_H8D&(3B8R
M0'[FO.H^Q5MCC)(Q[(F92;.]F.MPIQ-U('8[92)FK`!88]D0H.=+8W,4'28)
MW"CG96%5^:H8;C_>9-O/1]1T:88*,E(C_%?#!6C"*I-VY)TKR`W$<91R#",E
M#2JIIY#(D;`'%,!!B6RH,B:\SBC[%Q0WI71&;($?%UPRN)YMER>CI*.\VZK-
MQ;/M]7352S;7G8T52P"@FB=R.HRNJI9H/L9@&A;=GL!FR@4"@D3NKY0[CP]Z
MS>?V!1G59M.J9EJT%`H%`H%`H%`H%!IM.7RUN*WZ0FQ/W0Y4K-4K-KM5S64"
M@4"@4"@4"@4$L]>_*P<CWO$Z*>ELZT%3*!0*!0*!0*!0*"87-5Y)'D9^B!.'
ML(5*#XXG\NOZ?_[IZ#V^^8Q_LY1/WZ3_`.&V]![^Z!0*!0*!0*!0*"6>E'R[
M.7'W]-:ONJ1[04V7P5`PAK)=)!)F50=+/@IQ=1.#IQ`8\*5%#*A'3Y8@JF"1
M7,;+&P@H98QF'C>^5@\[V[6X0G=G%=/9N-]@&JTGW%)).G_3UK-1<AQ17GD!
M':7O(V(&-ZPB3D`]R;",*1M@N.'C)"R@`*V+J6:TU40X$&#F`)V0YT?0;::[
M[1"W@&`SS(,2[QUS$Z5\U)[O[^+&-46X19TGM));&<+BXKF2LG(!8RD*!DV1
MQ.8F\RQ@`KW*PH@87,<;VY92,X+CA'C_`%E+`P]G%I^RFCRTNM8\OJL2;EIL
MX98.A1!U[6E=51'.R4@F;1R1,PG`I2N"-BIV4[7)W)AQSIX@-@E6!GK&Z4G:
MP("\[]".0[714+H;I=UT=4F+:3:)C3M"RJ>,Y0BA9J3083?:(I0XJF`,5%./
MF_\`R1$<+'(7(-R]^VPI.:<N*,N)$+!>RX1G^;#"]'J\J%!&:C%%70S9A"-%
MLW(<9I\OX(+O!63B!`<=,)@'U(4D%?O848*V(:^@<2<NI<=3(RT98@PNM./3
MZ'(2BYYFQG`H**$[6)*DRR*Z(S5"=X])&T>`SK5DPFR2ADBI"J`[<3<<1DP'
M&V)>@RHN:$38Z)H2=AKM2)6^JN;:E&F=V1(;>I]81V&E9:L/G7ET/EO.7"/K
MEE^1%M;<Z8HG"@9-.+'D]LI_9-!&[Y8`AC"*>-*>D,C!"TMQY!K7E6(I3U)+
MR1(PVTFQ\LFYSCC5-:5#*4_DI$?3"-MR*G&J)BNH7)-@L3,7+#+YTOFX,2A>
MUE$,W:.\?,M:Q2_!K^<)*"DA#8VLFU$12"5C)?<IA37'S-FVK.G=B*)$N>BI
MF$UY`:[';ADB9-G1RIPN?.9!%RPA?MA\@L=0*"5D">5[Y%_HJ<>GIYMY09^Y
M!]3C6ZFK#[@I'<Y5FNXZJ,M\Q\Y%,`<VA)LA1D\$5^LS)RDRH8APTVC*Z@`@
MG\`+7&L6$RRPMEEC;'(.J3LUMMYK@I%2R\1P.VI+29#B1RK#57Y./O-",%6D
M^DA5>YZ/WF?B'-,25LLBE13#64EILG;=^XX7.I8'8MV`EVS>)W80*-46/9%9
M>NCJR-Z_[%:]"JZC(+C=P\?7DC<=Q[$,>2DD\X(>)*:T;3V@MX@"AA7*'@5L
MF7OV^0(H@Y8/^RWQE[LR2).223(:[`7D:`YSU^2W<HRZ[T!+/`O:7X?D5JR,
MILU`U^7%4DNN1*CK.[F[^5E]0'7L\A@CMB5P0`@V%E+CLE63IBV*47.PXL=Z
M&\5N5)0@F:EW8B>R2O'J]*\')L1+\4J&LB6D!12=*BXI8@.;G,*ITN.FJ&8@
MJ((.7L"8#'3;X]-KV2;55E!C_6DP;=+&XT"*P6RD-2**3:<FI;=>[2E41E+)
M^!5Y*++X`#F+GVTOFDP:XF08P0A$L)W(Q8*=Z`PK(NNFI430G*A5L%7C'I=U
MI)K%H.E5>*(,FFGNY%A"'`75IMM51,#"(RD!W7$0I;+#.U[7RROV>P&Y%!*1
MQ^6XBG_3&F/[SD24%&Y637>L1P\TEA$&8K.Y303I!%29%#,B,17'-X6`'27;
MB3(*IJR"J$\Q`#&6!0W?$,2]^X#=CN>00F5^'IVB,:8FA!X;7UGCK*2M==CM
M>]7\Y4=TEP"P-GX+D#-_N)QM@CFS$TQ#,1R;>^28:1V^6'`%[<-4LED!0/!H
MP5@D)'V8E^)#3/S:,>Q4KO/-O-QZXE9>7E=2;C6/'<<)&4V<Y4V)\RBVHX)&
M.9='+'""?BH8C7S-B)][=QH-:X7U%G?5R=-P5F)4V)9/UYV/`C5](3#EF77H
MVG0E3(FH(;#E3PQ9(@5_H!=CO!FIR>/AGCDH&ACI*P`@`(&?=<0V8TIUO/ZJ
MP<6B0TMX*!(N]7XZ6^W"*RNN!MQHWGBY3J^F1@S%ERAEUL^T&?B<R!)9#@%>
MUPSOC@`$'CAA8-M:!0*"1.ZOE#N/#WK-Y_8%&=5FTZIF6K04"@4"@4"@4"@4
M&FTY?+6XK?I";$_=#E2LU2LVNU7-90*!0*!0*!0*!02SU[\K!R/>\3HIZ6SK
M05,H%`H%`H%`H%`H)A<U7DD>1GZ($X>PA4H/CB?RZ_I__NGH/;[YC'^SE$_?
MI/\`X;;T'O[H%`H%`H%`H%`H)9Z4?+LY<??TUJ^ZI'M!2%]KJLUV4[7(@H6#
MG6T%N+*ND-P173V_@O*2>0'-$DC)<5A`DM(LHF`L0N^3&6((/;]MG>V-KWH(
M^,;D%F][RQ!2`>&BUI-W,SL6+/[8=K+DJ'7ZS3<1PDPW\7:+];TIESAJ.!45
M:>9S+)5)F5A$7TT@15B"C<F:,$\`U[4-S-BY_GG2I/2&^T67);-VC<"*!@*L
MR>TXH?B!+?%%M1-J:"[&H<"NZ5YNL5ZH@?>0YP$IFXL$PJI@`HO?5@P0_P!I
M9W/=FP\%2NJ"Q[E##P+13I<_%Q6:4ANL\I#+:KM[*T0.MIE3H9%JES[#)K,8
MJ)A)/6+`YKR,K!"&P`[7Q`P#;5S[O/5@M38Q9847,!0D9O[LO76Q@Q==TNQ1
M=>PDDXL2,U)B$&D!<D$51EE?)+EQETR/F60VRD)1A0,Y]ZA&36`?HMOOL8(X
MWSDF:],%QL&)E638EEIYI$RL8LWVC-\<0`C2[81)'6720DQWM9=?BK9J61@6
M.67"I$0!P=T&`$$3@0WHU2DF1)FU[B:8)-266@+\K,%E2240F(;7%!'145]-
M!"=!!),'W``5.GE1-S5!`1AL0@@A;88Y8X8]F]K!L/0*!0*!02L@3RO?(O\`
M14X]/3S;R@JG0*!0*!0*!0*"4CC\MQ%/^F-,?WG(DH*MT"@4"@4"@4"@D3NK
MY0[CP]ZS>?V!1G59M.J9EJT%`H%`H%`H%`H%!IM.7RUN*WZ0FQ/W0Y4K-4K-
MKM5S64"@4"@4"@4"@4$L]>_*P<CWO$Z*>ELZT%3*!0*!0*!0*!0*"87-5Y)'
MD9^B!.'L(5*#XXG\NOZ?_P"Z>@]OOF,?[.43]^D_^&V]![^Z!0*!0*!0*!0*
M"6>E'R[.7'W]-:ONJ1[04V7D%$=*(KMIRI*<O-Y?33B.N(BN3`4$I72E$N(5
M/IRB1-8"ECA(X6%R#%"$QRPSPRO:]KVO080"U,UC"Q;^-X%BDQ=JK*^X6^*=
M9*$H&$M:=#3"8;@4`#)XF8,9#JK)+`)`O;Y98W32I8M:U@BP&`8=/0]"M*FP
M1*)K;U6@=OE4_-M"IMD2,VJE&$P=GHJFVFP83#I%-`.IIE&;*T;3`10!`Q+)
MID4I>]R^>0=PR$I:P:TK.!H-8UX@Q6#/-9D,8]@I1*P3V!QDQDHXJ\;L\UB:
M;XMC#6CY6PL:0T_/LE$DQ:PA4,+.W;4'&J^H^J+@4O#*]K'KTMJ]G4ZGUX55
MX7C=24O5N^DHHA/=X]_'&T,:]53Q1$\N355#MN^U$J`&$8$$#PQQL''IVF6H
MJ0[EA^)6L4!ISP<##PB]=7R,2L4J>6(YP2C"!BR%+(%#P#.-CP`;%3[DQ,<@
M,B`F1:^-P+W#H,^-QN-YGM]#:32049K-5L(Z:WFTV6XED41OMY`1B8*<CH:&
MC)@!5.24=*3RP8!8L7##!`!#QPPQQQQM:P<S0*!0*!02L@3RO?(O]%3CT]/-
MO*"J=`H%`H%`H%`H)2./RW$4_P"F-,?WG(DH*MT"@4"@4"@4"@D3NKY0[CP]
MZS>?V!1G59M.J9EJT%`H%`H%`H%`H%!IM.7RUN*WZ0FQ/W0Y4K-4K-KM5S64
M"@4"@4"@4"@4$L]>_*P<CWO$Z*>ELZT%3*!0*!0*!0*!0*"87-5Y)'D9^B!.
M'L(5*#XXG\NOZ?\`^Z>@];WF>>T:=K9;D1[_`(,V?FCU:7U)[E_EO@QTS1ZF
M_4[;9KNGJS]37_3?ACP[CX.[O_ZSO4SVG_`RH/:WTHK=^8SR?_49E*@=**W?
MF,\G_P!1F4J!THK=^8SR?_49E*@=**W?F,\G_P!1F4J!THK=^8SR?_49E*@=
M**W?F,\G_P!1F4J!THK=^8SR?_49E*@=**W?F,\G_P!1F4J!THK=^8SR?_49
ME*@G1J5R'H3<W&Y.'.)J!R%+`;ZF.`5$%#;NG\C+#F:V*1K<R$3,F^40M_YE
MK**AF3[Z*`F/XS!(0,;'^'.U!1?I16[\QGD_^HS*5`Z45N_,9Y/_`*C,I4#I
M16[\QGD_^HS*5`Z45N_,9Y/_`*C,I4#I16[\QGD_^HS*5`Z45N_,9Y/_`*C,
MI4#I16[\QGD_^HS*5`Z45N_,9Y/_`*C,I4#I16[\QGD_^HS*5`Z45N_,9Y/_
M`*C,I4#I16[\QGD_^HS*5`Z45N_,9Y/_`*C,I4$XX8Y#4)+Y0-['YEJ#R$'P
M79K;HXBA-1+U`D4\^T#-K*^SHHJDZVH%;O\`0$9<\/VQ2S(W^[/YE#5@_P#@
M94%'.E%;OS&>3_ZC,I4#I16[\QGD_P#J,RE0.E%;OS&>3_ZC,I4#I16[\QGD
M_P#J,RE0.E%;OS&>3_ZC,I4#I16[\QGD_P#J,RE0.E%;OS&>3_ZC,I4#I16[
M\QGD_P#J,RE03=7^0M"%Y<HTD>VH?(-@`3X]959^3,%U!D4.1C`Q_8:-5?%P
ME&;E;PB9:!7!.N7'4<>R`$;'!!O_`!"6H*1=**W?F,\G_P!1F4J!THK=^8SR
M?_49E*@=**W?F,\G_P!1F4J!THK=^8SR?_49E*@=**W?F,\G_P!1F4J!THK=
M^8SR?_49E*@=**W?F,\G_P!1F4J!THK=^8SR?_49E*@F+MIR$H;AWCT:=>&H
MG((CA-6.=PR0J`X=0Y$2'6O7<K,8!0,RUD`Q;OM>)HMR5Q%(4+^$D$*'EGZ&
M=JK-LU3*G2,H/S.>13ZG$D_[*N40=(R@_,YY%/J<23_LI)!TC*#\SGD4^IQ)
M/^RDD'2,H/S.>13ZG$D_[*20=(R@_,YY%/J<23_LI)!TC*#\SGD4^IQ)/^RD
MD'2,H/S.>13ZG$D_[*20=(R@_,YY%/J<23_LI)!TC*#\SGD4^IQ)/^RDD'2,
MH/S.>13ZG$D_[*20U5F'?I%4=L^.)QXZG;ZD\&3.4W*8R,HZG2`2<3FQ6]9Y
M";>))E(XO8,.922\E+OXZ`!_&630!C%^SB'>UYU3<\^5D.E%;OS&>3_ZC4I5
M"SI16[\QGD_^HS*5`Z45N_,9Y/\`ZC,I4#I16[\QGD_^HS*5`Z45N_,9Y/\`
MZC,I4#I16[\QGD_^HS*5`Z45N_,9Y/\`ZC,I4#I16[\QGD_^HS*5`Z45N_,9
MY/\`ZC,I4#I16[\QGD_^HS*5!.B$.0]"2>2G?%\9:@<A2@"[H:TW30FPDZ?R
M*?>[?R;:?,6(AQVM<+L'F^G+/A.UTT8;^`[8`:^'_"RH*+]**W?F,\G_`-1F
M4J!THK=^8SR?_49E*@=**W?F,\G_`-1F4J!THK=^8SR?_49E*@=**W?F,\G_
M`-1F4J!THK=^8SR?_49E*@=**W?F,\G_`-1F4J!THK=^8SR?_49E*@=**W?F
M,\G_`-1F4J">G+1R)H4B<96]K%`T]Y#6<,[=7I?00G5(>GLC,]C-_-2:"B6Q
M578Z5'_R+?02=\^W,FQO]V"':^67H6H/EH_RZ_I__NGH/;[YC'^SE$_?I/\`
MX;;T'O[H%`H%`H%`H%`H)9Z4?+LY<??TUJ^ZI'M!4R@4"@4"@4"@4"@4"@4$
MK($\KWR+_14X]/3S;R@JG0*!0*!0*!0*"4CC\MQ%/^F-,?WG(DH*MT"@4"@4
M"@4"@D3NKY0[CP]ZS>?V!1G59M.J9EJT%`H%`H%`H%`H%!IM.7RUN*WZ0FQ/
MW0Y4K-4K-KM5S64"@4"@4"@4"@4$L]>_*P<CWO$Z*>ELZT%3*!0*!0*!0*!0
M*"87-5Y)'D9^B!.'L(5*#XXG\NOZ?_[IZ#V^^8Q_LY1/WZ3_`.&V]![^Z!0*
M!0*!0*!0*"6>E'R[.7'W]-:ONJ1[04N=)0,^V7"2%&/E@S:&JELS"4IJ**I@
M8#$1P\AD]82#1)52CH=LNR$8+#!#@YVMF'GCE:U[!Y8RFR^R4><=NV&ER]/$
MN*FSL9ZU9;)QEL<L.YS')A5]-)4A55F0*11)/.K(CS-/IA22BN.*P5XL:R44
M8Z*VCHHW=S7;6"E#(WO?S.:S.C_%HICI4V_)N@\"^JEWO5TJBVY\=KHO;JN>
M>:XI*8:NKFW`U7`I9#C8BF#62F7PR[80`2_;XAC!B<E^P:-#VL[R?C;BJ07#
M)*I'H\HIS3P=1%4142;-I0H):9VUBQ/)OQBAMA.,'#*<,L"*9MVBI61$J'W8
M,^H`!CJ6^5W:%-UTFI[(<=0ZRWN!I-NSLY$ZH26W.\2;?5M,=DVO`KC37806
M4)&++=GBFODFIIN((8090R1%",=W#,87`"H.T>Q$RP\]=3(MCAIQ@O/+9Q^2
MG'!A=?"VZ$ML,M786M<O3L06PDY$3#BFO)AL[%MR0Q;,P2$N$9M?$;"_\6(:
M)X<L$M>HEXRDI0I'3?9D6:YQG+3_`$M1>[J&73;[D>2IJ@T%OH:O9J$T=)C9
M,DN+`E*[C.!#""M<SW>Q+$83&P0=\>N\NR2)L`S("R0HR3U%F;-A1U*[Q)D%
MT-N2?%ROJ_)NP3;46.FGCKA-1VZ0C\<G4Q83S*@LYE@PBID,Q;!1L&5#B47?
MV9'Z!KTXY`UC;R)%.P<D:=.6#7B=E=F753C:G-7PQ51+LQA2`^7*H*L4'E%#
M&"6#X2.CKF*F($*2)#E<`#@92TUWZE38>6HZCZ18RC]HILM0#L!-C5-LITN-
M>/(6>O&S3?UZ741P9KJ$C`*&#KP>1!2*"%@P;DKE1PA.[=U#R""K-`H)60)Y
M7OD7^BIQZ>GFWE!VWENFR6]?M#9BD>%5$^VWB";8+7./Y+*XFU"+F:]G\VVD
M^)/)X"`&"X)ECM98-'@QQ<>YELP["WOCVEKV#G9/;C<U&1DF38L?2X&JKQ!C
MP>@L^6YAE:1F.X5]^/AMD$J0<&:I+CJ>,GS.9R#N`$$E#EEIU9F+@F#=\[X#
MA!+M#WVGMTR*4V]9L?-K'-/T/D]TR3";QDQX)K<,&81W75H9<^3+"34=P)"&
M]',GL\Z,3&&`,V)"&0B8PI_`/OC(/W;Q[\2/)D`;>1XBIA-L-DSJ\^YLBR4(
M\6WDB+R`9BZ98=9@K9-NS$9/3G<X3!EXCW5A$'N1!OG2`J0,*H#9#Y`AM_.&
M^VQJ6H["^XK!K94H[A)P3'#CFE=V/N/R!)DRFS8?1I&9#F%;YN12+T?"<X%U
MQE$@9LD6[@H!XY=_!'C6'9*7#$,2[_;3&U&24E[&8;53Q"->-L1C=NA.CO@1
MY[71T^'#(1\BU&N""O22X,E%LX#)C9(CIG=[6RQQ.E`L,\Z"I6G\]*&SNML5
M3HK-4)D*S]15$RK-4!2NK@(ZJB.%8;"D``?N7+7%!%/(@@N&-[97"Q$L'<07
MM>Z9ALI02D<?EN(I_P!,:8_O.1)0;Z;%@N`S!,M$FG)"7$#K4F&XDEK2:MW$
MQ264Y%9/&34%=4!`#!4V"5*JQH'MA"XH9D.V7;`Y8BVPO8/-3-\Q3K'VDFX,
M9/\`;6Q6J&[D*-/5$TNXM/:F9'9"TE-]5G%E1[C..M$UISJP=3>09.'-FBSM
M2S1)-7BQD[;)0*GC&/=\PRT^3FQ,CRQO?I.G3U-\!2<E25IQ(4#8,O8J6)+`
MC=->R([;8+2=.JXJM^0EIH2M(38+EU]@KQ,LEIQ#$6Y0`V6,7$P#DS^ZLM;6
M.OBJ>:&]7_%:4F[4)D)[61^SW$YF!@Z-CD5CN\M)L6/<%`52H3H83'56YF;S
M1S':!8FCA/(?$P%>V&(;,OO:J4&5R*P%(!I6?^&GDTN5VZ3XE3:6+A%0$JAE
M_59&DJ(2\`:$1%PW(KX3SS9+G;7[8,$KD#CE?*]PZ"V]`H%!(G=7RAW'A[UF
M\_L"C.JS:=4S+5H*!0*!0*!0*!0*#3:<OEK<5OTA-B?NARI6:I6;7:KFLH%`
MH%`H%`H%`H)9Z]^5@Y'O>)T4]+9UH*F4"@4"@4"@4"@4$PN:KR2/(S]$"</8
M0J4'QQ/Y=?T__P!T]![??,8_V<HG[])_\-MZ#W]T"@4"@4"@4"@4$L]*/EV<
MN/OZ:U?=4CV@IVKE$D\E*1)>+)QQ#-D#9=8**X)8PE&4P8`3`^`I`',<R@Q`
M4KEE8;$6UP\@[WME;L=F@TD,/[C?<UH[@;%5U">B?+S5<4,1]&*46B5XMIU1
M^U$M-=3BC4FW4P!30;L)+*Y)PPJ4('BFV,&"6%@KBCE\<PP!*CSXV6%*.L#W
M]RC3YVM^49&.PX'L*F&H;]3$%J.LL!2WL^P3"LO8)IINI">Q4%AGL$V]E%/,
M((JJ7'!Q[B)E?$..V)CW06)V4X'M;3[4J5D%BI\4&TE*0@(Z-.7-*G2:@E\-
M7&;X++5PD9L8//,JX48]D.,"I&[C]ZV+=QN(*&PQE@Z`H38=**_XST<83#(X
M2CK0G`980N303\?O$9+>,L1$J`F6\VB38#=KI$%.N9G89F0#)@N$=-]U%$MW
M,.#G6(]5YW?>J."Y+D+DV]JH.ZY[;\39JK-4B+BCY8@Q^08"X<P+.H@8;\?-
M5IR:8.%%<L7S+ESH!3.PV(>&6`H;",J/M1I-1W&Y8X96N;_074RB$(.UQ,=N
MQHZ$MQ1VTBPI=*B)P+#?)GBJJS6P45L\"R"8%S)$0S.5L`,+"7[(<J3U<UR(
M(+2;):$HTLAL1Z$9'9Y`9HI!K%O/],30T5/>::,:+#&07,20@L$\,[V]Q\$\
M/`K;+O?#$.P<"TM,-0V&`;+,[6"`FX7/207F$P`EQ(Q2X-I5)&U%0(2(7#LA
MWP)O%-4%DZ8*J`-@S)8<Z8$"SPS'%RS#O3,U^@6.%1OKD>0C$3#6FFVE]EM9
M89D;,UKJC:9SL<@;R=+3;Z@AHI$VC-IRN\'!54"!;,,J<4L;&1L,Q[6SH,NT
M"@E9`GE>^1?Z*G'IZ>;>4%/UM$17*CJC><:0EKZ`N$#:4M(:V0**J.L)9\#,
ML>351,/!#DE`@=+"9!B@BX9AB897QRM>U[VH,#6U!U<]SO.(\X!BD>,;F4(T
M"Q33,1C;9(YM56+KK4!24HR6%+(Y%I*Y4,PDEBM@2Z6)AC<K@%V*#\23I=J,
M@AMX!"UH@Y%+M0TY#;=+)$9M)-*I6;P<N#S=`)<L22P0+D5UXA!JQDMGCD7$
M4P0C5\.[A!B8AQ:CHEI4M+CB<JYJ=KNO+CO-N4\Z5!>A]B+@KB-/(ZG*;L$6
M<%5#.`J-G&J)!8V<Q%QRP,&P<1L[7%_CH.Y'M5M:5.3W+-2C`D1'9=>3+SCI
MV22:8#9&>CD8PB8:1!&LM.$1-R4E%&S1#PQ&X(HF6-R0N8'_``<KX7#JQO1_
M3H^2)IQW6""C1%/;\:M0@6'C%I"!$VW#9PR?B=$+6R2[W`38Y.'1A$8+'L8I
M^0PG<>T[?+LAFB-(LC:&6@0C^)F(U(W8Z694S::TF4A)S<;Q`RLJ)E65!BB4
ME@%B8&9Y2."C"7QPMV<\[_\`9V+4'?:"4CC\MQ%/^F-,?WG(DH*@.5LMUY("
MNU7<@H[H;"^1'3%UNN!-*+"&M)AK'N9I.54I0!,$5`@:#O?$0$;#,,3&][96
MO:_8H,(&]0]5E)JN)C+6N<)N1FNX9O#.AK.R,V@[$!P6:%[>HXNK)+D250D>
M(,S&UL48L)AD72<+6Q*8`XV[%!S:'K+K<V2IPBV]?(0;Q%0>*;(A\FAQ0PTD
MJ>D!%![V1WT<+D$`N"9>*27OW,LIYVR.@8?PX"XV]"@Y-<@"!W.HH:NY83B-
MPJS8>ZC)C:5%R-V:K*+>DA8!#+*T@(9T^C&#*2]U0N%@&95B^09\?#&V.8N5
MK6M0?F5M<]>U]A(,5+L$0TM1>UG"G.YL1NK1@R%)A-QV)"N.X$ESH+/.(8S>
M2'"EKQH4Z7.ERX9D`V)D-AGB)E?*X9EH%`H)$[J^4.X\/>LWG]@49U6;3JF9
M:M!0*!0*!0*!0*!0:;3E\M;BM^D)L3]T.5*S5*S:[5<UE`H%`H%`H%`H%!+/
M7ORL'(][Q.BGI;.M!4R@4"@4"@4"@4"@F%S5>21Y&?H@3A["%2@^.)_+K^G_
M`/NGH/;[YC'^SE$_?I/_`(;;T'O[H%`H%`H%`H%`H)9Z4?+LY<??TUJ^ZI'M
M!0^4VP9>L:OYGDTM!6S3H9[B0"R.Z3ZRE-M4&5DHT1#(+JHW<!5]-23>8]L!
MS!+'(V"'E?,*U\[8VH)+LG1#;%G.F,''B\8D<I5@J.Q"4DIDJOISRNNMAC2M
M`+'CUF$W%((4&1VN['FVV\&4&2'NZRY!<$;&05C2^IC%@BU@PY$W&OMPR)%B
M>5%])U>45".)8C"4SK!QFB45AM*QI"T1FW3-VHB.M&M9D4@SV^AG)/*+C=3$
MQN%DD)/*7202J4&"$8$#M2?Q:36THZ><;M-TQ*;2EV#=8(Z015-P.]&+H2W#
M^STJ;`.U$(I1"/5<),CI&2)2N@M0,(84<(BD%0AP0,,KY!AE%[Z1[0+J?-+%
M3C<+#1;L/N+(LWS&F!2I([(?#J@5?8<<H)&#TIZHT,.`VS[R*X(_!P>!DH'F
M+9OY"DT\QB;'P/DPZNF\>T[FY!E-:=C0UQ,I:N:D20X6=*1.NQY<U$+MD+6X
MGKJ+#Z)!F#*(PR19B,UBETS!Z@7N;';HER.+5`$Q#,X!476:+3\(ZZP1#RO9
M!R6XMAN+XZ7##8L-=`.K#%8J`TSQU)S-)Z4;%3C`R/V2^0Q8`7N/:6RPQO;M
M;!G"@4"@4"@E9`GE>^1?Z*G'IZ>;>4%4Z!0*!0*!0*!02D<?EN(I_P!,:8_O
M.1)05;H%`H%`H%`H%!(G=7RAW'A[UF\_L"C.JS:=4S+5H*!0*!0*!0*!0*#3
M:<OEK<5OTA-B?NARI6:I6;7:KFLH%`H%`H%`H%`H)9Z]^5@Y'O>)T4]+9UH*
MF4"@4"@4"@4"@4$PN:KR2/(S]$"</80J4'QQ/Y=?T_\`]T]![??,8_V<HG[]
M)_\`#;>@]_=`H%`H%`H%`H%!+/2CY=G+C[^FM7W5(]H*F4"@4"@4"@4"@4"@
M4"@E9`GE>^1?Z*G'IZ>;>4%4Z!0*!0*!0*!02D<?EN(I_P!,:8_O.1)05;H%
M`H%`H%`H%!(G=7RAW'A[UF\_L"C.JS:=4S+5H*!0*!0*!0*!0*#3:<OEK<5O
MTA-B?NARI6:I6;7:KFLH%`H%`H%`H%`H)9Z]^5@Y'O>)T4]+9UH*F4"@4"@4
M"@4"@4$PN:KR2/(S]$"</80J4'QQ/Y=?T_\`]T]!Z?O-2M!?\\=M\_\`_:F_
M^G_N87U=^0QL=_E_]T/U:_YB?_[1_P#X:[?5;ZDO4E_]D_\`3]X>$S__`(^^
M/X`]?G0%_C4<_P!^8W\3E!KQ,'%I"$#NUGL.3.<KSB--=[_;SV=;/06[N5*T
MA'5UOQP5('WVI%?<[UF=8(8;5(JI8<Y@+D&($"/AG?'M<K7H,-BZ=:.!9FQO
MU$G/(.WDUL0V]UB0B6^$A'XB06/L(?6$J%'PXYE(ZVF(H;K)DE4;YXLF*YY9
M+IPQ@J(%<;'/&^-!WMY<<NN["D%,BQQ\XOG(F+\7EMV-MLH2)LWL&[?5@ML1
MO8NMZ)[(5&GJ4MHSV&:R#?(8_=),',"V00H6=["@BX8!LRW^"A*=*"B.9!YL
M^?T^AN-(35U&/6Y%3!>QU*5R8*@G&[%S<+`&@+&29C#/M!0\!,>V[&6-KVO:
M@Y?H"_QJ.?[\QOXG*!T!?XU'/]^8W\3E`Z`O\:CG^_,;^)R@=`7^-1S_`'YC
M?Q.4&@VKW"YZM=L>15B]+'S5M+W)97@]#]6+)WM\`ON3?5+K\S75X8EQP^Y8
M:]6:Z@>$/!J88[B6[U2@`2_:Y=IV]PWH5^!\HAI2DM*'-/YP3<BDD#:D=[PY
M"E%8/=ZD@,S)CO-*2(1/*JD9[D'?M`"P(HXN78QPPRRO:UPUM1>-_5QQ:M'-
MUD;S@KG<.ZO)[3<[V/2W;D07@$@HW66HJJ,Z1C",9@0%U`J2&M(9LD.G9$+*
M-CH&1>P%QNQA<,OM'A>9KV2"CA1>;/SA,LWU,LU3:*MN3?=Q,Y.7P7J6+&6U
MX"&=L$(N2H,I6.`AV""QR%P'%P"SQQ$RMC<,B=`7^-1S_?F-_$Y08M4N'!@)
M$QM.!3_-WYP<#)CV8;ODIN)'^?Q>S3#S18JPV$)S'KN?&"[MH$ZGJ;Q3L.\L
MS=CN>`_=,0KAXY9V#*70%_C4<_WYC?Q.4#H"_P`:CG^_,;^)R@Q3&/#K'LQH
M;L<<><WGG""XE,I[.^.U_,;?AQ(AT!WL0WX/<Z4725Z"$Q7-]Y'^R$$,&!<$
MWV+9E\A0LL,\@[ZE<$Y16;Y!R!<S_G"I$BH))=8P*+/("JHRX4+&"N)RQ=3;
MZE"!9:35,`/+M12@P&!@(2U\,L+96[%!TN'.&M@3W'2#*T7\WWG!"XQW,,O%
MT=3/<@"VW#@XK:<:NTUD,RAN2"TE=312BZA&0;AF2P(G^[[/:]B]J#)O0%_C
M4<_WYC?Q.4#H"_QJ.?[\QOXG*#0&(^%[P]R.;HQ%TL7-2B^YWK_INZO=/0-[
M/!TOOKW0578T#U-R,]?<L&]4[49'J1[=O$^]@/!@BHH7[<3OG^`-JYKX=8TU
MVB]X3/,7.7YP$T(S8"4(N/%TX[_.-Q`H*.#EC@.IG$YJP*N+-R1>^=NZ"!EL
M\0[7[.78MZ-!A)Q\?^JK/9LHOMW<^/G"#61(4`:)V5B+CW.EI#>3%27^*,78
M[A7HZ4]82L@EVL[C)84).5<4O)-.#`BAA#Y9AB8XAF*,N(*+)?5GNW6)SF><
M#FW5&IU'(O\`9CAWU=C$?#/$<9(=1;9EP,A^:_MIV)J4Y2)0<5-.B$[$U#`N
M-<N*)W$3M0Q:L\<^N"$^Y.C4_P`Z7G&(CPA<PT"\KD4K:^<E].8.+^+F#;..
MN5R(6JBDV4Y(<!0H**`>R.=YW""SSR%MCAE>P9G&X:XR+RV1@<;G<YY`Y?4V
M"HRB08&7)$)9>-,!)74]LJ#G""]Q?N%R!9<5`"][7$L+?+/MK87PQRRQ#)/0
M%_C4<_WYC?Q.4#H"_P`:CG^_,;^)R@=`7^-1S_?F-_$Y03[6^&#O;E*CZ$^E
M@YIQ_"NBDE2;[KAG>ONLW)O@>=8[;/N?)+]]RW'O.,57PMX0.)/>F7=U0L7'
M[KCW/M+ANV]^#YNQRSG0_G?S:><#)S49B"J.9R*)7D&5UP9.0T4F*H*A_%)0
M(-5%D]@2)`9BYX%RXHG:87O;&_8H,0PUQ9PG/PZ,!%O.+YQ4LX...TB66V?7
M-PY<82,Y8Z7C!<LCNIN+L@ZQ-9%7R!\0V%EAB3,##=R$Q$OA8/*V5PS:C<%!
M9;S6`R_,WYPP3R1%DTB&;K._RLBX&S!0(N+F<1Q%2$"H:VC"XF+6".E;BE1<
ML<\<<[Y896L'2)3X;X]A<DS5"1.<#S@E'*O^16C%#5$*;_KJYW^^GR;&)-E)
M,60H*4?!!4^9`RQR/'.]R`%^QW4;#ML>R'=CO!06(K2*A"<S?G#(QE=#4Q2Q
MPEO\K'44EBE`!#CV6ETK"`J0AB&<1K8E<#0P69K.V6(5L[XY6L'1GCPY1\PY
M$BB*W-S>><&DWK-AIVDH[(`;^KI\@K&6.AX.-R!'5TC!9A#0A"B0)84+$\8+
MY&KVOB#83+'*U@Y/#A;9V4H#0[?FP\X<"?83,"?^)8SO.]2K9-MH16R1+B)L
M@F=>PH^5EHNH8]@=)*J@RL6!RQ'%+8`9XB7#(/0%_C4<_P!^8W\3E!.?9_AF
M]1>Y6FD>]*US0NSW0F#M:J>KAZ[S^'I#8_J&:+&/^#H[<ON7%?4RE/#PGW%=
M![@/X0+EP<.R'W/LWK/SUG:9+Z$[\6_FZ^OK\5-5']ZF?PZ$[\6_FZ^OK\5-
M(_O2?PZ$[\6_FZ^OK\5-(_O2?PZ$[\6_FZ^OK\5-(_O2?QWB/^"@@ZUL5-4>
M77G%!`P(Y&;9DM^00Q>Z6.D2W8OD/$1C#M.T,Y7_`/#V>S:WH_\`9?.\CGV<
M[/?IG/\`3MM+K@.=S\P!,\253/51P_3MM+K@.=S\P!,\25)Z1P_3MM+K@.=S
M\P!,\25)Z1P_3MM+K@.=S\P!,\25)Z1P_3MM+K@.=S\P!,\25)Z1QHCM/PCI
M,6;)\>;42N4[F8<`DNSU(C/$=;MW?+*KSC<$K!KY7#*]%"Z6BA/NSW,L@)UT
MT\:N&9L82C`Y>^%K"=M;)ZV.*(=`7^-1S_?F-_$Y0.@+_&HY_OS&_B<H'0%_
MC4<_WYC?Q.4#H"_QJ.?[\QOXG*!T!?XU'/\`?F-_$Y0.@+_&HY_OS&_B<H'0
M%_C4<_WYC?Q.4#H"_P`:CG^_,;^)R@=`7^-1S_?F-_$Y0.@+_&HY_OS&_B<H
M-!H<X7/5!R$;K13TL?-6A^YS$VIZ[[I+>WM\&RP^_5T2E@3P-([Q]RP;U4(+
M.\!=JA%^]@/!^)PU;MA.Z_PAOST!?XU'/]^8W\3E`Z`O\:CG^_,;^)R@=`7^
M-1S_`'YC?Q.4#H"_QJ.?[\QOXG*!T!?XU'/]^8W\3E`Z`O\`&HY_OS&_B<H'
M0%_C4<_WYC?Q.4#H"_QJ.?[\QOXG*!T!?XU'/]^8W\3E!HCR@<+/N+<=NZ<M
M=+-S7RS[G6N$J._W,YKWO]7<2/KP&UCY[U+R,S/<K2O5.SU?N7<3Q+OD#O@#
M++#M\>SV:#YN?\NOZ?\`^Z>@]OOF,?[.43]^D_\`AMO0>D/:Z%-BGIL9,+O:
M`6S5T)/ECBC.1B*PYFEUI,X)G-[9P_\`Y\QD!LM61$-N!%[:L*YH!5MF2Q&/
M9&<L$RPRK?+L!AQIZQ[)KL^ZKI"IGLK'S*B23N6)JAS$742;S?$=Q!.LE-\S
MK)9/>,Q)DK&E5-<#,(Y@)PIHLIFV\2+A`F_!U@B^.(8#ECC#DID/W8YBZP0^
MX5G5F,=?^--G,K5=UJ0*3%^]##U1=^UZU,FN[JD]5R"?;;=1=/E!$5$54.JQ
M!MN-R#XEEL!91LU,$N%7IL;L@RAN/QA3,A1;(B>RX[.;%+LJ"+B"$54(MM)\
M"K+&::6\"Y(^HE\U,=XF\2!CP8,I%BO8[Z$&Q(WQ-9!3F@4"@4"@EGI1\NSE
MQ]_36K[JD>T%,W$-WLWUP?N1L>X*0HB6`($S2@=&OB4&O8(H1(@F#APR)?T,
M`PL,Q,\KVMC:][T'FB7M$-FF]K)M1!#.BXR?UUG75QN3RU8V#[V!?2#OJ3@X
MO#SOA0-L#F"PB2UG+*C>:TCEU[`W@C`N!*5.[]T**@ARP9+?>ONRCOCA73E&
M/]AUE#9&TG#S(S/:I!YO%$4B#)@QVPIELSZ@DS%ZH8R<F-$FC+ILTGE<BP!H
M^#X0(!#&KES-P_@_&')1:/7*JQ27F!!V?;D5;LH4Y@N^05?U`S*Y'&Y%I4U<
M-0FX7&IJK"P=EB]DP9MJ)(,/!H(H9Q)5A"XHF)<T'^DIZ[/^6U5+>\80=NS&
M;7$U:W9R:"1($P/Y%EMHS&_RNNAU@-4LJMJ85IT,QNK*Y':H934<1=$3\5DN
M<-C!@A'R@AP.U"1WO2Y%E0/N<.>DB<2\ZP<]$AZ(KH=J?%:UI:/`L>I4]1@.
M0;*R7::')GJR)O,L"E"%<%^[M4DE9(CY%@`C*6&,8VB??2,(B:Y92;&TKQL;
MUIXJ3.R3?.2R]G;)+N>D<+JJD;VH<;+SKDH4<I)"BTAB^"O9'4$_!RE,+633
M(YG`(4,.S:XZQ304DE+`5XZVBCJ(4A:W[?Z,B"2M*;23Q'FY))AUXZX+CD2F
MG*%C3B4QT%,6O`X:KB;\'A8Y$!L"^5PRU!UY0:V^Q$IHYE:,=K3+OBMK\=1R
M6W-@]55T6="41F,5'W%:ZQ@)+*`ED',G,P##)U"+)%VF7RF*(0A(8H$0.&!0
MK7QT,!ZQ?J''+'D1L*K.=Z2Y)F.J3>60P@SY,JYIPD=V(0PMBXQ@"^*BW5TH
M9QMCGEEA8;M!+8"XYX8AN]0*"5D">5[Y%_HJ<>GIYMY09(Y7XSD&:N.?;R'H
MH:*Z^Y+D^&W&RF.TVYB6Q55IPK?>Y<D6`.*!DBDI=L?XL[F3A@N6!MCV<\[>
MA:X1PVMU)VYDA!Y&Q(VA>9W:R]@]6M9HU8QJ6E!D')R<4R1M*1)84VW&F1%R
M8BLV&FRR#9\V?S<N*;8ZX;A"$A#0>/9Q#?>$H-W(3]L=ZY7B,4E$;-F=KZ\$
MX[EW<^/;3J[%AX1X<>(;N;R%&$73U"SV)P@B-=P7"1P%M?0SI1>/&3018X5R
MSQR#FX(UKEHSOYNM+LD'9(9[><PNC"^T7>RB1YE1]-2_!4?OY(E,GBTS2H[E
MH@T\W,O@X8IJ@?&'%*BA8`&C]@!3%PQ?,,,[0G)TUYY!66QE99?C.V6R:SO@
MLC'(Z1+H>IKV+*$3.U(6GF>F`I'KJ3F4C&A'VE@71B9G,P/B7[MD;![7,+K8
M96SPQSQME:V>..5K9X9AYVME:U[6R#$QQSPR[%_1ME:U[7]"]J#^J!02D<?E
MN(I_TQIC^\Y$E!O9LRCJ[BURGMMMY*/+CA<L-2:VT!%32HAP\K+J^RUI(1TT
MN`':_P#&=43@8?;9WQ"#MEVPF6&%LLK!(-N:H3VR^-#7R.$)4V@]U<^W-)6;
M*$<E)-<;8<,<)L8)#=:DLMUN+;'7FN<2VD.GAG+J0912'+'L`L<@LQ;7P[(?
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MZ/EAE2TL.!H,IY2AAGVQE&/)A55/Y!GL2V)?+NN`;Z`,69UGCB93<>!R7F;L
M(/$K%:CK=S>;@C^F%%/(RJ0$,6<B81=3:=+^1<,"7_WTDGKQ565T\0SB7-7-
M#VSR#9/3,M)I37IE%I>:^32?0.:U@I)]EM]K!4\6LKG/!J\F%9167')#325X
MAW,T60%Q1/J2&")B2%,"7!ME0:7;J^4.X\/>LWG]@49U6;3JF9:M!0*!09:A
MG_JP?_E.?IJDUFJ5FVV]<UE`H%`H)5;Z_+`XEOI4RE]VZ2Z"JM`H%`H%`H%`
MH%`H)9Z]^5@Y'O>)T4]+9UH*F4"@4"@4"@4"@4$PN:KR2/(S]$"</80J4'QQ
M/Y=?T_\`]T]![??,8_V<HG[])_\`#;>@]_=`H%`H%`H%`H%!+/2CY=G+C[^F
MM7W5(]H*-R&\`H]83T?@Z6=6P68U5YTC(R:*3!4%4)!2S*F(GD1E$P4(!&SF
M):X8>0PH85L\K7RRQMV;T$O"O*^0LVFHJK.LTFHZ])"?H\YHQ;.3RC<[=W,K
M>J46S##$7#"T77+)B`I,.0G23`<!`>^>090Z5,%13%LS(90,@8<C9<;%`,X0
MRM8H[RD.1M>FHO@O!'42?^9^+8^<3N=$<N0N$1*W1&*,[&BJ-)-<]AAKG7"1
MOVZ>63S!10,!CZ'.44])$:ZON0]K9,3B7YFAG4J39:M#3->L@(D1X;<-2RTU
MED)116NK(N;-9(H>1YTF%9523:"@C@G`0E3+$P$"'$$N5)LM:/6^Y2L'3"YF
M>EP4A;"/IU+SVCTRMMF.%F:5:)5&V8=U>QUWN]$-IXARQ0N&"5,%\;!8&[9=
MC/(+&4"@4"@4"@4$K($\KWR+_14X]/3S;R@JG0*!0*!0*!0*"4CC\MQ%/^F-
M,?WG(DH*KC#`EP13!@4,```/,8<<;/$($$$+&^8@HHF=\<`PP\,;WRRO>UK6
MMV;T$;(,Y!'PY-PMGXS=XZ<X8\7('!V)T^;I9,NSU+)L14:66#+C(<:LJ$1/
M"CP77@4++((X0YPF`BF@A@;7#[:U@[.P^3U3%9^I:Q*,*60%C9W-AI]@V\_$
M$[@B+,INI:;+/R1&_ED>7EQK(HR9A=Q*QNZ6$G6&PN7#."YV+XA_H[.2IKJT
M([#O91BB66CEK6X$%ASXW4=WM1#DV,Y,4I.:C53627N**(06<59ON(HX@EA-
M%.(AU`,7#!-9GKYE`PV&;>\"`L[9_P"5-2CY:0UA5O)8+5<GJB;RR(='B<JW
MCSA..AO)(H_J-17&1<@0S>R$/&5-0"`&S-$"&&(>0H;S4"@4$B=U?*'<>'O6
M;S^P*,ZK-IU3,M6@H%`H,M0S_P!6#_\`*<_35)K-4K-MMZYK*!0*!02JWU^6
M!Q+?2IE+[MTET%5:!0*!0*!0*!0*!02SU[\K!R/>\3HIZ6SK05,H%`H%`H%`
MH%`H)A<U7DD>1GZ($X>PA4H/CB?RZ_I__NGH/;[YC'^SE$_?I/\`X;;T'O[H
M%`H%`H%`H%`H)9Z4?+LY<??TUJ^ZI'M!0N66LJ/B+I%9B((0"6'8R'0VTL54
M,&2B:&?6D4ZG%!#YHD34#A8G@.8QN)F$`,)CC:]\<,K]BUPTOA3CFA9G03"D
M:RNF+,BO6,VQJ6"K.\6495S$-/'3PVC.N(#2(J!N5%60F>T9+3,UTHD#]DD9
M,B8]_`F;!X8XASTGP-J5KBF2UM8\&RY$UM,TX_MAWBC(ZP^'`U$=[J4?GV=(
M$HM:,"2D91TUZN!BCF"QL0@6!"$$%&.=SP.CF#8@?CC/CHU,9040KL?HDI(B
M7'D0QW$[?0P)[G`-MNV+8W#.FHA;4L-:\@71)7"BTLMF0$`1Q`J(Z85,"%P\
M^X97#H.6OQLZ<79RHP<HT=6;368H(P@II><Y[`9YFHO3G^;E`JV;J6<I750L
MK/<\,;$/8#XJ0P0ERHAC,I_N*#>BUNQ:UK=GL6M:UNS>^5_0]#T<LKWO>_\`
M];^C0?\`:#C5A91VZE'UUP*J:A(B45%/*BPL'BJ8E)I(#&^8YL^H'10"A,J#
MA;LYB"9XX8V]&]Z#DJ!0*!02L@3RO?(O]%3CT]/-O*"J=`H%`H%`H%`H)2./
MRW$4_P"F-,?WG(DH*;O!IHC[:KB9;D#41F^ZD=00%L%)75ULJ(Z6J%A"9X`H
MX&PI([@2!1BPN6'=R9H`?"U_X<[7]&@PDZ-1X`>3B@EV.%EJ9IPZU(CC;4-J
M120))1Q&VW7>T`&(YD)8"17>GEG\D+;5+!EAR[BP5@L\L,1NU[O:PM!K\!Q:
MZCE`FT`33)E(`M/"/;I`29LC/B5CB:B9QJKEC-3->#9$*9&E1BFELT73!\[W
M$+$A;@8W[2UNP'=W=QTZ?/GPW9QQ<L#8N>-VY$SJP2Y<FIMX.QD-!\AR0V"K
ML#;<BI&#H7D-Y!]]%UL_8PN!X9YE['.]A!`<@YEM:*:]-&;"^P*$G2(6D,F^
MY.D@EB-,DKG6<1=DQI24DR2=),`X\!V85*NK!$+#F"V!*Q>YH.PML+94&X5`
MH%!(G=7RAW'A[UF\_L"C.JS:=4S+5H*!0*#+4,_]6#_\IS]-4FLU2LVVWKFL
MH%`H%!*K?7Y8'$M]*F4ONW27055H%`H%`H%`H%`H%!+/7ORL'(][Q.BGI;.M
M!4R@4"@4"@4"@4"@F%S5>21Y&?H@3A["%2@^.)_+K^G_`/NGH/;[YC'^SE$_
M?I/_`(;;T'O[H%`H%`H%`H%`H)9Z4?+LY<??TUJ^ZI'M!2%]DSB@R'B03B1]
M24#K77RA%/2CP*6IGCAE*-`EBB<I&5%'+IYTP/GCB$/F;+8!9WME<4.UNVL'
MGC1],MIT&$])(L>#&VZ`536IL/I,J.>`9YU[R?,-;RM!N1(`^I-E!^36J20+
MB`X_4-8L4=S(R7S!`L14"7>8P"Z(&9#%3*@">]A==9M7X7:,M+[G4!>:2#WF
M><\IE1FW.Z$M[;[21_KI%+3+2)*PR21$CYV$R)A..JF"0"WTU(/%^[AX*F%C
MP9]F^(-_5O99.=<&PY*$<*24I/-E%I,]T>/SK066:]..1_M*/UMVGQ9>S6R3
M*CC<$TDV'9J4WC!!+4TO-R8#*Q@^3L3#_=VPM.CRB.+\DS3_`'-B*.WJJ&$K
M8J#F'.VN+AF<A*JG$5F*!-*`ERG*,DPOFQ$%UD<11E5.5R;G4'(;Q>&:?WZ3
ML=-!RROIMM(I24375-G[`.?)(V)T0+%'ZN;-MP=:4X):T2)K(VP6UHP@RNQ@
M#UG';$Z7<H)1O)!ERG38I@@D]P%MB$&.&AJSND"F1+&TGL7<-/0T%0E*\+K\
M+3IK$`+`BJU-RY\?<8Y2L\9$6Y)<Z4SWGK4XF*DE#S4P7%,HAHI]!/D[7,X%
MS`8M?^ANYZU!KJ;1V$I;<`[WT\VF1I$:JS/+)=9QT37CO7'\K:S-XQBJSRNE
MSKA2X*).+%*.!&LDI,`4<B!DX"*-F%8/40BXAX(Z3@$G&D@+!,(8AI)[,`4Z
MEAXE0K8)QP4J<4"PAHEC;N8F09@<.^>-[XB9V[&5PY.@4"@E9`GE>^1?Z*G'
MIZ>;>4%4Z!0*!0*!0*!02D<?EN(I_P!,:8_O.1)05;H%`H%`H%`H%!(G=7RA
MW'A[UF\_L"C.JS:=4S+5H*!0*#+4,_\`5@__`"G/TU2:S5*S;;>N:R@4"@4$
MJM]?E@<2WTJ92^[=)=!56@4"@4"@4"@4"@4$L]>_*P<CWO$Z*>ELZT%3*!0*
M!0*!0*!0*"87-5Y)'D9^B!.'L(5*#XXG\NOZ?_[IZ#UO>9Y[+*.N]N1'O#6G
M9_8CU87U)[K_`);V"UGSZC_4_;9KN?JS]4K^8_@OU0>&\O!W<.^N[]Y&>W[G
MW/'N@>UOI+7%U:?)_P#`%%OC\H'26N+JT^3_`.`*+?'Y0.DM<75I\G_P!1;X
M_*!TEKBZM/D_^`*+?'Y0.DM<75I\G_P!1;X_*!TEKBZM/D_^`*+?'Y0.DM<7
M5I\G_P``46^/R@=):XNK3Y/_`(`HM\?E`Z2UQ=6GR?\`P!1;X_*"=&I6_2ZW
M]QN3AR!Z"<A3@$>TQP"H#-QNPQ')US,G)*UN9"-@GOE/,S02+)*BK8%._2F!
M<<W@(2%#SRRPRRN'8*+]):XNK3Y/_@"BWQ^4'_+\E;ARM?'+C2Y/LL<K7MEC
M>`8LO:]KV[%[7M>?.Q>U[4'`-KD!`9B;=&9_%=R/M1'N<.*%TIM:TPXA)MSZ
MB/D:4#UR*7.94K<X>,YY"#"]IVXHE[Y97O>_9H.P=):XNK3Y/_@"BWQ^4#I+
M7%U:?)_\`46^/R@=):XNK3Y/_@"BWQ^4#I+7%U:?)_\``%%OC\H'26N+JT^3
M_P"`*+?'Y0.DM<75I\G_`,`46^/R@=):XNK3Y/\`X`HM\?E`Z2UQ=6GR?_`%
M%OC\H'26N+JT^3_X`HM\?E!..&-^5U,Y0-['QCH-R$*8SHUMT<1Q6.EPQ'1A
M]M;!M*^SHH2PZT@6:`""<C.;P[?%+%!-F1!\R)JPF`/<\>Z!1SI+7%U:?)_\
M`46^/R@=):XNK3Y/_@"BWQ^4#I+7%U:?)_\``%%OC\H'26N+JT^3_P"`*+?'
MY0.DM<75I\G_`,`46^/R@=):XNK3Y/\`X`HM\?E`Z2UQ=6GR?_`%%OC\H'26
MN+JT^3_X`HM\?E!-U?WV71>7*-)"OH1R#!#E>/656GC'PL-1UC(QL$[L-&JK
MD[2B'C,^2=FT".:?8H.9R.X#X&S`.%@<L<[YXA2+I+7%U:?)_P#`%%OC\H'2
M6N+JT^3_`.`*+?'Y0.DM<75I\G_P!1;X_*!TEKBZM/D_^`*+?'Y0.DM<75I\
MG_P!1;X_*!TEKBZM/D_^`*+?'Y0.DM<75I\G_P``46^/R@=):XNK3Y/_`(`H
MM\?E!,7;3?5<7]X]&G1GH5R"(`K8CG<,F$UW##4=DG6Y[.)F,`J(<:R<7F8X
M44";=L3L*I9"F"^0`0P=\,1;Y7M:LVS5,J=((O=7WR*?`I&WCLJY0=((O=7W
MR*?`I&WCLI(=((O=7WR*?`I&WCLI(=((O=7WR*?`I&WCLI(R9%/(BOD'*(-C
MQW<D)^^:?D#W%/@^,QA\>R=(C]USP$G$''$&UB_:=MV?^)GAC_\`NJ==^&\M
MLUTEKBZM/D_^`*+?'Y4+.DM<75I\G_P!1;X_*!TEKBZM/D_^`*+?'Y0.DM<7
M5I\G_P``46^/R@=):XNK3Y/_`(`HM\?E!.+<[?A=<NT/&:NB:#<A#:S9FR,B
MJX*$YX9CE/7WIF;@1^I620R"16:#X"JL$\#O?8P9@8H'B4!$SL)EEC;"X4=Z
M2UQ=6GR?_`%%OC\H'26N+JT^3_X`HM\?E`Z2UQ=6GR?_``!1;X_*!TEKBZM/
MD_\`@"BWQ^4#I+7%U:?)_P#`%%OC\H'26N+JT^3_`.`*+?'Y0.DM<75I\G_P
M!1;X_*!TEKBZM/D_^`*+?'Y0.DM<75I\G_P!1;X_*!TEKBZM/D_^`*+?'Y03
MHA#?I=2N2G?%Z8Z"\A2H,ZH:TW3Q66DPQ'1E[M7%O)\Q8AJ+M2A9H+D4U.<7
MA*]TW,$V9S'L6&[?$+M<>V"B_26N+JT^3_X`HM\?E`Z2UQ=6GR?_``!1;X_*
M!TEKBZM/D_\`@"BWQ^4#I+7%U:?)_P#`%%OC\H'26N+JT^3_`.`*+?'Y0.DM
M<75I\G_P!1;X_*!TEKBZM/D_^`*+?'Y0.DM<75I\G_P!1;X_*!TEKBZM/D_^
M`*+?'Y03TY:-_EU_\96]K)'T!Y#6`"Z=7I?0Q7M(<+1RB,9K8*#042^2X[%=
M.FE:/)R"GVS[H9&!*&1,`[7OB'E?T*#Y:/\`+K^G_P#NGH/;[YC'^SE$_?I/
M_AMO0>_N@4"@4"@4"@4"@EGI1\NSEQ]_36K[JD>T%+G41)J;8<2<H%PS9$\A
MJI0X5%MV0S!8P1'"&"S['8OVN8>5[>AZ-O\`LH/*>6F_8&,N.[;71)8EN6#\
MOL'5C/::)-@%=QN0Y(I_2^4(84I64U'*2S2R*YS[T8LS)"[&`2@$HX+2*45V
MZH6MGC;+*@W,%VDF9BQZGH4/!Q6P7"W=C^("'G*]5)@*CK69$96UZW"S5?EW
M7CZMD'OAR%PW\/8-1Q$[J(5[MA;$(T-@>`#M2]RU2`Q(H2=C''&K+=T.2-&F
MXST:"0T_5(B/"*%K4UQ.)&Q3)E5CRBYRQ]OO`JTSUEE4*)"0&SERP*3?!7N-
MB>H.`V-E[9./-G6O)*4XM9'5),5Z?[O.TNN-D@_S<>O&/6@<U2?S1)NUD`/#
MPVTG^M763I*Q7!TK1)+33A5;"%-]^9)&(9:%Y*Y3<!52D1E1^S@HZ1-GX=U)
M<3`6TMR'I6;[HF^'HFD%MS((KEW,BIBHQ6ZO38EXGT,-$!&%;B8=5L%@*V?>
MY4.C1%RB3<[6/'BB^VG#R,Y9YB'C"D&-U%$3'IBTXZ6^0M84F@J)#]!5'?D:
M?A2.5M.P/)MRAQL"+O?>*5>Y48/%1,!T;4Z==A6NZ%Z!T8W#*A@[)9Y!Y2D=
MQN-G/E6)738/E>*T(XVV*VR4DI5T8%W)3]'QP"/'SV".8QM>^1[`/+`8.^HO
M(R^TEGZ5`MIAPG9G2RWM`6S)\9-,)PAK\7$]VWR/%386`CIM=3D-B-%NCD<\
MF\FXDG8INCO4U@)BD$R8ZCB&YG%H8,&='(ES-#C&!`G-/!,/,<7,7,,H0V'E
M<B1*X9"9998%R1(N&"%A;^$,(/'#&UL<;6L%!J!02L@3RO?(O]%3CT]/-O*#
ML7,BKK;;XO=V70UU530'8UX)=:\U'"AJQ]OKJ`X4_$N(F*R*X4G,)705$L/?
M^`V5RQ'!M>]\>S?T+A$3=.594C%"Y2H3,+#@CIPH.H.IL_0\R(XFV0)'8;"R
M,R\"P'._$J4%Y,9CVAR1)!.K(!,VWTU#`(&4TGFHX'#PUQ0@@I%`VQ+P@3<K
MD.BAZ,:6G@`S&=JQ*D?:Z:]+SEV9;S0;3['>3/<#D9RF\\&"X6NZ'DN8@'5E
MH!(R<CI"<DX*!$PH7-&[@ATEKK-]@I1Y>%S:-=>+2-ZZ78V.O"<MN9<CQ2UY
MAQ7U[(26TIA86*0I)F3$DAQ/\5:!/N(L-X4$S0\D[(QWH'F7$#"+!(O^5"W!
MF\9_,/\`)R?M\<E=8V<)V?+\:^,C9AZ4OQ8;AI8;B,OI":W0!Q&^F.`%-(%B
M!1-6!,S`!<`:^5!MIJ,RT?826N1ML["JCI\/:^3REP'#:*HO]XDW#!.O+<B5
MEJL92$P7$(X;*K<=$EF3RHH*+M*C!*:[D3N7/&3&!80.@M$WBP))`0R9=4%6
MRY1'3"P"T.*5''5P0"0`02H,,1"`)#"G\,+"Y9`X8!97S[.&-L>Q:@YB@E(X
M_+<13_IC3']YR)*#:+?J0)=BG2C::28$(&E*9&/!TAN6.RY%.P6#P3D2FZ=-
M%%`BDB!CAJ1Y)PPR-`@9!BXBB`XXW#$M?M,@DLX"5F@%P[*6NSP=[D<FW2LC
M,S9)1(OUSJR_L-!CF@M2><R2=)"B*IC*JT[F,MYESQ5Q=N`K-SOCO,H8*E;8
M%<0Z4HAO>*B'-?($(`/IP2?J8>0UC6A#$?+_`'&79APMK@$HF"Z:WU)RG22Z
MF`F#0RJ.FG`C190.@8B#A"B?M"ING\,PYC%VI$V-9[+JJ\%F&DI?5'E:0E=5
M.;#+D@L-$/N5X2F.HJITS*#B)',A#1$P=R,#(F.>1<KWN5PQ`Q#1/:;:5XOZ
M4HS>:<"UDJ/-6^15;B9798:>O!2VY%>+H-?3S5%>[FP7K(Q!J/G'/`,FG>`Q
MLARF&)BYH3T`K!U*;=E]H-BF5K.DN9OQ?'\33UMQIJ5203Q!J/XE-&O\\LR0
MU%WQU(T=-&?WQAD@(3A0@BHBD:/$R[DMC:X:>G"EL\,POC'K$;T8LAKQ\TBY
MLHVF@CE$-#)GEIPN$<FG$L.YEBEE=UK"^X#)8KA_NP<3)PQD"#CB'CEVF&-K
M!W*@D3NKY0[CP]ZS>?V!1G59M.J9EJT%`H%!EJ&?^K!_^4Y^FJ36:I6;;;US
M64"@4"@E5OK\L#B6^E3*7W;I+H*JT"@4"@4"@4"@4"@EGKWY6#D>]XG13TMG
M6@J90*!0*!0*!0*!03"YJO)(\C/T0)P]A"I0?'$_EU_3_P#W3T'M]\QC_9RB
M?OTG_P`-MZ#W]T"@4"@4"@4"@4$L]*/EV<N/OZ:U?=4CV@IBY!6X`WEP9X"(
M@+4"25#-R"N3,B&W@T+$J+=5S7,U2]DW!)Q)=OWQ<Q?N-@NV[?\`A[-!K1F[
M-%ER.%1#$<VIJQ$:&51H?6D?-9A]0CA'(N()/6F]%RHGY&1FRGE5T#O4V21!
M<,,#6'<A0@<K=IE0<$;3^/0XWW@U329IPHMI193-F=]M3P="JBDJL?,`BENB
M.Y2<[=P`'+*329R?@24$-9,@B%"`7<!B@V%NYY4'_([<V@SV2D:48WRU8-Y[
MBM,XYDQ>)$(Q1G%L4W'*B%EU:R5L1B95Q2#@;2"P8BL7-AFQ0L0+V-!VN%?'
M$.IL1M<>#*9<;,W%B:%Q<45T1593!CEG8P2$TQ$26EHPDJ;.CLJ60&J56$64
M%1,[B:)$$X(%8.`Y`YA#YA4&S5M>-?[.(-WV@R';.P)K$V.$Z+1DRK.(-E)Z
M,IMP@SPUOP)X2P:Q%O+9T@"GV%L4")FQ@,0[!"YXY!QRAK!K2K-Y9:*IKQ!B
MDU'$R4*-7`V%")6"<;R['+7,7-MI@+**8;XB:ILENF\KBD4H<+,@4$OVP06%
M_1H/]FIK1KBPQ@3#&U_A)F&"Y=S$RX[4BEB-T8`H]`B(#Q*@BI""3S"+NP!,
M+8*>&-[8G\"X5A[9V#Q[`=?5-/-1UP9OF%K5K7)8':2$@-9JCJD(QFH#-ELM
M1P8.UKMQOB&VP-FC(3;=0>*F0)EKAER:AC8P#A@-:V=!FEI,UH,!`)-1B-5M
MLIKIN9P1.;;20TQMH!`11/&5-0S)(Z,5)IQ7,\I'!C`UPP\;BCBYB9=G++*]
MP[)0*"5D">5[Y%_HJ<>GIYMY04E?,?L.3VRHLJ2V2T9#9JQAA@K-)\MM&=K9
M5,`L\10\%%!7R2@E'<`Q,;98V%"RM;*UKV]&@QQAJ[K,&T5Z/P]=H*P8;J4"
M2LYV3A$;`Q:+C54T,,).4UYMXM^R,L*!`('#$$8P"((%CC:V-[6M:@[PP8JB
M^*2BFGQ=&[!C8@M'[*JR28+/;S.**RI8`,K924RS>3DX$^?L6!P#[L+CF)W/
M&V/9[%K6H.%?4#P=*"VF.62X9BB1'&B%;$49??4=M!VK:01L=!4K$TQ57T=0
M/$"ME$L&8[F$)AAW</'/L=MC:]@["XHTCAWN%K.UV1^R70ZV,:,GF2YG$U$)
M:<+..G`,BQLVUEI2(&5)O&C1;.X8@A00'//"]\<KWMZ%!P:_!T*.I\$9-=$/
MQ:Y))3$L-#39!7X_::P^$]$"-]_A(Y%V**287BB6&>MW;$N&8Q!L+_';'MO1
MH,I4"@E(X_+<13_IC3']YR)*"K=!BAD0-!L9KRLZHWAF*(^<Z]B;P7'(R([:
M#47EG$^>R5#V*LL(*.04%'$ZIYW,#6&$SL(/>XF79SOV:#L#:C*-V6N.MSLZ
M/F0TW*^SH"D^'"VFH@H2X\E$L'D"6/NM62R!4^XCI<+*^.`IP0;/#&][6O:U
M!PT?PA"T3#JYJ*XAB^,S3@/G55?,Q^P&HS!UQ441\C2@I*XS<24T12/GS6=Q
M!AAKYB"B7OEE>]_1H."5]:-<7!).,RKVO\)+<OX&$(WA*RO%+$4I)P-M<$<N
MVC6+Y.((SHQ,-TN:$P(YV-=L4P$RQ"OA;*]KAQK8U/U99"9FB,S6J`&BC"2%
ME+F:0V(;CI`3,Y7SQ$QRD[,@E-PH4RD++$;.UUJ^'A*]LK_[[T;T&?Z!02)W
M5\H=QX>]9O/[`HSJLVG5,RU:"@4"@RU#/_5@_P#RG/TU2:S5*S;;>N:R@4"@
M4$JM]?E@<2WTJ92^[=)=!56@4"@4"@4"@4"@4$L]>_*P<CWO$Z*>ELZT%3*!
M0*!0*!0*!0*"87-5Y)'D9^B!.'L(5*#XXG\NOZ?_`.Z>@]OOF,?[.43]^D_^
M&V]![^Z!0*!0*!0*!0*"6>E'R[.7'W]-:ONJ1[0;T[#VRR@2:L<0Q!<\HK?V
M&`0(0A@47/-KJF.`08`.`@PV8F5[6MACC?+*]^Q:U[T$1H0X_)DE;7K5:0SB
M-$D9.8E%W$*36(_P7G?@346;H]-;+V/=(L@`&HD0U`K)YNR8.WDA$%)"%VZ,
M=4K#GQ^[WP##:%%X_I>`D-)+K3DC8U'D?;<33M9'4F)ZVYB<S&P)?B)[QY:'
MG,U<&2&VB;?;_JWS11%7!P*-SS*(ETW!.*"X!&`0P1"G&9L6R4S69H2<E:_2
M&V(WUPT@C%U*`6P^S2+>+)5T6**A)EOZ-([;K$:[&FPD[CN95:(W<F37,,]9
MR&O?!?`[`8@?E,\6>PIN'7*Q!E2`_58J:7I.M*2O9.I[B@I;H`V159E/K(9[
M*),%$NV\40X!8/N0=C`JF6QQR!##MB8Q"_>/;7QQ[:UK9=BW;6QROEC;+L>C
M;'*^.%\K6O\`LOV+=G_NH/\`M`H%`H%`H)60)Y7OD7^BIQZ>GFWE!5.@4"@4
M"@4"@4$I''Y;B*?],:8_O.1)05;H%`H%`H%`H%!(G=7RAW'A[UF\_L"C.JS:
M=4S+5H*!0*#+4,_]6#_\IS]-4FLU2LVVWKFLH%`H%!*K?7Y8'$M]*F4ONW27
M055H%`H%`H%`H%`H%!+/7ORL'(][Q.BGI;.M!4R@4"@4"@4"@4"@F%S5>21Y
M&?H@3A["%2@^.)_+K^G_`/NGH/;[YC'^SE$_?I/_`(;;T'O[H%`H%`H%`H%`
MH)9Z4?+LY<??TUJ^ZI'M!2QVGU!+:KE4TG,F$JIJ`L'TT11*CGD_`\33S!@I
MD>)%CR89-E+#AX]T##,@9YX=FUA,+W[:P0I:O)5MFL0KK(Y\DC7%4EJ?-/(E
MW<LCJB%C#T:YL5\H<0J#NC%'<$B;5F'6(H,(RYU2Z@[4U+<>!+!90PQF[VV(
M@B@&*MBMQ=CI=U*GA)D9*A5<C66XLY:8N#3H^8SZ;C[CA:TDE:>8T:<G.15<
M,FOM$5F8_4&,2)`X4Q34T=(=:J3R"/&0C.!0$,\R]R;2%KW+**RR"%&,F12A
MWDZ.U=O-0HKVE%%?,/<>[DW1P;2FX5!]D\AWPXPT)-)8(J>R3Z0"D+I,U=Q7
M4L[H]@[8[>0.;$5O1LD,U[ZIRN]9\233PAE^LE,Q3HLLC"0EE(J$RG:2D3:%
MB%3SO7E9.4%`J8274.9,-0B8-V1\!"V7=`X50WZVX//A-*(Q'6I`;(\UZ4PN
MIHP[3D*1%(N>W`BY)73J^C2&CRZRD%PI46/98P%+98(@(;K1PNYXB)(HN)O$
M.I,SE`V0>K;;:8EM&",)2:X;W4Y+#<1A.84?R0VHPW(G[5I]+<8BO'81.?K)
MNGIL%A*XH19(DCP<?<Z>GF<_X@C!H,+2ER8[H#0>]#Y59@1D.%TZK[*S<R7:
MV8P?-CL?*.M^[<=ZOJI10+N6959.<MWTSI#"5"HW<D_%`4RF>`@:H")C8,/2
M4GXG<"!'!3-$SJCB3+8J!Q/)C)Q`V=Q!PL;-$4\P?51R!,<>V680.9HSF%A>
MV-Q1+VOG</V4"@4$K($\KWR+_14X]/3S;R@JG0*!0*!0*!0*"4CC\MQ%/^F-
M,?WG(DH*MT"@4"@4"@4"@D3NKY0[CP]ZS>?V!1G59M.J9EJT%`H%!EJ&?^K!
M_P#E.?IJDUFJ5FVV]<UE`H%`H)5;Z_+`XEOI4RE]VZ2Z"JM`H%`H%`H%`H%`
MH)9Z]^5@Y'O>)T4]+9UH*F4"@4"@4"@4"@4$PN:KR2/(S]$"</80J4'QQ/Y=
M?T__`-T]![??,8_V<HG[])_\-MZ#W]T"@4"@4"@4"@4$L]*/EV<N/OZ:U?=4
MCV@J"?($54B;3%0D44DU0+#$SZ>?+`G")XF9#R!,%#90Q@(`9+&`L[XYAYXY
M8YXWO:]KVO08[/PG#2IC'^*C$L9'[1*H@K$4]^L)J&_<Q6"X?<BRM'MC*2+B
MS%,N'_"&.G6+B8V]"U^Q088U_P!)H$UY8+S8"&UD]]`2,]IB?$@N>2&I'"J[
M7T:FV7WQ-CJ07>HMUCM4@Y&NFN]_G@DPH<*C7*D,00<\Q<@^Z9!E_P!P>#K.
M<L]K0S%%GF2';YHF[O<[:'JG*&6DB*;9:I@LO^!_"H`[9;:T<3T_/$6V1(B;
M&`!O@$+GAD'#VUEUMQ8X$8XZ^0A:-2SFQ>I:/;1.P[,<N\<#>"A@[0&G9`\`
MA.;`_AB/8_B7L:L-:V?;]M;LT';CD214HJAI<4(RCX^M'EY*=1U8.,QN&E0X
MZ$(L(21'(:4!TW,V87D8F+D$4.9YW,%PLKXAYXXWO:@XB\"P9D?9RKE#$3Y*
M<=JRPOQ^I7CIGW/L5=<.>(J^M,XY='[X;"LN"8VR.&260`QG*UKB997H/X%@
M&"!DL5#&A2)!40=NJS0&1Q8X9PB6,TU\SF<76N*GY(UR@C=6C@N0ILE?"Y8R
M)E?(3#+*][T&4RA0HGE"I`@5+DB)(N"4)DR@(98H4*%@\02Y4J7!QP!+ERX.
M%L,,,+6QPQM:UK6M:@_10*!02L@3RO?(O]%3CT]/-O*"J=`H%`H%`H%`H)2.
M/RW$4_Z8TQ_><B2@JW0*!0*!0*!0*"1.ZOE#N/#WK-Y_8%&=5FTZIF6K04"@
M4&6H9_ZL'_Y3GZ:I-9JE9MMO7-90*!0*"56^ORP.);Z5,I?=NDN@JK0*!0*!
M0*!0*!0*"6>O?E8.1[WB=%/2V=:"IE`H%`H%`H%`H%!,+FJ\DCR,_1`G#V$*
ME!\<3^77]/\`_=/0>G[S4KCR8F^EM\_5ML%M_!/N57U=\&?Y4I^68-]5/JY_
MS$]^>KWP2E*?JH\!^H\+P7W3M.\N_#?:]GOC+L!Z;GYQ0\=L6/53CN3N7/D]
MCMXHJ6U%U91WSR+NMJ724!]K:DV&2X5,^NM0@ED&^[G.C'$Q,/"CX%#RD3'*
M@B9F`1`\0V._3R03U@G+]]?MX^U6@_@7S>B!@0Q!<^03F`[0+#,3/M-^'H)E
MVN&-\LNU##:>8@F78MZ&.-KY7OZ%K=F@Z-''!EJ=+C%1)+CODEY=G(QW$">,
M([@"WRD!/+G`4U1.I)_.Y9792>?+=ZJ*<,%G84(.]KAWO^SL7N'^+&X.=2Y)
M59,0V7R1<ORNKPY(.<5R6FB;SR4E&VH_<&6RY%P03@*RQ4[,S<TQ9$0U4N9+
M=V)F22F"($+G;*_8#(7Z>2">L$Y?OK]O'VJT#]/)!/6"<OWU^WC[5:#'DA\'
M6I<4A,\=_P#)%R_-\!^O]I1<U1\]YY*40%%]OI2P1FD@C#)#$/A)62XKBX%@
MC!RY<I8<3##(7'+/"V09#_3R03U@G+]]?MX^U6@T(U>X/H=?.V'(M'YW=OE!
M1"$/RS!R$EKK7W3=2*ZW@$YM?F>[3"A(RX$W117<KI9E3S*$3`N&&19/##`M
M:]L>S<-Z5/S?77](3CRJ>Y!N83$DFE#!XWD7WP?A\?$L5"S''R!)$&>9.FA,
M0\+WL&$'F)G?T,<;W]"@P7$/$EQ[3ZH`(\-<N7)M(RR;:0;_`"*,V>2)P'5A
M380RI9#P?*2DW;0:@K,RZY>Q*ZJ6#%(8G,K`W%L+>V-PV"_3R03U@G+]]?MX
M^U6@Q^_N#?4R+K,_)^<DG+TWL'\^FS&C3%'WLD4V`J/AXG;)K80,ATYCG`4X
M9:4<L0`1360!>XV>.%Q+99XVN'(O[@@U>C!F.>07QR,<OZ*T6<AJ3C<:IAO7
M(BMFGHJ.4%/*1W%,162HJYZQ0F#F)D&7`&%OCC>]L;]B@YE`X`=<W0A(KE0>
M1'EZ4D-Q)*<NHJ@%OP]@PCZ2K$P3Z<=#P':00V`9HF8PSM;/''*ULO1M:_H4
M'+?IY()ZP3E^^OV\?:K0/T\D$]8)R_?7[>/M5H,>I'!SJ6O20\HB2^2/E],2
M+'Z`U'2[6UGO1))09+;SX&7"[55L#YQBETE3**QAM'P\;E#`]PQ"N>(EL,NQ
M:X9"_3R03U@G+]]?MX^U6@PPJ\-.DZ'+K<@E4Y-^7@K*3LMGB@MR^\<I"E3A
MO%`7G6&D"N8"/A6FGN$VV&LI*)9-,G@5`T2(&!@0<PPL\K!F?]/)!/6"<OWU
M^WC[5:#0.).$&'G%R.;I0X8W:Y0""3&VOFFKJ3WBD[INLC([D,2&J;%ECJ0]
M7?BW<S+C;S<P90-T4H('A@G9&S=\+W[O?M0V\E'@XU&A1BN&3I7Y,.6AAQXT
MB62DZGFX-_WJ5;S:2\,L<!55?4\6B(72$DOEG;NIHQ<,N%:]KYYXVH,4*/%9
MQRI#/?#^5.7;D^3VE&(R&#)BN<Y$W>7QCB[HMVS9&?Y(5HXJ++)N+'T2`ZF"
M5!.6]$'/.U!D^/N$33B5A'*7CKD_Y67:?9:H$AO1'2>0UU"KS-6C!:QPLDNY
MOB-<);;"D:)WL,$`>+EQ10;VSQQOA?LT&2/T\D$]8)R_?7[>/M5H,?NK@[T]
M8[@;34>'*!RIMIRO$QB6:Z"L\BSB(*JX*(:!(A]X$1VY@.*$*H&0BV`G:V#R
M,BAA6O<3/#&X?M2."K4MP/%VQXA<F_*NLOM@ED$X^&>F<BKA/.-H%72`:,ML
M9R)!9NB'D7!>+$1A"G?&`??`8666'9M:]Z#N?Z>2">L$Y?OK]O'VJT#]/)!/
M6"<OWU^WC[5:"?RWPB1`7Y28[@FV[/)\*BJ>B,F2?D^!]TG6+*1(^CSO'[8#
M:J:];M[OHDPSH"Z(;-)>(7<ASX00]\NVP[%PWQ5O-^M=$!*4UU<Y%N7!&145
M/.*RPKJG(,ZB"8E):<7$.*"BHGC39"+$B)$H#F*,*)EB&&'C?+*]K6O>@UF-
M\87&TF--POI<Y<^4YL-%H>HX1VKKOW\D5GDVH1D4Q@7CQ:<WJG8B2,@-N0,A
M<,T)3-X@IZP!GB,3&&"RMG<,M/\`X3M,(M]0>,@\HO*LU1Y2=J6PXT)*?(<Z
MK*4@O1:+#G4IKLI,`:PR@YUP\2*BCX%R00PEP`LQ+VMACEE8.P]!'JEZN\8O
MZ2_E?M(V;1R?V+&OR'.:SJR9."Q@WLW79#NVK*'@#!=$Q)W-=S[E8SE8.^7;
M7[%!V[]/)!/6"<OWU^WC[5:!^GD@GK!.7[Z_;Q]JM`_3R03U@G+]]?MX^U6@
M?IY()ZP3E^^OV\?:K03HV@X2(?9&Y6F<;D]U>3E;3Y&8&UJJ?<3HW-="V\FX
M(PFDQU(D49CA&;H8S=3UT55S#5@@\,K'@@@L<NU[3LWK-L[3)706PS\^+E,^
MNRZO:W5PB?PZ"V&?GQ<IGUV75[6Z03^'06PS\^+E,^NRZO:W2"?PZ"V&?GQ<
MIGUV75[6Z03^/TE>#F)"0MAB>]G*H4&QOV<12N\#O`%QOVN6/9L($W<,K7[7
M.]OV_LO>LCC9<AT*$==8!RR_7M?'_P""IYX>NG0H1UU@'++]>U\?_@J>>'KK
M.<?<!D-.=-L:4N0'ETQ%N4`,=DMOL]`L;9B*:X1RQMCFVQ?X.Y)@=_\`O[:^
M7H]B]K6CO(ZKG99!_3R03U@G+]]?MX^U6L:?IY()ZP3E^^OV\?:K0:!;;\(4
M/Q[L?QW,LANUR@+Y.7=@7\UE-8=NZ;K77(T"Z7"3U<P:O'2N*W@1&BX39A(P
M+&#86.>8I$00&]NQEV;!O[^GD@GK!.7[Z_;Q]JM`_3R03U@G+]]?MX^U6@?I
MY()ZP3E^^OV\?:K0/T\D$]8)R_?7[>/M5H'Z>2">L$Y?OK]O'VJT#]/)!/6"
M<OWU^WC[5:!^GD@GK!.7[Z_;Q]JM`_3R03U@G+]]?MX^U6@?IY()ZP3E^^OV
M\?:K0/T\D$]8)R_?7[>/M5H-"(=X/H=<O(1NM$9G=KE!3TN,XEU-74YVH^Z;
MJ(2$Y!7X0E;,XGO5V8MW,RXTA`]3P=DDOF'AB0Q''MC>_=;]@-]_T\D$]8)R
M_?7[>/M5H'Z>2">L$Y?OK]O'VJT#]/)!/6"<OWU^WC[5:!^GD@GK!.7[Z_;Q
M]JM`_3R03U@G+]]?MX^U6@?IY()ZP3E^^OV\?:K0/T\D$]8)R_?7[>/M5H'Z
M>2">L$Y?OK]O'VJT#]/)!/6"<OWU^WC[5:#1'E`X.(;@[CMW3F%&W<Y0WLJQ
MKKA*CR3VC*&ZCI>D=N0V@M8^?!1WJTC3<+%G&VSV85@S9/,3#$<*]\;WMV:#
MYN?\NOZ?_P"Z>@]OOF,?[.43]^D_^&V]!;#DEUIV,G3;';Q3C&/9`?<4+.A.
MFC%DV),FDJ-IG[D,:-=E-PW[L#JXS9L.(!>[#E15C.0$H1&4DM6*AB'%+`D.
M)C8<0TGAFEQ2KLF[YZ=*\T".Z4=M5FEDF28"B9FZER\E$)0UX.:L(R.[8M<S
MSD1TM_5J-I;:T^"+YPDD.]"#?F!]+2;)>:BC';ELPQ%#LH;5EL`V])"'O<KZ
MX*&T,2&7@JA11N4#,J'"KZT6+'$\@FKBNT4O9U>;J;N>0+@/,ZW2Z<823F(V
M9A)1&P='*X``B+=93X7INA]'9:FG)8FB^UR,QF.$DSRQ-V%"<<2LL'F$F8H1
M0!M"&/5,X>\+AD\`;"+0)JP601@L9N&('=HZ9LR-+:>0)2C]%V[0([E#DS;1
MD\GJS=V"*(+OU>7N(B!(W-OU^MMU(]ET\*7G^,B*===<&%UU"6D7$+$4E<<]
M@;#J;/3-Q$B$H-+R(L[Y%E&1](I%=YMX-SW?'C*#.Y!R0<;(312I#990F:/-
M-LIK913QI!2%\J3C)34<E45?"-'3B<*(&4P)+W>;4KI#0DU,GLHY/\T>HSU>
MBZS6))*]K\APNX=3&LE;$8ILE`(IB-,H[2]CD5?[Y1Q5&Y]*N,6/"%2Q(<$U
M0:KIQR>IT2=86X_GOM&YWH<<?'@YG:P#4([7MHQFNQ-L*@K&T.UA5V23"#/:
M#,P7T=Q-SOU&9ZPLMMJ6L-9).YE\@SYL+:<?0LLVUI)I<U928*\FS->U;21S
M<OEG.'("C$+8VEF1&UY5%U1>1<!RN7)2U^*-@8)6.Y#G%('/$<R,(9S&RN&"
M=*/EV<N/OZ:U?=4CV@I8[1>XM5RB]P-F;AH"QG8NGD3JF>'OBGF+V!)IR<`:
M4#YH6_\`"&"`&(*)E>V..-\KVM0>7;0F#-KM?2FK+YD>%)1D%TAZ(23"6K3@
M<,8.%!4]+)R5'"9=<@13-3'1D!$.W84\X-QMBI#Z5RXF*..B"I9DR7!4+&1@
MRG=V;9*D.DSQ-S\B:N-)SG;P.9,WK/M/$YZ&9<0]:)D`=Z,[TL=V/38YU,-=
ME$DV#&!QMJ;8B/%UX$KD5@RBF5I/&#\0"]LY-RAK:=GF-]R1Y5:^SG&Q)3;+
MWAK8%(B*T)EXXAE0F-U2,C(C)3XG;4FMG8@P^AG*47`"3B1R15*&#!+IML:#
M-&[L;;7N]1B-5F=IN)X._*&=VVF$1T_*;,.>'"KB<,'E@HK]6K3*7/IX+C5U
M/%9(AFUTEX/.!CA)V&8HAJY88.J(3/VO;UF]#B(>W1+1KE+G&")FH8"3D05$
MUKNEG*B;N$B)[Z+$B*HTX[3R"*G>&")$T126L>,"=X8)QG+M<`Y)(+[]GT*Q
M!#$V=39H0TG?1F[&HSE,2MG':DUVVAR/_DH>NO[Z=7<(V5WP:/DX]!`%9AKP
M@JDCZT*X.ZJI=0O8/R8[!;0J3B#<"F#MH@QRY%G2X<-K.J$=J&@YW=B+KY+)
MC8,NV6^S8D<<]M;-OR&E(J@L$TAMYX"J!$,N?P(I:B84:#%*2W]CC*P[9P8;
MRVPDF2&S#6B",0DQ`B^>8_#DU_,39.84Z;V\\F"N1\T5YV%6>TG!<BI(;E2L
M`<THQ95%30!,RY@N%)-XE"?<IA0VZC?Y@T:%%C66:AV,]-;DB3EYP-[<--6V
M88BZT@)L3$C2J(UQV5X:N1#<EA&0:.8Y@J./?>2=V0XOCKC.6&O,FUK\G5L2
M`@2Q(*9K*>?9Y0.R9E%+@DHM`C1`F@>,`EXWE'2F@I$J@J)4F910KA@$\<00
M,L"U[87"LM!*R!/*]\B_T5./3T\V\H.Z<O3->4C\:6Y4=1TTWB^7Z_(4<S49
MS48366GBZEIP*]@`"!5)0T),5S8X]A/XNWS`R+A]KV1?X.S014V_A+9A^HG)
MB=84;[*S6RILU+U<831E!_02N-";#4NQ[+954$AZ-HJ;T8QT,X(W:S/5E!=-
M+YUD]G!5OB5$5SX5K%2X9\>;)VN+S%OY(44D-K5EG3%GHRBMC851C9UQ-L,L
M+++>ZTBOV,6>QV<PHV/90U'4=.X\=NXA&:0,=^J)C`PJJE@0LB(9F=K&V:(S
MLM)K=<^[83#1-UX+C%O`%75/ZRUQ]773&!TO-*F.X%')5NOHP*K;#+)W&CIA
M415+'',@HE#.5[Y!KXWX3VWD'7F6D:2X_F!ZR]L?KGGK_'2U)+7=6*VW%:)]
MI):*HA>5W.MI1E1:Q=SPX?;3@P7UZQ8LL62[Y"&AU(7#`4*TPNUG8D<@.W3B
M5FV[@FTOPGJTD(+X4FHX$YJ.I6:04F!N8LB.8T0P;ZHHI>:V5R,ERYH44'N]
MNS;T,KV"@5`H)2./RW$4_P"F-,?WG(DH-ZMET!O.J`9=;#N8KHDMK.-C+B$X
MF*R,U`-X.-%5BN1!2)M@1(RQ5L%T,H/F,5N5O8S88/'N7\?:T$48_@^9#T5S
MWJ--YB8MM=/3C>B!BQ/*\P:UR$RMF`6(XUK-)<\#2F3-,%"/3,GQVUP\%,F^
MPD8IW`;&P*D((<QP%N&*#VO6W01#C\1)QC>0'@HZ.\B$<QFP'.UFZZ7^7=6M
ML>)CQ!OM$N@HI1?.-6QUIJR0W<Q3EPC1K$L:RRQSMG;M0V"E%D;#I6SNM/)6
MV&:\G`6.SDKP7(\-(D`RT1G%+U/D@N99*2IOI&#<"AD<)Q.[DK!TWL&WB6'>
MYZX^9@?M,<<@OI;T?1_[_P#OMV/_`-+^C:@4"@4$B=U?*'<>'O6;S^P*,ZK-
MIU3,M6@H%`H%`H%!M;#?_LF/_+2GI^[*C5KS7^LR5*B@E5OK\L#B6^E3*7W;
MI+H*JT"@4"@4"@4"@4"@EGKWY6#D>]XG13TMG6@J90*!0*!0*!0*!03"YJO)
M(\C/T0)P]A"I0?'$_EU_3_\`W3T'M]\QC_9RB?OTG_PVWH/?W0*!0*!0*#\2
MDFIRRGGDA7($E5*5"9E/4DQ2*@'D]0('`<RYLD>)&<!2QLH:`$RP$#$QRPSP
MRO:]KVO08DB37.!H%".@PO$$>1@&?!#*&?46U4E"SNF@7PR*(H(I$L$*5;Z?
MD':Y5."O@1*^CW(+#LW[(9HH)9Z4?+LY<??TUJ^ZI'M!39>74AKH:PY%]0+)
M2$@)AY96%,X)8(JGIB:6$.'CA@3+T,`2Y8'+/*__`'6H)")_(8H+&PKF)KX4
MR1O!*\WN.,U$P9]AQ=9SJ2[N'L4](N:ZV?+#J#@6$Z.)7S*H24HE5"Q=V-H$
MR9&S))AG''/`-G"W(O`)AI.=]9A.(DT4*0U&*45Q'UB*2B&]I#27XM1VI-!&
M6Q).\#M5PIZZ@&1C1%V#MLV23L>^S(0(-LLL0ZZW^4#6YR9P89)ITH%6W/YI
MIH;.>BJTTU-:Y9\/)UR`PTR/A3!ER8J;M=":](R52"OFU"KB2T/'O,ZH'"R:
MHIYTR'X!N4W6XO$3=F@4@\PVH^449T1H'FJPX&/)K3*-Q8=2DO,I:$ES!D'!
M49*1LL#R.:5RCB)'S)4@.GAGC();,-C7;M=&;?9,./)N$7C*!C81*#78293!
M1"N+WD9(]SQ0E@V=24M[JC*3DOP=':484A`50X0,9Y88DP0Q5`8`H*&+%/D(
MAI$DUCQ2O,^9FTY)-;2\NQY9W,(-EC.U4:L)&-@W0SB36=ZVAR&F+K9C<J+=
M1.***2;Y!:"S1AU(-7QR)6#7:6-T-`-@$J&TR3(L$F#)\-+7^<(,37HTX\23
M9DKLHRG@YHY/M-SR8\V@C-!Y*;4:BF4-)XJHG*)_,2R85#/C&PRPH9,1]SX5
MB(V;CQLQU,O_`)>2(GAQG0DUHQC1K8,]Y2I&1J3&PS4-)+K32+(9<X1`&Q51
M5PV$$E*O;X#B@`6S$L'.F.376XM'R1)5RTDC-TQ%X4NN@$NTR8RO';2]U3&%
MC_JN3<%WNIE41Y)!.)YD!$NL6M9/''#R$+W`%&"A(6=Q`PQ+AYA7SPPSN$+V
MO=`[Y8VRN&)VF6>';X7OV+]C*]NS;T+WH/[H)60)Y7OD7^BIQZ>GFWE!5.@4
M"@4"@4"@4$I''Y;B*?\`3&F/[SD24%6Z!0*!0*!0*!02)W5\H=QX>]9O/[`H
MSJLVG5,RU:"@4"@4"@4&UL-_^R8_\M*>G[LJ-6O-?ZS)4J*"56^ORP.);Z5,
MI?=NDN@JK0*!0*!0*!0*!0*"6>O?E8.1[WB=%/2V=:"IE`H%`H%`H%`H%!,+
MFJ\DCR,_1`G#V$*E!\<3^77]/_\`=/0>WWS&/]G*)^_2?_#;>@]_=`H%`H%`
MH%`H%!+/2CY=G+C[^FM7W5(]H*-R&BM5R,)Z-Y\D,U5EK;67DIV)H90^?$/-
MT^F&2RR5#))0)A3-9C)X@F-L"X>8V5[]C"U\NQ:@B!"T':$2,;BL)%WEV+E-
M1="!K`=@O"4+1\UE>46GH-,"G/\`"Q:)Q5#6:.U:<?<_<104-<,IF2ZL*285
M[*J8&,=T-YAE8#7_`$QEEMNO99D;23*>>+XEACL8CL?%"3&H4O,&9HBE%906
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MQ$".8!&<`Q(/QIQ::FI&FL[,VQ2D?1)-%E<JRUIUQ\OM05S*6L[AU1<Y8VL+
MT7*4HCM]UQBZ#I@R1]4=@2:\9,**=WB.</=\AT)J<24.--H^H0.<=AG(TAH1
MBO7!4;CX!UM>;<7X2A),>"+%K"<#5<&N)YJK!-II#S&!P.CD<E,T*3*&C1D<
MZ%<SF&6&_P`<\.MAR-ER)#ZF,,9I/V%)#1B!QP,U4*8J\"1)G"[')GCBFP3:
M^IIQAHY=T4LS!T0\</\`^^[XPM?+"X:`H>J2ZXY)Q:NI+X,+K)U1-O"!3[Z=
M"]#29(;%FMP/XCLG(R._FG.G'S,B:H)Y?-^-Q30U=B&TO$T`+8(QEGF`5-@!
M>Q)!42R6FEU@^75%<!/)@JBF4(72RJBHA%P\#Q\LF7-J%TXN<,XY"8`7''N#
MCE;#NF?8[:X<A02L@3RO?(O]%3CT]/-O*"J=`H%`H%`H%`H)2./RW$4_Z8TQ
M_><B2@JW0*!0*!0*!0*"1.ZOE#N/#WK-Y_8%&=5FTZIF6K04"@4"@4"@VMAO
M_P!DQ_Y:4]/W94:M>:_UF2I44$JM]?E@<2WTJ92^[=)=!56@4"@4"@4"@4"@
M4$L]>_*P<CWO$Z*>ELZT%3*!0*!0*!0*!0*"87-5Y)'D9^B!.'L(5*#XXG\N
MOZ?_`.Z>@]OOF,?[.43]^D_^&V]![^Z!0*!0*!0*!0*"6>E'R[.7'W]-:ONJ
M1[04L=@EPFLY!+`FS%\$%7O8N0)'%(Z/EW@8[4$HGIX!D\=,B7]#`($/,03*
M]K8XWO>UJ#SCQ'KU/$I:9<46L!6$).CU^:P3W`<]3I)LB-)5CU-A-NP2^UE\
MN%O-,VX21=>D.0)81`KMDF7;!14(!E%H?)3-%@,<PA0S&1U*FZ-'VP)WUF9!
MP-FSYNLE+.[4!N5/6&&*92"&X2F^&-N.PDMP)Y/--DEJ,6Q$HZ2HA<+%T,_N
M/;Y8J",2QR#FML8PV-<\H1SR!1DT5M:=VMNTK%2VG")6%GN6FMW:Z%Q'#"LX
M)1!:47B`BW)/AH2DXW*1MBABD3EDQ"&%-`&"N7<0V8Y`K3J95(B6(/\`=G<7
M<T)XY*L2LH"?&$B2+DI'F8$0)"39"2PF'H.EI-*B&,D$X^4E88N1?-0P4@"Q
MG`H<+AHNPHTV!CT89B.%O[H(T&J,J\D@3L78W<VQ^<@D9P=LRW=&I;Z)F6HX
ME21%F$C\.JJN&"83L332#<1I.\)7N*4&N`'6H6_SHO*8!&L]9.V/4MM8BD7C
MG./TBV7E)(&LZ<D'(U8QO=5->2`C*@VLPI-T(6*V.833/;#W5\L1FAB$:N7$
MH-\9[.[#&=RUIJ&6QLV:CL_%D0.O4IYP2MNA"BA(FQFNY_J$TL[9XV@K!=FX
MM%X$,V=D#@\$\\3-)!55+)N89P6X)@-*DP/D1(QHC.MN)^U8SA):QIR1O.P'
M(K2&>=*GL(DSA&@C]7=+CCT5A$T%878MRD(5NXL`S9M73!4@#.X"J$F8XAU*
M,HZG1J2;L>6*LW=]IZMRUL!M6]FDXFR+M(CSCG*+MUNTS2=;Y$>9[`[>=7%'
M`F31?R7ABL]^$4=<`(`K8)4,$#`,,H1FS^0%/>L</275W9=1EE%V!T507Z40
M'')MX.-LU3A),2=O5$*/$12,0LK-0R[KFAE`W@4-)J8LX=V1!"O;!99AZ$:"
M5D">5[Y%_HJ<>GIYMY053H%`H%`H%`H%!*1Q^6XBG_3&F/[SD24%6Z!0*!0*
M!0*!02)W5\H=QX>]9O/[`HSJLVG5,RU:"@4"@4"@4&UL-_\`LF/_`"TIZ?NR
MHU:\U_K,E2HH)5;Z_+`XEOI4RE]VZ2Z"JM`H%`H%`H%`H%`H)9Z]^5@Y'O>)
MT4]+9UH*F4"@4"@4"@4"@4$PN:KR2/(S]$"</80J4'QQ/Y=?T_\`]T]!;[AK
MY#=^>&RVQUHSX^7_`#+_`)C;Q#X:]74>S.@^IOW(?=0\&^"_`#8S[[\,>Z@/
MW?NO8[GWJ'VO_BRH+>_JR>4WJBK>M[8KVJT#]63RF]45;UO;%>U6@?JR>4WJ
MBK>M[8KVJT#]63RF]45;UO;%>U6@?JR>4WJBK>M[8KVJT#]63RF]45;UO;%>
MU6@?JR>4WJBK>M[8KVJT#]63RF]45;UO;%>U6@?JR>4WJBK>M[8KVJT&M\0^
M<<<F,0S/M%,Z;Q6JJPJ;0O2/7FO(QYJ3\`GM8Q'T:(<:$R20.`U;F#H*B10L
M#(F0W8RP%SRQQ_A[%!LA^K)Y3>J*MZWMBO:K0/U9/*;U15O6]L5[5:!^K)Y3
M>J*MZWMBO:K0/U9/*;U15O6]L5[5:!^K)Y3>J*MZWMBO:K0/U9/*;U15O6]L
M5[5:#IS?\Z%Y#FFX7D[FMPHLUM.N13J8I2"YV_&\X(SA?2BBD;I:,?>2TG,@
MLI.<ZDIM[ERPIT4<0`#_`'>%\</0H.X_JR>4WJBK>M[8KVJT#]63RF]45;UO
M;%>U6@?JR>4WJBK>M[8KVJT#]63RF]45;UO;%>U6@?JR>4WJBK>M[8KVJT&M
MC*\XUY,&5M-/6TI3BN53J_/49P3&BLU3#4G[!'0"4%')1.):HG'`VKWZ:-+V
M<I&+&,!;6P"L5#[2]^VRH-D_U9/*;U15O6]L5[5:!^K)Y3>J*MZWMBO:K0/U
M9/*;U15O6]L5[5:!^K)Y3>J*MZWMBO:K0/U9/*;U15O6]L5[5:!^K)Y3>J*M
MZWMBO:K0/U9/*;U15O6]L5[5:!^K)Y3>J*MZWMBO:K0:TJ'G&7)<H;@-C<#+
MBN5PW*V==79KL$S\6I/N2&;1W7(S9D0=R"';M2Q\)2*&VP$6P!MV0L@Q,\KW
M[;L6L&RWZLGE-ZHJWK>V*]JM`_5D\IO5%6];VQ7M5H'ZLGE-ZHJWK>V*]JM`
M_5D\IO5%6];VQ7M5H'ZLGE-ZHJWK>V*]JM`_5D\IO5%6];VQ7M5H'ZLGE-ZH
MJWK>V*]JM`_5D\IO5%6];VQ7M5H-7)=\XFY+I=G:")V4>+)72%:"6U,K;24$
MDTI]'3EX&9$5O(BF943([6L9+"HP+>PS`Q#[-A,A,NW]"UJWG89WDNV?J4N3
M;JIU'UK;`>U6M]=9Y/U*7)MU4ZCZUM@/:K3UT\GZE+DVZJ=1]:VP'M5IZZ>3
M]2ER;=5.H^M;8#VJT]=/)^I2Y-NJG4?6ML![5:>NGD_4I<FW53J/K6V`]JM/
M73R?J4N3;JIU'UK;`>U6GKIY9-:GG3W*&U"7>9;B4'-VL"$!80=N;#87[F$;
M43O9OB&U/1SN,IYV[/9[':XXV['9[-[YWLMYR':OU9/*;U15O6]L5[5:QI^K
M)Y3>J*MZWMBO:K0:US7YQKR7S7*>L$IJO%<K(BCK#);DDI#2D]J3\.2=)QR1
M^OL`9+513+4[N2+%B;@$,8B`]G+(0/'&]NU[-!LI^K)Y3>J*MZWMBO:K0/U9
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M>XK>,6*[H1&I/YY70$]XHYE',JJ:3/M:Q(R<)AF;YX8"_P`&65NQ?T*#S"_Y
M6MF_<^[C_ESG?NWN#]Z=R]R*0.Z=]?YG>_N]NT]3W;=\=X_[[M.QVW<OX^QV
%OHT'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>v371611_tpg61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v371611_tpg61.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!F`)R`P$1``(1`0,1`?_$`0T``0`!!`,!`0$`````
M```````)`08'"`0%"@(#"P$!``$$`P$!``````````````4!`@,$!@<("0H0
M```&`@$!!`,&#0P+"P@$#P$"`P0%!@`'"!$A$A,),10802(5UI=847&Q,A:V
M%U=W.!D*VF'10M(C,]/55M>868&1DE-TE%65EGDZLK,D-+34-;4WMWBA4F)R
MDR4V.?#A)G9#8W-49(2D976&ID<HN"D1``$#`@($!P@*#P4%!@0'``$``@,1
M!"$%,4$2!E%A<9%2$P>!L=$B<A34"*'!,I+2,U,T5!7PX4)B(W.3TY0U5196
M%QB"HK)CE?%#@T49LR1$=#8)9(2E9J2T)29&=I;_V@`,`P$``A$#$0`_`/4+
MPG_$[XM_@#U;]J,7G,[;YNSR!WEQ6?XY_E'OK9W,ZQ)A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(O.QRHY;\B*YRJYPZ^TWR7W"GOC3EIX?QW#KAE4
M-55386L]V&V3KFEV+94+LXI=1S5HB*S*2$F^4?V!2WP!*\U`SHINZB4AHN>>
M5MPYD;G;8ILM`!&@:<*X\N&)U8[\449B8YS1LFNTZM"--*8T[E,5O/?/,AEJ
M!.\QY64XSV-UI7AEL)OIJU;,C=I556?V?NJV5[5$CJW6VI];NH=N]D5;=9=O
MQ,.^DY22CF,.HZ07[SM,7)6NPZ[(VSL'88:5KI)I04IIQU^&F`6X(:-KQWBM
M*:!C4D]Q8+Y@^8WRET9I;E77O9MIVH^6^D--:KY`52-D-RP^X-3SFFK_`+;+
MJ><MS"R-]?59>2N-#MS,T3)UQU&-4C#(MWK60<(E$HX9[R2-I&R&RT!&-13'
MB&.!K7VUDBMXWN:=JL1)!PH:CN_9BLB<C_-11XTVN=UK=M1ZT:[9U9HN'W_O
M>@S7+"CT[X%@['*7%&NZWT%,6FC,G/(O;4M`45_(D8D8UR/3`[-LH]*X>)%S
M*^\ZL[+FC;#:D;5.X*BI.!PP]E61VW6`.!.R30'9/.>`8\:_*7\P8:==MQR5
M"H&Y-]K6_DIP<T3J[6\U?:)3(&.?\K.+\?MZI2='1F*G&.M?5_PETE;0VG7\
MLY^$%'#INHDFF5B>PWFS*6-:YQ<13&FH:,./%7"WVF`DAM`2<#J)&/-@MWN)
M?(66Y#MMIQ-ZU@?4.T-"[XG=!;:H2-T9[&KS>S0\!3;K&SE.OK"$JX6BI6JD
M7Z+>MEEHR.=H**JH+($.EU-M0R]:#4;+@:$=P'O%8)8Q'0M-6N;4'1P^!1SQ
M?*3?R_E!Z6Y(K;)E%-W6C9VBH.?V",;7@D9*'MG/FM:AL3-5@$.$$DE*:W?*
MQ1S)M2'*B<3D,5;HH&OULGF;9:^.2,>5X'>6QU3/.C'3Q`#A_9KWUG"R>8U:
M(#9FQ6JO%F<#CWJ;G'7."E_WF&WJJ$JTO][L=$J51N-4U%]CRDY8Z/'V394,
MUGE'$G'.6`/`.T3D027\(V\+J.V#U>T!6NBM*8<I'M55GFXV?=>.6;5*:L=?
M<6I?'[EGR'J6PN3%SVCJBV;%W1N;S$-F<*.,VIFW+)W(ZL:NM;QLA9']2^Q^
M4H<=1M.4?3.NZ'(34I<VD;)3=F4>K(`R,L9(AL$%R_:<]X+G.=1HJ>/BH,!P
M5X=(662%FRUK2`T,VB:8]^IJ3R<:S1.<R[MLC=G$NCS<%8..VP-4^8C<N/\`
MRKUE'7Y"ZT^7B4>!NZ-]51ZQNL+&5Y#8>K[-`2,'8&0NXR/=-WS3N+M$EVP"
M;.9W/>P4+7"2CA7[PD=S0<?:5G4AK'$4<#'4'^T!W#I"QP;G/O7>6V?+[V+&
MZCO.B>,N^X+F1LRA62,W/69V=W/KJK<4]B6K7IMEZZ95]L&N;:J>.96VO-%U
M;(Q;`<AG*R3M$S4^,W,DDC'`%L1J1CIP.G5P'737BJ]2QC7MJ'2-V0<-!VA6
MA]C4KQJGF0;-C=4ZZ9ZQXS[%Y'2%7\MK1G/?9-XV1OS75,M*FNKM"W0\G"3<
MJVUZBPO&]'I-?.7"!(^(BH66=*+"HI%$(D"UXNBUC0UCG?@VNK7AKP#3AQ#D
M5#`TN)<X-'6%HH-8[NC'EY5W^V?-?/7)50-,:#B=J5N/+PG0D'-XWY`:7O,Q
M*<]$*N_TTGKK62]"OL_?(2"C+@R/8)!)5L#=8CQ%HD\,P="2AOP32-M1AI--
M)`PP/#RZ<,#0VTJ*O=33JK[FM=8X.]72%,(<ADS&(?N]\@B4X%,!R@<O8<"G
M```Y0,`]!Z!U#MR06HOG")A$PB81,(F$3")A$PB81,(F$3")A$PBJ'I#Z8?5
MPB\SGZ2'D/Z8I/T93B\)_P`3OBW^`/5OVHQ>2-M\W9Y`[RT9_CG^4>^MG<SK
M$F$3"+`6T.5G&;25D0IVX-]ZJUI;7,0TL"%9N5PBX:<4@G[AXS83'P:X5]:)
M&OG4<X316,4"*G04`HB)#=->6ZMH"&SR,8XZG.`[ZV8+*]N@76L,LK0<2QCG
M`'@.R#18Y_*%<$_G=Z!^4*(_;YB^L;#Y>+W[?"L_U1FWT6Y_)2?!3\H5P3^=
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M;&QGQ@%)DCU2(++$:',=E\)DC7`H"<`!7P%.[U[ANF>*>"<$P/:\#3LD&G,M
M:>UNK5P;=1R1.(J`]I:2.$!P%1QK+^9E@3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(L+:ZT;6=9[<Y&[D@IFR.;%R;
MF-5S5ZBY!TS-`Q3C4>N6NLZ\E6V[5FV=I(/X1H59X#I9R8SH1%,4R="9C;$U
MLCI1[IU/8%,.;%7N>7-:PZ&UIW358@M?!O35YU_R[UI:G]VD*WS+VL&Y]@+L
MYII#SU*OC*K:KKM;F-8S+"-(M`NJ?(Z=A9F-5=%>J)2J1C*"HB((A8Z!CFO:
M:T>ZIXCAHY*`JX3/#FN%*L%![.GG6-)SRXZ3L>H<C(G?N\]W[\V#R6T[7-"6
MC<MO'6=5N%)U;3)]_<ZE`:UKVNJ!5M?5YRPV!(J6!\\7BGCB8E2IF=F.@DF@
M3&;2-X/6$N<12N`H!710`:SJ5PN'-+=@!K6FM,<3QU-5<,WPAG'MZ;;?K7+?
M?=%W;.:MJNH=S[4@ZGQYE7V]JS1)ZTV"CS-JIMKT[.Z_J%\IZUUDVT?+UR-C
M#$8NO!627`B9BW&W.UMA[@\@`FC<:<5*`Z503#9V2UI8#4#'#AUUYUWTUP7U
M?/;,F=JR%MV&K9)WDOQMY3R"9GU?%FKL'C#J0VG*9&F`(`BHUVQP!S/)@@&*
MX5D!$S=1NE^Y`-JPS"<D[8(/%J'M()WAFP`*4(YS59QU+I.M:<MV^[G6I2=?
M2G(;=([SMR4PJQ59PUJ^YUKW681M;(T9-548,L+K9DN!')W"_K2RP^)W!(0F
M5C`PN<*U<:GF`]I8W/+PT'0UM/9)]M:?0OEG:\A7,!3@WGON0XM5'=2/(&I<
M-WS_`%T.FX/8K'8;C;L*P&TMZ`AN65U;7-K.!L,?4G=B5B6[]-(A@4:I$;AA
M%JP8!SNJVJ[.%*UKII6E<:568W#CC1O6$4VL:TI3AI6F%:+*\[P>UA8*AMBF
M/+/?$X[</,NI<W[([1>08/V.SZ=>M37^/K<.=2%.BE1W4MIV.2726(J^%NY<
M`5P4XIF3N\WCV2P5#2\.[H(-.3!6"9U0<*AFSW,?9Q5OVK@%K>?@II""V-M2
M@7TW,F]\ZM?[;JCNHJW+5.\]B-'\18TJW'6&K350GZ!(5B9D(AU#3<?()/8Y
M\J58XJ`DJG:+5@;1I(<';0.%0>]3$\ZKU[JX@%NSLD<(\*I2O+_UE5YNA76?
MO^SME;/K/)BS<L;SLJ[.*E\.;FVM9]&67CF=K=HBNU>#J\+0J[JJP)QL/"P3
M*,;L$HYN`&/WG`K5;;-!#B27AVU7#$TIP<'`AG<00``TMV:#4*UYZZUCS6GE
MAT#6TMI@`Y!\B[C0.-,#M^F<<-26N7UX:CZBH.Y]>6G6<]4VSB$U_#VN\'KE
M9M'J\))V"1D9&/:,&[4JAD1<`O:VT8TCQG$-J`,,`12FBIIJKX5<ZX+J^*T.
M=2IQQH:\/>63M><!M3:U@)2NPEIV`\9RW!/67E^N%I-Y`J.4]2:K8;`CX&V(
MBV@VR8;#?);&>&=K"48\QD4>XU(`'`][;=C10$_%AG<%?9Q5CIG.-2![LN[I
MI[&"B_N'EU\J==;ZNURXX03]&W0T5Q@I'%+D(_V%QU>:]UW1-*:1U;IJ=DN0
M6N=GZKMNYI"X/VE-DS/FM`<1\;,LEVI6PQKLSIR.D;2>.6L.C"A--0`QUCN`
MU'`:E;3;B)T=)>.HQTDUPH:4Y='&,%Z)C]WOF[GUO4>@@42@(?1`@G4$@#[@
M"8PAZ.H^G)5:"^,(F$3")A$PB81,(F$3")A$PB81,(F$3"*H>D/IA]7"+S.?
MI(>0_IBD_1E.+PG_`!.^+?X`]6_:C%Y(VWS=GD#O+1G^.?Y1[ZV=S.L281,(
MH7>2)C$YS[D[AC%Z\>>+O7NB(=>EEY'].O3T].N=2=HH_P"_VWXIW^)>LO5P
M<1E&:T^DP_X'*U/&5_OJG]V;]?.O*!>D-MW"4\97^^J?W9OU\4";;N$IXRO]
M]4_NS?KXH$VW<)3QE?[ZI_=F_7Q0)MNX2GC*_P!]4_NS?KXH$VW<)3QE?[ZI
M_=F_7Q0)MNX2GC*_WU3^[-^OB@3;=PE/&5_OJG]V;]?%`FV[A*>,K_?5/[LW
MZ^*!-MW"4\97^^J?W9OU\4";;N$IXRO]]4_NS?KXH$VW<)3QE?[ZI_=F_7Q0
M)MNX2MD."1C&W9R3$QA,/W...(=1$1'I\.\@^SJ/N=N=M=G7ZON/QX_PA>0?
M6+).]%A7Z`?^U>I/<[$7GM,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A%4/2'TP^KA%YG/TD/(?TQ2?HRG%X3_B=\
M6_P!ZM^U&+R1MOF[/('>6C/\<_RCWUL[F=8DPB810N<D_P`>;<?_`(>>+WVR
M\CLZD[1?G]M^*=_B7K'U<?U3FO\`YF'_``.5HYUXO1Z81,(J]!Z=[H/=Z].O
M0>G7Z'7T=<(J81,(JB`E$0$!`0]("'00^F`X14PB81,(F$3"+9/@A_VV<D_P
M<\<?^O>0>=M]G7ZON/QX_P`(7D+UBO\`U/8?^0/_`&KU)]G8:\^)A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB815`!$>@=HCV``>D1RB+"&Q>2
M>@]26RJ4/8^VJ55;O=IR*KM:J#V6(O8WLI-NTF,85U$,"NWD,Q=.UB)@[?%;
M-0,8.JG;DC:Y3F=[`^ZM8)'VS&DEU*-HT5-":!Q`!.RVIH-"TI\QL;:9MO/*
MQL[B`&UJ<2`"0*[()(%74%2!59O,42F$I@$IBB)3`/8("`]!`0]P0'(Y;JIE
M43"+@R4G&0K%:4F9*.AXQL*97$E+/FL;'H&64*DB59Z]50;)&65,!2`8P"8P
M@`=1S)%#-<2"&!CI)3H:T%Q-,30`$X:U9))'"PRS.:R,:2X@`=TT"YV8E>F5
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PBJ'I#Z8?5PB\SGZ2'D/Z8I/T93B\)_P`3OBW^`/5OVHQ>2-M\W9Y`[RT9
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M\LQF56\-KP+!))HJKJD372$3&\$$R@8T6<HN/-?/7.C;`6;0J[$Z3L@4Q=3_
M`&KF[>T#*#GAW;BBO)LSCN1`\MB!:TU#3*XAU&Q;1`)-",<*+H;!YMG'*`F9
MZ0^P'D#-:&J6QBZFMG+."UH#_CO`7OUPL>M'+V@9A*:>QC5ZH1,[Y!@HD;Q"
M"D"I5$A/<W)+IS0-J(7+F;0C+O'(Y*4[E5AF[2<CAE>_J;U^3QS]2^\;%6V;
M)6E-O:VB`?N@VF(I6HKJUR!YK2W&[S;)%A//-Y[.U=)\,(-Q3=$::CYW8![=
ML.9FDY5I,UZB,GJ4$#\(",>NEI50$_#:)F_=#=XI#;EMEXN\D!;U;)A<&KW4
M;1H&@G3IH*<*X[G6]<N1=I+F3&\N,O=E32RW@#I-N1SJAS8P=FNR'$O-*`:=
M2WSH_F,Z+V3Q>0Y44*K[EN=>6NI=8CJ^H:\<6C<B.RSF)W*8I4H>0<L_6CMU
MDUP=^N`R!NJ014!0WA9&R97<Q7GF<AC:_9VMHNHW9X:GO4JN8VF_&47^[XWB
MLX[J6`R]5U3(R^?K>AL-)%:4.UM;-",:X*Q(KGW4=Z4?EOK*,H.]N.G(33?'
MG86P7NO=T55"CWF.AEJ1)JP-UKCF*F99(Y&<@\9*%4`Z*R1ETE$^^7J8N5V6
MOMI()BZ.6UDE:W:8:BM<0<!QK4CWRMLWM,RR^.&\L<[M;*20QSLZN0-ZL[,C
M2''02TUJ"*@CBP%Q-YZ5?1?EO</+_OZ>VIN';>YC7&K46HUEE([,W5MNRQ^Q
M;6R*TBVT@_3=/TXE@+-N=RZ<E*GXB")!.H<A!V;W+7W&:SQ6P9'!'0DGQ6-&
MR._CHXU#;M[XV^4;BY7>YR^XNLSNMMD;&`RSS.$KQ0`FIH-D5)Z(Q)`6U>IO
M,IX^[(@]\N[7#;5T);N,M4<7O=.K=W4A:L["J].01!4E@90T>\EB3S1R=1%)
M--N?U@5G;8!3`CA$Y]*?*;J)T8862LF-&.8:M)X*X4^T>!<BRW?S);^&\=<,
MN;.YL(^LGBGCV)&,Z0:"[:!P&&-2W"C@3<_'WG13=]Q5@M+S3/(/1FOXG6BV
MY8;9V]:"TJ6NKGJUL<AE[;6[5&3DZP4*DP5*]%JL*;@[$17(!R`.676726S@
MP2122E^R6L=5P=P$4')RX+8R7>^USB-]P^UO;.R;!U[9;B,,B?$-+VO#G#1X
MU#CLXBH6*=<^:GHC8-RU;".]8\BM<Z]WS9W%-T-OO9FLR5G3NV[,DZ]1:1==
MG/AIW*L3S+W]R9&>,T06./O_``P`PESRY-<Q1O<'Q/EB%7L:ZKFCC%*8:Z%1
MUCVB9/>W5O$ZWOH+*\D++>XEBV()GUH`UVT2-HX-VFBNNBDT$!`1`0$!`>@@
M/8("'I`0^CD0N>IA%LGP0_[;.2?X.>./_7O(/.V^SK]7W'X\?X0O(7K%?^I[
M#_R!_P"U>I/L[#7GQ,(F$3")A$PB81,(F$3")A$PB81,(F$3"+7C>O+3C1QA
MEM6PO(?=M"TR^W78Y.I:O/?Y4\%&6FP0[9@ZDF!9U=N,'"D:$EFA3.)%RS:^
M*Z23!3OJ%*.*2:*(@2.#=HX55[(I)`2P$TTT6PQ#$42172.FL@Y12<MG"*A%
MF[ELN0JK=RV72,=)PV<)&`R:A!,0Y1`2B(#US(K%C&Q;OTI4)AW7K;N+556L
M$>*0/X*Q[$J,),L1713<(`]BY*8;/FIEFZI5"`H0HF(8#!V"`YNQ9=F$\8E@
M@F?$=!:QQ!Y"!0K6DO+.)YCEEB;(-(+V@CE!-5TGM*<<?G!:/^5FA?Q_F3ZH
MS7Z+<?DW_!5GUAE_R\/OV^%5]I3CC\X+1_RL4+^/\?5&:_1;C\F_X*?6&7_+
MP^_;X5JWR'\T7A[QY9*I.MC,]K6\S<%F5)U"ZCK>\4$Y.\A\*V1N["IP*"O4
M.HK.S.`+VE1/Z!I<V'U;:^?Y_-#EN7?*7+M@NXHXZ&65W$QAY0I3([#-]Z\P
M^J-S[*ZS;--<=JSK`RNN66HAA;]]*]H7G\Y+><URBW4$A`:R6:<?:*Z!5`&]
M*=*/K\_9GZE[LI?W:"#UD=1,??%BF\=T]'?.';G6N<]K>0976'=.S-[=C#SF
M\;LQ`\,5JTU=Q&9_+&O56Y'JC9[F6Q?=IF8BRM30FRR]P=*1T9KUS=EO&+>,
M\4JB3=R\J]DUYU]*R+N:7=_"+B:=OG+F65?@H"P2"\DY54=JO2K`!P5.<3]X
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MM=7U_NE$QR>]`V=T;F[T[IVN2RY2Z%MAG#XR#,99&-GH,6FX8'2P;0PV0-C'
M`ZEUAO/D&\5QFD>8ME=>98UX(B$;'&+@(A<1'+LZ=HG:X0MM?N/\H#*"93F.
MY!,0Z^&AQ]UFGW>P.@%\1\OW0#W0[?U,X5]>;H4PR(5X[V<^T%RCZIWD)J<V
M-.*UA\)7Z?<?Y,?/&D_D$U;_``N4^N]TOV$S],N%7ZIWA_:SOT:'PI]Q_DQ\
M\:3^035O\+CZ[W2_83/TRX3ZIWB_:SOT:'PKC_<6Y,?//G_D+U;^VR_Z^W2_
M8,?Z7<*WZGWA_:[_`-&A0-+<E^H=[F=81+U#J`:,U:`B'N]!$1`!Z?J#E/K[
M=/5D,5?_`#=PGU/O#^UW_HT*_<VEN1ABB7VR[87K^R)I;5!3A^J4?51Z#EHS
M[=<8_44/Z5<>%5^I\_/_`#>7]'@\"_#[A_(SYZ5V^1S5'_,\N_>#=?\`8%O^
MDW'A5/J7/OVO-^CP>!/N'\C/GI7;Y'-4?\SQ^\&Z_P"P+?\`2;CPI]2Y]^UY
MOT>#P+\U=%\BU``/;6O:?0>O5+4&J2"/Z@B#(>H95N\6Z[?^06Q_^9N/"J')
M<_\`VQ..2"'P+[#0V_\`H'7FQLWKT#KTU9J,`Z^[T`8<1`.N/WDW:_8%I^D7
M/PE7ZESW]L7/Y&#X*?<&W]\]C9WR6:C_`(GQ^\F[7[`M/TBY^$J_4N>?MBY_
M(P?!7Y'T#OY00'VW=JDZ!TZ):QU&0H_JB`0H]1RHWEW:'_\`'[,\MQ<_"5IR
M//2?US=?D8/@KX]G[?WSX-L_)IJ3^)<K^\N[7\/67Y>Y^&J?4>>?MFZ_(P?!
M7'D-)[A@XUU+6#GCLV%BX](7$C,2U+TG#0[!N!BE\=](2<&DS9(`8Y2B=54I
M>\(!UZB`98[>;=P8C=^Q`XY[GX:N&1YWH^N+LG\5!\!<HW'?>!A!3VW]V=U4
MA%B"G1]2@D=)4A5$E4NY7O#,DJF8#%$OO3%$!#L'+AO1N^,/W?R_\M<_#5OU
M#G/[9O/R<'P%\#QUWAT_'AW<'ZOV$ZG^+^5_>C=_^'LO_*W/PT^H,Y_;-Y^3
M@^`MN$2'200245.X420124<*`4JCA1-(I#N%"D`"%47.43F`H`4!'L[,X4X@
MN)`H"3AP<7<T+E+00T`FI`T\/'W5^F455]%#O&*7T=3`']L>F410$[.\VCD%
M5=L;;HM4TMI9_`:ZV==-?QTC8+)>T9B10J<RO%$D'R4=T9)KO"(@H8J8`4HF
M$`#H'4>ZLB[*(,YRF#,A=2-,L;7$4;@2`2!@<,>%=7YMVARY7F,MB;=CA&\@
M&IQ`)&.(QP5E_E@.4GWC./G^E.Q\E_Y*0_3).9OP5&_S2D^C-]GX2?E@.4GW
MC./G^E.Q\?R4A^F2<S?@I_-*3Z,WV?A+$TYY\N^J_*/8AYH#2YW3!PJU7.WL
M-].B95$P`8R9CO$SB0>O9U`!SI[M#_<[LTOH+#/I<RDFN&/<TP1PN`$;@T[1
M>]A!JX4H"O0/8_N!O_VV9=>9GNG]4PV]C)$R074LS'$RM<]NR(XY00`TUJ1C
M2E5U/Y?[>/S?=/?Y^O?_`#_.O?YE]F'#GGY&W_/+N'^E/MK^6W;_`$BZ]&3\
MO]O'YONGO\_7O_G^/YE]F'#GGY&W_/)_2GVU_+;M_I%UZ,I5/+5Y]W7G*TW`
MK<]>U&B+:U7I98XU3DIM\E*(VE.Q>L%?)S2BQT56:D&7PS)FZ&!00$.H`(\L
M9-DN9Y':;PY"^Y-A=/F;2=K&O!A<&G!CG"A)PQT+I7>?=G>'<?>R\W-WG\T.
M:VD4$A=;/>^(MN&=8T`R,8ZH%*^*!7A4H>:RB4PB81,(F$50](?3#ZN$7F<_
M20\A_3%)^C*<7A/^)WQ;_`'JW[48O)&V^;L\@=Y:,_QS_*/?6SN9UB3")A%"
M[R0*8_.C<12%,<P\>>+W0I0$QA_^TG([T`'41SJ3M%^?VWXIW^)>L?5P%<IS
M4#3YS#_@<H?-!Z-W#6O-EYS;IG]<6N)U/L/3^IX2CW][&F3K=IEHB*UPC)Q\
M.]`YA<NF*T0Z*J3N@)!;FZ].I>]Q6YN('Y+;V[7@SM>XENL`EVGG"[+R;*,S
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MPDW=SW*L]NY!,[9-M.1:2L+@YCB"X,8:BI)!.@D`A2YTSC]M&M><9'[B9ZVM
MC#1<)P3K>J8G82S1=S76MCAIF`;-ZH,X8QSN)MM%,3`IZ5%"E,<1$INHPDES
M"_(NH+VFY-R7%NNE#C3@79=KDF8V_:>W-&P2#*&9.V$24JT.:YHV-K6X`=W2
MH\J3HCS#M,\&^0L#J'7&[-?7:U^85;+G<8F@-T(+=EDXSS,-%MIJ7T\NL*JA
M7TC)-$2)JMP]8.DD<2`9$%.]*27.5SYA$Z=\;HVVH`+L6"0'`.7";3)]]LKW
M1O8<L@NX+N7.WR/;&-F=UJ6@.=">$D"A&-`:855Q\>>,6\PY+\P=F1/'KF%4
MM7;0\OG8VN]827*VUJ;"VY9[F]:Q$:QKTY*.)>6<P,W.R#!PHP@UEN^V:`10
M0(14I0LNKNW\T@A=+`Z9ERUSNK&RT#A&`J!K/"L^2;OYO]?YG?QV69Q9?<9+
M+'$;Q_63/>0`&N.T=ESB#LQDX-H<*JVZ3Q7Y<:/T]Y2W(J,XX["V):.'GW:X
M?<G'R-;(LMI,(+9%VM#F/L<!"/1/ZY(HQ$@=7P4P.N17U,QR%3%0Z5\EY97%
MQ>VIE:QD^P6O^YJT#`GE]M8+3=W>7*,KW;SR.QGGN,LZ]L]L!28-ED>0YK3I
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MO#<LS3*,NAS&SW3N,N?'%%?$;3+AU`T1@$D1Z03H(.-32EJ\6^*JZJ/&+3V_
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M4_)Y^>+_`%]I?Z"NIOXXQYM??2/[H3K[/Y#^\4_)Y^>+_7VE_H*ZF_CC'FU]
M](_NA.OL_D/[Q3\GGYXO]?:7^@KJ;^.,>;7WTC^Z$Z^S^0_O%/R>?GB_U]I?
MZ"NIOXXQYM??2/[H3K[/Y#^\5]EX`>>BUZD;>>U!OBG]\8\GP9U655,P=G<2
M!-VZ#PQ#M'J(=ON>[E?-[_Z1_="KUUEKA_O%?7L%>>S_`%YM1_H-ZO\`U\>;
MW_RX]X$ZZR^1_O%/8*\]G^O-J/\`0;U?^OCS>_\`EQ[P)UUE\C_>*>P5Y[/]
M>;4?Z#>K_P!?'F]_\N/>!.NLOD?[Q3V"O/9_KS:C_0;U?^OCS>_^7'O`G767
MR/\`>*>P5Y[/]>;4?Z#>K_U\>;W_`,N/>!.NLOD?[Q3V"O/9_KS:C_0;U?\`
MKX\WO_EQ[P)UUE\C_>*>P5Y[/]>;4?Z#>K_U\>;W_P`N/>!.NLOD?[Q3V"O/
M9_KS:C_0;U?^OCS>_P#EQ[P)UUE\C_>*_0G!CSY6O4C;SNM;OB']\923X.ZT
M*J0P=G<2!-DZ#PQ#M^N`>ON8\WO_`)<>]"==9?(GWQ7W[$7GV_UUVI?Z#VM_
MXHRG49A\NWWH3K;+Y(^^*B&\Y33'F8ZMXZUK6W*SS`JES6>[^LS^EZ1XZ4;R
MW*);K5=-AQK-FJHO`6QG#(N=8RT8VET3)2;%R67.!S`T0<`1<":EXRZ9&&S2
M!^T<`&`U/M+:M76[G[43"S9&)+SH]M2,_F_/`SS2N'FMTAYE<@UH+2<A!JDH
MG"J>3:;*L]$<ND43,)AU?EWRQ-/E8CWA/68=>0;KB;_A9&BX&+FSE\%U"W\,
M[Q*8-TT[NKD"U[V:VE=^";X_2T>QKY5K-SAA8"1YS\L59:+AWJQ+]5"IJ2+-
MDX4*0=:5`1*0SE,Q@*)O<#LZY[`[+HX9-T8#*UCB*TJ`?NG:*KS7O])*S>*4
M1EP&&@D:F\"UH^Q6E_R>J_\`FN)_@<[%\WM/DXN9JX7U]STY.<JAJE23E,0]
M>K'=.4Q#=V-BRF[IRB4W=,5(#%-T'L$.T![<H;:S(H8XZ<@03W(-=M_.5I#9
MZTY@[.]KJ"2CM4K[U>.3;$%=5\1P8#,@:I(@<ZZSA)0O0A`$PF'H`=<^;O;?
MV:;U/[4IHLG@N[^*^8)HB-I[8A[F1AD<=B*-CO&`<YK0UX`T+[%^J_VV[@6G
M81!)O->9=E%QD\IM9P=B)TY]W!*(F#K)Y9(SL.+6/>Y\;B<2I)>-/E#<L=_!
M'3UF@D-%:_>`BN%DV8V=M;`^9*=#^-`T!#N6-X*B8]2'>A'-S=@@J(9'9/V/
MY78$3;Y7W6SC3:V1#C7HRW3AU;>,1-D/`X+0WV];VYN-NR[+\L(9B!?9BTL;
MY4-DTB1_"#.^,<,97H+XU>4YQ)X[C'S;^KJ;JV`R%)<+AM-NSDXYF]3Z&!Q`
M45,AJQ%]Q0.J9W!'[HG8(+=<[-LKBUR:U-CNU:P9;9.%'=2#UKQ_FW#JS2<=
M7!O`T+R=O+GN\F^U\,RWWS&ZS6\::M$S@((C_DVS`V"(#46LVN%Q4F)2E(1-
M,A2II))D2123*5-)%),H%3223(!2)))E``*4H`4H!T`.F:G&=*C57")A%'AS
M>F/-/BY_7Q/+LI/#FV5E:"F3[07Y13UYAY9E9"R:)8!&H)U"5C45XI6(\0SD
MRX'."_0"]`].M/YW4>;!A&O:K[2SPBW(/7EP.JE/;6C?V6?G-/WG?*3_`--]
MU?&C,%<TX(><K-3+^&7V$^RW\YI#M^XWY29NG;W0O&Z0$W3M[H"-I``$WH](
M8KF?!#SE*9?PR^POU^Z%^<O?-L\J/Y4MN_'_`!M9GT8N<^%-FPZ4G,$^Z%^<
MO?-L\J/Y4MN_'_&UF?1BYSX4V;#I2<P3[H7YR]\VSRH_E2V[\?\`&UF?1BYS
MX4V;#I2<P50V-^<MI""BG&/RJGA"CU,V;;8VNW76#T=U-9Q?_!3$.O7J;LZ!
M]'&UF8^YBYSX4V;#I2<P7Z?=5_.3OF@^6%\N&P?YP,=9F70BYRJ;-ATI>8>!
M/NJ_G)WS0?+"^7#8/\X&.LS+H1<Y39L.E+S#P)]U7\Y.^:#Y87RX;!_G`QUF
M9="+G*;-ATI>8>!/NO\`YR0T$#K\+_+0DR&ZE!%AOJ[-5$S>D%3G=[!`AB=`
MZ=`[>H_0QUF9="+G*;%ATY.8>!5^[;^<??,4\N3^D19_YP<=9F7R<?/]M-BQ
M^4DYOM)]VW\X^^8IY<G](BS_`,X..LS+Y./G^VFQ8_*2<WVD^[;^<??,4\N3
M^D19_P"<''69E\G'S_;38L?E).;[2UXY9[`\Z;8?&[<5#YA^7YY93[C78:BJ
M&W)"V<OIO7]2B:PP?,I-*2D[8MM2(=0#N)F6#5TS=HN$E$WB:/A]XX@0V*=U
M\Z(MFCCZHZ?&XQ]E5DB;:-D!B?)UE</%^THH?('Y)^<;*[BD]3\?JBPWMY?-
M4NKZ`EY'>EVLS_3NH:VVDG"2L=HOD+)P1;G,24:T#_@4*Q82[1<A2'5CVQ53
M.BZN7RWA?L1C:MP=9P'(?:]A;-[':[.T\[,Y&H8GE"]YYN[WA[HB)>H]T3``
M"(=>P1`!$`'I^KD^H9?.$3"+Z((%.41]`&*(_2`0'*(O,SMCR\N;$ING>%GJ
MFIJA/U>[[CV'=ZY*K;<I\.N[A+-8',C&J+QCQ07;-86JA1.FH!3E,(@(=F>A
MMVNTW=W)\CMLNG,AFCB:'>*[`AH!&#2#HTU73.>[B9UF>:S7L08(GO<1XS<0
M22#B133H5C?DZN>_WC:9\MU%_;Y.?S@W8_S/>O\`@J)_EIGWWGOF_"3\G5SW
M^\;3/ENHO[?'\X-V/\SWK_@I_+3/OO/?-^$L!V?R?.?5CG)*9#65*9_"#Q=W
MZN.VJ.L*7C&`?#\7X03[_=Z>GNAUSSYVMY3NUVI9G:YB,S?8^;,D;L^;/EVN
ML<UU:[;*4V::#6J]9>KUVJYWV$91F.5/R1N:>?S02;0NV0;'4L>RE.JEVMK;
MK6HI2F-5T/Y&#GU][ND_*K1_XSSJ3^2^[?\`$+_T!_YY>AOZS,X_A'_ZFST9
M/R,'/K[W=)^56C_QGC^2^[?\0O\`T!_YY/ZS,X_A'_ZFST932^4;PSWWQ%9[
MX+O&`@H!2]KZ^^QI.&M4-9SNR5XEL&45<C#+N$V1$C2Z!2`H8#*"(]`Z%$<[
M$M<NRW(-V+#=O+[IUYYK)</=(8C#7KGAX&RYSM&(K7F7F;?K?&][1-_;_?>[
ML1EPNX+6-L/7"<CS>+JR[;#&>ZTTV131CI4R68%QQ,(F$3")A%4/2'TP^KA%
MYG/TD/(?TQ2?HRG%X3_B=\6_P!ZM^U&+R1MOF[/('>6C/\<_RCWUL[F=8DPB
M810:<QZ;7]@\O=^4RU-Y!U7I_CCQ9:RC>*G[!5Y%5!&W<AWA"M;!592%L,8?
MUAL01.U=(G,4!*(B0QBCU/V@R.BS&VD93:$3M0/W7`01["]4^KW:P7N09O:W
M(<8'W$(-'.8?<..#F%KAB-1'!H6G7L'\9?Y-[._I*\F_YX<X/]8W?2;^3C^"
MN\/W.R#H7'Z5=?GT]@_C+_)O9W])7DW_`#PX^L;OI-_)Q_!3]SL@Z%Q^E77Y
M]/80XR_R;V=_25Y-_P`\./K&[Z3/R<?P4_<[(.A<?I5U^?3V#^,O\F]G?TE>
M3?\`/#CZQN^DW\G'\%/W.R#H7'Z5=?GT]A#C+_)O9W])7DW_`#PX^L;OI-_)
MQ_!3]SL@Z%Q^E77Y]/80XR_R;V=_25Y-_P`\./K&[Z3?R<?P4_<[(.A<?I5U
M^?3V$.,O\F]G?TE>3?\`/#CZQN^DW\G'\%/W.R#H7'Z5=?GT]A#C+_)O9W])
M7DW_`#PX^L;OI-_)Q_!3]SL@Z%Q^E77Y]/80XR_R;V=_25Y-_P`\./K&[Z3?
MR<?P4_<[(.A<?I5U^?3V$.,OH^QO9W3_`,2O)O\`GAQ]8W?29^3C^"G[G9!T
M+C]*NOSZVY;()-&S9H@!P0:-D&B!5%55U"H-D2((E477.JNN<$TP`3J&,<X]
MIA$1$<TB:FJY,T!K0T:`*<WV:U^V455LGP0_[;.2?X.>./\`U[R#SMOLZ_5]
MQ^/'^$+R%ZQ7_J>P_P#('_M7J3[.PUY\3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PBJ`B!B&#H!DS"=,W0.\F<2'2$Z9NG>3.*2AB]0Z#W3"'H$<(J81:L;!X
M/\1=K7&;V#L;C]K^WW:RK-W$_999M*_"4LX:,FT<V6>&:2K5`ZJ3%FDD`@0!
M$I`Z]1[<F;7>+/+*W;:VEU+';L]RT$4%37##A*B[C)<INIG7%Q!&^9VDFM3A
M3AX%9OY-W@?\UK5_^+SW\>YL?O9O+]-FYQX%A_=W(_HT7L^%/R;O`_YK6K_\
M7GOX]Q^]F\OTV;G'@3]W<C^C1>SX5DW5O$+B[I.=/:-4Z&UM2;*9,$B6&-@2
MNYIJF'7LCI*86DG<4)NOOC-C(F/Z#"(9J7F?9UF$747MU-)#T2ZC3R@4![M5
MLVV4979R==:P1,FZ0&(Y":D=Q;&F,8PB8PB8QAZB8PB(B(^D1$>T1'(A2*IE
M43")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(L?[5U/K/>>O;/J;<E%K6S-
M975FVC[;1;?'DE*[8&;.19R[-"19',03^J2L<W<I&*8ITET2'*8#%`<L>QLC
M2QX!:=156N<QP<PT<-:N&J52K4.KP-(HU:K]+I=5C6\/6*C5(>/KU9KT2U("
M;>.A8.);M(V-9I%+V$23*`CU$>HB(C4`-&RT``(27&IQ*[_+E1,(F$3")A$P
MB81,(F$3")A$PB81,(F$3"*H>D/IA]7"+S.?I(>0_IBD_1E.+PG_`!.^+?X`
M]6_:C%Y(VWS=GD#O+1G^.?Y1[ZV=S.L281,(H)>9^QJAK'F_L=Y>GDS!,K-Q
MZXYDK\@G2[S.QLLK!V?D"290:R5:K4RP%U%FDVWCI&4*JF"Z8B7H<HCUAOWE
M]]>7L#K2&21K8B"6@FGC+TMV#[R[OY#EF8QYU>6]K)+<1%@D=LEP#'`D<0)"
MP7[4.BOY:2GR:;:^(6<%^H\Y^BS^]*[Y_F'N)^U['\H$]J'17\M)3Y--M?$+
M'U'G/T6?WI3^8>XG[7L?R@3VH=%?RTE/DTVU\0L?4><_19_>E/YA[B?M>Q_*
M!/:AT5_+24^33;7Q"Q]1YS]%G]Z4_F'N)^U['\H$]J'17\M)3Y--M?$+'U'G
M/T6?WI3^8>XG[7L?R@5?:@T7TZ_9G*]!]`_<TVWT'_\`H+'U'G/T6?WI3^8>
MXG[7L?R@5/:AT5_+24^33;7Q"Q]1YS]%G]Z4_F'N)^U['\H$]J'17\M)3Y--
MM?$+'U'G/T6?WI3^8>XG[7L?R@3VH=%?RTE/DTVU\0L?4><_19_>E/YA[B?M
M>Q_*!/:AT5_+24^33;7Q"Q]1YS]%G]Z4_F'N)^U['\H$]J'17\M)3Y--M?$+
M'U'G/T6?WI3^8>XG[7L?R@3VH=%?RTE/DTVU\0L?4><_19_>E/YA[B?M>Q_*
M!;T>6]<Z[L':'):RU%S)R4`2F<>X7X6>5FU5UHK*LI3>SQZP:C:(2$4>KLVL
MDW.MX)5"I`NGWA`3``]G;AV=U9V,[+N-\;S,"`X4J-FE5Y?[=<[R?/=X;*YR
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M61^"!61<,W+])R@JD%AC^\4Y0,7X0:]0_P"$(]^FTT8$BJK0Z:&BN42F`1`2
MF`0]("`@(?3`0ZAERHNI6G()LI)I.9R$;*PB;)6<3<R\<W4A$I),ZL:K,D6<
MD-$IR229C-C./#!<I1%/O``Y2H2A7VYF(=DP1E7DQ$LXIRI')-I5W)L6T6Y5
MF'3=C#I-Y%=PFR74EWSQ%!H4AQ%RLLFFEWCG*`JC3J2A[JX[*R5N3-$EC+'7
MI(T^R>R<`6.G(M\:>C(U1LC)24&#5VJ,Q'1JSQ$CA=MXJ2!UDRG,43E`51J(
M5:%=UT'Z`^GIZ!]/T/IY547#>OX^-]1^$G["-^%)%O#QGP@];,?A.8=E4,TB
M(X'2J7K\J[*B<4FR7?75`AA*4>Z/2A--*+F``CZ`$?I`.515*0QAZ%*(C]``
M$1[.O7ZF$5.@]G8/;Z.P>WZ6$5>Z8HE[P"'7NF#J'3J4?0(?J#A%YF_TD/(?
MTQ2?HRG%X3_B=\6_P!ZM^U&+R1MOF[/('>6C/\<_RCWUL[F=8DPB81<E%Z\;
ME$C=VY0()N\)$5U4BB80`!,)2&*`FZ`';E$7[?"DG_E%_P#XVX_A,*E`GPI)
M_P"47_\`C;C^$PE`GPI)_P"47_\`C;C^$PE`GPI)_P"47_\`C;C^$PE`GPI)
M_P"47_\`C;C^$PE`H5>(._=V7;SHO-RU#9-K[!G-1Z<UOP^-K;6LQ:I9]3J-
M+V_7T5)6B4J,"JY-'0B]@>IJJO#I$*HNHJ(G$?<TH7.=>S-).P`V@X,%N2L8
M+2)P`VB75/#BIJOA23_RB_\`\;<?PF;JTZ!/A23_`,HO_P#&W'\)A*!/A23_
M`,HO_P#&W'\)A*!/A23_`,HO_P#&W'\)A*!/A23_`,HO_P#&W'\)A*!/A23_
M`,HO_P#&W'\)A*!<=9TY<B47#A=P).H$%95142@/3J!?$,;N]>G;TPJK\,JB
M81,(F$3")A$PB81,(F$3")A%Q7K]A&-E'LF_81C)'N@L]DWK6/9)"<P$3!5V
M\50;IBH<0*7O&#O"/0.W*:-*:="Y?01`!`.H&`!*)??%,!@`2F*8.H&*8!`0
M$.P0'"+B@]9&D5H<KUD:7;,VTBYB2NVQI5O'/%G#=G(.(XJHO46#QPT6326,
M0$E5$3E*83$,`.+6F.G4NNC[)6Y=ZZC8BQUZ7DF)7!WT;%3D7)2#$C.3=P;P
M[UBR=KNFA&DY'N&2HJ$*"3QNJ@;HJF<A0(.`(JJT(Q.A=WT'Z`_VLJJ+JG<Y
M!Q\I#P4A.0K"=L7PA]CL&^EH]G-6$(AL5Y+C`Q#ERE(S01+,Y5G0MDU?5DC`
M=3NE$!RE0#364H:5U+Y7GX!J:;*ZGH-J:L,DI*S%<S$:W-68U=JX?(25C*LY
M(,#'KL6BRY%W?@I'12.H!A(0P@J.9*%=GXJ0H@Y!5(6PH>L@Y\0GJXMO#\;U
MD%^]X0M_!]_W^O<[G;UZ=N$72)6JJKNJ^Q0M-97?6Z.=3%19(V&'6>VR'8MF
MSU],59HF],XL<2R9/$5EG+(JZ"2*R9S&`IRB-*C`5%3H5:'@T+]0L=<&9"N!
M8J^-C%7P`KH3<6-@%<8X)@$`A`=_"@K##CZYW/"[WJG[MT\+WV5J*TJ*JE#2
MNI<R-DXR:8-I6%DHZ9BGI#*,I6(?-)2,>ID4.B=1G(,%G#-T0BR1B"*9S`!R
MF*/:`@`8BHT(01@=*YX$.(]`*81Z@'0`'KU'T!],>N51<%K(QSY61;L9&/?.
M(=]\%S"#)\U>+Q$IZHU?_!DJBV554C9+U!\@OX"X)J^`NFIW>XH01HBYF51,
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M&<?/I)+6.61<F=MFIU4CN6*"RZ7?32,.8WW,#(S)M`M'`05<V"8O$>R0X\(6
M69SEKQ5K,3KN?L/);0T)`;>*JKJF=E=K4J/A]D-4)%*(5D*7(.YA%M/Q24LN
MFU,[0,9L1RH1(QP4,4HWF:$`$O;0Z,1BK1'(:@-=4:<#@OS=<D*%5[5N6(VK
M8M:ZEJNJ+90:<SO%OW-KM!K99>\ZZ#8A64W!*2323U?+LF*;@&C";,FZF&3<
MT@T*9H(&P96-<6O+6TX2,<*Z-2=6X@%H))XCPT[JR%0]PZAVA04]KZZVIKV\
M:J,C,NE=E5.W0D_1VK2M&<%LSEY9(QZXBVB=;]36%^"JA#-`2-XH%Z#ES7L<
MW;:06<-<%1S7-=LN!#N!:)<6_,TTOOG2E]Y+[!V'QMTSHF-VM/:XH%A=\A8.
M;GEB0UHM]<C4MLLI"%K<%0[S=HVKI3\-"1[Z95<0<@18R@>&8Q]>*Z8]AD<6
MM96@Q[_`==,<%EDMWL>(VAQ?2NCO+89WRIJCK>W&/5M)4JM]H/)73G(/<4)N
M*M7.-E:PTA-'!JD[92&<Q9'T)8H>T);*4,=\1\DFR!@/8IWS>'D,S>L:P4+7
M`FM>"G?JK.J.PYQJ'-(%.6O@6#)CS*--RNQKS2]%3^G^04%0N)&VN3$S=:=R
M!UW%59E8-6[`IU*-JZSW&06=4J@I3+.VA(FGI9\BS9MT@.9,Z)A5+8;IFT6Q
MT<`PNJ"*84PKJTZ2KQ;O#07U:2X"E#K%:\:VCG.4O'"GV>NT"^[[TI1=EV5_
M6H*/US9=K4B.MRMIMD/#S<)6FL2ZF&[U](2C*>9F9&(D!'Q'2!D>\"Z0&RF6
M,$-<YH>=50L8CD(VFM);PT7Q:^5_%VB;,9:7NW(S2-2V_)2$+$,-7V+9M1B;
MZ[F+)ZO]CT,C5GDJE+FF9PKQ$S1GX0.5TU2'(02'*81FB:[8+FA_!4501R.;
MMAI+>&F"S^("41*("`@(@(#V"`AV"`A]$!S*K%3")A$PB81,(HF^=O!G;?)?
M=U5V#J5Y1Z0NIQ^VCHF[[+M-Q>NI=O3KK4MIMH^"HU$0UM)3]!O+*^6Z,?-K
MU5[A7Y$D8+]A(M))MZJCFG<6[Y9`YE!XI!->&NJF!J=((XZK9AF9&PM?4^,#
M3FTXX\A!6HMJ\O;S%;J>HL)W853'7%`:<:I"'U0ES%Y%J.9:?T1.:1G"R#+:
MDM3IV=UYL#U>J6]DE:H)@R66^&6RIVXG*HL3"ZVN'$$D;(IAM'5373`X'$<2
MR">`:CM&N.R-==6L8C`JY(GRU>;3L:S/[%W=K*^['C8]DA-WR3D9=U+2[M[!
M>74SM3EXL]HYCS#R1?\`%:W^(\>%.X>"_CW!Q(HX6*TKYM/@7.!=P^\XOO3[
M"&XBT-!#>#WW'QA9)J?$3S(D]@:HL<_R-F:Q4X;?NWMB[`J-?Y-;$V&@C6[3
MM?7]FULPAW&QM=K+VW7U7U%7)&J/:;,'7(9S(.Y!J\05?@:.N;#=5&T\T#C7
MQB=8IJX,*=WDM,MOLD!N):-5-1X#IKC7P*PJ?Y9_*FQZ+Y04#>^QZA8=B\AK
M]P(EI>]2NS++O%Q/LN+E[BYS;=ODB[:UFK#0Q;\T:NGU?I2L9+5N*%R6-4$6
M@'#+1:3%KA(07.V<:UT$$G$:Z:-`T*XW$8>US`=EH=JII&&@ZM9[JR3LOA'S
M:M^QOL,C]KT5WQ6JNV=?;"I$/,W:8B):0KE-N'!JR0%)D-/U/6,1K2F--:.>
M.%VD(<L0Y+'?"%Q`K5G'HF6[M[H)R[9J.J!!&/!L:J4PH:<JL;-"UM:'K*4T
M>5C6M<:CF7&L_`#E?&Z$XIT[3>TZ)KW;G'GC#O#3$E;8NPV6'%W,;2W!Q_NK
MJ-IMDCZZ:7@8VS4#6,Y"N)<B2#V,<R2"R*9NZ91,ZWEZMC6$![6D5Y2TX=P'
M%&S1[;BX$M<X'F!]LA6!N;B;YFM3UC.WW67)';=SV/3-.055K-"9[SLLU,60
MXZ1WO5KTFI$)5RK4JW[(4VG:Z-(1=@610F!:5I99)P1\80?6/AN@S::XEP;H
MKQ'G-2,>)7LEMR[9<T!I/!QBG<I7#C6*M>^6_P`K]P+ZZV%LRU[DJ!W[K2TK
M<EMF\JMTMMR5>;T+N/E`_5E*1$M22CBKM+M2MJ5U>JOEY)A::_$QZS"0#UQX
M[74M;;2OHYQ<-%:N-<"[1R@BFL:U<Z>-@+6T.G0T4Q`T\A!KJ6[%]X?\U=DH
M\72SG*:[5U;6^B>-5%WJ?6N\=E:W^Z1LRN;#BU>3]T4&H145]D+K8&I324=$
M/W8-G2,@X(N0C-=-)REF=#.[9J\BC6@T)%37QCAPBM%B;+"W:HW2214`T%,.
M8K5NY\"/-#V1JJ1U!L;DA!6N$+3(N7/8FG(W<55L5WV'%Z]XMQC"F3*L#063
MJOU>-V%I.U2X3Q'CM9P[N1W1X\%/6@4Q&WNG,V'.!PZ1TT;AHX0<>-7B:W:[
M::T@UX!HJ?:(PXED"X<+/,OV!?MQ23CD^[UIKRXS=MEZ55M=\F]\A(0[EKKW
MD]$:O7">E8UU.P;5M<+OK1S/L&3I&-D5*N\6!H"7A-W%Q@NG./CT:>`G@=3O
MBNK!4$MNUH\6KAP@<(K[=.5;Y\'N/^U>/4'OJ)VU9!N4QLSD1;MR1%H^Z9=+
MZ5_'7R#K3J49?`5O8-$-='A[2V?H@PC%%F+M'PG!?!$003V((WQ[6V:U=723
MIY="P3/:\MV<`&TT4_VJ'C])#R/],6]Z,IQ>$_XG?%O\`>K?M1B\D;;YNSR!
MWEHS_'/\H]];.YG6),(F$3")A$PB81,(F$4`?`0XNO/6\]9PIT!1G7.#4:D!
M.PHMQU8J;J<!ZB97JT+V]0#T]G;D?;_/I^1G>6]/\SA_M=]3^9(+13")A$PB
M81,(M2.;/(2]<7]&.MNT77T;?_@6U0B%Z7F%+$XB=;:M!I+RM^V_+UJDL92_
MW2%U_$1/CO8Z`:NI,C111X"2B#1<HX9Y'11[;17''B&L\)IQ++#&V1^PXT]L
MZACACQK3,GG!:R:Q$@YL>J;1".Y#>.PM(:_D8JZ:UN$-:TJO,46H57;RL(QM
MD9L%EK"V7;94*U5.$2=>/0=E,H8RABIC@\\8!B#[H@8C'0*\-,5E\U=7`C0"
M=/'AP5H%B>K^<F]O-)U6M#:F;5?:4U2=.3VS*9=?5WD.U?[6LW!I-A-T&T4>
M_62-4J$E1>8!I!BVD3&FD7+-!%\BU.19->T7NTT4%'T%0>/9T4.BCN57FTH3
M4^+4T[FUIP^]69HSS==7Q=+83EVUCL>6DE-=ZTNRTIK>-J;ZJ/IG=.])+1&I
M]?(1TCL-_<:I;K98XIXX23F4$4%(^*>O$E3H^K%6N%XRE2#6@T#A-`-/V4*L
M\U=6@(I4Z>(5)T:%?M#\R6`W!R;X^Z%UMJJ^14)LW[)4MB6S:L7&4N8IL^TX
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M6T&/$J"V<0#4;1U8Z*`UT<:MN:\YG5+EBR<ZSX_;ROQIRQ4&%I[J3>:LHT)=
M4++M'CCK2X+0LC+WYV\CI&@K\IZBJ="5:1[>1</3HI.2IMW+E&AO6?<M<<1P
M#6!PZMH*HM7?=.`T\/`3P<14R!BB4PE'J`E$0$!Z=0$/2`]T3%Z@/IZ"(?0$
M<W5JKYPB81,(F$6G/.?C7/<L=+5K4D!,5F"\'?FA-BV*0MM=@KA$A3=;;#C;
M1:VZ=.M<%9*C;95S$-#E9QLNR6BW2XE*YZ)]1S!/$9F!@H/&!X<`>!989!&\
MN/1(YU'ZQ\O7F?4=M:]HFM^2=JIG"C6S32>N&T'#<C]TQ.V[?I76SW2HRZ<@
M5BT"%I>RI*'JUN8N'E87@VSMO,MRE!(>^HCJNMKD'8B?2(``8G532.>M*56<
M7$)&T]M9#4Z!I-?M::K&L;Y<_F":\TW:M?:CW'4X&T/:DUU_"W60Y%[X/<2H
M1N[>66RX^_1U^9PS2V02WJ6W*8)ZX\7EX=,\3(E!)94Z*BH6UPUA:QP!I3W1
MKI<:U[HPQ&"N,\#GASAA6N@<`&CN'%<2W\#>?&F:IM3;>B]B0I^14TJ1G4OL
M`E)A;[*Y;;'-7=M]ORFPV+F,KL>O2X;5G(=:Q.%#*&!E8H!-<B1RMTS*4=!<
M1@OC/X0\'&XDUXJ&O*$$T+R&O'B<?$T`4[HIR%;A<F>-'/J?N:$+QKY!MH/5
MX:AU55`M5RV[?86_Q=\U90N1=2EYX8.*IE@C[,ZW#/[*I\S,RJTDT7(O5`,=
MNX4!N(9I(K@FD3O%H,2<:BO%KJ,>)8HY(`*R-\:IU88D=ZAYUKQ)>6US%2NL
MCLB/Y$S-EN5-UUL2@:@GKCR$V^YNK6I;%V?Q:O=XHBNPUX64FJ<IL"O4'8T,
M6QMDWLC7OAZ*4:$$C%N1EC-M-7:VJN`(&)UEI(KQT(KJJ%D%Q%39+<"030#2
M`16G-AKHL:['\LSS`[EK/;]=/O"JSLSO:I-Z1?XMYR`VW57TO66VF^2.N]<P
M%]W!$Z\D;EMB"T.]VM7$5FLFT(38+6'65DO`.8I%,9M)]D@$5<,<2-1TFF-"
M1Y6M5;<0AS30T:<,!PBM!JK0\E<%EEYPB\R(U>V_"O>33ZUL[1LZKN86IL^0
MU_U94[#I6-?[,(A3(&7JNN)6X:$DJS`6:M,GJ,,H[C;,SJ_JRZ11=*N%,O47
M(:1M:3PD"F.&`PU<M%;UT%1XN('`#CAQXZ^2JNMQY>_(NI(<4[WK*[U5KM_B
M_P`"N-_&1F@79U^I]1LMQU3O/25ZVQ`M%(VM3#.$H.W=6Z_F:\M*&BEG9_7D
M`<,CI$_<WF\K=AS"-MK&C21H()[A`IW53KXSM-<#L.>3H&L$#N@D%=IQ3X(\
MHM<\E-5<BN0&P-?WBQP%CFK)L&5C+3:K/8I-Q)<=;!IUBVCI2P5:&<2Z<.^D
M&C=%1R+8PQ34H]TIP!'+H;>5DHDD()&GFIP*DDT;HS&P$"F'/58>IGE]>8OK
MZM+4NG<I$:A7(;BQ;]8:PB*)M.S5BGTC:<_![/1"0E:J>@/0EBFO=MB[,TLS
M,[69CW3(&_0[5'U=UC;;7#!1KJ#9H*'70\7)CI5YG@<:EM3M5.&D8<?!A18F
MW!Q!\Q:Q[LG..RVP^2=MXW6W7V_JKK_9D5R!V.G6JFUVZWY2$U^&\;DI*-)^
MY1^M$;#34IIF^!Y/N#-XQ&&7<,T))-2U\-P9#'5QC(-#4Z]JE>&F%=>BFM7,
ME@#`^C1("*B@U4K3EQXN%;S\0.%/(?0>^E-N6'8B[&G7I.QFVOJA#>&Q]HU^
M1<H<;^*.L=;RPI6Z"BH^RWZN;`U!:E7MG61;2SZ(D&9%5%2F,V;YX8)(Y-LG
M`Z14G4T#3KJ#CIHL,LL;V;`&(T&@&LD]RA&"EGS<6LF$3")A$PBB?0\O2(VU
MS%YM[5Y%1U^E]+[0NO%"PZWUI&[AGH?3>VPT[IRO1LK([@U)5)EFTN8U/8L&
MD5JTL)#,W)$"B+==#TZ1M0^X?+)[@TH*Z:`:<>$:#IPX%L]?LPL9'3;`-33$
M5.H\G`L<[AX'[7V)J#S:X>!HU#;;.Y7\JJ?MC5[V?DH!H3<^J-<4OC(Y3UG=
M;4R1D9"K5383[7%HK*C60("+9*5666;BV<*">CK8EDK6@`N>".,`-P/$:$*Y
ML[6OB))V6MH>(FN(Y*@K'/)/B9R0Y@QG//:<+QI0XWRVVN$VI.-VK-(W6[ZB
M<VW:^P]6;OEMX*VBUR.LYZSZXJ4/!1;DM2JKI[)G=*$=N5EB,F?A%'!-;33@
MO#=DAH%*BKB-K@)X<*DJZ.6.+987;0#B2<<`:#7CQE<KD?QCWSM_?>V-TS&A
M.3J^I.6W#K77'VSZ/TKMGAI6KWJQQ5+!M\ESU?MHVW4[/3%-?[!A]C-Y-"6I
M4TX%C))K@[;J+$:+)7R0RO>7EKMES`*`MPI734G`UU'VD9(QK`P.;M-<34AV
M.C$4UX:PN^L_`K:<KMF7,;6L;9=3#Y@'EC[DCV]VM53MKB2TOQ:XD,]4WZ>L
MQ)5P)K#.52[QK=`R:[<'<LNGZXW1.F(&"UUI(ZY#J5BJ->JC?`C;A@BI6C]E
MP[I)/MJ0#B)IJU:?V;SFEK/6XZN4_=/-.4W3KAO'N8ERQFJ9.Z,T36)RP*Q$
M6HJ6&=S%[J,R+INX32<N%2F<'((+%.?=AC,;GU%&E]1R4'MU6O*\/:P#$AE#
MSE1TZHXH<C>/=;\NO9KKCVEN:2XM2O/F)VAH:I6[53*Y1B_)_:<Y8-8;JU\^
MO%A@-:66RU.J,PC73=6792#6)LK@K=03I+MS:K8)8VQN#=HM+JBO"<",0-`X
M=>O$+8=+&\O;M4#MFAQU#$'7_L6,E?+;Y1V77!:RT@ZIJ.5VGIKSIA<P45=(
M=]6.-EH\P.TZ\LFC=0(OX`$?AF/CT(E\2<?0#96,8O57@MQ,D9N=6TVTI;0`
M`D2:_<[9%!W.)5Z^,.KB:&/N[-:E<[9W%CE)O^,WK+Q?"6#XV+3?DX;8X+U6
MLNME:/?S-TW2^L-$D*O7B&UY,/8:+U?&M(MXUKDE)/BG%L54SAM'`=)-889G
M[9V`VL1:!4:<*#2<.`X<@UFR1,+?'VJ2AV@Z,>'7PK+^^N"FU-A:_P#-U3B=
M45&:V%REUSQ1K7'R8>/Z8G.6*0TQHO7T&\9#8G[DCBGH5+:,"Y79"]6:I>M)
M`[1Z]2J#?);.>)33QG!NSW`.\1K5C)F@Q8G9:37NGP+22H;(C(_G)<YS8;LU
MITPS\YFY2^O]>:^NVA0VL')RP1C7CA7KS:-669%#E3+:SK(23E_,-FBQF)VC
M<TPU`:\BDW'6:Y@NR#M;(DP`T5]R,.+@TTQ]RMAS'&V!%`[JZ&O![K_8=%<-
M*]2Q@$IC%$0$0$0$0'J`B`].H#[H#DRHQ4PB81,(F$3"*,;E[YC"O%?D-KW1
M#;4T9L->YT6E7M8R6PW$%?I!E<]GV76"S+7.OV]*GRW96CF@@L%@55D8Y-A7
MDW*X=\R(%-JS7/52"/9K45TXXFF`IC32>);$4'6,+ZTH>##17$ZJZN-:;;#\
MXW>L#0K&M!\5-?Q6U$./*6ZXBGR^W;C:W\.RF.-JG*>(O<Y5HG4U;DYG1</2
MO#JDM/-WC11/8AC12:?@$]<'`Z]?LFC!M;-=).K:KHT:B>E@LK;5FUBX[.U3
M1QTX=.NG!BLM)^:+>KI?KKK^MZ?:UYCKK>G'77+W8%9V%5KXC;HZ_;DU10K4
M^8T^7KK&RMM97R`V"K)U6U(LO">P;?UD%6CI9$A;_.G.<6ANAP%:UK4@<QK@
M>!6FW#6AQ.D$TI30"=/"*8CA5VTOS2+,_P"+^VN3FQN,[VG1.FQXN7:VU>L7
MN7O#Y'1/)FJ4NXFO39937%=?O;GJJ&M:JDW!(,E43>I'!)Z(B(A47;NK,CF4
M`H3C7`TXM5<>14-N.L$;75)KJIB*\>M:PNO."W]:HE:^4[CE'ZLCJC7HN)V!
M4=[6"29U:"OT'R)XB:?W^-BM\%1"6&'C])+[[F(M&20.:(>%BG<JLB=-H1`^
M+SR1PVFMH`,:\.TT'&FJI[ZR"U8#LEU:Z*<%'$<]/:6?M/>8]N2.U%RSM>Z=
M+&N<OQVUON/?=#D==3"WKFW=<UWE9R2T56ZK)P`T:)9TF?KS+3+98[EJI-%>
MP:I9-7N+G.@-[;M[6NVVDD5(IK%7#'@]SQZ5C=`PN:&.H'$`UU'9!]OVE8EX
M\YZ7U[6:]/3_`!FC7!9G06V=Y.92%WA&3E(8&U0_W<U:4Q>Z5RF6*#;3>Y(S
M499:H)*+^LKQQ9D'B+=Q$%1?'7I:`2W[DG3AA7"M-=*CN\"N%I4TVON@-&.-
M-7%7'N<*[RJ><#8++=J'2T.,K.13L+#<\E*WBM[GC76O;3$ZIO>UJ*E:^/<]
M9JC4WN[:H[/K).0?"T9MY%NRED3(-7`$[RM6WA+@W8X<:X8$C#`5T>RJ&U`!
M.UP:L<0#CP:5B+9'G#[M/3ZY78?053TUM:V3VL7+68G]BR=W@5JK>'/#&Y-*
MOK..>ZEA_NF[G=ZXY4+?"L$N2);1#>O2;Y%\X*@3NV.O)*`!H#S3773LF@PQ
M-'>P5>VU96NT2T5U:_&TXX"H]E<;;7G4;-5XR;"V3K_CU!:JN$D^W'6M8S^Q
MMK1<Q$UR8HNGY_8D1`6BLQ-*L$PCR#5FXTD6QHDNRCD9EXFJ"3T$B&'*.O7]
M42&@/Q`J=8%=&..JAYT9:-ZP-+JC"M!QTX='&ME^3'FN/.-F]+5I;[@@[77H
M^IZSL&7;U#8#E#;$R>R\?-K;P+/1&K$*'+-T=6U=WJ@\/8IU25[\6XG&!TF;
M@1%(]\E[U;RS9K3CQT$Z*:,-/&%CCMNL8';5*G@PT@::Z<<.182=^;_?JJ_V
MAMZV:A8630&K*-5XBSAJ.QNKS592T2G(#=NF([=^FME+4&$E]I:OO=KK]1KZ
M**C%B5@I(.G@"H1J85[?/7"KW-_!@:N4BH-,1H"O\U!HP&CR=>&H&A%<",2L
MF:1Y][RN/+S6>G=E6/4%5L.P]^\E])7SADE754-MZ`J&D-8S-TH^ZG&T'TXR
MD+ZQV/,P;4J8GA&L3*1UC:C&`"K%R=1%=2ON`QVR&DG#6-.-=>@<M>)4?!&V
M$O;M$@`UU&I&'?Y*<>&H_P"DAY@],6?T93B\)_Q.^+?X`]6_:C%Y(VWS=GD#
MO+1G^.?Y1[ZV=S.L281,(F$3")A$PB81,(H`?+I#Q/.U\_1P8/$,G+\'F::X
M@)NXF34UB[S4JG:!0(*9>I.O9W0[.S(ZV^?7']GO+=G^:0_VN^I_LD5I)A$P
MB81,(F$6.MHZ_P!1[)JPP&[*9K>\TEK(M)L8C:D'69^JMI:-3<&92HM+:W<1
M*#]D@JL!%A`#E2.H'7N&.`V/:QPH\`MXU5KG--6$@\2L.6T-Q2D;6:TSFG^.
MKN[N+,PFCS\K2=:*6=:XRS>+CHF2,_=Q_P`)'LLJVJS))HIWO6G`1R/A=X4"
M]VTQQ5J0W:KP#3]@5P?)2@+MFG'H70Z_UKPM+6T5-4Z\XPA56MEN[5FEKVGZ
MP^"_LRJL_"/=B,8QC78[NN+1`V?648K*(-DS.T'D`S,H4#LVXD-;!3Q`RE3H
M`TZ^]["J735\8NKQU[G?]E?%:TEPUV-$H6>OZ1X^SC79>NH$%#.-3TN/L%CU
MBZ4B+'7F$[`2]=86AO7VKLK%VBS?M4?4G9$3>&DL4G2@9"X5#6XC@&A"^5N!
M+L#PZUDZ&T3H^NW**V+7]-:J@MA05<CZ="7N'U]5(VY0]2B8A6OQ=9B[.SBD
M9IA`Q\`L9BBT27(@1F/@`7P@`H7B.,.V@T;0&FF*M+WD;))V>5<9;C]H1S&'
MA'.D-0N(92,3A3Q"^MJ<K&'ATJQ-TE&*,P/#&:C'(TRS2401'N^&2,D'+8`!
M%=0AG5QZ-EM.3N)MOX3SJVE^)7%1S&14(XXS<?UH:"BG4%"1)]/:^&-AX1]8
M4+<]B(QC]CX-F,<\M;8DFJBD4I%)`!<&`53&,-O4Q4ILMIR#E5>MDT[3J\I7
M?/>.G'N2@W-9D-$:;?5MXP?1;N`=:SIBT,XC91W5'\DP5C3PPM#M)!_0X)=9
M/N=U1:%8',`F:-Q3J8XR*%K:<@^S4.94VWUK4UY?LX5F0`Z``!V`````'H``
M#H``'N``!F16IA$PB81,(M;>4^^9[CSKNLVNJZZ1VE:KKM[6&FJQ4GEP"A19
MY[:,VK!QTO-VO[&[<I%0D.LGXKHR<<Y5%+J!"B;H`XII#&T%HJ20.#2KXV!Y
M()H`">'0HNH#SNH7X+B76Q>-[G7,O:J93;K189WN>*E$KC]TJO\`%^WT"D1<
MLI0(@JNQI*K<CEW;^,;MW0L25AV8AW*1SJMM47PIXS:$@4QX=FFK3XWL+9-F
M?N75`..'!7CT8>RK5/YWDE1ZO`_=,T11[%LA1CR0>7*E:CV]/.I"I.-+2O)-
M&L1<BRL^K4&+-Y9FW'-TTDDC2BC^*<R+5RHS!!=),UOGQ:/':-KQL`>#:XN+
MN*OF@)\5QV<-(X:<?&MF-0^8WLV_[WV'K&[:+H6N(766@>2.PIUDEN%]:+I8
M-G<;-IRE,LM;UVHM0JS%7&F/ZT2.?*N@0:O8U1_WU4SHD3!7(VZ<7EKF@``Z
M]8-,,%C?`UK`YKB22-6HC7BL`5/SN'=RI4E=X+BNVG(:MZ[N.UK;-UCD'%6.
MEQM,@*9QDLK(L1<66KB,YRQPLSREB8JYM11;-Z<>"FEE7#L&A4E;&WQ<W:#*
M@`G3A3Q==/OL>"A5YM`#0NQK31QGCXL.&H7R^\YVV0TG=Y*5X_:^>4N&IU$)
M3%Z[O=63+>;O.\L]H<6K'L&M71;7C2"LO%ED]H+>5;VYJQ352;R;`%D.LFB#
M:GGQ!)V12@UZ]HMKH]SAIY.%/-`:4<:U.KB!IIT\7@5USGFSWBGKVR4=<<I>
MT1[=./O;ZK/;_5*S(ZLUM#<<N)6X+W',;#6H"[0^W+2C)<D54X[PW#)H]58F
M(5TFW$AR7&[<TFK:Z].@4:3PU]T@M@:>-Q:-)JX#DT+:'GAYB];X$W'6\)>]
M1W.\578L'.61*Z5%X!R0$'K>T5\=Y24M"A#O5O5]5:?G%+F8"K@>2:L'#1(I
M%2@H.:XN1;N`<TD'@XM/,,5BA@,X.R0"/;T<YP4>^S_-BY0PU3V$[@-5T"AR
MSW7W):UU-KL>?2&W4>\:DTGQ&VS4M6U^';5TD!M:0,WY`/S27K8M7RB35TL0
MA$(HQ76LZ\E`-``:.TZB`TTX]/V46=MM&2*DG$:-=217BT*:?C3NR6WYK:4N
M%CH2>L[75]L;HTW<*:UM(7>*C[9I/9UEUG.NX"W?`%54L-=F'=<%VR<*1K)4
M45@*=(!+U'>B>9&U(H02*:=!HM21H8Z@-10'G%5G_,BL3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(K9+2*02TGO1*13"7I1L+)2\DJ=>+=5&0H@V%F>V
MEC@L)VHMB@F*8N1)X8=WIW>S+=EM=J@VN%5VG4V:G95S9<J)A$PB81,(F$6`
M+OL[C%JK<%96V+?-1T'>FQJ:-0J:MJG8:%OUKH4'-2<X2!CC/%DWBU<;6-^\
M50(;N)+OE54TA45$Q,Q.?$QXVB!(1APT5X;(YOB@E@/<76J<R.):,-K"SK<D
MM*(U_=KEU$:>GUKY`)1FT%6=FCJH]:TB05<%1L+-M;IAHQ4.@8S8KQVB43=5
M2"9U\-`=IM':,=.K!5ZJ7$;)J-.&A6/*\_.($59ZU7FF[=>3Y)RVW/7\_:JU
M9JU(U/6DYKNF2]T>M=FS@2:'V-QCN/AW#2+<%(X;.'Q3)$,4"*G):;B$$#:!
MQ(Y*#6JB"4@FAT<^-,%=JW,?CTGO?6?'-C>4YW9.V&FRUJJ>ML%)RG-Y/5$I
M:H2W5.RW%B92'KUR-+Z_LC5C&+F\=ZO6I1,@`9FH&5ZZ/K!&#5QK[&G'AP/,
M53JG[!DIXHI[/^T<X6SAO?@8IP*<IBB0Q3E*8IR&`0,4Y3`(&*<!'J`]@^[F
M98U]`82CU*/=$/0)0`!]'3TAT'"*V+;3*C?:C/T"ZUF$M-'M46M"62I34>@\
M@)R'<%`B\9(QQB@@X9*$#H*8ATZ>C+2T.&RX5:54$@[0P(5R"!3>%WB)CZOW
MO5^J9!]7[Y`3."'O?W$#I@!3=WIWB]@]F55%]=?1V%'NB)B]2E'NF,4R9C%Z
MA[TQDSB41#M$HB'HRJ+Y`"@)S`1,#*+>L*""9`$[@0Z"Y./=ZG<"`]J@^_Z>
M[E$5O1E0JL+:+3=HBNQ$;<;NVKC.XV=FS31F[,TI[1XPJK:9?E#QGB-?92"Z
M34IAZ)$5,`>G*``$N&DZ>YH5220`3@%^-OI%.V!`!5;Q5X2V5@).N3/V/SK!
M%]#C*5"?C;55GIX]0/5E%("RPS1\U`Q1(FY;)G[O4H8+6N%'"H0$M-0:%=G+
M0$!87<.^L$#!SSZ`F&=@@'LU#QLJ]@I]@FZ08SL*[?MG#B)F62#]=-%TW,FN
MDFNH4I@*<P#4@'2*J@)&A>;+])#R(],4GZ,IQ>$_XG?%O\`>K?M1B\D;;YNS
MR!WEHS_'/\H]];.YG6),(F$3")A$PB81,(F$4!OEK@*WG"^?N]3[6WW4.(3#
MO#[TWK3/5MM37+W![>Z!B#T-Z!R/MOGMP>-O>6Y<?-8.1W?4^62"TTPB81,(
MF$3"+2#GMQ<M/+C5VK];5:5U]#!6^1.M=H6=WL^EM-E5(]/J<+>(^8;N-;R:
MC6'OKQ1>QMQ2BWKIBV6`ICF<)F3)WM>XB=,P-;2H<#CHUK-#((G%QKBTC##V
M=2T8>^1QJ4*(PIT-N*4"4]8EXNQ7ZXZGI=[N4[3)C0.FM!-@;2<A*QZ\)M?7
M<;J`\O2;<11=6J2-BE/5V*@+F,;!Y@S9H'=T@'4!SBF!U5*R^>/K4C#@!(QJ
M3S&N(UT"O:!\G;7==VEKW83#:!/@;6VR-Q7JO4I#685YLW0VGO%UON.6)+4O
M8E7(XV)4;)(*0YY]ZR?-IBMMF#)S%E]2*=6X6;0\.K@"32G":ZCI'#P4%%0W
M3BTMII`&G@%.#1[>M90XT>5[KSC5M?66Y(?84A:+MKNM(4US-OJ/`1$[;ZHT
MXL:7XS,JS-6%E(N94M=9KZ:2M:3$3*MDYB25*4@>&5<]T5JV)X>#5PXM6R&^
MU7E5LEPZ1I81@>/1XQ/MTY%*!FVM=,(F$3")A$PB81,(F$5G7V_4#6-7?779
MUOJM$IT2LQ3?V:Y2\=!P;)V_=I,8Q$[^351;@^>OER)-TRB*RJI@*0!$<M<Y
MK1M.(`56ASC1H)/$L2S_`"IXDUEF]?V;D-Q[AF,&"*[]W*[(H+=O$@O&UYPR
M7545D^ZU]=B+C%&:&#IZRWE&O@]\BZ?>L,T(TN;AQA7".4Z&NYERG?)/BHQ7
ME%7^]-`M5HBE1NR9ATZOU"2"/U];O@!>+N[Y\I(`FC6;&6RQ2I7IC^"X)),U
M3&$KE`QW6P])NBND)U<G1=IIKTK&ERYH<+326JM?2>X]1757DDRG8NIQ]=M=
M-L#21U]+T78]CM%YLCAO,I*PNJ'==UC-M'\P8?5@=-_!5$!*<R=KIH,&DM.U
MR:*$UY,#BKA%-B:$;/?J/9Q7RIRWX6:CJ^@J?4=FZI=06T;'1=(:%HNLIRJS
MSN90F+=%:ACVU>KS24*_6I]1G5$64TX*546)$#^,4YTCE!UL#&M`(H2``.;F
MX4ZJ5Q<X@U&))YUD6<Y.<3(%[L"MV/?''Z*D=0Q96NSJ[*WRB-WVNHAQ.,*R
M6,M<*N^!Q`M%[(Y:,/4EDB=YZLW2\/Q%42FN,L()!<VHTXC!6B.4T(:['1IQ
M7153F%Q;MLSL>#8[4US&(ZQ5@"R4Y.V&GQ54LE=L5%U+>(^Z46=/+*,;304H
M?=-69K227=;)2$BW;=O?0$]&SQ.)`(PY*:`:CA&(53%(T`D''[?LX%=/I_G!
MQRWO+3,36):SPJ$;K![NZ%L6U=?3NMZ=L'136<<U:5W1K>SW-HQBK-K!G+(`
MD[?B=N*39RV<J)`T=(+*6QW,,I+6G$"N(IAP\F(YQPJY\$L8!<,":8</`L@5
M;DSQ=V&ZK#.F[UT==I"WQ-KM508P-YIT[(S\+2P?L[Q88ADU>N'B["K%C7",
MHY`@%:%2,18Q0Z`-XEA=2CFFO&%88Y&UJ'"BZ^'Y@\1)IA7)2$Y0<>7\1<KR
M.N*Q*1VVJ*O&6#8*B<.Z4JL8\;3!T'L\9"QQZQDR"8QB2#8_4?641/3KX:5V
MFTK33K0Q2C[EU0*Z%R-)\J=%;_K-*L5`OD,#V^NW,9!4:?E(>*V*2::Q4O8C
MP,C3B2;N1:32E2@W$T1N'?.:'*#O]ZZB%8Y8Y`"TZ=6OF]GD1\3V$APT:]2Y
MNB^3&F^2)]L)ZALCRPFTIM2?TW?_`%V"E8(&MQKJ:*KEQ"&E6[<+)49(BIO@
MZ99^)'R`H+`@H?PC]*QRLEKL&NR:'[.#C1\;XZ;6L5"SSF16)A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M-]]\&-*<CMB,-D;!D=CM'Q:
MS2*E::U4[:VA*?L:%U;>YG:.J4KQ&+P<E(N5];;'GW4Q&GCGD:*KA0$WH.VY
M2HA@D@9*[:=70!@<#0U%>0XK*R9\;=EM-?<J*'G"QAMORW=8[=?<8J_+7F^P
MNEN-VA9CC^KK2!D6C.1VK2C6/CU/UJ`OUN48.%5:HW]GUD26:L6S)[)*+E,D
M\:%3.16U]LU^R"2&-;2G",-/,KFSN;M&@VW&M>#3X5;37RG>,T3%S"4>]V-8
MY8-8W;4-(^Z5;4[37*9K6QZIVSJBL:S1A8J'K3N2U[KZ*W3/.8Y-9T:;,Z=`
MHM)JF21%.WS.*F!=6E!CJH13DQ/'QJOG,A.---<.&H->4T"KJ7RG>,VLVNB)
MY^\V-:MR:&C..X5O<"EXG(N6^R+0+6=<.)5M7TW#J`"/VW:;S:I2TH/TI)Y(
M+6J2`KM+QN\%&6<32UQ+B]H&O@U]TUKRE'7,CMH8;#JX<O@PIR!2?BFH)!6\
M(X)=_N>(!#>$!^G>[@'Z=WO=/<Z]>F;BUU^>$3")A$PB81,(F$50](?3#ZN$
M7F<_20\A_3%)^C*<7A/^)WQ;_`'JW[48O)&V^;L\@=Y:,_QS_*/?6SN9UB3"
M)A$PB81,(F$3")A%`CY8)?6/-7\_>1'W@AR$XTQ?A!VAT8:YO"0+=\1#M5!/
MKW>G9U].1]K\[N#]\WO%;EQ\V@\D]]3W9(+33")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$6NW*'C)KWEIK%IJW9+NP1D5$WRE[,@)BL*PH2L-<Z%(+/
MX!_ZE982R5J:CS`Z70=,9!@Z:N4%S`)0.!#EQ2Q-F;L/K2M>97QR.B=M-X*<
MZT9OOE$ZHD;3%WW4NU=E:AO2MOXON;38(A#7[MD.O.*+2(B]45>BTXU"+1Z=
M.4F(B54(=P$:O')EE'P/&;L@LRL\#K-I.TPEKJMX-#=%,/LJLS;IU-EP!;0\
M.DZ:XKNZKY.O$"D_#36M)W]G#3E+UC35HM[(4N:>,/N6L=*1,=/0]OF**]O$
M4^M$1H&NMYMDC)%AWWAKJ`S3.H04JMLX6UI6A`X-5.+B%4-U*=-*U/#KKQTU
ME?E8O)VXJVF1LRDK9=WA5[L_O4Y=*`QN=9956S6>^1/(JN.[*Z63HQK1'R$#
M5N4-GCXY!C(M6!$@9JKMW#A`RJHV<3CB74-:BO#7B^^*"ZD%*4J*>Q3CX@KE
MK/E4<?:K/ZKLD3<ML,Y'6DY0;))MXA35E9A]K3>J]S2N^-=R6RXBLZMB&KA[
M7;[//CJKQ'P0YED'0ED%71TTE"5%I&"""<".#&AJ*X</VU0W#R"*"AY<*BAI
MBK=_)4:]GMJ[*W5=]Q;3/L28Y#7[?ND).CJTZ!CN/DS<MEZQVEZ_68F>IEE;
MVZU.Y[4L.E)J6(9B(7:H"1JQ:&44.-ILV.<7/)J7$BE,*D'CX!6N"KYRX-#&
M@;.R`=..!'MK@#Y0?'>#<\=F-'?6%E4]+\AJ/O&U1-PDEK*_V##4'2%?U6UU
MFL[9(PK8M7N=JUS4+/8$'B;ILYDH+O()(`9$B%#91^*&D@!P/,*>T"=.(3SI
MYVJZ2TCDJ:U]DA756_*VUA7PG*H_W'N>^:5G.)%]X3L]3;!=U.45UWH>XSK&
MP1]<U/L2NUVJVJOJU]RS(@=S-!9'TBT:1Z2K@A6(>-46<8)Q<6EI;0\!X#AH
MXZZN!4-RXT-`'AP=4</&/]BRKJG@/J[3D_MK8,!;=@W#;FZ-:[`U_?MB['>5
MB1=V)W?Y@9Y_:7L-4:I3H2,D4'35BT!"+;L69H]@F0417%1P?(VW:PEP)+W`
M@D\?)16NF<\!I`#`<`%J[K/R8M$5*DTN)N>UMUW*]MM?4C66W+@SF:9!Q^W-
M=T^FZ`J9-3.X!&A'1K&LT2\;*R9DI&&:6I-!!8CB8<'<*J#B991M:*EQ=0`Z
M,1AAHT8#CXUD==O+B0`!4D<1QQTZ<3Q<2SAIORX];:-Y(UC>](LLZW8T7BL^
MXZU"&>+"\L*-GF]CVFW2>XY:3%)"O.[A%5&PA6XI8D:5=*-,JDL=5+PTPOCM
M6QR]8":!M`.#C^SO*Q]PY\>P1I=7V-'MK)G%?@AH?AK)S\EHX=@QP6_7&M-?
M7./M=_G;LPM3O5CJU.8+8C\EC5?.(^_29;F_2D#QRC*)62.4$F"(D`1OBMXX
M#6.N(`-371KY5;),^4#;I@2='#JY%N9F=8DPB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB8105.+U=P_.3(S6P7*UAKHWE)N;<:@!
M8I@*2:UAOE_'A9S53USX!&P@P`$?7?5_6?"`"=_NATS0+G?60;4[/5:-6G@6
MW0>8;5!M=;I[BG5S?6HF$3")A$PB81,(JAZ0^F'U<(O,Y^DAY#^F*3]&4XO"
M?\3OBW^`/5OVHQ>2-M\W9Y`[RT9_CW^4>^MF/'0\?U;QT/6O!]8]5\9/UKU;
MQ/"]9]7[WC>K>+[SQ.[W._[WKU[,S+$OVZ#W3G_8)$%14X]A$TR].\HH8?>D
M3+U[1'H`95%\)J)JID5243625(51)5(Y%4E4SE`Q%$E4Q,11,Y1`2F*(@(#U
M#LRB+ZRJ+C-GK)[ZQZD]9/?4W:S!YZD[;._4W[?N>LL'?JZJOJKYMXA?$14[
MJJ?>#O%#J&41<G*HF$3")A%`KY58>-YE7G\/%.US[7.D&'?]`>JM:-L8C<G<
M#H7J4B8!WO2/3MR/M/G-P=>V.\5N7'S>'R#WU/5D@M-,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(H;O/<W[N?C7P(3V;H78]EU5
M?S<E>.U0&V5)RBTE_L9M=JD&-BAO&7;N4_49=LF4BQ>[[XI0#T=0'1OY'QP;
M49(=M#OK:LV,DFV7BHV2IEEP`JRI2AT`#F``#T``#V!F\5JK\L(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB810`.?\`
M:@8K_4Y.O_\`860R./ZT'XGVUN?\O_XOM*?_`"16FF$3")A$PB81,(JAZ0^F
M'U<(O,Y^DAY#^F*3]&63Z7Q3YMWC5M,V%QQW+(ZB@-B\3>/J,2_J6S1IECD;
MCJWA]NV`UU'SB3FKV!!I4TN1-NJ;R132[OKT2@Y%43)E,@KE9%.Z)KHG;(+&
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M2!!@K8)61244.J9(5D\CH[G8:&N\85KCQX$X8@#2-:L#[?:<7#`TIAQ8@8X8
MZ#J6V7!'CE,<6N/:.L+.[-)6Z0VUO[9=HEE+`>U.)=YL_=-XN,+)/+`LQ8.Y
M*2<TZ2C!>"N514CWQB"H<"@.9K>,Q1[!T[1/.5BFD$C]H:*`<P6XN9UB3")A
M$PB@7\I/HMSW\^YX3]T14YXTYJ5R'OBG49UB_$5;@H/:(MA.`"7T%Z_JY'67
MQ\_XP>VMVY^(A\CP*>C)%:281,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB810(_G)?_`,LY'_Q<<5?MUD\CLR^;_P!H=];MA\?_`&3W
ME/HX_?UO_P`H?ZHY(G2M)?CA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3"*`)N`+_G/<B97WYF'D]-$V@CV>"1QOXIU
M@``Z`;OF7./ONO3KV9'?\T_X/MK=/ZN_XOM*?W)%:281,(F$3")A$PBJ'I#Z
M8?5PB\SGZ2'D/Z8I/T99QIGFHT#BWKSCAHJ;UZ-P&`XF:7M]EL<5?"0CNHFD
MJ?2Y90UKA9NFI0\=5VE.FE),\JWF7GA%:&(Y;MB'!4N:.[;%&R,BOX,'DP'%
M[:Q/MG2O<\&GCD:.,KOB^=$DXN=N0C]0:R5ULX"H1NG[A8N2$!26=I>2VZ.4
MFI9B_7>TR=1DJS5=+N2\9EUXZ::D?`63FXF-5\56604;W^>U<1LC9U&M-;A4
MX:/%T\8&M6^:8:3M:\.(&G+C]E%:$]YU-BV"I'T_0^@1A=@3UIT4SK<?L#8]
M6=6-)*Z;!X8)VBN;3UXTA3RNG8:V4SEFE%5^TNUGS=2;BWIDVB@()@I:;XN.
MS&WQ\-/&6Z>#!VE5%H&^-([Q<=`X`[1PXC$+OI[SW-9P#>"5=Z.?>MS.MF-F
MDHDFT?%?42_+VNB59Y3+EX>LSI*U=`;T1ZVG809EV[9MNV*176(@6IOVC[G5
MPZ#AAHX]./(J"S<:^-KX-6/'Q<2W*XL^8"[Y([>1T;+:`LFK;]'Z8@M^W+UB
M^0=XJU9UK?JSK"7U+)L+3"0K",M3W8%ANL]!B@U$OP:_I$H*AE""EUS0W/6O
MV"TAU*GDPISXCN%8I(.K9M[516FC7C7FP/=4C6;2P)A$PB815#TA],/JX10*
M^3P/K/,/SW)$G8@MYC(LB%/V*@K'0=N36,8H=XH$,*H=T>O4?=`,C[/XZ<_Y
MBW+KXJ$?Y?@4].2"TTPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB@/\`SD414\N>LL3?O$GS.XHLG/3L4\`UMFU1\(W:!#]](.WH
M/9D?F7S<>6WOK<L/CSY![RGY>`!73DH>@JR@!](#B`9(+37&PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%`&R_P!I
MZG?]3Y'?]_B&1W_-#^)]M;I_5W_%]I3^9(K23")A$PB81,(F$50](?3#ZN$7
MF<_20\A_3%)^C*;+AA"PCWB%QA=O82%>NW/'75\6Y=O8B.=NG,6I4&)5(MPY
M<-E%UXQ0KE0#-SF%$04.`E]\;K(6P'F[/('>6E.3US_*/?6RSBM5EVB9L[K-
M:=MC,_@XS=U7X=RW-'>N)R/P<9!9D=(T?\(HD<^`(>%ZP0%>[WP`V9Z#@"PU
M*Z*MZTU[3Y6[SM8IE>AIK95M4OE]EFL<D:1M=O580D8,[+.W'CKJNB,:VP(F
M0HD12,U(<A"J=3#0-:TD@"I-3QE5+G$`$X`4"Z79.D]1[@K+NG[)UY6;37WK
MJO/E6RK,\2^1?U&=;VBJOH^?KZT188I[7+(T3?,E6KM$[=T7OD$!$W6CF,>*
M.`(56O<TU:<5P]8:!TKI4YU-2ZSJNOS'H]#UI_\`9QHLU*GK_6`V(]`J"!%7
M"Y&\)6%[=*+HII@45',@X76%590R@T9&QGN`!@!W!H1SWO\`=$G$GNG2LNYD
M5J81,(F$7T7M,7_U@^KA%`EY+W_">2/GE21_>JK^:!<6)DR_O94XZ-GR)'#K
MU-WU`6'O=O3L[,C[+XV?\:5NW?Q</XL*>O)!:281,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB810'?G(/\`\O.D_P#C:XG_`&TS^1^9
M?-Q^,;WUN6/QQ\AW>4_;W_CCK_"%?]V;)!:0T+BX54PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*`-E_M/4[_J?([_O
M\0R._P":'\3[:W3^KO\`B^TI_,D5I)A$PB81,(F$3"*H>D/IA]7"+S.?I(>0
M_IBD_1E.+PG_`!.^+?X`]6_:C%Y(VWS=GD#O+1G^.?Y1[ZV=S.L281,(F$3"
M)A$PB81?:?[X3_UR_P"Z#"*`KR0S"MN+SMG2@^(LKYL>Y6YEQ'J)T6:3XC=/
MJ'O1*@100#]0<CK#W<Y_SBMV[]Q#^*"GRR16DF$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$4!WYR#_\`+SI/_C:XG_;3/Y'YE\W'
MXQO?6Y8_''R'=Y3]O?\`CCK_``A7_=FR06D-"XN%5,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A%@/DGNQ7C]K:)V`C7D+.:1W'Q]U6I&.9)2)30;[PWC0-/
M.IPCI)J\,HXK;>[&D$FXD`KI1L5$QTP.*A<4LG5MVM/C`<Y`]M7QLVW;.C`G
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MT-\F8:RN;^/OLG)FL:SWC1<6WK<2SE(7Q(](_KOA.VZAZB[C+@*.XSJ&G`X_
M>G156.MWM:7$C#V1AC[(6)C>:M";&V7Q[U9Q]T_=YJ3W=NZB5G[*=D,:U%UI
M7C]9F_(15UNNH-(+8_PTN>3?\:+,S81TN2/DVA&HO',<J4[9LYIYV'.:R,'Q
MG#3P8XZ?O3X%?YL6M<YY%`#HX<,-'&%+F/3J/3T=1Z=?H>Y]#W,W%JJF$3")
MA$PB81,(H`V7^T]3O^I\CO\`O\0R._YH?Q/MK=/ZN_XOM*?S)%:281,(F$3"
M)A$PBJ'I#Z8?5PB\SGZ2'D/Z8I/T93B\)_Q.^+?X`]6_:C%Y(VWS=GD#O+1G
M^.?Y1[ZV=S.L281,(F$3")A$PB81?LW#JNB`>D54P#^R<N$7G[\B`Y7%H\Y)
MZB/?:N/-UY%)HJ]!*!SMT6`K%`I@`X=P%R^D`]/9D=8:9OQQ6]>Z(OQ04_V2
M*T4PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB@._
M.0?_`)>=)_\`&UQ/^VF?R/S+YN/QC>^MRQ^./D.[RG[>_P#''7^$*_[LV2"T
MAH5D#?J06WR]`4ML`C=8"J0=ZFZPXDD&TK%4RRR]@@:_9GR3@R2:$/,353DV
MR"HFZ'58+!T]YURW:;79J-JE>XKMDTVJ855QG?L$W!VBDA'INTS-"*-%'[0C
MI-1^/=8)J-CK`L11^;L0*)0%8?K.]E51?"<G%K"S*C*1:QI)1RE&@E),E1DE
MF0J`]1CP(N;UY5D*)_&*EWS)=PW?`.@]"4*^F\C&N_5O5)*-=^NMW#MEZK(,
MW/KK1HH1%V[9^"N?UIJT6.4BJJ?>(F80`P@(],5"*SJGM'75Z;VEW4KE`S;.
MDWV8U=:7J#P&[&)V#`EC#RM6,]>E;-7D@V+-->Z9N=9%85R@D<X]0"UKVN%6
MG0:=U5+7"E1I%>XNYG;C3ZM\#_9/;*S7/LAL,;48`)V>BHH9NUS*R[>(K,2#
MYT@,A/RCEJJFW9I=YPJHD<I2B8H@%2YHTD"J`$Z`NZ3?1ZHE*G)1AA._&)*(
M23'NC*E<)LSQ??%P!0DDW:Q$C("/BE4.4HE`P@`UJ%2A5D4/:VM]G5-K>J)<
MX*P5)[-3=<;S2;KU!`T]7+-+4V8B%$)4K%XWD&UF@G;0B2B93.#H]Y'Q$S$.
M:UKVN&TTU'V!5+7-.R1BNVD;S48FQURI/YYFE9+8_G(N"B4".GZR\A6X%U9Y
MQK(+1[=TSKYV$"R5<",BHT*H!.XF)U!`@U+F@AI.)2AI74%<J"Z#I%%RU<(.
MFSA,BS=RU62<MG"*@`9-9!P@=1%9)0H]2F*82B'H'*JB_7*HF$3")A$PB81,
M(K<M<'4+!#"SO,57)>O,9.#L1D+8VC74*RF*O-,+#6IQ0)8IF+:0KUAC6KUD
MY'NG:O$$E4S%4(40M(:1XU*<:J"0<-*Q8MH;C&S368N=1:):)-*JUJ;EFXJ%
M%;%:4AQ!M*DQKKE!5HGZO5G-;(A&(MC@5JHS!-`I13[I<MZN+@;HXM&A7;<A
MUE=<[XS<392>C9Y]H7CW)6=I'6&J1$NZU[K]Y.(Q=Z3MKRTUR/=JQRCT&MM2
MN$\L\:)CT=EE'ZABF!PX$U.JB)KLMKR#7_M/.4ZR6E*NIR\'V!?4EQ]XH2;J
MXN)C3G'U^]OK.3K]]5D*=0'#JW-"15>8S$/9A7:&5E/"AZ!$D<HK=XY$81J)
MP#U-(4QCB-26MJ=.`^S4$#Y,*%U!HT_9K75ZRA^(3U6&<:@K>C!;T2`U':JI
M8*-5JTSK4+7I2%N\-I6:I-SC8QO5WB`0,]8&L0>*>KJ-$)-VGT3]=$%J-$)]
MP&T`')KICHX?L*JXR_=$XU^VKLKNB>-VOYB8L=4U'I*E3Y[O]TB>G(*GTFO2
MI-B2+*PUXEUE)!FS:.6MI>LK1+,DW:AB+'+)/$RB(N5P/<(XVFH#0:UT#3PJ
MA?(X4))%*=Q9MS(K$PB81,(F$3")A%`/!%!?\YRV`HJ'>-'^4-7$F@A[WPR.
M=Z0QU@$`Z>)WC.#CV]>G7L]&1X_6A_$COK</ZO'XWVE/QD@M-,(F$3")A$PB
M815#TA],/JX1>9S])#R'],4GZ,IQ>$_XG?%O\`>K?M1B\D;;YNSR!WEHS_'/
M\H]];.YG6),(F$3")A$PB81,(N0T#JZ;!]%PB']M0N$7GQ\@0?66GFVR8>\*
M_P#.`Y4%*B/:9+U5O5^O>.'0#=_UD.G0`Z=,CLO_`-]^.<MV]_W0_P`IJ]`V
M2*TDPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB@-
M_..Q%3@3JIB/8C*<\.)C%P(?OA436"SK"9(1Z@53O)!VB`AT]S(_,OFX_&-6
MY8?''R'*?U^'1\\`/05TX*'TBJG`/[/9D@=*TAH4;7*?RYJ/RPVX79=ZMY1A
M%*CK2IRFN92D15IK<RCK)ERD1C7<F,E*().BN9'DQZZ"*C<Y&[BO-S%$QEQ,
MCK2VS9G[3CA0"E.#:^%["V(YS$W9:,:G'EIX/96O=0\G*HQ,K"J77<378,?7
MYJT6MC9)#3L(TW:]MMHXU2G'UA,6'<+NW33N;1U))OT[-04#QI35=ZW*D158
MX$<DP"P;M;1<3W,=!&GNX<'<"R&[-*`4[N&FNCCT''%6=&^2JQCZ7HRBEY!,
M4X'4-N=W2;8-M0RW@WN>4=ZR*:21E'NYGMSH:EHKVM@C+"SAY="'?IR;EPW9
M,WH^M&KYD`UK0[`&NC3HXZC1C0TXE7SO$G9Q/'HT\7&OJ,\DZ*1)#)3O)BT2
MAHKCK<./T8\C*1(520U^RGH/D!6(&4U8-?V6RCF,;#5K?JS.19V5K9W5@&'0
M=O'HR"ZCLE!8C07'W)&C1IT8\>NJ>=G4W[JO+HTX<6JE.17[9?*5/8.'UFXG
MLMZU>FM+OO[8^]+/+TGCE58"CL_NEZ]?T=S3J#K,EU76UZRJ#YXE,1#Z/FR.
MRNVQ4G'BMU5TU+C9UB,6U0%Q.#13$:AJYU:+FDO6;-:-`Q..''3%=6_\GU"8
MNR-OL/(%E:VU3V@PV/J>"M.CH693IIEN2-XY(6EI/R;F\G<6V9EYG9<O%LI-
M!.)/'-4F2@I.#HKE<#9U=4NK0U&'&2=>.E5\ZH*!NJAQTX4X.)8#F_(TF576
MMZM&;PICJDHQ=K@-B61?3$9&3$1'QVJ-=:PH>PJ53$K@[CGG*FU$J[R6L.S%
MGR3DD^#9\G&J`GX68S8FH&T-G7AQ`5&/NN%W#J5XO!B2#75CQDT/%P#@64[E
MY(]5G*M<:E4-_J4-ELPIQV<Y2TE59UQ=9E787*V\)7Z3<'M,3*)[+A4.3+5B
MRF4':+OP:@S37.LS<*,TKW6(+2&NI73AI-7&O+XVGB5HNR""16FC'B;AR8>R
ML0Z>\FO;LFQWM&[QV34=?O[].[C=16Q-5J2-POMT;;=J>]*1ZI<U90]8BPIM
M+B]HM'K-LHA\+RZZ\HT?K%;BR63L99/HX2$"M<1B<:CFQ[]5<^Z9XI8*@`8'
MBIWZ=Y3U:HI*FN-;TZBK$I*:U8B`CUDM:T%KJS7Z2IG;IVHE3]<L9>?:TZ!2
M.Z$J+(CUUW``3"H8QAS?8W9:&X8<`H.X%IN.TXG'NXGG60<O5J81,(F$3")A
M$PBUQY8Z$?<FM&V333&[-*`:QS-/D7LY(TB(V'&/(NM6>-GY*MR=9F'L851A
M96C`S0[IH[9R#(3@LV734(`YBFCZV,LK2O%59(G]6_;I7V%YQKMY'W+I)>[5
MNM2FA-EU=5W5*]#7G8=GGXG8-MUK2=9LZ!7ZR]CFT4]C(J*LSJ,:OK,W>.E7
M\:=L@-??B=N`J1IL9L0-DC#$Z:`4_P!OL+>%Y%@3M`\`T5K]E/94E++R>J86
MT:AV*>\0,';:9M[8>Z;W7*]4;*QIMBL%_P!AZQV=#1-<F(#852N4>YTN^UBV
MKU6F)%:2`:VNHBZCC=XZ)]GS-M0ZHJ"2=-,2#PZJ4'$L'G1H6T-"`.8$<&NM
M3QK5[CEY+>W6]>I[+D%L'5-/4IFYJ?M";8Z_IK;8T[N%U7CZ;D91U9[S*K51
M6KI+_<N<UUH@V:KMY.OS+EW,,5)4_B9BCLGT`D(%'`X8UT:\."G)IQ622[;4
ME@)J*8X4T\O#7ET8+."GDI1/W)JMJ]OOBND:U/7>N=7LHY[QX@Y'63^#H&H^
M0>ED[A+:M-L-"-=[85@M]GL+*<!X0(ZZQ))0&ZI7)FZ-YL`6!FU@`!HPP!&B
MNG&O*K!=D/+MG22=..)!TTT84Y,%VMD\E6EO&EE4JF\'\):[.]L4F^OU@ULT
MM=I=V%YN]GM^C7JS'+<X2,V'=M6L$5X6,&QMI6%<H/G)W,<=)8S<*FQ!Q#J.
MX:5UU&O&G'@J"[.MM1R\5.Y73@IN"`)2)D,<RIB)ID,J<J9#*F(0I#*F(D1-
M(AE!+WA`A2E`1Z``!T#-Y:B^LJB81,(F$3")A%`17/\`:;]F_P"J*JO_`'XU
M_(\?K0_B1WUN._5X_&^TI]\D%IIA$PB81,(F$3"*H>D/IA]7"+S.?I(>0_IB
MD_1E.+PG_$[XM_@#U;]J,7DC;?-V>0.\M&?XY_E'OK9W,ZQ)A$PB81,(F$3"
M)A%RV(=7S,!]`NFX?VUB81>?3\WX3*-%\SUZ/7QY'S=>7#ASV]">(4E+('AD
MZ>\+T]SJ.1V7Z)3_`)SENWONH_Q35Z`,D5I)A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A%`9^<<?B+:8_P#'[Q*_Z[M>1^9?-Q^,
M:MVP^./D.]I3_P`A_P`???X8Y_WX^2!TK1&A0\<[=B^8+&<A-6U7C-K.X6/6
M56>ZHV>V+5:1(KUW;-B8);V&_P!"VUNEO=86-UG2H5_#TEL:"<1KD;&E8%5P
M73*R,=#1N#<]<T1`[`%<*XZ:U.@:M6M;<`@V"9"-K$<FC0->OF6HDOYBOF#T
MVV<8-6;%@-=TK9&VX>Y667B)?0>RF%GL:I[-'U36FMBT:="#GX.V6>U^MPZ$
MA',E88O[D_=/"LB*+&Q&YN`YK'4#C74>X*>PLG40$.<VI:*:QW37[.#2LNN^
M3GFVUVPQ\`[T5(V)BCJC5<YL"_QO%B2=1U1N-KGN.DML&4U=2(G:#]3:[C75
M.V+>(X*LO-$EG\G2S'.W:E$GPA<9;VE-G[G$T(TTT4-<`3QU'/:([8X[6LT%
M>73AA6@QXU@.'W/YRD/I:GZU@-:[LAK+7]+-K-==HW'C\C?-@N+FUVE4KB_&
MLB_N4NSLLS,T"4G(12LO7*\HV!@#=LC[QI(/;`^]#`T!U::2*FM?!A3[#>66
MI>7$BE=%:#1_LQ6>U-]>:C25&L%3M!6:T-_6MRS\*C;]3V^U!?63W;_*Y=&0
MM6QYG9IG.E'-&H=7UR]JU471>#94K*,>T%)%$A&>3K+MI`#:C'2#PNYL*4''
M0<5FQ;'%SJ'#7HP&JF.NIU4YY*.'MJY.6>A79+E;!Q$;?JYLGX'K<U!45UK>
M+N-$D]8ZQNJ$LVJCJTW(S<:W=K;.5D[@K\_K1X`5#E(J90,VH3*6GK?=`\%,
M*`]^H[BUY1&".KT4X:XU/)Q'NK;+,RQIA$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$4!%<_VF_9O^J*JO_?C7\CQ^M#^)'?6X[]7C\;[2
MGWR06FF$3")A$PB81,(JAZ0^F'U<(O,Y^DAY#^F*3]&4XO"?\3OBW^`/5OVH
MQ>2-M\W9Y`[RT9_CG^4>^MG<SK$F$3")A$PB81,(F$7,C_\`C['_``QM_OQ,
M#2J'0O/O^;T@"FD.?KSZ_P!?\U7EVN+KZ[USW]'#QO'[?6.P?KNHY'9=\7)^
M-=[2W;WW;/Q;5/YDBM-,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(H#/SCC\1;3'_C]XE?\`7=KR/S+YN/QC5NV'QQ\AWM*?^0_X
M^^_PQS_OQ\D#I6B-"X>%5?F9%!15!=1!!1=KXOJJZB"2B[7QR>$OZLL<@JM_
M'2]Z?N"7OE[!ZAE$7Z95$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(H"*Y_M-^S?]455?\`OQK^1X_6A_$COK<=^KQ^-]I3
M[Y(+33")A$PB81,(F$50](?3#ZN$7F<_20\A_3%)^C*<7A/^)WQ;_`'JW[48
MO)&V^;L\@=Y:,_QS_*/?6SN9UB3")A$PB81,(F$3"+FQO;(L/\-:_P"_IX&E
M4.A>?G\W9`5>+'+R0+_Q:3\S3EZY:"/8<40<4,/W0GI3-U-Z,CLM^*>?\UWM
M+>OOC&_BVJ?G)%:281,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB810&?G''XBVF/_'[Q*_Z[M>1^9?-Q^,:MVP^./D.]I3_`,A_Q]]_
MACG_`'X^2!TK1&A</"JF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB810&TT@./SFC=RBO431OE*4-)KW1[H%(ZW53E%04
M`/WP1,Y/T$?1V?0R/;^LW?B1WUN._5X_&^TI\LD%IIA$PB81,(F$3"*H>D/I
MA]7"+S.?I(>0_IBD_1E.+PG_`!.^+?X`]6_:C%Y(VWS=GD#O+1G^.?Y1[ZV=
MS.L281,(F$3")A$PB81<Z+[9*.#_`/3FG_*$\HJ'0O/U^;E_NO"GD#(#[TTM
MYB'+J0,D':5`RDE2$12*?TG*'@=>H@`]N:&6_$._&.]I;U]\:WR&J??)!:28
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB810%?G&0B
MIPLX]QX]B4KYB'$=BLH'[XFF:4N2HG2Z^][X&2#T@(=,C\R^(:/\QJW;#XYQ
M_P`MWM+T!R8=V2D"_P#FOG8?VEU`R0K7%:2X.$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(H#Z/_M,F_?]4QKO_OGH
M^1[?UF[\2.^%N._5[?QOM*?#)!::81,(F$3")A$PBJ'I#Z8?5PB\SGZ2'D/Z
M8I/T93B\)_Q.^+?X`]6_:C%Y(VWS=GD#O+1G^.?Y1[ZV=S.L281,(F$3")A$
MPB81<R/$2OV1@[!*Z;F`?H"54H@/;V=@AA4.A0`?FX``;R_]CNA[7#[G-RQ=
M.S]1_=7!K'6DA/W?K2=4TBAT*`!V>C([+?FY/^8Y;M]\>/(:I\\D5IIA$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%`3^<7?B=\:/
M]8[Q%_Y?=\CLR^);^,;[:W;#XUWXMWM+T"RO_2<E_A[S_E"F2`T+27`RJ)A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M4!]'_P!IDW[_`*IC7?\`WST?(]OZS=^)'?"W'?J]OXWVE/AD@M-,(F$3")A$
MPB815#TA],/JX1>9S])#R'],4GZ,IQ>$_P")WQ;_``!ZM^U&+R1MOF[/('>6
MC/\`'/\`*/?6SN9UB3")A$PB81,(F$3"+]D!`JR1A'H!3@81^@!1ZB/]@`PB
M@*_-M0[WEH+.BAU1>\MN5#INMT['*)KPQ3!<IA[3@)DA+U'M][D?EOS;^V[O
MK<O_`)Q_9;WE/?D@M-,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(H"?SB[\3OC1_K'>(O_+[OD=F7Q+?QC?;6[8?&N_%N]I>@65_
MZ3DO\/>?\H4R0&A:2X&51,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB@/H_^TR;]_U3&N_^^>CY'M_6;OQ([X6X[]7M
M_&^TI\,D%IIA$PB81,(F$3"*H>D/IA]7"+S.?I(>0_IBD_1E.+PG_$[XM_@#
MU;]J,7DC;?-V>0.\M&?XY_E'OK9W,ZQ)A$PB81,(F$3")A$[P$`YQ]!$U3B`
M>GH5,QAZ?J]`RB*!+\VI'Q?*HICT.Q.2Y%<GI!$@_7II*[*61*13I[WQ`,@(
MCTZAT$,T,L^:CRG=];N8?./[([RGMR06DF$3")A%C[9&VM6Z=AOLAVQL:E:W
MA3%$R3^YV.+@"N@#T@P0?.$G<DI_Z+=-4PC[F;=G87V8R=380RS2\#&EW/08
M=U:]Q=6MHSK+J1D;.%Q`YJZ>XM,9/S2^'C=8Z-<LFS=C@0PE]<UOI;9%DBU.
MG8)D95>"BV"Y!]PQ%#%'W!'*WUK:Y2=G.\PRFPDZ-S?6L+QRL=+M#F44=X\L
M)I#UTO&R)[AST`7&9^:?Q+,H4EB4W;1$C"`&>W70NQH^-0Z]@BY?1<7-)(E+
M[HCV`';Z,PV7U3FCA'E&;9'>2G0V',;1[CR-ZT$]P*G[QY>WXUMQ&.%T3P.<
M`K;;4W(;1.]VQW.F]N4'8PI%[[AA6K"R<SC,`#J;U^N.#-K`P$@?7>,U)T]W
M-F^RK,\L(^L()8@=!<T[)Y'>Y/<)4E:YA8WPK9RQR<0(J.4:1S+,6:"W$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3"*`G\XN_$[XT?ZQWB+_R^[Y'9E\2
MW\8WVUNV'QKOQ;O:7H%E?^DY+_#WG_*%,D!H6DN!E43")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(H$]=$!Q^<M<F5U.
MO?CO*JU.T;@7L**3S:U%=K"H';WS@J/O1[.@=F1[/UF_\4.^%NN^8-_&'O*>
MS)!:281,(F$3")A$PBJ'I#Z8?5PB\SGZ2'D/Z8I/T93B\)_Q.^+?X`]6_:C%
MY(VWS=GD#O+1G^.?Y1[ZV=S.L281,(F$3")A$PB81<9\J9!A(KE`!,A&R"Y0
M-U[HF19+J%`W00'NB)>W]3*'0B@<_-H2A^2+T^XZCWWVX^2CQ4O[$BAMNSC<
M2I^[W.XW`>T1'J(]N:&6?,P?OG=];N8?.CR#O*>S)!:2814,)2E.<YB)D3(=
M1110Y4TTDDRB=1550XE(FDF0HF,8P@4I0$1$`#"*'O>7/B\[1FYO6W#9W%Q-
M5AGKJ$N?*:;C4IN(^$6JAD)&$T=7'0`QMLDR4*8BDX[[T8BH'[@17H50>%=I
M?:EN9V-VK6[RM=F&^4T8?#E<3]AS6N%6RWTH!\WB=I;&`9I![EH;5PXW+F=U
MF,A@R<AMLTT=.145&D1-T.(Z1\4:JK3R)TQ3&\\O=+6$MM38ST_C26R-KR:U
MYMSQP8>\<[=S,^.QA6_>^L08H-TD@["AT#/!F_GK#]JN_P#MVMWF+\NW?)\6
MRR^MK;M;J#NK(EF--+II'UX!H58,ILX7]=(TS76N20[;CSX#D`"RT4YB%*F0
MPD3*'0J9![A"E#T%*0O0I0#Z`!G1[FM>XO>`YYTDXD\I.)4D,!0:%7Q%.G3O
MGZ#V"'>'H(?0$.O00RWJXZUV17D2I6+;9IO7%R>MYF0KJ45:F*@+Q5XJ+AQ4
M+Q#NB#WDWD9:J\=A*I.$C@`AWSJ$ZAVE'.UMQNVOM0[.I&C=G-[D9<#XUK.?
M.;1XZ+K>;:8`=%8]APU."T+G++&[.W+&!,-#V^*\'A#FT/?6?]4<UMS<:W#2
M&Y&2DMO;00*)-?NS(1I#[CU2V,8J23O8\5%HD0V+4&H"'CRC9,DHW(`G5*L`
M=T?=W95VZ;G=KDK,BNXHLB[0WBC+?;)L;YW!:2/.U#.=5M*2':(WN.`P-O+[
M*/GI=<99\I3\+'QO`]VT:W#$:U-37[!!6R"A[15IF,L=:L4:TF(&?A7B,A$3
M,4^2!9G(1SYN8Z+EJX2-U*8H^GJ`]!`0#MF6*6"5T,[7,F82'-(H01I!!T%<
MDCD9*P2Q$.C<*@C$$'6"NWRQ7IA$PB81,(F$3")A$PB81,(F$3")A$PB810#
M_G%(^)Q0XFQX]A)7S,.(3!14.TZ)#N+\MXB9?K3&`40#H/9T'([,OB6#_-;[
M:W;'XQQ_RW>TO0-*#UDY$?HOG8__`+0ID@M)<'*HF$3")A%4`$P@4H"(B/0`
M`!$1$?0``':(CE$6&MG<B=!Z6ZEVUN?6>O''3O!'6BX0S"9.'3J'AP0.5)I4
M1]SNMQZ^YDC991FN98V%M-,WA:PD>^I3V5IW.86%G\ZFCC/`YP!YM/L+6];S
M/."B2PI$WY'/"`(@+R/I&S'\<'3]D+]M3#MNX;W#=[H/N9N.W<S9CMB1L3).
MBZ>!KO>F0'V%'_O)DNJ>HX0UY'/LK*VO>:O$?:CY&*H?(S4\U,.#%(A".;4U
MKDVL<W0"IHQ%I+"2*RHB/0"D3,81]S,=SN]GMI'UT]I.(.D&[3??,VA[*VK?
M.<JNG;,%Q$7\&U0\SJ%;/B`@!3=/>G*!R&])3D,'4IR&#WIR&#T"'4!R&4DJ
M95$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBQENNM[*N6F]K5+3-
M]1U9M^RZ[N$)JS93F*83C:B;!D8-ZVJ-H<Q,J@ZCGS:)G#HJ*$625(!`$W<,
M)0*-D@<YA##1Y!H>`ZE<PM#P7BK*XCA"_GMZZ\R+S"=C^8Y;=?4&B2U0\T/<
M/'#5GEM62W249!*LJ)M356W8MSMC?3^&,P6AVQ":_HJSQV(,SL6+E=V]22,W
M00*?CK+BX-R6M!%TYH97C!Q/,IMT$+8`XFMN'%W<(P'.OZ*]:CI>'K5;A[#8
M36ZPQ%=@HJP6T\<VB#VN>C8IHRF;.:)9E*SBC6"305>"V1`$F_C>&0.Z4,Y(
M*@`'$T4&:$U&`7=9543")A$PB81,(JAZ0^F'U<(O,Y^DAY#^F*3]&4XO"?\`
M$[XM_@#U;]J,7DC;?-V>0.\M&?XY_E'OK9W,ZQ)A$PB81,(F$3")A%U%B,9.
MMV94AA(9&M6%4%`'N^&9.&>F*IWO07N&#KU]S*'04&E08_FT!?\`_CEQU6[O
MOG-_Y&N%5.@_NRAMYW9+QC&]!A,1$"]?_1_4S0RSYDWE=WUN9A\Z=R#O*>7)
M!::811"^8)NZ<V#<R<,-<S+V%AS04=:^4%OA7)VTDPIDSU/6=/1#]$Q5&,QL
M%%,7,H<@@HE$=T@=BQP'A_:9VCVO8]N0=[BV.7>N]D?;Y5`\5;UK1^%O)&_=
M16H((!P?,YC-!)'',TEDO[KZF@<6PAH=.X:0T^YC!U%^D\#>5:\Q,3%P$7'0
M<''M(F&B&:$?%Q;!$K=DP9-B`F@V;(D`"D3(4/IF'J(B(B(Y\ILTS3,L[S*?
M.,XGENLVNI72S32.+I))'FKG.<=))[@%````%OQQQQ1B*(!L;10`:`%V&:*O
M3")A$PBH8I3E,0Y"*$.4R:B:A"J)J)G*)#IJ)G`Q%$U""(&*("!@'H/9E6N<
MQP>PEKVD$$$@@@U!!&((.((Q!Q&*IIP.A7#P\VVYXL[E@]&R[U0.-^^[`X9Z
MV([5,=IIC=DB*CPM28JJF$&5$V><I_5$.H)LY<``@%*J?O?3KL&[69>US=6;
M*-X9`_M&R2!KGR'W686`HP3NZ5S;$M9.[2]A9(<2ZD3:N^IKYMK_`,KN748-
M44IQV1P,?J&IV&M3HB`@(@("`@/00'L$!#T@(?1SMM<H5,JB81,(F$3")A$P
MB81,(F$3")A$PB81,(O$/Y^'.S<^J-Y'XE\N(%C]RN"YG<1^:'$#95"JBC5.
M3XYTW[-H3:U&LY_'/\.7ZH6!X0`5,H*JKA)QU!-NNR($%F$[V2=3-[C;:YI'
M`-(Y0I>RA8YG61>ZV'-<#PX4[B]*_E;<C.4/,#C?,\J>2E7K5`A=];5NU^XP
MZ[AX0T58:AQ==N$&>LRWU[ZRN6P6.P`U<2";[H0SEDNDOT!)9)-*3M))98NM
ME^Z/B\.SJKQG2H^XCCBDZN,U+0`>76I(<VE@3")A%B7=N\M8\=]?R6R]L6-.
MO5M@JDQ9HHH'D)ZRSCL#!&UBIP3?J^L%CE%"]U!LB'7TG4,1,ICEV[*QN<PF
MZBV`J&ESG.(:QC&BKGR/-&L8T8N<X@`+5O+VWL(#<73MF,8#67$Z&M&DN.H#
MO*&S9'(;D_R;4<@[GI[BWI9[WBQVNZ'(I([KM46?KW%]B[&1(<]0!\B(">+A
M03.D4W<56.8.N>;.T?UI-U=SII,D[,[>#/,]C):_,+@$V$;Q@1:P`M==;)T3
M2.;$=+&O;BH)WUIFGC3N=:61T1L/X5P^_?\`<UZ+<1K*Q=5-+ZJI2AW5?HL`
MG*+&\1W8)1H%@LS]<1ZG<R%CGAD9AVY4,/4QS+=HCGCO>WMD[4M^9"[>;/<Q
MF@)PA9*8+=HX&V\'5Q`<'BD\96>VRS+[3&")@?TB-IQY7.J?963B@!"]PA2D
M(```$(4I2@`>@`*4```#.M7$O=MO)+^$DD\Y6_R:%9]GU[0KLV.SM]*JME;J
M!T,69@8UZJ'_`*2;E1OZTB</<,0Y3`/H'.4[N[];[;HW#;G=?-\RR^9IPZBY
ME8WNL#MAPXG-(XEK3VEI<MV;B*-XXV@^S2J_"A.MY\<5B/\`C3L^12KS=3QG
M6AMM2<K==1S*)1[RC&!>/W"]HUP\5)[U)>/<B@0PAWTQ+U#/5FX?K>Y@^5F6
M=K]DS,;$T;]86C&07T6K:DB;LP731I<-F*0ZG.."T!87=AX^42EK1_N9"71G
MB!/C,/&#3B4M?%KF+0^3"$O7#1,CK/==-;(K;`TQ:G""D]$(*""9+'6)%$J3
M2ZT9ZJ(>!)-"^\[Q2KII&$O>]AV\F69KE%OO)NY=PYCNQ=C\#<P^Y)&F.1I\
M:&9FA\4@#FG4I7+\TBOBZ![3%?1^[C=I'WS3H<TZG#NK;S+5*)A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A%I+5O+\XWT_G;LKS$86J@CR$VAJ>`U
M7./!2:?`K+X+4%K-WN+;E1!PA>;I6&,7#23L3CWV$9T*`'=.S*8!;Q"<W('X
M0BGV^593/(81`3X@-?M+=K,ZQ)A$PB81,(F$3"*H>D/IA]7"+S.?I(>0_IBD
M_1E.+PG_`!.^+?X`]6_:C%Y(VWS=GD#O+1G^.?Y1[ZV=S.L281,(F$3")A$P
MB810R>=D\Y8ZGX\4KF5Q.NEL%[P]M<Q?=Z:$CY1VVI7(#CO;(=*K;.86^):]
MDJ\H$289%HJH"H1S-5^\33%P@B(:-]US(Q-"3XAJ1J(UUY%M6G5.>8I`/'%`
M>`ZN=0:_FO,WRYY`MM5'0N=MU?P8X"TG;E!&FP<DJC!<FN07(*\6_8#S[-FA
MD@93#/5]6L[)R0G=$\6X:L#(J%&2<AFCE9FDIB1!&"/*))./)X.%;F8B-E<`
M9GD=P###E7MER<42NFL=ABZC7+#;9M0$86J0$U9YA4Q@*!(NOQKJ7D#=X>P!
M]49GZ?JY?#$^XF9!%C(]P:.5Q`'LE622-AC=*_W#6DGD`J5YQ-(NIFU5F7W#
M;.^I>-^VJ<W%:5U>HK)A:W9U:Q#%,;J8K*OU1-FU03^M3(40`.W/GCZT^^!W
MG[7KW*K9]<DR!K<MMVCW-8/G,@^^EN3(7'6&MX`N-Y,QYL_/)?G%RXRN_M>Y
M'(&T`69,\YJ63")A$PB81,(L=;:I0[!UU:JN@L=I*N(\9&M22)A(ZA[;!G+,
M5>79*E$#HNV$VR1.4Y1`0#J'NYV)V3;\7'9SVC91OA"3U%M=M;.W5):R_@KF
M-W"'0O=AT@TZ0%I9C:B]LI+?0\MJT\#ABTCD("FWXK;@4W[QQTQM]V!22]VH
MD0\LJ)>@`WM\8"L%<&XE#ZP4[-%.O>^X`AGUESFR9EV:SV<1VH&2'8/#&[QF
M$<1805OY7=F^R^&[=[M[!M>4,'?W@5G[(U;Z81,(F$3")A$PB81,(F$3")A$
MPB81,(HVO,D\K_0/F<5/2%8W:#J,6TEN.O;%C)^';)GF9>CG=-";0U,J]\5N
MX8P.S89@W24<)G$[%XT;N2$.)#$/JW-K'=!HD^Y=7N:QW5GM[A]N26:Q3NZC
MW%(U'QT;#QT=#0L<QAH6&CV,1#0\8V39QD1#Q;1%A%Q4:S1`J+2/C6#=-!!(
M@`5-(A2AV!FR``*#0L&)Q.E<O*HF$716FT5ZD5FQ7.VRK6"JM2A)2R6.:>F`
MC6*A(9FJ_DGRPB(=2H-4#"!0]\<W0I>IA`,R002W,S+:W:7SR.#6M&DN)H!W
M2L<LL<,;II2&Q,:23P`8DKSU/[K9^5.RB<E]ELW;&#0!VUXXZQDNIFFM-?N3
M]&UOD6)OW!395\03([=NC%\1HW,F@D(%*7N^._6=[9WF>?L=W*GV<DMG[&:W
M,9H;VZ;[JU:X?^$MG>(YH-)I@[:JU@VN,V;),QG&<7@P/Q##_NV=(CIOTDZA
M0+(6>*%,IA$PB81,(L<WFGS<B_KFP-<SAJ1NO6[LTUK*^-B@"K%^4IO6:U/D
M#H$O2K,B)FLBR6[R1TE1,`=0'KW9V(=LN9]DF\),X?=;CWSFLS"SK4/9H\XA
M&AEU`/&C>*%X!B=XI!;'W]D;D-FMW=7F$6,;^`]$\+':"#RJ:+B=R,B^3VG(
MG82<8%9N$9(/J9M2C'4$[BC;*KOA(6.#'OCXJD:X,H1Y'K&_?F+A(>HF`W3Z
M:W45HWJKO+9FW.37<#)[:=ON9K>4;4;QQD&CAI:X$&A4CEE^,PM1,1L3M);(
MS6U[?=#DUCA!"V4S54@F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3"*H>D/IA]7"+S.?I(>0_IBD_1E.+PG_$[XM_@#U;]J,7DC
M;?-V>0.\M&?XY_E'OK9W,ZQ)A%4"B8>A0$PCZ``!$1_L!VY1%^PMG!>@&06*
M(CT`#)G#J/T`ZE#J(_0Q4)0KY.BLF`"HDJF`^@3IF*`_2$P!BH.A*%?EE43"
M)A%Q7S"/E6#^)EF#*6B99@]BI:)DFZ;R-E8J2:JL9*,D6BP&2=L)!DNHBLD<
M!*HD<Q1[!RA`(H=":,1I6`^*_%C2?"_1]4X[\>ZI]A^L*<\L4E&1JSM23DW<
MK:IU]89J5FI=<I74M(N';[P2JJ]3$:(((![Q$@!CBBC@8(XQ1H5\DCY7E[S5
MQ6PV958M2^>TD[B>$W*M^Q4%%TGHV]H)JE$0$A'\6:.<"`AV]?5G9P_LY/;J
MM:_>6P:[%OG49YG5[X45GKBS);IPT]0[V1112U1H@PJE58M2`FV95BO-&Y`#
MH!46\.R12*`!V``$(&?&;>>YFO=Y\SO+@[4\N8W3W'A<Z>1Q]DJV!H9!&QON
M0QH]@+OL@UF3")A$PB81,(OT2[%4Q^@H3_=!EDHK&X?>GO(-*W0\JY90.*;R
M+ZB+2N[^Y!P<8'[%..2V+(/T44^W]Z26D5``.@=,^SL=Q)>9'DM]/C<3Y!EK
MWG67&TBJ3QFE2M+=W"P>S[EMS,!R;9/MJ1S+%/)A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3"**SS3+HZD*?J#C7&.5$@WK<9.=V`5$XE44U+J%BWM=@
MC%@*(&%G9;(K&,U`]!TP.0>PPY%[T[T'<+<7.-]XS2_M8([>T/!>7L@MX7#C
MB#GRCR*KCV?N,_498W1.\N?^+C&TX<CC0*`JM[YY#3L%&2Z>RXB.3?MO%38(
M:\K)T6:1%%$4FR)A*3JDBFD!2]@="@`9S^T]1OU?[NV9=2V%Z99&[3BZ^NRX
MN/NG./6XEQJ2=9)74=QO[G5O.Z`;%&FGN6_!7=?=CY$_?8C?DYK'Z^;']"?J
M]_L^[_3+O\\L/\P\[^\YF_!50W%R)$0#[K$;VB`?]G-8]T?IX_H3]7O]GW?Z
M9=_GD_F'G?WO,WX*UPD.</(YFZ6;A;88_@JJH=X*?72=_P`!4Z7B"7U$_0RG
M<ZCV].N>9^U+L7[`NS7.X,F9NU<WHFMS-MG-;N/9_"/9LT&W4>+6M==.->RN
MP/L1S/MMW7O-XY<].6NM;[S?JVV;)]K\#'+M[1ECI[O9I0Z*UQHN#[=?(_\`
ME7#_`.B5<_B_.L_W;[!?X.G_`-9O/@KO/^BR^_BU_P#IL?I*>W7R/_E7#_Z)
M5S^+\?NWV"_P=/\`ZS>?!3^BR^_BU_\`IL?I*D0X8;EOVYJE=I2_R+*3>P=D
MCH^.6:1;*+%-F[BA<JI*IL$D4EA!<G4IA+W@`1#J(=.G4GK`[F;D[KQ[M9KN
M182Y=:YQE=Q--"^YDN0)(;I\+2V27QA5K<0*#BK4GREOCNO<;C;\9ON5<7?G
MWU;/$P3]4(2\201S&L;7/#:%]/='1770;X\1K>KJ3FNWK9510IO*^C2K!^SZ
MB5HEN/4;`TU!RZ:?4"%?6"BJO&BIOKE3-R"/7NAGH[U5][I=Y>R^^W0O7;=_
MNW=,E@)-3YC>N=M1^3#<M<6C0!*`,%PZ(^9YZ*807D9!X.MC%0>5S*CCHIR<
M[^7)$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M15#TA],/JX1>9S])#R'],4GZ,IQ>$_XG?%O\`>K?M1B\D;;YNSR!WEHS_'/\
MH]];/``CZ/<`1'W``"@)C&$1[`*4H=1$>P`S,L2C&W1YCT*RGIG7/%>FM=^W
MF$<K1EDOCR6/!Z&HDHD84UF<G<6I%GEXF&9P'Q&$(!R@8.Z9R4>H!%;X[U[E
M]FE@S,NT2_\`,WS,VH;.)O6W]PW4605'5QG1ULY9'QE0,^=&60VV41BXF::.
M>32)AXW?=$<#*\JTEL]BY1[6.JOMSE)?V+-T(BI1]#$;::IC1,P]?5"R,61W
M=I=(@#W?$=/P.<.T0#/*>\GKD9@V1T/9]N_E]E;#W,^8%U[<G[XQ@Q6\9^]#
M9`.$K6-E?W.-_=RT/W,5(FCBJ*O/=*Q:MQRU@\.*\J%_GGAA[QY">VSLZ3D#
MG'M%4SI:U@?Q>O7WP=!#J.=;3^MCV\S2;<><PPMK[F*QL6L'%0V[L.(DJWZB
MRT^[;(X\)DD)_P`2[Z%UC+4A0KO56[^0VJWR70R!JUM^U2T24Q?K0<5NX.K%
M"/$0Z=J9TNZ8.P<F\J]<'M:M9`,]CR7-[;6VXLHXGD<4MJ8'-/'0TX%49/%%
MC:37,+OO9'$>]=M`K9"C<VN5^FE$4]N0$+REUV@)0>V2C1+&@;TA61?KWJM6
M25"D7X4$P$QTFOP>[4Z=@B/9GH?<?UDNRO?B9F79ZR7=?/I"`TS2><9=(XZ!
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M6`X"5VZJ40SE$3]BK6:AFQ86::+%'M(NUE(]4ARCV@(9\H^V7=F7<_M7WAW=
MD!#(,UG='QPS/,\+AQ.BD805%97/YSET,VLQ@'E&!'."LI9UHM],(F$3")A$
MPBX4G*,X.-D9N05(A'PL>]EWRZ@@4B3.-;*O7*AC#V`!44##FYE^6W6<YA;Y
M/8-+[Z[GC@C:-)?*\1L`Y7."L?(V)CI7X,:"3R`5*D1\M.HR%3X6:><R[<[6
M7V&6W;?D6ZI3$62-M*WS-MCBJE,`&`XP;YH/0?HY]H<ZMH;"];E%N0;>PMH+
M1I&@BVA9#7G85AW>C<S*8GOP?*72'_B.+A[!"WLR)4TF$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(H3><"BLOSGJ,:N;]PK7$5^I%@/4Q4'=RVF_9R;
M@"^X8[:'1*/3M$"].O3.BO6DOI+'L<RZ./XN?>J)T@Z0M[261H]\ZO$5QRY'
M6;P!I^XLC3^W)0]X**F'X@;@@XQG$,=C:T,T8)"@W,YKMG.N*?B'4`53$=$(
M)^I_<``SGEM_[C6ZEM;LMV[M9ILL:!\=;>%=?S=G+II72ON&[3C70?`NR]E7
M=?WQ-7?Z-6K_`)YF?_J0;K?PUFGY:V^$L7\M/_B![/@50XK;K`0'[HFK>P0'
M_P"&K5[G_P"N8_ZD&ZW\-9I^6MOA)_+3_P"('L^!8:=^7'>7BZCA39U,`ZJB
MBI@+$3Y2@=50RAP*`E-[T#&'IV^C.E=^O6H[(^T+,XLVSW(-XV74,/5-$-W9
MM;L[;GU(<QQK5QUTI3E7H[LH[5>T7L<R.XR#=4Y3+8W-UU[S<P32/#^K9'1I
M9-&`W98,"":U-=2XWY-F[??/IW^:9_\`@\X3_.OL(_86]GZ;8_FEVA_5CVV=
M#=S]%N/24_)LW;[Y]._S3/\`\'C^=?81^PM[/TVQ_-)_5CVV=#=S]%N/25NI
MQ<T#+\?ZW:X28L<78U[%.LI5%:):/6J+5%G'"S%)7U[HHHJHH83=2@!0+T](
MYU7VU=IV[7:*<CL]U+&^L<JR6PFMP+N6*660S7#IRZL+6M`&U314]S'HK/\`
M/L[WMWGS#>[>(VWUOF,K'R"!CF1`QQ,B`:U[GN%6L!-7'&O(LRS+I2(W)Q!L
M;41*^B.5^K&:!R]0.+6S_#%;E4`$H"<2.&$@8I@`!]Z';G8_J;74K.T+.<O!
M_`7.[-WM#56&6WD8>X0:<JXOFGBRV<H]TV\C'OJM/L%>BLP=!$/H"(?VASV\
MN3JF51,(F$3")A$PB81,(F$3")A$PB81,(M+=[\\M'<<][ZIX^[(;W-*U[;C
MJW+1$_$,:PYJL!'6V_K:UAGMB"1ML3;%V25F0,>27B(J52A8LIY&0%LR2573
MP23LBD$;JU/AIR^#2LK(7R,+VTH/!7[.%6O>/,XX6U*A0-\@]SUW9A;;<8>B
MT^JT`[E];;+.RENUE4W/JT7*-8SX)C(@-OU^04>R1F3-W'RC0[15P9XT(M8Z
M[@:T.!VJFF'V<8YPJMMY2:$4H/#X"LN+<UN)23FMM"<@=>NW-Q=51M4VT<ZE
M9%Y80NY+6M5GL<Q8Q3AZ:)DFM&F%U'ITR,V+:.76=JMTB@<<G7PT%7"II[/^
MPJWJ9<?%."PYLOS0>$FN]4S&V6>[ZML6/CY-[`Q-7H#A:3MULGXYM4Y)U'0,
M:^;,$RLQ@[S$2",J[4;0KIE)M%$':@.VWBXWW<+6[0.T*TP^SDYQJ5[;>9SM
MDBAXUD.\<]N(^L=@[@UAL?<<;1K;HN0HL7L)O8Z[;VS%!]L6GRNP*ZA79!K`
MO4K8+>E0;V3DS1X+EB6+1=P[%)!!95/(ZXA:XM<ZA;2O=%1RX<RM$$KFAS14
M.K3N8)(\[^*K><C(&'W)1+0N:Y+TZX/(>V5YM':Q%M3MG7A:?O;R=D8A)G#?
M`6HYE=(K47;QRS0]?004C@.[+3SB*M`X'''BTG'F/^Q.IDI4@C#GT#V_L*QR
MX\T+ABPL;&%E=GK1L1.OT6%9NIZW/O*U+E3U18]RS4G*M6$<XM="AH"EU5VH
MHYL,;%D=F`JC3UAL)G!;?.X:T)PK[5=6C`:Z*[S>6E0,>#NT[O<6YU%V30-G
M,9F4UW;X*Z1E>L+JI34E7G@2#!A9649$3+R&.\3*#=9XUC)YFLIX1E"E!P4!
M-W@,4N=KFNQ::@%82US<'"A5[9<J)A$PB815#TA],/JX1>9S])#R'],4GZ,I
MQ>$P"/#SBT``(B.A-6```'41$:C%@```=HB(Y(VWS=GD#O+1G^/?Y1[ZCOYB
M<B[%R&O=KXSZDL4C7-)T)\I7^0FQZX\49R^Q;4F!3/M)TN9;&!5C7H@A@)8W
MZ!N^LJ(M"&`A3^)P'M?[6K+L5R"&2U9%<]H^91%]E#(`Z.T@J6^?7#/NB2"+
M6%V#W`O=XC37B=Y/+F]R_+[=Q;ET1I,]N!>[7$TZ@/NR.18F@8&$JT-'5VMQ
M+""@8AL1I&1$6W(U8LVZ8``$213#IWC=.ICFZG.81,81$1'/F#G6=9QO)FT^
M?;P7,UYG-U(7RS2N+Y'N.LDZAH:T4:T4:T``!24444$;886AL310`8`+MLBU
MD3")A$]':'8(818Y6:7[4]]3W_QY<-X?:T<DF2V5-90[>G;UJ[<WBNJ9>6*1
MB(GEU$@-\%RP`#MDZ[H]X2CV>I^P/U@I]R)8MQM_))+GLUG?LL<:OERM[C03
MVY-3YN":SV_N=FKXP'`A\5=V<T4WUEEE&WX'C-T-F;T7\?1=I!4Y_'[>M)Y(
MZGK&W*&=RC%3Z;AI*P,EW23M.M<2KZG9:98VY>@MINO213(J!T`JJ?<6)[Q0
MN>_+^R?87'4.<R2,M:]DC#M,EC>`Z.6-PP<Q[2'-(U%35A>PYA:MNH:AKL"#
MI:X8.:>,'PZUF?--;B81,(OHIC$,4Y1$IBF`Q1#T@8H]0$/U0$,HB\_6W-=*
M<9.4%SURHW%EJKD!+SNX='/^Z*<:QM4BJ5WM?5I%.@)(/V$RJ,LP0Z@*C)V/
M<`1`0SS-ZV/9[-O#D=IVMY/&7WN7PQV6:M:*NZEII9WAX6BIMYG?<_@B<`2.
M+Q#ZLS.2P=A:W#C)"=0<?C(^6OC`<!79YX"4NF$3")A$PB818SL%-E>0FQ:1
MQ1JBJY'.QU4I[;LNSZC]@^B(-Z@O;Y-XJ7WK5_;C)EB(TAA`RRS@W0.@=<]A
M>J3V=/O]XY.UC.8O_P!OY$XMM-H87&9N;2)K:^Z;:M<9Y",&OZH::TA\R+KR
M1F30G\)-C(1]Q"#XQ/&[W+>'%>C&/CH^'CX^'B&:,=$Q#!E$Q,>W*!&["+C6
MJ3&/9(%```J+1F@1,H>X4H9[6>]\CS)(:O<22>$G$GNE<H:UK&AC!1@%`.`#
M0N7E%5,(F$3")A$PB81,(F$3")A%4`$0,(!V$*8YS>@I"$#J<YS#V%(4.T1'
ML`,HBU1V1SFXA:ED%X6[\@M=MK`V,8B]:KTFO>+&DJ4>AD5H:D-+"^;K`/8)
M%2D,`^D,F8-W\YGA\Y;;O9:_*24B9[^0M;[*B[C.LIM7=7-/'UG1!VCS-J5A
MS\J=PV\3H%GVF+;_`"D&AMN#&].OUWC_`&*^+W1+[[][^M_M9J>:6PDZGZPR
M?K^A]86>US==PX+6_>/*]-9MGAZJ2G^%9>USSLX?;6D4(6F\@]>'L#DY4V];
MLT@ZH=A65,/0J*,1>6===N%A'L[B8'-U[.F;<V[V=0P^=>;O?:?*1TE9[^,N
M;[*V8,[RFY=U<4\?6'4X[)YG4*VSZ>](?TD4(51,X=I%$SAU(HF8.I3IG#M`
MP"("'HR&4HJ95$PB810S\_HA6M<ON/5X4()(O9FE=C:I,Y$.B8V.DV2.O\6S
M,?T>,YBI9T*8>D?#-T]&=.>LGD\F<]A-U<P`NERC.K2[=35#,R2T>[D#I(ZK
MCM\.ISVWE/N)K=\?]II#P.:JTOY+6ZRT;3ECL=1E3PL^WD:NR:2:;9H\4:IR
MMDC(YV=-N^1<-3G,U<G*`F(/3KV=![<\A>K3N=NYO]VSY3NKO9;B[R&Y;<F2
M(O>P.,=M(]E71N8^@>T&@<*TH<*A:^?W<]CE,MU;'9F;2AP.L5T\2TJ'8^^0
M$0^[?8>P1#_X6I7N#_\`P?/K>?4L]7:OZA9^7N_25T\-_L_Z8YF_!5/ND;Y^
M_?8?]%J7_$^/Z+/5V_8+/R]WZ2G[^Y_TQS-^"NAM.X=^U^O2LTCNB<<JQS8%
MR-U:Q32)JB*R27=.<D,)RAT4Z]GT,U;[U-?5WM+22Y;D$;G,;6AN+O'_`/$+
M9L]]L^NKJ.W=)0/>!6C<*_V5KI[9_)'[Y#O_`#)6/XDSPH^P[&FO+1N+EE`2
M/G^9:C3Y=?4R/U+<L?&V0[UYJ"YH/S2TU@'A3VS^2/WR'?\`F2L?Q)EOF/8U
M_`F6?I^9?GU?_15EG\5YK^B6GA6W'#+D)MW:>U).N7NVJST,E39>329K1D,U
M\-^T?Q"2#@B\?',UP$J3I0HE$PE$#=H=0`<XGVM;I]G#NQ^7?#=?=^VR;.K;
M/[6UVH;FZF#XIK>>1X<)Y'M]TQM*"HIIQ(7G'MF[*6=C^]66Y';9I<YG;W^7
MS3N,T4418Z.9L8#>JT@@U)*D<@X=2[<IN&^OVQ!6.&YG&V)A,H=?5ZWJ&K2T
M^X=K!^Q1/+NVB("/8)S@'IZ9N>IIE$GUSO-O6\?]VM,F;:-=J,U[.RC1QB.!
MY/%RKIJ^_#7]E:C29S(?)C:3WR`O0GZ>T?=SV.N3)E43")A$PB81,(F$3")A
M$PB81,(F$3"+5+>G"CCKR0N+"_;;J,E.6Z)K58J,--QUCE()]"0=4O;O8#5"
M%=1AT7<2O-24F\CY=1!0AI6"?.8YQWFRQBYAD@CE.T\8T]NOV<6"R,E>P;+3
MA]JGV<:P*V\K'AQ7*YKVO();*@(37KAK%1`LMKN:C]E$(>X:DMU;UY?W$`P@
M$=@UJ-NVE*HZ8-I`JT@X=QI"+N7(+K$5Q>9P4:"#XIPQY/![6M9/.IL:'W6G
M#[.%=I4O*WXJ42S15RJ2F\(6TP$JW7@)MOO*ZJ/8*I(L+M#N-1Q!G"RJ;'3\
MI`[!DF#N$*7]V;F2-XY5T@6&OF<'`:@@Z>#0.1/.9=&%*4T</MKHT?*2X:,Z
M#`ZTC(C:<%4JXVLD&R;5C:$G5)!]0;4TU^TE-5666K,?$OK=KKIJJNJ$;2AW
M;\58E(57BI3K$4>9PAH8*T''3`TPY,!S)YS+M;6%>37CCRXE9?W5P)T)OG8%
MMV?<7FVX.Z74D`$U*:\VK8:01-:#UO>],N'L4VC2J)1;RTZ?V3,5F8.GV/8M
MP7NE2<HI.2W26T4I+GUJ2#IUC0?L[ZMCN)8P`VE!75PK';CRN.$K7[+GDA2;
M*E"WR3C7%SAY+:-K3JEAD&>M-FZ)JC=ZR<R::"!Z]I[<,E4(=-NH@9O#(QK8
MG>.Q;'"GFL&-1@=./$1WC3DIP*OG$V&.CBXP>^*J^X#@#H6`L->N"TIN.U7:
MNVVK6\UPO6V)^U3UF<5'4]ST6SKEU5>HD9V.DR^IK[(P<G%G032>,SI^^(HF
M"@A:0BF!P=7''''P\^*&XE/!HIHU8:.97WPZXQ4_A9QFUEQRJ,TYG(/6D7-G
MD;=,)C'O+',S\_+VNQV.33<R,H9DFH]E3D2(J[<"V8H(IF5."?>R^&)L$0C;
MB`K)9#-(9#I*V38/V$JQ9R<4_8RL7(-D7D?)Q;QM(QL@S<$!1N\82#)5=H]:
M.$S`9-5(YTSE$!*(AF4$'$:%CY5R\JB81,(JAZ0^F'U<(O,Y^DAY#^F*3]&4
MA+_>,SH+RJ='6BGJ%)LNVZ.TIJO5!1Z"<NPMAUR,@XB3(00'O?8XR.ZDQ[.@
M>IAU[!R?R=V7P0NS/.';.26%I)=7+N""WC,CQRN#=D<)<N.[P7<EG;2O@^=/
M?U<?EO-`>YB[N+377M&B];4R`I428ZR$*S[CM^L85'<S,.3F=3<](+F$5',A
M,RBJKA50PB8QC]!'L#/DEV@;[YMVC[Y9AOKG1/GE].7AFJ&$>+!`P:F0Q!L;
M0,,"=)*T[.UCLK9EK'[EHQ.LG6X\9-25>><.6TF$3")A$PB8171P^O"ND>7P
MT3QA;ZWY;Q4FN1AWNZRA]_:_BS22,BU3[$T%K_2D5T7`%Z"N[:)&'J(9](O5
MBWYFWS[,[C=+,GF3.]UWL,+B:N?EMPXAK"=)%K."QO1CD8W0%%0'S#.@P86M
MZ#AJ$S!6O]MNGA(4Y&=ZKDR81,(F$6">1W'JB\G-7R6L[R+V.ZNVL_3[C"B1
M*T:]N\5WSP-SK#HW=%&1C5CB55(1!)VV.H@I[T_4-NSNQ:O>V2..>RFC=%-#
M(`Z*:%XV9(I&G!S'M)!X-(Q"TLPL(<QMS;RU!K5KA[ICAH<T\(]D8*#^6>[!
MT7=6NF.33-I7;HX45;T39[1,S;6&[XU`W<0EJQ+J@1K#6PZ7=%_!NC)N4%A'
MPP,02]?"?;7ZM5_NUU^^G9E'-F&X9)?+;MK)=Y;7$LE8*OFM6_[NX8'%K:"8
M"FVZ$@OIK:86&;49=:&OT1RCA:=`=PM.O0LCB`@/00$!#W!#H/\`:'/)`((J
M,0I=4RJ)A$]/8'IQHQ.A%C:7ND[,W!KI_2U85VMO*92`S"G1:H%AZDS4$"'M
MFSY\O5E3JK&][Q%!<'(X7Z=Q(@F,`YZ%[&O5\WC[3I&9]G!DRKLYC?\`A;U[
M:.G`.,-C&X5GE=HZP`PQ:7.<1L&,N\PZN7S.R;UV8N&#!H;]](?N6CCQ.I3`
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M4=F&909>UH<'/N9#1D;<7//%P`:W'`*'O8<]OSDVLJ]Y%WUY7Z2Z4\9AQUU'
M,R-<U_&M1$3(M+W:6"K6S;+E"$'HN*JR,?W^OA)`7H&>0NT+UN7VDLF4=C=J
MVWMVDM.:7D;9+J75M6UN\&*U8=+3(V24BA(C."AS9WN8>/FTA$1T0QDM8.)[
MAXSSPXAO`OVJU&I5'9)Q]-J5<J[-,``J4'#L8\QNG[)5P@B5RX./NF4.8PCZ
M1SR%O)OEO=OC=.O=Z\TO\QN7'$W$\D@_LL<[8:.)K0!J"D(+6VM6[-M&QC?O
M0![.E7=XRW]]5_\`:&_7SB_4P]!O,%LU/"K3M%)IMV9J1]QJE=M#)4!*="=A
MV$EV"'3JFJY0.N@?Z!B'*8!]`YR;=W>_>O="Z;>[JYG?Y==--0ZWGDBYVM<&
MN'$YI!UA:\]K;7+=BXC8]OWP!7#U]*[VXSK)O^-FP'DA46ROCO\`COMB7D[-
MK*7;=>\LSITZ^6<V76<FH3L14:KJ,@/T\5(2`(9ZZ[/O6ZN+B6/*>V.U;>6C
MJ-&9VD;8[R+5M3P,#8;I@TNV6QRTJ1MG!1PLKS+_`!\HD.Q\C(2Z,\37'QF'
M@Q(X0I@.,'++7?*&!ES0323I6RJ8=NSV;IZVF01N=%D%P[J3@Q4NZA8*K(G`
M18R[0!;."]`,"2G5,/8.S:7%A;YUD]S#?[O7C-NWNH3M12MUT.ECVZ'QOH]C
M@0X5"E\OS.',&N:`Z.ZC-'QN]TT^VTZG#`K:/,*DDPBTHY]Z+L&[]`/5J`U!
MUMS4%AB]R:H1``\64L=0(X-*U(AO3W;I5W+R/`OH.X41Z^C,\=GE><6EYNUG
MPKD&;6<MG<?>LF;02#[Z)^S(TZBU1&=6DMS9]9;?/('B2/C<W2W^TVHYE#-;
M(Z+Y/:+32JDX2!:W`L%*-WKV/4?*P<E!331_(0DK&`X:+D?QTA'J-%TS'*8B
MA1$0Z9\W-T,TS?U9.W(7>\MBZ\S'))9XW1-D$0G9-"^.*>.0L>.KD8]LS#LD
M%IV:@UI&7446?Y08X7[+)@,:5H0<6D88@@@\:P2/$G9XB(CN.J=H]?\`LZ=>
M[_\`S'GLW_J11_PM/^FQ>CKA/\M+;Y<\Q\*>R1L_[\=4^3IU\8\?]2*/^%I_
MTV+T=/Y:VWRYYCX5ULOPSV'.1CR)?[BK!F;]($7`(Z_=I*B0#D4]XH%B,)![
MQ`[>F8;C_P!QNWN876\NZT_5O%#2]B!IR^;++!V=PV\S9XKC\(PU%6DBH[JQ
MC^35?_?<C?\`1)]_'F>>CV^=C[G%QW0SBI)/ZX;K_P#E%Z\;ZSO;LQ@8V_R?
M9:`!_P#IS=`%!_O4_)JO_ON1O^B3[^/,I_/KL>_A#.?]8;Z(KOZG^WCZ?D_^
MG-_.K/G'3B&OH2\/KJZOS*Q(KUN1A!9)P:T25#UQRP='?+O7,FZ(5%NFP'J'
M=#Z[J)@`,XIVC]M6ZF]VX)W"W1R&]RYLV;07CY)KT79<Z&*6%L;&-@C(+NM&
MLXB@!)76.^V_F^O:1G-KGF^UQ:37-E:R01=1;BW`9(\2.VJ/=M':&!PH%*9Y
M;FOW&P[WLSF!*-5"UAY&K:1X_&<)&(,A3866]=V-L%D50`$&=OM;1-DS5`/W
M5JP4[1*8.OM+LKW"D[+.S*RW3O6AN\][)]89B-<<TK`V"V=QVT&R'C5*YZX/
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M83U9.@$UICS=ZNG!70NM=D!P&V!K`IJY]?'3C7WHC4GFA[DN^TE;CL;E1H!O
M%[4OMBA'FS-CRL941JZ=9Y2P^C*I"PK9M,-[:O7]A/\`7DK<TX'N5*8KD>T3
M1<.7BDJ@NC9=/<:E[<3I.%/&H*:\:5IA3AQ1[K=@%`UV&H8UPK[=*XU[BX;G
M6'FOZ\O'$.BS]QY&[-8).K)8-H3E0VE)R].;6Z4MU!C*_`[`V=#-&*SK4T<E
M&2LS+HV4[A\WK+]TVA"C*>J,T&S=M<QI+CIK0Z\-)X.75HQ3:MG!Q`:.##ET
M#AY->G!=]5>`_F02EIIESV]MEC;I9N,=$/(J<Y&7B[5.DUF#Y/\`&G>C=LO5
M;?`V1ILU=:OTF[,(YP_=J2<2NXC1(\`I$O50M[JH+W5/*3K![N@\F'<H9H*$
M,%.X!7`CN:O95U'X>>;1.UZQ,)7EM9*S*FAK@[;/8+DA9G[JT;I9:HVBSJNS
M&,G]S:.5U[IRY;CF*B\4UPB1>/@X^#=`(K$=JMUKNINR,7D'EUT..C`$TPU4
M3K;4&NS[&JHPTXFE<==5E?FMQ+Y\<B;CMFOT#<Z=;TSLG0LE0&T8VW+8:57&
M9YGCMMZB7C7<[JB&IKUG-2FQ-ZVBLV%*[_"174+`Q3B.3;@0YD759H;J1Q`<
M.K+2---(.%.6F/V&V*6W8T%S:R!U:TXQ[6K[!*UK&DQ^M-::ZUQ$I"A&4"B5
M&F,D1<"[%-"LP$?#E`71DT3.O?-!'Q!(45.O>$`$>F;K&[+`W@"U7.VG%QUE
M7QERHF$3"*H>D/IA]7"+S.?I(>0_IBD_1EE;:DBI*:4\HFA',88U/4\AM1XA
M_P#@UY"EZ?K$'`G,`^].9FYM2QR^Z`CU#.&]LF929/V`;QW4!(FNH[&RJ.A<
M7+3(/[3(RT\1HN(YZ>LSFT@/N1)+)W6MH.8N7>9\LEM)A$PB81,(F$3"+$.W
M91:J_<CV*R$4Y/6O(325L9+E[%")'O49`2J13!V@1W$S:R9P_9%'IGJ+U0,R
MDM>V-N4U/FV:9/F%N\:CLP&X97D?`".!1&<DQV\5RWW<5S$X>^#3S@E>E1P4
MI%UB%^M(JH4O_JE.8`_\@9[T&(7*#I7XY5$PB81,(K(V-K37VWJA*4#:--K]
M]IDR4`D*[98]*08J*%`02=MA/W7$=)-A'JBZ;'2<HF[2'*.;-I>7>7W#;JRD
M?%<-T.::'DXP=8-0=86"XMK>[B,%TQLD)T@BH^T>,8A1AW'RU+W2SJN.+N_%
MXV!()C--2<@6#^_U9@GVB5A7-A12K>^0C(OUJ:;DDB"9?V0YU_OCV2]DO:'*
M^]WER@V6>2$EUYECFVLCW'[J6W+76TKM9<8VN)TN4(<HO;3]5W'X+5',"]HX
MFO%'@<1JL&R.B^>5;4%"3XRTR[E(/="4UEO:JE:.`#L\4D;>&5?E&Y3>GNG[
MQ@SH_,/4YW:FD+LBWNDBBU-O,N<7#B+[>8M/+L#D5IESR/"2S8_CCE;3F>`5
M^#/37.N;4!M&\38NN',/=^$+[OK7K.,2ZB`>(=*M%GI-5,O7M`B7>'W.W,%G
MZFV3,DVLVWPC=!K%MELKGGD,T[&CNU3KL[?A'9!IX7S,`_N@E9BJ?EW;_OBB
M:F_M^P6O:TH("]H/&Z*?%G7R`_OC&0VS=4/7F*:A/>G-'1I#"`CW3E].=P;I
M]@_8ON3*V[M\NN,]S=A!;-FCVNA:X:'-LH0V$XXCKC)17#+<VN_GMPV&'6R`
M':/$9'8C^R`I*=*:`T]QUJAJ;IRC15-B7*I74P[0\9_8K/(@'OI:VV>14=3M
MDE%!$1\5TNH!!$03*0O9G;=]F-YF+VONW[36-#6-`#61M&AL;&@-8T#`!H`H
MI>SL+3+XNJM&!C3I.DN/"YQQ)Y2LPYI+;3")A$PB81,(F$3")A$PB818BWSN
MFH\=]17?<=X,LI!4R*]:3BV8A\)V2=>K)Q]<JD,00$59>RS;E%H@``/=%03B
M'=(;-S+K&3,;QEG&6MVJESG&C6,:"Y[WG4UC07.)T`+4OKR*PM'W<U=A@T#2
M2<`T<9-`%!)5V%VM]KL&^MV.$Y7=VR$DSR293&5B]:5+O&6@=54I)03!&P=>
M:J`5T8G0[UYXBJHF$>H_.SUANVM_:/G7[L;LR/C[-<KE+;=@J//)F^*^_G'W
M3GFOF[3A%%0@![W*%L+24/=F%]CF,HQX(VZHV\`&OA.E9(SS>I1,(F$3")A%
MC:VQ%SKUEKN\-,/4H+>>M"JN*V[,(IQM[KQA!2;U;=4DQ*$K6+2U(*1`4ZF:
M.1(JF)3!U#T3ZOO;5+V99X<@WB>^7LUS.5K;N+$^;2'Q6W]N/N9(L#,UM!-$
M"""YK"(S,+25Y;?65&YE#[DZGC7&[A:[5P'$*=/CWO&I\C]/4O<5.(LSC;6P
M5"2@GA@&3J5IBUSQMJI\P7H`DDZY-MU6Y^H!XA"D5`.ZH7/HUF%D[+[MULYS
M9&4#F/::LDC>`Z.1A&!:]A#@1J*F+"]BS"T9=Q5#7#$'2UPP<T\8-0LS9IK<
M50$2B!BB)3%$!`0$0$!`>H"`AV@(#E$4+_+CBY;=&W6U\D="U9_;M5W1ZM8]
M_P"F*TU%Q/5BP'+WI/<NKH='I\()/DR>+8(=$/$.<HND2CU."?`>UGLGRGMJ
MR*&W=+%9=H67Q;%C=R817$5:BRO'`$AM2?-YL3$XD&K'$'C-W;3Y5</S"S:7
MV,AK+&-+3KEC&NOW;=>D+!E3MU9O4"QM%/FV%A@)$G>:R,<L"J??#]\;.4Q[
MJS)\W-[U5!8I%4S!T,4,^8V\^ZV\6Y>=S;N;U6<]CG=N:/BE;0TU/8<6R1NT
MLD87,<,6N*W[>X@NHA/;N#XCH(]O@/"#BKBR`69,(F$7PJJD@BLX752;MVZ1
MUW#A=0B*#=!(HF46765,1)%%,H=3&,(%*':(Y?%'+/*R"!KGSR.#6M:"YSG$
MT#6M`)<XG```DG`!4)`%3@`K5U5JNV\Y9]6K4I>5K7%^)D3,MM[J;%68+;%(
MT4#U_5FG'*A2'D`D0**,O.)@9JS0,8B9CJ&*4_T'[!O5]=N'-!VB=ID#?WJ:
M!)EV6/HXVSM++R^;B&RL]U;VQ\9CJ22T<`UL*729Z\VMH2W*P:22C#;X8XN&
MNAS]`&`7H#K=;K]-KL%4:G#L*]5ZO$1\!78&+0*VCH>&BFR;./CF:)>PB#9N
MD4H=>IC#U,81,(B/I&::6XE=/.XOG>XN<XXDDFI)Y2N4QQQPQMBB`;$T``#0
M`-`"[K,:O3")A$PB81,(F$3")A$PB81,(F$3")A%'1RMYSWGCYNNFZ6H7'EK
MM^0M<!J:3<V&4VZCK.-AY/=FVK3I>C18MQU[=EY!HUM=>([EG13)"TBU3G22
M76*1%76FG=&\,:W:)IKII)`U%9XX6O87N=2E=5=`KPK1FP^>&$YK%>:U)HNM
M([20KD9?)6E;8VT$/'TC7JJ?#26<W&]*0%47E(>NR\-RK?)QTBH5%D!JD[>&
M.JAXJ*.`WU658T;>FA.@>+B??>PLPL_&HXG9XAI]UX/95U6/SK$&D_MF`HG'
M)ELX=6/MA2*\W7MUN(VMS%$U70=X;`N\FW?3VGX^43N31CH&7:,HH6/J<@X?
M,%$WX-E3+A4WV)#6UI77J`).K3A]M4%I@"74K35K)`&OC62WGFBV:G<>;ANC
M8&L-/LIN+YT;.X@PU>5WX%'J]=B:R&P)6FW+<=PLU)E%-?2TQ7J6B=1F#)R1
M^62:NFHII.$T2W&Z+8R]P;7K"W3317$X8*WS<%X8TFFP':.31SJP)7SFWL90
M$-H.N*DA7:A)S%CC:XCL#<\?2K//.=>Z%UMOJ]TEO#+ZYD4$=S3+#:T9!4BK
M`X4<6R79R/59BDU**UGGXT[%.4TU5IHTZ@-?$KA:5.SM8\0XR.'1A4G4JT/S
M<[Y.;"@]-VOCK!(7Z>V+R+J<D_IFUXX4*)7]4;HM^HJXI(UB\PD,]GMFQ2,"
MVG+)7$W:+DD&]9/V9%0D46:-6WCBX,+1M$G0=%#3GUD<%#K5'6P#=L.\6@U<
M(KS:@>'D6:N'_F+VGD#L+4>J[/IIU%-;UK-D]'<'V61R2\ULN&XP<<>2UM9O
M=5LJR@A5:\[@>0231JY2F7?22CED0;E1,10,D-R9'-:6X$::Z]EKM'=5LL`C
M:7`Z#HXJD:>XI7,VUK)A$PB81,(JAZ0^F'U<(O,Y^DAY#^F*3]&64]HL%8W4
M'E$710!".<Z9G-9+JC^]HREHU#49^%3,/3H51Z:LKD+U'M$O0,X5VTY?+FOJ
M^[PP0@F2U^K[P@="&Y:V0\C6R;1X@N(YYXF=VDQ]R7S1]US:CGV2N_SY:K:3
M")A$PB81,(F$6'=S1JUE8ZPH;(OBR>Q=^Z0J$>@4.\=4R^P8>6?&*3M$Q6\;
M$K*&]P"E$1ST_P"J#E\ESVT19D`?-\NRG,+AYU`>;N@97E?,T!1&=>/:QVX]
MW+<1-'OP3[`*]+#@P'<+F+]:994Q?I"<PA_Y,][C0%R@Z5^.51,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB818YL>XM1T^_T75-NVCKVJ[/V@WEW>M=>
M6.X0,)<]@-X`S<DTK3:[)/FTG8PC5'2950:IJF`QP*`"/4`L+V-<&.(#CH'#
MR*X,<6EP!+1I/`LCF*8IA*8!*8HB4Q3`(&*8!Z"`@/:`@.7JU0Q>9'=UK?O'
M3&D$C`YK&J:98>3]\C!.(-I6R-5'U6U+%R)"]0.BR>MY%^4I@'WW<-TZE#.O
M>V?>*3=?LIN(+60PYMO)F,&3Q/;[J."8A][(SCZFD7_$I5<:S5_G&9PVAQA@
MC=.X:BX5;&#R&KE$=#\N=USL5'3+:C:L3;RC1)ZB1>6MH+D37#O%*J!>^7OA
M[O01R5B_]N7<F2-KV;PYOL$8?@[4>QU2Z^E[1Y(I'1.MV;330Z?A+LO:DWE_
M(G4W^=[?^UR__IQ;F?Q#F_O+;\TL?\RW_1V^S\)!Y2;R`.OV$ZG[.W_I>W_M
M<?\`3BW,_B'-_>6WYI/YEO\`H[?9^$L)K^8[L-!4Z)M<T;O)F$H]U[8A#J`B
M`]!%Z`].H9T%OAZMW8KN3GTN[N:YQO3)?1,8XNB@L2RDC0X4+BTU`..&E>J^
MS7L,[3.U+=&#?3=^7)(LKN))6-;/+<-E!A>8W5#(7MH2*MHXX::+\?RD>P?O
M<T?_`!RQ?\]SB_\`)KL$_:N]_P"CY?\`#7//Z2NV;Z3NW^7N_1T_*1[!^]S1
M_P#'+%_SW'\FNP3]J[W_`*/E_P`-/Z2NV;Z3NW^7N_1UO_QKW%*[QUN-WF(:
M.@GQ+%+0HLXI9VLS,E'HL%T7!1>F.N150KWH8O>$.I>H>GIG2_;9V>9'V;;T
MVF4[NW5W=Y/>Y/:WS'7+(V3-%SUGB/$7B>+L5PX:8TJO.UY8YAE&;7^0YKU/
MUEEU]-:R&(N=&Y\+MESF%P:XM)!H2`::@MUO+ZMBNO.3&Z]%F5%*J;AJ+3D+
M2V(B(-V%V@7[2G;3:L4^O<2";:.8V15*4`ZG2,;W1'/</J^[V2[Z=B]F+UY?
MF^[UV[+9'$U<ZV<WKK(NUG887P@G5&%$9>?-,XFLQ\3<,ZYHX'@[,@'+@Y3,
M9VLN1IA%4IC$,!BF$IBB`E,41`P"'H$!#H("&4THH]]Y^7;K#8UCE=F:ALDS
MQPV]+J'=S5BH3!B^HMW>CU-XVP]7O3(5Z:<K'_?'K06+XW43&44-F'/\LW<W
MTRIN0[^9=;YOE48I%UM67%O77;73*31>2'%AUM(4)<Y)$^4W5@]UM=G26T+'
M>6P^*>44/&M*+%QVYUZX4.C(:?U_OR)0$2IV73%]9U2<=I%]"SJ@[(^#CMW)
MBAU,FV?KI@;ZT>F>;-X/5!W)S&1T^Y>\5UEU<1!F-OYPQO$+FV+7$#A?"3PD
MK6+L]ML)K>.X;THGAI/]A]/8*Q^H;D$W.*#OA9RJ2=%'NF2;TBOR"'>'L`$W
M[.U*-%2&-Z#`;I[OHS@+_4TWV#Z0[P;L/BZ1GNFGNM-K4<F*M^L;D8.LKROD
MM/LARN:%U9S7O*A&]3XGOZ0DMT`+!O78U1IL<U*;L\9:OUMU:+0Z[@#U%,B1
M3CTZ=F<ER;U-[*&02;W;UVW4C3'EUK+,\\0EN##&WE+'#B51<9O/A;63F??2
MO:T>];M.6S6OO+-4LSIG-\N]IFVTW;K).TM+:Z9/Z)I5-=,P*)IV58SD;GL-
M-$P=J;Q9HU/T]\B8H],]'[D;@]G79?2;</+-G.MFAS"\<+F]QT]42T16U?\`
M(C:ZF!<5D;DLUT0[.)NM9IZI@+(O[7W3^Z0.)2FP\/$5Z)C8"OQ4;`P,*R0C
M8>$AF+6+B(F/:D!-LQC8YDDBT9-$"!T*FF0I0^AG)I)))9#+*YSI7&I)))).
MLDXDJ?8QD;!'&`UC10`"@`X`!@%V.6JY,(F$3")A$PB81,(F$3")A$PB^U$U
M$CBFJF=(X=.I%"F(<.H=0ZE,`"'4!PB^,(F$3"+X,DB<P'.BB<X=WH<Z*9SA
MX9A.GT.8HF#PSCWB]!]Z;M#MPBXYH^.,"P&C8TP.4`:.0-'LS`Y:%3%$K1R`
MH""[4J)A("9^I`(/=Z=.S*4"(2/CTQ5%..CDQ7445<"FP:)BNJL42+*KB1$!
M646((E.8W43E$0'J&,$5L6C7="NRE<5M].KMC4J-QCMAUH96,;N"Q%YB(J4@
MHRUH)]TJ:TRQA9IVU356!3H@N8O00Z=*%K74V@#0U[JJ'$5H=(HKL5;-5^[X
M[1HOW':4@0%VK=8$Y!N/5O($!1,P$?H#VD6#HJ3W#!E51?B>-C5%B.#QD8=R
MDZ6?).3Q[,SA-\X0(V</DUS("JF]<MDRI*+`(**)E`IA$H`&*!*K]RH-TQ`R
M;=NF8O7NF3;HIB7J0B8]T2$*)>J292]G[$I0]```$7ZY5$PB81,(F$50](?3
M#ZN$7F<_20\A_3%)^C+?2RZ7GMU^5+H1I2&OK>S=9Z9TCN?6"!"]5WUNUU68
M^4/!("`";OV>O'?1Y2A]>HX(&3N5V^6YC:2Y%G6.29G92V=QQ17$9C+N5A+7
MC@+5QO>*UDN;:1UN*W44@D9QN8:T_M"H[JU3H]RAMA5"NW:OJ>)%62,;R3<@
M]BK150!(\C728]#(O(QZ11NL0P`8JB8@(9\B=\]TLWW#WJO]SL]86YIE]RZ)
M_`\#%DK>%DL9;(PC`M<%KVMS%>6S+J'XM[:\G".4'`JZLXRMA,(F$3")A$PB
M[SBK25=W<S(:9*B+C7_$:(>VB<>]WO,GN\+]%.(:G5]-3][4>U.JJNY-<H=1
M0542`W03!GT6]5?<F7=;L[OM^<Q869GO(]L%J"*.&7VSRZ27B;<7%&M/W3(0
MX8$**8//\[:UN-O9`N<=1E>*-;RM;4G@)4ZF>@5R98QVYN?5>AJ@XOFX+S`T
M*KH*>KHOIIR8',J_$O>3BH"):D<2]AF%^H`1JR077-UZ]T`[<V['+[W,IO-[
M&-TDM*FFAH&ESG&@:T:W.(`X5K7=Y:V,77W;VQQ<)UG@`TD\0Q4:%M\R';5W
M.HCQPX\IQ5>4$09;,Y(2SVJ(2")OWN0A]65CUJVK-3A[Y,7SMF)RB'4A?1G6
M6]O;1V.;B2OL\VS9^:YS&2'6V5,;<!KAI;)=O<RV:1H(8Z0C@4,<US*Z_5UL
M&1:GSDMKQB-M7<Y"PN^WKSTGCF6D.35'J'?ZC\':]T'53-&_7]@D_N4C.22W
M<Z]ACCU$0ZB&=-7WKC[LQ/+<FW1DDB&AUUF3@X\K8(`T<@<5:8L\DQDO&,XF
M0M[[B2JL-\<]8`Y5X_DO0[D!.@C&[#T)64VCCI^P4D*9)P<DAWP#M,3J(>D`
MRMCZXV[$KPW.=T98HCI=:YDXN'(R>#9/(7#E3J\\CQCNXW\3X1WVD%9JJ/F2
M;2I*B:/)3CT#NO)]`>;/XY2KVY,(]$/WR0F]86,&MR:-$P]\H9DY?"0.O0AO
M1G<VZ/;+V/;^S,L\ES=V69U(0&VN:,;;%[CH;'=-<^V>3H`<]A/`KAFV86GZ
MQMMJ+6^`E].,QFCAW*J3'5&X=7;TI[2_:BO$!?JF[/X`RD$[\4[!Z4O>5BYN
M.7(A*0,NW]"C1XB@X)T[2].W.R[VPO,MG\VOHW1S4K0ZQJ<TC!S3J<TD'A4S
M:W=M>PB>T>V2(ZQJ/`1I!XCBLDYJ+94-6\=9>?)*[@V/)<>.5'`*HZ-?6Z8<
MZJK&QM.W":O<#2%7)C0<7;99G3Y%I(SK1H($<+)KJ$4.`F`>@]`TGMS`O)C?
M&&5PJ,:+98ZS#0)&R%],:'!8K^Y%^<D?/*\L[Y"KS\0LLV,SZ<7-]I7;5AT9
M.=/N1?G)'SRO+.^0J\_$+&QF?3BYOM)M6'1DYT^Y%^<D?/*\L[Y"KS\0L;&9
M].+F^TFU8=&3G7R.L_SE-O\`N27*GRMY`A>T'3O3FRVRZG>[1*9%M101*!!'
MH'3T@';C9S/IQ<Q\"KM6'1DYPGW.?SECYSOE7_)'M+XC8V<SZ47,4VK#HR<X
M\*?<Y_.6/G.^5?\`)'M+XC8V<SZ47,4VK#HR<X\*?<Y_.6/G.^5?\D>TOB-C
M9S/I1<Q3:L.C)SCPI]SG\Y8^<[Y5_P`D>TOB-C9S/I1<Q3:L.C)SCPI]SG\Y
M8^<[Y5_R1[2^(V-G,^E%S%-JPZ,G./"J#KO\Y:(`G)R8\JQ<Y0$Q45-3[423
M6,':"2BJ=&!1,AQ[!,7M`/1C9S/I1<Q3:L.C)SCPK\OL,_.9_OY>4G_H#NOX
ME92F:=*'F/@5:Y?P2^PH$_/4C_,=2U]J>C\][?Y:VT=V6V0=!Q7JG&_4'(A_
MRV&43FHHDJZU-88&J1"4)%GETVQ5D)-X+)\\(0$FKAR0HDT+X7.R!<&(R'W(
M`.UW%N6?4;1,(D#!IJ1L]U3_`'D8T'S@:-HTK7S,+M7Y*EF@F26GZ/L,KNR<
MKJRD06Q6OW2+RP?_``<C7BQJ9@3C)P96RIJG("JS(B8MSR%@V\;'_P!Y.&H'
MW7=/V%:5XZU<_P#[N#76?N>X/L"Z7D05S/<VN8(#T4>,M>:-ID24Y@*5-DXU
MO+2I$.^;L3(M+2QSF]P!'J.>=?6RS$6-KN''*2+".\O;I],<67%HTFFLB-II
MK.@+AFR9,WO^EU<3![QQ[Y454!I#D+7*[%13C5C%0D-&)-EWIMA5)N@)&J8B
MJX/XC@002*4!$1,;H4`ZB.>T;;UW_5]#66L6974DF#6@65X2XDT`#1`2220`
M!4DX!=33[A9W+*^8A@#B3[IN'=VEU?P-L3_(.OOEQUE_&V<M_JI[-_HN\7^B
MYKZ&M+]R<P^5@_*1_#0878@@(?`.ONT.G_;CK/\`C;']579M]&WB_P!%S7T-
M/W)S#Y6#\I'\-:T.>,>S7"ZJP/-;%\0YC=W[K6N!Z=1$>G7[)0Z^G/)_:)F.
MX._>]<^\L=_GMJR:.)O5G=W-WD=6P,KM"!M:TKHP7N_L8]9@]DW9]:[CS9'Y
M]);33R=<W,((@[KI3)38,;R-FM*[1KIP7X#Q=V<'8+S6P#]`=LZX^,V<(&0;
MBD5&;YY3_P#K6<?FEVD?7AB&G=@_ZI;_`)A/9=V=_P#GNMOE9UQ\9L?N_N-^
MU\\__P`UG'YI/ZXH?X8/^J6_YA2@<16L=J;4AJK>+=0(R;/:YN5!HWOM2DB@
MQ=MXQ%LH9PQEUVX'4,T./=`PB`=.O3KG1_K"9=F>^.^&7W&YV6YY?918Y!96
M1G=E=]!MRV_6[9$<L(>!1S=.&)`)I5>.\TWB@S_>'-=XYQ%;.S+-+BZ$1F9(
M8VS/VPPO%`XMK2H`K2M`MP]*3#,_-SAW/04@RD6\V&^:JJ^C':#]F\B7FLW,
MBND1TT550630D8A,P]#"!5"]O:&=F>J%!F>76^^>0YI!/;31V^6S.BE8^)['
MB:5@+F/#7-)9)A48BA&"B)7L=F]C-$0X.,S:@U!!972.,*?W/4ZY.F$3")A$
MPBKU'Z.414RJ)A%K;RRW%N#1&EY78NB^--OY;;$8S]=BF.E:-9XRH6&5BY=V
MJA+6!&;EXZ59(M:X@0JJJ8H&,H!P`!+T$0Q2O>QFU&TO=70,%DC8U[]E[@UO
M"5%+^5(\T+^H'Y._T@Z!\0<U?.KKZ._G'@6QYO!\NSF/A3\J1YH7]0/R=_I!
MT#X@X\ZNOH[^<>!/-X/EV<Q\*?E2/-"_J!^3O](.@?$''G5U]'?SCP)YO!\N
MSF/A7PKYIGF@))G4-Y`W*$Q2!U$$M_45=00Z@'O$4-?**J#V^@I1'IE#=70_
M\._G'@3S>#Y=G,?"N#^5=\SG^H!Y8?+36/YL\IYY<_1W\_VD\V@^79S'PI^5
M=\SG^H!Y8?+36/YL\>>7/T=_/]I/-H/EV<Q\*?E7?,Y_J`>6'RTUC^;/'GES
M]'?S_:3S:#Y=G,?"GY5WS.?Z@'EA\M-8_FSQYY<_1W\_VD\V@^79S'PI^5=\
MSG^H!Y8?+36/YL\>>7/T=_/]I/-H/EV<Q\*?E7?,Y_J`>6'RTUC^;/'GES]'
M?S_:3S:#Y=G,?"N(X\VGS-&QBD4_-_>7AQ,7O`+;;,.\(`=1#H8[352Y"F[/
M0(@/3'GER/\`P[^?[2>;0?+LYOMKB+>;9YESE!=L;\W\YE%(Z06;',WVHV;N
M2D<)&1.9LX0U*5=NX*4XBFH00.F?H8H@(!E//;BF,#Z<OVE46T%?CF<WVUYT
M.*?FW^9-PBYKO>(>M-%<D>1&N9RS)`VX.<C+VEOCD7K9W..E7LO%U#=5+KC>
MP5]W&*.O%43EHX\>W2`3OF2:G?=#'17ES!/U+6N<TGW)-2.0A;\EK;S0]:XM
M:[I#`'N+^@S1YZ;M-,JEELM)G-:V&?K\7+SFO+-(UZ8L5(E'[1-P]J\W*U*4
MFJQ(R<,L<45EF#MPV.<HB0XAV!R%I):"10TT<"A'``D`U'#PJZ<N5$PB81,(
MF$3")A$PB81,(F$3")A$PBJ'I#Z8?5PB\SGZ2'D/Z8I/T93C<)3&+P]XLF*(
ME,70NK#%,`]!`P5&+$!`?<$!R1MOF[/('>6C/\>_RCWU&7RRT+*\3;Y:-Y4:
M%=R7%W9,XK8MJ0$(T5=NM!;`EUBA*7V.BFI#*J:MM[LX*R1$2_\`NEZ85.@(
MG+G67;;V/,[9\FBS/(^KC[4,M@ZN+:(:W,K9E2VV>\T`NH<?-GN-'@F)Q`+7
M-XC<QNR2X?=,!.42NVG@8]2\Z7@?)N^ZI[DXZ%:C!^PEF+.4BGK23C)%LD\C
MY%@X2=L7S1<H'1<M7*)CI+HJ%'J!BB(?V<^8U]8WN67LN6YE#+;YC;R%DL4C
M2R2-[31S'L<`YK@=((]A2S'LD8)(R',<*@C$$<(*Y>:JN3")A$PBQS.3MRM-
MRB]&Z,B4;?O2V(`HT9G`RE>UK7U#E2>[(V4^2*HE"5Z%34\1%%3]W?K`1)(A
MN\`&]&]@_8->]IEXW>;>82V?9C:2_AI_<OO'MQ\SLZXO<\C9EF;XD+2<>LH%
M&7M[(V06%@`_,WC`:HQK?)P`:AI<="FYXS\>JIQCU)":OK+MQ-O2.7EBO%UD
M4P+-;!V!.F(XL]QF#=3&*M(NB@1NB)C%:LTDD0$>X(C]%;RY9<R,;;Q,M["&
M)D,$+!2.&",!L<3`-#6-`'&:G6I;+K&/+K46["7/J7.<=+WGW3CRZN`4"MSE
M=R@K7%W7[.=<Q*UTV-=)(U6U#JZ.<`A+7^X'2!3P3K`!S1=7@T3@YEI`Q1(U
M;``!U543*.)HL8+2YS?.+B.RW?L83-=7,GN(8FZ3PN>X^+'&*N>\AH!*LS+,
M69?""&F2ZD.S&P:7N]IHTN.H*&9*KVV^78VZ.0EB1V9N5T4_P>J=(P475L<J
M<5$ZGJJMK"HSA(YB`@11^)3/WJ@"HHIU$1'Y\]LWK&Y[V@F7=C='KLI[.&N(
M$+7;-Q>T_P!]?2--7;6EMLT]5&*!P>[$1=ME[C-Y]F+A-F!T'[B,=&-N@`=+
M2=*R4(B(B(B(B/:(B/41'Z(B/ISS0``*#`*45,(F$50$2B`E$0$!Z@("("`_
M1`0[0'*$!PH<0BQK]C=QUQ=AW3QUGV^N-O(@F,PT,0P:]VW'(&!12K;2K:`I
MLY)%X`"1&3(4C]DJ8%"J=0ZAZ=[&/6/SO</JMU=]3-FW9RYP;U;CMW-A7#K;
M*1QVMENEUJXF-XJ&;#M,5<V#VS>?98X17^OH2#HR-UUU.TA30\5N3E6Y1Z[7
MM$9&.:A>:I)C5=LZQE5RJSFN[LW1\1>-7/T(,C`RB0"YBI`I03>M1Z]BA%"E
M^@<K+22WM\SRJXCO,BO86S6MS'C'-"[W+AP.'N7L/C,<"UP!"ELMS!F80EVR
M67##LR,.ECAJXP=+3K'=6S&:ZD$PB81,(F$3")A$PB81,(F$3"+HWE7J\C/P
M5LD:Q6Y&UU5.11JUJD(")?6:L(S"::4NE6[`Z9JR\"E+)(D*Z*T61!P4H`IW
M@`,I0$U(%0JU-*`X%=YE5109<J8=2F\^;JJX**3#=VA==W&%5$.A'<SK"2E:
M-8VQ#>@[AM'.F*Q@#M!,X#Z,\X^MQDTF8=F>0[QP@D97FUS:RGHLO8F2Q$\`
M,D#F\I`7&W#J=X)6G1/;L>.,QDM=[!!6*-D_]G.PO_N)</M=DL\2]GN':!D)
M&GZ[L?\`\U$MF]^93?BG_P"$J(*IU2HKU:MK+URO*KK0,2HLJK&L#JJ*G8HF
M444,9(3&4.81$1'M$<_2O##"Z)KG-:7%HK@%YFGN+AL[VM>\`/.L\*[_`.P^
MF?R9K7^:X_\`@LR=1;]%G,%B\YN>F_G*XKZHTXK%\8E:KA3E9.S$,6,CP,4Y
M6ZABF*()=0,4P=0_5RR2"`1N(:VNR=0X%<RYN2]HVWTJ-9X5H*N``J(```'=
M)V`4`#M('7W/HY\S^V/?'?3+>T?,K++,SS."Q8Z+99%/,UC:P1$[+6N#14DD
MTUDE?:'U:>SOLWSOL2R3-,]R7);O-96W.W+/;6\DK]F[G:W:>]I<:-`:*G!H
M`&`7Y?\`T]'_`-6=9?O_`-H?[9SC])G^$N]?Y3=D'\.;N_H=K\!/_IZ/_JRQ
M_:!VAAA(SG.*T/\`XF?X2R1=DO8^96@[N;NTVA_X.UX?(7H`\H>&/<]T\>D&
MR?B,=+:QY!;)G3E#]S9R%[L2.NJPBKT["+.@7>*D`>T2IB8/1GHJPRNZ@WDW
MJWMO2YTF9P;O6C'.J7/\VRUES.ZIQ/CS1AQZ5:KX[RPPMWQNK.U:UEK:7^8D
M-:`&L:;J2.-K0,``T4:!@`,,%ZC``1'H':(]@`'I$<RKDJTOW_SNT=H6=6H!
M59_;>Y"I`<NGM2LD;':8\3AU24N$F9="N4-H;J`F-).4UP+[XJ)@S->"QR?*
M7;P[RWEIE6[K30W-W((F./1B:?'F?P,B:XE1-YG%K:2^;,#YKWY.,;3AY1]R
MP>4>XM&[#S4YO7M0YZG6-%<>H143>K)3R<UNN^D1-]89ZH@YK-*:NP+Z2$37
M*4W[(<Z"W@]:;L=R.1UOD5IG&?SMPZP;%A;$_>F427#F\9B;4+2-QG]QBT6]
MLSCK*_NTV6]]6"?;?.993UA3F%X*_:/JS+0>K$8L!'M$/5E6ZS@2!T][^Z]>
MG7KG!'>N7EVW2/<VVZC[[,K@OYQ`&_W53J,Y.)OC7BA9179!\M.>=*5(L_G-
M`[WC4A`58JPTV8U%8W*8=.\5K/U*2EH%%P8.O05F(I]?3V9RK)?6T[+<SD$.
M\62YQE!.F6WFBOHV\9C>V"6GD[1XE4/W@@Q$EO<-X'-,;NXYI(YPMMM/^9#J
M&YST70MS5VQ<9ME2ZR;.(C-E.6#O7UI?'$"$;4_;$8):L^764[$T'WP>X-U`
M"E,8>F>@]WLRW<WVR]^;[@YG:YQ81BLC826W,(_S[60-GCY=DMX'+/!GD!D%
MOF#'6MRXT&W0L<?O9!XIY#0J1`0$/3]`!#Z`@8`,4P#Z!*8H]0'T"&95.*F5
M1,(F$3")A$PB81,(F$3")A$PB81?DX02=-W#5<HG0=MUVC@@'42$Z#E$Z"Y"
MJHG362,=)00`Q#%.41ZE$!`!RB+47B%P'XB<#JS+5CBOI2N:S"QN7+JU6L[B
M3M6R+<=RZ6>>!:=D6MY,7.:CFRJP@@S5>>J(@`"5(#]XQL4-O#;BD3:5YSW=
M*RRS2S&LAKWN9;?YF6),(F$3")A$PB81,(F$3")A$PB81,(F$50](?3#ZN$7
MF<_20\A_3%)^C*<7A/\`B=\6_P``>K?M1B\D;;YNSR!WEHS_`!S_`"CWULRL
MBBY07;.4$'35T@LV=-7**;AJZ;.$S(N&SINL4Z+ALX1.)%$SE,0Y1$!`0$0S
M."0002"#@1I"PD`BAQ!446V_+?D:U*2ETX:V^%UPI).EY.;T#?$W[[2<T^7.
M95TXIKU@"\[JJ0>*"/5-J1S&"8?WE(H=,XUOYN!N%VKP!N_EI(,\8P,CS.U+
M8[UC1[ELU08[N-NILP+@,&O"X_)D\]H\S9,]L;2:F%]3$3]Z1C&3Q5'$M,+1
M-[<U0<[7?''#<6O1;B)%;55ZZOMS6SKN=AG+*W:_)**(-3=.H`Z:H*E+]<`#
MGDS>/U.=];>1TNXN:95G=EI:Q\GF-V!J#HK@]47<;)R#J`6`YG+;89C;3Q'I
M-;UC.XYE3S@*QB\H-`=.B^T(%@J'4#MI1K.1;Q,P#T$JK20B6[A,Q1[!`2]@
MYUG/ZL_;W;R&-VZ^8O(UQF"1IY',F<T\ZJ,]R@Z;A@/'M`\Q"YD=OZC69R2.
MUS%;&VY+JF[C>*U;K*[6Q990>@%(+Q*&;12`"(_7J."$#TB.3V4>J;VX9D\&
M_P`MMLJMM<E]=V\(`X=ACY93R",E4^O+!QV;?K)G\$<;W>S0#V5L71N*O,7>
M*B/PW%1_$;7;D0%Y,69Q%WC>TBR,(=]*`I\6NM5J6[63$>CB3=K+H"/4$3"'
M3/0NY'JL]GFZDK,QWZO';R9JRA%K`U]OES7#Y61U+BY`.EK1$QWW0(P5XCSJ
M_P`&M%E;G2YU'RD<31XK.4DD<"E9X^\:M1\9:FZJVK(!9JO,N"2-QN4\\/.W
MV_S92B!YJYVAT4'LJZ[QC"DB7PFC8#"5%),!'KZ,NKV6Z9%!LQQ64#`R&&)C
M8X88Q@&11M`:QH'`*G62I>QR^URZ,QVX.TXU<XFKWGA<XXGO#4%G@QTTRG46
M53002(=5==8P$1002**BRZQQ[")(IE$QC#V`4!'-3$X#2M[ET+SIK7]UR9W3
M>^3\N95>N+.I76O'F+<=X4*[J&N2;ABYLC1`_O$9?9LVW6?N5B@!Q;>&EU$@
M`&>0/6Y[0Y8[ZW[&\HDV;#+Q'<YD6GXZ^D8'QPNII99Q.;1IPZYY)%6!<6L#
M]874F<R>Y=5D(Z,8-"[ED-23P4"OW/$ZF$PB81,(F$3"*R8K8+CC'O6B<E(U
M11M4)1["ZJY&1J(B#69UG8Y-&/@[H[0+[Q27UE87*+E-<0[_`*D=5+KW!$,]
MO^J-VAS7,]SV-9Q(76EVV2[RLN/Q-Y&TOGMVUT,NHFN>&C`31DC&0J'O3]77
M<><1_%U$<PX8W&C7\L;J8\!HO1-[T>TAR*$$`,11,P'34(8.I%$SAV'34*("
M40[!`>N>M^72N4IE43")A$PB81,(F$3")A$PB81,(F$4<OF1Z=L%MUA5-ZZ^
MB5YG8_&:=D+R2$8IF4D+?JV78%CMKU)J0@"HX=C!()R;5,.O>6C^Z4.\<.NM
MFV[>7;];L9GV?YL]L5GF]MU<<IT07<9ZRTGY&3!H=KV'."@\\@EZJ/,;<%UQ
M:N+J#2Z,BDC>;$<86@T7*5J_U-G+1:[:>J5Q@P7;*E'OMI.%F&ADU450(8#$
M%1!8R2I.H&(<#%'H(9\D,QR[>#<?>>7+<P9)9;SY5>[+AH=%/`\.:YM10@.:
MU['4+7-V7"H*RL?!=VXD80^WD;W""/L!6'R\4^.Q0`I=4U\"E`"E`'4[T``#
MH`!_[W]`!G;9]:'U@":G>G,*G[VW_,*,_=_)?H[/[WA5?94X\?>J@/\`&YW^
M-\I_5!ZP'\4YA[VW_,I^[^2_1V?WO"GLJ<=_O50'^-3O\;X_J@]8#^*<P][;
M_F4_=_)OH[/[WA7S[*''3[TU<_\`;S?\;9:?6<[?":G>>^)\BV_,+(,DRMHH
MV*@X`YX',')[*''3[TU<_P#;S?\`&V4_J;[>_P")K[\G;?F%7ZFRWY/^^_X2
MZJ<XV<7:S"RUCL&M:K%P<%'NI67D7+J:(@S8,DC+.%CF&6#J($+T*7TG.(%#
MM$,DLG]8/UC]X<VMLAR3>#,+G.+V=D,,38[8N?)(=EK1^`T5-7'0UH+C@"K)
M<KRF"-TTK-F)@))+WX`?VE)_Y5/'-MJ?3]HW"[J!:1/<C)MI:H"H&2<$=4W4
M$61PGK6!<E=J+.T7\TW?.)IV0QNOB/TP$`$G0/I'>/S2URVPW?SF^?F6;6%L
MUEU=NV0;B[(!N)!L-:W8:X"*.C12-C0LN[EBVWMWWNQU;KEVTUN-6QCW`-:F
MIJ7'C*M3EYR[NMUNUDXR\9K(M5B5=8(O?V_HKPUWE.=KI=Y;5NK5C=YNIL15
MN;_WE)>^+#%-X:?1QU$O77:7VE[O=C>[T6=9S$R]WJO6$Y?EY)`>`:&[NR/&
M9:L=@UHHZ=PV&X;3FKV]N+ZY=EN6N+(V833#2W_+C^_X3]SRK5*C:_J.MX<T
M)4(A.-076.[E'RJBCV;L$DL85',O8YMT921G)9VL83J++G,(F,/0"AV9\RM^
M=_\`>_M)SQV\&^=[)>7YJ&-/BPP,U16\(\2&,:`U@!.EQ<ZI.Q:6=M91=3;-
M#6ZSI+CPN.DD\)5Y9PY;281,(NFL-=@+;#/J[:(:-L$#))&1?Q,LU2>L7)#!
MTZF15*($5)Z2*%[JA![2F`>W);(L^SO=C-H<]W<N[BQSFW=6.:%Y9(T\HTM/
MW375:X8.:1@L4T,-Q&89VM?$[2"*@JZ>/?)FU<-YJ$H6T+!,W3B/-OV<'`VZ
M?=.)BV<;)207(VBV,U++"J_L&FG3A0J)55A.XA!,40,*("4WTG[%NVVR[9H?
MW>SYL%IVJ0QES=@".#-8V"KWQ,]S%>,`+I(6^+*T%\8%'-;%Q3RY$\1S.=)D
MKB`''%T!.@$Z71G14XMY%.\0Z:J::R*J2Z*R::R"Z"A%D%T%B%417062,9)9
M!9(P&(<HB4Y1`0$0'.VB"#0X$+E(((J-"^L*J81,(F$3")A$PB=/_)VX1,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*H>D/IA]7"+S.?I(>0
M_IBD_1E.+PG_`!.^+?X`]6_:C%Y(VWS=GD#O+1G^.?Y1[ZV=S.L281?9%%$Q
M$4U#IB(=!$AC%$0^@(E$.S*4!TI5=:XB8AXH*SR'B'BP^E9W%1[I8?IJKMU%
M!_MY>))&BC7.`XB0K2UIQ(!/(%ST>C9+U=L!6S<`Z`@V(5N@`?0!%$")]/[&
M6'$U.)5PP%!@$RJ)A%J+SXOLCK7AGR,M,,N=K-FUO(U>$<)F$JB$M?7C&BLE
MDC`("55$]B[Y1#M`Q0R:W<BAESRV\XQMF2=8_P`F(&1WL,43GD[K?*+B1F#^
MK+1RN(:.^HIJ?6V=.J57J4>F5%E6:]#039,H`4`)&1Z#0QN@?LE%$C&-]$QA
M'/C9O5G]UO5O/F6\UZXNNLPOI[AQ./QLCG@<@!#1Q`!4MX6VUO';L%&L8&\P
MHKCR!69,(F$3")A$PBM2]UAG=:/<*@_3*JTLU8FX54A@ZAWG\>NB@H'T#HN#
M$.4?<,4!SDVY>\-SNCOAE6]-FXMN<OS&WG!'!'*USAR.9M-/""0M>Z@;<VLE
MN_W+V.;SA2Y<&]@R&T>'W'*[3"YG,W(:LK\5..#B)E%YJI`O3Y-=41[157=P
M!E#=>T3&$<^Q6\5O%;9[=16_S<S%S/)?1[?8<%ER6=USE-O,_P!V8@#RM\4]
MY;4Y#*43")A$PB81,(F$3")A$PB81,(F$50'H/7L^D(`8!#W0$H@(&`0](#V
M"&4109<E^,EHXG66R[;T_69.V\7K5)O;+L/7-:9JR%ET#89!47$U<:7"MP.X
MF-5RK@YG#Z/;E%:(4$QTRBAZ.K^V;L9L.VJR9FF5OAM.U*UA$<<DA#(<RA8/
M$@N'Z([E@\6"=V#A2.3Q=ES.+3V\N22NN+=KGY0\ESV-%70N.ES!K8=+FCW.
MD8*P:Y9*_;X5C9*K,QUA@)-(JS"6BG*;MDX(8.O=!1,1%-8GH.F<"J)F[#%`
M0Z9\T,^R#/-ULWFR#>2TGL<ZMW;,D,S"Q[3PT/NFG2U[26.&+7$8J3AFAN(A
M-`X/B=H(-1]G%I7=9$+*F$3"+J)^P054AG]BLTQ'0$#%HF7D)>6=),V+5(H=
M1%1=40`3FZ="D+WCG'L*`CV9*Y)D><[RYM#D6[UK/>YS<.V8X86%\CSQ-&@#
M2YQHUHQ<0,5CFFBMXS-.YK(FC$DT`5X<;^--FY?V*N[.VI796I\4*S)L[#3J
M18V:\79.1L[&K@YB)^R0[@$W<-I^,=)E7;MERE6FU"E$2@AU$/I9V+]BUGV+
MVKL[SIT-UVJ7,1871D/ARN)XH^*%XPDNWCQ9IF^+&VL<9(+G/BX8)<\D;-,U
MS,F806M.#IG#0YPTB,:0#B[D4AO.W?LYH'0SUS0CHDV[M"=B]0Z<1[A.ZQN%
MK3725LWJY2@7U.BUYNZDQ``[A3MTBCT`W3.W8[G*\LM;O>'/W%N[V5VDEW<G
M68H6[6P/OY7[,;1K<Y2><WDEG9[-M\\F<(X^)SONN1HJ[N+SX2&WE>/,L.D*
M3K@+F2IPD+-3EID[DE#R%BGK:FO)R\[(@XB'RSV3E9`JBRZQU3',8P!V``9Y
MIW+]77>3UMK&Y[:\YS\6%Y?WT\3;46O6MMX+=_5PPQN-Q&`R-@V6M#0,"XDN
M<XKA68[R6FZKVY7U1>T-!VJXN<<7..!Q).DK\O:\OOWD8[Y2VGQ=SF/_`$WL
MP_BEOZ"/2U&_S)LOD'<Y^"GM>7W[R,=\I;3XNX_Z;V8?Q2W]!'I:?S)LOD'<
MY^"K9>^8)'5QZ[B[AJ:68R+<6YB)PELC)-N*+A`JY!46<QS(04$#!V%`P=/2
M(#V9UWOWZCKMQHH[O,=[[""P<\,+[BRN`>L<"YK6BWDGJ"UI)+MFA%%V#N!'
MO+VFY@_*=R\KFOLS9"Z8QLEB81$QS6.>3,Z,8.>T4!)-:TTKC?E(Z#][.X?Y
MZA/X+.M/Z:]W_P".\D_0LQ_-KMK^1?;G_"MY^DV7Y]/RD=!^]G</\]0G\%C^
MFO=_^.\D_0LQ_-I_(OMS_A6\_2;+\^LIZBY64/D=8I/5QJ!,LVLM6)IQ)$G7
MD7(1<A&(D0;OXUR@V*54/6D'@]TW00`2^X/0<@][.QB][,]VF]J&ZV]%CF,F
M6YI:Q`VL-U!-!/+MR0R-=,UH.R8C4#5IJ*@\(WIW1WOW-O8,GWYRF;+I;Z"1
M\0DDAD$C(RULGQ+WTH7`8TTX*7?RT]KS!8*_<4;K*N9:Q<?/@A_K>9D5C+2-
MET':SN"T[UE9014=/:')-U85<_41!$K8!]';[RW3WRM>TS<?+>T2U:R.ZO6N
MAO8FX-BS""C;@-&IDM6SQCHR+C&22O@=+E$Q)?;T+"=+HG>YY2PU:>0*4/)=
M<@3")A$PB81,(H]?,<7Y!H:VTC[/CC;;19;DE4$=ONM,L[^^M2&FC4#9IIL[
MU+5<=*;$)`_9>2$!4T2B9<'`H@H(("KFM<]9L-ZNONA6E=%#P8Z:+-!L;1VZ
M>YPK334<."TEOM^\VNZ6BJQD!65J/"QVX92[4ZR1FD[."->I=$MG,/7,)2MS
MQR^TVH[;B=G4.K4"SK`J>%*C(3K53P3D[A`P.==O(%*"NFAP'C"AQQK@=6E9
MVBV`K6N'#Y)PPPH:C7H78L.4OFSWB\(UB#XWKZLB)^*U&C(VB_<?)R<BM76.
M7K31_LM>*.TV/$1^P:ZG(OC`T,O($=QZC?PWB2!Q.VQUMVYU`V@PTC1PZ\53
MJ[8"I=73H.G@U8+I)KEUYN"M4;R4?QF2JMX?V+7L=+U25XW[3LM/U_5I;C]'
MW(+J%TJ,]:Y[8*UUWTNXK$U"1L,=]1V3</6#D4,5Z:TS7O0`T:B=53HXZ#BX
MJ55PBM.D3IUCAX^+'CX]`VCXVWCFO?.=>UEM[5"Y4?2-0U1N.G5.O-=?SU7U
M"2Q,.0M*3U;/0]_D[3+Q^[+;=-,LUIGX5;Q\6,.B^=1AR"HDH1+-$9S.>LJ&
M4.K#2*:\:C'5189&PMA&P07DC7CHQPU4*E+S<6NF$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB815#TA],/JX1>9S])#R'],4GZ,IQ>$_P")WQ;_``!ZM^U&
M+R1MOF[/('>6C/\`'/\`*/?6SN9UB3")A$PB81,(F$6@WF@,UW7!?>*Z!!.6
M%)KVQO`#]C&P&T*9)2*OZ@(LT3G$?<`N36[T;I\S\V9\9-;W$;?*DMY6-]DA
M0>\@)R:9P^YV''D#VD^PM"/$(L`+)F`R:Q2K)F`>H&35`%$S`(=@@8A@'/B=
MU;X289!21A+2.`MP([A"VZ@XC04PB81,(F$3")A%^:RR;9%=RL8"(MD%G"QS
M?6D202.JH8?U"D((CF2**2XF9;Q"LLCVM:.%SB&@=TD*A(:"XZ`%(/Y93)PR
MX)\>3N"&3&6KUFL+<I@Z"#"PW^VR\<8.P/>*,G:9R^X)3!GVPWE88LZEMW>[
MB9%&?*CB8QWL@K6W<!&2P$_=!Q[A>XCV%O;D$IM,(F$3")A$PB81,(F$3")A
M$PB81,(J@(E'J`B`]O:'T!#H(?2$!RB*.O<OEP:MN=@E=AZ1L\WQGV;,+*/9
ME[0F#&2UI<)`X]\[FYZGD#(UYRZ<'_?'4<>/<FZB8PG,/7,&\>5;L[\Y:S)]
M_P#+;;-[",4C?)5EU`/\B[CI-&/O2YS#K:5!SY'$93<Y>]UK<G3L@%CC]]&?
M%/**%:?SW&3GE0E#HJ:UU%OF,1$03G=9;#^Y[/.DR^A5S3]BM4V:#DX=HD;R
M"I`'L`?1GG//?5$[/LQD=-NGO!F&65T0WULV[8WB$]NZ)].-T9/"2M<_7UOA
M)##<-X8W[!/]EXIS%65]BO+KO^`/![=7K'7N>]MNHQ9]_P"B#_[,_!\'W>_T
M_L=<X:?4QS;;_P#5N0]573U%[M4\GJ]/%7NJGGN8Z/,+C:\J.G/M*\H'C3SR
MOBA$4=6ZET5&K"`*3VTMCEODTT3-V&5;T[6[5P@X<$#M!-=^D01[!'.89'ZH
M>X.7R";>S>&_S*FF&QMFVK'<1GN'2O`/"V('@HJCZ^N,(X(8&]*1^V1_98.^
M5MYI_P`MS6-5GHJ_[XM<UR:V-#KIOH8;M',H?551D$S`H1U4M3QYUX,7;=0/
MW-U**2"P=`,4"&[<]&;M9/NON)E[\J[/LLM\HM)&[,LC*R7<X_S[N2LK@>@T
MM9P-6>#(XC*+C,I'75PTU&T`(VG[V,8=UU2I&Q$1Z=?<`"@'H`"E`"E*`!V`
M4I0```.P`#-E3JA=YXS:EMYEZ8HRAQ4B=.:,M6SSM1'JD%MV=9@I48],3T>.
MTKU<<`F80Z@"QNGI'.E_69SN3(^PY]C`2V;/,Z@MG$:X+6-UU(WD=((JCB7'
M;S\/GT,1]Q!;N?\`VGNV`?>@J*'>&O-IN]W6VT5K6EBMT!-URELVDE#NX-)$
M',.Q=(OD5"2,FU6`Z:BP!];T_L9R?U0O6"[(>S7L=AW<WRSJWLL\;?W;W0O;
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MNS&ZIVJUIAP8U]G'?/WH[_\`Z-2G_-\\W_N_NO\`QAN;_J3?S:]T?UE]F'[.
MWC_0XO24]G'?/WH[_P#Z-2G_`#?'[O[K_P`8;F_ZDW\VG]9?9A^SMX_T.+TE
M;?\`"/4.T*1ND\U;Z#::W$!3K$U&2F8AW'L_6G)XXK=L"SE-,IEUA(;NE#J(
M@41]`9QGM8N]ULI[$<QW>M,_R+,\YO,]R^:.*QNA</ZN%EP)'.:&M(#2]N.C
M'36@7E_MZ[6=W^UW>?)LQW:M<R@M<OL;J.4W4+8JNFDB<S8V9)*BC#6I&/"I
M;=1S:E"YO<6[4V.**&QB;(T)9`*/=(]96&L+W*K$7Z=`4%E9ZR!T^OUHG'IZ
M<W?4XSN2XRC>K<Z5U88X[7,HAT7LD-M.1P;3)(J^2%T/.>HSBSN&_P"\VX7<
M8+=IO,YJGUSU:N2IA$PB81,(F$6KVV>0MHIN]=.\=-7ZA6V[LS:5+V!MF41=
M[!A]9U^E:@U?9*!4K;9E)B5@[$K9+0O/;)CT8V%0;H$<`191P]:)D(8^%\NP
M]L;15Q%=-*`4'/C@%D;&"PR.-&@@:*U)KX%K'I;S7N-FT(FHQT^I/U?:DQI%
M;=MIHL-$/[1#5..;U*3V">J*755"%CU[.OK^."71*X29LSH*D2,Y(X$$1Q,O
M(G@5J'EM:>S2O(LC[9[3A0MK3VM'*N6EYM_#IU2KCL)@[W#)5#7=<B+'?)MI
MJ>4+&U0)J9N<(TKLA+/I-E!O;D5SKF>5^#&#IXNNVBE56WK`*-@7>>P4K4X"
MNCN)YK+6F%2>%7!%^:7Q.GYY:K5M;=-FL[NRMJE1:_!Z/O+F5W%.*7.WT*30
MTV@X:M27IO6+#0Y8)9<AT$F+=H94QA#H&5-Y``22:#B..FM.2AJ@M9C0`"IX
M^33RUP6;^.O,K07*N:V?`Z4LDU87>HI9")M3B2K$K!1KKUFP7"JHR5=?OB`E
M+1HV6@S#,P&!!VF=F"IVY6[AJLODCFCE)##6GV>TL<D3XP"_7]GMK:/,RQIA
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$50](?3#ZN$7F<_20\A_3%)^C*
M<7A/^)WQ;_`'JW[48O)&V^;L\@=Y:,_QS_*/?6SN9UB3")A$PB81,(F$6/-N
M:XB]PZJV3J>:,4D9LBC6>E.EC@`E:C88AU'MGW0?=CWBR:X?0%,,V\OO),NO
MH;^+XR&5KQ_9(-.[H6O=V[;NUDM7^YD8YO.*5[FE>??2,U,R-`8P-M0.RO\`
MK=](ZLV+%K@)7,=<Z"X&OR95DS>_*1^DT2=I&'L437`P=0SYD>L-N,=PNUG-
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M$3")A$PB810=\L43L_,"MIG!1($YQ8U8[C3#Z%T8>_79A(=SJ';ZNY<$`W3L
M#O!GG+UNX9).RW=ZY8*Q19_=L=Q.DM&.9SACJ<BXX[Q=XI0?NK2,CN/<#WU:
M>?/522T)WGMG;D+N2;IM,NS>KP414:G+D;C5H.:57>S7PCZVHHYDDC+E#JV+
MT*!NZ`>@`]WZ8^J5ZM/9-VM=E7[T;YV4T^=?65S$7MN9XQU<98&-#(I&-%*F
MIH22<3H76^]V\^99)F#8+0MZHL!H0-.DFI!6,_NN<AOOO(?)[4_X+/3_`/0S
MZO7[,N?TR[_/KBG\PL\X6\S?@I]UWD/]]Y#Y/:G_``6/Z&/5Y.G*[G],N_SZ
M?S"SSA;S-^"L*7OEUR-ID^K"DV"RD"IMVJ_K*E.K#8PBX1!42^$5@J``3KTZ
M]>W.@^V7L![`>RB>RA@W:EOO/!)B[,KV+8ZL1G4]]:[?%2G&O4WJX=F68]O<
M6:R7.</ROZMZBFQ;1S]9UQF&.T^/9V>JU5KM:J8V;[<W)#^6<?\`Z*UK^*\Z
M2_=_L(_@L_ZO?+T[_17/_%T_^G0^D*GMS<D/Y91_^BM:_BO'[O\`82-&Y;O]
M7OE3^BN?^+I_].A](6UW"#?6U-Y<M^,%:N\TUF?@O?%3LD4FVAHN-6:DAX"X
M.)M<RL<U;BJW^#@Z'`X&`O8("':.>A^R'</L_P`MR2]W\W*RA^4S2VEY8SM-
MW/=->T/LI(C68^*[;+J;(&`-:X4\J=L/9Y<=EG:-9;EOS%V9QNMX+L2N@9`0
M7NG8YFRQ[P0!&#4NQKH%,?9%G*5&)A$PB81,(F$6&MK<>-(;RDZ+-[:UK7[O
M-ZRDWLO09R04EHZ;JSJ4]1^&&\?,0,E$22D+.?!;7X0C%U5HR0]51]9;J^$G
MW<;XXY""\5(T*]LCV`AIH#I6./89X@@SFXU/C_1V\19M<)ZCLL&S4L;&OV/7
M2#->.95V?KS*>;PDR>+CG)V[*0<MU95@AW2-G212$`MOF\.C9%"*=Q5ZZ7I&
MM:]U=:YX`\+7E.DZ`ZXXZ_6J$U-1=DEXDYK)XLG8(=M>V3&9?3);`%@<2)F&
MT+(W<JF=B9\VG7R+KQDW"A1H;:`C9V13[/">=5ZZ6NUM&OV>`+L93@OP_F8Q
MC$2''N@&912JSB'%D2=AY"$=.;S([+<NX&:AIJ/FX)ZYO<P\DE%F;A!4ZCM=
M,3"@JHD:I@A(H6BGVZ]]4$TH-=H_8*=Y95U=HK4.DQM/W):)%T)"Z3+BPV*.
M@GDV$(YF'DA*2[UW&5]]*O8&L%?2\X\=KHQ39BW7=.E%E$S*&$V7MC8RNP*5
M5KGN?3:-:++&7JU,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBJ'I#Z8?5
MPB\SGZ2'D/Z8I/T93B\)_P`3OBW^`/5OVHQ>2-M\W9Y`[RT9_CG^4>^MG<SK
M$F$3")A$PB81,(F$4-7/+24OIK8<ES#H$.\E==VQG&1G*:K0S91T_A%8A(K"
MN[YB8Y`IE'18MAW65B(F43BU(FY'KW5#%X)VL=F$';+N:S([8QQ[]97MR99*
M\AK9FOQFR^1Y]RV8@/@<<&3`5HUSJ\:S*)^679S>$$V<@`G:-(I@V4#708/X
ML5A>-DHZ9CF,O$/VDI$R;5%]&R3!=-TR?,W!`40<M7"0F3514(/4!`?U!Z"`
MAGROS#+[_*;^;*\UAEMLSMY'1RQ2-+)(Y&FCF/:<6N!U=T5!!4DQ[)&"2,AT
M;A4$8@CA"YN::N3")A$PBX$K*Q<%&2$W-R#.)AXEHL_DY.07(V9,&;<@G6<N
M5U!`B:9"A],1Z``"(@&;V699F.=9C!E&3P2W6:W,K8XH8FE\DDCC1K6-&))Y
M@*DD`$JR22.)AEE(;&T5).@#A*SIP(T=-;7OK'F3L6%>PU.@XR3A>+-/FFIV
MLBYCYM(6ECWI,QRX`HR=V9CU9P*9R@HG'F.OV=](QOJEV5]F=MV-[ENW<D='
M+OIF+F2YI,PAS6%F,-A$\>ZCMZETKAA),7$>*&TC\LB?F-V,WG:6VK`1`TC$
M@^ZE(U%VAO`W%3%YS=<D3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PBB*\RVKJ5'8O&GD<0G<@6DA8./6QGH!T2CXC9"C>:U_*OCAV$9M+K$J
M-C'-[TAGI`_99P7M>W4FWZ[',\R"S89,WL1'FELT"KG.M-H7#&CI.MGR4`TE
MH"X[FX\UO[7,3A%4PO/`'XL)Y'BG=6!1`2B("'00$0$!]("'8(?V!SY0@@BH
MT%2*T\V[QSO5[V9)W^J76IP;>5KM>@W$=/P<O)."'@O7.BZ2S!T@D!%Q=^@0
MZATZ?JY[I]7?UOLF[#^SX;EWF2WE_=>?3S];'-"QA;,6D-V7C:!;0U-2#A1<
M)WBW1.?7@NC*&-#0`*&M0L?>REN7[Y>M/]$[+_&6=[_]2'=[^&<Q_+VZ@/Y:
M-^D#F*>REN7[Y>M/]$[+_&6/^I#N]_#.8_E[=/Y:-^D#F*QO:/+_`-@6Z4/,
M2NT*21VHB@@(,Z[/HH]QNF":?0AW"H]X2AVCU[1SJSM$]<+LS[3I;:;>/=S/
MFOM0_8ZB\M8_=[(.UM1OK[@4T:UW?V/[Z[\=B++YFYLF72-S#JNM\ZADEIU)
MD+=C9DCI\8ZM:UPT4QMW\FQ;OOIU/_,4Y^WSK;^=W8;_``]O3_J%G^87=/\`
M5=VW_P#V]^AS^DI^38MWWTZG_F*<_;X_G=V&_P`/;T_ZA9_F$_JN[;__`+>_
M0Y_25O-Y47$!Y3>:UIL<A.QULC-!:Z.]?2T8Q=M6#+8.T&CF%@(#J\,8RDFR
MJ0/WRH!T\,JB8#VCGL3LQWFR/-^QV.]W;R_,,NRC,LRF=$R\FCFEE9#L-DF:
MZ)C&B)TK.K8""26/-:$+H_>[?7>;M/W_`!O3O6;,YC:6#(/^[1NBC`VI',!:
M]\A+Z2/+CM4ILBB].^2"M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB815#TA],/JX1>9S])#R'],4GZ,IQ>$_XG?%O\`>K
M?M1B\D;;YNSR!WEHS_'/\H]];.YG6),(F$3")A$PB81,(OA1--9-5%9))=!=
M)1!=!=)-=!P@L0R2R"Z"I3I+H+I'$IR'`2G*(@("`B&`2#48$)@10Z%$!NGR
M_;QK.7F+_P`,C0SJL2KQS,6GBW:Y/X'K8OW)S+OY/2EL<>(A2'[Q01,:'>_^
MZCJ#^Y'2#NIAPOM)[+MQ^V*W$F]`?8;X1QAD6:P,#GN:T49'>PU:+F-N@/!;
M,P8-?3`\;ERNZR][I\FV76Y-70.-&UUF)WW!/1/B\BTQ^[75(6<&G;18V/1M
M_2-X3BD[CAW%+D#+=>Z/P3,/P"MV%H8W[VNS=J$4#M``SP]OIZL?:YN?MW=K
M8?7>0MJ1=9:3<LV>&2%H\YA--(?%0:-HZ5;'G%F7]3<[5O<]"4;![A/BNY05
MEEHZ:R"17$>[:2"!P`Q%V#E!ZB<H^@Q%6RBJ9BC]$!SH2ZMKJPE,%_%+!.#0
MMD8Z-P/`6O`(/<4FUS7BK"".(U[RH\=M(Y(SB1>-(]`A1,==^Z09(D*':)CJ
MNE$DRE`/=$>F+2UN[^406$4L\[C0-B8Z1Q/`&L#B>9'.:P5>0!QFG?6)R;JK
M$_.?8=JB+LN][\H;PD*;IV(7N#E-81[H#-3[0/L7KC,IOWQ=X\3(F7J(@/3.
M_MR_5@[6][MB[OK$9%D+J$W69$VXV>&.`CSF8TT!L0!UO&E1DF<68?U-KM7-
MST(AM<[O<M'&2MUM)>7Y<MAS4+L7F<>$&&AWK:9J7%ZJR/PS36,BV."["6W'
M9T_#1V#,,5``Y(ML'P0DH'OS+AU(/N'LW[,MR.QZU=^Z8?>[V2QEDV:SL#9=
MDCQH[.+$6L3M!=4S/'NWTH!?%E=S?O;/G.R(6FK8&FK:ZC([[LCHCQ1QJ7DI
M2$(1-,A$DTR$2222(1))))(H)I))))@5-))),H%*4H`4I0````#.8Z<3I7(U
M7")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB818SW+J6H;WU9>
MM07QLHXJM^@'4%(J-^Z#Z-64$CB+G8M0W[Q+P$J@@]:G[.ZN@7KV=<V["^GR
MV]COK>G71NJ`<01H+7#6UPJTC6"M:\M8KZU?:3_%2-H>$<!'&#0CC"@0JZEU
MU];K!QWW3W6VX]:(IE+)"4R,?M>A=XR-;VI5#J=`?,IADF4L@D03*,GQ5"*`
M`]0#Y[^L?V,'<'/#OENM$YW9QFTQ=$6BHL;EY+I+&6GN`'5=;..#XO$!VF&L
M%E]S,'.RV^PS"$:?E&:I&\-1[H:CI62\\RJ53")A$PB818\V'>7%1:P\37(5
MS<MF7F42J^K=>Q@>++W*VOA!-HW31*/>0AHXQP7D'9^ZBV;$,8Q@ZAG;/8YV
M39QVN[U-R>T+K?=ZVI+F%X1XEK;@XXZ#/*`601Z7/-:;#7$:%_>BRB&PW;NI
M#LQL&E[M7<&EQU!3&<.^.!>,NFF51F)%O8MF6R7?;!W)<&X=4[+LBQ%2/*^I
MJ&`#C`UYLDE&QQ1Z`#5L!P`!4,&?4>?ZOAAM\KR6$6V[]A;QVUK"/]W!$-E@
M/"YV+WG2Y[B2M[*K$V%KL2';NI'%\CND]VGN#0.(+:?-92281,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*H>D/IA]7"+S.
M?I(>0_IBD_1E.+PG_$[XM_@#U;]J,7DC;?-V>0.\M&?XY_E'OK9W,ZQ)A$PB
M81,(F$3")A$PB816U;J73=@0ZE>OM1J]X@50,4\-;Z_$V2,$#`(&$K*8:/$$
MSB`_7%*!OU<S6]S<6DG76LCXI1]TQQ:><$+%+##.SJYV->S@<`1S%:>S/EH\
M%YERH[#CQ68!=4PG4"F3]WI38QC#U-T85>SQ<>0!^@5(`Z>@,EG[RYU,*74K
M9Z?+1Q2GGD8X^RHEV[N2N-1`UI^]+F_X7`*L+Y:?!>$<IO/9WJ\^ND<%$_LT
MG+I=FY3%'J418VFS2K`X!]`R0AT](89O+G4((M9FP`_(QQ1'GC8T^RJMW=R5
MIVC`UQ^^+G>PYQ'L+<2IT^HT*'2KU%JE9I4`B!2IPM2@8JMQ90*'0HBQAVC-
ML<P`'UQBB;]7(B>XN+J0S74CY)3]T]Q<><DE2T444#.K@8UD?`T`#F"N+,2R
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+6/D_P`5
M-?<HJO%L+"ZDJ?L"FN%Y35^VZL5%.Y:^FEB@"IFIU.XE,UR3$I2R$2Y$6KM/
M^]J`50N=K[6:RN,HS6WAOL@O(^KN;68;44S#J(TM>TXLD;1['`.:00H[,,MA
MS!C:ET=RPU9(WW3#[8.MIP*AOV"CN3C(\^!N4--5;UPBP-8CD3KR,D9O3]E2
MZ]U!Q9D6B#B8UA-K$`!6;2"0->^(^$J).@YXW[1O5(OW2R9UV-S',<N-7'+)
MY&LOX-9;"]Y;'>1C0VA9-2@+9'8J'-]<Y>>JSEFRW0)F`F)WE4QC/"#AP%7-
M`S\%:8]&5K$W$V*,<$!1%_!R+25:'(8.H""S)98A1Z>X(@(>Z&>/<ZR3.MV[
MUV6[Q6=U89@PT='<1/A>#Y,C6D\HJ.`J4BFBG9UD#FO8=;2"/87;]TWHZ#U^
MAT'(JHTU%%D7'>NFL8V4>R3IK&LD2B=9Y(.$6+1(A0ZB95RZ.D@F4`#TB8,S
MV=M<YC<-L\OBDN+QYHV.)KI'N)U!C`YQ/(%1SFL;MO(:T:S@.<K&E<O-GW+.
M+4KB]19'>-I35!K(61B96)TY2SF-W#/;ILQTD2&*DU^N%I'F=/%NG=(7O"&>
MI^SWU3]]L^='FO:&X[M[L&CJ3-#LPG;T8+2NTPD?[RXV&MT[#]"B79KYP\P9
M2PW-QK(PB;QNDT=QM25*UQ.X4Q.A9)[M79-C0VQR-LD8,9+WXS$S*N4>#7$%
M%J/J:"<=\]=KG?\`>N79^C^3$.JHD((I9[BR?*MWMTMWXMT-R[06&[,+MK8K
MM37$M*&XNI=,TSN/Q6"C6`-``D<ORLVTIO;Q_79DX4+J4:P=",?<MX3I=K6]
M&;"ETPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3"*H>D/IA]7"+S.?I(>0_IBD_1EDZE[Y\P+5VKJ9'\>M:%V'16O$WC[
M8Z-]FNK;M<Z:S=4CA[N[:]PKE.<4&4JDF^M6U=F4FMU/Q'+YZDP?R[8$FQUC
MD06RQR7#8F]6*MV&TJ"1@TDTIPF@6)[(72';-#MNU_?`#3P"I6;G?,CS&)1[
M<5Z?QFB%9"JQO+FU/M46'1.\HR5:(:1;-O9^UA"[B=VN,H&Q[;R7:/D)AO*P
M[06S!#Q8\C55V!1+EZ^YQHW1M84.K0*Z#M:59U4&%78'9QJ->DTU45MCSL\P
MTK;1[-IQKA)29O%?V;)W*<4T'R1C]:Q[%B&XFFN[%*S20.KS0Y:(DZ5`?9+7
M5*[)*+-YHBD4]=BZ;D1IU]R`WQ:D@UP=373C&@5%->!5>I@Q\;`$:Q757B.D
MT/%B%TL7S^\R>3;6B1:\-18LX'CFSO\`$1URTQNJ&MUPNBT.S7E[97H.N2UI
M@W\)6+"9ZB-(5EF-IEHQDDX;J)NGJ3(E/.+HUHS#9KH./']K2J]1;X#:^ZII
M'V=W0N0O?_,7?\>N-%\KR.S[I?V'++G-?MCTI76VQ=5R^W]6ZQB.2M[XN:\E
M(B:F&-RU)J;9[ZM5B(C8V8.Z66+)1;9RHY`BB#MM7/5M(J7;;B<"*@;1:.$`
MX4KQ*FS!MN::!NRT`U!H30$\!(Q]E=O&<R?,SL%>FI.L<?Z;*,:[6+;.PEPL
M'&SD-1ONQ/$]B<?J'6F4)J^Q7QG=-:C"&VI:WC]"25>NY:.H:SUF1!J[%9&A
MN+K#9948X[)XM5:C7S)U5O6A=31A48:==*'5SJV+ASG\T+753LJDWQ8BKS;R
M*$7HJ^NN->\7=9E5JUL;E)1):JV]J;:$G-0;C9D'HNLV*'E&8/$XQ"]LFRK9
M=$Z$D>KKBZ:#5E3JHT\+ACCKH#Q5[JJ(;=Q%'4&NI'`#P:JD=Q?-;Y2>8[6I
M.]2-WHUFGUH:P6&AS%J/QFW*XU_JBK.>:-RJ##8*&F:9)I3._)6J\>4X650=
MUB0*L_B)-`[@RHL7ZRH2W(J2*ZO<F@\8BM->%#AJ5.J@-*'572,?%T5U8\*V
M.XP<HO,"V3M"EL]Z\7X/6^O;/3K0A*0+*F;#@[76;]7..&CMPQ<E*7ZQV.0J
M;>LWC8]^GZ@TCEHY-RP?1!TEGBSIHY2&]DUR7#:9@=6-1@TUKHIB>9621P-:
M=AU7`\7"1HY!58?X_;R\Q#DIR"XHCLVFS>DM,P=TM=EW*2#TSN34K*<F3<=8
MJSK:4O"M\M*TA(0>FMM3#N`3L!4S5NZR*1%V[8X-#)C8Q]S)(W:!:S7@1JT&
MO`<*Z#J5[V01L=LXNIAB#KTX<(QII"MN6\Q;G]#/MN.DN%]ZG*Q!S.SH+5JP
M<:]WL[1,6EA2;K(:OJ-BKL#9K>BM%O[I3TVS^R-798D[.21[ZC)8R93#<W`K
MXA(QI@>`T]D:="J(("!XX!PKB.[_`+%]0O,[S):=.!5K?IMM?',;N+;D:_E7
M'&3<52C;%3(KDM)T]E7F%\B[%]SS7\/JSC(9KL5&W2PO8ZV,%DXE$QY)J^<*
M!/<M-'"OC'[DC#:IIT"@QJ=.C2J&*W(J#3`:QP<^)PIJTK$.M.<GF>[L::?W
M_4=/-G=#8:TF[J^@XK1.]*MKS=\7>ZSPMM*U.B*]9+0K:$;SKB5V!<XJLW0%
MG<%-M8Y\\:QSA)-426-GNI-F1H\6E=!H:[/>J:'0>!7NAMV583XU>$5'NN_0
M5&E=A:?-?Y?5+;M2UK=M34O3%<OF[%(6N7W=^E=LTAP34S6VZBILX62JZ.PI
M0XS,),['79)3L8[EF#F7-&MCMD4EW#A&KKN8/#2T`%VD@C#`</'I5!;1%A<"
M20-`(TX\7%HY5OUP/WERGO\`+,M?\C-?VC7`5;0VHIMFUO.KMI.;I>K+8:-3
MIR[W2Q;UE7C?7#:1@;S-2E97IZC`EC*M$F?J*`@82YL6[YG>+*"*-&D&IP%3
M71IPIIUK#,R,>-&0:N.L=[3QUT*3;-I:Z81,(F$3")A$PB81,(F$3")A$PB8
M1,(N.Z>,V*0+OGC-B@99!N5=\Z;LT#.'*I4&S<%G*B20KN5SE(F3KWE#F`I0
M$1`,HBJDZ:KN'31!VU7=L#(%?M$7*"SM@=RGXS8C]JFH9=D9RB/?3!4I!4)[
MXO4.W"+DB0X>DA@Z``CU*/8!OK1]'H'W,JB"0X`(B4P`'3J(@(`'4.H?VPPB
M=TW_`)IO1U]`^CZ/TNS"*O</VCW#=@@4?>C]</:`>CTCA%P$)&.=/Y"*;2,>
MYE8DC)26BFSUJO)Q*<DFJM&J2D>DJ=Y')R2+=0[8RQ"`N1,QD^\!1$*5&C6E
M-:(R,<YD'L2VD8]S+1B#%U)Q+=\U7E(QK*>L_!;F1CDE3O6#:3]27]645(0C
MCP5/#$W<-T5%::TX]2.)&.:/(V.=R,>TD9HSLD+'.GS5M(3)X]N+R0)$,EE2
M.I0[!F`K+@@1044@[Y^Z7MQ4:-:4.G4C"2C99%PXBI&/E6[20D(EVO&/FL@@
MTEHEVK'RT4Z69JK)MY.*?H*(.FYQ*LW7(9-0I3E$`5!T(N=W3=@]T>@^@>@]
MO;T[/H]N51?"R!5T%VKEN1PU<H&2=-7*)%VSELJ'0Z3ENL0Z*[=0H]#%.42F
M#TA@5!!&!&C[2&A%#H*T8V/Y??"2ZV)JZE-70&NKS:%)%6-D-66J6T]9K"YC
MFXR$LO'1E0EX=E..(UH/K#D2,5Q12]^IT+VY*39W>W=N+'-.HOK*E!'=PQ7+
M*<`$S7T[A4/+D&53.,HBZN36Z,NC/=V2!["QV/E6Z4%0"-=Q<MF[4PAX;!+=
M[A=,$Q'H*9%G-;7?'*;T=14$WZO7.-.W;W`D?ULFZN[#IM-?JZ`8\@`'L+#]
M00C`7-X&\'6GP*Y*+Y;7"-(&-H5IS[>9?$.=C/;2VA9MNPBZ[1PJW7.@R7FC
MT]V9N\;J)J%]5.!%4S$,`&*(!R&PS,Y/%U.[UO899"12EE:P6V'!M1,#O[RO
M;N[E37;4S'S/'RKW/]@FGL+?2$@X2L1#*OUF%B*Y`1J8(QT'7XQC"P[!(H`4
M$V<9&H-F38O0/V!`ZYI2RR32&69SGRG2YQ))Y2:DJ98QD;!'&`U@T```#N#!
M=IEBN3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$50](?3#ZN$7F<_20\A_3%)^C*1_C-S4X[:PXYZ`UC;+G,);$J6
M@]5JS%)AZ5<9ZP`R/HV-VFG,L&<3#N22%=-4DQ'X23.+`D@461UBN@%,-R">
M-D+&N/C!@PH>"JU989'2N<T>*7'7QT68Z'YCO$?9Z,&\HFPK/8H*P3M1J$7:
MVVK-GI4LU\NM27OL/KAQ;G551K[+8C6H)?"$A#*+E>QR"A!7(03=`R-N87TH
M30X:#2NFG*L;H)6Z0*CC%:</(L?3OFJ<7%(^LJZTL$_LN3N=GTS"5I+[&+K2
M:O8FVU+UH>JSJT#L"SU5*I35HU'7N1-<F[%`(KC)L&[LJ"Q45`6%"PWD)-&&
MKL/9('L55XMI/NL!CQZ`>_3!7UKWS+.&NV)BH0&M]MO+?*W[9_W*:@UBZ1>/
M_?5I/6D;DSDTEG,&@V1J<C5%ROVTJH<K=9OWA+VIJ@2]MU"Z@::DFF@JUUO*
MVI<*4%5O2)C"(]1$1'L'J(CUZ?1^CT'-A84$YQ$1$YA$1ZB(F$1$0#IU$>OI
MZ81`.</0<P>YV&$.SH`?1^@`?VL(J@<X=T0.8!+];T,/O>GH[O;V=.N$7SU'
MITZCT^AU'IZ1'ZHX15$QC?7&,/8`=HB/8'H#M]P/<PBKXBG_`)Y_1W?KA^M[
M/>^GT=@=GZF$7P?]T3.DI^Z)*IBDJDH`'242,`E,DHF;J0Z9BF$!*("`@.41
M?DV009-FS)BW08LF;=!HR9,D4FC-FT;)@BV:,VC<B;=JU;(E`B::92D3(`%*
M``'3"+KY.!@)MS$O9N`@IM[`/`D8![,PT9+/(&1`I2A(0;J0:N5X=^!2@'C-
MC)*]`#WW8&"`=.I*D:%VXF,(=!,80ZB;H(B(=X?2/0?='*HOG")A$PB81,(F
M$3")A$PB81,(F$3")A$PBTE\P/B:XYL<>$=`DEV,%&RVW=/V^S2CQV_9.6E6
MHEO;V":<U]Q&MG*Y;:R30(XB@-X:(OD4_$53+U-F"XAZ^/J]51[!66"7J9-O
M70^RHNX/RX?,EH2VU=JT[D/J9;D=R2KYG/(2TL+[L_7E=G]KS>F=\ZT0OT2I
M"T>>D%HO24E<Z@XJ<<J@D=4D&<XJLE2$%34;;7+*N:YO6.&.)`K0BNC544Y%
MLFX@=1I:=AIPT'"H--.O&JNM7R^?,(J;\(/3V_(*DU='>_(W;"MN<<D>1<I:
M;$RW-<I*QQ3*;J$K&RE,0:,Z_.?!JK`$W)V\FP-*(O0.Z%$MQM[@&C'4&T3I
M.L\&C[*JWKH"*N;4[(&@:EGKCQP7Y*:EY+ZHW#L?=$YN"J4*H[KI?@VSD#N:
MRV2$9;2U5QF7^$@CK&S=0^Q$5M\:WO3OX.E%D$HUC8X]TU4`T>@Q;7QP2LE#
MW.JT`C$G6&\^(/..!6OFC=&6-%"::AJ)YL".8\*UMXZ\)/,XG]=5*P;6Y1[`
MU-8WVM;-*)TZ7Y!;;V'::WOIYQZ7IE,V5?E7;!HP=1J.YEVD[)T%NY>UF,^"
M2G;G>F=+)#B9!=E@+G$.IH+B<:4J>[C31AQJ^2:W#B&M!;730#"N@=S"NE?<
MEY<_F!KN1O,!R"+6;ZOKC:>N:W'/>5_(>[*:EJEEOW'2Z(5&.V+8*K\,;)+L
M9MK>\MG<M(L6CVJ*W)H9B+DD0V!*OFUQ[H.HZA'NB:8MUZZT/)7B3KX*;);5
MM0=`Q./-2HY:<:R#9?+[YR3L!(LHOE99J[+R6M:Y%JV1IO"_Q&PY'8%&XT;Y
MH]`<7?8M$I5/?7:"J^^;O49=4RZ!0D8N"5,Y065$Z+JXVTY%`^F'":UV2!4@
M#60>.BIU\(/N12O`*4)%:`\5>=9DY*<,>6.X=A7*ST/D$XUI#6_7VL(A^I1]
MCW_6%J?737/'+E'3F[Z0FZ%$LY!6N'Y!;1IEA]5]:%)=C!N?$1ZE*V<7/@G>
MXG:I7@)&@.IHXR.961RQ,:`6UH3J!P)'#Q`\ZPY8^#_F,3ZM]?M^2]=83J\C
MN2:UY;)?:&QIR[1<ML[1SBCK,HZ=:TR+A]9U-*Y'!.%2KT6VDJ[%JF76<2SM
MNW,-I@N34[8KC3$ZQ3@P[FA7B:`4\4TPK@-1Y<?;XES^*W`OFCI'>>LK99-Y
M!&Z+B=@[IV39=-TK>VP;8TCI':FX]];&DH6XR.P=<^O<B%+/7]E5ID_FI92(
MF&\C6@=)+]TW[O6*WF9('%WB5)H"=9)QJ/&TC3P*DDT3V$`>/0"M!J`&HX:#
MPZ5T6Q>'_FLR6R-\7;7?)"@PD+L!]M2*H='<;YWU&UFOL[W1^2-'I^RT&[RI
MW5U4K+KHFPZ-+%@HXXQCB8JZBC4[`J;3*.ANRYQ:X`&M!4ZP177HJ,.)5;+;
M`-#FFHI7`<6'L''C58GR^^<M,F`CM>\@AKU9=<B]P[8-.'Y)[Y4?QCC9N[]0
M[1C=G2=.<P$E%;`>P6MJ[;*,O0))Z6M.U9P)H5P776(C3S>X!HQU!M$Z3K(-
M>:HIHUH9H2,6X[(&@:@13BU&NG"BP10?+J\Q;:]$HM_VMO>VZVV77J?=Y[7\
M-/\`(_<5BV7KO=5CT=9Z*TOLG<F\1XE4CK3=GD&K/T>,</ZTBP@>H"^]=70-
M8VVN'`/>ZDE#K-0:&F/+I&CG61T\#26M`+:XX"A%1[5:'2OTW]QQ\V.M['3L
M#&Y;,V9K?86]0MDY1>,F_MG0LE!U^N/[PLP(QEKU),'.K#WV#L<*U!`'+^H1
M[V'<K.D&R0,"XDCNPZH)+2[0TGCX=%<.)49):EN(`<!K`^PTYU(GQ"XN\G]%
M[1:O]N;!A-A:Z9:O5K=9;5W;.QHJ(U[/+W_9UEL,6AI,*PPUWL`]V2M<0\-:
MI%PC,1)XTS)!(Z/=54V88I8W^.:MIPG#$ZM!K73I6"62-[?%%'5X!C@->GN*
M3/-I:Z81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB815#TA],/JX1>9S])#R'],4GZ,I*./O#'B_O#CAQZV1M/3\!;
M+_9N&6F-,3-O5D;)%3J^MX&1K&TX*`;/(.;C!C7$-L"%:2;60;`E)(JMR$*X
M!$!2'<A@B?"QSVU<8P*\6![ZU999&2N:TT;MD]W1WEDUOY9G!UE77U2C='C$
M5B1>U67<P4)L_<L)'%L5,;(Q\'<&:$3L-G\'7H89N2->SK<4I>4BB^I/'"[8
M3)#D\U@`V0W##6=7=T\>E6><35J3CR#P+NH'RZ^%58E&$O!:$@&"\02EA!L@
ML=\<P-><T!]J^1K\K7*P\M3BN5^>7=Z4J0RL@S:HO9TD`T))*NR%.4]1;0`U
M#1JX=5/`.6F*H9Y2*%Q_VU\)YUV\)P-XH5V`I]1B-5K-Z=K_`&=!;AI=+5V#
MM!]3JW?JH]8RE1D(RK/[HZ@TX>G2L8W=1$09`T1&.4@4;MDS"81J+>$``#`&
MH%32O.AFE)))Q(H<!H6WHB)A$PCU$1$1$?2(CVB/]D<S+$J81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81:K\R>30</\`2#W?LE0I
MG8-,J5LJ<=LAC6S/EK)7*5:'RM?/<86'CHJ6=6->(M+^*079%*E_P1VLOX@>
M!W3X9I>I9UA%6@X\BR11]:_8K0D8*-R+\X*XK;1<:BL?'ZCT2<9W+6E$LUWN
MNT[S7]5:GM5C1V8C?JSMFR.-.*341+0=FUJ,+7EVL:JPL<C,L!15!JLBZ<ZO
MGKMK9+16H&DT&FH.'%0<-5L>:C9V@XD4)P`J=&C'CQX%T$_YVCAI!R;R`X]1
M!Y6N1*9K>>Y;'M=9J=1V!',.4LQ-:,G9UCJB=?-]R6!#CM'1E9BP9C\)3MM;
MMES-_!(#JCKXAM0RIPUZ#CAHTX>SSU%I4XNT\6K#'3HQQY%<6M/-#W0&R:SJ
M6V:`?V&4NUYY,S2-@NUMJFDG-=H5,WANJE4*B1$?.,&T3;+'K2N:ZCPM:R:R
MCQ-G(HONXJ'?.I<RZDV@QS:DEW%@":#CI3%4=;LV2X.T`:,=0/LUP4F'#SD(
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MB81,(F$3")A$PB81,(F$7T4QB"!BB)3!Z!`>@AU#H/;](<(OKQ5.T.^;H/3J
M'7L'N]SNB8/V0E\,O3KZ.Z'T`PBKXZW9^ZG[!`0ZF$>T#@H!O_6!0H&Z^GO!
MU].$7R*AQZ=3"/=$1+U'KW1$H%$2]>O=$Q0`!$/2'9A%\B(CTZ_L2E*4/<*4
MH`4I2AZ`*4`Z``=@!A%3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$50](?3#ZN$
M7F<_20\A_3%)^C*<7A/^)WQ;_`'JW[48O)&V^;L\@=Y:,_QS_*/?6SN9UB3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBJ'I#Z8?5PB\SGZ2'D/Z
M8I/T92M\/.2G'&!XG<;(2=Y!Z.A)N(TAK:-EX:8VU08R6BI)E5HYN]CI.->S
MZ#Q@_9N$S)JHJD(HF<HE,`"`AF[;S1"!@+FUV1K'`M2>*0S.(:ZFT=1X5L=[
M5/%SYRW'WY:-;_&3,W70]-O.%BZJ7HNYCX$]JGBY\Y;C[\M&M_C)CKH>FWG"
M=5+T7<Q\">U3Q<^<MQ]^6C6_QDQUT/3;SA.JEZ+N8^!/:IXN?.6X^_+1K?XR
M8ZZ'IMYPG52]%W,?`GM4\7/G+<??EHUO\9,==#TV\X3JI>B[F/@3VJ>+GSEN
M/ORT:W^,F.NAZ;><)U4O1=S'P)[5/%SYRW'WY:-;_&3'70]-O.$ZJ7HNYCX$
M]JGBY\Y;C[\M&M_C)CKH>FWG"=5+T7<Q\">U3Q<^<MQ]^6C6_P`9,==#TV\X
M3JI>B[F/@3VJ>+GSEN/ORT:W^,F.NAZ;><)U4O1=S'P)[5/%SYRW'WY:-;_&
M3'70]-O.$ZJ7HNYCX$]JGBY\Y;C[\M&M_C)CKH>FWG"=5+T7<Q\">U3Q<^<M
MQ]^6C6_QDQUT/3;SA.JEZ+N8^!/:IXN?.6X^_+1K?XR8ZZ'IMYPG52]%W,?`
MGM4\7/G+<??EHUO\9,==#TV\X3JI>B[F/@3VJ>+GSEN/ORT:W^,F.NAZ;><)
MU4O1=S'P)[5/%SYRW'WY:-;_`!DQUT/3;SA.JEZ+N8^!/:IXN?.6X^_+1K?X
MR8ZZ'IMYPG52]%W,?`GM4\7/G+<??EHUO\9,==#TV\X3JI>B[F/@3VJ>+GSE
MN/ORT:W^,F.NAZ;><)U4O1=S'P)[5/%SYRW'WY:-;_&3'70]-O.$ZJ7HNYCX
M$]JGBY\Y;C[\M&M_C)CKH>FWG"=5+T7<Q\">U3Q<^<MQ]^6C6_QDQUT/3;SA
M.JEZ+N8^!/:IXN?.6X^_+1K?XR8ZZ'IMYPG52]%W,?`GM4\7/G+<??EHUO\`
M&3'70]-O.$ZJ7HNYCX$]JGBY\Y;C[\M&M_C)CKH>FWG"=5+T7<Q\">U3Q<^<
MMQ]^6C6_QDQUT/3;SA.JEZ+N8^!/:IXN?.6X^_+1K?XR8ZZ'IMYPG52]%W,?
M`GM4\7/G+<??EHUO\9,==#TV\X3JI>B[F/@3VJ>+GSEN/ORT:W^,F.NAZ;><
M)U4O1=S'P)[5/%SYRW'WY:-;_&3'70]-O.$ZJ7HNYCX$]JGBY\Y;C[\M&M_C
M)CKH>FWG"=5+T7<Q\">U3Q<^<MQ]^6C6_P`9,==#TV\X3JI>B[F/@3VJ>+GS
MEN/ORT:W^,F.NAZ;><)U4O1=S'P)[5/%SYRW'WY:-;_&3'70]-O.$ZJ7HNYC
MX$]JGBY\Y;C[\M&M_C)CKH>FWG"=5+T7<Q\">U3Q<^<MQ]^6C6_QDQUT/3;S
MA.JEZ+N8^!/:IXN?.6X^_+1K?XR8ZZ'IMYPG52]%W,?`GM4\7/G+<??EHUO\
M9,==#TV\X3JI>B[F/@3VJ>+GSEN/ORT:W^,F.NAZ;><)U4O1=S'P)[5/%SYR
MW'WY:-;_`!DQUT/3;SA.JEZ+N8^!/:IXN?.6X^_+1K?XR8ZZ'IMYPG52]%W,
M?`GM4\7/G+<??EHUO\9,==#TV\X3JI>B[F/@3VJ>+GSEN/ORT:W^,F.NAZ;>
M<)U4O1=S'P)[5/%SYRW'WY:-;_&3'70]-O.$ZJ7HNYCX$]JGBY\Y;C[\M&M_
MC)CKH>FWG"=5+T7<Q\">U3Q<^<MQ]^6C6_QDQUT/3;SA.JEZ+N8^!/:IXN?.
M6X^_+1K?XR8ZZ'IMYPG52]%W,?`GM4\7/G+<??EHUO\`&3'70]-O.$ZJ7HNY
MCX$]JGBY\Y;C[\M&M_C)CKH>FWG"=5+T7<Q\">U3Q<^<MQ]^6C6_QDQUT/3;
MSA.JEZ+N8^!/:IXN?.6X^_+1K?XR8ZZ'IMYPG52]%W,?`GM4\7/G+<??EHUO
M\9,==#TV\X3JI>B[F/@3VJ>+GSEN/ORT:W^,F.NAZ;><)U4O1=S'P)[5/%SY
MRW'WY:-;_&3'70]-O.$ZJ7HNYCX$]JGBY\Y;C[\M&M_C)CKH>FWG"=5+T7<Q
M\">U3Q<^<MQ]^6C6_P`9,==#TV\X3JI>B[F/@3VJ>+GSEN/ORT:W^,F.NAZ;
M><)U4O1=S'P)[5/%SYRW'WY:-;_&3'70]-O.$ZJ7HNYCX$]JGBY\Y;C[\M&M
M_C)CKH>FWG"=5+T7<Q\">U3Q<^<MQ]^6C6_QDQUT/3;SA.JEZ+N8^!/:IXN?
M.6X^_+1K?XR8ZZ'IMYPG52]%W,?`GM4\7/G+<??EHUO\9,==#TV\X3JI>B[F
M/@3VJ>+GSEN/ORT:W^,F.NAZ;><)U4O1=S'P)[5/%SYRW'WY:-;_`!DQUT/3
M;SA.JEZ+N8^!/:IXN?.6X^_+1K?XR8ZZ'IMYPG52]%W,?`GM4\7/G+<??EHU
MO\9,==#TV\X3JI>B[F/@3VJ>+GSEN/ORT:W^,F.NAZ;><)U4O1=S'P)[5/%S
MYRW'WY:-;_&3'70]-O.$ZJ7HNYCX$]JGBY\Y;C[\M&M_C)CKH>FWG"=5+T7<
MQ\">U3Q<^<MQ]^6C6_QDQUT/3;SA.JEZ+N8^!/:IXN?.6X^_+1K?XR8ZZ'IM
MYPG52]%W,?`GM4\7/G+<??EHUO\`&3'70]-O.$ZJ7HNYCX$]JGBY\Y;C[\M&
MM_C)CKH>FWG"=5+T7<Q\">U3Q<^<MQ]^6C6_QDQUT/3;SA.JEZ+N8^!/:IXN
M?.6X^_+1K?XR8ZZ'IMYPG52]%W,?`JARIXN=0_\`\EN/OI#_`/O1K?Z/_P!Y
M,==#TV\X3JI>B[F/@7G4^ZUJG[YVO/\`:"_NG?\`QK6_^S/[X_\`TE_\`_\`
B[Y_Z-_\`QV1/61](?.ZZ1HX>3C4EL/Z)^;4T'3P<O$O_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>v371611_chrt-bar.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v371611_chrt-bar.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^(,6$E#
M0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`
M,0``86-S<$U31E0`````245#('-21T(``````````````````/;6``$`````
MTRU(4"`@````````````````````````````````````````````````````
M```````````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````4
M8FMP=````@0````4<EA96@```A@````49UA96@```BP````48EA96@```D``
M```49&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P``
M`]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E12
M0P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`
M````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V
M,3DV-BTR+C$`````````````````````````````````````````````````
M`````````````````%A96B````````#S40`!`````1;,6%E:(```````````
M``````````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4`
M`!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO
M+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`
M````````````````````````````````````````````````````````````
M9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````````````
M`&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````````````
M``!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@````
M``!,"58`4````%<?YVUE87,``````````0````````````````````````*/
M`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`
M*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5
M`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!
M#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A
M`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"
M9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/
M`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$
M<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U
M!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'
M/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG
M"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*
MW`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS
M#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/
M7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H
M$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4
MSA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2
M%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;
M.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^
M'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(B
MKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W
M)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K
M-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'
M+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XT
MV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY
M.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_
MHC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D55
M19I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+
MFDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F
M4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8
MRUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S
M8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG
M/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$
M;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV
M^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C
M?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(
M!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6
MD3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R:
M:)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/F
MI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN
M+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9
MN-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#
M6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XV
MSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9
M\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$
MY@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q
M__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+
M_MS_;?___^X`#D%D;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&
M!@@+#`H*"PH*#!`,#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?
M'P$'!P<-#`T8$!`8&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?_\``$0@!"`(V`P$1``(1`0,1`?_$`*<`
M`0`"`P$!`0`````````````%!P,$!@@"`0$!``(#`0$```````````````0%
M`@,&`0<0```&``,#!P@'!P0"`@,````!`@,$!1$2!B$3!S%RLG,4-39!47&Q
M(C05%V$RDC.35%710M(CLW06@9%2)&*C@@C!0R41`0`!`04&!@("`P$`````
M```!`C$#,P0%$7&!L3(449$24F(5(7*ADD%A$^'_V@`,`P$``A$#$0`_`/5(
M``````````````'C@>'+Y,0%=N7W$U&MF=,=II<S]<]9ID]DEX$EA]EG=FGM
M7*>_QS8^3D`8F>)UM(XAR-+M,1D5JD.U\"W4E:D+NH["93K*DDM)&T3+FPB/
M-B1EB`V*2^XD3=86U`_(ITMTS<%Y]Y$241NHF[XS2C&2>0T[CE/'E`9+WB+.
MJ>*=/I1R,U\&LHQK>GF:B=:D+6:&$\N7*XO!')CF,@&!?$'4$_B;8:-IV8C<
M>+7K=:LI*''2[<RIDW6E(;<;Q2AN4V?*1XF`R:7U'Q`L;6\:G.U78]/3CAR4
MQXTDGGR**U)S-FJ0M*#_`)^7:2N0!I:3X@:OU!`K[VO746L"8ZV4ZAA&M-A`
M9=7E-3CZWUH<=9(\7&S9;Y#(C\X=EK'4#M'3=HC-I>L)3[$*N9<Q)"Y,IPFF
MB7@9'ES*Q5]`#FV.+-7$O=0UEZ9L-TDEAA4N/%E.LH;>90O>RG6TNML)-:C(
MLZBV>@S`35KQ&TE5V+\&7*=)4/(5A);CR'8T0W=J"E2&T*99QQQ]M18%M/`M
MH#6MN*^AJJ9.B3)KQ.5:VV[1UN)+=9BF\DE-F^\AI32$J)18&:O_`,@/KYEZ
M:>J[F9&<>0[2L%(DQI<9^(X2'$F;+A-R$-*4VX:=BBV`(.DXNQVI=M!U4GL<
MFI=BM2G8L66['9.1';<,Y+J4O-LD3BS01K47)CYP'1VG$;259:.5TN4XER.M
MMN;(1'?<BQEO?=IDR4(4RR:L2^NHL/+@0#GY'%E2SU&J)7.H;TK-::L5/L22
MWT0\N^<94MME!.)S8I3F5B19N0R,!V=_;*KM.V%M')+RHD1V4R1[4+-MLUIY
M/(>`#F=)7.N+B%63Y%E2&U/BM2EPV(\@GD[YHG"21G*67LFK:>4!"P.*VHIT
MJ-I1NL9:U^B8<>VAN$YV1B&V>=4]*B5F4TXWANBS8FL\I\@"0TQQ.E6.O;_2
M]G#1%;B276**8C'+*[,TAR0VK$U?S4;PE8;,4^@!T/#_`%)*U+I"ONY;3;,B
M63N=MK'(6[>6V6&8S/D1YP'0@*PA:VX@2],6>J&UTK5?7N3,(;[4EM:FX:U)
MP5(WRD)4LD<N[PQ\@";;XL:8;JZ^98%)C/S(+-C*B-1I$I4-AY)*SRE,-K)I
M!?\`)>&/+R`-VVXE:/JW]S)ENN$EEJ2^_%C293+##_W3K[S#;C;25\I&M1;-
MO)M`)G$G1\2V*L>F+-TG6H[LEMA]R(T^^1&TT]*0A3#:UYBP)2RY2\Y`-O\`
MS;3'82G=L_ZIS?AA.;I[WO>;K=9<F;Z^S-AE^D!K)XC:35<)JBDNFZN0<%$K
MLTCL9RT[3CE+W?9][L^KGY=G+L`25_J6GH8S3]DZI)R'"8BL,MN/OO.J+$FV
M66DK<6K`L?93R;3V`.-U%Q9BH50LT!J<=MK/X?+4_`G/+B[LC4ZV[&;2TXV]
MR$1+,L"]O!22`=5J/66G].O08]H\ZF59J<;KHK$=^2Z^MI.=:$(80X>))V[0
M&HKB/I,JMBP;D//IDOKB,0V8TAR8J0UCO63B);WZ5MX>V2D%E\H"-G<6J!M[
M3I0&9$^/?S7(&];CRB5'<:)1+)ULF%*2M*TY5(7E,BQ4>PC`9(?$VD:JHK]A
M)[9,EJD&TQ4Q)LE2FHSIMK<W*6UO$E&&"E&G+CR8@-J7Q/T7'[`E$QV8[:1C
MG5[$&+*F./1TG@IQ*([3AX)_>QVD`TOFSIU>H:BMC$X_6V]>]9M7)-R"CH::
MP/VU;G(E.7',I:TY#+!6TR`2VG]?::OIO8H#KZ9)LE*9;E19,3?1S/*3S!R&
MVB=1CY48@.9O>)TR'JZ\IVC9APJ2O9E.29D*>M"WGWB1COVBR)0E.PDDE1K,
M]AD25`-BKXMU/Q.ZA7.>*FLLU5Y2V8TER,VE64F3E2$H6RRIPU_O*+R<F)8A
M,N\2=&LV%G`<G*2[2H4Y;.FP^3$8DDDR2X^:-T2UDLLB<V97[I&`A=3\7:B!
MIBSLZ[.F?6%$>>A64:3#6463*;8.03;R&5J;RJ5@I.S$L#V[`&2\XJ5S54Z]
M4I6=DQ+K67X-A&DQ'"CV,UN*3Z6WTLK4@R6K*HL2S%@?E(!*N<2-)(MRJU2'
MMX<KX><LHT@X93"/#LQRR;W!.8[,,_+[/UM@#]^8^D_BWPS?OF]VER"F0424
M<54QHE&N,B236X4ZG(HLA+QS%E+VM@"(T_QBT_:4S,^1$G1I4F3+C1ZUJ%-D
M2'"AKRN.H;3'2M2$I4DUJ).5*CR&>;8`[&FN*VYJXUI6/E)@2T$['>(C3F2?
MG2HDJ2?G(RQ+R@-P````````````````````````!&5O>MKSVN@(]UUU\.3&
M+928D,@``````<C9T5V7$!O4D-E#T=BBF06T&X2%*E.R6'FT[2/!)DRK%7D`
M<6?!F[BZ0KI46RD2-9U\MN\W#D@B@KLUN;Z21)R;$KSK;(_^(#KV=&S)&J]5
MS9CCT:NO(M8S&>AR7(\E*HG:-[@XRI"V\-\G:2MH#G]2\+K>3+EE5OK4EFF2
MQ43ITAR3(38QYR9L=;CKRENJ)*T%[1JY-@#;T=H34%9J*EN;$FC?.#:KNUH7
MC_W[.7'D$A..U26VV=T2O,D@$]IG3MM73]8/N*2R=S9'+KG4F2S)'88[!*4D
MRY2<95L,!Q$S06H[@JTYFF(%9JV)(8<E:VANL-&K=*(W7VR92B0M3R2/^4XD
MD^UAC@`Z[BBRMNKJKCVC8I+6'/F)3^6;<)+R\/+NT*-?^@"&O-"7TZDXC1HZ
M6E.ZG,CJC-PB)1=E0U[9_N^TDP&.QTGK*-%U70UT!F;$U4^J2Q:.OI0F*;\=
MMAY,ELRWB\FYS-[LCQQP/+AB`PVG#34"]+ZTJ8I-N.W"X95BW'"(UHC,,M&I
MP_W3,VC`26H-$WEEKQZ83:#HK!NO;F.YTYLD%Y<A;:FSVFET\J-GG`:]YH'4
M$RCXB1&$-&_J5TEUF*R(E$3#;?MG^[[2#`0]MPSU(=CJ"$U$D3X5_-[8W*.V
M?BPFT.MM-NMRXK2TK<-&Z]G=I/.1X&:<`&Y?5%O35FO6GHAK9U`XRBE=:<2L
MWG7V414LY#/>$X2DX[2P/S@.DL>'Q'42^RS9SMDNJ77,QESI)0#7V;<)5V0U
M[A)^7-DY=H#8TCHBFTYI^L7'HH+=]"@-,NO1V6&W5O(92EQ._))'[:BVGB`Y
M.'P]UK!F1=<(>1(UU(DXWD(WC3%=K7%$GL#:C+*79DX+;7EVKQQV&`WW>&MG
M,K]3)<<3#M9%VY=:;GH/,IATF6D-+/###,;:D+3Y4F`G>&FG+6FX>5E)<DEJ
MR:9=3,*,L\J5NNK6K=K3@989]AEM(!,:>T[%HHBXL>5.EH6O.;EA,D3G2/##
M`G)"W%$7T$>`"OJO@IIYS2-M&N-/5;^HIKD]QFP4PRI\E/K6IA?:21O4J3F3
MM)6)`(ISAUK1AU^0[&E6<FWJX$25V>W<@(:EQ(YQW>U;M2=\RO'-F22E^3#:
M`VKSAYJ>.XT='`4Q9M0(L.OO:JR>B;I4=.7)/9?6M,EE"MJ,4+5E]DR+E`2M
M70:_I5SJ=B#$L8]I9ILGKR0M!M(2\:%R2<B['#<)2#W67V=I8F6`"-<T;KIM
MMNC8K65P&=2E=*M5RD$E<0Y&_P`J&<-YO2QP42L"\QF`UJOA=J&+(8IGXLB3
M`CVBIOQ1VVD%#-C?J?0:8#:TJWY&K+DP)'ES'R`.YUM17$FTH+^I91-DT+[R
MW*Y:R:-YJ0UNE[M:O8)Q&PTYL"Y=I`.;BZ%U1)U%&U%+CM17)-ZFSDP"=)9Q
MXS,,XK9&I)95.J^LLDXE])@-GB3(LX^O]!/UL--A)0Y9F<0W$M&IOLR,^1:_
M9SEY,V!'YR`1CNB]=)2W.4RYNK*RFV-S35L\X<E!/H0F,VB:DVE8(R'OMVM&
M8SV8X`,&G^'^L*J-3$Y7I6JLU-+LG6D3.T&J'-SX.(?D&EQQ3>\]O>8*/#9B
M`U87##5M/(AV)1Y,Y919$*1$K;-5>ZVI4UR2RX3A*;2MM27<%I,\4GM(CY`'
M3Z,T#;4EY1RG666HL"G>AR$M/.ODB0])-\TH6_BZM.WZQ\OF(!#47#S5M7'T
MTRY"C2CBU%G5SD..)4RVY+6;K2G4XI4XRK#*O)[6WD`2?#W2FJJ>_;-,>33:
M<9B*9DU$BQ.RCKDYD[M<`G#==8:01*V&I..)%D+#$`UGH/4%M/U8]#0T:+BO
MKXT+,LDF;D9\W',WF+*>P!'RM'Z[7'U9I]%;'.OU-8J?8M^TI(F([F3>J=9P
MWAN$2#W9(Q_\LN`#?G<.;R53ZOAMJ9;?M+2+8U9N*,VW"A=G<0A_*1FDG%QL
MJMAX$>(".UKH[7>KD6-B58Q63$0(T&O@/R4+-YU%@Q,=<=<:):4M$3&".56T
MSP+D`9=0Z+UEJFP5<2J]JK=8^$QH\$Y"'5.(B63<V4\I:"R$G(G!M/UCPVX8
MX`-&[T'KV?-)Z1%>G2HEXW8HD?%%M0E0FY>\0W'KTJ2P3J6OK&\C'$CP6HS`
M2+.C-7Q=7HF541RGWMHN79S8E@M57+B.*4I>\K7E.993B<"4:$I+-[6<^0!H
M-Z`U&W61(TVC7)563K-4>976*H-@A,Q_?-/Q7T.LIW:DGE=:=P/%)'@H!8^A
MX6HX.EX$74<KMENV@RD/&HEJP-1FA*G$I;)Q2$8)4O*68]N`"=`````4_K_B
M+JNGU9.KH$E#<1C=;M!M-J,L[*%GM41G]91BXRF4NZ[N*IC\JS,YFNFN8B?P
MF^)>K]0TO!J3J2KDI8NDLP5-R5-H<2E4B2RTL]VHC2?LN'Y!5WM,17,1_B5A
M=SMIB9\%?SN-&MG/ENQ$D-LRI\B*QK`C9;5O%N6)5RD(Q3_*S.1I/U?-L&MF
MZ2N<XJGQ4>TH_K5+L*%7QK5QSX7%2IU+LA;:F-A^S[+?UR/':`Y]'%'6K6M'
M(-QJ1K3UI\75&C:6MJXV:Y^!OLB#9LT-.+4\MK!25YB2:CPRX;0$CKKBIK6)
MIO7VH*%6,:FLX^GJM"41U)CO-K;1+FN;W*IPU.ODRA&TB,DF:<,Q@.A;XP*I
M[*LT?<U%F_K"2U!3&:4B-C--]HS?D$N.LXZ"84VO?X8)2?U<4@/M_CC7LW+\
M15#8'60[LM.3;HCC[AN8X:$M8(WF^6E1N%F,D>R6'G(@$SH;4EK*U)J[3-L^
M4J9036G(TG*A!J@V#7:(R5);2A.9KVVL<-N4C/;B9AV8```````(RM[UM>>U
MT!'NNNOAR8Q;*3$AD````````````````_%)2M)I61*2HL%),L2,C\X`A"$(
M2A"22A)$24D6!$1;"(B(!^@`````#X<99<-!N(2LVU9D&HB/*HO*6/(8#[``
M````````````````'PN.PMUMU;:5.M8[IQ22-2<Q8*RF>TL?+@`^P```````
M`````````````````'-7/#K2EQ8NV,^,MR6_EWBR=<21Y$D@MB3(OJI(2;O-
MWE%/IB?PT5Y:BJ=LQ^7YK/0D#4VB9&DE/N0X3Q1TI>;(EK0F,\V\DBS<N.Z(
MA'JJF9VS_ENIC9&R'*%P#HD7,^T;L9"7)]W"OMT:4FAI4%]V24=LO(VX[(6H
M_2/'KL6-'1FM>2M8%(6<F57M5JHN!9"0RZMTED?+B9N8`.1L^"\NR-ZLEZKG
MR-'R)J;!ZA?;8>7G2\3Y,HFK2;R62<26">4BV9@&NOA;*L&-=Z1FFY%H=0V;
M%]`M&20H]XZZT_(8-)GCF2_%QVEM2O9YB"1ON#C5QK(M8N7DMB]B/1E4SK9%
MNX;$<EDY&2WC@XB3O#WN;:?DP(!DD<'JUZ%913L'B39:D;U0M1(3BAYM32MP
M7_@>X+;R[0&YH73UFQJ?6&J+-@XC]]-99AQE9344&M:[.PXK*9[7E&XYARD2
MBQ\Q!VH```````(RM[UM>>UT!'NNNOAR8Q;*3$AD````````````````````
M````````````````````````````````````````````````````````````
M````````K.^N]34FJZ^6[92I=?/L%QUMM-1CJF8^1Q#452DI.44M3K:<%&K+
MG5E,R3[(#8T1<:B5/TVNQM7+-K5%*[:O,+0RE$9]OLJR*.;3;:MSEEFC!9J/
M8D\<3/$,,G4&HDV,J]39NIAQ=11*)-&2&=PJ-(>CQ%K4HV]]O=Y(-XE$X192
M).&&.(=O6]ZVO/:Z`CW777PY,8ME)B0R````````````````````````````
M````````````````````````````````````````````4GQ'UWJVKUE808%B
MMB(SN=VT26S(LS"%'M4DS^LHQ"OKVJ*MD2Z73LE=7ES%55.V?SS2?&N7(D?_
M`%^GR7G5&\^S6F\ZD\BCWDV.2]J<,,<3Y!+HG;$*#,4Q3>51%D53S5'*N+.P
MG\/ZAV2XI_0=O755I@LR,Y+UNN*V3O)F,X]:2]OD6,FE8-5PPT.SQVF5C=<I
M,"#30[*+'[1)-*)9RW"WNUS$_J)V'L^@!R,NN*DM)6K;:&=W7)OC=+B'169%
M81]Y+)"(C\1XED;:3632V6RRX?[@)+6LN;9:7XA:B)66V3JN%20U+-1);BUD
MMAMEOV=I(6ZXXXK#ES`)>[XN\0M._P"0:?D]EM;V#<U-3!LXT-2$9+B,J3F.
M(;_M*:)!H06^+,HTX_2$=:ZSXKV$;3,>9-52S&-81:QV048XZIK$AA;C1R([
M4I61*,BR=8-1DO%!XEEVA!\6>(B$<5Y6H(\V22-`R:^-&AQV7W&91*6I5LE;
MB$*90I#;B4?S%I^KL`6S)MHE3QFA38SR2J=4:??DSUI/^4:ZM:%LRU'U$A2#
M/S9?,`LT``<^G0>G$W9W!-O[]3_;#B]ID'$[4:23VCLN?<;S`N7+R^U];:`P
MPN'&E(3<EN.S(2B3'5#(NV2L6(RU$I3,56]S1D&HB/!HT\A>0BP#8<T1IUR_
M^.*9=.8;J92FM^\494E#9,HD*C$O<J=2VDDDLT8["\I%@&W6]ZVO/:Z`CW77
M7PY,8ME)B0R`````````````````````````````````````````````````
M```````````````````````0-IH325K.<G3ZY#\M[+O'34X1GE222V)41?52
M0UU75,SMF$JZSM[=T^FFK9#<L=-45G2'13X;<FI4EM*H;F)H,F5)6V1[<?94
MA)_Z#.(V(]54U3,S;+15P_T6J5(EG41^TRIK-G(=))DI<R,9FR^K`_K(,S,A
MZQ22*.I1=.7:8J"M7F$Q79FW.IA"C6EL_H)2C,!`N\)^'#NH/\A<T_$.VWQ2
M3?RF23D$>.^-HCW1NX[<YIS8[<0&)CAM5E;ZA7+2W,HK^3&LG*IU)X-6#!)2
MMY*B/:3FY:5AAL4D_(>P).RT'HZS3:IL*F/**\-D[7>)S;\XR20PI6W8IM)8
M),L#(!IM\+.'B*!&GRH8IU#<DII15)-6,HL2WZEJ,UJ<P/#,:L<-G(`DF-':
M8CU=E5,US**^X<?=M(^!FF0Y*+*^MS$\3-PN4P$*QPTJ?\@E3I:4.U94S>GJ
MNJ22DML0#Q5(0I1J,U&Z9(3Y,$I(O.`[(``````1E;WK:\]KH"/===?#DQBV
M4F)#(```````````````````````````````````````````````````````
M``````````````````:%]?4]!4OV]S+1!K8I).1*=Q)",ZR0G'#'E4HB`1\K
M7VC8J*1<BVCMIU(I":(S4?\`VS=R9-U@6W'>H_W(!"Q>.7"25,9A1]40G93[
MB6664J5F4XM1)2DO9Y34>`#?/BKP[+4?^.'?12N=\<7LV8\.T$>&XWN&ZWN.
MS)FS8^0!OV6MM*UDJ7&GV33#T$HQS"5FP:[:X;<8EJ(C22G5)/*G''R\@";`
M8)4^#$-DI<AJ.<EU+$?>K2C>.K(S2VC,99EGE/!);0'.7W%3AWI^X*GN;Z+"
ML?9-;#BC_E[SZF^61&AK-CLWAD`FXU_3R;&;7,2D*FUZ&G9C.TC0W(2:FG,3
M(B4A1(5@I)F6PRY2`;X``````C*WO6UY[70$>ZZZ^')C%LI,2&0`````````
M``````````````````````````````````````````````#C97$=B/(<9."I
M1MJ-.;>$6.'_`,155ZI%-4QZ;/\`;7-XQ?,YC]/5^(7\(Q^VCV_R\_Z'S.8_
M3U?B%_"'VT>W^3_H?,YC]/5^(7\(?;1[?Y/^C<JM?,V$]J(F$ILW5$G.;A'A
MB>')E&VXU&+RN*?3:]BO;+JQ9-@```````"LM86]M'U)-98FOM-(-O*VAU:4
MEBR@SP(CPY3'/Y^^KIO9B*IB/Q_EIKF=K#QR)^1P*L_94^ZM->9E@:U*_P"_
M',\>4S%W<3MHIF?"&V+%-JJ[5=Y0UDB.Z3&@-15=)#=4DS2XF3;OO;QL\/JI
MB,1B,;7J[X#3I?\`V$MG<BMV>FX:27@>7$I;QX8^<!4<^S9IK*34:>GN3C7>
M[T^&-]5DY)4^Y+)3DF+*:S*)LL5.MN*5E));3QV&$EJAB5.T/Q()XUE:.ZX8
M9<6WM>1':D0T1#3B2MB8^4T[,`&+5TO6FGBUK0U%K9'0U]U1[Z9*DRWGHU?-
MB&[-44I).R4-F_DSFWM21GAM,!$R&I<O2^G+*PO9=II^OUI&*).B/V;B6(;C
M"]\:7W4-.O):=01-/8*-&924JVF0#LH.J=(Z1=XBT6M(;LFVN[F;+BU91W'7
MK:!*0@HK48R3@YE3BWAF]@_,`E[2+&;XAT,2'2N'&?T5.CVNG2-.]["VIGL\
M0_;R9R<6II)Y_*>W#:`N0``5T],O3UJF/`MY5A/:GD=E"90@JN%6*3CNI"U(
MV2%-X+3E6;AK,MFZQ`.'EGJ)%E'BZH59MV=I"<F1V);L%V(>[6WOB:*(DEH4
MWOD926H\4GYR/`,$JZOTV,J^39ODW%U)#HT4I;OLQQ)#T>(O,G)G-S-(5(SY
ML<")/U<<0[FM[UM>>UT!'NNNOAR8Q;*3$AD`````````````````````````
M```````````````````````````````I6U[RD<\QR=_B5;Y1IM:@TO```3&D
M?$$3GIZ1"9D,:GCREE1:MT=,D````````-&31T\EY3\B&RZ\O#.XM!&H\"(B
MQ/T$-->7HJG;,1,O)B&XVVVTVEMM))0DL$I+81$0VQ$1&R'KZ'H``"+AZ<K(
M5]8WD9*VYMJAA$])*/=N*C$:6W,A\B\BLAF7*1%Y@$H```",BZ<K(^H)VH$I
M4NSGLLQG77%&HD,1\QH::(_J)S.*4K#E,]OD`28``YYO0&EV[5RT;8?1+=?5
M*=PF2R:4ZH\5*4QO=R>/E+)@`Q0.&^CH$=^/&AN)9D1SA9%RI3A,Q5&1FQ&W
MCJNS->PGV&<B=A;-A`-M>B]-KOOCRHJCL=XEXSWS^X-Y#9,I?5&S]G4\ELB0
M3AHSDG9B`V*WO6UY[70$>ZZZ^')C%LI,2&0`````````````````````````
M``````````````````````````````"E;7O*1SS')W^)5OE&FUJ#2\``!,:1
M\01.>GI$)F0QJ>/*65%JW1TR0````````````````````````````C*WO6UY
M[70$>ZZZ^')C%LI,2&0`````````````````````````````````````````
M``````````````"E;7O*1SS')W^)5OE&FUJ#2\``!,:1\01.>GI$)F0QJ>/*
M65%JW1TR0`````````````````````*PXL0D0WV9\0KB;:SB=-$"+?3JF(EJ
M%'4\ZK!A2T)4:6\"2EOVE'B>&TP&SP?D6:OB\:>V['-)0Y,9B1;3+ITV9+2E
MH>)^6EO(A>&4D)26U*L?(`L8```$96]ZVO/:Z`CW777PY,8ME)B0R```````
M``````'`:LXLQ]/73E8NM7(4VE*MZ3I((\WT&DQ'O+_TSLV+;*Z5-]1%?JV<
M$/\`/R)^C.?CI_@&'=1X)'T4^_\`C_T^?D3]&<_'3_`'=1X'T4^_^/\`T^?D
M3]&<_'3_``!W4>!]%/O_`(_]?2./41:R3\&<+$\,=^G^`>QFMO\`AY5HDQ$S
MZK/]?^K5$I1```````````````````````````````````I6U[RD<\QR=_B5
M;Y1IM:@TO```3&D?$$3GIZ1"9D,:GCREE1:MT=,D````````````````````
M`#B^*#M>S75LF3918$F--0]6HEP561/24H5E0W':-,@UY<=K*B5ACREB0#7X
M0P3BTLO'2R=,[QXC1E4YA*02")+A-/DE]A*2]E+3A>R7U=@#0FR+O_+7/A-A
M/M;*)--RS::S(JHM?DS%$<2K%M<A2,,N[S.DM1*5E1L`?6A)ULBPTNZ_:R+,
MM3T3MI8MOKWC:)".R+2['3_^EO\`[2D9$^S]7R\H895I<E92[]-E))Z+J:'2
M-TY+_P"MV-]V-&<2IG#`UY9"I.\PS$6!8Y`'>5O>MKSVN@(]UUU\.3&+928D
M,@````````````!YYXO>-I/5M^HQ79CK=?I.!''FXL:%D``#)'^^1Z2&5-L-
M=[T3NEZV%LX(``````````````````%?<7-1W=)%KUU<I453RUDX:22>)$18
M?6)0L=/N::YGU1M0LY>U41&R5:?,S77ZLY]AK^`6?977M0.ZO/$^9FNOU9S[
M#7\`=E=>T[J\\3YF:Z_5G/L-?P!V5U[3NKSQ/F9KK]6<^PU_`'977M.ZO/%>
M&B9\NPTM73)CAO27FB4XX9$1F?\`H1$*+-413>3$6+;+U351$RYC7W$Z?IFX
M3`8A-2$*;)>=:E$>)^@0+V_FF=B]R&FTW]'JF9C\N:^?5O\`I<?[:QJ[J?!.
M^CH]TGSZM_TN/]M8=U/@?1T>Z3Y]6_Z7'^VL.ZGP/HZ/=+]3QXMU*)/PN/M/
M#ZZP[J?`C0J/=*X83YR(;$A193>;0X:2Y"-22/`37-2INU[RD<\QR=_B5;Y1
MIM:@TO```3&D?$$3GIZ1"9D,:GCREE1:MT=,D`````````````````````#A
M^(U+9G`78P+!YA"7T/34*M7:I"64-&V:67TH=0C$\%&E195'RF7*`^.$=O56
ME/,?KI%M)0EXD.N6TDIR<Q)Y8LIM;S#K1^=M9_3@>P!.-Z"TDW;JMVZ\DV*G
MSE*?)QTL7C/$UFG/DQQ^@!\QN'VCHS<YIFL;2W8MJ8E(S+-.Y6>9339&H]TV
M:CQR-Y2QVX`-E>C]-+O2OEP$':DHG-_BO*;B4;I+IMX[LW4M^P3AIS$G9C@`
MRUO>MKSVN@(]UUU\.3&+928D,@````````````!YYXO>-I/5M^HQ79CK=?I.
M!''FXL:%D``#)'^^1Z2&5-L-=[T3NEZV%LX(``````````````````%6<=O<
MJOK'.B0MM+MJ5VH60I\7"L````>D.'7@NJZDO6.:SF+4O<KAPJOC;XK;ZA(I
M\UU.PT7!G]E>",N```?3?WB/27K![%KU;4=TPNH:Z!"X?/IM5!:]Y2.>8Y._
MQ*M\HLVM0:7@``)C2/B")ST](A,R&-3QY2RHM6Z.F2``````````````````
M```!P'%I91TZ?L%Q:N?'A3U./0;A^)%97FCN)2MIV4AS*\VLR4G)MPQ+R[`F
MM#:L>U'#D/.QX4;LRTMI3!L&;%!D:<?:6RE)(/Z#`=*```",K>];7GM=`1[K
MKKX<F,6RDQ(9`````````````#SSQ>\;2>K;]1BNS'6Z_2<"./-Q8T+(``&2
M/]\CTD,J;8:[WHG=+UL+9P0``````````````````*LX[>Y5?6.=$A;:7;4K
MM0LA3XN%8````](<.O!=5U)>L<UG,6I>Y7#A5?&WQ6WU"13YKJ=AHN#/[*\$
M9<```^F_O$>DO6#V+7JVH[IA=0UT"%P^?3:J"U[RD<\QR=_B5;Y19M:@TO``
M`3&D?$$3GIZ1"9D,:GCREE1:MT=,D`````````````````````#E>(,MV/"@
M-LQ::8_*EICL1[Q];#:G%I5E)G(Q+4IS9R92]G$\=@"#X/.Q9WQVYBNU*&I[
M[)'7T:G5QFULM9=\:WF8JE*?2I)YB;))I2G`U<H"Q@```1E;WK:\]KH"/===
M?#DQBV4F)#(`````````````>>>+WC:3U;?J,5V8ZW7Z3@1QYN+&A9```R1_
MOD>DAE3;#7>]$[I>M'5Y&UKPQRI,\/06(MG!.&?XE/M/N-]@2>11IQWA[<#P
M_P"(I9U6?;_+5_T?'S.?_3T_B'_"'VT^W^3_`*'S.?\`T]/XA_PA]M/M_D_Z
M'S.?_3T_B'_"'VT^W^3_`*)"AUT[:6C$)4-+1/&HC62S5AE;4ODRE_P$C*Y^
M;VOT[-CVFO;+KA9-@``````````*LX[>Y5?6.=$A;:7;4KM0LA3XN%8````]
M(<.O!=5U)>L<UG,6I>Y7#A5?&WQ6WU"13YKJ=AHN#/[*\$9<```^F_O$>DO6
M#V+7JVH[IA=0UT"%P^?3:J"U[RD<\QR=_B5;Y19M:@TO```3&D?$$3GIZ1"9
MD,:GCREE1:MT=,D`````````````````````#F=<:,=U-%CIBV;M1-C[Y")C
M*$.GN93*F'T95[",T*Q2LMJ5$7*6)&&72NCVJ"5/D)D;[M28\:*TELFD1X4)
M!MQF"(C5G-!+5F69^UCR$1$0".DNW,;BO"0]:K<IIE+9/M5AI2VRRY&D5R-X
MI1;7%'OEX&OZI&9%RF`A^'$BZB6<*-J`I#EA=5SD^-)*U<LHRTM+9-XMR9$T
MP9'(1D-HUH-/[_(1AKRIUF5G,OTSY96$;4\*F:K"D.E%*$^Y&8<;5$S;I2C:
M?5)WAHSELP5DV`._K>];7GM=`1[KKKX<F,6RDQ(9`````````````#SSQ>\;
M2>K;]1BNS'6Z_2<"./-Q8T+(``&2/]\CTD,J;8:[WHG=+UE)]W=YBO4+9P2E
M)OOLCK%](QQ]5J,PC%X``">T/XFA<YS^@X+#3,7A+.[M6N.B;P``````````
M59QV]RJ^L<Z)"VTNVI7:A9"GQ<*P```!Z0X=>"ZKJ2]8YK.8M2]RN'"J^-OB
MMOJ$BGS74[#1<&?V5X(RX``!]-_>(])>L'L6O5M1W3"ZAKH$+A\^FU4%KWE(
MYYCD[_$JWRBS:U!I>```F-(^((G/3TB$S(8U/'E+*BU;HZ9(````````````
M`````````%;<6M2*A'!166<0[""ZMUZH79QZ]Q3BF%=D=>WKK.=EMXTK6V9^
MT6W!6&4P^^#L<H[5NS%L3L*MA<9EIU<]%BMZ4VT92YF9+KYM(DN8*2A1I/8:
MLJ<P#OUP8:YK4Y;*%3&&G&&9!D6=+3RD*<01_P#%:F4&9?\`B0"&B\/M$Q(\
MV-'I8B(]@T;$MG=D:%LF>)M93Q)+>/[B<$_0`VEZ3TTN\3?+K8ZKA.!E--!;
MS,2=V2_-G)!Y"7];+LQP`?=;WK:\]KH"/===?#DQBV4F)#(`````<OK#7];I
M=^,S+CO/G)2I2#:RX%E,BVYC3YQ*R^4JO8F8FQ'OLS%W,;7/?//3WY"7_P"K
M^,2?JZ_&&COZ?"3YYZ>_(2__`%?QA]77XP=_3X2?//3WY"7_`.K^,/JZ_&#O
MZ?"3YYZ>_(2__5_&'U=?C!W]/A*P*V<W/KXTUM)H;DMI=0E6&)$LL2(\!75T
M^F9CP3::O5$2H+B]XVD]6WZC%9F.MV.DX$<>;BQH60``,D?[Y'I(94VPUWO1
M.Z7K*3[N[S%>H6S@E*3??9'6+Z1CCZK49A&+P``$]H?Q-"YSG]!P6&F8O"6=
MW:M<=$W@``````````JSCM[E5]8YT2%MI=M2NU"R%/BX5@```#TAPZ\%U74E
MZQS6<Q:E[E<.%5\;?%;?4)%/FNIV&BX,_LKP1EP``#Z;^\1Z2]8/8M>K:CNF
M%U#70(7#Y]-JH+7O*1SS')W^)5OE%FUJ#2\``!,:1\01.>GI$)F0QJ>/*65%
MJW1TR0`````````````````````*JXKU[\&6=LB>XX[,(TQ:F-55LQ]11F3<
M=6;\PD8(0A!J4:UX%L(MID0":X5.H*+81EREO2D*COK:<@Q8!DS(9)QEQ)1"
M)#B'"QP4>TC2I.S`!W8```(RM[UM>>UT!'NNNOAR8Q;*3$AD`````*=X[=X5
M75.^M(N=+Z:E7J%L*N%JKP```'IW27ABJ_M6N@0Y?,8E6^707/1&Y1_%[QM)
MZMOU&*C,=;L])P(X\W%C0L@``9(_WR/20RIMAKO>B=TO64GW=WF*]0MG!*4F
M^^R.L7TC''U6HS",7@``)[0_B:%SG/Z#@L-,Q>$L[NU:XZ)O``````````!5
MG';W*KZQSHD+;2[:E=J%D*?%PK````'I#AUX+JNI+UCFLYBU+W*X<*KXV^*V
M^H2*?-=3L-%P9_97@C+@``'TW]XCTEZP>Q:]6U'=,+J&N@0N'SZ;506O>4CG
MF.3O\2K?*+-K4&EX``"8TCX@B<]/2(3,AC4\>4LJ+5NCID@`````````````
M````````<-Q.@QK5[3](;;B)MG+=98L69/9'(S79W#E*0HVWTNJ6QF2EE2,J
MN4\,N)!\<,JYFGG7]&[OI%G7.QT.V4B24I;\,VS*$1FEJ.EE2&DF2F4MX),\
MV*L^(#O````1E;WK:\]KH"/===?#DQBV4F)#(`````4[QV[PJNJ=]:1<Z7TU
M*O4+85<+57@```/3NDO#%5_:M=`AR^8Q*M\N@N>B-RC^+WC:3U;?J,5&8ZW9
MZ3@1QYN+&A9```R1_OD>DAE3;#7>]$[I>LI/N[O,5ZA;."4I-]]D=8OI&./J
MM1F$8O```3VA_$T+G.?T'!8:9B\)9W=JUQT3>``````````"K..WN57UCG1(
M6VEVU*[4+(4^+A6````/2'#KP75=27K'-9S%J7N5PX57QM\5M]0D4^:ZG8:+
M@S^RO!&7```/IO[Q'I+U@]BUZMJ.Z874-=`A</GTVJ@M>\I'/,<G?XE6^46;
M6H-+P``$QI'Q!$YZ>D0F9#&IX\I946K='3)``````````````````````@=9
M%HIRI[/J[L2JYU:3;:G9,%.I/V-T2O:-PC/V<GM8\@#7T%_B#=;,B:6KCK(4
M.4IF0PJ*Y$4I]33;QN*0\E#JLS;J/;46WT`(ZP.ZB<4XJTV+\J%+HK5Z/4*)
MM+#3L9^M2E2<B4K6I>]5M<4K+C@G`C,!"Z!D+C3M+22LI,O_`"#3[UG>'*DN
MO-G(0<11/I0ZM26,%2'$94$DL,"P]D!CER9A6LR]*;**XC:IA5#,$I#Q,%!>
M7%:<9.*2MTK&,^N3F-&;'VL<"+`+"K>];7GM=`1[KKKX<F,6RDQ(9`````"G
M>.W>%5U3OK2+G2^FI5ZA;"KA:J\```!Z=TEX8JO[5KH$.7S&)5OET%ST1N4?
MQ>\;2>K;]1BHS'6[/2<"./-Q8T+(``&2/]\CTD,J;8:[WHG=+UE)]W=YBO4+
M9P2E)OOLCK%](QQ]5J,PC%X``">T/XFA<YS^@X+#3,7A+.[M6N.B;P``````
M````59QV]RJ^L<Z)"VTNVI7:A9"GQ<*P```!Z0X=>"ZKJ2]8YK.8M2]RN'"J
M^-OBMOJ$BGS74[#1<&?V5X(RX``!]-_>(])>L'L6O5M1W3"ZAKH$+A\^FU4%
MKWE(YYCD[_$JWRBS:U!I>```F-(^((G/3TB$S(8U/'E+*BU;HZ9(````````
M`````````````'/VNAJ"?;E>(0Y`ODM[HK:$LV7S07(ES#%MY)>1+J%%]`#-
MIF@EU'Q-4NQ79OV,LI1R'&FV5D28S,9*5$UE0H\(^)J2E);?JD`E51(BI;<Q
M3+:I;+:V6I!I(W$-NFA3B$KPS$E:FD&HBY<I>8@$6QHO2#")Z&:2"A%H1ILD
M%':RR$J,S-+J<N"TF:C,R/9B9GY0&=6F=.KNTWJJR*JY0G(BQ-E!OD64T[',
M,WU3-/H/#D`?E;WK:\]KH"/===?#DQBV4F)#(`````4[QV[PJNJ=]:1<Z7TU
M*O4+85<+57@```/3NDO#%5_:M=`AR^8Q*M\N@N>B-RC^+WC:3U;?J,5&8ZW9
MZ3@1QYN+&A9```R1_OD>DAE3;#7>]$[I>LI/N[O,5ZA;."4I-]]D=8OI&./J
MM1F$8O```3VA_$T+G.?T'!8:9B\)9W=JUQT3>``````````"K..WN57UCG1(
M6VEVU*[4+(4^+A6````/2'#KP75=27K'-9S%J7N5PX57QM\5M]0D4^:ZG8:+
M@S^RO!&7```/IO[Q'I+U@]BUZMJ.Z874-=`A</GTVJ@M>\I'/,<G?XE6^46;
M6H-+P``$QI'Q!$YZ>D0F9#&IX\I946K='3)`````````````````````````
M```",K>];7GM=`1[KKKX<F,6RDQ(9`````"G>.W>%5U3OK2+G2^FI5ZA;"KA
M:J\```!Z=TEX8JO[5KH$.7S&)5OET%ST1N4?Q>\;2>K;]1BHS'6[/2<"./-Q
M8T+(``&2/]\CTD,J;8:[WHG=+UE)]W=YBO4+9P2E)OOLCK%](QQ]5J,PC%X`
M`">T/XFA<YS^@X+#3,7A+.[M6N.B;P``````````59QV]RJ^L<Z)"VTNVI7:
MA9"GQ<*P```!Z0X=>"ZKJ2]8YK.8M2]RN'"J^-OBMOJ$BGS74[#1<&?V5X(R
MX``!]-_>(])>L'L6O5M1W3"ZAKH$+A\^FU4%KWE(YYCD[_$JWRBS:U!I>```
MF-(^((G/3TB$S(8U/'E+*BU;HZ9(````````````````````````````1E;W
MK:\]KH"/===?#DQBV4F)#(`````4[QV[PJNJ=]:1<Z7TU*O4+85<+57@```/
M3NDO#%5_:M=`AR^8Q*M\N@N>B-RC^+WC:3U;?J,5&8ZW9Z3@1QYN+&A9```R
M1_OD>DAE3;#7>]$[I>LI/N[O,5ZA;."4I-]]D=8OI&./JM1F$8O```3VA_$T
M+G.?T'!8:9B\)9W=JUQT3>``````````"K..WN57UCG1(6VEVU*[4+(4^+A6
M````/2'#KP75=27K'-9S%J7N5PX57QM\5M]0D4^:ZG8:+@S^RO!&7```/IO[
MQ'I+U@]BUZMJ.Z874-=`A</GTVJ@M>\I'/,<G?XE6^46;6H-+P``$QI'Q!$Y
MZ>D0F9#&IX\I946K='3)````````````````````````#\<424*4H\"21F9G
MY"(!5?#=]=1.@IMW8TAVXJG+,KF-:2YK!H:<9WJUIDGND)<.0E2%MD1<J?-B
M'Q+<<^,3+KM+Y:B8U5!JF(^_=)!0751D.,$QFW9H5#=<DG[/UO;\A8!8M;WK
M:\]KH"/===?#DQBV4F)#(`````4[QV[PJNJ=]:1<Z7TU*O4+85<+57@```/3
MNDO#%5_:M=`AR^8Q*M\N@N>B-RC^+WC:3U;?J,5&8ZW9Z3@1QYN+&A9```R1
M_OD>DAE3;#7>]$[I>LI/N[O,5ZA;."4I-]]D=8OI&./JM1F$8O```3VA_$T+
MG.?T'!8:9B\)9W=JUQT3>``````````"K..WN57UCG1(6VEVU*[4+(4^+A6`
M```/2'#KP75=27K'-9S%J7N5PX57QM\5M]0D4^:ZG8:+@S^RO!&7```/IO[Q
M'I+U@]BUZMJ.Z874-=`A</GTVJ@M>\I'/,<G?XE6^46;6H-+P``$QI'Q!$YZ
M>D0F9#&IX\I946K='3)``````````````````````````B8ND=)Q$341*6!'
M198_$4M164%(QQQWY)26\Y3^MB`SJT_0JN$W2JV*=RA&Z19&PV<DFS_<)[+O
M,OT8@,=;WK:\]KH"/===?#DQBV4F)#(`````4[QV[PJNJ=]:1<Z7TU*O4+85
M<+57@```/3NDO#%5_:M=`AR^8Q*M\N@N>B-RC^+WC:3U;?J,5&8ZW9Z3@1QY
MN+&A9```R1_OD>DAE3;#7>]$[I>LI/N[O,5ZA;."4I-]]D=8OI&./JM1F$8O
M```3VA_$T+G.?T'!8:9B\)9W=JUQT3>``````````"K..WN57UCG1(6VEVU*
M[4+(4^+A6````/2'#KP75=27K'-9S%J7N5PX57QM\5M]0D4^:ZG8:+@S^RO!
M&7```/IO[Q'I+U@]BUZMJ.Z874-=`A</GTVJ@M>\I'/,<G?XE6^46;6H-+P`
M`$QI'Q!$YZ>D0F9#&IX\I946K='3)````````````````````````````",K
M>];7GM=`1[KKKX<F,6RDQ(9`````"G>.W>%5U3OK2+G2^FI5ZA;"KA:J\```
M!Z=TEX8JO[5KH$.7S&)5OET%ST1N4?Q>\;2>K;]1BHS'6[/2<"./-Q8T+(``
M&2/]\CTD,J;8:[WHG=+UE)]W=YBO4+9P2E)OOLCK%](QQ]5J,PC%X``">T/X
MFA<YS^@X+#3,7A+.[M6N.B;P``````````59QV]RJ^L<Z)"VTNVI7:A9"GQ<
M*P```!Z0X=>"ZKJ2]8YK.8M2]RN'"J^-OBMOJ$BGS74[#1<&?V5X(RX``!]-
M_>(])>L'L6O5M1W3"ZAKH$+A\^FU4%KWE(YYCD[_`!*M\HLVM0:7@``)C2/B
M")ST](A,R&-3QY2RHM6Z.F2````````````````````````````$96]ZVO/:
MZ`CW777PY,8ME)B0R`````%.\=N\*KJG?6D7.E]-2KU"V%7"U5X```#T[I+P
MQ5?VK70(<OF,2K?+H+GHC<H_B]XVD]6WZC%1F.MV>DX$<>;BQH60``,D?[Y'
MI(94VPUWO1.Z7K*3[N[S%>H6S@E*3??9'6+Z1CCZK49A&+P``$]H?Q-"YSG]
M!P6&F8O"6=W:M<=$W@``````````JSCM[E5]8YT2%MI=M2NU"R%/BX5@```#
MTAPZ\%U74EZQS6<Q:E[E<.%5\;?%;?4)%/FNIV&BX,_LKP1EP``#Z;^\1Z2]
M8/8M>K:CNF%U#70(7#Y]-JH+7O*1SS')W^)5OE%FUJ#2\``!,:1\01.>GI$)
MF0QJ>/*65%JW1TR0````````````````````````Q2E/IBO*CI)3Y(4;23Y#
M61>R1[2\H"I]`2Z6OF::G19R2^(:=?G:K?>?V*D(5$PDRS6K!#I.N/(]K`\,
MQ88)]D/R8N/\?F69O'_F#6JH-?';WJB<*O<.,3C"6\WW*H"W'S3R9L5<I8`+
M$;E.0K2>IR+(<0\ILVUM-*6DR2C`]I")%?HKJVQ/YV?X_P!,=NR6Q\<1^2F?
M@*&?<?&KR/4?'$?DIGX"@[CXU>1ZCXXC\E,_`4'<?&KR/4?'$?DIGX"@[CXU
M>1ZCXXC\E,_`4'<?&KR/4KOBC276HY<!VLKY"D1T.)<WC:D;5&DRPQ]`LLCJ
M-%W$^J*_ZH6;N:JYC8XCY;ZR_37?LG^P3ON;KPK_`*HG9WG@?+?67Z:[]D_V
M!]S=>%?]3L[SP/EOK+]-=^R?[`^YNO"O^IV=YX'RWUE^FN_9/]@?<W7A7_4[
M.\\%V4%@Y"I($-^#+)Z.PVVX1,*,LR4D1X&*.]S455S,4U?F?!:W?XIB)5EQ
M!TCJ6\U*]80*Y]49:$)2:T&D\2+;L$"^JFJK;%-7DZ/(:G=75U%-6W;N<W\M
M-:?IKG^Q_L&K95[:O)-^ZN/EY'RTUI^FN?['^P-E7MJ\C[JX^7D?+36GZ:Y_
ML?[`V5>VKR/NKCY>3[9X;:S2ZA1UKA$1EB>!_L'L>K;TU>3&\UBXFF8_-G@O
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M%?\`5"[.\\#Y;ZR_37?LG^P/N;KPK_J=G>>!\M]9?IKOV3_8'W-UX5_U.SO/
M`^6^LOTUW[)_L#[FZ\*_ZG9WG@N+1\B15Z;@0)<&64B.V2'"2RI18_08ILQF
MXKKFJ*:MD_Z6=Q$TT1$N&XEZ9U!J"^1-KJ]]3!-)09K0I!XE]!BNOZIJG;%-
M7DZ+3=1N[F[FFK;MV^#D?EIK3]-<_P!C_8-.RKVU>2P^ZN/EY'RTUI^FN?['
M^P-E7MJ\C[JX^7D?+36GZ:Y_L?[`V5>VKR/NKCY>3]1PUUHE:3.M=V&1\A_L
M#95[:O)[&M7'R\E\0+7<08S"X4O.TTA"L&%X8I21&+#N/C5Y.2FI7L^@O7IC
MSJ*^0:%J,TF;:BV"AO<O>553,4S^9\&F:9:_^-:@_3W_`+"AK[6]]LO/3)_C
M6H/T]_["@[6]]LGID_QK4'Z>_P#84':WOMD],I'3]/<0K:/)?@2":;41J,FU
M&>!'CR"1E;F\HO(JFF=D?Z_T]IB8E8'QQ'Y*9^`H77<?&KR;?4?'$?DIGX"@
M[CXU>1ZCXXC\E,_`4'<?&KR/4?'$?DIGX"@[CXU>1ZCXXC\E,_`4'<?&KR/4
MVH<TI1*,F7F<IX8/(-!GZ,1LHO/5_B8WO8EL#8]`````````````````&DU1
MTK7:MU7QF^W'FG966RWYGY7<"]O_`.0#[.JJSL4V1PV#L4HW29IMHWY-G^X3
MF&?+]&(#:```````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```````````````````````````````````````````''2]0ZHM=46%%II<&
M&U3MLJL;&>R[+)3T@C4AAIAEZ+R(3BI:G-F)8),!CI^)4)+:HNIMW5VD>>[5
MR5(-2HAOMM$^A275$61+S1XH)>!XXIVGR@:XH4)JF37)/_\`)9AQID=M,:1V
MIQ,IQ3;1I1@><GC(MVE*<Q\O(8#3J^+,61::@9EPY#,:J?@1(D9,9XYSDF:V
MI9M*:V[2RE@HO9PVF8!-XOU96%%%KXDAY-O(G1):W([Z5PGH+!NK0\V2-BB,
MBQ+$O9]HM@"4J>(^GWJ=R9,F()R)`9LIBVVG4-FP_CD<:2LC49&:<,.4CY0'
MW"XE:9EV+$)OM*427NRQY[D9U$1R5ES=G2^HLN\\GFQQ21XE@`V]1ZWI:"4U
M#E)DR9CC*Y1QH;#DAQ$9HR)Q]9((\J$F>'G\Q&`Y[YR4+-Q?L36GV*BF8KWV
M[-+#ZTOE8),T9$DWMVX$G+CFV^8!(.<4]--.)2^S/90DFE3G7(;R40]^>#29
M9FG^2I7+E/:DC+-@`V&N)&EW+-R"2WR::<>8.Q4PX4,WHR#6\TE_#+F0DC^@
M^0C,P&?3>NJ/4$DX\),EIQ3"9<?M4=QA+\99Y4OLFLB)2#/_`%^@!H6O$*%5
M6EVN>9,T6GV8_P`0DDVZZ\<F69&VAM+>;,DD*+'!)GB8#"7%[2:9#L=]JPBK
MC/M1YRGX3[:(RI!D4=3ZE)RH2]F++Y?/@`T=,\5')FH]95=PPW%CZ<<><@O-
MDK%Z''+!Y:LRC(UI7LV8`,_#_B!<ZBT%8ZBL(;46=">G(1%;S9<L;$VLV92C
MQ4G#-M_V`0FE>+%S8S--(>FT=H>H#ROUE8I:9L,MV;ANN)4\^2D-X95XI3AB
M0#8T]Q)U+=V)=D>J''4351IND5&;%Q%CH6:%/...R"2I22(EY.SD1IY%&`E(
M6H]>:A;GVFFRK&:F(^]'@1IK3[KTXXZC0I>_;>:1&2M:3).+3GG,O(`V=,<0
MDW<VH(V29AWT!4ROY=XE^,HDRF'#Q-)Y,R3(\"]`#LP`````````````````
M``````````````````````````````````````````````````<A.TUJ6NU-
M.OM,NPW"MFFD6==/-QM!NL$:6WVGFDN*(\JL%H-!YMFU(""LN$4RYI7*BXLD
M/,W$]5GJ=YELVUO.)2DH[$8CS[IILVT8F:C4>!_\@'R_PNU%+WTN9915VZ8]
M:F*^3:R:5*J7U/-.NMD:<$N$99DI/8>.&S8`Q3.&^MILNVM)4V$4JUFP9+U6
MP[*9C.1X;2VCC.R&R2\HC-9+Q)&!X8&G`!KT_"#458<4VI-?EBV]A8);;)YM
MOL]G#.,M"4F3AI6TI6*<5'G\N4!('PBD*BZ48.>V2:=EN%=IRJ-,V(TLGTLD
M6)9?YR$GM\@#!3<'GJZ^9<-,!VNC63MHW.<[0Y-4;CBGDM&TI79T&EQ9_P`T
ML3PY$D>T!+\1M!VFI)D63#3!=W##K+9RC>C28SKAD:9,:9%_GI-/E;Q)*O.0
M"*F<*M0R')[;EJS*;L(].EZ:^2^T*D5*C-:U)(C29/$>..;$C\_*`_+[A`]-
MU):3F$P7X5T^S(E.S>T*>CFV1)<2VRVI++Q+))9<YIRG_P`@'TCA;?)U.JPC
MRX=>TI]YY^PA)=;?EM+;-MN/,A$28;N7$LSJL5*PY"`;W#WA[=:<MW);[L6'
M!.*4=596+D=D??SYCEG'=_E1E8;,C)>7:H^0!J7VB)]E9ZKIFU;AF_77V468
MM*U-I5$<;)YI2N3,>ZQ21>0P&W?\-)UG_EF[FM-_Y%*K9#.9*CW15^ZS$K#E
MS[K9@`C[+@].F/R'F[)#"IEU)G3#2@\7*V7NC=BF?_+,R6!\G*`Z:AT8_64.
MH*LWVS^,3+"4PI"3)+2)IGD09?\`@1^0!S=9PQU(J!IZKLWZN/$H'67VYL!E
MWMKBF$FE))<<-*6LV;VE$1^8!DG\/-76Z($"YDUDE%;+9DQ]2[ISXJ:([I.I
M2E!ED:6K#(I:73+#'V=H"1CZ7US1HL*[3,NN*JFONR(;DU#N_@JD*-;B4-ME
MD?2E1F:"4I&'(9F`UZC1K=?J?2];#0XNNTC7R<TQTC+>OSLJ,,2V&K!"EJ\G
@M`+"```````````````````````````````````!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>v371611_tpg65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v371611_tpg65.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!AP)E`P$1``(1`0,1`?_$`0H``0`!!`,!`0``````
M```````(`0('"0,$!@4*`0$``@,!`0$!`0```````````0,"!`4'!@@)"A``
M``4#`@(#!0T0#`8,"0H'`0(#!`4`!@<1"!()(3$305$B%%AA<=%3TY05U187
MEQ@9@9&A,E)RHK+2(S-C5I;65_#!0I*3U)6UUWB8.;&S)+8G66)#<S14)29V
M=R@X"N%$=#5%538WN(+B@Z.$M&>W2'EUI<5&9H=H$0`"`0(!!@<*!A`$!@$$
M`P```0(1`P0A,5$2$P5!87&1T10&@:$B,E*24Q46!_"QP=)45>%"8G*BLL(C
M,Y/3-)07"!CQXD-S)'34)34W@K.$-E:#HT3_V@`,`P$``A$#$0`_`/V_5_`(
M]+&@#T#U#UU*C";U9^(\CY.$FE<AQ=BCKU:?-'T:Z*[.[B?A0N?C])EU>?E=
MXO`B8=`!]$?1K%X;<>':L.?C9/MS'JLL^MWOLE.R1[WT1]&LO5.XO+7X?23U
M:?E=X=DCWOHCZ-/5.XO+7X?2.K3\KO#LD>]]$?1IZIW%Y:_#Z1U:?E=X=DCW
MOHCZ-/5.XO+7X?2.K3\KO#LD>]]$?1IZIW%Y:_#Z1U:?E=X=DCWOHCZ-/5.X
MO+7X?2.K3\KO#LD>]]$?1IZIW%Y:_#Z1U:?E=X=DCWOHCZ-/5.XO+7X?2.K3
M\KO#LD>]]$?1IZIW%Y:_#Z1U:?E=X`DG^Y#I\T1]&I6X>SN(>SO7*0S_`&_R
M,LMVY67K-Y.0J!--0#S.]6GB-U;HP3K@9:S7WWRMEVTB\Y4.L>CYM:%O$XBY
M<=J:I:2XBNXTXY"M;!KB@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H"O<'SP_;K)>(^5?E#A*5B"O")O!#K-T!YX]7?JVQA98Z]#!0=)W9*
M"Y9.G%ITD2EJ1<]"J:OG?,:-+7[E*RL6;*=Y.>FN',ER>)KEOK%MC6>>R'5^
M0D3;TQ*PC:8NZ]+476\1+<;77[WTCH.FFE?JCL1_25O[>F'A+$78QL7;:DFW
M!J2JU5M753PHYFZTY3ARW^FZJM4_A]JC[)M_&7#>$/*_YAQ`#NFQ]BT`^>.5
M0"N]O3^B3>CFKRO023TP?Q7V9KM"HY,K^'WH^/SEP.OE@\PX//Q[BX/G:Y5Z
M1KG?V9[W]/#O?M1[0+0^]\T?'XR[_JP.8?\`!YB_^E6G]F>]_3PYE^T'M`N/
MO?-'Q^,N_P"K`YA_P>8O_I5J?[,]\>GAS+]H/:!<?>^:/C\9=_U8',/^#S%_
M]*M/[,]\>GAS+]H/:!<?>^:/C\9=_P!6!S#_`(/,7_TJU']F>]_3PYE^T'M`
MM#[WS1\?C+O^K`YA_P`'F+_Z5:?V9[W]/#F7[0>T"X^]\T?'YRY_JP>8=WP_
MT>XNZ0[X?Z5>D*?V9[W]/#O?M1[0+0^]\T?'XR[_`*L#F'_!YB[^E6G]F>^/
M3P[W[0>T"X^]\TI\?G+FH!\F#S#N(0$0+[WN+N(0#0!$"^^KJ(`(AJ/<U#OT
M_LSWOZ>',OV@]H%H?>^:6*[^<N%3,<W+#YAJ94M%3B;'N+PXDTQ`YTRA[ZH<
M1U"`(`'=$:VL)_1-OO'7E9AB()K*ZZBJEG597HK+S\1;9WVKT]19'QM="/IX
M^W^GG\Y8NP7D/:9NKV^S>9%[Z96!<6:;2LB*M^>DL?6D[OJXX]1]`WU<3]-1
M"!1'Q<`;F*=0-!,`:C7Q/;7^FW>W87=]_>>+O6Y6\.HRGXM:2DK<553:?!F;
MSEZQZN-*-*RT49L2*J;MCH!](F`"'S1]&OSA=WA:N8J6[H1:<%6N7+SJG?-J
M#N-M/Q4<U26"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"
MO<'SP_;K)>(^5?E#A*5B"]/\(33ZHO\`A"MK`?OMG_<C\:#S'YM)3>/G+9'M
M7WSY.V_V5:U_95N3G-73B^(MRXFTJ>+>,[RLW!'LZJ@@DX\82?\`L:*PI:"`
M<6G0/57]H?=A!2]UN"<GJQV">G)H[Q\3OB6K>;6=)?*3IYCO-.E=NFR_;YN!
MV]0%NY!OK<:]QW/VI`7$JH[@X3%\@T@+GRG<LV9LJ'B[JR[=F02*J8#)INAX
M#`)@X!]"Q*MRW=AW<;C2=O@KX5'1<F3*^#.<^Q5PJM!Y#<]S:TMK#[()I8EO
MY:7@MW6W/;I$659=DY%<7%BF(S!8#6\[A/D!V:/<1]X76UB14=0Y8PO9K%6!
M$0[0#!70*B964N:]LQQ)D21QG=5]WTV>VL\M.$R1?,1C6[)O&6()R\TFBUOQ
M&8\A1T8:V[`FW*#LA3-Y!5,60GU7(4`'0#Z>?>:)M#VR9"?8XR9>EZ.)FVHR
MW;@R%)6#C>^+\M7$-LW81%[;]S9<N>VHR1M['MOS4>N5V1T^5[,68BL`D3\*
M@(L,><OA?'6<=WV-=P<A<,1`X&S+8EFP=]V#C2_+WL^WL6WCB[']UP>2LOW7
M`1SJW;)A)BXKJ=@+@ZY4TV;0%5N%,..@)3;@^9_M1VWWN]L"_9^_I^<MRU8S
M(-YNL88OOC*<'BFR9E=N,7<N49FR(I\PLB.D(]?QEN1VIHHS**IBB0IAH#Y^
M7>:=L^PU,1=K2][W[?\`=<EBJ$SBQ@\.8VN[*\E*8?N4B[F,R4U]R4*N`V@Q
M;HF.N[.`)($`>,!&@.[DGF:[/\;6Q@^Z0O.Z,FMMQ=FKY%Q5#X,L2Z,GW/+X
MP9),5)7(3Z%M-FO*0MBP:SH`>OE0;)$6(9("F4`Q:`B)MAYT6*KNVS8+RSN*
M&33R1N7O'/$3B&Q<%X^OW)#N^+7PY?KBUS/[<MR)BCSZ2Q;7=-W[]%R`@V,*
MQ]=$AH#/$/S'\.V194W>.7[]2R#<#_<KG#!6(K2P1C+(EUY-FC6!<K](MF(V
M:E&FGIN^+/A&I0N5=!$(D[SLU":)]F%`3$VN;L</[NK&<Y!PS.SDC$P=V2EA
M7;!W5;\O9M[V9>\(R:.Y6VK[M&Y&C*8@+@9HKD.9OV8$%-4J@:E,%87?T%S_
M`&Y?$3'.0XWO_P#;XY5'_/C=E_\`#9.U^7_ZL_\`T/?_`-W!_P#U8G?W3^\6
M_OOD9/1'_:__`"<?\>:OY88O]'A/^4C\9]C/,_OG\ASUJ%(H!0"@%`*`4`H!
M0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`KW!\\/VZR7B/E7Y0X2E8@Y$_P
MA/KR_P"$*V\`F\=92K7:1^-$/,?GEQOA?(69[8S(SQW9Q;L7L3_O!\#E.^VS
MAVDV28V!9,/M_F;KE`%00[<KB$3(DJ3KT,8.CIK^T'NPUOY5X.S)-SV"25'5
M/@36=96?%[X6M=I%9Z?&_B^4\!=/+3W?R6(=]F(UK&9SULXDM&X<'<O--O(-
M&SN]L:YKSY;N>K]F7AE%@3@E[+!NI;B)%>'B8(@4NI=!'TK&RLQW7@[48UN*
M[;;U:MY$E5JE=*IW>(YMG)%QX*,]UN5V=;N$9G>5DVT\!3F2TY#F#;!=QN/;
M5MB=BF-T9(QK@[&S"$R"X@SNG#=%I.PLL11(B:QR"Y`@%`=#:UL/(5GK+JQ?
MO%QMC7F$[.+2V779E4F_7)6>;_Q%GMK,VM%X_MJ"W51J!)5MN->S#M::MZZ<
M)C+.444R-GY'9&!"('3XRB`&0(?'^[_8]=>[+'6.=GC_`'A-]UR6&GV+[_\`
M9JWF^/F-TVYMRL/!-P6EN6:W.Z,XM_%</,V(I(D.@D_%U'R2J8)%.8`I049]
MN6VA;EWNW3G:VM[V[(E];M&*Q\)1L3*Q)X.]O&MIF.\;^QL*N1%`(MBQN^&?
M,&I'*12D1`@B'#KJHR:,\!:./MX^RN]]VB-J[.+TW+L-[]@X5D+/G+`NFU6<
M5C+)%J[?(7!D_C_-Z]VOD7L;:</*PJ+Y&19INVY$5G8@EQ&Z1![_`&';#,\[
M4\R/HV\;?3N2U67++PMMWCLBMIIB\:R^6X2Z[TG+QLEHS%,LA'6U;:TXF#=T
M?[P=H0@%('#PTHR:,PKM3PENZY?L?M#RLKM.OK/*J.QIOM8R-CK&-R6Z[O\`
MP]?%FYPOW*-M23;V?6CHUYCV^&5S@S?+HK>,-U$4U#)B0#`"C%&LYZ#EX[,M
MU>+<D\OZ],N87B;#2Q?#\Q:4RI%P\[%3,7CB4W$91Q]<.-+?B7B"+<LD"\3%
MNBJ(MDB%:G*L<3B!M#*,49B2[-LV^W%S!T[AL=[B2X@N7?\`;_LH92A=I-Q6
M!`[GY>SLPWVZN';Q-V->%V).$H7&,@FLZ7N0D<+1^HJJR%3P4C"`@V#<FC;E
MF[;=9.Z^,S7C2\\7K9-W7W+EG'\7?^54,QW?*8\NO']@LX5W=E]I$!U,W>BM
M;RH28.-`9O#*-D=44DA'&XF[%RBJ]G+XB5GKP'N-[W_;XY5`_P#^<;LO_ALG
M:_,']64)OW$WX)-S5W"9*9<EV-<F?)PG>W4TL1;J_MOD9/1'_:_]P'_'FK^5
MF)E&=K".#3IA(IT=:.N9Z'Q'V4VFG32SGK6*10"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`4`H!0"@%`*`4!7N#YX?MUDO$?*ORAPE*Q!R)?A4_KR_X0KI[
ME4GOC"*/C=8MT\Y&%UTM2?W+-?W*E`AD.8.74!,/,PSZ<"@(<0E#%^#`,<"]
M8D`QRZCU:F#OU_:KW4J_#LQ"-[QM6//_`('P5[%3UG*G!3FRFVHR@`(!W!Z.
MGJZN[YE??2PTG*5V+_.4R'(ZU-W%'C+/!^I3^?7+_P"]?<^<^@WNL/[KF&I?
MJ4_GT_[U]SSOH'6']US#P?J4_GU/_>ON?.?0.L/[KF&I?J4_GU'_`'K[GG?0
M.L/[KF&I?J4_GT_[U]SSOH'6']US#P?J4_GU/_>ON?.?0.L/[KF&I?J4_GU'
M_>ON>=]`ZP_NN8:E^I3^?3_O7W/.^@=8?W7,/!^I3^?4_P#>ON?.?0.L/[KF
M+3:"`="0>$77PNYJ%57);^@XN"B_#2>5YJY>`;1W5J^%S&IS>Z9+X_'*G`AB
M``7SNRU`I@Z./;9/<(^8!BE'3OZ#7@?]4-S'KW;XY7E2ULK6:N?;QKP:#J;O
MM3EB+;=<C^0GHW*`!U=/9CKY_;#T?.K^2V!CA%NYNU3;;3*LA]NH.$%7/3Y3
MGK(Q%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%
M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0%>X/GA^W
M62\1\J_*'"4K$%Q3<)BF^I$![G<Z>[T?/Z*V]WXGJ>.LXMY=E=C/S6F1*.M%
MQ>9HU38WV[<PC;?=FXI';KE?:&-@YVW#W?GUJ3+^),O2EX1$U>UM6;$2$0L^
MLW*D1;HLD"V:D`&*R)X1O-#3^C78[^I;L3N[LU:CO"[C8[Q4$IPA&UJ*6M+Q
M=:^I>)JY^&J/G[^YKDF]GJ4Y<OQ&73+<X;]SE/ETF'_9X4W$<(>=_IK[E=W`
M_P!6GNVC.3E/?$DJ^/:LT[G_`!!RI;CQNTBW"U2O`_L%.WYQ/ZTN7+\"FXC^
MFRMW^[_W8^3O7]39_P"H-OU+BON/.?0.WYQ/ZTN7+\"FXC^FRG]W_NQ\G>OZ
MFS_U`]2XK[CSGT#M^<3^M+ER_`IN(_ILI_=_[L?)WK^IL_\`4#U+BON/.?0.
MWYQ/ZTN7+\"FXC^FRG]W_NQ\G>OZFS_U`]2XK[CSGT#M^<3^M+ER_`IN(_IL
MI_=_[L?)WK^IL_\`4#U+BON/.?0.WYQ/ZTN7+\"FXC^FRG]W_NQ\G>OZFS_U
M`]2XK[CSGT#M^<3^M+ER_`IN(_ILI_=_[L?)WK^IL_\`4#U+BON/.?0.WYQ/
MZTN7+\"FXC^FRG]W_NQ\G>OZFS_U`]2XK[CSGT#M^<3^M+ER_`IN(_ILI_=_
M[L?)WK^IL_\`4#U+BON/.?0<2[CG#`BKQY1Y=HZD,"96^$]P8G,KH/`4_;9E
M<$!$QN@X\`B!>KIK2Q_]97NVP5J-ZU9WM<D[D516+3R-Y7DQ-<B*[FY\;&-;
M:A5?=/H/`6_MZWPY+W([;<T[HLG;5Y"S]N#O*DO;UL8(Q?E*UY^X9O)&-9#'
M"QI25OB^9UFT90J4@9<I0;F%8`T*)1Z:\J_J!_J+[)=M?=_B=S;D6,EO#$JT
MH)PAJI1NJ<W/5O3DGJK)D:;R'4W?@,3;Q$7?U=59\KT4R9#9V0-"D-TZG.?4
M!Z!#A```1#N:U^#MV;L6'W1UZ<X[>Y=RPJM9)K/JTK0^DO.+K%-9*')5AK"@
M%`*`4!6B3>8"IU9:&!35EH8%-66A@4U9:&!35EH8%-66A@4U9:&!35EH8%-6
M6A@5#36<%*`4`H!0"@*U.K)YDP*:LM#`IJRT,"FK+0P*:LM#`IJRT,"FK+0P
M*:LM#`IJRT,"FK+0P4J`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0%>X/GA^W62\1\J_*'"4K$"@%11`4`J0*`4`H!0"@%`*`4!6@%
M`4H!0"@%`*`4!<%76N$AE:N(%`*`4`H!0"@%`*`M'KK6N>.9(I6`%`*`4`H"
M\.JMF'B(ABLR!0"@%`*`4`H!0"H>9@LK4,A0"@%`*`4`H!0"@%`*`4`H!0"@
M%`*`4`H!0"@%`*`4`H!0"@%`*`KW!\\/VZR7B/E7Y0X2E8@4`H!0"@%`*`4`
MH!0"@%`*`4`H!6+DHY9.B`U#OA6+NVDJN22Y2:,IQ%^J#Y]5QQ6&D]6-R#DN
M-#5EH&H=\/GUGMK7E1YT*,N#POI>GSNFM[!X/%[QUNH6IWM15EJ)RU5I=,PH
MRP3E*)0,8I1,(E+Q"`:B4.(P:CH&H`&M96L!CK]Y8>S9N2Q#=-51;==%`TXY
M99$8'RONHVUX(E8F#S3G?%.*YJ>:+/X2*OV^("V)"58H.`:+/&#25>MEG35)
MT()F4(`E`_1KK7V.[O=M[P-X0=S![FWG<@N&.'NR7>BRB[B,/9IM9PC7-5T,
M6_*-;!^`3_''VW<`&,03>^[9?"!BCH8HC[+=8#T5TOY3>\SZAWM_"WOF%/7L
M#Z:WYR'RC.P?B$GQQ]M_$!0,)1R[9@#PFUT'IENH=*E>Z3WGRRQW!O9__:WO
MF#KV!]-;\Y%WRB^PGRQMM_PNV7[;5E_*+WH?_K^]_P"%O?,'7L#Z:WYR'RB^
MPGRQMM_PNV7[;5B_=+[SH^-N#>R_^UO?,'7L%Z:WYR'RB^PGRQMM_P`+ME^V
MU1_*;WF?4.]OX6]\P=>P/IK?G(I\HQL)\L;;?\+ME^VU9Q]T7O1FJP[/[W:X
ML+>^8.O8+TUOSD4^49V$"/"&\?;>)O`Z/?=LS7[X<$R='LM^Z..@>;6?\GO>
MI_\`KV^/X2]\P=>P7IK?G(H3F-;!E"@<F\C;<8A@U*8,NV7H(=\/^-JKG[H_
M>?!TGN#>R?'A;WS!U[!>FM^<B_Y1?83Y8VV_X7;+]MJQ_E-[S/J'>W\+>^8.
MO8'TUOSD?6M_?MLFNV>A+7MC=?M_GKCN269P-OPD5E2T'LG-3;\1*QB8UFC*
M&6>2#LQ1!-(@"<XAT`-:&\?=?[QMVX=X_'[CWI9P27CSPUV,<F?PG"F3A,X8
MW!S>I"[;<M":):!T@`@("`]0@(#KTB'1W^D*^'EAL1!TG"2:TIFTDWE2R%=!
M[U8QL7Y1UXPDXOAH14:#4K#WWFA+F8J*QV-W6<=66LLZH,^8Q[DS+.,,,6RM
M>F7,@6?C2T4'+1DM<E[W!&VW"IO'ZP-V34TC*N&S8'#M<>!,G%Q'-T`%=K='
M9;M)O^\L/N3`XK%WW]K:M3F^:*;*KN(L6%6_.,%QNA'`.8[L$$@G#>5MM$@)
ME5$P9>LL0!(YA(101"6Z"&,&@#7V'\H_>A:>SN;@WO&XLZ>%O)KE\`H6\,`U
M57K37WR+OE&]@NH%^.1MNU$PD`/?=LO43@'$)0_XVZ3<(ZT_E-[S/J'>W\+>
M^8.O8'TUOSD5)S&M@RA0.3>1MN,4VNA@R]98@.@B`_\`I;N"%/Y3>\SZAWM_
M"WOF#KV!]-;\Y%AN8]L#+VO%O*VVE[$I3*ZY>LL.`I_I#&_XVZ`-W*?RF]YG
MU#O;^%O?,'7L#Z:WYR.4.8QL)'I^.-MOZ?\`\7;+]MJ?RF]YGU#O;^%O?,'7
ML#Z:WYR*_*+["?+&VW_"[9?MM3^4WO,^H=[?PM[Y@Z]@?36_.1QFYCFP8@<1
M]Y&V\H=(ZCEVS--`Z_\`TKW*?RF]YGU#O;^%O?,'7L#Z:WYR+PYC&P@P`8N\
M?;<(&`!`0R[9>@@(:@(?\;=0A3^4WO,^H=[?PM[Y@Z]@?36_.17Y1?83Y8VV
M_P"%VR_;:G\IO>9]0[V_A;WS!U[`^FM^<BAN8QL(*'A;Q]MX>"J;IR[98>"B
M&JIO_.W4F'2;O5A<]U'O*A"4Y[BWJH)-MO"WJ):?$"QV";HKUNO*B5-K7=:U
M\6O!WM9MQ0UT6?<T0TG[=N>!D6TI!3<(_0(Z8RT7)M%%6KV/=MU"G353,8AR
MB`@.E?`8W=^.W===C'V;EF]'.IQ<6NXTF;:<9>*TST5:KA*,5*2:B^$SU9:&
M*Q,10"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*]P?/#]NL
MEXCY5^4.$I6(%`*`4`H!0"@%`*`4`H!0"@%`*`\E?M_6=BVS+DR'D*X8JTK'
MM",6FKHNB==I,(:!B6XD*O(R3Q<Q4V[9,RA0$P]T0KK[EW7OG>V)=C<>Z\;O
M;$QCK2M8:"N3C'AFTWXJS5)C%2=')1Y2#9>;5RWSE3,7=_A<Q%2G,F<MQG,1
M0A#]F8Q#@T$IB@?HU`=!KZM=AO>#)TN=BNT2BFJMX:.2JJN=&>S@O]6'.^@N
M^5EY;X=(;O\`"P^=<1M?_N=7W/=UVXL6U?M]B^T&M)T_=H]`U$\CN1[X^5GY
M</E>X8_.(_\`%*U_8;M]_P#I?:#^&B-G'TD>=]!RDYK?+G=%4['>)A5#L@`Q
MC'N);00$=/\`:V)S?0JVU[KO>KOI]7W5N;>VY:>/*_;N6E=3S1B[*RTSO6R:
M"N[B+.$C6<XRKF^#(&[\_P#O"6PW:';N+)BV;NA]T\9?U\GM2\X+#T^R>7%8
MT$E$.)3W6.HN>9MH^69BY0*W!#M"G$YPTZ>BO8NPG])7;O%WGC[V\HVL1;2E
M2=S$QJZYLMO/RG+Q>^HT\&%8YLR[O#FH6;$MUVQKFP\PJ]LM8GB[:S38=H[%
MK5@)>W\LXT;KS%B7,\SFZ4>L'4%>C.09,UB1B0#VS``34)T<1@X0K]P^YWW>
M;^[%X#'[L[08CK$KEZW*W+6G-)*#BTG<7"\VKD/E\?B%B+JG%>"EH^&4V$7Y
M??+)QINTQ#LJNK;[@J/S3FVV'EU64T3V]8Y<6[')-#2!HR#N29;P(HP\Y<2,
M.\7CT5^$72;=02`/"(5['ZHMZM>!?#0:->(F(^VP[.(=JF[G]NVV.+(NJW3,
MM*8IQ<T9^-.U#H-4$%9*"03!9THD)2$+X1S!H`"-8O=ZL9(I5?(.YE.4-KNS
M8SYY%EVW[8S2<<V2>2$87$&*32+%FN&J#IXP+`B[;-U@^D.<A2F[E1U?)6B[
MP[AP&VS;+".GK$^WK:T1[&QP2\BS-BG$173")$O&$H];C"@LUCA)T]N<"I:=
M/%4K=\;JUI47PY&*\1<CMBV7N([V8;[=ML#B'\6,\]ED<2XG5B_%"<7$Y]D2
M01F78%`HB)N/0`"I]4PI7)3X<1->)<Q<UVP[,GK-O(,MN6V%['NT0<-9%KB+
M$[A@Y0$3E!5N^3@C-5R:IFZ2G'J'O#5L,'*PM6*5.3[!!C/(V'=FMEV.^R)"
M;2<)Y,90[^'BUH#%N#<8W3/R"\]<D/;P'8HQ<,+<_L&,@=VZ`R@&2;H'-IJ`
M:Y;&=<J51D,@?%JV8)/64?([>]KK::FB&=QD6]Q)BMA+/F8&X4#-XM_!IOEC
M))<)%!3()>,!JN>[E>>O+/FS?8"?$>A^*'M-\EO;M\"F,OT=K#U3;XOAW":\
M2YC6+S9]NN`K$VS6#<UA8-PO8MQ16[[9JHUN"UL:V/;$TR([W$6(R>@WEX>`
M2>-ROH]=5N;A'4Y%#%$-!KSCWM[NQ7L3BH8?+;ZK?BJ5JI3MR2S4R5:KQTR&
MS@57$QR9=9=YY3:4R(X("R;DO"LF[5(=,O'V27T@E30%1NT,*!2F#A'AT\T:
M_D;OCLYOM8N[JJ5.'QLCJ\G%3A/1K,T[5>`[O9JAJ'1\_P#\-?+V=T]H:]7C
M&=%Q2Z2MN+=3CX@`_9=H3M?"^]Z^%X!"*GZ/]BF<HCY@UN3[/]IL/#::DZ9>
M"7!E^+*8ZT.$N3`3EXP$#%-H)1ZNCHZ=#:#6.#W'O^\Y7'&=9??&47&KH:I.
M:3;\3<[?8_;MUP<-<EJ3W,5VOQ$O"W&V;OXN6:/YIR1>+=,)"-<L'D6N<B?:
M)F,8#''0>\'ZV_IIW!OFWOZU+PU-3JWX7BNE5WLO$^,^9[1:KLTX:F5,V9&Y
M:&WK)UQXQOC:U:<A/V=:T)D2^INQ-GL5>-G8]LNZ5Y5M'S-_7):]F.F$'$II
MP[M<ZCH>$B*)U-!`@Z?TGN[JC?N2NRJY2=3Y:WD@DT21MW%FPRX(QY/M<`[;
MV=KQB$#*1-[3F&,80-FS,9=$9'R\!+V]<[F!0C)5A,,9-$Z"I!("@FT`!$!J
ME[HMI*OP[Q96O`>T=;?=C#>8CX)W@_::E/S3=)[%1#C&V'B3$NU<`847<;'K
M1!7TBW6X#<*B1#E-PCH/0-/5$/A_@17B1BJ_+?Y;^-[TL.P[QQ-M3B+ER!(S
M$5:S=?$^)UF[1Y`1I)B4":?C$`WMY$L<H"B?C!DBG#Z3B'HIZGAEXN+3W!7B
M1E=]MWV/1RL,E*8)VHL'%QBB$`G(8UPZ@O/G<]F+<(<',2126,Y[4HD['M!/
MQ!IKJ%0MTV\RIS?8)KQ=XY3[;]D9)<+?-@':L$^9JJ^+!>]9B+V:.S0U!=T2
M)"%&0.@B(>&<$Q*7NC4^J(5IP\GV!7B7,8_OFQ>7/C.U[MO:\L:[08.V[$<M
MVEVR:E@XD40MAPX>DC"-I\J$2?V)7-(G[`"+`005\'37HJ%N>W+-\.\0^0R`
MCMPV2NI5.$1V_P"UE6=7CD9DD&7%F(59LT4Y*"B,E[&)PQWHL5"FU!8""D(=
M(&TZ:E;I@\U*<GV!7B7,>@^*%M.\EK;M\"F,?T=IZIM\7P[A->)<QYZZMHVU
M1*V+E52VO[=DEV\'/J(*CA+&6I1(Q5-QD_Y/!IKUB.O3ITUH[RW5;6[<0U2N
MQGP?<OB,[;_.1R?;+XR$O*?XB\N'9D(H`5NG@VV"(&*?MCF)XJF5$%"Z<)"=
MF'"0H=!2``!H%?R&]_E+?O`Q\,BIC;RR9/MLBIHT'W6[OT46_)^1&Q;]V'GU
MY3B?W2WW#L+Q.X5K1-,4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%
M`*`4`H"O<'SP_;K)>(^5?E#A*5B!0"@%`*`4`H!0"@%`*`4`H!0"@-=_-I)V
MG+;W@EX2&#WIU!,4^HE$H7+;W'H`=9^`1X0ZA&O7_<M/$6^U-VYAYR@UA)U:
MDXNG<:KETY"C$.D%EIX1*&P,9XV-8E@F)CBQ#I#9%JB!3V?`F$J!H&..D7@,
MQ'B."PG$PCT]-?/=HNVG:^UO)VL'O'%RFFJI7KU*4263:++I9?;@I<A[4,98
MNX0_T96``]W2R+=`?YOJE^\/M?.S&Q=WCBE=CEIM;U?_`*AD[5'5O(/>QQ?^
MK2P?S)MW^(55[=]K?K'%?KKW[0QU(Z2AL98R`H@GC2P]1T`0"RK>T$/-`&(:
MA6Q8[6=J\;&3];7K=R"K%2NW_"?%29*M6)9+E&N,AEO%Y9>SC?+'XNM[/V)H
MZ7MW%M[.;\AH*VT$+0BIN8<03R`.TO%2!:MW\O"%8O3F*V!5,O;@4PCT5]9V
M%]_'O'['[XN8>SO"PU=MZK=^$[JI5/P=:YX,LF22^(TL7NO"XFVJ523X'3GX
MC$VV##.%=KO,TORPL18XL3#&-[;Y>5H/O8BR[?BX*+0:,,\O14DIEPR)VCUV
MFW*)U%W2RK@Y"CJ(U_1/W$[]WIOC=>,WAO?$;9SG;<7EHJQ;E1.3HJO)3)P'
MS.]<*K$H:GBY>\Z&HRY[!W][Q<?;M^81A;!>)9NW,I9YMO<SM<R/>F2Y>U\V
M0N)MFCU[#XQMVW[7BHJ1C7L1D&VXJ?.BT6<MR.!F^-4O&8!+[TL;]K5)9<E5
MP<1R'&2>9DME83;SS)=RN?LUY"8W'?F))7E6X2S+C*UWESW9%PUJ73=TCF=:
M:NB-M)A--(EMDRW'UKD2:.%$"N&*R9Q+J)@-6<+\;E=9JJ="7;GH9B7;9CF`
MQBSY&.?+75O%GFO<[@O,#C<;DB:NJ\YZY<JHN=E%T9`;M\B*7+.NFLHR@KDB
M6JC`BB:9T%TP!#03#KFY6UG:1"A-Y$F81P7M*PI*[>^17D640OB1OO<WEV2L
MW<W>SW(>0'UT9BQA)8BRU<LMBB^G3JX4G<CC9"?@V3=-FOP^*M&GWH0$P@9*
M\K:\!IKB[A.SG6E'4]I,06/L8WO>^VV_9N7Q[RX+>YQ5U8]R[:Z-R7:ECFV+
M'EMK&.;PQY8-V72XF$G=JX;N;-<@GXW_`)8BT;.EU45/O0FK#K,UE:&SF\R9
MY;.D?CQ=/<1A7:S=MSK;%#<PGEP63:2./L@W,\LN&R7=,O+MMP6.<+W@TDEF
MQ+&?,_$22+=@\7C2N72Y2F*.I:V[5^U*-;K2DG3*-G/0\J,H[JK(@-J]]\UO
M"FWQ25Q1B:*Q]RS\EP-@0=PW*E:=LWQ?NY6T[?O"[8M-:1<JQQKKBH8B,N5-
M0I%4TS*&Z3FUSC>LT6O*.MPU7,-2;61$..9?D2P;M2Y@^9+!A\)X_P`G85S9
M.V'"Y'S;N+S%<&]DV2[01BH]X.V;#%H`2%QQC-\DQ57B1=">/=-`775'B4*!
M=:]BE&>K:I)<1.SGGHS]RMBNO'K5@I`[GQM>1AH1\X<""8"JJZA8]8#CV*BC
M<3&(8!$4QX##T]>HC1UF6@QU9:#55SOH1U<NR5O;K.<G;97G=SNSZ-0N:UW;
M)E<5O.7&XFPR(RD(L_0=-QDFQQ`R0&3$.(/-KXCWG;SN8#L/BL6K<)1C:N2>
MNM:-%%NE*K*Z43KGSEV$N0ABDINE&N^><'E[Y>+J0W,YW\JG*8X"<MX8R*!M
M5#F#4IL>'-X`&X>D1'0*_EWC?>]AUB;MJ.!W;<FI-9;#;='3+^>SZ>,]!MV(
M[)5I\/\`XE`Y>V6AUUYFV_H.YJ2\<8Z]/GXZ"HW%[SL/B<6U=W9NN*CE;ZNU
M1++5_GF:[P^B4GRO[!#BQ=O^X>Y-\.XG;1(\R7?"O8F+<&X,R-;SYM=&/27&
MI,Y*EKR8S:+I\E8!"*((IP*8IE`NI"FZQTKT#?O;#=\>R>$[16L!NUX3$WI[
M*>Q;C=@HVXMI;3Q5)R5<C;JGP4Q5EJ>J]9=U:7Q$PDN7QEKLR%#F:;_2`0.#
M0]Z8U%3P>C4YE,=F.8P]\1&O+L-[WK5EM7=V[KBEDR8=TIP4K>99'"Y7ED^5
MKH(8[M=J%^X;R#L)O"Y-Z6ZS/,:/,%VO11,?9=N"QW]G*.7%X+&+*+>Q-I1#
MGQUN40!,`/T]6H5^G?Z<_>`M_P#:.%O"X3#1UFT]C:4*)ZN6KG+[&72?.;_B
MK-O++*^!_P"!E#?MM\S%=.ZO<E<,/C3?-<EKYCVOX=QS94EM3ORU+/L&Y;AM
MQYEYO+VMF(\LKXZC$Q[^[6"H"0I"%8+NC"H;BX`_>UV_<C=DHQ;C4^=MY81?
M$>`E]H>YJ$N&V+]SGMC5W(X[L]QAIOE/;KCYY$$M*_YR)VG*XZ5N.P+%N:8;
M6V[@\79,6$K%HIV2*22HKI%,HF"@5K$7,^JZ&=&8@RYM#W;75D3&RMO;+38S
M7MF6V?2&/5+*;VKDUQ9^.,:9)AYJ^+8NO<G>5X,L@V(YM:UW#E`\!`-ETI4Q
MEBBHLF8VL]8NMYF11F0[FV(7K:!]OF1KPV53FX@L7NYWG90SK::"ELRU]7':
M]].WS/#D]+$FY1.+NEA%19TDHF(44.T8-QU332$E.LW>"+;^'QDT/`R6PW=)
M"8]D;7R#M=N;-]Y9/VS(8RVJ2+._X)>,V)Y'<7OE2X(2#NBYG3LDQ;D39,+=
M-O"%U1P.USGACMBD\%N(0L3=X(OX:11DK`V,YK9W2TRP.(B7!N`B^8@XOTV5
MWDV6*N&<P.KA]&R70KSK"2.\;XXG)<'":\.44T`\8\;,AXP4#A'6;NAYN\*,
MUYPO+_W17;;.<V=S;.9AG&3NSY_:DUC(;4Q]8]J7'FBV<Y8^R2UMJV)2(NF>
MG\P2+,T'*/(^\;L/X_.E7!!3@[4U3UBZE75=>0BA*[&FS#=,UWZL+]G+$RM#
MP#K<\TSK;61("`QA;]N6UMY4LJ&9V]B2>R0[N)3(\:WM8C48-YCXC%:/4[$R
MR9RD4[2G6+M*4\'X=_Y2:.O&?IR3$>S)QB''P$X]`+IQ\(<6@%$2@'%WNBL.
MLST$ZDM!YR\S:VK='_-FX_YL6K3WE?D]W8A4_P!&?XK++47M(_?+XS5)RGP'
MY-?9D/<]XZS?_N:=?Q[_`*A(2C[P]X2DJ)XVY^.?=8&+C9CK>2OD-A^@\0#W
M->NO*,2_^$M]PZBG'5I7+05I&L*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`*`4!7N#YX?MUDO$?*ORAPE*Q`H!0"@%`*`4`H!0"@%`*`4`H!0
M&O/FQ_W;^\'_`*)5O\Y;=KU[W,?_`))B/^3F:F,_1+E)L8W_`/8"P/\`F#:/
M\QL*\YWI_P"?GW#=L^+'D/:!W?V=VN)>_?I?>_*77?%%9FN5"MC"RU;RXPSB
M5Z!#7K-X(=W41Z@^;6EO"&QWI;N/A>0RB_!:-::-^XYL[FV7\KD"_;%LN*F>
M7Q:;%HYO.Y;=@V;YRGGEX<[=$EPOFK-\=%/4RJ0@8P$$-0T-T_U9_I8WC8O]
ME<7/$-:D;EI9<SK!NGQ'RN_FZVU'/X7QFP*+SGM?B8)E`6]F3;O!PT:W,DQM
M^&R7C6-A69#&5$K(L9$S3>.3BSBNH*J94PX^,>@>FOU%<Q>[(O)<MT?=/GOS
MG"=:&RWM&A$U$X/)>VJVBGC_`&`,6+O/$S0JL.T7<G:,3`TDDA-!D%PL9%L;
M4I?&3^``F&JI;SW3::U[MO*^3Y.^&[G`<R.7]I2;:WVJ>5-MJ#2UDA:VTR+?
M.+B(VPS-'*1XM;=*C*<$8B:/6%F<J79E.WXB"'"-8/?6Z'FNVT^'C[WQ!;70
M$,N[2DT8%O[ZFV=%O:ZI7%OLVU[XR396\Y325(1S;2`2@$B#G16%$QD@2,)#
M'+U#TQZYW2E3;6Z_#B'YW1WSHRF2]G,[&ST)-9%VPR\+=SI9:[XB9N_%4G%W
M65<J':*W/&.Y1:/G7`F03`#N4UC<"1`UZ`IZZW1Z:'!3/P=P?G=!TH/(.S2T
M[<B;,MZ^]J\9:,#)MY:(MJ#N7#L%;D=((NCOB249;C%\WA8R30<F`R:Z"2:W
M&'%Q@/363WWNAU6UASM_)EY!^<[A]1]EW:A+K2:TWE?;9+JSS=DVGUGUZ8K?
M&FVD6N9_&,I4SR644D4(QZH!VB+@RR2"A1.7A'0:F6^]SMIJ[#G>;CR"ES,>
M->2VP^3NU2^I><V:R-Y.63ED]O%Q(X;>78[;NQ5%5JYG'SM9\]:*@<14(JH(
M<1QX1X1$*Q]=[I63;6VOAQ?$3^=,QL=QNW!HU2:DSY@INDW*"""#;)]@H-TD
M4@`B9444IPJ:*8@&H$```FN@=`5+WSNAO)=MTY?L$+:K@-97-MS=A6\=L-DV
M]:&7\7W7<#[=ULQ.T@[:OZU9R8<E0W(8^.J9O%Q<LZ>KE23`3'$I!`I0$1T`
M!&O,O>[O;`XCL)C<-AYQG-X>[*BX(QMR<G30DLI?A,/*>(4I+.X]YFT!02]H
MIII].J`^>"A@[_0-?QYWGN[9XN]B(K(YR?X3/14J6:LXDQU`P^:%:W9R3EB,
M2WGV<OQ65U3BFLQJ\PU_>V;TOZJ&TW^?LFUZYO?_`-$]EO\`;O\`_P!:(G^E
M?+\IM!*("=4![AC?X:\)P]B6+Q,[7W19!UFTL]35SS1)J$MYKL-F)^7C(&'C
MN8UM8>24O-/VT5$QS-&Z72RCM_)/ED&3-LFDV4,8ZBA2E`O2/2&O[-_I9G8W
M+VBA.[D5=#>2BJ\B>14;;X*'SV_\([\:K+3[!M,#<IMQ`-/C!81Z.C_WJ6+U
MAT"'_GWN#7]*I;XW4I-2O6]:ND^4BKD$HI9$5^,KMR\H'"/PJ6+[>UCZYW3Z
M:WSDUNZ!\97;EY0.$?A4L7V]IZYW3Z:WSBMW0/C*[<O*!PC\*EB^WM/7.Z?3
M6^<5NZ!\97;EY0.$?A4L7V]IZYW3Z:WSBMW0/C*[<O*!PC\*EB^WM/7.Z?36
M^<5NZ!\97;EY0.$?A4L7V]IZYW3Z:WSBMW0/C*[<O*!PC\*EB^WM/7.Z?36^
M<5NZ!\97;EY0.$?A4L7V]IZYW3Z:WSBMW0>=NK<IMQ=6Y<+5#<'@U1=S`3C9
M!+WVK`(91=S'JI(I@)[@*4!.H.FHB`!W1K2WKOC=<-U8F6UMU5B;SZ(R,[:N
M*[%M9-9?&0*Y4#EL'+7V9`5=)0OO(6>0#(J$7+Q)L14.'$B*A>@B1A\T`Z.L
M-?X^>_G$]<]XN\;<4WJXZ[WIU^)'W^&RX>+^X1L5-T!\T*\OW@MCA[:X<A;'
M.6UHDB@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`5[@^>'[
M=9+Q'RK\H<)2L0*`4`H!0"@%`*`4`H!0"@%`*`4!KSYL?]V_O!_Z)5O\Y;=K
MU[W,?_DF(_Y.9J8S]$N4FQC?_P!@+`_Y@VC_`#&PKSG>G_GY]PW;/BQY#V@=
MW]G=KB7OWZ7WOREUWQ169K@.L.]W:1;C>@_M4\HX#A<%,?LP`-2@83G,4PE4
M+P!Q)]GT@`B8X``Z]&E9[U:Q%R$K&5JCKH:Y3*%%G(_Y9VF[9\]R\7<&;\"X
MLRO-0L<>*AI>];0C)B6CHY=?QI9B1TZ35X4!<`!N$O1KTUZ#NSWE;\[*[NMX
M;<;E.<O'2:6;-7665YU5%$L+9O2K=>;,8A<<MG8`4"]ELMV]J"(CJ`XWM\^@
M=SK(CI]&NC:]^?;EM[2,U_\`*/R&#W=@^!]YG7#EN;!>[LIV]!__`*RM[U2M
MF/OL[67,M[637&C%[NPO!0K\FYL$\BK;U\&5O>J5E_.?M-I?.B/5^&'R;FP3
MR*MO7P96]ZI3^<_:;2^=#U?AA\FYL$\BK;U\&5O>J4_G/VFTOG0]7X8?)N;!
M/(JV]?!E;WJE/YS]IM+YT/5^&'R;FP3R*MO7P96]ZI3^<_:;2^=#U?AA\FYL
M$\BK;U\&5O>J4_G/VFTOG0]7X8?)N;!/(JV]?!E;WJE/YS]IM+YT/5^&/M0/
M+ZV16K,PMS6OM#P/`7%`2"$G!3<9CJW6\E!RK5R@X92S$3I+IE>1[E,BZ)_I
MDU$P$N@Z5SM]^]3M#O7=W592D]92C)5X)*FBCR/-6A99PEFW<UEF1,9D0R:1
M@.EV0F$3=()E44-PE`RRQ42E2*LJ8!$0+J`='3W`^4PV\,-=P+ABI*%Y\%,O
M=HJ5-W$2B[3C;=94^&<["?@$,)^CI#_#YFO?KF;LO6=W3OXG%2U,-.+C&65U
M;3262KRO)F->W":M)R66C-7V'?O?-MWI`?P1#:AM,#3KZ33N3!#JUZ]0KU_M
M0GNKW&]E[6\/S=R,;L6GEHYWH:J\&N>J^4B,XWKS5MU=:FT$`$IEA$.@3#IY
MO<_PA7DN$L+=6(N2WDMEEX<N=9/%J3;4HXAMY(,P9GRR<!7UCV<8[EK;QM<V
M*(E-K/3Z&5FL$O9D2>,45<1L[).9HI48U=FL50K=8QR??#B!#<717TW93?F_
MK6]XW=Q6Y3@Z^$FHJG=2?%PIUH78I6KD-5O+W2`L)AKDPW=8MR96@\9;')/'
M=I3#2`NV]C,<>I0%KS;X_81T3<,H[D&J,2ZD5``C(''9@\#A%$5`,41]?EVD
M][6*Q$WAL#?E%NJK*VJK+2E9*JR-57"GPIG(V.[EDE):RSY\YRQ."^3)/8^N
M?+,%C'8C-8RLK@+>-]Q*>,9&U[6<*HE7;Q]P2[.96:1$N[2.'8LES$=+B/"F
MF8W15,NT/O>CB%A)[OQ$<3))J+<$VG6C5994Z.C6>CIF9"M;L:JIQHN4]GC'
M:'RJ\U6DWOS$6V_:9DBS7*AD"7%9UF6E.QB+E,H'6:/5F+A48YX@0P"HBX!)
M5,!U,4`K@;Y]Y7;[L]/9[YLW+%RM*-Q?XK?^&4OA@<)/Q*,R63EN[`U"E.39
M7MZ,4P`8HAC&W]!*/2`AJIU"%<NW[Y.U-V&UMMN&FJ,GN_#+.7?)N;!/(JV]
M?!E;WJE8_P`Y^T^E\Z'J_"CY-S8)Y%6WKX,K>]4I_.?M-I?.AZOPP^3<V">1
M5MZ^#*WO5*?SG[3:7SH>K\,/DW-@GD5;>O@RM[U2G\Y^TVE\Z'J_##Y-S8)Y
M%6WKX,K>]4I_.?M-I?.AZOPQ]$W+8Y?:R0$4V9;>^D-.$<<P``'S2MM?HUK/
MWS]K+D7;FY*,LCRQS,S]7X12R/)W24MI63;%AV[!6-9=MQUIV?:S!&+MNWK=
M9MXJ!B8J/0\38QR#9N;B(D5L````70`#N5YWO;'3Q^\^LN;E"3JWPMYFVWE;
M=6S9BDH\9[4^H@&G3T@-:V^[D,1&U'"O746J\%,O&(Y,XK5(%`*`4`H!0"@%
M`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`KW!\\/VZR7B/E7Y0X2E8@4`H
M!0"@%`*`4`H!0"@%`*`4`H#7GS8_[M_>#_T2K?YRV[7KWN8__),1_P`G,U,9
M^B7*38QO_P"P%@?\P;1_F-A7G.]/_/S[ANV?%CR'M`[O[.[7$O?OTOO?E+KO
MBBLS7%`*`4`H!0"@%`*`4`H!0"@%`*`X7`\*9AX3FU[/0"$.<?IP#J(4:TL>
ML1>PCLVXR<=K#,J_;(O;I9[C-7F+E$V_-PWH`JH1,5]K&TA%#C,4O;+A,Y*,
M9%'4?OJI2%$1*740#IZJ_0/OJPF)PWN:[/MQ\)7$^"OZ6U7)PTX3G;NR8IU\
MDVCIJ)K$!1(Y5$U!$Z:A#`8BA#"(E.0P>"8A@ZA#H&O(-\7+E_&RLW?&R?$C
M<D\NLLU#6YS-+9DY/$V([G<6S*WEC+&NZ#"F2\WVE%1<G<:LSBBT9Y%U-O7]
MOQZ:SJ;@K;<J$D7<:1N[(Z3:&#@,<_"/KONRPD+%V%)1@W"4<JK76C)4X::V
MLXI\#RU6<U[F7(\_P^(UZ[S;WQ!N7QADF1V>8M]TTFTN_9@C<6>V^+)1OC>[
M%H[.D1)V[8"]LLBP3N^F]AQRCE[-$:L&[9DU+XNX?)+$$A?;-T8Y6;DGBTEA
M6[TK:JE)QC&.M1:M(U=*.2KPI.N7F7;*=V6KXU57X5,A[DMJ<MB^$R'N`W$W
MBN\O._+NP'!(7GM%P<6!Q]M]C<473)SEKY=N7#5S3.2G&3VT5<;XSB72D4I!
MJM':))I:``AS]W=I-UW.U-J"MMV+<KJG"Y.KGK*J491MQ5MK5\!I+[Y5*I86
M6S<JY72E."G=RDB.6Y<LS=\ON3D%#8TR=!/;\LYTEN=QCBN1PM#Y\?M+400<
MJ2%GNWQX]S+6H1--@K)1Q3,)%<##J`$T+\'[YE@L7A<(I3RZCN*,EX2UVWED
MDF]9^$D\J5(LZN'CJ4IFI1\IMC*44T@`0$H@4-2F.*HE'KX14-TGT[]>`8VT
ML)N[6CD64V?&EE*AU5RH/6@I:42*R(%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!
M0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!7N#YX?MUDO$?*ORAPE*Q`H!0"@%`*
M`4`H!0%:F,7)T6<%IC`4-1[X!T`(]8@`=`:]T:Q;2>J\X.%9VU;E%1PX1;IA
MV>JBZI$4]50.)`!102D$P@F/1KKT5O+=V,E:VT(.4,F;*\N;(LO!W!55IPGS
M`N2W!*!@N"#$IB@<IO9:/X3D$-0.0?&-#$\T.BH]78ZCEL;E$TO%?#FX.(55
M:9#B4NNUT0**]QP+?C-P)@O,1R0J''J(F!W("<YNX`:B-1'=^.FI.-F[2*J_
M`EFYB-9+*<@W/;0")1N.!`P'%,2C,1P"!R@83$$!<Z@8H$'4.L-![U9+=N/?
M^C<ST\5\/<,N8UX\V&Z+;4Y<>[A%&?AEUWN)W)&#=O*,5G$B=.XK?.HG'H)N
M#*O5"%#I*F!AKU[W+[MQTNT]^#M3BWA)I:R:3>A-I)FEC&MFEPZQ.''L]`-\
M>V$HXGX%NFG8EI)JJ+348F1)0(%@;@5,9T`)FT'NZ5\OO3L1VF];RQ75_P`P
MZ9=>'"D])LVK]I12;RI'K1N:VRE(<;B@.%4P$2$)F-'M3',)4P3_`,I\/MA#
MP-/INY7R>-[/;XP^(V]RQ+9RK%4\)U65Y%5KEX>`NE>MS5(O*6IW3;"IC)IW
M'`G43T[5(LQ'"JB)B$4`JR8.>-,PD4*.@@`Z"`]VM7U=C]52V-RDE5>#+H,%
M1Y47&N:VR"4#W#!E$X'$@&EX\!/V9#*J<`"XU-V:1!,;3J*`CU!4>K\=E_,W
M<GW,N30'DSE"7/;:OX.X(0_@E.`EEH\0,F<`,FJ40<>$DJ'24P=!M!TH]WXY
M9[-W.UXLN#(^`A-/(CE]T-OC_P"G87KT#_C5AUCU!TN.L>Y6[A.S^^,="=S#
M6).%M>%7P:5^^I7N%5W$6K#2NNC>;A.ZV?,GI"JLW;=VD<G:)K-EB+HJI\8I
M]HDJD8R:J?:%$O$41#4!"N3BK5S!W':Q"<9ITTY>59"^"VBK#*CMZ:5AP5X`
MU1T92A`H!0"@%`=9P]9M3(IN739NHX$X()K+II'7%,O$<$BG,45!(7I'3JK:
MLX+%8B&O8A*4:TR:2')+.7@Y:C_XVT#SW2`:>8/WSH$*VUN3>CS6I$:\=)8+
MQIV@)^--A,)0-X*Z1BAJ8I``Q@.)2F,)M0`>D0`1Z@&I>XMZK/:?.N0:\:TJ
M7@Z:#KH\9CPB)1T=(=`AU@/WSK#6L/4^\?1,:\=)\]PZ2[8X=H@JB!$UAX%6
MACG,0Y2*@@IX\BH44D3\0E$NI^HHB/17U>Y.RF,WA95F-MNZ[D9-:*25<M5P
M9:=PPNXNU&.I7*D^^?E'VS[B=^3C_O#&ZO;Q?UF8B5L\V-[=-=-V1$%.Q;M'
M;_C8LO,X@D8-VXN=LP;W?<SJ^01=JJIAQ$;J!PAP"-?KSWS]D=V[Y]QVZ98&
M4Y8[#7K=MQU4JR5RMY/62:4%'(U):^MD>>O)P.,C;QCMRT-\.:F3BSGZM8MR
MU3;E*+UJKVBBBQ#IKH`W[-PHJJDFWX'CM,J229>@I5!X2Z=``(!7XRWWNC&2
MWK=OX>VY6*Q2=*4R4I3BHU7NG85Q.*UGX1<LNF951,JC<Z2Z@J"NG*-Q*44T
MDT^P6*LJ!D45#IZ&32(H0W68-1$*LL7-^82U2U&6O%9$J9<OBU:=--<HK#A:
M/F,TVT8)D@-%-T5G22A00-&I,Q65!<4P!!L@V2%50^H.%.R*)D"E#K`1'?W;
MB^T2NSNW[349R=,L6M:B:S17C).+R45$0W:25'E.5N0Q2=D99D<JJ:R:G:OT
M'@+)O0XE0$SDZ@D;)&-]Z2*FHF4@`&FNH5RU'M'ZT>/G:ELWFRK+&3SYLFIH
M2=3*MJE$\QW&16T:@G'HF9H)(F*=,$CQB;4@F'0"HH,4VA$Q./TOWH@F$1TJ
MKM=A^U<MG?Q%NF$7A)N4,BIH23RI:"+5_#2DX)^&GH9]))P@X;E514!5-0H"
M0X&XP.'?`X=!ND.NN!/&V=Z8#J.&;EBUG33CEY6DC85J>M59CF#J#SJYT;L+
M25N=5..1Y'G1#MSKF*UEUFSI?,^@C9ST"G6;.E\SZ!LYZ!3K-G2^9]`V<]`I
MUFSI?,^@;.>@4ZS9TOF?0-G/0*=9LZ7S/H&SGH%.LV=+YGT#9ST"G6;.E\SZ
M!LYZ!3K-G2^9]`V<]`IUFSI?,^@;.>@4ZS9TOF?0-G/0*=9LZ7S/H&SGH%.L
MV=+YGT#9ST"G6;.E\SZ!LYZ!5V':Q-U6;.6X\W!WWD#A)*KS%=!K=G@,5;\:
M*YUTF%0("%:TK<H>,*E*P`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`5[@^>'[=9
M+Q'RK\H<)2L0*`4`H!0"@%`*`4!<'75MG](B'F+#<6O@`!C:AH`CH`AJ&O3Y
M@5KS_3KE,X\1K!YM;).2VJ6C;3P[E2"NS=%M)L>ZV+:1E8A29M>Z]P-@14]#
MGDH5_%R;1&2AW:Z)E$G"0E*<=1X=0K]8_P!+/57[T,(\=9C>P_5;ZU76E=FZ
M/)ER+-QG)WO>E9P4KD?&JOC-?^.\1\M6Y[;L7*]Z\KJ[,>;<<DY4CL.VSG-Y
MG6:NYI#3<Y=KJP;4/>]G1>87=[6?!W!?B!(P7JS446RSU`51*0_$'](XV.S"
MH^J-\&57.?HY#Y*.\[^1MMIY.#H)$/=LO(ZMQE9264,;XGL6Y,GR]Q,8"*;9
MBRK=**7N;N]Y8"DP,];]\+,(>#1GF8LU73A9N@1\(H\8B`B%BL]EUJN6#;BG
M3Q;BKR\IEZTO46FM/AD/388V;\F3.K;<B_M/`<2BQVR90NW'F67$CD'-AD8V
MX+)MMO<UPR8F]\H"G;1R,DZ35X!/]\;*%$>@NN/5>S.;JDJO*JQN9O@F([SO
MRJDW5<G08*Q=M*V,YG<XYN*X^4I?$?M>W"KMV%D95N#*EYWD!;<<L7<U;5X9
M;QBGE*0EL<V!=C-B1=B^=)"1H15`[KLP5)70W=NCL]C;DI6L/J7H0UHU4UE\
M7A>1Y\^?OF,MY7Y+*Z1ER?%3XSZ61[&_[OI8>,<S9,BK!Q]=T?@QI;DA>T+:
M60LU!*N(>X+EC;*924,T->;-*?@4)20%,SEF*[=/L#:B&@`-%WW:]F,4X;3#
M0C&5:Y9.E-/YQ?!YR'O.]E\)\WV#*SO:UR*AR*3#49C^P9K+KN'.ZAL=1F3\
MWFG9U>.MU6\T+6AY8^1DH-*[F\,R5=^(F<D>`@B8W9@4IM.=9[%=E>SZEBH8
M6'YS)X.NWGS9)2R9LY"WG>KXS>3X<!X';GA_D([CL0#EJ)L+%]OMH7%=O9<R
M;!3N6LP(O,=P4TR03>.YAZ^O]-O)M(>51/%K.6O;)%>MC)`83&*`WK"]FE)Q
M>%DFL]8W,AG#>=Y\//3H.G-85Y(ZD58,YBG`]JY!A;QNO)]G/9^.REERUFE@
MW#BW$%R9CFHZ_P!2=OR,=6ZE(VI`@8@."%!1J[(N&J6IJ;'LPFGU1M-/[6YR
M=[.'O2]D?`_AH,F1.U;D1N[MF;!DK1Q*QO6V+3/=%PP:^6,S/&4!;T/;C&YY
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M"`X&ZNYZ`5^=H[SM;R6M:5%')P_*;-R+C-U%28"@%`*`4!H>WT0>+KJY@"+'
M-MD7QF.SX79GC5GC_#EM99R1C:.GLRY3W+W?8=KRS\ME7S9T41DV*F4LE)/P
M<@Q8EXRE,)2E'^F7])>X>S6/]U\[^\[5FYBKF\+L9:]M2>JDJ-2>54T*E>$^
M1W[BYV<:K<6UX*>0]=-[3^7K@>U6[O=SMAR)B&=6NB8ATGEE[E]U.3;&E(./
M:14B>^T+B9Y::RL5:K09DC!<THT:.4G;90"HBCV:A_U6^R79!W/`PF&E'3LX
MQXLRYNX<GUA<B\LI=\\#,8\Y2$5DE"T"[?-P[RR58G),A,Y%CLF;Q'$/'2.'
M,DP.,+NE%%$\KB7WO[<E+A<)NYL=&9'"12`(B;HQN]D.QZE6>%PRFDTEJ)Y,
M^?2VDN+@>>L>LKFE]\]K,8FY+4+.7;;*^.<UN[DM*1AXLT##9.WA2LQ=;F<N
MX+`C%K)CV65U7-TH.KQ#Q#M$2E^^Z#IPCQ5K^R/8[@PF&\R/1TCUE<\I]\OM
M#"_)<O\`146B,=9D9,A9&EE7ERY.WDVXFO%(1,A)H.F2TCE5`%DI-:)<L&@E
M_P!]2C=1H354NE4X?L7V>CC'?L6;"AD:2MP^/.^[F+HXJ4HZ]75\I@JXMOW+
M@A\/XSW4P>U6,M.[,SYM5P`ZN[*6ZW<_9+R)@8'W:2+*XKMR+"9%E[S;1#,E
MN'X8SL%1*J](D)2\-=C&]E-QRALX6[4H1RI2@I1K))2>JWJUI%*N<RE?ULE7
MRKNG)A^U>6%=T_&066-LF6\;"XC+7D5[PC-P6["ZL8I3EY9'R7BIC-/+U:Y4
M1:16/KIE\:HC!2;XB`/P>%\$#=`\RQV-[(6\/&-RQAI7FO"_-17#7)SO1P)O
M,4RQ\[<M1-T7*98>V!R3HUG&O)/&^=HI:XI*";6K$2&0=Y;"7N^,NQA<<Q;M
MX6NQ=932"3LB:C[4D%&\F!R-UA0$A.(X@49?9#L?3]TPWFQZ"/65SRGWSSN4
M<?<HNRHR^UK9P5G.Z+DQ_*OHE.)?9:W@PL->$A`R$.RR)'X^F'V5$V%Z7)8L
M+,@\=,F9C+E1`PE`=#:;MGL=V/E2-S"X56FLZ@F\F59,F?B[I#WC<SU;YSU<
MGB+DOP+"T'AL19W2?77+S=M1[!SD?=LUG(^[H.:<VU[AKH2D\MI+VU<+Z5;%
M*W;KE\-%1-41*0X#54NQ_92XZSP>%2XHI=Y4^0>L;B^V??(/;CGO+MMW%FWJ
MZL`V3FW!VXR[<[[2G<5%3V8=QDP\@HV\<S,FK>S+J"<R?<%M(O[@M*.?.#-C
MMQ3!+0IAU'0?/_?#V,W!A=PSG9LV%8V%QY+,)/5V;;>5-Q>M2C3K'.FJE^'O
MUN*;;UFUPO/4_52Y.4%E2`4P<*A]->D=`,.@B(=\*_C5VJWC8W+OV_'"0E3:
M2IGTO/D>4]"P4W..5Y4`$F@=?5YOH57#>-FY%7)6WK257GX>X6.Y1M9"NJ?F
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M"AQ"!0UZ.Z80"I6*VKU,-"EYYL_RJA#GK*C*`N``CQ`<AEQ$$R'(8J@B`"(\
M1--2@`!W>^'?JV'77'6O)J*IW^X4M(YQZJFZXN'W1BLY96H9"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4!7N#YX?MUDO$?*ORAPE*Q`H!0"@%`*`4`H!0%P==6V?
MTB(>8H'TX5KR_3KE+(9S6=S6/^SGC`H@)@/O6V0)&+P(*`8JNY#'"9BG3<D4
M1,D8#Z'`0UX1'A\+2OUQ_2C.</>CA)6U%RZM>\9T7B:3C[VBIX.47FJC&>,=
MC.^=QAC'VR_**VWNUMNEA9K:9*NK)=H3]VW3D?)MM6KG,V;[8M.(M::AVD1:
M:DY.1S!M*++K*=DP*L5OHJ)!K^HZQ^+5YW-C9RK,YNBIPYLY\ALK+61OF,&7
M;R?MQ[E9G[#RF,YY#(-CO\4Y39R.5<I61;MO6PGGC+N3F3Q"U[1CUF61[8F+
M<RPHD[@WIVPI/(Y!`B@M3J&"][TORBOS&'4M9?;OG&RLU>>G!D-I^!MJ-ZX]
MC-ZV,+V]R:^*\_9'N.[<>RUHNG1+Q]SN0L1V3C>ZH>\T9)HDT2FX)U9G:-'2
M*BI7Z"Y%''W\AQ-5/'8B=U7%:LI)*L==TK5YN7)E#M6_M48.P]AKF8VM:.(M
MMLK<6WJRL6868(V?(YW@BR5W7+E[&-JVZ]MW']L$Q%,1[:)MN9=,`CD[A=.G
M:B2GB1_%BF!4`K"6)O7YR4XV[<6ZIJ5>YEX"=G:I15KR$`[?Y0V]5^ZNV8OB
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M\MY.3(-E9>3+3D/=9'Y<.[?.LQD++V1)[!]EY4RE<-\/)*R+`DKK<6!;$&7:
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M9+@?^!VN4`!5-B./%DS+G05O_.AFX.Q3[=))3,MZJ]B((:HF2(8P\`_3@70!
MZJ_D'[_=VX+$=ML3'&2C%[=^*LF51R*K72>A;KR8>+5?%7RFSSA`H!H&FOH!
M7CF.W9NW=MJU'=TJJ:;ED6=/)PLV+C;FZE*YI@*`4`H!0&J:_P#$5JYSYI]R
M8XO4C\T!)\N:RGX.H=Z:(N"#G(+=)=MQVU<UMS;9$7L7-0$["(+I'*IP"<I0
M,0Y.,H_U'_I#W)A<9[I7C+TDI/>5Z-,E>#C/EM]6H2Q>L\^K%$E;]Y86!LIQ
MA&F0+JSG>4J^?7"K=-W7%E%::N6YD;CB(6`E&K]26@7,-%M&T;;C5NV")8QZ
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MH2UH!ZD"92.G5W39NW<.0T4:ZI"`ETK;C@L+8M[.WXJS9N_E*Y6VG2--4D,T
MVC8A1@+!MI6"?.X?'F8)K.<"SEWK>7X+SN%.YV\JT?@Z050D895.[79@1.3A
M*)4@+TIA46[5J7#6CX3'4EQ4.._-I^,<ER=QR=X1+]8]X1F*8VX8Z(ERL8%5
MKAB[7=XV7'HQ"L:JW".3E9!0%T#`9!=N`$$A#%*H-=W<^[KMR5R3:E+/FS\Y
M=&S%KPL[1'&=Y6>WVY+4&TYN4RO*-2-;;A(UX_R$>07MW']D-IUM9N)H5&4@
MW[`;#MTMRNQ8E<-UI!FL?QE)VFX`IJK>X]VOAR=SIT=\R=F!\RP.6+CF#3N]
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M0DY.,>%T7BURYBJW8O*?@4;K59=#7-G)7C>G-\1$Y4MO6PM4J9SE!3W\\RE`
M_A&$3`#BR#+CJ(_NAU'S.JOYL8C!^XK?5W%;WGB\9*S;N2U];"T=4\M/S^4^
MVPUK'P_21BF]#;^1HK[N>;\/7MVV':_]..8OT$K04?<*TG'%8[5X/^#>;]>2
M[>,J_!CG\K[`]W/-]\G?8=\..8OT$J=3W#_2L=_!O]N1J8SR8^</=SS??)WV
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M[<:F,\F/G%Q+XYOIC`'Q>MAZ8?NE/?SS*7@+^[-Q)V()P$"Z]5;&%M>XF=]*
M&+QZ>5U6#RY$WD_/,E1QD775CYWV#N[3-SNY:_\`<WFW;5N;Q-B&P+QQ)C7&
M&3V$OAR];EO"$F6&2W]PQZZ+QQ=#"+>I*MO8(H@0$N[J'77)[8[C[+6-Q6M_
M[@OW;N[L3.<;<IVMG<E1PHYQUI))ZV;.FM&:^V[KEJW$J\O*;+M=1-I^YTU^
M:`"&G?ZZ\,O6KCQ&(MJG_#R49\3DJJFDV:42KPE*U@*`4`H!0"@%`*`4`H!0
M"@%`*`4`H!0%>X/GA^W62\1\J_*'"4K$"@%`*`4`H!0"@%`7!UU;9_2(AYBW
M70VO2.@".@=?0`CT>;6O+].N4S@:S.:JH0^W?%A`-X8[U]C:O!H;BX`W)XV,
M8P@`#H!`#41Z@`-:_6O]+&#ZW[S,);=Q075[LJU2R;.O"<7?6MU&6KGJOC-S
MRAA*?02+>$8P%T)KJ)1-U"'0&I1U#734*_IW+=-N<G.5YJKKP<-6?%ZUW@2H
M4XC^EN/WA?NJCU/:].^==!&O>T(<1_2W'[POW5/4]KT[YUT#7O:$.(_I;C]X
M7[JGJ>UZ=\ZZ!KWM"'$?TMQ^\+]U3U/:].^==`U[VA#B/Z6X_>%^ZIZGM>G?
M.N@:][0AQ']+<?O"_=4]3VO3OG70->]H0XC^EN/WA?NJ>I[7IWSKH&O>T(<1
M_2W'[POW5/4]KT[YUT#7O:$`.8#%`4U0`1#43@0N@"8H#UFZBATCYE7+#8;!
MX:<;EZ.K+A;2S<R)BYN2UL_`:5^3P(_$'QHD<JB:Q+XS<)B'3,40*;,%YF3.
M4PEX#E.4>C01Z*_DG_49V<O8KM7B<5A;D6G=>9I\$="9Z/NQTL1C]POC9L^`
MI@^F'77J^=7YRL83%X2&IBY-O@^%$;-QIS=!5Y6*`4`H!0&ORU_!YQC\V@CQ
M\N*W$R`703&.3<1D-42@7K'4H?/K^HO](6`NW_=1*]"\H1]87EJZR3RT5:/+
MR\1\;O\`=Q8_P?%V:YZ9#;4D10A-!`_A'54T*41T!14Z@`;P=2FT-TAW*_4"
MW;=RKK#R/2CBJ5W0CDXC!^X6'_Z,WW-;=O=CU%K7G7EB*W7HYQQ&^H6_@C?<
M5GZL7IGSQ%;O%SEX'Z/I3:@(`("0P"&H".NG#U5,;6'A)V974YQSIM5,7MZ\
M1Q%=)B(AHH42J)I&`R"Q1*=4@*$#I3`!`2CTB&H%ZAT&K)VL/;JY3C&G#5+Y
M0]OREXG$1U`BHAYB9A#YX%&J5@H7UM87GJO0XT,D[U.#G*<1OJ%OX(WW%3ZL
M7IGSQ%;O%SCB-]0M_!&^XIZL7IGSQ%;O%SCB-]0M_!&^XIZL7IGSQ%;O%SFJ
M+G&")-IELJ&*8"%W8[0#";A,/X7/UGH<(:!].0RH";N`'37P?O1P=G%^[W>&
M%M78.:L7E5R7C;*61Z,[X\ATL-EG#3]F)/`Y1`%`#4-5%@#734!`XE[FH=.F
MH5_%?$=G]XV>S^\KN&F]3:W<SX^)'HEF:E1G(77A#7KT#6M/!J4<):C/QU;C
M7EH:T_'=,U65K9,!0"@%`*`4`H!0"@%`*`4`H!0#]R?S4SA\T2"`?1&MW=_[
MTOO9?$P:L<._WO&\W\7M'VKD-]<-P9`,&GF:5ZQO?_U1N?\`WI_C6C#_`%7\
M-)M+)UK>>7[4M>0W/W[>_P#S%O\`%1=+-'N_&*YA`H!0"@%`*`4`H!0"@%`*
M`4`H!0"@%`5[@^>'[=9+Q'RK\H<)2L0*`4`H!0"@%`*`4!4.@:SMR49J3S!E
MARB8-`'3I*.OF`8!'YX!5;5;JF_%JJ\G"3F7&8-W#;=\8[HL4R6'\P0SZ7M&
M3DK?FUT(6X9JU91.8M*:;7%;3^/N.W74?.1#N,FX]NX*JV5(IJGPZB41`?0N
MR/;['=A]Y6]^;DBGO2U"45K.48TDG'*X24LB::XT47[$;]MVY>*R'(<IG:\*
MRJQKIW8E[4YBG2+O/W&F04()U5A<"D-]!P+F44TT`=`*'7W!]B?]67O"V&R6
M'PKFI*DMI?JU2F7P^1\K9S_4^&3JF^]T'-\DQM7_`"FW7?VR-QOZ?53_`'7^
M\;T.%_67_G$^J</IEWN@?),;5_RFW7?VR-QOZ?4_NO\`>-Z'"_K+_P`X>J</
MIEWN@?),;5_RFW7?VR-QOZ?4_NO]XWH<+^LO_.'JG#Z9=[H'R3&U?\IMUW]L
MC<;^GU/[K_>-Z'"_K+_SAZIP^F7>Z!\DQM7_`"FW7?VR-QOZ?4_NO]XWH<+^
MLO\`SAZIP^F7>Z!\DQM7_*;==_;(W&_I]3^Z_P!XWH<+^LO_`#AZIP^F7>Z!
M\DQM7_*;==_;(W&_I]3^Z_WC>APOZR_\X>J</IEWN@?),;5_RFW7?VR-QOZ?
M4_NO]XWH<+^LO_.'JG#Z9=[H*I\IS:VBLBX2N;=7VB)A$`4WC;BU$S`.@B51
M%2_#HK%$2AX)P$*7/ZINVV,P=["XZQA_SD:)J=YN.>K59YS4Q&XX7+EN=N32
MB\N5+\EU)D;?<"8[VR8JM;"N)(EY!X\LM!ZW@HZ1F7UP2)C2,@YE'SY_,2AE
M9!X\=O'9S'%0YNO776O">U';?M-VFWA+'XB4%*<M:2UIY\BHJMY$EFY3Z##0
MMX>VH)R=%3@,V".M?/7<3>Q*CMZ:RY?E)E1R;12J2!0"@%`*`A?N!V)88W&9
M+A\PW5<&<+*R/!V(3&[2Y\+9TR-AZ0<6>E.R5R)PS\+*F8]H]3"7EEU.U53,
MKH?AXN$``/>/=C[_`#M)[L=T^I=W8;"XC`N_*ZU=VM:R232U)Q5,E<V<Y^+W
M=;QD]><FG2F2ABE3E?8<4,!QSSOO((E*`@CO>SXETE*!?OA@N<164Z.DXZ"(
M:=ZO1+?]8/;2WK5W?N^6M)O*[^3B_2YC5]1X9YYS[W0<?R7>'==/?[WZ?VY,
M_?I+5J_K*[<ZVI#=N[4N7$?M1ZBPOES[W0/DNL/?K[WZ?VY<_?I+6TOZO^W[
M5>H;J\_$?M2/4>$\NYWN@^=)<M?!$,SD7TON)WU14=`13JX)J3=[Y,])M(^!
MC>-]*/W[A2YM$VS=JV4$3!KPE*.N@=-=7LU_4YVP[0[SN0]6[NC?BUK23O9J
M9XMW'7)Q>,8W-SV+<4U.=.!.FGD(?;#MES;<CB&3W!WSN%WUMK3RKD.\I[;_
M``QMY&<F#VWL#,YMS%62[D2I70;Q^3OZ*:&D%C+"<S8BZ94S"'7W.VO]3V]M
MRX^/9R6#P\]XVXQC.35S4UZ>'X2N^%%/)&5%FE5(B&Y[<UKIM1[G033'E>8=
M'A$<\;\D_!+]Z)ODS\)$@T_!$-[I=3%)U`(](]VOBK_]7G;C=EZ6"M[MW9LX
M/)26(I3/Z1%GJ/"O*YW*]SH+?DN\._KZWZ?VY,_?I+5/]Y?;OZNW;SXC]J/4
M6%\NYWN@?)=X=_7UOT_MR9^_26G]Y?;OZNW;SXC]J/46%\NYWN@?)=X=_7UO
MT_MR9^_26G]Y?;OZNW=SXC]J/46%\NYWN@Z+WE5;?Y1];#BY\@;M\A,+9N>V
M[O86WD/=]FF\+1]T%G336X;<DY*V;@G)"-EEFDJS3.)3%(3P>JN!V@_JB[2]
MHNS&-W-?P&"P^,Q$+JC*UMEEN0<:RE*XZ/+G2958W$K5YS=R<K=:I-K3FS9C
M9DB#GL"@Z.FHXZ>,Z11*F8PCKJ4IA$2A\VOS/NO?&^K.X,3NW'NV\7><FM64
MG'PJ9V\JYF?31N0C3.=D!Z*IM3U;48S\=)5Y2B663:S5&H59M8\9%!J%-K'C
M%!J%-K'C%!J%-K'C%!J%-K'C%!J%-K'C%!J%-K'C%!J%-K'C%!J%-K'C%!J%
M-K'C%!J%-K'C%!J%-K'C%!J%-K'C%!J%-K'C%`(]!OK1K>W=<B\4DM$OB8H:
ML\._WO&]/^J;M5_GW(%>M;X_]4[G_P!^?XULK_U7R?*S:43K6\\OVI:\BN?O
MV]_^8M_BHNEFCW?C%<P@4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*]P?/#]NLEX
MCY5^4.$I6(%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`
MH!0"@*]0:U?*"AAMMPU'"=8Z_`(>"<P:AQ<`<0D(/0*HE`>(R91Z!$H#IK7,
MP\L9C+VSLUSTX>?DTF=$LYK)YD%X35]0F,-D6-W;A'*.[VY5;8NQXP=(-G^/
M-L%O%;O]P-_R"R3@'+>,E+6.:`:J@4W:O9,Q$]5$S`'Z0]U^Z;>Y=VW>UF]'
M"W8P-IWY:TE!SN*JL6HUE"4I2N>'2+;4;<FU1FCB;CUE:CE<LFFBX7Q9/C-B
M]FV_`6C:5N6E:<<VB;9M&&CK8M^+9I`@W80T$S1C8UHF@4B9$>Q9-R`)2APZ
M].O37C7:[&XC>N\Y;Y4I3N/PI/+6KROA=.2IM6THQU.`].!N(->_7ST<3/%I
M8B?C2,FJ9!61`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"O<-]:-=#=?[X
MOO9?$R&:M,._WO&]/^J;M5_GW(%>P;X_]4[G_P!^?XULK_U7R?*S:43K6\\O
MVI:\BN?OV]_^8M_BHNEFCW?C%<P@4`H!0"@%`*`4`H!0"@%`*`4`H!0"@*]P
M?/#]NLEXCY5^4.$I6(%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`5%<M`5TJ^W9U_MHKE`#03`3B`#"'%H/>UTJ[JD:9;MI2T5R_$#A.L4
MBHHF(KQ`!!`W9F!,_:"<I2IJB`)G5$4Q\`!X@#0=.D*KE@\9JZ]FU.Y&K\55
MS4Y\^8GXRQ5VBDB55<P-B&(H<#NS$:D`B0"=4QCN#)D3*0@:B)A#HKMX#LSV
MHWSAXV,%NW&N+DUK;.6JWH37"8RE"%9.4:+/E-5FY_FX[3\(7))8@Q_>5G9V
MW')L5RI8PMF\[8B8.UQ.91,)/+>2YJ28VACBTXYRD"CTSAT+Y5$H^+H+&\$?
M:>P'N2[46[T,3OG"RLX)MMRN6[D<BRRC%2@JO,FD\[56DZE5V[7)%-R6CC^&
M0C!MIW@[&\33F0-P&Y3?YMJRQNTS0V8-[VEK`NLES63BVP(I0SBTL$XJ;Q;5
M7QJSK1=**KN7JJ;=Y*R2IG"R8>"%?3>\SL9V]W]NG#;C[(;HWC#=N'577#W=
M2]=;JYW8VW*,I1CJQA3Q%6*JLKHL.W;N2E<:UGFKGIWGE)B1O.&Y:14FS53=
ME8;<!$R0.I%&XVR)S<0ZJ+NW<*B0!,(])AZ/-TKS+">Z3WCV=V3P.(W#O6[B
MFO&CAKK7*VXU-B5^Q6JG&G*C,EH\QO8/?#A!E:N\+;U*.W!RII-!R9;C%THH
MH(`FF1O(O&BISF$=-`#76OE<1[KNU^YK<+6\\+>P]UKQ;EJ[&7)1PSF6VMS;
M<74ES"W%!7,B1U;,U#7(S.4%/'8*7C95L"9M!(H"K)TL4Y%`'4!+K7"N]F]Z
M6;FRG!Z^BC7QI,RUE2I],JY3&$H@8@@<2!V@<)3B`:CV9Q\$X`'7H/17(G@M
MY6YN$L-?4>!ZN1\:?"C))-9U4YPZ0UZ0U^J`0'YP@`UG'"MNER<+;^Z="'GH
M-/-I+"ZN:Y!KB8J*U9+5X^0%*`4`H!0"@%`*`4`H!0"@%`*`4`H"O<-]:-=#
M=?[XOO9?$R&:M,._WO&]/^J;M5_GW(%>P;X_]4[G_P!^?XULK_U7R?*S:43K
M6\\OVI:\BN?OV]_^8M_BHNEFCW?C%<P@4`H!0"@%`*`4`H!0"@%`*`4`H!0"
M@*]P?/#]NLEXCY5^4.$I6(%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`N``$*V+5M7(_=$-GSGT@BP,3MP4*F8!,*W"/9%ZP*0HATJ+',&
M@$#IZ0$=`JU;JQ^)2=A.FM1O+DT9B4X\)'//V\+;GM<C$I'-V1(^U99^H#6W
M+-:(NKBO^\GJB8*-8VS+'M]&2N.XGSDQP*4J2`$XQT$W0->B=D?=%OOM)@WO
M.VIR=MW'-+6I"%K+.<G3548IIR=?!65E,\3;MRH\^3OYB*!<\<PO<>1%SMZV
MVVIM9L1_X#7+N\=\Z=9!69@H<0?P>W*R5@F4NV9+$5:HW#(1XF4$P'(4N@CZ
M'8PG8WL-&Q+?N+M8MSUG*WAI6YZJA<<7&<[FJO#C%RMR@IIIQ;R%+G<O.6HF
MEI>3@[N;AS'Q7G*_?YH2<?'>WA9^W80[L>Q=8KCGR&WG";EFIH8T/+V#B!VC
M.S<8`G4`$9"9<IF3,`&+T#KM8;WOV<!OF6\.QBW7AMV^'&$,7"5V]E35;BA<
M5G6BZ.#A",D\M6S%X-.VHW=9RXLG?I7OF<,<<MG8#A-LDUQ]LTVZP35-5'LR
MR&+K=NYRV.@*?BCEH\O"-F9)-1,Y0U5*X`Z8].HZC7R._/>/[P,1:G>L[XA.
M[/6K6YB)1HZN>1W,V5)9<AM1MVU2%&DJ9J(EK;=OV?:"?B=KVY:MN$*X,1(8
M6WXN$9^.+#PE;L3L(]FFY<")"@;@3,<.CB$>BOB+7;KWH7[:Q-C?:C8S:JO8
ME<-%FNT;?$C-PP]<L71\AZ;V7?.E3M7CT%$5R\!47*W&+AR4G$K'KLGC0H`)
M$O"$0\'3H$=:ZL?>#[P[*?\`W^DZ9=:_B6^1+:5JN\5['"YE"G<1BNZ\!;?<
MFMG`7U@S#E[).C&35]V.,+1GU5BE^]GU5EHE=XB8!`0*8#CH73ATZJU'[VM]
MX7$1AC\7/$8RVOTJN7'6N6L92N:ZR<9/5HM:R61\1$NX.5!LE?+NI&P\=W#@
MBX7+@CI"ZMO>3LC8=F(M8B90(HVB[6N4EE/2IJEX@37B13-IX8&$3"/U>[??
M19C@K^$QMC#8F>(MZLKM^W&[>C]Y<G)RC19J9BN>&>LI1;5'F61<R/.#MSY@
M."UC+[?=Y$%N'ME`Q5%<4[T++:.9A=BW2XABX7.F+V\2_CI!<2\"2DG;S\``
M2\:H%#6OIL'[Q?=UOC!3PV\,)+#[S\%0EAU9V2BDU-2MW9MNY)Y4]=)9<E<A
MA*S>BUJOP:U=<_.EFXJ':B>9"RQA,Q-D[Z<%W]LZGY1VG&1>1)4Z61MM-PR"
MA3F(E%9OL])Y#P`K^"!$)M&/6*(Z&```-=#'>YY]HW'$=G<7AL9&=A77&Q-N
MY;33<U.VHZRV4:;62<HJ3HFR8XE03VB<6G3*L_\`CP+(;&H>Y8>XHE"?MV2C
MYZ`>@F,7-Q$DQDH>7(KP"FM&2;%PY9O&JA3@)%2&$AND.L*\0WEV7WSNG&W,
M'>C+5MSU<JDJTX,M'FTHVHSA-53/OHG*LF14H'*4Y>(`4+P'`.D/"*.N@ZA6
MO/!RLSE"[GBR*Z"ZM*5*NF8DI4`4`H!0"@%`*`4`H!0"@%`*`4!7N&^M&NAN
MO]\7WLOB9#-6F'?[WC>G_5-VJ_S[D"O8-\?^J=S_`._/\:V5_P"J^3Y6;2B=
M:WGE^U+7D5S]^WO_`,Q;_%1=+-'N_&*YA`H!0"@%`*`4`H!0"@%`*`4`H!0"
M@%`5[@^>'[=9+Q'RK\H<)2L0*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*6ZW,1&PE367C<"^4LC!R53C,<0'0""?P1$H%$.,QP$`X"D$=1Z.
MG7J"MC%8=8:ZK,9QN3EFU:Y]&4RV3X7D//W)>-LV7`3MU7C-1]J6Q;,,^N"X
M;BN)VVB(.'B(M$[F3?R$D[63;MVT>W3%18PCH0G3TZ@`]_=FXL7B<1;M0:K<
ME%+))Y9.B5%E;KDHDV^`IFM1Y?@M)JV?[C-R>^ATO#;(6J.#MNJAUHR5WRY0
MMEP>?O!AX1'Y]J^+9HC4US)*MU.)I<<T5O&F/J=)%;A+K[['LWN3W>866-[7
M:V)Q-ERUL+8:C=A.,$TK[N)*,7)I:L:R=&FTGDTG<E>R6FDFL[^0E)MJV0X+
MVVO'MX6Q!R5YYAFT`3NW<'E226O7-E[+J$(#MQ,75()IA%L5S`/9Q\:FT8MP
M'0B8=(CY#VC][&^.T-Z+[/P]6;JM0E;5J"=M/6;<\ENYJN,JI/6K*B2;:2-B
M&&A;3VGA2>6N?DSDM?$ET7(K-5"`DHIJHCQ&;EX1TXE![,BJCET8>LYS])=`
M[E?)RWI:Q:IO.,IY<FH]7XZEB6KXIU)A\QA4'TD_,X%HV:OI5T+<A$Q,SCFI
MW*K?[V;M'+P4DS&(4`XU0*.G56."[/=G-Y[WPD<6L6NN7=FE"]LU'43=6DLK
M?%E9,[\E;E')D[YI>;[J=WDUMV)S$3W#ADFW$DDYNI;;+(V@X2N\^"(Z_P!>
MSCW2.4U7B[D,F/&S8T@E'>*DBDR]DB=7M3'X?TE@O=5[MO6D>R]Q;Q>-5O:3
MO]8>Q:<-I&"AJZ](N.K)Y:NO`:DL5-*K2Y#Z*69-Z,?N:R#:=U9^Q3-X)Q-M
MV9;N)@C7!H1>4)?&;ZZ;M9R&/3"6X7+6(FAM>WP*J_2'B27,70NNM=;<GNT]
MW>.[+0WO8PF\JJ]."@[\7*2R9:J-,M<B;\'B(NXNDM5KPVL_!4RGMYO+?UEJ
M!PCN`D[IPHMB;+*S2XKRP2A`2EO36*\/W(S>.;0G;>RRH\>+77D.$,BW!^T<
M-TV*HJZIG$I1$?*.U78SW>[MOW=CA-[7)03:E#$QU6U)*--9)I5;5:MRHD^&
MED,5<E%:JCK9%E-I,,@FC'-B@<K@QBF45=%[/B=K*G,=5VKV8F3[9R<1,?A'
MAXA'3HKRC%V-QVKKMV,-B+:2S7)QE)/C=,N7O&S63RU7</I"4O<#2N/=PN&;
M_-)KNA2?"=%PW<:'.T4(54QP$`$3-B@7A`IA.JB111<_1X(F#HKIX66[;"AK
M6[FTBLZ:57I>GNAMO*?+D+:CYB)D(2::,9J,EVJ[*792S1&0:RK%TD9%Q'2;
M9RF=I(,E$CB42K)')H/TFO376M]J]^X-N6[+[L2::JG*.1YU6,EGX>!Z#'4M
MOQE7*:S;GV"W;@*<E,H<N;(#3`LZY6&2N/;+>*CZ6VI9;73'M7S0EM`9:2Q%
M<<B!CE0D8%0J`*F**C8"\0U[1V;]X6X>V=FWNGM%@;WK&WAU;6)CL]I.<<BE
M*4I-W$^%2\*3RZRHD]6Y8G9\*VUJ.5::%S&;-MV^&V,K7DXV_9;L.X-M6Z^W
MH=>5F<$9`4;<%SPL>(DD+UPS>3<2P64;!2,'$9TS,#EJ4VCA$F@F'C]NO=QC
M-U8=[WP.)L8S=D[[MJY94]77HI*$FTE&;33U7G5&FZT65J\IO4>26K4G`W<B
MX(FIXL[;D.3C-XTB"1D0$`$H*E`Y^$1`>X(@%>,=1OJ].U=3@H-IMYLE=&DV
MG2E4ZG8`?!*80#40`1`#`;01#70#!T&\^M/$:MC,U/D^R%E*U"RJI`J0*`4`
MH!0"@%`*`4`H!0"@*]PWUHUT-U_OB^]E\3(9JTP[_>\;T_ZINU7^?<@5[!OC
M_P!4[G_WY_C6RO\`U7R?*S:43K6\\OVI:\BN?OV]_P#F+?XJ+I9H]WXQ7,(%
M`*`4`H!0"@%`*`4`H!0"@%`*`4`H"O<'SP_;K)>(^5?E#A*5B!0"@%`*`4`H
M!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H`<P$2,<>G370.^.@Z!J(@`<0AI7
M0M6[?J^Y=K2]K43[G291N:CII(39@YA>T7`V0+[Q+EO,$)9N4L>XHC,SS%B.
M04/=DI9,PY=Q\2:S(PI!5O";EIIB9@A',14>J.#E$$^S$3AZ#V&]T7:KM#@(
M]H79N>JY7E"-UY(.YJQEJUUJII2572G&5W<9;3<5EDE5KAII(UV+@W*F_J8A
M<X;P;==8XP/%OF]PX9V0R#@5%7Q$S!(V_>.[1)F?Q2:NPQS).TK2`RK.)*)`
M=]LL)B%]#WKOG<ON\PMW!;BOX?&]H=64+U^,-:W933C*Q8VD(SA?MR3VE]97
M6.HXFJM?%TE=UE#@3>5\;I7)H1M3C8MLP:,V*3=L"<<@DA'$%%,4HXB:142M
MV)`(0C9F@F4"(I)E(1),`*```5^>+G:K>>^-ZS6+G<G;G+/.3DVV\\FVW+NF
M[LXPCX*1]O3A\$/I0ZA'43"(])A-W.D^NFG<J[>MG#V+\88;Q'!-\KSD)Y"E
M<P'S).,3DT'")Q(7M6RK<!$H'\%=)1)7C*8!+X2:@I\0>$5,Y].D0KO[DQ"M
MXB&,R_\``MSX/MEJ\/#Q\!+M:\>4UF#RT"IVV?#++<7D.-VCK7BG>RFUME`V
MR2W"$-<9+RDL8-\C';GOU+#<O=/:.'$/V@F,14R?'P=%>TOWI[LL8>/:F%B;
MWNUL]HVMGJ*.RHK>922^W7#EIK-LU>HW'X+:U._7E)8AMHM0N<KSSH=T9>4O
MK#4%@^=LQ9(GN/4M."N"8N5)9-!-,CLCA\XFUF3A'B\748#H(<?37!P?O=AN
M#=T=P:DME"3DGX-?"63+2N;@^4LE@G-ZSSD:[!Y>4M9#W%MJJ;I<N2^W/!]Y
M)7KBG;ZFP@(:/AUVII;V'M*Y<A1A4KRO3'=KH2QD8^&>G,W[))(JW:<`#6[O
M#WN=G-[8"?6,)-[ZN.DKC<-FH4C50MT\":FG)37`VJ+697'!78RR-:G=K6ND
MV0M$!;(%1,*9N`Q]!22*@F)1,(ET03`$D>@>DI`X`'JZ*\9WOC;6\-X7,995
M+=QUIDT9<U$N19C94=5:KSH[%<X"@%0"TY/!/J1(Y!#4$U"`HF)^Z<0/KX7G
M5]-C[T=UX"U?P#2O."D^6F700LKH\Q&S<5M6Q7NELY.V,E1BS.5@GQ)S'60[
M2=+V[DO%-VLCF5B;NQ]>C$2S$#)H*<(+H$.+)TD!DU4E"&,%?8^[KWC;SP-Z
M4,0XW+-R#A*W>BKMF54HN3MRJG*F12I6-7JM/*4W\/"=%F>E9'SD7<-;CLKX
M,RQ;^T'>I(,I:Z;O%RAMHW,6_$)0]F[A&$,15+WN;W9IG)%V+N":LT2+^Q@J
M>+3R!A79&*8!0#[KWD=D]U;QW)+?W8Y-;O>J[EMMRN8?7<E&-QI14XO4<HR5
M6HN*EERE=JZU<V5QY>\Z:.?GK0V5$<=B``X`H&*F85@1.58J!RG*GP'X-.'I
M-W@TTK\WX#=>+P]^F/:I1\F=JANRDFLF<[WG=/FATA\RLIK5FXZ&S$I6(%`*
M`4`H!0"@%`*`4`H!0%>X;ZT:Z&Z_WQ?>R^)D,U:8=_O>-Z?]4W:K_/N0*]@W
MQ_ZIW/\`[\_QK97_`*KY/E9M*)UK>>7[4M>17/W[>_\`S%O\5%TLT>[\8KF$
M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!7N#YX?MUDO$?*ORAPE*Q`H!0"@%`*`
M4`H!0"@%`*`4`H!0"@%`*`4`H!0%#&X>D0\$.DQOJ>D`#S]1&MS"X6W?MSG<
MN*VXTHFFZUY,Q9"&NL^4BWN)WH[;-ISNT&&X')"&/WV0$[C/9,?[FKUNR2N4
MUK$9J3)8^-L>VKE?$*R2D$#*'632(`*EX1,.H!]MV5]VV_NU]B>(W5'6MVVE
M+(LC;:BLLHY94=#6Q%Z&'='E(Z%YPG+N$50/GN11%%4$5"+82W!$4!7LDUA#
M@]ZH1X`*H&ANH:[TO<3[RYS:PF[IW8*F53LKO.[P9BBUCK-VM&E2FGA[A7Y8
M3EU>4"\^!3<'_113^0WO5^J;GZVQ^U+>LV?*7?Z#JON<1R[T4$>SSQ(O!<N3
M-_%V^$]P2BYBI-7#U82IEQ4)P-V#8P)B8"IG6$B8G*)P&NONS^GSWGXMZE_`
M3M6XRBVG.RZJJ5*J[D;;HN^5W,3:S)IU/R=;G+/Q#S)=]QN8->.^!]L9>V<I
M8\+A"RWFW//%[YC@[0Q3+2*UKWU/*L\?-+7M^5NM^\>/$([_`"U5JD)`55.!
MN$?W-V97:+L)V(M=B[W9J]CM;#MW9QQ5FW&$YIQE;:>LVTHPDIQ=,JHZJIS6
ME>D[D7JYJ.CJZ5R\F7-GSGZH[,YM6P.#MV':3VZ%]=,PG%1C:8N(V"-P<<>X
M)=DR2:24ZLP3Q6+9JZF'"8KJE2*4H',(!T`&GX&WQ[B/>S?WSB,99P%RYA;^
M(N75%W+.M%3E75E)WJR:6>7VV=G6MXBQ&TH-K67#\$>L^6$Y=7<W`/-?^A7<
M'_115+]Q/O04:6]S75<T[;#_`+4GK%GREW^@J'.#Y=?#J.X)X(][WE-P?5\%
M%2O<1[TH8?;8K=TU+6I3:6<W<NF-S%681UJJG=Z#J/.<CRX6"*KAYN**S01:
M.WZKF1Q5FJ(:)-(_LC/EEG<QCJ/013;)+`83',!-/W0=.FS+W!^\>.$ZV\#-
M_<J5IM\2I=S]PKL8VU?GJ1^'>1L=MJX(J[K>A+K@'B4C;]SQ$;/V_)MS"9O)
MPLNS1?QDBCQ`0X)/&C@IR@8`$`'IKRYX;>'9];PW9O;#RM8S%6U!)RB]11DZ
M3>K5/6IFJFN$ZCG&W2"RTS]W@/K]F/9\'%T_5:>;KU:]ZOF[F'OW.RUOL^KE
M,1"Y*3NTR-.6M35SY,V<RZQ'7UJ9#EZ>_7<OW\%B9JY=LO::L4WK9Z)*N;A,
M-JM`Z?V:UJM8/@MM?_(;5:!5;U:^"J1*I/6E45!B*`4!XR]\@VGC2V9J],@3
MT'9MG6^U6>S-W75.P]M6O#MD^$J:TQ.3KV/91Z2ZQRD*<1.7B$.[T5]#V8W'
MO7M+BNIX>U*<VZ1C'PF]%%D;?$JF5]6[$5-RSJKXN^^_0C(/,9V`::%WO;2@
M-H41+\8/&'$41`!$HA[HM/!'HKT#>?N1]X6'M;3`;OQ;?!2U+IJ:MG%X:ZZ:
MRYT80SON7Y6FY+'-R8ERYN^VASUCW2B51TDGN)Q[%ST).,C)NH&Z[1N".NE"
M1MFZH&3(#EJ_:G3<H*E`2'+J?B^Z[`=D?>=N+$1O8S=6,N**U=65KP6FI)J4
M9)QEDD\K3IP%%[$X.3HIQY\I&O:-S1\!6)=]V;0]RV]/;OD>Y<8VTC=N,=TY
M,SXM"R<Y8FE)0\-;[&^I]K<*3&*SW;BJ'9S\>5,Q'($&03%-)8J1?H?>)[GM
M][VM6\9V;W=BK%F\I-V'"5R[8>LZ0N3U81FG12MR57JRU998MO"SC[2D]HUR
MU5'QK1QFP'Y1K8`7P?CM[3.CH_[0.,"]71]+[I!T\ZO$'[FO><G1;FQK6G4S
M\><V.NX7TD.?[`^4;V`>6WM,_M!XO_2.H_DW[S_J7&^9]D==POI(<_V!\HWR
M_P#RW=I?]H/&'Z15L_R4]Y?U3C/,^R.NX;RX<_V!\HYR_P#RW=I?]H/&'Z14
M?N5]Y=/_`!.,\S[(Z[AO+AS_`&!\HWL`\MO:9_:#Q?\`I'6M_)OWG_4N-\S[
M(Z[A?20Y_L%0YC>P`1`/CM[3.D0#_M!XO_2/2K+/N8]YER[&W<W/C(0E))R<
M*I+32N6AC+'X6,7)3@VEI^P99Q?NAVX9PD'D5A3/6&<PR4:T/(2D=C#*%D7S
M(14>1VBR,^DVEN3D@HR:@X7*7C/H41$``1$:Y_:SW<=H.Q^7>EJ["V\SG;E;
M3Y-9Y=.1O(,%C;>-C6%%W:F=].C6OC,+@XXFQ.]KJ+C%NE&Z\53;NO924<]2
ME:1(H!0"@%`5[AOK1KH;K_?%][+XF0S5IAW^]XWI_P!4W:K_`#[D"O8-\?\`
MJG<_^_/\:V5_ZKY/E9M*)UK>>7[4M>17/W[>_P#S%O\`%1=+-'N_&*YA`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`5[@^>'[=9+Q'RK\H<)2L0*`4`H!0"@%`*`
M4`H!0"@%`*`4`H!0"@%`*`4!QJE`2:#TE$Q2B'2&O$8H`.NO[D:LMX&YC*N#
MI&-*]U\J+8244V:S<_SMJVOS,MEMYWFNQC[5L[:=OHO"Y)*41*ZC8>'MEMB)
M_)3CI!1,X"$9'(K&U#PP*8V@"&M?TA_I.NX'!;IO]8@FTH)RT5U^)YZ4/E][
M7^#+1Z,G"JF1<6[U[BO8UBW?<NR"_P"R<#9:C)=]C;-4JYL61.V;QEN25SPT
MIF:U(]JJ^Q3:ETP<4HLTF'"SMFW$Q".A1$Y=?VK<W@L3)RW7;VEN-7++J)//
M1*67+Q5/G;F*FW^;K')IX>`^G9G,OV03Z^48^Z+JL"QI3#SC$,7=Z3]]:LK'
MR$_FJQ(N_+,B;'?QK4Y[S)),I/LVSIHD+5YV1SH'.!%`)"EO=_\`^7_^R)4L
M3B.&3)#W5N0VW06,I+*L'.X_NJ.:(9#90K.%4MM1[=UR8PAIRX+UL:&$R*"J
ML]#-;8='7;#PF(*`B8H@`A6I<CV@NXF,,-8U<F5:T'E;HLK)=^[2K;;H8!Q?
MS"MO]]H34[==I6SBRTX`J\E-W;DB<L>$,PA?>?QOE]2;<1BA4WB[&*C<B(,)
M%5,!*R<H!Q<0'#3=N83M'L4]DZRR*LH<#<=.FJ[Y"OWJTJZ<IE..WP[(9O&]
MV9<894QB\L"R;J3L2=F4$8T3H7FZ:@^BK8CXE6,)-2LM<C752+2;(*GD$RB=
M$#%`1KG65O\`LUMXC#UN9ZZ\%D[@V]U9I.G*R2.-+DQ-F&RX3(F-5;1O&R;D
M:E>P-R0;6$?1LDV-J4_9+)L_`<-5BF272,`'16(8A@`0&K)8C>T'1X=U^_B3
MM[OE,]X-LV^0/!@H8#_4C#Q(Z!W.GQ*HN3WI=L^!;U+E?*B_CR&%Z]>=NNM*
MG*0UYAEO1'Q#]XYD(B(04)MFS8!7",1%D<(<>/YPHG04!K][4*;A,`@&H"4!
M[VGQ_;>7:7#=G+]W`P4KD;;;7YO+R5R+E1C@+TW=RMU3JN7N'%M)`WQ6-MQS
M`F`*X'Q$J3@*8#"4V/[>Z5S&.?M%Q,`\1@`H#W@K^/?O%Q6\L7VHO7M[14,;
M1)KP<R;H_!I'-H/1L+-W+"D\Y(2OAC8%`*`4`H!0"@-;W-G;-7O+ZW$MG[=-
MPP<AB9M)-=!`'S)3.N+$5&R@'[1(2+-554E.(A@.100TTU`?TK_3'O'#XSMA
M#"7[:E&$Y+FB^+.<;?ER]##MQX%\=#TF5<E;:,:9#]X_&FPA/<ED2S\=VUD#
M)45B3&6$6;''5IS;5[["(34UD.5M&.?7I/MXI5Q'0319P_<LP!P8$TC$,;^K
M-C=FZ_5\)W8TL[-/*Y9Z9,TJY=)\K8OWM=T;4JGO,?Y;Y8N0K1QU=S2*VNVP
MGDZ`=7!;MMWW;&,;.O9)O$'DF]T-Y:T;@8,IN,=6@_B5VLD55(H-G")R&'P>
MG&.Y]T89:\843RYY\.;[;X4*)7[SFT]/$?4>7CR^UK?F+CM:TMLF0+5MR^$[
M5O24L]CA!W$V1+N(I('RDTN_<1[4\@YB4RH@W9>-/W2*79I)&.0P!FL/NFZV
MDN_/I[ICM[V;H,(XUW=\J+)TI9C&,A=M-N1N0L?VED"R+GO.V,06U;-V)7G/
M2UMQ5GVW*ORE1E;]0E8DY'463[\V$P%/]\`2!;UG=<7J)UIDS2X#)8BX\B3Y
MS.\]=7+WL;W3J95L_:SB%K;%[R-CF=9&9X,A$YE]%A$E=.(I--5VXZ',R@B+
M=P1!RF<P=H0@"`BZSNU5555<4L]:$J_=?`^<]7**<ON$R#;>*IJ"VF1&1[T9
MMY"R['DH;%#:[;L9/&YW#1>"MLT>,P_!V0@]CP(B5P'2D*E4/%[NKF_&Z#':
MWN%/G,[EVU;<S%*(X$PR'$4!T'%MD@(:@`Z"!H,#`(:]T`&I6*W?7-^,-K>7
M`^<I\6?;G^H7#'P761[25;UK=NE<TC+;W=#YQ\6?;H/0&!L,@(@(`)<7V0!@
M$0Z!`?83H$.Y3;;NO?FE1ZV2GA<(5ZXW1IT?&:O(7'UCV!SD;KB[*M&VK28O
MN72SD)-I:\'&6^TEG:6?;79(/9-M%-6J3F02;@8H*Z`(D-II7XN_JBW3N[=V
MX[MRS&C=V%563R.$E2K;SNCY4?5[CK*2TU:YC:'X0Z:=7=^?TU_-7`N_.5S4
M_1JNC,=_%44HZ2^M@@4`H!0"@*]PWUHUT-U_OB^]E\3(9JTP[_>\;T_ZINU7
M^?<@5[!OC_U3N?\`WY_C6RO_`%7R?*S:43K6\\OVI:\BN?OV]_\`F+?XJ+I9
MH]WXQ7,(%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"O<'SP_;K)>(^5?E#A+-5/2
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M+&^B7G(;1:"TW&;A3$O")SAPZF#01)H<`$>C0!$-*W]WX+?.)NJUA;<$FU5N
MY"/XS52V$-K!R635-*G,*O/!EI;T]JS3<IDZV<)XAR)M%WYX;F,FWG+LK>MV
M(E,I6QCB#002GY)=",:3!XMP\%L18?OIDQ``UK^DW],N!]38*:QZL2D]GGO0
M2RZ]4Z-Z:)\?%D^4WQAIQ=5F5?C^R8;LWF&6\%B8^V\7IO\`>6E:N-,=65(6
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M>SZ1M>XH(_,GV`'5?VA>MN_Y;F>/[=9S<^WO`.'%#R8*1:IC)JR>+)%<P`!@
M4*X05`@B<2EMGOO?DK*M]?M:J=5X5FJ>>O.^0BE]*NR[YF?=5>6PS,.0+JR3
M8',9V6PZT'DW`]_V791-STCB`USLL88>E<9SK"X[YLEHXD+/N206D$C14DU9
M2"*";<W:MC&$.#4LX[>EE/:8ZS-U\JRLCRM9WRDRVR3_`#7?^P;`MAF]+EN[
M4MOD?BRX=]>S1K<3F[[SOR?C[,SXI<]O1DI?4RK.KQ[.Y;ZFW=R7"LW!<`</
MEP0%VXXU>Q3XN&K)8G%WTKES%V'<?#KVLW`LY,88AK6C;HN4F6;FS<L<-!#?
MEM<#OA[[UI#W>CI\?&J)6,?>FIPWA:A#R4[+[[DF6JQB)QI*WWU]@BCOHYH7
M+NO79INHLRQ]Y^VZZ+NNO;[EFWK;MZ$RI;DG-7!.2]CSK6,AXB+9.7#UZ_>/
M.S(4A""(B<-*^<[>7]Y0[/7<-@<39>)G!QKKVJMNBR*K7.UG,K%BY8NISCD6
M6E5\G*3.VGE<);6MMR"S51!9O@C$S95)8R8*%4;V+!HJ`8A#'$@\9!\$VA@[
MH5_'KWGX'>N%[77[>)E'$7G%2<TX+.WD\%M9#Z_#7E*S%ZNJZ9C/^JGI?V0>
MA7GVRQOHEYR+]HM`U4]+^R#T*;+&^B7G(;1:!JIZ7]D'H4V6-]$O.0VBT#53
MTO[(/0ILL;Z)><AM%H&JGI?V0>A398WT2\Y#:+0-5/2_L@]"FRQOHEYR&T6@
M:J>E_9!Z%-EC?1+SD-HM!KIYKYQ/R_=P1.R4."CG$:)SM^S4%`X9WQ1H"H*'
M2*&IA#7IZ`K]0_TM6L='M;"3P4=7:2\/:_<O@IPYLAI;UDYV*)5=-)Z6X[&W
M38!W(YLS=A#"L9N2L+<W:.)G$Q:R&3;9QI=6,<GXNL./Q^R</U;XD(V`N+'E
MS6\S;J+`Q,YDV;A-4R;5R50J8?U+WCA<9B]U1L6[:C><%DUUDJN;)F/A;^(O
M89IPM*:576M.X0ZM_E<9QA[*W(-[@-BV[<B9PV/;@L;H7!'O$(N)@]QFY7*>
M7,HW=:=L(.HF-5CK)C_=XQ:H2JS1!RL@B;5-/I+75O7L!?PEO"WI.W<A&,99
M&\T4F]&=9D7N]M?SCA1O*U7O&1[UY=^1%\FV_,6!:6+;8L5A:.P2*=Q<6]:V
M\S2D-N\IE\N1BC#L$B-Y)I"0-_-3,.VXCN%``#F4*0I2Z-C#;LM+6E?DVFZ+
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MFK)VJ<$W:B``H<_2EBMP4UHPS5R-3=>[541K/%R]#D^^/TY\:IM!`_0(!IQ@
M''IH&G'H73BTZ].C6N7UC`M95EY&3'$O(MEDY?L%VJOU1?G?_-JK:;MT/F9L
MZZ\GOLJ`JZAJ8NG=Z.YW?W-9PG@'-*">O7)GSD.:IDCE[II\FCZ<Z"XRD\)4
M_+>;'(GV:^G9CN(ML!$3D2,0N@F\_O\`17XA_JTW?C7N*].,]:N(M4S>CEDR
M';W)B9V[R@X9HOAX:I/,F;&BB(%`#%T$>YK\T.D`K\`]F\/=6[L3K6TYJW*G
MA+0?6W+>V2N5I1%FJGI?V0>A7!5K&T_1+SD4;1:!JIZ7]D'H5.RQOHEYR&T6
M@:J>E_9!Z%-EC?1+SD-HM`U4]+^R#T*;+&^B7G(;1:!JIZ7]D'H4V6-]$O.0
MVBT`3*``_>^X/[H/0K9PCQUB^KBLJ3S4UTL^0;3B-7.'BB7F[[U.C4P;3MJW
M@^9[.W]H.O5TB:O9M[6\8_=E@L+*TE+"XB7VR\)-6IUXLK:IES5*=J]L\F35
M^5Y#:,43^&/!TF$.CB#HT``Z]/,KQU2Q-WKF+5M:V)NQEJZR\'55*5X>9%SN
M9E3,-5/2_L@]"M+98WT2\Y#:+0-5/2_L@]"FRQOHEYR&T6@:J>E_9!Z%-EC?
M1+SD-HM`U4]+^R#T*;+&^B7G(;1:!JIZ7]D'H4V6-]$O.0VBT#53TO[(/0IL
ML;Z)><AM%H&JGI?V0>A398WT2\Y#:+0-5/2_L@]"FRQOHEYR&T6@:J>E_9!Z
M%-EC?1+SD-HM`U4]+^R#T*;+&^B7G(;1:!JIZ7]D'H4V6-]$O.0VBT#53TO[
M(/0ILL;Z)><AM%H&JGI?V0>A398WT2\Y#:+0-5/2_L@]"FRQOHEYR&T6@:J>
ME_9!Z%-EC?1+SD-HM`U4]+^R#T*;+&^B7G(;1:!JIZ7]D'H4V6-]$O.0VBT%
M=5-!^]]T/W0>;YE9*UC=1_FEG7VR^Z&T5<QY[W6VS^4UL_G##_QRN[[-]O?H
MD^?_`"FSUK#>4/=;;/Y36S^<,/\`QRGLWV]^B3Y_\HZUAO*'NMMG\IK9_.&'
M_CE/9OM[]$GS_P"4=:PWE#W6VS^4UL_G##_QRGLWV]^B3Y_\HZUAO*'NMMG\
MIK9_.&'_`(Y3V;[>_1)\_P#E'6L-Y0]UML_E-;/YPP_\<I[-]O?HD^?_`"CK
M6&\H>ZVV?RFMG\X8?^.4]F^WOT2?/_E'6L-Y0]UML_E-;/YPP_\`'*>S?;WZ
M)/G_`,HZUAO*'NMMG\IK9_.&'_CE/9OM[]$GS_Y1UK#>4/=;;/Y36S^<,/\`
MQRGLWV]^B3Y_\HZUAO*'NMMG\IK9_.&'_CE/9OM[]$GS_P"4=:PWE#W6VS^4
MUL_G##_QRGLWV]^B3Y_\HZUAO*'NMMG\IK9_.&'_`(Y3V;[>_1)\_P#E'6L-
MY0]UML_E-;/YPP_\<I[-]O?HD^?_`"CK6&\H>ZVV?RFMG\X8?^.4]F^WOT2?
M/_E'6L-Y0]UML_E-;/YPP_\`'*>S?;WZ)/G_`,HZUAO*'NMMG\IK9_.&'_CE
M/9OM[]$GS_Y1UK#>4/=;;/Y36S^<,/\`QRGLWV]^B3Y_\HZUAO*.NXO6UFY4
MQ-<UL"954J*1!N2%(*BI@,)2%,9V(<0@4>O0*SAV8[?3=%A9T2J\O!YHZUA^
M"1TW&1[%8&*21O6RHY40\)![>-M-E2F[WWV2*!N@*V;/9;MU-M=6N9/A7Q:?
M*8O%6%PG7]];&?ZQL>_GW:GMK6Q[)=N_H\^==!'6[&DXU,J8O-P=ID?'P`4V
MN@7S:AM0TZ2]$L&FM<_&^[O?^\W"6^<#>N[-^#2,I4T^)2G=)6.M0KJR67C2
M^,\I.75@^X?$23EXXDFF[`CHJ*,S<%E2I4E'!!*5=$CZ56;$51$=0$R2GF:=
M=;N![,;WW1#5PV[<3K15(O9W,F7[UUT92B[=LWG635.5=)YXSW;<BJHY%Y@4
M[E955<>!SC!N#]X8BC=JFX`RIC.7"B*A4Q$ZA2F!,N@%TTK9F^UUS>>'3W?B
MNKQ>7\U-U;DJ?Z?RT-=6,,LJU4N5=/V#75BT<`[B.8+F?*KQ7$##%FRRV&FV
MW%$2X]PJ4!/YCOR/@+YSG>9FZJS8T@M:D$E;UN,U=%T"J(NU$U`.90@>[;UN
M;PP78BS8ANW$O&8RM[Q+CI"T[EF%5L_!EM%=JF_"BH3I1IOGPC:N7Y:M*P\'
M+19<C>=T?`;(E%MM@*`IXY@UN8')E@%%QCA(YR&5*NLDHHH(G.5PJ)P4T$.)
M-0Q>[K7Y^P?M="=YW=W8K+/P:VIYLC]&=FS&S"%*QYU\C+!<;:N`2>-X&,(&
M*=-157&JBW&GP=D==3MB^,"F"90#4`Z"E`>JMMKM.TEZOQ5$J?HYY<^5^`75
MM976.7CS=\Y@?[:P5.<SK`RG&"9>T56QJHZ%,G$(IJ.3*B*I1.<1+J7P=1TZ
MZS;[3:BA'=V*5'GV<VVM'Z,C\UK5;C317)\9R"_VR:B('P(773J7QGQ#H&FI
MS&$W$/SM`JMQ[4?:[OQ2_P#XY_,)6QX=5]U])3V1VR@/T^!AZ.OQC&-:U>V%
MO$J4,!B]2GHI_LS&4</++X*^'&SC4>;9SJ$.1;`92\)BJ%%;&PJ&`0$OWI0B
MZ8(CH80$0*(B`]?56QCL+VCWC8V5_=V)=53]'/YA6H6$\Z[W2>V99/Q@V;E2
M3R/CTQ"F-PC[N+33T+KX!.$)7A`$TP`H:``:`&@!6A@^R/;/JZZMA+L+>7(U
MJOEI)5S47<+%B+%OP=8[?OK8S_6-CW\^[4]M:V_9+MW]'GSKH)ZW8TCWUL9_
MK&Q[^?=J>VM/9+MW]'GSKH'6[&D>^MC/]8V/?S[M3VUI[)=N_H\^==`ZW8TC
MWUL9_K&Q[^?=J>VM/9+MW]'GSKH'6[&D>^MC/]8V/?S[M3VUI[)=N_H\^==`
MZW8TCWUL9_K&Q[^?=J>VM/9+MW]'GSKH'6[&D>^MC/\`6-CW\^[4]M:>R7;O
MZ//G70.MV-)$W>O"6_N;VP98PC8N8L+6]>%Y(6TG;4Q=M[0CVVH^6M:];6O5
MN:<:1,@L^5:N%[9*D?LRF4*503``B`%'U#W2=H.W/8SM#9OX_"7>HJ^HMIY4
MGDE))6W743UEP3:I59S4Q=ZS*/@23D^//Q9S&J68>9.BU:(HY8Y4:BC1-!,C
MH<CYE#C*@D1%,13)!HIF$I2B'2'"(_N0TK^@>#]\V[I6(VG=QER<536>&FF^
M.BAPYSYBYA[CDW%)1;;IK+AX*UJ5]^WF5D(5$F5>5,4@"**VF1,T%%1D4#@D
MW3!"!12;K$[0=52%#BZ/!#0*YMS^H3L9;F[=U8QW4Z-]6O9UG^T-&6#Q.L]6
M,*5\N/2<PYSYE(@(FRARHC*\*A"J#D/-0E!)4A!.F*8P0E,`N"B<1UZAX>YJ
M.']PW8CR<9_#7OFF/4L5Y,//CTEP9MYF`G(=+)W*J77.0YS$1R+F<O$1),Y4
M6Y3&@%#)F.HJ)A5`!$.K00`!K>C_`%#]B:I;/%..3+L+U=7A=-7.N!<)GU#%
M/)&,7)KRX])'S;=OVYANY#'[R^H2Y.6?9$I"7O?N.[IM:\,BYA3F[>O'']TO
M;<FE5$D(<[)_$3<8V:R#-9N<Q"MW``/WWB*&]O'W[=D]W7G:O6L3XT:?F+U7
M"4(SC.FIPQD^1IJM3"SA,1>@KD5'5JUXR659\YG`V8>9.9-3L\K<J5-198RA
MEB9#S0)@04<IN!01/[`$72(4I1`FAP(!AXA(/24>)+^H?L+5I1QFKEI_PU_N
M?:U[AT%@GJITC7)]NN[P\)]/W\^9;^M/E3"&H]`Y$S&(Z=X1]S@:CIUCH&M/
M[B.PWDXNO_*WOF$/`RRT4?/7SA[^O,I_6CRI/A#S+^CM/[A^Q'DXO^%O?,-'
MJ6*\F'GQZ2H9TYE9A`I<H\J/4PZ!KD/,NFH]`:_\G>JL[7]0?8V]<C9LK%QO
M2:2?5;N1O,_$)A@L3K*L84KY<>D\MA>T<VCO%NK=7N>SCLT<.)';HUV^V[:V
M![RG1.`HY!C;]<S\H]O@T*JBF16,%L5!(IM2FXQ-T<(_GKW_`._M]]I]V]5W
M(L1BKEZXVY3MNV[;@M6,%'4\)33UG-TU:4RMU7T&`V5F2<TDN6K;>DV+!E;&
M8CJ.1L>=?Y>6G_@]E:_'&[^R?O$L*45AI[.7&OFGT+QV&6127P[IR^^MC/\`
M6-CW\^[4]M:VO9+MW]'GSKH(ZW8TCWUL9_K&Q[^?=J>VM/9+MW]'GSKH'6[&
MD>^MC/\`6-CW\^[4]M:>R7;OZ//G70.MV-(]];&?ZQL>_GW:GMK3V2[=_1Y\
MZZ!UNQI'OK8S_6-CW\^[4]M:>R7;OZ//G70.MV-)8IE?&H$.)<B8].;A'A+[
MO+3+Q&TZ`U&5T#4:SM=F.W&'N*[/#SU4UPKH'6[&DUA8HR7CUIS8=Y$ZZR!8
MB$<^VI[9&R+U6\+>1CS'C)V\2O$RRZTB2,7515=E*)"*"8-.D`KU[?>X^V6(
M[#K#X?#7'B5?E7,EJ[.W1IM4?A*61<&4UXXFPIJKS5?.WTFRL,Y86`/OF9,2
MD/Z4;)5E`H/F``S6@Z5X?N_L7[Q%"5R>&GLZZ5\TVGB\-P2'OZ85_7!BGX2[
M(]O*WO9+MW]&N=[H(ZW8TCW],*_K@Q3\)=D>WE/9+MW]&N=[H'6[&D>_IA7]
M<&*?A+LCV\I[)=N_HUSO=`ZW8TCW],*_K@Q3\)=D>WE/9+MW]&N=[H'6[&D>
M_IA7]<&*?A+LCV\I[)=N_HUSO=`ZW8TCW],*_K@Q3\)=D>WE/9+MW]&N=[H'
M6[&D>_IA7]<&*?A+LCV\I[)=N_HUSO=`ZW8TCW],*_K@Q3\)=D>WE/9+MW]&
MN=[H'6[&D>_IA7]<&*?A+LCV\I[)=N_HUSO=`ZW8TCW],*_K@Q3\)=D>WE/9
M+MW]&N=[H'6[&D>_IA7]<&*?A+LCV\I[)=N_HUSO=`ZW8TCW],*_K@Q3\)=D
M>WE/9+MW]&N=[H'6[&D>_IA7]<&*?A+LCV\I[)=N_HUSO=`ZW8TCW],*_K@Q
M3\)=D>WE/9+MW]&N=[H'6[&D>_IA7]<&*?A+LCV\I[)=N_HUSO=`ZW8TCW],
M*_K@Q3\)=D>WE/9+MW]&N=[H'6[&D>_IA7]<&*?A+LCV\I[)=N_HUSO=`ZW8
MTE??SPMH(^^_BG0!*`C[Y5D:`(@;0-?9SK'2LUV2[=ZC_P"&N9UH^ZXB.MV*
MYS19\F]L5\G"VOSNR;^F]?Z+/Y<=A_JW#_A_./A-:[Y<A\F]L5\G"VOSNR;^
MF]/Y<=A_JW#_`(?SAK7?+D/DWMBODX6U^=V3?TWI_+CL/]6X?\/YPUKOER'R
M;VQ7R<+:_.[)OZ;T_EQV'^K</^'\X:UWRY#Y-[8KY.%M?G=DW]-Z?RX[#_5N
M'_#^<-:[Y<A\F]L5\G"VOSNR;^F]/Y<=A_JW#_A_.&M=\N0^3>V*^3A;7YW9
M-_3>G\N.P_U;A_P_G#6N^7(?)O;%?)PMK\[LF_IO3^7'8?ZMP_X?SAK7?+D/
MDWMBODX6U^=V3?TWI_+CL/\`5N'_``_G#6N^7(?)O;%?)PMK\[LF_IO3^7'8
M?ZMP_P"'\X:UWRY#Y-[8KY.%M?G=DW]-Z?RX[#_5N'_#^<-:[Y<A\F]L5\G"
MVOSNR;^F]/Y<=A_JW#_A_.&M=\N0^3>V*^3A;7YW9-_3>G\N.P_U;A_P_G#6
MN^7(?)O;%?)PMK\[LF_IO3^7'8?ZMP_X?SAK7?+D/DWMBODX6U^=V3?TWI_+
MCL/]6X?\/YPUKOER'R;VQ7R<+:_.[)OZ;T_EQV'^K</^'\X:UWRY#Y-[8KY.
M%M?G=DW]-Z?RX[#_`%;A_P`/YPUKOER'R;VQ7R<+:_.[)OZ;T_EQV'^K</\`
MA_.&M=\N1<7EQ;&B`;LMNEN)F.42"8EXY2(/"(@(AJC?B1AZ0[HB'F5*]W/8
MB.5;MP]?_G\XC6N^6SOL^7CL59)`F.U;%;]37I=2Y+LF7IP^I,ZE+H>*"7N]
M_7NUA[`]B\++6ANS#M/(_'^<RNY>O02\)G>+R^]BQNK:3AD=.O2&E0^VFPK:
MM=BNQ$W26[<.O.^<5=:OZ2[Y/C8OY(V&M?\`^#R?MY5\^QVXL-3U'AK=FOCZ
MM<NBM6RF[<NW::TFJ#Y/C8OY(^&_Y'D_;VLX=G=7QK47W63&Y.*IK9C`^X_!
MG*YVIXKN/+69]OF`+*MZ&C)EU;_L[%3:2-W7Q#04G<=LV+'F0EU`-+W.O#J(
MH%4T3'PA$?!"M;'[OPF%M;*[8A&<UDEK.JX*YZ9,YD[UQY6\B/$[&^79L_0V
MC8#>WQ@+!61[[G;%;W5>]TLG"EUH/+IO9^^O67;I3,+.HL%VL8YN(6B).)15
M)-`"'-X(!7/P^X,#*[M-=N+X*9.#C,5<GP,E:'+WV,?NMH^&?,X8:6#Y_'<*
MG[5=R>XL)>2>&M1U4J/*\_.8NY>?BS:YBOR>^Q;R1L-_R/)^WM5^SD?0QYV1
MKXCTDN\4'E\;%`Z]I6%R?7P\KJ/G:3@U?;[-X#5_XE*%S0JO)W62IXCTDN9%
MIN7UL4+_`/I+PL;7ZF&EQ_\`ZY5%S<>[8ND55]WI&O?])+O%`Y?FQ7R2L+_R
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M:UWRF<1N7SL9.8XGVH8:5(=,J($5A)?5%,@B)`:J)3J)T#%$=>+41&J[_N_[
M#7XQ7JK#1:SOP_"Y?"15LY5<M9U9<;E^;&3F,=3:?AE0YAU.H>%F#',/U1C&
MG1,8WFCK6%KW?=B[3K'=V'_#^<6*JX:G#\GQL9$?^RAAH/,]@Y7H_P#YW55S
MW8>[=MSGN;".3RM^'E_#+/6*61VHONLXQY?6QD!T^*IA;KTT]A)77^?.NM27
MNW]V<<^Y<'SS^</62]%#G9>/+^V-"02#M5PR4_455&)ET5"%TT$@"2<Z0$*L
M7NK]US>M+<N":T5G3\8>LGZ*/.R&U@[(=FMM[WMQF&I[;EBB5@K\Q+C3<AB*
M(?0[P6%K>Q[AS8.6("VV[61:?\3$DVS!\JD<YCG=+G4,/55^*]VWNZQCA+$[
MIPD[ENVH:S<ZM+Q:^$O%5(JE,F<Q6\=5M*U!1?&^Z3%'E];&#B)_BIX6#B$3
M:>PLK^ZZ?_7GFUI_RW]W"R>I,'SW/G&N\5)Y:(I\GQL9\E/"W\BROMY3^6_N
MX^H\'SW/G$K%23K1%?D^MC7DIX5_D25]O*C^6WNW^H\'SW/G&SZR7HH<[*_)
M];&O)3PK_(LJ'T0G*E>[CW<Q>M#<F#4UF=;F1Z?&(EO&L6E;BGIJR\.7YL6'
MA,KM/PL944"MUUDX>42572)TD^^&F5C)F`0Z3%Z1#HK.'8/L>I:UW=]B?+K?
M)(T7>F^$Y/D_MBHB'_5-PIYP0\OT_,]F^NNA9[&]C-96_5F'47DSRS<Y7'::
MZEK.M3F^3\V*^25AC^19;V[K8N]@^Q,7^;W;AVO_`)?..AKW?*93Y/W8KY)6
M&/Y&EO;NJUV&[%M9=VX?\+YQ.M=\IE?D_-BODE88_D:6]NZGV%[%_5N'_"^<
M1K7?*8^3\V*^25AC^1I;V[I["]B_JW#_`(7SAK7?*8^3\V*^25AC^1I;V[I[
M"]B_JW#_`(7SAK7?*90>7]L6`JG#M+PP`BBN4!&%EAT$R*A0-H,WT\(CK7/W
MI[O^Q=_!2M>KK$:M9?"X&ONC&=R[&.MK,AACS91L^^4+W,66?;3B1>TK:VQ[
M89Z#MMU`.'D+&RLM-WDA)/&T>\D'"`K.P2`3"H"@>9T`-;>&[-]DUA88)[LP
M[MP;JZS\*O`\N9<%,N1593UJ[ERY2<X;'MEI3!P;3-O0!U>%C&`.8/..9'4.
MJNA'L=V-V&HMV8>CIPS^<90OW9O5JR_XD.S#R3MOGP90'J%4^Q/8SZLP_//Y
MQ;6YY;'Q(=F'DG;?/@R@/4*>Q/8SZLP_//YPK<\MCXD.S#R3MOGP90'J%/8G
ML9]68?GG\X5N>6Q\2'9AY)VWSX,H#U"GL3V,^K,/SS^<*W/+8^)#LP\D[;Y\
M&4!ZA3V)[&?5F'YY_.%;GEL?$AV8>2=M\^#*`]0I[$]C/JS#\\_G"MSRV/B0
M[,/).V^?!E`>H4]B>QGU9A^>?SA6YY;'Q(=F'DG;?/@R@/4*>Q/8SZLP_//Y
MPK<\MCXD.S#R3MOGP90'J%/8GL9]68?GG\X5N>6Q\2'9AY)VWSX,H#U"GL3V
M,^K,/SS^<*W/+8^)#LP\D[;Y\&4!ZA3V)[&?5F'YY_.%;GEL?$AV8>2=M\^#
M*`]0I[$]C/JS#\\_G"MSRV/B0[,/).V^?!E`>H4]B>QGU9A^>?SA6YY;'Q(=
MF'DG;?/@R@/4*>Q/8SZLP_//YPK<\MCXD.S#R3MOGP90'J%/8GL9]68?GG\X
M5N>6Q\2'9AY)VWSX,H#U"GL3V,^K,/SS^<*W/+8^)#LP\D[;Y\&4!ZA3V)[&
M?5F'YY_.%;GELY`V1;,>R.'Q3]ON@G2$0][*`T$2E6`HB'8]8<0Z>?4>Q78V
MM/5F'IRS^<*W/+9)VOIB10"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H"@CH`>:
MHD3S@.H4@CYX`-1*WM(OB->_F1&;.>2LVP&4=L^%,`6?BZZ;^W&7=D&VFSS+
MDS<T-:MMH6)8<K>QWIU+4.22<K/BQG8`300#CUTKXS?&\^H)R=4D:S>4R6EM
M[YLP]F"]A[!$$S]HHHZ]V^;S`V3*($X%FP.>%02B/$90JX!PB``36OE+?;_$
M8*35BL];/G^1_&*-Y0&WKFU&XBAC[8&8R:A"G.7(.<!2`H]!A$`(*I5#?3%*
M)=`*(>$(U<_>;O!9X=]])-")F]_E<\SK?/MJO;;CD*V]BEI1UQSMI7!!7E;M
MUYBEYNU)RV)I%VTFX]C.)A'*.5(I=ZS4!0!#Q=TH)?"`M<W']L\1O6<97E1P
M5%GX>Z1)55#-N'-D?,MP;BRR,-8FQ!L!MS'&-K?:P%KP;?(&;52MDB@+QTY?
MJ"H8ZDI+.79ES*"(@*9B`.FE6X?M'"W2-:)461/Y`EH,D#MWYMHB`$Q]L",8
M"E$Y1O[.)3$$W440("NO5U]`=[6M]]O,1@%J89.49976JRDT'Q=>;A^KO8%\
M(&=/4:Q_F7O'R.^^D%P;>.;>7A`<><O\H""OAGO[.)P`X$U1+H9'70ZG0.G4
M%4S[=7L9<5R_5262GP8RF.=O64,M7U.;A\?YQL['MFY*V\9O-B&:1Q?+7%,6
MC-MUK0A[L8SC1S<Z*4D1=5"5X#D#4@</7KK7V>YL<MX0C.+R22:KQD(D@4=2
M%-U:\71YQA"OK-39K5-NQXO=*T+A0"@%`*`4`H!0"@%`*`Q_E>_6F*\6Y.RF
M\9JRT9C3'UWW^X8-#`DK,(61;[ZX)N(;O5?\E:/BMFI2E%3P=3#KU5SL;B';
M@^"B.>\[,/V#*\R3)%CV;D*W.77906W?5I6]>L`[FMWEIQ;Y>'NB+:3$2G(1
M1,=/5(R5.T>I]LD*JI4E!$O&;34?.\;VC@KCMQE5Q;KRHBC/7%MWF?F3)Q<N
MK&B9QXS*''>?:QTB`3J;BF7%@+%=*#T%ZR"(ZZZ54NU+S5X-)"J8`NG;ES1[
MFW)86W$Q&P[&-O/,58]ROC^X;9=;MK?6D+LM;)GL<M&LD)A+'!8]!>$GHX79
MRG*8G`/4`T7:NE)-Y"<IGLT)S0#*'TY<^.%1[1=(R:&\NU!$BR1@,5;M#8RX
M!8O$C@*)M.(>$=>Y72]KL+2NLLWPX1E+BP/,\$ZA/DZ<<G.D@JHJW3WEVN59
M,YG/9LR]H?%O8J@HW`3F`O3KWNJGM=AJ)U64C+W>4O\`<WS0_P#5SXU_MFVS
M_194^UN&\I?#NDT*^YOFA_ZNC&G]LVV?Z+*>UN&\I?#NB@]S?-#_`-71C3^V
M;;/]%E/:W#>4OAW10>YOFA!TCRZ,;``=(B7>=:X&`.[PB;%G"!M.K7HUZZB7
M:[#J+<9+6I\.$RBO"1\7;OFF[\MHY?A\F8O2PWD/"&9YS#%\6G[LDKWBBSD+
M&L94ZT5=D7;[)E("HSE$!`O9)E$3"&H!U?6[@WAZRL[3*TZ<N>GRF^O"5>`D
M5^ST?HUU\3+8XB-OA;(%6$B@%`6F^E-]8I_BS5K8S]W?<^,KN^(R">/O[S+=
MK_5*VH?YQWM7/P_C]TTB=G=^:-=N/Z,NL^/W"ZL3;%`*`4`H!0"@%`*`4`H!
M0"@%`*`4`H"X/P9OKR?:J5'""VI`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`TUTU[BK<?\`Z],/VZLA)J,J<*->_F7*1YET@<<P_E@$,3M`1R'N9<BF0X)K
MJ%1V_76)@2,8H@?0HZG)J4QR:@`Z]%>8=JK5JY">M)J='3-0U>$S3@`FXK<]
MCM[O.D-Z-P8EET,UW7"1&+5P@R;9K)Q]CS*DE8R>/K^M-VE&GE9JZ8B+%5[*
MC)%?-WKINF0X%`2#YA'#QM7)QP?YURSZ^6CX=75,LYB%/F8[A+#O7*UXP./%
M+_P9B_#^6Y]W:U\7^@AE2Y<LQ6ZI'"<$W0<I6D2'C+57-+)E(D9T8&$6@FL'
M:G4-5TK&-I396TVTLTM')SH?$38)S`\B6E`YI8Y/PW;XWW@;(>T;'%Q,;"O=
MRO:LY-;JY+&T.<;>DY&.$SE"P!R."BWC)D5'7B2@$(4>$1I>&G5=:\#/2E?E
M2%2"&%]]><H^X+81R5?5U9"CY:X;&MJ.80RL1:ZB\I,;HMZMD)SKP[B)>_\`
M)QY9^)X9GH8QEC-VB>FAP4$UT%:@G23;XZ$&7D.<5?EEXN-F#-VW.V;>@,C[
M9K;W,X0AK*R0_O">]C+AR%8>+T;+R<1*U0]CY,EQ9(C%"N8E%V11)-<A$3*:
M:);*5,N1<A-2>6P;=_<V[2U\DA?6-5+'N[%=TQEO2,S&VSE*V[`OIE/1BDS%
MS=CMLPV58-\ID8H$,T?MW;#5%RF!BJ&35)IBXV5XN;N"I/@Z)>-+0I-/OHF)
MIT'T(&FNNH]?>K6G8L3O1GKM37`J9<O"2FLSS'YL,/\`_:GYGFHF,;X[B.IC
M&,8=/>@M$2%#41`I2%Z``.C2O8>R,;<</:<6W)Q5=!'"27)^#)YY_MS5Z%=D
MY--Z#:L^*7567"@%`*`4`H!0"@%`*`4!&[>6(N-GNZTBH\12[;<X(=F4`*@9
MN.,;J(X24;%`$53.TW8`HH8!./9EZ>O7F=H[>$P^&UX3DYN-:.E,QSGE9(/&
M]^YJR.GL>V:8=RXYV],5>7Y8^X;*.6+=M:U[CR-*1\4PQG9%G6?832\V$S:;
M!BF^GUW$V^=,'0D03112[-5<#A^?\8XW+]QU:K-OODMMGT\;[\<ZX^R=<NTJ
M^;-9[D,R6EN,N[$[#+"LW#X6MJ9Q5;V"VF?SWK>XA;\\V"\[9MMRHP<,HMHF
MU?/114*HU3.;31A*+EJRD\CH#X"7-ID+ILEQ/2&WC(&)K7R'C6^LCX0O.%O^
MR[MN^X6F,LGM\<7@G/VG)6J$78:[PZ*CANN\7DV[EH`@42JF+6]#"0N+](T^
M'*N]W.^,AB>S.8OO?E,G6C&)X%MN[6K[*F_2T5,;1N1("VHVY;0V[0MARUJR
MBU^2EFJA".HH9I=$J'BBAY$SGBX$$T3*&Y75[;D_SDZ9=`6309VM_F@J7<]L
M]]B?$&1<E2V;9'`EN8WQS<4_:UDVS:$QDO#%YY32GUKE+#R;UO`M`M15DZ%U
MVZB[G11`I4ATJ-A:])/G0J>0O3GJ8^M"$L/QO#`QV07]E7[?.3L:7AE:)M2;
MMM+'N2)_%$A9>-WWN2EFF5,C7!=MIRWL5'B6&;K-XU07#EKVA!IL+7I)\Z)J
M;L[#OB+R/9MHWY;R$@W@KTMN$NB';S3%>-FR1UP1J4DP)*Q:I15B70)*@!R'
MX]#`(`--A;])/G1&4]KIY_SJG86O23YT*CA#I`==!`0'N=?F]RLH6+>NJ7)U
MKI1*>4_-#@,YO?\`N9:<=-$N8!D9L``4"F.)+`LM3MU%2Z'.H8JP$$/I>$@=
M'77N/8:X\-AX..5RBLY;MVLB2)0=S]GF5]CBX[?$1NRR-/@,HWI.25%E*U8;
M`H!0%IOI3?6*?XLU:V,_=WW/C*[OB,@GC[^\RW:_U2MJ'^<=[5S\/X_=-(G9
MW?FC7;C^C+K/C]PNK$VQ0"@%`*`4`H!0"@%`*`4`H!0"@%`*`N#\&;Z\GVJE
M1P@MJ0*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`6B82F(``&@FU'OZI`*I/,
MT,<@`/F5DKD80DGPHU[^9$+,\9BQC@/>-RVLN9HO2,QQC&VL@Y_&YKVFEEV\
M+!OY'`UU$C"R*R*2H)(.G@E(3M`TXQ#IKS/M/@,3B82G:4I9,R3=>]G-;A,A
MS^8>0K<]^S=\2F]*VVUJW=>R&3+MPQ%YZOJ"P1=^2VCN,DVM[3N,&;UA;2\M
MX_').EFB:1&#EP';K('/X5>96\#O3=TY7(V[M9OR7DY,B);1]67S=_W?::%4
M7>Z;$Z!7K&]XF81C,QW-%-+BAL@Y#CLJ7#$W&Q82"#.;:$OJ,3?,O&"'.P4$
MP(&(!A"K]OO;AMW/-EDX\Y%4=[)6XCD*98RD?+EX;O<9.[ODGF-Y&?;M,_7A
M:-FW-*89FX.Y,73]SV=#SL99UPSUAN+9;D8*N6:KE<I2I'%0.BIM83'XJ/YV
M$UJUI5/EXR:G<8[CN0,P<,WJ.YO#2+AA-0]P,'">3YYJDE,0MYY)R.Q>,VY'
MQ2((I77F*><`CP@0OCHETX2ETS6Y\6XIZDJ/B?0.8^N_W3<@:5MNU[/D]RN#
M)*U[,P<KMUMF%D,F3CQK#XM--VQ<;:,8*+OSNFLU%S=G1SEE*IJ%D6:S8AT5
MB'`#!/J?%^1+F?0#)FW[F'<F3;5!W%#X]WP6#+/;QG?='>%Y9,S7=>5,AW9*
MI-4X]@K<=^7[*3MSS"41%HD:LR+.3E;H$X2](F$7J?%^1+F?0.8SRXYT7*V(
MB9R3>W@WA1`X"H>Y3F;E.H0_9E561:JD(8QRAT"(&$.JM6>XL>\1&["%QQ6A
M-_(*Y.`U8[3\H6!F?,_,>RAC*Y8V\;$N_>8A*VA=4*L=Q#W!&!B>T6WCS!91
M%$RB':E,74-0U#KKUCLMA+^%LP=]2BZ+(ZIKB!-<Q03\`!$0+KU]8"81,(#H
M`=^O0)S4VG&E*&U9\3NEM8%PH!0"@%`*`4`H!0"@%`1MWD:I;0]UI#B414VV
M9U!,`.@B4C@F,I9SJLN]7:($2.S>I`4.+7M->G3HKY/M-9Q-VQ15S<9SY9)<
M9-#'N!,%Y]VQ['<@%SI(X:S5BS;;C^)L+,F*K^LR,O>WH.\,<6FWNRUW*$^W
MN2V;BMR8-'(J'923)Z@DY1362`JJ29R^/W-WXIW94M7)--YHNGQ$I&7<8[.]
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M?W_&.*9;%\W;)GN4(A1!:1Q%B^[<0VFK,-T7"*4F4+.O-V1P4X:*+\"@:&`=
M2W7B5+64+F3[E]`H>&N[EN['[F:P1(G+MVX\E(UY?Z,_<6.,XM;4G;\LW)]Y
MS-^7CCR[WC-T(/+6<7%/NU6(HE0?1/C"GB:Z`G.)H]58GR+GFOH)H;)86ZL5
MV[#1D!#W[9K6,A8YE$Q*0WC#N%&<?'-",F;87#A^JLZ*BB3H%8QS:]VGJO$^
M1<\U]`/M>^3CS\O['_.J#_C]/56(\BYYKZ"*`<DX]T$?=_8XZ`(Z!=4'J.G<
MZ7X!6=O=M^$U-PN43\E]!-*93\X^WJ0:2.<N96[CED739US#[^(S6;N$%4G:
M)<>V?[(OD72QV;!9H4I$BI]DLJ?CX@T,.@5[#V1BXX:W&2:DHHQX25X=7S?0
M[^@U]I=_2(SM_I$5K,WA0"@+3?2F^L4_Q9JUL9^[ON?&5W?$9!/'W]YENU_J
ME;4/\X[VKGX?Q^Z:1.SN_-&NW']&76?'[A=6)MB@%`*`4`H!0"@%`*`4`H!0
M"@%`*`4!<'X,WUY/M5*CA!;4@4`H!0"@%`*`4`H!0"@%`*`I5UF-N4Z76U&G
MPSE=R3C&JSG$NNBW3%1=5%LEQ%(=TY<-6K=J!QT%PNJ\7;(=DB'2)>,#&#H#
MIJC%8G!6/%D^ZT4;>?$?+]TMK]F"@W9:Y2KF%1D8MRVVH5PQ*/9@Z,)9C[T"
MJP"!0&N7;WOA)7'"4XYM*Z1MY\19[I;8_*ZU_P`X[<]N:V/66!])'G0V\N(>
MZ6V/RNM?\X[<]N:>LL#Z2/.AMY<0]TML?E=:_P"<=N>W-/66!])'G0V\N(H-
MR6N.FMW6OT#J'_*.W.O^6:U\1O'`N*\-9^!HPG<<\]#B7F[*=E[-]<%E/T.,
M#BW?35KNFYA+KH4Z"TP9-0FO3PF`0$0Z=:UUO'`<+3YC`X`>8_74754D<<+O
MU4P4!4#V`V%R5HGH1H/BKE!N0YR"!2#P:ZATZUE'>&Y'DQ*MO1DA\HJ=MFWM
M20'2.:VE*E3`H.EHQO;$@BV<*%$_B1C1YWANU0+IQ&,!2B/56W96Y\1^AA:?
M<C\A.4A+S)X9HSV>W]=,;$1J#O&5\X0RL"K)@V9K`QL7+]G2DVFJJS20558K
M0(NB.$A,!5$3&`W16KO#`X93@HPC%-<"2^0MA:C=3UJY"=ZL7;R@BX;P\(L5
MUXN[%Q[%1QRNBO6+5X@Y+_DW9@)FS@A1X0`!$O55-G=V&N/PD^]T%G5X<9Q>
MQ,-_ZC@_Y&C/XK6X]S8/[KO=`V$.,>Q,-_ZC@_Y&C/XK4>I\']UWN@;"'&6^
MP\)J(C;]NG$QD>(%K>A7)#D15[4$C)N6*R7`<WTW@\6G4(5M6<#AK$=6,4\O
M"DW\1.PAQG;1;H-B@FV01;(E5.L5NV2(@V(=0>(W9H)%(DD77N%``JUX>WP9
M.0;"'&<PB)C&,/68=1[W4`='SJLA!0CJJI9&*@J(5D9"@%`*`4`H!0"@%`*`
M4!\Z9AX>XH68MJ>B8V;MNXHJ1A+B@9EBVEHN;C)9(C:1:OFTBFY**3MH0$3%
M)P%[/HTK#%6X8N.I<22I3)\&4NS%Z2+2FP78ZH<YS;2<"<1S&,/^CR$ZS"(C
MTB@(]VN=;W1@[3UEK-\=.@;"'&<?Q`]CG1_U2<!]'_X>0G<#_<*T<?NG"*+:
M3H^3H-5T1^;OG=X^L7!>Y/9#CS;WLJAFEJM;F9Y(ON5L;&3ITVRP^9SS563Q
MPR2AA>C.-HFTFRJ[QIV93ZG*(:%#2O@L9@(J_%0BVM9?'R&-<I^CE#8ML8FF
M$5.,]H&"VB4_%Q\Z1D^QO$(O&9)AFC)%:.D%&Y%6[IL5T":A#@!B'*(#TA7H
M<=PX%Q3\*M%HT<AN;&'&=L-@.QSN[2<":_\`1Y">H5/J#`_==[H&QAQCX@.Q
MOR2<"?!Y">H4]08'[KO=`V,.,?$!V-^23@3X/(3U"GJ#`_==[H&QAQCX@.QO
MR2<"?!Y">H4]08'[KO=`V,.,J&P+8V`@([2,!&`!`1*;'D)PF`!Z2FT1`=![
MM1+L_@)1<?#R\:Z!L(<9GK&V*,88:MYW:.(\>V?C6U9!^XEW]O6A`Q\5%O)I
MUV(.)I=N1$_%)JI-TTQ5`0'@(`=?36W@MV8?`?H7-\K3^1#80XSW_HZUT)+6
M>L\Z)5F*>LJU%26B@%`6F^E-]8I_BS5K8S]W?<^,KN^(R">/O[S+=K_5*VH?
MYQWM7/P_C]TTB=G=^:-=N/Z,NL^/W"ZL3;%`*`4`H!0"@%`*`4`H!0"@%`*`
M4`H"X/P9OKR?:J5'""VI`H!0"@%`*`4`H!0"@%`*`4!<0H&.4H]0F`!\ZJ[L
M9RMM0\8IO>)W2#^_>U;<OC&V!++O"+93-GW?O=VE0%VQ$FT%_&25O.<N11'[
M*08E$#.V3A(>%5,!`3E'34*\Z[0W<59B\K[YIDSH#:9R89W=)>NSV)V@8*#,
M%CX[@<B3D6YQ\Y:PA(*X7[D&L6QFUURQS^YXX4A=/HQ,P+,FBJ2A]"G"O,'O
M3%QO-:\\VG*29,B]@')LFD;J7BMMNSZ03LF3/$W8HU<6RHG;KY+7QEE,G&9*
MG'.VY2&.(*"!#@02D,8P#IGZVQ;_`-2?.#HRNQ+DN0MD-<F2FWW9E'8Z>.TH
MYK?CYS;S>TGDBJZ18E:,YGV5.U7="\7*B+<IA6(H/A```(A/K7%>DG3E!YS,
M6SCDG8$LN3OK*FW7:3:T''Q;BXTE74?$G?2EKIB)VTS;\,65"1N)L[2\%)5J
M4R"AP'A/H`Z0][8M/])<YP>@>;".3DA+I6V3;ELW"YY"V%[MA[<_X@6N&4@T
MT#27LBRA1F4GBJ"<*=-R83%(02G`2F%/4Y<X[SQ<LUR?.2>4QSM(Y(&3K%L/
M)UN[?MHJ5D95<R##&TE,1\-#.KHDHB4<Q$HP9,G\PDJY=-7+;B%-+B,!%"\7
M".@&R]88STD^<$DDN4ARR5S'3)LGP#PH*-EU01M`A!(LFH84"*\3KC4(H4W&
M40*!1#O]%:&,Q>\+DH:DI.CX6^;(T%2CJ:PIG;I@K:[S.,F8^V]8KL_$=F2.
MQC&-RR-O69&A&1\A/)YIOY`)9XD"BG;/3-Q!,3B.HD*`=RO1^R6)Q$FG<;>7
MC,>$R?N!QR.8,&9NQ4!RE5O[$^0+68@/"!AEYFR9EK!G`Q@,``A.+MSCT:^"
M&F@]->CXZXINW3R7\AM8?A/$[.,HCFC:7MOR6=/LGMPXAM!.?1'4%6EV0['V
M&NI@N0QCG2593C%9,"&'B(0I2CJ(:TPN<V"25=-YD0*Q)%`*`4`H!0"@%`*`
M4`H!0"@%`*`4`H"VN?<>UK%G/><@;>!W5Y\S7;C$-UURDP#MBS;EZ3.U<+H$
M:W#E.:88TM-=TFDJ")7'L>V<&2$A4U-`XN+KKEW-V1G<4J<-?AD(5-8GF!^T
M,5<=1$Y0,'&)CCH;PO",<1.8PZ](B.HCUU](E1)<1T.`K0D4`H!0"@%`*`4`
MH!0%IOI3?6*?XLU:V,_=WW/C*[OB,@GC[^\RW:_U2MJ'^<=[5S\/X_=-(G9W
M?FC7;C^C+K/C]PNK$VQ0"@%`*`4`H!0"@%`*`4`H!0"@%`*`N#\&;Z\GVJE1
MP@MJ0*`4`H!0"@%`*`4`H!0"@%`<B7X0GUP4<Y6TY1I6A3?\3ND.MZ/9^YC;
M,=4$3$1WW[2G`@N`F2$S?+,:NF0Y`35X^U53`@`(:<1@U$-*\_[22NW8NJ6;
M0:;R<YD2!V![RK6F\;[N5,A.;JS/+;G,CY=R[M?<,[1B;43LK/,8IC;)-HH9
M09<%PR`P&*XJ&5:`4`*F\15[,O&.I?(IX=*\Y-U)S$#\A;1,\;<L$9.C+YV\
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M)G.9)$$=3%.D83=`A7WG9F=Z,$E2FL_C(9C,N_IC8ZC9QN5VQ[E=KD#(KM8E
M3(U]VW$7QC*`EG8&,Q5NZX\=+2#ZSH4?$^$TBZ2\4(<Y0.(:ZU]]?G<C!3R5
M2,XW)0\7A.?9J:-QUD;=3MKCGK![;5JY30W+8;?1SHCB/F]OF[$7=^P*L4J0
MYTSIVG?ZLQ%J%((]DBV2`0#B"J-W8Z]<O:C<7"NC0^G(9;>:;7"3V$HE#I$I
MP`ZJ0*E^E5.@<4E3%#N`"A1"OJ,4W#5V6;5R\I=:G*:;>>IYZY[OL^QHE.?O
M>Z(.TX52:@8%&0N!^G&L'4M<4DE%Q44#M00!)Y(NUBIMPZ>-40+W:T9;QP]K
M]*RX\3D_.F&<$JPJ&9\I61CU>7<O2,4[LD7;%60CT`$I9E5G%M)%]&QC,%`.
M[6.0B"0E*3M-3#I5/?.!<&K4J7."KJOA0GE,EL';:1CV$DQ=MY&,D6;=Y%RK
M55%5O-1RZ8*-)Q'Q55PU3;RR)P52(DJJ0I!#PM=0"V&,5U>`TVVZ<G!W3'D.
MU6Y;<G&L\Y(K,"@%`*`4`H!0"@%`/G?L^;7,VN/=UQ6KLZY/!^R0/V?LZ:[&
M'LSN+P\Y(JN2U9-`5`.1NB=RNFW2264.X*OXH*!>U!=<_8MVB`]0)BBX[0YQ
M[I`\RN;FDZ:2IV8<9`[:JY:9;S_O&W,QZJ)[=F\C0&UC%LH@<RK2Y+0VY1+@
M+JG$5#%X6J%P9*N9PS(<HB7M(XW7W+(7KE>"G(81LQJWEH3K*.I2CP@34I1X
M`'4""(`(D`>Z!>K7NUO&P74(;HF^(I\X/V>?6$G)K\WG-3;3*_L_9TU3L]XM
MU6KJ?>_9&VGQ#YU64OC;S'SJ4OC;S'SJ4OC;S'SJ4OC;S'SJ4OC;S'SJR@KB
ME^<\4RA=G*23S"K7*W3)G-HM'J-]8I]H:M+&:VQ>C(5W?T;()X^_O,MVO]4K
M:A_G'>U:.'\?NFD3L[OS1KMQ_1EUGQ^X75B;8H!0"@%`*`4`H!0"@%`*`4`H
M!0"@%`7!^#-]>3[52HX06U(%`*`4`H!0"@%`*`4`H!0"@`&$H@8.L!U"FKK9
M"F]XG=(];F<,W5G/'UM6Y8E_Q>,KWLC+N+<RV==TU::M[Q#2XL778UNI@QD[
M72>L!E&DHLU!$Q3*@0@#Q&`0#2N)O#=T<0J2S&HU4^R3('-<0,9$F[[:TB!A
M$[9N3:I(',S^^F<*G6,-WI(D4564$X%XN@XCH`U\7>[(6Y.EG6<JZ7R:0WI.
M-W>W-9?H^+OMW>U-ZCVR3@4G>TQ5RF9R@J5P@Y,FM?)T_&$5R@<AP`!*<-0T
M&J%V-N:)=_I%4<_O@<V40,4V\C:^8IA./".U1SPE!4-%@*'NZ#0%]1X]=1-Q
M#3V-N>3+X=T51QDOOFPID%,F\7:\!!*8@@.U1P;[R9110&_A7R/^3I=L<I"=
M12&$/-H^QMQYU+X=T5.0F0.;&GQ<&\7:X7B``'3:FZ``T3*B(@`7V``)DB%*
M(::<)0#2GL;<T2I\.,5+RY#YLQ-.SWC[7D@`A4RE2VJ.B@4A-0(4/^78B!2@
M(@`=0`/0%1[&W'G4N_TBJ+!R/S8D"B1/>5M7:**^"@J?:G*%02$#=HJ4XMKS
M<B4%N^?0->KIH^R*@UM5++QOI)KPGD;#QEN&>;A;VW([F<WV!EN]KDQ!:6&8
M&)Q]BMYC6*MJW+8NV>N\[YRJM+2)9UQ*/YTY"CH4Z)$].D-`#Z/=>Y[>"BHV
MZZM:Y<N?/E(XR2QDTG+->+?%3<1+ULM'R+=\W]D(LT8Y062D4I:.4!5*7AEV
M!U2.V1TU`<(B(AH)`&OIGA(8C#24T\E'DXLJ[Z)J?G]S+;LUROMX^V#,4423
M6V*Y"N"6P+<*+QP9V&UV*RW.-)I#'+-X=199QAF)N]-I<-IJNCF69%DI5IJ!
M#``?+:W5L31+(F8Y(TT'Z!TTBI"FF/8JZ"HV,W364\92D^%Y)NBG3$.S&/4,
M;5-<@Z&(H'>"OJ88E7K-.&F0VK'BLUH;T<=94W/9/L/;WCZQ;$N:SK)QU<>7
M,COLL2MPVQ8ON^O)$]CXC:VU/V\`N9RY<:R;SW3(ME/O0N61.+3KKY?>F`Q.
M(KLZI_#C-@C6^RT[ET<3Y&R;?&0]KNXF(VXNL'WO>MY[?I'.>$\VS^/;KFHJ
M]L07/90VU/*1TG<3MDE,&?$59F<Q<B713C*%?-PW%O"%W6;=&_APD-TRUX3:
M)M8=2CW;=A-S-XX88AEC6!$D=8SC&SN.8V<BF9P#"-80\@X>2$+%JLQ*X:-G
M*RCA-!8H'X1#A#[3=N'N6$MI7X=TDSW7TD9*2JLP%9`4`H!0"@%`*`4`H!^S
M]G36,L39M+@UB#&ZF7\8IY@:X"->4>7+[^P#9$0LKLU#/TK4-,&B4IY4X`)1
M+XR02]CUBE]\TTK3EOZS:R)K)\-!)D@1`W2'8Z#W6ZAED!TZ!%)4WA*)B(=`
MCUUNQGM(JYY2KS@5((I;S<V7%AW"QHC''`YSCG:<0PIMXA6IU%%WV3KU;N(,
M9]XQ0`7Z4+9L.]<RK]0I>S119=IKJ>N9-M5IG,)-I9/&,NX-P];6W?#&.,(V
MNL1];V.[0C[?/.'3!JI<MR:J2-U7D\!5;QE:1NFZ7;N14,IX8&7`H_2A4K@,
MD9,,/9@4O$F8G"&BJ*:Y2E`0#345P`@Z!WATKI$E@JD$/P@I:=TQ-=>]YG34
MI5=")>*^0Y5!*@BJHL8I0:D,HX<&$"I$(!1.)C"(@!2D(&HCW@K&[)82.M,Y
MY%M3?%LL:D`CO=MM^3<$56,<RF3+;:-UA;F$GL>W5.X=`<7(@(E5`=0TTKGW
M.UF"M+9-QJ\GPR#)W"SX\^R?RN-O/PJVS]U6A[06]*[W0!\>?9/Y7&WGX5;9
M^ZI[06]*[W0!\>?9/Y7&WGX5;9^ZI[06]*[W0!\>?9/Y7&WGX5;9^ZI[06]*
M[W0!\>?9/Y7&WGX5;9^ZI[06]*[W0"I=\NRDQBE+NYV[`8Q@*`GRO;!"`(CI
MJ8QCE*4O?$1"J[V_H2M22:K3X<!G;\=&:,<Y7Q=F6'=7-B#(MFY.MR/E'L5,
M25BW+%7,TAGS<H)MF;]:-%8$1=F^_E,80$4_,J,%CW=D;I[\?I3?6*?:&KNX
MB.M@Y3Y/C*[OB,@EC[^\RW:_U2MJ'^<=[5SL/X_=-,G9W?FC7;C^C+K/C]PN
MK$VQ0"@%`*`4`H!0"@%`*`4`H!0"@%`*`N#\&;Z\GVJE1P@MJ0*`4`H!0"@%
M`*`4`H!0"@%`4J4Z9C&45)4>8H)2FZ#%*<.\8-0U#J'3OA4/PLYAL8:"T$R$
MU[(!0`W2<B(BF100ZC*%*.AS%[@CU4M_FWK0SC8V]!7A'ZM3^$-Z-7;>YQ<R
MZ!L;>@<(_5J?PAO1IM[G%S+H&QMZ!PC]6I_"&]&FWN<7,N@;&WH'"/U:G\(;
MT:;>YQ<RZ!L;>@<(_5J?PAO1IM[G%S+H&QMZ!PB("45%A(;3C3[4_9J`'2`*
M$UT.4!Z@&J;R5^FT6;1D^(;&!4I2%Z"E`H=71KU=[KZJJ5FVLR&QAH.0BBB1
M@.DH=)0O2DJF82*H*`(""[<X=*3@"@)`.'2"9SEZC#6W:BME*-:+1I*+L(P:
MIPF-,QXCQSGW%U_89RI!(35AY/@GEM3\<F5LBY2\?*;@N"!.NBH1K=EN$$[I
MBN02*I=D8I!#6OC]Z850DYV_&*FJY\QIRY:',Q:9+RZGRY+KCKEOG*NWRW+[
M@AW#.T7<7!9&Q[AUTJQM^8GK=D&+2YF-P+VD@FWDG"1C-W*S3MBZ]H<PT;LQ
M-YZT+TEK)I+(EGS<KJ3"Y*+U(F];MB+(&*"12$5#0O:)HIN.S!45$G;4J``1
MLP<"75N)=#"0H\737U.&E)I5:YBS;7*YSD,X4,!RFX#$6[<SE(2%%%XLY323
M7<NTA`2.':@($$53!QB8H#K6ZY/-DYD3MKFDL.J=0PF,;743&$`Z"BH<=551
M#NJKG\)0W68W2-4.U"56UG&UGF+-:F,(P5(YAM9Z1K65!M9Z1K2@VL](UI0;
M6>DN[U0;%MN4:O.*&8H!0"@*`<H&!,0U,H(`3S.YW/-H#E(HP([*V=/V:"R2
M)'4@FX<)M@:M2N!2(5%DZ,T?2+Z03\(HH',@4`Z!ZZY..ZDH/63UN'*S4E=F
MGGR&FF2Q/N@<72_WM$=VHTN>/W/M,A0.!QM)@EEE_@R$3+A=+'CC+Q[T)$P\
M(^Q>]/<989=F94TTR'C'C.)J^!WA.UM&X-\[S&+O7,]3<-[(0(`7Q27BO%3%
M*=L`RT.001.4#IE,1)VLD4Y"CH8"G,74!T$:]"PN]-WQPUN+\905<KT<A.VN
M%5):%;`91W,P;)(04=@ZD99HRBVT/'LA7E7[A^1R\$3(&*)@#@#B#J`.JMCU
MMNVGV7T#;3-,5LP.9M_.YN2W@XVSU$[?]OF%V5[X`VVS36S+-OO)>191!V@V
MRKENU'-\H%MZTV4Y*L%8-J\<MC.DV#<_BI@!8VOS<=]X6=UIR257IT\ACMKC
M=4^\2N':7E9%9)PWYG&\=.43/VB+I2X\/.XDRANGM48M>S%69&QS#J1/00*3
M0`Z`KIPWCN^Y!IO+32^@R5Z>GO%Y<`;OK=$2VUS,9ET103J*,,M;=<)7DP6X
MS:B967C&-FO"B<1U-HITB.NM:?KB:R*2U5D63[!&WN5RL^L9AS'X`H-6^5-B
MV8S%7[,$[KM#(.))D@@!5&K=T[MV]I2$<B_,'BY/%&IC\9PTZ:PGON\HR<)+
M62R9.'F(VUQY&\G(:KX3>ISLX')VX>U\B\O%GEC#",]?+*&7MJ?B\7/+1@TH
MU8L6-DWU>I8`]]P,>8>T\=>PKA9P'0)]0"N=/>N]<;NN5_%-.='E2BN#0BNL
MJTIDJ?H;Y7#S;JQVC<LS"UP8LLMWE?,VR"W\NQTF?'-J224@PQS$6`WN`]P3
M*\0JL65=O,A-C@J8PF44(?I#6O)8XB_B;LY8AZU'7)DIS4T9C)=XF58&5]D5
M^)SSH;9PE9:,%F*Z,`IQV1K,QA9LQ.Y(LUQ$(7"WMU-V9RG/MVBLJFF7Q8GA
MF-T@6L^M8GTD_.?20>Z9W1L<E$[Z5AU=I,F3&2SYOD0S-UB-XEC]6/7.W<GO
MM>,1DD[,9ME$C@LYD@;(HG**9]#5/6L3Z2?G2Z0>OQY$[3,L0A;FQ=![:<FV
M]X_[#GE\?Q.-[QAB3)"%668*3UNL7[`%R-S<8%X2ZE$.X8!IUK$^DGYTND&3
M_>,PE^IW%?P>6A[3TZWB?23\Z72![QF$OU.XK^#RT/:>G6\3Z2?G2Z06FP;A
M,I1$,.XKU#I#_1Y:'M/4K%8ENFTGYTND9LQ^?C%T'"6WO*YH,';\/%0<*SW)
M8B\1B(>.9Q<8PUP%!.E/$6+!%NV:]LY='44X"AQG-Q#TUZAV3K?PT)76W*F<
ML=ZXG1/)0DV(]!_K%/M#5]OC&XX9PCXK:#N2DJ/,03Q]_>9;M?ZI6U#_`#CO
M:N?A_'[I63L[OS1KMQ_1EUGQ^X75B;8H!0"@%`*`4`H!0"@%`*`4`H!0"@%`
M7!^#-]>3[52HX06U(%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`XTDR
MF45$W@"D()E#Z<#+I$/J.FH`4ANX(==`1GR7=VY6;W+X=VO[9H+!J]V9%QAE
M;+$S<.<W=^MX*.M[&DY9<-XM%A8H&7.]?+7TB!P7T#1`HEZSC7RG:7?WJ65N
M.?73=.1\AJXA94940VQ\WT2@9-+EU$$>W%5$LSN,%-)0SAQV91,D84SN6B!@
M3`X>$3IZ=3#K\=<[70NYT_AW"@C?DOED<S.],T8DW%QH<N'&.<L53[UPVR-:
MI<UMYB_['G(E2$O3%-[KNV9SRUK7'"J&U,)3KM#$$Z)DS")JY]WM5"U-:N2N
MFG030D@7:[S=/!*C'<N5(4TP*L0\IN,`Y53JK.#)(\/@>((BN((!H`@74!KH
M6.VNKGRTY.@@O^*YS>O^!\N3^5=QGH5LR[<0E]J^]T`O+M<YO`ET%ERY>+7N
M2NXWJT\[OUC[;0\E][H!:&V3FVG4[(B'+B\81T,NU"9W%&/V!A$H+F`!$Z8<
M91#N`.E/;>/DOO=!/=.`^V'F[%7,0[7ES%(1-<2Z36XE(5/#:'!53C;+<!$D
MNT`.K41Z>H!I[;1I75?>Z"#F^*]S=3`4J+7ERJ$2312,J:8W%G.LL1%,'"J@
M$3333.=?B\$H``!I3VWB\\7WN@%OQ7>;R)BE!KRYBJ]ND8W:2VXHS<6@E,FL
M7@(4')5NT,!BB`B41#3JUH^VT:52==&3HH#&FT?,]T[@,!6MDV^;>MZV+Q<W
M/DVS[CC+3<2SFVC26.;VF;+</H56<*22,P?.(8ZJ?:`(\)@Z1KT'<N-6\-VV
M\6OMZ_'W#<L_HT2.#Z4@]T2%$?/$.FNH6B@%`*`L,0H*=J`??$B)G(.H]!A/
MH.H:Z"&G<&I6<&L2U\7;%VP<U;=%N_VS0FY*3Q;NOA+/L:$9VXYN[)EPC*8Q
MM("8_P`>12KI,'DZ"L@Y<IM$@X!*@<X%U+K7AF^]^WEO*]:MRI"%V2>2OR'/
MFDY-OC-D9]B'(\;PN'K@F<#;5+49YTBF$GBT)8(B'GKO/-,F!0&W&:;]>0?&
MBTGP(OU!+V+-R<HB8ASB:N++>-ZZZR:;Y/\``BB/(1.SOD6W:XD"8WP5LXR?
M(P,Q;4#=%I6O+6*VN"%5GKTCK(&87).77%M$XUA.3*"2QB+NE'A]$&B9W9DT
MULO66*X)9.1#(<3K9KR.7RF1HJQ\';/+PNW'=OS=SW+8]L7%CTLT$5".$89Z
M51Y*73$PD:1F_P#O;I5TY4:(J*F(\!%0R:8/66*\H41[B,V.<A]SD)MAEG@O
M9<3)IRK-B8O;*VJ%S-)=%HC).[8:6['2ZJI+B:-G/CAV`)G=)HJ]N("3IKFV
M\5?=QY>$45#Z^,>75R1\Q3EU6WB3;MM0R1+6.]7B[S;6H+"X%X*207*U51>.
M&[[A27*]$R1^%)1(JA1*8Y#:@'5CC,7!*LJ1Y$2LJ)"?(Q<K(_"?XD&"DQ$A
M=02M@$P'H#H,"3D"''S>D!JOUIB5FFN8A)+,C7KS1>6/L'V];.KMRWA3:]C'
M&N2K,REMQ7M>\K6BW$=-0RLKN1Q<PD!9N2.A$I7+*9<)&*.H<"F@=`!I?A=Y
MWI7X0G*JE)+-3.^04IF,UW\NK[CKV2[0P((6G<RK5#75NS[&)5X$FB`_>VS;
M4=3)$`$S#U@->UW=W1M=GIOAU?DY2:&&=F=HY]MO;)R@-U>&<02&<XK&.Q5[
MA^^L<6]=-K6=>#AADBU\;SL)=4(K?,K`6N[3:2%@MTU4SO-3%>B)2F$@"'Y]
MM*$<3=CF3;"/88>Y>N?Y/)F/\L99LBP;8?7(VWRWW/-`DDKED\#WAN1;0[7&
MC2(<K)'93ER0D?&"I*O4C"V;N1$J/"70:R((L8FY;&]O'F,+QA0M!"=O_&^W
M!G@"SI'(F1L37S:>5&:-^1]USSJS+/C,8P[59:99-!F&KF^"2?B,RHF0[9VF
M05Z`VA<KC;EN"P8\W8SN=[;DK>6S%FJT[^LEG.7E9-U7$,*QQQ"6V]<SC+'M
MK6U8]MOU)"/.*R4<V3(HH)C:=.H@;<M%OJ0_?#ZC0#1;ZD/WP^HT!02JB`@(
M``:#T^$?[$J93&\X!"I6<'YN[(37'>SS2%125(0-S&(R]IP@0AR!M\MO0`!3
M4QPT#K+IKW*]7['_`+K#D^5AY^X2&[A_]S4^T&OM\=^@[I)!3'W]YENU_JE;
M4/\`..]JT,/X_=()V=WYHUVX_HRZSX_<+JQ-L4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@+@_!F^O)]JI4<(+:D"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`
M*`O((E'HT\,R2)M0`=4U%D^,O2`Z<7"'2'30$:6-V2-D<R'!]Y1EM3=Z2-K\
MO3>Y<,=:\`R<R<I.RD3>&#WL?%-&+9)0[ES++LR,TBB8A>T7+TUY5[QL'/%7
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MEGP-,D""(H9B#89`BK<XK8PW-B4G*%U9N+-S\1-7W3Y=J;H.8/:TM=\MDRTL
ML7);=MY9C"7*K:N!;D,2*M2787;&MK:MBS3V`TNB7C(^9:QZSN3BW=RM?%E"
M."O0*KXN79AAH8>&KBO#F\J>;)W",J9V('</S"AM^X9>98YE9Y$+B2V)&'QN
MXVYH/;4)!RR-L*3>07MWMFL<>-S5;B;J:6-:XF=%=':(MR,0%-11:Q=33\7A
MTOX=T92CR^=]EWW;8]OXYO?-L5:<I;ZL8YSO<6VZ+M+(%VH043FN5:K3F/;H
MCA96\[F)J#@40>>QS-%ZDN"R2+<CM(I*I[ONXC\[A9;.U2C63/W77*08-R3G
MOF.Y:?2]J.(3.EBQ<[A"/=7.QL?%SY@2#NU'$%C9`-)V*_1L^9='D)V[D9J(
M0:'E)%T945VZL<3Q=-<<5N;'-45W)_\`'DTDD]-D^7-YMVYMRK#9[]D#V'&L
MKR+!QKRP[D@64&]AL@$BL8DB;LDK"@K9D37SC%`'LFV)/3:C26!8O;)B;Q="
MSJT</%6L3X5Y</%P9G059MB;]BX[)<"ZG.=,!5$@%.JF7LW*``J0I2K)%[0-
M!*(D'3K&BAAZUC&C[N<'Y=N7>`!MA;<(%*'O[;HQ`I2@4@?Z<+SZ"D*`%('F
M``!7NO8Y079ZPK:I'POC-RU^C1-H/I$_]S)_@KZ<L%`*`4`-^[_W%+_&U*S@
MU%8]=XBNW>%N9LG->\>S-I^.\5;TY;.[Y8,K6CCS*\YDQMA6U(+%[VU8>^+9
MN.WYFSXABZDW,DZ40.<JZO9E,'`>O`-_[H:WI?FHMRG<E)<G+6G<-&56WHJ9
M<QG%[7\>D+9-S\P#:Q/X9P]@C?-@S!V17F;K<N7.49BK/Y+.?8U<>Q+*&CVP
MW3C]-H^;.7#,R1'()M100`1-KQ)[LQL'X-?%KP<-:=\QS*I'K'FX;$68,P8\
MCULQ[%L>0^)]I>UG'T;?EC9@:MK?N:'P[NRLG,:K^Z4I"/AY#'JK6Q[#DY%G
M;CDRCZ/=.3HJG$SA+2Y;MW@HZSK3(N#.\A!EJ^H';H_P=B^P+=WB;$F]X6C;
M7,$A;T,AG"R$"2,ONQNJZ;FQP1VJ845G))7QE$7RBQ05!1L7N@(!7U+&N;MU
M>NL^1:>DFADV97VGR,$]8#O6V/13^5WV9`W%REXM\UV4\ED<97UAR,Q<SN%)
M<CE!PO.HOFW9'35-P^*@!!'A$0K".#Q*5(MUHWFX":,KRX)?:]M@R7`W)FG>
M)M-"/Q7M_C<#6/.!O799']U\!'R2!R3$!:"MOV1`6/8T@9J7M&CX7KOQTQDB
M*F1(`C:\/CM3.]2B>99N`A++0WL$YDO+W2(1(F]';&D1(I4R)DR_8Y2)E(`%
M*0A2S(%*0@!H`!T`%:WJZ\\KKS#59K>YKV]S9SES9+?F/\8[J\!W_?UR9(VW
M#;]FVODRTI^X)X8O<IB)>4+"0T9+&>N7#%H0[@X:F*4J`B.@:A6U@=V7KF+M
MZJ;I.+?!PDT=54]M-M$)9M+QJ@&,TD8QPP=%*/"8S:1:^+NN$P:\)CIG$0$.
MH>JOT-*]=N8;JLW6PU2GPRFULH:"&>.=I.6,26!9^+<<<QG>]:UA6#;T7:=G
M6^RE\*+IP-N0K,L?%1#1\_P4ZDU&S)D4J9>U6.82E#B$1`!KY>793<593C86
MUEPZT\_G#90/9EP7N*)H!.9?OJ(``H4H$=8!*4J:S@CI5(I2[?@`J)W"8&$@
M>#J'5I7.]D<'Z+OOYPV5O0<:>!]Q:?9Z<S7?J?LT%6X`M+X+7*8BS@[DYU2K
M8$.59R54X@18^JI"`!"F`H``/9'!^B[[^<1LH'*7!NY`A`3)S-]^A2@3L^B4
MP2!C%X^/PS^\'Q'-Q=T1$=.CJI[(X/T7??SB=E;T#WC=Q_\`K-M^?\I8'_H!
MI[(X/T7??SALK>@>\;N/_P!9MOS_`)2P/_0#3V1P?HN^_G#96]!0V#=QHE'C
MYFF_(Y=.DHR^`T2B'^R55P&5),OFF$`[]6VNR6`C<3G:\#AROYQ#LP:HLC/3
MX/P0CAIYE^Y%\M9*S?>V:;\A+UR!D#*#FV7TY*RT+`-[99*"G:$+;,"Q%G"-
M4VP=@S3((%XC%$XB:OI,'@<-@8*&&CJI<ORMA684\+*S/1@#A-]8I]H:MJ_<
MG.VU)Y#&Y",8MI92"6/O[S+=K_5*VH?YQWM56'\?NFL3L[OS1KMQ_1EUGQ^X
M75B;8H!0"@%`*`4`H!0"@%`*`4`H!0"@%`7!^#-]>3[52HX06U(%`*`4`H!0
M"@%`*`4`H!0"@%`*`4`H!0"@%`*`4``X)"*AB=H4"E`$^^J99$J9^C0=2"(C
M0$.;RW%8=VH\QG:QF//D\ZLW%J.U_<_8XWD6"GIN*;7+-WGAAU&Q$H$!%R:J
M2<@W8.NS*KPIJ*$UT,)0$OE_O!P6/Q>)PSP==10E6E,]<F<UK]-95-@A>=QR
MP#-E$%]PH*-EQ[0[1:P,CJF05<E!^)"@:UOO21"/"BEP:<`"(%$```#SKU)O
MU\$N\4>">>M3G$\HJPTY%*QLJ6I9:4P^/*2R5I8=N^VTI.242%!1^_2AK+9$
M=NS)B("HH!C:B(ZZCK4^I-^Z)?@C)QGK"<\;EB$``+N*4T`B:8:V#D@X@1(H
ME(`">V#"`\(CJ/6;NB-/4F_-$N\,G&<9^>%RN#</;;ATB"!2%)_H_P`CHB4J
M:O;$[/LK7(!.%7IU#0>L.JK([EW@E_Q"\/CIF&3@.B?GH<JH9"-@D-SEN$E7
M0F5C[:2L^]?=&X0`1`[R-MTL`G*C'<9#%,Y10,CQE,01XN(*E[GQ%<RKRBJ7
M*=T>=_RPA.!C;@Q3%$>!$@8]R.D9`$U`$Z8%+;6I"F6)J8NA0$``!`0`*PGN
M7>K?_#IZG%3Y1D+_`)<3EA<"A`W$&(14YE#E3L#(Z6JAC<9S@*=L%$AU#])A
M+H)A$1'41&L?4>_-$N\,G&6&YWW*\/PB?<&)A*HFKK[@,C@(J(KBY2$P^Y@!
M/V:QA,4!U`-1`.@1"MZSN'>;MIW(ISXVDR#L)\\?ED*+E3#<>@@3C1_#8ZR0
MGH8X\(<"Y+5,F)C"4-0,``4O=JY;@QV=P5?OD*JF5FL[EL/?9;:/:TN#9\V1
MN'*^?[DBRR,8M$.UX6Y<OW=+1#U1DX,*Y`?QKI)4ICE(8Q3@/"7JKV+LSAI8
M3<MFQ/))5[[-RS^C1.82&3$2&'7A$0#HTT+KX(?,"N\6E*`4`H`/3KKW0`H^
M<`Z@'S!H#PUQXTQ'..I&[;^QQB24\)N[F[WO/'M@3CAHA'(JN`1?S\Y#'>MD
ME.'13MEDDBD$?OB@"):Y>)P]EMN6<T)>,^4_/9;&\>XMWN[RX-D&%ME>WK#=
MJ32EWK#O&8V'9^3D%L4V#(.HR9R#B"(?XRB+5N6YY<BP-8YV#Q<47R@'$IP2
M*`?/8FQ8<]6F;X:?CT:"NN6ANNQ#LRVR80Q[$8SM?#..)^*BWJLP_G;^L"R[
MSNR[+F=B523NRZYB=A9):0G)AR';+E`P-B*:`DF0I"@'T=K=V'=J+2SI:>DR
MHN`R63!F"DR\),&84*`MSM1'WI,>"<R!W?CPE.H:VQ4.8CKPB'$1.GJ)2B!1
M$*S]6X?1\?2*',3"F$4^#L\'X43[,ZAR]GB+')`U53%(Y3`2V0`Z0D,.A#:D
M`>D``>FI]78?1\.<4*!A/"``4H8/PKPE6!<Q?>CQT)5S@B5`@.BC;7"\13(4
M!(FJ!TR'\,I0/X50]V8=YU\?230X_>.P7^HS"7P0XYU^?[F=:>K</H^/I(H=
MQGA[#4:Y2?1F&,-Q<@W7%TUDHO$V/(V4:.15*OV[228VVW?-%"KE`X"FH42F
M`!#00"GJ[#K+3-\-)*64R.'08Y@^F.&AQZQ,'5W:K-\='U"?\&G]S6=MI33>
M:H+=`[P?O0KI[>SH)R#0.\'[T*;>SH&0:!W@_>A3;V=`R#0.\'[T*;>SH&0:
M!W@_>A3;V=`R#33JU*/<$NI#!YH&+H8H^:`U7=O6I6W&.>@.03F'34=>$HE#
M701T'KU$>L1[_77.(.,WTIOK%/M#55=_1LKN^(R"6/O[S+=K_5*VH?YQWM6.
M'\?NFF3L[OS1KMQ_1EUGQ^X75B;8H!0"@%`*`4`H!0"@%`*`4`H!0"@%`7!^
M#-]>3[52HX06U(%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4``=!U#K`
M0'YP@8/G"`4!SMW3EH("V640T3.D)4S""9TU%Q=&(JD.J:P>,")PXP'A,/1I
M4.,99T8N,9>,JEX/W@<6CE8.(2&-X8ZB*:*3<@B/7X*"!"AYA0K'9PT$;.&@
MKX^]_P"%+?OQILX:$1LX:!X^]_X4M^_&FSAH0V<-`\>=CUN%#:=6HZ_X:YN,
MP6$O7%*[;C*5.,;*WH,$YPV]XLW#1D8SR%#.T[CMU87]FY'L^0=VME&P'Y1$
MS>3M>^(4R4O%(H.OO@-U@<L%U=042#43CJ>K<!Z*/?Z1LX:#`*5Z;V=L[7L+
MWA)#?/BN,54(>\;!:LK,W:6S#%*B5NO?F/GXA9>4W3!#B6.M"/$GSA`"\1`,
M(A5UF%JPG:L1U;<7EII:J8N$8Y=5:IG'"6[_``)N&75C,598BGUYQY3>SF.K
MM*\L3*D2<A0%9A,8INY*-DX]X@8W`*C)5SQG`0*`B4:OJ]9JO`9;.%,R)"KO
MI8AAX"/4DQZ='!7"*B8].I!(Z(1<`#37PP`WT*NC9PLUK7HJ4]/P9K75%3HC
M@\=>+)*)J.EC$5(JDJ4%3E!1-9+L54S\`E$Q3)B(>9W*RZO@/1Q^'=*\@5<+
M+*]LLH9174!`YNGA$"%(`%```I0`A`#0``*NA*S;CJ6TE%<!N6O$.(QC''B-
MJ(CW1"L]K`M*5JW+LM=ZKR$'")R@<2AVIS@(`*92^"&H!II\RL-K<S58.615
M3B(E:;E5VT!$-$57CZ?N-Y$0$%'LD.,5SGDYMXUC%BE`HB)CG*J`]!2CH&K:
MW%PL$()G?ACZ[)Q]8NTJR+PW>W^W.+-X?&"0-,-6<\'[V,G?F=KG19VI%Q[1
M4=5FK%-ZJ)0$$]35&UN9JO*0WP<+/F*[4,@[@)9K<V]7)T;?%NQ[UA)6WM:P
MT\E[4P'$O&!BN&Q;]F'IVEXYYN&.6`>T;NSL(P0T$B9@Z!K:<FG+.8;-.C:R
MDYVL=#LV<6QBHB"C8N&C%H>!80L2A&QD'#N$RI+1D"T!DS5B(]0I`U2332\,
M.+3B\(:7AL/)MR@FWG)V<-".V```````````!W@`-`^A78@E&*BLB2&SAH%9
M#9PT"@V<-`H-G#0*#9PT"A.SAH*ZU7LK>@R&M-E;T`5&PM>2B1386O)0%-A:
M\E`4V%KR4!386O)0%%9M+-%`:U.RMZ""AOI3?6*?:&K7Q4(1L-I9<GQE=WQ&
M02Q]_>9;M?ZI6U#_`#CO:M+#^/W33)V=WYHUVX_HRZSX_<+JQ-L4`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@+@_!F^O)]JI4<(+:D"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*T\1X_<(/,7C>]FX[@QNF_[JA;+MI!_&Q1K
MBN)X:,A&,I.R#2-C2/WB8@JX!XX5!!-`.@#J=H/04:H;HJ@^B6Z[<1N9I97L
MW'C>;BV6M[,[-3DU$G9K65=N(M&ZXT0U(NP?O&*IR&T*)#`)>L*D&,,R[;\#
M9\(FAF?%UI9&7:@0T3.NH=U#WM#N-142>,;]@3,9@B[90XB03+&X3=.FE`1Y
M^)_G+':9U-MF][,%B-FQ#*L+#SU&Q>XK%P]?9QI5;E)'7/&MNS*1/LV+I5PD
M0`-IJ;IUYW'&5$S3NUUV1[R]N2YHVV*+4N:^]HF`-SN.VA#'F;ZV\W[?]M7/
M`,&X![+S\QC.6:3#Q"+C$M%5SMDGAT"F_!!ITU[:?"TLO^!4G+[9*ID^P-[&
MXR_K#ALBVIL)NC)5D3:1%8J\,.;C\0W_`!AUP$I1C#1S^(MZ8&93./`[82!&
MKIFIH50H"-2KU>'A-VS^C53V2F[#<J;A;I<LS<VW>J:*"25R-AF.:D74T,=-
M9\G-R8MB%'_:NR'LNKIJ=KQ]\MR'(7->_P"G>`(38#8UH)+="4GES==$LTV1
M=>'MG</8EHBY>%UZ03*OJ)>\-71;E%-.G?(X>(YE;-YC.0B"C.9]VY[>X1<-
M'R&#,12F3[R22TX#)M+QRI*-V;%SPE$060;&X##U#ITYY:@OB]@F%YEXQG]P
M%UY6W:W(T.FY3>;BKWE9^VD9!%4QD7D+CF%2B+*C.Q*4I02*14@\`";41&A"
MJ30BH:'@8=G;\##Q<!`QY"$90<)$1]O134J0_>A2B8=%LQ3.0.HP%$XATB/2
M-22?3,(F,<Y@`QU-.,XE*)S::::F$.+4-.B@`B8PB8QC&,/2)CF$QC#WS&,(
MF,/GT!97169$E:D"@%`*`4`H!0"@%`*`4`H!0"@+3?2F^L4_Q9JUL9^[ON?&
M5W?$9!/'W]YENU_JE;4/\X[VKGX?Q^Z:1.SN_-&NW']&76?'[A=6)MB@%`*`
M4`H!0"@%`*`4`H!0"@%`*`4!<'X,WUY/M5*CA!2M#:3TL@5E&<Y22J\K!;T]
M\*V>K7O*E\.X2.GOA3JU[RI?#N`=/?"G5KWE2^'<`Z>^%.K7O*E\.X!T]\*=
M6O>5+X=P#I[X4ZM>\J7P[@'3WPIU:]Y4OAW`.GOA3JU[RI?#N`=/?"G5KWE2
M^'<`Z>^%.K7O*E\.X!T]\*=6O>5+X=P#YU91LW+;K-MKC!6LP*`4`H!0"@%`
M*`4`H!0"@%`.R6-]\()`2)].`CX0CU]`=[2J+^'G=CK0;3!KHWDX\RKN7REB
MO;_8UI8_=XZMFU[GS#DB;S22[4L9S%P2S>6QOCJWVQ[.`9*5NZU%7<I.-VRG
MWI)8C5;H-H-?&;RPN]8M[&]=CE^U;Z!\9'G#^<[IL',^*[TW/V/EV'NV`VC7
M!MWOV[;;PSE6]XF8RM96=Y=F:;;N;-AK@EF\3<$.'C:*CIIJ=)V8XGX3]&C@
MUO:UX-Z]=DZ\+?0.7.;BX>1:3,3%S##QH&$JQ;23`KIJ\C52LGZ1738IHJ12
M:R49PI*A]Y<HHK%[I``0U^SW>I22VM6Z<(/HCX7TVINC30PB(!IW2@/04WFA
MH-=.[A\.YUU(\QBXQ>=(O*H<ABG(<Q#E,0Q3E,)3`9/4"#Q!H80T$=0ZC=W6
MJ^K8=YX1YB-2&A&N+,=EK;+[[E-X.(VBK;"\^]9!O)P5!Q_:L)"T".R>R&YO
M&T$R+XJVORPUW?;7&T*D!YN.1,L<1,W+7-=J,,9*L4[63)P?$2Z154LAL0BY
M%A)1L;+PTHPF8R6C64G'3<0\+(Q<Q'2+<CQA)QTD`B,@R?,ETU"*CX1M1`>D
M*W,9##3L*5F$8R:X%0RH=PIC$$1*/2/6/7K\_6IPEM=7CKKPJ`M,`'TXP`W"
M.I=>G0==>CO=-;&SMZ$"@E`QN(0U,.G2(B/4&@='4%-G;T(@NILX:$2*;.&A
M`4V<-"`K,"@%`*`4!2H>8%U:&TGI9`IM)Z6!3:3TL"FTGI8%-I/2P*;2>E@4
MVD]+`IM)Z6!3:3TL%I_I#Z`(CP'Z"_3#X(]7FZ5M8.EV^H7O"A1Y'FS%=WQ&
M0.QYQ_*9[MM4EBA\4S:AJ8X#H`#<5[Z:U\K@<5+U[*PY-V=;-P&F3Q[W[.Y7
MV^\W;MR4;*U53@+;/CEU<C:3TLVQ3:3TL"FTGI8%-I/2P*;2>E@H-7V)2DW5
MU`K9)%`*`4`H!0"@%`*`4`H"X/P9OKR?:J5'""G[/V:]%<T@Q1([A=O,')+1
M<MG?!K%]&@[9R\=-9?L5B]B7,=_Y\C7R3><!0DS'"(?3`!R=VIU]3P^!90?+
M^,CMJ[FY+`_F?Z6[#ZOY<JOUY#X?X@?&0VU>4E@?X6[#]O*>O8?#_$#XR&VK
MRDL#_"W8?MY3U[#X?X@?&0VU>4E@?X6[#]O*>O(?#_$#XR&VKRDL#_"W8?MY
M3UY#X?X@?&0VU>4E@?X6[#]O*>O8?#_$#XR&VKRDL#_"W8?MY3UY#X?X@?&0
MVU>4E@?X6[#]O*>O(?#_`!`^,AMJ\I+`_P`+=A^WE/7D/A_B!\9#;5Y26!_A
M;L/V\IZ\A\/\04'<GMF3`55=R>!2I)`*B@FR_8*1033#C.)E#31@*'"'>IZ\
MA\/\23)%K7S9&0(]U*6'=EH7C%,'9&4E*67<,1=D>VFET1<HQJTI$3CM%J!X
MT!6!/L1XC!W.NK\/O..*N;)9Z5^&493T=;X%`*`4`H!0"@%`*`4`H!0"@*=Z
MJ;F/CAWLI<.7X907]H<4Q1XQ[,3"82:CPB8Q>`QM.K42='G5KRQ-J[G7Q`N!
M98I>`JIREX2ET`Y@`2E`H%`=!Z=.`/G!4QP=N^MI%9.0'$.HZ"/<(F0/,(DF
M5)(H?[%-(@%`.X``%;$+2M=P"K4ZJH*T!8JQ:OF[IC)L6<K#RC=U&OXIX@DY
M:RJ<FR78KQTJV6*9)U#.&/:$<I'`4U$SZ&`0&M;%V]6UMJ#ES&NO8_?-KXQN
MW,'+TN&]8\+\VQW:[>XDC7SHAYB?VL7PB:\K%N=-,Q^-Z\L1E)>P9XTNH)@F
M54"@`!7+P5Z6(N;-Y4N?BR&,<BU6ZM?$;%^GLT#=D"(';HJ%2!7MC)D.0#$*
MHMJ/:J\(^$;741KO.&S>IH,A4`4`H!0"@%`*`4`H!0%*AYF"ZN<0<JA0[0Z!
MEFI!+TF<-UR%<,NH>%]'O4BG)Q`/="E&#C[,WIR7KEE]Q2C`[,WIR7KEE]Q2
MC`[,WIR7KEE]Q2C`[,WIR7KEE]Q2C`[,_IR7KAE]Q2C`[,WIR7KEE]Q2C`[,
MWIR7KEE]Q2C!RH*BT62<F.@H1!0IUB"[C2B*&NCC@%9,Z7;=@)NS`P"`GT"K
MK#<9N2SZK^(KN^(S\NVU=KOM8\^S/V*+]S9=4[C:Q;7-<%W2,NQM\$+]P;!I
M.)3#%IO7K9J1L'8/+T/]\3$5A,QX1,(`(!YUN_$R]HY5S:W'\-)I9:GZ@`.!
ME%"`H@'3X(^,LNC3O?>^\%>C8Z[*>(C%URIEUKQSD[,WIR7KEE]Q5%&;8[,W
MIR7KEE]Q2C`[,WIR7KEE]Q2C`[,WIR7KEE]Q2C!4J9A.0@J(&[0W``G>MDRD
M$0'PQ,F3B'ATZNH:48*B`""H`LBX\75!$RC4`,@!A`1X3+%3*45-"]6O?K8P
M_C/D!QUM$B@%`*`4`H!0"@%`*`4!<'X,WUY/M5*CA!W&A2BYCP$"B!S>$`@`
M@;I#Z8!Z!T\VJK\8J.1)`U2;!\`8%OS"E[W#>>#L+WU=LKNKW>A*7-=^+K.N
M&?D0;YPOJ-;^/34O#NWK@B$:T20)VBA@(@F4@:%*`!Q9REJNK,5F[I2?S!RD
M;>NF0MV6QE@DT9`7(>S[JR;#;56TG@2W;S:N"-7$9<&;6V-O>\MYS;JYP1?F
M>2C9D=00Z-:QP[PJ:<XP[J1+DEG)EGVF[5C-D%2;9=NSTLJ#=S$K)X7QF>-?
MIRJ(K0LJQDH^WS(JQDFSU.CH(D,;2NW&6[5!MVK6MJY/!C\*DGPHO`6RZ>NN
M^+,B,!;97EUX_5MX]Y0Z.(,5G6M\UV1!'EOLW*);3`2+/(UJ94I1T$QS"/6.
MM<V/452D(.BIE4=-><51ZQ3:=M;)X/Q6-OX*F`>R3/@G&Q3'-W``HVYTZC6>
MTP7H[?FH'G;GVX[0;,M:Y;UNO;1M^A[9LZWY>Z;IDE<#8X.6,M^!8K2<P_[,
MMN@=0&C!LHIH7I$`IKX+/L[?FQ`L_;GM`R'9]L9!L[;-MXD[6O6`A;NMR5:8
M,QWI(Q=T1D9*Q_\`D;FWN-`AD)(O"`!T`/113P2R;.WYL0>B3VG;6!!0AMK>
MWX5BAIP>\3C80`XAX('X+=$Q0'3SZ:^"]';\U`XB;3=KI^D-K>W8"A],H3!F
M/3\.GF#;O#KKT=-3KX%?Z=OS8D41RGVF[6":BIM:V_H@`=+=?!>-RJ(AT?Y0
MJ8+=`_9&'H#SZA]3N+P;<*_>HDX1VI;4?)CVX_`CCW]'JSP^%L2O980:IY*Z
M"JZZ0R9RGQ5MJA`'@VP;<51.`I&2'">/2E536^]*IG'W/=)#IG$#`/0(#H-,
M3A\.LUN"[BZ#5UIZ61NV5VI;-D9]YDEJV3:]L61:<1N/Q2$5:EHPT=;UOQGC
M.W:P7:_L?#13=HP9@N[>*JG[-,O$HJ<P])A$:<%"$<1X,4O!?`6V92<Z-LV&
M5V3:%`*`4`H!0"@%`*`4`H!0"@%82M6INLXQ;XTF!4*U:6:,>9`O(!C&`I2"
MJ(Z`"1/PAAU_<ATB.M4W+FPG5.D%P+,:MV4E/(VCG48N_!U8N6VI?I%D'1C&
M#ZL.`O#PCU>>%1ZWPLEJO5KW*_&5:TM+./Q%UZ2IZV>_<U'K+"K)5+F&L]+'
MB+KTE3UL]^YIZSPFE<Z&L]+.=-@_'0R2+I-0QDD4UB-%^P3(1<CI<RPG+J)G
M`)]@.O6F/#U=%4W-V/>7_$PQ,HVI?:Z[27<HT%.6EFCR_-B^+;#YR&W+=.[G
MLIN[HW"Q.;'P)*W>YAXN)RUC&(@)Z$M@J72Z5L-W9,BJU5CS&\4,=$`!/0-`
MUEV:5F>TAB9J3R54W7BS1X_E(UGKURU:SF[A%F8R*!FB1@;"D044RMW9NP((
M:@W.8B*13'0UX1'A#40K>6)L8)=5NSU[D,CDW5ONO*R=:6EG)XBZ])4];/?N
M:GUGA-*YT-9Z6/$77I*GK9[]S3UGA-*YT-9Z6/$77I*GK9[]S3UGA-*YT-9Z
M67>(NO2CC_\`9GOW-:BWE9G<:4EGTD:\M+.N<ADS"4P"40Z!`0.40_\`DG\(
M/FUU+-Z%Q55#+7GI92K'G-U9ER%:@D4`H!0"HEXKY"'F.PS`IG*93E`Y!=*D
M,40`0$G8&\$0'4-*U+Z2W'.XLERCR\.9\.<TG*6EFDG93MCP1N4Q1#VK9NR.
M"W1;H&KO,N1\_91R9N0R1B:RK3M>=W.9SLC#UJ/)N`D;Q7D+^E;-L!?V.CTX
MA*.30CRF='1`X'#P*WO7>G6+JZS?SY*SDUP9$JC6EI9-O&.W3D>WG!XZ0OO;
MJKB#*EYO,EP$CB"=R/F>YI/'4EB"XE;6R<O=]UV9?D_;T59EMW04FER2"H,E
MFKMN!3$XP*$>M=Y_2+_GRZ2->6EGD;QQIR`+<QFOD^UL(2-^-8[(..[">P,9
M<6XV*FE8O*EU!`VWD*/A9N\R2C_'[I4_^3SB!%VCHA=$=3F(%/6N\_I-_P`^
M72->6EGNL@8'Y!MD^^:R'!4U*S.+[0RE=`-DY_<9#0>0'^(K:5N.^;+QS?DY
M<C"QKZN*+;]@DZ;QC]=RR,L!U"IE(L8KUKO/Z3?\^72-:6EG=LO;UR%;DB\0
M^R.&@MV8S!:..[U9QTK<&X=NTL=AE<#ELLV2)=U>[9K83:YI$R4?%^S"C,7Z
MZB*C<%4UBFIZUWG])O\`ZR72-:6EG>W6<O78E@O+&`L&8=Y?F/<M7GFVU\I7
M0V=9$W5YFQ);5NQ6(4[`)(H'G%+@N=.2?2Y;R;E2`5.,ZB2HZZF$:>M=Z?2;
M_GRZ1K2TLQ+B_#O)BG;%F+WS+M?M+!$98Y+[MO(,9)9ZS'>4S#7[BS*K+"\S
M&6.XMN?D8C(%F2]\O4VK"52=G=/7:H(]CQ>"#UKO/Z3?_62Z1K2TLR')[>>1
M-9[%65OS"L3#-IBZ;F@;6@8"]MRUV9#E&]H6Y;ETW>]GK"8RPSEL2-@1=T)N
MIQF!.&,8D[=4YDRFT>M=Z?2;_P"LETC6EI9]NW-JG(GR$[2)B.P;!NU2+O?'
M,&K[/98S_;,.\MK)17IH*[+,D'TP0F064\K$G,V4;'<L5%$SD(Z0#B*9ZUWH
MLV)O_K)=)#E)YVS!:V$N2/(Y==V%B[:Y9ET/%,:RU[S.5YJ_MP%C6:$9;N4K
M9QVQ`+Z>OQ<WI:4U/W.LWB'T>9=BN\;&9@5/3M`UXXG$PGM87)JYI4G7GSD$
MB(+:=R";FR=<>)V-DVP%Z09,CJ2<PK?.>HRS&K[#[SL,DQ,1>:]TELAU/V;V
M;MPXBP<NGA&Z!E%B=FF<"[#WIO.4M:6(ON6G7ETA565&0MO>P'DG[G96=CL2
MX697`O:35@[F(Z5O#/\`:,K(P,HB=*W;PA(BX[KB)*;LR2.T51:3C4/$7RZ+
M@!U.!1IZUWG](O\`ZR729:\]+)6_(@\K7R7H_P"%3,W](]/6N\_I%_\`62Z1
MKRTOG'R(/*U\EZ/^%3,W](]/6N\_I%_]9+I&O+2^<?(@\K7R7H_X5,S?TCT]
M:[S^D7_UDND:\M+YRH<D3E>D$/%]K[0IS#PF,EE+,1A!,>D_'VF1#\*?1TB7
MPN]3UKO/Z3?_`%DND:TM+-:]Y;2\"[/^:'9EC[<[*<6!8]W;%+\NF7@4;KO2
MXXES<;++\+'IR^EUW;.`61%D()]H5`%.S#A`X!T#]WV$QF+Q..O1Q-VY<2M*
MBE)RIEX*MEUF3<FFW2A,P?IU@[@"CH'>U3,(Z=[4:]/-D4`H!0"@%`*`4`H!
M0"@+@_!F^O)]JI4<(.\S_P!]1P]X=?G"%5XCQ0:R-DZ%SR>RS/$3:)A0O*2S
M3OV;6JX1+PJ-;@FLI9(%DW'@T-VZ1BZH@'24XZET$:X5Q:L&1&-(TXW\9\[:
M=E?;;:O*BQP]OV8L",PA8&WE>U<\6)(+LDA/.HB>*RC8]U69)/UKAF<AW/?J
M#A)VU*R%RHJNCXN(``"'"OXE6E6J5><G,LN;C(\9\SE=^";ENFP<225Z6Q%<
MPG;UA-/9#:,^1_%^]IDUBY98SORW[<CWBCQ:T5+5QQ,)3K9HH*/9N6IE``#:
MFKDRWS<5V,=;AT_9(JZ\1@?)5NGVP9'YI%R8QR3E&+NR+NK8AANZ;YE[]?R\
MO:^/\EP,/!YES,]B)UU(IC)LV!"F92?8J(P@NC*$X2<0#L/>$]9M?#OD+)*3
M6?(97W-(-]IDQGW%6V?-&49NT[LY?>8LOW>TN+*=QY?EL2W?9\[:J>,,G6W>
M#Q],RUM/K^A'D@<W^5$9O#,!,@BGVFE3ZQDUX+=/E#R*BT'7R7"1.#5K"MO"
MF=+_`,PPNY;89NSF-QL7<^4)/+"-SV_:^"F-V63N!22=KR$;C1ZYO"0&/7<,
M!8Q;TKA5D1J59+BJ);PG]JZ/)GS?'G^4E*CKE,5W#(FRS8N-;-MN+RGD>9P'
MR^=M4K>ZB^Z9OM.P=@R2NW&871%7+'OX68A;JR9>TC&1Y'\DL<'4:S[`K1`H
M&-PUEZPEFJR'ESGRW,[FO<)B3:3?!KTE,[N&6PVW+ZR/B2RMT8[9LYX_E7]T
MRK=_N=LUPHZA[?S%)2#:U31*D;)+NF[)9+M!1**YM7K&5$W7X=T5JE+A)!0I
M8#>KEB67>9EW".,0PO*[QKG*U(F&R-,XGDYV^9*4N^WFF3;T:VXK&/DKQ;+6
MV/C+!$08NG>BHD,@<HUA+><E%YU3)E_Q)^(^'MG"[K5?<H//;_,F7+TRIO`6
MONS<\R%W9#=SEI9%L]MC9S-0'88\47/;%L/(M]%)'*LS02=J:"83>$;7H[MQ
MDKLUEJJ?#A)I1U-]!1_!]W5`1'7O\8=/GU]QA4G!2X2N]XA7O>?^W6OBN'X:
M#2(+[52E^,MS+C:!Q#N/Q+J.@:C_`-6W'/6/6-:V#_3KD9;9\?N$Z:ZQN"@%
M`*`4`H!0"@%`*`4`H!0"@%`1HWI79<E@;/\`<W>]F3CJV+QM;"U\3UM7'$B1
MO,Q#^)AG+@JS-ZX*\:MUE%E$BHB+8YRJ#J!NY7#W]==C!2NK0S3O>.2>LOD[
M6%/6G;<N]WM\QD[B3@(214*WW"VJBW27?Q+-X[(B1?$HK%2\=64$H&,<2@(!
MKT:!XDNT&*>+E"$JT?'3.^,K2R5X#U)>3!C<`\+>QS'`'4>O<1:(CI\S$U;-
M[M!C'.LI1K3[I?*'19JE?D8<:^6QS&_[0]I?T3U5Z_Q7E1YY=)%>4H/)BQIH
M)1WK\QH2FTXBCN'M+0V@ZAJ'O3:#H/3Y]9KM!O9+\U<:AQ.5/QA2IX.X>1-M
M^N.[K$O>XMV',)FKGQ?+2T]8TX[W#VN+NW9*=BBP\N9DF3%B8+>/1X??0$I@
M.&@&UT`*R]H=]9/SDZ\LOG"A[AOR8\9BW0*7>YS'52II$2!93<5:RBB_9APB
ML<ZN*#',900U&L)[^QRE2[);3AJY5_&!R_(PXU\MCF-_VA[2_HGK'U_BO*CS
MRZ15<8^1AQMY;',;_M#VE_1/4O?^*6>4?PND<X^1AQKY;',;_M#VE_1/4>O\
M5Y4>>72*\I:;DQXV`.C>QS&^C_\`Z(M+^B>KK&_L9K:T'!M::]),:,@AM$87
M-;4EO$Q=.7_?.366#]X^5\56)<F7)9K+W>>RK<:VZ2,0>ST4RBT)I^3Q@X]J
MJW2`QAUX"CK7JFX,9/$X.W=N>/**;IFJR"8`E`HB4`4*`=``L)15#S%!)X(F
M[^G17U9OQ\5<@H9"@%`*`5C+Q7R$/,=EC_OM+IT_RM;I'I`/\G/TCW=`K6Q'
M_@)\C^)F@R&_*;P+NFM';E;&Y3:A+85?2&7'.<;%REC3-`7C#6PXE,8[H\^M
M\8Y!M&\+18SDZ@=*/N>2"08.&12N"."`)BB'$7\Y0IUF[K9(UZ`3*LOE?N&L
M1>T1D;+#&8?9=V[;E;$R_=%OQ"L1++Y6W"Y@M#)UR7E:K!<'K5C9=KN+::Q#
M%BJ/C*[5N154>(YC!!!\"7Y=.ZZ_&<=.9,S!@-7*F+<?X`Q9AQ.S[7O*(L:;
MM[!^38/)WNARB9=O[+,+@G7$("!&D051DT25-P=`Z@!B>;Y26Y.]<QHWK>^=
ML=34:DZW$$1NT7.5G]^OF&=L?W/:T4DA:;B59X3L9+&Z]RB9DA$Q**DJR3,+
MEP#@:`^E(<I+*MS73#7-<]V8/N)6\+7VW1>82OY_<1&0\%-[>82UK&:7#C2T
MK:N>W++OQ"[+$MQMPH74R'V*E1!5,[A(H%,!/O<SL+Q_NFSKMMR+DV)M:Z\4
MX+LK-=NSV/KC0FD/9Z5R6YL$\#/1$E"OVJ[4L8K9JRAT!/V:A7">H"``%`8@
MS7RT6=W9-L*;P[(8VQ3CJQ+"Q[8D'CYE9QD8EF[LK<?8>>[@D&"D:F!4QGF]
MF.43G4(?M)=P+I7C6$YQ`[4UR^K[G<_Y)S3[O;80CKU-NE.SBG,?)J/61,_8
M9QWBZW>W6!AKV=M/;+<.'0%-Q&1<@!=1#2@,:2_*VO.XE<5,9#*-L)VU8^!=
ML>%+I8QK.</(2C'#JLV:_7,1XVV*FQ)<\=,G")U$BB)P`ZVH@4:`\`ERTMSU
MS*VK;%]9DPNO8N&</LL&8;2MNU+E;7#,VDPSACW)S&YLBJR#0K9M='N0L<(5
M5M%>,L"N-'(*]HJ<I0,CW9RK;EO[&-EXENS)-MH0\5E?>M?%WR<-%/#R;RV]
MW<-D2WVJ<0#Q)D0\K:Z%\=J]`ZZ(NA1'A4`YBFH#*6P/8;>FU_(URY#R,]Q0
M]N!]C2SL2P3W',WFRYI.:MVT7DN]4N.XY#-UX7*O:1)9RZ3%.VX`A8MFH0RB
M2IBB8M`;9=1[X_/&@&H]\?GC0#4>^/SQH"I1'B+TCUCW?]B-`?GZWE@`\W7$
M!A#42\N[)0%$>D0`V:X`3``]8`(ATUZ#[O?W^_\`[2^,OL9WR&11^G7\]#_%
M&KU@VBE`*`4`H!0"@%`*`4`H"X/P9OKR?:J5'"#NLO\`?4;]<'VQ:T&V\YH:
MTM+-?'+>4,GMXO-0BADSEW8;PE`.F;@4*H3/F0BD4*8.D%"E#0!ZP#S*K:6J
M\BX1"4JYWG,[3&T;:I.Y(]^J;V\XL?Y)2D@F5+W=6R91^ZF^V!P$_/H-%C0L
MK-IN@!4KI9@9QV@`8#\736B[5MYXQ?<1T#X=X8)N7)6Y_%.6[[N&T%\88$;W
M%<6)K(;0Z@WF?(%ZVXM:ES7C>5PJ!XL6WR0Q^U8LDQ!=!301TJ%AL.YJ3MPJ
MGY*Z"&JY=!EN0POAF;OZXLH3F*K,EL@79:R5A79=C^#,M+3]EIM?8].)GX!\
MZ-!7+'.6/WD3K$4[-/Z40T#3<V%CR(>:N@@CM=^R/!R.W?/>W_"6/[#P-[_U
MA25A3<[!P+P>P643=F:.Y]X\<R$P\1:>,\;)D1<K$A@`I2E*-0\/8X(0K]ZN
M@AJJHLYD3%&U+;CA^&N&,L'!V,XA>\[72L3);J(MU9L;($&E'Q_;(.3/'`H0
MULR[ADHLO&L@(@<ZIC`03CK4["Q3Q(>:N@DYKNVI;7[_`)RR+HO/`>++KG<?
M1#&V++D+BM8!0C[;CN$L=!FA(]4I)FW[?*4`;(OBJM42@&A`"FPL>1#S5T`X
M+NVB;5LAV_9EM7Y@#&]R0=B$>-<<QT];[MJ2UXIX]-(R,.@E`N45@A7D@H98
MC-;5J8YA,)!$1&FPL>1#S5T`S"RL2RHM^M<D?8MJIS#JSV]CC)Q$&W9OS8^C
M43,FEEN03<$;!:[-N<2IMR``IEZ@#4:.Q8>>$*?>KH!T([%N-(UM8T;'V);;
M)#%`KO<;Q;>%:M6=BF=I':N)RUW953%1>G:KF0$B(%T2.)>KHJ8VK4?%C%<B
M2![<?_!\SO>=5J;61/(5W?$9;1Y<YJ$&-J@Z[E>9;TZ_]8_$O_PW8YJRPDKF
M1<!99\<G36Z;@H!0"@%`*`4`H!0"@%`*`4`H!0$/N8.`#L2WA:@`Z;><C::@
M`Z:0RQPTU[QR@(>:`#W*X/:))[MG70_B-._XW<+=]B-EW1S'MI5CYBQ#NQW$
MXK+RY[FNEIB':Q*7\,LSOIIE"QHYMD*Z(&RK\L('$1'PKI:,!=9PIPKR"0`7
MHK\\3BNORS9U\N;X9BHFWA/*]H;9IK8_@O!.!\I8@L/>?E/."5PVGN'G[[<9
M5QY+6!AV>N@#G9W9<5ZR+=&8<V>@!4?'12)J8Q2ZB.O1O+P_"HW3@!X[*O-`
MSS"W+DW'&+L/XXN6^(7F16AL#L4+LN:X6%OO4+SQ=9U[HY&N0\6T4?E+;TA<
M#DKEHAX;E-``3$##T4T6A`Q#?',<YD5BV?O,N"0Q;M-E''+FN*WE<]RL=<N1
MV<?F^V)RW(B]QB<41+]$Z]A2499TH<[IU-++(G>D*5(`3XAJ<V8'WM\O--R_
MM]FIR9@+JV3XUM6T<*6SFRR\?YUOG(5R9YSD,O8A+RFK;@;6QA&29L;(L$A&
M):OY(A@?NU!<%(5J050`RUBC?SN@W/9^963A#'V)+/QU:FVW;'NKOM7*=TW.
MVOMS!9[:WDX=8OCV,:Q4MY.3C6EKK&:RSI<C%!PGHMJ76HHGG!'*R^;[G$^Y
M[#&$KUN/95?#O<#D24QFMBO!%\9&OJ^=LEX,[6O*=MQU?>1&D0;&N3X$D_:@
M,ITT2X150XQ,U351*(TU8Z$".>"N:?N*VZ[.\-L-P%X8+E\V[D=U.["V[%RM
M?$YE"1QO8-B8QR3D]W=T[D]&W8B3NJ8)'.X`T9;L9$(E[:-%F5P9`2G-35CH
M0-OW+9WZ36]6V\W-+A9P"]ZX$R/!6-+9&QE&7RRPGEB$G+60N>!O[&A,E1D-
M<"+&6XG#&2:G[;Q!VV+PG,4Y1%JQT(&U)LJ1=LDLGIPJ$X@`!$0+TF`2CQ>%
MQ$$-!\T!K**2>0'YH=N@![[W,F#0-!YCV8@$-`T$#1]M";4.H>(>OOU[!V(R
MV+:>540)2AU?/_PC7W4_&?*;\?%7(5K$R%`*`4`K&7BOD(>8[+'_`'VE_P"5
MK:]?5XN?7JZ>JM;$?^`GR/XF:#-/&TNW<USFUW'=PVZXSWE7$&-8C/3\UB;4
MLRV[9&8]N5^2&['<A*)9?N7&3\K8V;6U[0:;4D4Q%RD5H6%=D7()W!Q1_.=I
MM8N[F2J\^;@[X-N%G<S&X6H6KC2,3@\IWI=%K8,OW#UYR+=Y:DWF;`MV8PE[
MSRCF>Z+29I.&]H2UG^XA\#MJW6<%3/(-2@8.,-<2"-%[\Q??'=>"I&6:,<'8
MEN;,&VS'VY/$<]$JW9/>]?#K9ULG'5U6'>!12.%V2<K%SJ3EJ]:$(($770$O
M&4AA`R/:.\C==AS(&7KIS"GC#(>WU7F"9VP$$`C(7,KDZU$X;%,MD5F_M5VB
M@I"HV4P<6,];-VCPOCR"3LHF'PM*`\?BCFP[L\F6->5SV[MJ7F96Y,(16;,3
MDC+2N^`:6TK(Y*MNT7EHO'UTRK-UGN;0M">)+-$[=32&8<1JS!L8IG"-`>C8
M<RS-UR6Q#7QCRR+:RUFIIA_<.4UBVB\OBQ>RG,:9>P)9Q(.[,%WFTCY=OE.$
MM[)IY-S`JOBR`.T$XUD9?QH%"@;,>7_N'N+<WA,]Z77-V;+75:M]W%CZ[E+/
MMZ[K%.WF(5.+D4&5UX_OELC=-EWB:&FFZSV/7[5`4W::R:@E,`T!/C0-==`U
M'K'3I'40$?HA0%.`G3X!.D3"/@ET,)PT.)@T\(3AT#KUT!:"20"`@DD`AJ(&
M!,@"`F`H&$!`NH"8"!KW]`[U`7B4HZ:E*/#]+J`#IT@/1J'1T@`^>%`4[-/4
M!X":@.H#P%U`?"Z0'34!\,?GCWQH"Z@%`*`J7Z8OGC]J:@/S^;R_[W3$7_[=
M^2?_`,ZH"O0O=[^_W_\`:7QE]C.^0R(/TZ_GH?XHU>KFT4H!0"@%`*`4`H!0
M"@%`7!^#-]>3[52HX06E.)3`8-1$HZAH(AU=X>Y7/.>:[+/V09OQDE=4/A_?
MYF3'=CS>0\@9"1LF/Q+AZYT+?F,KW,K=TZVAI">9MEWY$;CG^R#B$1`*K<4M
M:4<[73P=TA*F1:3TQ=KV[\AC&)S+LR$,?Z<Q-O\`@\AC_7F*0!-\VM6ITBOQ
M7]X`@)1YE^9!*81$Q!P!@\2&$P<)A,7@X3"8O0.O6'14IJJY05-M=W>GTX^9
M;F(_"3LR\>W[!Q]$]-.S#B(.B>G[GJK;JC$J&U[=^&NG,NS(&H``_P#5_P`'
M](%#A*`^!T@4O0'>"E4`.U[=^(`4>9=F,2E$!`H[?\'B4!+]*(!P:`)>YWJ5
M0*!M=W?%-QEYEN8RGX#)\8;?L'`?LS?3$X@)Q<!@ZPZAI4%P;7]X!3"<O,OS
M*4YM.(Y<`80*8VG5Q&`H".E*H%@;7-WH%`H<RS,0%#40*&WW!P%#7KT#L]`U
MUZ:50'Q7-WFA0^4LS%H3Z0/B^X.T)KU\(<'@Z^92J!4=KV[[_66YC_L_8.^X
MJ4T57O$98.UW=V8.`W,QS&D*@@FF?W@,'APK'$"HCKV*FGWT0[@TY,YJ/+FS
MF4]M>W"3P,YS/<EU9HN_.N0,YWM`7[?%WW3;EOVIXO+6U9T+8+%LTC+=,FR,
M52"AVQQT3T`3:^;5UCQRVSXY)NMPW!0"@%`*`4`H!0"@%`*`4`H!0"@(?\P;
M_L);POZO.1_YD<5PNT7_`(Z?(_B-._XW<-R]L;6(J2W.XAWF'O&81E[>V<*[
M;`L4&30\$\AKLNNS,BNY]1ZH8K@C\CFV$D13#P>S*!NO6OSK=;6\&N"J^4KI
MPGR=YVTRZ=S,G@J_L69BD<"9TVT9&D\CXRR$WM&#OR',O=-HS-AW+:EYVE,J
M(-I6U)ZUIM4BPI+D736`APTT\+HW*5R9J!D8,><IA."5A;CO+<CD3(]\H[];
M3W^7/=,Y:=KQCJ<R1:]G0]HJ6N#"(.1DTM*0;0Q3-N#51!L8A-1$NHX$&8+]
MY<5H7S9G,7M-UDB>;1G,,<12]V+)Q$.K[W36)L&.L(Q8%%506\ZFZ;1@*F%T
M)?",)==`H"--]\H&XIJ[\XJX[W6RF,,7;I+%M6V,YP2F%\<7-E=6;AL40^&G
M$ICO+DX*\WC^)N*SH1$%XIN51%)4RWBPD*L8!`SWA'EIVIASWT6JN6+\NAME
M39YA39S<AQ8Q%I.D;:PS#W]",KN@):'XI5K=TI$9"=JC].D!B%$`+PZ`!&_"
M?)YO+&;W:6SNK=N]O#'>QR[825P)CRU,!XUQ4QF6UL6;)XY;R68)>WD#2=]W
MD:Q'ZS=63."9G3LJC@VJBQC"!]9ARCKQM>V+>B[`W6O[5R%A7<7F#<%M1R87
M$=DN'6*&F?7MXS&4,6Y!ME^92(RY:=TKW@]:JJ*G;NVC1%+30Y`$0-B&U+`^
M3\(VK=+?,6X&\MQN0+ZN16\)69N*`@+'M6U>)NW;%L?&EE6VS]A[2L5D1N!T
M43K.%E3J&.<^IQ``)>HF$R"9A*8HF*(\)R`D8/"-T"F7P2Z>9U]?=J8YP?F@
MVZ?^]_F2_P#[C^8/YNMJO8.P_P"AAR($HPZOFC_A&ONI^.^4WX^*N0NK$R%`
M*`4`K&7BOD(>8[3#_?B7_E:H>9TMS!T]W2M;$?\`@+G(_B9H,CURO=ANVW<O
ML/PE?65["7=WHC>>YZVY&ZK6N"X+5G+ELV/W:9[496=<DG;DA'$G[2;B]5[%
MJX[15+M3Z"':*:_G*W)1Q-UY*U>?N`V=-MFUL?&7B,X2C6SGUFXSV]2.WG`6
M+X6TRP9,=V?=0PY+W&5N0')B/$I&,MI*,;(E3!-D@<Z8ZF.(U!![F1V+;6YF
MU(^Q'V&(0UI,,/OL`QT*!WZ*+#$CN>;7,[M%)RD]*X:-@N)DD[;+D,58JB91
M*8!`-`/5Q6U3`]OQL%'1F-6#9M;>6QS7$HZ2;]1OE<L&[MPUYG<NG)U7SEQ!
M.U4#BN8Y5S'#CUH#$D#RV]F-M15_0,3@.T$83*<2TA[OB5%;E<,6T,SFD[I9
MP5N`\F3GL6"8W,B64;MXP6PMI``4)H4I0*!]>(Y>6S^/L%GCA3!]N.[;2M^[
M+3/[*.99U,R,9><U:MPW1*RMP'D_9MY/3T]944\&0.N9X@X:(@10O"`4!GK"
MF!<7;>;.1L;$%G-K+MLTBO*2#)!P]EW\K*N$D6II28FYEZ^EI-YXFU21[==5
M17L$2)Z\!"@`&:.`W>^B'HT`X#=[Z(>C0#@-WOHAZ-`.`W>^B'HT`X#=[Z(>
MC0#@-WOHAZ-`.`W>^B'HT`X#=[Z(>C0%0*8#%'3H`1[WU(T!^?O>84Q>;IB'
MB`0UY=^2NL.]FN!`?G"%>@^[W]_O_P"TOC+[&=\AD,?IU_/0_P`4:O6#:*4`
MH!0"@%`*`4`H!0"@+@_!F^O)]JI4<(+:41%$!Z=->G0=0UZ=!U`=0UZAU*`^
M>%31"B*5%%H)%*+0"M31`4H@*40%*("E$!2B`I1`4H@/VAU#S!#J'SPI1$41
M30-==.GO]WJ`.OS@H*(K0D4`H!0"@%`*`4`H!0"@%`*`4`H#'&9\70V<L-Y3
MPK<DC)0MM95L2XK+N*:A6\8ZG8N#DVI1D)*";RIE&:\E&"FFJ!3(F`0Z->G2
MN?C=VO&)SRTI2GP9IWTG.CT&+HW'&^2-CF,8SYJ.Y0&T>S;M4@7Q!MN,N4B2
M)2E17"2QTJX!5N4>S'PA`0+KKJ(UYUCNR&I)[&-%EX_C94ZG="Q-]?=YJ.Y#
M7NZ8@VP!KT`'4&-N\%1A>R2=E.ZFYU?Q\I%9\&;D*^X3?6'5S4MR(=SHQ#MA
M#H[W1C;J"MCV1M>2_AW2*W-*YBGN"WTZ</RJ&X_A$-!+[S^U_00[PA[VV@AT
MT]D;?DOG^R*W-*Y@-A;Z1Z^:AN/'00'IP_M@'I+]*/\`[MNLO<[U/9&WY+Y_
MLBMS2N8J-B;ZAT$>:CN0$2CJ`CB';`.@Z"&H?Z-N@=!'IJ/9"UY+^'=%;G%S
M#W";Z^OY5+<CKW_>AVPZ_P#Y;5/LC:\E_#NBMS2N8H-A[Z1TUYJ&Y`=!$0UQ
M!M@'01`0$0UQMT"(#3V1M^2^?[(K<TKF*^X3?7U?*I;D=.][T.V'3YWO;:4]
MD+7DOX=T5N<7,!L7?</0/-2W("'F8AVP!J'G^]M5EGL%+6UYU<'E^'A$UEP/
M+R'=V]817P/'9&1F<GWGF*\,JY>N?-.0\BWC$P<+<DI=5UF3,_*E$6TSC[?0
MC%3(E`/%&Z*!2AX)0K[_`'1A(;JP\;"7@P5%\,I*K3+G,]EZ2@()D1`0U!),
M1,1/7IX"F'I$"UNR=9-Z6;\?%1=6)D*`4`H!0`=6P#J`CJ`ZAJ/2!@$!#4!`
M0XBCU@.H:USK[VL=59B,A!!CRX]L42#D(!SGVS8MW*W#=#FW;0W*YRMVU6TY
M>5T+W9=(-K:MR\U?%]'+HQN@"EXC"(]8U\\]V.=R*I%MTJZ(B5-5Z*'/\GC@
M'3A]UFZ+A$#`(?&TS=H(&'B,&GNTTT,;I'OCTUO>H%H7,NDT"[Y//`?Y7;H^
MY_\`JUSAW.K_`/O7N=RI]0+0N9=('R>F!.KW7[I-.]\;;.&GSO=KU5'J!:%S
M+I!3Y//`8Z_\KMT?A?3?];7.'A=&GA?\M?"Z._3U`O)7,ND`>7E@$=-;MW1C
MIT!KNTS>.@:@.@:WIT!J`?.J?4"T+F72"OR>>`]=?=?NDU[_`,;7.&H^>/NU
MZ:CU`M"YET@K\GK@3\K]TG]K;.'Z:T]GUH7,ND#Y/7`GY7[I/[6V</TUI[/K
M0N9=('R>N!/ROW2?VMLX?IK3V?6A<RZ0/D]<"?E?ND_M;9P_36GL^M"YET@?
M)ZX$_*_=)_:VSA^FM/9]:%S+I`^3UP)^5^Z3^UMG#]-:>SZT+F72!\GK@3\K
M]TG]K;.'Z:T]GUH7,ND#Y/7`GY7[I/[6V</TUI[/K0N9=(+T^7K@3B`@7?NC
MXE1[,IAW;Y^*8AA\,#)*1]Y**IJAP=!C!V8?NNY3U`EP+F72,ID3$^SS"&$K
M_7R[9[;(\G?\E;3^RS7/DG,=\Y6E2VX\>,7CZ+;K77<<JDV;K/(U%3H1*<!+
MT&#4==_=^[>I7)322JJ9J%]CQGR$GNS_`-M[_@_/Z?VJZIM"@%`*`4`H!0"@
M%`*`4!<'X,WUY/M5*CA!=V1_Q?KAOZK367'S/H('9'_%^N&_JM-9<?,^@#LC
M_B_7#?U6FLN/F?0!V1_Q?KAOZK367'S/H`[(_P"+]<-_5::RX^9]`'9'_%^N
M&_JM-9<?,^@#LC_B_7#?U6FLN/F?0!V1_P`7ZX;^JTUEQ\SZ`.R/^+]<-_5:
M:RX^9]`'9'_%^N&_JM-9<?,^@#LC_B_7#?U6FLN/F?0!V1_Q?KAOZK367'S/
MH`[(_P"+]<-_5::RX^9]`'9'_%^N&_JM-9<?,^@#LC_B_7#?U6FLN/F?0!V1
M_P`7ZX;^JTUEQ\SZ`.R/^+]<-_5::RX^9]`'9'_%^N&_JM-9<?,^@#LC_B_7
M#?U6FLN/F?0!V1_Q?KAOZK367'S/H`[(_P"+]<-_5::RX^9]`'9'_%^N&_JM
M-9<?,^@#LC_B_7#?U6FLN/F?0!V1_P`7ZX;^JTUEQ\SZ`.R/^+]<-_5::RX^
M9]`'9'_%^N&_JM-9<?,^@#LC_B_7#?U6FLN/F?0!V1_Q?KAOZK367'S/H`[(
M_P"+]<-_5::RX^9]`*=B?4/P6NAM/\H;:Z:>'I]^UTTZZGK%R"U%";AI49-?
M$:M[Q^X5%%34=>SXM1UU<-]==>G75;776L7=C*NNFN5/H*BG8G[HI>N&WJU1
MM815(Q;7$GT`=B?OI>N&WJU-NO)ES/H&4=B?OI>N&WJU-NO)ES/H&4=B?OI>
MN&WJU-NO)ES/H&4=B?OI>N&WJU-NO)ES/H&4=B?OI>N&WJU-NO)ES/H&4=B?
MOI>N&WJU-NO)ES/H&4=B?OI>N&WJU-NO)ES/H&4KV*GXK3_RAMZM6TMX7]50
M5FYJKAU)?-('8JZ_[6(\/_"&^O#_``NO#6K*YM*ZR<>5/H`[$_XOUPW]5K+6
M7'S/H-^/BKD'9'_%^N&_JM-9<?,^@D=D?\7ZX;^JTUEQ\SZ`.R/^+]<-_5::
MRX^9]`'9'_%^N&_JM-9<?,^@#L3_`(OUPW]5J)26J\^;0^@#LE/Q?\.W]5K0
MLM.7AZ=#Z`"HGU'A%/7IXN%PWU_V6NBNO5UUV(6\+J:[DM=9D1)^"^0=B?OI
M_P`.W]6JCK3\B?FRZ#0H.Q/WT_X=OZM3K3\B?FRZ!0=B?OI_P[?U:G6GY$_-
MET"@[$_?3_AV_JU.M/R)^;+H%!V)^^G_``[?U:G6GY$_-ET"@[$_?3_AV_JU
M.M/R)^;+H%!V)^^G_#M_5J=:?D3\V70*#L3]]/\`AV_JU.M/R)^;+H%!V)^^
MG_#M_5J=:?D3\V70*#L3]]/^';^K4ZT_(GYLN@4'8G[Z?\.W]6IUI^1/S9=`
MH.Q/WT_X=OZM3K3\B?FRZ!0=B?OI_P`.W]6IUI^1/S9=`H.Q/WT_X=OZM3K3
M\B?FRZ!0J"*O[D2:^8NWZN[U+4ZU+R)^;+H%"P$3=P4>[U+MO,UZE:.\YJDH
MR7+&2^0OL>,^0N[(_P"+]<-_5:C67'S/H-D=D?\`%^N&_JM-9<?,^@#LC_B_
M7#?U6FLN/F?0!V1_Q?KAOZK367'S/H`[(_XOUPW]5IK+CYGT`=D?\7ZX;^JT
MUEQ\SZ`.R/\`B_7#?U6FLN/F?0!V1_Q?KAOZK367'S/H`[(_XOUPW]5IK+CY
MGT`=D?\`%^N&_JM-9<?,^@#LC_B_7#?U6FLN/F?0"\$C]F;\'].3_P`8;_4J
,?C:C65>'F?02?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>v371611_chrt-barcells.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v371611_chrt-barcells.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^(,6$E#
M0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`
M,0``86-S<$U31E0`````245#('-21T(``````````````````/;6``$`````
MTRU(4"`@````````````````````````````````````````````````````
M```````````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````4
M8FMP=````@0````4<EA96@```A@````49UA96@```BP````48EA96@```D``
M```49&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P``
M`]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E12
M0P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`
M````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V
M,3DV-BTR+C$`````````````````````````````````````````````````
M`````````````````%A96B````````#S40`!`````1;,6%E:(```````````
M``````````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4`
M`!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO
M+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`
M````````````````````````````````````````````````````````````
M9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````````````
M`&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````````````
M``!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@````
M``!,"58`4````%<?YVUE87,``````````0````````````````````````*/
M`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`
M*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5
M`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!
M#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A
M`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"
M9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/
M`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$
M<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U
M!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'
M/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG
M"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*
MW`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS
M#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/
M7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H
M$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4
MSA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2
M%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;
M.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^
M'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(B
MKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W
M)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K
M-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'
M+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XT
MV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY
M.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_
MHC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D55
M19I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+
MFDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F
M4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8
MRUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S
M8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG
M/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$
M;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV
M^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C
M?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(
M!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6
MD3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R:
M:)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/F
MI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN
M+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9
MN-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#
M6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XV
MSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9
M\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$
MY@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q
M__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+
M_MS_;?___^X`#D%D;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&
M!@@+#`H*"PH*#!`,#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?
M'P$'!P<-#`T8$!`8&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?_\``$0@!]`(V`P$1``(1`0,1`?_$`+H`
M`0`!!0$!```````````````&`0($!0<#"`$!``(#`0````````````````$%
M`P0&`A````4"`@,&#@T*!00!!`,```$"`P01!1(&(3$'0=$3%)0646%Q(M)3
MTU34%565-A>!D;$RDJ*R,W.3M'56H4)2PB,T=#4W1V)RL\1VP8)#),/A8T2D
MA"4($0$``0$%!@0&`P$``````````0)Q$@,S!!$Q49$R!2)2$Q0A@<'1<A7P
M0;&A_]H`#`,!``(1`Q$`/P#ZI`````````````````````````````<]N.=<
MX7G-ETRSD>/;DKL!,E>;K=C>6TEZ0DUML,QV#;6M6$L2E&LB+I@,6!M)S=;;
M3G`\XVAF-/RJQQENX0DOE;YK:FC6DVC>+$2DJ+"I.(P&=L8VA77.^2U7J]Q6
M;?<&)+L>5'9Q);02$(<2?7J6950X1Z3`1G+&W>;>[_G-?$F6<I9;@KF0K@HE
M\+(PJ4DE'UQIX-9MKPT+5I`;[8IM1GY[R_+?O,)NV7VW.I1.A-DLDI:>;)YA
MPB6:E46VJNL![Y.VHM7+*%QS5?FTP;8Q<I42&J,T^^I<=AW@6W#0V3KBE+41
M^]2`R=E^T8\^QKQ<XT)46SQ)RX5M<=)27GB:27"+<;/WG7'H3KIKTZ`$U6M#
M:%+6HDH21J4I1T(B+29F9@([DC,5QS%!E7=UIMFU/R%ILA)2HG7(K9X">=,U
M&7[19&:2(BZVFNH"1+6E"36LR2A)&:E&="(BUF9@/&#/@SXK<N#(:EQ72JU(
M86EQM1$=.M6DS2>D!`YN=LY7W--VR]D:/;FTY?4VU=[M=^&<:XPZC&3#$>.;
M:U&E.E2U+(MS2`PXNTW-MKR[G!_-]H9BW+*C9NMS(A/E;YJ%MXFU,FZ6(NNZ
MU2<1F`VFQW:!<\YY'*^WN.S;Y[3[[$QAK$EMLV3(Z]>I9EUID9U,!$\M;>I]
MZGYXF'!98RMEF$<NW3%$LG9'OL"E]<:<"\%2H6H!)=C.TV=GC+<J3>8:+9?;
M:^;-R@H)24H)22<:61+-2J+;576`U=HVU3)64(MW7:BE7B^763;<LVB.HVN,
M)9<4E+CKKF(D))"#6M=-6H@&UL&?<W-9[9R;FZTPHLR?#=N%NF6N2Y(9-ME1
M)<;=)YIA:5%B+214,!.^.P^.'"X=OCA-\*<;&GA>#,\./!7%AKHK0!H\[YEE
M62WQFK:TW(OMTD-PK3&=J:%.K.JW'"2:5<&TV2EJH?2W0$@;)PFTDX9*<H6,
MTD9)-5--",SH7L@+@```````````````````````````````````````````
M`````````````````````%KSG!-+<,C42$FK"G29T*M"`<8@96R)M'BO;0[!
M>+KD^\2<;=U?@3$QG$N1E&@DSV:N-U(D$9D=-%*@(G.S+FO,.R&38[G<BO#E
MXS(UE^R7DFTMJG1"?3C=PHHA184J+$7ONB8#.;?G)S7G/9?9%*BR;Y>(Z^$;
M(_\`U;2[#0<Q])UUX6N#3_B40#22TQRV=Y^DVMA+#6:,P1\L6J,WJ3%BJ;A)
M)&O1AQGTP$HVK2"V69ACYMA-J5:+O9W+!/06G#)C,F=O<,B+1JP&8">[/(:,
MG[&+23ZB0=OM/&Y"U=L6V<A=?^Y1@-3L>MF8X>Q6#(LY149CNR7KHD[@3AQN
M'FO*=JZ31DX98%%J,`NLC:'<8L;).8'[;XZOKBE2G[(B0AN/:&J<8<7QE:U8
MW#/@DTT54`D,V%M0BWN+%RZ=@CY0CI9:)B2W,5-2T@B2M*#;6ADJ$5$5+J@)
M1=)5KC0'G+H\S'@&G`^Y)6EMK"OK:*4LR3IK0!XP85JLED1&M45#%MA,F<:)
M%21()!$:\+:2T:=P!R6WY3R'M"@N[1LNWJZ9.N<XE>-7X$U,8TNL&:<,]FJV
M\2<-3*I:-8"*R\RYJS+LFBV.[3RNSM\S,U9;7=2;2TJ?`9?):WL**),C2V?7
M%KZ>L!EQ'9SV9,W[++2I49V\7XWI+C9&7%K,Y&;<DN).N@W*<$GIF`TTA,=_
M9OFUZWLI9:SKFAFQ6^.W^;#C.HBI)%-PFVE`))M>F'LOS"]FB(VI5JS'97;+
M*2G3AGQ63*"YH+15/6GU`&XL5[5E?+.5,C9?@1;GG"+:V9+KTU:68EO;>353
M\ETB-=5K49);;ZY72+2`D-GR=?83EPS0S<X69\_2FD1FY4M2HMOC,$K$<>.V
MP4A;:-TSTJ6>LP$1RE(VPW+:-FB\LP\O*?AG&LLO'+FDT@F$\,LHYE'-2M+O
M78B3UWM@)=9BN^:+S=<X0.`,H+3MLRB4HEG&-23I)EJP'CPNNIP%32:$@)'D
MY.T0F9//1RT+>Q)XIXF1)0G#3KN$XRM9UKJH`D0`````````````````````
M`````````````````````````````HH\*3/H%4!JWLQ16GG&E-+,VU&@S*E#
M,CIT0%AYGB=J<^+O@'.:)VISXN^`<YHG:G/B[X!SGB=J<^+O@'.:)VIS\F^`
M<YX?:G/R;X!SFB=J<^+O@'.>)VISXN^`<YHG:G/B[X!SFB=J<^+O@(?<<B[(
M[E=%W2=E&%(G.*-;KRX[?[19G4U+3[U9GNFH@&_?<RK(*WI>M3:TVEQ+UL0;
M;>&.XA)I2IDM2#2DZ%0!5E[++-WD7AJUH;NTQI+$J<E""><:3I2A2RTF1`,9
MJ%DEN-$BMV1E,:!).;#9)IO"U),S4;R"W%XE&=0&5>I.6KY!5;[S;4W"$:DK
M5'D(0XC$@\2585;I'J`>LVZ6.;;G;;+A<8M[[9L/15I2IM39EA-!I,Z4H`]8
MM\M<2,U%BQ5,QF$):89024I0A!84I21'H(B*@#P;GV)JZ/W5$(RN,AM#+TJA
M&LVFS,THJ9Z$D9UH0#,YS1.U.?DWP&CSDW:\TV4[-,090GG6ERB4VEQ1H:63
ME&ZJ(D*,TEUU#IT`&[3F6$E))2RLB(J$1$DB(B]D!#Y^0]D,^YKNDS*,%^:X
MHUNNJCMT6HSJ:EH]XHSW3,@$A?<RO(7;UO6IM9VE7"6RK;=(ZB3@(VBU(ZW1
MH`&'LL,767=F+8ANZ3FTM3)J4()UUM'O4K66DR(!C-0\DLQX,9JR,HCVU\Y=
MO:)IO"R^JIFZV7YJNN/2`RKV_EF^PB@WFV(N$0EI=*/(0AQ'"(.J545726X8
M#37G*NS"]SUW"[Y7ASYJR2A<F0PTXLTH+"DL2MPB*A`-CEV-DS++#S&7[,U:
MV9"B<?;BMH:2M1%0E*).LZ`,IB7EYEB8S'@<$U<5N.S2;(D&ZX\5'%K-)D>)
M1:S`>MONUGMT)B!!AG&AQD$VPPV24H0A.@B(J@,CG-$[4Y\7?`.<T7M3GQ=\
M!7G+%[4Y^3?`.<L7M3GY-\`YRQ>U.?DWP%.<T3M3GY-\!7G+%[4Y\7?`.<T2
MOS3GY-\`YRQ.U.?DWP%.<T2E>"<^+O@'.:)VISXN^`<YXE*\$Y\7?`"S/$[4
MY3HZ-\!4LRQ#I^R<T]3?`;<CJ50```````$G4B/HZ0``````````````````
M``````%KOS:^H?N`(;._?Y/TJ_E&`\%:NJ`:P`C`-V@!TMT`PD6Z)#=$`15T
M@%:^P``*5(2*&HB+3H`75*I`%=(@-P!2@!6FDP`U%3J@+B`4,_R@&Z`5(RJ)
M%:D6L0*:C,!0SU>Z`J6L!2I`*U`5+1HU@*"15/N"`.F@!4$`)-P!34``*D53
MJ`H9@%-`"T]VH`9:#`5_-`7)+KD]4O=`3E/O2Z@```````*-_-IZA`*@````
M```````````````````M=^;7U#]P!#+A7C\GZ5?RC`>)'H(`,P%/RF`5U%NB
M0KHT>R8@5(Z@'4]D!0S_`""13&6YJ,`-PO9,0*U28D*)`#(SI34(`JEJ(P`S
M.G0`4,S_`/H`43A(N@`5+7K,!4CIH`5Q%3I@*UT=0!0SH0"W'T?9`#615`6\
M,F@D7$K14CU[H@5T%[("J?>U`"*FH`K2H"A&6D!6NZ`H1Z"`5J?M`*UJ`J8"
MAG0!6N@$*`E3=,MP!;IK_P!0%V*I4``%R/?IZI>Z"$Y3[TNH"0``````4;^;
M3U"`5```````````````````````!:[\VOJ'[@"&3],^3TG5_*,!CJZ-=``9
ME0N@)"M-WV!`%4BH>Z`%KT@*U.G0`*T`>+CI).O1W`'GPR=>+V`!+R3,M("_
MA.F`$Z71`>R%$9?]`%:Z-8#S==(BU@+>%+6`<*9Z*@!ND1:=``3I&K0`O;69
MJ_Z@/2M*]$P'DXYA;,U`-:Y<$)/WU`&,Y=T(K57L@+?'3)G0E%T@&5'NB%%K
M(^D0#,9E(6NE:@,LC/HZ@%::=![@#R<<.M`%O"5/730`M-XDE0ST%K`52_HU
MZ#`7$X1[N@![IH1`*Z:`A0$@"AET`%2T5J`I0JUW`%*:>F`N33V=T!5O2I.G
M14O=`>EYVF6F#F^UY986AQ^0X93WC.B&$$TM1$9_I&I)#8HT\S1-3#5C1%44
MI-X_LG?['UB=\8;D\&2]!X_LG?['UB=\+D\$WH/']D[_`&/K$[X7)X(O0>/[
M)W^Q]8G?"Y/!-Z%4WVRJ424SF#4HZ$1.)TF?LA<G@7H9K?S:>H0\I5``&FS5
MG'+F5+<BX7V842.ZXEA@B0MUUUU?O6VFFDK<<4=-24F`UV6-I^3LR7)=I@2G
M6;NVWPZK;.C2(4@VJTX1+<E#1K3TTU`9>7<^Y2S'=KQ:;-/*5<;`^<6[Q^#=
M;-ETEK1AJXA"5]<THJH,RT`%SS[E*V9IMN5)T\FLP7=!N6^#P;JS<0G%51K0
MA3:/FU>_46H!=8L\Y5OUWN]FM-P3)N=B=X"ZQ<#C:VEU,O\`R)02RJDRQ(J7
M3`9<7,EEE7Z=8&)&.[6YIF1-C8'"P-R,7!*QFDD*Q8#T)49EN@-D````````
M`````M=^;7U#]P!#)Y%XPDGT'5U^$8#%4=#U],`,C,JD?L`*$9UKK,2*&9U$
M"I=<=-0#T(CIK`44=$F>L!IYDA1.84@/'A%GIJ>H![LJ48#T-:J4W`%2=TGN
M=`!FL*JD@'L9%HKH(P&!.7A5A(!YI-5`%Y5Z-#`745T:`*DD]&O0`]VL7M`/
M?V0&'/(^"53=`:!<1U1>R`UDBWOXC/3HU$`Q5PYA*))$>O08#80(<DJ&=2KK
M`;J$EPGR(RZH#>)*F@SUZ*`*J(\(D8YH,S$"TV3,]8#P=:7JW0%64*+6`]S;
MJ`R&TZ"T@+RZ0`9&`4`4U@*T`4PE0!:9*,]&O\@"NFG3`:S,J+VNS2$V=24S
MC3^S,]=-W#_BZ`RX5V]XMS'B;;OPWN`+:(I*V9C+RI^-7#).IK-=:G4M8OJ9
MIV*:8JVK^(M]Y2/@*WA-Z@NU'$6^\I'P%;P7J"[4<1;[RD?`5O!>H+M1Q%OO
M*1\!6\%Z@NU/>W05^-(/!1'TF4AHS-2%4IC+I#Q753L^#U13.WXOL)OYM/4+
MW!SR[<L0O-F><ZYHB1,R3,N6G*[S4"`U;D1S6]+-E+SCTDWVWL:"-PDDV6$C
M+I@,'9OM2NL7(]PS/GZ2Y(6_?),",BWQ7'TM)8+@R0AIA+CA(QL.'B777KU`
M-AFQJYYP=RAG/(\F,=ULZYDB':+REZ*F2Q(1Q9XS09$\VM&'K%&BFGH:PQX>
M;G9>?<MQ]H62G;!F!M<EO+5Y:EIEPE/.L*)YOA&3;PJ<:(\*'4G[>D!"=GA>
M(-J5PS,1DB%?<VW[+-S,SH7"K>*5;U4W3-U#C=?\1`+EI*][9[!G=1XVIV9)
M=GM"JXD\1M,%YE2VSZ#LI3RO:`>5NM%QM-WSKM+L#2GKMES-MS:N\-!Z9MF4
MS&7(9_SLG^V;Z9'KT`)GEG-N7O6?G;-?'$>(>;]GG\=TX>+X'W,5-=<.YKKH
MU@.P@````````````+7?FU]0_<`0VX&?'Y/TJ_E&`Q5%51"1729U$"W!4RIK
M`4-.D`2GKJEJ`>M-`"BZ&1],@&J>B&IPS`7%"*A$0#U1&PD`J;)D0"PHYF?0
M`9C*#26G0`]#I0NGJ$C'>C&YIW1`H48B(!>E@@%Y-$5-T!5+9%II[`D7)014
M$"Y1E0O=`>;S1+*@#Q**DMP!8J"TI1];4!9XO:K6A'0!>B$@MRE`%[<<DN8B
M+J@,DB/7ND)%?RZ!`L)!:P##ITZMP!7@R/08"G!)U$5`%20=2/10MP!<DNAJ
M`5UZ`"O1U`*&95H6OH`*D"%"Z.Z"2E3T`"M!`!%HJ`JBI&DR/=+W0&5==G5J
MF9MM69F$H9EPUF<MO#UCR%-+1I+](C40STX\Q1-+#5@Q-45)1Q"#WNU\!.\,
M-Z679!Q"#WNU\!.\%Z39!Q"#WNU\!.\%Z39!Q"#WNU\!.\%Z39"I081&1E';
M(RTD9(3O!>DV0]6_FT]0A"7/[SLYS.UF:ZWW)V8V[$N_H:3>([\-,Q'"LHX)
M$F/^T:X-W@RH9*Q)4>DP&=LLV;IR!9Y]H9N;ESB2ISLZ,I]&%UI+R4DIM2\2
MN$ZY)JQ4+7J`7YYR#*OURM5]LUV58\RV7A4PYY,IDM+9D$1.L/LJ-&-"L)&7
M7$:3TD`P(.S[-=PS#:[SG3,#%U197%2+9:X$(H<=,E2%-$^ZI;LAQQ24+/"5
M2(CT@,63L:2_E/,]B*\*:DW^]OY@A7)MBBX,AR0B0U@3PG7FTINF+$FO2`94
M39+%A1<B18L\T-9)6IPZLU.6MR.IEQ2CQEP9J6X;A^^Z'3`;K)>3"RTYF)9R
M^.%?[Q)O.'@^#X'C+;2.!]\O'AX&N+16NH!#+'__`)WRS;+AF9*Y2I.7<PNP
MG&[&;>%$9$*7QW@$N8U8V5NF98,":).FG6`ZP`````````````M=^;7U#]P!
M#+A^_P`GZ5?RC$C'T^R`K2M.B0@-.Y[`"E*G7<Z`!321`*E^4!4]6KV`%F!)
MZ2`4))5(C`5P]$`P;M1(H2"K6@@7D5-8!02!E6M=0@*%3J`%*@&&A5(^J`KJ
M`#`5,M!`*4KK/0`'301@**$@E)4TZ]T0*D0!0!732FL`(J:.@`;@"E.NZ8"I
MEI(]T!6IGIZ((4W02'6H!NU`#`4UG7=`5/I`*$5#J7M@!G10"M*@*$1%HKU`
M%R"JLMW27N@)PGWI=0!4``````4;^;3U"`5```````````````````````!:
M[\VOJ'[@"&W`_P#WI&G4ZOY1@,;45?<$BM2]L0*%JI42*ZZ$0"I$5=.Z(%=!
M`*5H?1J`H6@]`"M"(^F`&6H`H53.H"BL=.MI7I@+C(C(!31T0"FC_J`:.J``
M*EJH8`9EI`->FN@`J`:NH`:-X`UF`IIU`*E3J`*5`5`-W_J`5Z("A;HD7%J$
M`73`-8!0!2M``M("IZ-0!4B/7I/<`4T`%2]@@"I>V`4+14P%R*8B+IE[H(3A
M/O2Z@)``````!1OYM/4(!4```````````````````````%KOS:^H?N`(Y+EY
M93*>)Y#AO$XHG#+%3$2CQ;O1`>12\J'HX-WXV^`<;RIVMW3_`)M\`XYE0M&!
MWXV^`<<RI7WCOQM\!7C>52TX'='^;?`.-Y5+_P`;GQM\`XYE6OO'?C;X!QO*
MNGK'=&OWV^`H<W*GZ#OQM\`.9E4BTH=^-O@''LJE^8[\;?`..Y5,_>._&WP%
M>.Y5_0=^-O@!3<JE^8[\;?`..Y5/\QWXV^`IQ[*OZ#OQM\!4IF5M9(=^-O@!
M3,JGHX-S3_FWP#CN52T8'?C;X"O',K'_`.-WXV^`H<W*WZ#OQM\`X[E;]!W3
M_FWP#CF52+YMWXV^`<=RK^@[\;?`#G95+_QN_&WP`YN5MU#OQM\`X[E3]!WX
MV^`<>RK^@[\;?`#FY5W4._&WP%..Y4+\QWXV^`KQW*OZ#OQM\!7CV5OT'?C;
MX"G'LJF7O':?]V^`KQW*Q%[QWXV^`H<[*VCK'?C;X`<W*NZAWXV^`<<RJ6C`
M[\;?`5X]E;]!WXV^`IQW*OZ#OQM\`X[E7]!WXV^`%,RKJ)#OQM\`*9E6OO'?
MC;X"O',K$?O'?C;X"J9F5\140[4S*GOM?M@).5*%34```````"C?S:>H0"H`
M``````````````````````+7?FU]0_<`<^NE/&4OH\,Y\LP&+7=J`IB+1T=T
M!::RJ`H2ZGT`%V,]-0%V(@%*U]@!3$9GK`4KUW4U@!J(S`4-5=\`)P]("I*Z
M8"A+/'2G6[A@+C5300"A*J73`5QZ-(!B+H@!*W*@*DO<`5Q`+:T49`!G7_H8
M`2JUW`%#.I],`Q`"5E4!7%[8`:M&@`Q:"*H!CZ8!C.H!BU'4`Q@*DNN@SZ@"
MM=)=#I`!G32>L!3%4`Q=#5N@%='5`42HZ@+R,JF`),C+J`/1O2M%?TB]T!T=
M/O2Z@"H``````HW\VGJ$`J```````````````````````"UWYM?4/W`'.[J?
M_P#9S"_^^Y3X9@,-:R(@'D;Z"W0%O&$UI4`X=&C3I(!=PZ>B`O)TCII`5Q@*
M<)0!8;I$H]("WABK6N@`X8NB`<.G2`N)TJ&8"I.%KJ`J;A5`6FZDBUZ0%IOE
MT=("O#IIKT@*&\1'KT`+BD)I6M`'H3I'J,!0UG37I`4X4NCJ`6<.FM*@+5/E
MN'H`.'+=,!4GDTJ`].%29$=0%.$*M*T(!13A:Z@*&^DRT'I`4)])[H"J7DGN
M@+R=2>Z`<*6H!<2^GN:@%<==8"G"%2E0%,9`&,MP]`"WA"+5[(#T)PJ:]("J
M5>T8#V;]^D].LO=`=*3[TNH`J``````*-_-IZA`*@```````````````````
M````M=^;7U#]P!S:].DBYS:]O=I\,P$#S9GZVV1A3C[I),M1&>DP'-W]OD`W
M3))*-&X=#`9,;;C:%D1K7A/=K4!E^NJR5/\`;$1[AU`9L3;#8G#27&$U5K*I
M`-_;]HEFE&1(D(-70J0"2Q[Q&>1B2LC+<T@,2Y9CAQ$*-QPDD6LS,!#9^UJQ
MLO*;.2G1HT&`QRVNV0ZTD)]L@'K'VKV59E_[*:=4@&P:VD6=9:)*:;FD@&>Q
MGNTNF5'TZ>F0#<Q;Y&>22D+(^H`NE7J.PDU&LB(M=0$>G;0;3&,TKD(K7H@A
MKCVG6<E'22D^E4@2N]9=I4="D)]L@%3VE6DCIQA)^R0"YO:-:'%$DY":GJTD
M`WMLS1$D&6!Y*O9`;5=W9)!JQEHU`(_<\]6R&O\`:/)(^J`TJ]J5G)2J24]`
MM)`AY+VI6DBTR$^V"5[>U&TF9$3Z:;ND@0S8^T6TKT%(3IU5,$MY"S1"D$1M
M.I472,!G.W=E"*FHJ4K6H"/W+/\`:HAX7'TD9:])`-86U&SFHR*0G1NU($+T
M[2[4K5(2==5#($O9&T2VT/\`;I]L!EL9^M:S^?014TZ00VD+-,"0K]FZE5>@
M8);AN>A2*D?4,!8Y<V&_?+(M&C2`P9&9X+>MY/5J`\>=EO(J\,GVR`>9YNMR
M2TO)ZM0&')SS;6B,S>13J@/%G:395.DCC*",^F0"4VN]PYB"6RX2B/50Z@-R
MPLC6CJE[H#>W?:39H.:K7EMIUMV5*<,IKAJ(D1VR:6LL2M6,U)+0,]&GF:9J
M8:L:(JBE)/'=E[_C?7-[XQ7)X,EZ.)X[LO?\;ZYO?"Y5P+T<3QW9>_XWUS>^
M%RK@7HXGCNR]_P`;ZYO?"Y5P+T<54WJSJ424SHYJ,Z$1.H,S,_9"Y/!-Z&6W
M\VGJ$/*7.;YMI;LLMF/-R9F0N-2R@0G4QX9H??42E)2T9RR,\26U**I%H`2_
M*^8GK]!=EO6:X613;IM%%NC;33RB)*5<(DF77TX#Q4KBK4CT`%US3;[;F"RV
M-]MU4N^G)3$6@DFVDXC1.KX0S4E152?6X2/3T`&X``$9L&?(-]B6N9;[=/7$
MNDF;$X<VD8(RH"W6EKDFEQ6!#BXYI;,JU,TU(MP),```````````````"UWY
MM?4/W`'*LUJ64R=A+23SORS`?)>UZYRW\PG&<49-H*I)KH/2"$!`!(J(`E*+
M49D)'LS.F,J)33RT&7049"!T_9YM"N!I7#E.&I22JE1F=:`--G_/,^;*7$9<
M4A"3HHR,P$$4M:CJI1F9ZS,P%,2NB8D5):RU*,O9$"\I,@BH3JB+JF`]6[I<
M&S(T2'",M77&`E^4MHUUA2FV9+IK94="49GH`;;.^T::XV4>,X9&LM)UU`.<
MO7&<^HU.OK49]%1@/+AW^V*]LP%2DR"U.J]LP`Y4D_\`RJ]LQ(JF7*29&3JR
MIJTF`WV7<ZW:URD&;RG&:T41F8@=!ONT60U92=:6?"++1IZ(#E5POMSGNFX^
M^LZ_FU.@#"-YX]:U>V8D.&=_35[9@!//%I):B]DP%Z9DM/O7EE3_`!&(&YL6
M<;O;)*%$^M;=2JDU&`GF8-H\KQ0E;2CQ+30M.Z8#F$V[7"8X;C[ZU&9ZJG0!
MC<,]KQJ]LQ(N*5)3J=47LF(%Y3YI:GU_",!<5SN!:I"R_P"XP&PMF;KU;WDN
M-R%J(CJ:348#M.4]I92[83CJJ*077$9@E#<W;6[@Y)<CP3HA-2QU,$(0_G#,
M#RL2I:^I4P'GSJOO?2_;,!;SFO=*<:73JF`\';S='??R5G_W&`\.-RL6(G5X
MNCB,!T;93GV?#O#,"4ZI;3IDE!J,ST@/I*X2;JY87'+21',--4$>NG^'IC)A
M7;WBW/.)MN_#>XXLS5*6<PWCN!J/A3.N/%N],7]-W8IIO;7K3^)^.'@1XBG\
M3\</`>(I_$_'#P'B*?Q/QP\!XGO;N&\:0>"XQ7C#5<6.E,9#S7=V?!ZHO;?B
M^P&_FT]0O<'/+MS_`&O?O60O^50_LDL![9;DOJVQ9UCK=4IENW6533)J,TI-
M7&\1I3J*M"J`Y198<;,S>S&-<9SRXDV[9I)QUJ0XVX\TF0^:6B>0I*\"DI(C
M))Z4Z-0#-SW&+*,?/>6\NR'V+"S:;3<DQ^,.N%"F/W!3*T-+<4I:">::)9IQ
M=,M8#HV<)KC>U+9W%0^I!2/&ZG6"49$M*(::&I)'IPF>Z`@F09$AMO9<TVZM
M#3U^S23S:5&25DD[BHB41:#H95T@-0SD^#)V(7S.\F9/=S-`7>)=IN'')!*A
MG#GODVAA!+P$@S:JHC3IQ'TJ!]!\<?\`$/':EP_%>&K31CX/%JZH#/``````
M```````6N_-KZA^X`YG?FR7<9Q&52-YSY9@/FO;;D>4<TKI":-9%H<(N@"'&
ME(6@Z*(TF6LCT`+1("`$@`GVS3*\R<^[*-!I:PX4F>Z(&CSM895JO#I.I/`X
M=4J,!'1("````2/1A*E/-I3I4:BH(&=?([[,I).D=5)(RJ`UH``"0``%4I-2
MB))5,SH0"67RTS&\O1WE$9I*AGTA`B0D`````%4I-2B2DJF9T(!(+Y;IC%MC
M+<*B*%40(\`"0`!`"0`27*R)BXLHFJFFF@NF($=>)1.K)7OB,ZUZHD6`````
M`"09$@R)F:(*&2J:7"49]`A`^R[`RMN.PA1Z2PU!*4779E:)>;K5F6,VVR]&
M<4=PCFDC;?0II:25AU8R4HNJ-BG43%$TRP58$35%25>);-WA'^J1O##?GBRW
M8X'B6S=X1_JD;P7YXEV.!XELW>$?ZI&\%^>)=C@>);-WA'^J1O!?GB78X";-
M:$J)28,<E$=2,FD$9&7L!?GBF['!EM_-IZA#RE@7C+]HO"H"[BQPZK7+1/@G
MC6C@Y+:%H0YUBDXJ)=45%5+3J`:;,NS+)^8[LW=[E&>*X(9XLX_&E28IO1R,
MU<"_Q=QLG45,]"J@,63L<V<OVBW6A5IP0;0N0]:T-2)+:HSLM9N.K:6EPE$K
M&=4Z>M_-H`RK;LRR5`L5RLB+?QB%>",KLJ6Z[)?DU3@JZ^ZI;JC2G0GKNM_-
MH`\+!LER-8[G$NT.(^[=(!+3$G2YDN4ZVAQ!MJ;(WG5E@PF9$FE"UEIT@-A!
MR%E.!XJXI!X/Q)(ER[7^U>5P3T_A.,KZY9X\?&%Z%U(JZ*4(!>C(^5T96DY4
M3"I8):9"9$/A7NN*8XMU_P#:8^%+&MU1Z%:*Z*`-QQ2/Q3BF'_U^#X+!4_>4
MPTK6NH!Z@````````````+7?FU]0_<`<YO":W.8>O]NY\LP&BNEKC2VS0\DC
M(]%#(!!;KLIL<E2C..FJM)F1%O`(]+V)VARII:))]*F\`U+FPJ&=<.*I'HTZ
M/<`4+81%.I&I1>S_`/0$-C;=A5K0ZE3J370]TRI[@#I%HRI#MS!,L-$A!%N$
M0):7-VS^#>V30ZV1JH=#T5`<LF;"WTK/@7%$DCU5($,,]B<\CIC5[9`/!S8O
M<R+K5G6O2U`,1W8_?DD>'2`QSV39CQ4))`)9D_8W):E)D3^N4C2E.BE0&VSQ
MLNX_')48J/-IT'H`<KD[/,S,.*0<>I$=".NL!1&S_,:O_!HW=(#T3LYS(?\`
MX?R@+_5KF/=:*@#T:V7YD69?LR(!-,H;&I"):)%PTDG22=%*]0!TFZY'B2[9
MQ0VRPTH94($N-W[8]<H\I11*FA5301ZNH"&D>V9YD;*I-5`8;F0\Q(K6/J`6
MED7,)_\`X^CH@,AG9UF-PB,F2(M53`33)VR&43Z)-P*II.I(W`$[ONSZ+/MJ
MHIHH>&B3T:P2X_>=E5_A/*)E'"-5T&"&F<R3F!%:QCH6L!BN9;O*"JJ,KI`,
M=5GN2/?1UEN:@#Q3<<6'@%5Z@#-MN4KW.>2VW'41*/WQZ`';LE;.$0;7@?35
MQ1==U3`1[,^Q9UZ4I^"K!CJ9IT4J`CY[&;T1:5::TH5``]C5Y(]?N`/5&Q>Z
M*_//\@#W3L1N)I]^=>J0#U:V%W!3A$;IDD^F0#I>S_97#L"N&4G&\>M9T,$N
MJQ$83;(M&DM/L@.HI]Z74`5``````%&_FT]0@%0`````````````````````
M``6N_-KZA^X`YW=%)5<YE/S7W"/X9@,-2=(#R4T1Z0%AL),!3BR-.@`*.FI4
M+V0%Q,I(]!:#U@+L&G6`M-E)ZR`>3D1M1Z2`>1V]HSKA(P%#MS)I]Z7L`/,[
M:S2F`NJ`%:HY$=4ZP'LW#:05"30!:[!;7H40##<L<99U-!5Z@#S*P1MQ!>T`
MO*Q12_,+V@%WB:-JX,J&`';(;2<2TDDM53`9K,1E!=:6C<,![&P@R,J>P`QG
M;<PY3$@C,ND`QG;+&41U3H/<`8ZK!&J=$%IUU(`++\9.ILO:`>C5CCH_-+V@
M&8U;FD'UJ2(B`7JBH-1Z`&*_:6'$G5!&`PG,MQ55J@CZ5`&&>4X+E<3"2))T
M*I?E(!C.9(MJSH;*>GH!"YC(ML17]BFI]($MG"RO"8-)I:2FFY0!MV83:"T%
MH`7JB(.E4E[(#S5;V?T",]TP#Q>QBKA+V@%4P&2(^M*NZ`(M[2?S2H`]4Q&O
MT=8#*;;))`/=HBQH+ID?Y0'3$^]+J`*@`````"C?S:>H0"H`````````````
M``````````+7",VU$6NA^X`@]PM%R7<)3B(SBDK><4E1).AD:C,C`8IV:ZZN
M*._`,!:NS77O-[X!@*%9;MKXF[\`]X!7Q)=:_NCO3ZPP%?$UV[T=^`8!XENE
M*<4=^`8"GB6Z]Z/?`,`.RW7<AN_`,!3Q)=MV&[\`P`['==R&]I_P&`M\1W?4
M41[X!@*E8[J>N([\`P%/$EV[S>^`K>!)XDNVY#>^`K>!"IV2[&?[F[\`]X!0
MK'=J'6&[\!0"GB*[%_\`AO?`5O`*^([MWF]\`]X`*Q77<AO=7`8"CF7[DXG"
MN$Z9'KZPP%Q6.ZE2D)VFJF`P%3LEU(ZE#=/_`+#`4*R7:O[F[\`P2'8[K7]S
M=/\`[#W@0L78;N9%2&\1E_@/>`5\1W:A_P#IO?`5O`*%8KL1_N;WP%;P"\K)
M=M/_`*;OP%;P"WQ'=:_N;WP%`!V.[5_<W:?Y#`4.Q7:E.)O4_P`A[P"AV&ZZ
M"XF]\!6\`M/+]U*A%">/_L5O`+RL%U[S>Z?6&`J5CNQ%^YO?`5O`+DV.[4(N
M*.E_V'O`'B2[=YN_`4`>);K7]S>^`K>`5*QW7O1WX!@*^)+K3]T=^`8"A62[
M;L1WX!@*^)+K7]S=K_D,!<5FNM3+B;OP#`7(M%T2XE1PW:5*O6'T0'04^]+J
M`*@`````"B-"$]0@%0``````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````&+=+K;;5"<G7*2W$B-4QO.J)*2-1T26G6I1G0B+29Z"`1C
MUEQE.$;.7<P/0STE.3;74HIT2:<-$DRZC0"166_6B]Q#E6R03[2%FVZDTJ;<
M:<30S;=:<)#C2R(RZU:2,!G@/&;.A08CLR=(;BQ&$FM^0^M+;:$EK4M:C)*2
M+HF`TWK"R#^);5RZ-V8!ZPL@_B6U<NC=F`>L+(/XEM7+HW9@'K"R#^);5RZ-
MV8!ZPL@_B6U<NC=F`>L+(/XEM7+HW9@'K"R#^);5RZ-V8!ZPL@_B6U<NC=F`
M>L+(/XEM7+HW9@'K"R#^);5RZ-V8!ZPL@_B6U<NC=F`>L+(/XEM7+HW9@'K"
MR#^);5RZ-V8!ZPL@_B6U<NC=F`>L+(/XEM7+HW9@'K"R#^);5RZ-V8!ZPL@_
MB6U<NC=F`>L+(/XEM7+HW9@'K"R#^);5RZ-V8!ZPL@_B6U<NC=F`>L+(/XEM
M7+HW9@'K"R#^);5RZ-V8!ZPL@_B6U<NC=F`>L+(/XEM7+HW9@'K"R#^);5RZ
M-V8!ZPL@_B6U<NC=F`>L+(/XEM7+HW9@'K"R#^);5RZ-V8!ZPL@_B6U<NC=F
M`>L+(/XEM7+HW9@'K"R#^);5RZ-V8!ZPL@_B6U<NC=F`>L+(/XEM7+HW9@'K
M"R#^);5RZ-V8!ZPL@_B6U<NC=F`>L+(/XEM7+HW9@'K"R#^);5RZ-V8!ZPL@
M_B6U<NC=F`>L+(/XEM7+HW9@'K"R#^);5RZ-V8!ZPL@_B6U<NC=F`>L+(/XE
MM7+HW9@'K"R#^);5RZ-V8!ZPL@_B6U<NC=F`>L+(/XEM7+HW9@'K"R#^);5R
MZ-V8!ZPL@_B6U<NC=F`>L+(/XEM7+HW9@,RU9HRU=WG&+3=H5P>:22W6HLAI
M]24J,R)2DMJ49$9EK`;,``````````````````````44A*J8DDK"=4U*M#+=
M`</B9RL\UV:Y?MI5UL]U:FRV'[7$:AM1V29D+0VAKA(,A2T<&2:+-PS5NT.I
M$';6"1P:5I/'B2G]H=,2BIH,Z$0#T`1[:!Z'7/Z+]8@&^D/LQV')#ZR;9:2:
MW%JT$E*2J9G[`#2P<XVZ5;ILU<>3%X@RF4]%>;+ASCN(-;3J6VU.5)Q*3PE[
MZI&1D2BH`PWMH,%I+3?BZ6JX+EJ@.6[%$0ZT\EE+]%K<D(CF1MNH,L#JJXB+
M76@2DC,R(S*AGN'K+V@`````````````````````````````````````````
M``````````````````1W^X)_=2?M"P$B``````````````````````&HS:[+
M:L+[L1NX/2&ULJ2U:>+<<61/(-26^.&EBAIJ2\1EUE</74`<QDO9Q?E.OI9V
MAQT.N*6EAKFOP;9*.N!&(UJPIU%51GTP'8V:\"C%BKA*N.F*M/SL.BO4`7`(
M]M`]#KG]%^L0#=SH;$V$_#D%B8DMJ:=(M%4K(TG^0P$;CY1O<>',-J])3=I<
M=N'XQXK[QB.TZB/1HG2+A$N/&XI5:*/024E2@8:]GDIRSMV]4N`1DI\GEE;N
M$2XB2@D.+,Y,B0]QC1\ZIXR5^<A0"9,,(9C-QR-2T-H)LE+4:E&22I52CTF?
M1,!!K?DO*RLZ7F&JVM'%8@VYQEDZX4K<<F$M22KH-1-IKU"`;WF!DWR2Q[1[
MX!S`R;Y)8]H]\`Y@9-\DL>T>^`<P,F^26/:/?`.8&3?)+'M'O@',#)ODECVC
MWP#F!DWR2Q[1[X!S`R;Y)8]H]\`Y@9-\DL>T>^`<P,F^26/:/?`.8&3?)+'M
M'O@',#)ODECVCWP#F!DWR2Q[1[X!S`R;Y)8]H]\`Y@9-\DL>T>^`<P,F^26/
M:/?`.8&3?)+'M'O@',#)ODECVCWP#F!DWR2Q[1[X!S`R;Y)8]H]\`Y@9-\DL
M>T>^`<P,F^26/:/?`.8&3?)+'M'O@',#)ODECVCWP#F!DWR2Q[1[X!S`R;Y)
M8]H]\`Y@9-\DL>T>^`<P,F^26/:/?`.8&3?)+'M'O@',#)ODECVCWP#F!DWR
M2Q[1[X!S`R;Y)8]H]\`Y@9-\DL>T>^`<P,F^26/:/?`.8&3?)+'M'O@',#)O
MDECVCWP#F!DWR2Q[1[X!S`R;Y)8]H]\`Y@9-\DL>T>^`<P,F^26/:/?`.8&3
M?)+'M'O@',#)ODECVCWP&[B18\2,U%C-DU'823;3:=24I*A$0#1?W!/[J3]H
M6`D0```````````````````````.`YS@9`GS;K88N19R,TS%/)AR..6YA2I*
MU&;;Y$=P-TD*69*TLGHUIW`'>(3;[<*.V_A-]#:$N\'4D8R21*PUW*Z@'L`C
MVT#T.N?T7ZQ`)"`````CMM]/[]]W6O\`U9P"1```````````````````````
M``````````````````````````````````([_<$_NI/VA8"1````````````
M``````````#"O4Z=!MCTJ#;G;M*;P\'`CK9:<<Q*))X5R%LM%A(S5URRU:-(
M#A:X]W+*%WLS^S9$B]2WICC=RD3[+PJG9#RW&Y+SO&C>2\WB+WAZ#26$TE2@
M=[A(=1"CH><4ZZEM"7'5TQ*422(U'AZVIGT`'L`CVT#T.N?T7ZQ`)"`````C
MMM]/[]]W6O\`U9P"1```````````````````````````````````````````
M``````````````([_<$_NI/VA8"1``````````````````````#`O5ZAV>&U
M*EDLVG942$G`1*/A9TEN(U6IEUO"/)Q=(!RG-N1F;RQ=83&R6VE*FF\AF]*<
MMC*^$6H\,I2VTG(+KNO5H-72,!U^$TZS#8:>4E;S;:$.+0G`DU)21&:4[A&>
MX`]@$>V@>AUS^B_6(!(0&MO>8;;9FVE33=-3ZC2TTPR[(</`DUK5@:2M6%"4
MF9G3I:S(@'C=LVV.ULQWI#JW6I+2I#2HS3DC_P!=!)-;Y\"E=&TDM-5=,NB`
MVZ5)4DE),E)454J+21D>Z0"/6WT_OWW=:_\`5G`)$```````````````````
M``````````````````````````````````````CO]P3^ZD_:%@)$````````
M```````````#RF/.,1'WVF52'6FU+0PC0IQ24F9(*NZK4`Y_:=NN377VX68V
MIN3[FX>!,2_QUPT*46O@Y!UCJ3T#QE7H`-EM2B,7?)*6T)>EPG)]JD/J@$^X
MZ<1BXQY#ZVCAXGZDRVHTFUUW0Z(#4V3(^R6^$L[1<)TQ;/S[+=_O'"M'T'6C
MF$XV?26D@'2$()"$H37"DB(JF9G0NF>D!4!'MH'H=<_HOUB`2$!I,PV.XSI$
M2;;);42=%)UK&^TI]M34A.%984K:/$2DI41UW*;M2#473)EX>MENLD.9'\0P
M&TQUP7TO5D,M--(92^MIQLU$1H6:TZ$KJ1**A&2@F))ZPDG350Z:"]@!`;=D
MK+IYWO;!LO\`!-P+8I)<;E5JIR81Z>%J?O2U@-_S#RSVA_EDONH!S#RSVA_E
MDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#R
MSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDON
MH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA
M_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S
M#RSVA_EDONH!S#RSVA_EDONH#79BROEVU627<6XKSBXR,:4*F3"(])%IH[TQ
MDPJ+U<4\9>,2J[3,\'*^?5O\B_\`[\[NHMOU=/&5=^PJX'/JW^1?_P!^=W4/
MU=/&3]A5P;[)5WM.8;\W;7K6IAM:%K-Q$Z:9]:73=&OJ=#&'1>B67`U<UU;-
MCH_,/+/:'^62^ZBM;YS#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#R
MSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDON
MH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA_EDONH!S#RSVA
M_EDONH!S#RSVA_EDONH!S#RSVA_EDONH#=Q(K,2,U&8(R9922&R4I2S)*2H5
M5*-2CZIF`T7]P3^ZD_:%@)$```````````````````#7YA>?8L%S?CF:7VHC
MZVE$I+9DM+:C29+7UJ=.Z>@@'!-FT/\`_P`^W^/:+C?[TG,F;+D2&^*9CG\>
M?1(>/!P"8Z\#)]>>%/[/H4,!U.1;X^S39>Y"R[US-I0HH;EP6:VVBD2#4IU]
M2>#/@F.&-1D5.L32NZ`B>:93L2+-:S;XMOTA=JE3\I9H9BE&4<J,RMQR+B0X
MZ:%X:.-&VX6))++6FIAURVF:K=%,S,S-ELS-1FHSZTM:E&:CZIF`R`$>V@>A
MUS^B_6(!(0````$=MOI_?ONZU_ZLX!(@````````````````````````````
M&ASYZ(73Z+]8AGTV93;#%CY=5CYJ'3J``379!Z:L?1.^X-+N&5+:T69#OPYY
M=`````````````````````"._P!P3^ZD_:%@)$```````````````````".;
M0#SCS6F)RC'ARKRM)H0S/,^"-M23)="(C)2_T25UI[N@!Q?(]NSY<+CEZ,]"
MR+`DP)4)=YD0DQ7+L1L$3S[*F6VUM-2'$MJKP9)PG4TF1%4!]$N-MN-J;<22
MVUD:5H41&1D>@R,C`<8BD]F&RR+<N^Y2M%D:F2HR<JR+2W)3&XO)6@DN$N;'
M3PATQF9-$53JG09&8=F802&&T$9&24D1&DJ)T%N%IT`+P$>V@>AUS^B_6(!(
M0````$=MOI_?ONZU_P"K.`2(````````````````````````````!H<^>B%T
M^B_6(9]-F4VPQ8^758^:ATZ@`$UV0>FK'T3ON#2[AE2VM%F0[\.>70``````
M```````````````CO]P3^ZD_:%@)$```````````````````#"OD&1/LEP@Q
MGSBR9<9YAB25:M+<;-*7"IIZTSJ`^4,C9<N2,Q6G+7BZSV94*YV9]^[LW>"Z
M:W[5PB'ELLMJ-]QZ<;E,)IZTSPJZ0?7@#Y^2O*=RESI-WS5D[+]R*=+9DV>5
M;+:;["F9"VZ..27D..+42<1KPD2C/1H`=^8PDPWA4E2<)44DB))E361%HH`O
M`1[:!Z'7/Z+]8@$@6M#:%+6HDH21FI1Z"(BUF`UEJS/9+K#>F1)!E'CD2GE/
MMN1C2A2<:7#2^EM6!2=*5TPF6HP&+SZRPJ!!GQY3DR)<G'&H+D*/(EFZIDUD
MLTICMNJP%P:NOIA/</20#?$9&1&6H].G0?M&`CMM]/[]]W6O_5G`)$``````
M```````````````````````T.?/1"Z?1?K$,^FS*;88L?+JL?-0Z=0`":[(/
M35CZ)WW!I=PRI;6BS(=^'/+H`````````````````````1W^X)_=2?M"P$B`
M``````````````````!JLVDV>5;R3G#&V<&3C*+^\8>!57@?_N?H],!\_P"R
M#*E]*W9/G'LILIQ<,"069SEL<;X(S0LIW!&2E\+A_:8<5<6C1J`?1\R9#A1'
MI<U]N-$80;C\AY:6VT(2534M:C)*2+HF`XM%O$_*R8ML\89-5#NKSTZQ.2GG
MTO.PYCYNLK6I#1H41\+A)P]"NB9U,P[<WB)"241$JA8B3JKT@%0$>V@>AUS^
MB_6(!N+G!:N%NE073,FI32V5FG627$FDZ>V`TN7K#>H,Q<Z>_'?EOM1H<@V4
MK0CB\-#O!J02C5^T6Z^:E5T$G1II4PU-QR!,D6IB&CB,AUN3<7TN2VG%<%Q^
M2X^AUDT*29.,\(75/4I.L!-6&3;C-LK<4\:$$A3JZ8UT*AJ50B*I[M`$$MV2
MLNGG>]L&R_P3<"V*27&Y5:J<F$>GA:G[TM8#?\P\L]H?Y9+[J`<P\L]H?Y9+
M[J`<P\L]H?Y9+[J`<P\L]H?Y9+[J`<P\L]H?Y9+[J`<P\L]H?Y9+[J`<P\L]
MH?Y9+[J`<P\L]H?Y9+[J`<P\L]H?Y9+[J`<P\L]H?Y9+[J`<P\L]H?Y9+[J`
M<P\L]H?Y9+[J`<P\L]H?Y9+[J`<P\L]H?Y9+[J`<P\L]H?Y9+[J`<P\L]H?Y
M9+[J`<P\L]H?Y9+[J`<P\L]H?Y9+[J`<P\L]H?Y9+[J`<P\L]H?Y9+[J`<P\
ML]H?Y9+[J`<P\L]H?Y9+[J`TV<<G6")EBXR&&GDNMM52:I4E95Q%K2IQ23]D
MAGTV93;#%C]%5C@HZ=0`"5[,;=$N.;&8TM*E,FVXHR0M;9U(M'7-FE7Y1I=P
MRI;6BS(=HYAY9[0_RR7W4<\NCF'EGM#_`"R7W4`YAY9[0_RR7W4`YAY9[0_R
MR7W4`YAY9[0_RR7W4`YAY9[0_P`LE]U`.8>6>T/\LE]U`.8>6>T/\LE]U`.8
M>6>T/\LE]U`.8>6>T/\`+)?=0#F'EGM#_+)?=0#F'EGM#_+)?=0#F'EGM#_+
M)?=0#F'EGM#_`"R7W4`YAY9[0_RR7W4`YAY9[0_RR7W4!NXD5F)&:C,$9,LI
M)#9*4I9DE)4*JE&I1]4S`:+^X)_=2?M"P$B```````````````````!@WUZW
MLV2X/7%1IM[<9Y<Q2:D9,I;,W#+#I][74`^8LGV/*]INV5LRRMG]PLV5KG/A
M^(+QX[<DK0Z^X2X3DB$2M#;JL)GIH1?I;H?0VT2SW"ZY:-B#&3/=8EPIB[:M
M24%*:B2FY#D?$LR01N);,BQ'A,]"NMJ`@LJV9JEP\YWN1E>2[<LWI;LUGL[R
MXIN1X341:4N3'$O*:::4^XXM9(4H]*2H9@.L0([D:#'CN.&\XRTAM;IZ#6I"
M2(U>S2H#W`1[:!Z'7/Z+]8@$A`````1VV^G]^^[K7_JS@$B`````````````
M````````````````:'/GHA=/HOUB&?39E-L,6/EU6/FH=.H`!-=D'IJQ]$[[
M@TNX94MK19D._#GET`````````````````````([_<$_NI/VA8"1````````
M````````````C6T7-%FRUE*=<;Q$>G6]2%,/1([:G5.$ZDTX5$DCHDRT*5N`
M/G;(\W*EPN63HL9[-MY@-S8+UKRS-0LK=!-1D9.JDDT7#M0R5B1J(TIZ`#ZN
M`:^^74[;;GI##*9<PNLB0>&:84^^950RA;RD():]RI@/>W2)<B&V[+B*@R55
MX2,I:',)D=-"VS-)D>LMWHD6H!D@(]M`]#KG]%^L0"0@````([;?3^_?=UK_
M`-6<`D0````````````````````````````#0Y\]$+I]%^L0SZ;,IMABQ\NJ
MQ\U#IU``)KL@]-6/HG?<&EW#*EM:+,AWX<\N@````````````````````!'?
M[@G]U)^T+`2(```````````````````&BS3;;A*;8D,7I5HA0TR'+@G@FW6W
MFE,*07"&Y[U+2CX31KI0]`#A>6<W+8S/EB"6U&Z3H,]<5UF+XE88B*86^;4>
M.\XFBF"E<$:6^M]Z9'HT`/H]QQ#:%+<42$)*JEJ.A$71,S`?/\C*JYUMNDN4
MW9KE;H+-U3;'ERTF4J?<IM'KG(QMDIIR(PUAT8E:%$WHP@.\VNGBR)21QLN!
M;I*[:6`OVG_=K`9("/;0/0ZY_1?K$`D(#!NU\M-H90_<I2(K3B^#;4NO7*PF
MHZ$53ZU*34H]PB,ST$`])EUML)MAR7);9;DNM,1U+41$XZ^HD-(1T36I1$5`
M&4`CMM]/[]]W6O\`U9P"1`````````````````````````````-#GST0NGT7
MZQ#/ILRFV&+'RZK'S4.G4``FNR#TU8^B=]P:7<,J6UHLR'?ASRZ`````````
M````````````$=_N"?W4G[0L!(@```````````````````8-]C6^59+A&N2R
M;MS\9YN:X:L!)86V:7#Q'JHDST@/E_)CFSA^]VVVM9WN%Y=N%WM9NN*L[S*)
M3-J-+-KB$[APMH0LB-;NC%ND1U,!].YAMSURM#\%I$1WC&%#K5P8.3&6R:RX
M9#C)*;Q8F\1%4Z$=#,C+08<!DV[(ULN$N##9R0;,64^A)*RK<)[B%$ZHU-KD
MH?6E:VU=:>$Z)I0B214(/HQ@ZLMG4CJDCJDC26K<(])`+P$>V@>AUS^B_6(!
M(0&@S+:;O(EPI]I3&>E14OLJ8F.+::-N0C":R4VV\>)*DIT8=)5*I:P&'(R@
M^[EZT6C"PXJQRK8N'+>,U+6S`<86XX?[/]FZM+:TDE)F6KKM)D02LR(R,CU'
MH,!`+=DK+IYWO;!LO\$W`MBDEQN56JG)A'IX6I^]+6`W_,/+/:'^62^Z@',/
M+/:'^62^Z@',/+/:'^62^Z@',/+/:'^62^Z@',/+/:'^62^Z@',/+/:'^62^
MZ@',/+/:'^62^Z@',/+/:'^62^Z@',/+/:'^62^Z@',/+/:'^62^Z@',/+/:
M'^62^Z@',/+/:'^62^Z@',/+/:'^62^Z@',/+/:'^62^Z@',/+/:'^62^Z@'
M,/+/:'^62^Z@',/+/:'^62^Z@',/+/:'^62^Z@',/+/:'^62^Z@',/+/:'^6
M2^Z@',/+/:'^62^Z@',/+/:'^62^Z@--G')U@B98N,AAIY+K;54FJ5)65<1:
MTJ<4D_9(9]-F4VPQ8_158X*.G4``E>S&W1+CFQF-+2I3)MN*,D+6V=2+1US9
MI5^4:7<,J6UHLR':.8>6>T/\LE]U'/+HYAY9[0_RR7W4`YAY9[0_RR7W4`YA
MY9[0_P`LE]U`.8>6>T/\LE]U`.8>6>T/\LE]U`.8>6>T/\LE]U`.8>6>T/\`
M+)?=0#F'EGM#_+)?=0#F'EGM#_+)?=0#F'EGM#_+)?=0#F'EGM#_`"R7W4`Y
MAY9[0_RR7W4`YAY9[0_RR7W4`YAY9[0_RR7W4`YAY9[0_P`LE]U`;N)%9B1F
MHS!&3+*20V2E*69)25"JI1J4?5,P&B_N"?W4G[0L!(@`````````````````
M``85\A(GV6X05X,$J,\PKA:\'1QLTGCH9'ATZ0'`MF&9\S,/V7+L+:18;E9K
M5*B6@V$0'D+=0A)FF*S)4E#2UJ894E"B,ZF6LSUA]%`.%-9[N&5"F6QC-MGC
MVV--DFRW,L-W6IA+TA:B9X9M]I"R0I>$E4T]$P'<V5&II"C,C-22,S(C(CJ6
MX1Z2`7`(]M`]#KG]%^L0"0@````([;?3^_?=UK_U9P"1````````````````
M`````````````-#GST0NGT7ZQ#/ILRFV&+'RZK'S4.G4``FNR#TU8^B=]P:7
M<,J6UHLR'?ASRZ`````````````````````$=_N"?W4G[0L!(@``````````
M`````````:+/4_+\/*-U5F"XHM5I?C.1I$U:B3@*0DVNMZ*NNZTBW0'S)LJA
MIS1F2WY=C9HR](M-LD6N0GB;<V/<)*+$E9L<"S);922G"55]23/=473#ZX`0
M6_Y=VHWF+<+6[>+$U:+@EV.LO%DIR0F.[5.M<W@E.$@]9HPUW*:`$UB1TQHK
M,=*E+2RA+9+6=5&22(JJ/=,Z:0'J`CVT#T.N?T7ZQ`)"`````CMM]/[]]W6O
M_5G`)$``````````.;;;W7&[-;S;6:#X=6E)F7YO2%EVR/'/X_6&CKY\$6_=
MQKCDOM[GPE;XNKL*J])QR7V]SX2M\+L%Z76]A;KKC-XX1:ET./3$9GVWHBG[
MG'BIL6F@GPS:ZF*MO@```````````-#GST0NGT7ZQ#/ILRFV&+'RZK'S4.G4
M``FNR#TU8^B=]P:7<,J6UHLR'?ASRZ`````````````````````$=_N"?W4G
M[0L!(@```````````````````<MV[VJ[S6<IR8-A>S+%M=Z;G7"TLDA7"-ML
M.I2:DN=8=%K+6`B.89F9\V9@R<<?9I/L3]JOT"6]>'$QRX*&AVDA!J:HO`I"
MJJ+5H`?0`#C\K.^;HEYDQ\F3G\]$B0M#]L>@&TW'/&9&T5X;XM%1P:JIHM+B
MJ$`Z-EG,,N[(E-3[6]:+E!6EN5%=4AU%5H):5LOM&:'$&1])1;J2`;H!'MH'
MH=<_HOUB`2$S(BJ>H!AP+S9[C%7+M\Z/,BM*4AV0PZAUM*DE525+09D1D1Z0
M&(O.&46X+-P<O=O1`DK-J/+5*9)EQPB,S0APU85*(B,Z$8#;D9&1&1U(])&6
MJ@".VWT_OWW=:_\`5G`)$``````````.:;<OY+;_`*=7R2%EVO,G\?K#1[AT
M1;]W%Q>*D`==V#_,WGJQO_E%+W3JIL6G;^F;75A5K````````````!H<^>B%
MT^B_6(9]-F4VPQ8^758^:ATZ@`$UV0>FK'T3ON#2[AE2VM%F0[\.>70`````
M````````````````CO\`<$_NI/VA8"1````````````````````````XB>T&
MX95D3[*O/&5%IARY1MQYJY3TUE#CRG"CN<&[5:VL6`B)-=!)UD`[5&=)Z,T\
M1U)Q"5UHI/OBK[U5%%U#T@/0!'MH'H=<_HOUB`;>ZPUS;9+AMNFRN2RXTEY.
MM!K2:245.A4!"RRMF&79KS%=BLP'KO;6K2AEMTEM,\7COIXQUJ4U):W4H(B+
M%@))G^B08]QROF:4\_=4P%,SY,IQ^.Q'N!QU17#BM1VWG%H3A=+$T>,M/6X>
MM5I2`Z$PAXHS:'UDX\2"2ZXDL!*52BE$53PU/I@();LF6@\\7MGC%SP-P+:I
M)^-KF2ZJ<F$>)?&,2BZW01GHW-9@)!S'LO?-U\\77PD`YCV7OFZ^>+KX2`<Q
M[+WS=?/%U\)`.8]E[YNOGBZ^$@',>R]\W7SQ=?"0#F/9>^;KYXNOA(!S'LO?
M-U\\77PD`YCV7OFZ^>+KX2`@.U[+\"V6J$[&=F.*<=4E12ITR6FE"/K4R774
MI/ID519=KZY_'ZPT>X=$6_=RD7BI`'3=CEBA71JZG)=EMFT;!)XI-EPR/%PM
M<11G6<6K\ZM!2]TZJ;%IV_IFUT?F/9>^;KYXNOA(JU@<Q[+WS=?/%U\)`.8]
ME[YNOGBZ^$@(_GFSPK#E]VXPWKBX^A24DEZ[W<T4.NXF6@_RC8TN%&)7%,[F
M''Q)HHF8<NY\W+]%[SI>_#Q:_K,/C5_S[*[W]?"/Y\SGS<OT7O.E[\/#]9A\
M:O\`GV/?U\(_GS2[9Q+YS7.3%GJF--LM<(DV+M>$JKBIIQS5C3UFDIPJ8F-N
M]M:74U8E4Q.QT/F/9>^;KYXNOA(KFZ<Q[+WS=?/%U\)`.8]E[YNOGBZ^$@-+
MG+*%JBY8N$AI^Y*<;;Q)2[=+B\@SQ%[YMV0M"BZ1D,^FS*;88L?+JL<%'3J`
M`2O9C;V+AFMF,^MY#:FW#-4=]Z,Y4BW'&%MN%\(:7<,J6UHLR':>8]E[YNOG
MBZ^$CGET<Q[+WS=?/%U\)`.8]E[YNOGBZ^$@',>R]\W7SQ=?"0#F/9>^;KYX
MNOA(!S'LO?-U\\77PD`YCV7OFZ^>+KX2`<Q[+WS=?/%U\)`.8]E[YNOGBZ^$
M@',>R]\W7SQ=?"0#F/9>^;KYXNOA(!S'LO?-U\\77PD`YCV7OFZ^>+KX2`<Q
M[+WS=?/%U\)`.8]E[YNOGBZ^$@',>R]\W7SQ=?"0&ZB1FXL9J,T:U-LI)"%.
MN+><,DE0L3CJEK6?1-2C,P&B_N"?W4G[0L!(@`````````````````````!X
M3IT&!#>FSY#<2''0;DB2^M+;3:$E4U+6HR2DBZ)@/GJ7><IE8G56G.>5GV"9
MO%M<CS91,.*@S9*9"'S:0;CCDIEUM>$DD1.DHE$:3,@'T';5$JW15$ZM\C9;
M,GG$FE:ZI+KEI,BHI6LRH`R0$>V@>AUS^B_6(!(0````$=MOI_?ONZU_ZLX!
M(@`````````!S3;E_);?].KY)"R[7F3^/UAH]PZ(M^[BXO%2`.N[!_F;SU8W
M_P`HI>Z=5-BT[?TS:ZL*M8```ANUOT+D?2(_ZC<T&='S_P`:NLRY_G]OGX=$
MI0!TG8;_`#^=_#E\LA6=SZ(M;V@ZIL=J%(M@``:'/GHA=/HOUB&?39E-L,6/
MEU6/FH=.H`!-=D'IJQ]$[[@TNX94MK19D._#GET``"Q]TFF7'3*I-I-1ET<)
M5"!S9S;E:D.+0=L?,TF::XT;AT%I^KJXPK_V%/!;Z];3Y+?^&@/U=7&#]A3P
M9=IVRVRXW*/!1;GFUR%D@EJ6@R*O4'C$[=533,[=SU1K8JF(V;W0Q7-X````
M```````!'?[@G]U)^T+`2(``````````````````````8=VB3)<!<>)(1%>6
MI'[9QI+Z<"5I-Q!MJ-)'C01IK716H#BSUUF0I$U=MN3K&6HDJ0E=U8RPV[`8
MPOJX:KQ/$XM#2\6-U+>'09UU@.YM'5M!FHEF:2Z\M2M&LJ=$!<`CVT#T.N?T
M7ZQ`)"`````CMM]/[]]W6O\`U9P"1``````````#FFW+^2V_Z=7R2%EVO,G\
M?K#1[AT1;]W%Q>*D`==V#_,WGJQO_E%+W3JIL6G;^F;75A5K```$-VM^A<CZ
M1'_4;F@SH^?^-769<_S^WS\.B4H`Z3L-_G\[^'+Y9"L[GT1:WM!U38[4*1;`
M``T.?/1"Z?1?K$,^FS*;88L?+JL?-0Z=0`":[(/35CZ)WW!I=PRI;6BS(=^'
M/+H``'A</W"3]$OY)B8WHE\KROWI[_.KW3'60YR7F)&YR;Z46WZ=(P:G+JL9
M<#KBU]-#F%^````````````CO]P3^ZD_:%@)$``````````````````````,
M*]1[O(MCS-GF-0+BK#P,N0P<IM%%$:L3).1S5B34BZ\J:^D`X=9GKI+RK<;"
M>U&RVEER1.AR8,BW,-2HIG(<2ZTC%<3PH.IFV9U/`HJ'J`=XA,,QX;##.$F6
MFT(;)&A.%*2(L.D]%.F`]@$>V@>AUS^B_6(!(0`!CS;E;H"&USI3,5#SB66E
M/N););B_>H2:C*JCW"(!D`([;?3^_?=UK_U9P"1`-;>LR62R(;7=)28R7C,F
MS4E2JF6G\TE#+AX-5?3&UCQ,6FC?+5>LS(OE9OX#O8#+[+%\K'[K#XGK,R+Y
M6;^`[V`>RQ?*>ZP^+;67,=EO:'7+7*3*0R9$Z:245#56GOB3T!AQ,&JCX51L
M9:,2FO=+8C&]@``YIMR_DMO^G5\DA9=KS)_'ZPT>X=$6_=Q<7BI`'7=@_P`S
M>>K&_P#E%+W3JIL6G;^F;75A5K```$-VM^A<CZ1'_4;F@SH^?^-769<_S^WS
M\.B4H`Z3L-_G\[^'+Y9"L[GT1:WM!U38[4*1;```T.?/1"Z?1?K$,^FS*;88
ML?+JL?-0Z=0`":[(/35CZ)WW!I=PRI;6BS(=^'/+H``'A</W"3]$OY)B8WHE
M\KROWI[_`#J]TQUD.<EYB1N<F^E%M^G2,&IRZK&7`ZXM?30YA?@`````````
M``([_<$_NI/VA8"1``````````````````````#3YPS(66LN3;V<"7="AI2K
MB,!OA9"\:THZU)F6A.+$L_S4D9[@#CUMNESS]?(,6W\W;';KHU*DN/6U$:[W
M-LXZFB4A];C:8[+BN'K[Q9D`[NTV3;2&R,S)"221GK.A4TTH`N`1[:!Z'7/Z
M+]8@$A``$4SI9[G+DLR8D(KDVJ%,MZXBEMH2A<PF\+ZN%,BP))I2%X:JPJ.A
M'J,)'!C.1[?'C.NJ?<9:0TX^=24M24DDUGIK56L!%(FSB"UF*XS5R;CQ.1%B
M,L4N]SX7&RN0;F-7&,1IHZC#51[NK34-IS'LO?-U\\77PD!B3]F.4;@E*9Z)
MTM*#J@G[I<G22?2QR#H/=&)53NF8>:J(JWQM8?J8V<^37N73^[CW[C$\U7.7
MCT:/+'(]3&SGR:]RZ?W</<8GFJYR>C1Y8Y,R!LRRC;TK3`1.AI<,C6EBZ7)H
ME&6JN"051CJKJJWSM>Z:(IW1L9?,>R]\W7SQ=?"1Y>FO7D%L[^R\F=="M*8C
MJ'F/'%TQ')-QLVU_O&HD$LM>Z`V',>R]\W7SQ=?"0&+.V9Y3N"$MSTSY:$'5
M"'[I<G"(^B1+D&/5-=5.Z=CS53%6^-K"]3&SGR:]RZ?W<9/<8GFJYR\>C1Y8
MY'J8V<^37N73^[A[C$\U7.3T:/+')F0-F&4+<2RM[<Z&3E.$)BYW)K%AK3%@
MD%6E3'BNNJK?,R]TT13NC8R^8]E[YNOGBZ^$CP]-=/R"VNZ6QR).NB(+2W3N
M+9WBZ56A3*B;(O\`V#U.4/60#8\Q[+WS=?/%U\)`>$O9UEF:R;$P[C)8/2;3
MUUN;B#,O\*I)D/5-4TSMB=DHFF)C9+7^IC9SY->Y=/[N,GN,3S5<Y8_1H\L<
MCU,;.?)KW+I_=P]QB>:KG)Z-'ECDR8.RO)=O<4Y`8F1'%%A4MBY7%M1ET#-$
M@AXJQ:JM\S+U3ATT[HB&=S'LO?-U\\77PD>'MK[SD%IUAE-MG71IU+[2GE*O
M%TTLDK]HG3(5K2`V',>R]\W7SQ=?"0'G(V?Y>D,J8D.7-YE946TY=KHI*BZ!
MI.29&)B9B=L(F-N]K/4QLY\FO<NG]W&7W&)YJN<L?HT>6.1ZF-G/DU[ET_NX
M>XQ/-5SD]&CRQR>\/9-D:$^3\.++C/D1D3K-QN+:R(]98DR",>:L:NJ-DS,_
M-ZIPZ8G;$0V',>R]\W7SQ=?"1C>V#>\A,.VN0W;)MT9GJ(N`<5>+I0CQ%77(
M5N5W`&8C(UG)"25)NIJH6(_'%UU\I`55D6QJ2:52+JI*BH9'>+J9&1__`,D!
MJCV,[.C,S.W/F9Z3,Y\_NXS>XQ/-5SEC]&CRQR4]3&SGR:]RZ?W</<8GFJYR
MCT:/+')>SL?V?L.I>9@R&G4'5#B+A<$J(^B1D_4A$X]<QLFJ>:8PJ(_J.3:<
MQ[+WS=?/%U\)&)D>$[(EN7"D(BR[JB4II9,+.\76A.&DR2?[R>HP%MNR)!1`
MCHF2[HY+2VDGUE>+K0UD77'^\EN@,GF/9>^;KYXNOA(!S'LO?-U\\77PD`YC
MV7OFZ^>+KX2`<Q[+WS=?/%U\)`.8]E[YNOGBZ^$@',>R]\W7SQ=?"0&7EN!<
M(%I1$G/*?=96XEMQ;BWE\#C/@B6ZY5:U$BA&:C,^B9@,'^X)_=2?M"P$B```
M```````````````````&'=GKHQ!6[;(K<R6BAIBNNFP2TUZXDN87")5/>U*A
MGH,RUD'-<R-Y6O4],BX9#O\`&S&CYJXV]A,>6E1:J7&)(2T9:-&-[#T0'0[!
M)O4B%PMU@E;G#.C$8WTR'B;(BH;ZT$39.&>M*%*+_$8#9@([M$6AO)=U6M1(
M0EFJE*.A$1**IF9@,WG9E7RS!Y2SV0!SLRKY9@\I9[(`YV95\LP>4L]D`<[,
MJ^68/*6>R`.=F5?+,'E+/9`'.S*OEF#REGL@#G9E7RS!Y2SV0!SLRKY9@\I9
M[(`YV95\LP>4L]D`<[,J^68/*6>R`.=F5?+,'E+/9`'.S*OEF#REGL@#G9E7
MRS!Y2SV0!SLRKY9@\I9[(`YV95\LP>4L]D`<[,J^68/*6>R`.=F5?+,'E+/9
M`'.S*OEF#REGL@#G9E7RS!Y2SV0!SLRKY9@\I9[(`YV95\LP>4L]D`<[,J^6
M8/*6>R`.=F5?+,'E+/9`'.S*OEF#REGL@#G9E7RS!Y2SV0!SLRKY9@\I9[(`
MYV95\LP>4L]D`<[,J^68/*6>R`.=F5?+,'E+/9`'.S*OEF#REGL@#G9E7RS!
MY2SV0!SLRKY9@\I9[(`YV95\LP>4L]D`<[,J^68/*6>R`.=F5?+,'E+/9`'.
MS*OEF#REGL@#G9E7RS!Y2SV0!SLRKY9@\I9[(`YV95\LP>4L]D`<[,J^68/*
M6>R`.=F5?+,'E+/9`'.S*OEF#REGL@#G9E7RS!Y2SV0!SLRKY9@\I9[(`YV9
M5\LP>4L]D`<[,J^68/*6>R`.=F5?+,'E+/9`'.S*OEF#REGL@&H@W2V3\_K5
M`EL2THM:"6;#B'"*LA>O`9T`2P```````````````````````````%KC;;B#
M0XDEH45%)41&1ETR,!C^*;5WDQ]4C>`/%-J[R8^J1O`'BFU=Y,?5(W@#Q3:N
M\F/JD;P"$9;MMN/:MG5LXK)MI@V4TH-M-",^.U,BH`F_BFU=Y,?5(W@#Q3:N
M\F/JD;P!XIM7>3'U2-X`\4VKO)CZI&\`>*;5WDQ]4C>`/%-J[R8^J1O`(0S;
M;=ZYY#?%6>#\0)/!P::5XV6FE`$W\4VKO)CZI&\`>*;5WDQ]4C>`/%-J[R8^
MJ1O`'BFU=Y,?5(W@#Q3:N\F/JD;P!XIM7>3'U2-X!!]I-NMZ+GDS!%93BOL<
ME86TE4L"^@0"<>*;5WDQ]4C>`/%-J[R8^J1O`'BFU=Y,?5(W@#Q3:N\F/JD;
MP!XIM7>3'U2-X`\4VKO)CZI&\`@^UVVVY&7K<:(K*3.\6XCPMI+0<@N@0"<>
M*;5WFQ]6C>`/%-J[R8^J1O`'BFU=Y,?5(W@#Q3:N\F/JD;P!XIM7>3'U2-X`
M\4VKO)CZI&\`>*;5WDQ]4C>`/%-J[R8^J1O`'BFU=Y,?5(W@#Q3:N\F/JD;P
M!XIM7>3'U2-X`\4VKO)CZI&\`>*;5WDQ]4C>`/%-J[R8^J1O`'BFU=Y,?5(W
M@#Q3:N\F/JD;P!XIM7>3'U2-X`\4VKO)CZI&\`>*;5WDQ]4C>`/%-J[R8^J1
MO`'BFU=Y,?5(W@#Q3:N\F/JD;P#T8A0XYF;##;1JT*-M"4F?5H0#V```````
M```````````````````````````$'RU_5G.W\#9/]Z`G````````(,S_`%JD
M?\?3]K(!.0```````0;:9_,\E_?T?Y"P$Y```````!!ML'H[;?OFW?:$@)R`
M````````````````````````````````````````````````````````````
M````@^6OZLYV_@;)_O0$X```````!!F?ZU2/^/I^UD`G(``@VUU^,O+"X1RX
MS3Y.1Y;D.9(5%9D1F)#?#-.N)2M1-N5)"NM/6`Q=E<[+4EZX>)K5:;:I*4<,
M=JEE+-=:TX0B98PTW-8#H8``@VTS^9Y+^_H_R%@)R```````"#;8/1VV_?-N
M^T)`3D``````````````````````````````````````````````````````
M``````````!!\M?U9SM_`V3_`'H"<````````@S/]:I'_'T_:R`3D``13:=)
MD1<I.R6IR8#;#\9R4XJ3Q'A(Z7DFZPF5B1P"G4502\2:5UD`\<GNWRXWV=?#
M9E0+#-8;)B#,EL3#6^DZ<.SQ9Z6RRW@T84.=<>DTD>L)B``(-M,_F>2_OZ/\
MA8"<@`#09PS3)R[&AOLVB3=N-R6XF"*ME*FUO'A0I7#+;+":M%2U;H#WL=XO
M<]]UNX6"1:&T))2'GWXKQ+56F$BCNNJ+HZ2`;@``0;;!Z.VW[YMWVA("<@``
M``````````-!F;,\FU2[?;;?;SN5VN?#*BQC=3';X.,E*G5+=42Z4QI))8=)
MG[(#&RYGV%?;DQ"CQ7&5.0U2GB=-).,NMOJCNQW4%6BT+2==("4`````````
M````````````````````````````````````````(/EK^K.=OX&R?[T!.```
M`````09G^M4C_CZ?M9`)R``(]GR[R;7EY;L1UUJ9(>8B1>+L-2'ENR'4MH0V
MA]QEG$HU4)3BR26L]`"(Y+V?QV)SMQ:M]\R_=N':?E3I;]N0B82556VJ':I"
MX9XDZ#4I@E=`Z@.G@`"#;3/YGDO[^C_(6`G(``C.TB\W"SY/G3K>^J/,3@0R
MXVT3SU5K)-&6U)6A3AUZS$1IKKT`,3(\BZ.39*9DW,,I)-$:4WR);XS1'B_\
M:H<:,I2^B2C,J`)B``(-M@]';;]\V[[0D!.0````````````$2VH+MT3*;]X
ME16)#MJ6U(BNR%K92PYPJ$\*;C1I<(D$JJDI/KBZW=`:?9Z_9[AF>XW9FXV*
MX7-^.@I+MG9?9>-.(S)3Q./O).I[N$CZ8#HH````````````````````````
M```````````.?7&WOWO:I<;6_<[C%@P[%;Y+#$&8_%03S\N:AQPTM*22E&EE
M!:>@`UEMSYG".J)ER*RQ=[JY=[I:&+G/=..@V;>UP[;SW`-KQK)!\&K"DL2B
MW*Z`W#.TY2K#9KL["2VBZ7N59W4<(9\$W%D2F>&*B:J,RAXL--T!CY<VC9EN
M%PRIQZU16+5G!AZ9;W69"UOL,HC\9:2\A3:4J6XV9&9I51)U+3K,.B``````
M``@^6OZLYV_@;)_O0$X``&FO>:8MH?;9>@W&4IQ.,EP84B6@BK2BE,H61'TC
M`;"V7!NX06IC;3["'B,R:DM+8>30S+KVG"2M.K=(!D@`"#,_UJD?\?3]K(!.
M0`!#=K<%$S),EMV3$C1VWH[TGQC)7"B.M-/)6ME]YM#JR0X183(DZ=0#4;*+
MSEZ9/N,>UQ[4TZAMMQY=HN4RZIPFHR(G5OQ8K;9]`B49GIT:`'20`!!MIG\S
MR7]_1_D+`3D``1S:'"D3LH3X<>$5R=?)"$V_ACC*?Z])\&AXGHIH4=.M5PA:
M0&LR`B)QV8<>U7V`;:>"=<O%Y*ZM8R456TME<[GP;A:S,T)T;H";``"#;8/1
MVV_?-N^T)`3D````````````!%MI[27,CW$E(D*)'`N8H22<DH-M]"B<90:'
ML:D4Q8<!UI0!C9&NO'9DA'.&XWG"TD^"G6WB"45/WR5\5BXE'NE4^H`F0```
M````````````````````````````````(U><AVZYWU=\*?<+?/=BM07EP9!L
M$MEAQQULE$1'I)3Z](#VA9&RY!79UQ&%M>(U2'(1<(M9FY,2I+[CJEFI;JW#
M6I2E*.IJ.I@-:QLLR\Q<8\M,B<IB%/<NL"VJD'Q1B6^IQ;JT-D1&9+6\LZ*,
MZ5/#2I@(YE#9QF"'FNSSYR%0[9EUJ6W"B%.5+CUD)X)"(C)MMJ;92@U'^U6I
M::)0GK:@.J````````@^6OZLYV_@;)_O0$X```````!!F?ZU2/\`CZ?M9`)R
M``(9M1E-MVB$V<"Y3'>/Q'X[EK92\MEYA]+C;CB552:246DC+3T@&LV<6J7'
MS!,>4Q=$0FXRF8B[@PW%2E#DA3_!&DEK6\I*EGA70B2GK=>D!T8``0;:9_,\
ME_?T?Y"P$Y``'-]K-CE7&7;W56EN\04QY<9##SL5M+<R2W@8=24IQM.(CU&G
MKBW`&!LHMDEN^LO,VQBW1K;96K5=CCR(3W#7)MQ"E+<3$==/$1)7USE%:0'5
MP`!!ML'H[;?OFW?:$@)R`````````````YUM7EW5F3;TL>-RA<5G.$JRLSG5
M\>0VCB?#<00M>''7K7/V:OSB,@&)LO>F^/$MM)O9Q'+4RY=%WEBY-).Y<(?"
M*;5<$-EB-)Z29ZWI`.H`````````````````````````````````````````
M````````(/EK^K.=OX&R?[T!.````````09G^M4C_CZ?M9`)R``(CM5CRWLF
MR%1W$(0P]'?F-NR^(-/1FGDK?9<E5+@D.((TFH!@[,'[%(XZ]:;9'@H-+9K7
M'N*+AC)1JPU)*E8/>G3H@)X``(-M,_F>2_OZ/\A8"<@`#GVT[*UXO4V$[%M#
M-ZBMQ)L=4:0ZVA+;TEO`V\1.DI)F71+2`Q]G>5LQVV]P),^T,VF+!L+5K>-I
MYIWC,IMQ"N%-+9%N)5I5IT@.D@`"#;8/1VV_?-N^T)`3D````````````!SK
M:OXV5)MR8[5U<A)BSEEXH*4:BG);0<,W>*==0EUH2^L_2`8FS!J:S?4I:B7>
M/$<M+*KJNZ(F)2Y<B</&LCE:%.&GWQHUE0!U````````````````````````
M`````````````````````````!!\M?U9SM_`V3_>@)P```````"#,_UJD?\`
M'T_:R`3D``1/:`=KFQ8MG=FJB70W$W*`I#"Y)(5;UI?X5]M&$N!)222K&M)&
M9DFM3(!$=B2H\M]V2Y(>=EQX+:8R'(2H"%0YKRYC;I)<>?6]B->A9&24EHU@
M.M``"#;3/YGDO[^C_(6`G(```````(-M@]';;]\V[[0D!.0`````````````
M```````````````````````````````````````````````````$'RU_5G.W
M\#9/]Z`G````````(,S_`%JD?\?3]K(!.0`!%LQY>O:[ZQ?K*420^41RWS;;
M/4XTR_'=6ERJ7FD/*;6E2-UM1&1GHU&`LRIEB[1;JJ[W5$.&MJ&W;;;:;:I;
MD>-%;,E4-YQ#"G%&:4D5&D$DBW:@)8``(-M,_F>2_OZ/\A8"<@```````@VV
M#T=MOWS;OM"0$Y``````````````````````````````````````````````
M```````````````````0?+7]6<[?P-D_WH"<````````@S/]:I'_`!]/VL@$
MY```````!!MIG\SR7]_1_D+`3D```````$&VP>CMM^^;=]H2`G(`````````
M`````````````````````````````````````````AB]E5F6M2SO68B-1F9D
MF_70B*O0(I%"`6^J>R^6\Q^?[KX0`>J>R^6\Q^?[KX0`>J>R^6\Q^?[KX0`>
MJ>R^6\Q^?[KX0`>J>R^6\Q^?[KX0`>J>R^6\Q^?[KX0`>J>R^6\Q^?[KX0`>
MJ>R^6\Q^?[KX0`>J>R^6\Q^?[KX0`>J>R^6\Q^?[KX0`B&7]FUI=VEYNA*NU
M]2B-#M"T.HO5R2\HW>-U)QU+Y+<(L'6DHSPZ:4J8"7^J>R^6\Q^?[KX0`>J>
MR^6\Q^?[KX0`>J>R^6\Q^?[KX0`>J>R^6\Q^?[KX0`>J>R^6\Q^?[KX0`>J>
MR^6\Q^?[KX0`A[.S>TGM:?@>-K[P961+Q/>.;EP^+C1)P\-P_"8/\-:5T@)A
MZI[+Y;S'Y_NOA`!ZI[+Y;S'Y_NOA`!ZI[+Y;S'Y_NOA`!ZI[+Y;S'Y_NOA`!
MZI[+Y;S'Y_NOA`!ZI[+Y;S'Y_NOA`"'Y_P!F]IB7'*:476^NE)O+#2S>O-R=
M-)&A1U;-;YFA6CWR:&`F'JGLOEO,?G^Z^$`'JGLOEO,?G^Z^$`'JGLOEO,?G
M^Z^$`'JGLOEO,?G^Z^$`'JGLOEO,?G^Z^$`'JGLOEO,?G^Z^$`(?M1V;VF%8
MH#C=VOKJEW6`T92+S<7DD2WR(S2EQ]1$HMQ6LMP!,/519?+68_/]U\(`/5/9
M?+>8_/\`=?"`#U3V7RWF/S_=?"`#U3V7RWF/S_=?"`#U3V7RWF/S_=?"`#U3
MV7RWF/S_`'7P@!%KWD:/$V@98L[-^S$4"Y1[BY,;.^W,S4J,AHVC)1OU*AK/
M4`E/JGLOEO,?G^Z^$`'JGLOEO,?G^Z^$`'JGLOEO,?G^Z^$`'JGLOEO,?G^Z
M^$`'JGLOEO,?G^Z^$`'JGLOEO,?G^Z^$`(M;<C1W]HUZLCE^S$=NAP(<B.WX
M]N9&3CRG"6>+A\1UP%K`2GU3V7RWF/S_`'7P@`]4]E\MYC\_W7P@`]4]E\MY
MC\_W7P@`]4]E\MYC\_W7P@`]4]E\MYC\_P!U\(`/5/9?+>8_/]U\(`/5/9?+
M>8_/]U\(`/5/9?+>8_/]U\(`/5/9?+>9//\`=?"`$R9:)IE#234HFTDDE+4:
MU&1%2JE*J9GTS`7@```````````````````C&=[[=8*[+:+,MIJ[9@G<28DO
MH-QMAMN.[*D/<&1HQJ2U'42$FKWQE714!BN7',64F9\[,5P*\V%EAM<:0EE#
M5P.6MPFBC$TR2&7"=4M)-G1)DK0=:U(,>3M6A04K8N5DN,:\MRH<0[.1177U
M'<5+1%=0M#YLJ;6II:35PG6FDZ]$!>WM0C+2N)XGF\XD3SM9V'%&-_ARC%-Q
M<+PW%^"XLHG#7PG2IBT`)+8+R5XM;<[B<FWK4MQMV',03;S;C+BFUI4236DR
MQ)ZU25&E14,C,C`;$``````0?+7]6<[?P-D_WH"<````````@S/]:I'_`!]/
MVL@$Y```````!!MIG\SR7]_1_D+`3D```````$&VP>CMM^^;=]H2`G(`````
M``(-F;^K.2?X2[_Z;`"<@```````@UF_K#F3[JM_RW@$Y```````````````
M``````````````````:/-F63OL:&<>8NW7.V2DSK9/0DG."?2A;1XVS-).-K
M:=6VM-2JE6LCT@-).V=W&]1[@O,5ZXU<I3++,)V%'.+&AG&?3*:=:C./2C4Y
MP[:%J-;AUPD182J`\U;,YDZY(O-[NZ)=Z*9;I"GXT7BS!1[6XXZS';94\^I.
M)<AQ2UFXJIGJH1$`NG[-'E7^7F.V70HEZ=N2;G$<>C\.PW6W-VYUAUI+K*G4
M+;:QU):#)5-.C2&^L5DO5NXN4N].W%"6WSEI>:21NR7WB=2XA53-IMI.)MMH
MJD23*IF95,-V``````(/EK^K.=OX&R?[T!.``!IKWFRUV9]MB8Q<75N)QI.%
M;+A/015IURX;#Z$GTC.H#86RXQ[E!:FQT/(9>(S0B2P]%>*AFGKV9"&G4:OS
MDET=0#)``$&9_K5(_P"/I^UD`G(#&N2K@FWR%6Y#;D\FU<50\9I;-RG6XS(C
M/#770!R]G/V;&9T[+RYS4FZ%)MT1F=(M[L(VG)KJFGUMQ75(5(8;PU;<(\)G
M0L2JU`9D?-6=)]W<RI'G1F+M`>E\:NJHN)+L>.TRIG"SPF%"UKD$3FFE"/#2
MN@)IDZ^.WW+4"Z/H2W(?092$(J2.%:6;;F`C-1X36@\-3U`-R`@VTS^9Y+^_
MH_R%@)R`HO'@5@ICH>&NJNY6@#F"<W9T3:[G%G2V&[LYF)FR1941HC;C,R>#
MHM"'25C4@EF?7UT](!;&OF;YN859,3?7F'XLB0;E]0Q$.4ZPAE*V4&A3*HV/
M&K]H:62JG5A/2`F>0[[*ON4X%SED12G2<;?-)84J6PZME2R+<)9MXJ=,!OP$
M&VP>CMM^^;=]H2`G(``C.T:Y9CMF4IT^P.1FID9'"*<E)4LDH(^N-"4Z#7T,
M6@!&[]F+-+[]S>MUT5;VLNVV-.<8)EAQ,QUU)NJ2\;C:U);P(-)$T:#Q'6M-
M`#H=OEE,@1I9)P%(:0[@/2:<:253V*@/<!!LS?U9R3_"7?\`TV`$Y``$,NF;
M,P6W.3T.7&C)L+-LD3VE,NK<DNJCT,\:5-MH:T5(B2I=>CN`(W)S[G6T0HK\
M]^'+>O\`#1(M;:(ZFT17UOMMX%_M3-QM+;Z5:>N-1'IH>@)AE&ZWI=TO5CO$
MAN;)M+C'!3FFN+\*W(:)PL;9*61*0JJ=!Z2`2<!!K-_6',GW5;_EO`)R```#
MGV:<S9KLF9H!O26FK9/N$:%#A%$><:4PZ9(<<DW#0TP[C5^S0?OM":*,ZD&G
M7M)S5#L\/,TA<:1;;]$E/VVW$PI"HSJ")4-*W2<,UI62OVQTU^]IJ`2O*MXS
M`G,,W+][E,SWVX,6YL2V6.+T;E+=:4TI.-PCPK85A/\`1,JU/2`EP```````
M`````````````````".YVNTN%%ML&$[P$V]W!BW,R"PXFTK)3SZT$K1C*.PY
M@_Q4.AZ@&$K:/"3`<F<3<PMW]O+AHQ)KPKDQ$,GO\I*<Q4UT`8,?:DZ],MJT
MV1WQ%>+HY:+;=2?:,UN-*=2IUQBF)#:E1UX#J9GNDFI`-<6TZ[Q7Y26+4[=U
MRHTR^QJOM1V6K9%=*,V25&2E*-Y"">05-)KTF1:@Q<Q;6KLO+-Q=AP7+-/5:
MX]ZLTA:V9!KB/OMM5=;PJ0VZ7")JCKBTZ%5(P$URY>93N8LQ6*6YPKML=8DQ
M7#IBXI.0I3:54II0ZT\@O\))UG4!(P````$'RU_5G.W\#9/]Z`G````````(
M,S_6J1_Q]/VL@$Y`8]RM\:XP)$"4DU1Y+:FG4D9I/"HJ'0RU&`BI;,;>Y'=*
M==[E<9YI83%NLE<;C48HKA.L\#P3#354N))1FMM1J/WQF`N7LSM_%VN`NUQC
M71#[TA^]-*C<;?7)03;W"DIA4?"M"$E1+18<)8<)D`DMIM<.U6R-;82#1%B-
MI::29U.B2I52CTFH]9F>LP&6`@VTS^9Y+^_H_P`A8"<@`#1R\F6"7#N,1UI9
M-W204R2M#KB'"D$222ZVM)DIM2>#33"8#`7LTRZJ"U&)V:W(:?=E^,D2G4S%
M/2$$V\M3Q'IX1LL)E2E-5*$`D5LML*V6^/;X+7`Q(R";9;J:J)+HJ49J,^B9
MG4P&2`@VV#T=MOWS;OM"0$Y``&+=+9#NEOD6^8@UQ9*#;>01FDS2?3+20#2W
MG9]EV[R&7Y12$&VRB,\VQ(=90^PVHEH:?2A18TDHJ]'<K30`DB4I2DDI(B21
M4(BT$1$``(-F;^K.2?X2[_Z;`"<@`#6R<OVZ3>&KJ\2ER&H[D0FS,C;4TZ9&
MLE),M.H!'H^RJQ(CR(TJ;.GL.1RAPD27&CXFPETGDICJ;:;55+B4F2W#6K01
M5H5`&ZRYEABR%+=XY)N4^>XEV;<)AM<,Z:$$V@C)AMAHB0A)$1)00#<@(-9O
MZPYD^ZK?\MX!.0```1>?L_@3;LY-<N,Y$*1(8F2[*A3/$WI$8TJ:<5B:4^FB
MFTJ-*'4I-15,C`8[>RZP$X\B1)ERK<IF5&AVIU;91HC<VG#E'-MMM[3A+":W
M%8/S,(#9Y;RC'LC\B4J?+NDZ2AME4R<IHW$L,$9-,I)AMA!(1B,_>U,S,S,S
M`;T````````````````````````!'\YV65<8MNEP4<+<++/8N,5FJ2X3@\33
MS9&LR22G([SB4F9D1*,JZ`$,MNR[,$SQJFY7>1;HBLR.WRW0FVXKB34S+3(C
M.J61*6;:^#(S;,R.O0U`-7(R%FZ?>85GB%<+18K==IEQ:6XJ"Y$92\4@T.1G
M$'QITU.ODI#2T))LC41F>%%0Z`[L^LZI/"LN.,-ILRK`TPC#@1&4:3)2:E7$
MG`1%N`-=<=DUFG0FXCDR2E#5G:L1*3P=>`9=:=2YI3[\S9(CW.D`VV7+-,9O
MV8+Y.:)E^YO-,1FL25**'"0:&E+--2JXXXZLBKH2I-:*J0"1`````(/EK^K.
M=OX&R?[T!.````````09G^M4C_CZ?M9`)R```````"#;3/YGDO[^C_(6`G(`
M``````(-M@]';;]\V[[0D!.0```````0;,W]6<D_PEW_`--@!.0```````0:
MS?UAS)]U6_Y;P"<@````````````````````````````````````````````
M`"/VKFWSROW$L7C_`(O`\;UQX>!_]CBF&O6=MKA]G<`2````````$1:\5>M9
M^G#^-?$J<5<'%^`XR6K\_'B]B@"7````````B&?O%7C#*O'^'X3QPSQ+@,%.
M'P*P\+C_`#.CAT@)>```````"(;3O%7B2!XSX?@/&D'@N+8,?"\,7!XL>C!B
M]]N@)>```````"(W_P`5>LC*?#\/XQXM<^)<'@X##@9X7A:]?6E,.'IU`2X`
M``````$1M?BKUGWW@N'\9^+H7&<6#@."QN\'@IU^*M<5=`"7````````````
1````````````````````_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>v371611_chrt-barcells1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v371611_chrt-barcells1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^(,6$E#
M0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`
M,0``86-S<$U31E0`````245#('-21T(``````````````````/;6``$`````
MTRU(4"`@````````````````````````````````````````````````````
M```````````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````4
M8FMP=````@0````4<EA96@```A@````49UA96@```BP````48EA96@```D``
M```49&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P``
M`]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E12
M0P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`
M````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V
M,3DV-BTR+C$`````````````````````````````````````````````````
M`````````````````%A96B````````#S40`!`````1;,6%E:(```````````
M``````````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4`
M`!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO
M+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`
M````````````````````````````````````````````````````````````
M9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````````````
M`&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````````````
M``!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@````
M``!,"58`4````%<?YVUE87,``````````0````````````````````````*/
M`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`
M*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5
M`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!
M#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A
M`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"
M9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/
M`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$
M<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U
M!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'
M/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG
M"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*
MW`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS
M#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/
M7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H
M$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4
MSA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2
M%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;
M.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^
M'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(B
MKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W
M)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K
M-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'
M+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XT
MV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY
M.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_
MHC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D55
M19I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+
MFDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F
M4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8
MRUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S
M8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG
M/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$
M;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV
M^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C
M?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(
M!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6
MD3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R:
M:)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/F
MI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN
M+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9
MN-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#
M6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XV
MSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9
M\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$
MY@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q
M__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+
M_MS_;?___^X`#D%D;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&
M!@@+#`H*"PH*#!`,#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?
M'P$'!P<-#`T8$!`8&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?_\``$0@!^P(V`P$1``(1`0,1`?_$`+L`
M`0`!!0$!```````````````&`0($!0<#"`$!``(#`0````````````````0%
M`@,&`1````4"`0<%"`D2!`0%`P4```$"`P01!08A,1+2$Y0'0=$65A=182*3
M%%0557&1L3)RDK)3-H%"4H(C,W.STS1TM-0U=95V-Z%B),7!0T3$X<+#)1CQ
MHPB$9;4F1A$!``$"!00"`@(!!0````````$"!'$R`S,%$3%1%(%2$A.1%4$A
MH;$B8O_:``P#`0`"$0,1`#\`^J0````````````````````````````'/[EC
MO%=UQ3<L-8&@07G;(397B[75UU$9MYU.FEAIIA*G'%Z.51F:2+O@,.%Q2Q!`
MLV,#Q;:68-WPDP;ZGHJW5P):%M&XTIEQQ"%%57@J2=3(!M>$'$"=CC!J;U<X
M:+;<$2'XTN&@U&3:F5F15->7WM#`1?#W'AV]7;&RVK>VC#F%8)S8LY2U$Y*+
M16I"J'D2AW9&:>\9`)!P:XGN8_P[(F3816R\P)"H]PMQ&KP*D2VE%IT51;:B
M,!3"G%JVS\$O8POQMVJTJG28L):2<=-;3+RVFU&E"5*-2]F9T20#8\,N(+>.
M[-,O<6(J-:RFO1K:XX9Z;[+)DG;*29%H&I6EX/(`ERE)2DU*,B215,SR$1$`
MT&"L13,1VQZ\+82Q;)+Z_0M*[1V&BB6WW*G3[L9&XBA%X!IKEJ`WZE)0DU*,
MDI255*/(1$6<S,!9'DQY+*'XSJ'F'"JAUM1+0HNZ2BJ1@(#+QSC"]XDNUCP+
M!@.-V%Q$>ZW>[.O)8\J4@EG'89CI4M:D)46FI2DD1Y,H#"1Q8OMNP?C*X8EL
M[<&^8/2HG$,+<7!EJ6T2XZF'5H0K16LR2HJ53R]P!O\`A7CF7C#`T:_W.*BV
MS]K*8GPTJ,TLN17UM&DS5E]Z@C.H"%8>X_2+Q&Q]=TVM#5@PE%*5;9"E*)V8
M3C;CC!F1Y$D\EHE)Y=%2>Z`EG"/B2O'6$EW29$*VW>%(=B76W5/[BZWX2??T
M5HJ;4E5?9[@#3V7C0]/P59KTFTG*O6)YDF-ARR,+T%/H8=<23KKKA&32$M-;
M1Q9E0BS$8#:X7X@XAD8T=P=BFQM6FZG!.YPGX<KRR.\PETFEI-2FF%H6E2BS
MIH?NA."DQSD*C$Z@Y"4DXIDE%IDA1F1*-.>AF1Y0&BQEB27:(\&+;&42;Y=Y
M*(=LCN5V>D9&MUYPDF2MFRTE3BZ9:%0LI@)"````````````````````````
M``````````````````````````````````````````+'G2:96Z9&HFTFHTI*
MJCH5:$7=`<=MN#L*8_:?XB8,O]XPC<+F:DSU17FD(6[',T&<R+5UM2DZ/V9`
M(E<\68JQ+PB>L5[EMW=R[8F9PW#O3#:6O+H:)"5.2"0WX)4)I2:IR`,IF5,3
MB'&7"^T+4Q<<17Y;BUH++%L[T9IV6^5/>Z1*V3>3WRN\`TLIA@^'&-3MS>Q8
MQ=B6/AJRZ!4T8;#K<1"4EW"0RL!)N*4X^%>)7\3Q2-JTXELCUKE;,LC=S@QS
M."X>3P26GP,G*0"=X50>!.!T1U])(>LUD.4^1\KZ6#=7GY5.`,7A?9L16;@A
M9(U@;B]('8;<M#=R4ZB-MY:]N]M39);F3:*I0LX#RNLG'UVA1<$8C]'-7F_N
MN*GKLJI"FF+(T2?*%*5()"TNOK5L$Y,RC,LJ3`;^2SQ1BXBCQ;)'P^U@QE3#
M9$\N6F>EA*4DZ2&VT;`E%X1-^%3-4!)[HJVE;WTW-QMN"Z@VI!O*)#9I<+0-
M)J,R]]6@#PB0K5AZQ)BVZ*3%MMK![")'36C;:3/10FN4\F0!RJVX)PQC2$[Q
M(P/B:[X0?OB3E33CO->3&\WX*US(AFXUIH-/A4<+E[H",3L2XEQCPIL-BQ`^
MBXOXBQ6S9$W)ELFDSK;#DFZY,)"?`(C\F,O!R`,BVR),^Y8JX40%J9DW?%%Q
MD75UO(<:Q/(9E2%$9>\5(4_L&\E/",^0!I'&&Y_"^[,Q4;-KB)C1JTVS9E30
MMS$E$=E":'[U#,%:?8`;[B]=E\,<37^\1:LVO'-D?C(T"\%J]06#1&7W$DXR
MO1H6<R`2FV37\/VS#6!\,V1B\XTLUICE(DR32U%MB'6TH<=D/D2W$F\M)F3+
M1&I9%R%E`;6WX)Q59';CBPW8^)^(%P;:B[20I4"$Q#2X2SBQDI3(4AM)U555
M5+5E.@"*8(NO%:X8VQ7?D6.T.%Y3%LLHUW%Y*6$V]LW5DR?DQFX6E,,S,]'+
MDY*@)794W;$EQO.-K<EAQYAI^UX+1-TTQM%M5'Y3AMDI9)D2&R35)5V:",O?
M`)%@Y7$(V9)XS1:$/Z2?(RLRY*T:-#T]J<E*#K6E-$@$B```````````````
M````````````````````````````````````!KY-]ML9S9NN&2\N0DJ/,9I/
M,7=(!Y'B>SD5=JK)_D5S`*])K1\ZKXBN8`Z36?YU7Q%<P`>)K07_`#5?$5S`
M'2:T?.J^(KF`.DUG^=/XBN8`Z36CYU7Q%<P!TFL_SJOB*Y@#I-:/G5?$5S`*
M=)K/\ZKXBN8!"9_#O@G/N+MPDV&,J3(5IR"2AUMIQ=:Z3C*#2TLS//I)`2%Y
MK`;OHM*X3)(LB]K:6TLFA$99(-!&VA)$E-$G0L@"Z.>"(U\F7]B,AN\3VT,R
MYR6U;1QMHJ(29][O`,2/:.&\:#`@L6]IN':Y)S8#!(7HM25&I1NI+[*JU'E[
MH#*Q$6!L36X[;?8S=Q@DXEWR=]M1I)Q%=%7)E*H#WNLO"=WM+]HN+92;;);V
M3\5:%Z"T?8G2F3(`RV<06-EI#+*MFTTDDMH2A1$E*2H1$5.0!BL3<*,W63=V
MTTN4QMMF1)-+AJ4TSI&V@JU)*4FM1T33*9GG`9G2:S_.J^(KF`:'&K-@Q5:6
MK1+?24$Y3$B6E;*EJ6B.X3I(1E(DFI2"(U&1T36A5H9!OBQ+9R*A.*H7^17,
M`A$GAOP0DSW9KV'HIO/+VKS9-NI86NM=);"3)E67NH`21X\$.R+6^N(UM;*:
MCM-&C2F-IM[)6R2DB2GP/!S9`"&6"(5XN-YB1D,76[$V5QFH;43KQ,IT$:2O
M\J>X`QHELX=1(MIAQH#34:Q.*>M#*6UZ,=Q>EI+07=\-6?N@,C$2,#8DAM0K
M[%;N$5EY,AIIYM1DEY!&25EWR)1@-'?<"<&[]=9%VO%CC3KE*-)R)3S;BEK-
M"20FIUY$I(@&WPO"X?X4ANPL.PF[9%?<VKK3#:R)2Z$G2.M>0@&0PY@YB!,@
M,-[&+<''GIB&R<0;CDDS-U9J29*)2JYR,!EP;OARWP8\&$11X<1I#$9A"%$A
MMIM))0A)4S)25`'MTHLWSJOB*Y@%>DUH^=/XBN8!3I-9_G5?$5S`*EB:SGF=
M/XBN8`Z2VCYT_BJY@#I+:/G5?$5S`'26T?.J^(KF`.DEH^=/XBN8!7I):/G3
M^*KF`4Z2VCYT_B*Y@#I+:/G3^(KF`.DMH^=5\17,`KTDM/SJOB*Y@'K$O5OE
M/$RRLU.&1F1&DRR%GS@,X```````%$J)22468RJ7U0%0````````````````
M````````$(OYGY>>3[/\:L!K#Y:%4^X`J60LOU0%",@%5?\`U`",`(RR`*GG
M[X"F6@"AE0RR@*'3_P``%<@"N0N^`MK0JF`NR4J8"C9U(R[G+W0%Q4`6F1U,
M^3/0`H8`1&=`"A4R\H"I5^H`4,!:HCR%F[X"[+D]T!:9=_E`5IDH`J9=^@!2
MAYP#E[W*`*25,^3E`6Y2SY0%:%3.`&7*6;E`52GP2`5*@"I$1$`KFY,@!DR4
MY0`B]L!0>@6<>"I@%#,P&UPS^]D?`7_P`3$```````%C'WEOX)>X`O``````
M```````````````````0F^D?EZNYX?XU8#6T+N@**IW<X"A&7_B`NR`%2RY*
M@&3N4`5\'(`)RGF]D!8M1%6N0!YDZ7+[8"[:IR5S@*Z7M@!*I0!72KDSU`>A
M$=.^`I7O@*'_`(@*5[O(`*4FG<`6UJ8"AJ/ZT!4G,I%R]P!::M)5:^#EJ`N-
M="H6;D`6&Z1&53R`+C67=R`+341UR@!+3FKE(!ZE6E0%<GM`+=(M(!0CRY\X
M"^N6E0%ND5:D>0!6IED/+4!=GR`+LG.`IRUY.0!3P:5,`+N@*U(LIGFS@+=(
MC+)F,!<1^T`VN&J>F$%_D7_P`3$```````%C'WEOX)>X`O``````````````
M```````````0F_?GQ_;_`(U8#5J41'3/4!A2)A(422.N7(`N:E$HLX#V)])%
MG]D!<IPN0!3;Y*9`%[:R47L`+N7.`T]\N28C)K,Z`-/%Q0RO)IE[(#.1?F>Z
M50'NB\-*^ORD8#T*ZM?9D`RX\QM9D1'4!G$9&`M6>3(50&,[)21TKR@+#EI^
MR`4\K3FJ`\7;BA.<Z$`I%N+;BJ),!GD1F52S'G(!8LC(J\A`,"1=&FCHI1>P
M0#P]-1ZEX19`'F[B&,@Z&><!C.8FCH/WY`/*/BR.N039**IGD(!+(SI.MD=<
MAE6H"]:C)->YF`8#DQ*3/*`L](-_94H`JFXMZ1>$64!?Y:V9UTB(!0KBT2DE
MI%4!L&G"4DCK4CR@+C.F4P'@Y((JD9T`>?E15H7*`]"D%W<@"A.IKGR`+C<0
M62OL4`>J%$99P&WPQ^]4?`7_`,`$M<D,-N-MN.)2XZ9DTDSRJ,BJ=![T>=7H
M/'H`````L8^\M_!+W`%X``T>+,;89PG%8D7R7Y/Y4O90X[;;C\A]RE=!EAE+
MCBS[M$Y.4!B85XDX0Q1-?MUKEN)NL5!.R+9,COPY2&U'0E[&0AM2DY2\)-2R
MD`R,*X]PEBM=P;L$\IJ[4^<6X(V;K1MNE7P:.H14LAY4U+O@$C'N$XV,8N#7
MIY)Q+,8.5'@$VZHS:(EF:C<2@VDY&U'12B/O92`789QQA7$[]SCV.X)F/V:2
MJ'<VB0XVMEY)F1I-+B4&952=%)JDZ'0\@#+M^)++<+Q=;-#D;6Y613";FQH.
M)V1R6B>9\)220O2;.O@&=.7*`V0``````````````A5^+_7J^W_&K`:ASN=T
M!'KBW(-^J.Z`R64+T>^`R4:94J6<!>9J+.`\EJ53_B/1D05*,LN8>#,.E*^T
M`YYQ(5+)DB9KFS`(%`=FD2<X/&U9D3Z<M`&?'E3=(M*N3,8#9L/2%)KE]GN@
M];.V39'E*$T.F2H"9LGI-D=?J@#M20=,]`&BD&\;N3,1YP&*XX\FI%7O`,"1
M-?14JG6N0!KUSI2ZU(\F<!DVIZ43Z*UT3/\`P`3R+I&TDZ9:`/*>O084=,Q&
M`Y7>;O+1)70\A5(B[H/&G7?II5(JY<H#7R;]/694,RS@-?(N\XR.JCRD/1@Q
M+Q<&[FV>DHBTLACQZ^B\,OJ=MC*U5TC26<!L)SBDLJ,N0N3N@.>W6[RFWS)-
M<^4'C'3=):C(E9`%[]VD-F1G6F3,`\'+_(T:%7V0'B=^DI-"CTLX#HV'9OE$
M)M9YZ<H/6U>51LSY0$7N5Q6EXT%F`8[5V65-/-W0&P9G*.F?*`RTN+454\F<
M!Z)=4JG=`9K!*/O=\P&3TCMN'$N76XKT([#:B))%52UG[U"2[IC/3TYKGI#&
MNN*8ZRY/+XFXHFXO9Q*EK2:C::84)1_<T(45.3E[XN*;./P_%5U77_;JD';Q
MC/U:Q[?_`(#7_70V>])V\8S]6L>V?,']=![TG;QC/U:Q[9\P?UT'O2=O&,_5
MK'M_^`?UT'O2V6%N-.)KIBFUVB9"9:9G/$TM23.I),C.I9.\-6M9113,MFE=
MS55$.T,?>6_@E[@K4YR>VN8RQ[B'%<F%B67A^'ANXNVBSP8;;"FG)$5"3<?F
M&ZVXIU"UJILTFFB2SU`8_#?BT^QPTB8LQO)?DR+S/F$PB%$=D)90V\IM+24,
M(6I*$DWDTC,^Z8#8XJBWS$%YPOCG`S\.3<H,.0:;'=S=C&]$F:!&ZA.CM&7"
M4WHU4FAYCS90\;)BQ%PXC6:-CG!K^&\8^3RFK#<4RDRXDALDI7(:0ZP:$J5H
MITR0X@]'+F/.$&X*%T=Q=#NA'H6_&,J\VF9EHGR^WSGI$5:C/)5;"W4%['MA
M7#1>E^->$\<K/2/$\[$7D"O_`-MM\5F)#R?YMFMS[<!BX6AR\*IN?%&U-K<;
MM^(+O!Q=#;J9OVE4U1[<DEG<B+/3+E--2K0@'1,`7>V=I7%.\>4M^BZ629Y9
MI%LO)_1*7-KI?8Z'A5[@#JP``````````````A5]/_7*+X?XU8#5K29T[Q@/
M!<1*E:6<`3'H=*9`%=B?*60P%YLER%]0!9Y,64Z9>^`O992@JED`>AT^J8#4
MW>SLSDT65:`-6WA2(BAZ)52`].C,?2KHY.4!Z(PXQ4C(LP#(196"Y"`>K-H9
M;62R30^Z`VB")*2(@%JT5+.`\%1DF=:9P'FJ$E6<J%W@&*_9VE_6YLM0'B=A
M9ID3E`>S%I;;4DR+,`VS9:**>V`\I+6T:-!YC`1&7A-#SBCH64P&"O!""J1)
MK7W`'@K`32C][D`>"^'C:BS9>0@'DWPV:*2E5/>F`Z3:8918K;=*:)$1`,IY
MO:-J2`C\K#K+KIJ,L^4!XJPRUD[I9CH`\G\,H65#(LA`,;HFW0SIG`6O810I
M)%0J$>0LH"366#Y-&2@RS`-FXDJ4`:B39VG7#-2:U`>*;*VDS\'V`&2W;4IY
M,G=(!EMQ4I+N`+E,I2=:9#]T!>V9TKR`,ZVVRWW=YRVW!@GXDAI:74*+)R4,
MCSD9<AC*FJ:9ZP\JIB8Z2YM-X*S8N-HMI.0Z5BG&X<>:WE4C1+2T%D>2HLZ;
MSK1U_P`PKYM?^_3_``D__P`<[9Z[E?%2-7]A5X;/2CR?_'.V^NY7Q4A_85>#
MTJ?)_P#'.V>NY7Q4A_85>#TH\G_QSMGKN5\5(?V%7@]*/+88>X%6ZS7Z#=T7
M5]]R"Z3J&UI311D1E0S^J,-2]FJF8Z,Z+6*9Z]736/O+?P2]P0DISNY\,<3L
M7F]2\(8F38H&)5D_>(JXB9*T2303;DB&YM&]FXXA)5TB41'X1`-UPQP`6`\-
MJP^S<%W"$W*??A*<;T%M-/N&X32CTEZ9I4H_#\&O<(!X8RX?S[M?X&*,/7<[
M'B:WL.0RE*83*8D17%$X<>0R:FS-)++22I*B,C[H#PL^`,22,3V_$N,K\U=Y
M=G0\5H@PH90XT=R0G9NO*-3C[KJU-EHE51$FIT(!J)W`Y,GAT_A)%[4Q-]*.
MWB!>6X]%1GW9*W\C6U\*B'5-UTRK6O>`;QOAA#C7?`\R%+V$3!,25#8B&UI&
M^B3';8(S<TTZ!HV6D?@JTJ\@#.P1@=K#-JN=N>DIN+5SN$VX.$MHD)),YPW#
M94DU.$HDDK1KR]P!#,/_`/X\6:T6K%5D]*OOV3$TJ$[Y+HFAQB)"=)?D>VVB
ME.(6T6QK1)DCN@.M@`````````````"$WXO]>K[?\:L!KJ>"15S9S`6DDDIH
MG(`4(ZT/*`$:C+*`K0OJ$`K6H]%*4'@`*&5<H!HD`:)>R`IH4R$`:-`%<H"N
M3F`4KE[X`992/VP%:5K7Z@"FC[0!HGW,X"NC0!6E"[H`9%F`>>S3ER`*&V5:
MT`4V*2/(7L@!L([@"I,I(ZD60!6.VZAO1<7M%5,]*E,A\@#TY#`6&G*`&DLI
M\H"AM]W/W0`F4TK0`V99^0P%Z4D6;Z@"[DR@*&0"A(3G/.`KH]P!71[N<!0R
M(\AY@%J2HO1Y#RD`W.&OWNCX"_\`@`F%"]H```````%C'WEOX)>X`O``````
M```````````````````0F_$7EZOM_P`:L!KSI4!0S*E?\`%E>Y[0"_N>P`ID
MY`#+F(P`S`-+NY``\I9`%#R@*F5*90%#++4`-/=]H!4ZTR$`KG`6Y:Y2`7'F
M`4,U9BI4``7?6@*9\X"ZI`*9`%"(!4R]H!2A`!T`*$8!R4`5`#+*`HHB*AU`
M6JJ?>[@`7<[I`+BI6G<`5K3*`KW0#-[`!2A@!D1`*90"E%UK[!`"BR=TRS`-
MKAD__=D=S07[A`)B```````"QC[RW\$O<`7@````````````````````````
M([-<L*7U>6LJ<?JYX23,BT=JNF920'@;V$_-G/;5K@*;?"?FSGMJUP`W\)>;
M.>VK7`5\HPF7_3.>VK7`"?PGG\F<]M6N`IM\)YO)G/;5K@*F_A/S9SVU:X"F
MWPF?_3.>VK7`#?PH7_2N>VK7`"DX2,\D9PS+OJUP#;X3\V<]M6N`;;"?FSGM
MJUP%=OA/S9SVU:X!ML)^;.>VK7`-OA0O^F<]M6N`;;"?FSGMJUP%-MA,O^F<
M]M6N`KML)^;.?&5K@&VPGYLY\96N`IY1A/*7DSGMJUP%3?PIYLY[:M<`)_"F
M;R9SVU:X"I/X4/\`Z9SVU:X"FWPIYLY[:M<`\HPIYLY[:M<`V^%/-G/;5K@!
M/84K^;.>VK7`">PGR1G/C*UP`W\*>;.>VK7`">PI3)&<]M6N`;;"GFSGQE:X
M`;N$_-G/C*UP%-KA.GYLY3X2M<!4GL)D1?Z9S+WU:X!ML*5(O)G,O?5K@*[;
M"A?].Y\96N`;;"GFSGQE:X"FVPIYNY7X2M<!7;X5\W<^,K7`-OA3S9SVU:X"
MFWPF>0X[GQE:X"NWPIYLY[:M<`VV%:_FSGMJUP&7:7+`J<283*T2-%5%*,S*
MG+G48#>@```````L8^\M_!+W`%X````````````````````````"$W[\_5R^
M_P#QJP&L.G*`IDK0@`C+.`II'7,`'W@#(=?\3`7%WP%*EW0%3S5[F8!:FA)R
M<IU,P%:Y,F<`KDH`H2BIDY`%3/)4!6N8P%#]@`(ZY0%2,J`*:?>S@*E0!32.
MM`%:]T`KGRY`#2J`II%G/D`-(CS&`&K*67V`%<_U`"N0!0C*O=`5Y2`5J=*9
MP%NF5:<@`FA@+JEF`*^"9]\!;D(JD8"M:'7/R`*:7M@%3,\_L`!GG]P!4CRT
MY0%Q9R`;;#)?^[(/_(O_`(`)B```````"QC[RW\$O<`7@```````````````
M`````````(3?J%//[?\`&K`:M1'E.H#R4HJ9\W<`6I>J0!M/J'W0#3Y0%=H7
MUQ`+B66B19@%2668!12^^`IM2I7D`4T\V4!53A9C/)R`!**M0%=H9Y.3N@*Z
M63.`&KOY`%JEE7.`&X19#`$N%W0%26DB]CD`-(JY,I`*FNI9<X"W:=\!0W$F
M="/V0#:EFS@*I=+*1@!K21@+B<3RF`&HN3*`M)="`5VGMGG`-H15[P"W:5R@
M*I<+ZG(`OVA>R`M)Q1Z14I3,`H;AF1=\`VM,I'D`-H5:YB`5)95KREF`4VE<
ME0%^E7G`>A'E]T!ML,'6[M_@U_\``!,@```````6,?>6_@E[@"\`````````
M```````````````!",05\O5]O^-6`TSSY-E4SS9Z@(1B+B58;0X:'Y"$K+ZV
MN4!I&.-&''3(O*$E7-E`;>-Q)LCR:IDH/N^$`R"Q_9?.4?&(!>C'ME,OSENG
MPB`9D/&5IDK)MN2@U'FHHJ@-RB8A2=(E$9=T!IKGB^U0,DA]""+E,R`:YCB1
MAUTO!F-GWM(@'J>.[-7))09?"(!ZIQO:%%^<(,N\H@%.FUI2JFW1\8@&7'Q=
M:G%$DGT&?*6D0#;LSF74$I"B,LX#'FWF+%(U/.$GNF9@-*]CRQH53RE%:_9$
M`M1CNSJ.A2$?&(![)QG:C,J/H^,0!TSM-2J^@L_UQ`,Z'B*!).C;J3KW#(!L
M3EH)-:E[(#1W/%]K@UVSZ4F6<C,@&J3Q)L1JH4EO)G\(@'NGB'9*U.2C+WR`
M>I8[LQY2D([_`(1`"<=6<ZUD(+[8@&Q@8FMTPZ,O(73D(R,!L')S:$:2E$1`
M-=(Q/;6ZZ3R4^R9`,4\9VHE&12$']L0#S5C:UU,MNCXQ`+DXSM9EE?27VP"]
M&,;5I$1OIR_YB`;"%?H4C[VZDS[QD`S%S6TI-1JH6>M0&LEXHMT<Z+?21^R0
M##Z;6DR(MNBI_P"8@%',:6LJ4>3D_P`Q`+%8]LZ"\*2@OMB`>)\0[&:BI)13
MNZ1`-C`QC:9--"0@SY"TB`;EJ[1%$1$X67*64!)<*.)7=6S3F-M=/:(!*)-Y
MMT:?%M[SR4S)FEY.SG4K1*IG3N#**)F.K&:HB>C-&+(`````6,?>6_@E[@#G
M%PXW(M\Z'!EX(Q.W)N+RX\!!QH7W9QM"G%$C_6?8(-7L`)KAJ_/7NW>6NVF=
M9E::D>1W)#3;_@_7:+3CR=$^3P@%DW%%OB8HMN&W&W3G72/)E1W$DDVDHB&V
M3A+,U$HC/;)T:)/ES`-P``(QAG'T'$<"Q7"W6Z><&_,/2&I*VF]G')@TEHRE
M)<42%.:7W,DZ5:'F`2<````````````````!!\0'_KU?;_C5@(/C:>["L<I]
MJNFA!FFGL`/C.[7*9<)STB4XI;BUF>4\V4'C#(S+,8#T1)D(]ZZI/L&8"[RV
M9\\OXQ@'ELOYY?QC`>L6\7.*\EYB2M#B3J1U,!V&'Q6N3."42U&:I*?`KW\P
M#D]YQ+=[O)6_+D*5I'4D$="(!KDR'TYG%%]4P'H4^:7_`#U_&,!<FYW!.:0X
M7VQ@!W2X^<N?&,!ZLWV[LK);<MPE)S'I`.K<.>)MZ5#>9E&;ZFJ$E?>,!'>(
MG$2\SYZHK+JF6DEX1%D,P$#.=,5G>6?VQ@+DW&>GWKZR^V,>B]-XNB2HF4X1
M?",>`J\716>4YD_S&`V5FQI?K9*;=;E+4E)E5"CJ1D`[LOB`ZO")W$E'I[.I
M>S0!P"\8DNUTE./R9"STU&9)KD(!KBD/E_S%>V8"\ILLLSR_;,!<5QGE6DA9
M5S^$8`=QGGGD+^,8#:X=QA>;-.0^S(6:*D2T&=2,@'3\7<49I8?:<B*HX^DJ
M*]D!RB3BF_R%&;LQP]+.50&,5YNI?]4Y[8"I7JZE_P!2OVP%2OMW+_JG,G?`
M/3MW\Z<]L!N<.X_OUIF(<*0IQLU%IH4=<@#I>,^)TYBP,.Q%:+LA)$7>J0#D
M$O$U\E.&MZ6X9GW#H`QRO%S(R,I+E2_S&`JJ]74\\ISVS`>2[A-6=5/K.O\`
MF,>BTIDHLFU7[9CP>\>]76.HE,RG$*+,9*,!TKAKB+%=ZNC,0W5N-)46FKO`
M/IE&(BPM:W+HIE<AR.R:4-(*M5*H1&KN)[IC9I:?YU=&.I7^-/5R5S&&*)>(
MBQ-Y<E%Q\+8F=#)M*BIHI2>2E!=TVU/X_C_A4SKS^77_`"W':KQ%]<(^*CF&
M/HT,O;K.U7B+ZX1\5','HT'MUG:KQ%]<(^*CF#T:#VZSM4XC>N$?%1S!Z-![
M=;;8,XF8XFXTLUNG7(GXDN02'D)2G*FAY*D7>&G7M:*:)F&W1N*JJHB7T$Q]
MY;^"7N"H62`\1OIWPV_B\K_^-D`&#YCI\4N(K;[ZO)XSEK-"%K/0;2=O0I1D
M1G1)&>4P'*\'VJ+BCLHAWJ6^Y'DVJ\JD)3(<:7*)+S)DRMQ"DN*2?OC(E9='
MN5`;+$2%X;/%N&;-)?:L-LNF&'X3"GW7/)7)TQ'E,=#CBE+)M24)7H&JA:?<
M,!T2]S7"XTX5AH?42%6>Z.O1R4=#^ZQ20I2:T^RH?L@.?\*I$A#7!IA#JTLO
M6F^&ZT2C)*S1Y-HFI)9#T:G2H#26W"L2+_\`C_;,?^63G<814QI<6[.3)"EM
M5FH;V*6S7LMELS-)IT<M3,\I@/IKD```````````````!!L0%_KU=_3_`!JP
M$8O4!$V$['<*J5I.I>R`^7L;\(K[;KB\]`:-^,M1J))9RJ#Q#EX4Q"BNE!<R
M9RH`\%8?O23H<-VOP0!.'[THJE"=^*8`6'[V>3R)W+_E,!GP,"XGG/H::A++
M2,BTU9"*H#M^'N$Z$X7*W34Z2U)JH^^8/7)<6\,+]99BR885(BF9FA2<ID7L
M`\1L[!>BSPW2^U`6JLMV3GB._%,!Y*MMP3GCN%]J8"SR.7\ROXI@/1JUW%U9
M(;C.J4K(1$D^4!W?A-PXDP[8M^X-T=D>%LSID('J+\3^%UU;N3EPMS1NLK+P
MT%G*@/'.5X:OJ/?0G?:`8[EIN;7WR,XG[4P'F4*69T)E?Q3`5*WSCS,.?%,!
ML+1A6]7*8W':BK+2,B-2B,B(OJ@.^M\/7"PAZ/455[+1KGRT!ZX#>\,7>TS'
M&)$=>BE1DE9$9D9`\:M33J<Z#+V2,!12%III),JY2J`I0^X/0T5=PQX,VU6>
M?<I2(\5E2U*,B,R(Z$0#JV(>',WHJTTTDU/L((Z%W2`<AD1),9PVWVU-K2=#
M)14`>5#`4'H``\&UP[8)UYN+4>,V:B-1::Z9"(!U/'G#NX'AR.<1!N.QR(S0
M6<RIE`<>=@S6EFAQA:5ED,C28"A0Y9E]Y73X)@+DV^<KWK#AUS>"8#W18KNL
MZ)B.&?P0&='P1B:0HB1"7E[H"8X9X'WV>\VNX&3#)GE0651D`^@,%X"M6'XZ
M$1FB)9$55T*I^R#UT'#L&,_<R;D-I=;4TXA2%%5)I415(R'L3T)CJB,_@9#;
MQO&=;;4]AN6;AOLI.BF5:-2*OV-<PGQ>3^'_`*0IMH_+_P`I/V%</O-WO&GS
M#3[FHV^M0=A7#[S=[QI\P>YJ'K4'85P^\W>\:?,'N:AZU!V%</O-WO&GS![F
MH>M0R[1P?P5:;I&N<-AU,J(LG&5*<,R)1$992IWQC5=5U1TE[3;TQ/6$S8^\
MM_!+W!';V%<L/VBY3[;/FL;67:'ER+<YIK3LW7&E,J51*B2JK;BBHHC+ZH#1
MW[A;@N^WWTW<(;OEZVT,RU,29$=N4TW701*;9<0A]*:THLCJ60ZED`8\K@YP
M[D6VUVX[8MIBR-.,V=3,J4V[%2\I*UFTZETEDHS07A&=:9,QF0#+C<,,$,88
MG89]';:U7-1NW)+[KKKTATS)6V=D+6;RG"4A)DK2J5"I2A`+,.\+,%V"Z,W>
M!%>7=V6G(Z+A*ERI3^Q=-)J;4IYQ=4^`6B1^]Y*5.H9EJP!A*U>A?((&QZ.L
MOQ[/]U>5L6I6CMD^&M6GI;-.5=3+DH`%@'"1801@\H/_`/7&T(:1!VKV1#;A
M.I+:Z>UR+21^_`2````````````````$'OY?^X*/X=?&K`:AQ*E5T<E3IE+D
M`8DB"RO*M)'W*@,!S#\%1_>B(LY@/`\+VY1G]Q3[0`G"UN(_O23+V`.BI86@
M$?WI/>*@#,CV6$T1$ELBIW@&:B,A*:$63N`,5ZU1WJJ<21US9`&"O"]N54S9
M3[%`'CT0M9YV$GRED(!YKP7:3/[PFOL$`\TX#LQ*KY.FI]X@&5&P?:65DI+"
M2H>3(0#=,0FVD:*$T(N0!9)M[+R:+34CY#`:UW#-O7D4RD!B/X+M3E=)A)GW
MR(!B]`;*9E_ITY.\`]$X%LZ3*D=-/8(!L(N&;?&55EE*3//0B`;1,-!H--,A
M`-/<,*6V8HS=92JIY3,B.H#2R.&=B<,ZQT^T`PU\*</F9&<9)5,!87"?#U3I
M%2?=`>C?"FP$NODR:`-U:\$6JWGI1XZ4'FJ1`-RY:F#:V1((T\IGR@(U=.'-
MEFK-QUA*E'W@&G<X0V`UU*.1`,9W@U85&K_3D1?4`>2."^'JE_IRK7_`!DM<
M&L/$K+&(_9`2FPX$M%I+_3L)2?*9$`W[MO9<;T%)(TTH`TDK`ME?7IJC(,SS
MG0@'BGA_9".GDZ:<N0@%Z<"V9--%A-?8(!D-80MC:JI921^P`SV[#"10T-D7
M=`9[4)ILJ$FA]X!EMH(J>Z`W.&*^ED5*G@+I_@`F0```````+&/O+?P2]P!>
M`````````````````````````A%_3_[@9_#_`!JP&KT:%G`6K+NEE`6:&3)E
M,!=LP%2:+E`#;+)W0%4(Y`'FAUEQ:TH41J;/16DN0^^`]#17ZG(`H;9'D`8I
MJD%<29)K_3$T:C>_S5][0!D;,J>R`KL_;`5T*`*Z)T[X`:2`6&C*1GF_X@&S
MJ>0!39D1T`"0DJY`%313,0`DCI0\E0%32DN2I]P!8:",CJ0"W8]ZH"Y+)$>;
M(`;(RY`%Q-5J`;/_`!`6J;RY<P"TV<N:@"FQ(_8(@%D=I*DF=/KCS@/79$68
M!ZI;*G?`5T",B(!0VRS%R`!)29TH`;)-*<I`&@D\P"NB19B`7T(!4N\`VV&"
M_P#=T?`7_P``$R```````!8Q]Y;^"7N`+P````````````````````````$:
MNMAN,F4;C1)T#TLZJ9UJ5[B@&%T6NOV*/C`!X7NWV*/C$`=%KM2FBCXQ`*%A
M6[?8H^,`=%KM7WJ*<GA`*GA:ZY/!1\8@#HM=B^M1\8@%A81N)+4I+;:5+]^H
ME%4_9`7]%KMW$9,WA$`H>%KM7WJ*<OA`!85NU:Z*/C$`=%;K3(E'=]\0!T5N
MWV*/C$`=%+I]BCXP"O1>[?8H^,`=%KK3WJ/C$`IT6NU?>HI\(@`\*W8S]ZCO
M>$`H>%;M3WJ#/X1`*]%;M]BBG<TB`#PM=N1*/C$`H>%;OEHE%?AD`=%;OD\%
M'Q@#HK=\G@H^,0"G16\%F)!][2(!<6%KMRI1\8@%.BMV^Q17X1`*EA:[TRI1
M\8@#HM=J>]1\8@%#PI=OL4?'`#PK=OL4?&`6JPG=S(Z);R_Y@!O"=V2FF@WW
MO#`7=%+M]BCO^$0`6%+MRDBOPP!6%KO0]%**TR>$`(PK>"26D39KY3)1$0"O
M16[9Z(^,0"O1:[?8H^,0`6%KM]BCXQ`*]%[K]BCXQ`*=%[M]B@OMB`5Z,74L
MR4?&(!GV2QSXEP2^\22;)*B.BJG4P$B```````!:TDTMH2><B(C^H0"X````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````````>$
MZ?!@1'9DZ0U$AL)-;TE]:6VT)+.I2UF24E[(#3]H6`>LMJWZ-K@':%@'K+:M
M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H
M6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M
M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H
M6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M
M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H
M6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M
M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H
M6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M
M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H
M6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M
M^C:X!VA8!ZRVK?HVN`S;5B7#EW<<:M-UAW%QDB4ZB)(:?4A*CH1J)M2J$=.4
M!L@`````````````````````!AW9FZO0EM6N2U#EK,B*2\T;Z4)KX1DV2VZJ
MI[VJJ5SD>8!RE^[X/1.=VF-<6RY\=U;#LN'%G/1MLTLT+)*8D!4%6@LC2=$F
M7=`=1L4:[QH9M7*>5S42JL2S9*.ZILRR$\A![,UERJ0E!?Y2Y0V(".\0?HA<
M/@I^6D!(@&IQ#>)5O:BM0F&Y$^<^F/%;>6;31&9&I2EK2EPZ)0DSH2<N8!I;
MACJ8C#]ON4*`;C\R0Y&D-Z$F0AA4<W$O&?DK+SBD$ME1)5H%7(9T`2>#,;D6
MYB:;C:FW64/&ZV9FV9*22M)*E$1Z/<J`TZ>(O#Y1F2<3VDS(B,R*=&/(>;Z_
ME`7=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@
M'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?H
MVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@
M'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?H
MVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@
M'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?H
MVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@
M'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?H
MVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@
M'K+:M^C:X"G:'@#K-:M^C:X#>1Y$>2PA^.ZAYAU)*:=;42D*2>8TJ*I&0".I
M_N4[_!F_UI8"3``````````````````````#%N=RB6Z&<J7M-B2VVSV33KZM
M)U9-I^YLI6NFDHJG2A%E.A$9@.,Q,17;#[LJTP,7+:A,S)*F(R\&WF1L4N/J
M7L4/M.)0XA!J,DJ+D[U`';FC-32%&=3-)&9T--<G</*7L`+@$=X@_1"X?!3\
MM("1`,*[V:%=HI1I9.$E"TNM.LN+9=;<0=4J0XV:5),O9RYCR`,!_!ME=B,Q
M$^4,,1R23!,27VC1HDM*C)2%DHS<)Q6T,SJO.=3`;:%#C0HC,.*C9QHZ$M,M
MD9GHH05$E4ZF>0N4!H+/]/,2?HMM_P"Y`24`````````````````````````
M```````````````````````````````!&4F7:6Z7+Z&;R?\`ZI8"3```````
M```````````````#!O5H9N]M>M[[\F,T]HZ3T*0[$?+042RT'F%(<371H=#R
MEDS`..7_``_BBRQ9T]5DQ#)M\'3<4ZUC*X&XIALS^Z$UI5]X6EHE4^0JF`[9
M%<;=BLN-JTFUH2I"B5I5(R(R/2Y?9`>H".\0?HA</@I^6D!(5J)"%+5[U)&9
M^P0".6#&#EREDS+B(AMR8[DZVNI>-W:16G";4MTC;;V2O#0K1JK(>>I&0#4/
M\3W50WI,"TJ>04_R.,IU;Q(<9V&W\J/R>/+<2A22/0\`](J*J1&`F<.8A^WL
M3#6WH.M)>-;:]-JBDDJJ7#)&DGN*H52Y`$&M&/,#EC7$#YXBMA,.QK<33IS(
M^@HT^4:1)5IT.E2J`D7:%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':
M%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK
M?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':
M%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK
M?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':
M%@'K+:M^C:X"QWB-@%MM2^D5N<T2KH,RFGG#^"VVI2U'WB(94435/2.[&JJ*
M8ZRQ.U;`/K3_`.Q)_)B3Z&MX_P!X:/<T_/\`R=JV`?6G_P!B3^3#T-;Q_O![
MFGY_Y>K'%#`+SFAZ:89R5TY)+C-^,>2VBO>J,-2UU*(ZU1_I\,Z+BBN>D2R>
MT+`/66U;]&UQ';CM"P#UEM6_1M<`[0L`]9;5OT;7`.T+`/66U;]&UP#M"P#U
MEM6_1M<`[0L`]9;5OT;7`.T+`/66U;]&UP#M"P#UEM6_1M<`[0L`]9;5OT;7
M`.T+`/66U;]&UP#M"P#UEM6_1M<`[0L`]9;5OT;7`.T+`/66U;]&UP#M"P#U
MEM6_1M<`[0L`]9;5OT;7`4[0\`=9K5OT;7`;R/(CR6$/QW4/,.I)33K:B4A2
M3S&E15(R`1U/]RG?X,W^M+`28``````````````````````#S&`X1/L=YN<"
MY8H7$F3,(D[*<?M3^)+LF1(B,.K0Z?D]2BH)9(4:6%*IHT2:D\@=RAN1W8C#
MD8B*.MM*F2(M$B0:2-/@Y*9.0!Z@([Q!^B%P^"GY:0$B,B,J'E(\Y`-##P79
MHBG3:-Y27?!)MQPW$H9-S:KCH)1'1I:_?)Y2R9B(B#&9X;X5AH?3:8QV8Y+J
M7G%6S1BU-+>RT-%M))-&@9^"HCH>4J'E`2"#"C083$**C9QHS:6F45,Z)05"
MJ9U,_9,!H;/]/,2?HMM_[D!)0````````````````````````````$>XA?0J
M[_HY^Z0D6F[3BT7.W+YM'3*(`3G@U]-$?H[ON$('([7RF6.X[T*!<```````
M``````````````",I_N4[_!F_P!:6`DP``````````````````````P;U:&;
MO;7K>^_)C-O:.D]"D.Q'RT%$LM!YA2'$UT:'0\I9,P#AN)>'5YM-GNZCPQ+G
M6)"GI,J.G&-SK(1IFXX\Y'5'T%+5[]1&HS,^Z8#O<-UMZ(P\THEMN-I6A9*-
M1*2I)&1DH\IU[H#U`1WB#]$+A\%/RT@)$`U=_O+MM9CIC1RESICR8\2.MS8H
M4M53,UN:+FBE*4FHS))GW",!J[ACZ!#PF5_..XZXLUM-6Y!IVJY#2U-N-),_
M!HA3:M)>8DEI'D`25MY*V$O'1*5))9U/(1&5<X"%6C$^&BQOB%T[M")I<:W$
MASRAK149%(K0]*ATJ`D?2S"OKF#O+.L`=+,*^N8.\LZP!TLPKZY@[RSK`'2S
M"OKF#O+.L`=+,*^N8.\LZP!TLPKZY@[RSK`'2S"OKF#O+.L`=+,*^N8.\LZP
M!TLPKZY@[RSK`'2S"OKF#O+.L`=+,*^N8.\LZP!TLPKZY@[RSK`'2S"OKF#O
M+.L`=+,*^N8.\LZP!TLPKZY@[RSK`'2S"OKF#O+.L`=+,*^N8.\LZP!TLPKZ
MY@[RSK`'2S"OKF#O+.L`=+,*^N8.\LZP!TLPKZY@[RSK`'2S"OKF#O+.L`T.
M.L28=DX0NK$>Z0WGW&#)MIM]I2U'4LA))1F8D6F[3BT7.W+Y_'3*(`3+A-.A
M0L7(?F2&XS),.D;KRTMIJ9%0M)1D0@<CM?*98[CMG2S"OKF#O+.L*!<'2S"O
MKF#O+.L`=+,*^N8.\LZP!TLPKZY@[RSK`'2S"OKF#O+.L`=+,*^N8.\LZP!T
MLPKZY@[RSK`'2S"OKF#O+.L`=+,*^N8.\LZP!TLPKZY@[RSK`'2S"OKF#O+.
ML`=+,*^N8.\LZP!TLPKZY@[RSK`'2S"OKF#O+.L`=+,*^N8.\LZP!TMPKZY@
M[RSK`-FTZT\VEUI:7&ED2D.(,E),CS&1ED,!&T_W*=_@S?ZTL!)@````````
M`````````````!%.)MYN-FPPU/MZ7G)*+I:&]A&T-L\V]<X[3K"-HI"*NMK4
MCPE$67*99P$$EV>P3I#SLSAWC)\I*U+?9=N9*CKTSJI*F#O)M&@Z^\T-&F2E
M`'9&B232"2C9I))$ENA%HE3-0LF0!<`CO$'Z(7#X*?EI`2(!@7JS,76,AI;S
ML9YEQ+T:7'-).M.(/(I&FEQ'>,E),C+(9`-3.X>89GVI-KG,JDPVT&EA+FB:
MFEKT]J\A>CI;1W:&:S,SJ`D$6*Q%B-1&4DEAE"6FT<A(26B1>T`BUHMEM/'.
M(T'$9T"C6TR3LTT+)(Y*`))Z)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P!Z
M)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P!Z
M)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P!Z
M)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P!Z
M)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P!Z)M7F3'BD<P"/X^MMN;P;=EMQ
M64+2P9I4EM)&1U+,9$)%INTXM%SMR^=ATRB`$VX0,,O8Q0AYM+J-@Z>BLB46
M8N0Q`Y':^4RQW'<_1-J\R8\4CF%`N#T3:O,F/%(Y@#T3:O,F/%(Y@#T3:O,F
M/%(Y@#T3:O,F/%(Y@#T3:O,F/%(Y@#T3:O,F/%(Y@#T3:O,F/%(Y@#T3:O,F
M/%(Y@#T3:O,F/%(Y@#T3:O,F/%(Y@#T3:O,F/%(Y@#T3:O,F/%(Y@#T3:O,F
M/%(Y@#T3:O,F/%(Y@#T3:O,F/%(Y@&2A"$))*$DE*2HE)%0B+V`$:3_<IW^#
M-_K2P$F```````````````````!AWDXQ6B<<IQ;48H[IONM5)Q+>@>DI%*GI
M$68!\^82O7&HYS)</DW>]85(SJ[C=IEDC1R*8DI4B6X1YB\`R[P#K#$I[&7#
MF)<\0,2,'RDK;G269)-I7$?MTK:H6YY2WH[/:1TN$:DE5-,V<!B6G'MW5:W[
MK&F6?%]CADHY=RM,E$5]HD%I*VC#SCL>I)*IF<A'=T:'D"?L.D\RVZ1&DG$D
MLDG2I:15H=#,O:,!>`CO$'Z(7#X*?EI`2%2B2DU*.B2*IGWB`1^QXP;NDE3)
MPW8^U87+MYJ4A9R(S;A-J61)/P#TE),DGR*+OD0:)WBS#::=0[#;8FMR&8QL
MOS&4-H4^TX\2'7DZ9-O(0RK:-4,R.F4ZU`3B)()^(S(/0(G6TN50LG$>$DC\
M%94)1=P^4!%[1<[:6.<1K.6SH'&MI$K:)H>21RU`23TM:O/6/&HYP#TM:O/6
M/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6
M/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6
M/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6
M/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6/&HYP#TM:O/6
M/&HYP$?Q]<K<Y@V[(;E,K6I@R2E+B3,SJ68B,2+3=IQ:+G;E\[#IE$`)MP@?
M99QBA;SB6D;!TM)9DDLQ<IB!R.U\IECN.Y^EK5YZQXU'.*!<'I:U>>L>-1S@
M'I:U>>L>-1S@'I:U>>L>-1S@'I:U>>L>-1S@'I:U>>L>-1S@'I:U>>L>-1S@
M'I:U>>L>-1S@'I:U>>L>-1S@'I:U>>L>-1S@'I:U>>L>-1S@'I:U>>L>-1S@
M'I:U>>L>-1S@'I:U>>L>-1S@'I:U>>L>-1S@'I:U>>L>-1S@,E"T+22D*)25
M%5*B.I&7L@(TG^Y3O\&;_6E@),```````````````````#4XMD0F,-7,YDEF
M(RY&>;VTAQ339&MM1%5:#)9?:>%W,H#BV`<5<4[+;L*0)V)<%W##\AZ##:?0
M[<GKF^Q)6E+:4%H(+;*0JB3<015II\H#LF-;`]?\,S;4PMM#[Q(4UMTFIE2V
MEI<2AY)93;6:-%9?8F8#EF.KI:5MS9#6(,-6G%LZWOV7$MA>O#+;+B5)4EE9
M.*2A>VCJ55&FR54J4@Z9%$':(*-"%'09D>BV@JD=2.B2S&`]@$=X@_1"X?!3
M\M("1*(E$:3*I'D,N\`CUNP7$@.J=9GRS42=C&TC9_T\93NU7&9-+25$VLR(
MC,S-9$1:*BH0#&;P"3:7%E?KH<YTFVUW`U13>4RTE:$LK+R?9.)HXKPG$*77
M+I5R@)#;[?&@VZ/;V",XT9I+#9+\(S0A.B6EW<A90$0M&&,-'C?$+1VF$;2(
MUN-#?D[6BDS*16A:-"K0!(^B>%?4T'=F=4`Z)X5]30=V9U0#HGA7U-!W9G5`
M.B>%?4T'=F=4`Z)X5]30=V9U0#HGA7U-!W9G5`.B>%?4T'=F=4`Z)X5]30=V
M9U0#HGA7U-!W9G5`.B>%?4T'=F=4`Z)X5]30=V9U0#HGA7U-!W9G5`.B>%?4
MT'=F=4`Z)X5]30=V9U0#HGA7U-!W9G5`.B>%?4T'=F=4`Z)X5]30=V9U0#HG
MA7U-!W9G5`.B>%?4T'=F=4`Z)X5]30=V9U0#HGA7U-!W9G5`.B>%?4T'=F=4
M!H<=8;P[&PA=7X]KALOML&;;K;#25I.I92422,A(M-VG%HN=N7S^.F40`F7"
M:#"FXN0Q,CMR638=,VGD)<34B*AZ*B,A`Y':^4RQW';.B>%?4T'=F=44"X.B
M>%?4T'=F=4`Z)X5]30=V9U0#HGA7U-!W9G5`.B>%?4T'=F=4`Z)X5]30=V9U
M0#HGA7U-!W9G5`.B>%?4T'=F=4`Z)X5]30=V9U0#HGA7U-!W9G5`.B>%?4T'
M=F=4`Z)X5]30=V9U0#HGA7U-!W9G5`.B>%?4T'=F=4`Z)X5]30=V9U0#HEA7
MU-!W9G5`;-IIIEM+32$MM((DH;01)21%F(B+(0"-I_N4[_!F_P!:6`DP````
M```````````````([Q"L^%[IA"Y(Q/"*=9XK#DR0QG52.A2])&4O"(B\$!\\
M\/9&%;3*LMVD</[9#;3.LK,"4V\M^8RQ=VG#B2W%K\!QXE(0I6B@C*IGG(!]
M4'F`<"M^.%89=FV-+F$):(L^7H.N39NW(G9"W-!\V[>^E3R#7HK/3SY\N4!W
MMI6DTA63PDD?@YLI<E:`+@$=X@_1"X?!3\M("1`-;?+TFU,,J3'<F2I+J6(L
M1DT$MQQ67WSBD((DI(U*,SS$`UT[&\1BP1[RQ#?D,/&M+B*M-;`V=(G2?<<6
MEM&@IM2/?'560JU`;NW3F;A;XL]DE)9ELMOMI<+1627$DLB466AT/*`T5G^G
MF)/T6V_]R`DH``````````UMZQ)9+(EI5TE)BI?-1-&I*E5T:5]Z2OLB&S3T
M:JYZ4QU85ZE-'>6J[3,"^MF_B.Z@W>EJ_5J]K3\G:9@7ULW\1W4#TM7ZGM:?
MEMK+B*RWMMQVURDR4-*T7%))2:&95IX1)&K4T:J,T=&RC5IK[2V(U-@`````
M``````"/<0OH5=_T<_=(2+3=IQ:+G;E\VCIE$`)SP:^FB/T=WW"$#D=KY3+'
M<=Z%`N```8]P4I$"0I)FE26U&E19#(R(949H8U=I?-72_%GKJ?O3VL.F]?3^
MM/\`$*']U?VG^3I?BSUU/WI[6#U]/ZT_Q!^ZO[3_`"WF"<3XDDXKMC$B[3'F
M7)#:7&G)#JDJ(U%4C2:C(Q'NM&B-.9BF/X;[?5KFN(F9?0(Y]<@`````````
M``(XZ1%Q"84144JUK)1\ID3]2(P$C```````````````````!A7R8U"LL^8]
M'5+:C1G7G(J$Z:G4H0:C;))YS414H`^;N%G#B]/WVPXS@8%MT:QS7H\^(3EX
M?DE#CN'I$ZU'/P#=;;<4:25[U68DGF#Z>/,?+W@'&<%WG%C%J>C6W$V&+=#8
MN$]MNV3F'7946DQT]@ZXB9%)2DUS[/*1D=5>^,.RH,S0DU&2C,BJ:<QGWLX"
MH".\0?HA</@I^6D!(@&MOEE3=6&4ID.0Y49U+\66R2#6VXG)[UQ*T&2DF:5$
M99C`:Q[!)';&K;%NDF+&:KI()+#A.FYM#?4\EQM2%FZMW3/)1*B+1H52`;JV
MVR+;[7&MC)&N+%91'03E%&:$))):60BS%W*`(3:,!X'/&N(&#P[;#8:C6XVF
MCAQ]!)J\HTC2G0H5:%4!(NSW`/5JU;C&U`#L]P#U:M6XQM0`[/<`]6K5N,;4
M`.SW`/5JU;C&U`#L]P#U:M6XQM0`[/<`]6K5N,;4`.SW`/5JU;C&U`#L]P#U
M:M6XQM0!SGC#AS#UHCVQ5IM<2W*>-XG51&&F#62=G0E;-*:TKRBTXO-."OY#
M+&+F(NE6`.I<'\-8=N]NGN7:U0[@XT\E+2Y4=I\TI-)'1)N)50JBEY3-2M./
M[2Z%V>X!ZM6K<8VH*M8'9[@'JU:MQC:@!V>X!ZM6K<8VH`=GN`>K5JW&-J`'
M9[@'JU:MQC:@!V>X!ZM6K<8VH`=GN`>K5JW&-J`'9[@'JU:MQC:@!V>X!ZM6
MK<8VH`=GN`>K5JW&-J`-'C?!.#(6$[G*AV&W1I3+)J:?9B,-N(54LJ5)01D?
ML"1:;M.+1<[<N#CIE$`)?PLM5KNF*T1;G#8G139<4;$EM#S>D1%0]%9**I"!
MR.U\IECN.R]GN`>K5JW&-J"@7!V>X!ZM6K<8VH`=GN`>K5JW&-J`,>?@#`C<
M&0M&&[6A:6U&E284<C(R+(9&2!G1FAC7VE\YCJW.@#=8,AQ)F*+;%F,-R8SK
M[:76'DI6A234524E1&1E[(C7FU4WVVY#O79[@'JU:MQC:@YI>G9[@'JU:MQC
M:@!V>X!ZM6K<8VH`=GN`>K5JW&-J`'9[@'JU:MQC:@!V>X!ZM6K<8VH`=GN`
M>K5JW&-J`'9[@'JU:MQC:@"G9Y@#JS:MQC:@#>1X\>,PAB.TAEAI))::;224
M)268DI*A$0#0/?W!C?PQ?XX@$C```````````````````!K\1,27\/W-B*MU
MN4[$?0PXQ]^2XIM1)-O*7AD?O<N<!\V\-.'UCMUQPPJX\(;NQ?HC\,Y6(7)S
MQLHE-K1I3%-;8D:)++:&C0I3)E`?0N-+],LMDV]O9;D7*5)C08#3ZC2SMYCZ
M&$*=-.700:]-5,ID5"RT`<POD9YV\7_T?8,,N=$H3$J_NR;8E1W">^TJ0\RR
MYIUC))LB7IKVAU652/*`[-!D,R84>2P5&7VT.-%2G@K22DY.3(8#V`1WB#]$
M+A\%/RT@)$9D1&9G0BRF8#26G%MMN;[K3;3[.@VM^.MY*2*0PVO9J>9T5+4:
M"7D\(B/*1TH9&8:QSB5:D,:1P9A2E*8)J"OR9IU;<E"W&724Z^VTE*T,K.BU
MI65*&DCR`)6RXIQEMQ;:F5+22E-+T34@S*II5H&I-2S'0S+O@([9_IYB3]%M
MO_<@)*``````````.5\=OS6T?"?_`/3%GQ>><$#D,L8N0"[50`[)P*_=5R_#
MI^00I>4S4K3C^TNGBK6````````````"/<0OH5=_T<_=(2+3=IQ:+G;E\VCI
ME$`)SP:^FB/T=WW"$#D=KY3+'<=Z%`N```8US_=TG\$OY)C/3S0QK[2^51U;
MG0!O\`_3&T_I+?RB$:\VJF^VW(?2@YI>@```````````(X]_<&-_#%_CB`2,
M```````````````````&#?BNAV*XE:3(KJ<9[R`U4H4C9GLJUR4TZ`/ES!T.
MQE=,(=%X&(&.*B)\0\9RII3"0;1'_P"X^6J>4;.R5X6AHEI9JY0'U%?+';KY
M:WK9<4*7%>T5'LUK:<2MM9.-N-N-FE:%MK22DJ2=2,JD`CG91A@[(]9S>GJB
MSI1S+PXJ6Z;]P4IO9*;EO&>T6T:"21H(R+(19JU"9$1$1$14(LA$0``CO$'Z
M(7#X*?EI`2%24J2:594J*AEWC`1BUX.F6YXGFKDE;D9I4.V&IC[S$<>2ZMM=
M'/NBST$I)?@T(B\$SJ9AKXO#ZZMVTX\BY09,TWB>=FN6TW3?4;:VUJD;>2\X
MI?AU0;;B"1[VAH\$!++7;&+?:(ML29NL16$1R-RAFI*$DCPBS92+-F`0JT8#
MP.>-<0,'AVV&PU&MQM-'#CZ"35Y1I&E.A0JT*H"1=GN`>K5JW&-J`'9[@'JU
M:MQC:@!V>X!ZM6K<8VH`=GN`>K5JW&-J`'9[@'JU:MQC:@!V>X!ZM6K<8VH`
M=GN`>K5JW&-J`'9[@'JU:MQC:@#G/&'#F'K1'MBK3:XEN4\;Q.JB,-,&LD[.
MA*V:4UI7E%IQ>:<%?R&6,7,1=*L`=2X/X:P[=[=/<NUJAW!QIY*6ERH[3YI2
M:2.B3<2JA5%+RF:E:<?VET+L]P#U:M6XQM05:P.SW`/5JU;C&U`#L]P#U:M6
MXQM0`[/<`]6K5N,;4`.SW`/5JU;C&U`#L]P#U:M6XQM0`[/<`]6K5N,;4`.S
MW`/5JU;C&U`#L]P#U:M6XQM0`[/<`]6K5N,;4`:/&^"<&0L)W.5#L-NC2F63
M4T^S$8;<0JI94J2@C(_8$BTW:<6BYVY<''3*(`2_A9:K7=,5HBW.&Q.BFRXH
MV)+:'F](B*AZ*R452$#D=KY3+'<=E[/<`]6K5N,;4%`N#L]P#U:M6XQM0`[/
M<`]6K5N,;4`8\_`&!&X,A:,-VM"TMJ-*DPHY&1D60R,D#.C-#&OM+YS'5N=`
M&ZP9#B3,46V+,8;DQG7VTNL/)2M"DFHJDI*B,C+V1&O-JIOMMR'>NSW`/5JU
M;C&U!S2].SW`/5JU;C&U`#L]P#U:M6XQM0`[/<`]6K5N,;4`.SW`/5JU;C&U
M`#L]P#U:M6XQM0`[/<`]6K5N,;4`.SW`/5JU;C&U`%.SS`'5FU;C&U`&\CQX
M\9A#$=I#+#222TTVDDH2DLQ)25"(@&@>_N#&_AB_QQ`)&```````````````
M````"#<6Y[7H%NRM8D7AFZ7<W4P9C<=<@W"CLK>>;/12LD$;:3,U9^YE`<1P
M)BK"LZYX2L\WC',NZHTJWICV-JU266WI+*D)98\J6RA9MFY1)J<]\7OJ`/J<
MSH5>X`Y)B/B1=+O:7(,*U-*:DQKG/F).>[&=1:;<\4;3)YELE,R9#AGH)K1!
M$>DJM:!TVQLQ&K1%3#-XXJFTN,>4+<=<)#A:9$I3IK7DTLQGDS9@&<`CO$'Z
M(7#X*?EI`2(!@WB\Q;3%2^^EQU3CB66(["#<=<<6=$I0DO=/(193`84K%]I9
MML2X-D]*;G&I,=IALU.&;:5+<)23T='9I;5I$JF:F?(`VL*9&G0V)L5>TC2F
MT/,.4,M)MQ)*2JAD1Y2/E`:"S_3S$GZ+;?\`N0$E``````````'*^.WYK:/A
M/_\`IBSXO/."!R&6,7(!=JH`=DX%?NJY?AT_((4O*9J5IQ_:73Q5K```````
M`````!'N(7T*N_Z.?ND)%INTXM%SMR^;1TRB`$YX-?31'Z.[[A"!R.U\IECN
M.]"@7```,:Y_NZ3^"7\DQGIYH8U]I?*HZMSH`W^`?IC:?TEOY1"->;53?;;D
M/I0<TO0```````````$<>_N#&_AB_P`<0"1@```````````````````P;[*G
M1+)<)<!CRF='C/.Q(WSCJ&S4A'VRB(@'S3AGBSCR[WNQ3F<3.3(S4RT6DX)0
MTM-W27<%&_=$F6B6R\A:<)&EF+1(^7*'TK?9[T"TR)+"XJ)*2),8YSQQXYO+
M,D-H<=)+AI)2U$G(DS[A`.$L'(5!NT>?`P!#NEV?<]+&[>#0XMQF4MQK;,M1
ME(41+(E*0:_#/WY$9J(!]`QMKY.UM7$NNZ"=HZ@M%*E4RJ(JG0C/O@/0!'>(
M/T0N'P4_+2`D0#58@LTBY,QEPY*(D^$^F1$D.M&^V2B(TJ);1+9-1*0HRR+(
M!HIN![TNS1K/"O#+$)MQ3TQMR*\ORE;JG''TN*9E1EDVMYTE$A*BR%HJTB,!
M*XL5+,%F(:6R2VTEHT,HV35$I)-$-U5H)[B:G0@$%M.!\)*QIB".=K8-EJ-;
MC;10Z$9E((Z9>\`D/0#!OJECVCYP#H!@WU2Q[1\X!T`P;ZI8]H^<`Z`8-]4L
M>T?.`=`,&^J6/:/G`.@&#?5+'M'S@'0#!OJECVCYP#H!@WU2Q[1\X#G?&+#U
MEM,:V';8;<4W5/DX;94K39TJ+3B\TX*_D,L8N8"Z58`ZEP?PY8[M;I[ERAMR
MEMNI2A3A&="T:T++W3%+RF:G!:<?VET'H!@WU2Q[1\XJU@=`,&^J6/:/G`.@
M&#?5+'M'S@(OQ)PMA^U85>F6Z"W%E)<027FZDHB,\N6HF6-,3JQ$HUW,QIST
M<:\MF?/N?'5SB]_31XC^%/\`MJ\R>6S/GW/CJYP_31XC^#]M7F4[X2VR#>KI
M,9NK136FFDJ;0Z9J(E&JE2RBNY*BFFF.D=/]4ZQKF:IZS_AU+H!@WU2Q[1\X
MIUF=`,&^J6/:/G`.@&#?5+'M'S@-)C;!F%H6$[G*BVUEJ0TR:FW$D=4G4LI9
M1(M-VG%HN=N7!QTRB`$OX66NWW/%:(L]A,B.;+BC;7FJ19#$#D=KY3+'<=DZ
M`8-]4L>T?.*!<'0#!OJECVCYP#H!@WU2Q[1\X#PN&`\'H@R%HM3"5);4:3(C
MR&1>R,J,T,:^TOG/..L<Z`-U@N+'EXIMD>2V3K#DAM+C:LI&1J+(8C7FU4WV
MVY#O/0#!OJECVCYQS2].@&#?5+'M'S@'0#!OJECVCYP#H!@WU2Q[1\X!T`P;
MZI8]H^<`Z`8-]4L>T?.`=`,&^J6/:/G`.@&#?5+'M'S@'9_@SU2Q[1\X#>1X
M[,=A##"";9:226T%F(BS$`T#W]P8W\,7^.(!(P```````````````````8-^
MF2H5CN,R(E"Y<:,\]'0ZHD-FXVV:D$M1F1$DU%E.H#@/#K%UWO<O#ERG<8[6
MJ5.>CO2,+)M-O;>-Q]:=M!2]I)>)2S,VM,DU/.50'T1(CQY#1M2&D/-U)6S<
M22DU29*2=#J611$9`.(P9<"].2YTK%^%[-)\ME,NVERWP7'6#9D+;)#CCSZ7
M%K-*24:M$B.M2R4`=P:ILD4,E%HEX19"/)G*@"X!'>(/T0N'P4_+2`D1F1%4
M\A$`U5IQ19[J^^Q#<6:V2-7W5IQHG$)6;:G&C<2DG$$M)ITDU+ZAE4,/IYAM
MR*J3#>7<&REJ@)*&TM\UR$)):THT"/2)*3RJ+(`WS+I.LH=)*D$XDE$E9&E1
M5*M%)/*1]T@$=L_T\Q)^BVW_`+D!)0`````````!ROCM^:VCX3__`*8L^+SS
M@@<AEC%R`7:J`'9.!7[JN7X=/R"%+RF:E:<?VET\5:P``!"^+OT*D?A6_=$W
MC]V$6\VY<`'0J4`=+X&?OJX?@$_*,5?*9(Q3[#-.#M`I5J``"/<0OH5=_P!'
M/W2$BTW:<6BYVY?-HZ91`"<\&OIHC]'=]PA`Y':^4RQW'>A0+@``&-<_W=)_
M!+^28ST\T,:^TOE4=6YT`;_`/TQM/Z2W\HA&O-JIOMMR'TH.:7H`````````
M``".3RT,>6I2<ANPI*'.^E"D*3_B8"1@```````````````````U^(9I0+!<
MIQQO+"BQ7WCAD5=L3;:E;.E#]_2F8!\S8*QP:9]HN+\+#$N3/NEDV$"!!C-N
MLLW1+IK;CK06U-^(M*#69GX)D9`/JD!PW&1Q;?&O%QB8VPNN9&-]]%M>MUO-
MPU(4:C84LGE.&Y];70,]+DY`';(;INPV'32I!N-H5H+3HJ*J2.AIY#+N`/8!
M'>(/T0N'P4_+2`D*T$M"D*S*(R/V#`1:QX1N5LF,R%S67_(63@V]),K1HPW'
MTNN$[]T5INZ+:$I45"R5,CK0@Q[O@%<Y$WPH,@Y5Q7<$M7"(4II)+BHC:))-
M:#):=#2)1'W@$FM=O.%:(MO<>5(..PAA;ZJDI>@@DFH\IF5:=T!"K3@K#RL:
M8@8-E_9-QK<:"\JE5J92".I[6IYN4!(>@>&?F']\E_E0#H'AGYA_?)?Y4`Z!
MX9^8?WR7^5`.@>&?F']\E_E0#H'AGYA_?)?Y4`Z!X9^8?WR7^5`.@>&?F']\
ME_E0#H'AGYA_?)?Y4!SOC%8+9:HUL.$AQ&T4_I[1YY[-L\VU6NGU!:<7FG!7
M\AEC%S`72K`'4N#^'K5=;=/<FMN+4VZE*#;>>9R:-<I-+01Y^44O*9J<%IQ_
M:70>@>&?F']\E_E15K`Z!X9^8?WR7^5`.@>&?F']\E_E0$5XF85LENPF_)B-
M.I=)QLB-<B0X64S^M<<4G_`3>/W81;S;EQ8="I0!/N$-FM]TNLUJ:A:T-LI4
MDD.NM'4U4SM*09BKY3)&*?89IP=5Z!X9^8?WR7^5%*M3H'AGYA_?)?Y4`Z!X
M9^8?WR7^5`:3&V#K!#PG<Y,=IY+S3)J0:I,E95J6=*W%)/ZI"1:;M.+1<[<N
M#CIE$`)?PLMD.Y8K1&EI4IDV7%&2''&CJ1?9-J0K_$0.1VOE,L=QV3H'AGYA
M_?)?Y44"X.@>&?F']\E_E0#H'AGYA_?)?Y4!X7#`V&T09"TLOZ26U&59<H\Q
M=PW1E1FAC7VE\YCK'.@#=8+BLRL4VR.\1FTY(;2LDJ4@Z:19E(-*B^H8C7FU
M4WVVY#O/0/#/S#^^2_RHYI>G0/#/S#^^2_RH!T#PS\P_ODO\J`Q;K@C#C5LE
M.MLODM#2U)/RN4>4DGR&Z,]+-&+#4RS@^>_+)?S[GQCYQU/XPY_K)Y9+^?<^
M,KG#\8/REN,(FN9B:VQI#KBV79+27$DXM)F1N%]<DR,OJ&(UY$?JJ;[:9_9#
MNW0/#/S#^^2_RHYQ>'0/#/S#^^2_RH#>1V&H["&&B,FVTDE!&9J.A=]1F9_5
M`:"Y?3FS?HLO_P`@"1@```````````````````@W%C%^([#`L\###,=S$&(K
MBW;(#LW2\F9TT+<6\X2/"5HI;.A%_CF,.7VC"&(^&6.+'>[_`&[#MVCXAN;5
MJ5<+?"*'-B2INDAMQHB)+>@H\BZ%I?X@/HD!"K=B+A7+OJX!(@P[^AY1%$G1
M2A2UNI5E6TF0AM3N7*2V](CSU`34``1WB#]$+A\%/RT@)$`P[M>(%IB>535K
M2T:TMI2TVX^XI:ST4I0TRE;BS,SS)28#%G8LPY`LS=YF7!J/;7M$F7W#-.FI
M9T2A*#+3-9GDT"+2KDH`VP"-6?Z>8D_1;;_W("2@`````````#E?';\UM'PG
M_P#TQ9\7GG!`Y#+&+D`NU4`.R<"OW5<OPZ?D$*7E,U*TX_M+IXJU@``"%\7?
MH5(_"M^Z)O'[L(MYMRX`.A4H`Z7P,_?5P_`)^48J^4R1BGV&:<':!2K4``$>
MXA?0J[_HY^Z0D6F[3BT7.W+YM'3*(`3G@U]-$?H[ON$('([7RF6.X[T*!<``
M`QKG^[I/X)?R3&>GFAC7VE\JCJW.@#?X!^F-I_26_E$(UYM5-]MN0^E!S2]`
M`!AWK]T3?P+GR3&S2S1BPU,LX/E@=4YX`;W`OTOM'Z4S^,2(MYM5-]KN0^EA
MS:]``!'+E].;-^BR_P#R`)&```````````````````"+8_X=67&\2#&N<J;#
M.W2/*XDBWO>3O)=T%-U)S149>"L\P"+P_P#\>\+Q[K;;B_?<07!RU2V)\5B=
M<52&-O&62VS4VM&7*0#J)Y@'($V_"^.H\A>,L6*F0$3)#"L,K7%MK3*H[ZV]
MF^EE;DE9^"5#-^BDF2M$B4`Z+AC"\3#S4F-`D/*MKRTN1(3KBWD1BT"2I#*G
M5+62%&6EHUT2Y"(!N@$=X@_1"X?!3\M("1`-1B.TS)[<1^`XVW/M\A,F/MR4
M;2C(C0M"]'PBTD*,JEF/+0P&K<P?-5@V=ALI#7^J9=),G147^HDNN//J-.6B
M--SP"K6F<!*E))232=:**AT,R/+W#+*0#G]HP9:#QKB!DY%ST&XUN-)E=KF2
MSTO**Z2RD:2LV32/(`D70>R^<W7^<77]I`>+^$L-QR(Y$^Y,DK(DW+U<TU/O
M5E$/8IF>SR9B.[QZ/8/];3OY[<OVL9?KJ\2\_.GR='L'^MIW\]N7[6'ZZO$G
MYT^7NQA'#D@C5'G7)XBR&;=ZN:B+VI0QFF8[O8F)[/7H/9?.;K_.+K^TCQZ=
M![+YS=?YQ=?VD`Z#V7SFZ_SBZ_M(#G/&&PP;7'MBHSLMPW3>)7E<V7,(J;/W
MI277B3]K06G%YIP5_(98Q<Q%TJP!U+@_8(-TMT]<EV8VIMY*4E%FRX9&6B1^
M$F,ZT2C[YBEY3-2M./[2Z%T'LOG-U_G%U_:15K`Z#V7SFZ_SBZ_M(!T'LOG-
MU_G%U_:0$4XFX7MMOPF])8>GK<2XV1)D7&?);RGRMOON-G\43>/W81;S;EQ8
M="I0!/N$-HB7.ZS6I+DEM*&4J2<65)B*J:J951G&E*+O&8J^4R1BGV&:<'5N
M@]E\YNO\XNO[2*5:G0>R^<W7^<77]I`.@]E\YNO\XNO[2`T>-\(VJ)A.YR6G
M[BIQIDU)2]=+B^V9U+WS;LA:%%WE),2+3=IQ:+G;EP<=,H@!+^%EMCW'%:(T
MA;Z&S9<5I1I#\5RI$7_,CK:73O:0@<CM?*98[CLO0>R^<W7^<77]I%`N#H/9
M?.;K_.+K^T@'0>R^<W7^<77]I`8\_!5F1!D+*1=#-+:C(E7>Z*+(7*1R3(_J
MC.C-#&OM+YS'5N=`&ZP9%:E8HML=U3B6W7VTJ4RXXRLB-1>]<:4A:3[Z3$:\
MVJF^VW(=ZZ#V7SFZ_P`XNO[2.:7IT'LOG-U_G%U_:0#H/9?.;K_.+K^T@,2Z
MX+L[=LEN)D70U(:6HB5=KFM-22>=*I)I/V#(;-+-&+#4RS@^=AU3G@!N,'QF
MY6)K;'=-:6W9+25*:<6RLB-Q/O7&E(6D^^DR,1KS:J;[7<AWSH/9?.;K_.+K
M^TCFEZIT'LOG-U_G%U_:0&\CL(880R@UFAM))2;BUN+,B^R6LU+4??,Z@-!<
MOIS9OT67_P"0!(P``````````````````````/,?+W@'SM=)UVG.3IT*S8/C
MM/1;K<F4R+3MY:2MDI+#[3SQOMM>4T=2L])%"5D/)X0#Z"M[B7($9Q*C6E;2
M%$LTZ!F1I(ZZ'UM>YR`/<!'>(/T0N'P4_+2`D0#6VW$=EN3TEF'))Q<4SVU4
MK05$J-"E(4M*4N()232:D&::D95J`PNG>&/)U/HDNNI)Q#26V8TEUY9N$I3:
MFV6VU.N(6E"C2M"329$9D>0!O&74O,H=02B0XDEI):5(41**I:2%DE23[I&5
M2`1VS_3S$GZ+;?\`N0$E`<OXZ_NRV?AE?(,6O%]ZE?R':''!<JL`=GX&_NBX
M?A4>XH4?*9XP6MAEG%TP5J>``#E?';\UM'PG_P#TQ9\7GG!`Y#+&+D`NU4`.
MR<"OW5<OPZ?D$*7E,U*TX_M+IXJU@``"%\7?H5(_"M^Z)O'[L(MYMRX`.A4H
M`Z7P,_?5P_`)^48J^4R1BGV&:<':!2K4``$>XA?0J[_HY^Z0D6F[3BT7.W+Y
MM'3*(`3G@U]-$?H[ON$('([7RF6.X[T*!<```QKG^[I/X)?R3&>GFAC7VE\J
MCJW.@#?X!^F-I_26_E$(UYM5-]MN0^E!S2]``!AWK]T3?P+GR3&S2S1BPU,L
MX/E@=4YX`;W`OTOM'Z4S^,2(MYM5-]KN0^EAS:]``!'+E].;-^BR_P#R`)&`
M`````````````````````-9B6Z>C+))EIE183Q$EN-(GFHHQ/O+)MDG-$TJH
MIQ:4T(ZY0'!)F(8TV&[;,28@X?JNC,V0\ZJ4P3KS4O:*;)TT$I+9NI0E"?"3
M4R21*J`^B8I+**R2W=NLD)TGZ$G3.A570LA:6?(`]0$=X@_1"X?!3\M("0K0
M2T*0>91&1T[X"'V?"5ZAO(-]<92(<5RV0C0MRJXK[R7%O.D:/!=2AM))01F1
MG4](JT(-27#J\^2QMNU`EO068T&*RX]):2;,5EQDI&V;21H=5M25H&VM)$1I
MTLNDD)W:X3\:T184J0J4^RPAI^29J)3BDH)*EZ5=*IGRUKWZ@(5:,&6@\:X@
M9.1<]!N-;C297:YDL]+RBNDLI&DK-DTCR`)%T'LOG-U_G%U_:0'/>,%@@VNW
MP%QG9CAN.J2HI4V7,(B)-?!*2ZZ23[Y"UXOO4K^0[0Y:+E5@#JO"'#\"YVR<
MY)=F-J0X@DE%G3(B:45G3&=:2KV3(4?*9XP6MAEG%/\`H/9?.;K_`#BZ_M(K
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M.K=![+YS=?YQ=?VD4JU.@]E\YNO\XNO[2`=![+YS=?YQ=?VD!H\;X1M43"=S
MDM/W%3C3)J2EZZ7%]LSJ7OFW9"T*+O*28D6F[3BT7.W+@XZ91`"7\++;'N.*
MT1I"WT-FRXK2C2'XKE2(O^9'6TNG>TA`Y':^4RQW'9>@]E\YNO\`.+K^TB@7
M!T'LOG-U_G%U_:0#H/9?.;K_`#BZ_M(#'GX*LR(,A92+H9I;49$J[W119"Y2
M.29']49T9H8U]I?.8ZMSH`W6#(K4K%%MCNJ<2VZ^VE2F7'&5D1J+WKC2D+2?
M?28C7FU4WVVY#O70>R^<W7^<77]I'-+TZ#V7SFZ_SBZ_M(!T'LOG-U_G%U_:
M0&)=<%V=NV2W$R+H:D-+41*NUS6FI)/.E4DTG[!D-FEFC%AJ99P?.PZISP`W
M&#XS<K$UMCNFM+;LEI*E-.+961&XGWKC2D+2??29&(UYM5-]KN0[YT'LOG-U
M_G%U_:1S2]4Z#V7SFZ_SBZ_M(#>1V$,,(90:S0VDDI-Q:W%F1?9+6:EJ/OF=
M0&@N7TYLWZ++_P#(`D8``````````````````````Q+M=[5:(#MPNLUBWP&=
M':RY;J&&4::B2G2<<-*2TE*(BJ><!PUSB39',/W+$R^)Z&,0QGI2H]C9D07(
M?W%Y26(Z(I(-V0VM"4EM4KJJND2BY`[Q%=<=BLNNH)MQQ"5+0E1+)*C(C,B4
M615.Z`]0$=X@_1"X?!3\M("1``##NMYMEICID7"0F.TI1(0:JF:E'R)2DC4>
M3*="S90&2R\R^RAYE:7674DMMQ!DI*DJ*J5),LAD99C`1VS_`$\Q)^BVW_N0
M$E`<OXZ_NRV?AE?(,6O%]ZE?R':''!<JL`=GX&_NBX?A4>XH4?*9XP6MAEG%
MTP5J>``#E?';\UM'PG__`$Q9\7GG!`Y#+&+D`NU4`.R<"OW5<OPZ?D$*7E,U
M*TX_M+IXJU@``"%\7?H5(_"M^Z)O'[L(MYMRX`.A4H`Z7P,_?5P_`)^48J^4
MR1BGV&:<':!2K4``$>XA?0J[_HY^Z0D6F[3BT7.W+YM'3*(`3G@U]-$?H[ON
M$('([7RF6.X[T*!<```QKG^[I/X)?R3&>GFAC7VE\JCJW.@#?X!^F-I_26_E
M$(UYM5-]MN0^E!S2]``!AWK]T3?P+GR3&S2S1BPU,LX/E@=4YX`;W`OTOM'Z
M4S^,2(MYM5-]KN0^EAS:]``!&[PHT8XP[3+MF9R%5Y"2AM14`20`````````
M`````````````6/,M/-FV\A+C:LZ%D1D=,N8P'&;E=\08%:5"O$["RVURGUV
MU,YV8]<G&'GE+;;V3;+KKJFR7H%H)]Z1%R5,.SLJ-3*%&5#4DC,J&5*EW#R@
M+@$=X@_1"X?!3\M("1``#08KLUSG.6V9;28<E6YUU9,27%LMK2_'<CJJXAMX
MR-).Z1%H9:4R9P&?8[6JW6*%;%N;1<6.VPMU-4U-""29IY2+N=P!&;?@!QK$
MEVE.3[DF))9AHCO%.=VBU,DZ3A*,E:63332H#;=#8WK6Z[^_K`,"[<+\/W=M
MMNY2KE*0T9J;2Y.?.AGDKD4-FGJU499Z,*].FKO'5K>PO`/V$[?9&N-OMZOV
MEK];3\'87@'["=OLC7#V]7[2>MI^&SM7#&P6AI;5MEW**VX9*6EN<^53+-G4
M-.IJU5SUJGJV4:=-/:&=T-C>M;KO[^L,&;`7@V=Z<:T+I=/1/DZMK_KW=+;Z
M9:/UVE[WZ@#/Z&QO6MUW]_6`8%VX7X>NZ&T7.5<I263,VB<G/GHZ5*THKET2
M&S3U:J,L]&%>G35WCJUO87@'["=OLC7&WV]7[2U^MI^#L+P#]A.WV1KA[>K]
MI/6T_#9VGAAA^T-K;MLJY14.GI.);G/D1F62N50U:FK57FGJV4:=-/:.C.Z&
MQO6MUW]_6&MFP)N#9OI.W^2W2Z>0?=?+ZSW:^]+94JJN>N8!G]#8WK6Z[^_K
M`,>?P]M%PCG&FS;E)CJ,C4TY->4DS+-D,QE37-,]8GI+&JF*HZ2U?8I@;YN5
MO+G.-OM:GVEK]>CQ!V*8&^;E;RYSA[6I]I/7H\0S+;PLPU;'%N6YZ?$<66BM
M34MY!F1<AT,85ZU=6:>K.G3II[1T;#H;&]:W7?W]8:V;!N^#9FRC^C;K=-IY
M2SY1I3W?S?3+;>^5GT*]\!G=#8WK6Z[^_K`/*5@*VRX[D:5<+F]'=+1<:7->
M-*B[AD9CVFJ8GK#R8B8Z2U'8I@;YN5O+G.-WM:GVEJ]>CQ!V*8&^;E;RYSA[
M6I]I/7H\0R;?PFPK;I'E,%R=&?(C23K4MU*J'G*I&,:]>NJ.DS,LJ=*FF>L0
MV?0V-ZUNN_OZPU-C!OF#9OHJ1Z)NMT](Z/\`I]*>[32J6?253,`SNAL;UI==
M_?U@%%X*B+0:%W.ZJ2HJ*2<Y^AD?VP1(TG8I@;YN5O+O.-_M:GVEI]>CQ!V*
M8&^;E;RYSA[6I]I/7H\0]8O!_!T20W)C>6,OM&2FW$2G24DRS&1U'E5QJ3'2
M9GH]C1HB>L1#;]#8WK6Z[^_K#2VO*5@TO)7O)[I=?*-!6QK/>IIT/1SJ[H#R
MM&#7_1,+TE=+H5Q\G:\MT9[U-OH%M*:*J>_KFR`,AS!,-QM3;ESNJD+(TJ2<
MY\R,CSE[X>Q/0F&E[%,#?-RMY=YQN]K4^TM/KT>(.Q3`WS<K>7.</:U/M)Z]
M'B'K&X/8.BR&Y$?RQI]I1+;<1*=)25$=2,CJ/*KC4F.DS/1[&C1$]8B&WZ&Q
MO6MUW]_6&EM5+!L:O[TNN_OZP#,PS!N<"Q1(=TD^5SF4FEZ3IJ<-?A'HF:UD
ME1GHTSD`UE\^G&&/P=P_%-@),``````````````````````--C&P2L08<F6>
M+=9-ED2R2ENY0U&E]O162ST3(TGX1)T54,CH9T,@'*K)@G$>`<2P;N6%HEVA
M1V),>;=;#I'<7_*#9T79,><ZMYPT;)7O)#A^$="(!VU"R6DE%4JD1Z)E0RKW
M2/,`J`CO$'Z(7#X*?EI`2(````````!8^VMUE;:'5,+6DR2\V236DS^N3II6
MFI=])@(KPL=EN8,C^5RGIKZ'Y;:I4A6FZO0DN)(U&1$5:%R$1=P!+0`````!
MYR7$-1G7%N;%"$*4IW)X!$535E[F<!SKA=<(=PN\V5;+PJ7;3C-H3%DW`IDQ
MUXG%&J:ZREQU,9*R/12DJ&=,J4Y@'20```````<QM]Q85Q'@(M-T?G(><N"+
MU$=E.JE,N$JJ">A*)+349HTZ#2B22LJ:&9*49ATX```````'-L97K$:,?X<8
M*+.CV9BYM,(6R;>QFK?AOK<4X9+TM!GP22DRSDLS+(@!TD```````',>)EQ\
MAQ"Q-7-CFJ#!6N'87ERV7ISJWD&:(RFEM(6[X!)*A.F5::!$JH#IR3,TD9D9
M&99CI4O:```````!SGBQ.GLSK)&7<6K39'_*CF3I#KS+&V0U5AIQ3#D=?A'[
MPMJGPN17O0$OPA+DS,+VR3*:<8?<CH-;;RS<<R%0C4M1$I6D15JK*?+E`;<`
M``$9OGTXPQ^#N'XIL!)@`````````````````````!AW:T6Z[P7(-P9)^,Y0
MS29J2I*DG5*T+2:5H6D\J5),C(\I&`C:N'<G:4;Q=B!J'F\B*4PM.CW-NXPN
M7]7;5[X"062P6JR1%1K<R;:7%FX^ZXM;SSKAD1&X\\ZI;KJS(B+26HS`;`!'
M.(:DIP?<5*,B22$F9GD(BTR`;A5XM*"-2IL=*4Y5&;J"(J=W*`Q>EN%?7,'>
M6=8`Z685]<P=Y9U@#I9A7US!WEG6`6IQAA)=="]P%:)Z*J2F3H9<A^%G`7=+
M,*^N8.\LZP!TLPKZY@[RSK`'2S"OKF#O+.L`=+,*^N8.\LZP!TLPKZY@[RSK
M`'2S"OKF#O+.L`MZ882T]GZ;@:9%I&CRIFM,U::68!=TLPKZY@[RSK`'2S"O
MKF#O+.L`=+,*^N8.\LZP!TLPKZY@[RSK`'2S"OKF#O+.L`=+,*^N8.\LZP"U
M6,,))-)*O<!)K/101RF2J=*T+P@%K^-<&L))3]^MS23.A*7+821G]58#Q[0L
M`]9;5OT;7`.T+`/66U;]&UP#M"P#UEM6_1M<`[0L`]9;5OT;7`.T+`/66U;]
M&UP#M"P#UEM6_1M<`[0L`]9;5OT;7`.T+`/66U;]&UP#M"P#UEM6_1M<`[0L
M`]9;5OT;7`.T+`/66U;]&UP#M"P#UEM6_1M<`[0L`]9;5OT;7`.T+`/66U;]
M&UP#M"P#UEM6_1M<`[0L`]9;5OT;7`.T+`/66U;]&UP#M"P#UEM6_1M<!3M#
MP`?_`/IK5DS_`.NC:X"O:%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@'
M:%@'K+:M^C:X!VA8!ZRVK?HVN`=H6`>LMJWZ-K@':%@'K+:M^C:X!VA8!ZRV
MK?HVN`=H6`>LMJWZ-K@-0]B+#]YQSAU-HN<2XJCM3U/E$?;?-M*FVR2:]FI6
MB1GFJ`FP```````````````````````````/.1'CR65L2&D/,.%HN-.))2%$
M?(:3J1@->6%,+$9&5G@D992,HS.J`RO1-J\S8\4CF`/1-J\R8\4CF`/1-J\S
M8\4CF`0?A=;K>MS&)+BLJ)&))A((VTG0MA'R%4@$X]$VKS)CQ2.8`]$VKS)C
MQ2.8`]$VKS)CQ2.8`]$VKS)CQ2.8`]$VKS)CQ2.8`]$VKS)CQ2.8!!V+=;^V
MN6WY*SL^CC)Z&S32OEKF6E`$X]$VKS)CQ2.8`]$VKS)CQ2.8`]$VKS)CQ2.8
M`]$VKS)CQ2.8`]$VKS)CQ2.8`]$VKS)CQ2.8!">(=MMR+]@,D164DJ_T41-I
M*I>CY9T/)W@$Z8@PF%FMB.TTLRH:D(2DZ=RI$`]@`````!">*OYCAW^HK5^L
M$`FP````````````````````````````````````````````````````````
M````````""\*_ON,_P"I9GXB.`G0```````(*Q_>^7_3C/ZZX`G0``Q[C<K=
M;(3LZY2F84)@M)^5)<2TT@JTJM:S2E)>R8#!L>+L*7]3J;%>H%V5'(C?*#)9
MDF@E5T=/9*7HUIDJ`VP``@_$;]_X!_C_`/MTP!.````````0GBK^8X=_J*U?
MK!`)L```````````````````````````````````````````````````````
M``````````@O"O[[C/\`J69^(C@)T```````""L?WOE_TXS^NN`)T``(;Q-:
M*5928;6_&EQ'6;A&F-V]ZXMH6PYDTF6E-DLSR^":LV4!Z8$O]^NKDPKH^3Q,
MZ!-TLTVT4,ZURRY,K:>PFE`$N``$'XC?O_`/\?\`]NF`)P```````"$\5?S'
M#O\`45J_6"`38```````````````````````````````````````````````
M`````````````````!!>%?WW&?\`4LS\1'`3H```````$%8_O?+_`*<9_77`
M$Z``$5XEP$3,+K)6FHH[[$C8IBO3VW#:62B0]%CDIUQL^71(Z9%9:`-5P]5&
MNF(+MB-,^UKERF68LJVVE:EZ"F5*,G9>T2T[MS)6AX;:32DB+*`GX``@_$;]
M_P"`?X__`+=,`3@``1_%]TQ9;VH*L.VQBYKD2$L2DR'76MDA>9[[FV]5*3]\
M`R;&[BY;KI7V-;V&B(M@<&0\^HU5/2TR=99(BS4H9@-N``(3Q5_,<._U%:OU
M@@$V`````````````1?%F(KU"NUKL]G*&W,N*7W$2+BI9,J-@B,F&TH-)J=<
MTLF7(DE*H=*`,7"&/U8BO3MO\G1&7&ADY/C&HU/1YB7E-.L+/P:D6C5*M$M)
M)DK,8"9`````````````````````````````````````````````````(+PK
M^^XS_J69^(C@)T```````""L?WOE_P!.,_KK@"=``"+\2;D];\+/.M*>;4XZ
MTSMVI)0DMDXLDZ;TLVWS8:^R6E!F7(`CF#L)6&?+.7*MMJ;N<)QI]F[VZ\2+
MQ<%**I:+\N3'CR$H,OK=-1*[@#I8``@_$;]_X!_C_P#MTP!.``!%.*,N9%P7
M*<AN/MR%/Q&D^3.G'<63LMIM3?E!&@V"<2HTFZ1U01U+*`\\#6F=!D2E2;9/
M@)6A!)7.O<N\)49&=20B2\\3=.Z1%4!+P`!">*OYCAW^HK5^L$`FP```````
M`````"(<5+@Y;\*>6-)0J0B9#0RKR8ICR5.R$-UBL*2LER**^Y$94TJ`//`F
MF[<)\I^1<I<E:$)4_<[4W;E&DC.A)<3'CJ<]@S.@"9@`````````````````
M``````````````````YM.PKAC$'&.[HOUHA75,?#UK..4V.U(V9KFW`E&WM$
MJT#/1*ID`T5DO6*$KM.'+#=$Q;7,O-ZA0;B\WY8M,""A2VTLFZ9$K9NI6TA2
MC46BDL]`&VC<1;^K#F&[BX;:Y-TQ#/MDAI""JN/&DS6T(;*OO]"*C*`\L*8N
MQC(N>!7Y]U8EP\80WYTJ`F.ALXRBBE(0TRXD](T-Z6@K3JHS*M2]Z`ZJ````
M```""\*_ON,_ZEF?B(X"=``#2WJ]7V#)0U`P])NS2DZ2GV'XC24JK[TTONM*
M]H@&RMTF5)@LORHBX,AQ-7(CBFUK;/[$U-*6@_M5&`R``!!6/[WR_P"G&?UU
MP!.@`!#^*D.%*PL29,E,9;<J.Y$-<-RY$X^E?@-%":6VM\UY2T:]_D`:?A5B
M%NY3YS#;<8T>3,R42(MC>LB%I<6M)%_J)4E;WO,Z4$DOLC.I$'2``!!^(W[_
M`,`_Q_\`VZ8`G```B/%%ZUKPNY;9DVUQG[@ZRF(Q>E-%$D*:?;<4TXAU#I*2
MHDT.B:Y2H9'0P&IX5%AQ<BX.6:V88@Z*6TO.8<IM%D9J-)N_Z>-5L\[:B-23
MRT`=$``$)XJ_F.'?ZBM7ZP0";`````````````(OQ)@29V%'F8\%^Y.)?C.G
M$B.FQ)4EI]"U&P\EQC9NI(JH5IE0P'A@1+9.S#;BWQ@BHDU7J64I)F1Y2:(I
M$G1,N7,`EX```````````````````````````````````-'>\"X.OLTIUXLT
M2?,)I+!/R&DK5LDJ4I**G]:2EJ.G?`9[=CLS:H*FH+#9VM*D6XD-I24=*D;,
MTM$DB)!&CP:%R`-:U@'!C-U5=V;/%1<U/*DE+)LM-+ZZFMU%<B5K,ZJ---(\
MIU`1K"W"8K3BIB_S'X+CT%$A,4X,+R-QQ<H_#<?/:NMUT35X+2$)-2C499B(
M.B````````@O"O[[C/\`J69^(C@)T```````""L?WOE_TXS^NN`)T``(9Q2D
M36+)'=8M2+@RS):??D+FH@>2;-1&E\GEFFAE7N^S4C`:/A1'MRK]<I=O3&**
MW%9C,-M71FY+803KCFQ0B.6BVS59J(UF:C,S+,1`.G@`"#\1OW_@'^/_`.W3
M`$X``'-.+K"D2HLCTA:X93;;<;0:;H^XP6C.)HE.HV;;U4MZ!:>E1.4JF0"W
MAA(>N=^?N*I=N=1#M42W(9@+D*-3;;CJT2*2&(]6G-(R0I&DDZ'0P'30`!">
M*OYCAW^HK5^L$`FP````````````#F'%JP7>YW2(XS8GKY#*V3H\5++T-HXU
MS><8.-(3Y7(BFE:6T.DEQHS6FN3.`OX5VIZ+=I+T2PJL-K3`C0Y+6U@+2].C
MF9.+-,"1*+3(E95+HH^4!TP`````````````````````````````````````
M```````````!!>%?WW&?]2S/Q$<!.@```````05C^]\O^G&?UUP!.@`!$.*,
M)F5AE!*DMQI#,R,]"-Z.Y,0Y(0Y]S:\E:,EO:>;1+V>0!A\,\4+O9.J==@Z;
ML=F6PS%@OP7#9=-1$XK;.O$M.DDT^"?@J(R/*`G8``@_$;]_X!_C_P#MTP!.
M``!"L?X.O]\EHD6=^&T:[;/M4A,PG#\">39::-GRIV>8P%V$<+8F@WP[G>GH
M2DMVR/;([4(G2R,..+TU[3N[3,0"9@`"$\5?S'#O]16K]8(!-@``````````
M``'-.*N%;S>;I'=C6+T[#*TSXC:#<C(\GG/N1S8D)\H6WHJ2VAPB6CPBKWP&
M1PYP[=;;>77W+`6'X/HR)#6RE<4R>D1S,MIHQEN%D2HR(U90'0P`````````
M```````````````````````````````````````$%X5_?<9_U+,_$1P$Z```
M````!!6/[WR_Z<9_77`$Z``$0QS<[,X96:0S)>EQV%7@WX:D(7"1$TE-R#6L
M\AJ<0:$D255RU+1J`C/!F+$AR7XCL2<Q.:M\4X+]QD1GW'+:XI;C1-%#:8:2
MA+BEUTDZ>EGY`'50`!!^(W[_`,`_Q_\`VZ8`G````````(3Q5_,<._U%:OU@
M@$V`````````````````````````````````````````````````````````
M````````07A7]]QG_4LS\1'`3H```````$%8_O?+_IQG]=<`3H``1V_85F2[
MNS?+/<$VV[ML'#=4\P4N,_'-1K)MYG394>BLS-)H<2>4\X!A["TR#=95[N]P
M1<;Q*9;B:;#'DD9F.RI2TM,LFX^LBTUJ49K<4=>X60!(@`!!^(W[_P``_P`?
M_P!NF`)P```````"$\5?S'#O]16K]8(!-@``````````````````````````
M``````````````````````````````````````$%X5_?<9_U+,_$1P$Z````
M```!!6/[WR_Z<9_77`$Z```````!!^(W[_P#_'_]NF`)P```````"$\5?S'#
MO]16K]8(!-@`````````````````````````````````````````````````
M!#%\%^$SBU.+PC:E+69J4HXK=3,\IF>0!;V*<(^J%JW5KF`.Q3A'U0M6ZM<P
M!V*<(^J%JW5KF`.Q3A'U0M6ZM<P!V*<(^J%JW5KF`.Q3A'U0M6ZM<P!V*<(^
MJ%JW5KF`.Q3A'U0M6ZM<P!V*<(^J%JW5KF`.Q3A'U0M6ZM<P"'\.>$_#.<O%
M:9F&+;(*)?Y4>-M(S:MFREE@TMIJ61)&HZ%WP$P[%.$?5"U;JUS`'8IPCZH6
MK=6N8`[%.$?5"U;JUS`'8IPCZH6K=6N8`[%.$?5"U;JUS`'8IPCZH6K=6N8!
M#V>$_#,^+LJV'ABVG;TV%F0F+Y,WLR>.6M!N$FE-(TD15`3#L4X1]4+5NK7,
M`=BG"/JA:MU:Y@#L4X1]4+5NK7,`=BG"/JA:MU:Y@#L4X1]4+5NK7,`=BG"/
MJA:MU:Y@$0QUPFX90[U@MJ+ABVLMS;WL):$1FR)UKR&4YH+(BRITT).G=(!+
M^Q3A'U0M6ZM<P!V*<(^J%JW5KF`.Q3A'U0M6ZM<P!V*<(^J%JW5KF`.Q3A'U
M0M6ZM<P!V*<(^J%JW5KF`1+B/PEX908=B5#PO;8ZG[Y;8[QMQFTFMIU\DK;5
M0LJ5%D,@$M[%.$?5"U;JUS`'8IPCZH6K=6N8`[%.$?5"U;JUS`'8IPCZH6K=
M6N8`[%.$?5"U;JUS`'8IPCZH6K=6N8!$;YPEX9,\2<+06L+VU$.5%N:Y,<HS
M9(<4TEG9FI-*&:=(Z`)=V*<(^J%JW5KF`.Q3A'U0M6ZM<P!V*<(^J%JW5KF`
M.Q3A'U0M6ZM<P!V*<(^J%JW5KF`.Q3A'U0M6ZM<P"(67A-PS=XH8GM[N&+:N
M#%M]J<CQCC-FVVMU4HG%)32A&K037V`$O[%.$?5"U;JUS`'8IPCZH6K=6N8`
M[%.$?5"U;JUS`'8IPCZH6K=6N8`[%.$?5"U;JUS`'8IPCZH6K=6N8`[%.$?5
M"U;JUS`'8IPCZH6K=6N8!4N"O"0C(RPA:B,LQ^2M\P"9-MH;;2VVDDH01)0D
MLA$1%0B(!<```````````````````")8^N%T*3AVQ6Z4Y;UX@N)Q)-P9))N-
M1V(C\QU+1K)24N.E&V9*T<A&9EE(@&!<7I.`V9TXKK(O$%QEAN#8YS^UD^6O
M2$1FC1*<TG":=<>0A6GI$D\I4S&&+<>*%_M4H[+/L<9S$GE=NCMQV)JO)5L7
M1;K;3Y/KCI66S7'6E:3;KDJ6>@"YGB9?'9J\/)M,7I8BYKMAL>5.%!T6X2)Z
MI&WV&UT=BZE.CLJZ>3-X0":6"==9MK:?NMO]&7#2<0_#)TGTD;:U():'$DG2
M0X226FJ2.AY2(\@#8``````""\*_ON,_ZEF?B(X"=````````@K'][Y?].,_
MKK@"=````````@_$;]_X!_C_`/MTP!.````````0GBK^8X=_J*U?K!`)L```
M````"$XB_NM@[]#NWR8X";````````@]@_N_B_\`AEG^5,`3@```````````
M`````````````````````!J<2X9M^(8+466MUER,\B5"F1E;-^/(:KH.M*,E
M$2B)1EE(R,C,C(R,!J#X:VB3'N*;O.FWB=<V6X[UTE+91(;;87M628**U'99
MV;OW0C0V1FHB-5:$`HQPTM.V3+GSIMSN?ED2<Y<I2V2>6J`:CC-&EAIEI+2#
M<6>BA!5-1F9U,!=/X;6:3/E7./+EV^[R)Y7-NXQE-;5A\HB(*B;2\TZT:%L-
MZ*DN(47+GI0-E8L*0[+Y.467,6VPT\VMIY[:(>=DO$^[)=*GA/&NM%%0B)1D
M1$5*!N@`````!!>%?WW&?]2S/Q$<!.@`!I;U?[K;Y*6HF&[C>&U)TCD0G+<A
M"3K[TRES(JZ^PFG?`;*WRGY4)J0_#>@/.%5<.0;2G6SK[U9L./-5^"LP&0``
M(*Q_>^7_`$XS^NN`)T`UV(3<]"RR;N2+0M2-%-R<)*DLZ1DG3HM2$UR^#4\X
M#E3-QQ'%O3V%7I=S@1)MQ@LLO2Y1292HKK+JG769:%.;,GW6:)3IZ2<M-&M"
M#W@3+W=;G*PW(OLV)"LZ;FJ/<VWM!YY4=\VF=J[0MIY*DJK(SHJOAD`Z-@RZ
M3+KA2U7&8G1E2HS;CQ4I51EE.E"SYP&Y`0?B-^_\`_Q__;I@"<`+7"6IM24*
MT%F1DE=*T.F0Z`.4-3L1IMDZV3[S)DJE8H3;9-S09QW6HBB)>@T;1EL24:2:
M(TF1^%D/2R@+;<4VX8I/!TBZW%-CAO714:6U-D-RG38*(IMI4Q*R?6494MQ/
MA+/2H6G6AU"=</+I.NN!K'<)Z]K,DPV7'GJ4VBC27W2G^?WP"0@(3Q5_,<._
MU%:OU@@$V``$/XM*O;.!+I+M%S<M;\1E;SCK*$J<6A)96TK/*V9_9I\(N0!'
ML=S;F4K&%S:GRXLK"MMC2[)"8D.LLNO*2\]5YE"DHD%(<;V&BXE1%H^#153`
M=1``$)Q%_=;!WZ'=ODQP$V``'/KM=L3VS&]U-<[RR"BQ29MNMC;6S2TXTZTG
MPS)2S=6=??4*A9"+.`C,J[8@M+5KM\>^3)J,1V^`_-N+CA.+C.R9\.*Z^P9D
MI+27&IBU)27@)T/!+.`GF!WIC4V_V=V4].BVJ:AN')DK-UU+;K"'#86Z?A+-
MM2JZ2S-5%%7D`2L!![!_=_%_\,L_RI@"<````Y5B:??;/B2)=HMSEW**]<U,
M3'F7FS@1F]"B;<N$A;BS>6HOOVA5)G4S(L@#43L08DLUE@7"/>I4N3B&VN/S
M5/+2ZW#=-Q!D^T@R-+1()PVM$J)K0S\(!/,&JF0L1X@L"YTBX0K<41V*[,<-
M]]!R&U*<0IU7A**J=(M+-7N`)@`````````````````````````BV/I[R&K)
M:&G5,'?[HS`==09I7L4MN2WT)4G*DW&8RVZYRTLAD=`&K7Q'FIM:YGD;6DG%
M#>'=#2539.3T0S>^%HKTJ9J@,&)Q(Q0\[9;DJ%"+#M^N[MKC)TG2ELM,J?23
M[AG]S4;GDQGHD1:%2RJRT#"CXTQ:W*;:M3<1UR]V^X8F.1.6\M"(K+S+41IM
MMLR^^1UMZ15+149JRYC#48BXF8KFX34;Z&K<Y>+%'Q#:W[<Z\EZ.TJ5%;4PZ
MX>CIJ-,M)Z2"26<J<IAT7#MQDM8UQ+A]UQ3K#"(=TB&HU*-M$_;-K9*N9*7(
MBED7^<^0!*@````$%X5_?<9_U+,_$1P$Z```````!!6/[WR_Z<9_77`$Z`>,
MR'%FQ'H<MI+\60@VWF7"TDK0HJ&DR/N@-''X>8.8MTBW(MQ''E*0M]3CKSCQ
MJ:R-&3ZUJ>3L_K-%9:/UM`"3P\P9)ML6VO6QLX</:;!"5.(41/??B4XE1+63
MO_,)2C)?UU0$@9::9:0RT@FVFTDAMM)42E*2H1$19B(@%P"#\1OW_@'^/_[=
M,`3@``:Z5AVQ2H<N%)@,.Q)Z]K,94@C2ZY4C):O\Q&E)DK.1D1D`P7L!8,?M
M+%I=L\95OC+6XPQH9$K<,S<5I%X57-(],Z^%4]*H#>,,,1V&V&&TM,-))#32
M")*4I25"2E)9"(B`7@(3Q5_,<._U%:OU@@$V``'C-A0YT1V',91(BOI-#S#A
M$I"TGG)1'G(!K[GA/#5TN,:Y7&VL2IT31V$AU!*41(5M$$?V1(7X225715E+
M*`VP``A.(O[K8._0[M\F.`FP``QEVR`N?Y>MA*IFQ5&VQE56Q6HE*1[!J21@
M--$X>X,B0ID%BU-%$GH2U):4:UD;2*FAI&FI1MMH,ZH0BB4\A$`V=EL5ILD,
MXELCDPRI:G7#-2G%N.*H2G'''#4MQ9T(M)2C,!G@(/8/[OXO_AEG^5,`3@``
M`&C/!&%3OGIL[>@[CM-OM#4YL]OHZ.VV.EL=KHY-IH:7?`60\`X.AG-./:V4
ME/;4S)0K26@VEJ-:VT(6:DMH4L](TH(BTLN<!FV+#=EL,9<>U1BCH=5INJ-2
MW7%JI0C6XXI:U4+(53R%F`;(````````````````````````!I<5V)Z[0HRH
MBTMW&W2V9\!;AFE&U85X2%FDE&276E+;4=#H2JTJ`B=KX/Q%.7)V]3)+BI%[
M>O4)B++?2PTYY03\9W9F24DZC1*I4-/LGE`:N1PDNUSQ"R4U*(-BBW"7<"\C
MN$I2%^5)>+[A"6WLX[JU/Z;J]HHM+2T"+3.@=#>PG8G;@W/./HR&H#MJ;T5*
M2E,1Y3:UMDDCIG930\Y`-9(X8X/D0XD-V*LX\*VHLT=.U<(RA-N,N)172J9Z
M45OPL^3O@,ZQV&1$O=ZO,Q:%S+JXRVV39F9-Q(J3)ALS42:JTW75GD^NIR5,
M-X`````@O"O[[C/^I9GXB.`G0```````(*Q_>^7_`$XS^NN`)T```````"#\
M1OW_`(!_C_\`MTP!.````````0GBK^8X=_J*U?K!`)L```````"$XB_NM@[]
M#NWR8X";````````@]@_N_B_^&6?Y4P!.```````````````````````````
M```````````````````!$.'?DVTQ3L-A^_I6U\GV_O\`8LUVNW_YF:NS\#-3
ME`2\```````$09\F[6I--AY3Z":K3;^4:'E:Z5K_`*?9U[GAU[P"7@``````
M`B6.?)_3.#=ML-/TS]QV^WTM/R&3]YV/@Z=*_??`I7ZZ@"6@```````B?$7R
M?R.Q[?84]-V[0\HV]-/;EHZ&PR[2OO=/P*^^R`)8```````")WSR?M&POI[#
M;^2W+9:>WVU-%G2V6A]QI]EM,N;1Y0$L```````!$;-Y-VFXFT=AY1Y!:]KH
M;?;Z.E*T=II_<-'/H[/PL^ER`)<```````````````````````````````#_
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>v371611_tpg68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v371611_tpg68.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!UP)U`P$1``(1`0,1`?_$`0X``0`!!0$!`0$!````
M```````&!`4'"`D#`@$*"P$!``$%`0$!`0````````````$"`P0%!@<("0H0
M```&`0("`@H,!0P.!P0$#P$"`P0%!@<`"!$)$A,A%!75%M97EQE9TM.4U%65
M5I87&%B8,2)4-IE!4=$C4Y.DM'5Y"AHR<R0T=#6U=K9W.+@Y.F&R,R7%)K=Q
M@;-%0E)#)S<H>)%BDF-$1D>AL66FB!$``0,"`P(%#0D,!P8$!0('`0`"`Q$$
M(1(%,09!42(3DV%QD=$RTE,45%46!QB!4I+3E!65%PBAL4)R(S-SL]0U5E?!
MX;(D-'0V\&*B=989PD.T"?&"8T0W9#C#A"5%M29V_]H`#`,!``(1`Q$`/P#O
M5RR>6)R[\R;"ML64LJ[+=N&0LCWK'*5AN5WMV*ZM/6>T3SZ:ES/9B<F)%@N]
MD9%V<.DHJH<QC#HBWL]#SRK_`%?>TWS*TGO7HB>AYY5_J^]IOF5I/>O1$]#S
MRK_5][3?,K2>]>B)Z'GE7^K[VF^96D]Z]$3T//*O]7WM-\RM)[UZ(OYX>:_L
M`V0XGYD'+!QQC7:G@NCT+)N+M]$KD2GU?'T'"5V[R-'JF)'5->V:*CF[=I+N
M:LYEG2C$ZI3&;G<*"40Z0Z[SU;6-EJ.]<5KJ$4<UL8I26/`<TD,)!H<,#B%R
M._-W=6.[DMS9R/BN!)&`YI((!<*XCC7Q]079#]D_!'S`B/:]?1OH=NIYNL^B
M;VEX?Z3;Q>7772.[:?4%V0_9/P1\P(CVO3T.W4\W6?1-[2>DV\7EUUTCNVGU
M!=D/V3\$?,"(]KT]#MU/-UGT3>TGI-O%Y===([MK#F;=N'+\P17:G9+1LWQ5
M--;GE''>((5I6<<U%=YX891GTJS4Q>]VI6$:-8A687(1RXZTPMR&Z8D$H#PU
MVI:!N;I<,<T^F6KFR3QQ`-BCKGE=E;6I:`*[37#:LVPU?>?4)7Q1:A<-+(GR
M'-(^F6,9G4H#C38*8J%8^QSROLCO7;"*VQX2@W$$VRR%X1N-(HE:=XYF\)6^
M&I.0JW<HUW/GDV[Z+EYQ)1-ZS1>PRC3HJB]+US<JV-::;N'>.+8]/LVN:)<^
M>.-IC="\,D:\$UJ"1B`6$8YL16_<WV^%LT.?>W+@XQY,LCW9Q*TN8YI`I0@;
M"0ZN&7`TRVIM:Y:"+N`CW&%MIS9]:HV0F*TR=15-:NIZ)B4))U*244@X<I*/
M&,>VA7JBRA0$J9&3@PCP06Z&>=W=Q@YC3::<'R`EH+8P7`5)(XP*&IZAXBL,
M:UO:6N<+F^+6$!W*?@32@/$344ZXXPJ)OMLY83T(PS7$.TAV,W'STM#@A&TY
M=24BZJJT;V=^Q3(Y,JY:UQ9^W*^.4!!H*Z76]$%"=*D:!N([*6VFFG,'$<F/
M$-IF(XPVHS<517:JCK&][:YKF^&4@'E/P+NY!_&H:<=#38O%]MSY7,77CVZ2
MQ7L]CZFE.*5A2SOF]$:U].QI,590T">87?$CRRYHM$SDC<5.L4;AUI`,00,,
M.T'<)D/C#[73!!FRYBV,-S4KEKLK3&G%CL1NK[X/DYEMQ?F;+FR@OKEK2M-M
M*X5X\%>ZIM.Y;M\#I4C!.UNX%Z<ND)JS7ZM-D!:ONV4?/(F/'*."E6A7TDW1
M=D$0,W573*<"B<H#=@W;W(NO\-9:?)M[EC'=R0';.(D`\1(JJ)M<WKM_S]U>
MLV=T]XV@D;>,`D<="IK]079#]D_!'S`B/:]9/H=NIYNL^B;VE8])MXO+KKI'
M=M/J"[(?LGX(^8$1[7IZ';J>;K/HF]I/2;>+RZZZ1W;3Z@NR'[)^"/F!$>UZ
M>AVZGFZSZ)O:3TFWB\NNND=VUH5NPV?[5:KN8Y;U;K.WG$T!7LC;@,HP%^A8
MFHL&49<H.,PQ,3,=$V-HB!4I2/8RR)'*2:H"4BQ0,'9URVN[L;N0:UHT,-C:
MLAFNY6R-$;0'M$)(#A3$`X@'A70Z/KVMS:7JDLMW<.EBMHRPEY):3(`2WB)&
M'66^OU!=D/V3\$?,"(]KUU/H=NIYNL^B;VESWI-O%Y===([MI]079#]D_!'S
M`B/:]/0[=3S=9]$WM)Z3;Q>7772.[:]$=@^QTBJ9U=IN"3I$.0ZI"X]B3F.F
M0P&.4I`)Q.8Q0$`#]4>QJ1N?NF#4Z;9T_1-[2@[R[QD4%]=5_2.7)JE\K]>M
M[6U;V;!T6_W3.0AZ-&XWL=+QM/0M:JQ]US^R3]W=,9U_,5ZUW%W@^8,@5^Y=
M%,UB&:#)!$JZ8]+@K;<..'0_&O$XSKAHP1NCB<&M\:+G/HZK7O,)IF)P8`T"
MH783[WOEU7Q?QEXTD5>7M?("YWBX:UM11S6\Z*T`Q<2XFA6PN/>7[&166<WP
M=DVT[>[31:JS:Q>#IN^XCH$34\EQR\#CY2-M]FM..DT;1`79G8&]G2FHU&N@
MR5*Z:';BBDBF"FWM-S;9E_<QSV%B^UC`$)?#&&R#+'1[GQC,UX=S@>T1T-6D
M4`%=;<[SSOLX)(KR[9</-90R60N8:OJUK7G*6D<WE=GJ*.K4DTK\<\OG$M;S
M3N+^F#9UC.YTS)XX@DL-/,>0,.[H5`81]!0KF2J0T2E9"NS5(=M+T1S+A*+-
MBGF&CI,X*]L(]K$JL]S=*AU*\^<=,MI+:?F3"8V-,<8$>61@KE+"'U?F(Y8(
M-:BBIN=Z-0EL;;Q*_G9/%S@ESN=G>2_,Q^&8.!91N4'DD'"AJH76>7W6HS-B
MPO-H^.W&*YK>]F.0FE9.F4669,]KJ^W.*:XW5@2/7CF4@Z^7-S$>U6C,B3Q-
M514ZJ`(*&,.-!N;9QZD<VFVYL7:G,36.,@6WBX$>6N+6\\,`*&I)(H5?EWGN
M7V`I?3"[;81@4>\$S\\<]:8%W-'$G"E*&JPUB/8SDTV/NCE+9YC!>Z_2?LV>
M&4=XFP6U=$HTA95TMVD:@G7NUXI2(A:VU24()P,^!5419**B;HEUVG[IW'BG
M]^TRV\9Y^T.,-N.07'QH<G"@:!_O5/))6=>;QP^,UM+^?F.:N=DLQY8;_=SC
MC4N]SWP"K,H;),@-<?95=T/9CCYUEE3)V4X6DU^)Q!MW7QO'TJ$CLN2^&[?5
M;'-S"=CD8"VM#5%C+-))L=XG,ME"'%%NZ<G)5?;J3-M)W6NEVYO^?E#&B"VY
ML,`E,+VN<<Q:X<TUP<,V<'8'.I3:;PQ&XB;<:A,+011EQ,L^<N)C$K7`"@+3
MSA:6FF4C:0%N!@7E]8&3R%N:D\I;1\6-:Q/Y#QM*8?:3=0KKJ,95<N"\?,;F
MSK$>T?2`P4:CE!I,=>V."0G=&.L4#D4*H;H=*W-T3QN]??:;;"%\T9B#HV$!
MO,1AX:!7*.=#ZC#''&M5I=0WGU3Q:T99W]P96Q/$A#W`EW.O+<QPJ>;+:'BP
MX%LU]079#]D_!'S`B/:];KT.W4\W6?1-[2U?I-O%Y===([MI]079#]D_!'S`
MB/:]/0[=3S=9]$WM)Z3;Q>7772.[:Y^;\=H6UBBV+86WI>WS%%50O>_?#=$N
MJ,#4F,<G:Z5,0%V<2M4GBMP*$E`R*[)$ZS93BFH9(HB'8#7)[T[L[NVLNE-M
MK&UC$NJPL?EC:,S"U]6.H,6F@J%T6[^O:W<1:@9[NX>8]/D>VKR<K@6T<.(B
MIQ700=@FR'B/_P"*?@C\(_\`\`1'M>NL]#MU/-UGT3>TN=])MXO+KKI'+\^H
M+LA^R?@CY@1'M>GH=NIYNL^B;VD])MXO+KKI'=M/J"[(?LGX(^8$1[7IZ';J
M>;K/HF]I/2;>+RZZZ1W;3Z@NR'[)^"/F!$>UZ>AVZGFZSZ)O:3TFWB\NNND=
MVT^H+LA^R?@CY@1'M>GH=NIYNL^B;VD])MXO+KKI'=M/J"[(?LGX(^8$1[7I
MZ';J>;K/HF]I/2;>+RZZZ1W;6A&RC:!M6NF2.8/'6[;UB:S1^/\`>Y;J51F4
MW46#]M4:@TQ_19!K6:^DN!BQL(W?/EEB-T^!"J*F$`XB.N4W:W9W=N;W5F7%
MC:O9%J;V,!C:<C!&PAK<,&U)-!QKH-=U[6X+7370W=PQTE@USR'D9G9W#,>,
MT`%5OO\`4%V0_9/P1\P(CVO75^AVZGFZSZ)O:7/^DV\7EUUTCNVGU!=D/V3\
M$?,"(]KT]#MU/-UGT3>TGI-O%Y===([MI]079#]D_!'S`B/:]/0[=3S=9]$W
MM)Z3;Q>7772.[:\UMA&R))!=8NTK!:QD45E@13H,(5184DS*=4F98$TBG4Z/
M`!.8I0$>R(!V=0=S]U`"?FVS-!X)G:0;R[Q$T\>NND<N?=6NO*3LT'6+"IM'
MHU:C+4M@]5JYLF*J&U:1,#N!GKE6:'9[)),;5(Q<#&-IFAR))1!PL619(D(N
M#95!0%`Y.!_J\FB9,=-@8R0PT+H8P`V=SVL<XAQ#0"QV8$Y@*&A!JNCF9OK%
M(^(7\SGLYWN97U)A#7/:T%H)-'MRD"A-14$+=!':IRUG$E6H=MA/:@O+7.(;
MSU0CF\5357EI@GL:^F64Q`()NC*2T8_AHQT[061`Z:[5JNJF)DT53$Z,;N;C
ME[(Q9Z<9)&YF#)'5S2"06\8(!((V@$C`%:,ZWO8&O>;J^R1NHXYGT:00"#Q$
M$@$<!('"%3M]KO+/=MZ^[:X6VG+M;9*F@ZNX3B:>*-CF"=H]*,A%.V`+)O`&
M5:`!$>F(B[0`.(KI=.!N[N,YK'-M-.+9'96\F/E'#!O&<1LXQQA2=:WM:7--
MS?58*NY3^2,<3Q#`]@\15AL&VSE]5O-V-,"/MGF*%;CE2F9$O=<D6N.*J:N-
MH3%ZU=0M!)AVM(H2;9^"MJ8@V32:+E6ZPW$Y.@;5J;=_<V'4H=*=IEJ;B>.1
M[2(F90V++FJ=H/*;2@->/!7(]8WGEL)=0;?W',PO8QPYQ^:LF;+3@IR37$46
M7OJ"[(?LGX(^8$1[7K8>AVZGFZSZ)O:6'Z3;Q>7772.[:?4%V0_9/P1\P(CV
MO3T.W4\W6?1-[2>DV\7EUUTCNVGU!=D/V3\$?,"(]KT]#MU/-UGT3>TGI-O%
MY===([MI]079#]D_!'S`B/:]/0[=3S=9]$WM)Z3;Q>7772.[:T5V^[/-J<_O
M6YA],G-N^)9>HX^?[3TZ+6I"HL',+4"6K"CR:LQ*\P4`4(PL_+D!R[!,`ZY<
M`.;B.N7TG=C=R7>35[:6QM76\1M<C3&TM9FA)=E%,,QQ--I70:EKVMQZ'IL\
M=W<-FD%QG<'FKLLH#<QX:#`<06]7U!=D/V3\$?,"(]KUU'H=NIYNL^B;VES_
M`*3;Q>7772.[:?4%V0_9/P1\P(CVO3T.W4\W6?1-[2>DV\7EUUTCNVGU!=D/
MV3\$?,"(]KT]#MU/-UGT3>TGI-O%Y===([MJ#9.VB;"<48VR!E*Q;1<-O:[C
M6E6B_6!K"XZK[F86@:A"O9^9+%MGKB/:NI`(V/5%)(ZZ0*'`"](!$-8M[NSN
M?864U]-IMH888G2.`B97*QI<:`T!-`:"HJK]IKN\UY=1VD5_<B25[6"LCJ5<
M0!6E<*GB6JL)(<IF3F:Y"S&UW$]'//VYW2G<S=L>4*&J=8ETL)0^X%@K8K:G
M97D`BPF,>3S84C-UW*S:2.+1VFW.`".BB9ZO7R,BDT^UB+Y"PE\408T\R)QF
M?F+:&-PV$D.Y+@"MN]V^C6.D9>W$@:P.`;(\N<.=,)HV@-0\':!5N+25M4^V
MJ<M>*F)>OR6$=J4?/5Z'<V&=AGD13FTI#03).-6>R\DR5<E<,V#-&:9'54.4
M`3(];F-P*NB)]Z[=S<>.1T3[/3FRL:7.!9&"&BE21P`5%?QAQA:ANM[V/8)&
MW5\8W.R@YGT)-:`'A)H:=8\150WVD<N)W(UV';8&VN+R]O8+2E4BDH"J&DK'
M&M^V^N?0K$%NVI%LF,>X`3)%,`BV6`./5*=&H;M;DN>R,66GF205:,C*N&.+
M1M(P.SB/$5!UW>MK7/-U>AC#1QSOHT\1/!M'9'&%KAFNM<M#!%HR)4[?LKI,
MB_QCCO%>3[(ZK>+**\8JUC,.52X:J!8H\C98IR[E"W81*\1.DD#=H45@.<!`
MHZ;4K/<;2YYK>XTJ!SX(8I'%L,9&6:7F64JX5.?:*"@QQ6SL;G>W4(HIH=0F
M#999(VYI7@YHX^<=6@-!EV'&IP6X1M@6R1,PD4VFX((H01*H3P!AC=`Y>P<G
M2(0Q#"4P"'$!$!_4'AKH?0[=0;=-LZ_HF]I:7TFWB.(OKJGZ1R^?J"[(?LGX
M(^8$1[7IZ';J>;K/HF]I3Z3;Q>7772.[:?4%V0_9/P1\P(CVO3T.W4\W6?1-
M[2>DV\7EUUTCNVGU!=D/V3\$?,"(]KT]#MU/-UGT3>TGI-O%Y===([MK0J@[
M/]JK_F6[D\;O=O.)G>/JWM0P!:Z_2W%18*5J%LT_<;4SG)^-BC`+9K*RS1HD
MFX6*`'4(F4!'L:Y6UW9W==OI>63K&U-HRP@<UG-MRASGN#G`4H"0!4KH+G7M
M;;NO:W3;NX%RZ\F:79SF+0UI`)XAP!9^RWAOE>8+EX^%REMUPK6G,C2[7D4K
MDF&7TU&,:)1)&O1=TM<O(P4/)(1,/5W5KCA>J+=$4D70*\!3*H8FVU#2-P]+
MD$=]8VC"8W25YBH#&%H>XEK30-+FYJ[`:[*K76>I;X:@POM+NY<`]K/SU"7O
M!+6@$BI<&FE.$4VT4XH&U;ERY02MJM&VW8!FRT:[6/'EI*&.6+-6,M=35;I3
MC(4GK9!1TR0,Z(*3U$#LW!1XI*'`!X9-INYN3?"0VMA9.YJ1T;OR311S>Z&(
MQ`KM&!X"K%QK>]5H6"XO+IO.1M>W\H35KMAP.W#9M'"%-B;$MB:H-!2VN[>E
M0D"F/'BE3*^J$@0A0,<[#H&-VZ0A1`1%+I@`#V=9(W0W1-*:?8X[/R;,>MQ^
MXK!WDWD%:WMWAMY;L.OQ*F?[&]B4?$R<VMM5P.O'0[*3D'RS#'\._.1O#(KK
MR14DFI5#+N6I6J@&2+Q4Z91)PZ78U#MTMT61NE.G698T$FD33LV[!P4V*6[Q
M[R.>(Q?769Q`%9'#;L6J1FG*#+59*[FP/B$*O$XEQYG5_*_0+.=!'$^5[*I3
M\>W`&X07;BK6RV-$[9-N1,7B(D$ZR*:?XVM#XOZN>8=<^)6O,-MXYR?%S^:E
M=DC?3+6CG84VC:0`MOSV^_/"#QJXYXS/B`Y__P`R-N9[>ZIR6XUV'@)*F>[_
M`&3;0*EM(W/VRK[9,.5FT5K;SF"Q5Z<C*1&QTW7YV)Q_.R,5*,'2(`LQE(M\
MB15,Y1Z22I`$!XAK)W@W4W9M]`O;B#3[1D[+29S7"-H+7"-Q!!I@0<1U59T7
M>'7IM9M(9;VY=$^YC:X%[B""\`@\8(4MV\[&]FM@V^X%GYW:_A27G)W">)YJ
M:EY&CQ;J0E9>5H-??R<F_<J$%1R]?O7!U55#")CJ'$P]D=9&D[I;KS:3:RRZ
M?:.E=;1$DQ-))+&DDFF))Q*L:EO'O!'J5Q''>W+8VSR``2.``#R`!U`%E_Z@
MNR'[)^"/F!$>UZV'H=NIYNL^B;VEA^DV\7EUUTCNVGU!=D/V3\$?,"(]KT]#
MMU/-UGT3>TGI-O%Y===([MI]079#]D_!'S`B/:]/0[=3S=9]$WM)Z3;Q>777
M2.[:?4%V0_9/P1\P(CVO3T.W4\W6?1-[2>DV\7EUUTCNVGU!=D/V3\$?,"(]
MKT]#MU/-UGT3>TGI-O%Y===([MK1=7:%M8)S.&6+"[>\4%QJXV"2F0EZ&%28
MA55KVSW%Q%;:7!2&X=J&L3:O/EF1'0EZPK94R8#T1$-<H[=G=T;\LL?$;7Q,
MZ0^3)S;<N<7$;0^E*9@TEM>(T71-U[6_1%UWXW<>-#4FLSYSFR&![BVNW+4`
MTXQ5?V#\G_\`X9NS?_5"Q_RS,Z^85[XNDFB)HB:(FB)HB_E[YT'_`!5.43_J
M>YB/^AN%->C>JK_64/Z&;]65Q/K#_P!+3?I(O[87AKZG7SVFB)HBPEGG!\1G
MRLT^LS-DFZNG2<MXRS+%/X)I$O'#BS8HL:-JK3!^A,M7;96$<RS<G;B9`(LJ
MB`D(HF(]+6LU73(]5ACAD>Y@BN(Y@6@'E1.S-!J",I(QX2.$+/T^_?ITKY6-
M:\R0R1$&HY,C<KB*<--G56`H[E_8?C):P3:<U9920NU1W!5O(GA.PJEC8Y"E
M-S5[J=^RA:K/%O80C!1TX>TQDP9,6Y$&#2+)U14Q4*18NJ9NGI[)'RASW.EC
MG;)F#7"0W+V/E<X%M*DL:T-%&AN%*XK8NWCO7,;'E:&QOA<S*7-+!`QS(VM(
M-=CB234EV.S!?J.P/%Q&;^'=W;)$Q7[%MS#;/=(J?D(6PN[)36)LAEK%A9VB
MP1$K;*I=*FPRE-,6KY@]*HO'KD0<BMT3G5#=2QRF-TLSH7V?BSPXAQ<P<YE<
M'.!<U[1*]H<TXM-'5QK!WBN\P>V.)LC;GGVD`C*XY,PR@AKFN,;201@144X+
M["[&\11RE/D923MD_9:GFJSYR4LBCQG#NY^?N6.H_%UEJLBSAFK9FVH,Q5H&
M)%S&H`0KAY%(+J',;I`-V/=C3V<V^1TCYH[ETV:H!<Y\8B<TAH`$9:UM6C:6
M@E42:_>.#VM#&Q/@;%EH2`&O,C7"I[L.+J..P.(5IH^PK%E%QIB#%C&QV*0@
ML,YGQ[F6$DG\!1"3EF=8KAGM:HM8O;F/K;%&UL8>M.DV)Y!P3NJN@T0**Y2D
M`NK=KNK8VME;V+7O,5M<QS-):S,[FFEK&O(:,P#3ES'E$`8X*J?>&[N+J:[<
MUHDG@?$0"^C><(<]S*N.4EV-!R02<%EG">%6^.;EGC([F&C*W8LX9$):I6O5
MZQ/[!5H]*%A8ZK-IV((]AX$L+-9":0K>6GFR+<4PDA`O7+]6"IMAINFBSN+J
M\<UK)KJ;,6M<7-%&AH<*AM'2`![P!W7":56'?7QNH+>V#BZ.WBR@N:`XU)=0
MT)J&5+6$GN>`5HMB=;=:U-$31%S?WG_[6?*K_P#RE\O_`/H-.:X[>/\`?^A?
MYV;]0Y=/H?[GU?\`RL?ZT+I!KL5S":(L*[D,K/<$;?<UYMCX5G97F(\8W#(J
M%=D'CB.9SHU*&=3)XA:0:HN'#$'Z;44P6*FIU9C`;H&`.&M;K%\[2])N=38T
M/=;P/DRDT#L@K2HV5IM6=IEHW4-1@L7.+6S2M94"I&8TK0[:<2U<8<PW'54M
ME\H&=&!*5:ZA'85GX,U*"7NC&^0.;L3V?+L2$-%@Q;S<?8*E`T.="38GZ\54
MF*:K0RQW*;<-&S>VT@N);35!S<\8A<W)5X>V:)THH*9@YC6/S-QKE!;4N#5M
MG;MW,T,=Q8'G(7F4'-1I88I&QFIK0AQ>S*<*5(=2A*R[;=Z^WZCR]X@++/SS
M"9Q]:J139^--7'!7:LQDZ.KTCC9:'07<(*24)>PM#-O'2``1H=X*J*ATC-U^
MKV%QO)I-M)+%,]XDBD8QPRFM9`TQTXVOS`-=LK4$BAIA0Z%J,[(Y(FM+)&.<
M#FX&%P?7B+,I+F[:4(K4*/FWI41IDFPU^4;BWQXWPCMORQ3;6@VF`MENF]RN
M3+1B^D4,E)D&+%TPEWT[#LDT`6.DH5=Z<C@J)4#J:L^DEJV\?$\4M!;6\K'4
M.9[KB1T3&9"`02X-I6F)(-*55WYCN'6K9&8W)GFC<W#*T0,;(Y^8$U`!->H,
M*U5<??=MM*\HS9.SV!TUR#7:E:H:;:U*45@(Z'NV6E,$0)[1)#T/!YT?,!`@
M'"2Q!,V>'*8_!`#K$K.].C9H@'O+9F-<'!AR@/EYAN8_@GG>00=AVX8JD;OZ
MI20EC08W.:1F%26Q\Z<HX1S?+!&T=7!6W&7,!VTY;M-,I]1G+HG+W]S$-:PK
M8*#.0,4Z4L%$N>2(`[F4=@+=BC-5/'4ZLW.IP`3Q:I#]#I(BK19;V:+J$\=O
M;NEYR4@-S1N:#F8^1N)V59&\C\4[,*U76[NJ6<,DTS69(P<U'@G![6'#AHY[
M`?QAU:?JW,!VS$QI'9;9V"WS%(F;@UI$*_AJ).OG4U+R..YK*T0[BF0D1,\@
MI>AUYV]1=E-T$S(B@X!!<#)E'>S119-U!KY'6KI`P$,<228S*"!PM+&EP/4H
M:'!!NYJGC1LRUC;AK,Q!>!0!XC()XP\@$>Z*C%91H&X^D9-RJ\Q?3XZPORML
M$8IW!(715FBUK,C3LS/K$A2&K0BS@LL22=LJTNNH"J"8)CQ3'\8HCK.M-8MK
MV^-E;AYI:Q3A]*-+)B[(!PU(:2:CJ+$N=,N+6T%W,6BMQ)#EKR@Z,#-U*5<!
MMZJV"UMEKDT1<S^8W^='+@_G(\$_Z-Y`UQ>^/Y_1_P#G,']F1=3NS^9U/_ED
MO]IBZ8C^$?\`VC__`'UVBY9?FB)HB:(FB)HBYN;`O_PJ\S;^<#N__IGCK7&;
MJ?X_6O\`FS_U<:Z;>+_":5_RUG]MZZ1Z[-<RFB)HB\ER'507234ZDZR"R)%@
M(5443*I'3*J"1_Q%!3$W2Z)NP/#@/8U!%00,#12,"#U5I6QV+8UC-NF'MML=
M9[*QK>&;I2;U$VQK$5!"VVF7H+^:?P87$Z$(E%RG3--F376*@FN9)(@%.3L\
M>:;NO9,T>WT9CWB&VD8\/`9G<8R2W/R:'NJ$T!P"WCM?NGZG/JCF-,L['M+:
MNRM#P`<N-1LPQHK'`<O^A5ZS;<[(TR9D5<NV.DX[I%"A74?0SQ<DVQU0,FXW
M9RUE$E7(\DI.:KN4'0NBBIVNFLT1[7313.NFK;BW3M89[.9L\Q\2BC8P$,H1
M&R2,%W)J26RFO`"!0`$@W)-XKB2*YB,47]ZD>YYJ^HSO8\AO*H`'1BG#0FI)
MH1^5CEYX?J<AAY_&V"TK(8:F+\\@JY*,:O-TQS`9"F:'9Y"FL:M/Q$NRI\%7
MK;C:*E(08DS92&=D4!H*2(HI((-T=/MW6[F/D(MG2%K2&N9ED<QQ8&N!#&M=
M&US,M"PURT%`$N\E[,V9KFLK.U@+@7!U6![0XN!!<2U[FNS5S"E:FI.Q]EPI
M"V?/F+-P;N?FVUDQ/1\G4&&K[9&,-`2L5E=>L.;$\EU5VJDMW0:*U!GVH*"R
M:9`ZP#E/T^)=Q-IL<^JP:LY[A-;Q21AHIE(EREQ/#49!2A'#6M5K(KY\6GS:
M<UK3%-)&\G&H,>;*!P4Y1K4<2S/K9+!31$T1-$7.S;/_`+??,^_E+9A_Z`O]
M<AHO^J];Z]G^H*Z75?\`3NE=:Y_7!=$]=>N:31$T10#*^/8_+>+LD8IEY*1A
MH?)M$MN/IB6B"-#RT=$7*"?5V4=Q8/T7+()%%A(J"@95-1,BO1,8I@#@.)?V
MC-0L9K"0EL<\3XR12H#VEI(KA6A-*\*R;.Y=9W<5XP!SXI&O`.PEI!`-,:5&
M*UAS/L1QEFO%6+L1RMFLM3K^+*-?J)'NZ=$4^.>3S/(^'W6%;#,S39>$<1H3
MHUIXHZ(LBD0#2`@HH!R!U8Z34MU[+4K&"PD>^.*"*1@+`P%PDB,+B>33-E)-
M0.ZQ-1@MI8Z_=6-W+>,8U\DTC'D.+C0LDYT`&M:9A3'@P'&J:T;#L?W+*ULR
MO9+Q:YIU;Z';L;OJ9+U^A25'2JEWIN+J;88\\4K7$W4F#UOBEFY%1TNJYZUV
ML3K@(FU!"F?=:TN+^2_FED<9(GQEA:PLRO9$QPIEJ:\T#B2<3C@VE46\%S#9
MLLXHV-#)&O#@7A^9KI'--<V%.<(P%,!AMK(*+LIQS0<D8QR<QM-TL,UC/%59
MQ0W;W<\'<>[3"CR]SEZ1:%)RPQ<A:(&W5KZ0)9F5ZP>I+.HYR"#@ZG`YU+UK
MNU9VMY!>MDE?)#`V(9\KZAA>6.S.!<U[><>*M()::&N)-JXURYN+66U<R-K)
M9G2<BK:%P:'-HTAI:[(TT(H"*CJ4&=]D%(S[;<F6ZPWZ[UYSE+&6(<5SC"`:
M5A1I'P&%\P%S967L4I*Q3UR66D;:`HO3JF42.Q-U:9$S@"FJ-4W9MM5N)KB:
M65CIX8HG!H;0-AEYYI%0<2_!U:C+@`#BJ]/UZ?3H8H8XXW"&620$EU298^:<
M#0C`-Q'5V\2W7.<ZAC**&`RAQ$ZA@*!`,H8>)S`0!$"`8PB/#]372DUQ.U:*
M@&`V+YT1-$31%S?QO_Q8MUO_`.1AMJ_TZN6N-L_]>W__`"VV_MO7377^D+/_
M`#T_]EJS]E;;%6\PYXQ-EF[A7;'4,;8VRKC^1QG8Z^I,1UM-DR8H,VG*OU57
MY(P[:NN\?M^BR<LW2#H7!A/T13)QVU_HD.HZK;W]SD?;PPRQF-S:A_.&-U3C
M3DF,<D@@UQV+76FJRV6GS6<&9LTLL;P]IH6Y`\4&%<<YQ!!%.JM<$.7S*QU^
MW(Y`B,J5QI([@*CN*K7:KO'"[YK".<Z7ZEW>)?SJ1+6R"VM\?IU$[)!N<6X+
MD>J'*9$`,FIIQND]EW>W<<[`^[CN&XQU#>?D8\%W*&?F\E`,*YCLV':.WC8Z
MWM;9\+BVV?"[!]">:8YI`Y)RY\U2<:4X=JNV--@S^@2.)9%3,LBX>8OGL\/5
M)2%@WT6^L%:SC=;_`'=Q5%F$I8K!!,/!64NB"L;)MVZ4FQ<1XF06*BZ5;A79
M;J/M'V[S<DN@?.:AI!<V9[WEM"YS1E+QE<`'-+<#1Q"HNMX6W#9F\P,LK8A0
MD$-=$UC<U0`3F#3F:26D'$5`*S3MLVQJ;>MO[_"Y;5'VF;D(9Y$R%W3B;!%I
MS[LE+CJ#%6>=@Y:W6D$K&X@85F>4[GKLV;MVF=5-!(ZASFV6C:(=(TDZ:)`^
M4M(+Z.&8Y!&'.:7NY64#-E(!.(`JL'5-5&I:B+[(61AP(;4&G*+RT$-;R:DY
M:@D#"I6H9N6),FQ18L7AFJ&*2>VA[<=IQ9OP!D1.U9[><F/<BM+R+`;9T5G5
MK%\9FI']:4C0"@J5=7LDUH/0J3Q!]CXRVC]/M[7-D.`MY#('TS[75IEKAMJ=
MBW(WJC\;;=\P[DWLUQ3.,>>8&9*Y?P:5KP[*!;E[XSG/LJW>'5`@*FVQYR,J
M"72ZKK!QI8Q4ZOI_C]7T^/1X]GA^'71;S5]&]0KM\2G_`%;EI-`_?ME39XU%
M_;"F6V0Z:>V3;DHLHFBBGM]PTHLLJ8")(I)XTK1U5E3CV")))E$QC#V`*`CK
M)T6@T6S)P'BD/ZMJL:K4ZK=`;?&9/[96$:+OTPY9Z3>KU8DI>GQ-!W%Q>WJ;
M,=-";2C%[W)PJ6&LA6%['K]IU^AY-@K3%/"/UC]KQQW8HN#E,DH(:RUWJTZ>
MUENILT<<5X+=WX5,Y;S,CB,&LD:YIS'!M:'85GW&[U[%/';Q4>^2V,PX*Y`>
M<8`<2]A:X4&+J5&U?=]WW8>K$'E4(QQ+-KIBW'C?)<I`WJI6Z`8>"Y[G5:2Z
MDU58R+EIA=HTE+@Q#I-6JW;!'!%6_7HE5437>].G013Y"X7,$/.%KV/:,N=K
M"<`30%[=@-:U%14B+?=^]EDASAI@FER`L<TG-E<ZF)`Q#3M(I2AH:+TF=[E!
MQXON9?9@8/JG4=O>;%L4)6"O1LU:U)N,:82IV:I"S3C9HR3;UT["*L;I#J16
M/VV=F0C7KG*Z;<9DWEM;0WK]0!CM[2YYK,T%V8"%DQ<X`<F@<12N-*-JX@(S
M0;BY%JVR(?-<P<Y0D-H3*Z(-&.-2T&M,*U-`*K&>9.8=!X<?;KX28IR:TS@^
M,(YQ&X.O,%K.7IM/;27<J[J4[.(,%O`R>4K35^5F4$UTW+=D=3I%5Z*!L+4=
M[HM.??Q21_E+5M8CCEE=XMXR6.=3D.RAU,#4-KMP659;MR7K;.1C_P`G<'\I
MLS1CG^8#@*\H9B*[*$TV8K:ZH;C,77/)LCAJ(EW;G(\!!,):RQK>(D582&?.
M:I3[FZKRUB!'M`LVRKU[C'?4J=#K47`]68ZB+A-+?6^L65S>G3HW$WC&@N%#
ME!RL>6YMF8->TTX0<,00-1-IEW!:B^>T"U<XAIJ*D9G-S9=M"6.'7&.!%=8%
M_P#BZQG\VG.?[TU>UH'_`/Y$C_Y))_ZJ-;EO^B7_`/-6?^G>OZ?.3_\`\,W9
MO_JA8_Y9F=?(J^D5TDT1-$31$T1-$7\O?.@_XJG*)_U/<Q'_`$-PIKT;U5?Z
MRA_0S?JRN)]8?^EIOTD7]L+PU]3KY[6IFX;=*TPI$9T-!UA*XV3`FVB9W+VJ
M*>RJL)'*P2;ZPQE1JZ4@@PDETY:W.Z=+FZ[JC)LD&0&,505B%#0:OKC=-CNN
M:8))K2R=<N!.49:N#&UH<7EC\:8`5QJMQINDNOGV_./R17%T(&D"IK0%SJ5&
M#<S>'$G@HL=5C?/6B)V*=R8C6:W1Z[M^LNXIU.U<N2IN<+2J5:HBE7-96K2^
M/H=04ZS9G+MLH";E1X[*BBNV:J(+"HGAP;SPT?+>Y&6K+1UQF;SCG9&.#'\D
MQCN7$C;4T!:T@U&3+H$M6QVN=T[KEL-'9`,SFES>4'GNFT.R@J034455EW?_
M`(@H6"[7EVEA)7J?B(S-KBO8[?PMDK$Q+RNWEZT89693W;$.X>5.+K#Q^W15
M?KH'1%1XWZ!5`4'HU:AO9I]KI<FH6V:65K9LL9:YI)MR!*'5%6!I(!<13$4K
M519[NWMQJ#+*>D<;C%5X+7`"8$QD8T<7`'`&N!5VF]]^$J#`VRQ91E7=?CJ]
MEO+V*T#5>M7FX+=M86HC3)%V<3J"%68J1;J&IYG+YP9`'4:*#?\`:':Z@BF6
MY+O1IEI%)-?.+&,N)8N2U[\86"1^;DBA#*N-*MH,'$X*B/=^_N)&16@#G.AC
MDY3F-_.O+&TY1J"Z@%:.J<0`LL1VY_#,QF=+`438)22R4KW4)VDTK4V>#2<0
ME'J>29=FO8SM4XQ)VPI5\AGQRB;HB6223*8RH*$3SV:WILFI?-,;W.O<<`UV
M7DL;(1FI2H8]CO\`Y@-M0,-VE7S+'YQ>UHM<,2X5Q<Y@.7;BYCA_\I.RA,0L
MN]O;=3;5=J=:[K)UZ7H$O::Y/+2M0LS>&<6FFP%)M,[5*]-!''86.RDK^189
MTW:-#*'=$>`"72.FJ4F/-O+HUO/+;3R.9)$YS758ZA<QK'.8UU*.=ED80!MK
MAL-+T6A:G/%'-#&',D#7"CFURN+FASA6K6U8X$G93'@5JD-\^`HN;,P>RL\U
M@(_%65\LVRZ.H%XW@:3&8:R='8>NE9LB)@-*M[DRR&\4C!9)H*?W2D0A3'[9
M1$;;]Y]*9+D<YXB$$LKGEIRL$,HA>UW#G$A+<M-H&VH5;=`U%\>9H:9#-'&U
MH(JXR1F1KF\&4L&:M=E>(JY6#>[MRJY<<J3EKGV:64V\DZJRQ*-:W2"2,+E.
MKX4FSV-9I&+)5LL/DVYQL8N9R)2"+HJR1E$`%35<N\NCP<R99'@3@Y>0\[)6
MPNS4')I(]K37CJ*C%4QZ#J<O.B-C282,W+;PQNE&7'E58USA3BH:'!4[;=]2
MY+)*6/&</+12K/<7DO;A,2%HCYMH:0M6+<..\MV5U2D8*&GV\L5NV0!$$WZT
M:55L0ZR1U%C(-E8;O!;/O?$VM<TB\DMR7!PJZ*$RNR90ZN&'*+:BI!)HTR=&
MG9:^,N<"#;,F`:0:-DDYMN:I%/<#L<#05(MD=O5QS<KEA"N8N25N$9E+-=OP
ME:9&3;S%4E:#/UO!,EGAFY-"2D4"TKW6KR3$O5&,W,@5^'3$JZ*K<M#-Y+.Y
MN;:&Q_*,GN7PN)JTQN;`9QR2,:MIAA3-CB"%4[0[F"">6[Y#H8&RM`HX/#I1
M$<0<*&O'6G$05N;KHUI%S?WG_P"UGRJ__P`I?+__`*#3FN.WC_?^A?YV;]0Y
M=/H?[GU?_*Q_K0ND&NQ7,)HBMTO#Q%@BI*!GXJ,G8*98N8R8A)E@UE(B6C7J
M1D'D=*1CY)=E(,':!Q(JBJ0Z:A!$#`(#JB2..:-T4K6NB<"""`00=H(.!!X0
M54Q[XWB2,ELC34$&A!&P@C$$<:L)<?4`DLA8"46F%GVK^)E6TZ6K099IM*0,
M(YK,%)-Y4&`/T7\)6GJT<S5*H"C5@LHW3$J1S$&UXI:<X)>:CYT$$.RMK5K2
MUIK2M6M):#P-)`P*N>,W&3F^<?S9!%,QI0G,12M*%P!(X2*G%?4E0*%,R:\U
M,4>G2TTZ"N`YF).L0;^6<A3I)29J';$D[8JO%O!285,[C.D<>T')A50Z!QZ6
MC[2TD>99(HW2'+4EK2>0:LQ(KR3BWWIQ%"C+BXC8(V2/;&,V`<0.4*.PK3E#
M!W&,"JB0IE.EY!:7EJE6)66<E@B.963@(E_)."5:85L57*N_=M%72I:U85CO
MX\#''M)Z<RZ/05$3:J?;V\CS))&QTARXEH)Y)S-Q(KR7<IOO3B*%0V>9C<C'
MO#!7`$@<H9785_"&!XQ@<%;"XQQF1-JD3'-"(DP:LV+%,E.KI4V3*.LGAE'L
MVA`C@*V:L+C_`-[HID`")2G]U%`%_P!LU;\2L@`!#%0``<AN`#LX`PV!_+'$
M[E;<55XU=8GG9*DDGE.Q);E)./"WD_BX;%\QN+L8PSB/>0^-J!$NXDS,\4[C
M*97&#F+-'QDK"QYHY=K&I*L3,(:>?,T12$HI-7KA(O!-90IC+&RC(='#$US:
M4(8T$4!`I084#G`4V`D;"5+[NZ>"U\LCFG;5SC6I!-<<:D`GJ@'@"JCX\Q\I
M`PE44H=+4JU:Z/@W65*M!'KU=Z#.0CB=PH0S`8R'Z$=+NVX=KI)\$'2R8?B*
M'`U1M+0Q-@,4?,,[EN5N5N!')%*#`D8<!(V$J/&;D2.F$DG//[IV8YCB#B:U
M.(!QX0#P*Y1E6J\(Z[?A:U7X=]W#AJOV[%0L;'._!FN=LC7JYVRS;(K]P(`7
MJW:3/I=K-.N/U1"=,W&MD$$3L\;&-=E#:@`'*VN5M0.Y;4Y1L%314/FED&61
MSG-S%U"2>4[NG8\)H*G::"JOVKJMIHBYG\QO\Z.7!_.1X)_T;R!KB]\?S^C_
M`/.8/[,BZG=G\SJ?_+)?[3%F?>Q9[Q5JK@)Q0YRU03R8WC;::S;EJDK)).7F
M+IZ\=J9(83AHPBBB537K_'NBNIT$FZ(=,5$^'2UL=Y9KJ"WM#:ND:YVHVS7Y
M*U,3GTD#J?@9>Z.P#&H6!H<4$LUP+AK'-;93N;FIA(&U817\*O<CA/`5IZ$[
MNNID?D5E*W3(N1,6VO!VZ+-6$LN,Y.62MV.[S$TN;CD<!W5*.125L'<"UF8S
M%">N2&='1Z]F;KU&X#KG^=UVV;,R26::Q?:W,T,H)SQO#".8?3NLKLKX''&E
M6XD+=EFCSNB<R.*.[9/!%+&0,KV%P//-KLJVK90,*T=@"LU[&;MFVU7%RUND
MW>;9AU3:GM5L\K9LADE`=Q&YJPUIXIFNJUZ>F63&5>-`BDV<A--`56;PDPL*
M*7:YE%$"[+=BYU.>X(N72R:=XA:N+I*U%RYIYYK7$`D4HYXJ0QYH*5(6!K\%
MC#!6!L;+WQNX:&LIC`UPYIQ`)`-:AIH"YHJ:T!6NVT[(&XYS'[/[3E"8R?.)
M9-SIFG'-E7F[[D)R=>IPS'</+Q5DR/3)!BRB:VK!C5("-B2]$&;MH^:NQ64=
M&3*73Z#=ZR6Z?/>NG>)[J:-U7R=P!<$.D80`W+EC:W@(<UU2ZBV>KV^EAU[#
M:-B:8K>)[:,8.43""UC@275S/<[A!!;0"JRCM-W+[@I./V98IN].E9Y]D3`[
M2_9%RCDI*UQ]GL$VG?+S6[-7XEVG#C$MKS2(F*B9%RQEBH'?,)'IE40*CUBF
M=H.M:L]FG6%U&Y[IK4222R9@YSL[VN:#2F=@#7%KJ5:[:*5.)K&EZ<QU]=P/
M#1'<%C(V92T#(QS2<:Y'DN:"VM".&JFVRW.68\XYES/8,CQM@J-><X:P',1&
M,GD3:8VOXUOCBUYPA,A55!:R(E*^ND<T@8=.<4;&(DJ<J"I4$B*%$^3NWJ>H
MZGJ-S+>-?'$;:`B,AP;&\NF$C>5M>`UF>F&PT`*L:Y865A8P1VI:^03S`O!:
M2]F6(L=R=C22[)7':*E?FP+_`/"KS-OYP.[_`/IGCK4;J?X_6O\`FS_U<:C>
M+_":5_RUG]MZZ1Z[-<RFB)HB:(FB)HB:(FB)HB:(FB)HBYV;9_\`;[YGW\I;
M,/\`T!?ZY#1?]5ZWU[/]05TNJ_Z=TKK7/ZX+H+*2<?"1<I-RSDK*)A(R0F95
MZ<#&(SBXEFO(2+LY2@)C$;,VQSB`=D0+V-=8][(F.ED-(VM))X@!4GW`N<8U
MTCQ&P5>X@`<9)H!V5S3R3S%C4*/-.I8Q:NH64V(6[?'4B/IJP#+2<7"SK!G6
ML=S:,%5YAG`/K'`RB#QQ)J*"TCEC&0,57H@H;C;S>_Q5G.B`&-VEOO65<ZI`
M<`V,Y6D-+FD$N)HTX8[5U%KNUXP[FS*0\:@VU=0"@)!+GBK@2&D$!NTC'!;-
M5C=MB68N=$Q1*RCV,R]=8C';HM2:0%@>Q3>9R/B*=S5#1+:SFCTXQPB>EU24
M5*N<Z9149]4<"*J)D-N8-?L)+B*PD<6ZA*V/D!KB*R1.F`S4IW#78]2AH2`M
M7+H]XR&2[8`;-CG\HD`T9((B<M:]TYN'5KL!4=QGOPVT9>M%,I](M=G=3>07
M<2RJ19?'=TK[&4<6"E6S(-?+W2EHALS:EG:K1)I=H*IB@J>,73[!NKZRU9;T
MZ+J$\=O;2/,LQ`96-[0<S'2-Q(`&9K'D5VY2.*MRZW?U2RADGN&,$<8)=1[2
M11S6'`'&CGM!_&"]U=]&VU.MSEI):;,ZCJ[D.GXLE&C/'MR7GD;KD"JJW6EQ
MH5X(DLN"5AKJ!UDU3I$!NH44G((*@8@2=Y]&$+IQ(\L9,R(@1OS9Y&YV#+2O
M*;C6F&PT*@:!J9E;#D8'.C=(#G;3*QV5QK6F#L.KM%0LASNY?#%<QUBG*TI:
MSDHV;G-.98OE48J1.I:'E^KSFU51HDS50178NY>$:*'21<`DLHL!6Y"'<G32
M-ERZUIL-G!?OD_NMR6"(T/*+VYFBG`2T8`XUP%20%C1Z7?2W,UFUG]X@#N<%
M1R<ARNQX0"=HPIB<,5BC-&^+$N**WN&<1B,Y=;_MVH3V^63'R,/+P*\G'M;@
MC0#+,)J3C@:*Q32VN2(N7295`Z@>O;@ND8AQP-2WGL+""[+,\EW9Q%[HZ%M0
M'\W@2*4#C0G'#$5&*S+'0;R\EM@[*RWN9`QKZ@T);GQ`-:Y<0./`T*\YG?!B
MVET;,DO=#G?9`V[4J8L^8Z+CIM-61G&2E=7KS.P5RL62;B*VWF'L)(6^*1>@
MLFV.S.[,!BJ`@L)8EWFL;:UN9+G&[LXRZ9D8<X`MRAS6N<&U+2]H=6E*\-"C
M-!NY[B!D&%M<R!L;WT:2'5HYS074!#74VUIP5"S;2L]8[OMYM6,X)>P)7ZBO
M6C"Z5F7K4K$O:TM(5.!ND<YD#O44DCP\I"61KVF_2%1HZ<F.@F<5DE2$V=MJ
MMI=74EE$7^-Q$![2T@MJUKP37@+7"CA@34`U!6#/IUS;V[+J3+XO(*M<'`AU
M'%II3A!::C:!B<"%`+#O-V]U:0R?%35JG&\CAY&NNKRQ2I%L</6C2U9+4P_#
M/8EFE%"[G6B^1D^YPG;)GZ0&(Y3!1HHFN;%EWCTF!\\<DC@^WRYQD<2`Z3F0
M0*5<.<Y.'4(JT@K(CT34IFQ/C8TMFS93F;2K6<X037`Y.5CUNZ!"QKE3?YB>
MGXLK>0\?)O,B2MN+"2T)47$=/UIXC4#[@J?MSN%ALJZ\.Y4JO@O?+6+1--VD
M`O7K4Z1/VOI+$PK[>NPM[%EW:5FDDH6L(<TY.?9;O<[`Y<KW4H1B139B,JTW
M=O)KMUM<TB8RH+JAPS<RZ9K1CRLS&UPV`UVX+?1=+J5UD>/2ZI51+I<.'2ZL
MXDX\.(\./#74D4-%SP-0"N6#*Z5_&W,IWPY%MKI1E5:!L$P;=K*[22%=9O`U
M6Q7Z=EE4$`$HKN"L6)^K3`0Z9^!>(<=<,VYBL]\]3O+@T@BTJ![C_NM<]Q^X
M%UKH)+K=?3[:$5FDU&5K1U7!@'W2I5E??G8L3RE\5E,/1\E6\7[2<9;P+LDW
MNZ[6V(TJ^9#?4J;JD(U6KZD&_M5-C68R(BLY0;2)R':D.B(D6-?O]ZIK"27/
M;!T,%A'=OY='!CY"PM`RY2Y@&;:`[N<-JM6>[T5XR,,G(EEO'V[>3R<S&!P<
M<:AKB:;"1MQV+(&1]^F&ZWBK-.1,<*/\K26&`@6\I7(QC)Q#>0D;%D9/%2/4
MS;I@JV5CX.ZE<-),R!5ED%&ARE(8%$5#Y=YO5IT-C<WEG6=]ME!:`0"72<UW
M1&QKZAU*D4.&(KC6N[U]+=P6UU2%L]:.)!H&LYS97:64+:T!KMP*\E]]6-<>
MU2S3>?%&U,EZCEG)N'IN-QW%Y#R0Q96G$&,F>5;^BX=KT2M2)"0E2*]>BN1J
MHQ4:MB]6X.N8R)!WHL[2!\NJTCDCN)(7",22`.BC$LF.1IP9F=6F6@P).`D:
M!=7,S8]/J]CX62`O+&'+(_FV?AN&+J"E:U.RF*D]VWB4:AV.^0TC%R-B1JEI
MVK4Z,;TYI,2-AD97=<]684A[)M).(BH-G"=,I54E63^064(!B+)-UA23/?N=
MX;6UFEC>TO$;[5@R`EQ-T:,)!`:!U0YQX"`:`V8-%GN(HY&N#2]EPXYB``+<
M5<`022>N!U"155==WAXL>J1$?8WZT;-6K)&X3'5,:PL);I1A/2VWBSOH.U08
MR4I78))M>NT6I7'<H`4*Z.58(]9ZBB9;4P[Q6+BULQ+9))IXV`->0XV[BUS:
MEK:/H*Y>''(7`542Z+=MJZ(58R*%[JEH($S06F@<>14TS<&&8-)HL79_SWBK
M/VQ3>M.XGLPVB(@MN>:&#U^$;(QS=8)'%-DD(J1C5'[9`LE$2S(HJ-W"0F*8
MI1`P$,'#6#JNJV.K;KZE+8/SQMLY@30C;$X@BHQ!&PA9>G:?=Z=O!8QWC,CW
M7,1`J#LD`(--A!VA9ZP)!Q-HVE8%JTX55:)LNVW%$-(M&\B]BG;Z->8MK;>2
M;-GT8Z92C?IM%Q*H=NJ10A#_`-D''6VTJ..?0;6"7\V^SB!%2"08FU%00=G$
M5KM1>^+6+B6/NVW4A&`-#G-,#4=E>-^P;MCAXS,5TR74Z3"UG)=*J=1S=)VN
M47AZ5/TRBK&+44;8S=R;2L,25Y=V8$7W5(.2BJ(&6$!`-4W6F:)$RXN;V.)L
M$T;&3%QHQS&=QG!(:,M<'4!QVJ;>_P!5>^&"U?(Z6*1SH@T5<'/[K+09CFXL
M1U%%VVU_:%E=;)5YBZ=5KO\`2VE:*SDR>@+Q9Y-C8225GJMCM5=?EB;4>/AC
MIVFD1:ZS-N1H=FLT`A2)E.H4]ANB;OWYFNHXXY?&,S9'->XAU7-<YIHZ@Y3&
MD@4H1P8J\=5UFT$5N][X^9RN8"QH(HUS6D5;4\ES@":U!X<%79&VQ;4LA24Q
M6<DTZNS4QEVYVJ^RD!(W6SQ\C>+F3%;;&5QET8V/M#!P]798G<(,7C=`@(-F
M8I+&3(H)51KO-$T*[>Z&\C8Z2XD=(6E[@7OYH1O-`X5I%1I`P`H:`XJFVU75
M[9K9;9[FLA8U@(:TAK><SM%2TTK)4@G$FHK3!2"U[1-NUZ>V]];L61T^[O<2
M>'MYWTM:#%F6JN.BXD,Z613FTT6LT;%P&@0D4"I/PC5E4P6_;51-=GW?TBZ=
M(ZX@#W2MH^I=C^3YJO=8'FN1F%'9217$JU#K.I6[6-AF+6QNJV@;AR^<XMG.
M<O*<,P!I@%/*QAS&E/O=IR'5:VG#W>Y1%9CK@_93,Z*4^UJT0E6ZU*3%=/+*
MP"\ZR@8M-@26,S"16:-@1.N<A.B&5!IUE;W4EY`S+<R-:'D%W*#1E:2VN4N#
M1ES4S$"E2`L>6]NIK=EM,[-`QSBT$#`N.9P#J5H2:Y:TJ:T6G"__`!=8S^;3
MG/\`>FKVN:?_`/D2/_DDG_JHUOV_Z)?_`,U9_P"G>OZ?.3__`,,W9O\`ZH6/
M^69G7R*OI%=)-$31$T1-$31%_+WSH/\`BJ<HG_4]S$?]#<*:]&]57^LH?T,W
MZLKB?6'_`*6F_21?VPO#7U.OGM:TYIQ1@J7=7.W9BFH2O5C*>)%]ON4&]DLZ
M-1@;S0PD)RTQ,*YG32<,[C9.&[J30E5;."J*1SYT4P`"9%$]+J5CI<ADN-1<
MUD,]OS$@<[(U[*N<`34$$5?B#W+G5V5&TL;S4&".&R:YTL,W/1Y6YBQ]`TFE
M""#1NT=T!QT-E-BS:9GT+&P82-.R@HE@SZN]M;U7)R\XY;83MCQE/)U6=)6K
M(HNR2L;B&272D50(_=)HB*;@Q!-QM^(Z#JN=K3'.?%?%W99,Q$+R'979789J
M`AQY1I@:*YXWK&G97.#XAXQSS<S*?E6@C,,S<<M2"T8#A"]9W9)MFLM8/3YO
M'"SR"6E<L3+E$MPNS-^\6SJ9LKEUD\F&-@;2SF"OKADW6>L#+"SZ]NDHFFF9
M,HA,N[6BS0>+RPUB+I3W;P3S].=!(<"6R4!<VM*@$`441Z[JL4O/QRTD`C'<
MM('-?FR`12K*D`TK0D$XKWM>RS;;=XF8@K1CUQ*15@N&3;]+M36ZYM@?6S,5
M'-C;)<HHLUGD5R^%%'.:/41*8$$$SF.B1-41/J9]W-&N8W13Q%T;I)'D9WXN
MF9S<AP=^$SDTV`;*'%1%KFJ0/;)%(`]K&,');@V-^=@V?@OY5=IX:A66N[=X
M:N[I)O+<3FBQ)3SZ`B',IAXDG'N6JE":TQCC2OM9**D'4A+(UM&:K)7Z,B@F
MU,O*M12$Y@*L![4.D1PZXZ_CN7\Z6`F&H/(R"-H(-3ES-S!PI5PI7:JY=2?+
MI+;-\#>;#C22A[O,7FA%!FHZA!K1IKQ4HV&R#$TG><Y73)K!#**N8\C66\Q4
M3+-Y:.98^1N%#QG0YV+A$6D^LU<3CMOBV/7)-IHM)!$PBFD)"EXFI;NSI[[J
MZN;UHG-Q,YX!J!'G9&QP;1U"X\TTYZ!PV"BJ=KUXR"W@M3S0@B:PD4)?E>]X
M)PV#G",N(.TJE)A#8[=73['Z1,8VF5D:9DS%,]5FV332,]8J_EZUAE3)$58X
M]I:1E)RPV:Z,#6$SQ8IY-!VF9TW43`O$M(TS=FY<;0<P^0QR1.:)*N<V5W.R
M!P#JN<YXYRIY0/*!"GQ_7H`+D\ZQ@>R0.R4#3&WFV%IRT#6M.2@Y)&!"R/<M
MI>"<A%I7AO5)FSN,>UQ*J5>1F+U>WDNA"I76F9&ZJ4EUK$:2L#Q6[8\A9!1T
M^5<.%%8],@GZH3IFS+C0=+NQ'XRQSS$S*TE[R:9V28G-5QSQL<2XDU:."H6-
M!K&H6V?Q=[6"1V9P#&4KE<S`4H!E>X4%!CQJ[.-LV%75H<7-2GKEL+K)]PS,
MH];V6TM4BY.O^/SXMN=L;LVTPDS:/;!1ECLUDTB$1*8XKD(1?@H%TZ+IKIC<
MF,\\9WS5S.'Y22/FGN`!H"YF!IAPTKBJ!JM^(A`'_DQ$V*F5O<,?SC6UI6@?
MB.'@V8**8\VA[;,82%:+0J6:*D\=W)ODJ"14N]QFGL-<'N+DL+HV1ZC,V*17
M=*26-(KN7_=0*(+@D=7HBN!E`Q[3=_1K)[/%8\KX9!(WEO<0\Q<SF-7';&,N
M.!H3MQ5ZYUG5+MKO&)*LD9D/):`6B3G<N#1L><V&(V;%M%K>+4KG!O.`!W:<
MJD!'@`[F,O`(C^H`X&G.S_[M<=O%^_\`0O\`.S?J'+I]#_<^K_Y6/]:%C+<%
MEG-$GMBS3FBO7C(M`R!2MV3_``Q6:I27JC)O%4B`W/8_Q>N>2AVL>[=3,I+X
MS8OI=5TKTBHMYQ9P0"II-SI86K7^I/T2YU*&6:*[BOS"UK#0!C;F.+$4)),8
M<\D[`\G8`1E:=9V+-5@L9(XI+:2S$KG.%:N=`^3`DX`/(:`-I:!PFN1([=9E
MN#K^ZAE#8Q)8S[;KY*T:H-<@79VGDB\%0R<2(CY"P.99"&A9-I<,>R9)BJOA
M?,&DB":3%=UTNM?AELUZ_BAOFQP9_$Y2Q@D>><?^4H"XF@(?&<\3LS0Z@:7;
M7+&=I%G)):.DER^-1A[LC>0S\G4AH%2,KQED%"6XN`V-41LVZ[-3VY3#<(5Y
M%4T+'RU'54B(ZMVVDVX\1N3M"BF6WTR]DTI5PXBJR`=IRL:JW(#9J@+==5`X
MK+FQYM>U%]RX92VWSZ<6@->Q]+AWY4DFN#=CFTP`H2#4J]%I%@V`',#/EO<Q
M+FN;6!OY,`"F+MK37$FH!%`O%IS!,J)CNC5G<2T:+88.J5_M-2E7\S9ZS$3+
M>C[G+)@41M4K82$C$^Z=5BVUE039K(]>54$2*=6NDN2&[V7_`/?C+;Q-9:QR
M.:27-!R7+H.4788M`D%"*UH#0@@=W+0^*<W-(77#V-<`&N(SP-FY(;C@XEAJ
M#3;3`A90GMRE_G-G54SJV:UE>S6+->,JR#;#-S+.1!J;+[E*_0>WTK%!.[JF
MFY>410)*;C^M6!FDLY8KG1%-18F=+K-W+N['J@##,^YC;2%^89#<MCKF:7[6
M<I[:FE2TD4JL6/2[:/6WZ>2_FFP2._*MH<P@+Z93E_#Y+3A7!PK6BON'=U^1
M,B[KLI8$L6.(*$IM/?YV95BYQ@6DDC)AAZ\8UK46O+!*)&@3DN<9?G#A`K0X
M``Q*IDQ4(8X(W=/UZ[O-=GTJ:%C;>,SAKQFJ>:?&T5KR>6)"13WII4;+=[I%
MM;:1#J$4KG3O$1<TY:#G&/<:4QY)8`:^^%<=N.X[="_Q=DOF*NL@W"0F&&,[
MS0$,"4:PGL;I@NT7P%"6J=B*LSK5>L-B=0"U\.\-)NF+*148=!0@%#JRI:Q&
M:V^QO=8==R%S(96<PQV8BG,-<X,#6N<6YZYBUKLN/%19+]);=VNF"V8&NEC?
MSSVY:UYTM!<7$-KDIE!+:^[58)LF^7<)*(X=RW5:,NT)&)[Y:]:<0]S[8%:R
MS+XBEL8,<.M$P2;NY:$NM\83#DU?(#AT@+QTH)>VT"=$NJFWGU9XM[^"(C+X
MZUT5'Y93$8A".$A[P3S>)%2>Z`6PCT'36<]9RR5)\5<V2K<T8D$ADX@6L(&?
M`&@'<E9?L&_#-,='99<LMO*+:2HT]5HJ)B[`I:D@BW$]NS?;<@KE\=Q;1R(V
M*1HS0E\9K1J9FY(A3\=-1OU;I78R[TZDQEP6V='Q.:`'9L"ZZ-OE>0#RBP<^
M"W#)M!%''"CW?L7.A#KFK9&N)(RXTMQ-F97@#_R1#L<W$:@+_O5SG6KEN%Q#
M'XYI<K>\0[<\[7N-M55B,E2]8>9?Q%0<6VQC664?.QL0ZL$=9U<BN1:M6QU#
M`G&$`CMXH=TBT7>\FJ0W%WI[(8W75O9SO#FB0M,L4<3@T!P&8.YPT`][@YQ+
M@U;Z%82P6UXZ5XMYKF)A:XL#N;D?(TN)!-"W(*D^^V-`!-Q:[V<O,GMB@W.(
MVMA-5<+7&[IV1LQLK-.?D:5MAQ_G&,OCEFB*K5OCK)-YMKNGL6[8XOB2L>IT
M%%#]8W0J;O+J#7/B-N'Y+9[\U'#,66T<P?39S<CWF)H&.9IH3B!2[0K)S6R-
MF+<\[6Y:M-`Z=\197;G8QHD).&4BH&TY3QIGC<;8[_@2HW_%5%85K<-B`N4X
MBWT%:^.VM%6BUZU)W2@7-U/&CE(VSM:7<6)XEV1(J;F7!9$4@*EQ'.LM5UB:
M[M;>[@B$-W;\Z'LSD,H6E\;RZE'9'MR&F+ZBF"P[K3],BM[B:VFD,MM-S9:_
M(,]<P:]H%:MS-.85P;0UQ6F6>LAVC*%%Y:-FN!.LFF/-<B*,$P"";4ELA\:7
M7.F/:]<R((E(W*:TP=:;NU12`$5%U%#I@"9B@'.:K=SWUKHL]Q^=&O!E:4S"
M-\\;7T_WFM!-,*U(P6\T^VBM9]4BA[@Z07T]Z7MB>6__`"EQ''3;BNVP**)F
M.*9SD$P&(82&$HF*;^R*/1$.)1_5#7I=2-BX6@.U.M4Z73ZP_3XE-TNF;I<2
M_P!B/2X\>)?U/UM*G;PI0(=110>DHH=0W_UCF,8?PB/X3"(_A'0DG:FQ?HK+
M&$XF55,*A2E4$5#")REX"4IQ$>)BE$`X`/X.&E3QJ*!!66,"@&55,"H@94!4
M,(*"7^Q%0!'\<2_J<>/#4U/&IH$.LJH!2J*J*`7^Q`YS&`O8`/Q0,(@'8*`?
M^[4$D[4H!L7-C8%_^%7F;?S@=W_],\=:XS=3_'ZU_P`V?^KC73;Q?X32O^6L
M_MO67=PN3KO!9!4Q[`O)&MP8[1]S^:$;'%<49.5R%CXE+KE-KT>]*0ZB9H+P
MR5ESH)?MCIP5J!@%),Y#['5KVYBN_%(B61?-]S-F&TR1Y&L:#_NY\]!B3EX`
M0L/3K6"2V\9D`?)XY!%E.P,?F<YQ'5RY:G8*\*YYXQW4[GZ=!2&0[1W?R0\J
M'*OV]9S1H,S*VB6B+?F:;OZ\;D>>L2;2LP<C$9"6K(BK(Q;4'!8U)(J@$`HF
M'7(V.NZW;Q&[GSS.CT*WGR$N(?,Z2DCG4:TB3+W317+2M%TEWI&E32"VBRQ-
M?JTT6<!H+8PRK`WE$%F;N7&F;8LTY*YA.8*GB"J9)J^&:K/R4Y9MY\:\AW9;
M]VN>#VOS$PA1GL5W.15?IO<P1,6D9`5R'2!5X0[8%B`"9]E>;VZC!I\=[!;1
MO>Y]X"#SG<VQ.0B@K64`4KA4@MKL.#:[N64UZ^UFG>UK6VQKR-LX&8&N%(R<
M:<`QIP5ESYAF1J9C:O6Q?$4#+69]G7-&+W]?CD\A&0DJIB3+--I!;C`G)"N4
MH]O-5"UGE3+/79P`[8HM6SQLHX49U7.]MY;6;)S;L=.;J:(M'.8MBE8S.W`T
M!8[-4G@Y(<TDMB#=NUGNG0B9PB%O%("<F#I(W.RG'&CFY:`<.)::9LWXGW69
M#OF[C)^WN>QW!15(J$MG>*K%ZC0M)).5+AV?Q#&Q+V5[II&KYTKJQR8\.@5H
MH``>%5,F90HJ%1V>GZ[>76OSZ3+"QMM&Z<->,U3S+H@":\GEB0TI[PTJ*TP+
MS2+:WT>+48Y7&=XB+FG+0<X)"0*8\DL%:^^&SAA&1M[F1*(WW"E/BJ,,^Q;D
MNKTC':P(6V>@L@Q5L<WIG&2"4K64G@>%2;VF@@^AGQ8`8Q50QSN%FZK!=YC7
MF\UW:B[',-SP3-9'W;FR!^<`U;7EU91S'9,IQJ06%U^VT*VN#;?ECEEB<]_<
M@L+<A(HZG)HZH<,^;B!#@W!TQO%S8PN5FS2:+GE:0RPOL1DJ_BHA9=ICBCR>
MZPEF'*=WR>[)&(R]E8XG=H,RK+E4CU(SI-Q7ZA$[CK-7)O#J;;E^I97FU%M8
MEL6(C8;K-SKY#2KA$:5-6Y<*T!-<]FBV#H&V-6\^9[L&3#.X6^7FVL%:-,@K
MACFQI4TIFV[[H]R=1LN=9%IC2JSL1A_;-MJSJ.-6+.S/Y><3N4[<3[A4:3=6
MYXY"XR]#K=?.:);]IH$=JI-DUDT5')C#L[G6]9MYKI[8(WQV]E;S\V`XEV=S
M_&,C\,Y8UO(%!7D@@%RP8-)TN:*W:97M?-=3Q9R6@#*&\SF;CE#W'E&IIC0F
MBSKG7*V6:/C?`UCK;""C)[(FX;`-#OG;U<FIEE5,=Y+MP-9YVLR0D2.(I_'1
M)VS5XZ75,BV765Z/0-U1B[35+^_M;.UFA#6RS7D#'U:2&QR/HXTK@0*`DX`D
M[,%K]/M+.>ZN(I2XQQ6TSV4<`7/8W`5IB":D`8D`=5:\UO=1G"URV`[19Z9`
M5>H73<)N3QP$14Y&_MGY:_A&G9[;-[#DQJ_@)5%S!6J1HL0ZC$&A1X+O2*IG
M7.#=NMJ(=<U.>2TGFC8RWDN[B.C3)7+"R<9I`6GDO+&%H'"X$$X`[*72+")E
MQ%$]SYH[:!]7!E*RNAP90C%H>X.)X`1AB1#\:;PLK[@[#MF=HP4ICF*DMY(X
MONK*KHV=K%WO%-BV>SF6HB1DT[)&(2T;&M[Q.,FB+@Y6RAGL<B)R-7"JC)/'
MLMX;_5IK)P:Z&-VH\T\-S`/B=:.E!.85`#W``X8M%0TDM%ZZT6TTV*Z:7"5X
MLN<:79:LD%R(R!E-"<H)(QP<=H`<=Y]KV0[1E##K"S7`G633&\Y>HP3`()MB
M6R(QIEFZ8]KUS(@B4C<IK3!UIN[5%(`14744.F`)F*`=/H=W/?:<)[C\Z)96
M5V9A'*^-KZ?[S6@FF%:D8+0ZM;16MZ8H.X,<;Z>]+XVO+?\`Y2XCCI2N*UOV
MS_[??,^_E+9A_P"@+_6GT7_5>M]>S_4%;/5?].Z5UKG]<%T)?,64HQ?1<DU1
M?1LHR>1DDQ<%$S=['2#95F^9KE`0$R#IJL=,X<0XE,.NM<UKVECP"QP((XP1
M0CW0N;:YS'![#1X((/$1B"M7VVS7!RM;95NRPDM:DF.WI_M/[H/;'88QW(;=
MWKMNN..I-*&E63%8#H,&J;B1221?.!;@?ID$QBZT@W=TPPB&9KI`+0VM2YP)
MMR1^3-"!P"KA1QI6H6U.MZ@)3+$X,)N1<4#00)A^&*@GA-`:@5X5)FVU?!;3
M(U4RVVICE+(5(85-A7+"6T6OI-$J-1K)C.JN'<;W9&(E)"(H5OD(LCET@JL=
MNO\`CF,<A#A>&A:6V\CU`1GQN(-#79G89&.C;45H2&/<VI!-#QA6SJ^H&V?9
MEX\6D+BX96XYWM>[&E0"]K74!I4+"E<P7L)PK8H><B97'%*L&')RFL&1YG-K
ME)2DV&%IU^I=*C)=G.W4Z;223IEWL+1NW>DZQ9)RN<2F.B4Z>MATO=739FRQ
MNABFMWL`K,>0X,>Q@(<_`Y'R``[03PC#.EU#>&^B=&\2R1S-<32+N@7,<X@A
MNS,UA)&R@X#C,*OLGVI-*>2+JE(.ZJ%AL>/LG(NVF1;U.(35@H]9?0&/[:VG
MG%J?N'X,ZO-J)I*$7,@\1.110%1*0P9$&[6A-M\D$5;=[XY*B1[JN8TMC<'9
MC6C7&F-"*$UP5F77=7=-GF?29K7LH6,%`]P+VTRBG*&.%1B,,5E.6VYX=G,3
MU/!<M3^W\34B$@ZS`TEQ,3BL86O5N-1B(2%ECGD#.YYBP8-TR)@]47.51,BQ
M3`N0BI<Z31]/EL(]+DCK81-:UK*NIE:*`'&K@!3;78#M`*PV:G>QWC]08^EY
M(XN+J"N9QJ2,,"3Q4XMF"@TSLLVW6&2RS+2^/WKZ1SI$S]?RDNK=[X(VF%L]
MNC+S,175>$@I0[):TQ"#E(C`K8&P%%)'H)&,0<:3=O1IGW$DD1+[IKFR\M_*
M#G!Y'=8#,`1EI38*#!9#-<U2)L+&2`-MR#'R6<DM:6`]SB<I(QK7::E7.T[>
M=N;:M9]>7"%81='SXS7?YW/,WJPP])GE'L=%0LG;'2;BQ-*[5)V::1;$KV78
M`R=/%6R)U53'`!&N?2-';#=NN&AMM=BL]7N#'5`!<>4&M<0&YGMH20"3540Z
MEJ9EMQ"XFXMS2*C`7"A)#>YS.`J:--0*D`*1PU!JN+;9E'-]SGZNUD9V#J]8
M>7>6CV=2"M8GH*TLYJ5:M]HE)IZG87$+*69Z=:9=G:G<$40(HF`H@8UZ.U@L
M;B?4[E[`][6M+R`S+%'4L:]Q<<Q!<:O-*X`C!6Y+B6[AAL(&O+6N<X-!+LTC
MZ9G-:`*5#11HK3$UQ4`-LWVPS,EDF<"E*2,CD]\D3(SU._W=Z>6>QN3FF:FK
M)8/"=9.'&+R,1*31;M@;@@4X(E*#8_5#B>CNB2/FEYO,^<_E#SCS4B034[K"
MDE'`"E-G<FBR/GO56-BCYRC8AR!D:*`LYJO<XU95I)K7;MQ7W(;)MLLI"5BO
M/<<**150;33"&11N%V9KFC+!E6+SA)1$N^9V%N]GHD<N0K6?1;O%%DFSY(!2
M`A#&(:7[M:*^-D+H?R<8('+>,'2B8@D.JX<Z`\`U`<,*!&Z[JC9'R-EY;R">
M2TXB,Q`@%M`>;)82*5&U;6G.90YU#B)CG,8YS#^$QC")C"/_`$B(ZWIQQ*U`
M%!0;%R\A:I`7SF:[UZ-:X\DM5KKL,P/4;+%J',F21@++9KY#3#(52<#I"YCW
MJA`.7\8@CQ#LAKB(X(KK?74K6<9H)=*@8X<;7.>"/=!75R326^ZUA<0FDK-0
MF<T\1:UA![(6TSS:+A.QKLY/(-><Y!G@QA0\.V&0G9J?;QEWQ[C2>+:*?7[E
M4HZ70J\XS:65,LDY25;&0>O1,94@I&!$N\=N_ILSA)=L,TO,,A<7%U'QQNS,
M:]H.4@.Y1%*$[13!:ENLW\0+;9PCCYU\@``JU[QE<6N(S`Y>2,:@;#7%1&W8
MRV7UN-RGBBYSM$J,9F2VAD7(./)G,+RLH/[4ZEV60GD]#UEW;V7@@:;FXI*:
M?%B462+U1,7"Q3D$PZQ[BRW;A9/87+HHV7$G.21F8MJXD2%P:7C)4C.[*`#M
M*O0W6N2NAO(&R/?`S(QXC#J-H6`%P:<U`<HS5(V!7N[[4]KE[>2U2NM992<K
MD&V96S1(5]:^V1A,V2PY(H[;$>6;DSCV=B:R*T9)TJ<1B7?:Q08L@>IB0J*R
MI#C=N="T.Z<ZWN6!TDTDLQ;G<"YTC.:E>`'`T+'!AIR144H3540:OJUN!-`\
MAD;(X@<C2&M8[G(VDY:5#AF%<33A`5UM&"-M:T_+M[8QAVMHN:.(K@\;25\E
MXF<D&^U1XQ7QA:HML:P-'C5MC!V[0[8>-2D2,+@H/C*=:'&Y/I>BF5S;@-$\
MHB>07D.(M2#$X#,"!$2*D<?*K541:AJ@C:823$SG&BC`0/&`><:<*?E`#0'B
MY.Q3",V[X8B&U?9MJ+'+H53-%CW#UH)-U(RZD)F6VN[$_L-XCEY)XZ51>23N
MV2*@H`;M,@NAZ"10*0"Y#-(TZ,,:(@1'<NN&U).69Y<7/%2<27NPV8X#8K#]
M2OGESC(:O@$+J`"L3:`,-`,`&MQVX;5KSN+P_CS!^P#=Y1\7PCBM5!+;KN$D
MH^NFGK!-QD&,I0K9(N(NMMY^4E`KE=1>O%E&\:R%%BV%4_5)%Z0ZU&KZ=9Z9
MNIJ%M8M++?Q.X(;F<X-K&\T;F)RMJ31HHT5P"V6F7MS?[Q64]VX/F\9A!=0`
MFCVBKJ`9C3:XU)X2L/(;?,QY.QQM2R'B2\Q]$DX7EP6S$4'8G,]/LWU.RAD_
M'V&WF/KU'P3!LYC9)",3K4@T<N!Z#MGVTDNF58R*92:[YIU&]L[&[T^41/;H
M[XFNS.!9++'"8WAH%#3*X$[14$5H%G'4K*UNKRVO(S(QVIMD+:`AT;'R!["3
MB*Y@0-AH0:562K[MPSE>MD.Y3;]*V6&E[_E\^5&.-VU@M4M*PN/:7<9QHYIM
M'F+N^C7DQ-MJG'H*F.Y[66,'7@W3Z::1##FW6CZI=;LWNDR/:Z[N.=$>9Q+8
MV/<"QA>02X-%<:';08`+$M]3L+?7K746-<+:'FR^C0"]S0<SPT&@S'@J-E3B
M5'\L;4<R1+J@GVLSZ=%&1R<;-F>)RP9:ML?.W?(C_(&%96Q.73.-@)*%L0SN
M/*/+PH'5!LT:-%"-$FH).EU"6K_0=1C=%\QOYJL_/3N=*\.?(9(2XD!I#LT;
M'LQH`*-#:.)%RSU>Q>)/G9O.4BYJ("-I#6!DH;B2"*/<UW"2:DFH%;=7=J&X
MRIVAX]J60HFJ-GN5N8)=U+"E<[1.K"WW'PI$]NTRZK$LQ4;NY+%DT"9G;,RP
MIM0:@=!1;I]$*(=!UB"<NMYFQ@SW[\V=SO\`$#^[DM(Q,1VBN%*@E5R:OIDT
M0;-&7N$-FVF5H_,G\L,P.R0;#3&N-%!L@[4=ZEDV_P"(*;5\PRE?RM6XK,[J
M^RRV?;H+-2X6W&,=7<?*P]KA:C7I:<J4#DV//8464BV64C2N3DZQT/$FL6[T
M+>2;2K>W@N',OV-FSGGWTSNB#8Z/#&ES6R#G`UP.6M*NV*_;:QH<6HS3RPAU
MFXQ9!S+:Y6O)?5I<X!Q8<A+3RJ5H%D'*6UK<7-Y*SYD'&E]9U65R?8-M]BJL
MD-]LR#%!#%6-+)4[O2;U5F[-$%J;8+-*$?%&%D(]\FHH5X@<J[86[C+OM#UB
M2]N[NRE$<D[[=S3G=3\E&YCV/93N'..;D.:[\(&HH<>TU;3&6MO;749>R)LP
M<,C:_E'M<QS'>^:T4Y0(_!.!J+XN(>EWC!X!P]&I.#P[/1_VIJ]^I_9='C_[
M^&I?_P#D2/\`Y))_ZJ-0W_1+_P#FK/\`T[U_1%RFL]8+K7+CVC0-BS3B6!G(
MK%+-I*0TQD>G1LK&NTYB8ZUI(1[R91=LG20CP.FH0IR#V!`![&OD5?22Z(?6
M6VY>7_"?G5HG?[45")]9;;EY?\)^=6B=_M*A$^LMMR\O^$_.K1._VE0B?66V
MY>7_``GYU:)W^TJ$3ZRVW+R_X3\ZM$[_`&E0B_FBYP^8L06+FA<IN9@<LXPF
M8>%Q+S!6\S*QF0:B]C8=>1I^&"QJ,L^;S!VL:I)'1.5L"YR"X,F<$^D)3`'H
MGJMEBBWPA?*YK&<S+BX@#N#PF@7%^L".23=B5D;7.?SD>`!)[H<`Q7S]+>(_
M*UBKSDTGO[KZ?\?L/#P=(SOEX#XI>>!F^`[M+#NX2?QMD[!69<?P&3<+/+3=
M<3Y+IM3&8R=1&K%I8KG1I^IQ[I>15E7)HQL4TT)7"Z9#'!L90`*;I=$=?JTM
MG>Z7<6D4UL9Y()&-K(P`.>QS`:U-.ZQ/%59NFLN;74(+F2*<11S,<ZC'UHUX
M<<*8[,!QT7/W&N'[?CW<3A/*4'FC!-7JL'C+:#C;,S.!W!5!`+E#X1PMFRB7
M^/EZVT=H1UT:^%UQK;F(4=B"PMXY0Y#-S)E(IR=EIUQ::Q;7T5S:L@;!:1S!
ML[>6(89F2`M&#QG?&65QHT[*`'H[J^@N=,GM)(+A\SI;A\1,+N2998GL(=M;
MR6O#J<+AMX)36:EFUSAVE4_(6\&KN<@GW)4&R9:M5:W75R)":PQ!&L,=D%3'
MLM$)0=@JQ,B1#UDX&O++*@R?I',W6;`5/C>@M]3=IT5O=Z@PW?CD;I7-NFBL
M+<PDYLC*YO.`M/-DFCA@6X*S+-8"]DFMK)PMO%7MC:ZW<:2FA9G!JUV0@C.-
MHV@K%6=)[/\`CRN[K[JSW%P3JD2=<I\!A:"I&YU*\9&92,?N9J[B/L+9JP38
M2\,^E<+R+EG("T$YFK9$Z3H[OJ^W%,'5)=6LX;^Y;>--LYC&PM9<YY`1<M(<
M*4()A):ZFP"CLU,QS+!FFW,MG`;9PG#G&4N@RL(,#JMQJ"!*`17:<13N5-AI
M^Y&/89O6@=VF&TINRXE=5K$2LQN/@9=Y77C?=A>,FQ%+E+.LY>2B3H=NLTRJ
MOA.4SA=%SV>"@-R.3Y/BVLL;<F*_M^<?`6Q5N&DM/C3Y`PNQ/^'<(N<Q(/6J
M;'/Z6YT`DLY^;;,'24A(S#Q=D9<&[*<\#)S>`(Z]!F@JF4(*XT"P5C<[CV7A
M('!5EIT_6\C[AZ+-`MD9Y&7=S3;,G)5M6N(2EBKLY.QC*3=/F#QE*1D>DND+
M9ZT*=YLO[]%<1307L3HF6KF.;)<,/Y0A^1U6Y:N:YS0XN:0YK01E<VKL#^Z2
M0R1RVL@D=<-<',A>.0"W,VCLU&N`<6@$%KB0:M/)P%(;:8MUD7(\;#9:V_5O
M&UCW![#LI53(`YGI;FYU^J[0<?0M<M(L*\U<]LM[W?Y"&49M5!=D;$8R#A5R
MITO[G4U+]%8Z\F9'/:,LWW=C*V3GF9VMM(VM=1H.#Y""!C3*XDG@.Q;JKA;1
M.DAN'W3;:[C<SFG92ZX>7-J[WC`:G"M0`!PCSN&-]Q)L`52+I.\BKDSV[E]Q
M9\BR,QO+#N(5A=*AEN`P.K5Y4\BY08-,>2=@K;QPV1;)J`X8=<4RJJ72.N++
M6/FF..VU%GSJ77'.$W?)H]DK8,IJ:",NC)``Q;7$C&8;K3/G![I[)_S>&PY`
M+;&K71F7,*8EX#P"3L-,`5^V6]WJS[HLF55MG?(4+`/Z-,U>CV6L9UQ3&X[@
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M@`',UHP&:E2*@K=KZ6\1^5K%7G)I/?W72^/V'AX.D9WRT7BEYX&;X#NTN=F\
M;)&-GVZOE=.V.2,>/6<3N0RTZEG;*]51VTB6JV"YMNBZE7+>740C6RS@P)D4
M7,0AE!`H")AX:Y'>&\LW:[H;FS0EK;R4DA[2`.8=B<<!UUTNB6URW2-6#HI`
MXVL=`6.!/Y4;,,?<705EDG"<:\E)"/R;B%B^FW*+V8=-,B4ANK)O4&2,:D]>
MBE.E!P\+'-DD!5,'6&12(0PB4A0#K&WFFL<Y[)K<.<:DB1F)I2IY6VE!7B`X
MESCK:^<T-=%,6M%!R'X"M:##CQ5Q^F#%'`H?2]B[@0!*0/I+I?`I3!T3%*'=
MW@!1#L"'ZH:K^<+'RB#I&=\J/$[OP,OP'=I/I@Q1^#Z7\7?_`$__`.9E+_\`
MM.PI_P#/O_IA^']?]73YPL?*(.D9WRGQ.[\#+\!W:5CL]YP1=(&0J]LR/B*?
MKLJ1NG(1$ADJGG:.BM'+=XT$P)6%)4BC5VS252.0Q3IJ)E$H@(!JU-<Z7<Q&
M">:W?"[:#(RAH01^%P$`CK*N*"_@D$L,4S91L(8ZN.!_!XBO"K7#;_1XP8:H
M9`PY78L[Z1E%FD9D6F)%<RDPX.ZEI1XL>P*.7LE*.5!.X76.=58P_C&'L:B"
MXTJV9S=O+;L94F@D9M.))Y6))VDXE3-#J$[\\T<[GT`Q8[8-@&&`'``I$.7\
M3B4"#E[%HD#H\"CDNEB4.B`@7@49W@'1`P\/UN.KWSA8^40=(SOE;\3N_`R_
M`=VE]%S%BHH%`N8,7E`@"!0+DRF`!0$>D(%X3W8`3=G_`-NGSA8C_P"XAZ1G
M?*/$[OP,OP'=I?HYBQ4(B(Y@Q>(CT>(CDVF"(]'CT>(]WNST>(\/UN.GSA8^
M40](SOD\3N_`R_`=VE\_3!B@.'#+V+@Z("!>&2Z6'1`2`F(!_P!_=@!('1_]
MG8_!I\X6/E$'2,[Y3XG=^!E^`[M+]#,.*0*4@9?Q>!""`D*&3*9T2B4>)1*7
MN]P*)1'L</P:?.%CL\8AI^D9WRCQ.[\#+\!W:7Y],&*/*_B[L&`P?_>72_[(
M#"<#?X^_"!C"/']<>.GSA8^40=(SOD\3N_`R_`=VE%T[5M[2M,U=TL@8A);K
M%!Q]:FI\N3JJ#]_!12KM>/CC#X3=0W3;K/5#=-$B:QQ$O3.;JT^C8$^DB=UR
M);?GWM#7.YQM2T5H.ZZO!CV`KW-:B8FP&.;F6N+@,CJ`G:>YZG#@N>N_V[8G
M1EN6_%U:\XQ+$5KF%X(4%A7KC4%(^O0$=6+XAVPNA'2AT(F'9%,0IEE`313$
MP=(P"(<>1WKN;`2:.R"6'FV:O!@U[*-:&OXC@!Q[%TF[L%X6:F^6.7._39<2
MUU22YG&,25TP'+>(^(__`'M8J_"/_P#,FD]_==IX_8>'@Z1G?+EO%+SP,WP'
M=I?GTMXC\K6*O.32>_NGC]AX>#I&=\GBEYX&;X#NTGTMXC\K6*O.32>_NGC]
MAX>#I&=\GBEYX&;X#NTGTMXC\K6*O.32>_NGC]AX>#I&=\GBEYX&;X#NTGTM
MXC\K6*O.32>_NGC]AX>#I&=\GBEYX&;X#NTGTMXC\K6*O.32>_NGC]AX>#I&
M=\GBEYX&;X#NTN=.P[)&-H_*/,H6D<D8\CT93?O=)&+5?WJJ,DI2./C?'R1)
M&,4=2Z1)"/.JD8A5T1.D)BB`&X@(:X_=:\LV7VLE\T(#M5>15[14<W'B,<1U
M1@NEW@MKEUII8;%(2-.:#1CC0YWX&@P/4*Z#NLCX2>NXJ0>9,Q`Y?P3E=Y"O
ME<AT<SN*=.FBK!VJP<]W`6;"[9+&26`H@55,>!P$`#AUKKS37N:]TUN7--0>
M<94$BAH<W",#QKG!;WS6EK8I@UPH1D?0XUQPXU<_IAQ3QX_2_B[CTQ5X_292
M^/6&#@93CW>_LS!^$?PCJY\X6/E$'2,[Y4>)W?@9?@.[2?3#BD#"8,P8O`P]
M#B;Z3*9TAZO_`+/B/=[B/0X=C];3YPL?*(>D9WR>)W?@9?@.[2_0S%BHO'HY
M@Q>'$I2CPR;3`XE(`@4H\)[^Q*`\`#]33YPL?*(>D9WR>)W?@9?@.[2^1R_B
M<Q0(.7L6B0.CP*.2Z6)0Z/'H\"C.\/Q>D/#];CJ/G"P\H@Z1G?*?$[OP,OP'
M=I?I<PXI*("7+^+BB`<`$N3*6`@'`I>`"$]V`X%`/_8`:GYPL?*(.D9WRCQ.
M[\#+\!W:0,PXI`0,&8,7@8!.8#!DRF<0,IV%!`>[W$!.`=G]?]73YPL=OC$'
M2,[Y/$[OP,OP'=I1BU6W;]>(]E$V[(6(9^,CIV)L[)B^R94P;H3\$Y[<B9+H
MMK(W%55HXXCT#B9%4HB50AR")1L3W&E73!'<2V[V!P<`9&]TW$'NN#L'A!"O
M0Q:C;N+X8YFO+2TD,=L.!'<\/_P4E^E_$X&,<,NXL`QNETC!DJE`)@/_`&0"
M(3O9`WZNKWSA8>40=(SOE:\3N_`R_`=VE^_3!BCB(_2]B[B8"E,/TETOB)2<
M!(`CW>[($$H</UN&I^<+'RB#I&=\GB=WX&7X#NTOQ;+V)W!%4ULOXP.19(Z"
MH#D^G%,9)0!`Y.F2P%4*`\>/$!`0'LAP'LZ'4+$[;B'I&=\@L[L8B&7HW=I4
M$=DG"</'L8F(R9A^+BHQH@QCHV/R#1&C%BR;)@DW:M&R,T1)!!%,H`4I0`-4
M,O--C8(XYK=K&B@`>P``<`%54ZVOGN+WQ3%Y-22Q]2>PM!=MN2L:M=^',PD'
M62<=M8^4D=G(Q4@YO=4;L)0&6!WS=Z,8]6ER-9$&3@>K6ZDY^J4_%/P-V-<K
MH]Y9MWIUE[IH0QQM*'.VAI`:T-<:<--BZ+5+:Z.[^EM$4I<!<U&1U1644J*8
M5X*KH/\`2WB/RM8J\Y-)[^ZZSQ^P\/!TC.^7-^*7G@9O@.[2?2WB/RM8J\Y-
M)[^Z>/V'AX.D9WR>*7G@9O@.[2U5S5,S]MS7@&PX]W+8YKN(:L-@-E.`@\Y4
M2K33B>\):+/56QK-G:<_'WBMC!U^7@I&'5ZA3M:9.JB<JG!9'1:E)-<:E:36
MEY"S3V9N=:V9C3FS,<UU#F#VY6O8YF&#Z@UQ&WL61PV%S%<VLCKU].;)B>X4
MRO#F\!8ZI:\.QQ;0\1TI^K<W3DJ_,(9!V]]TXK/?,3R@N^6W!U=PY/$;DJ7;
MXO`BQU'4FN+Z7K-EG6Z[U-7I!%F*LLD=<YS`IS?S,`]D@EM,[;K4):\^VM+A
MCQ!M.):YP+J]SB16N.]^=.0Z/F[G*;>S93F74K`YIEX,`YH('OL`:<&20BL[
M,8H$_K'XRF9*&VFX@I%%3A-W=>H$9!YVK-'EZIEU.X,T8F=9W*(ODV_:34=/
M@DD\8KQY$^"!>`FS>;U5L=/'('/;81,9ENFQAL[6%LN<4<'A[B'MDH"TM`P6
M+GTYSZ^+2M:Z\D<^MN7DQ.>'1Y34%I8`6N9L(/"O6DM,MP2>&3YJW04NQT*A
MPF=C900Q]ND:QEU2>+9B<7?%=J:N(E-]-Y5C4,)I'JRM>4X2#910HMU5%C`N
M1;-U"(6QU*]C?:Q-GYWF[D!]>>+XG"E72CF?R1C[H<!)Q$3NLI#/XC:/;<2.
MBYO/!5OYO)(W&@C/._E,^P\(`P63L1+N)+9C<:%<MTM)MV5+]C7)%/J&0K)E
MA*O3:D*X@I^GX9M5E2DY].R5>ZRU;"-E[&JFBW=]U7*YS)]80`UFZ>7/W<DM
M+F^CDOI89&,D=+E=3*YD+G5=F:\MROD(`.8G"JQ;VC-<9<0VDC+2.5CG,;'4
M5J'2M;097-#LS68D90,5K]9,39*E,:W^N0>YJDUV39[1=NN+L*UAGN^:)TN%
MS?3XF<A,R6*S1X2RS"0CI1D[8F8/'"3H%56A3@@F9-,PZJ;3[U]G+#%>QLD&
MGV\4+1=C()F!S9G.%:$$%N4D'9L%`MC'>VK+J.62U>YAO)I)7&WY1B<08PTT
MJ""#4"E*[3BJO<12LUYBL&[.$C\^8/\`H?S#@S+F,\?4Z=W.UAY&>$UD;8=/
MCV>E:\HU3CZFTB7$-:D5"-NV5FQ'G2.L[!R`(SJ]KJ>HRW\3+JV^;KBUECC8
MZY:1F<(>;<6THT`B485(KM=7"--N+"RCLY'6\_CD%Q&][A`X'*WG,X!K5U:Q
MG&@--C:8[CXRM]6CMP.X"YO,K8RCL>V*F[?*M!1R^2:61*7R%0J]<4,A6Q@@
M:<+Q9C%3D'#"[`H%>J1)@*)B-RF'HK*X@9JUW<NGA%H^.!K1SC,9&-?SCARM
ME',97AR=1:2ZAE=IMM`(93<M?,XG([!CRW(TX;:ASJ<&;JK9/Z6\1^5K%7G)
MI/?W6Y\?L/#P=(SOEJ_%+SP,WP'=I/I;Q'Y6L5><FD]_=/'[#P\'2,[Y/%+S
MP,WP'=I<[,=9(QLES4MTLNKDC'B40[V=;<6+274O543B7;YK=[>HZ9-9(\N#
M%R]:IG*95(BAE$RF`3``"&N0M+RS&_5](9H>;.G6X!SMH2'OJ`:T)'"%TMU;
M7)W2M&"*3.+V8D9'5`+6XD4K1=$_I;Q'Y6L5><FD]_==?X_8>'@Z1G?+FO%+
MSP,WP'=I:?9_AZ7DC.FTW(=<R#@9U7,/VK.,YDHTEE>@1\G),\C8)FL4U]*.
M:FD%AG7"3Z02*XZU1($6*8]$3"!4]<]JL5O>:I87<,MJ8;>28R5E8"1)`Z)M
M!7E8D5J11O86ZTY\UM87EM+'<"69D092-Y`+)1(:X88##C*USHU$S!2*KC=X
MKNCI-NR-';.<U4+)#VR[OXJ0"1W,6KZ-$,=352GI<)P*W5XMI2W@B^;,2@S<
M/!6%JJJJJ<NGM;74;:"%QOHY+P:=,R0NNP:W+N;YLL<:Y6@,/*#<":Y225L[
MBYLIYI6BT>RU-[$]@;;D4@;GSAP%,SCF&!.(%*@`*[8DK5MK%]Q'DG/V9\*W
MYIBRG[Y:W8!;YQK-WL#^H9QNM"L>)ZC"-'C@9.<;Q]7JKB*6;K*J*-O[G2*=
M<@](ERP@N(+JWO-5N;:5L$=ZUWY9KW%DSXW1,:#BZC6EA%:C`8C91>2PRV\U
MKIT$\;IGVKA^2+0'1->V1QX!5S@X$;<3@MPML%MK]`VXX,H^4,SXMD,AU+%M
M/@;@X4RI27ZJ<S'Q*"*L>M(!/J!(+PZ`)LSK@8P+';B<#&`W$>AT2>*TT>UM
M;ZY@-Y'`QK_RK#B!LKFQILKPTJM+JL4EQJ=Q<6D$HMGRN+?R;A@3MI3"NVG!
M51C>QE#%S_9INT8L,H8T?OGFVO-S5DQ8Y`J#QZ\=.,<6))NU9M&TRJX=.7"I
M@*FFF4QSF$``!$>&K&\M[9.W=OVMGA+C93``2,))YMV`%<3U%=T*UNFZY9N=
M%*&BZBJ2QP`Y8VFBF.VG*F*VNVW;LU=93QBU=-L#8<;NFKK(=.;N6SA#'-;2
M7;N6ZTT19NX05*)3D.4#$,`@(`(<-9.C7UBW1[-KIX0X6L-1SC,/R;>JK&J6
MEV=4N2(I2#<2?@.]^>HLU_2WB/RM8J\Y-)[^ZV7C]AX>#I&=\L'Q2\\#-\!W
M:3Z6\1^5K%7G)I/?W3Q^P\/!TC.^3Q2\\#-\!W:3Z6\1^5K%7G)I/?W3Q^P\
M/!TC.^3Q2\\#-\!W:3Z6\1^5K%7G)I/?W3Q^P\/!TC.^3Q2\\#-\!W:3Z6\1
M^5K%7G)I/?W3Q^P\/!TC.^3Q2\\#-\!W:7/A;(^-QYL4=-!D?'@PA.7%-11Y
MH+S51AR2JFYZ!>)Q1I4)?M`LHHS2,L5N*G7&2*)P+T0$=<<^\L_K!CDYZ+F_
MF605SMI7QJ,TK6E:8TVTQ73MMKGT,>SFI,_SHPTR.K3Q=^-*5IU=BV(V3\OS
M8KDK:=@N_P"0]GVW2[WFWU%].6NWVC%56F+%8YEW:['VS*S,J\8J.G[]P!`Z
M:JAA,;@''7AFFV-E)80ODBC+S&"26BI7U%#%$86DM:21Q+:+T8W+C^PMM6\S
M-.[W:S?FW3_`Q?!"N<S#[UO83T8W+C^PMM6\S-.[W:?-NG^!B^"$YF'WK>PG
MHQN7']A;:MYF:=WNT^;=/\#%\$)S,/O6]A/1C<N/["VU;S,T[O=I\VZ?X&+X
M(3F8?>M[">C&Y<?V%MJWF9IW>[3YMT_P,7P0G,P^];V%H7D'E_[&8[FN<N3&
M,=LZVZ$QU?\`"V^B;N^.V^+ZHUJEXF:/1:2_ICNQQ0L>Y\B]KKYVJ=BLN0W:
MJBQC%X<1US&\5O!;NA$#&LKFK04KL6#>,8PMR`#;L]Q;O,=OO)C7QOMLR/)\
MO+:37$=RBV-G,56YS$N)T9K'E8R?!VN?@[C?W#=NO#,(5LUISPBO5N!,LJDJ
M#<50;KB3FUA*\$V[\C$,GIXV?;0MB$2A(U*+L-;O,IC+&+*J62<<W3)-%G<?
MH*NH]%Q#7.H36+I`C]M(@U'K#D03`RX&3T19`C=F_(WF9Z"J\5M>V`/[)9I8
ML#!P3;$M$/*/9Q2R2=-3AU&@PX*QTFK;X9U%$0=@@H>12[7*`JG3(<B^)?9Y
MR,X!@[E)G;!L`CF#%ZWCW"ZV)*,<1<O*_8[8Q[5;H0JSJ1:2-8I\N_:N6Q%F
MKIK%NU$5#E;+=`BFT?R\^3A+VYG0HK9OL3DKI)0*EHC:RQQ+CMU*25=08P,H
MXEXY)&/.F_:MHJU1;M7JC'.DTDFJYRE272.8BR!Z)SE?>KWV@>8NC]Z]$3T3
MG*^]7OM`\Q='[UZ(GHG.5]ZO?:!YBZ/WKT1/1.<K[U>^T#S%T?O7HB>B<Y7W
MJ]]H'F+H_>O1$]$YROO5[[0/,71^]>B)Z)SE?>KWV@>8NC]Z]$3T3G*^]7OM
M`\Q='[UZ(GHG.5]ZO?:!YBZ/WKT1/1.<K[U>^T#S%T?O7HB>B<Y7WJ]]H'F+
MH_>O1$]$YROO5[[0/,71^]>B)Z)SE?>KWV@>8NC]Z]$3T3G*^]7OM`\Q='[U
MZ(GHG.5]ZO?:!YBZ/WKT1/1.<K[U>^T#S%T?O7HB>B<Y7WJ]]H'F+H_>O1$]
M$YROO5[[0/,71^]>B)Z)SE?>KWV@>8NC]Z]$3T3G*^]7OM`\Q='[UZ(GHG.5
M]ZO?:!YBZ/WKT1/1.<K[U>^T#S%T?O7HB>B<Y7WJ]]H'F+H_>O1$]$YROO5[
M[0/,71^]>B)Z)SE?>KWV@>8NC]Z]$3T3G*^]7OM`\Q='[UZ(GHG.5]ZO?:!Y
MBZ/WKT1/1.<K[U>^T#S%T?O7HB>B<Y7WJ]]H'F+H_>O1$]$YROO5[[0/,71^
M]>B)Z)SE?>KWV@>8NC]Z]$3T3G*^]7OM`\Q='[UZ(GHG.5]ZO?:!YBZ/WKT1
M/1.<K[U>^T#S%T?O7HB>B<Y7WJ]]H'F+H_>O1$]$YROO5[[0/,71^]>B)Z)S
ME?>KWV@>8NC]Z]$3T3G*^]7OM`\Q='[UZ(GHG.5]ZO?:!YBZ/WKT1/1.<K[U
M>^T#S%T?O7HB>B<Y7WJ]]H'F+H_>O1$]$YROO5[[0/,71^]>B)Z)SE?>KWV@
M>8NC]Z]$3T3G*^]7OM`\Q='[UZ(GHG.5]ZO?:!YBZ/WKT1/1.<K[U>^T#S%T
M?O7HB>B<Y7WJ]]H'F+H_>O1$]$YROO5[[0/,71^]>B)Z)SE?>KWV@>8NC]Z]
M$3T3G*^]7OM`\Q='[UZ(GHG.5]ZO?:!YBZ/WKT1/1.<K[U>^T#S%T?O7HB>B
M<Y7WJ]]H'F+H_>O1$]$YROO5[[0/,71^]>B)Z)SE?>KWV@>8NC]Z]$3T3G*^
M]7OM`\Q='[UZ(GHG.5]ZO?:!YBZ/WKT1/1.<K[U>^T#S%T?O7HB>B<Y7WJ]]
MH'F+H_>O1%J5O\Y8W+DHNQ+>E=Z7L6VK52XT_:EN!M%3M,!ABFQD[6[)`XKM
M$G"3T+)-HXCF/EHF1;)KMUTQ`Z2I"F*("`:(ML]N_++Y0-6V`8%S_G/8YLO8
M0T)M#Q1EC+62KA@G'KHR#1KAVOVNZW*R2:U><OGBX@#AXZ5'K%ECB8?QCF[)
M*K/U'Y7G)GOT0]F8GET;1(MM&S3*O/4;;M;I=0=)R\G$PLY&-VJ=BJ4>27;R
MD78F2K9TR,Y:.!6ZM-4RA%"$*:J5O>4=R<8U&6<R.P/8E'MX"/?2TZX>X0Q&
MU1A8N,3%62DI95>&3)'1\>D`F766$B:1>R<0#1*K#V.-A'(?RYD&?QACC9-L
M7MEOKN.<5Y<=-8O;M0%(R1QQFMO;G6-+97+`>JD@K/&61O194X=SW#A1L5KQ
M7*F"B0G)59K/R@.3\FDHNIR]]CA$47;A@LL?!&*2I)/VA5#NF2BAH0"$=MB)
M'%1,1`Y`*(B`<!T2J]VW)VY1#Q9PW:<N_9&Z<-"MCND&V`\6KK-B/4NO9G<)
M)01CHE=H?CI"8`!0G9+Q#1*KD^[Y8/+I3Y[L#@9/9!M>)A9YRDK;EQUBLN%Z
M*%"<Y1CMXM*IL?D!:KA#=R%+<RJ<JYCDGXI=LD9.%$@/T#"&BA5W+Q_V(-M'
M^KU;_2NRZ])TK]VP?HPMU!^99^*MR=9ZNIHB:(FB)HBYSY';KNN<URLV[85B
MK*X%YAR::C=(BRZ)CX\H!07224362.=$1Z0`<AB"(?C`(<0UR.]'=0=9_P#X
M5K[[:WW?Z%N]8>5IABST.MXSD[5G=.E0F.,/XTEHJ-L-=CUK?&X#:9!C\2V"
M;D4Z*=Y&VNKQV3Y9$[F(-&HO@,@=PBHHW(?7*K`4]O7+XQCE:M3E3RM-94R#
M%7.@5;'^132"U5K3N^(46_6+*%)LS\:'1ZHSKMIK5ZLJS]):%0CFZZJ#?KT5
M>K.*I%>T]D-=7EJI8;!>\O6NQ5AMBI!Q,RS?'D>K:5\09A-FRMOK%'57&M=A
M.VY&T]%O)"R:LP=,2=@".3'<F(K&UY>N*V$74(QE)92;C0ZU`T&JR0OX9Q+1
MV-:?0LY8YI%`6=NJJN62AZE7]PUC%NZ7(>37<"U,Y<K%;B10BR3A_:;7,)6R
M5L]1G,CNVDS`5*,=U&?"LOZXE/U/'U-Q=X<,'+>FLK;'SMAIE!BT9%FE*%@E
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M$2````:(MR-M-(<Y+Y9FW''C1Y7F"UVV2X1JPN+=38[(=4[7G,)56.=M[/0Y
M=TQC+C7GC1P=%[&KKHIO&RATC*$`W2`BYZY6Y':-IVP2FUO$.=VF$<<R&3\K
MY"KM4\#;GD^LX7B<BX6:XV:8[P$-NRVWL>.:3'WAFI;%F17KAL1U)NV;!-@U
MZ`:(LD2/)]&:W0;FMP\CFF%0:[FJCNXIEEK<;BX$Y)C$;I<'[8,/)MG<XYN2
MR-B88\=[;SS+9JY:@BZ<6)P3@@9$5G!%9\><G%]0]Q.U#/R>;:N=[MFH>T"B
M##Q.)%89Q9(_:]@K<_AB;0BIA.].%JQ%Y35W)C+.F@)NDFZT`@FIVUUXJ($7
MC2>2O!06WO%6`;OE:!R@QH6[_$^XJ\6>VX_L<LYSQ1\0+6-I#4?*M=L>4;+6
M'5TL]6G4XR>G(]LQCI9-J"CB)4.JIQ(MC]K/+MFMM^\C.FZ0V6Z[-5G+=-LE
M"@<057%ZM"AJ/75\S3F4:64'Z-YG6$W(UN*L;J*<+]SF@NC<%TBM4Q%J!%A%
M]_S&U9_F3KU_OU8[T1:1\O'_`&(-M'^KU;_2NRZ])TK]VP?HPMU!^99^*M*=
M^63-P=4W!Y9A<-WC,T._C.75+7O"55QZUGYF"L6[UIGZ.B<>0O@VVB9>O6:<
ML]</VC(1;Q-1!2!57<JD3*EVRECWTD[)W-A+P?%ZM`K0OS88;"2.#BKUU1*Y
MX>0TGN,.O7!3M/?7N5C*;NDL5MVYQ\=+[<[#3Z8_K,6PR!,V=JN_N]'K-HRJ
MY@H^,.WOF*$Z/9)&Y,%*^[!THRB56/`X@H[3K\=N`R1SXP#&0*8UV@$TX6T)
M<*'8*=53SKP#F;B.O_M3A7[=-Y^ZVG-]QTXRQ/BW(59VZ8EV\W5PYH5<S.^>
MY/F,V,G`6><QRG(IL5Y*CXB1:'G))J+4\NO&<&W[2KT7"A]W=,$A#6N;&UIP
M#N5FVD=1NT\-$,CQ7`$`#CX>+K+*L!NNSI(9UVZXCEL34QG!Y/PXTRG<,A,G
M>0753ES&M5L@9Z'Q3-FK)4>[55KD7"V)6-F4$EW<?-F*FJ4K4'#BZVYF,T<1
M:,KF9B<:;2#E-.`4-#P'J*H2.S!M!0BO_P`%F;:#F_(F>L8S=JRE0$<<V^"O
MTY3G</&(O5:Q)-(R+@9-E8:=87K]Z:W5F51FN*+X4V#A-0AVCQBS?-G*);MI
M-)/&72MRO#J=3@Q!X1V.(@$%51N+FU<*&JT8WLX%HFY3F@<LW%629K*$!47V
M%M^E@D)/#F0;-C"_)J56F8\FFJ,7;:@LA/H-W"K;HN&R)N#Q,12,`@;AKF]Z
M.Z@ZSO\`PK"OMK?=_H67VO+FY<CVC4K)+7-7,S5I>25<5HX_F?K3;MBEN2F;
M9A"OXO+7VAD@>O#6F:>-VY0%,IFIW*(N`1(H4P\JL!7K'W+-Y<659BMP>/=Q
M?,`M#VVXZE,K0*K+>MN80CG5)@KLIC:=>N)%^NT:QDM!WU!2)>1;HR,FV>I*
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MB][GRL@RDV0K)#QZIPBDL3\!B%'B&B*6^A%VA^5WF`??QSSWZT1/0B[0_*[S
M`/OXYY[]:(GH1=H?E=Y@'W\<\]^M$3T(NT/RN\P#[^.>>_6B)Z$7:'Y7>8!]
M_'//?K1$]"+M#\KO,`^_CGGOUHB>A%VA^5WF`??QSSWZT1/0B[0_*[S`/OXY
MY[]:(GH1=H?E=Y@'W\<\]^M$3T(NT/RN\P#[^.>>_6B)Z$7:'Y7>8!]_'//?
MK1$]"+M#\KO,`^_CGGOUHB>A%VA^5WF`??QSSWZT1/0B[0_*[S`/OXYY[]:(
MGH1=H?E=Y@'W\<\]^M$3T(NT/RN\P#[^.>>_6B)Z$7:'Y7>8!]_'//?K1$]"
M+M#\KO,`^_CGGOUHB>A%VA^5WF`??QSSWZT1/0B[0_*[S`/OXYY[]:(GH1=H
M?E=Y@'W\<\]^M$3T(NT/RN\P#[^.>>_6B)Z$7:'Y7>8!]_'//?K1$]"+M#\K
MO,`^_CGGOUHB>A%VA^5WF`??QSSWZT1/0B[0_*[S`/OXYY[]:(GH1=H?E=Y@
M'W\<\]^M$3T(NT/RN\P#[^.>>_6B)Z$7:'Y7>8!]_'//?K1$]"+M#\KO,`^_
MCGGOUHB>A%VA^5WF`??QSSWZT1/0B[0_*[S`/OXYY[]:(GH1=H?E=Y@'W\<\
M]^M$3T(NT/RN\P#[^.>>_6B)Z$7:'Y7>8!]_'//?K1$]"+M#\KO,`^_CGGOU
MHB>A%VA^5WF`??QSSWZT1/0B[0_*[S`/OXYY[]:(GH1=H?E=Y@'W\<\]^M$3
MT(NT/RN\P#[^.>>_6B)Z$7:'Y7>8!]_'//?K1$]"+M#\KO,`^_CGGOUHB>A%
MVA^5WF`??QSSWZT1/0B[0_*[S`/OXYY[]:(GH1=H?E=Y@'W\<\]^M$7/WFJ<
MLC".U+EY;IMQ.&<W;ZHG*.*J+"SU-D9W>OG&PQ#21>WVH0#A1]"NYU-M()&C
M)A<H$.8``Y@-^$H:(NPL!_1]]E,E`PDBOE[F`=<_B(UZM_\`CX;A?^U=,T5U
M/[&U$+_9J#^``#]8`T17?^KU;)/*]S`/OX;AO&S1$_J]6R3RO<P#[^&X;QLT
M1/ZO5LD\KW,`^_AN&\;-$4;M_(<Y>N/JU,7.^[B-[M)I]>:'D)^UV[F%YTK=
M:@V"9BE4?3$[,75G%QC-,QP`RJZI$R\0XCHBB$9R7>5Q-1K"9A]W^Z^4B)2Z
MQ^-8R4C^9?EMY'R&19=JT?1-!8O&^0E&[JZRC)^@LVBB&,^7263.1(Q3E$2*
M;5CD)<OZ[5^(ME,W`[X[=5;`R1DX&S5CF#YVGJ_-QS@.DWD(B9BKH[CI)DN7
MLD514.F8/P".B*^_U>K9)Y7N8!]_#<-XV:(G]7JV2>5[F`??PW#>-FB)_5ZM
MDGE>Y@'W\-PWC9HB?U>K9)Y7N8!]_#<-XV:(G]7JV2>5[F`??PW#>-FB*S6/
M^CL;#)FOSL/8,C[[K!`RL/)1TW`S.^//LE#S<2\9K-Y")E8][9G#-_'2+10Z
M*R*J9TU$SB4Q1`1#0;4.Q=C,68KKM!QAC>B520L\75J10*;3ZU&]WW;@6%?K
M%<C82&9F<+`99P=M',4R&4.(G4,`F,/$1U->LJ0*BN*GG@N3X>L_QTO[#2O4
M"FG73P7)\/6?XZ7]AI7J!*==/!<GP]9_CI?V&E>H$IUT\%R?#UG^.E_8:5Z@
M2G73P7)\/6?XZ7]AI7J!*==<67L&7^L4UEEW5G.`\E2\+=L]TU>W`Z.^C'I.
MJ!QT>D"(]+B)?U1`/UM*I1<S-H6>ZOC+;#R_<0]R9BVY6W!U:[Q>,Z7"JQK#
MMIACI6S6V^VJPSTTZ:15>J]7B#H%56.*JZ[QXW0014,H82>@Z?.V.QM8J$RR
M,P`Z@J2>(!;F%X$4;?PB%LUCO>M@"]X_J-Y7R"TQRWNM]R)BF.J>17C:N6@N
M6L32DS"Y)QN$<@[?,I:TUAS`.E#)L5W1';$@.6YE$3<0S8[R!\8?FRU<6T.!
MS-VCKCJ<&*N"1A`-:5-/="MF2][N'\2XOSAE&URPI,<!V?*E06K#"TT]];+K
M8L04EMD&W0U)BV5A<=ISR5<546&.E#1KYJ5'K':;=%1%4\27D44;Y7G",N%*
MBI+14TQVTX#0\:&1K6EQX*_<64&.Y?!KPLN*^8J)%OZC5F%XN47)VZ+0E*-!
MR2T6U4>V-$KHX,56,Q,M6#LI#'.C(.$FYP!99(A[@N(,:O:"!4X[.O\`>ZZG
M.WC&"UL@N95MXL%+M%D2DYJ,FH&KY]OCJC3[R"@7\C4MNF89'"%NLZMKFIF/
MQ]$1<W>(U0(I:4E&?3;`91QVN)3%UCMU"W<PNJ<P#C0T&#792:[-NRI5'/-(
MKPX_<-%LQ([BL&,#V8);,%#:+TJ>\$[@D\L;7MBL6H(^!EBU:9)TCG:V!:/M
M48J@S[*[DLBVZDJG7I=/(-Q"*U>W`T..PX8=?$=E5YV\)&"TJO,K&6SF[\J:
M;JLQ$3</9MMG,'D:W/Q[M*3@96/F<7X^6B99F^CU5$G\4[0<$5(HB<042'B4
M>R`ZY;>8AQ@<T@M(=0_!6#>XY2-E#_0M]JYL@L$#@7#F"R7"AH,\6R>TN3FK
M%&0E]1D,@.=L%R@K.+IT"UR$]47M+"#%FW)'GX,%':BYU''5HIARRP%F!UM4
MB&N26$_0K&YP[CN)VWO-O\'6L0D&F7&K]M9=B<L&LE6M`)2,3%D<.(P[1TB>
M/77==MKK'6ZPYN)%9KIM9L%JR)3<PH9$2;9-QYF6GVFJ3$BTEG\6IA.%I$IC
M6VXEG6*#YFZ=3.0:C;I]5[*HK(MB3<DF_!H86B20D6)Z]R^"U1"F2,+DU(;A
MB^ET7%&.Y5_6EU89OC+'V&<^80AT;-$(S":LI<75>W"R4@N[161;=T(YJ0J0
M(J+\2+)&)=E5>PY>:#.5NV.GM/QA-FNU1KDFR4--*7E3:[0MIJCF<GDW8H.:
MZ%"HO=`K=)L18)204`3]2BD42+/FWW&#["F#L4XADIME97N-J5$U!>P1S!Q%
M,YD8DJB1)!"-=NWSAB"Z8E$4S+*B4W'@80X:(LP:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HBY(\^+_A`[[/]5M;_`/5?'NB+^CNG?FC5O\W(
M3_)C71%(]$31$T1:1\R;`F0-TVPC=OMOQ4G!GR-G#!=]QE3ALTJI"5U"=MT.
MM$,G<W*HLI)=E&,SN>M6,FW74Z!!`I#&$`T1<M;SL)WS7[,F%EWQ6$CA'$>9
MMCF689&\Y[!Q;AL>`LJ9(N^X"ZVN`IV/XNKV^X7RG6RJUJIN5E#KQL91&Z9E
M&)%2E$BR!C39YS0ZIC7;C6FFX]C6[M3MB&0,%Y1?3=UE[?1V&XY]2LP,\9YQ
MJ+.,C(1].6BMWVPUQ25[N,)6+E81L4Z+>/D8I$9(BQ;FG93S=+;AB(KV-MQ]
MAJ5P:VS<W/0#1MN:R%#RM0A[9MDI-'P-7[9?V,0O)9+2KNYJ#E[F<'O;"4='
M2A&I"KD2%IHB_HLCNVPCV`2'`'X,FO;H`8AP!WU!.V>!TRE(8.NZ79*``/Z@
M:(JS1$T1-$5#*?XLD?\``7?\74U(VJ#L5)7?S?@OY&C/XDAJ$&P*\Z*4T1-$
M31$T1<3GW_,;5G^9.O7^_5CO1%RZV>X*J63-J^P?*3A[,5C*6!*O<9G%]Z@!
MC57T.C?5K34KS796*FX^4A+%5K7""D#EHY0$2.6C=PBHDJB!A]#T^%LEA;2X
MB6./DD=44(QP(*W$30Z)A_"`64IC8'B&0PW0L)0=ER148?'^9_K&Q%P@)>"6
MR0_W`GO3K(RF6I*S2]<D4S69U:I1\99%NV0CUF;Y1F+?M8J22>0;&(Q-A:7!
MK7YZBE<U:YJTVU]RF"K,32T-&`!K[O&HQDKEM85RBWR*,S<,JQ+_`"ED/<=D
M6Q3->EJLU=)I[K<30N&,QU&)0?5*2C&U6E:G6V*C`YT59"/?-P43<B0QTS4R
M:?#)FJ7`N<\FE/PVY7#9LH!3A!X5!A:ZNW$D]D4*M4URQ<(V.T9)MT[?\SRD
MQDFGMJ8L=S/U`B53CH?(>)LJU%S5"M:0W,BYIUZPU$NVA'@NVRY%'*3E)8BO
MXL'3H7.<YSGDN%-HPQ:X4PX"T?TIS+2223B.UVEZ/N65A&2K-\K+N]9?51R;
MBK<1B&ZR(S-/*_E:WN:SD?<-D%Z@1.EIL(V:8Y%<.#1:B*)4F[);J54U^@0P
M#IT):YI<_E->T[-CW9CP<>Q.9;0BIQ!'9-?OK(.7-@^"\Q264;#-JW&`MF6&
M>WX\]9:O+1K=6/M.VBQMK+C.^Q<%+PTQ5EK49Q%QS.6.]9.VTG&131JJD":7
M9N2V,,I<XU#G9:D<;#4'BKLKAB`%+HFNJ3M-/N+33=!ARV37,DY5.*,*Y\LF
MU&4KVW[?*C#Y=H-"Q?8I2LU^JT3'#B4CVM+MD`&-V<;.1S<Z*X)1[=!DD<1;
M)I`4H%YO>5H9XNP;`'#^SQ8+"O13*!Q'^A;BI8$W$KPS>Q(_T@W*ZM?=C7"L
MIQ+".Q@\0^-<7"K2H`QDBU86;[PK=H'2C.J.?M]4HD0ZPW8URZP5)(G:ENVG
MY2+A('GT9SG)B<JQ+U"1<-M^V12K^8I*CPD>G<8IJPJ3A:0JQY!4K<)!$#M.
MO,"?6=,>&B*@C=M&Z*9R#*8DB.?UF25RK!-#OYO&<;@G8T^R!#L4TX]91Y*T
MYK5E;#'M4T9=H8RBK<A2E=(B(@"I.D1?2.V3=*Y>TR.;<_?,SA_D<LD;'C-#
M`^QQ5S?"PX.C2HTU%.JF/9@CRL5Q5[3!;H`@IQ_L#\"*>_40WZ^NOW1_=9V=
M^(NB)]1#?KZZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^
M(NB)]1#?KZZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(
MNB)]1#?KZZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(N
MB)]1#?KZZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB
M)]1#?KZZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB)
M]1#?KZZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB)]
M1#?KZZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB)]1
M#?KZZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB)]1#
M?KZZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB)]1#?
MKZZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB)]1#?K
MZZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB)]1#?KZ
MZ_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB)]1#?KZZ
M_=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB)]1#?KZZ_
M=']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB)]1#?KZZ_=
M']UG9WXBZ(GU$-^OKK]T?W6=G?B+HB?40WZ^NOW1_=9V=^(NB)]1#?KZZ_='
M]UG9WXBZ(N;/.#V@[PL>\LW=Y=,A\U7<#G:DU['\`\L6(;;M[VR5&N7MFID>
MDM$XF6LM)J4?:XAN@[<)N@49+)JF4;E((]`Q@$B_LNJ,;81J=7$ME*4HUR#X
M!W$9C_\`*VO'_P"W_5'L_P#1HHH>-2#N98_E.7XD9^W:)0\:=S+'\IR_$C/V
M[1*'C3N98_E.7XD9^W:)0\:=S+%\IR_$C/V_1*'C3N98OE.7XD9^W:)0\:=S
M+'\IR_$C/V[1*'C3N98_E.7XD9^W:)0\:=S+'\IR_$C/V[1*'C3N98_E.7XD
M9^W:)0\:=S+'\IR_$C/V[1*'C3N98_E.7XD9^W:)0\:HY&-L(1[X3V4IR@S=
M"8O<1F'2*"!Q$O$%N(<0U(VH:TVJF@HZ?-!PQD[(5),T5'&33[C-#]606B(E
M)TQ6`3=`O8XC^'10*T"NO<RQ_*<OQ(S]NU"FAXT[F6/Y3E^)&?MVB4/&G<RQ
M_*<OQ(S]NT2AXT[F6/Y3E^)&?MVB4/&G<RQ_*<OQ(S]NT2AXUQ9>LIG^L55E
M'NX7MOT*MX.#SN6WX`B&^C'H"AVOUO5B)CB`]+CQ#APX=G4X)0\:T]Y>/^Q!
MMH_U>K?Z5V77I&E?NV#]&%NX/S+/Q5FO<#6W]RP5F"GQ9KZG(VS'5IK+-?%D
MA%Q62FJT]&+17;U$D)Q9O"M[1'D=BNT[;43;J*)@FH8I3"(94[2^![!FJ6D8
M;<>*N%56X5:0*UHN=V,\?;T*E);:X.?4>#4H#>-?%LOW3$5(C,6(99P:7;;(
MQ^/LBY*PM-.YXF-3GRPW;1<G&01TX]=PV))IMD^V$U2Z^-EXPQAW<B8YBT!N
M9N3`EN-.5@0,.%6FB0%H.S-C3"HIQ==?>()GF<@KLZ-E-[)+MLC0<U8-RBKS
M$>,B&Q1=H.XTAE'XMG8ZM2<$[B*1<L9,[`[2L3=9XX9V)VB8W2;HMV*LQ.U'
M\CSE>4*OY(P((Y)I3`BN/'U,$;SW)S<.W`8=17J4N7,A;-[*:-JAYI:*W/-2
M0!4:Q6H`U[VVRA)L5HMD$C%2I,;VZD&?,>N?R/=J'L'<XW4R4?VVIVM)?J&-
M!6DF&`%68]@C#$U!IM%<%9O^+[G]"ZKK`0%E02$#)@H<$S!T@`2`8>@(`;B8
M`$OZ_9ULU?7-?*I5E.<=RODVR15G*FWSF+)MD3*E0*LX4QM0R()&7,4Q4"J*
MF`!.("!0'CP[&N1WH[J#K/\`_"M??;6^[_0MLZKM;SW#;9MM^%5DTD;/B"7V
M-R-AG7.68V9819MMN0ZK9;N3%J:]&.6,8JQ5?568I/DS@^>F;$,D@1-50>56
M`LK5W:C8,5Y/KY<`RD5B_&]4VJ6+#57MLRF3)EEB;W9MQ+'-4]+2=*G7,2E9
MFEC2/)*.72DFW!*0?<4T`3(4H$69[%B*V62V62=96B$ILA]%T)0*I<F-5;2[
MWNM9+6A9<V6>3JR$G7^K5N+&M0L:B5.4*NBD190BQ3E((D6N&(]LF9J3BG9[
MBBQ2%4!_M[R`SR)9[K4E8B/I4I&,+3D@?HW+C:5AYN6DEB4ZYD"(EV[]AW(E
M%#."=$6_5N2+HMHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(N2//B_P"$#OL_U6UO_P!5\>Z(OZ.Z=^:-6_S<A/\`)C71%(]$31$T1<_^
M:ICK)F7.7)O.QCA>N3ULR]>\`9`K&,:_5U4VMAD;W*Q"K:L$B'RSM@C&ODI8
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M_BR1_P`!=_Q=34C:H.Q4E=_-^"_D:,_B2&H0;`KSHI31$T1-$31%Q.??\QM6
M?YDZ]?[]6.]$6D?+Q_V(-M'^KU;_`$KLNO2=*_=L'Z,+=0?F6?BK9+(^1*OB
MFGR5ZN*TDA7XIQ$M'2D3$/YM[VS.2[&"C$RLH]%4Z2"LG(I%6=+BBS9I"99R
MLB@0ZA<R21L3,[ZY1[NW!7"0!4[%K+'<P/:[,6#!E;B[=9G[O<;5L3W+%4@W
MH-I-!R<#F^U3%'QHM.2QF)4*P[L%Q@G$:+=X":J#CHB<`3-U@8POK8N8T$UD
M#2W`THXT%>*I%%1SK"0!P[/=6/X[F"U:XY:NN/<:5IO:JW$8QHMKHM^D7\I7
MHZ^7.U;F;MMGFH%DW>11B&IM5GJ'(R"DVBH8%FK)P)402(192@7S7RN9&*M#
M00=E27EE.L*$U4<Z"X@;*?TT4U)S$=J[RLQ=L@[/=K.PL%QQM2*Q$UC&5RL%
MOLLKF>C3N2<./(.I14<YFY&%RC3*V[=0[I-(2JG3ZE4$5>)0K\?MBT/!)!(`
MH"22X$MH/]X#!3SK*5ZOW]BW5:."O&C1X1-PB1XU;.R(O&ZC1XB1T@FN1%XT
M6`JS1VD53HJI'`#IJ`)3``@.LL8BJN+CWO29;E'_`#2.6(VVE6'"M6S:;#^^
MP\',[@H"X6;&"$*G4<<FLR4K$41_&V-:1<1`'*R.DL5--P)3*`).(:Y+>CNH
M.L[_`,*U]]M;[O\`0MVQJ'/^*`";-W*7*`B<`$<)[I0`13-T#@'&Y=D2&#@/
MZPZY58"^?!/G]C^#./*4'@/`>&%=T@\![`\!_P#.?8'@.B)X)<_S@(_3ARE>
M`?A'Z%=TG8[/#Y9_KZ(G@ES^_P`/TX<I40'L@(85W2"`A^N`^&?`0T1/!+G]
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MBN<Y)GRUMV[K<7EGEP3^$$:#`FR+#X<Q7N"@LGOX8<BTLK=&G2]MM#^ML)(L
MN9L8YW:*B8MRJ%`.F)1`B_M/J*EK\$ZOT&M>$O@Y!\.D_D@'CW+:\>P$:/8X
M_@_Z-3AU5&*D/66[\EKGQA)][=.3U4Q3K+=^2USXPD^]NG)ZJ8IUEN_):Y\8
M2?>W3D]5,4ZRW?DM<^,)/O;IR>JF*=9;OR6N?&$GWMTY/53%.LMWY+7/C"3[
MVZ<GJIBG66[\EKGQA)][=.3U4Q3K+=^2USXPD^]NG)ZJ8IUEN_):Y\82?>W3
MD]5,4ZRW?DM<^,)/O;IR>JF*=9;OR6N?&$GWMTY/53%4<B>U]SWW3:UT"=IN
MNF)7\D)@+U!^D)0&-`!-P_!V0U(I7A0UHJ:!/:NX<-U+6OBEW*CNJ%1])%4%
M/M-'H"<I8XQ0.)>'$`$0X_JZC#JH*T5UZRW?DM<^,)/O;IR>JF*=9;OR6N?&
M$GWMTY/53%.LMWY+7/C"3[VZ<GJIBG66[\EKGQA)][=.3U4Q3K+=^2USXPD^
M]NG)ZJ8KBP]/8?ZQ761[7ANWO0IW@`)VV][4ZCZ]&/>D85>TNNZWI\.`=#AP
MX]G]33!,5IYR\?\`8@VT?ZO5O]*[+KTC2OW;!^C"W<'YEGXJS/D"N87SVRLN
M#[J^@+F>#?T>UV_'\9<G4=9H%S#3\?;Z+)V!G59N-L\,R<3<&BY;`N9)N_(B
M8@@JETRZR9&PS@POH:4)%<1C45H:C$>ZJSE=R2L71FQ?:Q#O,6/XO%96;K"4
M-C:NXM53N-_,%2A<07:5R-C2/;IGM!TGZ52NDVZ?-Q>%<&.97JU141*1,ML6
M5L"TAN+``,3AE-1P\!-5'-LPPV;/<5YI6S7;7CF]$R33,7,X2V(#*@S<%L%N
M?0T8VF[)?KC(1L559.>>5:+AU+9E&PR2;1!FFW0>2RZB1"?B`666EO&_G&-H
M[KGA).RM-KB=G"@C8TU`Q_V[:^:ULRVSTY*K(UC%4?#EI-_Q_D^J&:S=KZZ%
MMN)ZK)4;%RS5=2=47/`X]ITRZC8B(4,I$LVJYRD;\3";1MG;LIE;2C@X8G:T
M4'#L`P`V((V#8-AKV-BV='C^$?U?_P"NLE5KFMEPA%><-RQ4E&YWA%=NW,<2
M.T30%T=V53&5%(+4C8I3BX.X`W0!,`'IB;AP[.N1WH[J#K/_`/"M??;6^[_0
MLZXHPUN3VY[/ZM9L=H91=;@,B8LVY4RTXOC*M7'++$]@Q7AFWP;Z;D*K9I:<
M:2=EM=X68M;9.H',M(D1CQ$B#5!=X7E5@*91,YOQ(%[4K.-%JO+VV1LUPK3L
MU"ID6C.9>&A[4QJ\#E)L`+*IXTGW1L@1CZ>(H$FW5B&Z1G9>H8@X(L6JY'SE
MN%R@Q;,_""ZUS&F>;]+P#.#QU!.ZPWK\'!;OL<-[NRL;)!RS?5A[%6:CP2L!
M+.I!XYER/7BA005.DW(I*VF]^=&P'<DZK1\KK977>8]4H<`SI&-W=1J$9'[$
M:<]3J4!6E2-F</3D-TE??PKUHW#BQ=K))F708KG<"19K=7+=])9`GI!G"99K
MV*Y#)4?3"0Y\>T1[=JSCEC6+H[GLU5T[F)6:22L]E>3KL-%5\QI1TTID4\EG
M@=N/1*T(JC"%CWRN<NT=+.4:\;U)\@,/D&+@Z=4T,>0KXFUW$UH<S]>M+)J:
MT+)&W)GLT.@91ZX;=2)T.@=)-LYT1=#]$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1<D>?%_P@=]G^JVM_^J^/=$7]'=._-&K?YN0G^3&NB*1Z
M(FB)HBX0;X+SF]YO[LN%:QG;-F&,2VCEJ2LPTL>.G3IK%4;/<UO`Q+0(#($&
MY<Q3V`6R/#8[GY-1".<G41=L$U3K-S)$,J0BP#/Y?YG]?QC:&&0G44PW(8'S
MQ]']YK5AN=_Q+A3?+C#'.W-5^TR3@/,%1K]@C=M]KRAX8QMG:QT@V6A'-XAW
MT`^`Z:94!(O+*>X3.:^[1VTM>3-QF&,$I\KO;3FB4@Y^Y62HY'HV?)V6S8YD
M(=I6:94)&LY$SI,2D/3X.UULAT4&[)XNZ;M@,H50I%@7:=F7?;G7`]SQ=EG<
M#G[;=E;)^QKES2&%[98G$E:9:?S7DRQM*_F+='6,A/ZG'-Z:NC<K&TK-SQ6\
M254A%8A5_P!!)L^(L)%NGR_]Q6]S,F_*A?6E8Y,Q3&VSE@5B\6C;M*L#L<?T
M;<-5\_N,7W2?*Y:QJ;1S:[TW@'\ZQ:KNSN&]7DH_B@0Q#G$B_H)T1-$31%0R
MG^+)'_`7?\74U(VJ#L5)7?S?@OY&C/XDAJ$&P*\Z*4T1-$31$T1<3GW_`#&U
M9_F3KU_OU8[T1:1\O'_8@VT?ZO5O]*[+KTG2OW;!^C"W4'YEGXJU.SUM&W7V
MG<AN(RQARQMJ3!9BG]E#=*7KF6Y?']NE:'@&F9I@LJ5^87@&B,@S:S\CD"+%
M@@5P8')&RISF0,FGTK,]K<NGDEA.4/,>(=0T:'9AAQU%%0Z-Y>7-P!IP\55)
M/H`WW/8:IM+)E*1E)B*V&UW&S:6K6<YNG&K^\F(QWD2J7.[7!FRK*B&5ZMDJ
M:MD/(H2YSM'\-(UUNY(1,>F5:KF+T@9G5(@`P<122A!)PY0)(-=H(!4Y9:8G
M'+Q\/]:E6)]N.[&B9DP[-6+-5]M>**_@:F%N\7,9MD[#)K;C&\3=VV72V5E:
M*O.&N^/,BR=FBW,2LT78J5Y>OH=0DDWZ:+BJ*WNF3,+GN,08*\JO+QS5J,0:
MBG%12UCPX5)R@<?#PK#5!VZ<R9I1U&EORZFVN".?L7Y)B6*N;)NZ5I;'C'$=
M6J64<<7.<)"U.WNXN7O#64F6SB)7:"G*J(OBL3H*+1X6H[?4`RCW\OG&GNJB
MF4!P.P[:G#AQIP*D,FIB<:CAZF*W/VN8SW%T2T9[F-P&1)&\A:\FVU[CL$;>
MA-5(,?.;[=K'1'L-3SUJ+?XUG(BBV2-KDG'E>NV*X03=9$H#TUU\NVCN&.>9
MW%U7&F.%*DC"F!H0"*\"N,#P3G/"M-MZ>0,SXQYI'+$M^`=OSC<]DUGA_?6T
MB\0-LGU/#ZLS&R-2QRUFI8+W=FKVOQY:]'G,Z%!1,5'0$ZM,0,(:YS>CNH.L
M[_PK#OMK?=_H6ZOUV^;#ZD>:_2';:/%S7*K`3Z[?-A]2/-?I#MM'BYHBH6>\
M?FFQRKY>.Y&2\<O*.>W)1>/W^[7&*\H\$!*+R26:U5%20=B`\.M6$ZG#]71%
M7?7;YL/J1YK](=MH\7-$3Z[?-A]2/-?I#MM'BYHB?7;YL/J1YK](=MH\7-$3
MZ[?-A]2/-?I#MM'BYHB?7;YL/J1YK](=MH\7-$3Z[?-A]2/-?I#MM'BYHB?7
M;YL/J1YK](=MH\7-$3Z[?-A]2/-?I#MM'BYHB?7;YL/J1YK](=MH\7-$3Z[?
M-A]2/-?I#MM'BYHB?7;YL/J1YK](=MH\7-$3Z[?-A]2/-?I#MM'BYHB?7;YL
M/J1YK](=MH\7-$3Z[?-A]2/-?I#MM'BYHB?7;YL/J1YK](=MH\7-$3Z[?-A]
M2/-?I#MM'BYHB?7;YL/J1YK](=MH\7-$3Z[?-A]2/-?I#MM'BYHB?7;YL/J1
MYK](=MH\7-$3Z[?-A]2/-?I#MM'BYHB?7;YL/J1YK](=MH\7-$3Z[?-A]2/-
M?I#MM'BYHB?7;YL/J1YK](=MH\7-$3Z[?-A]2/-?I#MM'BYHB?7;YL/J1YK]
M(=MH\7-$3Z[?-A]2/-?I#MM'BYHB?7;YL/J1YK](=MH\7-$3Z[?-A]2/-?I#
MMM'BYHB?7;YL/J1YK](=MH\7-$4`PES+.9/N+ELU0>'^3%-6B4V\9;EL%Y>:
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M=2!W*!$E'"`<Q_:V!T2+BJ"!CF-!%3,"W4'X=$QO['L\-$7M]9#G)^HTD_TD
M.U?O+HB?60YR?J-)/])#M7[RZ(GUD.<GZC23_20[5^\NB)]9#G)^HTD_TD.U
M?O+HB?60YR?J-)/])#M7[RZ(M0-_D?SE-Z>S?/FUD.3HKBD,RU2,KRF1I+?_
M`+8[:PJ*$7;:[:7,L[K<<VBGTNB5O`&3%))PD?\`;.D`CT>B)%_5_7I">CJ_
M!,%J?+F68PT6T6$DA71(*K9B@BIT1&9`1`#D']34T'&HJ>)7CNY-?(Z9^,*Y
MWZTH.-*GB3NY-?(Z9^,*YWZTH.-*GB3NY-?(Z9^,*YWZTH.-*GB3NY-?(Z9^
M,*YWZTH.-*GB3NY-?(Z9^,*YWZTH.-*GB5(%ID1?&C0J4SVX5H1\9+MVO\`;
M'6.W*IUG=CJ^(JIB'#CQ[''2G545-:457W<FOD=,_&%<[]:4'&IJ>).[DU\C
MIGXPKG?K2@XTJ>).[DU\CIGXPKG?K2@XTJ>).[DU\CIGXPKG?K2@XTJ>).[D
MU\CIGXPKG?K2@XTJ>)4<C-3!H]\4U0F$RF9N@,<S^NB!`%`X"80),&,(%#L]
M@!'0`5VJ"338J:"F9<D)#$)4I=8A(J.*18C^OE(J4K1$"J%*I+D4`IP#B`&*
M`]GL@&E.J@)IL5U[N37R.F?C"N=^M*#C4U/$G=R:^1TS\85SOUI0<:5/$G=R
M:^1TS\85SOUI0<:5/$G=R:^1TS\85SOUI0<:5/$G=R:^1TS\85SOUI0<:5/$
MN++V4D_ZQ36G/@Y(]L!R5+PF##MR%[8%,=]&/1%P"O=+M3JRF``$!4Z?$>P'
M#B.B5/$N.==R?G3#_*LVW7W;LC!2N1J]7'4^>G6&&;S+7(=0I2&5LC7>AQH*
M*H.8NS66L4IRWBWB!A40>G)Q(<HB`=[;R3Q:/"^WH9`P&AX0`21UR!AU5MVN
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MAX#V(=,0`X#DU/NT![&Q;,2',+QVTR<SQLVH5Q=G?URM23:<4=1S1,T_<-KE
MUW<04,:+ZMRY[@?1I1W#-W.D4.T:SBZ;;JE"%56)DF_C$G-Y3L&/5+"\>Y0;
M>-5\ZW-3J?T56"X/FLUG(F"7N0*MBRQ4VZV*VQ&,Z-$V.U5.3A6%EN^S$=Y]
M3M-ALC=J:'1CH^A*@T5CS('4>3*8-4CBFKUZ=@:FU\&=K2'DT%2#B8^<!)ZW
M!QX*D3@MJ!C6GW*J!U?)>2<I;T.2KF5BU@9S,F1N7)O4R?',2-R156FLK6W;
M%BZUQS$&H.3)1E>D[F_32%,%NB@V/PZ?`O2UH-?D=+#:2N[IT9)ZY#2L.Z)<
MV-QVEO:71M*[WR8IF'4)W*^=:]6+ALUOLAO`ND4O88S)F(=PJ['%37&TA1V?
M:9`I>:%<H3%GC&]58HDC7<>R`KEH#5LBL?FUAK[KN5,U_5XO:V2K+=ZKNMQ]
MN7VQXZS5`5Y[-GI<3&FRWAN#%YB=(ZDW%OL7Y7PU*.)F=<LUUC%E'LNV>*)&
M8=%,BZU+``*J@7AT04.`</P<`,(!P_Z.&B+ST1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$6AO)2_P#PL<Y[^=@R
MK_Z*X/T1=XM$31%S_P"9-G#-.U_;JWW-XE5:/*K@3)>.LB;F*F>KIV:9M.TY
ME8VL?N`6IX],CB&M]#HDBO:&SDA5NM0A%VW5&,N0Q"+6R\<PZS8(NF0)'(:-
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M9%I)O(W%DZ2>)R:':S%-JS1`R<DZ8B=L=P1=L]$31$T11J/_`#ILG\GUW_QC
M4\"CA4EU"E-$31$T1-$5@M?YL6+^1)3^)+ZENU0=BO+?^]T/[2E_U"ZA2O;1
M$T1-$31$T118OY[+_P":S7_*SS4\"CA]Q2G4*4T1-$31$T14,I_BR1_P%W_%
MU-2-J@[%25W\WX+^1HS^)(:A!L"O.BE-$31$T1-$7$Y]_P`QM6?YDZ]?[]6.
M]$6B.P"'B)79)M85E8F,DU8BDK2,2K(Q[1\I%R/A';&8OXT[I%4S%\+-TJCU
MR0D4ZI4Y./1,8!]'TMH.G05%:1A;J#\RS\5;4J8XQRK+C85<>T12P"^A9,9Y
M2G5P\T,G6T5&U;DNZIHT7_="N-ECIQZW6=:Q3.8J!DRF$!SN;CKFRMS<=!P;
M.QP*Y05K057T%$QVU79O`I%$;.HF;E+;'.2U6N(NHVRS3DCJ:L\<J6/*NTL$
MR^3(JZ>I"5TZ<%(<YS*`409(QCE;@:[!M.T]<I1O44/@:C@[(E:8VZ-QI09:
M%R"+K(*8SN*XJ*EK$^FHDT=)66:KEGK4?81LDA"/3-'JC]J60,W7,@O^*H8A
MJ6LAD;G#6Y78XC;U:$5KU\5%&D5H,>HOS&,KA#,])I>9L:1=+M=/N=("/I5S
M0IK5@XD,?*F=Q7<)H68A8^<CZT8$%FXQRJ2*()](@I=`P@*,PS,;-'0L+<#3
M@XME:=1!E<`X;**1$Q-BA*'=5U/%N-4Z\^>14B]KZ="J9(-Y(P35%A!R#J(+
M$!'.'T(P;IMV:QTS*-6Z94DA*0H%">:BIERMR\5!3#8IRMV4%%RFWBYIKVU7
MF<\KC(H8AR_DNO5;"N^6NL<8[9<6*9&OY6DK3L;P[+P:QW!N(DO<""(<IW0H
MF329-""8"]$O#7*;S@`P`8`!W_A6!??@^[_0MY/314OB4WH^.;UTB`($'ZB-
MOXE`2]`0*/A9Q*`D[`\/U.QKEE@('.BI8`0`Y?'-Z`$RG(F`;$;>`)D4X],I
M`\+.!2GXCQ`.P/'1%Y>F;HOJ\N;K]PVV^->B)Z9NB^KRYNOW#;;XUZ(GIFZ+
MZO+FZ_<-MOC7HB>F;HOJ\N;K]PVV^->B)Z9NB^KRYNOW#;;XUZ(GIFZ+ZO+F
MZ_<-MOC7HB>F;HOJ\N;K]PVV^->B)Z9NB^KRYNOW#;;XUZ(GIFZ+ZO+FZ_<-
MMOC7HB>F;HOJ\N;K]PVV^->B)Z9NB^KRYNOW#;;XUZ(GIFZ+ZO+FZ_<-MOC7
MHB>F;HOJ\N;K]PVV^->B)Z9NB^KRYNOW#;;XUZ(GIFZ+ZO+FZ_<-MOC7HB>F
M;HOJ\N;K]PVV^->B+]#G-48P@!>7CS=C&$0`"AL,MHB(CV```\*^R(CHBL-!
MYX>(,K1DO-8OV)<UO(T/`6B>I$]*T?9!8+3'PMSJKL&%GJ4J\AKB\0862N/Q
MZA\R5,5PU6XD4*4P"&B*<^ETBO5I<X_]'W=_&;1$]+I%>K2YQ_Z/N[^,VB)Z
M72*]6ESC_P!'W=_&;1$]+I%>K2YQ_P"C[N_C-HB>ETBO5I<X_P#1]W?QFT1/
M2Z17JTN<?^C[N_C-HB>ETBO5I<X_]'W=_&;1$]+I%>K2YQ_Z/N[^,VB)Z72*
M]6ESC_T?=W\9M$3TND5ZM+G'_H^[OXS:(GI=(KU:7./_`$?=W\9M$3TND5ZM
M+G'_`*/N[^,VB++O(VDKHZ#F89?O>#=P."XG<'S$[]E['%1SOB"UXXR([HDY
MB+$$='2\G4WS5VJR(J^B7"7$BJJ8G2,`''@.IHHJ%W?\*XS\FG?FU/\`>[2B
M5'53PKC/R:=^;4_WNTHE1U52OIVOR;)Y&R45)R$=(-7#%^P?5.:=LGS)VD=N
MZ9O&KB+40<M7*"AB*)G*8AR&$!`0'2B5'545G8+%%H>/)"S8YB;$_D:G)4*0
M?3N,CR[Q]19E=)S+TMXYD*^X6<U.5<H$4<QQS&9KG(4QTS"`#I1*CJKZ-#8L
M-+PU@-CR+-/5V$-6J_-CC149>"KAVZ[0\!#20P';L7"&:NE4Q:H'(@*:AB]'
M@80%1*CJJSGJ>#&--CJ.IBRJ,\?0,DSF(BGFQ0@A3H:8:2?=./E(VO>#A86.
MDFTRKVPBNDB14CDW6%,!QXZ4*5"HVV--OK-]6)-IA*CM9*D,HF-I<@VPPP0?
M5&.@'K^2@F%7=I58J\`RA9&5=.&B30R2;9=RJ=,"F4.(J%*CJK]>XUV_24%"
M5>1PG2']9K32=85RNO<,,'4%`,;2!PL[.$B%ZLI'Q32Q@H;M]-!-,CSI#UH'
MXZ42HZJII'%.W*7CT(F6P3C^4BVLG89IM&R.$8Q['MYBW`0+7+(,W-45;I2=
MG!,H2*Y2@J]Z(=<8_`-*)4=59="U18```UG0`````*U/@``'8```(W@``&E$
MJ.JOWPKC/R:=^;4_WNTHE1U4\*XS\FG?FU/][M*)4=51YC98XECGUA;S0D68
MP)2@6OS9E`%+NKTNL2*P%1,H],.B)@`#=GAQX#J2,%%<5(?"N,_)IWYM3_>[
M444U'53PKC/R:=^;4_WNTHE1U4\*XS\FG?FU/][M*)4=5/"N,_)IWYM3_>[2
MB5'53PKC/R:=^;4_WNTHE1U59++9XY:NSJ)&\T!E8>23**E>FTDP,=FL4HJ*
MJL")IDXCV3&$``.R.I`Q4$BBNR%JC"HHAVM.]A),.Q6YX0[!`_`(1P@.HHIJ
M.JO7PKC/R:=^;4_WNTHE1U4\*XS\FG?FU/\`>[2B5'53PKC/R:=^;4_WNTHE
M1U4\*XS\FG?FU/\`>[2B5'53PKC/R:=^;4_WNTHE1U5&RV6/\+UG/:\SU8UM
MLB!>X$UUW3+*.SB(H=H=<"?`P<#]'HB/8X\0U-,%%<5)/"N,_)IWYM3_`'NU
M%%-1U4\*XS\FG?FU/][M*)4=5/"N,_)IWYM3_>[2B5'53PKC/R:=^;4_WNTH
ME1U4\*XS\FG?FU/][M*)4=54<C:8T\>^(#><`3LW10$U<GBE`3('`!,8T>!2
MAV>R(B`!J0,5!(HJ6"L\<E!PR1F\V)DXJ.3,*=>G%""8C-$HB11./,FH01#L
M&*(@(=D-00@.`5V\*XS\FG?FU/\`>[2BFHZJ>%<9^33OS:G^]VE$J.JGA7&?
MDT[\VI_O=I1*CJIX5QGY-._-J?[W:42HZJ>%<9^33OS:G^]VE$J.JN+#V?8_
MUBJM/NIE>I#DJ7A`2=Q9?MGIFWT8].`@T[2[:%+@7LGZ'0`>`<>(AI0I5:?<
MO'_8@VT?ZO5O]*[+KTC2OW;!^C"W<'YEGXJW)UGJZM2\R;58/-&X7!N:[4K6
MYB!PKCW,58;42Q0#F53E+AD65QO-T^\HO`?I,6;K'$MCPKAL15LNH99T*B1T
M3I@)\6:V$UPR9U"UC7"A'":$'W**AT8<\./`#_1VEJ?C;EQY'Q_<MD=C/GJM
MRD=M`I>+*L_:HT>TLIK)[BAUO.E6G7#Z85O3U"+BK&PR^V51:"V5!%>-4[9,
M[!1`S?%CL)(WPNS@B(-&PU-`X;:\.;[G"K;8G`M->Y`]VE>VMWMIF#GNV?;7
MAK`,A9F=R>8HJ`55>U1\4X@V<Z))>5DB/D8AT^DG$>`IR($%,SA7\8@B!N`@
M`9EK";:W9`34M%*[*JY&W(P,X@MAM9"K7,O-MECJ7S=>6M<Y@[I.&IVV7F56
MR9.P;JO'Q8>LXHI4Y*"R9H\%GCL&#!3JD2_C*J<"AV1UR.]'=0=9_P#X5K[[
M:WW?Z%FY7>MNUR1EFR4_`S:H2CRPU&[W+#%#?HTN?CG8,\`[*,NX\9W^]A-5
MT6%7D'>X69[O.V2JKYHW,@#/M@6R8N>56`MT*QF'*5@G<_P+NU,F3F@[WL58
M)JB;*`BCNFF.+E6-OEBE62R;U$QIB5=HY.F56DDJB10K5LB<$Q!%43D6*L0[
ME,^73:)`9<763D\QY5IT)7<11L[3(]K1)K,%E>6YLQLD>QQW)3%MDL:UF/BP
MDIULNBF_1913DZ(@"H"!%D[$&]>!R:CMK9O*Q/UZ6S[3'*[I[)G=LX6J9?J:
M-SCLFX0=K!'ND$,CTRU8YF6YXN0<1KMTU:JKLB/`:/BMB+=;KU_W97]\/^SH
MB=>O^[*_OA_V=$3KU_W97]\/^SHB=>O^[*_OA_V=$3KU_P!V5_?#_LZ(G7K_
M`+LK^^'_`&=$3KU_W97]\/\`LZ(G7K_NRO[X?]G1$Z]?]V5_?#_LZ(G7K_NR
MO[X?]G1$Z]?]V5_?#_LZ(G7K_NRO[X?]G1$Z]?\`=E?WP_[.B)UZ_P"[*_OA
M_P!G1%4-%U^VFW[<K_?"/_VA_P!T+_TZ(M!_Z/V(CMHW@B(B(^E,Y@'9$>(]
MG,BPC_\`G$=$7=O1$T1-$7&#+O-;G,6[[[%LN;8@KEOFF.4=G>/J;&1MVFV6
M2,DQ.Y^)R#.7NVUF%4I;JJM4MN-6QZ[L<VV>2B!)"!1<*)N&RZ)$ER+.$SS7
M-K)\63>6,:N+OF*"A<[X0V_@A2*H^2-+VC/N9&F#Z)/P4C8.X\1+U!S=3NDC
MND%SJ`#,W[4`+-Q5(KC(\U7:'$)7I>2F<FLF^/\`*&5,-2CMSAW(B#"9R-@E
MAER=SC7J9)K0)(VZ*XAJ6#[%-3RD:LX2:QC9$Y3**NVR2I%1%YJFV)&=S#'2
M?ATSA<69!Q]C6"L[.KKS[#,5@O\`MB#>&1QBQE`*R,I,0]>V]$6LCUPY2:@#
M%JJ9,IS]414B\+)S>MAM0E;&VLV6I&&KE9AXJ9>9(=4:XCC-^2Q;<$-VU7C8
M2XH0ZL=,S5JV^**V&.:(=-9TFU5;%#MP"-SD6\&&,QT?/6/(C)V/'4DZK,N^
ML,40)F'D(&593%3L4K4['%OXR300<)+Q=@A'*'6$ZQLY*F"S=59!1-4Y%E+1
M$T1-$4:AA'NU;@XCV)6.X?\`1_Y>B!['_OU)V!0I+J%*:(FB)HB:(HI=OS9D
M?[9'?Y49:D;52[N2I7J%4FB)HB:(FB)HBC4?^=-D_D^N_P#C&IX%'"I+J%*:
M(FB)HB:(K!:_S8L7\B2G\17U+=J@[%>6_P#>Z']I2_ZA=0I7MHB:(FB)HB:(
MHL7\]E_\UFG^5GFIX%'#[BE.H4IHB:(FB)HBH93_`!;(_P"`N_XNIJ1M4'8J
M2N_F_!?R-&?Q)#4(-@5YT4IHB:(FB)HBXG/O^8VK/\R=>O\`?JQWHBTCY>/^
MQ!MH_P!7JW^E=EUZ3I7[M@_1A;J#\RS\5:%KYSW2T6^;^\L(&N=^Q_MXW61<
M!CBL35SO2T([H5JC]O-2EJZ7'4;%$92^-JHUR);[*A.-G+E=K,P)45`3:-U`
M4Q>>N6/GEY3F1RT`)-*'(*4XA5QKQCB5O,\%[L2`[M<'%M*O%KYE&X*#HNWJ
MZQF!*U(&R?'98EKW#KPV3RNH1MCO>+C3;K"LH`$"]LQLA;L=7AY:2=TD50(2
M*54(4[0IS%J?J%PUD;Q&.5FKMX)`S#K@YL>+B4F9X`--M>/CI_6LCYCWD;B6
M<_F>O4&IU"F(8BW?X,P$^3L=,R+9\@FQE=<O8PKTKF\[)LBPI,CC&\T6WOG3
M&29NQ/%"R434!10%%VE<UW<!SVL`&25K<02:%P&;BH030\%.Q+I'XTI@X#W*
MC%19SOCSY0("65C,'6/(KI?<5O+K;09E6Y2;FQ,\2;A*#0L;8OH1BL4%X:<R
M93KX^F:\+@KJ+:QE>5(B#E'K%D:?')XVFC"[\I(.''*X``=5P-1P4"<XX#97
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MZ1#`)4DP+RJP%)5.<)R:%9XUI5WK[7E+.=N1J>QF:S8SIVZ399DBDI+#2>WS
M@@R<*()B*@BFBH9,H@0PE$BIHSF[<ER$:UEC"[R]JD.QI2SQS3&45&RT<SJ#
MB00=-7Z]6;,Z.BA7UGS5\NDL9H5$5$UU"FXE.8!(J*'YLO)+KTH,W`;O-H\'
M,B[DY`TO#P3^,DS2,VZ>OIJ1,^94-%T:0EWTFZ7=+B;K5UG2QSF,9503$4W]
M-CRE/M_8`^,+;XIZ(GIL>4I]O[`'QA;?%/1$]-CRE/M_8`^,+;XIZ(GIL>4I
M]O[`'QA;?%/1$]-CRE/M_8`^,+;XIZ(GIL>4I]O[`'QA;?%/1$]-CRE/M_8`
M^,+;XIZ(GIL>4I]O[`'QA;?%/1$]-CRE/M_8`^,+;XIZ(OSTV7*3^W]@'W?;
M_%+1$]-ERD_M_8!]WV_Q2T1/39<I/[?V`?=]O\4M$3TV7*3^W]@'W?;_`!2T
M1/39<I/[?V`?=]O\4M$7LVYVG*2(X;G-O_P`!2KI&,(O[?P`I5"B(C_Y2_``
M!HBOW]'8R-0K=M`W,W6M6^!EZG=>97OFMM3G4'Z:+*?K5BR@C-04TP!YVLX,
MRE(E^BX2$Z9#"FJ41*`CPTH5%0-J[Y^%-9^4,)\:L?;]30IF'&$\*:S\H83X
MU8^WZ4*9AQA/"FL_*&$^-6/M^E"F8<86G^0=F6R?*=WO.2KW1Z[.W[(MKP1>
M[);1R);XZ<2NVV1[*2&![=5WT3<&"E$L>.%IU^1H\@^YRZ[=^Z0=&70<+)G4
M*9AQA?,7LQV4PF+93"<53(5CBF2R_#9X;T9')MX"#K&4Z]E!GFN#L5`1-=3*
MXX:165V19Y"+@3QT2F_45,#7H+*D.H4S#C"3VR_9)9J7*X^FJ'5W=7FLMY=S
MI(-O#VTHR1LH9]C[M#YKL;2P(VQ.PQB63X+),_'R[!JZ1CG#"7<MP0*D?H@H
M4S#C"IK#LCV-6<;B,ECJGM_#NR4^WV`L)=K)7$R62B84<[;J]+5Y*`M,:E3G
M),`O5:>Z[D%8ED(!06KH%B:4*9AQA8#8<K[9G)Y/W&V_*;*A92QUF\*)'U#"
M$H@:%Q]ANN5':C%[/I&&KL5%VX8>5=3F)F3EFWD18,W\.UD5V[-4A1`X*%,P
MXPNBV/XS'&,J;7:%4[``5VK1C:(B?"._3-VG19M"`FCW4M=SGY^TSKH"%`!7
M?/'"Y@``$_```%"F8<84Q\*:S\H83XU8^WZ4*9AQA/"FL_*&$^-6/M^E"F8<
M83PIK/RAA/C5C[?I0IF'&%'8BR5Y.8M2AYV'(1>3CSHG-),RE5(6!BDC&3,*
MP`<I5"&*(AQX&`0_"&I(-`HJ.-2+PIK/RAA/C5C[?J*%3F'&$\*:S\H83XU8
M^WZ4*9AQA/"FL_*&$^-6/M^E"F8<83PIK/RAA/C5C[?I0IF'&$\*:S\H83XU
M8^WZ4*9AQA1BXV*ON*Z_20G(=94QV`E32DF:BA@+),SFZ)"K"8>B4HB/ZP!Q
MU(!JH<112?PHK/RA@_C5C[?J*%34<83PIK/RAA/C5C[?I0IF'&$\*:S\H83X
MU8^WZ4*9AQA/"FL_*&$^-6/M^E"F8<83PIK/RAA/C5C[?I0IF'&$\*:S\H83
MXU8^WZ4*9AQA1UC8Z\6R6!8T[#E258P!4E323,$U#)=U>M*F<5NB<4^L+T@`
M>QQ#C^'4T-%%17:I%X4UGY0PGQJQ]OU%"IS#C">%-9^4,)\:L?;]*%,PXPGA
M36?E#"?&K'V_2A3,.,)X4UGY0PGQJQ]OTH4S#C">%-9^4,)\:L?;]*%,PXPK
M'9K)75JY/(HST,JJK#22:22<FS.HHH=FL4A"$*L)C'.8>```<1'4@&J@D4VA
M79"T5H$$0&PP@""28"`RK$!`0('$!`5^P(:BA4U'&%[>%-9^4,)\:L?;]*%,
MPXPGA36?E#"?&K'V_2A3,.,)X4UGY0PGQJQ]OTH4S#C">%-9^4,)\:L?;]*%
M,PXPGA36?E#"?&K'V_2A3,.,*-%L5?\`#!=QW<A^H&M-D06[I,^J%4)1V<4@
M4Z[HBH!#`(EX\>`\=*&BBHKM4E\*:S\H83XU8^WZ4*G,.,)X4UGY0PGQJQ]O
MTH4S#C">%-9^4,)\:L?;]*%,PXPGA36?E#"?&K'V_2A3,.,)X4UGY0PGQJQ]
MOTH4S#C"HI&S5L\>_(2P0ICF9.BE*648B8QC(*`!2@"_$1$1[&@!JE13:J6`
MLM=2@H5)6>ADU$XF.343/)LBG(<C-$IR'*98#%,4P<!`>R`Z4*@$4&*N_A36
M?E#"?&K'V_2A4YAQA/"FL_*&$^-6/M^E"F8<83PIK/RAA/C5C[?I0IF'&$\*
M:S\H83XU8^WZ4*9AQA/"FL_*&$^-6/M^E"F8<87%9[.PG]8LK+WNQ%]IAR4[
MPB+OM]KVL"QM]./#%2%;K>K!42E$0+QX\`XZ4*5&W@6G'+Q_V(-M'^KU;_2N
MRZ](TK]VP?HPMW!^99^*MS^O7XICURO%$O11'K#\4B]G\5,>/XA>R/8#A^'6
M>KJ^@=N@$Q@<N`,<0$Y@64XG$I!3*)AZ7$PE3$2AQ_``\/P:5*+Y!=<H$*59
M4"I@8$R@H<`(!P$#@0`'@4#@(\>'X>.B)UZ_9_;E>R0J8_MA^RF0!*5,>S_8
M%*/``_``:(OPZZZA`3.LJ=,O1Z)#J',0O0+T"<"B(@'1)V`_6#L:(N9&:&4<
M^YP7+!3E(F%FVJ&W[F)OBQUACFTK$+.6..*$Z:F=LW3=T0Q$UD@'I%(90GX2
M_C`&N1WH[J#K/_\`"M??;6^[_0MM*%NYH-^K6U9)KMDQC#95SAFHV$LQT%_'
MU=VSV\S;"O629>RCZ5;4Y%W<6%E/&QJU:`K=@$O$2Q7_`$DR-U$S<JL!1/"^
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M5K4*XU;R3=+:I;UDD)!%O&))O445R@H0JH&`B@`8O`P`.B+^B'Z(L3^3#'GS
M*K?>W1$^B+$_DPQY\RJWWMT1/HBQ/Y,,>?,JM][=$3Z(L3^3#'GS*K?>W1$^
MB+$_DPQY\RJWWMT1/HBQ/Y,,>?,JM][=$6)<QYVV\[3@PM"7\8BBM,]YPJ6!
ML<M8:MMDXQUDS(*4B-=1EBQK=%K"1DJ^C",1D%P*CW0>,VXFZURB4Q**SW[>
M-MBH=P3QJ?).-;+E1+)./<836*X'(&+F^0JQ-Y&M="JD8[L-9L]OKKUBSCU,
MEPSM5``/).FS]`K!J\<.&R"Q10*8DW+[8%%;\@3-.'S.<6#6BY(:!<*SVY1U
M+I*O(.EHV9IVYVS$+W.:CUVD.FL4IY1RD9-J"IPX:)0+Z1W*[7G%VIV-F^<<
M)N,@9#B*[/T&FH7ZFK62ZP5OC+'-5.:JD0E)F>V"(L\34)9Q'.6A%47J4:Z,
MB8X(*]$E`KY5\UX-OD/>)S'M^HF166-R*C=2X^EHFZO(%0D.,\@U=L*VK)/!
M=R,0'7LTRD$SP@@*('XZ)0+5#'7,LVC9!P'$[G0LC*O8.L\_B6JT_(#EY3;3
M#6BV9KL#.JTNCM1QW8KD[B,B1]CDFS">@)-)C)P#M8"NTBI@*NB4"S)?-YNT
M''$#8['9<VXM-'5&^8[QC9B0,Y%6B1@[UEBZ#CS'U=DXNNFDY!D[LMT1<1Z)
ME$RI`X8O"G,46;GJB4"S75<AXIO<U;ZW2;C1+=8:!(A#W>$KDW!S,I4Y07$@
MR!A8&,>X<.(ESW0B'C42K%()73)R@/[:W6(0E`M3<1;]\&Y;QZURP2NSN/L;
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MB*H'CW'6`7JC\"4"@!-\VUIC*56"N%SKU$F[WF#<#A>DQT_)521&Q6/;,C:'
MV5I,'].F[1%0$+`Q%37=+%EEX^09`JB@]:M79Q;E)0+9"@Y`Q9E2';6+&ELI
ME]K[R*KLXRG*C)Q4_#O86WP3&TU:792<8HY9/(RQUN4;/V2Z1S).6;A-9,QB
M'*82F@6F4SS`L:5;<;:MMUTP[DBDSM(QO7,T6N\6ISAR'H$)ANWYAMN$*SD1
M[(N,G!+D82MRIKA8&':0RQ(QPV7,V!144"%%`L^6/=?M(I[JI,;7N"P-7'E^
M@(:U4=M-Y&I$8K;ZS8Y!2(K]@K1'<HD,U#3<PGVFT<M^L2</#%03,94Y""2@
M7J;=1M.(XQJT-GS!A7&9(*`M&)TAR#3.ED>M6J;C*S6K!2O^\N%CA9ZRS3*-
M:.6HJHKR#UNV(85ETB')0+)-#R)B?**$VZQM<J+?6U;F7%>L"]0FH2PI0TXU
M(11:+DE(M=T5F]*DH4X$.("8A@,7B40'1*!8[OVX_"&,\\8'VW7"62C<J[DF
MF2W>*(CN2*K"9-BB`:6BT,7LJ4G:D7)K0*ZSF/;JB"D@G'O!1`P-5NB2@6)\
M7[SJ9E#=+<-I;/"V4J]D+'^+VF7KS-33#'+JHT>J62X3-2QK'W9]6KW/2E5O
M&64*\^FH&!=-"R9X!J=X[2:`)"&*5NSVBQ_(VON='V&B4"=HLOR-K[G1]AHH
MH$[19?D;7W.C[#1*!.T67Y&U]SH^PT2@3M%E^1M?<Z/L-$H$[19?D;7W.C[#
M1*!1M@S9C9[$46C82E85X2EZA+@`F[K](0#H=@1X!QU/`HH*J2=HLOR-K[G1
M]AJ%-`G:++\C:^YT?8:)0)VBR_(VON='V&B4"=HLOR-K[G1]AHE`G:++\C:^
MYT?8:)0*PVEDS+6;"8K1L4Q824$I@;I`("#);@(#T.("`_@']34C:A&"O#=B
MR%!`>TVO_8I__NZ/_P!0O_Z&H4T"]NT67Y&U]SH^PT44"=HLOR-K[G1]AHE`
MG:++\C:^YT?8:)0)VBR_(VON='V&B4"=HLOR-K[G1]AHE`HN5FT\-%R=JMNA
MX+M3='J$NCTAEG@";AT.''@&IX$X?<4H[19?D;7W.C[#4)0)VBR_(VON='V&
MB4"=HLOR-K[G1]AHE`G:++\C:^YT?8:)0)VBR_(VON='V&B4"H9-DR"-D!!H
MU`08NQ`0;I<0$$%.`_V&I&U",%2UYDS-`09C-&HF-#Q@B(MTA$1%DB(B(]#L
MB(ZA`!0*\=HLOR-K[G1]AHE`G:++\C:^YT?8:)0)VBR_(VON='V&B4"=HLOR
M-K[G1]AHE`G:++\C:^YT?8:)0+BB]:MOZQE64^UD.K]"?>3=7U*?0Z0;ZL><
M#=#H]'B''\.BE<^>7_D7',7LLVXQTID;'L7(LJ$X;O8Z3O-5CY!DX):[)TT'
MC%Y+HNFJY./9(H0I@_5#7HVER1C3H07-!YL<(6Y@(YEN([E;@?2IBKRJ8O\`
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MU"1:PF))]Y9\1R"L@>]G<O[CBB:D7*E=GG`JS$6BY6;)N>U55$#*%%Z4G&&U
M^ML*Z2VYOH65;%6,BJ960O-TRM14;3:,AI/X]Y"9!R&2"L4;6[9D6NMXAFR:
MS"<>Q%..9I-$T$FW31.H46SOTO8@\K^)?.=1>_\`I0HGTO8@\K^)?.=1>_\`
MI0HGTO8@\K^)?.=1>_\`I0HGTO8@\K^)?.=1>_\`I0HGTO8@\K^)?.=1>_\`
MI0HGTO8@\K^)?.=1>_\`I0HGTO8@\K^)?.=1>_\`I0HGTO8@\K^)?.=1>_\`
MI0HGTO8@\K^)?.=1>_\`I0HN7^]#)V,7/,#Y(\@TR;CAXPA=W&X=Y,O65]J3
MUI$-%MJMO;H.91PUF%D8YNX<F!),ZPD*HJ($*(F$`U%"B_H:^GK!GEGQ/YQ:
M?WXU-"B?3U@SRSXG\XM/[\:4*)]/6#/+/B?SBT_OQI0HGT]8,\L^)_.+3^_&
ME"B?3U@SRSXG\XM/[\:4*)]/6#/+/B?SBT_OQI0HM%=X^W_9]O?K5SJ>7=R<
M(QBIZ@1U0I:U/RU2(*5Q'98ZZQ>0$,JT-Z2061/D!O::O`O6RLJC),FCJOL5
M46Y3%7Z]0HL?S.T+9S9'^49NP;K(J1LF8-W.UW>5<K`6]859OE\E;5(?!\53
MX-D#6*32:4JT*8#B',NTX&6%=R\[46:E42*BH45L:[,]H9?I>D);>&E8[=EG
M=;C[>@XO,S?<)J6F#SCB2[P%KQ4HF_:1+0)W'N.8&GP]7AZV_*M&,JZQ$B9`
M?.%WQU"B@E.Y<>P+'^0]N-]J6Z0\>GMC@=L%>HM;=Y6Q')QTHTVJI;DRTM>R
MOW<8:9=.K*YW469>7[67:I&5(R!H1JFW,FJH46:-HFV':AL\'<`[IN\=U<I_
M<9'4QG<+3;\G829ST,^HL%:*W!3=34I5>J<=$R*$39"E*06RC5%1DB9%)(O3
M(90HHDMLBV(J1>3>U-PU0KMPRWF7:EG>\7>E6S!M+=6/).SW)L3E3&UOG:I7
M89C0Y.W6RQ10%MLMW+2>3Z!B%,9$&S7J5"B@\9R]-ED=,YGLJN]:=E+)FG*6
MV[+LK,R.2=OQ%J]:MJNZ^^[ML4(P+.,IT;&=Q&UOO[B'>M7*"Y',,V1`.@[Z
MQT=0HMJ]J6'=GFT*9S5*X[SW0I@,S9-O&25PM%PPPK-50,AY!N66+!2HZZ0<
M7"76R4MIDC(T])1;:>D)52*"351;J%()NFH46'VVS_9HRPMN"V\M-UK1'$>=
M4-VI&5='(^'3O\7N=ZSJUR6;W=2G#1G;TN<96\RRD&69[HA%I/3)'[9(1'JU
M"BH\0[,ME^'+?B"Z0>ZQI*RF'-S6;MTT(A+9'P\#&6N^=\)O\$VF"ETH^-9*
M^"T75)-=PP3;G1=D>B4RJZJ1>J%0HK!2N7YRZ\;7S`5YHF=*Y$I[?9O-[FM4
M^;R)AN]4V2J.:<QUK.R&/SP]YA[`-7@L/Y`HT$:D.8)2+E*^QBTT$W)Q$5`4
M**[2^R'8M-U>4K#W<G"IJ2F]+)&^=&V1V1L30U^K.7LF71[=9(M'O$.U862I
M,89S)NX]HHV<=L+P[Q=B_.];+*)F4**XQFU?:E0+-4,JT+<M6)O)6*MQ^\_=
MA1H6V9:Q;&4FS9#WGPUZ0O\`CVZK1U<EY!EC=&3NA@8N6;=67CT$BB8[P>F1
M10HI/M7Q'A_:]CW;/C_&VZBB8YHN)YK,5FR/AZ&RW1KO1[DWRPC/O:WC)O8[
M8P;V]&E8!E)9BRJ"[)2'%*$@V[1=H=)0"-U"BB^Z;9SLQW99+R[E"\;KTJU.
MY9P#AC`AT*9DW$#-I4&FW_<*;=!BZ]5_NS&3:CJUQ.6>@L[1D1>13^/3*T5:
M=$3F,H44?RAL5V.Y/NV(KRMN>KE0?8<HV#:/7X2CV;;_`%FI.F^!MR55W3UN
M14J\76VT/#J3.2Z@U(_:QB3)CW-,HDW104$JQ%"BUL6Y;&VTU^VW8X4W0T&2
MVCX+V6LMMTJ5YEW'C;,EWG*CN[P1N?I;*56CX5K!,*JZ<862;RC^-5828B<J
M;<B8G,Y24*+<3;MMJV[;1Z'C?&NWO>=`U:MT[-;*^V5Y*6#;R]LN1<21</<8
MN'P'?K'&U.*F[C6J^E9T$XZ8>.?"1JG&M0,_621,@LH44CW"[=-I.X^]5_*5
MMW3QD'DW'^:\*9KQ%=ZOE/'C.3Q8_P`(F=FBJA7XUZY?UR3J=O3L%@;3A9%D
M[>O(^SR;4CA))5$$%"B]=N^#\"[=<C9!R+![X_"Q]E_-^0=P&8D+1=,$"_RE
M>+I7S5*O1%ML\5!Q]D''F(JHDSCJG`LG#-E&-8UH"@+F3.910HM]OIZP9Y9\
M3^<6G]^-*%$^GK!GEGQ/YQ:?WXTH43Z>L&>6?$_G%I_?C2A1/IZP9Y9\3^<6
MG]^-*%$^GK!GEGQ/YQ:?WXTH43Z>L&>6?$_G%I_?C2A16!EG+"2=BGG!\R8H
M!%PQ@BHJ?2-3A`YFXRH+%#A,B(&3%0O$!X=@P?KZ4-%'"K_]/6#/+/B?SBT_
MOQI0J4^GK!GEGQ/YQ:?WXTH43Z>L&>6?$_G%I_?C2A1/IZP9Y9\3^<6G]^-*
M%$^GK!GEGQ/YQ:?WXTH45CLV=L'K5R?23S-B<RBD-)D(7Z1J<7B8S-8"AQ-,
M@4.(C^J.@VJ#L5W0SS@TJ")1S/B?B"28#PR-3Q#B!``>`A,B`AJ%*]?IZP9Y
M9\3^<6G]^-$3Z>L&>6?$_G%I_?C1$^GK!GEGQ/YQ:?WXT1/IZP9Y9\3^<6G]
M^-$3Z>L&>6?$_G%I_?C1%'"YRPEX6KN_IDQ1VL-=:M@5^D:G<!7"2>*BF`=V
MNEQ!,>/X.&IX%'#[BD?T]8,\L^)_.+3^_&H4I]/6#/+/B?SBT_OQHB?3U@SR
MSXG\XM/[\:(GT]8,\L^)_.+3^_&B)]/6#/+/B?SBT_OQHBHY'.^#E(]\0N9\
M3=([-R0O'(].*'2,@<`XF-,@4H<1_"(@`:D;5!V*E@,[X.3@H5,^9\3@=.)C
MB'`,C4XP`8C-$I@`Q9D2CP$/P@(AJ$&P*[?3U@SRSXG\XM/[\:*4^GK!GEGQ
M/YQ:?WXT1/IZP9Y9\3^<6G]^-$3Z>L&>6?$_G%I_?C1$^GK!GEGQ/YQ:?WXT
M1<8GN7L3#_2&ZW9`RACL:Z3DQ7:$//!=JT,*2:5WP8_?I1!Y0)/M$DFJQ2.L
M5`3@J9(AC@42E$0(N3^RKEW;#<G;4<&Y#R+M`V_W:]W*I/IVV6^RX]B9.?L<
MT[M=B!U*2\@N45GCYP!`Z:ANR/`-=[IUA926$,DD3'/+`22,25MH8HG1-):*
MD<2V?]%KRVOL+[9/-?">PUF_-NG^!C["N<Q#[T=A/1:\MK["^V3S7PGL-/FW
M3_`Q]A.8A]Z.PGHM>6U]A?;)YKX3V&GS;I_@8^PG,0^]'83T6O+:^POMD\U\
M)[#3YMT_P,?83F(?>CL)Z+7EM?87VR>:^$]AI\VZ?X&/L)S$/O1V%H!E/E[;
M$X;FE\NW&<7L_P`"(8YOV&M[L]>L?,J!!(5R[RU$IU%D*>YGHYPF9B]>0#IX
ML+)18.#<ZQC!PX\=?G/_`.Z1OCO9ZL?LHZAO1ZN=3N]!WE9JVF1-N[.1\,S&
M37D4<@#XR'Y7,<0X#NA@MUNW96EQKL4%Q$R2$QR$M(!!(;48=1;E16V3E$S.
M'J#FACRT=MR]=R0[V],X&.0J6$G,Q%+;D9Z-KM-2N*#>542JZ\.]FFAY,JIS
ME(@=06YG!T5"!_/G>>M?[:=COOJ.XEQZU=Z6ZGI;-9=,\W&JMBD&B0OFN3;$
MQ@W`E;%(("T`EP:)!&U[7'T-MCNZZV9="Q@R/YN@HRHYP@-S8X4J*_<K15E*
MVR\G/)==2GL=\M+#UH<,\0*9RM5>)@['D?-UFA>%EYI,</!X[)%V&=M4]C*?
M[B(QSIRTE&L89TFZ*W7:*.+.O>M?[;^ZNIG3MYO6KK=I')K8TJWF.JWKXI[O
MQ>TNG]RTR0Q6\-]9^-.GC9);R3B)T1DCF;%,5CNW.S/#8QN(CSD9&U#:N:.H
M22UV6A((%:T(KM?1N5IRD<DTFG9%I6QK:I.4V_5:O76I3:&'JRDA,5FU1+2=
M@91%-Q&)+II2$4_25*4Y"G`#\!`!XAKQS>#[7?VS]UM?OMV->]8.^%OKFFWD
MUK<1'4IR8Y[>1T4T9(D()9(QS202*C`D+81:#N[/$V:*UMS$]H<#D&((J#LX
ME*?0_P#*W^P-M9\T-3]X:T_ML_:Y_F-O?])7'?JYZ.:#Y);_```GH?\`E;_8
M&VL^:&I^\-/;9^US_,;>_P"DKCOT]'-!\DM_@!/0_P#*W^P-M9\T-3]X:>VS
M]KG^8V]_TE<=^GHYH/DEO\`)Z'_E;_8&VL^:&I^\-/;9^US_`#&WO^DKCOT]
M'-!\DM_@!/0_\K?[`VUGS0U/WAI[;/VN?YC;W_25QWZ>CF@^26_P`GH?^5O]
M@;:SYH:G[PT]MG[7/\QM[_I*X[]/1S0?)+?X`3T/_*W^P-M9\T-3]X:>VS]K
MG^8V]_TE<=^GHYH/DEO\`)Z'_E;_`&!MK/FAJ?O#3VV?M<_S&WO^DKCOT]'-
M!\DM_@!/0_\`*W^P-M9\T-3]X:>VS]KG^8V]_P!)7'?IZ.:#Y);_```GH?\`
ME;_8&VL^:&I^\-/;9^US_,;>_P"DKCOT]'-!\DM_@!/0_P#*W^P-M9\T-3]X
M:>VS]KG^8V]_TE<=^GHYH/DEO\`)Z'_E;_8&VL^:&I^\-/;9^US_`#&WO^DK
MCOT]'-!\DM_@!/0_\K?[`VUGS0U/WAI[;/VN?YC;W_25QWZ>CF@^26_P`GH?
M^5O]@;:SYH:G[PT]MG[7/\QM[_I*X[]/1S0?)+?X`3T/_*W^P-M9\T-3]X:>
MVS]KG^8V]_TE<=^GHYH/DEO\`)Z'_E;_`&!MK/FAJ?O#3VV?M<_S&WO^DKCO
MT]'-!\DM_@!/0_\`*W^P-M9\T-3]X:>VS]KG^8V]_P!)7'?IZ.:#Y);_```G
MH?\`E;_8&VL^:&I^\-/;9^US_,;>_P"DKCOT]'-!\DM_@!/0_P#*W^P-M9\T
M-3]X:>VS]KG^8V]_TE<=^GHYH/DEO\`)Z'_E;_8&VL^:&I^\-/;9^US_`#&W
MO^DKCOT]'-!\DM_@!/0_\K?[`VUGS0U/WAI[;/VN?YC;W_25QWZ>CF@^26_P
M`GH?^5O]@;:SYH:G[PT]MG[7/\QM[_I*X[]/1S0?)+?X`3T/_*W^P-M9\T-3
M]X:>VS]KG^8V]_TE<=^GHYH/DEO\`)Z'_E;_`&!MK/FAJ?O#3VV?M<_S&WO^
MDKCOT]'-!\DM_@!/0_\`*W^P-M9\T-3]X:>VS]KG^8V]_P!)7'?IZ.:#Y);_
M```GH?\`E;_8&VL^:&I^\-/;9^US_,;>_P"DKCOT]'-!\DM_@!/0_P#*W^P-
MM9\T-3]X:>VS]KG^8V]_TE<=^GHYH/DEO\`)Z'_E;_8&VL^:&I^\-/;9^US_
M`#&WO^DKCOT]'-!\DM_@!/0_\K?[`VUGS0U/WAI[;/VN?YC;W_25QWZ>CF@^
M26_P`GH?^5O]@;:SYH:G[PT]MG[7/\QM[_I*X[]/1S0?)+?X`3T/_*W^P-M9
M\T-3]X:>VS]KG^8V]_TE<=^GHYH/DEO\`)Z'_E;_`&!MK/FAJ?O#3VV?M<_S
M&WO^DKCOT]'-!\DM_@!/0_\`*W^P-M9\T-3]X:>VS]KG^8V]_P!)7'?IZ.:#
MY);_```GH?\`E;_8&VL^:&I^\-/;9^US_,;>_P"DKCOT]'-!\DM_@!/0_P#*
MW^P-M9\T-3]X:>VS]KG^8V]_TE<=^GHYH/DEO\`)Z'_E;_8&VL^:&I^\-/;9
M^US_`#&WO^DKCOT]'-!\DM_@!/0_\K?[`VUGS0U/WAI[;/VN?YC;W_25QWZ>
MCF@^26_P`GH?^5O]@;:SYH:G[PT]MG[7/\QM[_I*X[]/1S0?)+?X`3T/_*W^
MP-M9\T-3]X:>VS]KG^8V]_TE<=^GHYH/DEO\`)Z'_E;_`&!MK/FAJ?O#3VV?
MM<_S&WO^DKCOT]'-!\DM_@!/0_\`*W^P-M9\T-3]X:>VS]KG^8V]_P!)7'?I
MZ.:#Y);_```GH?\`E;_8&VL^:&I^\-/;9^US_,;>_P"DKCOT]'-!\DM_@!/0
M_P#*W^P-M9\T-3]X:>VS]KG^8V]_TE<=^GHYH/DEO\`)Z'_E;_8&VL^:&I^\
M-/;9^US_`#&WO^DKCOT]'-!\DM_@!/0_\K?[`VUGS0U/WAI[;/VN?YC;W_25
MQWZ>CF@^26_P`GH?^5O]@;:SYH:G[PT]MG[7/\QM[_I*X[]/1S0?)+?X`3T/
M_*W^P-M9\T-3]X:>VS]KG^8V]_TE<=^GHYH/DEO\`)Z'_E;_`&!MK/FAJ?O#
M3VV?M<_S&WO^DKCOT]'-!\DM_@!<P^<YRS^7WA;EA[O,H8FV<[>\>9$J%!@W
M]7N=3QK78:Q0#U?(%/CUG<5*,VB3IFNHR>*I"8A@$2*&*/8$0U]<?80^U5]I
M+?W[7.X^Z&^>^^\NI[KWVJ2,N+6YOII8)F"TN7ALD;G%KFAS6NH1M`.T+0[S
MZ'H]KH-S<6]M"R9K`0X-`(Y0V%=R0Y._*`KN-R7:Q<NS:?W.@Z2G9YURUP37
M)5Z#*.@RRDFX18LHEW)R+DJ")S@DD15=8W8*4QQ`!_JC7B*U+A-O']&XM$+M
MMGJMM.V=V9ENZA\F3NWM*"VR/I"1OT;AN#F[%E$YXM*B]OU1W2HNM2/;C::3
MCG(.&#AN1,[A%1(I%5S&V7^CIP&"ZUN8EME^UAI@BW8SI>8H3)1MI\PI!*8T
MR';(2E5"VOTTJ$I*0T;*SUE8`?MQN@HS:N2NG146I5%B$6V-?Y0_)ML]@N]9
MB.75M55E,>2T3!V@SC;W",8U"5F:Y%6QFSC9AY!(14ZH2!FVBRXLEG!6PN"$
M5$B@]'1%:O14<D+Z5EL&_4;V2AEYOCM'+2^/1Q%2PLR6-'%D<U!&ZG8#&@8L
M`I9VBK$%^/#M@@ET133T,?)XZA1SZ/C9IVLB*!57'T0T7J$C.A(5L"BO:?5D
M%P94H$XB'3$P<./$-$4>BN4AR49R9ME=AMC&QV4GJ'*,X2[1##&&/74C4YF0
MA&ME91-A:HMCK1,DYKSY%\1!<"*BT5(KPZ!@,)%XU+E)<F"[L)&2@>7IM0!G
M&7*S4%=2;V]1-8,YLU2FWU?EVT2C9:[$K3<<>2CE>TG[,J["20`%VBRZ!BJ"
M107/W+=Y%.V"FL[[FS8IM"J-<DI=S`Q2B6WV+L,I,2["JV>]R3"'@:U7)>;E
M7,92*5,2ZY&[=0Z;",<*\!`G`2+]S3RV>1=M[QK'Y=RQL-VF5S'TK9L=T]C.
MMMN;.P&6L66+3"4C'D<,77JO*3"1K-;K(P8)*';E227=I]<9,O2,!%D"L<H[
MDIW1!^ZJ.Q;8_96T7:IZBR+B#Q?CV30972K.7+*RU1PJS;+)DL,`\9K)/&G'
MKVRB)RJ%*)#`!%$,5<L?D9YK@)ZSXVV+[.)V&K%_R5B^><N,%0$$K'7K#]RE
M\?Y'@U6E@@8MXH-8MT$Z9JN$R':JF2Z:*JB9BG$BRJ]Y*?*/09.UT^7-M#Z:
M+5PJ3CA6G<.DFD<Y>/"/`>'$/U!U(VH=BIX;DJ\I)W#Q3I;ES[1#+.8UBX5-
M]"E.#I*K-4E%!X=S^QQ.8=0H&Q7+T)O*-]7-M$\RM.[W:*4]";RC?5S;1/,K
M3N]VB)Z$WE&^KFVB>96G=[M$3T)O*-]7-M$\RM.[W:(GH3>4;ZN;:)YE:=WN
MT1<EW7*OY<"?/6@MOZ>R7;:3"3SE+VS,3O%I<6UD*2YRG&[PZ72H^_K0':7:
M![4RJ4LZCDW@DZXK1P=,!Z)A#1%?N7C_`+$&VC_5ZM_I79=>DZ5^[8/T86Z@
M_,L_%6WQI&.(X(T/(QQ'BA^K39G?M".SJ=$#=61J98%S*=$P#T0+QX#QUG5&
MRN*NJKU*+]$!*/`0$!_6$.`]GLAV!_Z-$7P8Y""0#G(05#=6F!SE(*B@E,8$
MTP,("HH)2B/1#B/`!'\`#HB^M$7-?+;8SSG%\KEJ591N+G!7,$0!PD1,ZC<5
MZ-CI(%R$6(HB8Z0G`0`Y3%$0X"`AV-?EC_[P\H@^Q=JDQ:'!NLZ2<IJ`:7T1
MH2"#0TX"#Q%;_=05WCA'_P!*7^RNF\;LKI<?BK&.&U+U=7U+Q*XP&O5V[B.Q
MXF^>!MWLL':*82SNVE(;C8#2;NMM$9$RI0Z;8%2MP;'754-_+9=>OC7;G?#5
MM^&Z?81Z]K+=7%P6OO2QOSU!+!=&!KKIW,\VV>1T(:31^0R\ZV-C1ZJW3(A;
MQVV=QBCYNF#?_+(+:\G&M!7J;*563+IMTJ5KM]@O47-V>B66Y8J;83N3ZG.8
MUH%AQU&R,_*U^/,A(1DBC%S-3=VV7[E2+0J+AJ25<E'K`ZGJ>5T+UG:SH^B6
MV[UW;VFHZ58ZP[5+9ERU[N9O7LACF?5DC#)%<-M[;QB&0N9(;>(C+R\]^6RC
MDD,K2YCW1Y'4IBT$D<!H14T(V5/4IERFU"MX^J%5H5-B6T#4*16X.H56"9]8
M+2%K=:C&L-!Q+45CJK=K1T8R21)TC&-T2!Q$1[.N*US6M4WEUN\WCUR9USK>
MH74MS<2NIFEGGD=++(Z@`S/D<YQH`*G`!9,4;(8VPQ"D;&@`<0`H![@4DUJU
M6FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBY$<^D!'E$
M;W^`<?\`[M:\/8_6#)E&$1_]P:^VO_;C_P#WM^KW_G$O_HKI<WO=_IN[_1C^
MTU?T$R];D;E@Z2J$0_:1<K:L5NJW'2;]LN\91SV<J9XML_=M&KEDY=-V:SH%
M#IIK)'.4O1`Y1'I!_9$OGU<J(#DYUNE9JQ/E.E93/%U^F;F]Q>Y"PX^>5YV]
MBXXNYC;;:\*WK&&(G03Z2=!IB&1\E6J_I`JV?BI+SBK<Z?5@"H$6=-OW+CB:
M%M(B]G&<;9`9AQC7MI7U)F@Q%2>U!:SX:+$N:ZO.6ML_LEH*C>)>!!J546*J
M;5J[;G70X=:0B!%F#`VW[->W&H;4,2UO+<=DVE8^J]EAMSU\R;6EW.5LU6(M
M*8,:C?8>P,+&DUKLX6XL2B]:N6<HFO#G!`KA%1JD+@BPS:]@%TL.\S#^]]CF
MEK#91HERRK6KS"^"JKRH9!VH9+JD;64\#@T2EH^7BY2`E:E7;*A*.'D@Q3LD
M:Z<)1R1)-R0I%HWC+D8VR@;?<CX0=;H6[^3M`[70H^1(&@SU9FL?OMKV,K=C
M2M6HT.YR'8JY<Y:PHSC5Y*Q<PU>5^1;$=QR[,Z;A%TU(MA\A<HJ$R1D;(5EM
M%XHL[2<G<PW"N^:Z4R9Q.BOX3PN-]K<7MRMN%K*X1LZ4;.05S>QAITCA9H+=
M`7KILLS<@J*HD6*,K\F6_P!\QK'8TJFY*I4.,CMU&Y?<DT>-\13CV0AV>:MP
M^.\^T7'M7<LLIPA:Y%8\5HHQ#I=),YY)NHBH@5@5%5NY(ME>8IRYLD[Z[;C1
M[$;EEL44G'\*:3@JVI0EK1)8WW`UB[5N_8AW58DEF=QJS>.RQCUY7UH59G-M
MIB&DZU,2#(44!<JJ'(K_`)7V$9"RYL-Q)M(L&7*4UOE"R)MLR/:,H0^.;`RK
M-JF<`YXI&=I%1E1Y#(LW,1#G(,O20;NE5)QV5JJ_6<)IB4J;8"+5:?Y-5T<R
MF-?!3<)1JC`8ZWE9BW;E)'84D6]IGG&3M^&--Z$=27MBB\GQ;9JS@HJGOJ>N
MX39B9ZT7:K]%-)N=DJ12U+EC247DC`+%S)STTI3]Y&]W==9,P5V,J<14#X;W
M8WBYV[(6SR]U:>M\G:;#&9"<7J*+W18QZK8PU07)SL%3I)*D7:Z3_P`62'^`
MN_XNIJ1M4'8J2N_F_!?R-&?Q)#4(-@5YT4IHB:(FB)HBXG/O^8VK/\R=>O\`
M?JQWHBTCY>/^Q!MH_P!7JW^E=EUZ3I7[M@_1A;J#\RS\5:@YEVQ;A)S=5OES
MMCVNHM0E=L^'2[=W3R`QW,+W;</BK'&:B5!S7IBQ.UI.@RU"RI8JS(%<N$FK
M"7*@9-P=1!`0U9FMYW74T\8VQMR8#%[0ZE*[*.(/$52Z-Q>YX]Z*=<5_IHLB
MMHWF#5_-6V"$:3N1[OB52*HDCN2NMI-@)DW0D[G3\T*9#@(V+KT?`3Y38YO*
ME2*U709K@BR11!NH[Z4B=:L"^;-&T%SHJ#.3EX0ZHPQP.7W-E<5/Y4.:,2WA
MV=7^I8LV]PO,GHLGL=IUQC,E25(KD%5&V[B;N5IP[:`E969#<(7(*B$DUEUK
MQ+NF-@\#'R+I`QQ29JHE:%[,@F-JW&H,,+'AQ8`,Y):??5ZNW+_1PJEG.C*#
M6G#LZO\`4II0*MO=E+1AUCER!MMPC\;<P0EL-?;HEAERO(;.Y/%>3RUF?-$0
MB:2]5RA1YZULZ_.JQB9)%T='MAF=1HNXXUL;>%S!*"0V>M3E_-Y339L()H:8
M\6"D"4TS8T?MPV4*R3L51WUM;#D]+>"XL+V`=5:I/:&O8!QD<6-N+D_.;:S1
M<8?'J3=P$=]%I*,L/;Q5>DY,L)%16[9(%RR\=#G>-URT%*TVYG5V?[N7:JH^
M=J><V?\`Q_HHM?\`?+@JI;C>9QRSL6W>UY6I=<?X=WT3CRP85OUFQID)L:MU
M?&TLDA%6JH*)V!%L[%`4W#9`?[J3'JQ`P#P'X`_]SKUA:SZK_LNWV]V@6>CW
M^J1ZIIT38=4LX+ZS=S]W%&3);W(,)<VM6/?^;=R@12JW.@6D=[K<5O*Z1K#'
M(:L<6NP;7`C'KCA66V_+RV%.J-5,E([M>9Z:D7L^,$Z3/&W1[NTT+6;,TFUA
ML9=PFRL:1\^"U2C]LBGP2#M8SI$7/4E53$W\]$GVF/M%1;P7FZLFYGJE&OZ<
M+\W4/S!NX3;_`#8QTM]SK@\L9XO&Q[C5W+$<G-9RQP'H0T;23$V<7%_S3\N4
M\[-CG-&TPX33K5%:(UY?/+UD:^PM,-O:YAE@@WU+FLC*.J_O6W(S:\-0ZW,/
MJ]8;79XZ.6<2=5B82P13QBY&11;*)/&+M$2=8T<E2F;[2GVEK74I-(OMP?5G
M;:A'?Q60;-NOHD0ENYXF30V\#W@1W$DL,D4L?,N>UT4L,@=EFB+PT?1W,$C;
MJ\+"TNPGD-&@T)(&(`((-:8@C@*F5UY76Q_'C/&<G;]Y?,'BXC,5VJN.L;3:
M6^;<!*P5HN-Y:N7=,B&TW#R$A%,RVE-H8K!RZ60:.EC)I$5%59$A]%H/VN/7
M_O-/JMIHNXWJUFO=#L+B]OHCNIH\<UO;6CFMNI'12L9([Q<N!F9&U\D;0Y[F
M!C'N;<ET'2H0QTES>!LK@UIY^0@N=W(J,,>`G`^Z%21_+#V2S&0KEBR"W:<R
M>P7G'4_3*U?X:!WB[FI9*ERV0*T]M]42L<NR,K"QS>0KS$7"BQG`HM`60*X,
MD=P@52]<_:R]?=CNU8[WZCN9ZK+;=_5+:ZGLY9MVM"C-U'9SLMK@P1NI*]S)
MGY&M#,TF60Q![8Y"V!H6ENF=;LN+XRL+0X":4Y2X5%3L&&.W#"NT++:?)3VV
M*GZ"6Y_F)*'$%1`B>_'-QS\$5>I6'HEG1'@DM^(;_P"J;L#V=<8[[>7K38,S
M]TO5D&X8G=+2AM%1_P"5PC$<8Q63Z,67A[WIW]M16:Y0VTR$2E14W4<QJ5?P
MT-&V%]7ZSOASY:;46#F'KB/BY="K5^5D9]U'/W;-<J2R;<R:G:ZHE$024Z.X
ML/MJ^N6_?#EW0]5\-M/.^%DT^ZND6]OSL30^2,W$T;(6O8US"YKG@C.RHY;:
MVW;N:>RO]XO20`:">0FAV&@)-/<4I-R5-M91$#;H.8B42N"-3`;?CFT!*Z4*
M0Z;80&=[#@Y%"B!/[(0,`@'9#6H'V\?6H<1NEZLC5I=_I+2NY%07?FM@(()V
M8%5^C%CX>]Z=_;51Z$G;K]I?F,_?KSEW[U:]O?UG?PIZL/\`I/2OBE/HO9>'
MO>G?VT]"3MU^TOS&?OUYR[]Z>WOZSOX4]6'_`$GI7Q2>B]EX>]Z=_;3T).W7
M[2_,9^_7G+OWI[>_K._A3U8?])Z5\4GHO9>'O>G?VT]"3MU^TOS&?OUYR[]Z
M>WOZSOX4]6'_`$GI7Q2>B]EX>]Z=_;3T).W7[2_,9^_7G+OWI[>_K._A3U8?
M])Z5\4GHO9>'O>G?VT]"3MU^TOS&?OUYR[]Z>WOZSOX4]6'_`$GI7Q2>B]EX
M>]Z=_;3T).W7[2_,9^_7G+OWI[>_K._A3U8?])Z5\4GHO9>'O>G?VT]"3MU^
MTOS&?OUYR[]Z>WOZSOX4]6'_`$GI7Q2>B]EX>]Z=_;3T).W7[2_,9^_7G+OW
MI[>_K._A3U8?])Z5\4GHO9>'O>G?VT]"3MU^TOS&?OUYR[]Z>WOZSOX4]6'_
M`$GI7Q2>B]EX>]Z=_;3T).W7[2_,9^_7G+OWI[>_K._A3U8?])Z5\4GHO9>'
MO>G?VT]"3MU^TOS&?OUYR[]Z>WOZSOX4]6'_`$GI7Q2>B]EX>]Z=_;6JO*IY
M5N&=V>$=QN1,V[H^8+W0Q;O?W;X-@GD5OES57H]CC3#.0UZ_40E.A.`@L_8P
MB?\`=;TXEZXQ14,!0[`?T[>IOU1^IG?7U0;J;Y:]N3N8_7-7W;TR]N7,T33F
M,,]U903S%C!;G(PR/<6MJ<HH*FB\9U"_U&VOY[>*YN.:CF>T5D>31KB!C7B"
MWEEN3_RQ(&"1M$[S!]X<+6G#UW'(6&7YH]_C8-:0CV+&3?L$I9[=$&"CUE&R
M;9PJD"@G30<)*&`"*$$?2/9]]0G\#[G_`$-IW[.L/YUU3RFXZ1_;4[KG(NV(
M7&/CY:H[P]_MIBY=&8<14E7.8UEZ<CY-O79%.'L"\>\C+(Z;O48*75*U>&3,
M8K5R8$E!*<0+I[/OJ$_@?<_Z&T[]G3YUU3RFXZ1_;4*J')VY9F09XE6H7,`W
MDW>SJ)G63KE0YH>0K+/'138IRAU21$-<WL@9,D8L1P)@3X`@8%/[`0'3V??4
M)_`^Y_T-IW[.GSKJGE-QTC^VLF3/(-V7UR'EK#8=T_,5@8"!C7TS.3DSS!\U
MQ</#0\6U5?2<M+2;Z>091T;',D#K+KK'(DBD0QSF`H".GL^^H3^!]S_H;3OV
M=/G75/*;CI']M53+D`;.Y)FTD8[<YS'G\>_;(/6+YES`,X.F;UFZ2(NV=M'*
M$V=%PV<(G*=-0AA*<H@("(#I[/OJ$_@?<_Z&T[]G3YUU3RFXZ1_;5+*\@+:3
M'HM5"[C.9,J+B3BV'`V_K.Q0(5^^0:G4#A,#Q,F141`/U]2/L^^H3^!]T/H;
M3OV=0=5U3RFXZ1_;5S_J^>T?[2/,G^_SG7OSJ/9]]0G\#[G_`$-IW[.I^==4
M\IN.D?VT_J^>T?[2/,G^_P`YU[\Z>S[ZA/X'W/\`H;3OV=/G75/*;CI']M/Z
MOGM'^TCS)_O\YU[\Z>S[ZA/X'W/^AM._9T^==4\IN.D?VT_J^>T?[2/,G^_S
MG7OSI[/OJ$_@?<_Z&T[]G3YUU3RFXZ1_;3^KY[1_M(\R?[_.=>_.GL^^H3^!
M]S_H;3OV=/G75/*;CI']M/ZOGM'^TCS)_O\`.=>_.GL^^H3^!]S_`*&T[]G3
MYUU3RFXZ1_;5J8\@/:2[?330VXSF2D"+>MFQ#EW]9V$5BN(MB^$QRC,<"F*=
MT)>Q^$`#4^S[ZA*?Z'W0^AM._9T^==4\IN.D?VU=?ZOGM'^TCS)_O\YU[\ZC
MV??4)_`^Y_T-IW[.GSKJGE-QTC^VG]7SVC_:1YD_W^<Z]^=/9]]0G\#[G_0V
MG?LZ?.NJ>4W'2/[:?U?/:/\`:1YD_P!_G.O?G3V??4)_`^Y_T-IW[.GSKJGE
M-QTC^VG]7SVC_:1YD_W^<Z]^=/9]]0G\#[G_`$-IW[.GSKJGE-QTC^VG]7SV
MC_:1YD_W^<Z]^=/9]]0G\#[G_0VG?LZ?.NJ>4W'2/[:M$]R!MI,/%.9$NXOF
M2KB@9J'5'W]YV(4X+NT&X\3!+F$.B"W$.Q^$-2/L^^H2O^A]T/H?3OV=0=6U
M0"OC-QTC^VKO_5\]H_VD>9/]_G.O?G4>S[ZA/X'W/^AM._9U/SKJGE-QTC^V
MG]7SVC_:1YD_W^<Z]^=/9]]0G\#[G_0VG?LZ?.NJ>4W'2/[:?U?/:/\`:1YD
M_P!_G.O?G3V??4)_`^Y_T-IW[.GSKJGE-QTC^VG]7SVC_:1YD_W^<Z]^=/9]
M]0G\#[G_`$-IW[.GSKJGE-QTC^VG]7SVC_:1YD_W^<Z]^=/9]]0G\#[G_0VG
M?LZ?.NJ>4W'2/[:?U?/:/]I'F3_?YSKWYT]GWU"?P/N?]#:=^SI\ZZIY3<=(
M_MJU-^0)M)7EI.-'<9S)BECVT8N"OU^\["94S\7W2`2]V``I4P:AP_#QXCI[
M/OJ$_@?=#Z&T[]G4?.NJ5_Q-QTC^VKK_`%?/:/\`:1YD_P!_G.O?G3V??4)_
M`^Y_T-IW[.I^==4\IN.D?VT_J^>T?[2/,G^_SG7OSI[/OJ$_@?<_Z&T[]G3Y
MUU3RFXZ1_;3^KY[1_M(\R?[_`#G7OSI[/OJ$_@?<_P"AM._9T^==4\IN.D?V
MT_J^>T?[2/,G^_SG7OSI[/OJ$_@?<_Z&T[]G3YUU3RFXZ1_;3^KY[1_M(\R?
M[_.=>_.GL^^H3^!]S_H;3OV=/G75/*;CI']M0W(7]'3V.VFDV:#N^8^8#?*J
M\BEU)BH7/>]F2QU>>18"611934)+2#N/D&G;;1,_043,`'(!@X&`!#:Z)ZF?
M4]NWJL.N;N[I[M:?K5N[-%<6VF64$\3B"TNCEBA;(QQ:2VK7`T)&PE6Y=1U"
M:,QRSS/C(Q!>X@]<$T*[M1]42:L&+5O.61)NV9-6Z"8291!-%!!-)(G$6W$>
MB0@!Q_5UZ0L.G757X-C\H++\9D][:)3KIX-C\H++\9D][:)3KIX-C\H++\9D
M][:)3KIX-C\H++\9D][:)3KIX-C\H++\9D][:)3KJQEBW(V56*&P6+M0D&A(
M`'=!/I]L*/W#8PB?M;I"3JT@['X..IX%%,:*^>#8_*"R_&9/>VH4TZZ>#8_*
M"R_&9/>VB4ZZ>#8_*"R_&9/>VB4ZZ>#8_*"R_&9/>VB4ZZ>#8_*"R_&9/>VB
M4ZZHY&NB2/?&[O6,W19NC=$TD00-P0./`0[6_`.I&U",.%7FN_F_!?R/&?Q)
M#4(-@5XT4IHB:(FB)HBXG/O^8VK/\R=>O]^K'>B+BGCK<[:-KNP79K;FE$E)
MS'3S'=^<94R/%T^Q9*:X:CX&0EW54L]WH5(E(^\DQ=+3KLS>=LD<C(A7$$R*
M*M%>V"&)WMK<NMM,MW!M8^;Q-"<N&!(&.6NTBM.+%;9CRR!AX,N/#1;)6KF)
M8UQ^;<=(72DW<U,VX+XI83%XIQ("SQ%S=9*P*[W#&DJXB:<CE&%>:4EN0K)=
M^=`\D[62;D*"ZR29LQU_&SG"\')'EQ%#6K<V&.RFRNU7#*T9JC!O:JL8Y(YF
M,%B^\;B("RUM9"G4V@XNL>#[^PKSV89S5ER3M5R;N>:0&3H/PIB)ML+B`QD]
M[1+'HH%5!(S9PX;KJ(J&MR:B(GR-<.0UK2TTX2POQQKL&%.M@H=-E)!&%!3L
M54I<[[)IAD:W522AZPUK43;>6U7*U848.Q/G\N.^=A(N)A&6B"V1L:(/$NF*
M:,6Y*=<C'MCI/$70)FZ57CKA(6D#*#"`<?\`S/=['W4YPU(PVM^ZLG3._K#=
M>/F4DU6LH,?H3R]B_`$ZJ6O0$@SLV;<NN&2=5QA2W\9:WC*4M<>TEF+F:1<'
M:$ADGZ";DY7)C($N.OH6Y\P=R'ANP8N=L`QV[*\2JYUN-:X&GNG@7U9M^F+*
MQ,6&(4QSGZ8"G[?Z-N8NKZ&Q>=0*1B[(;&[N*ZK;8.0FX^XQ%F)(T%]'O8L(
MQ5TR=B7K0!$JRJ4NO8FDC+(:1AYPV`UI7&M<*4HAE:#2AV5V+7N6O,%E[FD<
MHC(M%>MGM=R'MFWZ6.JR!G<;)LW,=-8_QVI&NS/:])2L6]:JE,4W3:.EDS$'
M\4_'\'Y=_P#O`SP^Q9J5R^I@^>=(<<M*EHOX2:'$5ILVBJZ'=(YMX8"WABE_
MLKHG7=C5IA<"X=P>-NI#='%\AM,>R]CBXR]MWMU4VTW&LV5XXZE2ZF\$U[2S
MK0MVX,3B+)9Z=8YW`)))Z_FBU/[0.D7WK%US?\65^Y^K1[Q-C@DDM"VU&N6T
M\#146O\`>!;NGSOYT4E;$UC6QE[WKT]FE2-M([7,RD9BJ0'<KFG`^^PK3"FR
MM<5EAUM(:4^VVNQ8)D*OC>*O&WN"V\2E3<5@TA7JY$U&RY(L]2N579,WS#IS
M#)_EV?/),W)A1F5ED%E%T54UC.>.B]<\VMZ-9Z9ZPXKO5+S3]Y9M9CN&SY)I
MY+F"Q@N+:=SF/I$YFFV8@EC&:V:V1C8WL<P19!TX1R.?:%K&OA$9%,``7$.'
M5Y;J@]U@:C&L1FMA5==81K&WAGD:]2V,8&%J]78,;K)MYA_1H2B8;L>+Z._Q
M<YBH^$5KMFKDW(1MA2=.E'HA)129B=6(@8NZL/M%:G#O]=^LR?2]/AWLN)Y[
MA[[6,Q,NY;O4X+^[9?MD?*)H)XF3V;HXQ%^0N'!V8`@VG:2PVK;,/>8``.4:
MY0UA:W+2E""0ZIKB%C-UR^;JO+STLYR[7IR1LL_B"V6.=EJ0\:2UKMM'Q'ES
M'U_LTVWB;$A%MWF1+%E9:3(W:ID:QK5#M(A5$^K,EU</VE-!CLK:RBT6YM[6
MUMM2MX(8[IKH[>WNM1TZ\LX(G20F1S;*'3VP%\CC)/(_GW%KLP?9.CREQ<9&
MESBPDEN)+6/:XFAIRB^N&`&"CT5RU;+!Q4DQK66*Q2)B2I-OJ(6ZI4208SC1
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M#4'W5OI%[\T7.C>+3:?)=L=:Q7#X8(IG::]D$5SIT+GVT5Q&(YGO8[-!,+F`
MR-EJ&E39`TR-YP29@\-.8BI(SU):\XD&H'&*&E.E.OE=;M-$31$T1-$31$T1
M-$31$T1-$31%ROY/U#^E/EY<RC&(UB*NR>1M_?,^HCBFSMCEZ=#6QI;K[,P#
MRMR=NKZ#J=JS*;:R!VRDBS25=,2J"LD0QR%*/]RGV;__`-N^X7__`!>B?_XR
MV7S5J_[VNO\`,2?VW*798Y;>Z6U\LO?%M#3N09JN^62H5K:]8MP4Q2'&9*WC
MM:`Q`P>U?.N;:?66K3(*\1,45VC'3*K1U,.:\TBT'YU5T"D0]H6N6P.<]J^Z
MFP;O]M^[W$$?3H0N!\IR&,)K#LA-DA(O(>TG.-3;J;DK%(RD7,.ZT;(3K*18
MNPL(]:'Z]Z]J+(%I)-)TL!"+7++6P?>\USYO(R=MW>5[&5:SENZVDWV'6HN0
MX>@Y(DMN^+]F;G;1D2)IT^-0G([&MWKM^[F6"+;J)J,9:'B#,')@3=+,E"*'
M9?J>^+(^[K>-A^M6;=VO%6+;YGS&.`K"[FZQ"[:U<I7C9-B>(I$W>6C.WQ4E
M7J74,LUZ?>Q4\A0W2+JV6EVBL]5309-6Y%L3*;8.8[+/,ZLW6:+M622V"<$U
M[;I:L9YF9-8O'ME88_P[`9DK-UP[/5R/K5NGV>4*%.6%C86TI&.I2"L[R)!_
M'&!LHW(NI&,(O),'@O"4+F-Q"/,M1%:Q1&9+=UN4GYRON[TP:P;6U.H:8M2[
MJS2D:XFDECHKR"JSQ4@@991103'-(4'9[H6=]0I31$T1-$31$T11J&_QU;_Y
M5CO]'8C4G8%"DNH4IHB:(FB)HBBEV_-F1_MD=_E1EJ1M5+NY*E>H52:(FB)H
MB:(FB*-1_P"=-D_D^N_^,:G@4<*DNH4IHB:(FB)HBL%K_-BQ?R)*?Q)?4MVJ
M#L5Y;_WNA_:4O^H74*5[:(FB)HB:(FB*+%_/9?\`S6:_Y6>:G@4</N*4ZA2F
MB)HB:(FB*AE/\62/^`N_XNIJ1M4'8J2N_F_!?R-&?Q)#4(-@5YT4IHB:(FB)
MHBXG/O\`F-JS_,G7K_?JQWHBYU;(<9T#(&R7:VO=*I&6)>-Q79(5DN]%VDLC
M"6JS2Z%I@S*LG311Q!V9O&MTI!DJ)VKU)$A%DSE#AKT738V2:;!G`/Y(?=VC
MK'A6YA`,+*C\%;!7;:CMGR0YGGE]P7CBUN+1(5V6L9I6!(=.9DZE2)G&=9?O
MFR"J#51S"X[L+V#1,!`X13@S8W22`A2Y;[6WD),C&FM*^X*#[AIUE<+&':`?
M]J+TDMJ6VZ=6DG4M@^@RJLG4&5$EU7D.HY[>IT;0Y'%D;"/@.X$BR$;C68>P
M#=<X=M(1+URV35*DX6*>3:VYJ2QIJ*>Y3+]ZHZQ*9&<0_P!L/O*ZK;9L%.7_
M`'07Q!5%Y)U)8>D^VE&#PSEQ*[?DA1P8]`PNN*CO%2:PA"&[(M.EQ#I"/'4^
M+P5KD%:M_P"'N?@\"9&\6.'W-G86.ZOM^V<9$HMT94['&*KICN_76PO+NE"K
M+S5?FLDUK([^?M4DZ43DU@C+]`Y88.'+YVV,VDF\TV$5#@JB4"6VP6DC"&-:
M8W$UXB0:GW<WNU4!L9!H`0?O_P#Q67UL,XJ7E[#/J42#+.VRG5+'UCF4"O6D
MG+TF@R3V9I%:</6CQ!PG'527DG+ICU1DU$'"ZAP/TCF$;W,Q5+LHS$`'K#8/
M<X%5E;MIBN36[;"5\GN9!RK</[6\Q_4_GHS#&]]"H7ZGXRIF14:E!QE>QP^E
M8-C1+L'@TZ1GT#J)*+J\5DSJF6`15$3#^>'_`+GF\NY&YOV5M0UK?_=J'>O=
M6+4=/:_39+RYT]DCWW<;8Y/&;3\NPQ/.<-;@\C*[`K:[OP7$^N0PV<I@FR24
M>&AU`&XC*[#%;[?4/YI7KN,@_<5VM^QU_-'[0_V1?Y!Z;_U9KZ].^:=>\Z/Z
M")/J'\TKUW&0?N*[6_8Z>T/]D7^0>F_]6:^GS3KWG1_01)]0_FE>NXR#]Q7:
MW['3VA_LB_R#TW_JS7T^:=>\Z/Z")/J'\TKUW&0?N*[6_8Z>T/\`9%_D'IO_
M`%9KZ?-.O>=']!$GU#^:5Z[C(/W%=K?L=/:'^R+_`"#TW_JS7T^:=>\Z/Z")
M>:NQ+FDI)J*#SM\@B"9#G$/J*[6_P$*)A_4#];53/M#?9%>\-^H/3<2!_JS7
MU'S3KWG1_01+"?+0VX<U+F`[(<';O)?G,7C%\CF!K?'#FBQ6R3;#9X^!&F91
MN^.DB-YU\WB73\)!&H%=F$[=/JSKB0.(%`P_T,6W_MB_8:EMHIG;CBKXV._>
MNL?A-#J87XV5IL7E!WSWE!(\9V'WD?>K>ST5'-`]>MDC[@VU;WSJ]_VPOL,?
MP./I76?V]1Z:;R^4_P#!'WJ>BHYH'KULD?<&VK>^=/\`MA?88_@<?2NL_MZ>
MFF\OE/\`P1]ZGHJ.:!Z];)'W!MJWOG3_`+87V&/X''TKK/[>GIIO+Y3_`,$?
M>IZ*CF@>O6R1]P;:M[YT_P"V%]AC^!Q]*ZS^WIZ:;R^4_P#!'WJ>BHYH'KUL
MD?<&VK>^=/\`MA?88_@<?2NL_MZ>FF\OE/\`P1]ZGHJ.:!Z];)'W!MJWOG3_
M`+87V&/X''TKK/[>GIIO+Y3_`,$?>IZ*CF@>O6R1]P;:M[YT_P"V%]AC^!Q]
M*ZS^WIZ:;R^4_P#!'WJ>BHYH'KULD?<&VK>^=/\`MA?88_@<?2NL_MZ>FF\O
ME/\`P1]ZGHJ.:!Z];)'W!MJWOG3_`+87V&/X''TKK/[>GIIO+Y3_`,$?>IZ*
MCF@>O6R1]P;:M[YT_P"V%]AC^!Q]*ZS^WIZ:;R^4_P#!'WJ>BHYH'KULD?<&
MVK>^=/\`MA?88_@<?2NL_MZ>FF\OE/\`P1]ZGHJ.:!Z];)'W!MJWOG3_`+87
MV&/X''TKK/[>GIIO+Y3_`,$?>K>'ER["+5L`P3:L0.=Q#_.MAO6<LL9\N62K
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M`PRA@#]L2#CV/P:FHXE!!(I55W<VU_*EC\VR=]M14<2G'C3N;:_E2Q^;9.^V
ME1Q)BG<VU_*EC\VR=]M*CB3%.YMK^5+'YMD[[:5'$F*=S;7\J6/S;)WVTJ.)
M,4[FVOY4L?FV3OMI4<28J/LH^RC8IXA+&S*L1C!"LL-?(8JI3=U>J*5+NF'5
MBET3<1Z0]+I?J<.S-138HQJI!W-M?RI8_-LG?;45'$IQ3N;:_E2Q^;9.^VE1
MQ)BG<VU_*EC\VR=]M*CB3%.YMK^5+'YMD[[:5'$F*=S;7\J6/S;)WVTJ.),5
M9;)'V<E>G3KV1FLB6'DC*HEKQ$C*I@S6$Z95>Z9^J$Y>P!NB/1_#PU(I78H-
M:;5=48VU"BB(6AB`"DF(!X-D[`=`.`?XU#\&HJ.)3RN->O<VU_*EC\VR=]M*
MCB3%.YMK^5+'YMD[[:5'$F*=S;7\J6/S;)WVTJ.),4[FVOY4L?FV3OMI4<28
MIW-M?RI8_-LG?;2HXDQ4<*PLOA<LGX1L^V?!QL<7'<`G1%$9-V!4>I[I]@Q3
M@(]+I=D!X<.QQU.%.HHQJI'W-M?RI8_-LG?;45'$IQ3N;:_E2Q^;9.^VE1Q)
MBG<VU_*EC\VR=]M*CB3%.YMK^5+'YMD[[:5'$F*=S;7\J6/S;)WVTJ.),51R
M,;:0CWPGL[(Y`9NA,4*X0HF*"!^)0-W5'@(A^KP'4@BNQ0:T5]KOYOP7\CQG
M\20U2=JD;`KQHI31$T1-$31%Q.??\QM6?YDZ]?[]6.]$6D?+Q_V(-M'^KU;_
M`$KLNO2=*_=L'Z,+=0?F6?BK<G6>KJT2W28/W*Y0S1MVN.&<@0U*HN,+51[-
MD)F]R!>Z])V9O!9CH]DL]>9U:"A92J2S*QXOC9>.5</3)N%C.2LS]%HJJ(X5
MS#<231OA<`QI!.)%>4"1088BH^YL5M[7N<"TX#M]I:O0.RC>O"$W/"UW!-VQ
M\MPDR6B)KY9RI,(QT@.\^\9NCH14TC&JJ8^C9;;;8VV/UGT(!EH\"&ZI)5!)
M$XXPL[P<Y23NQARG>$+O<Y!RU&Q6Q')RL=O5/'7[V"WEV:8/M&WG"CW'5O4K
MIY9WFC</DM!&K2TO.1,;!YAS9=\H5Z$[K3D7#R3^1@H>U(LW:IT.BHX0,<IC
M%,`ZS+2%UO#S;Z5SN.&.#G$C;UU=C:6-H>,_=-5M3K*5:YJY=75:\XGE=.4$
MTUEF^">8*NBDLJ9!)55&BX[43357(BX.BF<Y0`QP3.)0'B!1_`/Y9?\`O#1L
MF^Q?JD4A+8W:SI()`J0#?P@D`D`D<`)%=E1M6_W4--XX2-O-2_V5T+D=[CV-
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M-VTQ0&'5K24SQMG+3*QACH)GP0_5;0!I8X.!J=CJT`?6G)Q-8W"AIL..RM=(
M[T<.5YTP6MDRY@(F?QQCC(=;8%JV1YN^NF^0:WEVZH-I2GP-$DD6"#>GX<EW
M::B#]VL=2/>)+(MQ2;F=X]KZB=^-3AD9HT#;F]MM4O;*=_C%E%:-=9SZ=:ET
M=S-=L+R;G4[:-P=#&T":!\<DN>40U.U.V809#1I8UPP<7<H/=B`T\#"=IV&H
M&%=J(29BK'#1%A@GS>4A)Z,83,/)-3=-K(Q4HU2?1[YL<0`3MW;1<BA!X!Q*
M8->07]C>:7?3:9J$;H;^WE?%*QV#F21N+'L<.`M<"#U0L]KFO:'L-6D5!XP5
M5N_[U<_X.M_\,VK$/YYGXP^^I.Q:8_T<#_@M[*/Y,SE_O-9HU_??9?X&W_R\
M7ZMJ^6W=T>N?OKM_K)4)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBC4?^=-D_D^N_\`
MC&IX%'"I+J%*:(FB)HB:(K!:_P`V+%_(DI_$E]2W:H.Q7EO_`'NA_:4O^H74
M*5[:(FB)HB:(FB*+%_/9?_-9K_E9YJ>!1P^XI3J%*:(FB)HB:(J&4_Q9(_X"
M[_BZFI&U0=BI*[^;\%_(T9_$D-0@V!7G12FB)HB:(FB+B<^_YC:L_P`R=>O]
M^K'>B+B4\S)?=OG)-K.9<7V)M5+]1L7T]U7)MY'0<NT;+3.=F-9?I.(VQM'L
M.Z(YB)MP0`5)^(<2G`0Z.N]BED@T)DT1H]L3:;.,#AZZVH<66C7-P.4+(,!S
M!WU%W%XVVOW*O*Y!G+Y<<)QEHM3O(V/1L>(I+</9<E5RNXREX;'M-:U6X25"
M6QL5V[>H/&BJ[":1[!U4@%:^+\LN&VSQF<XMJ:BK<Q(`P%#2G8*K$I#PPX[/
M<K58\V[\S6P/*/GIOF6(@)NR87EY2<CKL>X5NH1%JJ%RWPYJVL4.`E8U&OLF
MT#/5)''K,>BV[HNI\%"%2(#U8$S6[?47%C^=`+F&M:@5!D<P#J$4ZM>NH9,:
M'-M';(4QJO-=AK99-IT2SPLHVB=SU0P!9UY-SDV-[HT%WGK-]YP*RB`AB54R
M-H"LVJE&=N%^W&`JL5A#JR+DZ!JVZF'.B`9A(&';LS.+>+&A'44B>I:*=U3[
MIHKS8>:"SBFRC^)PH$VVEMQU]VS4UFXR_3*W/FR%C(^9"V*'R?$6!BQ3Q%+6
MHF)$#U4DDX.SFRV5C_=*(H.>%3M2`%0RM9"P<H`U&:M:]S7+R:[:A29J<'#3
M;Q5[&S#KJ;9)W]6BASFZ<D=M\7M5,VJ6G&-1MT_'Y-8>&$U)9/H>/,E-EX3&
MC>IO).3;U.H6Z2<2;=B]?22PP_18-7AU^BC5)?.8Z6D=61$`FN)J`<!3@!->
M'#`%#*0788-IP\:L]GG6=LYMW*'M#(458^U[;M[]D9BB=99LHQL.,\6R[845
M'35DX6;F;O2]$RJ"*AB\!,F0PB0/R\_]XQU?L3:L]O#JVE$?+8BNEW2QWD@/
M_P!.3^RNOZ.TO$#>AQV-4FUH"G5N*K\%18L;7+F''<)4[A6+Y68FG.S+"Z9L
MH6S4B&51*Y.Z$48MNW.)VQ.J'^55_KEWVDWBEWJ>ZT^>[J::6[D\7C_OLMQ;
M3VD\ERVF5SY8+JY:XL$8S7$LK0V5V<>M#3[81"#E<VT`-%3R0"'`-ZQ:W;78
M!L6'LM<O/#%^K&1$JRM9Z5D&XP]F",NK"VV=+N=:K+3<F526F9AC&RD>>?C+
M8IE>6=V%BJH"<NX6*J84UD6ZJ/;[F?:7WZW<U;3'ZJVTO]V[&>#G+5]O`<]O
M!<V-Q'%&]\;Q#);C3[>.SE:VMLQI8`YCY&/QKC1K::-^3,V9P-'5.!+7`DT.
M(.<EPX>N!2Y5OE\X#B>XKZ2:6M_*Q[%ZW<MD;O:4*QQG4LI*V1C&0!Y)5!A"
M24KFVU.4T>D95`942E4`J#<J6+JGVE/6-><_;VK[..SED:YKC:VYG_)&P$#Y
M)@P%\K(]+T]A=0-?XO4MK)(7U,T>T;0N#BX#WQICFK05V$O>?=Z@4UD-EV%Y
M5W5W\B:\NWM1H50QO%NE;M,&65K='I>7J#`!(FZ8`_DDJWG6RIJN3_MBRKTB
MA^)VZ`IZ&V]>V_=G#=V]K\WL@O=1N;V1HM8J">[NM-O)LF'(89])L7-8.2UL
M3FCDR2!UQVF6KBTNSDM8&CE'8UKVBO5I(['J]0+9&H5>)I%3K%+@2.$X.H5Z
M%J\,F[<JO'1(F`C6T5'$<O%A,LZ<%9M"`=0XB90W$P]D=>6ZUJ]YK^LW>NZB
M6G4+VYEGE+6AK3),]TCRUHP:,SC1HP`P&"SHXVQ1MB9W#6@#K`4"O+O^]7/^
M#K?_``S:P(?SS/QA]]5'8M,?Z.!_P6]E'\F9R_WFLT:_OOLO\#;_`.7B_5M7
MRV[NCUS]]=O]9*A-$31$T1-$31$T1-$7'^][G,W16^W>/M]^DLU8IU0VK[/,
MEX!KXU^B$FGE]RSE_,E#R2[K3B:KCN5NR1R4F%9"V4%ZBP</1`I4U'"0E(M=
M+MSI7<O1.8S&PN)7^/;%L^V^[JLK5>[UW)U1M\G9D]MVXK,VV:6?-X2T8S4K
M]9FY.?Q2$S%H/VLXQ.D](@Z+^((JD6<L[<VM?;Y9LW4^X[=YLRV'K+M1;Q]N
M>7HL72;?B_>',5V@XMS1)6IQ1D:[3:Y$9;7GH&PM5W"IXT*VN\(HHBX0+HBD
M>0^9IDVIY!4QW6-HBMNGX#8UCS>S?(1QN#Q]!V6"9Y!LF1J,TP_5T$82<IE\
MO"%WHR#)L[;S[6*DB/\`IMUQ.1!%V1:O9SYP]JJE+ROE_$M70FT*_P`L['.\
M6GT6Z/5(2DM9^X[E[/A25&T(R.-JWF*,F:RVC!4>MG9VK+^Y!;F;-5NL>&(N
MFV#MV]MRKN7S_MELN&CT:P;?AI\_)V]&VR5DJ-\Q=E*H0TYB3(U'DS42!8/D
M[=9V=M@WD:=P#B)=5!PJ8ZR;I#@1<Q]Q_.#R`_Q9N#B,$X]/BS(M"NV-ZW7+
M]>'K*;;0E=G.92MR^;@O;:P^J[F.IF2)!W7)"R5F-?A*-7,&\1>K%4,U69K$
M57S6]Z6ZC978\*4_%N0;M<GKK8AO8RC='57QOB"=L<]E3;]';?65#S1::S,0
M8*,<9UF4R%*S5VC*RB=T:`3<'CV9CLRET19(=<XYE3O#FO3>+XK*4GBW!&3K
M_)9%Q==00Q[DVT83V28@WF6BVTQ![!2[N"V[Y*A\LH0E5M:[E\967;F05:&Z
M9#B10S'O/2C+*ZRZ2U[992(;XFP!NVSHX2HV68_(L[8PVG8MVN9AFJA#08T.
MJJ*/+C4MU,4@S<]:8$).)?)G1,WZER<BZ.8XS!EK=]LYE,CX<7KN`LJ9`K]G
M;XJMKB;IV<J3'.4GBZ--R(Q>P/;,-9ZQ8XPJ#\C1VV;OFI5Q;NFR:Z1RZ(M-
M]Y.0-X>W%_LG9K[K5"N]R?,;K.VJR(0.+\/,6#3".3YC<Y?:T2*-::/8'I,A
MUW'\+4((SWI&:F6AUUS(+K/5%A(L843G22D_BNCOX/;M.7;(-FR+LEQ'`MK7
MDB#QZA89?>;)Y*J=0>WF384"4C*%DJH36+EG=QJK5@["%;RK;M==<1*B)%ME
MO;W![D=L]IV6YLC8R2EL(VW(I,"[IL(TJ"BKS,L;MG:L^#^WVZU:Y*5II9`B
MJIN%)&5B142(V;/65F2>JMTP:&*)%#X_F)V#'F7,^;7K10);)U[V?;=F64\S
M96D[GCZB#;;$XP@IF9B^@L?MXB+DU\;V19JZ@4YZ(8/4HV99JMW30I4Q6.11
M#&G-0S#D2W[0JG]3`T<XW98ZP9FJ-6B\]Q5I)3L-9P7F%PMT@9GC5@1Q*XSK
MT&9_/L'/<]NJ+UJWBWLBMVT#8BPW5>=PXS+X*M<0XIHS51UOHVA[7['89W*S
M:UT]>@;F:1/WXUTK,_4(,6+N:C1JSF#2$#.(EP[.5RV=NB<$A(L_;8-_%VYD
MC#*L+MMDZ[@F;P!EW!*UKMBLK5<W5S)&)\@5`UUF8>N.V46E%LI1RD5Q'!(-
M3.V9EV77,WBJ2@B0BV^<Y8E:UMFR]7WF<J)D#=!MHV_HDSK8ZCX+).:]FAMA
M-&[(V:?H14W#*F-KBN)9V/C7K1-`T<Y)T4Q1T1<9,#\ZG*M:P`RN^>*YC:_O
MZ]LIY9^7^[XWZ(QM:,IYCWJ8FRGD"WE;0#>J#`MXIE,X^-'QT3!-'KQ(P"8Q
M5""N+(BS/$\V;(+!_N>W!GH4AD+;CCG:KRM-TB>*HEQ#M[[B'%6[M'+4GG[(
MJ<O7:Q.R62U,54R#CYYS#CT.VFD0\!BND=4B9R+NG1YN8LE0KE@GX-.M2\W$
MLY1Y`)OUY/N2+Y('*+)5XYC(9=1TDW4("Q3-DA35Z1.`]'I"12K1$T1-$31$
MT1-$31$T11J/_.FR?R?7?_&-3P*.%274*4T1-$31$T16"U_FQ8OY$E/XDOJ6
M[5!V*\M_[W0_M*7_`%"ZA2O;1$T1-$31$T118OY[+_YK-?\`*SS4\"CA]Q2G
M4*4T1-$31$T14,I_BR1_P%W_`!=34C:H.Q4E=_-^"_D:,_B2&H0;`KSHI31$
MT1-$31%Q.??\QM6?YDZ]?[]6.]$6B^P".CI78MML8RT='2S%7'QS*L95BTDF
M2ID[;9#IF59O45VRADSAQ*)BB)1[(=G7I&E@'38`<1S86Z@_,,_%"VS;4ZFL
ME4UV5.J#)PBNFY1<,ZO`M5T7*2AE4G*2Z$>FJDY25,)R*%$#E,(B`@(B.LX,
M8-@'8"N4"]2U6J$(Y3)5*L1-Z4A7J9*Y"E(]*F[[H)E>$*Q`KLJ<@';!04`P
M%<?MH?C_`(VF5O$.P$H.)?H5:JE.V5+5:P55EU7:*I:[#%48]0Y4>H`R4!B!
MV@(/5CK$ZL2]!8YE`X',(BRMXAV%-`O5>NUQSV\+FNUYR,H^9RDIVS!Q2_=.
M5CNK[G2LEUK0_;\G'=23M=PMTUD.@7H&+P#0M:=H&/444"^W$#`O"OB/(&#>
M$E%T'4H5W#1KDLHZ:@!6KJ3*NU4"1<M2E`$E%NF=,``"B`!J<K3M`Q4T"YD[
MBFMK>\U_EOLJ%(,(B\N]M',>:TN4DT>OC(NUKXSHB-<?R#<$U.N8,I<R*BI.
MB;I)E$.`_@U^8O\`[MLNC6_V1[F?>**2;=]F\>B.NHXS1\EN-2@,S&&HH]T8
M<UIJ*$@U"WF[`D.OQ"$@2\S-E)V`Y,/NK>+&S;)51Q#M_F*YB;+5;S%'QN.<
M7[I;'.13N:N<='OFW_WF7F(0E',O6LSVDN2XELY&;9MYDHPD@\<HB<>BWU_,
M[O3+NKK6^N\EEJFLZ-=;D2RWM_H$$4C8K5[V._N-I(8VQSZ9;^(R/8+61]J?
M&H8(GAN,B]-@$\=M"YD<C;D!K9215P]\X5J'G,`<PS<DDCB6-YW(G,J+#/'"
ML3.1%K9TLG6PM1Q15Y^N+VQ#:).9`%:-DY(DHNX._P!R$#'P)T0<JMT2R[ED
M4QS$;OD.HT[=G[*YOF1LFMYM'DOS26YU"XAG%N=XXK.CXV<V`&:)--=AV1KW
M&VBG(:'2V\EE\VMY2:$2!NP,!%>9+L":_P#F`-V\)'$1=?I[WJRUQW$3F-F"
MV2*_BV<O=27QDECZ#CG,$XBJ5MPO$$%-GG+V)=W'):;>]VMN6$>O.UW1FK9-
M46JJ8&>8?U=>H>ST3=G3]Z9&Z7J6KV]I<"^-Y*]LK9+K6[2;QF%K9&VUB3::
M>\W446>,22N9SK'$05>-ZHZ29\`SLC+AER@4HV-PRG#,[E/Y)-#0;.&1*/\`
M=-+)7E2R-+_D6)E(W958:,QM&%86NP_:H[G[&KEIXO1"*R+ZNY!JV,"1#^12
M=N^V&JK-)^DU;&*#1'6-MO5#9OT]NEOTW2[V&7>B&[?;ZI+-+F^881IS1=D,
M9-9W%^;F&%T<>21LK[=\TH)FDKK?NSYP][2("VK`!^=.?DXT<&T)J<*5H-@]
MJ7<]]T=5<702M=M$I8`8&7G+!=JY!'4L=R9;F4(&[U>_N(YFT0J521P*Z4DZ
MY*QZ2";TQ#'*HN*"+-W1KNA?9YN=8U?4675I#IO.4BAM9Y0(+9^A&:UN+-KW
M.-Q<G5VM@O;>9SW1`AI;&)'SPHI=6;'&S*XOIB7`8NYVC@ZFP<WBTC;U:`&4
MXTN>\T)'#SN]M;!9X2Z7?)K7)T"\QY#T*5Q_4FEOFZ[0I5*21AI"&DZ^C78=
MO(R#-R]BYEP$F5TQ<.R)C&!J-Z]"]1AM=;AW>?;6E_8:?8.L)FWLEW'>7#K:
M*:\C+#*R6.8S2/AADCBN+5G,&&XCA+A=JY!+J>:,RU<USW9AE#2T5(::TH10
M5()#C6H)[E9/_HX'_!;V4?R9G+_>:S1K^TVR_P`#;_Y>+]6U?.KNZ/7/WUV_
MUDJ$T1-$31$T1-$31$T16=Y7:_(RL7.R$%#OYN#!T6$F'D8R=2L.5\4A'I8N
M070.[CP>$3*"H(G)U@%`#<>`:(K66AT8G='H4RIE[L-W#27Z-=AR]U&KQV+]
MVVD>#,.WF[I\85E"*](IU1Z8@)NSHBNDA7J_+,'L5*0</)1<E'I1,C&R$8R>
M,'\6AUW4QKUFX04;NH]'MA3HHG*9,O3-P#LCQ(O%Q5:N[,Y.[K<"Z.\B4X%X
M=Q#QZQG4&B<54H9R91N85XE)0PF*W-Q1*8>(%XZ(O-2H5-8BJ:U7KJJ:\$6K
MKIJ0D:<BU9*)A+752F;"52"*)AX-!XMPXC^)HBCE%Q=5,=R%UE:_W>7D;]9'
M-FG7=BM-BM2Z"JQE3MH&`/8I*2-6:9#J.5S1T(P[7BXX7*W:Z"8*G`2*1.*=
M47?=3MNK5QUW;>,Y&:[8@XQ;NO(1P)ECWTIUC4W;[Q@5(H(JJ],Z0%#HB'`-
M$5:Z@()](M9=["Q#R69-G+-E*.HUFXD6C-X0R;MHU>JHG<MVSI,YBJ)D,!3@
M(@8!`=$5N0I-,;)J)-JC6&Z2L&6L*IH0,4DFI6B&4.2O*$3:%*>#(=8X@T'B
MW`3B/0[(Z(C"DTR*=`^BZC6(UZ4CA(KQA`Q3-T5-VD@@[3!PW:)J@1T@U2(H
M''@<J90'B!0X$5VB(>(K\:TAH&*C82(8)]2PBHABVC8UDB)S*=4T8LTD6K9/
MIG$>B0I0XB(_JZ(O.3@H2:.P4F(:*ECQ;Q.0C#R<>T?GCGZ7_9/F!G2*HM'B
M?_T54^B</U!T1485*J%`Y2UBO%*K/>%*I0A8T`4L_2`WA&<`;<#SW2*`]N#_
M`'1Q#^ST17U1))8H$6335("B2H%4(4Y0505(N@H!3`(`HBLF4Y!_"4Q0$.R`
M:(K2YK==>2+B7>0$*[EG<,I7'<HYBF*\BYKRRYG*T"X>JH&<K0RKDXJ&:F,*
M!CB)A+Q'CHBUGR9L<VM9@RKC[-&1</U.RY#Q8TI+*@SCZ-:G6J;?'%L=7FC%
MK)Q1%>K&KUK>'=E&+49"[_%1=]L-TR)%(MB&M%I#)$S=E3JJT0.ZC7QT&M>B
M&Z)WL,Z.]B'ADTF9"&=13Q0RS900Z:"IA,02F$1T15T-6*W7.V`KU>@X'ML$
M2NNXT2PB^V2MA7,W*X[1;H=<"!G*@D`W'HBH;APZ0\2*@;T:G-9:W3J%9A2S
M%]2BV]TD3L$%G5G;0D>I%1#2946(H+YG&QZZB2*)^*1"JJ<"\5#B8B_!H5&,
MBBW-2ZF9!NA'-4$!KD.**#:'=.7T2V13%GT$T(MZ\66;$*`%055.<@%,8PB1
M1"ZX/QO?(R,AY:%<Q4=&RU9DE&]-F)>C%G&=33<-XFI6HU2>PYK50#LG:C9S
M`2`N(ATW/U:K<Q0``(LMZ(FB)HB:(FB)HB:(FB)HBC4?^=-D_D^N_P#C&IX%
M'"I+J%*:(FB)HB:(K!:_S8L7\B2G\27U+=J@[%>6_P#>Z']I2_ZA=0I7MHB:
M(FB)HB:(HL7\]E_\UFO^5GFIX%'#[BE.H4IHB:(FB)HBH93_`!9(_P"`N_XN
MIJ1M4'8J2N_F_!?R-&?Q)#4(-@5YT4IHB:(FB)HBXG/O^8VK/\R=>O\`?JQW
MHBYY<O\`R+CF+V6;<8Z4R-CV+D65"<-WL=)WFJQ\@R<$M=DZ:#QB\ET735<G
M'LD4(4P?JAKT;2Y(QIT(+F@\V.$+<P$<RW$=RMP/I4Q5Y5,7^<6F=^]9W.Q>
M^;V0KM1QCLI]*F*O*IB_SBTSOWISL7OF]D)4<8[*?2IBKRJ8O\XM,[]Z<[%[
MYO9"5'&.RGTJ8J\JF+_.+3._>G.Q>^;V0E1QCLI]*F*O*IB_SBTSOWISL7OF
M]D)4<8[*YT9/R/CGTPW*[F"9$H*T1&87WYI2<JWNE9<QT:J^IN.DV24@^;RB
MK9DJ].0P(E5,4RHE'H@/`>'Y=?\`N_6%]J_V,=6LM)AENKQVK:61'"QTKR!>
MQ$D-8'.H!B33!;[=5[&;QP.>X!O-R8DBG<KN]]-F&?*YC'Y^U7OKK^2#T"WY
M\RZM\CN/BU['XU;>$C^$.VGTV89\KF,?G[5>^NGH%OSYEU;Y'<?%IXU;>$C^
M$.VK='Y4P%$GD%(K(^((Q27D%I:5/'W"ELSR<JX3227DY`S:13,]D%TFZ93K
M*=)0Q2%`1$`#65<[H>L:\;$V\TO6Y6PQB.,/MKIPCC!)$;,S#E8"20UM&@DD
M#$JD7%HVN5\8J:G%N)X]JN/TV89\KF,?G[5>^NL7T"WY\RZM\CN/BU5XU;>$
MC^$.VGTV89\KF,?G[5>^NGH%OSYEU;Y'<?%IXU;>$C^$.VO%SFK#1FS@I<MX
MPXF05`.-^J@!Q%,P!Q$98``/^D>P&KD6X>_(E:3HNK4#A_\`9W''^C4&ZMJ?
MG(_A#MK3G^CLY?Q-7.3;LQAK#E''4%+LHW-H/(J8NU9C))H*^Y/,CE$'+%[)
MHN4!6;+$4+TBATB'`P=@0'7]X=EA8P`[?%XOU;5\Q.[H]<_?7:OZ>L&>6?$_
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M^_&B)]/6#/+/B?SBT_OQHBL=GSM@Y6MSZ1,SXF$ZD-)D(`Y'IQ0$QF:P%#I&
MF0*'$1_5'AJ1M4'8KNAGG!I4$2CF?$_$$DP'AD:GB'$"``\!"9$!#4*5Z_3U
M@SRSXG\XM/[\:(GT]8,\L^)_.+3^_&B)]/6#/+/B?SBT_OQHB?3U@SRSXG\X
MM/[\:(GT]8,\L^)_.+3^_&B*-%SIA#PP7<?3-B;JAK35'I?213.EU@2CPXAU
M?=KK.`%'\/#A^IQXZG@4</N*2_3U@SRSXG\XM/[\:A2GT]8,\L^)_.+3^_&B
M)]/6#/+/B?SBT_OQHB?3U@SRSXG\XM/[\:(GT]8,\L^)_.+3^_&B*CD<[X.4
MCWQ"YGQ-TCLW)"\<CTXH=(R!P#B8TR!2AQ'\(B`!J1M4'8J6`SO@Y."A4SYG
MQ.!TXF.(<`R-3C`!B,T2F`#%F1*/`0_"`B&H0;`KM]/6#/+/B?SBT_OQHI3Z
M>L&>6?$_G%I_?C1$^GK!GEGQ/YQ:?WXT1/IZP9Y9\3^<6G]^-$3Z>L&>6?$_
MG%I_?C1%QB>Y>Q,/](;K=D#*&.QKI.3%=H0\\%VK0PI)I7?!C]^E$'E`D^T2
M2:K%(ZQ4!."IDB&.!1*41`BY/[*N7=L-R=M1P;D+(NT#;_=KW<JF^G;9;[+C
MV)DY^Q33NUV('4K+R*Y16>/5P('34-V1X:[W3K"RDL(9)(F.>6`DD8DK;0Q1
M.B:2T5(XEDZC;'>4AD><RA6ZEL[VQ/)G#-\4QCDAH_P^V@RU^])0D/9%(`CF
M:9,&TPJ6"L+!T*S([AOU;M+]LZ1NB&2RSTJ0N:R*.K'4/)V';3[HV*L10$D!
MHJ#0X+)BG*]Y:2)Q26V0;6T503(L9);&]>25*BHL+9-8R:@E.5$[D.K*<0Z(
MJ?B@/2[&KGS;IW@8^P%/,P^]:OU/E=\M18Y4T=C^UQ90Z77D31QM7U5#H=<+
M?KR$3Z1C(`X**?3`.CU@"7CQ#AI\VZ=X&/L!.8A]Z.PO,O+`Y9QR-E";)-K!
MTWAC$9*$QU7#IO3E`PF(S.4PE='(!#<03$PAT1X_@'3YMT[P,78"<S#[UO87
ML3E<<M93IBGL<VP*`FJHW5%+&4"H"3A$>BLW4Z`&ZM=$P\#D'@8H_A`-/FW3
M_`Q]@)S$/O1V%Q2YDVR'9QC/>CL*J&/]KN%JG4KQC7=S+76JUREQ<5$7"0IT
M%0'577FVI"@@\<PBSY<6AU.PB98PA^$==IZL]!T34?6%96&H6<%Q8NMKISHG
MM!8XLBS-J#A4'8>`KRWUOWMYI.YTEWI<K[:[Y^$9XR6N`=(T'$8T(V\:U2<4
M+8BE6H"SH;0L:OFE@Q0RRZFS:5VE*OHZ#?6BH51&(D4RR(IHSI7MU:*F(!A1
M!(BW!03D`IOH1^E^JUME%?-W>LG1S6`NP!'`7-8Z6*(,<,V#\TS#2M*!V-10
M_.;=0W_==26KM9NFOCO#;U+Y:%P9))F;ABRD3A7;6F%#A/9'`FQZ%0RFG-;3
ML=,I[$+"+D['5VU`A9>7F&-B9NW-2<4T(U=9&Q!;'4>X8LDRBDOW0040533$
MH".VFW5]6-LV^%SH%FVZT]K721"W8][VR`F(PY21)SI:YC!@[G&EK@*8Z^+>
M#?N=UH8-7N76]XYS6/,SVM:6$"029L6<V"'..(R$.!*J2;>MD$H\CHZG[6,3
MW:0DL;L,L(MX6I5QNF%*FCJ(5MT5W)N6C563M#MLNDP:@8!4%LL90Z1"=(U8
MW2]64\C(=.T*PN9GV3;H!D,0_(OJ(S5Q`+I"'!C:XY7$EH%30=X]^XF.EO=6
MO((VW1MZND>?RK<7BC03E8""]W!F%`25436W38W6[)'P%BVQX=@FCO'D[DE]
M9)>JUYA"P,+79:M0TBUFC+K`X;/B/+4V[(%,B!2J=(X"4`-7<[G^K&RO&6MY
MHFFQ1NLWW#I'Q1M8QD;HV.#ZXAU96]3;4X8TP;R[^75JZXMM4O9'MN60AC9'
MESW/:]S2VF!%(W=79AQ4*6#>7VM;H*JIX#P29.RP[J0@["%9@^X\A+,KHWH;
MBII`(@\)8B6!R5'JE$R%ZS]JX]:)2#9&['JE=J$5@-*TJDT9<R3FH\CGB80&
M(</.<X:4(`KR>ZH%<.O>L1MG)=G4-0K$\!S.<?F#3$91)Q9,@K4$X8[,5'4\
M5\OY.:E*_*;=L"0LDU@7,Y"F?M*5W,M)VLWD6$6B(J72=F8H2C53&KQ1R1P9
M,&P*`F;BHDL4N(-#]4PN7VD^CZ3%,V(O9F;#EEH^X86,>#E#@;=Y<'4RUH<6
MN`R3JWK$,#+B+4M0?$9`UU#+FCJV%P<YM*EIYYH;2N:E1@6DS.,V^<OR2A'\
M^."\#,8Z)E7$#+.7E1CTFK.;80S>>E6*+L42H22$7&+BLJ[;]8U!!(ZW3ZHH
MGUL8=TO5+-;/N_FO2FPQR%CR8F@![6![F@THX-::ES:MR@NKE%5@R[Q^L2*=
MMOX_J#I'L#V@2.J6EQ8TTK5I<X4#31U2!2IHI%#;5-B%CE)F$K^"L`3<O73-
MB3T=%5B(?.8@[PG6-2/BH=,J)W"7`Y"\>(D$#?V)BB.9;;B>JR\GDM;32])E
MN(2,[6Q,<65V9J;*[1U*'80L:?>W?^VB9/<7^HQPR5R%TC@'4VTKMI]_K+XO
M6TO9I0:7;;O([6,3/F%.K4W:7[%C2X9-^[80,<XDWJ+(7AT&HNC-FI^K!0Y"
M&/P`3!QXZC5-P?5SI.FW&IS:%I[XK>%\KFMA9F+8VES@VM!6@-*D"O"IL-[]
M]=0OH;"/5KQLDTK8P3*Z@+W!H)I4TJ<:`K'4/A?8S.R+>`CMI^,5K0^N4K2X
MV'+4:TJRE'<#4(R\3TW'65NZ6A7=;@H*70(\<$.95"2,+(R/;`='6GMMV_5A
M=3-M(=`LC?/N'0M9S,1:XLB;-(]L@)88V,>T/<"2V3\D6Y\%LIM;W\@C-Q)J
M]T+1L#97.YR2K0^1T3&EA`<'O>TEHV%GY2N7%>IL$;-6[]NU?;*Z6BR>05\E
MF$M&TVDV5"0?XY8GD[#`,F5<G)*36>N&!0[06ZH&SQP8&X'(L8I#2=UO5RR8
M1R[M6PB=%.]KVPPR!SK=N:2,-C>YQ<6_FS3*]W(J'$`Q\_[ZNC+X]<G,C9(F
MEKI)6$"8Y6/)>UK0`>[%<S6\JA;4J@@,/[&[/5:;=87:1C%]6[G=&5*CY1&N
M4CM4[F3D&D7'S$.HM+H#;HE=V['I=S"N%TDVKLQD_P"YC@-JTW>]6%[86VI6
MV[]BZRN;EL+7"."E7.#6O95XYUA)_P#+S.`;(2.05<N=9W\M+N:QGUBZ;<P0
M&4MSRUHT%Q:ZC3S;@!^'0$N90\H+(4!M7V;SEJN52-M.Q/&OJ:6"77<KUFI/
MFTBSL190T<L1*)D7SV(=B6(44,T?I-W':ZJ*P%$BH=';VFXOJZNK^YT\Z!8,
MEMLA),43@X29LIY#G%AY!.5X:[*6N`H[#6W&]N^D%I!>?.]XZ.?.`!)(""S+
M7N@`X<H#,PD5#AM"FGU(]GGV9L,_,J.]CK9?5GZO/,FF]"U87IUOGYTONE<G
MU(]GGV9L,_,J.]CI]6?J\\R:;T+4].M\_.E]TKD^I'L\^S-AGYE1WL=/JS]7
MGF33>A:GIUOGYTONE<GU(]GGV9L,_,J.]CI]6?J\\R:;T+4].M\_.E]TKD^I
M'L\^S-AGYE1WL=/JS]7GF33>A:GIUOGYTONE<GU(]GGV9L,_,J.]CI]6?J\\
MR:;T+4].M\_.E]TKD^I'L\^S-AGYE1WL=/JS]7GF33>A:GIUOGYTONE<GU(]
MGGV9L,_,J.]CI]6?J\\R:;T+4].M\_.E]TKD^I'L\^S-AGYE1WL=/JS]7GF3
M3>A:GIUOGYTONE<GU(]GGV9L,_,J.]CI]6?J\\R:;T+4].M\_.E]TKD^I'L\
M^S-AGYE1WL=/JS]7GF33>A:GIUOGYTONE<GU(]GGV9L,_,J.]CI]6?J\\R:;
MT+4].M\_.E]TKD^I'L\^S-AGYE1WL=/JS]7GF33>A:GIUOGYTONE<GU(]GGV
M9L,_,J.]CI]6?J\\R:;T+4].M\_.E]TKD^I'L\^S-AGYE1WL=/JS]7GF33>A
M:GIUOGYTONE<GU(]GGV9L,_,J.]CI]6?J\\R:;T+4].M\_.E]TKD^I'L\^S-
MAGYE1WL=/JS]7GF33>A:GIUOGYTONE<GU(]GGV9L,_,J.]CI]6?J\\R:;T+4
M].M\_.E]TKD^I'L\^S-AGYE1WL=/JS]7GF33>A:GIUOGYTONE<GU(]GGV9L,
M_,J.]CI]6?J\\R:;T+4].M\_.E]TKD^I'L\^S-AGYE1WL=/JS]7GF33>A:GI
MUOGYTONE<GU(]GGV9L,_,J.]CI]6?J\\R:;T+4].M\_.E]TKD^I'L\^S-AGY
ME1WL=/JS]7GF33>A:GIUOGYTONE<GU(]GGV9L,_,J.]CI]6?J\\R:;T+4].M
M\_.E]TKD^I'L\^S-AGYE1WL=/JS]7GF33>A:GIUOGYTONE<M<]SVT;:W6*/0
M'U<V_8IA'DAN.VU5Q\ZC:FQ;+.X"RYGJ4-88=<Y`XJ1\U$NU6SE,>PHBH8H]
M@=>4^NO<C<[1?5W=ZCI&F65M?LF@#9(XFM>`Z5H<`1QC`]1>@^J[>K>75-]+
M>RU*_NI[1T<Q+'O+FDB-Q!(/$<0O[Q1Y)W*-$1'T<VT/LCQ[&%*:`?\`N`(X
M`#7P^OJM?GH3>4;ZN;:)YE:=WNT1/0F\HWU<VT3S*T[O=HBP?FKEL<C?;ZIC
M%OD_E_[6XMYF7(K;$N,F$+MG1M[^VY'?5NR6]C4V+.IU6970D7M;I\FZ2,X*
MBB<C)0H'Z8D*8BO6&N5_R,]PF-:7E_#.R#93?<<9#BWLQ3K-%88JS=&991<B
MO#S`%CY.&82[%[!S+55F_:N6Z+I@\2.@X335(8@$5/>N6-R-<;3V)ZU<=BNS
MF,E\X9('$6,4&^"8&71L>1O`BT9'+5S/(:!D&<,[4I5,DWY%'RC9N9-MT04Z
MPZ9#D6/S;$>0F9_C.!9["=L\G<<P5VX7*@8[CMI\FYR7+4K'\LQ@[I=7V._`
M8EQKM1@)>5:-E)"29-&R[EZV10.JJY0(H19RI_*&Y,=\J]9N-7Y?FT%_7[C7
M&-MKKES@NN0[Q]7I%LU>-I%6&FH2.FHX`0>I=:DZ;HK-SG`BI"'XET17T.3%
MR>3-EGA>7QLU,S;F`CAV&(:,+9`YBI'*19<&75)&,1<@@!A`1`Y1_5#1%7^A
M-Y1OJYMHGF5IW>[1$]";RC?5S;1/,K3N]VB)Z$WE&^KFVB>96G=[M$5HG^2O
MRDV,%,O&_+HVB$<-(M^X0..%*</151:JJ)FX=SNST3E`=2-J@[%<T>2ARCCI
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MTT6KA4G'"M/X=)-(YR\>$>`\.(?KAJ1M0[%3PW)5Y23N'BG2W+GVB&6<QK%P
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M%?R-#7KJ%D;O2`@95X!42$0%,CC6//I;IB\YP,[W.V;,S,G'P4JJ'0%U<=I)
M[(HLKYPY=<IF9SNJ5?91K(J[D,?8_JM=L5CHTY,WG"LA6Z_C>LW.*I]D976*
M0>8ROC7&3*2-$JM".F<TJLX(Y_;5!-=FT\S&6KA^4:`#0U;0`&AKL-`:<?"J
MG0YB[':.QL[2D+WE\1\?E7/E]H-KJ=5K64\'O\7XRH2U/LQX3!<W*8SD<:S2
M<!%5N_U>L3^*['VV2<>P;B/3>%FNO7;/43N#G"HV($DCXR`US*`4-&FE#2A`
M+3M(IMV%.:Y1(V$8=3"G845Q#RYK+C-]A"3>9T+*RN&]P.6LTIRD36)6,)-U
M[+]MK-PLF,%JU+V6Q50(?NA7@%J^!JG(13HJ+M@J@8BZ#JF*P=&6$OJ62.=L
MVAQ!(I4C@V[1M'5-B(H:X@D]E;#[*MJ;C:1C68HDE>2Y+FI6P&?/KVHRLL9,
MVF/CNVVE<E+E'SEPM<6>^!"N$VTJ^BDXUK)*-B+G;]:)C:OV=L;6,L+LSB=N
M./%7$XTVTI551LYMM*U*YE<U=`[G?SRW&Z8J%.MBG>TD!TB`HHGUE=QJ3K"$
M,4Y#&3Z7$`$!+Q#LAPUZ3ZI&E_K/L&"M3:7@PZL-*KR+UXN#-Q)7&E!<0;?T
MK5JXYVNU=Q6Z_5RS%M:L:[BQGB-LX;-J^F^>5UC9JG:D'\@J,`*:T[V_2V1#
M*@0J0HBJ'5@93I%^JG[C6+[*&Q$EPV*&Q%H"!'F,;9(I0YQYNA?FA8*T`IFY
M-34?)S-Z[MEU)=Y(3)+=FX()?0/+)(R!R\&4E<:5K6F-!13L,-Q"MF?VZ47G
M)R;FY^&G[&K*(QYVDV-6B)2)IT*HR;1K9".@*D>9=/62#8$SC(K'<+**G'6T
M&[D#KU^H3F66ZEE9)(7!M'\TQS(690T!L<6=SV-;0\X2]Q<5K_GJ86K;.(1Q
MP1QN8S*35O..:Z1U2XDODRM:XNKR`&M`"CE3V]Q-$<Q#VHV"XPKN(A)>H)J(
MI03A%S0W]KE+E$TQ9H[@5VR4=2)::=$@W"12/&+1<Z!E54Q``Q+#=&#2WQRZ
M?+<Q21Q/BP#"#`Z5TS(2"P@-A>]P@<*/8QQ:7."R;S>.;4&O9>1P/8^1LGX0
MI*(VQNDJ'@UE:UIE!Y+G`.`!5\OV%HO(;MV[E9&RL1>8WLV+UDHX&(E&!M<M
M79B3?=:_C7BXS)7-8;%24$PI`05.DF83<0R=5W;AU>1TD[YVYK.2V(;E[B5\
M;W.JYI.>L;:'92M02:BQI^N2Z:QK(6Q.RW3)QFKW<;7M:,'`9:/=4;=E"**P
MK;=H->5=3"DU;A<O9QS8%R`2)!$SUWF*$S>JF!1AQ/VMX7P""0`)A,#$3)\>
ML$%0Q';GVSKAUR9+CG'RF0]Q2INV7I_`V<[&T?B5%:\I9#=Y)VPMA#(<K8PP
M=UL%LZU'X6WFWD_C4.S!4*^V.INF\TS=R-M<M+`58TDW4[E]`[PEVO\`D&'?
MH&)#E40<0%ER1(*(%`135(FW*L"@)GZRT_<BPD9+'(^X='-7,.3MYZ>=CAR,
M#')<2%O`0&!P-#FK;O3>,=&]C80^.F4\K9S4,+AW6(>R%@/""7%M*BE>TV[0
M#%@V9-YBX%,QF[!-,'1C19EFH6_'R.-K=%BGW%!LZC9Z!2ZT06(HJV>=$Z)R
M$*"8WH]S[2*)L3)+GD2R/:>34<[;BVE;3)0MD8*X@EKZ%I`&54/WDN))#(YD
M/*C8TCE8\W-ST;NZJ',?A@0'-J'`DU4UI>*H.BP]@KT2VD'4!8)8LFI$R2::
M[9@BE6J[4T(IH9-LBLK'HP]7:E#KS*K"<#")QZ0`&RTW0;;2[>6TMVO=:2R9
MLCL0T"..(-&`):&1-[JIK6IQ6#?:O/?S1W,Q:+B-F7,W`DYWR%QQI4ND=LH*
M4P7M8<80<]2+C0D(]>O0]W@)BNS"\"U10>D9S<:O$O'#0SIL[;%>E9.3`F=1
M-0I#<!Z(\.&JKS0[6ZTRYTIK'0V]U$^-YC`#J/:6$BH(S92:$@TXE3;:K/;W
M\.H.<))H)&O:'FHJUP<`:$&E0*T(4+C-O=<@I>.FX![985W`VB0N57;,B1H1
M57G[+"]P[\$/%J11FZ4!D9,1=RT8;I-.Z8B\:E;+B)AUL&Z-I:W#+FT=/%)%
M.Z:(-RY(I)&9)\C<M!'<=W+'W'.5D8&.-5G2[QW-Q"Z"X;$]DD0C>3FS2,8[
M-#F=FKGA[F-_=9.0[,W!>$!M]:5Y"8C&MRR`I79N)NL4Z@"DK#!)L&0)";FK
M*[B9J,JS.S1#EQ/V%P^3ZAZ4A'!$.(&(@F4*+3=%EHR2".YNS9RQS-,=(VTY
M]SWR%CVQ"1A,DCGC*\`.#=H8`JKC>-]RYDKX+<7,;XG!_+)/,AK6!S72%C@&
M,#35M:9MA<2J]G@6O,H1I6"*29JR6S-+C+P!8B`;Q\S9HZ0KTM&RQ"MH5)6M
MK-I2LH.5`BC,@<N%G"JG%18QM7H]U+2.V;9#/XESXF?'DC#7R-=&]KL&`QD.
MC:X\T69G%[CBXE6W[P7+YS=')XUS1C:_,\EK"'M<W%W+JUY:.<S4`:!@T*;0
MU#3BK1/W-RM(3%EL#!E"N)-U'1;%1"NQ4I,2\1"`2&C(XCU.,=3K@$W#KKG0
MIB4HGX`/2V=MI0@OI=1>7R7LS&L+BUK2(VN>]C.0UN;*7NHYU74H*\>!/J!E
MM8[)H:RUC<7!H+C5[FM:YW*<:9@T5#:-KC13'M9S^3K_`+TI['6QR/XCV%A9
MV\83M9S^3K_O2GL=,C^(]A,[>,)VLY_)U_WI3V.F1_$>PF=O&$[6<_DZ_P"]
M*>QTR/XCV$SMXPG:SG\G7_>E/8Z9'\1["9V\83M9S^3K_O2GL=,C^(]A,[>,
M)VLY_)U_WI3V.F1_$>PF=O&$[6<_DZ_[TI['3(_B/83.WC"=K.?R=?\`>E/8
MZ9'\1["9V\83M9S^3K_O2GL=,C^(]A,[>,)VLY_)U_WI3V.F1_$>PF=O&$[6
M<_DZ_P"]*>QTR/XCV$SMXPG:SG\G7_>E/8Z9'\1["9V\83M9S^3K_O2GL=,C
M^(]A,[>,)VLY_)U_WI3V.F1_$>PF=O&$[6<_DZ_[TI['3(_B/83.WC"=K.?R
M=?\`>E/8Z9'\1["9V\83M9S^3K_O2GL=,C^(]A,[>,)VLY_)U_WI3V.F1_$>
MPF=O&$[6<_DZ_P"]*>QTR/XCV$SMXPG:SG\G7_>E/8Z9'\1["9V\83M9S^3K
M_O2GL=,C^(]A,[>,)VLY_)U_WI3V.F1_$>PF=O&$[6<_DZ_[TI['3(_B/83.
MWC"=K.?R=?\`>E/8Z9'\1["9V\86K&[Y!8F.\:F.BJ0H;J-IW$QDSE`..>J3
MP[(@`=G7C'K_`&N'JNO200.?MOUS5Z=ZGG-._P!:@$5YJ?\`5.7^CUK\]5]E
MIHB:(M"]^&RGZ[3#;=7WE^?T&O83W$QV;[&M7W%GA;E8XUIBK*N+58"F7:H6
M:KSN.K(FCE-219S;91=9HZCT@*B8JAA*1:C[8.4Y:,`98VP9`M><ZSDR`VRX
M`@L$0-9C,96'&(&5QM:<Q/,?Y7KT?2LHM*A$9`N]'S,]BLB(O8N5B[3(,D9-
M-!HN)2($6J?+^Y/>8*%!;+<S98MD?A_(F#K%B>RWG`S*O,YF-EW>'X3>Y3B3
MEAL]?N[Z$E,HW2-W:H`O.($732AJRQ9&34,H)FI%L]A/E*7C;NUP_<,8[CTD
M,X8\V=9TV63URD:9*)U^6HN5<UO\\4J_52+:V\\Q4<@8GN[D.J`[Q^QF&1SH
MJD;B1!5(BS!BWEPW6D[FZMN/R+N,E,^SL)M@Q'AQ_(9#@;-&VE3+6,\>9%QQ
M:<LPBM:R,SI3*NYM990D92PUJ0A99NVF$4'#)PD<B9T2+1_&G(@N&--NTC@Z
M.W/PCD%<A;,+^HV)C.TQ-`O`;7L/DP]>ZQDVM0.5XF>EXG.,>)I5TX82S%]&
MRZ#1?K71FI!,1?T+4VL,:33ZI3(P531M1K<%6(\R[J2?+F8P,6UBF@K/9B0E
MI=VJ+=H7I*NG3ERH/XRJJAQ,<2*2:(FB*P6O\V+%_(DI_$E]2W:H.Q7EO_>Z
M']I2_P"H74*5[:(FB)HB:(FB*+%_/9?_`#6:_P"5GFIX%'#[BE.H4IHB:(FB
M)HBH93_%DC_@+O\`BZFI&U0=BI*[^;\%_(T9_$D-0@V!7G12FB)HB:(FB+B<
M^_YC:L_S)UZ_WZL=Z(OY\\1/LX2\?RI\68PL=UBJ+D';=N1'*3.`OERQ[`(*
MQ60*0WK%H<V"K-5T$KY68&5L+NMLWBS5M)O$#)+',FF(!W%H9C!9QQ$ACH36
MA('X-#4<(%:<:VD>;+&T;"W'&G%_L%DF=YA>Z>A8'QQE:;PS2;'*W^]9-K,#
M0X2F9R7N"%1PMEHN-YNQ7-Z#1U#Q4E<ZIT;`U6,='HD,`MFDB@*ZC;(-_=,@
M;*Y@)<X@"CJT:ZA)ZXQ^\"JC*\-#J;2>/@-%<LU;]MRF"5]RSCZ.8W);RF[L
MLC8YQ334L8Y1:.W6&*#B;$EVC)9&7K:$E&2I+8-FE50EW#A+BY;J%9-GI2G;
MM)FO;B#G#ES$2D-%#W(:T\''4X]@'8)=*]N;"M'8;=E`I?N<W@9JJ3S?)C:(
MJR;I/$F+J3D;;]9L<Q636%AR@QF+E2ZW>JD>W11W+:$R-BV4?KE?H1J:IY&-
MD6KA%,A&[\H57-W,PS1M'<-!:16KJD`BO&.&FT$=52^1PS-IL&&WW?="R[1=
MW&9++OMO&VJ9QC!-,01%CS'7ZYD1C!W9I,.2XYQ?M[R'7YA],O'+BFO&%ID\
MLSD.D5NFCUB]>.*2ACIN$BWF74KKTVY:.:!<`<>`-(ZF.8CW.NJA(XREE.3C
M]RG;4.RIO9W`4>];GZU!;>QE8S#&.MRMKICIS%7!VYEW&%<38<OV+K%..8TX
M,IJK;B+;D68K\.QBRIR*+BNJ]`[A4'2;>B6\G8^1K8ZAC7D;?P6M+2>HXD@4
MQPZZATC@7`#8#]P#[ZY>\TBGSV=\^<KJ/ST[+"2]MP]N\NTN3!4Y=Z*I$LE8
M+%UFKT(REGSQ:V%DXV-72:R@=,B;QTFIT$DTS%3+VGJ[T>VWAWZL+#4W3QP.
MMKI[C;R/BD&6+,`U[#GX*$#NME%YIZV=3N])W0??6K8'7`FB`$K&R,Y4C1BU
M]145P)V'%:8.MN6T1E#0U@<90W4$B)^C-\DQ+LN:,TJ`ZI;J9@J^WF>I(F9=
M$%9:S,$@0.4KD`=$.*8$Z1B_0S]SO5[';1WC[[7?%Y;47##XY>8PE[(P^E*B
MKY&#*1FY0-*5(^;V;S;XR3OMFVFD\]'.87#Q:VPE#7O+:[.Y8\U')Y)%:J1K
M;2=K#2+O<Q(Y5W(Q+/&"*[C(1)C<%E:+?5%NWBN[G;,Q&O547R;5S$#VPV53
M(HD[3X]2900$`S';@;B1P75S-?:S''8@FXSW]TUT0#<]7M=1U"SE-(!#AW)*
MQF[X[V/EMX8K33'ONB!#EM+=PD)=EHUPPJ'8.!(+3W0"JI39SMHBE&R"N1]S
MKYT[K3FY(LX3/F5YY[X(M`1ZZRG:1"KQ<D0)G!")*='BX4-T$2J&`P!7/ZNM
MRK=S6.O-;=(Z$S`,O[J0\T*5DHPDY,0`?PC@T$U5$6^F]$P+A:Z4U@E$9+K2
MW8.<->15U!FP)(X!BZ@55]2W;CX1Q-4^D/<WW;G*N^N<8A]8#*8-G%;C7D3'
MO9`\@+@&+<4'DZS)U2BA%A%<H@00`PA<^K;<WQR.P\;UOQF6!TS1X_=4,;2Q
MI=FKE%"]@H2#RAAM5'IQO+XL^[\6TOF(Y1$X^*05#W!Q`I2IJ&.-0*8;5[AL
MEVYFLS>GAD?<H,\\KRMI:-_K$Y+[6<PJ,JE"*N&\CV[V@NNG(K%(*!%!6`H]
M/H]$..JOJSW--Z-.\<UKQMT)E`^<+FA8'!A(=7*3F-,H->&E%3Z=;R^*F]\6
MTSQ=LG-D^)PU#BW-0MI4"@VTIP5JK4RV>;;7\C.0R%ZW6$F*]"%L,A$.<X9=
M:22D2K(V>*;.8QFY436ESO7=/?\`4)M@5453(FH`=!9(36(O5WN7--+;,NM>
M\9ABYQS#>W8<6%TC06@T+ZF)^4-J2`#L<VMZ3?3>>.*.=UOI',R/R!PM;<MS
M!L;B'$8-H)&5+J`$D;6FD@C]B^WJ5;*NF.2-Q:R39PFR>@.Y7(1%HV141;+]
MRI1$\D"D=+)$>)`HV5`JR9S@4Q0-V-9</JNW0G89(KS6"T$-=_\`U&XJUQ`.
M5PS<EXJ*M-'`FA%5CR;_`&\<+@R2UTT$BH_N4/*%2,S3EQ;@:.&!&(*N8<O_
M``<)SIA>]R8J)\!42#<CD05$P$1`!43"0$Y`$2B`<0#B(#J_]4VZ]2WQK6<P
MX/G&X[Y6OK$UZE?%],H?_P!%#VE9K+L>V]U"NSMKG\@;FF<#6HB0G9IXEN$R
M@].SB8IJH]D'?:C-TN[<%:M43J&*F0YQ*4>`"/8UC7OJQW0T^SEO[N[UMMK#
M&Y[SX_<FC&BKC0$DT`)H`3@KUKOYO'>7,=I;VVENN)7AC1XG`*N<:`5(`%2:
M8FBBS7:CM7?'5;-<G[G5I5&SDIBE=^GC+B=F"T*5YM;B0X0"QTY$51J;M*4%
M7H=K%8'!<5`)V=8,>X6XDI+([W6S.)^9YOQZ[$G.\V)<G-FCJ\T1+6F7FSFS
M466_>[>R,![[32A"8N=S^*6^3F\YCS9QA3G`8Z5S9QEI5>R&TG;&N_+&C?\`
M=BU=J0T[.)`_S%G"/17:5ARBTL+5LX=MD4',Q$*N4NM8IF,[$BQ#$3,!N.JF
M^K_<ATO,>-Z^V0QO>,UW>M!$1`D`)`!>PD58.50@@&JI=OCO2V/G?%](+,[&
M86UJ:&0$L)`-0UP!HX\G`@D*B8[6=K$DRAGC'(>[%RK.VB3IC.')F'-_A,VL
MD&MU,['S-9,W"=@DX$1(=ZX=H(MFR2J:AU`343,:U%N+N)/%%)%=Z^XRSNA#
M/&[WG!(PT>U\=,[,F!>Y[0UH(<31P)N2;V;V1/>R2VT@".)LI=XO:Y"QPJPM
M?7(_/^"&DN<00!4$*1PVS#;58963A8?)VY!])1(/#.D$]Q632$41CIE[7))R
MP74=D0DFD;88Y=@X50,H1%VD*9A`>'',MO5ON5=SOMK>]UETT=:CYPN<0U[H
MW%IK1P;(US'%I(#@05C3[[[T6T+)Y[73&Q/I0^)P?A-#V@BE6ES"'@&E6FH4
MH]'YA'Y;[E_O&Y']_P"L[ZI=V/*=:^D+COEB?6+KO@-+^1P]I/1^81^6^Y?[
MQN1_?^GU2[L>4ZU](7'?)]8NN^`TOY'#VD]'YA'Y;[E_O&Y']_Z?5+NQY3K7
MTA<=\GUBZ[X#2_D</:3T?F$?EON7^\;D?W_I]4N['E.M?2%QWR?6+KO@-+^1
MP]I/1^81^6^Y?[QN1_?^GU2[L>4ZU](7'?)]8NN^`TOY'#VE]I<OK"!E$RC=
M]R_`QR%'_P#&.R.'8$P`/_[_`/K:J;ZI-V"X#QG6MOG"X[Y0?6+KH!/,:7\C
MA[2Z2\E'DN;0-\6U'(^6\^6K=/+W*M;LMQ6(HIU`;H,K5QFG2\<6MM%59JJQ
MCI@B"SULQ5$JS@0Z:QOQC?K!\*[R:[O!IF\>H:;::CJ`M;>]GB8#<S$AD<KF
MM!.?$T`J>%?6.AZ3H]]HMG>W%E9FXFM8GN(@C`S/C:YU!EP%2<.!=?OZLIRT
M_A;>%][_`#+W[UI?2K>CSE?_`"B7OUM/1_0?(K3H8^]3^K*<M/X6WA?>_P`R
M]^]/2K>CSE?_`"B7OT]']!\BM.AC[U>2_P#1FN6:V16<.)K=^B@W246765WA
M9C(DBBD03JJJ'-.`4B:9"B(B/8``T]*MZ/.5_P#*)>_3T?T'R*TZ&/O5C?'W
M]'^Y-^617#%>;L[Y+%K',9AR%`W\WVX]1$2:[MK&RJO@];Y'H1D@ZCW"2#@?
MVI51!0I3"9,X`]*MZ/.5_P#*)>_3T?T'R*TZ&/O5DI7^C,\L]%-19:9W?I(I
M$.JJJIO!S&1---,HG.H<YIP"E(0H"(B/8`-/2K>CSE?_`"B7OT]']!\BM.AC
M[U8]@/Z/IR>+42.4J^9\^V1.8I9LDQ"D!OUO\P25QV1V$>>_1QXZW."OJ65^
M/4#*I=)B"WXG6]+L:>E6]'G*_P#E$O?IZ/Z#Y%:=#'WJJ*5_1Z.4)DGMCZ.\
MM[B;WVFRCY)T%.WUY'LHMHV7%T$1)+A#6IX*4=+=I+=JKCP2<@D<4S&`H\'I
M5O1YRO\`Y1+WZ>C^@^16G0Q]ZI[_`%93EI_"V\+[W^9>_>GI5O1YRO\`Y1+W
MZ>C^@^16G0Q]ZG]64Y:?PMO"^]_F7OWIZ5;T><K_`.42]^GH_H/D5IT,?>I_
M5E.6G\+;POO?YE[]Z>E6]'G*_P#E$O?IZ/Z#Y%:=#'WJ?U93EI_"V\+[W^9>
M_>GI5O1YRO\`Y1+WZ>C^@^16G0Q]ZG]64Y:?PMO"^]_F7OWIZ5;T><K_`.42
M]^GH_H/D5IT,?>JUL?Z-+RUG;Z:9FD=X!"Q3QJV3.7>#F816*O&,7XG4`9L0
M`Y3NC%['8$H!V./'C/I5O1M^<K_Y1+WZ>C^@^16?0Q]ZKI_5E.6G\+;POO?Y
ME[]ZCTJWH\Y7_P`HE[]/1_0?(K3H8^]3^K*<M/X6WA?>_P`R]^]/2K>CSE?_
M`"B7OT]']!\BM.AC[U/ZLIRT_A;>%][_`#+W[T]*MZ/.5_\`*)>_3T?T'R*T
MZ&/O4_JRG+3^%MX7WO\`,O?O3TJWH\Y7_P`HE[]/1_0?(K3H8^]3^K*<M/X6
MWA?>_P`R]^]/2K>CSE?_`"B7OT]']!\BM.AC[U4J_P#1M.6C47,%<BH[H+$]
MI5KJ5QAXNU[I<K6&`//UJR1DM!NI"&DY1PQ?IL9)LFJ!%""`B7AV..K%UKVN
M7\)M;Z]NYK9U"6232/:2,15KG$&AQ&&"NPZ3I5G)S]I:V\4X!HYD;&N%<#0A
MH.(VKOV:N`8QC=W+&7I"(]$LJ<"AQ'CP*'5=@`_4UJ%L:==?/@V'P[9?C8_M
M6B4ZZ>#8?#ME^-C^U:)3KIX-A\.V7XV/[5HE.NG@V'P[9?C8_M6B4ZZ>#8?#
MME^-C^U:)3KJS-(E9:<F&!YZQ]KLFD0L@`2@@8#O>Z/7B8P(\3`/:Q.`#^#@
M/Z^IX%%,5>?!L/AVR_&Q_:M0IIUT\&P^';+\;']JT2G73P;#X=LOQL?VK1*=
M=/!L/AVR_&Q_:M$IUT\&P^';+\;']JT2G75ELE?!&NSJO=JPJ=7#R1^K5E#'
M24Z+-8>@H3JOQTS<.!@_5#L:D;4(PX5=D*X!D43=W;('%),>'=8_8XD`>'_9
M:A*==>G@V'P[9?C8_M6B4ZZ>#8?#ME^-C^U:)3KIX-A\.V7XV/[5HE.NG@V'
MP[9?C8_M6B4ZZ>#8?#ME^-C^U:)3KJ.%@0\+EF_=FP=BMMENN[IFZX>,F[)U
M8J=5Q%(.CQ`/UQ$=3P**8^XI'X-A\.V7XV/[5J%-.NG@V'P[9?C8_M6B4ZZ>
M#8?#ME^-C^U:)3KIX-A\.V7XV/[5HE.NG@V'P[9?C8_M6B4ZZHY&N@2/?'[N
M6,W19NC=$TJ<2FZ*!QX&#JNR4>'9U(VH1@J:"KP*P<,IW;L2?614<?H)RABI
MDZ;1$W0(7JOQ2%X\`#]0-%`&`5U\&P^';+\;']JU"FG73P;#X=LOQL?VK1*=
M=/!L/AVR_&Q_:M$IUT\&P^';+\;']JT2G73P;#X=LOQL?VK1*==<67L*']8J
MK+/NK-]GDJWA?MGNB?ML.&^C'I.J!?H<01'I<1+P[(@'ZVIJE%J!R\%%`V.[
M:T@4."1\?*"=,#&Z!A+;++T1,0!Z)A+^IQUZ1I7[M@_1A;N#\RS\57;'^\JJ
M9"S-EW#L-6K6QE<(Y$L>.,EV.0L5'38PBE3H-=R`ZNAX)"U*7-QCH8VW1C$L
MKW/Z",H\*W.0H`90+L=VR25\0!JQQ!-1A0`UI6M,0*TVJ1("XM`V&BE]$W9X
M;O6VGZV\1<G45@QG1[A?IFQS;-_&/ZO7\>N)U&ZH6"!`JDG&S59?UUZBY8"0
M7)'*0I@03B`#4RZA?;>-`TARDUX@*UJ.,4."D2-+.<'<T592MPS:Q4V"R/9:
M9=\38TL&-H_+,5?<B/JI&UQE6I4T,,+'6=:+LTDK4KK(Q=B;NTXMR43`B<R8
M*F<$.@6IDX<P2.#FQEN:II2G5QP..Q2'X9L0*55U>;DL#,9*B5R0SAC5I+9/
M91$AC>&=7:'2=7F/G)X*S!NZJU4>!W8;25H5"-1,B!@&1.#;L+&`@C<0`M:7
MMJ[9B,<:8<>.'73.W#$8J:UK)-(M\K9:_4+S7+)-461".MD/`SS.2?U:4[;D
M6/:TLT:.%%(]P61B7C81,``5TT<(B(+(*D)6V1CR6L<"YNVAV*0X'`'8N%_-
M<*HMOWY;Y$S%!9;%&]LA#J](Q`54KN-2D.J!1`YB`<W$W`>(A_TZ]`]4H)]9
MU@UM,QM+P8[,85Y!Z\"!N+*3L%Q!^M:M'UMK#\*?6:PPM<$T<0>#H[#[^2/#
M3*Q)1Y'W2@6T+,1J>:-VHBJG100[4`PB!G8GZP03`IOI1VXLOS=!8Q3Q-?%I
M;;1SLCSF+9H)><IGP!YC+E_WZUPH?EUN]D?CLMU)#(YLE^;D-S-&4&.:/)7+
MC^=KF_W:4QJ,JN<0.IBZ6>Y6&=:.CWJ7I9[7#QK%PR8^"F-F,^>E5>,4<.GA
MW)BVBQKR4DZ=D,#P`(W(BDD0..^?N\^XU*?4;N5KC=20\ZQK2UO-6[9.9B:2
M37\K(Z21SAR\&!K6A:ENLLAL8K*VC(%NR7FW$@GG)BSG9'4`IR&!C&M[G%Q<
M25&L>8.M.-9"!DX:ZP\DXB*$&)%T9R$E'22V.Z[;YZRXQ[6<)32+I.T4J,L2
M\6Y4.)FLL@1-0Q$%"!QP](W8OM%FAGM[F-[X[3Q4A['$&WCEDDMJ$/!YR%LA
MB<35LK0TD-(65J6O6FJ1R13P/:U]QXP,KFBDSXV,GJ"TCFY7,#V@<J,U`+@5
M>\L8:D,EO)%=*P1D:A(X<NN*U$WL2Y>J`YN%@I\[W?X-WK5'J8_P3`G:P`!C
MF7Z0*%Z``;)U[=R;6I7N;*QC'Z=-:\IA)K+)"_G,'`4;S5,O#FK44QL:/K<>
MEL:TQO<YM[%/@X#"-DC,F(.)YRN;J;#50L^VMSW<:S"$]6VI(NROY^":H5QR
M3P?1?[@(#-IV$,<CXA8X"L(=6&$R!4BB1T97H]#I(FUAW+?XTVY;+"T,F=(P
M",_DPZ_CO<K.5R>2PP\FF#BZE*M.<-Z&^+F%T<I+X@QY+QRR+1]K5V'*Q<)<
M:XM`V\H621VE(2W=,S^P01W+I*2&+DDZVN64KRZV0<NWEJC$O32)E$(R2;Y6
M-&2R)>AVTS9F*7@#C@EC3;@-N,YEFBSN#LKN;.:,FXNYP&G-@UPNC'*,,S&$
M#!]&WHM\'0Y!''(&M+<S<XRO`AMXB7#+BYIM\\9QRN=7\'&1,MN+YG7A@1M$
M(NV-:+9.NF:M;7[DS#6[8L3QS*I33,)3INY:#?`:3BG0&+U1OVLY1,<5BYD6
MYTT=IXKS\19S\KR#&<CQ-:BW=G&;%['5DB=P;"*DN&/)O-')<^,\U('<U&P$
M/&9IBGYYN4Y<&O'(D;P[1LRK(F,L0,L=(W8O=`LC)6^9:.SVI!N+&X*Q+"K5
MNNLVDS.B99Q(2";J#7?"L42)@Y?*F!,#"8Q]OHF[T6CMN1GSS7$@/.@992QL
M4<8#WXESJL<^N`S/<0*U)UNJZR_4G0'+ECA81S9-8\QD>\EK,`!1P93;E8!6
ME`+[=J"M:,;9!H+2P21%[S4K'6$Y>R.7,^6)&P0SN&%V5`%&BRJ+4CL5>I*H
M3K#APZ0<>.LK4])=?:-=Z5',\/NK>2+/(3)EYQA96F!(%:TJ*GA6/8ZB+74[
M?4'QMRP3,?E8`S-D<'4KCB:4K0T'`L75[;^_J=E@;'"6MDH-2N=HN%<92T6^
M?JG1R/5VM>R)5;'-'DAE)R,.[8HNX%\J)G\0BDFP.+AHF0A=':;I36%[%>6M
MPT^+W,LT;7M<XTN(A'<12/S9GMJT.@>?RD30(CGC``VUSO%'>6LEM/"[\M`R
M-Y:X#&&0OAD8W+E:ZA+96#D2$F097DE72IX>M-9D(V;4N,=(SU:CLFMJ[)N$
M+6X!\.2)Q6QIP]R:O;.Z2F*S2Y,42QJ:'4.>H:I%!1$`,4U^PW=OK*5ER;AC
M[N%ER(W$2G-XP_G`R8.E(?'"ZG-AN5U&M%6T(-F\UJTNHWP"%S;>5T!>T&,4
MYEN3-&0P97RMKG)JVKG&CL*58XBE)F$KD3;U:#(/(JVJ75U9(:L3+&RLK*E/
M1%A;6&J2\A/R+J'GY-XQ73DES&,19LN5%,A44^K/<]'I[FUAM]1-H^2.XYXR
M,C>V1L@>R021/<]Q9(XM<)#L+7!H`:W*:/GF*">2:S%PUCX>:#'/:6%F1S"R
M1H8T.8T$%@VAP+B23472A8A;4>SN9\DN+YNVBKE`UUB#4R"C&*O>3)+*4T$F
MX,NJ5\\0F'R35N8A4R@U;@8P"HH;HW]*W>9IE\;L29FMCFCC;2F5L]RZZ?F-
M3F(>X-:0!R6U.)*M:AK+K^U%N697%\;WFM:NB@;`W**8`M!<:UY1H,`LRZZ-
M:1-$31$T1-$7JA_VR/\`;4_^N&JF=T.NH=W)ZR[7?T9+_8%S/_.`;Q?]/&.O
MRTWT_P!8ZM_S.Z_7O7WYNQ_IK3O\C!^J8OZ)M<TMXFB+R7.HFBLHBB+A4B2A
MTD"G(F9=0I!,1$JB@E3(*A@`H"80*''B/8T1?RE;?N4YS(=M^)&*5&N>+E,T
M-=D&+=O='M2&2Y*J2N"SXXW9I9LS#@>E3M6QZQ;V+&&ZB@.%B-[;(MU;539]
M,$2&/'J@H@1;3WS$^_>4WFX7P_CS+N?V45C[:1M`O5CR#=\F6EYC$]IIN\V<
MD-P,7=EZY5J]C',^5K_MP8N*HNW5CFZZY)!I(*E1*F1VF18?:\I#>M:=F\;M
M!D,J5#%E>=\I13:#)J0=SG9VIL=Q[/.C*](.W,.P@8M\_P`=6G'K):#EI-#J
MWIHZ061[35$I0$BW9SAAGF3Y*KN6W.+V.$<$(E#9=&XPJE(M0UK+<_C_`!K>
M9"?W6XAEL[0%6<HURG66NKD9T)P@Q35:G<R`/$&A'8&(14&1-JW,-5W8[7[Y
MC[/EU<8-Q=4MF]<RE%V3/,VT<7][CNQYS2W-62X4"`JT/0[M9\C4JW55,[L6
M#%-^]C%%"(,10;F$BV<Y>N&MW.(JIE,N\7*TOE/(D_D:Q*1LJ%\3MU'D*XTM
MEO>UJW4:O.*=7)C%Z5BITY%,Y"NJNY!FQ=P_]Q]4D83N"+H;HB:(FB*-0W^.
MK?\`RK'?Z.Q&I.P*%)=0I31$T1-$31%%+M^;,C_;([_*C+4C:J7=R5*]0JDT
M1-$31$T1-$4:C_SILG\GUW_QC4\"CA4EU"E-$31$T1-$5@M?YL6+^1)3^)+Z
MENU0=BO+?^]T/[2E_P!0NH4KVT1-$31$T1-$46+^>R_^:S7_`"L\U/`HX?<4
MIU"E-$31$T1-$5#*?XLD?\!=_P`74U(VJ#L5)7?S?@OY&C/XDAJ$&P*\Z*4T
M1-$31$T1<3GW_,;5G^9.O7^_5CO1%I)R\"B;9!MJX!QZ./%C&_Z"^%MD+Q']
M8.(@'']<=>D:5^[8/T86Z@_,L_%5=$[,<<0<QN/G6TS8#3NZ#)OTB9'EUV%:
M+*MF+R,H$%9L:U^3;1#:398\M\'C6-;/FRBRKL.*ZJ+A)54#$O-M(VF0@FLC
MJG9U`1UC0557-MJ3PN./:^XJRC;-L/TB@[D<0E)/6+#.YVVY$MESQ5/2`*UF
MM&RW!)0F2H.D/&Q$;%%PMN5(>2<`X>.5TY9PNZ253,J8`,M(F1R18F*0DEIV
M#,,:<..WKXJ!&T`M_!/!UUB:T\N3%EZK%CJUURAFNPM9C;_C/;C"/3V*O1SB
MI4_#M]B\CX[MS-BPK24%.94B+%`1R;J;D&BW=*/8IM7"!TS*=.T[3XGL+'N>
M:QA@Q&`::@[,75`Q.T8*#$"*$G93L?TJ\7KE[XHR!;,0W1_:+E"R.&*[CJO0
M;.J1./JW7I0<=[@*UN68R<E7H:FLH6,=3N3*J@9ZC&(,6@LU5DT4DU#`J67V
M$3W->2X%@`PH!@X/V4X7#&E%)B:2#Q=NOWUEW;]M:QUMM?Y1>T)U+O$\H7RU
MWIPE/LJHL_K0W2XV3(<U58NT1=<BK;.51*[7&4?L&\T^DCQPO5$T#D(8W2O0
M6T=N7%E>4XG&F%232M*D5)(J312QC6$TX5Q4YU=<MEJWB\NJ)I64Y##$]]&N
M\=^7(49`0%F=1$?&Q&,G<FW&)LQ3PRC>09IF3554#I(D$3%X"&NNW"L]0O\`
M?VR@TR_?IMUXO=.\8;''(6-;'5PRR<BCA4$G8,0O,_6W=6=IND^:^M&WUOST
M0YESWL#BZ1H:<S.54'$`;=A6CRV(-P#=G'R"W,SLI&$M&I342^^B#!1VDI#K
M+L&R,M&N$TSI/HQ5Q*M2%72$Z0F<)!TN)R\?I1V[V]K(V3.WUFYJ1@>QWBEE
M1S"6@.:=CFDN:,PJ*N;CB%\O#6=WG/=&W=:+G&.RN'C%U5K@"2UPX'4:[`XX
M'B*DP[:]V(")1YA&2`$.("`X'PUQ['8'L=J?J"&LWT+W^_BZ\^0VG:6)Z3[H
M_P`.6ORJY[:H7>W[<^P5CT'O,7OK1:5?%C(Q)Q@["R2DA(F:.GY6+0IFP"N[
M,Q9++`0O$PII&-^`!U:DW2WXB<QLN^-TUTCLK0;*S&9U"[*,,3E:33B!*N,W
MBW5D#G,W:MBUC<SJ75S@VH%3C@*D"O&0JWZMF[#UA.1_P<?_`,`^&?P?K_WI
M^#5WT+W^_BZ\^0VG:5'I/NC_``Y:_*KGMK\';;NO*43&YA61RE*`F,8<$89`
M"E#LB81[4[```:'<S?T"IWNO*?Y&T[2>DVZ.ST<M:_YJY[:LS?".XYWW`[5Y
MDMQ<>%;9=Y5P2PMA$XV)HV9%DG+F%*"'2D46\<<%SF2`P$2$##P`>.L5F[.^
M4G,Y-\[@^,`F*EG9_E`&YB68<H!O*)%:#%7W:[NTSG,^[$`YDTDK<W7().4!
MV/)).`KPX*\_5MW7^L)R-YB,,^]=97H9O[_%UY\AM.TK'I-NC_#EK\JN>VGU
M;MU_K"LC>8C#/O73T,W]_BZ\^0VG:3TFW1_ARU^57/;3ZMVZ_P!85D;S$89]
MZZ>AF_O\77GR&T[2>DVZ/\.6ORJY[:?5NW7^L*R-YB,,^]=/0S?W^+KSY#:=
MI/2;='^'+7Y5<]M/JW;K_6%9&\Q&&?>NGH9O[_%UY\AM.TGI-NC_``Y:_*KG
MMI]6[=?ZPK(WF(PS[UT]#-_?XNO/D-IVD])MT?X<M?E5SVT^K=NO]85D;S$8
M9]ZZ>AF_O\77GR&T[2>DVZ/\.6ORJY[:?5NW7^L*R-YB,,^]=/0S?W^+KSY#
M:=I/2;='^'+7Y5<]M/JW;K_6%9&\Q&&?>NGH9O[_`!=>?(;3M)Z3;H_PY:_*
MKGMI]6[=?ZPK(WF(PS[UT]#-_?XNO/D-IVD])MT?X<M?E5SVT^K=NO\`6%9&
M\Q&&?>NGH9O[_%UY\AM.TGI-NC_#EK\JN>VGU;MU_K"LC>8C#/O73T,W]_BZ
M\^0VG:3TFW1_ARU^57/;7Z7;?NP*(&+S"LC`)1`0'Z",,]@0'B`_WI^OH-S=
M_@:C>^\K_D;3M)Z3;H_PY:_*KGMK,6V^-YA>T6BR^--NW,WR1CBCSU\MV39>
M";[;]O5A(\O-\?$D[;/&?6R!G9)(\N_3!04$UBMDA["29`[&O,;W[,]CJ%Y+
M?WFMW+[N>1TCW>+QC,][BYSJ!X`J230`#B`7>6OKTN[.VCM+;2K=MO$QK&#G
MI#1K0&M%2RIH`!C4\96?_K)\X7UN^3_NI;5/$C6-[+>D^>;GY/'\8K_U^ZCY
MLM^F?WB?63YPOK=\G_=2VJ>)&GLMZ3YYN?D\?QB?7[J/FRWZ9_>)]9/G"^MW
MR?\`=2VJ>)&GLMZ3YYN?D\?QB?7[J/FRWZ9_>)]9/G"^MWR?]U+:IXD:>RWI
M/GFY^3Q_&)]?NH^;+?IG]XGUD^<+ZW?)_P!U+:IXD:>RWI/GFY^3Q_&)]?NH
M^;+?IG]XGUD^<+ZW?)_W4MJGB1I[+>D^>;GY/'\8GU^ZCYLM^F?WB?63YPOK
M=\G_`'4MJGB1I[+>D^>;GY/'\8GU^ZCYLM^F?WB?63YPOK=\G_=2VJ>)&GLM
MZ3YYN?D\?QB?7[J/FRWZ9_>)]9/G"^MWR?\`=2VJ>)&GLMZ3YYN?D\?QB?7[
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M1\V6_3/[Q/K)\X7UN^3_`+J6U3Q(T]EO2?/-S\GC^,3Z_=1\V6_3/[Q/K)\X
M7UN^3_NI;5/$C3V6])\\W/R>/XQ/K]U'S9;],_O%Y+[BN;\Z2,@YYN.35T3B
M03I'VI[5RE,*9RJ$XBE2TS_BJ$`>P(?@_6T]ES2>#6;GY/'\8GU^:B=NF6]/
MTS^\7K]9/G"^MWR?]U+:IXD:>RWI/GFY^3Q_&)]?NH^;+?IG]XGUD^<+ZW?)
M_P!U+:IXD:>RWI/GFY^3Q_&)]?NH^;+?IG]XGUD^<+ZW?)_W4MJGB1I[+>D^
M>;GY/'\8GU^ZCYLM^F?WB?63YPOK=\G_`'4MJGB1I[+>D^>;GY/'\8GU^ZCY
MLM^F?WB?63YPOK=\G_=2VJ>)&GLMZ3YYN?D\?QB?7[J/FRWZ9_>)]9/G"^MW
MR?\`=2VJ>)&GLMZ3YYN?D\?QB?7[J/FRWZ9_>+S+N,YOY55%R\W+)Q5UB))J
MJAM3VKB91-$5!1((&I8D*5(5C\.B`?V0\>/8X1[+>D^>;GY/'\8GU^:CM^;+
M?IG]XO3ZR?.%];OD_P"ZEM4\2-3[+>D^>;GY/'\8GU^ZCYLM^F?WB?63YPOK
M=\G_`'4MJGB1I[+>D^>;GY/'\8GU^ZCYLM^F?WB?63YPOK=\G_=2VJ>)&GLM
MZ3YYN?D\?QB?7[J/FRWZ9_>)]9/G"^MWR?\`=2VJ>)&GLMZ3YYN?D\?QB?7[
MJ/FRWZ9_>)]9/G"^MWR?]U+:IXD:>RWI/GFY^3Q_&)]?NH^;+?IG]XL%[F=]
MW.)P/@?).7DN:CD&YFH\.RD3563VQ[8(B/G47T]$PKA@[DH^B*O6:2C>3,(G
M2*)^)>`<./$.6WV^S[INZ6ZE[O)#JD\\MI$'B-T+&AU7M;0N#R1W5=G`N@W6
M]<=[O%O#:Z'+80Q1W,A:7B5[BWDN=4`M`.RFU?Z!]>;VV0K\$_4M38%7L-%.
MU?\`R\V']M<,4%5![#X@=DYQ'L``!KYAP7N]#QJ[]R[5\JVWS=;]\-,$H>-.
MYEI[/_FMMV.P/_EUOV/U>S_WA^L.F"4/&OWN7:OE4V^;K?OAI@E#QIW+M7RJ
M;?-UOWPTP2AXT[EVKY5-OFZW[X:8)0\:H@KEB"1-*>%2/;9V1&`CX/M^K[73
M74<%#H=O<>GUBH]GC^#]32H2AXU6!&6D>(!:VHB`\!X5UOV!X`/`?^\.P/`0
M'_WZ8)0\:=R[5\JVWS=;]\-,$H>-?O<NU?*IM\W6_?#3!*'C3N7:OE4V^;K?
MOAI@E#QK\[F6GY5MOFZW_5_!_P#,/U>&F"4/&O-:&LZZ*J"EJ;]6LF=(_1KS
M<!Z"A1(;@/;X\!X#I4)0\:^&L%9635LS1M2`(M4$6R('KS<QNK03*FF!C=OA
MTC=`G9'AI@E".%5'<NU?*IM\W6_?#3!*'C7YW,M/RK;?-UOWPTP2AXU^=S;0
M'X;8U#L@'YO-_P`(_@#_`!A^$>.F"4/&OWN9:?P>%;7C_FZW_4X<?_F'_3I@
ME#QK][EVKY5-OFZW[X:8)0\:XLO6,]_6*:TCW?1[=]"K>%`>]QD>B"`;Z,>@
M9#M7MOHB)CB`]/I<0X<.'9TP3%<(4<492RGL]Y3@XRK\A*MJ3D:TV;)$NC2B
M9!A*S17F-\YUEM(6JG'D([PIA5+O-1)08E%<W7@1QU*@-QUW$,4DNGV?-BH;
M0G"M!E<,1PBM,%M6M<Z&++_M@I3D/-^[?;YAK=7-H0.1\6XMH;G;:IL^F+O0
M,;E&HX_NF9J!BZ_XCMT:9*6<S%YIC-TN,&X?'5*]@91NJHH=\W.);TDUU!#*
MZCFQMR9*@8`N#2T[<1P5V@\:J+GL:[:&BE.TLCDE^:B\/>3,2N(UU3=OF?;5
MC")L./\`%B#7,.8:_G;*4!MYI>29%1-L-*L%MP66N2\RTCACVP/R)@8[,57:
M&KE=2-2."-Q;4-Y3@XAH/%5M":</%BJORV/4!X!B:FGW%E^K6C?*67VJ.Y.-
MF+!5+"%V5W`QLQC>L4"YUB,E9!^_H#V<,F_L-?7FJ/&LR1<O%M58%2;%PE(L
MEB*=8QU=:Z]K$34M-<V`!'%QXC81A7:.)5`R\GBX5B2HN>87*2V"[)=\;Q,Y
MDFG5'?5&O;1+PD'"4Y_9G.*,?'VU2KIDBA#3^-H/(]^:O6+^+7%\JW,V73,^
M<,RLWBMIOCY+'/:#(!)C2@KE&3\4$U!&/7I0JD<[49ARAF^\*=:JQWDB^\V]
M#%,6]Q_4[(:ZI2N6UFW''.*WMJFX^(VQXZL%"872`?(=PH!M*;KEK)",%694
M%WE?11,L<I!3>GMR/U3F@8P<]7<#:]P"*\7+J.MV523/EY(QQXN(?TK&_-/5
M<J[[N6BOU(I/5L/;SUC-A$6XIO5:MC!0[<14Z9D!3<&$GXW$2<.SQX:]6]4F
M;ZSM/IW?BEYU,>9^YBO)_7A3T$ES;/&(/UC5H[&8"R+38)&'H4TPB8+P&CDX
MZHIS3V.4HF0G=MQW*WE*HV-FW$I,?VV/K+UT9B*10:R*ZH)%!N\,DA](P;IZ
MQIMJ+?2I61VOBK<L6=S3!<&6W?.(I`/S$K8WNR4&61S@T9)"UOS!+O#IM[.9
MM18Y]QXP<TF4.YV$1S-BYQA/YZ,O:W/7E,`S<I@+I$&/LX.HXR$G+I"^&9M[
M.P.H[(UA0+<V#V$NK.B7>)0"/;%Q_(UN4FHMP[B6YE$G!F/$#G!NW*KF?-&\
M[X<DT@YWG)A(6W$@YYKF3-@F8,HYAT;GQ.?$TD.R;3D8'8_SCH+9<T3#S>2,
ML!A8>;(=$98G8GGFO:UX;(:$9]@S.(HSXHS&Q@IYA'6(CBPRN2GUL>6=M<):
M$-/QLA@@])6679)-SA#JIY)32?D9I\4$B%*NF)3)D)J@Z!O'%:RQ0S5NY+UT
MIE$SF<XUUCS)):!R#XS20,')``<*%H"K&KZ+)<1R2QTMF6HC##&U^1PNN=`!
M)Y7Y&K"XXD\DU!)5`&,]P#%K#LH^<ZY&/N</81<O,G3Z[]./;-L,JSD<JH^8
MO2R3*;?UVV`**PGZD)-,$NK2<+%2L_,N]D3(XH9:M9<LDJ;F0NR@69>TDM=F
M#W1W6!K3G!EHU[@VY\Z;NR/>^6.A=`YE!`P"I-SD(H1E+`^WQ&W(:U+6DU%/
MQ3FJ$G:K*RUDD7R3"2JCBPI+9/LDF@^:(-<NL+D0C!\`LW!Y-G/58$@$I`Z<
M890G5*)]-:O3M!WEMKJ">XF>YK'Q&0&YD<'`"[;-R78','VM,!C&2,I;5U-Y
MJ^ASV\L4436ES9`RD#&D$FW,>(Q&4LGKU'T-0:""+X:W-'3H[Y:<@I:STAI&
M+-IQ_D*92,[8JXUK-6MU($IJ_($1?V*PQ,JJ-@,FHJ*,T"AR])$R0ZMV[F^I
M%K*Z2*2^MFM(>ZX>*M-M'%+#^;=1TDC)3S]":35(JTM6>-;W6!GC;'(RUG<Z
MK!"TT(G?)'+W8J&,=&.9J!6*@-'`K=.EQ;Z$J<#%2:LBJ_9,`3<C+3Q[3))'
M.LJN5J\LAV,8>;58IJE0[8%NEUA4P['#LCZ3IL$MM816\Q>96LQSR<ZX8DT,
MF5N<MK3-E%:+A[Z6.>[DFB#1&YV&5G-MXJAE79:[:5-*J3ZS5BIHB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBTIYC/^Q%N'_S3AO\`3>K:\T]<?_XP
MUG_+-_6QKNO5G_KW2_\`,']6]?Z1E._-&K?YN0G^3&NOS<7VZI"?H]$W2#I%
MZ(](O1$_2+P'B'1`!$W$/U.'9T1?RKX$KG-QP'4\7XWQ;1\GTFBN<P9BN>2F
MCS'V++@].RRGS95C*/%9>X%F9ELTB-@%SD)Z/:LU`(T4C&B'1[81-'K$65)?
M=5S7&[_8UAL#N8O=?D'97<LOY5Q,\QSBDK*TY@QON[VK8VDW.1'PMG#>A8_=
M88R/9G$NM`/&9$EC(KL^K52204(L^PUXYOUDP9).[`WDL?YME][N(L<243!X
M<Q?,-,9;=UL[35?S-?J1+2UDF8'*.-PP4YC)N%?O&3:::/$UTEC/%Q,U0(L1
M9*FN;%@_#.Y-KM[Q;<;AF:5WI[A9&AV9CC'"O4Y,QC7MO=#D<=Y,O+9]8X:)
M9)9)R?7GD>`1L4FX>*B1J)HM`$G1B+<W$&(]TD=7N<0UII9K%N2\W[@,FVK:
M#<[NL1S`M'<_LTP32:+>8QJ5S+ECJW#YHKLB9PW,@F;MAHNL*!RJ@=4BQ;B'
M'.;\3[!(>1P#MHN5)YA&,MJ$12+'(Y65CI)6YYG?'HBF9)":M[NX/8'/MWFK
M%67\Y#S[Q5^S?N03(H[;IOEVQR+5+<9ASF#YSA<NV*S8RR++V>P<L'F]X$H+
MR%4A*Q,6*9O6X''P;&6EPA866A(6O9PN^&:J616,@@U0BGHK]8:/65.V*1;*
M7K+_`#&L3%WF2[\J6,\*X)V4DM^W&>GL3PN1("S7-GMLJ+\)R?F8NXM+L;)E
M`S_$V%G(UAPS<-IF$78';E(<BB[@B@.VK<GS&,TV?;DM6[;/V_$4QE_/T?GJ
MZ3VW$E:M>,'%?R3AVS8@P)E.I7:KX`L;&,DML\S/`K>H.'[6/:W;94060138
MNB+;'<O7\GUOF8[3-PL-B;*N0</XUVE;O*G?'N-X%*PBGD.ZVS`<EBR$4B%)
M6.%]-2,34[(FS<"`H,>N.599N1UQ.1:TVW*?.==QN<74)CAS5WH2\$K2V$=5
M<665Q4&\MOKJD!7XO'2KXZS3(+`=@3N1F[<ZENV#QUL0!-D*2H]IE(L&9V9\
MV?/&W[;ECO)6,+^^<RH8]MF2GE&@L:UNW/,KXAYEV%I9FID=5A)QZ%'K+K9M
M6Y*?0&OF9-Y5^=TW6`!ZB/5(L[K9&YRSFFW@)&IOJ_9@R]M7BD7M6H^+9MS`
M1$_NNR]![J6>.F$NB^86G$].VELZ7+0\U)I.9969>.P(=PN55DW(M^]DV;\_
M7#&N!L8;LL47^N[D'FU''V5LVW-W6*C$XU-D=_,2%-N5`.%;L+XL1?VDC%A)
MK,4F"40JP>E.Q<*@DNB@1<I<9;4MR5?Y:>:MO5DPW?CY]Q[A/FTTR&6,JS=K
M7.U[B\E9&F=NA,57<)E;NX%BJLQ$G:/"+-P@"($;NQ9*(%2`BW`Y4=6W,X[9
MV7'&[["TFTRG4,68.AZ%N9912,?4LAX70H40[@\*NH12SV.1H.2,!6:0D8BP
M-@$T?8W8=VD'+A5RX3;$79+1%Q.??\QM6?YDZ]?[]6.]$7`3:'%<W=;;-AU7
M"MSY=C#$BE<DC8[99.J&X5]D-M5QM=A[02N3RLRR%><SQ?QNN,S(5`>QT0_#
MKN=/&J^(Q<R;?FL@IF#ZTZM,*K:0\_S3<N3+3#:M@WM7YV\DV.SD[?RI)-DJ
M9,RK*2QSN8D&:ID5"JHF4:O)99NH9%4A3D$2B)3E`P<!`!UEENLD4)M:=9ZN
M4N/]S[JJNXW/&^7W*R^8NZ'OWJ::S[ZU[#T_O'^Y]U.XW/&^7W*R^8NZ'OWI
M36??6O8>G]X_W/NIW&YXWR^Y67S%W0]^]*:S[ZU[#T_O'^Y]U.XW/&^7W*R^
M8NZ'OWI36??6O8>G]X_W/NKEWNUQ-S2\I[^-A5&R/>MA2.6)+&V[=[B:6IM7
MSPSQ\QA8JNT=YD)'(367>/;"[DWC,C4L.:/Z*2:@*]L<0$NM5>^LC5?5->P;
MZ<U!<7$+7QM8&N+2)J1DD%[-E:BCA[JY#?;0K3>31CI.K.D;:/>UQ,1`?5C@
MX8N#A2NW#8MBQY?/-U#@(Y=Y=(=(.)>-6W&!Q#B(<0_%[(<0$/\`W:K]O;>#
MS5;=&?VE>/\`U-[F^&U'X<7Q:^O1[\W?B8/I;Y=?$@=(X>"NXWB0O$`Z1@Z'
MXH<3!V1_7U'M[:_YJMNC/[2GU-[F^&U'X<7Q:_/1\<W81`/I<Y=?$2],`\%=
MQG$2`43B8`Z/9+T0X\?P<-/;VU_S5;=&?VE/J;W-\-J/PXOBT-R^.;L0>B?+
MO+J*;@`]$U5W&%'@8`,`\!*`\!`>(?\`1I[>VO\`FJVZ,_M*?4WN;X;4?AQ?
M%KY]'WS<_*]RZ/FON+]CJ?;VW@\U6W1G]I3ZF]S?#:C\.+XM?H\OGFZAV!R[
MRZ0'@`\!JVXP.P(<0'LE_`(:CV]M?\U6W1G]I3ZF]S?#:C\.+XM?GH^^;GY7
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MWN;X;4?AQ?%K[3Y>_-U44(F&7^70`J'*0!&K;C.`"<P%`1X%X\`$=0?M[;P4
M_=5MT9_:4^IO<WPVH_#B^+4:V3;'^;9OGQSD7)>.LH\O6H1.-L_9BV\2S"Z5
M?<$:0D+1A>RC6)^=CA@U9!L$!+/`ZQF"IB..J_[0A#=C7I]G]J+?B]LXKV.T
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MLDFJS@!J>YH$RD>BX!OT#]0(G,/:I^D'1``['9'B/![3&_GDNE]'-\<H^HS=
M"M.?U#I(OB55^A,YU?E\Y8WS6W-^]=/:9W[\ETOHYOCE/U%[G^'U#I(OBD]"
M9SJ_+YRQOFMN;]ZZ>TSOWY+I?1S?')]1>Y_A]0Z2+XI/0F<ZOR^<L;YK;F_>
MNGM,[]^2Z7T<WQR?47N?X?4.DB^*3T)G.K\OG+&^:VYOWKI[3._?DNE]'-\<
MGU%[G^'U#I(OBD]"9SJ_+YRQOFMN;]ZZ>TSOWY+I?1S?')]1>Y_A]0Z2+XI8
MHSI_1_\`F_YEQ%?,97K</RXV%1M<,1O//*S7=Q[:>08QL@RG.E%K2$4^9$<F
M6BR%_;$CE$HB'8$0$-'O+Z^=\-ZM"N=W=0M]/997;`Q[HV2AX`<'<DNE<`:M
M&T'!;70_5)NSN_JT&M64UZZZMWES0]\9:3E+<0(P:4/`0NVL95/Z2!'1L?'M
M<D\F,[9BQ:,VYU,>[SNL.@U;IH)'4Z%J(3IF(0!'@4`X_@`->)+U%5O<#^DC
M^4?DP>;W>AXVZ(G<#^DC^4?DP>;W>AXVZ(K>I2?Z1BK)MYI6Y\E!29:-5F+6
M64QAO'/)MF3@Y5'#-N_-:!=(M5U"`8Z93@0Q@`1`1#1%<.X'])'\H_)@\WN]
M#QMT1.X'])'\H_)@\WN]#QMT1481_P#2/AD#1?TD<F3MPC--^)?HZWG]5VJH
MLHW*(*>%_$5.M2'B7H\.'`>/Z@%'#15G<#^DC^4?DP>;W>AXVZ*4[@?TD?RC
M\F#S>[T/&W1%YK5K^D@N$56[C(/)<7073.BN@MCK>:JBLBJ42*)*IGMAB*)J
M$,(&*("`@/`=$5-'4W^D;1#-&.B;OR4XN/;`8&[&.QGO)9,T`.<RAP1:MK2D
M@D!U#B8>B4.)A$?PCHBK>X'])'\H_)@\WN]#QMT1>:T+_21$$E5U,C\F$$T4
MSJJ"&/-Z`B!$RB<X@'A:'$0*`\`_5T1>;6)_I(3UJV>(9'Y,8H.T$7*(J8[W
MGD.**Z954Q.4+><"G$A@X@`CP']4=$&(JJCN!_21_*/R8/-[O0\;=$3N!_21
M_*/R8/-[O0\;=$3N!_21_*/R8/-[O0\;=$3N!_21_*/R8/-[O0\;=$3N!_21
M_*/R8/-[O0\;=$7+9S#\\3TU\,V6N_*]'=6/*TLR\=*ITS="&!B[?0W:5).9
M8/(PUC\/39</D8S!1LN1?N0$,5<AT^V!(8"+8?EX_P"Q!MH_U>K?Z5V77I.E
M?NV#]&%NH/S+/Q5N3K/5U-$31$T1-$7*G<DZ*QYMG+"?';/7A&6"N8,\,SC&
MYG<D\*UH./UQ:1S0H@9T_<@GT$4P$!44,4OZNO$O7F,VZS6U`K*S;@/SC-O4
MXUI-;_,-Z_\`2%FBC.MS6-+GE^6D:I;K<&X2C5C+U*ZM*=LM;PIG%S)-<<R.
M-YY!W&-E*I5HNB.ZY+*LVZ;IN"E8FEQ.9P](5;YBG&EW4$+&O8SQ:1T;MC72
MQ4+P\4/*<7A[030\N,;&FG..YMP%*8&G7''V:]E1)MB+.4-@ZYX_+#6RZ95V
M>9W:9EVN6VP3;]\GG>IM5DLD-<=+W6;3C#SK^5A;/8\>/U7R*22#@C![P$$T
MU"W3>6$E^RY+F1VE[;F*=H`'-./(SY16@!:R84.(S-ZBJS-S`X!KA0]3@K]X
MJ49;QKF97!;FJ-*#"/E9[*V`<LR;FI/;!9[XO=9K<=CS(^:DK!1T8.+A4*A3
MZH24:`=G-N3R$:Q!`4"==T!M6=U8B_$SI'#+#-&,P#691"]D5'5)S.=E.+11
MQK7!4M+<]:\!'4V4"Q;C]YO*Q?)-Z3"4C(*M'6SCEZ;;V!2@Q\[776++U<,I
M2L!(Q=/D;"XM6-&E-=.(0D;4W$LEU481-5(YTWCA&.R[D:)=M,\DD?/\Q&*9
MR'<XQL8(+@,K\PS9I`WNL".2"ZH\T[E&E<H[.'9ZZD++)O,$,SN22V-)QO:*
MM0;'-T%J2D5J>H>8I1I%W=BHW>W"2D,>SF-[,C8F\0_KT-)PR#E^Q.DT===U
MSMZWM.M=W0YE)6\T^1H?RG!\8):<&@/#VTS![FN(!J12@:66'#'`G'J=OJJ2
M1BNX.@;>\J.\;T_+BV0+9NFSA8Z@2?H];4NHT:Y.K%9:=9Y^GNBD8Q,(_E4X
M]JX(@S(LV,N(*(MD1<.4+;QIUSJ40N7P^+LM(FNHYV7.VC7-#MI(%2*FAIM)
MH#!R.>*TIE'"L-O]Q6[9O0,[Y0-9W$9&8U/?:C88:7Q74&K+'5VAIC;MX',J
MZX%N9Y;;0Z&\VR/EHUVN\20*U:F#J'!"F=9K=,T<W%O:9*OER.:1(ZKVD39B
M>!K1DC+7`"M3M&RH,CS!M,3U=NW^I9M<2^^J+7NA6CB<LY*;CF]S%%;2&-:)
M`KY8EDLZW2MU%"UK]HL4:]D=O@8T;-IPK,8QH\EV[<JY$2.734,$,T!XC+@U
MI?*P.H]YYL<TUSLN.+.=JW,<Q#2:5H"J/R6'7QQ.&'WJKQN.0-\,--PL?2*-
M/6QF-VN@0,G,4JOLH>S8U<W&PQ&/U,J.$.T)"C7!I##&N)#JDHQ,L>)7?4G6
M,\0:S!;:$^-SIY&L=S;:@.)+7Y07\WM#FUS`=UCR:TRDR&Q</$.SPTXU%%W.
MYZ5O&),R0U9S0QFT,:I0=JA;KBVF1,FU0LVX/;.-ZQO88F$6E6!V,)3VESDH
MV6:BVD5&3(%$ECI`D9Y=`TID$UE(^`LYVK2V1Q!RPSY'@FAJ7<TUS35M30@&
MN5R*%IIMXSQ''[RF4!?=ZKL\%*R]2LZ3OZ46,#>\<+XU@:XUCH)A8U(B?EL:
MY42E+G$VRDNH)TUF&3B5919'S-)T@22:2`$;DL26^A@.8Q[*<T2Q^<NJ2VH#
MXZ-+75JTAI=0Y3E+:E01%Q\&VO\`1_MUET8.``<P%$#%`Q@*8.(`8`$>`@!O
MQ@`0_7[.N:5E?.I1-$31$T1-$31%[M?[Z;?V]'_XA=0=B+%W]'A_V4-U?\YU
MOR_]6AU]A:#^XK+_`"D/ZMJZ&+\TW\4?>7>[6U5Q-$31$T1?"O0ZM3K#]6GT
M#],X'%+H$Z(](_6`)13Z(=GI`(</PZ(OY4MGN\/=4^B\0SFZ^^Y[^KO&;:^8
M9E5U<X<5:]?LO[D,3[V\DTN@X<DK0LSA5&$Q4]J4+&R5*K0KQ:-N4>F>*#(]
MJ<2$5)NBWA;MH#,>,I/"=^W3-JK(;+^5ME>)HT[6&[_.,M;,J[OI2J9G;/L!
MQE6<4C(N>+7@;M5*X5-64@V-<:'7ED5&ZS5,%2*OWWY[YBV(:US.BX;R=EN7
MQ?8\7W'-6WO+]<CXR?F=L^3-O684\69+VUU@QJ](/)%WF9&Q5"7@6ZR3Y=!B
MI/BB(%21%,BZ&;6LFY-RSF[=97MQ6:<I8CR+C_=M!4K;-BN#?`PK%JVFP=9Q
ME8\97Z#C',#(-LS1V>3NITUKLJZK]:(5.X8)+1)HXI@(LU[MMP=GR5M5C,C[
M+,O4>,L3G/,?263O)33)5!H]Y>XPR!8H+*V%+E>XFMA><$DLKVBR<,G;A8`W
M8/2H&Z8M70+"1:&R?,?W?8WID7<D<,V1""K/*@W+;P5,6YIAI*TY,N&XO$N6
M(.MPN,%LM4%I#5VRQ"]?7ZR'7C(A%[-P\BC(G;B95$J)%F1]S,=QM-W/XVVT
M7'#N)IV6M>.KE<;7:J8]S(PIE+?JX#S3GW%K29MEDH)8Y!I+L\6MH*0,S3E>
M#EZJY`[98B$4N1:X6[F0;S5+=M,SC7,1V1GX4;=-T+7)NU1_#37<*^YEI.[_
M`&HX>JU6H=EKKVVQ,E?G-/M-L>5*;:R4C`SD2BY?@F=H0YV9%FEMS7MQRM/O
MEND=JI*RWIN6MJ=6FR3C>\"GC^O9^W<98VY9"J5^5:QXC])F#Z/0(FZRKAJ!
M(KN?:&95"(-Q1>.B*VP?-,W=6^BX<NU>VZX@A2SW+!N?,)RW'9(LV1J,RK]E
MH<VC#2>#X2S/ZXK%UZ2E3/2JE=SQ4#QR+-PHNB<@"*9%M]L-YA,5N9J=2/DZ
MR898WW+V0\UP^"HK#-C4OL%>*!AJ-J4I*S%AF:_-7BOT&^#&6A-^O6Y260E$
MV"B:A$5.BL*9%S5F=U6]'$]ZYG.=8]&W96I>US>O`4'"=(L^1KBQK4[7,F0>
MT['9,=N<:P=+>'E,;UZ4S)<;.ULS1T]>-9NO@S43(S:JD5(L_P"5^:CN/PYF
M3.F"YC!N/KS;<(;3]R&6I2?H;3,@5&2S3A#;UB7.U8HC-W/U5@K(1.2?I!?Q
MR#>/,^52)')G1?.GIGL;'D7G2^:MN/M./L;N9+`V/JC<K]O%R3M?6O\`9%,K
M-,#5I&JX58Y?Q])6B085B5N<"OE^9DDZA%R`MG,<G,)F5Z*ISI,#$6\.Q?=]
ME+=;/;C$[WB&,Q+"XARY=<7P,,[EI<<C-7])R7D>EK-\A5F3BVJ$;X24ZKP%
MJB)!HL+60C[)U229DV9'KTBZ%Z(FB)HB:(FB*-1_YTV3^3Z[_P",:G@4<*DN
MH4IHB:(FB)HBL%K_`#8L7\B2G\27U+=J@[%>6_\`>Z']I2_ZA=0I7MHB:(FB
M)HB:(HL7\]E_\UFO^5GFIX%'#[BE.H4IHB:(FB)HBH93_%DC_@+O^+J:D;5!
MV*DKOYOP7\C1G\20U"#8%>=%*:(FB)HB:(N)S[_F-JS_`#)UZ_WZL=Z(M(^7
MC_L0;:/]7JW^E=EUZ3I7[M@_1A;J#\RS\5;DZSU=7[P$`X\!X#^`>'8'1%^:
M(FB)HBXD<PC(&5,8<RGEFW'#."Y+<=?6&)-\C=CBJ*R!4\8.Y6.?5;&[>8EP
MN-W`:ZP2K[`QG1TU?QURD$A/QAUX_P"N2VM+O=YL-]<"VMS(VLA8Z2A#V4&5
MF)J<.HM-K(:Z)H<<HXZ5XEG%'>SS('"95F_)POKA$_'H+-][6VA=$_`1*/05
M23.F?@8!`>`CP$-?,)T+=D8'6XP?\K.N<YJ#PH^"5Z_72YDX]@.33D,1_6^N
MKML]IU'S'NOY[B^33IS<'A1\$KQ3WM<Q]8RQ$>3C?%CME>H<D2WM[:%3ME^J
M37ZAR4B9C(+]0L0_0/P-T#E-PX&`1'0MV1MUN/'_`/2SIS4'A1\$HEO:YC[@
M%!;\G&^+@DLJV5%#>WMH6!)R@;H+ME13(8$W"!_Q3IFX'(;L"`#H="W9&W6X
MQ_\`RLZ<U`/_`#1\$K]#>SS(#*G0+R;[\9=,A%%$"[VMM`KIIJB<J2JB()BH
MFDJ9,P$,(`4PE$`$>`ZGYBW9I7Y[CI_E9TYJ#PH^"5]CO5YDI2F./)KR&!2%
M,<P_75VV=@I"B<P]A$1'@4-1\Q[L>>XODTZ<W!X4?!*C^W7>#OYW<X-J^=<`
M\E6?R%A#+"T[,0,^IN]VN5]C:W<!:96K3DG)5FUQL1*F?M[/67"0K/FA5E3-
MBJE$Q>K./;M]4EZ<L@U%M0,#S;Z@<0_*8"G`%E?-[]N<=C^M;"_2KS?O4BWW
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MQV/ZUZ)98YOJ2J2GH0[Z;JU"'X!ORVG`(]`P&X<>V^QQX:'U/7)%/'X^B=WZ
M?-SO?CL?UK>WDBX,W,;9]J.5('<O@:8Q'DK*.\;<SGHF/B7G'5Z4K]8R];VE
MI@6KFS5.R.X2070(NJ@8R9B&,*`G,FF!BEU[/I]J;+3X+)S@XPPL96E*Y&AM
M:8TK2M%L6@L:&[:`+L3W>EOD?.^ZJ[W[UF4ZJFIXD[O2WR/G?=5=[]Z4ZJ5/
M$G=Z6^1\[[JKO?O2G52IXD[O2WR/G?=5=[]Z4ZJ5/$G=Z6^1\[[JKO?O2G52
MIXE3.K0^:$3.YJ4Z0BKELU3'MB`/TG#I<B#<G`LR;ATUCE#B/``X\1'2B5/$
MJGN]+?(^=]U5WOWI3JI4\2=W9;Y'3ONJN]^]*=5*GB3N]+?(^=]U5WOWI3JI
M4\2HF#Q:*;BTC*#)L&QG#MX=!F>LMTE'<@Z6?/W:A$IDH*.GSUPHLLH;B=55
M0QS")C"(J=5*GB5;W>EOD?.^ZJ[W[TIU4J>).[TM\CYWW57>_>E.JE3Q*F1M
M+YPL\;HU*=.LP630=$[8@"]4JJV1=IEZ1ID"GZ3=<AN)1$`X\/PZ42IXE4]W
MI;Y'SONJN]^]*=5*GB5AM31G>*S8*9;L;O[#5;7"R==L<%)J5QQ'3,',LUH^
M4C'R`S8`LT?,G!TU"_JE,(:4ZJ5/$H?0<:T#%R*Z5!PH2MG=2[RP/'K0*\O*
MOIV0B(BO/)F0F'T\ZE7\HO7Z^Q8"NLL=4&+-%N!@22(0%.JE3Q+)W=Z6^1\[
M[JKO?O2G52IXD[O2WR/G?=5=[]Z4ZJ5/$J5[:WD<V4>/*G.HMDA3!13MB!/T
M155(BF'13F3''I**`'8#]72B9J<"JN[TM\CYWW57>_>E.JE3Q)W>EOD?.^ZJ
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MJ)$P'B(%*8W`.P`CJ0,4)--BNJ$[*@BB`5"=$`23`!!U7N`AT`[/9F@'L_\`
MLU%!QI4\2]>[TM\CYWW57>_>E.JE3Q)W>EOD?.^ZJ[W[TIU4J>).[TM\CYWW
M57>_>E.JE3Q)W>EOD?.^ZJ[W[TIU4J>).[TM\CYWW57>_>E.JE3Q*.%F9/PN
M66\%IGK!K;9,6W;,%UH$"3=F!<3=UNIZLQA$H!T^EQ`>QP[.II@E378I'W>E
MOD?.^ZJ[W[U%.JE3Q)W>EOD?.^ZJ[W[TIU4J>).[TM\CYWW57>_>E.JE3Q)W
M>EOD?.^ZJ[W[TIU4J>).[TM\CYWW57>_>E.JE3Q*CD)R5,P?%-49PA3,W)1.
M9U7Q*0!0.`F$"3)C"!0[/8`1U(&.U"338J:"FY1.#AB$J<VL4D5'%*JFY@`(
MJ4K-$`4("DP10"G`.(=(H#P'L@`ZB@XT!--BNO=Z6^1\[[JKO?O2G52IXD[O
M2WR/G?=5=[]Z4ZJ5/$G=Z6^1\[[JKO?O2G52IXD[O2WR/G?=5=[]Z4ZJ5/$G
M=Z6^1\[[JKO?O2G52IXEQ:>RLA_6*:TY\')7KPY*EX2!AVQ#]LBF.^C'IA<`
M?NGVIU91#@(=9T^(AV.'$=%-3Q+3_EX_[$&VC_5ZM_I79=>D:5^[8/T86[@_
M,L_%6VL\>;3@)]2LHL7-G3@9I2LMI0_5QCBR$C'1H!"34Z1.KCEI<$2KFXAP
M2$P\0_#K.=7*<O=4-.OP*Z:TPVKCOB3-N>J-@S&TM(8GW,YCW@P6T//67<RQ
M%BE;FRH[S<34&K5-?#F0J>Y8E@64W/6QV!*$WK9$$%X5LN+,5$Q(934Q33L@
M:2V1]V(G.=6M,X_!(XZ]S3@V+':YP:,'&3*2>OQ=I7++V]3>71\?X`MU)P_6
M+V[R%4\G7.XI1.(LXR)>YM8RKA^OX_AR1:Z5<GL?6RV8_O<RXD&D@U>E0?0B
MZC,7#5$YAF6\NV1QO8P.+@2>2[@<T##`@D$UKPC#!29)``0*UKP'C"W)PUFO
M-60-R>Y?&MRQU&TK&6(+7(UJBR+R'O#2SW"(*VIKZF9$C[$]B?H[M=1O["7F
M!,6/>E>Q3N+(W40-Q64+EQ33/N)(WMI&PT&!J=E#780<=FRE%6USB\@CDA;@
MZRU<7*/<T3K>;)RRD@0,Z%7`7,,3!J1,BIW0J8\H1`;$24$J:AG`FZ`%,(%,
M(\!'AKQ/UY&FZ[3L_+,_6,6DUO\`,MZ_](69*E'[C,<[/=NN,J+B^^0-TQW1
M\*5#+#>"^C0UO:PR%4?5V[DQ6C/76-J5@M%4L:#"1<'=/V;5W'@L5NHNN?JM
M?,4KM,N=:N;JXEC=!+)*Z.N?+7,"WG*-+@US:M%`2#2H`Q7.'(9"XD8UIM^Z
MH=9ZUOH?Q618I2<RO-)/&UM)"*QS[$]4?JIU7*>VN6I*M9<UL8<(J7N=!3R*
MBY24=&:KEZINH9'BU,>]%+H#7Q/RPM(+:U$CARHY@_-FK4-?S-,*C$BN*D&(
M4V?=XC_4LW+U7<H7,=NF:PY>0F.;)GN;B):/.G0X113$EEP=B?N7F%@[C8M6
M5L%OQYDZER\,BA(*G>.V4P!C@JV9,Q)@B72_$F,E`=<MMP0>6?RC99*QFIH&
MOC<UU1@"W@+C6FK,H![JGW:G#W5CL83=Q&7+.,C$-LAQU2CRYMLV,:O44,&P
M#*^V>P9:>(5!:1>/X!V]=RY,82?=%!5XHU6=O&*7;BYG0F!3)YS1WPP->8S,
M>::]SN=)8T1C-0`T`YP932H`)RBBJ_)D"M*X<?%VU/\`;!5<XM\D7.]9OKDJ
MPGIO#="HZ]DDPJJ:U@?4/.^YY_$$70K$U+I@[0Q=<JRN90YAZP7!BF.9=-<`
MQM5FL#;,M[!P,;9WORC-R0^*`'N@/PVO'N<5%3(6Y0&[*_T#^FJW;7_O=U_@
MKK^+J:T0VCKJT%9OZ-Y_P5MD?\D9N_WE\SZ^TX_S;?Q1]X+I!L'67<+5:E-$
M31$T18"^M1MO#*KK!JF;\9H9?96:/I3K'+JVQ+2V(W.7J1[]#U`T2Y<)./"F
M8HR9YEG'@`O'44F=VDF=`AE`(L^Z(FB*$V3)-`IUEH%-M=RKE=M>59F7KN-:
M],2K1A+7J?@:Y*7":AJLR<JIK34G&56$>2*R"`'4(R:K+"'03.($4/F-Q.#(
M"UWNBS.5*5'W/%];J]QR)5EYMJ$_2ZI=I%Q$T^QV*+*8SR+AK/*,UV[!PJ0J
M3I9NL5,3"BH!2*?W2ZU+'53G[U>[%$U*G5:,<3-CLL\\2CH>$BFA.FZD))ZX
M,1%JU0)V3',(``:(I.`\>R'9`>R`A^KHB:(H:ZR'16-JD*.]MU?9V^)II,AR
ME>=RC1M)QU%/)/8@MN?-UE"&:U_NG&N$!='Z*0*(G`1_%'1%,M$31$T1-$31
M%';+_>L;_G%7/\L--2%!V>Z%(M0I31$T1-$31$T11J&_QU;_`.58[_1V(U)V
M!0I+J%*:(FB)HB:(HI=OS9D?[9'?Y49:D;52[N2I7J%4FB)HB:(FB)HBC4?^
M=-D_D^N_^,:G@4<*DNH4IHB:(FB)HBL%K_-BQ?R)*?Q)?4MVJ#L5Y;_WNA_:
M4O\`J%U"E>VB)HB:(FB)HBBQ?SV7_P`UFO\`E9YJ>!1P^XI3J%*:(FB)HB:(
MJ&4_Q9(_X"[_`(NIJ1M4'8J2N_F_!?R-&?Q)#4(-@5YT4IHB:(FB)HBXG/O^
M8VK/\R=>O]^K'>B+2/EX_P"Q!MH_U>K?Z5V77I.E?NV#]&%NH/S+/Q5!-R6^
MJ7VWW6STZ5V^S%N"!P!G;<Q&R,;E.MPZMBQ;MZ<4QO=W"$:]K3PD7/R`W(%(
MUDNY'KTF:@J'1.=,@S<7IMWEA96D;G]T,0VE>#JX(^7(:4K@3MX`LQ1.]G;)
M)X\J.2'V9:K`UNUV*0I3,)QU),7,9?:]',)*Y5"29NXYN]8/*.C(HC)NUD4F
M#9%5)<RP(K)'-=%Y;&,2%X#2:>Z-H]SA.Q5<XRF:N"N5DWE[:J=9\@4^RYDA
MHBU8QDE(G(4,M&VY5U7)M.,A9D(9ZNT@%V3N<7@[$T>HM&ZJ[E=FJ99,ADDE
MC)RZ[MV.<QSP'-..W#AXMM#5#(P$@G$+PDMYNU^+FF%9?9JK7=60J]2ND4U;
M-++)-7]9R%2[-D6A2<=)1T&[B79KU2J5+R$0W26,[DDXU<B"2BI!3U!N[8'*
M7BM`>'802.R`2..B<XSC66\=9/H&7*TQN6-;.QN%4E(ZOR\788I%^6*DXNU5
MJ'N->?QSMXT:D>MI.LS[-V4R72Z!'!2J=!0#$+>CD9*W/&:M-,>N*C[A50<'
M"HV+G=N%*)N;URM2E`3&-A7?X4I0#B(B-(QV```!V1$1UXIZ]?\`2@_2,_6,
M6EUO\P.O_2%M_!;P\52#_.J$V,K7(W!]OH=>4E@9N;1X>0&2Y,E-I5XJ,14V
MLQ,N(*=RI'S%91(*`K=N1)EC`5!=(P_*TFBW;6VY91SIV/-*Y<A8,SFN+J"H
MC+7G&E'4V@KFC$["G"/O;?N8JZ,-X6WN3?TV,:7.7,[O?<5.&!;'V1&J$>]L
M5UM>-(:(N#QQ5DFE%GGV2J1)UT&,P=FZ+.-P9F("RJ13T.T74FM>XL;ECK7E
MLQ#6M>2T9N6`QS7U;493FV`IS3\<-G5'7^]BKA6]U^!K7%U>;A[D^+#W$:@>
M#DIBG7.NMC,,B6%*HXZG9$9^`C58>M9"M:H1L)).BI,I%X!DTE!Z!Q+3+I&H
M0N>Q[!G9FJ`YKL6-S/`H35S&\IS1BT;0H,;Q6HV?T;5<('<YA*ROE(R$MC^1
ME6TVE!R$*TI]Q<6"+.JE2'`RTG7D8(\TQKS9MDF"4</E$"HMBR:77"F8%03I
MDTJ_B;FD8`PMJ"7-H>ZP!K0GD/H*U.4TX*C&\;=G^W:5)MUW#US<%4PDV;%Q
M7+A&1K"2MM.<HS!R0K6:G;?!P,A$SLI"PC6UP<PO29`J3YFF9'KVJR0\#)]F
M=2TV73ILI.:$DAKL,:!I((!.4C,,#C0@\*/86'J+8!?^]W7^"NOXNIK7#:.N
MJ`K-_1O/^"MLC_DC-W^\OF?7VG'^;;^*/O!=(-@ZR[A:K4IHB:(FB+A+?N6%
MN`N?,-GMV3"]8HA:!([V]KNZ!A%R\E;KB^3I.!MIDCMRMU7=XID:FRH`91N#
M^1.O`VLLH=W4V9SJMQ4<"*)R+"-^Y2.^1UMHQU2,:[IRPNX,$MXS',E\G-QF
MYQ>OV0F:C7-#;Y+5N1.VF)*+/@R'?Q+=-@UBHQ`BK<RR"IE$2'6(MMEMBN\(
MW,%OFZ")W$-:QAVX/\A)Q],:9)RI,OJY`VC:+B3#]:;,\8R42GBP[JN9^H4A
M<1*15(J@/BK=8+DZR>B*-8!Y=VYZD1G+HD,NY8@,@7W:IGR]Y>SG89W*>0<B
M!>5+'M!NFVA26Q8M9<>P+ZNJ7.WV$EODX-^86[)\_DC$D'J[CIF(MA+ALWRF
MZWK9\W`UN<I+S'6YC;QMJPI:FTO)SD7<,<R&WO)V6;BZFH2):0$I#W-C<:]E
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M31$T1-$4=LO]ZQO^<5<_RPTU(4'9[H4BU"E-$31$T1-$31%&H;_'5O\`Y5CO
M]'8C4G8%"DNH4IHB:(FB)HBBEV_-F1_MD=_E1EJ1M5+NY*E>H52:(FB)HB:(
MFB*-1_YTV3^3Z[_XQJ>!1PJ2ZA2FB)HB:(FB*P6O\V+%_(DI_$E]2W:H.Q7E
MO_>Z']I2_P"H74*5[:(FB)HB:(FB*+%_/9?_`#6:_P"5GFIX%'#[BE.H4IHB
M:(FB)HBH93_%DC_@+O\`BZFI&U0=BI*[^;\%_(T9_$D-0@V!7G12FB)HB:(F
MB+B<^_YC:L_S)UZ_WZL=Z(M(^7C_`+$&VC_5ZM_I79=>DZ5^[8/T86Z@_,L_
M%4PS5M*Q%GZS/+9D,;B>4?8$RYMJ<$K]D2A61L59Q[E?2*P(B$6[63G)(T&T
M%N_*J"C04`ZLO9-TKTUK%.[/)6N1S,#^"[;][:JG1M>:FNPCW"L=1O+VVZ1(
MTI=BED%.2Q_F:_9SKLTK<4W,F%LRG5H>F9&A)+MB%5CI*CV^O0#-)Q'*-NFB
MJ@19LN@L4IPMBPMQEIFJUY<,>%PH1UB!L["CFF=7`U[*E5YV687R%#9F@)QY
MDEG%9_S+7\Z92:UZ]NX0D_<JY2(/'3.,Z+9B9,M)=U2M,4742J5=%=9N583`
MH`&"M]G"\/#LU'O#C0[2`!V*`8*3&TUK7$U/WEA"O\O>&J67G^18>PLY:NT'
M&FU&!VX4JVNYR28UW)&T>@Y:HN.KAF)2.1C7=[B6S?)P*E;LG+,YE&IE%04.
M9($[+;$-EYP&K6M8&`UP+`X`NX]O`J.:&;-P`"GN5V]E;=;>,(U3;GARG8?I
M<='14)623+T[*'[?"'2F;1/R=IGDX5.4<O)!M`-9:85;QK=50QFD:BW0#@5(
M`#*@A;;Q")@HT?TFI]SBZBN-:&-#0N5G,/S/4\!<Q_EKY'NT%EFQUUMAK?97
MW<;A"CV#(>2@4M%0QW#-WT!6ZN`S?_=ZKD%57B/]XE+UPB'1UY-ZX[&;4=WV
M6T#H6R<XTUE>&,Y+V&A<[#&E*<.Q:C6&E\30*5KPX<(4(REO&V<7.#AD:7@W
MF)4&UP-5QGCMA9&NRO.8H+X\QUEZ@Y<2C)R+CCL4;%93RE#(5C+O.M=,%W:Z
MI1,59PFM\[6FBZU!(XSSZ;)"Y[WEOC,7=OC?'4$UHVC\6B@(`'`"-`V.4'$L
M(Q/=#:13^E75EO=V@-,KKW?Z"^8<:FI4RFQ4;2`V49S%9Q?:IF+(>;C9&M4D
MHJ=&R2KF]7\\DD51(HI2;<'!A.!BIIT.T'639\QXQIO/YW$N\:B[AT;(LC1^
M",C,I_W33KN:DRTJROXPXJ44ABM\&P:&;4EDUVP<QI9G0J3C['46UD-H.>'Z
M$O3<36Q.]XPA[>1P<WA3X`W!,9",7<\7"*RB@&.=-0Y!MOT'>%YD<;K3,TDC
MWDBXB%'2-R/+?>YVX.`P(IPJ.:FQY3,>J.':HG4=V'+[HE@KMKJNW[FI1-FJ
M[Y!S'3R&WG<\$HZC4ZS6*>ZJDXZ+*$4GZ9,0-(A$W\:[ZU%ZM$-5U1,N0ZA[
MTVD;QW$;H9KG271/&(YZ"E<SG9AA@X%SJ.%"`X@8*3',003'0]4+)^+N8=LK
MPVN^<T/;MS(V:DA6:Y4'(2NT#.<XF,#4YVZV.";))R(*E17:R^0I90RQ>"BI
M7)2'$2I)@7$N]V]=O0!<7.F$![G87$0Q<&M.SJ,;AU.J52Z&5VTL[(67E><'
MMR.BN0,!\PCI*(+IE_\`Q'<O\.DHD<A>/[3V`Z1M87H9J=?\1IWRJ-4^+/XV
M?""L/)QYON"-E/+;VT;8LX[>=_+#*>+H_);:UM*WLNS-885%6TYGR->(H&,P
MVATD7I305F:F.)2AT%!,0>R4=?2C-:T8,#3>6M0`/SL?%^,MR)8Z=TWLA=-?
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M.Q^^;V0@?TB/9@(@`8#YBHB(@``&Q3-HB(CV```"*[(CI\]Z+Y9:]+'WR<[%
M[YO9"Z*[,]_.`=]>'%\XX/-D%"GL[W<,;2#&_8\L5.M<7<*(Y:LK/$RM<=-W
M+V-7CG;LJ1B+=!0%"F*)0$HAK9L<V1@DC(=&X`@@U!!V$'A!X"JJA;7^%T%^
MZR'Q'.][=54*5">%T%^ZR'Q'.][=*%*A/"Z"_=9#XCG>]NE"E0GA=!?NLA\1
MSO>W2A2H3PN@OW60^(YWO;I0I4*R3MDBG;=B1N,BJ9*;A'2@!!S8=%!K)MEW
M"@]*.`.":1!,/ZO8['9U(!4$J]^%T%^ZR'Q'.][=10J:A/"Z"_=9#XCG>]NE
M"E0GA=!?NLA\1SO>W2A2H3PN@OW60^(YWO;I0I4)X707[K(?$<[WMTH4J$\+
MH+]UD/B.=[VZ4*5"C\3:(9.6M"IE7W0<2;`Z7"&F3F$I(*+2-TRDCS&2'IIC
MP`P`(AV0#@(",D&@45"D'A=!?NLA\1SO>W44*FH3PN@OW60^(YWO;I0I4)X7
M07[K(?$<[WMTH4J$\+H+]UD/B.=[VZ4*5">%T%^ZR'Q'.][=*%*A1FWV>'<U
MY^BBJ]%0YV`E`\/,I%X$D6AS<5%6!$R_BE'\(AQ'L!V=2`:JEQ%%)O"Z"_=9
M#XCG>]NHH554)X707[K(?$<[WMTH4J$\+H+]UD/B.=[VZ4*5">%T%^ZR'Q'.
M][=*%*A/"Z"_=9#XCG>]NE"E0GA=!?NLA\1SO>W2A2H4>8VB&)8Y]<RK[JUF
M,"4@A#3(FZ27=7I]),(\5"!^V!P$P`!OU./`>$T-%%152'PN@OW60^(YWO;J
M*%34)X707[K(?$<[WMTH4J$\+H+]UD/B.=[VZ4*5">%T%^ZR'Q'.][=*%*A/
M"Z"_=9#XCG>]NE"E0K)9;3"KUV=035?"HM#R29`/#3291.=FL4H&44CR)D`1
M'LB80*'ZH@&I`-5!(HKJA;8,J"("J_X@DF`\(.<$.P0/P"$;P$-10J:A>WA=
M!?NLA\1SO>W2A2H3PN@OW60^(YWO;I0I4)X707[K(?$<[WMTH4J$\+H+]UD/
MB.=[VZ4*5">%T%^ZR'Q'.][=*%*A1LMGA_"]9SUKWJ1K;9`![CS/3ZPLH[./
M[5VAUH$Z)@_&Z/1$>QQX\=*&BBHJI)X707[K(?$<[WMTH5-0GA=!?NLA\1SO
M>W2A2H3PN@OW60^(YWO;I0I4)X707[K(?$<[WMTH4J$\+H+]UD/B.=[VZ4*5
M"HI&V0BD>^(55_TCLW12\82<*'$R!P#B8T<!2AQ'\(]@-`#502**F@K5"HP<
M,DHJ^`Z45')G`L+-'*!B,T2FZ)R1YB'#B'8$!$!_4'2A0$4"NWA=!?NLA\1S
MO>W2A4U">%T%^ZR'Q'.][=*%*A/"Z"_=9#XCG>]NE"E0GA=!?NLA\1SO>W2A
M2H3PN@OW60^(YWO;I0I4+BP]L,7_`%BJM/NL>=K!R5+P@)NY4KUO6&WT8].'
M]S=I=LB3HE'\?H=`![''B(:4*5"T^Y>/^Q!MH_U>K?Z5V77I&E?NV#]&%NX/
MS+/Q5N3K/5U-$31$T1-$7*G<DLZ;\VOEBK,EQ:NTL#<PD[9P!>LZE<F/J`9)
M04ND0%2D4`!$@B`&`.''LZ\2]>8!W6:'"HYUGZQBTFM_F6]?^D*;U[=_N;MU
M*PU(U"M0T_><B[)H[<$I5I5A'TQM;<C.LF83K+N(Q[,3-T"(31=5C(\B6%CI
M-PW2?S:<<BN\1276-KYHDT;2H9YVS.<VWCOC#F!+LK,DK@7@-KW3&YBT&C<Q
M#20%SO-L!-=@=3W*%7NJ;QLE6:Q-*XQL[)3Z<H.7@]MB]AQ;8*+:*UFK&67Y
M;'^>L49DI$U9%71;IBNI/8N=?,T%6Z!T(V:4;K*MT4%`MS:+:Q1F5S#_`'=P
M,])&O:Z)\8?%)&\-[F1P<P$@FKHP0"2$,;0*\6WAP(J".OVET$8Y"@Y&YS./
M6$])NK?78N.F)>,/%61LDC&R@HECW:<TO&(UI\JZ,N3BW:/%UTA-P.0O`>'.
MNMGM@;<N:!"XD`U;M&W"N8=<@!6<IIFI@M-Y/?`O4;QG]M;:W).\>4+%DEEC
M#DC7#NT;#E*#Q=8U*)G9FW6L:T16G4A`VJ1B7<5VLZZIQ"R)%SGX_@W3=!$U
MO;F%P%S),(Y`[9&9&YXCR:N`+0X.J,'"BN"*H;3NB:'J5V?[<:N:N^IHRGAK
M<KA[+D;*05BD:]DPG=BAOTL;#&9QJ&!',JN=E;55+K&C:+_#/B#"$=*FBW2I
MNAVPV5;A2-`<Z/G630ECF@LP>,]8G2TQ;R3E8X<J@S`<!!3FL*U'4VXX57HU
MWW5T8)6Q2N/LE0C!"&M5U607E*G)RA\84O,,!@FQ9`8QT'89%2029Y$G#)!$
MD,$HHQ:*.02_;6J3B#N_)SG-,DB<XN:W8X#.Z,RAA)`IR!W7<U(%<"0YHUH"
M.+W:5^\KE%;X:E.6N2HD-5KG)W1&==Q-=@$K%36K:\-8^I7>[O7]:M3RQHU-
M98(''LB*2!G@D56`A06`@.5&U+]!F9"+A[V"#+5QRNY-7,:`YN7-M>,:;*X;
M*C$0*U%/=_VX5<]L^Y6QY<>VBFV^/>LK=6U;]/L[`P.Q;5JTT:)W#YFPS77#
M".:3,I(Q,M'DQ<4CPCKH]M'4[82X%.)"4:II<5F&30D&%P8"#7,UYABD-30`
M@\YA39L*I>P-H1L_J!_I6VO;KS\K<_OZOL]:?*WB"H3MUY^5N?W]7V>F5O$$
M3MUY^5N?W]7V>F5O$$3MUY^5N?W]7V>F5O$$3MUY^5N?W]7V>F5O$$3MUY^5
MN?W]7V>F5O$$3MUY^5N?W]7V>F5O$$3MUY^5N?W]7V>F5O$$3MUY^5N?W]7V
M>F5O$$3MUY^5N?W]7V>F5O$$50U>O.VFW]UN?^W1_P#MU?W0O_Z>H+6TV!0L
M2_T>,1-M1W6&,(F,;F=[\Q$1$1$1'+0B(B(]D1$=?8>@_N*R_P`I#^K:NBB_
M--_%'WEWMUME<31%PRW*<Z-OMD6W\5NW;=7DID/:)1HG,.(ZJTR<U8-=T6%0
MF;57LA7R!EW-*6/1E,.3E&DVMA9J-Y7J5#Q_05$)!'HD6\3?F.;36[O(E?L&
M348BYXBAJ'(Y$K05>\*N6KS(N47&"JK'57KJPV7NBT]FYFI6&!6":JCN0,B)
M"=2NBJ<BUEQ_SD,%6C#+^Y6RNV"BY?0Q[N@RFWQ&:NY6M\4QQYMJS-G'"LC?
M;QD2FXEFF6/:?+6'"+D[UQ(L`<0YWJ3<4'2QD2N"+*TSS,,8I9@VDX5IT0CD
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MDC6+54).'M4?"P%D4BW\'<86!F4#+UNU1D@@H*'5+-'R1RF'I"`$6?M$31%&
MH;_'5O\`Y5CO]'8?4G8%"DNH4IHB:(FB)HBBEV_-F1_MD=_E1EJ1M5+NY*E>
MH52:(FB)HB:(FB*-1_YT63^3Z[_XQJ>!1PJ2ZA2FB)HB:(FB*P6K\V+%_(<K
M_$5]2-J@[%>6_P#>Z']I2_ZA=0I7MHB:(FB)HB:(HL7\]E_\UFO^5GFIX%'#
M[BE.H4IHB:(FB)HBH93_`!;(_P"`N_XNIJ1M4'8J6N_F_!?R/&?Q)#4(-@5X
MT4IHB:(FB)HBXG/O^8VK/\R=>O\`?JQWHBXM[*N8CL-QCM1P;CS(N[_;_2;W
M3:D^@K94++D*)C)^N332UV+MJ+EX]8P+,WS?IATTS=D.(:[[3;^RCL(8Y)8V
MO$8!!(J"MM#+$V)H+A4!;/\`I2N6U]NC;)YT83V>LWYRT_PT?P@KG/P^^'93
MTI7+:^W1MD\Z,)[/3YRT_P`-'\()S\/OAV4]*5RVOMT;9/.C">ST^<M/\-'\
M()S\/OAV4]*5RVOMT;9/.C">ST^<M/\`#1_""<_#[X=E/2E<MK[=&V3SHPGL
M]/G+3_#1_""<_#[X=E<W\\[_`+8E9>9QR[\BQ^[+`4UC&B8>WMP.1;@VOT2Y
MJU6>7NF4B/JT399$I^H8K6I9FNBT3/\`]N9,X!^#7D7KBCEU?=L6^D`W%R)&
MG+'RG8/8:T'$!7W%J-7(FA`BY1KP8\(6^">^KD[)-H9DEN<V1ILZY6$J37FA
M;13`;0--;RD?.-ZI#H=K]5&UYM-Q#1XDS1`B";IH@J4H*(IF+\RG0-]"7.-K
M?YG/S$Y78NH1F/&:$BIQH2-A*Y[FKGWKMM5*&/,@Y4T8G!)1^\3:`R)5W<I(
M5KM>]55,\!(SC=^TG)&(5!/K6$C-MI5TF]<)F*L[*Y5!4Q^L/QM.W9WN<7%U
ME>G.`'<AV(%*`\8%!0;!04V*.8N/>N4E-S4^6N9/JC;[]L9DOQOVL<J0W0#I
M@(&X%ZS@`F`>R(=G5KT2WGV_-]U7]&4\7G]X[L+!.3MX7)YRICA7&,SO!VF0
M\(C3K)0ZU(UV]49M.4*LW!BC%VB.HKF1C)-G74IR*0*V<D30,DL@`%.0P%+P
MV%KHN^EI=>-,LKQS\[7N#F.H]S35I?0@FAQ&.!538[EIS!KJUXE7%WK\HTF3
M*YE(F]+:N26J5(DJ17H-/(%))68Q.7O$9D1]9VS((WMXEO5M$0BOVV#GH@8.
MLZL5NBJ6GYCWQ\5=:>(W>1\@<3D=F-&%@;6M,N4D4I[M,$YJYRY<KJ$_T44K
M:[_N40Q1KK=ENKV6M4*B\E)"K(H6ZGIIUUY.2J4]-.(8A4`!@:8G4$WSH$^!
M5WJ2:YP%5,ARV3N[ODXN+K2^)>`'<EV(`H*\=!@.(8;%',W/O7*,&WD\E4Z2
MR!\^[!SH.9^(M2Z)Y''9TE;-`/9F1@I\Q#QQB]UX=]8I!1LN'!1$7S@"B!5E
M`-=^9-^*U\7U&H:6[']R0`1MV$-%1PT'$IYJZXGJ8U_F'<I>IR#B7JV[C9S7
M)5XS=Q[N2A;Q58UZY8/[#)VU\R7<M4TU56KRU3;V35((B4[]XNN("JJ<QK,F
M[>^$S0R:SO7,!J`6N(J`&@^XT!O6`&P*##<':URF/I4>6I]NS;#YTH3V>K'H
MEO1YONNC*CQ>?WCNPGI4>6I]NS;#YTH3V>GHEO1YONNC*>+S^\=V$]*CRU/M
MV;8?.E">ST]$MZ/-]UT93Q>?WCNPGI4>6I]NS;#YTH3V>GHEO1YONNC*>+S^
M\=V$]*CRU/MV;8?.E">ST]$MZ/-]UT93Q>?WCNPGI4>6I]NS;#YTH3V>GHEO
M1YONNC*>+S^\=V$]*CRU/MV;8?.E">ST]$MZ/-]UT93Q>?WCNPGI4>6I]NS;
M#YTH3V>GHEO1YONNC*>+S^\=V$]*CRU/MV;8?.E">ST]$MZ/-]UT93Q>?WCN
MPGI4>6I]NS;#YTH3V>GHEO1YONNC*>+S^\=V%[-N:ERTRN$#&WV[8`*59(QA
M'*4(```'*(B(]/\```:'=+>BG[ON^C*CQ>?WCNPL:<CGFC<N;!>VS<A6LP[V
M-M^-Y^R<PG>;D*`B+AE&M04A,4:Y9-&2J=LCVL@\06<P-CCOV]FX*'5KI#Q*
M/X>'U)HT<D.C6D,S2V5EK$UP.!!#&@@]4'`K>Q@B-H.V@^\NSWIL.4=ZQG:'
MYZZ9WRULE6GIL.4=ZQG:'YZZ9WRT1:8Y;W8_T>;.M?R'7LK;U]I5O)D^GY=Q
MU:)MYN28M;6&.<[VFG7/*V/X*TQUF9SE<J-ML="BW"C1DL@"`MQ*@*1550.1
M8Y3R]_1O`E<KS[K>[MVE+#FII$-[[/S.\^T2TPZ<UG,R&X2F2\*_?Y%76J\S
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M(N2)X]WKW5AD3<A!(JN[NNX1&^7",0>$<%.#F+,GT6*C8AC%,1;`[=^8ER*]
MK%=M]6POO[VJU^&O5W5R)9T)/<A&6=9_;5JE4J.I)$=V*QR3EH0U9HT6WZA$
MQ$`[6Z8$ZPZAC$6P/IL.4=ZQG:'YZZ9WRT1/38<H[UC.T/SUTSOEHBLD;SI.
M4HWD[$Y5YC&T($W\@S6;#]-E-$3)(PT:U.8?^\.`?MZ)@#L\>QJ>!0KWZ;#E
M'>L9VA^>NF=\M0I3TV'*.]8SM#\]=,[Y:(GIL.4=ZQG:'YZZ9WRT1/38<H[U
MC.T/SUTSOEHB>FPY1WK&=H?GKIG?+1%8+1SH^4K)0;QDUYB^T(RZQV0D*.;*
M<`<$GS98XB(2!A[":8C^#4C:H=L5_P#38\H[UC.T/SUTWOEJ%*>FPY1WK&=H
M?GKIG?+1$]-ARCO6,[0_/73.^6B)Z;#E'>L9VA^>NF=\M$3TV'*.]8SM#\]=
M,[Y:(GIL.4=ZQG:'YZZ9WRT161ISI.4HE/33T_,8VA=KO&<,FB8,V4[B)V@R
M8+E$!D`#B4%R#V.("`ZG@4<*O?IL.4=ZQG:'YZZ9WRU"E/38<H[UC.T/SUTS
MOEHB>FPY1WK&=H?GKIG?+1$]-ARCO6,[0_/73.^6B)Z;#E'>L9VA^>NF=\M$
M5HL'.GY2;V"F6;?F+[0SKNXM^V0)]-E-#I*K-54TR\>Z(\.D<P!J1M4'8KFC
MSKN4<1)(@\QK:'Q(F0H\,UTWAQ*4`'AQD0'AQ#4*5Z>FPY1WK&=H?GKIG?+1
M$]-ARCO6,[0_/73.^6B)Z;#E'>L9VA^>NF=\M$3TV'*.]8SM#\]=,[Y:(GIL
M.4=ZQG:'YZZ9WRT16$O.CY2H6=:2'F,;0NU30+=B4WTV4[B+@D@Z<&+P[H<.
M`)G#]7]74\"CA5^]-ARCO6,[0_/73.^6H4IZ;#E'>L9VA^>NF=\M$3TV'*.]
M8SM#\]=,[Y:(GIL.4=ZQG:'YZZ9WRT1/38<H[UC.T/SUTSOEHBI'_.MY1ZS%
MZD7F,[0^DJT<)E_^^JGF_&.B<H?BDD#G'LC^``$?U@U(VJ#L5-"<ZKE(MH6(
M;J\QC:(55"+8(J%'-5/*)5$FB1#E$IY`IRB!BCV!`!#]4-0@V!73TV'*.]8S
MM#\]=,[Y:*4]-ARCO6,[0_/73.^6B)Z;#E'>L9VA^>NF=\M$3TV'*.]8SM#\
M]=,[Y:(GIL.4=ZQG:'YZZ9WRT1<EW7-/Y<*G/7@MP">]O;:?";/E+VS#SO*1
M<IU@:0VRG);PZ7=(^@+6#MWM`EJ>U*)=2*;,3]<9FW.J!>B41T1138-AG#,[
MLQVZS,[AO$,[,R5$<NY.9F\7T27EY)VI:[)UCN1E)&`<OWSI3@'2454.<W#L
MCKT33(87:="7,:3S8X!VEN8&MYEN`[GB6K^3\K06/-TF[VB*[=,&R.&MJF%\
M2Y]D%8':WB61?.JK(8JRIE;)E2M-RD'\8:$G[+&XS.QJ+E&/,W(_7,#TQB%(
M!K<DK8[B5G-LYJ)C78,;LHYQ!/`32C<-NU4N<&O<*#*T`[!US][!9>8[A=K!
M,CX`Q9:MDM1I=MW&-X1_28^5H6VV7681MQJF4[I09&P)58\ZK%L[3`8G=&.9
M4J9F:S]ND!7!TGP-+HGM><CC="&NDV8-X0XBM*[0W[O7I5F94-+:$];J]I0+
M!V[7:MD_ZGD':MG.)JG=-X4)`S-8:0U%PG98&J^&3+,LS46\TJ2$;V(&Z\5A
MEXD[=*,6Z9';I$&I712N^U*(;FVEYH.B:'RBHP::5S4ZOX/%V<:0V2-V6K15
MW4'5[2DU1SMMSR:]PPV@-JV*\?OK=ODF-EE]JMHP[@NU6&"OE6HV2+)/P\H,
M&HT;UB.7/5&;YA-(=U1>Q[A(Z+,Z+@5T9;-;R%F6-K29N;(+6DU`)(ZFS`X]
M;%,S33D@<JFP=53G:/FG:7N^F+_!U;:10J,]H,#6[.J-LQ7A&00G(*S7_+V-
M6CR/4KD9("T51L^%)?I(N034,V4;J!P$YR$KM9K6[+FMB#2T`XANPES>#JM*
MF-\<A(#0*=0=7M+7_=)B#$#'FG<LZ$8XBQ0RA)G#V^AQ,PC/&E(:0TRXC*?C
MU2,<2\2W@DX^47C%%3F;'734,@8YA3$HB/')M((3KUJTL9E,<M1E%#R1P47E
MWKBDDM]SY)+=SHY.=CQ:2T]VWA;0KHG]!6"O(7A/S18[\6]=KXI:>"B^`WM+
MY.^<]3\IN>ED[Y/H*P5Y"\)^:+'?BWIXI:>"B^`WM)\YZGY3<]+)WR?05@KR
M%X3\T6._%O3Q2T\%%\!O:3YSU/RFYZ63OD^@K!7D+PGYHL=^+>GBEIX*+X#>
MTGSGJ?E-STLG?)]!6"O(7A/S18[\6]/%+3P47P&]I/G/4_*;GI9.^3Z"L%>0
MO"?FBQWXMZ>*6G@HO@-[2?.>I^4W/2R=\GT%8*\A>$_-%COQ;T\4M/!1?`;V
MD^<]3\IN>ED[Y/H*P5Y"\)^:+'?BWIXI:>"B^`WM)\YZGY3<]+)WR?05@KR%
MX3\T6._%O3Q2T\%%\!O:3YSU/RFYZ63OD^@K!7D+PGYHL=^+>GBEIX*+X#>T
MGSGJ?E-STLG?)]!6"O(7A/S18[\6]/%+3P47P&]I/G/4_*;GI9.^3Z"L%>0O
M"?FBQWXMZ>*6G@HO@-[2?.>I^4W/2R=\GT%8*\A>$_-%COQ;T\4M/!1?`;VD
M^<]3\IN>ED[Y/H*P5Y"\)^:+'?BWIXI:>"B^`WM)\YZGY3<]+)WR?05@KR%X
M3\T6._%O3Q2T\%%\!O:3YSU/RFYZ63OD^@K!7D+PGYHL=^+>GBEIX*+X#>TG
MSGJ?E-STLG?)]!6"O(7A/S18[\6]/%+3P47P&]I/G/4_*;GI9.^3Z"L%>0O"
M?FBQWXMZ>*6G@HO@-[2?.>I^4W/2R=\O=M@K!(N6X#@O"0@*Z0"`XBQUP$.L
M+V!_\M:"TM*_FHO@-[2AVIZGE/\`>;G9X63OE]_T?C;W@&Z;3]RDE;\&8<M,
M@QYCF]R%9/K#C"D3#MG#1F402C(AJXD(-PJWBXU$PD;MR""2"?XI"E*`!KPC
M4@!J5P`*`3O_`+17VGN^YS]`L7O)+S9PDDXDGFVXDG:>JNZ_U3-JWV9]OWF:
MQSXMZPEMT^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6
M.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%
MO1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$
M^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9
MM6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^
MS/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M
M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S
M6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?
M%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1
M$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J
M9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6
M^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/
MM^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\
MS6.?%O1$^J9M6^S/M^\S6.?%O1$^J9M6^S/M^\S6.?%O1%2OMJ6UMNR>+H[:
MMOY%4&KA9(X89QP(D432.<A@`:V(")3%`>SJ1M0[%2PFU/:XYA8APOMKV_J+
MN(M@LLH;#6.>DHJJT2.H<W"M@'$YS"(ZA0-@5T^J9M6^S/M^\S6.?%O12GU3
M-JWV9]OWF:QSXMZ(GU3-JWV9]OWF:QSXMZ(GU3-JWV9]OWF:QSXMZ(GU3-JW
MV9]OWF:QSXMZ(N-;S;KM]+_2#ZY2BX)PV6FJ\FNZVE6IAC"D!6E;,AO:H,2A
M8E(((/N6I.H13A1L1V*0N"-U#)@<"&,`D6!^7C_L0;:/]7JW^E=EUZ3I7[M@
M_1A;J#\RS\57?-^3-HF#IV:^FUC2:Y-YMQW>).Z23_%TE939!Q3AZ'8JY`7R
M-+P-2G$Y:DX\K=E24>I3"AFS2/=',!.I%7A=FDM82>>H"]IKA6K6[:X'``\/
M`JG.C;W5,1Q<`67T<88/EI6JY'0QYB>3G("%JIJ3?256HNY>#KM>:O@I/@Q9
M^T3O8N&@V5F<EC`;+)HMDI!0J/1*N8#7>:A)$F5M0!0T&P;*'B%<.NJJ-VT"
MCD1B3;&PMY6D#C#!3&^XOCZX_33B:51&EKQS%O7MN>5)RD=I&IR=29N'\S.J
MQ_1%N7IO'AT@#KU!/2(K8/Y+69VTX!4;:=;AI[J@-97`"H7M`8\V^,KI.0U>
MQ7CR'N-&EJ)>I)XVQ?'0?<ZS.*]+U^B6B+M*E>9QDG;8BK1SJ/2<,7:\A%,3
M`V4%!-9-,\AD`>0UK0]I![GAI0&M-M,.,!`&UP&(4SIN+,78\7>OL>8YH%'<
MR[)JRD7M+J5>KBTI'-W\G,LFCQS!L&9WS%O*3CUVDF<QDR.'JZI0`ZRAC5,B
MCCQC:UM>(`?>4AK6[``N9VZ[_BP\KW_4SOU_T-QSI:?Z@M?T<W]D+R;US_Z,
MD_2Q?K&KI'KN%\B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O=K_?
M+?\`MZ/_`,0N@VJ'=R>LJ_\`HZ7^R%N>_G+]]/\`ZJ%UX#J?[SN/T\G]HK[?
MW=_T]8?Y*']6U=^=8*W":(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MJ&4_Q9(_X"[_`(NIJ1M4'8J2N_F_!?R-&?Q)#4(-@5YT4IHB:(FB)HBXG/O^
M8VK/\R=>O]^K'>B+2/EX_P"Q!MH_U>K?Z5V77I.E?NV#]&%NH/S+/Q54Y]VE
M0&X7.6W[)%Z4K,_CG#]/W`5"W8KL</*/VN266=(*F0AT'SIG+,8\(:#"G%,X
MCWC=XUE$W)DEB`0O`UR>U;<31R/H8V!P+3PY@.ULX54Y@>X$[!7#KK7VT\MR
M.G)S,USC[;4&-TR5NF;9ZB'+BF/CPR6-FV-8*A);>KHS;S)%9BC-YR%3LZ1&
M8-6I9MLT4%L(HB<UAVG@N>\$9W2YMG!E`RGJ5%>O3!4&$5)X2ZON4V*!S?*W
ML"L):HV%SRWD)"Q,-BJ,E.W2HS+J7R`;9Y19#'MG@LL2U<MD/.3]6S/%.TGZ
MP-72+R.EFK=4RCGJ""-#M-=0AK\3S>)&WFQ0YJ$5#MO4*@PFFWB^YVUD_)G+
MZD;VMF9LPR9$,*[E!#8"RBX2;@+)8>X4=LCM?A#*,Y9\_M3A]8398C0".476
M5%RV2#INE'QA,`W)+`O+Z.&5W-8$$_FS7'''-L^_528B:XX'+]SMK:_:KA62
MVY;=<38+E[4WN[[&-==UT]J:1[R);2S=2PS4NP%",?R$HZ8(1["32:$2%PH4
MI&X='HDZ)2Y5K";>W9"XYBT4K[JN,;D8&G&BT(W=$=J<U7ED)L'"+-^I@_?\
MFQ=N&PO4&CP]&QZ5JZ79@LW%XBV7$IS)=8GUA2B7I%X\0JM:_/\`:TP/-S?V
M0O*/7+E&YSRX5;ST51LJ.<;45X.NMA\898M:E>SO=LDS["7KV(LLYAQNTBX"
MH)Q4M*-<=3,8S@7*"C62D#OK'8P=BR!F1'HK/5T02`H\2'ZF"XDR32SD%D<C
MVT`H3E-!PG$[*<9"^7KVQ@YVUMK-A;+<012$N?4`R`EVT"C6TK6N`!JL.OMR
MF6U-K.4LFN"U.FYLP+:;!2<H5`]8E)2NJV!&TUDM5=QK>?>0LZQK=BQQ<8V:
M;*JD!5P+H"@)2IG`V,Z^N/$))SE;=0N+7"A(K44VT-"TAWNK8-T>P&MPV8YR
M33;IC7QNS`.RY79@2T%I<V1CF$#`4ZJV%W"W2]X?Q0,_"R\?,6IKE/$5.4DE
MZLV,D_A,B9SIF.Y`B5?[L-F:4TVK5K,""G;)41?(D4,0$S&2UFWDLUM;YVD&
M3G&-V;0Z1K=E=M#ACM6ITFWM=0ON:D:6P&"5],QP='"^0<JE:9FXX5RFG54)
MD=R\A3I:PU:Q8]M<P_J,)CR9F;`\=T6FB9]F*RV6)QY3O!4+'+2SFT%;UIV5
MZ$<D[*<[7I-TU#+D3+:=?&)SHWL<7-#22<K>[)#6TJ37`UI79AM62S1V7$;)
MX98VLD=(`T![\(FM,C\V4#+RA3,1MQ(I50Y'?)6_H^O64G-!EPJ=:/27-<8M
M[#!&MEEA[7MJB=S+YTK#K'3(VE(2JOU6QF;0[X3*("NHHDT*NX0M#56<R^X+
M#S;<M,14@Q"79Q@&E!79794C(.[4WC<5D)6\^_/F.5V5I;<&W`KP@N`-33;0
M`NH#)[?NH8,HW.,>SK]BK<_ARN56VOGJIJG-.)*H7A_6B4VWU:%>RK-G8(N;
M0E'S=X11=)2&>QJK=R`+JM`7KDOP&R@`M?&T'@-0ZF4@5QK4U]Z10XTK9M]$
M<Y]LYSV/BN'N:!RA1[`[.QQ`):11I&'+#@6X!U,@X>W!Q68K%:JZTIM@J3BN
MQ8SS169DH*21F88N3\JXD7<(]QGCH\>X;VO$,D((K_C*-%FZH"!C*)IW[:\;
M<O<QK7-+17$@U&9[.#JL/N46+J&DR:?#',Z1D@>[*:`BAYN*7A`KR96XCA!'
M$3L#K,6I31$T1-$31$T1-$31$T1-$31%[M?[Y;_V]'_XA=!M4.[D]95_]'2_
MV0MSW\Y?OI_]5"Z\!U/]YW'Z>3^T5]O[N_Z>L/\`)0_JVKOSK!6X31$T1-$3
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M6\FU.5\+4.I437<%7`"$6.['S3]J%>M>Y.A!(Y#E;QM:H&XC(>1*ZRQS9&P2
ML9M;@<:V3,<92)Z7;1M8M$W78C,-96*DD]*18LNGT3\4UP2(J^D<SO:Y<5NX
M:\U:("]QF`XO<!=:,ZJ<U)25%@9'$<9G)2JS\E$-'D,6Z(8QET)9-F1<0=-5
M2=28RA@3`BL&8.9)4*UL9'>UAO&61LC5FRV7"=5Q?"72GV[$2UR^G_(>-<>T
M&]D;7&OM[`;'+A3*#&03?-V*HR""9D6_[88#%(CKFJ;5*74[Q(Y4NX1%GQ!&
M(AE-C1ZQ?;K7CS\'G.(VL90^BR1"I1<]DFKXWW+R?@F^>(1B#DCD"*F;%3.!
MM$7GN\W]S^WZJ[1+-2,3OID=UN5IS%[."RI%9'H-RICQE@3,.:X4TICV'H=J
MOJ\Y,/,3=Q#101Q'J*THFN!5.I,BH17'&_,^V\S\'-MLNC/X#RKB[;XEGO<E
MBZX1,U+J[=PB,14/->1\>7:UP\-W(<W7&]%R1$O7C5(A%W"+H`12%PDZ;MR+
M$&%^:]7,F9KN.,[30SXZAJUD3=%7HI:3:9'E\@6BC;<L#;8,[NK6RHT'CJ1(
MQG5X7<65%Y"+O2O3`T;FC@D%7*K=J19*8<V#:]8YS#D11TLBW1OEJ^;E,?NI
M:+I[EHTQY,[4\=KY'RJ2XH2B[-^95&)58@Q(P2>`Z*\$_3**)R:(K9"<V/;3
M/&JUY-,3%.P+8MIN4MW*-_R;C_+./[!+8NQ[,8-:-+G4:S8*"W:S](FV.:V9
M470O47SQ\=!!@T>`+E1L13C==OO+@7:3#[IJECR8?LY'-^&,.R-1R[$7+$\]
M7`R=N.K&W.QSDS"/JP_L9#4B7L"LHDFFT.WFV3,#,W!D'3=T8BQ5MRYMN#LL
MU/%$AD9`*%8L[99R]0L%A53S.0:KFG&^,LUUK!<)N.I\FQ@6,I#XAR)<;U`(
MLU95HV<-%9,3*=8R;+ORD649KFI[*H&K2=P?Y+D30\9FV_[>SI,*A8Y.;=9/
MQ1"6RSY/@VM;CF#JP`K0JQ1I60D4E6R3HC9NGU:*BCMD1R12G)7,>VIXEN^9
ML>7BWV2,L^!\'Y.W$WYH6@W!=(,58:AJ#8<F6&MN"Q`$M1*Q#90@UN#'KB/C
M/#I,SN%VCU)L18GR9S4<)P.*LY6O&M:R9<,A8=VZ9,W`.*-:L69/H4=&M*CC
M?+.3*##Y0L<E3G`8I:YFKF')=[77LFW*F^CP152*=1VR0<D6T.T3==CW>%B;
MZ3*$E+1KN"GUZ%D6K3D/,PTG2<EQ$'`3=CJBQ)N.C%Y%!@VLC15N]22ZAVV7
M34+P$3$*1:46;FW8QPWEO>+2=P]9DJ;3=M>=J1@VEV:@Q=OR;8,DRMDV>OMY
M\[(RM5@ZR56HI5C&L#,%,/7.VZYHHYQ63,LDCHBN^>>:YBG'60,04?%<83*R
M-UG$V>2+,8EI@H'%D+9MF>>-Y.-W[EVE5I52=G[31L+IKJ0J*97S>*EDW7`R
MQ4VBY%ERG<R3;I+K[>*K8K#(,,C;B,%P&;:=%PE/O[NJS<=*82GL]O&%8LL_
M5*XK*"GC^H3#Y'KVK59,C,J#Q-H^<(-%"*&P'-YV1V7;]<]S,9<K]]%E`>UI
MK9WCW$>1(^;CFMPP+%;FZS.+P3R`1>M:]-83F$9=N\7!%%90Y&)!-(K(-%2*
M]WKFO;(L97&PU._9.EJJSJD+5)V?ODM1+DCC>.;7O!-VW*4IHK<"PYV)I:U8
M<QO/2C-J4#+J*1:C02E=JMD%R*(RW-/Q`AE['=3AXUXYQL_QOO9N.;+5+,[)
M%7S"%CV506$K;;Z;+XR1KLA*SLG+5/,J#\I&RW6]01N+<CKMD`3(M_<,Y?HV
M?,74S,6,I4)R@Y`B`G:I-$%`Z$M$'<N&S:29KM'#MF\CWO:XJ-W""JJ#A`Q%
M$SF(<IA(N+RO.7NM4IU9S5DK;Q!1.W!KN#W<X"SQEFLW^9G5]N+3;YGU]MTQ
M_FZZ5-6E,WT_A^^7UNAX2.F*Q'-,:/4W"A'R!%E"$7;'%-LD+[C#'5YE6T6R
MDKG1JI;'S.#>K24,T<V*"8S"K:+D7"#5>08('>=%)<Z29E2`!A*7CP`BGVB)
MHB:(FB)HB:(FB*AE/\62/^`N_P"+J:D;5!V*DKOYOP7\C1G\20U"#8%>=%*:
M(FB)HB:(N)S[_F-JS_,G7K_?JQWHB_G[#+69L6[/>5DUPR3(,^]O;W-,+;L:
MXUL<!5+1DR%KN%,\7:N5N,L-DBY2-A9<<@0$49@J<J97+T4V9A.#GJS]Q#++
M'I]F(LQ);B`0":,<0*GJ@4ZN'"MHUSFQ1Y:XC9[A6PNU;?+DV^R&`</SK*N9
M3G)3:=0\PY%SH\*ZQHM>+1+0&3B7!6F8W?QD6X7<XPO-!80-MC"MVSQF]ES.
M139)(IHN<RVO9'ED3J.<8@XNV5-#6@ZA`#AQFN"N,D)HTXG+6O\`M]U8;PYS
M&<S;A<G;,W1ZLPQS2KJJTNE^&D2<I/T"XU_(>RG*.:V>-;',S=?<2$=:L1WN
MIL#/EF/9,619`*?35,@K9AOYIY(<,K#B:8@@QN=0U&UI`V<85+9G/+3L![&P
MFGN*>8XYI-SR;6ZN\B\04:`DKEN`;89A;?;K7=8;#K5I+;::MN$J3^QV7P0<
M6*`=Y!EK`M4H1PX8$1<2+05E6R*YAC"7(]2?(T$,`)DRU).7N`X5-*BM<HPV
M]A2V8N&P;:=397^I3Y;F&9(<4//%WC\'5Z+'$^Y>@;>(BO6FW2:%D!S:]RJV
M!Y:4R'78R.7F:R+:H+Q]VCG)$@9OXN0%(H"FW,]5K\?D,;WA@Y,@;0G'%^7$
M<&%'#C!]U3SIH338:?=I_6L84GFI9$F\.Y7R79L!04:^Q[$[7I5%*$GK.Z@(
MR-S]EZ]8AMEFNZ\O%1KR.K&*#T8T^^51.0"1C]%-PJ@!3.S6V:F\Q.D<P`MR
M<=.4XM)->!M*];LJ!.2TDC93[II]Q>N:+#-VWF0\H:U62%85NQ6/;?O8FYR`
MB9U&SQ,-+26/,9.GS")LK9!LWGXMNX4,#9Z1,A7*'14``Z6MA8.+]=LW.%'&
M*4D;:<D</"O+/7,:[ER$[>=B_6-72A.@T9)C(QB5,JR4;+V8+I+1Z4!%ILI2
MXED&LL%LD6Q&I47ME"58H.NWE`,Y[81(IT^F0HAVXAB`+0UN4NS$4&)VU/5K
MC7;5?)GC5R7!YD?G:S(#F-0RA&48X-H2*;*$BE%X26.,>3/A;W7H=.E?#\\2
MI>PD:U#/0NJD`DBA!'MH.6:@6(\*@V3(T%WUPMR)E*GT0*`!#H(79LS&G/3-
M4#E4V5XZ<%54R\NX^;YN61O-5R4<1DS=UEH>37AI2O"KS/5JNVJ/)$V>!AK'
M%)O8V33C9V-9RS`DE#/4)*'D"M'R*Z!7T3(M4G#97H]8@NF10@E.4HA4]C)&
MY7@.;4&A%<1L/N<"M132P/YR%SF/H15I(-"*$5'`0:$<(P*M$WCK'UE<2SJQ
MT6GS[J?"O!.N9JMP\HXF0J+U62J?=19ZS64?^#$@NHO']:)NTU5#G2Z!C&$:
M70PO)+V-)-*U`-:;*\=.#BX%<CN[N$-;#+(UK,V6CB*9A1U*'#,,'4VC:K"O
MA'"[F--#N,18Q7B#EA2'BEJ)6%(XQ*Y"NZU7R&9'C!;"6#K;]>.:!T>"#!8[
M<G!$PD&CQ6U+<ICCRX8913`4'!P#`=3#8KHU+40_G!<3"3''.ZO*(<[&M>4X
M!QXW`';BJ]?$V*W274.<:4%PB$9(PO5+U&!63[C3$E'S,M$"11@8!BY.8B&C
MMPW_`.R6<M453E$Z1#%J-O;D4+&4H1L&PFI'6)`/7`5(OKX&HFE!S`]V[:`0
M#MV@$@':`2.$J[0%$I%4=+/JO3JO6WKEEW-<.X&!BXERO'=UY2P=H++L6J"J
MK,9^<>ONJ,(D[<>+K<.L64,:ID,49K&UK32F``X2?ODGKDE6Y;JYG:&S2/>T
M&M'.)%:!M<3MRM#:\0`V`*5ZN*PFB)HB:(FB)HB:(FB)HB:(FB+W:_WRW_MZ
M/_Q"Z#:H=W)ZRK_Z.E_LA;GOYR_?3_ZJ%UX#J?[SN/T\G]HK[?W=_P!/6'^2
MA_5M7?G6"MPFB)HB:(FB)HB:(FB+7_)NU7;GF>8N$_E7#M'ODU?\7,,*7.3L
M421\[L6)XNVKWR/H<BJ8Y15KS2Y.3R1$0X<'8@?CQ`O`BN#S;CAQ[GAON:-4
MUV>;DL>ML5.KK$6>VP8SM!CY>7GH6O6RNPTZQJMQ0K4U89!U$JRK%XXBEWRY
MVAT3*F$2+$%*Y>^T3'#"MQU#Q.I5$*?A`NW"L*1%_P`FI.H;"I,A)94"BMW:
MUR6<+,AO:)7AW"QE7JJ8"U46,T,9`Q%/)G:!MMG<*8[V[O<40"&(<0/:%*XE
MJ\2O+02^+IW%KMN^QU9<>62%D6%IIMHIKMJ4["2CWK=ZB`G*"HD44*8B^+9M
M$P)>I;$5DM]4G)ZWX*N,Y?,7WEUD7)*-ZKMCM,,-<MQE;BQMK2Q3D#<(#@RE
M89^X=0L@T3317:'322*0B@JO+TV=KWK*.27.&6+NXYIA<X5W*$D\MM_=M;;"
M;DH?'=?S?&/81S:U8)HUR#"XEK;=T#5LAU"<0AVMU(]8)R*Z5G8AM7ITC=96
MM8S<Q#O).%*IM[R&5K?\E`QO.+Z-2UL<U!A;(LUP-&3UJKM"<GAVME<HJ65*
M.-U`/^K`I0(IK8]J>`[9@.G;8)ZA%>8+H#+$D=4*(G9;>R1AF>"9JJV+$J*<
M\PL#6TN@I<Y2(ER@9=\J991B3M@5@$X&(L7V+EU;,K8;))K!@^%?_2T_&2NQ
M2V"Z,`=.%LT--Q<F2$&,LC(U1:6+.[).V2R$2+%&7FR]L/2KCV-$6>\E8)Q9
ME^RX?M^0ZTI/V'`F03Y4Q-(%GK'$>"5_4JUAI![$FU@Y>-93"YZE;9./%&03
M=MA;OU@ZOB;B!%`)+9OMLF+=N`NLIC%B^EMU-.1HFX>/<3UL/3\M5]&G!CP#
M6V@=W@HKRP*4(A(528)')RZD4DFU,Y%$A2`18J@>6;LHKCEX_C,/O1E9&,RY
M$2,U(92S#+3D@USQC''N&LLJO9F4O[N2<2-PQIB>N12CL5>VFJ<0@JU407`R
MIB*JIG+9V58]8U:/IV%4(5O2[3E.Z5DZ=ZR8[>QECS;C1KB'*ST)*0N;N1=(
MW:@L46CQLNJHUZY(KM-,CL`7T17R4Y?.SN<J=6HDWA*%F:;2]KUAV7UNMRT_
M<Y*)8;8[4E34IW%*C5[9%RR$:\#'L&8K]SUTN@I%H'1=IG*)A(LB7#:OA+(&
M'ZG@F\5VPVW&M)L..+97XV?R1DN3GTK-B*UPMYQS.25[=6]2^3TC5[A7&$BB
M=])N>L<-$NMZPI>CHBQU6.7WM%I&0*[E&EXE"H7:IY#RUE"NRE8O.28%K%6G
M/$A!S69&[6#C+@V@24O)%CK3"6E:UVKX..9AL5^+'MLQUCD22Y?NTF6F$K,\
MQ4<+@AEZ`SLA>F%YR-$9`1RC6*A+8\AK&2^Q%M8W`R:&/IY[`JLC/3,'4,Y.
MR714;\$P(K7;>7%LRO5[S'DRVX;+-7;/]$R=C'+DRYOV4$PMM`S-5,=4C)M4
M-&-KJA$0D3;*QB:OME2QR#,R(QQ54#)+*+**$4JLNQC:W;IS(5AF\9'4DLMX
M`0VNY5[FW?(D"PR3@]E#V*O15.O43`VV-B[0Z@H*WRK..EWB*LW'-Y%<C9XD
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M!1+B^4F:;/251)DG+Y&;^0Q_@DVV:G]MNR9`+*.&$+@H2UTK0RXM%FJ2:JJ:
MCI,BY2*)QG*DVUN\TYKR3DN$8Y8H.3JOA6IT_"UO9SCNH8U88?V^W_;0+E11
MW;9!OD"7L>+<ER[`KZ59B^C47JP(K&55%8"+/U?V&;5:M,0ED@<8K1UJK[/-
MC1A;F]ZR,G;%%=Q;.GQV9IB4LI;<6:F[-=&./H)$TJ\67D6"40T*R7;%1(`$
M4@Q'M`PA@FZQ]SQ+7Y&D$B\:S6,&E2A[%8"4<T39,J6',]@FW52<2;B"7MTG
MD&UR3TTH5`CT0D'*9E#I'(1(BIJ/LHVRX[@+?4:SC1,*A?V^9VMVI]@M-TN-
M3M*&XBVKWG-9)NMV^QSD,_#(EJ=+.WP'1$`ZY1)+JT5#IB1;%56L0-)K%<IE
M5C48:L5&!AZQ7(AN=8[>*@8"/;Q4/&H'<*+.#HL8]HFD43G.<2E#I"(\1T17
M[1$T1-$31$T1-$31%0RG^+)'_`7?\74U(VJ#L5)7?S?@OY&C/XDAJ$&P*\Z*
M4T1-$31$T1<3GW_,;5G^9.O7^_5CO1%I'R\?]B#;3^#LX\5`>P'X`MMD,'_Y
MC%`?_:&O2=*_=L'Z,+=0?F6?BK<9TF5ZU=LW735;/F[IJZ3ZQ0@JHO43-W1>
MFF8BA#+)&X"8H@8.P("`@`AGG$4.Q75CVKUS&>WW$\35:\C#XWP]A^F]J1K=
MY)N$J[1J+56)W!A<2TT\=+M86!C&HG.LY7,"*"7$Q^B3B%MK8X(@UM&Q,'N`
M#^@*`&L;08-`4-/NIV^'2QRY89DI5A:Y;R8IAO'SVK3C>T,;%DAI"/K0]JR+
MV$.];-7D7!QIW:XK&3*DF9(>/[:ETJ/&8.31X(>[**&M32M,.HHSLPQVFGNK
M/1C'$?QC&$0#H_C#QX!T>KX=GCV.@'1_]G8_!J^JDZ9@'B!A`>!@XAV!$#@!
M3@/#\('*'`?UPT1<CMUXB/-AY7HB(B(X9WZB(CV1'_R;CG\(ZMVG^H+7]'-_
M9"\E]<_^C)/TL7ZQJZ1Z[A?(B:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB+W:_WRW_`+>C_P#$+H-JAW<GK*O_`*.E_LA;GOYR_?3_`.JA=>`ZG^\[
MC]/)_:*^W]W?]/6'^2A_5M7?G6"MPFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB*AE/\62/^`N_P"+J:D;5!V*DKOYOP7\C1G\20U"#8%>=%*:(FB)
MHB:(N)S[_F-JS_,G7K_?JQWHBX`;1.9;5,5;9\.XV>[.^8A=W=(KDE7W%PQE
MM/L%RQ[9%&=KL/2E:=:VL^W;V""<=9^TN2)D*?@/8[&NXT_46Q6,49BN'%K`
M*M82#UC7$+:0S`1-&5YH.);&^EMI7V$N:3]RJT>,NLSYT9X"YZ,]M7.?'O7]
MA0+*W,IQOEW%N2\33NR#FM1D'E+'USQS-R41LIGNZS"&O%<D:S*O(H7T\Z9%
MDF["44,@*R2J150*)B&`!*-$NHQRQ.B=#=97-(/Y,["*<:ATP<"TM?0CB6I>
M.LU[?L:!CP\+M.YQKEYC3<XKNG@GCS940HNKB]P67;U)UB3:MUDVRU2?4+B8
M`3*F^1?&%0BX$X)ABLF@CRY8KNK9,_YOARY*=:GNU5`<T4HV3!U=G4HM\1YM
ME+^PES20_P#^*;1XRZS?G1G@+GHSVU<Y\>]?V$]+;2OL)<TG[E5H\9=/G1G@
M+GHSVTY\>]?V%S,W0\S;'BG,#V$9GG-L&^JD5_&&--W,$_KE[VT2U7O=L<9`
MK=(CV#N@5I_80/:8V`68":76(LGV@FLD80-TP`,*7>+3M*U&#4M1YR"TC;("
M7M#<7@`4S$#;U5R6^6Y^\7K"TD[M;J6LMSK,CFO;&UCW.+8W![R&L:]QHT$F
MC<.%;8>F_P!N'$0^K=OYXAQXA]6)SQ#A^'C_`.<>QPULOK2W+\J;V8^_7E7L
MI>O3S%>=!<_$+\'G?[<`'@.V_?P`A^$!VQN0$/\`_<=/K2W+\K;V8^_4>REZ
M]/,5YT%S\0@<[_;@(\`VW[^!']8-L;D1_P!,=/K2W+\K;V8^_3V4O7IYBO.@
MN?B$].!MO^S?OX^[&X\<=/K2W+\K;V8^_3V4O7GYCO.@N?B$].!MO^S?OX^[
M&Y\<=/K2W+\K;V8^_3V4O7IYCO.@N?B$'G?[<`Z0CMOW\`!0$3<=L;G\4`_"
M)O\`SCV`#3ZTMR_*F]F/OT]E+UZ>8KS#_P"A<_$+*>..:;6<Q4N#R3B/8IS/
M\HX[LZ;Q:MWS'VS&S6^GV!&/D7D._5A;'!61[$R:;*6CW#54R*IP3<('3'@8
MH@&S]-]$XI_@#OEQ)]3N]X-";,$'PKA__#4W](#8?5K<W'[AM][\Z>F^B\4_
MP!WR?4[O=[ZSZ4]XGI`;#ZM;FX_<-OO?G3TWT7BG^`.^3ZG=[O?6?2GO$](#
M8?5K<W'[AM][\Z>F^B\4_P``=\GU.[W>^L^E/>)Z0&P^K6YN/W#;[WYT]-]%
MXI_@#OD^IW>[WUGTI[Q/2`V'U:W-Q^X;?>_.GIOHO%/\`=\GU.[W>^L^E/>)
MZ0&P^K6YN/W#;[WYT]-]%XI_@#OD^IW>[WUGTI[Q/2`V'U:W-Q^X;?>_.GIO
MHO%/\`=\GU.[W>^L^E/>)Z0&P^K6YN/W#;[WYT]-]%XI_@#OD^IW>[WUGTI[
MQ/2`V'U:W-Q^X;?>_.GIOHO%/\`=\GU.[W>^L^E/>)Z0&P^K6YN/W#;[WYT]
M-]%XI_@#OD^IW>[WUGTI[Q/2`V'U:W-Q^X;?>_.GIOHO%/\``'?)]3N]WOK/
MI3WB]$.8)8$UD5#<M;FY=$BJ9S<-AE]$>!3@8>`=V@XCP#3TWT3BG^`.^4'U
M.;WD$9K/I3WB]^4MS"['L@P)F?&>9.6IS;G=BO\`O%W,9Y@E*3L/R!/QI*/E
MZ[A8JHC(.G4K$G;3R4>'!XV*F<B"OXI5%`_&UY9>S,N+R:>.O-OE<X5VT+B1
M7JKZ2TFUEL=)M;*:G/0V\;'4-1F8P--#PBHP*ZC^G5H_JRN<_P#H\[OXTZQE
ML$].K1_5E<Y_]'G=_&G1$].K1_5E<Y_]'G=_&G1$].K1_5E<Y_\`1YW?QIT1
M/3JT?U97.?\`T>=W\:=$3TZM']65SG_T>=W\:=$3TZM']65SG_T>=W\:=$3T
MZM']65SG_P!'G=_&G1$].K1_5E<Y_P#1YW?QIT1/3JT?U97.?_1YW?QIT1/3
MJT?U97.?_1YW?QIT1/3JT?U97.?_`$>=W\:=$3TZM']65SG_`-'G=_&G1$].
MK1_5E<Y_]'G=_&G1$].K1_5E<Y_]'G=_&G1$].K1_5E<Y_\`1YW?QIT1/3JT
M?U97.?\`T>=W\:=$3TZM']65SG_T>=W\:=$7R?GL4-,HG4Y9W.;2('#BHKR]
M[FDF7B(%#I**6LI"\3"`!Q'LB/`.SHB^O3JT?U97.?\`T>=W\:=$3TZM']65
MSG_T>=W\:=$3TZM']65SG_T>=W\:=$3TZM']65SG_P!'G=_&G1$].K1_5E<Y
M_P#1YW?QIT1/3JT?U97.?_1YW?QIT1?(<]BAB8Q`Y9O.;,<@%$Z9>7O=#*$`
M_'H"HF%K$Z93]$>B(@`&X#PX\!T1?7IU:/ZLKG/_`*/.[^-.B)Z=6C^K*YS_
M`.CSN_C3HB>G5H_JRN<_^CSN_C3HB>G5H_JRN<_^CSN_C3HB>G5H_JRN<_\`
MH\[OXTZ(ODW/8HA"F.IRS><XF0A1,=13E[71-,A2AQ,<ZA[64A"%`.(B(@`!
M^'1%]!SUJ,/9#EE\YX0'L@(<O2["`A^N`A:>`AHB>G5H_JRN<_\`H\[OXTZ(
MGIU:/ZLKG/\`Z/.[^-.B)Z=6C^K*YS_Z/.[^-.B)Z=6C^K*YS_Z/.[^-.B)Z
M=6C^K*YS_P"CSN_C3HB^?3L4/IBGZ,[G-]8!0.*7H][GUH$$1*"@I>%?6`F)
M@$.EPZ/'L<>.B+Z].K1_5E<Y_P#1YW?QIT1/3JT?U97.?_1YW?QIT1/3JT?U
M97.?_1YW?QIT1/3JT?U97.?_`$>=W\:=$3TZM']65SG_`-'G=_&G1%3/>>A1
MUV;M'T9G.=)US9=+IGY>MU*0O6)&)TC&-:@*4I>/$1$0``T&U#L7A$<\VD-(
MJ,:&Y9O.;4,UCV3<RB7+VNJB2@HMDDQ.DH2U"11,PEXE$!$!#LAHH&Q7#TZM
M']65SG_T>=W\:=%*>G5H_JRN<_\`H\[OXTZ(GIU:/ZLKG/\`Z/.[^-.B)Z=6
MC^K*YS_Z/.[^-.B)Z=6C^K*YS_Z/.[^-.B+ELYYM=35YU\-N*#8?S0B1['E:
M6;"YL2*;+[43/+EY*;M*E>"9%9XQ\(.Z#C$3)&'-&.9X%@11F7"#02"94#`1
M;%<O!54-C^V@`4.`!CQ8``#F``#PKLOX`XZ])TK]VP?HPMU!^99^*MR^N6_=
M5/\`]<W[.L^I5U<(\C9,W3-L^Y5C(>WY-;XW9<V_9E0XDS*>R25\UVZV''%)
M=Y<A("/:QRU>4P@ZM#F5[O/0=$;M'9%$S&("8`72R27(G<`7<WXU&-I[@@9J
M<&6M:K%)?G-*Y><'8X?<5_4W^9RQPWPQ4Y(F**G+97SMN<@%I7<5>;+"O#U^
MB;T(;&D2K#&NMKJZS&NN,*69[/PXIN))-1=I'1C-H5FN1<*O'IHPQIR@O>\<
MHG8)*<)&&4DC;P`"BJYUPIL%2=O7I][%9MV59\W"SNY+<;@O*$?8YG'D;D/=
M3>\;WVUQ%T:ST-#5G<XXH%+QRE.3"@UV5J"E"=)2$$DW31629(B<IW"!P.G>
MLYYS<20R5+,SR":U`#Z`5V4IB%,;WEY8[94X^[L75#KE?W53_P#7-^SK95*O
MK^='G,*G^N?R[#',H<"XJWJ=@#*B<0\'\;<2DZH>NZ1N'8Z'XW'\'9X:\D];
M^.@,_2M_ML7N'V<C3UMVAQ_P%]LKY.[BQ[&/$N55<4RVV:X<K,ZZNRL-3<D5
M?MFUN3RSAYD"IV2GSDQ%^%RJ8A(K(4%9P$=,"]ZHJ\DBU4.)C<=>"S#3G.N9
MXA$))('48*`1O:]K3DX/RG=,I6C2X+[*TX[VQ1:-IEZZ]-G9ZE!FG)D+KN":
MWED9XP1RR+4GF;CG*!TS8G.J5)Z'><HHPS4DM&RS!JX/AI@(+U6><(T:!L--
M<*6Z=32D%7$U8AC+BV*T<I.73ARR*KUBPBFGTC6+NUL#*>;<TN'/'NV\MS7C
M(W#!M6&H(`#J4&)6ST'7=Z&6;&W<4K(G'3FXP2D6T4MN3<2@/+I)LEPWFWM>
M][XP[,_DMJ;;:KYERPTNSPDI7YRGV@M$K<PWCX.LVMZ$J[DFD8X>OX6W1;HC
M>(>PMF(HU7B%3G>BUX`8!`XJEKM[33H;J.6-[9(.=<"7.8*`5H',(Q#FXAXP
MKUJ+&U77=[=0T2ZLKFWGL]4%A#(&Q0SNYQSVL<YT=PQP$;HY@6.MW$R9-HH[
M.)NVR-EA>118#72N#HS[ABD^\'I6/86YDTS+)4R5.D<[I1*J*1N-$FUA144.
MJB[!813$R)#%#%=9Z>&%^>E65IF!+"80\<'+K+6,TH13'$K>1[Q[UR7+;<VP
M<1<%H=S+V-N&MU%]O)3$B`LLPR[:27-DS$MJQI"AZ>4LO.X)TWFH-XD69:PJ
M"TU#T:THN:HE8&6463@`B4GCR0D%D96KP:77D,0[$9L%52@F"9PR38:<V4&)
MPJTNY)D;1^4Q';0`8.>:?A9*#&H6F;O3O?+8/CO8'@3,C!DCMIP8!*V^:?R8
M<Y[R)(+9N8$&+QD.<`T-*]L8V3*$A$XL\+6SDR2%G7J;AJ\K-NB9R*BX7$<Z
MJ%DL,BZF1)).)J=,W;'5>M>U>O,;HAVP<ATHOH+!DD_BY%3'GJ',+23,WDM`
M;@`VIHTUIU*UN;L:EO1<6FE_.S'EC;HP$.AGCD8R.PE//2O=)RS)+D872,R9
MB:?E""W^T;^C?2D;$<C[8L]EI%C%LRUO+J9G<B[;LFQ5%-QV82IIBNY422`Z
MANP4./$1_!KZ!9W#?Q1]Y?DY<_XJ7]*_^T5W/;2#!Z=TDS>M':C)8K=ZFV<H
MKG:+G2(N5!T1(YS-UC(*E.!3\#"0P#PX"&JE87VD\:.%G39!TW6<,5$T7R"2
MZ2BS-59!-TBDZ2(8QVZBK98BA2G`!,F<#!V!`=$51HBIG;QI'MU'C]TV9-$0
M**SIVNDV;I`<Y4RBHNL8B28&.<"AQ$.(B`:(JG1$T16I2=A$EY)LK,Q23F&;
M(/9=NI(-"+Q3-T54[9W))&6!1BV<$0.)%%0*0X$,("/`=$7M&RL7,M0?0\E'
MRS(5%$@=QKQN^:BJD;H*I@X:J*I"HD;L&#CQ*/X=$5?HB:(J5V]9,$R+/G;5
MDB=9%L15VX2;)G<.5"HMT"'6.0IEG"QP(0@#TCF$``!$=$55HB:(J=H\:/VR
M#U@Z;O6;E,JS9VT72<MG"1PXD5071,=)5,P?@,41`=$7B\E(R.48I2$BQ8JR
MCPL?&I/';=JI(OSI*KD8L2+J$,[>'10.<$DP,<2D,/#@`Z(OQW*1C!9FV?2+
M!DXD5NUX]!V[;MEG[C\7]H9I+*$.Z6_'#\4@&-V0['9T1>K)\RDFY'<<\:OV
MBAE"$=,G"+IN<Z*AT5BD60.HF8R2R9B&`!XE,40'LAHB^FKQH^1!RR=-WC<5
M%T07:KI.$15:KJ-7*0*HF.05&[E$Z9R\>)%""4>`@(:(JC1%3KO&C4S8CITW
M;'>N`9LR+KI(F=NS)++E:MBJ&**[@4&ZAP(3B;H$,/#@`\"*HT1-$5M0F8=T
MC(.6TK&N&\2Y>,Y5=!\U61C'<>'2?M9!5-4Q&3EB7LK$4$ID@_L@#1$B9J'G
MF:4C!2T;-1ZP<47\2_:R+-4.(AQ2=,U5D%`XA^H8=$09F'!041E8T%2R!(DR
M0OFO6%E5$>V4XP2=;T@D#M_VP$>'6"3\8`X=G1%Z,Y.-D%7R+"08OEHMV+"2
M29NV[E6.?%227%D^314.=H[!!<AQ34`I^@<H\.`AHBKM$5,F\:+.7+-)TV5=
MLRH&>-4UTCN6A713F;&<H%,*J!7!4S"F)@#I@4>''@.B*DE9R%@D".9R8BX9
MLJH*2;B5D&D<@HJ!#*"F15VLBF=0$R";@`\>`".B*XI*I+I)K(J)K(K)D525
M2.51)5)0H'3434((E.F<H@("`B`@.B+R5>-$%VK9=TV1<OCJILFZJZ2:[Q1!
M$[A9-JD<P*.#HMTS*&`@")2%$P]@!'1%';J(EK4@)1$H@I'\!`1`0_[S9!^$
M.SJ1M5+NY*E6H52:(FB)HB:(FB*-L#"-HL8"(B!8^N]$!$>`<1F!'@'X`XCJ
M>!1PJ2:A2FB)HB:(FB*PVH1"LV$0$0$(24X"`\!#^XE_P"&I&U0=BO*`B*"(
MB(B(I)B(CV1$1('$1']41U"E>NB)HB:(FB)HBBY1'PU7+Q'H^"[4>CQ'AQ[K
M/`X\/P<>&IX%'#[BE&H4IHB:(FB)HBH9,1"-D!`1`08NQ`0[`@((*<!`?U!#
M4C:H.Q4M>$1@(,1$1$8>,$1'LB(BR0XB(_KZA!L"O&BE-$31$T1-$7$Y]_S&
MU8_F3KU_OU8[T1:/\O<XI;&MMRI4E%C)8W=JE01`HK+F3M%G.5%$#&*4551+
MT2\1`.D(<1#7I&E_NV']&%NH/S#/Q5B2<YEU)I=QL-5R-A/)M#847/V'=N>3
M+C(V/&DI7L=7;-V,$<M5*6GB1%G<R3VI1]:5%"2=L4G*C:0**)$E2"54QVH,
M8\MD8YH:]K":B@+AF%:'93;3A4&8`T((H0#LX15;:RVZS;G7WU3BYO/F,XAY
M>:*RR12T'UQ8-D[-C2592,DRO4,X.J#1S3'3&(<K=O@<&I2(F$YB]CCDFZMV
MD`O:"6U&.T<?6ZJN<XSC&(6/[[F793825NVY+R'A>3*]C+-'5V7MDHWXN8>K
MVRI0]P@W*+P$S*L*_=9Z#1D(U^D)&SYVT,JB45$S#0^:S=1\CF'`TKQ`BH]P
MD5!X:*"Z,XN(57FS>Q@G#=9SA)R5YC[Q;\`8_ON2;UB:H3#!Y?BP^,6$2_NC
M-FVD'#6%2F*^VL#`CI%=TEVHJ^;IKBD99,!F:\@B:\EU7QM)+1MPV]BH1TK&
M@XU(%:+.>.,C4?+M2;WG&MGB+G5EGDG%*R\"[(_:,9N!?+15A@7ZB0?W',U^
M7;*M'B"@%.BND8!#AP$;T<C)6YXR"W^D;1[BJ:0X5&Q<$><4<J>]OEPJ'.5,
MB>-MY2AU#F`A$R$AL9F.<YS"!2$(4!$1$0``#CKR7UQ"N[S0-O.-_MM7NOV;
M"&^N&Q<31HL[PD\5(#BM2F]YK[VP05?C'Q)5:QQ=EE6,E%N&;^(!.J.8!M*M
M7+UNZ.9-\![(V,0@$,!B](1$O`.E\TNM9F0OF>,H8YH(-0>6'$$"FSDE?HS'
MKFGSW]O86T@F?<Q3/:]A:Z.D!B;(US@XT=69E!0X5J1A6W5[)4%8BG7(5Y$M
M2S-AKR3R;<0[-)Q.5JP2%:D(Y`B4LY="Y<2$0Y,UXIE!RB@<Y!_%$NJYK*6'
M`T<[*UU&U/)<T.!V`;"*\1(6-IV\MAJ(+VA\,0FFB#I#&T&6&5\+V`"0NJ7Q
MO+*@9VM)&RBOC&Z5"2.LE&6ZM2"C5F,FX386"*=G;QY2-S&D%B-W:@I-"D>(
MB*IN!`!8G$?QR\;3[:X8`9(W@$TQ:1CQ;-N!PZAXEG0:SI%RYS+:[MI'-9G(
M;*QQ#,.6:.-&T<WE'#E-XQ6V*9&J)S/48Z=C9MU'DK*KUI&2T48R+2V3!X2%
M=&=/'[...FN\06X)E6%8_4F(F0ZPD3/6+.XP+V.:TYJ$@[6-S.%`"=E."F-2
M0*D8KMX]()>RVGBGEC$)<UDD>#9Y#%&[,Y[64+@[#-F.4M:TO+6FYN[I46";
MM=];JVS18.Q8O%W<_&-DFKWJ'+CM1=1=VF"3DS9DLH!#<#"1%0>'`AN%#;6X
M<0&QO)(J*-)J,,=FRI'9'&LN76M(MVODGO+9C(WY7%TK`&NHXY22X4.5KC0X
MT:X_@FE^ZXJS85D5BK(KM3*I+)*%526150%1)5)0AC$524(8#%,`B4P#Q#L:
MLTHZA%""L[.'QYV$.8YE00:@@BH(.P@[0=A79785MOR/NR_HJNWS!^(86&LF
M2)R/1MM6K\[)QT*SGEL4\P.4RO*02$Q+B2(C96=@:4[9LE7:B#0':Z8+K(HB
MHH7ZA9W#?Q1]Y?B-<_XJ7]*_^T5T(WR8SYFDZU/<=AD9:<535ZF<_P!\M=?8
MV7`$!.N;0RV]8?I&W9MD$;B\FX1XD[R90W:SA.->N`1BU.K>K%*<R05*PIUD
MG#',20N^]3(N!'D+3I^1W<;0,O8"AI5WB^(@,]89J.&\.8^W%8NRI/PL=(W*
M,BGKAE8Q8.Y(X3+5>-CRL5NT.BB)%CJ:QQSA&V(]^</#9(M;[+*5NCZYLWE&
M[K`"<#/8_896KLC5,B0T[.2YG4+=$\-G=QENB;/#L63J5:F<,U7HN0.!%Y[G
MMOG,ODX7=CB[&5IFL^8QGL-XO98">9E=8&);$\HUK)F%).TM)J/D6#;&U^@[
M-6&MF?\`=&8AZX\AWK-5F"$DBZB7+0BHLN4W?-C;<+F^=H^9K!5[%F[?_@:6
MVW8_NEZ86+'V9=K*VW#&>.,_X_AX=JVG);%TOB"Q+6J_H@",8HZ7KR'14=-G
M3GB1;<[[*GS"%T<01VR:U)`C"T;(+"PR<W(TQL^=9E2E,1HX7M>2U;,W3"=Q
M$SKS2Z&M#")2-(.W;ID*+=02E%$BPEC/9;E*O8LYQB]EQBG)9>W;Y@W2*86F
MIFQ4B=LE[P[=,*U:KXCKA[2>75/5ZFTN:<F1G#2SEFG$IFZT44BJ=(Q%K7BS
M8%O9VK8BVEI[:;!<Z;>\MHX+8<P-")DL+R\CC:6P]M'KF%,;O,94R<FZQBJ<
MHU5OE3;*7(S21>V"SHG*[,I(I(E8@19FEJ3S=TMQV\25A;!:UL)6;'6]^,VV
MQSJWX'[DP-O>8RVR&V;R%=9&,E:X61+D]EDT%UIHZK=N@NU!^4C<S;H$5GI%
M'YQ\9MY91\]:)V4S57]WM;LK9K<+%A)=/(.VA7!N-F]OIMEO-%>M"T4I,W2%
MJ>Q+]I&3#I!2/9-G<8YB'`F3(HMDK$&[[=/B;=358.](;DL>UWF%;=;+MDDU
M)VMUI\IBC'6Z_;UG+.%<MR,VQJD6$MMHD:-9JE`KD7.]EF+(R:PN'J@'T13?
M<MC'G`0\+NHB<!WV?OB\OFZUR6U&?C+OAJK34+BS)^"9FS#$Y,87F(CX\T#@
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M`#)*G2-K+-K;HC'?:V5]\59W,X^[8QI'0Z&,LH9GRQEO;CG*N'QU$K1C[(M=
M:QT'#OF;<X*R"-P>NI,BCUFHX`BLE)QAS:[-MDVRU_)&4,CU#.\]NPQVONOG
M*Q(;<(Z4HN`"XFL=9S6MC";!U>JU9:;.Y70;6&N`I'IV6/1DB-RQR#=D1$"*
MZP>'^9-(9"Q&3)1T,DTW'7,=ALDL;I:E<-HVQKM-<X1W`U^1-+5059B&A+A2
M[O;J]&-Y6J/&TK.1AC.@CHLQI-LX(L>;:Z!OOQI9MEV%+QGJVC?I"Q;PI+>#
MC.Z7Z.O,^[PQ8L]7?)6%=R>/KK'QD\/;K0];CJ6>-<O4"D8WD>N9(+,$NB1;
MH9\KG,'D=XN/Y##TZT:;7TQP22=;-Y*HLF#6OMY;/?UK&]OCY7A<)2Y62MO,
M>)45>,Z;=A(-7BBQFR7;1G!%H)4N75N7KO*'VK[=8NCQ$;G2F9QV^YIWB8>?
M7"H`[W557'F9HVRY?Q3<\GQ<BZJUIELBT.$9(IN9:048R:$<VC)%PFT46%,B
MVJWPTG>07;U/NN6OA*8PQG?(-JM;^:(QGMO=(6.ZA-O=QBL;7"[LIV5F*X[;
M$R9%UJ-(TCGY'BB;5`\B"L61VS5(L,LMJ>\B-W`WK)$/C6(9PF2N;5M=W,6A
MU(R6')=17;U5=@>/\*97M39E+R4NO`V"(S%6%FJ*<8"%A,B4'#(3-55!,18=
MVQ;1N9GMPJ^$X/'D-#4AS/92R)=<\/Y"QXOL,_9[':.8PTNDE:L\VLCR4G,D
M5R1Y?DE-1M>1C7+N1BK*X(FL5NJ1HLW(I?E?"W.15P,M(XVRYF97.UEW(;S7
M#^N>'>V)C#4O;VQJ6\@FRMI7'K^!28'6G+=8\4&GNV7TA*I)QYNV!;IHO`5(
MI?D3&?-/9O\`=+;L:U5=I>LNT_8-"4RPU2P[;JO,$L57Q+DN+W+R4],R9>[3
MJO5"_P`O%'1:G>).51.H$(L5H9V"A%E#==M_W4[@=KW*Y3NN+T\DYUPONCV/
M9_W90!9?%;(68XPJS];/SR.%_886CSKI6RR2Z;=A%+G0>`IT4"]2'$"+5S`V
MW'FP;<9/;#CV@,GT9@Y#='?\N9/IL9D3#4O2,/[<\N[J[_82;<V#2P*L[C/R
M&,<$V9BKUL2HYAF"B/:4&456Y%UR+.-<P!S+XK,.`I3(MI-E2O88W`;WXUID
MHSS"<E:Y';Q;<*Y<5VN9"DXNT0T.,'F8MXR-%T^03@P;MUXRM)N)$.U'SPIB
M+>3:9$[HH#:DQ@]X4@TG,V1%DG8^2M+1VQ.-RK;:X$3J=N>PD<\F65+E;!"`
MDX=P:4K,HQC@QTD7RR()@21M5+NY*WLU"J31$T1-$31$T11J/_.FR?R?7?\`
MQC4\"CA4EU"E-$31$T1-$5@M?YL6+^1)3^)+ZENU0=BO+?\`O=#^TI?]0NH4
MKVT1-$31$T1-$46+^>R_^:S7_*SS4\"CA]Q2G4*4T1-$31$T14,I_BR1_P`!
M=_Q=34C:H.Q4E=_-^"_D:,_B2&H0;`KSHI31$T1-$31%Q.??\QM6?YDZ]?[]
M6.]$6D?+Q_V(-M'^KU;_`$KLNO2=*_=L'Z,+=0?F6?BJS7?8)B"^V3*EIF+5
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M2(*LY9:TI%TE3;Z>M$=5J7>.J8@XGE'!91*871;**%,J@FJG2;`OEE=(X<U*
M'`@`5`=38:8;,=M5'-5<ZIY+JK:7%>T7#&*F[#M2)D+A,0N6\I9KK=GNKIL]
MGJQ=\PV`+-=%816$90+!&-7E"AVNBLW6,BD`$$YN''63':Q1\%7!Y<"=H+C4
M\2K$;1UZD]E<0^>;;J;2-UG+XG+[;8ZC5I3&&\J&=6B5<(-FL8YG(3&L:Q.1
M5TBY;=MF<+AU)5$SIF4``,4P<0'S7UJV]S=:-'%:1F6?G&D-&-0U["=E#3C7
MKOJ-U?1M#]95M?:_=QV.F&QO(W3O(:UCI8',:07`MS5/)!!!.T$+EC0LP;2:
M),1TRGNJH$RNP4MZQTG+V-9)NG%T8T1G)K',U(=1,45*$@JF'$PB9RJ!A$`)
MP\%N]-WANXW1FPF:#DV`FF0R$;?TA'N#JK[-T'?#U2:%>17C=ZM/FDC-P:.<
MQH<;EMJUY.7$4-JUPVXO<#P4^T,O[/6L$6+:[F<9MI5/([K)2=D16B0?GDG-
MNF[>6+?(&1%.0C&CBQ.D$>L/UA$S%-QZ0#TH.G;QNEYQUC.8^9$>7&E`QK*C
MB)R@GJJ6;W^I^*P\5BWFTQMT-2=>"8&/.7NN);C(X4H]C3-(UM34`@UJ#6#Q
MMGV;QD"2!0W;5`H(1DNP9RB#^#:R;5S(,L8-F$GTB-#LW"\.YQ1'+@DHB*#D
M55DU2]68H%RGP;R/EYTZ?)BX$BCB"`921MKB)7"M:B@(Q6CMM3]3EK8"P9O=
M9@-BD:UX=$U[7.;9-8_N<I,9L8792W*_,]KQE(I.WF:-J$@,TJ]W68Z6<V)#
M'(S"B)H)BW6E<<W-Y=FDHS8L6S=O'A,/GZB*Z!.)2$'K"G%41,.*W3-?9E#-
M/F#6&2G=$TD8&$$DDF@%0?<V+?2[Z>JFX,[I]Z].,ERVSYPCFF@OL[EURU[6
MM`#.<<XM<T;!R@2ZI-B1R'LT0+`]#=%1%%:TC$1L4X=2D<X5\'Z^CD%*&B7_
M`!23*_=-/I&=])\8"K*@@D`@`BJ92Z;/>4YZV$M'U)H#W3N;S$<0/-CD[!4]
M2F`S>'U-1B#+O18%]L(V,+I&$\U$+L1QOP&=S?')*R&CCE8*"KR[,5;W5;3Z
MS58"KH;B\:/4:Y6XJNMW:TZBDN[1A8E"+;N%DDD123672;%,8I?Q0,(\.QK6
MSZ!O!/.^<V<X+WEU,NS,:T^ZNQTWUJ>J?3-*M],CWCTQ[+:V9"'&4`N$<88"
M0!0$AH)`PKL7]H']&TFX9KR3-BJ+F7C&ZQ:OEXQDEW[5%4H'W%9?4()DU%2G
M+TB&`0XA^`=?03`<@'4'WE^3-PYKKB1S35ID<1UBXD+N-X1U[X>AOC1C[?JJ
MA5FH3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3P
MCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#
M?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_
M2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3P
MCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#
M?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_
M2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3P
MCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#
M?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_
M2A2H48N,[!KUU^DA,Q2RICL!*FE(LSG,!9)F8W`I5A,/1*41']8`U(!JH<1E
M4G\(Z]\/0WQHQ]OU%"IJ$\(Z]\/0WQHQ]OTH4J$\(Z]\/0WQHQ]OTH4J$\(Z
M]\/0WQHQ]OTH4J$\(Z]\/0WQHQ]OTH4J$\(Z]\/0WQHQ]OTH4J%'6,]!ELMA
M5--1)4E6$`5-09%F":AD^ZW6%(<5NB84^F'$`_!Q#C^'2AHHJ*J1>$=>^'H;
MXT8^WZ4*FH3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_2A2H3PCKWP]#?&C'V_
M2A2H3PCKWP]#?&C'V_2A2H5CL\_!+5N?22FHA152&DR)IIR3,YU#F9K`4A"%
M6$QCF$>``'9$=2`:H2**[(6*O@@B`SL,`@DF`@,HQ[`@0.(?]OJ*%*A>WA'7
MOAZ&^-&/M^E"E0GA'7OAZ&^-&/M^E"E0GA'7OAZ&^-&/M^E"E0GA'7OAZ&^-
M&/M^E"E0GA'7OAZ&^-&/M^E"E0HR6>@_#%=?NS$]2-9:I`MW19]4*H2KLXI@
MIUW1$X%$!$./'@.E#11454F\(Z]\/0WQHQ]OTH5-0GA'7OAZ&^-&/M^E"E0G
MA'7OAZ&^-&/M^E"E0GA'7OAZ&^-&/M^E"E0GA'7OAZ&^-&/M^E"E0J*2L,`>
M.?D).0YC&9.BE*639"8QA04````7XB(CH`:H2**E@+!`IP4*FI-Q":B<3&D.
M0\DR*<ARLT2F(8IE@$IBF#@(#V0'2A0$4"N_A'7OAZ&^-&/M^E"E0GA'7OAZ
M&^-&/M^E"E0GA'7OAZ&^-&/M^E"E0GA'7OAZ&^-&/M^E"E0GA'7OAZ&^-&/M
M^E"E0N*KV9A_ZQ=67?=6-[5#DI7A$7/;S7M<%3;Z<>&*D*W6]6"@E*(@7CQX
M!I0J:A::\O'_`&(-M'^KU;_2NRZ](TK]VP?HPMU!^99^*MR=9ZNKG3S`\MYU
MQP]VRU'`-CFH2W9GO.<J:6-K=:I%FGK-,UG:_EC(V.(B.;7J-D(UF0<G5:)[
M:5**/29&634.4A^D7`OI9HS&R`D/>YPP`)-&.(V]4!6I7.%`W:2?O%8=@YOF
MB2V1\H5:YPK^%J;O#>X`]2L-4B<8(U>.RH^VZ[?'^$V=2M2H+SYS1N>WF0FJ
M*C]-1$$T4"O#G2(U.-D.U(R.:\49D=0C+2N5N6AV]UGV^[P*BLV8@[*'BXA3
M[M5T0VW,;M%[>,$1N3#6<V2&&'\<L\A#=%&*]L+>&]3BDK8G8'$;Q9.9)*>*
MN0ZI#'%4"@<QSG$QS9]N'BW8)*\YD%:[:TQK[JO,KD&;NJ+-&KRJ7\YW.=8Q
M\AO.Y<[>3BX^9:!C3>4X-'2;-H^9N%6T+C-9$#H/D7#;I@H4.B8Q!Z`]D->2
M>MYSV:`TL<6NYQN()!Q>WBQ7MGV=8+>X];=E'=11S0BRO#D>UKFDB!Q&#@16
MNPD8;5S\K%QPE/5^L6.3J6.:PSN36%6KR#Z*ILD\=O9B*3FC0CA&*BUQ93$9
M'+I*N4S_`(A$E`4Z?0*<2_.\]MJ<4SX6232.C+LU"\``'+F%3B":@=44I5?>
M>F:SN3?Z?:ZE<VFG6L-XR,PAS+=[G.DC$G-D,8<LC&%KGM.`:<U:`D2%"8P(
MZ>-V36+QXY.O&6.8,X2I<.+%I'5)"$=3SB1?'A"-F':;2QLE@*J8IE4'!%"`
M8A@,-HQZLUI<YTP`<T=V:DOS!M!6IJ6D8;"*'%;".\W"EF;!%%ISG.BFDJ+>
M/*UD`C=*7NYNC,K9HW`.(+FO#FU!!5>Q7P;)/6,<QB\;N7TD"YF+-*GPQG;D
M&DX-:?`DV&$*L*L=/!VHY((`=LKP!4"`("-#QJK&E[G3!K=ISF@JW,,<W"W$
M<8V55^!^X]S,RW@BTYT\E<K1;QYCEEYEU&\W6K)>0\;6.[L-K56N`F,'SRT/
M&IPN+DI^:*!F<&V@ZS)J*=8:<.T*B_;0I&2QWS2N/54B\2F.#98I0,*1^%<T
M>J0ASRZ?F6[7$N'O:X$UP+F@]<<:QM/N]R+]\-NV'2Q?SCDQ".%Y->=RT<(P
MTES89'-&!.1X`)85D3P$HGR%I'S0KG>S6'XW=>%E^&[MKH?F+0O(;+Y/#WB^
M5*+1.K5_\BTC_L5?_P"$*Y^YF_\`\9J?&KJOYV7X;NVH=H6A93_<;+8?_MX>
M+\1?U@_T;*-CEN25L5468,E5#5C,'245:H*'-T=Q>8"EXF,F)AX%``#_`*-?
M3+.X;^*/O+\6;D`7,H`PYQ_]HKN3W(BO@R/]Q-O:]5*Q0)W(BO@R/]Q-O:]$
MH$[D17P9'^XFWM>B4"=R(KX,C_<3;VO1*!.Y$5\&1_N)M[7HE`G<B*^#(_W$
MV]KT2@3N1%?!D?[B;>UZ)0)W(BO@R/\`<3;VO1*!:$Y-W][?,0;A,A[;;Y3;
MQ%WBD;=;-N5@Y1&JUQW5LJ56EN:^SMM'QG(%GTW\UEB#<6Z($\(Y:LS*HR:"
MR:QTA4,F2@4APAOLVCYNP_BG,+>]4;'+/+N$&&XB"HV3Y^B5W(D+BE_4"Y!&
MPVFO-)^51BB1E'/W5>]!PNFU8D47,?JDCG*2@68G6X7;`QA8&R/<O8:9UZT.
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M0T9#V:*775D5&;5LA*-%G"J2"Y%1)0*]4?/6`KX_Q[6XZXXZ99"R9CB#RG6<
M7N[11'M]<5&=@V=@1D$8BOSDTVEF[:.>`<[F.</62B9#+(KJH`"HDH%KYN\W
MYX1V96ROU/)./+G8'$]@C<+N++(4Z/Q^+!ECK;`QIDKE8BQK;<:HLYM",7>V
M*T7'H%5/)B"R9#E4(!3DH%GJI[B]M-R:QRL9D;'#&0?XTBLOKUNQR4+6+;`X
M]EJM$74EAM=7G3L)NK(QU5GV3Y^1^B@K'MG22C@J9%"&,2@6%H/F`;.;%N(K
M.W"(O]'>6.]8RB,E8]NJ$Y15<<7]:5R==L1FQO4;"2?,\F,J1ERH$BBZA4VG
M6I]7T.D*X'1(2@6>7&?-L[5K;GR^6<.$:T*QLZA=%@MM3.6L6F0?OHEC7ID$
MWAC,9AW+13QHFW.`*F=LG*(!UK9<B9*!0LF[O:'X19?K#S+V+X>1P/9Z72\J
M.+!(QE>AZM:\@TYOD*J0*LY,E8Q+^0D:2Z3DQ*U66*BS$RB@E*FKT"F@61([
M,^WF7RC(80BLF8DDLRQ+$924Q4QM%5=9#CHP(F#G@DGM/1>'GVL>>$LL>[*N
M=`$C-WJ*@&$JA1$HH%SRM7-[VFTNGYEL5CQWEEC8L%[KJ%M&NV-@I=,5NY[?
ME&7KL3CW)<,W+<@AGV$;9X2I+-9\[Q$PE162,V*X(")B4"S?AK?S@O-F:L@[
M=8+'UZJ^:,4YCF<37RA7RO52N2[*'8P-[G(+-];`;$[2N^"[LMC>7C8R:BC.
M5PEFIFKMJU4`>!*!;]=R(KX,C_<3;VO1*!.Y$5\&1_N)M[7HE`G<B*^#(_W$
MV]KT2@3N1%?!D?[B;>UZ)0)W(BO@R/\`<3;VO1*!.Y$5\&1_N)M[7HE`G<B*
M^#(_W$V]KT2@3N1%?!D?[B;>UZ)0*+W.,C4JW('3CV*9RGC^!R-&Y3!QDV91
MX""8"'$!X:D;5#AR5*.Y$5\&1_N)M[7J%-`G<B*^#(_W$V]KT2@3N1%?!D?[
MB;>UZ)0)W(BO@R/]Q-O:]$H$[D17P9'^XFWM>B4"=R(KX,C_`'$V]KT2@4<8
M1D::S6%,8Y@)",*^)""S;]$HG[K],2AU?`!-T0X_K\`U/`HH*J1]R(KX,C_<
M3;VO4*:!.Y$5\&1_N)M[7HE`G<B*^#(_W$V]KT2@3N1%?!D?[B;>UZ)0)W(B
MO@R/]Q-O:]$H%8K1%QB=:L!R1S`AR0LF8ARLVX&*8&2P@8I@3XE,`_@$.R`Z
MD;4(%%=T(F*%!$1C(\1%),1_N)M^$2!_^RU"4"]NY$5\&1_N)M[7HE`G<B*^
M#(_W$V]KT2@3N1%?!D?[B;>UZ)0)W(BO@R/]Q-O:]$H$[D17P9'^XFWM>B4"
MC!8R-\,UTNY['JPK#50$^U&_0`XRKPHGZ/5\.D)0`./ZVIX%%!7W%)^Y$5\&
M1_N)M[7J%-`G<B*^#(_W$V]KT2@3N1%?!D?[B;>UZ)0)W(BO@R/]Q-O:]$H$
M[D17P9'^XFWM>B4"H9**BRQT@8L;'@(,G0@(,VP"`@@H("`]7V!`=2-J$"BI
MJ_%QAX&$.>-8&.>(C3&,9FW$QC&9HB8QA%/B(B(]G0H`*!7?N1%?!D?[B;>U
MZA*!.Y$5\&1_N)M[7HE`G<B*^#(_W$V]KT2@3N1%?!D?[B;>UZ)0)W(BO@R/
M]Q-O:]$H%Q2>Q[#^L85E#M%GU`\E&\J"CVLAU0J!OIQX`'%/H=`3@`B''AQ[
M.BFBY<X#RQ9L(<L/`>2JGCFS93D8.JUI"1JM.AGEHL[:JRF3I2/N-OAZ9%.V
M$[>G%&K"[J6-"QJR<A(IM#)HF`>(AZ%92NATB&1K2XB-N`Q-.$TVF@QH,2MQ
M&XMMVD"N`6;,<;X<27R'PQW*D7>0[)F>IV&_PJ.&JI;;+$Q./H#):>+'%WMK
M.?90MHH\3'VY^UC9A"1:@Z@Y(':;LI&[-9R&5'>Q/#*<ISP3R03@#EJ:XC'`
MUV&M=E56)&FG"2.#KT5BQ[S"=M>6I+"+."B<JIR6<XZ,M>(@M6(92/>25,G9
MJHU",R2@0RC][%4AY<;HTACRA"]%%T@[.L";)JJZ"&7UO*6`!U7BK:MX#05Z
MU32O7X!50)6.I2N.S#[JN1.85MO=TNR9`AG60['5J[E*DX>3D8''\BZ3L]PR
M%DBQ8BJXT]9TZ9,IV(<9$JKZ/<J@LDNQ`B3APBFV<-U59\?MRPR#,6AP;@-I
M)+13CQ%.HIYUE,PK2M/Z%8U.87A8D63)!7<JKA@=D2^]\TDG4I\;\..&UW0J
MKI9.&.LE"];'H*&!>-,N$EVT7BGUB/XVJ?'X:<YCS7,\YL-:5I_L-JCG6[?P
M<M4L/,HVSUBD05[DPRF+&?N.6J(C!-<=N5;3'V+"%TKV/\B-)..4E4&!%(^S
MVR-2:HH.W#J02==:@B=-%P*)VH6S6!YS4)<*4QJT@'[I'7[*&9@%<=I^XN:/
M.4`B>];ERINEBL0/C/>6@HHLJW2%N=6$QFF("=83M^N3,;@`#TBB8/U0UYCZ
MX*^C[:"IYQN'_P`[>)>[?9PR?6]9![@QILKT5)`I6!PX<*\55I)&8\IL1$X\
MAF-B<HM\:QKV*@W*4U"H2#QL]J+ND&4EWC9JB==ZW@GA@261!`Y%BE/V>'#7
MS?)>W,DDTCV`F=P+A1U`0\/P!.S,,0:X8+]![7=W1K.STZR@N7-CTR)T<3A)
M&'N:ZW=;5D<`*N$3CE<W*0X!W!11>*PE1(=!TDSN]E(X>Q5KB7,B6S5UO(J(
MW&NT^N2SHCEE$->ID2I46/=)+D`J@/"J'.)RJ&)K(DU2ZD(+HF4#F$#*XCD.
M>X#$G#EN!&S+0"E*K5VFY&A6<;FPWUR)'Q3QN?ST(>1<0V\,CLS8VT?2VB>U
MPH><#B[,'%JNL3BFEPJU;=,K;)E>U*U3-OK[SNQ6$5H^2L\D_D;:T(1G%-6Q
MH6TDD3M7C44Q3%J1,J?5G3*H%N34+F4/:Z-N62-K'"CL0T`,.))S-I5IXZUJ
M#195INGHMD^VEANY>>M+J2XB=SD`+'S/<^=M&L:.;G#RR1E*9`T-RN:'+R@L
M142OOHA^SM$BJI"2D)+-$G4Y`*(G<P!;Z5B1P5-@B<Z)BY'D>L`IBF-P1X"'
M5CTYEU*[F8YCF-HYK@:-=L=S=>'_`.FW[O&J;#=#0M/GAN(;J0N@ECD:'2Q$
M%T7C66M&@D?WR:M"">10C+CF3NE&_"<9\8LO;]:W(_WKNP5V/C%MX6+X;>VO
MA22C>J5_[SC/^Q5_^8L_W,W_`.WT#'U[EVWB*AUQ;93^5B[D_AMXNNOZLOZ-
M;_P1]BG^;&8/]XS,.OI]G<-_%'WE^)5S_B9?TK_[17<S52LIHB:(FB)HB:(F
MB)HBTIS!L3Q!G/*$%EW(B\O*W"AV]Y>\4.DD8=L3'=FE,)VS!TRLU,2.%S8H
MJ5@[0G)J,9%1=L$S$1[@"@#8"&(M/<=\GO'>!Y[`.2\=Y+R1DZW;1,&L\18)
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M:U#MG9@2"/[1/T46J2@`IHBBMEY36&+1GO-^X)]DO*B%GSM&[CHVR0S4]*+`
MQ)-S.`L";=KFO!@K4E90BL)3MND"YC.V'#@J<@J\,L"R*R:*)%ZU?EA0^(&N
M19+;YN&R_C"\7G;KA#"+.R*1^*[0-6MVWK&S+#^/,W5P+/C:;<P-T=XXCT8N
M=8LCMX6802*(M45>*PD4WWH<LW`V_.TTBP9^DK9),:-AK-6'XN`@30$8BB;-
M;K'$N\R5$S#B$D)ZM9.Q]9L40DI6))@Y0"->-U!43<$5$@$6*;-R=\`9%?9!
MD<LY)S3D5_E:A91K60Y)].5:ORECNV:]KF--GN4,NG>5BI11&-PLV&<3Q)2L
MT4R0329.Z?),2]<1%$BN4]RGL:6_*&$LQW+-.6K%?\,,=O27=;N5B:!;W^6V
MYYTM&X&MV2X1E9QU#1_=VVW6UN"SJ[%-H+U$`.7JW!CKF(J9MR?MN+3!6;MO
M*<_;G5#S5E67R@L_D(;')[[2CR61K[F"*KU6R7&4J)R$9+'N4\FS,W4Y9[)N
MIZMNETP9O2)E5*N15^4>4KA#*D[;K'-Y(RN,G:MPN&]RQ@E`QQ<XQ*_8IVR$
MV@3$?,P5YQ_8X2[5'+&#!68V%A--WQ3OW*KMJ=L<W0T1;9X=VGX]PIF[<;G:
ML/I=W9=R3C#REDBY!M`)PM4:X5QA&XHK$93PC(9A(M(UY`122SI)PNX+VT)A
M1!),>K`BU*R[RB]N^9BW.;LMCO<?DO(,?A>`MF3H#P68SDE5\![J9+=SCV$+
M#K5YW6DE4,@O48QX_%H>0=5UFBSZX@E%82+8MML<PVIF[">Y6>3D9C/.!I'/
MW@AD=N2.@I.2J6XN6M,]=,=6QM$LT6UBI45.6@7L0W7`5H]XU(L17IK/!<D6
MY>B)HB:(FB)HB:(FB)HBBEV_-F1_MD=_E1EJ1M5+NY*E>H52:(FB)HB:(FB*
M-1X?^:+)_P!,?7>'_3_CC4\"CA4EU"E-$31$T1-$5@M79K%BX=G_`+DE?XBO
MJ1M4'8KRW_O=#^TI?]0NH4KVT1-$31$T1-$46+^>R_\`FLU_RL\U/`HX?<4I
MU"E-$31$T1-$5#)_XMD/\!=_Q=34C:H.Q4M=_-^"_D>,_B2&H0;`KQHI31$T
M1-$31%Q.??\`,;5C^9.O7^_5CO1%S^V-U"N778AM<C+-'&D&L;6(ZS1AD9"4
MB7L78H"Z69Y!SD9)PKV.DV$G%.AZQ%5)8@E-^N'8UZ/IK&OTV`.V!C3[H6YA
M`,#*\066;#B?:M4+5AV4L\-CNFW:%=VZEX8?R-J5J=FEGV2Y="<N]6AU?""-
MD;^YNEH72DGS-YW2%U,*)NC%%V<JALET5LQS"X-#Q4-QH<=HVXU./#CCM59#
M`16@/`K_`%[:]@.HNL-OJQBZ&K[[;S5W]&PT\B7EA8NJ)2I)9D\?4ULNC,%4
MFJLJ^BVSH(^4%\T3=-DER$*JF4X2VV@86%K0#&*-VX#BZW4-5(8T4H-FQ8V<
M8@V3PT9?\7+QV*H>,@LBU3<!D+'PWYQ'$I>0I6X^%=+R(^K(6M);'Z,SD!<T
MBP!NBPBWLNJ=8B2BZAA&WS5F`Z*C0`X.(KL)-0:5PQQ&P55.6/%N&VM%+`V<
M;90K!:4&&JX%4+@UUMH+`=MV7M$,!/)SPD=XLZ/=OKO!A:<#M@P=+MGI!T>M
MZ'XNJ_%+;+DR#+DR4Q[FM:=93S;*4IA2GN<2Q9E#8'BJ[-*2PI%FR'@=K2+A
ME/(C(V)[A<J](.<BY=>P,G:K^I*,[:P>*6DDG!]LH`\%_&=<Z6%5DH!N&K4E
MC$_*&%S`"3R21BZE3MVX=;J*'1--*84KLZJY&\\?'].R1NNY=E.OU?CKE75L
M:[O73B*L!%EF;U]$1&,74>\>E8KQZBBR3Q(JH]`R8";CP``[`><>M:[N;'16
M7%H]T<X>!F%*T+F@[01B.HO7O49H&C;S>LVTTG7K:*[TYUG=N,<@)87,A+F$
MAI:>2X`X$+BLXQ)MI88[QUD"5VZ8ECF-Q:MG4T*M.R4L2#(;%5GR.]7CVR%F
M%[.QJ"T*@W!TEP3*DHL8W`4N.O%AJ.MOO9K..]N"^,D-Y<7*_*MC%3EHT\HF
MAQK3C7T_)NEZM8-W=.W@NMW-)C@O&M=)6WO"(AXC->.+`)LTK`8VLSMP#2\G
MN:J[O\&[?HFO9`M,IM9PVU2QMCK&60I^M)/+"^>.$;=!R4S:(6+M#.Q*1#EY
M$DC#EC%RMCMWQS$*82@<%`MLU75Y)H8([^Y)FFEC:ZC0.0X-:XM+:@&O*%:M
MQZRR[C<;U?VFG:AJEUNMHS6:;IUE=RPATSG$7$;Y)XV3MF,;G1AA$+@PLE)`
M)`(<LB,=NNSYYEEWC8=N6/$F)ZZ\>P<X8\QVQ*6:O+,%KC6UHX9;I,SP\1/L
M%DCB81743?$X!VL(CA.UG>-NGB]\=FS9P'-PP:ZN1U:8U+7`\56'\)=%!ZN_
M4_-O:_=OT<TX0&W<Z*6LE7S0EIN(2SG.3S<<L3FFO*(G%!S2C\Y@C9_"M\GV
M&0P1BF`I^)KG!TNP/I:+NDB]>NGD=5)>6?$3A)996+9E:VYNWCS&;N"KN"B=
M44T3`(7HM5WBE,$++NX?<W$3GM`+```7@#E#$U82[$4&`J5@7VXGJ@LH]4U"
MXT'2K?1])O8K:5TD=R]SG.9!)(ZD<A+&Y;AC(B6/#GC,XM801=/H1V1EE(Z)
M<[8$6*\DK$=4XD*O*L6:;*>LM>J<-+BJYLZ:KJ*?S5J8IE5;)K\`4.(@'4J@
M2W\Z;S\V9&WQ(;78X$U:USR,&X$-8XT--@XQ7*]"/4B+J.TDW7#'RF.A?#(U
MH;+-#!')5TX+HWR3Q`.8';23W#Z3"I[7-F5V;/W<)MUKA8Y!N@Y83$A!V%C%
M3K-X#]-%]`/59<4Y%%):/4*J`=%1$1()B@"A!'&N-=WEM7!LMX_.30@.:2TB
MF#A3#;AQX\2V^D^J[U,ZW')-8[NVPMVM#F2/BF;'*UV<!T3C)1X!80X8%O)J
M*.%?[6_Z-S5X)_R3MB[EVQZU8]8R\4Q^V7B?$$]Q.7TB!T4G!"`!4R`'8#]3
M7OC''(#PT'WE^5EPQK;B1K11HD<!U@X@+N'X%UKX-_AC_P!]:JS%6J!/`NM?
M!O\`#'_OK3,4H$\"ZU\&_P`,?^^M,Q2@3P+K7P;_``Q_[ZTS%*!/`NM?!O\`
M#'_OK3,4H$\"ZU\&_P`,?^^M,Q2@3P+K7P;_``Q_[ZTS%*!/`NM?!O\`#'_O
MK3,4H$\"ZU\&_P`,?^^M,Q2@3P+K7P;_``Q_[ZTS%*!/`NM?!O\`#'_OK3,4
MH$\"ZU\&_P`,?^^M,Q2@3P+K7P;_``Q_[ZTS%*!/`NM?!O\`#'_OK3,4H$\"
MZU\&_P`,?^^M,Q2@3P+K7P;_``Q_[ZTS%*!/`NM?!O\`#'_OK3,4H$\"ZU\&
M_P`,?^^M,Q2@3P+K7P;_``Q_[ZTS%*!/`NM?!O\`#'_OK3,4H$\"ZU\&_P`,
M?^^M,Q2@3P+K7P;_``Q_[ZTS%*!/`NM?!O\`#'_OK3,4H$\"ZU\&_P`,?^^M
M,Q2@3P+K7P;_``Q_[ZTS%*!/`NM?!O\`#'_OK3,4H$\"ZU\&_P`,?^^M,Q2@
M3P+K7P;_``Q_[ZTS%*!/`NM?!O\`#'_OK3,4H$\"ZU\&_P`,?^^M,Q2@3P+K
M7P;_``Q_[ZTS%*!?)Z15U"B12*(H0>'$BCEZ<@\!`0XE.Y$H\!#B'ZPZ9BF4
M+Z\"ZU\&_P`,?^^M,Q2@3P+K7P;_``Q_[ZTS%*!/`NM?!O\`#'_OK3,4H$\"
MZU\&_P`,?^^M,Q2@3P+K7P;_``Q_[ZTS%*!/`NM?!O\`#'_OK3,4H%\A2:N!
MC'"*(!S@4#G!T^`YP)QZ`'.#GI&`G2'AQ'L<1X?ATS%,H7UX%UKX-_AC_P!]
M:9BE`G@76O@W^&/_`'UIF*4">!=:^#?X8_\`?6F8I0)X%UKX-_AC_P!]:9BE
M`G@76O@W^&/_`'UIF*4"^34FKG*8AXLIR'`2G(=T^.0Y1#@8IBF="4Q3!^$!
M[`Z9BF4+]\"ZR'8",X!^H`/'X`'_`+`[:[&F8I0+]\"ZU\&_PQ_[ZTS%*!/`
MNM?!O\,?^^M,Q2@3P+K7P;_#'_OK3,4H$\"ZU\&_PQ_[ZTS%*!/`NM?!O\,?
M^^M,Q2@4;+4Z_P"%RS7N?^T!7&S@"=M/O^U-)NTQ-TNV>GV2%`.''AJ:FBB@
MJI)X%UKX-_AC_P!]:C,5-`G@76O@W^&/_?6F8I0)X%UKX-_AC_WUIF*4">!=
M:^#?X8_]]:9BE`G@76O@W^&/_?6F8I0*CD:=7$X]\H6.X&(S<G*/;C\>!BHG
M$!X"ZX#P$-2":J"`J:"J%=6A(992.Z2BL5'JJ&[;?!TCJ-$3G'@5T!0XF'\`
M=C2I0`4"NO@76O@W^&/_`'UJ,Q4T">!=:^#?X8_]]:9BE`G@76O@W^&/_?6F
M8I0)X%UKX-_AC_WUIF*4">!=:^#?X8_]]:9BE`N++VM0@?TBFM1_:7]QCR5;
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MG6&1QYH%Y(#CPD%@/OJ`&M>.F(4!C\P)/)%>'JX=>BN6X797/Y>S:AN$HTRS
MQCEVG73%,?%6UK(%79Y@V[(#4OIHP7D^)08&$D(_7@SR==5/VPK%SK5!RB9$
MJR^JI[,RS<^PY906X^^;AF:?OCB.*E\>9V<8.P]T<(*A[G:]O1F<>;FV<EN&
MFF67K%FIMD/`%M0R3.*X_P#!ZLYLGLB4^&L%+C*]`S%+A9;%LVE1[/")R,C'
MR3&.;JI$(=,%U*/%KPQR`R'G2^K37"@=45%,,#E(J0:*"R0@U/*K4=GM846U
MVTS#N4,(XN7I>8,KS.9[:SMUO:Q%ZG927DY9_C-A9IDF+$[`M*N%A7NI*8X;
MFFW*8%*Y?F,'$Y4B'')M89(8\DKB]]3CU*G+7JTV]55QM<UM'&I_HX%QVYQQ
M$U-['+D(MP!$^,MYI%A$XI`")H3&A51%4IB&3#JQ'B8!`2_AXAKROUPDC=YI
M&WG&_P!MJ]V^S<&N]<%DU_<&RO:XTPYAU<<*8<-<%J,PJ=#[3JD5&QT,LQH/
M05J+!H^,Z1KI2QCN"3%JB1ZL(HA#OEV@%6ZPG4*G3X<!$-?-3[B[S22/+@Z;
MNR13-B'8X<8!PX15?HO!I.@\S:6MM'"8+"AMVM=F$/(=$,H#CAS;G1T=497%
MNPJ@CL38UB2%2CZ;$MVQ"P296(F?.(SJJNJLO64#13IXO&J-JZJN<S%(R0IM
M1$.J*7@7A6_4+V3%\CB>5CA7E=UB!6KOPC6IX5CV^Z>[=H,EO9Q-B`B&7E%E
M("3",CG%A$)),32VD?X(%!2^C3:N(P!C0Z)CU::D['7E#N'YU8J=FB22<M)M
MUCNQ5.XD4YEV5;K!.0Y7!P$O`>&K7C,_+Y1I(T-=@,6MI0;-@H*4X@L[YFTO
M^[DPM)M9WS0DEQ,<L@>)'@YJU>))`ZM00]PI0JDFJ319=TY=3\!"O%YQ:(;R
M!'_XC>PN893MN"0E6`KI,;`YC#M^FV*X27.F5/@7\4@`%45U=1M#87N`96E/
MP0[!U#M:#PT(5J]T30KR5TM_;P/DG,8?FV2F,YH@]E0V5S*58'M<0!A@,+6P
MQ'C6*;,6L?3XUFVBD&3>/33<2@E9-HV=C[-&H)'4?G.5".GHAJY0()A*B9LD
M4@`FF4@5OU"]D<7/D<7.)KLQ):6G@X6D@\=3PFJQ;?='=JUCCBM[.-D436A@
M!?R6LE9,P`EYP9+&Q[0<&EC0*-:`+U6JI4*PSDU*=$1<4SGW#R<=#$',=@]=
MR`KO%GC4I5UFC=NZ<.5%@3;`FW%14YREZ1S"-N>XN9W-%RYSG,`:*[0!A0\.
M%*8XT`'`LW3-*TC3(97:/#%%#<.=*[FS5KG/JXN;B6@.+BZC*,JXN`JXD_UG
M?T:W_@C[%/\`-G,/^\;F'7TRSN&_BC[R_%FY_P`5+^E?_:*S/OVW0[C=LNX7
M:Y:,9(*9!P*O/Q5.W+81A*O#S-^F(W-UJ;8:PYDND2Q40LD62D9TL=>9S")#
M*LW$5+JJ'*0[<##4K"Y35#F3[U'C;"D3D#<U0:9,V1WSSHW(=Q)CG&)J@TD^
M7GD*OUG!4@UCW\4#A.JLVSAP:813=D>S#54.BZ05`BH$75^?WF;DIGE@8>W!
M4_%$=7M\VXG;E4;5C3!$Q7KA*L&>;[)BOZ0)6(>U*-;25[)6J\@S=N%$5DC.
M&A`11>J)&,HJ4BP5&<\?&MGMNRV+HV(E[;3=WN/-K-T4N!<E14/*8RF-S&X)
M?;0M1Y2FK5E\I.67%63VJS:=2"09]7VHZ3+^W(E36(L"6#G@S5=W*VM^I4$%
ML#$HS;'-2Q9(V&LPMLC\YEYC=YV0!D'+=O>0*;G#U3D1J/;AV+T9%!NU=L#&
M.1RY.4A%N[DCF;Y"IN0+10JUM`G[K)X^V<80W@9!AT\UT",NL(QSC+94JD+B
M>NUUK'3L#?,A1=TQH$?PC9LS.3[>`6"KA<K=L\(J>C<W&AY!RW@_&=<Q18WD
M;FN!P0\C;>$I),B-9?<'A;<EFZJN&%7GZ;!661H-2A=M,C&6:9=(1KF&F))!
MNHP$4'8I$57R_.;7C#>S59:PW&JP&V]V5]MDBZ?&V[+M9L:%\G-UF'8S+V-:
M=`22D14.V;^NT=.&/<A!!RLY5:B=N=3I&(D1:0<ROF+;M]MN3.9#7,06EFSK
M^W/:QL3RQCJ1=06+7K+'5NSSN"R+CG(,A8VEG:%G;A&35:JC1)FU+VUV@X5.
MKP+UB/1(ML\I<X&M8NF]W,`3!-SLP[4L5[Q,@]L+69G$R=X6V35#`-KR"VFX
MY.LO"T"$R*AN`8IU"74%ZA+]S7:ID6Z9FX*$5WH_-PK=T=8F53PG--:OD[>A
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MM<_DW:_)2%48Y3VLOJU<'^-;7AVV5-@QAK>Y1QS?JX]BE9Z49E[L.^+A`P-5
MFR92+G]M4YOZNX/F$/L5IWJN*X#S(P?.-HL`="FP`Y(ID,BSK5[N$C/2KAO:
M:QF#"^7\96N&GZ!(+'L,G&W&NOVT4Q0CY)98BG.\/>;O&P#NIS/0Z1*Q5CPQ
MDG;YE^MX0F1H<)+_`%9]UF&,&0&X9Y8LF2S,&JDICB[8>EYN48-YCIE-,U8C
M%,XDD`*4BM^R'G!2V6;1LDVVY-HGA%E_/N%]L-EM66V]MK<''2UGS9L)M^\N
M:L\=CB,K+7M2`9R5!?0`(-G`IHJN45"G-U:B6B+!^X+G=Y:>[%&.;\98;A<`
MW_-V`<YYYP#;[AE"JW^O-:IM]N.'Z;;`E8YY1(^)EKW/6+)YDXVN`(G<0C!W
M('=-E4P;%(MK)OG5T*%>Y#CW6$[%'#7;]7,?U::LEP95VIHOK'OEO.PMK*YQ
ML3BNN4,#0WTBT1:P)K.DY4%JPZ17#HK@H@4BHMO_`#+<KS_,AR#L_P`LTN*+
M6\@6.AQF*4H:W4^4D,)S[387B3=+D>BSS^N1':F4X=].VV33:6!N_P"B0Y$B
M)(J-3@JF19:9;DLRY4WQ;Y]NK_,43M;J^UZA[>5L*I257H\F[S(OFNF3=FG<
MV6!QD!JX4L..ZW;F0U)I&5]>+.E(Q;X7CPRR[9)L1:NGYK&3:=N$YD&WN[1B
M$XEA]KO2OF`;]7I"H1DM3*UM4VK[0<K2E$G:L^K+IE-/W=DW$N7L?-/EGA1%
M$6CMH9%,JAB*[8\YIMY@[UE=Q?0&[T5Y0^3=&XGAW1*M3STZ]\P\MWK=KN&4
M+Y!P3IC&U%I+LXZ0<K=H+H-E$3-V:(`Y3(4BQ3MJYUV4$=J;?)N9L.!F20P]
ML*K>]K<5E2CW&MU=92$NE\W146NU^J8OC:FY;/W[>>V])(R#LCUFQ:1LB>0.
M`"U%LX(MFLU<XP,&CMJ\)]N)W9,^UF;N,DI&YQI<@C5JM#[O=O>TUG8*T_@H
M*>A<A1]L7W%Q-IBB@\BEQB4%&[Q-F]Z229%2\W?>OGW:'=]MS+##^ZNHF_XE
MWU7"Y4[&M#QS?LA3LE@/!$;D&@2U<B;^B(.(ZKV%T9Y-M&)E'CV'36*@BHN5
M,HD5=@SFPS-X2L&/#8QK><\D89V<8PSUE/)&$\G4J`Q9DV^WG;A%9NA@P?%Y
M%DX>:D\.Y+F%7,%!V95=5%E+IG;2*3<B)W&B*=XFYLU6S'E_;)ARGX4M+J=W
M!XI=9?EG,E96=,<8]K3#,%WPE8&):SDR#HMGM]JQS=:.H2W0[=LVDX--XW,D
M@^`_'1%@JI\\B!R17)=WB_;TE=K63=5MDVM56&9YWIY:I:9C=/1I:V4BUH9"
MBZS/0P1$#)PZ\=(F9(R+18J1W4>[>D`J9B*/;@^;3EL80\CA?'M5I;O$W,0P
M[M'R?'VC)54F)>URR&1)^GYGQM-UMU4E;%B^&GXV.;R=5MY&KX):%>-WR2*)
MSBT$BSON[W\WP.4CC3?WM_>AB6SY?C]C%YKC2QLZS<O!NN;F,UX+JUGK,FG*
ML5X*7>LZ=DM\V3=)II]%VFFX(``7H"116"YRI9N[[M,?QFV&SV*<VQQ&9Y:#
M8U3*%:G;#EQ'!V[N>VC65M&5]S78`\-/34["EF(J-05E'TDFMV@W2.^%LDY(
MH9D/FUVE\_N3RGP->@L6Q6,>4KEFIVVO6#MK(=B:<P?<^XQ5,L!K>2\?QL:E
M582%B!9.#KLF4NB5PHH0&SU1%-F16?)W.YF<"4/.>0<FX&KEACL>[M.8%M[J
MD?4<I&@5SPFQW!EWS,T=VIY8ZBZ;H6O+#?'3MJT;H`!&QY%N8I5B)F%0BR-E
M;F^RN&<O;BZC9<-04]5,=9#V-X@Q1W,R(A7I>P7?>#BZR9);RN3;#8H8M3H5
M-:.8M.#8/A.LBM+=2B<X=N=)J1;V[I<_Y/I&U!Y=<+5%`NYG*-"%C@'&-K9.
M[>),OS])?6:,BK-&XX&RN9Z,HZ#)R]F#Q1W34S:/5,5?J3`MHBYZM.>?C9_"
M[,IF%Q&\GF>[;%N%+B=P>^Q]=>8^O>1-W^$-F>1\524"]K\@YD[;A?(N8%UY
M5%)<JABP+IN)4C&36T13JV\URR*7:L8\IV&8JMV@>9%BO9%=&F3;9*-P2H60
MV^6IJ&S+5)"!J[FKV"/OT'BL1@NT9.1;IN7YVCTZ,@Q<LBD6,+;SRV>/L,UG
M/-[VV,8.BW[+F8<8X\9-]Q%-D+M<&>`MP3K;]E2T-*@I4(^0;-X:623DT""*
MC4&:A2/W<<JJU!R12C'',#RNKN=D<47NR%DZ\\YK>Z7:?5TX:.HD(W8XJQ)L
M"8;EH&NVYU(Q2CUV2/L_;RXR;5RQD>L*V3<JJ,P7`Q%LCL0YHV&=[<=:5"!5
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MM7KY'2<(>9R$MBJIUVW[BL<N*[4*4UJM>O\`3:19(^>:BFHTBI@S\6C8C843
M"!%G&.YG5KL4ELRKM2VUL)FQ;Q&VX.?@A7W"4-O4:]0MOAJ-,2E_C[C$0-B8
M6J#N5#NI)6,0.E&/D%TBLWR+0QU5FY%B2J<V.4RE;-O"T!C:TT&0N]8W[>&&
M&++)0Z;R/O>U+%F*L@LJM>9E]15)9(72=](HQDJFXD85\R=)/D7$FT7;B4BR
MOLZYD>0=P4UM0Q]?,%Q<!;=S^RO#.\FLWVFW*7G,82U;M$<)<XUZ/67I0+0=
MEPA8)ZJME8YZ]4&1+;&HI.`%LOQ(H_N.YK)\97S=-A6DXE?GO>%L?[ESU&XV
M>3/W!>9&P%M"QSNR-+6NI-(PDI&X<F(3*D?$,YXCTPO9UDX9`BD"B+@Q%O;L
MDL>2[OM+V^Y#R_>TLBY"R=BFDY1L-C;P,!7&:;C(]?C[HE`1T?6H^*BE8NKH
M398YJY!NDN[;MB++@*QSB)%GTOY[+_YK-?\`*SS4\"CA]Q2G4*4T1-$31$T1
M4,I_BR1_P%W_`!=34C:H.Q4E=_-^"_D:,_B2&H0;`KSHI31$T1-$31%Q.??\
MQM6?YDZ]?[]6.]$6D?+Q_P!B#;1_J]6_TKLNO2=*_=L'Z,+=0?F6?BK<K6>K
MJXX6'>OGRJ[C,ATYA)5J\URN\RK!>S>$Q.%6B&UDD\4YBP#6\DV:YQ5@ARH3
MWA'B>;E7,HY=.2N8\T$T62<IE4`C@NI=>3MN',%'-%PV,-ICE<T$FNVK=O%3
M:L<R.#R.`/`IU"%[2/-UB(#$N&,S6C;G8H.I9\H-QR1C<GTN4J1D)&M4B\X>
MQ[*FD$VT,1"-D7<_E@3-6QCF54;19U#@GVP0J8ZH&Q,F=&0Q[21RAL!:/ON^
MXIY_`.(P(J,>MVUNKC_<_+Y!W,90V^L\*7.)@\5.KS'3N7)*3;FKJLE3EZ"W
MC&X1C:*41;ER%X<*N(,O=%1RHSAGRCE%N8I$C9D=R9+ET`80UM:NX,*??KAC
MP%5A]7EE#0<*VSUE*XOYVN<<BDXWL<N-NX2360<8SWF(+HK$*HBLBM"XS352
M53,!BJ)*)F$IBB`@(#P'7D7KA)&[S2,")&_VVKW/[-S&2>N"QCD`=&ZRO00<
M008'`@CA!&!'"N=#>EW.'J&3"UF)<5RV3V99>8@G\*>K-I<U#G+S67DBLS=N
M#NH]HDM66KLP-E^BJ0Y2@5,%.AKY[==6TMS!S[@^W9;`.#LQ'.-8X"H%">41
MB,.K1?=,>BZS9Z1J8TR%UMJT^LR21/C,`D\5EN87/+7$EC086R'([E`@4;FH
MK;(QN>%;BZ8,W-O;TD)Z*9EDR3U*4D%Z_'3CQ%W)-G)A0>(*3-:604.0K-%<
MCD@@(G4+UA[C'Z2+8.<(S=9":97TS%HH",1@ZO"13B&"Q;FUW\=K#X(77C=$
MY]C<XEMB\Q,E<'/!P<#)"6D@1M<'@@YG#,?%0NXQNA5G1V<C,I!6:*G>XIK+
M5>&GR2+9M74;P6HOAE%*_)2TFX,]6(HMW.[6.@J1-=5-RWZ@/F9QD;5K3GDY
MLD.+:$NR9Q3,`.2,,U:@D`@UH</6-'':RN9),WQ:U%U&V2".4/#81<^+NSF)
M\CSSC@7<SD+7ALCFR1\W[341EMFVF9QS+V=<D-<8I[&IRKZB/&D=1HK%)NZ]
M@33;QZ/5SZ=[,X%51("KFX_M"7:X\!B*33W.;$&L!=&0:"0$O,N#<3W/-TVX
M<9JJ[VSWMABFOI)KIS8;R-S`]UJYK+5EC^4E`#!2476<N+:./X#>;./ECF.R
MM).<9VJ;FK;-U=\P6F'24E+0"4FU\)L1UD5EY=E&F9,9*'+>R/S1R/07<,BN
M`Z102$.KF\?I[&SV\38VS@T%`ZARS.[DFI#N;RYC@'4X]M.[MOO7<R:9JM[/
M=SZ7)&9"'R1![>>L(:F1K"UKX_&N=,+:.?&'X@-(RW?&L5FUEX((7`Y6+.+8
MM&\^U35KPPSJO!BZ/9BP180_8:6]AE)!=8ZS<I69HX_1(82"1,EN]DTMW.&V
MQ<XDM/*S!W.DUJ=K#%04..;;CB<S=JUWWA\3CU@B.&*,"5H,7-NB\18W(&1]
MS<,O@YQ<P",PFC3EHUO]FG]&M_X(^Q3_`#9S#_O&YAU]#L[AOXH^\OR+N?\`
M%2_I7_VBNW)X2&4E"SBD1&*316(1A9@[!J:4+&@Z(^"/+(&2%V#$'J15NJZ?
M5]:4#\.D`#JI6%$@Q/BPJC18N-,?E68.G+YBJ%-KH*,GKU9-R\>-#A&])NZ=
MN$BJ*J$$#J'*!C"(@`Z(I<\AH>0>QTB_B8U](1`O!B7[QBU<O8L9!OVH_&.=
M+)'79"^:_M2W5&+UJ?XIN(=C1%$V^*<7,SLE6F-J"U4C5DW$<HWIU=0/'N$9
M)29179'2CBF:K)2ZQW13)]$Q7)A5`>F(FT1>SO&.-7_A%V]CVCO?"\BB=L[;
MJ<`Y\*$U5D'"I+%UT>?NV11PU2.8'/6@)TRF'LE`0(KD\I5.D5)!60J59?*R
MT4U@I55Y`Q3I23A&*IEV4/('7:G,]BF:YS'2;J"9%,XB)2@(Z(O0*A4RO&$B
M%7KH2$5$*5^+?A"QH/(V`6*4JT(P=`VZ]G$*E(`&;)F*B8`#B7L:(HPMAO$Z
MS5@R^C>DH,XRQU2W,6C*M1,>V0LU$=IOZ7-]2Q:MTU)"JO42+1YS@86JA"F3
MZ(E#@17B5QWC^=<2CR<HU.F7<X@S:S3J5K,+(N)=M'J$68-Y1=VR65D$&*R9
M3(D5$Y4C%`2@`@&B*O\``^I=L2[SP6KG;=@BT82>==Q(SMB;A6S<[1O$2Z_:
MO6R46@U5,D1NL)TBIF$H%`!$-$5`PQWCZ*[F!%T6G1H0CUS)0P,*Q",^Y$B]
M3;HO'\9VNQ3[0>NTFB1554N@HH5,@&$0*'`BJ24>E)K1[A.GU9-Q$S$E88I<
ME?B2K1L_,J*K3$Y'JE:`=G,2RJYS.7*8E67,<PG,81'1%^PE(I=9>.I"MU&L
M5]^]2,@\?0D!%13QV@=XXD3HNG+!H@LND>0=*KB4YA`5E#G_`+(PB)%XN:!1
M'LFYFWE*J3N9>NXM^\EW-;AEY-V_@S]9"O7+]5D=TN[AU/QFJACB=N/93$HZ
M(K9#XHQE7KG(9$@*#482]2T6[A92UQ$!&QLW)1DA)H34@U?/F;=%9T5_+-4G
M"YCB8ZRJ*9CB;H%X$5:SQQCR/?\`=5A0Z8QE/"![;>Z3.KP;9_X523-2/D;-
MVXBQ(X\('[!8Z"SWI=LJHG$ACB41#1%=5:M6%^[8+5R!6"R\/",%8B/4[O\`
M19#&E[M]-N/=7A'#VN'7]9^T_B?V/8T16IGCC'D>^BY1A0Z8QDX-DWCH619U
M>#;/HB/:)OD6C"+=HL2.(]DU1E')$TDC$(0KA4```4/Q(OQSC?'CR)B8%Y0J
M6[@H!95S!0KFK0:\3"N%R.$UUXF.58F9QJRR;M4ISHD(8P*G`1X&'B15#NAT
M9^VLK-]3*F]:7/JO#!J[KL.Y;6OJ$BH(>$J"S,Z4[U*!0(3MH%>B0``.QHB_
M4*)1VLTG9&U-JC>Q(F*9*>0KT0C-)&+&DABF3E$V97Q#%B$BM0$%`X-B@E_8
M`!=$6GD3O.V8Y.R'C9F26AYY_9\O9%P-A++$YC]\I0[=F_&)9Y?(6-<892DX
M8T0YL\4O19A(@MG"365=P3U%BNZ6:*$*13?.69=HN`J19,T9/7QNE%JS<-29
M)_!UF(N-NM=LRK98W&D'2F4378^4L-DG[Y:%&\0#0"*"X43$JW!)!0R9%E&*
M-@VP5EV_[B4-C$3D+2X^RPMEKD+7Y%JQ78,W=*JE\K$\Q924)(1S9ZD1K$2C
M=%PS4'JRHD.'1T10-WE_;!3\PXHP(W/2D<D[A:+>G>/X:LUAE(L;-0\814/8
M;(TE)F!CW$3&0*$5=D7+%!^JBWD"N51:@J)5>!%!<\9PVJ8`N^%\-Y`QRI*W
M/(-+R;+88I=)P>]ORJM0P8RK-GR"R@&]=KK]G!(U=K+Q;E%@`H*.U3I%:)++
M$`I2+8QE9<071%E?DY&B2ZE4BR3"-BD#0:DK2H^::J'46>.WW_>%1%VW;J$7
M*J+8W[2<APXD,`$6(8;*.U!7,R^!H%OC[Z0F^W8^4C$BZ?&A5S[?G6096FO4
MDKLTB_!-2`3O;-R#F(!YQ(H)ESH=$PGT19B(;#B#ZAJIFQFC),6(EQBH0:LF
M^9QMC1(Q$*&<O!PW8SK=(J/_`'?P3=$*!/Q@#AHBQ/'7S:ZQW!MMK$/"TAOF
M8N-W&X)*K1%$8E9LJI1+=!TL+"YFV$/W$C+)7[!D)F#5JLNE)$1D170(*1E3
M@19S?8\Q_)NY1_)4:G2#Z;>Q<G-/7U9A7;N7D8-J=C"2$HY79*+/WL.Q4,BU
M55,=1ND82)B4HB&B*J=4FFO8!I5'M2K#NK1X,RL*TZ@8IQ`,BQQBFCRM(95H
M>.;`Q,4!1`B9>J$`Z/#1%;2XPQJ09(2X\HQ1F4'#:7$M2@`&5;.WY95TWDA"
M/`7R#F4(#E0BO2*=P`*"`G#CHBKGM#H\B<JDA3*H_4(QB8PIWM=B'1RQL`^&
M3@H\IEV9Q!C"R1A<-$O^S;+CUB8%-V=$7E)8\H$R@\:R]&I\JUD9E2QR#:2K
M,*^0?6%6.[D*SSQ%TR53=3*D3_<IG1P,N+?]K$W0_%T1?4CC^AS#:49R])J,
MJTG&,/%S361K<,^;3$97ESNH".E$'+)5*08P;E0RC-%4#IMCF$R8%$1'1%?'
M<-#OW48^?1,:\>PBBZT,\=L6KAU$K.FQV;E6,<+)'68*.&:ADE#)"03IF$H\
M2CPT118,78R*G&I%QU1`2AGCN0ATPJ-?!.*?OWS.3?OHT@1_18O'LE'MW"RJ
M0$.HN@FH81,0H@17,E(I:::B)*A5R)+3Z%L52)`1)4U;2V<D>MK*H0&@%//M
MWB952/!`7!%2@8#@8`'1%0.L98W>L6<8]Q]2'<;'*RB\?'NJG`N&+%><4%:;
M69M%6!T&RLPJ(F=&(4HN##Q4Z0Z(J\M(I9'H21*A5RR)9EY8BR!8")*]"P2+
M((V0G0=`T!<)E]'%!NLZZ77JH!T#&$O8T11]/#V*4'5:>M,<TI@XI\ZE9ZP>
M.K<3&EA;$WK<C3VLTR28M6Z2<DSJTLY8(JB43(M5C)DZ(<.!%='^-\>2LE*S
M,I0J7)3$Z6&)-RS^K0;R2F"5URD]KY)5\X8J.I`L$\0(JS!8YP:JD*9/HF`!
MT17:>JU8M23%"T5R!LB$7(H3$8C/1$?,)1TLU*J1K*,4Y%NX(TD6Q%C@FNF!
M52`<P`8.(Z(J-:B4=Q-*V1Q3:JO85Q4,O/+5Z(5FEC*QHPJIE90[,SY058<P
MM#"*@])L/5#^)^+HBN#*MUZ-91\;'0,+'QT0Q5C(I@RBV+5E&1JY$TUX^/:H
M()H,F*R:)"G23*5,P$`!#L!HBMT=1*/#HP+>(IM4BT*JT?L*NA'5Z(8HUMC*
ME`DHR@4VS-(D.TDB``.$VX)D6`.!P'1%],*-28HT0>,I]6CC5\LF6!,PK\2S
M-"%F@*69+$"W:)C&EEBE`'((]#KP`.GTM$44JF&:+2[M.7NO-)1G)3$!$5AG
M"GG99>F4^"BB(%5CL>TI5V:LT)M/JL6JTJ2*;-2R;ADW6<`=1(IM$4S>5&IR
M#V2DG]8KKZ1F88:[,2#R%C7+V5KYCG4-!23I9L==]#&.H8PM53'0$3"/1[.B
M*[L6#&+9-(V,9M8Z.8-D6;%@Q;HM&3)HV3*BW:M&K<B:#9L@D0"D(0I2E*``
M```:(K`7\]E_\UFO^5GFIX%'#[BE.H4IHB:(FB)HBH93_%DC_@+O^+J:D;5!
MV*DKOYOP7\C1G\20U"#8%>=%*:(FB)HB:(N)S[_F-JS_`#)UZ_WZL=Z(M&>7
M\[1C]B>W60<=;VM'XQD'[GJ$5'"P-V=DM+E<46Z)3K+J@DD(E(0!,8>P`"(Z
M](TLTTV$_P#TPMU!^8;^*I90]ZVVG)D(TGJ1D)Y-H25'I&3X:,)1[\ULU@QI
MD6VDHE0R'6JJ\K*%@L5,?VXXL7$@R;KHQJI#B]%N4HFU>9>6\@S,=7D@[#4@
MF@(%*D5PJ-G"JA(PBH/^Q6?D*K0HB:F+&TK-$C+&H=<+#96<'6&,ZJH_210<
M&G)]NT2D55'[?JR'%PL(K)]`H](O1#5_*P$N`;FX3A7LJK`8X55`^H.+G$=&
MP4K1,:+P]5#_`+F@I.I4]6)JQ983?XJB'D<9C7RRADQ_[!)$'!B\?QA#L"R,
MC*6MRCJ##M)1O$%B*I;5MO=,SE:=QM:JD:TS);E;9(V*W)OF7=%X6V=RV-G.
M_<-44)*2C#&A&Z2:$@X=M(TZ?!L1`WX+++:!DQN&@<Z:U/7V_P"QV*D,8'9Q
MW16Q7=".$QB!)1PG)T.F0L@S,<H*B0$A,4%A,4%14*!>/]D)@X<>(<<BH5:_
MGAYR;E%CO3Y=+UR8Q&[+%V]!XY,5-14Y&[6!QJNN<J213JJF(DF(@4H"8PAP
M`!'L:\D]<#2[=]K1W1D:.R]B]Q^SA*R#UNV<\F$;+&]<<"<&V[B<!B<!L&)X
M%JA3[Q6[XP<R59=N739HJP27!Y&R,2X($K"1=DBUNU)-LU<BVDH*::ND5`+T
M3IK!^J!@#YHN;6>T>&3@!QKL(.QQ:<02*AS2".,+]'-'US3==@=<Z8]SXF%@
M.9CXS^4C9,PY7AIROBD8]II0AW'4"6ZQUMDT1-$31%\J?]DK_:5O_AFT&WW5
M#NY/6/WE_5+_`$:W_@C[%/\`-G,/^\;F'7U"SN&_BC[R_$6Y_P`5+^E?_:*[
MF:J5A-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%R+QURFJ=
M0HO;)BT<J2DMMTV@;O<C[SL)8W&KHLK>CD.Z2^6[)5JE<<BEGG!9^B8OLV:Y
MMY'$0BF4@_*G'HO7*I6BYGY%&Y'E'INI+<'W.S3682HY\WG[9=\2U&8X+CAB
M:-E3`68*KE2WQ5>>'R`5\ZK.<C4>/++H+CP8S3N7ED"G4EEVQ"*(W'DIUNXQ
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M9`1M2?X];1MD39;J]SU?W2S![7D<EL?.+:ICVS1*T'!@,8T!.`.@B?BHWZ:I
M%U"T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%%B_GLO\`
MYK-?\K/-3P*.'W%*=0I31$T1-$31%0RG^+)'_`7?\74U(VJ#L5)7?S?@OY&C
M/XDAJ$&P*\Z*4T1-$31$T1<3GW_,;5G^9.O7^_5CO1%P)VK\PRNXWVCXTQBY
MVB\PVVO:K0;/5UKSCK9QD"^8NF5"35J2-/U>Z0SY./LU7`%^F#MN8I%"D-P$
M.'$.XL-0;'811<U<$B,"HC<6]<'A"VD4P$36Y7X-XC1<FH[->UX,0X`K4XKO
M;>3]#VAX7Q!@:VQ&QVT1=8L^&*ANYQ=EJQY?0:J95>2%P#).0:S"5!D[8/"P
MT8N\(D0[MVZ*GK7B>UYIC7<]5L36M(B-"T2!Q=MQJ0&X8#JDJR'1Y0#FJ&@#
MDG96M?=V+83*VZ3![]]N!MKND[]JW6IO=/1\VW>@Y#V*WNQX?B9>!G<OL+UB
M?+997(\1:6U?R2SM[PBT*:8;LHBRP9Y".;-NFLR1R);J`F1Y;.&F4.(,3BW`
MNJUV-:&NRN!%138JW2,Q-'TS5[DTZQZZL%NW%[/I.3W**WVG\P]M0KYC/,<%
M)PQ]G5JAY#'B.=%MNYZ'8+7.R>07!>X&`[%CZO'QX58$#-2SR*0KF,JF9U2Z
MYM"9,XN.;<UP_-G#-DH2:_@D#+UU!?'CF#Z$'@XZ?>X%E#'FZ["51W#Y!NC_
M`!MS%,@W.P8'4JTK79W8[DEI>ZO?(;'5FQ]F3(P15?R8QKP42^2CM_8IZ*?0
M*QHR<2741=(CTC$NQW<+)W/+;ASRRE#$ZH-"''`TH<213`\*J$C0\FCR:>]/
MNK%VW'>!L<J]EV:(8FP;O6L<UMTPMX(YALF,=HPN$-ST<]0QE%5V4N]18VZP
M3RCF.S/6:=.M959=<P.W:,>1PIVV!3VK>\LFNAYIDQ,;*.(C[O92HK7N@TU]
MSA4,DB!;E#L!C0;?]C16KFC[T*YEW=#LJM/U:M[="C*1CK=7$3$%E?;5;L;W
M&SMKE"4=LJ^H,%,/2OK1'U]!@H>7<MA`L815$Z@ATPUQWK*S:IH[(8J0/$C2
M#/\`DFU#VD"KL"<*4X30+U_U(Z[:Z'ZQK?4KRUU"ZM197;'1VD#YYRV2!S2Y
ML;.5E:"2]P[AO*.Q:NT'<WC"":2"5&P1NT>M'"=7!\9OAFRSI$TXZEU^*K'%
M7NJY[7*M2V<<HD/$.V4#)N/QNMZ9O#+O0-0E<#=7>G!PS4_+L;M>XNXOPRZO
M$:C@HOM;0/6GNG812-T/0M[WQ.$&:FEW,M`RWB9!C5U*VS8BWW[2V3'-F,^^
MMQ$_9[W>?=[LGOS6)Z-S>6:;\I8M_P#7#I_\/;X_0URGUN(G[/>[S[O=D]^:
M>C<WEFF_*6)]<.G_`,/;X_0URGUN(G[/>[S[O=D]^:>C<WEFF_*6)]<.G_P]
MOC]#7*?6XB?L][O/N]V3WYIZ-S>6:;\I8GUPZ?\`P]OC]#7*^3[N(D4U`^KW
MN[#BDH'$=OED``XD,'$1[<[`!Q[(Z#=N:O\`C--^4L4.]<.GY3__`*]OCL/_
M`/9KGB7]"/(MYIE=V^\J7:-A]_L3YH^6G=,@<F-ULA8`V*Y2R]B&QC*YOR9/
ME6IN1JT92#LK=@25!HZ.@(@@_070-^.D;7O[<&`=0?>7Y03G-<2.H161QH=H
MJX[1P'C76GTV-1]6;SJ?T9F;_P!C52M)Z;&H^K-YU/Z,S-_[&B)Z;&H^K-YU
M/Z,S-_[&B)Z;&H^K-YU/Z,S-_P"QHB>FQJ/JS>=3^C,S?^QHB>FQJ/JS>=3^
MC,S?^QHB>FQJ/JS>=3^C,S?^QHB>FQJ/JS>=3^C,S?\`L:(GIL:CZLWG4_HS
M,W_L:(GIL:CZLWG4_HS,W_L:(GIL:CZLWG4_HS,W_L:(GIL:CZLWG4_HS,W_
M`+&B)Z;&H^K-YU/Z,S-_[&B)Z;&H^K-YU/Z,S-_[&B)Z;&H^K-YU/Z,S-_[&
MB)Z;&H^K-YU/Z,S-_P"QHB>FQJ/JS>=3^C,S?^QHB>FQJ/JS>=3^C,S?^QHB
M>FQJ/JS>=3^C,S?^QHB>FQJ/JS>=3^C,S?\`L:(GIL:CZLWG4_HS,W_L:(GI
ML:CZLWG4_HS,W_L:(GIL:CZLWG4_HS,W_L:(GIL:CZLWG4_HS,W_`+&B)Z;&
MH^K-YU/Z,S-_[&B)Z;&H^K-YU/Z,S-_[&B)Z;&H^K-YU/Z,S-_[&B)Z;&H^K
M-YU/Z,S-_P"QHB>FQJ/JS>=3^C,S?^QHB>FQJ/JS>=3^C,S?^QHB>FQJ/JS>
M=3^C,S?^QHB>FQJ/JS>=3^C,S?\`L:(GIL:CZLWG4_HS,W_L:(GIL:CZLWG4
M_HS,W_L:(GIL:CZLWG4_HS,W_L:(GIL:CZLWG4_HS,W_`+&B)Z;&H^K-YU/Z
M,S-_[&B)Z;&H^K-YU/Z,S-_[&B)Z;&H^K-YU/Z,S-_[&B)Z;&H^K-YU/Z,S-
M_P"QHB>FQJ/JS>=3^C,S?^QHB>FQJ/JS>=3^C,S?^QHB>FQJ/JS>=3^C,S?^
MQHB>FQJ/JS>=3^C,S?\`L:(GIL:CZLWG4_HS,W_L:(GIL:CZLWG4_HS,W_L:
M(GIL:CZLWG4_HS,W_L:(GIL:CZLWG4_HS,W_`+&B)Z;&H^K-YU/Z,S-_[&B)
MZ;&H^K-YU/Z,S-_[&B)Z;&H^K-YU/Z,S-_[&B*PEYU%/"T*O/1J\Z/IF@6[;
MM4.6AFOM@"ED'2O;!DNEUH(F$_1`W1Z(F`0X\0X:G@4<*OWIL:CZLWG4_HS,
MW_L:A2GIL:CZLWG4_HS,W_L:(GIL:CZLWG4_HS,W_L:(GIL:CZLWG4_HS,W_
M`+&B)Z;&H^K-YU/Z,S-_[&B*E?<ZZH*LGB9N6ASITRJ-7!#*&Y9N;@*F!TCE
M$YA,)2@4H#Q'B(!_TZD;4.Q4\-SK*@WAXI`.6CSI5@0C6*(+(\L_-JB2H)M4
MB`HDH03$.FH!>)1`1`0'L#J%`V*Y>FQJ/JS>=3^C,S?^QHI3TV-1]6;SJ?T9
MF;_V-$3TV-1]6;SJ?T9F;_V-$3TV-1]6;SJ?T9F;_P!C1$]-C4?5F\ZG]&9F
M_P#8T1<L'/--KJG.VA=P8;$N:01@RY6%GPV;$JFQ7*1,_N7DGNVJ-V)D5EB`
:3>$SG#S)")-&N;(4O:"$TX09&'K5BAHB_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>v371611_tpg69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v371611_tpg69.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!E0)R`P$1``(1`0,1`?_$`2(``0`"`@,``P$`````
M```````%!@@*`P0'`0()"P$!`0``!P$!`0````````````$"`P0%!@<("0H+
M$```!0,!``@,#@H*#0D%`PT"`P0%!@`!!P@1$A,55=465B'3%%24U)66UA>7
M6#'1DI,T='6U-E<8F`D905$BTE.S-7;7V6$R(S-SH[0*.MIQH5)B8R0E)W<X
MN#D:@9%"9":V-WC8L:*R0[=R1&;!X46%I4;&1X<H2"E)$0`!`@,$`@@0!P@/
M!0@`!`<!``(1`P0A$@4&,1-!42*3TQ15!V&!D=$RDM)35)05E196%PCP<5(C
MU!@90K(S-775-@FAL7)#<[,D-'2TM78W5SABPN(EEL'Q8T3DY=;7HF3$)H*#
MHX1%92?_V@`,`P$``A$#$0`_`/T"T)Z0_H[YEI2T@I\@X#TJR/-V0-.6.9R[
M-\JCL$6Y0FA[E'^JG66J&EQ,O)GVZU4E4F'++$F6&(HT5Q?<#O;MG#,/PF90
M4XFR9!J'26FT-O&RTPTGXUUU7UF(LJYQ9,FB2V:X6%T!;HVEFDY?1U_1YLK>
MXNSSHYTQM#4T(SW!V='/%\20-S6WI21J%2YR6JDI29"C3)RQ&&&FB"```W%>
M]K6O>MQ.$X2T%SJ>0`-.Y"T0Q'$"0!.FDG_:*XW#Z/'Z.UH:E;\[:/M+K4Q-
MZ!4Z.#VYXTAZ!G0-:).)6M<USFK3DHDC<C2`$:<>8,)110;B$*P;7O4.$X2U
MMYU/(#0(QNM@@Q'$2;HG32[]T5T8WH#^C:F;(DDT-TH:39?&UX3!H9%%8#!9
M$PK0DG#3'72O#.!:W*-P4EB+'M#+W`8&X1;`K7M1F%81,;?ET\AS#LAK2.J%
M78AB3#=?.G!VT7."G;_1M:`[;.SHJTWVVH+#%LXEC/W(!>@._P#B/0!?[%_0
MJ^2,*\&D]H.LL/E+$._S>V/77S]6UH#\RK3?T0;I;_-+&>B7_=^P?VG0]'T*
MODC"_!I/:#K)Y2Q#O\WMCUU&!^CT^CK&]*XX'1]I@%(4#.@D*UCMC")W=4C"
MZK7!M;'E2AZDZH);'!P:E1!)X@V+,-3F!#>]P"M;#Y*PF]<XO(O0C"Z-&W^P
M5B\H8C"]KIMV,(WCI^!4:AT&_1HNDE=X8UZ6-(SE,H\E1+9!$6^#P%;*6)$X
MA`)O5O4>2V-=VI,N"8&Y)AY)83+##<-[V$'9@PO!R\RQ(IS,&D76Q'QC2$-?
MB0:'F;.N'0;SH'IJQ_5N:`=BXOD5Z;MJ$6T$+Q31G8L/^YO?J+8L+]CT:Q>2
M,*\&D]H.LL/E+$._S>V/744A^CY^CF<UCXWMND+2XO7QET+9)(B28SB*A4P/
M)S2V/Q32\$%I1&-[B:QO2-8$DVP1W3*BC-C:F!O>#"L()(%/()!@=R+#",#T
MB#TU3B&(@`F=-@=&Z-JD_JW_`*/[S+M-?DHB_:57R1A7@TGM`IY2Q#OTWMCU
MUU5_T<7T?X$#@,&C#3:$8$"X8!!Q3&+"","4X0!AO9'LV$$5K7M?[%Z>2,*\
M&D]H$.)8A#\/-[8K"72]H1T52/31IYD,@TIX&>GY]PABMX>GESQQ'UCD[.SE
M!V18XN3@K.2B.5+5RLX9AI@[W$,8KWO?9O7F*IJZIM3,:V8\-$QP%IT1*]Q8
M1@&!S<)I9LRCIG3'4TLDF6TDDL!))A:2=*]T^KWT)^:!IX\E\:[3K)XY5]]?
MU2MQ]',O^!4N]MZR?5[Z$_-`T\>2^-=ITXY5]]?U2GHYE_P*EWMO63ZO?0GY
MH&GCR7QKM.G'*OOK^J4]',O^!4N]MZR?5[Z$_-`T\>2^-=ITXY5]]?U2GHYE
M_P`"I=[;UD^KWT)^:!IX\E\:[3IQRK[Z_JE/1S+_`(%2[VWK)]7OH3\T#3QY
M+XUVG3CE7WU_5*>CF7_`J7>V]9/J]]"?F@:>/)?&NTZ<<J^^OZI3T<R_X%2[
MVWK)]7OH3\T#3QY+XUVG3CE7WU_5*>CF7_`J7>V]9/J]]"?F@:>/)?&NTZ<<
MJ^^OZI3T<R_X%2[VWK)]7OH3\T#3QY+XUVG3CE7WU_5*>CF7_`J7>V]9/J]]
M"?F@:>/)?&NTZ<<J^^OZI3T<R_X%2[VWK)]7OH3\T#3QY+XUVG3CE7WU_5*>
MCF7_``*EWMO63ZO?0GYH&GCR7QKM.G'*OOK^J4]',O\`@5+O;>LGU>^A/S0-
M/'DOC7:=..5??7]4IZ.9?\"I=[;UD^KWT)^:!IX\E\:[3IQRK[Z_JE/1S+_@
M5+O;>LGU>^A/S0-/'DOC7:=..5??7]4IZ.9?\"I=[;UD^KWT)^:!IX\E\:[3
MIQRK[Z_JE/1S+_@5+O;>LGU>^A/S0-/'DOC7:=..5??7]4IZ.9?\"I=[;UD^
MKWT)^:!IX\E\:[3IQRK[Z_JE/1S+_@5+O;>LGU>^A/S0-/'DOC7:=..5??7]
M4IZ.9?\``J7>V]9/J]]"?F@:>/)?&NTZ<<J^^OZI3T<R_P"!4N]MZR?5[Z$_
M-`T\>2^-=ITXY5]]?U2GHYE_P*EWMO63ZO?0GYH&GCR7QKM.G'*OOK^J4]',
MO^!4N]MZR?5[Z$_-`T\>2^-=ITXY5]]?U2GHYE_P*EWMO63ZO?0GYH&GCR7Q
MKM.G'*OOK^J4]',O^!4N]MZR?5[Z$_-`T\>2^-=ITXY5]]?U2GHYE_P*EWMO
M63ZO?0GYH&GCR7QKM.G'*OOK^J4]',O^!4N]MZR?5[Z$_-`T\>2^-=ITXY5]
M]?U2GHYE_P`"I=[;UD^KWT)^:!IX\E\:[3IQRK[Z_JE/1S+_`(%2[VWK)]7O
MH3\T#3QY+XUVG3CE7WU_5*>CF7_`J7>V]9/J]]"?F@:>/)?&NTZ<<J^^OZI3
MT<R_X%2[VWK)]7OH3\T#3QY+XUVG3CE7WU_5*>CF7_`J7>V]9/J]]"?F@:>/
M)?&NTZ<<J^^OZI3T<R_X%2[VWK)]7OH3\T#3QY+XUVG3CE7WU_5*>CF7_`J7
M>V]9/J]]"?F@:>/)?&NTZ<<J^^OZI3T<R_X%2[VWK+[!^CWT)[8.SI`T\?MK
M?_ROC?V_:E..5??7]4IZ.X!X%2[VWK+%#3WH=T:OD,F"MZTN8-=527/FI5D3
M*'#'K$J.3L\?SWD)D8FLDPU,(1:!G9T!"5,5;[DD@H``VL$-K5Z-R=AN'U66
M:2HJI$J9/?+)+G-!)-YVDG2OFKSPX]CF%<YF,8=AE744]!*JH,ERWN:Q@N-,
M&M!@!$["]R^0)H?\TK3_`.32.]JUR7R+@_@LCM`NM?2[-7*-;OK^NGR!-#_F
ME:?_`":1WM6GD7!_!9':!/2[-7*-;OK^NGR!-#_FE:?_`":1WM6GD7!_!9':
M!/2[-7*-;OK^NO`]5.A_1O&M-.=I!'M+V#F1]9<82IQ:'AKQ\Q(W)L<$R`8T
MZU"K)3!.3*2!]$`PWM<-_0K:L=PK"Y.!UDZ33R6S64LUS2&@$$2W$$'8(-H*
MWK+F:<RU&8*&1/KZM\E]7*#FF:X@@O`((C:#LA9OJ/H[]!@5!X0Z.M.E@V.-
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M/J]]=UTXQ.^4[JKLH_H[]!8UB0`]'.G,01*2`B"+%L:N$01&AM<-[71[%[7M
M>H[-&9+I_E]7H[Z[KJ:^=\IW56N;C+31IY<8F8J7X4QLL4VFV6$=CU,6;S3;
M)6S+4Y:VY-88R[WW%"VHR2"@^@`HH(;="UJ\5\\G.MSG85SHXUAV&9@Q>GP^
M35,#)<NJFM8P:B48-:'0`B2;-DDK[,<PW-=S:XUS-9;Q;&,`PFJQ2HPQCYLV
M;32GS)CR]X+GO<TEQ,!:5?\`Y+>FWXBL7=Z3;TJNL_;/SN^LV.>-SNZ7;7L;
MYI/5G`_$Y/<I\EO3;\16+N])MZ53VS\[OK-CGC<[ND]C?-)ZLX'XG)[E/DMZ
M;?B*Q=WI-O2J>V?G=]9L<\;G=TGL;YI/5G`_$Y/<I\EO3;\16+N])MZ53VS\
M[OK-CGC<[ND]C?-)ZLX'XG)[E/DMZ;?B*Q=WI-O2J>V?G=]9L<\;G=TGL;YI
M/5G`_$Y/<I\EO3;\16+N])MZ53VS\[OK-CGC<[ND]C?-)ZLX'XG)[E/DMZ;?
MB*Q=WI-O2J>V?G=]9L<\;G=TGL;YI/5G`_$Y/<I\EO3;\16+N])MZ53VS\[O
MK-CGC<[ND]C?-)ZLX'XG)[E+:6M-FS;_`#%8N]&W_P"Z3;TJAYY^=V'Z38YX
MW.[I/8US2>K.!^)R>Y7YX^*['',F._Z^/BL_)X/_``TY@?MO@A_U#V/_`'M>
MP/3W._*^(_X/<>_#S/Y[X5I_G'_B]ET5Y#]`\D\DX?\`XP<1_`2_YEX+H_F_
M_A=CT%L0:8M*6:<AX6T39JQPZPMN2MNE+2*K8E$OE3LG94<HQ7!\\-RXF1P9
MAA9TD?1/B#,I29K<VV4,IS*/JA7N9YI)!9GUNH:*IF4]-422T-%/+TDZ6M=I
M`&TZR!$-.Q`_*>KJI,N?/DS`23.F1@-@EN@DP^YM!!CH60#'I!U>HHRG;#<@
M-1+JH9=13"2!SS-.7V,0=@RK!U22'I8PUI8NU.=IJP9`&`\EU,5JD"%E/4)N
MI#SRTJFVK;0UP;`O$8/'9$AH<+(6:0[9T`1$#85IS5TEZ-VR+3V(!,#;&W01
ML:2;8Z5D"_Z<<K2>&ZVH8]*65Q==0,*RA%,<Y$<LHSIT3E,4XB-V&$P5XQ:N
M9SHG`6O&0S32+N37=6H<BQW/&7<P\\%:EU)/<RH8X@F:UP:;QT$0`NP@(:(B
M,=,(DK3BHE-?)>V($MS21`:08DQC$QVCH7E$9T7YXA.48HN:,IN*S&;)E663
MY0>T3\4.F3LZ23(\2GRB<3YL28_51.5O+M$V\^#N2!"F;DYS(W$&%;B:Y+1D
MY+,.J)<X.#R95\FQT"8N!B=S`V180(6?&89SJR2^406C6%H&B(L!$!;$6[H$
MQM/0"X&32=JG*68E3NN4'5%$(/.I>Y*FYBS0]F9"`E<YEBN3QW(,PF[S`W!C
MR3+B&R,2)H6I"FEH2J&MW*MN85"AQ-N;15EYEYY#&N.AYCI:022V#C8X&P1!
M^-#54T'0:+Y:-+1#000!&(%H(M-H^)=V'Z2-33C-Y"^9&R:W1^/+Y^\SUI8H
M%E+*JEB;987CO+D=C$I3L2LUO6*65+-Y)%GLR/N3BX)3SF/;J-TN`LF\%#6N
M>7/F71?O;ESH6!VP=@DML).B.TH^KI@P"6R+KL+0(PBTD1VX`B(`TKLP;1WE
MIMDV,\B+5:*%3>!M>G5B<C&S4%F3(9<D#`LKR&2Y\?G=7(DK40^@R_#I"J`F
M:W%*J2HSUAP`W3C,,.K%)H*AKF37&$UMS[MQC!Y+HZ(WFF`!!ZMJ/JY):Z6+
M6.+CV+1"+0&BSY)&D*1RMI@U"O<ZS0Y8=?&#&,"R/(HW-)7&@9(7."O,,H0S
MG&KA)ES2K-QP6[X$'-\;1!>T2)&0YOC.]K3$1MDR;:*E!MGT=4Z9,,@ADIY!
M(O6N,6QAN=Q%H((B03`PTQPRJF0UC!-!=,:"`8=B(&$;=U`D$6`BVTV*/0:4
M-4265@<2L]S1.0DP(7!(1)%V53WAR@\PMAJ9P50CF3,#'J%/DM"/(;\ADI;P
MF&U+;JD!!A@;F(B@J0HJN_'6.AJX`WM!ND6V;K=$.C8;.A;354Q9"X.SB1#2
M+P-AC99$0MT]&S(/1]A"781CN5R)@TLL?59%RF@GC9'6;)DTR_=D;TN'L48[
M5$.D_GS8U2)X<G!^@2U=M1`$2G(5%E@%?:WM;4T-.^G:\/`!<^]`.+H;EK=+
MK3:TGIK(JY[9SFW23=;")`;'=..@6:#!9=UKEI%TW'\FN7N:X?R,ZBAT%8!Z
M1/\`50TQ_P#E^P[_`/3^/UY)JOYU-_A'??%?0?!?Q-1_T65]XU9#UD+<THB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$7V!^W#_P#:#_[;418::9_@)./_`#(:K?\`:.R;7J/(_P"B=%_!
M'[YR^4W/A_BQCG]+_P!QBR%KE:ZI2B)1%C?K$_U4M1/^B.8^]HZV;,7Z/UW]
M#G?Q;EOV5OTEP_\`IDG[\+]`5/LE1_#F_C!5\M&]B/B7K-<-8D2B)1$HB41*
M(E$2B)1$HB41*(NTA]G(_;2?\<"L+NQ/Q(M77$WP,,_/[,W_`-:,A5X)Y]/\
M7L>_I;/ZO)7W8]W3_`K*OY)9]_,7I%=4+NA*(E$2B)1$HB41*(OFWHV_LVH=
M"+\L_P!9;7M__P"CUXE_^[UL5Z1M6KWBG27IOQHW0,F:/*31KIE<\;MZ-[:8
MR>OD4EP]J,R++U,KD$J<T<=1,,;B>GT9Z0D%BU*U4<(C;6L/=B/L_05SY.'R
M936WG<7E7?C+7DQC9`!GP"^/%92B;639A=!NN?'9T.:!`"V)+OALY-8J^D!9
MYE#3G=ZQ_)`WB>*&"0S7(HB1QG%JC)]H%B.3R"%EO+@C7(HR2\NN64R5@N)4
MX*G$U,>2!-<5D@EFMD8F)C(N8=RP$NT-O0:2([$;PAI^+1'2S:$M?!KA:\@#
M2Z$7`'H]C;HAM[7K.#M8$?S?*HS%DV/Y5!1RJ"2.6LZ^9+$R,M\>83-'R#3V
M(Q!/9$7>4JH,ZL(C'4VQB18B(6)##D("S]T!GT]<VH>&77-BTD1V2"0X#;@1
M;H(B++5E3J1TEA?>#H.`LZ(!!.U&-G3M67]:Y:1*(E$2B)1$HB41*(NFX_DU
MR]S7#^1G44.@K`/2)_JH:8__`"_8=_\`I_'Z\DU7\ZF_PCOOBOH/@OXFH_Z+
M*^\:LAZR%N:41*(E$2B)1$HB41*(E$2B)1%Y-GR?NF*,&9DRBQI&]>]8YQ?.
MINT(74I6>UJW.+QMQ>$*=Q3H%"1>H0G*4@;&ED&E'#!>X0#"*]KVS)3!,FM8
M=!<!U5I*Z>ZEH9U4P`OERG.`.@EH)MA;U%BB3K-FL!CCHJS+AJ1G*&*-R^?*
M9/'FDS'A#KCI'D!BQCC5]OBJ;OK_`)!CK]DF:2(E*!N--4]1(BC'$XP!0BDX
ML_BS7GYMPT@0TVPB;1`&`ZRVKRQ.IY9-9)?$-<Z\!=BP.#&&XXES2]QA`DP&
MZ)M`4G,=8\@M!,BKHAB.21Z80'#L@R7)Q9#4MK(BA!Y<BR7$(;?DV]"8I1D!
MGE;UBMP4DG(TZ.X6L](>,`1G#)*C:<7@'.!:70$-G03T!"/5BL<[%YFHF.DR
MG-G,DEYOP%VU[6V&!>'%A-@&Y(.S`6-9J^2L4LY,KX%()$A*R)(HP_RQI5QI
MA;X8Q`U/)=,,84JF5S?W!XE*XZ8NZ,9UT5B[C0A.4W*(,"!(/"*>+;P(!A&&
MWN;Q^*Q9IQ8,FZITMSAK"TN$`&C7:EL022XWB-&Q$V:%T(SK)(=8F!\O"QNA
M;+C[$,BE<B626-P5LO,\W$;OCV$L<74N,MD[FL?@W+!MD%G,0%9Y25.!8=<R
MQ==3P=".DF`@38-)C8/VEAE8P'2KY9$"7++G1#1>F=BT-BYQCT(VV")T6[3O
MJ259\4.SXUQ=:GASBOQER>)4G,C>^0]ME^&R)\\"EP53N`R0*"946:WDA:R3
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MY^`TQ`C>$#`#3:3'1U-.WL+4LQECG%FJ>'M#R\$@%C678D@VQ-X$-$8BT$@B
M,&DUY1@"YJ8Y#BN9Q^3284-10UF*D4.D1$LD>3V/'DKQ5#FU[9G`;>7*YM$Y
M\8O$E'T&\MC<+C&:2$@\^FE=I#@6B,=-D(Q/Q`C]D++;CLHD,F2GMF.NAHBT
MWB\-+&@@Z7-='H!KK2($]Z*ZVD\_2,2B!8+R;(!3C(+!!\;'.*IIAS'-$D@;
M,J/`9&"2RHIM:F^S*W8C7'.*`F[@H3EKD%@C,,/,+(CJ:X3?<T0$3LPT;`^/
M]M8I6,B>&F1(F.OS`UD8-#HAYC%T`("621:1%NV0/;<"9^B^H>/O4HAK.^M[
M(PKF-A7*GNR,L89BJBK/))C#1$)3SC"GO&:][+9GFPM@`'8D\DNXMQ%>LN;*
M=)-UT(G]J,`>GI'06MH:^5B$MTV2'!C2`8_*N@N;\;";KO\`:B-A>ZUE+7)1
M$HB41*(E$2B)1$HB41*(E$7V!^W#_P#:#_[;418::9_@)./_`#(:K?\`:.R;
M7J/(_P"B=%_!'[YR^4W/A_BQCG]+_P!QBR%KE:ZI2B)1%C?K$_U4M1/^B.8^
M]HZV;,7Z/UW]#G?Q;EOV5OTEP_\`IDG[\*<?]0&552S+\J8EN+&>%XZU,1S3
MBDAKLS/R_)#BM'E;$<)D,P7OEI<C94!3TVSQ:I;6L+*8,MLNC7W5F7,$37S2
ME8=2!LB5,$YT^;2F<7`@,`U<QP:!=),"P!SKW97FPV5ZYN-L%L2(]#05%->M
MD@P48;U>/W]>0^I64AQR"C/C+8QL,@GK_G]CQZU&0E1*'"1NH5*C`:X*XU.J
MW$D*I.9M[;<TLC,?@1%]PF-!:3!FZ)(8))>;UT-'X80B(F!Z!(RM)CHV/BA'
M]M<A>MU$3`'2<6QXK>6R.H\>L2AT-ET8B:B7Y3F.*X'EQ9"8G"!*)5+1#31&
M=$J"#2P+@&FIU!=A=3DW6CAP)QJ!(U@:YQ>877.NRVS'R[SG;EO9,(.C2#I-
MU-5;"/\`W1(7R7JAF$KPE*<GP0$81*7743AC%N.3Y='U[@B:(5F9PP&G0.<L
M8F:4LJAYD3*WY:5&B+3N:0HP\HH&WV@;B&.%2)->REJ+Y`IIDQ]T@$NE";$-
M):8`F6-+382IJP'W3\DD_&(]91V/=;B^03L6&W#%SU.LCQ^:R.#S"2XD2.2G
M'(NH\CSG&D/F;,-S`ZFHXU)'J"*PNUE;C<N.'`-!=0NL4*]L=1@39=/QULUL
MNF=+:]K9A%^UC'N:80W30\78#=V6-BJ94!>C!L-G3HC\-M<3)](CCV5K8@EA
M.+,JS6TI"6H':.M8')8W)FA)B(&24H4+60YF+'_%4FS(A97=&8)*79>VN8;*
M`B3`+//RW4R6O=/G29=SY1@#'67+3"`F-EES3;8YMEL0U)$8D#X&'5@I>-:S
M=Q4MS)*(:M?59$Y,CDVE4:7L;6TQ%NG>JG+>F["9B.,N;@.03,]V<L;_`.6!
MM]O\0+V5.U,N.Z<O!-P2(,R4\-;JXM:X$EQ9(ESIL7`0;`/W,=.BS2896R-K
M_L!*J(_I%6<,9L_EX&GZE<.!I<O$Q]+.<8'GBQ"JQ#.LTAEY[P6_"94SX&+X
MW=D]V&YHEO5P4H;CL0IN>3GC+3];JS42PW6:N-U_X36,E780C"\]IOZ(1V1`
MW4VZ1",-G3&'_:KDVZZ&1QE<=@(<,90,G+A*'ACE$99`(9<HA[,TR/&,?O*!
M+XL2ZMKZFN3EQJ7J"`FI0HTA*W;GB-)(+59#\`F-DNJ-?*U`8"UQBV\2UYNP
M=`C\&X`VQ-VR!)$,J`C$0_[^LHYFUON<LD./H]&<'NJ=1.<A8]94YDGR%$$@
M#\;9`79\844^;1,PG8);L1(=/[G8+,JVAYB$\@W;A-,$25BF8$R3*F39L\0E
MRWG<L<=VP2C<,860G-W0LB"-`B;J@`23H'[-G76?E]BU[VM?9M:]]B^QL;-O
ML7V/L;-<>62OBB)1%VD/LY'[:3_C@5A=V)^)%JZXF^!AGY_9F_\`K1D*O!//
MI_B]CW]+9_5Y*^['NZ?X%95_)+/OYB](KJA=T)1$HB41*(E$2B)1%\V]&W]F
MU#H1?EG^LMKV_P#_`$>O$O\`]WK9JT1:3<GY6T&Z45#QEC!SI%W_`$^806D1
MN=:/(3D$\A!'XR-;$&]W>7O(!8Y$=$N4"T"12<07<'5:@0"R[*#0BZ'YY/UU
M7./S2<ZN8^:JDR'EVNH,O8S58?+GSJNK$R<RCG/DLFS&M;=:]P;>+6[EI<0+
M%\\J'FCPS$::7B9K*J7-GL$PAMV`+P"0-F'6"RQ.T1924'/2@_+NG4T^21E)
M"Y"8/0WC^]WR(($K>@01AVMXR+!7L2)"T(R24QEA%%DHTX`VL$@JP.MOM[^=
M"W__`)SEBT0/\LK;1M'<Z-'4&TM3[%<)@!Q^L@#$=C8=OXUW8UHSS%#'5(^P
M_->`(H]H&0R-('>-Z(X*R.2&.G*QN![&B6-N2DQZ5J4+AW.,(+$$LPV^V%:]
M^C6)OZ_#G2EF]+YN<L-<!"(K:T6;78Z%'<RF$O$'UU81&-MTV]1>A>(_5QYW
M$!^:HR_I;K,^WWYV/\O,M>/5W667[#L$\,JNHSK)XC]7'G<0'YJC+^ENGV^_
M.Q_EYEKQZNZR>P[!/#*KJ,ZR>(_5QYW$!^:HR_I;I]OOSL?Y>9:\>KNLGL.P
M3PRJZC.LGB/U<>=Q`?FJ,OZ6Z?;[\['^7F6O'J[K)[#L$\,JNHSK)XC]7'G<
M0'YJC+^ENGV^_.Q_EYEKQZNZR>P[!/#*KJ,ZR>(_5QYW$!^:HR_I;I]OOSL?
MY>9:\>KNLGL.P3PRJZC.LGB/U<>=Q`?FJ,OZ6Z?;[\['^7F6O'J[K)[#L$\,
MJNHSK)XC]7'G<0'YJC+^ENGV^_.Q_EYEKQZNZR>P[!/#*KJ,ZRZ;CA'5L!O<
M!#U;P*X+(5FWL'2HR[:X+IS+#VNSENUMMM;WV/V:S9/Z_/G8FSF2O9[EK=.`
M_GU=LF&TH>8_`X'^65749UEAII.PUFA9I:P:H0ZSL<LY$;TVX3D[]'CM/$:=
MG.$1UZQBU/#1R@.ME,E98B[8C.N4J.()ZK`G&8$-MB]K3G"_6U\Y>4L^XEE:
MFYN\-J*.3CU?A]+/=65K15OI*MU,XLA*N.?>N:QC"0QSPTZ1'M/#)E>W#9#&
M5,H-93R[-4"6BX(1W>T-,!%9*,>G;47)F1GDC!K,@;NPR!K;WMD=4.E]A.1.
M;0ZI"5[:X(S@Y5VIJ5:C4`,+%;H"`*UZX)B'ZYOG$PJOGX7B7-U@TG$::<^5
M-EOQ"M#I<R6XL>QPU=CFN!:1L$%;@Q^*/:'LJ9981$'5:0=![-<#I@#4"R7%
M9WUJXZ;A@,921EJM,\;*.`.1O!4>8+#)%EC=0A>'TX*1,*]MJ:HOM`WN*U[5
MCI/URW.37P-%S;X3-:1-(+:ZN((D2C.G0.KA\U*!F/$8M9NC8HZ9B;>RJ90T
M?O0V3`?=[)L"K4.QAE[("QU;X9KHQQ(%C*O?FQP(0Z7FBXBU48?5$8?[IQ'9
M0*`N2-<C1G(35!%S4_59)A5AW&6.UMVQS];USNY;D2:G'>;+"::1/ER7L+\0
MJ[6SY39\F,&$L=,D.;-:Q]U^K<UY:&N:3@E5%?.)$JJE$@D?@MHP/W>P;/C5
MW5::-2J&Q`ENL>"(PJ51"%,)5IBCJ>RA:J'N:5(1<W+`+&JE)E]J66'9&,70
MM:]ZV"3^NCS]4%PD<WF#/+&%[KM?6F#6B+G&$LP:T6DFP#25FEV*#34RQ_\`
MRAW:ZC)IVU%21K2/;#K-@3NT+P#,1.*#3#'U"14`LTP@P1)P,K7`.P#BA!OL
M>@(-[5G5_P"N;YQ,+JWT&(\W6#R:V60',?B%:US20"(@R[(@@_$5&OQ1[0YE
M3*+3LZH=VI7Y+>J'SNX;\UMB_2K6C^VKSO\`Y?X)YQK.#6+_`)MX1+WG_C6+
MMR,ZL&4-0,/R3K/Q!CR&810874%3B1Z>XVTIW==EMMDBHMM5B<\M$(BU92YD
M*3HB2;B.5#/VE@B'M;7[;^U1YT,1REEO&\K<W-!B>.X_,Q0&DD5==,=+9ASY
M#2]NKE%Q:637/FN<`V6&1)#8K0<?Q%D^=*GU,EDJ4&;HRP(WP;+7]"S;60D9
MP)GR:1YIEL/UN8SE,6?D)3FR22/:;XJ\L3NW'AN(E<VNK?EQ0A6I#+6OL&%C
M$&^QZ-=:XK^N3YS,"Q*=@V-\VV%T>+T\PRYLB=6U\J;+>-+'RWRFO:X;(<`5
MK&3,2FL$R752G2R(@B4"".@0]?+7@'4`]JU*%FUK8Z=52-N9G=22WZ9XVKN4
MU2(M6<Q.-Q$98&`2)W*0G"3FAO<!H2Q7#>]K5*O]<KSE4$EE17<V^$R9+YLV
M6TOKJYL9DDM$YELL&]++VA[3:TN`(1LS$W&#:F42`#^"&@Z#V>SL+LJ-.NHM
M([-C$IUF0(AY>4KFM:FPS3"P!6."1FNA"ZJ$I%\K;<XIONYI[&WMT`;L#9]&
MU94K]<YSB3J.;B,KFZP=U#(?+;,F#$*VZQTV_JVN.K@"_5ONC9NG:5+\4#@P
MU,J\8P&J&QI^[Z*[2S31J5;DXE;AK'@B%*`9)8U*S3%'4R<!B@XM,G`(X[+`
M"PC/4&@+!:]]D0Q6#;9O>UJR9'ZZ//U3,$FFYO,&F3B"0UM?6N,&@N)@)9,`
MT$G:`)-@5+L5:(FIE@?P0[M=5JTZZBWTI6>SZS($Y$H'1S9%AJ/3"P'`3.[*
MM.;79N.$#*U[`5MR].,DT%^B`P%[7Z-JSJS]<YSB8>]DNNYNL'E3)DF7-:'8
MA6@NES6A\MXC+M:]C@YIV005&OQ1XBVIE$`D?@AI%A'9["YG/2/J/>VU>S/.
MJO'[NT.J-0W.C4Z:3XTX-KDWK"A$*T+@@5Y1.2K4:H@8@&%&`$`8+WL*U[7K
M2C]=7G@&(YO\$C^4:S@T<W%'M+'SY181`@R001M$7[0O`LZX*U"1!]PFP.N?
M<1S%-GS)P=/4D,D.DJ+K.I84Z8UREDA6C&2?DL\MV;#W+'Q1(V]1LHQ64C-N
M"Y@`US[)'ZWK.6:\-S'7S,CX/(?@6`NQ%@;B%61->VOH*/5N)9%K;M8Y]YNZ
MO2VMT$K1U<S$I;Y3'S9#Q.?JS&2#N2U[H=G:(MT:+8J^B^COGAEF"QF8L!G<
ME6=VCT9N?HCQZ>)@87\2@;XRM(CLAC$A:W@Q6<)407>Q9XSC!#M>Y@[BX']M
M?GNW_P#8."VZ?^95O!K-XG5;F+Z;<`@?R=M@.D#=6`[*LIFB/-AIIYYNHO$9
MARI3U8I.,T=0L9JA7RF*FO51Y@LDW&<IY9D`=]N*]Q;Z`"JV=WM8RI]M;GGU
M`P3SC6[4.][5GQ+,U->;3-D1_@!MWOE_*W7[JW2JPZ_1VSI]-3'O>7\`.YZ.
M.$PY&>XZ(,=K#DD33*NKDL:2&GY"&-,QHUO[L2F!<)1)E[B`$-[WO>C]=?GL
M6#(."Z8_C*MT[VLM]'5/,7OIB0V[;3M['3#LM`V!L*P-&AC,4?LTV8=0.&V,
M+`>F5,06;1G!VL+*I1,2F+HU#0%#D<BS:>DC*TYN*&3M!%H#1IPWL4(0+P_K
MK<]'3D#!3'__`&-;\?>]NU9C)%=+AJYLAMW1"0T0LA9!]FYL^*S0HUJT`9+8
MG"0NS)FS!3.ZRYT3O<J=&S1+CU`Y25Y2/9<E2NK^O39"*5.[BGDA0'$!R@9A
M@5X;*+7W:UAU3^NNST0`<@X+`:/^95MFQWO:L6%M+6,<Y[)E.'O,7$4[028Q
MB3>M,;;=FW2O/8GHZ*E$A=8W"=3.EE^D^))@>_.[3'='V*W%XQ]/'@(4ZMW5
M$(<E'*6&2K=Y0D''7VA]QH0E"O82<(2]_P`5_7"\\&!X=1XOC7-C0TN%XC++
MZ:;-K,0ERZB6V!+I3G2@)C8.:X%L06N:X1:X$Y,N5,>\LE3:0S)3XP$AI+7'
M2>SL)A^QT%*0#1Z^GJ'J&XVU%X!)OB'(:9U<VB,:)H.@;H1E0R/E'$.Z`:6?
M$-J*<(HV\!)$J1CNM1)C^IQ#+#?<ZRL5_7&<ZN#T=%B.+\W&$2*7$J<SJ9S\
M2JXSI`F.EZP-NWQ++V.#2YH#[I++PM6*3+GVRJ>;3`2GQ@*=H#7PTC=0#H&$
M1:!8KA&M#F3FA8O=XCJ&P<W+3Y4KD#FX1[1S`DQYDT36=VQ>[JU#=DL`PR0B
MSRX)SCKWLI#U8I`*]KG&V%M,_P#73<X,DM94\WN#L+F-<`[$*X18X!S7",NU
MKA`M(L(@18LR7(K&$NE3:<.O1)$AO96@FQ^FTB.FT[97;@.AG/&,F)7'(AJM
MB"%M<97-IPY7.TP,2A6XRK(DM>)O+GE<I\:1=SU3I(GU09L[6U@%[0NWW(+5
ME/\`UUN>'F+N;_!(P`_&-9H`@/WM61(Q&F89<J?+#2]SC\UI<]Q<XG=[))_:
M4G(,$9\B@V`N1ZUL>LPY5(D,2CH5^F)@(N\R5S(6*F]D0[;*O[LX*T[>>,!=
MNB()0OM5N.&_KD><S&&U+L+YM\(GMHZ5]1.N5]:=5(EEK7S7_-V,:Y[03L%P
M6-\W$I<+]3*%YT!\UI)V.S536P7(#<RS21N'TB&"$,?QO*B8-D)[5X.@"=I@
MTU4&L1">(RYP.S,!)'),>=)VT`$*L9*D8G!-:P+W/+VV\R/UM_/=55U!A=-S
M3T\S$L4HS5T<IL_$W3*NE:)I=4TS!(+I\@"1/)FRPZ6!)FDN^;=#+-56M:YY
MK)`8QUUQU8@UUEA^<L-HL-MHVUZ=\EO5#YW<-^:VQ?I5KB?VU>=_\O\`!/.-
M9P:S_P#FWA$O>?\`C56FF$,[XZB[Q-9MK7@,<B[`F`J=GA?I<9K)TI9J@E(G
M+"63E(U0I5K%J@LA.02`PY0>8`HL`C!A#?=\!_7&\Y^9\7D8#@'-O@]5B]2X
MMERV8A61<0"YQB6!K6M:USWO<0UC&N>XAH)&7-FXE)EF;-J9398TG5?\:L:?
M3%J=5)R%)&KV'B)4$E'DB%I79BA"*.`$PNXBS<I@-+%<`K;(16L*WH7M:];7
M-_739ZDS'2IG-]@8>UQ!_P"8UAM!@;0P@_&"0=A8P<5(B*B7#^!_XU]$FF?4
MLO*$>AUC0180%0K2".2:8HZH*"J0*SD"Y,(PG+`P64(ER8PDX&SMBS2Q`%:P
M@WM;%._729]IWZNHYO,&9,+6N@ZOK6FZ]H>QT#+!@YCFN:=#FD.$004#L5-H
MJ99'\$.[73MIVU%7>QQNVLV!7?RVHI\,:+:86#J\#0<K.0%.(D_C6V]DABT@
M95A^A<8;V^Q6>?US?.(*`8H>;K!_)QG&4)GE"MN&8&AY9'5PO!I#H;1!4OXI
M>N<9E7X1AJAHV^S4K\EO5#YW<-^:VQ?I5K1_;5YW_P`O\$\XUG!K%_S;PB7O
M/_&GR6]4/G=PWYK;%^E6GVU>=_\`+_!/.-9P:?\`-O")>\_\:?);U0^=W#?F
MML7Z5:?;5YW_`,O\$\XUG!I_S;PB7O/_`!I\EO5#YW<-^:VQ?I5I]M7G?_+_
M``3SC6<&G_-O")>\_P#&GR6]4/G=PWYK;%^E6GVU>=_\O\$\XUG!I_S;PB7O
M/_&EM+>J*U[7^5W#>A>U_P#5;8OL?_U5I]M7G?\`R_P3SC6<&G_-O")>\_\`
M&L)<$2>-8I@$V8LH90AQ+TR:@=45GF2/A[-`DKSM]5TWAP)$!D5NRE,QM[M+
M7Q$@*+LI.+`M6D)PF",,!87Z5_=FYPG\YWN\Y-YR\0D2:"JQ[`*6O?3LF%[)
M)J6WS+8]X#GM:YP:'.`)LC:5\QN>2EK:GG2QDRV/FS.-P)8PVN$IKC`",-RU
MSH1,&@G0%[7(\S8@ARU$VRW*6/HPO<7UWBZ))()<QM!RB1Q\QK)?F,-EZTBP
M'1E.?$0%9([A$G&L("/:B-!87>3ZJFED-F3&-))%I`M$(CXQ$1^,+K*3AU?4
M-+Y$B:]@:'$M8X[ET;KK!H==,#LP,-!7I=[7#>]KVO:]KWM>U^A>U[="]K_L
MVO6>M&E$6-NL8LT[2?J+((.LG//Q#,R2%(BK*`ICSFPPLE0)/<9=E`2#!6'<
MNX@V':VUV;;.S;C.=*LX?DS&,1:T/=3X5630TF`<95/,?=)%H#KL"1:(Q7(L
MH,$S->&2SH=7R!U9C0K.[869%.5I@N==96D=;FV/*(BR3@\S2EBAPR@TGN,C
MAK="D$@$#*"B5$B#)GV/DH]V]CJ%*`-K@N)/7Y7I'ZS'GG?@=)BDKFL>,N5L
MN=,IYQK<1;33FR)4^;/=*F&0)3@V33U+W776LDSB(W'P^C1YM,%#W2?*$R^T
MB+=Q$7B`(B.R7`=,;:]N!HIS66`LH&H+#0"RC&\XH`-&<("`LYH4/BII-+#;
M)-@@,:U4G<S4PK6M<@QQ5"!M;J#;CX1]KOF33Z"8=L__`.5K-F$?WK9NMCMW
M1M!:CV44'AD_M6JKNWT>4W?U*E8^95TZO"M8U,+$K5.>AC&ZY0I98L%,"--)
MQRG()AAC<P%(R2T9-[[1.42`L%K``$-LUGZW[-<L`2\CT+0"39BU:+7=D?P6
MDVQVU1S4T(T5E1VK5S)M'>09O$7Z%I=1^GV5P,3Z:T2>)D:.L=O,2%)8@I;V
MTUN>V(O)9[/=[BZN/)"-S.*W=$-"2#8!<D%@ZFL_6SYVPFHE3*_F^I*>JF2&
M3I9?B=<Q[I,YM^7,87203+FM=>:X;E[71!(*P,YJ\->2YE;.)!(L#;"-(^,;
M*\BR7IURCBC(VEYL%F;3NA3+W^>1*/RY3HX@;&/#L9A^),@Y74JXFL)R0G3Q
M]NNKAVU.+`(E.4!0:?\`<F6VU^991_6AYJS;E[,>)R<D4IK,,I*2<R0S$ZR8
M:N;58E1X>);AJ2XF%47-N@N<]K60(*R*CFQP^1,ERW5D^[-<X$D-$`UCG1__
M``[.PIB&Z?&[+I,.*@&KC2CD5*4[3C)$(O$]).+9&B0R%(_1UQR),&4UHR:I
M2MT@,DDX:U;LI#<M4H6.2<\^XQF`'6@S!^L\YW\H&H]*.;#R:^2Z1)G"IK\0
MDN!GLGFG8X3)#21,92U&K@"V$F8`=R0L4GFRP>?#48A-?>![$,,0V`.C:O#J
MA>LJ-"V6E;TP253G7"!TDB8WHV*R(>BR"B?8R?(URYU?E#`[7R/U<T*'=V<U
M*M080,`C%:@TZ][FF#$+AX_6]9G#'2AD7#]4^%X>5:R#H``1&J@8``".P`-`
M6H]E%!"'')\#_LM5#C7T?LBP;C4YC;<^X"B./(E&W0Y_<7C1YCU.DNR)X>*-
M2=_FKVLR204XF+X2E,3.ZY:*_5*'=`'BN4(=JW&3^MRSQCV*2J6CR#1U.+5,
MYDN5+EXG7/F/FOF#5RY3&R2XN=,($MC1&^1=$8*3.:S#@#-F5L\-`B20V``M
MCT`-/05E2:.9Y-5A3TAU'Z>Y2X0R:.:LEV2:/,>.RV,9!0A:$;PH"N(R:<>U
M2M,%D0%J;[8"D/42:P^B05M,%9^MGSQA-R57\WU+3BHIV3&-?B=<S62)D3+>
MT.DB]*>"XL<(M()@;2L+.:O#7@W*V<0#`P#-(T@_%M+'B08]?HQD7*\$S'J:
MTLX[@V)TNGQ2Q2^;Z5,;L;<XR"5+LG3*+MA9CWE!*VHUD-?&%:YM5B!6,3GK
M%B@-@7N:9?LVB_6.\Y..94P3',F\W?E7',6F8H)E+35U?.=*E4)HY;I@$J0Y
MY;,XRUDPN$(B6T6N`6C=S;X5*GS9<^NFRY;`S=&X(EX=9;^YZGQ++B/8;U`R
M\3S>,ZVL;R"S$XI&MY.:],D>7$HW%QCK%+T*<U03E@9)@UL8E#>O*$`0@F)E
MA0[7O8=JZQQ/]:IG/!1(\K<W%!3&IE.F2Q,Q&L:7,9.G4SW`&3$79\B=)<"`
M1,E/:1$%:IG-5A4R.KK9Q@8&#6[(!_:(/Q%6+Y-6JCSNX5\UEC_2M6U_:WXY
MZ@X7YSJ^!6/V38=X7/[5JKTCPQGZ'ITJN6:W\6QI*M,<"4:A^TW15I(5FM#`
M\RMU*3FKLND`.,;8Q'5[B?8-[W*1(CSA;!90Q!W/"_UJN=,;F/DX-S;4=5-E
MAA<V37UTPM$R=*IY9<&2"0'SYTF2PGLILV7+$7/:#@?S585+$9E;-:#'2&#0
M"3U`"?B!*YXWA?4))+JED7UM8PD);,Y$('$QFTUQ=S*0.=VYM?"D"T:/+AP4
MRLQI=DBJQ8]@=TZDHS8VHPWO@Q+]:OG'"'2Y>*\W%%3/G2R]@FXA6L+V![Y1
M>T.D"\T3)<R7>%E]CVQBT@&<U6%3(EE;.<`8&`8=@']H@]-:TN.)=%H@P)8;
M+)U'`RZTIS8K,+6GH6%:])6?,>3"W:2D,0EBB[:UFF-:DX5MT,)3A+&#=!6+
MN*O1^>6X]GC,E9GBEP^>*.O903GZIKYDJ5-JZ&CFB0)D!><TSFL;$7W1:2`7
M!?5SF,Q?`L&YHLL8+65E/*K1A)<QDQ[6S'2I<V>#,ND]B`QQ+NQ%UUMA7H*#
M)..W1AO*FZ=Q!;&;.3>RC?TTB:C&DMX=E2)"U-)RZRK<"'-S6.:8I.0.X33A
MJ"[`#?;AV>'U&6<QTN(>2:F@K&8IJGS-49,P3#+EM<Z9,#;L2QC6/<]XBUH8
MZ)%TP[:I\S9<JL/\K4U?1OPS6LEF:)S#+$R8YK9<LNO0#WN>P,:8.<7M@#>$
M;&XO+.T*6E&[.K<V*W]SWD8DK@M3HU#T\]1K''>EJ)4&%F+W+>]O4'[B581F
MY$C%L;`;WMMM-15E9+G3J25,FR:>5K9KF-+A+EWFLUDP@$,9?>QMYT!><T1B
M0MRJ*VCHYDF35S9<J=43=5*:]P:9DRZY^KE@D%[[C'NNMB;K7&$`5+;B=]S^
MY&?=[-P?<"^[V+;-]KT/NMBU_L5H[[+;19IM6KN/LL-NBQ?-B3K^@49?9%<-
MM@L5_N@[.V#Z'[8.QT;?8I?9MCJI<?M'J+ZV*,O?8L6.]^AT+`%L]&][6Z&Q
ML]&X;_\`-5OMA&(@EQVB!BHY.YMRM>[-:980<Y,1J(AY0@%>ZAL.<D1;D@+5
M@O:VY#5H#@G`MT=D`K7K4S*6IDT\FJFL<VFJ`XRW'0\,<6/+3LAKP6GHA::7
M54\ZHG4LI[75-.6B8T:6%[0]@<-@N80X=`KO5IUGI1%\V]&W]FU#H1?EMM@?
MW'__`$JVO[:_[?\`N_\`\WH5[?\`_H]>)?\`[O6U7]'CKET@0O0GI$B4JU%X
MK89+'-/6*V9]97*3I4S@U.S?$6Q,O;EJ<RP1DJD:DL19@;^@,-[5\9O>B]S_
M`-Z?-?O'YYS-EKF]S=79?K\U8E/IJB1AE5,DSY,VKFOES94QDLM?+F-(<QS2
M06D%>+<&S7EBEPFFIJC$:*74,DL:YKITL.:X-`((+H@@Z05F1]87HA\Z'#O?
M<A].NB/J0>^%_EGG;S36<$MR],LH\IT&_P`KND^L+T0^=#AWON0^G3ZD'OA?
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M]R'TZ?4@]\+_`"SSMYIK."3TRRCRG0;_`"NZ3ZPO1#YT.'>^Y#Z=/J0>^%_E
MGG;S36<$GIEE'E.@W^5W2Z3E](/HC-;EY0-4&'KB,1*@!MRM1B^Z$08&W0#8
M0K]&_P!BU[UGTON1>^"RIEO=S9YVNB8T_BFLV"/_``E'9RRC=/\`S.@T=_E=
MTOPL9,JZ1Y[I_P`9V!K@T=)3I#@?2RQ2C%>1<TN$/2F*\>Z5LC8I<$,U5101
M[R!RA4ZR"WOZ!&$NX!K63:&#2GV3JT_M3$,G<].6^<G%@_F_SPYM+F+'YLBO
MHL+94N#:S,%%B#'4K:@"5<JJ2CG4<Z871$JJO-;-EZR3,UM-E',M=ATFHIL/
MQ"93S:>21"DJRQ[=2YH<'LDD.$7A[2TD.A$'01?(M-=(#;:<-TD^DPTUO*&1
MQ3',/0.:#4F2PI1Q*..6`3WR#N4/98^V.I+>U-6*W=&Q.)<I.N0G>C@V0IQ+
M%Q@^.8O@//95>3ZK"^:G-4BHI:RMJ7RWX&9SN,SV8P)54RIFSIDLOF3,0IIM
M7).'MOOI99-1-$BG:W52\D9K;?:_#\5(<UHCQ.L%@,N+2!(!L#"&F_\`=&P1
M*NL?RGH8BL[;90RZ\]&1=D:!IBR"0WS8>5+HGC>&:X'W4;#L;L)@U:VSE%3,
M-2"T3/(/5IP(AMI!1=E",X=BMAQ+*'O!8QEZ;A%?S=9Z)?,F5#Y/DL&FJ*ZJ
MRK*P6IK9P#6W*@8G)\HM>R6\S1/F/<9<]C2_-9DO,\N:)C<,Q.P`1XE61#6S
MS,#1\S:+AN:;(#2"H%+D/15%<<HH)#=?NB\3"A/LN<\=*<XJXU`YZ!1JCD>;
M'R,216SG.BYJ9I-!GA.TJU!*-8,:A)8LU.>B&,L>XSLL\_&,9HF9AQSFXSV,
M1F-N2ZUN%-GU=(1@$C"Y4^0V8);)DV15RGU$MCILL!DPO9,ESPUXP#).:9<D
M2I6&XG<&EO$JP-=\Z7D&$DP!:8$P.C00H)5D724_Y#?IQ+]=&@)Y:`3["<VC
M./BLV'$1,T[$^4U4@1*W#=&4UU;Y0SXO=#F4AS5'OZEQ5DV,%="C/"B2;A*R
MQSS8;EFGP#!>;WG'D5IPW%*6?6'"P:@#$</;)<UD)HEOIYE?+;5/D2V4;),M
MQ:!43Y9GSL!R5FQ\XS9F&8B6WV.#>)5D-P^/>(Q#3=B;Q)V@8"8<\L:9%KU&
M5GUF>DQ0J9X8T,J6?GZ@WM/,X<H;$F7R)'&HPT$+C&=WB^6ASMKW[6+%1"Q*
M%`/:DJQDMPT>BI,F\Z\B@JY'LHSFV3/KIDUU&,&E.I:ELQV&F1/GS"P39<_#
MA25'%9<N6^7,,YL9DEKZIL_&[)>;BYI\GXI$-`O<3K;S87X@#4P(?>%XDQ$-
M!@V&9.ES6+]'MIW89S%?EY:9'"-ODHB\@BS61FQ(ZA8`I,/XQA\Q"-5)7Q<M
M$HE&1XJ\OQH@FBW8UU$<;>ZDT^]^CN=SF0]Y7G-Q'#\8]G>;)6*4])42:B8<
M+=+UU[$J^IIH-D2F-NT]%44U(T%HNMIPQD)3)8&Y4&5<R43'R_)F*EA<"!Q*
ML,-PT.TR=EP<[IQTQ6,DLUFZ1)/JURIE2%ZO=)A:J`3[31DJ#$Y+RFC9L>Y*
M$S8/U!XDF#$5*F=._*6QSC"3*UG!,M3-[GU&Y)4X#2-J;<8.U\&YB^>G">9G
M!\H8[DK.9DXEAN.4-6:'#W3:RAUN*X-B----/,=);,ESW8?J7RGSI&LD3)KF
M3(L#7:&9E;-C\0F5$K"L4BQ\IS;U#6!KH,F,<(B08$7XQ`,"!8O,6G+NE`65
M(Z!VUP:,2HTFY,Y&DTU;,\N32AB4JFNI_49G#-N-,,0-&[B87J/RR)9!21!U
M5/MD!Q[$K`=M3Q[=$5RRMR7SQC*%4:/(&>CBKM?12*69A#)CZBGI<!P7"L+K
ML3JW2]=*G4]11S,2IY=)KFLJY;I<98NSWY#<EYMU[;V%XGJ['%PHZT`%TV8]
M[6-U,""'!A+H;DQMT*P1:<:'",78^Q=)=>^C5NB<-A>+XJHA<1SX[DQ)6OQG
MAC4?CP+ZG+)71Y0`,DG&5([)3T9A8BR5+48`8U(TZ4X>VXOE_P!X"9FW$LW8
M5S<YYFXS75]?4-JJG")9J&LKL3P2MU+B63@=12X?6T+)@(<YE0UP;*;,G,;C
MEY(S0)#)#\,Q,2VM:+HHZV&Y9,;'\"-+GM=#;&S`%<Z#*ND^*P&81.+?2/:.
MG>[U`9JQ-;--\Y.;S&3)G.\/:8X8]RN0W<7%\6.)QV2L32F4B&:!0,Y<_`-,
M"(P];MLNHR?SQXQF.AQG%^:[.\C48C2S9DVEPJ7*GBEI,2QVJE4\FXR4U@%#
MB.'T`#2P-E4CF-(;+IX!DO-DN2Z7+P[$S%C@`ZBK2+SF2FDF,DQW3'NV;7=$
MJD3:6Z0IHI>FU1KMT)%X]2X2BF-(GC]TU`+9"D=SH*+3\]0]GR;(5C`FD4LL
MQR?$COM9*>>I4=2O98R&=,>4LNOW_`,&YZL"E2*J7S><X9S*_'ZBNJ*R7@[9
M+I8J_+$JIF4,ELYTFGULC$::-"QC&:RE<V9739;Y`I\J;D?-<TEIPS$=3J@T
M--'6&-W5D!QU$3`L.ZML=8T&,?5Y3G+2F^S.(/I'TC>D:[:T3I_D[>8HU!.B
M9TPZ6X:DRLQE.V,D:,\35*'MWQM:T+6)G/>Y(0@3%6+&:C-5(#N'81S?<\.'
MX%6X?,YK\Z<:G8?)D/#<'ENEXD68&<,,NO<X:RGE2Z[_`)I+?(UTQ\Y[[S63
MV2:B7J)F3LVOFM>,.Q2Z'D_S.MBSYR_%OS,"2W<$&`@-J(/NFE;5/H'T\N\I
M7+_I`-,3PDF,!QZBD*1/G&SN)RRG'I=E]VF$]/,E#\M$$V21J9L#<$0+@,W%
MC+*$$))*8(>O>>#FA]XSG,HJ2GI^;?-DB=0XC6.DN.%:NYA\ZFPV734@$B2V
MR1/I:R>08B]5.>"7S)I.KP_*>9J-SB<-Q4AS&Q_D588O!>2ZV5LAS1__``[0
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ME5\"OR9RKF[3?+TN=HW`OI`M#D&QKE&5*)&V8V5:A5,G9TLG>WC);]+,M1I;
M((LZ%X8F<F?)0TN+@RM2-Z9U3BD6K$YS>XK++RO963\@\Z."SLO8IF+FVYP,
M0S5A%&)$RN;@S9$QTB5*H9-/AT]LFHEG$Z61*IZB3)JJB92U,N3,IY$UE332
M#3/X]49-S?,$UDG#<29(F.B&\3K"(DN)>(TYN.)():`X$@D$.,5`*I1HT3-[
M(E9_I(-+2<*W+^2LGY$3QS4,@@2^1R&=1_&J!DR:GE2F,Y&6!R7!'2&.AJ00
M4:8TRS^>86X)307N;N4G".?.;4U$ZMYKLWN,O!*&@HG3\&?5LD2:2=7/FT!I
MVSZ)O$:N754[9@,V8UO$Y;74TYC@&8#D?-0:`W#L5MF.<Z%'5MB7!L'1XN[=
M-+3"P=D;0I\W-^C**YBBRJ$ZW]*<=@>0-4F6LAYO6PK-2!%:48;DDA:=03`3
M+41[RV%->04N:(,V1>QB$3@4NBKRZW&,G=Q$%[:S('/IC&2*R3C^0,XU68L-
MRCAU%A3*K"WNXOB<B3,P><:9PE3#,HW875SZ\B:)+I6(4U&&MF:L3'8_0W-4
MNI:96%XH)+ZA[IA;15EK"1,%[YD0=?:&61BPNT1@K;E'.VDO*.H>=9!<_I$]
M'+;BR5%11D/CC%FOD^^2:&L^0=.,Q6L,S*8^H%2IP(08LE"`E;OXH(-22(M.
M4C0`ZN&LV;*/-YSS91YL\/RU2<V.>)N;Z,U$T3YN%ZZ5(J9M'C=,R=2F;?:U
MA?B%!-=*XHQ[9E$Z8^?4.XNV1F3\G9LGUCYSL.Q,4[H"`HJP$M#I9@Z$G3N'
M"-XV.A`6QI,:R+I`9,O80EKE](7HQDL2P_.6&1L"IWST\GR>!0V+2'4`-NQG
M`V,]8ICRYF=HOE!A)4+%ZD!R8QBW&Q:@LM`:DW_%<L<]E?DK'\&I>;3/5+C.
M-X?.D3FR\(E"15U-1)P</KJN:&MG,FRZB@JW,ER6%KQ5WRZ6Y]2R=E,R5FMM
M3*F.PW$W2Y;P1&CK8M:#,@UHU,($.;:39=A;9"!R,XZ()M(,X')/I(-'+?"\
MY3#*&5)=#SLAM1A;QELEZ5VTZRUQ5EN5BPEP>.2MQW[+L2:-6XL,<&0.P$1F
MSN&6*7G^P'#<`9.YKL\3<=R_14&'TU2**8#*PXRF^6J=C2R,:N?3R.*NO-$N
M35XFV8"Z>V&"=D7-$U\TC#L3$J:YSR.(U=KX_-D_,_<@F]MEK(:%P&S#2U*D
MF4"9Y])-HW!:8N\YED?:8EG-<SQAHR(]8CGL'CN0$[.SWC-VI8CF#^TO0DIQ
MCPJ3'M19XG%:M*(4!S&8)SNX/.PB9EWFLSR30R:2GG3*G"639\RBE8C25<ZC
M,R;K]8UU-)J*43&BFEO94.EBEIY#YDHO0C-LP3!.P_$]T7$`458`'%CFAT!)
M$+2'0M(A&\3`J[SW+VE'*BR11C(7TAVBJ08P$[O[RRI7#-Z]R=Y"KE>I_`NH
M%2*5,2DXIB:!PYEQ@[L+4)*H67,"XEF_XH6,Y.'8,NY*YXLH2*7%LM<V>?*;
M-HD294US,*8R7);3X#B^#MXO-:#.F"IFU]-5U`F,E`&2YGSSFLF'-G9,S94%
MTN=AV)&1$D?R*L),9LN9:-3`0#2T0CIV+0HI9F'36NR5.YT\_2`Z$Y3%9%E-
MEF`\.G9[71''\X9V13J!3-#C+.3C*8X,DI86[)L76V`/E%=Q=HF`1JTDJZ`+
M=K)&2.=2GRKAV7Z'FWYPZ3&*7")M,,3&$,J:REF36X.Z8RGU\T,FT\Y]#7RB
M1Q+4T^(.#)$Q_&#583DS-YGOFNPW$72W3`;G$ZP-<!K($PD6$!S3]U$LTBR[
M(L>8]*T&7HVO'.OC0O$H8LRU(Y1)B6S/CRWK%,6<-8,1U-(WQ(SI"+H5,Y=(
MDVKX>X)3U=DMB+$*NK#RCCT(=-B&1^=_,%.^LS1S<\X5;CLO!I%/(,S")3VM
MJ&9;J<"=*=-<;[:274/DXE)F,EZR_K)6HEO9+J#69,S;*(;)PW$6RC,),*.M
M%FN$V,-1V1`+"(PT&)!(5@9<DZ"T+"QQ5Q^D/TO+XZO'C)?E-N,S\['<OGN.
M9]7Y4GZY<J422ZU45,HB8F9;DFFA)&G(LC,!9`$)5;9796]XJHQ&HQBEYLLV
MR\3EBO9A[Q@\L<3E3\'9A]&QC1(NM--4A]5>:TN#WF>UW&"7K&W)69@P2W8=
MBI8;M\<3K=T1,ON_>ONA!O[&A>6:;]5&FW%VKJ#N62=86")]"\<XW0P2.Y,#
MJ!CI;$VHDN'(NQF.X3WES<G>4(#I$A5-"=A.-2JDBQ0J>1A,`98PWE_.CS0<
MZ6;N9;$*7*V2,Q8=CN*8H^KG4/D><9KWNQ.HFB7"5+9+IWB2^74OJVMF2YDI
MDJA:6N;=9DT64<X4^(,?/PK%WR6,NA_$ZN'8`1MDDFV+;MA!BY?LI]:)]'/Y
M[&FKRLQ+C&O#?U2/>>]0LU>;JGN%R3R#F/DO%?$JO@4^M$^CG\]C35Y68EQC
M3ZI'O/>H6:O-U3W">0<Q\EXKXE5\"GUHGT<_GL::O*S$N,:?5(]Y[U"S5YNJ
M>X3R#F/DO%?$JO@4^M$^CG\]C35Y68EQC3ZI'O/>H6:O-U3W">0<Q\EXKXE5
M\"GUHGT<_GL::O*S$N,:?5(]Y[U"S5YNJ>X3R#F/DO%?$JO@5^`,GRQHJS&^
M3I5*M6&FDJ'.^5]0;.]Q64S1/MY7"WOZ0!LSL!:GW$(R3&.88\B)I2(ZPK;<
MQP3G!O8K9';]FGN>\0RU[I_-SE;-M12X=F##\GX?35=)4S62I\B=+;+,R5.E
M.<'2WMNEKFN`(.E>!.<;FWYWG<X&,5V$92S5/D3:TS94Z5A=<YAC2NE-<UPD
M0,'O!LL@"%4V:=X,C;"YL8=>VC#(:V2-VK6"/TGR%.7(M29!-0AN)FN(R-U9
MFYN<2)C/(S%<8!WZ3&J6]$ZNA^[%J2P"%8/HMF/Y;8PL\L82\N$YI+JF7V,R
MX`2+QO.`;NA$`G97#9G-=SM3IK9OH1G*4UAI7M;+PFMA?D:TN:"9`N,<Z9N"
M`XM:($$K]'8WKIT)QJ-1N,D:P\&N!$:CK%'"7!PR*S#<'`EA:4;24O7C"9<(
MURPM'8TZ]NA<P5[UO;,WY08QK!BV'$-:!'C,FV`A\M<1G<R7/=.G/G')F:@7
MO<Z`PBO@+Q)@/Y/H$;%-?6!Z&/.XP%Y0V?IE8O3+*'*N&^,R>[67[#N>WU,S
M7YHK_HZ\(U0ZZ-&,ETXYNCT=U281?'YYQO)&YH9VN=-:QR<UZA)M$Z-"D)&(
MU0I.%T`@#:][WKBN>\T99KLBXY14>(T$VLG8-72Y;&U$HN?,?2S6L8T!\2YS
MB&M`M)("W_*?,KSSTN:<-J:G)^:9=/+KI#G.=A->&M:V:TEQ.HL`%I.P%>I;
M._HV9N]9NE<G^D`TVOCWDK-#9+HJT+,W-*6(0S&KC,].LDR6Q)&]H4-SF7+Y
M\WX)+3*%MU2BQ=KDA(&G`-3M_P`?.#9>]Z;`*#`,'PGFWS33T&%8%,IJB8W"
MICJFJKF4N-2*&:Y\QKY9IJ-^+.>R5JV7MV9@FN;*N_229DG,,UTV9,PW%2]\
MT$#B57!K2Z67"R2#%VKA&.U"%J\S<LEZ7SG^'HTGTCVD`O'L,C>8XFV)F'48
ML@\[%"<AWU)(6#''+-,SRE]3,,99\HQ(+:J+663LQL:%_DMQ&%&<3RNERISM
M,PZMGSN:[.QS+7U6&5$QT[!6U=)QJB\B/G5O%73:>4Z=/FT&(F?+=+OU+:X?
MRNF:9[)F0[)6;B]H&'8GJ6M>!"CK&NNNUD&WM03`!S(&,&W>Q=81Z#B#/.E6
M(YIQ)DW(/TD.E-\;(#!HPP;RPC/<;AK3&5D?9LDL2^/MD2(@QB&8Q*6)Y:W+
M'*Q:^*I3G=OLKLV;4E"G2\:SMS=\\&-9$QK*F6N:W.%/5XCB$^=K:K")]3,G
MMG3:&<R=,J#5A]-44[J:=+D7I.(3&TTXR>-1F5$V=G4V3LVRZJ7/G8=BA:Q@
M$&T=6T"`<(`<7M!B";6"(C=L`&9F"M>7T?F*6G(S>[:ZM++F9-,X9?RDB,;<
MK1HL"1JR--7*3MK:KLI7`$)Q;TJT)9X@;)8C`WN&][5T9SA>[M[R6<:S"ZFC
MYO<WRFT&`8;0.#\/GDNF45*R0][;K#N'N:7,!W0!M$5N=)EG,M.UX=AF*F]-
M>^RAJ]#G$@?@=*\4U?Z\-">67[`T?C.LG3B80>[Y\97I]'DI@6,D6)F^E/-T
M&9WB1G(EAG4329(Y$D3;85PW,-/`6#9&,-JYYS)^[O[PN3<.S%B6*Y&S0)C9
M.$394H4,YLVH-+F#"JN;+D!S1>F"1)F/@`;K6.<Z#02M+B.6<SU#Y3)>%8M"
M,P$\1JX"]*>T$_,Z(D!>!/C_`/1R<GH>*.?2'Z=%&2([`)`)7DN4YZ3#DQ^;
ME8M,;-%9^B5QQ8S(TK;#8)I]"T("`)"]P($1?<QF#5&&=CX?AOO0>4ZX8IS9
M9G;E:JQ*3=H:?"'"0,*;Y=FU%&YL]LUSGU-7C!J9SS,-YXF"\UK9+6Z-^1LQ
M7&W,.Q;7M8=T:.LC?^:`=9)%C6RX"S:Z*A5F9=/"R=S^;C^D6T0!52'-,#R7
M&6M+G-.B@R(<0EV9U2V1RO'%HFI;98ZO$#R&T(3FQ2O&MN[,I3@3(4PDR$I/
MKI&1N<R1E[#<`;S8Y_,FFP&KH9\QV$N=5OXS388ULBGK>,-?3RY5715,UL]D
MD2N+U3Z:9ADT3:A\W"<F9P,U\WR=B4736N`XE67;"^TMXO`DM<!`F,6W@\0$
M+[CK-VCB-81U<8SE?TD&FF42[4'CN=0-MFCOJ&8WUG=7*2-^3T"#(,GB)<4C
M1L8E"\F<I"GBY;C(E"M.W$$A5[BE3%VX[F?(//CBN?LEYKP?FNS528+EK$Z2
MK?2R\&FRIDMDA]`]]'(J343Q/D,-),=37I-$R6^=,>9-^=-<<Z3DW-3*6HD3
M,.Q5TR<QS0XT=602;VZ(XN('="-KHP`C`!9?X'UW?1^XF09.2.VNS2PZ#G6:
M\CY/0";<JQLL*)KFKDG6HFY9U2N!<;BD`3>QP@;)=[W^YO>ND^<3W>?>1SE4
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M1(;,E-?(:9<R7@?DG,S'.?289B;8@M`-%60N:MC&M/S)T%L=!V#;:#YTFR%I
MZ1Q7D^V_2;:1FY4HQ.M@#NY*M0Z20GKVY#GH[*<8QS&A+(2@!CR'J8(K/B;^
MX(RU:)V;S";<G"K)"["Y/-RUSES\8\I57-1G2;);C+:R6QN#.DACWX0,/GUL
M^[5/-;4MJVLQ"CDS#+FT\X/_`.:/,YY&2,DYP$NXW#\4!U=TGB=8;-9?#1_)
M]R+NX<1$$0W%BR/E>H70O(]/>&\0I/I`-+B)VQRJS"K7JI-GQEG!02LEX#U%
MXF:69KD)#'#35;5%W7-"'J8&]#<2F9FZZ8DD.T*#?J[!N;3W@\+YR\<SK.YM
M\W3*/%&8:UC9&$3:0QH<7P7$9DV9),VI#9E1+PR;?/&9SGU,[6S'F\\C6S,G
MYG?1RJ88;BH<R_IHZMW92YC``=0VP%XA8(-$`%[MILUM:`\)M&1VY\UX:5'@
MR:9"03%$8T94CI1:-$DQ-BW'PTBNRQ<6(2H3C`U!]K@V0;@>7;]M85K=><Z?
M,)[QV?:W"ZG#^;O.$AM!ACZ9XF8?.)<YV(U]8'-NL.YN5;&6VWV..@A:NBRO
MF6E:]K\,Q0WGQLH:OY#&]YVVK69;E&/ID=D66H\J%I44RB>:X"Q)VT<LWE<1
M/^:<].[9(7PAN:36V1QQ4U3E(I1[40Q6V+F`_;!V?L[2Y(YTZ/#,'HZ?*6+5
M4JEJ,+K'S11F80).&85*F2I$R$9<ULVDF2YI%D=P;08>H\@X_D'#LF4M#F/,
ME!A6.MRR[#IE'45)IILJ<Z=7/_EE.^ZXM#*ECFL>T.;:X"T1J[[!F?()1Q,Q
MRS#XLD>&2,-+^W0J,260@/.Q_`9##(8Z752N)(25[L%=,USB8H$E),0C;VP"
M>XQ$B-MR&@R_SDY=<'X+DO,U7.DSY\R4^IIYDD@5=7)J:F7=D.<62[E-*DA@
M>X31.JC,`#PQ;A7X[S<YA:68SG3+%))G2)$N:RFJ94Z)I*2=34S[T]K0^9>J
M9LXO+&F49-*)9)87JZY#()R.&`NB_-<=9I/CJ(-*QI4HXC(')N<,Q)7N-O;C
M*50W*.B7M+"H%$B$Q8D>U7V2.*XH7W([6%LF7,B\X&6G8A2T^1LQSL+Q*LF-
MF!TF:Q[,.=*G2F2&AAN3)HXP]Y$R,K629#Q:V(WO,6=\A9D&'U4_/&7).*8;
M1RW2RV?)>Q^(MFR9KY[B_=RY1XNQ@,N$W5SI[38X`^4FH3S[O;V-SCHQ/N22
M;.$34/>4`AFD8^4*JF0'?("P#2:6S-#-CXN[>E(;++!&MJT8#";`#9)7+69(
MSS+U%",NYC`I\,-RH&&2SQ:?Y(;3:ND:6@S9DRK.N>Z=J[LZ6US7WCKEQ)^<
M\DS-?6G,67(U&)B](.*._E,CRNZHUE6Z\1+ERJ0:EC9(F7I,QS7,NC4JT((5
M&D#*G&X9$C$R?"%>.REC0_J<K)8R^PZ*,+FB=,>+%Y;.Y.*)AL_+TRU,=9*>
M:LNT);+`WO?]SVJHR[SH5%<X4V4<R45`YE86S)6'RW3Y53/FL<RL:PAC'3=4
MQ\I[=8ULOC$W4D?=;K3X_P`V4BB::C-V6ZVN:^C#I<W$7MDS:>1*>V92.>'/
M>V5K7,F,=JW.F<7E:X$]C]DL7LVH%S??.++*48(7&T+8WR9MGJ@A1-5@80T9
M/='$U:R/A(VQXBT#*+9;J$SA=&O<EBA2G/L.X#,,W*V?:FHEU`R+F&DG&NG/
M>^120(IF\9F4,M@:)1ORY]4XU-Q\G62I,F7*F,N@MQ2LS9$IJ>93G/.7JJ2*
M*2UC)]8"#4NXM+KICRXS1<F2*5HIK[)NKFSITR9+>'$.]9P:XQ;&+,Y(I/DQ
MLD3BX((2D&N3-\O4&7%%(LGCIF[J7!A3GJ`BLG#8D6T#?<@VV0A_:VXCGSFX
MYTLTULJ?A>3L?IJ:7,J77#1N`^?GF<(-9$#2;PB=T3`G2N79$YP^;#*]%-D8
MIG#`*FIF2Z9M\5C"?F)`DF+GD$Z!=,!N0+!H7N/C@QGSL3]RI!Q17!/8?SR>
MJ^.>*3>LN=>VSF>]:,"\<D]TGC@QGSL3]RI!Q13V'\\GJOCGBDWK)[;.9[UH
MP+QR3W2^;9@QGLV_[6)_1M_^BI#Q13V'\\GJMCGBDWK)[;.9[UHP+QR3W2_-
M7EI%N&"_]X?RG]AN7Y`X2]A?M/\`!?O_`/>5Z_\`9YGSD?$/\(/)_P"!?_/O
M!-'\X_\`#TKR)[0<B\L8=_B]Q_\`#L_F7A>G^;_^+V/16T=H#5*@Z'=)`0J3
MPA#I^QI8(0G&6L&UHZEV+6M86Q:UJ^QV"N<,'I;3^`9]Z%\%\WM;Z58E8/Y[
M-^_*RYZL5]=*/7S?OJW2^_;/57';K=H)U8KZZ4>OF_?4OOVSU4NMV@G5BOKI
M1Z^;]]2^_;/52ZW:"=6*^NE'KYOWU+[]L]5+K=H)U8KZZ4>OF_?4OOVSU4NM
MV@G5BOKI1Z^;]]2^_;/52ZW:"=6*^NE'KYOWU+[]L]5+K=H)U8KZZ4>OF_?4
MOOVSU4NMV@G5BOKI1Z^;]]2^_;/52ZW:"=6*^NE'KYOWU+[]L]5+K=H+A4K%
M?4JO_&E/L-7_`//-ZW-_OJH>Z(M*RY[6ZE]@[$_M+1/A'1AD1_-EA]ZTM?#S
M.7Z7XK^4JG^.>OZ1_NW?Z=\A?W+P3^S:96>N-KNE*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?T?_HD;[/T;^DG9Z/\`FQM;
M_FD;]:W_`#6KZ*\T_P#AUA/]&_WW+\97ZP7_`%F\X/Y<_P#T\A?HO78:\<)1
M$HB41*(E$2B)1$HBU)MN/^Z%_2Q=MZ/_`$OMT15S0=DK&Z'2;H_Q\MR'!4<_
M7X`Q99!!5<OCR:9KKK(PD/261Q8YQ`^*NJB/NR]H0+;@Z-MFU=Z8-/D##*62
M7L$XR&;F(O=B-C2O&F;:.L=F/$JMLJ::45LZ+PQQ8(/,8NA=$/C6>%RC;>B6
M9;9%<%MD`K?=6Z-P]&W[:UOL>C6\+BD0HX+DW"=U4?"N2"?436D?%C-8\%W-
M(S."Q:W(750BV=W);UC@W*""C1!L`9I`PVO>X;VMAO-O7([L",-F&VL5Q^K$
MV!U1<6@[!(`)$=L`@D;1"D=R-MT+ECV=ING[07[W^$]#]I^SZ%8EAB%Y^ZY5
MQ@P"<0R#(L'CN],E)ACB.1RAFCY*:7*&9LD149ZH>5B%.>^787I(K$F*$,P!
M"@`A6MLUDNJ)#(WWL;!UVT@6P!A;LP(,.BM5+H:V;#529K[S+XNM+MS$MO6`
M[F\"([85N;G1M=Q.@&EP1N8F-T5,;T%`H+57:7I$2D4K&IQL2(74C@E3KR!F
M%#V!A`<"][;`K5F-<UT;I!@8'H':*R'L?+NWP6WFAPC9$&,"-L&!MZ!4E8HV
M_H%F7V0;IT`"_>_PGH?M/V?0K$L$0NBL7(6\:`M>M2(3'5>6U-8%BDE*-R=#
MDZA82VMX3Q@NL<#4B0TT))>V,$64,5K;`;WM"0(1($3`=$[7QK$UKGQN@FZ(
MF&P-$3M")`CT5WKE&A]$HRVS<(;;(!6Z(NB&W1MZ(K6Z'VZL%@B%]1!$&]PB
M#<(K7V+A%:]KVO\`:O:_1M>BJ^*(N!3[%5^TU?\`)S:K=(65/_`O_<G]I:*\
M(^!D1_-EA]ZTM?#[.7Z7XK^4JG^.>OZ1WNV_Z=LA?W+P3^S:96BN-KNE*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41?T?OHD/
M]V_I)_T8_P#\1OU?17FG_P`.L)_HW^^Y?C+_`%@W^L[G!_+G_P"GD+]&*[#7
MC=*(E$2B)1$HB41*(E$6I'_6Q*(OSPPI.,)R#2[IV/;=1^#H%.&SZ/668+"H
M<L@)(U-XEDB<6Q@L8G(#DWE"=V$<=##U8351)H5J,\1>X@O?9N'MZBG4K\-I
MX3Y3)HHC+[*#@YUR!CI$(&W2#H7EO%Z;$968*X/HZF;3.Q@3K&%S'2V&:'"!
ML=>OB`(ND1BN_E":PV/I,N+L8:J,:G(+,DX1P/>G5+.%$MD\4D3+CMDQ_B8U
MA6K%94/%C)[9G5U%*4BY6[J;*1##MC5*H(<=1-E,$QTBHEP@Z[":Z)!#0UD/
MN;I!-\$DQZ)6114]1-=3LK:&=>O,+XTS+K7-,POFWA"_K`6MU9:&"$-#6JPL
M:[%:.6H9[;5_A*+/[*_Q<4(;V_4A*Y<FQU`4VH>;S^0X]/=78Y`'*3:EQ7*M
M[$8WM,<7<XXU,6%.G`6=?&TTXF";QF4UX(N_.$W6ZQSBV)[/<&`O#22+!:LJ
M8VM=(-+Q"I?)<QU\FG:TS'ZAC&S(".J)FMO&X18`XQ,0H>-3)CC*>(.Y^JW"
MBYQBDKQ7('B,#U6RB7QJ9N\,8EK;EW)CRE?F]`\+GW,-UG5+5'DBYN1LCNB3
M'G&J"CU9-L,N8R6&NXQ*+FN82-:2'%H@]QC`Q?I#00&D`F()"S)U/,G.F,%#
M4ADQDQH=Q9K7,#W`RI8ND@-E0@Z80XO:7``$-*LY<]Q02VQ6;EYATFSF=S7$
M6=8YEN&9/RVTM;-',A:CY8PS][DS<N01Z:)GM%%@-X8NY("RDYJYF0)0IU-@
MEW`+,UU.&MFZVG?.=+F![7/``=-(<3H=&'8D;+0(%9'%:XO?3&GKI5++J)+I
M3Y<HDNET[72PT@N9=+HZQKHD![G1;:JXW&8]BP\<,C'KDQ2?$8I+USD[#8,W
MMT+D"U20SX#9H]D=8-6QR9&].Q39BYZ1*V@[;!NE>;A`H'NI]P9;=3++&MJY
M>K:Z)@\`Z)8#M!B=RX$;3M-I6<_C<_739F&3Q/F2P!>DE[0(SRZ6(%I`C,80
M\;++18$E$K9'8,M1-NKK!@65TF67W>'@7:K)6VRN+OV0$,?'!,P/DGC38A32
MT[#CXB<+,L7ZC2$7:UA12D]0H3[L),F-=>#:F5=+GEL9I!!="Z\D"VX8W6P%
MAM)(BDF1,EZM[Z"IUC9<H/A3-+7-877Y0:XF[K6EM^9$F\"0`#!7IMR#%4TG
MGCJNUN817-,@RK><0A&=G)S-%C^&<D\W,2G'R5(=8:-60YS*;M<KZH#M;I#U
M1S45;J%E:KCS1.EA[W&JE%KIEYOSAW+8/%WIEP=T(ENAK5IGTL\R93&X;4B8
MR1<>=2-V^])<)FW8QCI4-D`/.ZF/7FBHF&,S&YDX]UZXS89$M8!,.^;QJ=GD
MD`-N6X%@$>DS>"TC='\AO52O.L>=G@;F60)8C*<^JBKV'MDE9!$MK")-7+#R
M(1,UQLU;01:3IF`F.D1B-I:MIJ)DUIJ\+G/DAUZ`IV-M$][FG<AL0V0YK+L8
M$MNFS=+.C!^I+3=`,9L46DVI[%Z]W1K9$L&%YS)'9DJ:D3Q(G1V;8\GD13;'
MK+6J/H%I:1&"Z;93)2@$[H=8NQ@MVI:VADR!+F3Y9<"=+PZ$22!&`B!H%E@L
M7&L2P?%ZJL=/DT4X2R&BR4YD2&@%UV+H%Q$3;:23`1@O6?EBZ3_./PSW^L7;
M5:GREAW?Y7;!:'T?QSP2H[1W67"HUB:4+IE5K:CL,WO=(JM:W+UBV;WNG,M:
MUO\`&O1O>]48EAT1\_*[8+*G9>QTRG`4=1&Z?N'=9:6,-R1`"(A%23IG&BS2
M8XR%&EC>$01EF%MJ8`P#"(ZP@C`*U[7M?HVO:OC=FS)^:ZC-.)3Y&&USY#\0
MJ'-<),PAS3.>000V!!%H(TA?T#/=_P#>0]W_``CF&R3A.*9URO3XG2Y1P>5.
ME3,2I&3)4V7A].R9+F,=-#FO8\%KFD`M<""(A63QFX\Y[1CNT@Z=6P>A.<.2
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M1T*>;W*TT[WK/=EIW7)_.!D]CR(P.+4(,-N!G17?Y1L?"2?_`-_[RL7H%G;D
MG$?%YO<K*^MI[K_^863?.]#PR<HV/A)/_P"_]Y3T"SMR3B/B\WN4^MI[K_\`
MF%DWSO0\,G*-CX23_P#O_>4]`L[<DXCXO-[E/K:>Z_\`YA9-\[T/#)RD8^$D
M_P#[_P!Y3T"SMR3B/B\WN4^MI[K_`/F%DWSO0\,OZ0/T3,A8T7T<>D<E8Z(D
MAPL6$GV)5'!(-W%0_OAQ!NY&W`.P#B1A&&][?=!O:]NA>O>7-E1U>'Y#PRCK
MI4R35RZ>#F/:6N:;[K"TP(/QK\FGOR9ER]F[WL\\YDRM74N(Y?J\8OR*FFFL
MG2)S-1)%Z7-EES'MB"(M)$01I"_0_E9&>'FKLTC[^N=+RC$;:<K(SP\U=FD?
M?T2(VTY61GAYJ[-(^_HD1MIRLC/#S5V:1]_1(C;3E9&>'FKLTC[^B1&VG*R,
M\/-79I'W]$B-M.5D9X>:NS2/OZ)$;:<K(SP\U=FD??T2(VTY61GAYJ[-(^_I
M!(C;6IGONU<(HOZ5IOM[(+_)G7W[;V-_?58%(A6C0((7R'])/1__`,?\:?8M
MS=2UWQ@OXHI?X!GWH7BS-WZ58C_39OWY67&W%]O^U;TJW-<=3;B^W_:MZ5$3
M;B^W_:MZ5$3;B^W_`&K>E1$VXOM_VK>E1$VXOM_VK>E1$VXOM_VK>E1$VXOM
M_P!JWI41-N+[?]JWI41-N+[?]JWI41<"H8NI%G1_^YJ_L6ZV-_8H-*CNQ*T?
M\>_`.&?FNQ>]J>OGSBOXTJ?Z1,^_*_2AD@#T*P:P?BJDV/\`\O+5PK06KD\&
M[0ZB4M2#=H=1*6I!NT.HE+4@W:'42EJ0;M#J)2U(-VAU$I:D&[0ZB4M2#=H=
M1*6I!NT.HE+4@W:'42EJ0;M#J)2U(-VAU$I:D&[0ZB4M2#=H=1*6I!NT.HE+
M4@W:'42EJ0;M#J)2U(-VAU$I:D&[0ZB4M2#=H=1*6I!NT.HE+4@W:'42EJ0;
MM#J)2U(-VAU$I:D&[0ZB4M2#=H=1*6I!NT.HE+4@W:'42EJ0;M#J)2U(-VAU
M$I:D&[0ZB4M2#=H=1*6I!NT.HE+4@W:'42EJ0;M#J)2U(-VAU$I:D&[0ZB4M
M2#=H=1*6I!NT.HE+4@W:'42EJ0;M#J)2U(-VAU$I:D&[0ZB4M2#=H=1*6I!N
MT.HE+4@W:'42EJ0;M#J)2U(-VAU$I:D&[0ZB4M2#=H=1;4O\U\Z(=?GYX:<_
M^XLZKMG)'XF/\._]IJ\">\TUHYQY9`'XKI_OYRVOZY@O/,`E$@$HD`E$@%6H
MA>XH^CO>][WN<Y;-[]&_Y46UB=I4:`&P&A66L*Q)1$HB41*(E$2B)1$HBU(_
MZV)1%0-&F;<6P/1KI/C\HEA:.1%8#PD7:.-[+))%(E(Y7$9(YL5F]AC3,\.S
MG94U0%[6&73$FV2HVM0>?N10-M?O'":JGDX53,F.@_42[($FUI(L`)-C7&S0
M`2;%XYS-AM;59GQ&;(EQE<<G[HEK6[EX#HN<0!`O8+2(EP`B2LM4V<,5+9<D
M@3?+2W27+'9_9=Y6EEDKL<WKXP\!CKW=_5-S,J;XRWI9"+J`"QQ.2HU"S9))
M-,&$5K;F*JG,S5-=&821``F$#`Q@++;(F`)T+CIPVN;(-4^7=IPUIB2T1#A>
M%T$@N);NH-!(%I`5?(U,83-F!,#,F=T4G5R9QB+>E6L$C`VN#TW2US@%BB9&
M0U*(TE3NT\8U[*VF*U:;?)S0GITUC!@M86`5U+K-3>A,+B-!A$$MTPA:X%HB
M1$@@+..#8D*?C0EQDA@<2'-B`6A_8QO&#"U[H`W6N!,`O38K-XI-&&.22./:
M):URR,(9FP;L;9`X+8LXD%*$KW=I773N:9!<LX-AC,*"$H=]J.]A="L^7-ES
M6-F,(+7-O#;@=F&E:*?33Z::^3.:0^6\L=L@.&EL19'IVJ73/3(MZCZB>V5;
MOE92)MZB=VY7OC9$`!BV[?U.I,ZNLB+,"([<MON5A6N/8M>U8@]AA`@QT6BW
MXEEF7,;&\UPA",01".B-ED=B.G85>E>0(G#8RY2YV="U+.UN3,R*-XMS?5QK
M[(7MHCC(PI$+<::<H>7-Z?D9!:>VP9>YX;WM8-]FL$R=+E2S,<=R"!9;:2`!
M9LDD6+.D4L^HG"G8V$QP)W6Y%UH+BXD[`#28]!5!=J"PRWH9>X#GK:N)@F31
M88DZ9B;WZ1NZ/*P4R9;R!0L#`TN3Z_2.Z)4$ZQ+>F56N2`T>VVI)UR\LUE,T
M.-\;B9<,`2;_`,F`$2?B!_8*SVX5B#G2VB409LG7-O%K095HOESB&M;$0BXB
MV`V1'E#GK$(YPAQP&;)>5[BX-S*D0B:)&6VWDCQ'+3!JAZB3F,P8JAG+C%!6
M<2F,]:4["2"L/J?[H-KN-TVM$F]\X2!H,(D7@V,(7B+;L8PV%/)=?Q8UFK/%
MP"28MC=#KA?=C>+`[<EX!;&R*]>K4K0)1$HBX%7L19[35_R8V@TJ.[$K2!Q[
M\`X9^:[%[VIZ^?&*_C2I_I$S[\K]*.1_T)P;\E4G]7EJX5H%R=*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(MJ3^:^?M=?GYX:<_^XLZKMK)
M'XF=_#O_`&FKP)[S7^(\O\ER/OYRVP*Y@O/*41*(E$59AWP>1?PSE[Z+:KM*
M@T*S5%4HB41*(E$2B)1$HB41:D?];$HB_,W")D&F6E+$`$ZG*37(W[3CINB:
M=Z%H]U5S$S'3_BB/9/3H<DXFR%C-NC(R)JA69,W=K<T*XU`,M&,DWJA,L,L'
MMJB,F;ADFV8'FGE".IFFZ6-=NF.:!NMU80860M!7F#&.,T^8JJ(D.E,KJET.
M-TS-8V:^7&7-ES"[<$2X.:YH=;$0<T+W5X<V9I=6Z90-YS0.<QK).1,M-4L=
M-%.K5ER&]N,M>@2@_%[K,&&)I8V;C.?.2!,DDZ5Q8G-,(L1BM$G(5A(&3K7.
M8UPF23-UK7N>"9$X.,3&X7`0NNL#@6G;`!@MHEMF3&&GJFTW%GR9<HL%92F6
MT-%W6!CG%VL8"3++7M,8-<2V,8Q7&\4G27!S^B=M03:+$\*Q$Q.*\6C/5XKD
M[A*<;9-?<L2*7L:Q+&&F+A7Y-D,H<4SE=Z:7CJ9.M.-3!+4#L,.$LIM9*>#.
M&K:P'YF=&+7EY(L`W1)!O!T`3"U8VSJX2:F4YM(=?,FN`XW2AH;,EME-807%
MT);6M+;CF1(`,1I\PR#CV)C@+\V0U;F1]D*3&K:S1I4OT/ZF6*=JY*Q:=U^G
MHB)$9#/A2A*S8>>FYP,?CV(Q-<(WS9L-2$HT1Q>1.DRS)+91F%]P`?,30Z(E
MZN%Z[8PQO%L.RV;5K:2KG\::^H%.V49Q+@*RG<P-=/$^]J[\3-!%P/CV&AL1
M`SN$F&",$DQQD28Q?-4><8<[+UID-2Z1]5Q:@I:VY2R5D9EGS89"8]:(QN83
ME5D<Z\C:"A.S$`M*G)(VQ`+IP8Z5LEDQDZ:V:'-/8ZF;L/<X.%T0!=>W0M;8
M`++%E8E-J9LF=24[Z9[)C0+_`!JFT&7+EEAONO.8S5C5NW+[23;:K]C5'BW$
M\AQPCB[=F7D#'DV+)%+6U+HHU+1\#UDW`^.Y-$L?R92RM^+S$[T.2RR8!D+J
M:<:6I+41Q"7<U1<=ADYLCB].]@EZW4M#21J)HBZ6TAIA=MB3>.SN1IV-+6.K
M:Z5.=.-/QIYF-:364[H2Y\QKIC03,LNM9JV@"$)CC`:#"H(CC..1&51IFE&H
M69F3Z*P4F8"S!HFU6/:,&5(9()?(@9B@RS'<.QM*X-*M\YNK4(S27)0O2')T
MMNK!`+O6%LNG9+<QKISB]K8WY$T[MI)OMNAI:=T86Q$!:LQU163I[)TQE)+$
MI[[FJK*8'5/:QNJ>)CYC7M@P`@M#2"[<Q*OT7=XNP+&1C=)UJ,E^.4.9H9J)
M?M_M#FJ"^597EN)1R.H5![G-4\-"P%1F23.,D2%6$#/=P"888A`HZG%88<Z6
M^6PACGSG2!-$PQD3;Y>`-+H0@7"\;([$8+2SF3IK7362J.75FG?(;=K*;5-E
M.<XV,OWKS6.+!N[NAQ$;%F;\KS%'-G49\TK4W^BFMR\I4_R9V]3>X7'?(-=\
MND\:IN%3Y7F*.;.HSYI6IO\`133RE3_)G;U-[A/(-=\ND\:IN%3Y7F*.;.HS
MYI6IO]%-/*5/\F=O4WN$\@UWRZ3QJFX5<*G5WBBZ57:T9U&;(DBH-MG27J:M
M;9$G,M;9O?%-K6MLW]&_0M5&)4\>QG[U-[A1V`UUTQ?1P_I5-PJTVH+E.+)8
M5$DQR2:[J1&V4HS<L<3Y05<0&].&]RSR(Z82<7>]N@(`KA%;HVO>U?/S%L3P
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MA^#5/*F"<H8=XU(X1/9WSJ>IV<_,.*_1%:X._J<FRIK@N.(+EZ?39[`X&,T1
MA^&,I2*2.Q;4@4.KH-N9FN)J5ZL#<V)#5!UP`O8LDL0Q;`;7O6Y89+EXW.=3
M8//I:JH:V\6RI\E[@V(%XAKR0(D".V0N%9YG8CS88;*QGG(PK'L!PB?/$F7/
MK\*Q"EE/G%KGB4Q\VF:USRQCG!H,;K7'0"L@_DU:L/,UUG_-*U`_H^K>_17'
M_!SVS.Z75OMVYJ.5F;S4<"GR:M6'F:ZS_FE:@?T?4]%<?\'/;,[I/;MS4<K,
MWFHX%/DU:L/,UUG_`#2M0/Z/J>BN/^#GMF=TGMVYJ.5F;S4<"GR:M6'F:ZS_
M`)I6H']'U/17'_!SVS.Z3V[<U'*S-YJ.!6SG_-OL:99Q"U:UW7+N&LS8G33*
M:8-!%2,FXGGT#='\$=A<N3O2IM9I.P-KLH0MZAP)+&HL3N-S![4(KWM>UNQ<
MJX?5X=AAD5C+DXS7&$0;"&P-A.T5Y`Y]LU8!F_.S,5RY4"IP\4$F67AKV[MK
MIA<V#VM=8'"V$+;"MFWE0V];OG>V_P#%M<E@NF(IRH;>MWSO;?\`BVD$BG*A
MMZW?.]M_XMI!(IRH;>MWSO;?^+:02*KL4D2`AB1E#(>!"":X7O<I@>S@;`W)
M6.VP82@&7>]K"Z.Q?H7Z%^C:JX6J`V*Q<J&WK=\[VW_BVI!6*<J&WK=\[VW_
M`(MI!(IRH;>MWSO;?^+:02*<J&WK=\[VW_BVD$BG*AMZW?.]M_XMI!(IRH;>
MMWSO;?\`BVD$BG*AMZW?.]M_XMI!(IRH;>MWSO;?^+:02*<J&[K=\[VW_BVD
M$BM3/?5+^#7_`-*TWS_)CA[&_!>Q_9__`%;V1_>5$BK3H$&.VA[23:PQ6M;3
M_C3H6%?FZE_9KOG!?Q12_P``S[T+Q9F\?_NK$?Z;-^_*RXW0S^['ZJ_IUN:X
M[`)NAG]V/U5_3HD`FZ&?W8_57].B0";H9_=C]5?TZ)`)NAG]V/U5_3HD`FZ&
M?W8_57].B0";H9_=C]5?TZ)`)NAG]V/U5_3HD`FZ&?W8_57].B0";H9_=C]5
M?TZ)`+A4F&=2J_NQ^PU?_2OUN;^S5;I"RIX&I?\`N3^TM%2$?`R(_FPP^]:6
MOA]G+]+\5_*53_'/7]([W;O].^0O[EX)_9M,K17&UW2E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B+]8_H+[_\`^U;3)^RRYYV?V?\`,=.:]#^[=^E]9^3G
M?QTI?&[]==_IURU_?&5_9U>OZ&=>T5^91*(E$2B*NH+WO))%:][WM9(PVM;[
M7W#C?H?:Z-ZNPL([(JQ5%B2B)1$HBK,/^#R+^&<O?1;5=I4&A6:HJE$2B)1$
MHB41*(E$2B+4DV;_`&[_`-+%V?\`E^W_`&:(I70($7R'M)0MB^QX@,:6V=B^
MQL\G4G0V?0V:[YP7\44O\`S[T+Q7F[]*L1_ILW[\K+D98R[[4P`P"MZ(1AN&
M]O\`D%:UZW-<=B#H7UHB^;`%?T`BO]SMNA:]_N;;-MM_8V;>C1(KXM:]^A:U
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M1?PSE[Z+:KM*@T*S5%4HB41*(E$2B)1$HB41:D?];$HBPETP8IU$S'#F`Y;`
MI5,(-#XEH@T^K8TZMCQ,E%I+(^0&=TTAA$3@85'BQ>U;RZN<;4.;@ZISUR$2
M1%U(';BL87W'AM/6S*.1,E.<R6VDE0(+K3=?%H;V)B2V)-H@(+REF"NPBGQ:
MMD53)<VHF8I4!P(9N6ZR3=>Y_P"$``$P-:TAKHNO66'W^"M>H[%<7Q+!VIOR
M8TB4O6EMBD<I'BQ;D!)>-@PXVR'.1DS0]3/QD?6FS`*ID`O;2D`BGQ8%2N.$
M62H&/6RFUM/+ERFB8(F4";EZRX#,CIANHMB(;HQ)L*V:I?A%;.GU,PR70;4N
M:W6!AO:TMDW#N;PN0?==>BP0:(D`3^-9EK2DC*P+,E!!C3JC*+#XR%1>)'%0
MKQG`VK'V3Y-DEH3J93%HW&'F,ERB/,+>V/Z,<@N62M-$):J&<0(K'(FXH]@,
M_<?."]N#N6AKBX6@`B(:`X7M.DQ"RJRGR[)FO;1_/0D.U?SHA,>7RVRS!KG.
M#KKGN<PW+0-RV!CY/)VG*:F-N&4)-%M2JYIS#AO,&:X,S8*+R2=((GJ`ESPE
M48?99&AQ^K3N:95%L'M490L]G<!D>*7IG7JD.['6L9IWMJ"PU#VSRV;*>]HE
MWHB83N`;MMC`T".YB'1M*U\F90MG"BDOHQ,IZB5)>9VKNND,!UI:9@A!TXS'
M/N?.%I9"P6>A,&4-4D\11IA/@<K>$@0('B13)!C>21R+2%%?,&FDR%.<5E`!
ML1R^RO'#S-%[@F)"`95D(@.!)0B!)AYS)^(3@&%CB+"772`=W*ND&R.Y+R1T
M($606DFT6"TKGS1-EM=:&L,QKG-.JJ+X<W=0A,$D-)TQBPF-X<4DG^N:.PR7
MK#(O,9#(GQH8WB&GQK#C0`4!?EDYSDTJ(JXM:1DF:Z1Q\,5A\2.4'W;5;B%4
M^A,W1&C/$<A/G8JR4XW7%Y`(@P;DESQ=A!T1`,C83%VP#$632Y9FU,MH?+;)
M:YP?>FG=M#))#@26!KKSYH`O!L&0@YP@[[^,S6`K02%Q6M.4XPWFS**,RLA!
MIFO)I;C]L*PY)7]^=8<S@:3$61XK+,Y@01T@T5W9:SLQ/5:HTD2X)R-K\1+7
M$B8T7@/P42T7"26B&Z!?!NR6MM,(Q$XG@#7,:UTA[]6XB-1=9,.M:UH>8QEN
M;)O3"-R'O-UH-V#OHS_+&;VV32&T%>V/([^FG;X:6)E=);&XU,)$GT=MMT;$
MQGOMF5U8&^YDT-0D#$9;_):@11P0V.N<;Y2:US[A$XWCH)`)U(L$8$#=P^(P
M.F-F>C[WLE:UKJ1A8-(:YS&\;-INQ#C\S>/^T(C1"V1:7ZT_'!"(;)V(14!0
MR%^:7>9.&,G<L&3&!GRYE>-J7ET.B43>6/'SZ/%S'%G=K&8XL#4L/<S3;`5%
MBZF39C)F)\99*F#YD$@DM.Z`>\1,`0TW0TBUH,=G0,B?3Y<\GS:B2[^5%C2&
M"8/FW&5*<`+S@Y[=8Z:QT&O<`T"+3:?T`ZC5]:J?6#?O:W>!7%8C;"=1J^M5
M/K!OWM(%(C;"X5*-7U*K_P`54>PU?_R#>MS?[VL308A94]PU+[1V)_:6B?".
MA#(C^;+#[UI:^'N<OTOQ7\I5/\<]?TC_`';O].^0O[EX)_9M,K/7&UW2E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+]8_H,/\`>K:8[_8WESS;_EO@V=>E
M7H?W;OTOK/R<[^.E+XW?KK0?JZ9:.QZ92O[.KU_0SKVBOS*)1$HB415QO^$D
MC]JL/XMQJ["PCLBK'46)*(E$2B*LP_X/(OX9R]]%M5VE0:%9JBJ41*(E$2B)
M1$HB41*(M238O]J_]+%V/0OZ/VO[-$7@FB323@&4:.],,D?(E)E3R^X0Q^ZN
MBE/F'-S20>O6L2<]2:2V,V2&]I;RQFBO>Q*8@DDNW0``-MBU=UX1AU',PJF>
M]KKQDL)W;QL#8#H=1>0LTX]BLC,M?)E3&"6VKF@#5238''9,LD_&22LH?D6:
M;>94L\N.H#]*E;CY,H?D.[>9W:V'TBQCODO>9'!)?17IMOZ,*EE_L;%\XZ@+
MVV/M;%\J>A3R90_(=V\SNT](\8[Y+WF1P2?(LTV^CR+EGEQU`?I4J^3*+Y+M
M\F=VGI%C'?)>\R."7R+1;IN&*XA0R7"$*][B$+.6H&XKWOZ-[WOE2][WO4\F
M4/R';Y,[M/2+&.^2]YD<$OCY%FFWF5+/+CJ`_2I3R70_(=V\SNT](\8[Y+WF
M1P2?(LTV\RI9Y<=0/Z5*>3*'Y#M\F=VGI'C'?)>\R."3Y%>FWF5+/+CJ`_2I
M3R70_(=V\SNT](\8[Y+WF1P2?(LTV\RI9Y<=0'Z5*>2Z'Y#NWF=VGI'C'?)>
M\R."3Y%>FWF5+/+CJ`_2I3R70_(=V\SNT](\8[Y+WF1P2?(KTV\RI9Y<=0'Z
M5*>2Z'Y#NWF=VGI'C'?)>\R."7"IT6Z;0I50K0J6;(4BH5O\^.H"_1"G,O;H
M7RI>U^C:J,+H?DNWR9W:CLQ8Q=/SDO>9'!+3A@N)X"JA424GLZ\9Q\;9331V
MEDS+L(PQO3B%>Q94A`47:][]"P0V#;T+6M:O`N*RJ4XI4QIZ4GC$RTT\@D[L
MZ299).V223LK](&1L4S`S)&#-E8QF"7+&$TD&LQ?%);&CB\N#6,95M8QHT-8
MQK6M$`T``!6OQ08\X%<.^^;>$E:#4TG@U'XM(X-<J\K9DY;S'YYQ;Z:GB@QY
MP*X=]\V\)*:FD\&H_%I'!IY6S)RWF/SSBWTU/%!CS@5P[[YMX24U-)X-1^+2
M.#3RMF3EO,?GG%OIJ>*#'G`KAWWS;PDIJ:3P:C\6D<&GE;,G+>8_/.+?34\4
M&/.!7#OOFWA)34TG@U'XM(X-/*V9.6\Q^><6^FIXH,><"N'??-O"2FII/!J/
MQ:1P:>5LR<MYC\\XM]-3Q08\X%<.^^;>$E-32>#4?BTC@T\K9DY;S'YYQ;Z:
MGB@QYP*X=]\V\)*:FD\&H_%I'!IY6S)RWF/SSBWTU/%!CS@5P[[YMX24U-)X
M-1^+2.#3RMF3EO,?GG%OIJ>*#'G`KAWWS;PDIJ:3P:C\6D<&GE;,G+>8_/.+
M?34\4&/.!7#OOFWA)34TG@U'XM(X-/*V9.6\Q^><6^FIXH,><"N'??-O"2FI
MI/!J/Q:1P:>5LR<MYC\\XM]-3Q08\X%<.^^;>$E-32>#4?BTC@T\K9DY;S'Y
MYQ;Z:GB@QYP*X=]\V\)*:FD\&H_%I'!IY6S)RWF/SSBWTU/%!CS@5P[[YMX2
M4U-)X-1^+2.#3RMF3EO,?GG%OIJ>*#'G`KAWWS;PDIJ:3P:C\6D<&GE;,G+>
M8_/.+?34\4&/.!7#OOFWA)34TG@U'XM(X-/*V9.6\Q^><6^FIXH,><"N'??-
MO"2FII/!J/Q:1P:>5LR<MYC\\XM]-3Q08\X%<.^^;>$E-32>#4?BTC@T\K9D
MY;S'YYQ;Z:GB@QYP*X=]\V\)*:FD\&H_%I'!IY6S)RWF/SSBWTU/%!CS@5P[
M[YMX24U-)X-1^+2.#3RMF3EO,?GG%OIJ>*#'G`KAWWS;PDIJ:3P:C\6D<&GE
M;,G+>8_/.+?34\4&/.!7#OOFWA)34TG@U'XM(X-/*V9.6\Q^><6^FIXH,><"
MN'??-O"2FII/!J/Q:1P:>5LR<MYC\\XM]-3Q08\X%<.^^;>$E-32>#4?BTC@
MT\K9DY;S'YYQ;Z:GB@QYP*X=]\V\)*:FD\&H_%I'!IY6S)RWF/SSBWTU/%!C
MS@5P[[YMX24U-)X-1^+2.#3RMF3EO,?GG%OIJ>*#'G`KAWWS;PDIJ:3P:C\6
MD<&GE;,G+>8_/.+?34\4&/.!7#OOFWA)34TG@U'XM(X-/*V9.6\Q^><6^FIX
MH,><"N'??-O"2FII/!J/Q:1P:>5LR<MYC\\XM]-3Q08\X%<.^^;>$E-32>#4
M?BTC@T\K9DY;S'YYQ;Z:GB@QYP*X=]\V\)*:FD\&H_%I'!IY6S)RWF/SSBWT
MU/%!CS@5P[[YMX24U-)X-1^+2.#3RMF3EO,?GG%OIJ>*#'G`KAWWS;PDIJ:3
MP:C\6D<&GE;,G+>8_/.+?34\4&/.!7#OOFWA)34TG@U'XM(X-/*V9.6\Q^><
M6^FIXH,><"N'??-O"2FII/!J/Q:1P:#%LR<MYC\\XM]-6WK]#+]$O]'GJ/\`
MH],19<S9IP:I_D=_F6?&YYE3MD#+A"]P1Q;/^38M'B#BFV?HD0`-4=9DJ0O:
M%!V2B`W%MAW$*_;^$9<R[/PNGG3</H'37R6DGB\FTD6GL%\\\_\`/1SS8;GG
M%\.H<XYLET4C$)TN6P8SB4&,:\AK1&I)@!8(DK]2?J)/HG?,^C/E%S3^DJMQ
M]%\L\G4'B\GN%Q'VZ\^'KIFWSQB/TE/J)/HG?,^C/E%S3^DJGHOEGDZ@\7D]
MPGMUY\/73-OGC$?I*?42?1.^9]&?*+FG])5/1?+/)U!XO)[A/;KSX>NF;?/&
M(_25'/'T&?T4C6UN#BFT>Q2ZA&D./)L?D#,QY6Z`!>X;F$F9($68&U_L"M>U
MZ#+&6>3J#Q>3W"AY]>?"!_\`WIFWSQB/TE2/U$GT3OF?1GRBYI_253T7RSR=
M0>+R>X5]NO/AZZ9M\\8C])3ZB3Z)WS/HSY1<T_I*IZ+Y9Y.H/%Y/<)[=>?#U
MTS;YXQ'Z2GU$GT3OF?1GRBYI_253T7RSR=0>+R>X3VZ\^'KIFWSQB/TE/J)/
MHG?,^C/E%S3^DJGHOEGDZ@\7D]PGMUY\/73-OGC$?I*],PO]%9]']I?RO$<J
M8)TW1R`Y$1E2-F02Q++,DO+DW-SU'7%$[DMX))-'A$C,<40A$F&@*L=N(A`L
M*P1"M?646#X1ASS.P^DII$TM@72Y4MA(B#`EK02([&A<=S)SC\XF<J27A^<,
M?QO%J"7,UC)5;7U55+9,`+;[63YLQK7W7%MX`.@2(P)6?_)%AZV5=UGCM^MQ
MBN%W0G)%AZV5=UGCM^D4NA.2+#ULJ[K/';](I="<D6'K95W6>.WZ12Z%`H8N
MRC?WXD2=3N9*9E$"UG1UL*US0+]OMAV6V&/9VEMC9O?8^Q2)@D!$A3W)%AZV
M5=UGCM^D4NA.2+#ULJ[K/';](I="<D6'K95W6>.WZ12Z$Y(L/6RKNL\=OTBK
M="KT5B[*H8DAQJ=3<8C7"U[A<W4NVP!R5@#L!+6A#;[D-OL='T;]&JXVJ``A
M6'DBP];*NZSQV_4BET)R18>ME7=9X[?I%+H3DBP];*NZSQV_2*70G)%AZV5=
MUGCM^D4NA.2+#ULJ[K/';](I="<D6'K95W6>.WZ12Z$Y(L/6RKNL\=OTBET)
MR18>ME7=9X[?I%+H3DBP];*NZSQV_2*70M37>=O_``)W]*SWI]FK_8'X'V5^
M^?X7]^_OZBL`K5H$`.^A[23>P!7L+`&-K!O8-[VO<,<2"%:U]CHW"&^S?[5J
M[YP7\44O\`S[T+Q9F_\`2K$OZ;-^_*RYW,S9V-S'L[;:;&U%L[?8V=IZ'[;8
MZ.QZ.Q6YP*X[$+ZEA$<,19-KFF%[%S"ROW09>R&PK;H`&R(&R&]KVV;6V;7V
M?0H+="&RTZ%\41*(N41!X`V&,DT`!6M<(Q%C"&]KVV;7L*]K6O:]J0.E2(T1
MM7%15*(E$2B)1%P*O8BSVFK_`),;0:5'=B5I`X]^`<,_-=B][4]?/C%?QI4_
MTB9]^5^E'(_Z$X-^2J3^KRU<*T"Y.E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB45&E;X7\WW_W5V"OS
M_P!3G^T]E^N]L#_$U+_`,_:7RUYS?\1<<_*E1_&%?M%6Z+@Z41*(H"4_!QZ]
MSE/XN]%#H*GZ*I1$HB410#K^5XQ[?</>5PJC05#I"GZBJ41*(E$5<;_A)(_:
MK#^+<:NPL([(JQU%B2B)1$HBK,.^#R+^&<O?1;5=I4&A6:HJE$2B)1$HB41*
M(E$2B+4C_K8E$7Y_8:Q?J>6Z==.F0\-HYT],+QIBT.8X<H>WR,UM9G*,\O'&
M43>?Q5&H=$B)OEF,AHT`W4PNQ)SM&71:FV5`RDY0>WZ.17G#Z>=3!Y8::G:6
MQ@"(Q<X6Z6V1VVDBVQ>6,6K<%;CE=28@939K:^MF!Q;$AUVZQCC");,BZ[I#
M9C6FR)*]K488U:I<C*V<\G)9.(B)@Y:95+]>5GC*(TWE9+%J%!J.``+Q=U$[
M)XAM\=74V#=YN?:UK`W"UC*UAIL1UUW=\6O&5&/[W>UFLTQC#YOY726U-Q'`
MG48F#4\?,L5%V[_YC5ZCB^B$+_\`*(=A#9C8I&90/,TCB[9EPW%<^GB3,;%F
MK+H\=,R&3JP1W+TP7P<.G9%D:'QF>XOE*Z/L>!XP".D*2W+<8P^*#%IY`1""
M:7BFR:E\L5&K>\30]]T1L>Z[J[S0YI@)8NBW<NM(V5@IZG#I,]U`)\J4ZG=)
ME:PEHO2F!^O,MSF3&ASI[M81=C,8`T'8/HD5MKP?'*6MTDL]0`E1,X(PH43-
M"(^_I8A!E>8(BA<Y-!)K(V=<T2,Y'@\US&Z!<CG]6%UMU1M4XR;)S\Z7Y6>Y
MS9D61<T6-!@V^`2UQ$#!D8QO&-MD('23_1B6R6^3=FD2WN)+W-+WB4XAKV-(
M+8SKMVZ&"[9:#$36+%VN%5E#&"#)B%R:H2EC#*&5'W@K0L12U0F*R6@E2J4.
M;`UV30N;&KD,:6H[DK$3<(@T8"4"CJ@ZR7%3G%3/EB>")5T1W(M[*,2!N7=B
M1:!M`QLRZYN6FT4]]&0ZI+S=W9!;^#+;H<8O9`S`8@NC"+A`7J_*=+LV\;T[
MDV/VB<P,QWU&82D3#/&)R&^GL\$+PT\&92=6!AG*V2Q),D49,4V"J`>UFALL
M/W0L@0+6V,$R@F\9?,DA[(SF$.!C!MPWR`Z([+39IV%FR,;IN(2I-4Z5-#:.
M<US'"[%^M&K#G,#7?@]$'"P0)4`V.WTC#HBE1KLU+XM(PX6:3(XT(\<1]W95
M,Y78JQ^<<\I'0U&)F;YTS9?52$*QJ6N:E"<WDEDE(BR;%+!8&NQIP=>!:_5"
M`N@B]<;;'0'!]Z()@19"%JS7R\HL<P2W!\GC)O$S'!UP37V0C$L,H,@X-!#B
M27$Q:OODV9ZOX%D"5-B8C,P\3(GW&<`;9O:#XJE4KD:IWS!@^)F2K'*%)"8Z
MPJ'Z;0632DT2!2%R*2+48!B+2FA)1CL^;B4F<YHUO%P6M#KK"3%[!%NY`BYI
M?88P(V-"E%38!54LMY-/Q\MF/++\UK6@2ISKLPE[G76/;*W0NQ!TN$7"_8,E
M>K-PR]#\;98)5A:"\2AS5+7)=&HNW2%(A7.,GQ;#\92E+'R+M[3,']Q:4\Q7
M#1[`"E!*U`4,*8NQ-LZDF8@ZI;(J(W=7?)@(Z2P-,-!)%\PV8@6+2XG(P)E!
M,K*&&LU^I:`YQ:2`V8^8V]:6-!,IL=(+7'=&*S[ZB6=:*?6#?O*W>!VBN+WF
M[83J)9UHI]8-^\I`[12\W;"X%2)9U(L_Q13[#5__`"#>MC?[R@!VEA<YMTVA
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MC/4"]*D0K<?M'J+XW(W\&/U`O2I$)<?M'J)N1OX,?J!>E2(2X_:/43<C?P8_
M4"]*D0EQ^T>HOG<C?P8_4"]*I$(&/CH/46]]_-]_]U=@NWV;9`U.6O;[5[:G
MLOVO:_[-KUWO@?XFI?X!G[2^6?.:(<XV.@Z?*E1_&%?M%6Z+@Z41*(H&4_!U
MZ]SE/XN]%#H*GJ*I1$HB410#I^5XS[?</>5PJC05#I"GZBJ41*(E$5<;_A)(
M_:K#^+<:NPL([(JQU%B2B)1$HBK,/^#R+^&<O?1;5=I4&A6:HJE$2B)1$HB4
M1*(E$2B+4DV+_:O_`$L78]"_H_:_LT1>":)-'^EZ5:.],,FD>$(4\R!_PAC]
MV>G98!YNK<G-<Q)SUBU3<IW**W90<.XA;4(;;-^A:U=UX1AM!,PJF>^4TO,E
MA)MM,!T5Y#S3F#&I&9:^3)J9C93*N:`!"``<8#1L+*#Y$&D6W1MI^@-KV]"^
MT?>.JW'R5AW>6?L]=;#Z2X]X5-_8ZR^;Z(=(HKWO?3_`KWO>][WN%]O>][]&
M][WN][-[WO3R5AW>6?L]=/27'O"IO['67Q\B#2)YOT!]0^\=4\E8=WEG[/73
MTEQ[PJ;^QUD^1!I$\WZ`^H?>.J>2L.[RS]GKIZ2X]X5-_8ZR?(@TB>;]`?4/
MO'5/)6'=Y9^SUT])<>\*F_L=9/D0:1/-^@/J'WCJGDK#N\L_9ZZ>DN/>%3?V
M.LGR'](E_1T^P&_]DM\OT;=&U^B]>C:]/)6'=Y9^SUT])<>\*F_L=9/D/Z1.
MC_\`V^P#9OL;-]S?-F^QL[&S??K9OL;-]C[6S3R5AW>6?L]=/27'O"IO['63
MY$&D3S?H#ZA]XZIY*P[O+/V>NGI+CWA4W]CK)\B#2)YOT!]0^\=4\E8=WEG[
M/73TEQ[PJ;^QUEPJ-$.D6R94*VGZ`VN%*I%:^T?>A<)!E[7_`"U]B]JHPK#8
M_@6?L]=9<[,V/B4XBKFQNG:ZRTP(=B['Q\1BQYL5:QFG1UE.-'<)VR,PQM3#
M,'?]V]$0Q7O>OCUFO/><:7-&)4U/B56R1+KZAK6AY`:ULUX`'0`$`OWV<P?N
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MU#RWXHQ;`W\WGT+:/]2^7M8#)G[3QC3+C5"\;:?'2)(9PRB>DT=<)'*,XI']
M4U$GJ-R2GO"=A1`4#M;;#"D*ML[`=B_JGF"Q;$LPY?KZC')SZN?+K&M:Z;!Y
M:TRP2`2+!&V"^!GZW+F[R3S/\[V4\&YK<-I\`PJKRW/G3Y5"'4\N;-;6N8V8
M]LL@.>&"Z'&V%BVE?J6OHI/,*TX]XB7IU=\<6IN]R^U;UE\G/+.,^&5>_3>[
M3ZEKZ*3S"M./>(EZ=3BU-WN7VK>LGEG&?#*O?IO=I]2U]%)YA6G'O$2].IQ:
MF[W+[5O63RSC/AE7OTWNT^I:^BD\PK3CWB)>G4XM3=[E]JWK)Y9QGPRKWZ;W
M:R_P?@'"N&L;M&,<3XRB&.L>Q%RE""-0V(M9;,P,R8^4/"]2%$WI1`)+&L7J
MC3SA]$1IQHQBO<0KWK.`#0&M`#0-`6W/>^<\S9SG/FN))<XDDF.DDVD]$VKU
MGD?&>!TO\;TRK$K!=;M)R/C/`Z7^-Z92)2ZW:3D?&>!TO\;TRD2EUNTH61Q2
M.IV%V.*:4H#"T"@8!6W39"*P+WL*W[IZ-KT!*%H`*FN1\9X'2_QO3*1*MT)R
M/C/`Z7^-Z92)4NMVDY'QG@=+_&],I$I=;M)R/C/`Z7^-Z92)2ZW:4(Y16.EN
MD>+`TI0@/6K@&AMNGW80-"XP-K_NGH6&"U_^2@)@D!$*;Y'QG@=+_&],I$I=
M;M)R/C/`Z7^-Z92)2ZW:3D?&>!TO\;TRD2EUNTG(^,\#I?XWIE(E+K=I0*&*
MQX;^_$B:DURB4S*(L'[IL`N:!?NE[?NG_2VEO^:D3!(")"GN1\9X'2_QO3*1
M*76[2<CXSP.E_C>F4B4NMVDY'QG@=+_&],I$I=;M)R/C/`Z7^-Z92)5NA5Z*
MQ:/*6)(<<U)C#!&N%A"ONFS>P')6`-OWS_H@#:W_`"57&U0`$6JP\CXSP.E_
MC>F5(E+K=I.1\9X'2_QO3*1*76[2<CXSP.E_C>F4B4NMVDY'QG@=+_&],I$I
M=;M)R/C/`Z7^-Z92)2ZW:3D?&>!TO\;TRD2EUNTG(^,\#I?XWIE(E+K=I.1\
M9X'2_P`;TRD2EUNTG(^,\#I?XWIE(E+K=I:FN\S5UB3_`$K/>GT3?R9UC^^?
MO'['H_LTB58!4S1MG3%\!T@:4XO*9"L1.C9I;QE,9&8AB\L?F>%1,Z.K.HY)
M/Y`P,;FQP5F<;L"[J4YU4)`J+(SA`V0%B%;N_"JNGDX732YCB'"F8382&B[I
M<0"&@P,(PT%>.\S896U69<1G2&`L=B$UC8N:TO=?M:QKB"\B\V(:#"(CI64%
MM1F++DPT=U4V`MGB1:ZQU@%BG*-Y7>.-ZYJ;E<Q>HH7#S)!&H.6K?400O+@G
M3-QO59=RSAVN+:[CQVG@WLXOM`N/C"P1(A$-M&Z(A;I6P^2*V,RR7=E$!SM;
M+NWB"0P.OW7/@T[AI+A`Q"[2/4'BA9E%%AKE&-)D%YDD_B<9:5C<N+22Q[Q6
MP1219$31]Y*)/:#^2:68I2%%CSDXS5A*HD@)MTIUPT5E.9XIKT)Q<X`0-I8`
M70.BR('QQ`T%87857-HCB%R-(UC'.((BT37.;+O#3NBPD0!L+287@N[",]89
MR-'BY5$,DQ1Q8E"Z>MZ-6J<RF0]P,Q>[N3'/5;8VON]KHYL\:7M"C=ER<DQ&
M(@%CP&B)$$R]E5=-.9K);VED7#3#L3!T`8$@0TZ-G0L-3A>(TDW43Y,P30&$
M@",-8`Y@);$`N!$&DQC9"-BL[#DG',H01UTCF0(2]H)='1RZ+*&Z4LA_***E
M%;LHD;.19=92N9$9=KW4*0`N4FN$03;@$$5K9C)\B8UKF/:6N;$0(M&V.AMG
M8V5DS:.LD.>R=*F-=+?<=%IW+ODFRPG8&D[$57G_`#CB.,/$#8GF?,)+AE!+
M.5F/[HSS7=NE96-6:\@FI;6]-!2YF&K96D`S=P&>`Y2(HPL@)AI8P6P/JZ:6
MYC'/%Z8'7=D&Z(N@198.KL+-E8;7SI<V;+E.+))8'QL+=8;K(@P,";(P@(@F
M`,5:&:?0B0(&MQ:9;'E!#Q$F2>("37="B<10R1I4RQDDRIH7')G5O9G$A87M
M#U!)0-N.P+WL/9#6-LZ4\!S7-@6AVFVZ=!AI`^-9,REJ93G,F2W@MF%AL)%]
MI(<T$1!(@;`3MJ15RF+(%`$B^4QE`K,NYV+2+I"SHU1EV0H]0]V`G4K2CAW9
M"$IIBW8#?J0!0Q&[2P!7MB,R6#`N:#;LC8T]39VE@;(GO%YC'EMEH:3V78[&
MS$0VXB"X$TRABT;&6BF406&2@BZJ+EI)0PJC).EL!09=3&RR'`P;^FL6D.%N
MB2QP-@H=]G[@6Q!-E&$'--[1:+?BV^DJZGJ&AQ=+F`,.ZBUVY_=6;G2-,-(V
MU9*S%DI1%P*?8JOVFK_DYM5ND+*G_@7_`+D_M+17A'P,B/YLL/O6EKX?9R_2
M_%?RE4_QSU_2.]VW_3MD+^Y>"?V;3*T5QM=TI1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+9S_FNW_CIKG_T3Z8O^
M^&H>O9/NU?HSB7]/9_%!?FK_`%W7^.&2O[J5']H/6Y'7H]?%=*(E$2B*OQKV
M"L]WI)[_`#C5*@T=,JP5%4HB410$I^#CU[G*?Q=Z*'05/T52B)1$HB@'7\KQ
MCV^X>\KA5&@J'2%/U%4HB41*(JXW_"21^U6'\6XU=A81V15CJ+$E$2B)1%68
M=\'D7\,Y>^BVJ[2H-"LU15*(E$2B)1$HB41*(E$6I'_6Q*(L'-'$D7Q_`N$I
M1"VS/S:1/-,V#H;DUG.T8Y"RY%9&IQQ%7YGC[["I(E<V)LWJ=6F2F(W`LTET
M0N*0DL9'4Y@S#!]PX5,+*&3,E"<`^GEM<-2YX-UI`+3$"!!@=((T07E/,TEL
MW&JN14&E)E5\]\L\;ERG-UCP7->TAQB"T%MK7-),8B`7H>-V=RPTY(I9C9)J
M1;I*6T2J,N$:6:&,R*<5HH,\2IOF[!`L7Q=9*ESSBUFBD@2*^HMLYO2(H#RK
MV$.YEI""-3)!IG"9(UPF0(AJ'W+I-X-:(Q8`8PM<-T;-`&AK)C,089%8:,R;
MS7!PK9(F%X:6.?,<&@3"YI$=RPFXW=1+B8J28_89G`\;-RYLUCPW)4)A,P*-
MR%$=)V3%SFFRUD_(\)RED3)+*H=&E/>YJ]W8G=K*).*M8QK?#+"VMR@@O@?)
M9-E2VD5+9[&NW0E.)OO<USG"(V2"/B<L<FJFT]5.>UV'S*.9,9\VZJE@:J7+
M?+ERS`G0',=$:',&VNDQ8;QE&I<L<6>%:I"(,Y3QBG)T2/T2Y$52!@!"I3D"
M20N(P.=';)L7BH2)^8A?"!-ZL;RF2VV!)NJ5%A1E-3LF%S6U&J+PZ&H=$72X
MM#7;`W4'6&]#8B5BFXA6SJ<,F3*+C(E.9>XY+#77VRVO>]GW3MQ>8;PN$_=0
M"CQ8?C:QG;(^[,^I0YN306%Q1>K:M!&16F0[Y8WQ1/\`#L271M[$Z+A1B,.D
M<G0ELB90E*"W=U)/,+4)"5QY-IQ>66ACA/A<:+*=P,6L<P0,3`$.BYNR8VB)
M"Q^4)S9CIK'48>9KW"-;++83)K)K@X0%YP<R$M]EUI`(<6@KV#+3%B[*4,BD
M+38UU9P%'`\4RO'D'6P_2'D%$?#I$[FX[<(KD:-I2V8AO;G:$OF.B%):.Q=T
MZXM4<G.%8H8[#U%0VGJ);9094,#)9:V$EUA-V#A9I:6QAH,2"MOH)M;15#Z@
MSJ":Z;/;,>'U4LWVC6!TMQC$A[9A$=(@"+0(>4%X:Q^6.7!O&=62KE+C%#"&
MQX7Z0<XJ9#$WQ'A^`8>.>&@L$F(A:B+KFS'2-:8T'L@U(3SC2RW``+%"!D<6
MD[K<U!O2[H.IF1!N-9$6W8$-!A=CIM6N\H51U>[H1<G%Y`JI-UP,U\V!W-^\
M#,(O!\(`$MTQG%F.XA($60%LQB^IM]G4_09#N=*R-"V0$:!@?,B9P:<Z.9K.
MP.!KVI#%3'9D3M"]J&XW$[,^Z%*%.V,O>V(R93P\S6SS->'6ZAUA<\3#`6V1
M$"(VC25EMJZB2Z4VG?1-II1E[GCK"7"7),D1<("]!Q<UUW<O@0VQ=QCQ_CUN
MD1,U<8%J953`4ZA>0U"YFT09!86MH>(UGV69Z>66!MPBW1;"HC)5TK$UB1E+
M%`RR";J#35)IQ@:Q-E2`_6N9/,R^UT1(<`")CIA#1:6@QA"/1M6&;55;Y/%F
M3:,4^J?+@:R6XD.D-D`O-@>]H;>B0+3```!9P?*9CWQ-ZKOFQ96XEK=./L[U
M4;T_K+C7D:=X10^,RNNGRF8]\3>J[YL65N):<?9WJHWI_63R-.\(H?&9777"
MHU,QZZ95;Q.:K;;*15;9OIBRM:UME.9;9%?>7H!M]F_V+517LC^"J-Z?UEES
M<%GNEN:*BAB0?_,RNNM+:&2\((?%0!BF03;`CC("QI,%DAI)FT;4P+C*-+0"
M+,+%</0$&][7MT;5\B\S\V>:ZS,N(U<AE-J9M=/>V-1)!@Z:\B(+P08&T$1&
M@K]VW,9[\_N^9:YD\G9=Q2JQL8G096PJGFAF#8G,8)LB@D2I@;,93.8]M]IN
MO82UP@YI((5EY8VYH9%[P9/Q?6Q^RK.'R*7QF1W:[2^T"]V[PO'O,F*_14Y8
MVYH9%[P9/Q?3V59P^12^,R.[3[0+W;O"\>\R8K]%3EC;FAD7O!D_%]/95G#Y
M%+XS([M/M`O=N\+Q[S)BOT5.6-N:&1>\&3\7T]E6</D4OC,CNT^T"]V[PO'O
M,F*_14Y8VYH9%[P9/Q?3V59P^12^,R.[3[0+W;O"\>\R8K]%3EC;FAD7O!D_
M%]/95G#Y%+XS([M/M`O=N\+Q[S)BOT5.6-N:&1>\&3\7T]E6</D4OC,CNT^T
M"]V[PO'O,F*_14Y8VYH9%[P9/Q?3V59P^12^,R.[3[0+W;O"\>\R8K]%3EC;
MFAD7O!D_%]/95G#Y%+XS([M/M`O=N\+Q[S)BOT5.6-N:&1>\&3\7T]E6</D4
MOC,CNT^T"]V[PO'O,F*_14Y8VYH9%[P9/Q?3V59P^12^,R.[3[0+W;O"\>\R
M8K]%3EC;FAD7O!D_%]/95G#Y%+XS([M/M`O=N\+Q[S)BOT5.6-N:&1>\&3\7
MT]E6</D4OC,CNT^T"]V[PO'O,F*_14Y8VYH9%[P9/Q?3V59P^12^,R.[3[0+
MW;O"\>\R8K]%3EC;FAD7O!D_%]/95G#Y%+XS([M/M`O=N\+Q[S)BOT5.6-N:
M&1>\&3\7T]E6</D4OC,CNT^T"]V[PO'O,F*_14Y8VYH9%[P9/Q?3V59P^12^
M,R.[3[0+W;O"\>\R8K]%3EC;FAD7O!D_%]/95G#Y%+XS([M/M`O=N\+Q[S)B
MOT5.6-N:&1>\&3\7T]E6</D4OC,CNT^T"]V[PO'O,F*_14Y8VYH9%[P9/Q?3
MV59P^12^,R.[3[0+W;O"\>\R8K]%3EC;FAD7O!D_%]/95G#Y%+XS([M/M`O=
MN\+Q[S)BOT5.6-N:&1>\&3\7T]E6</D4OC,CNT^T"]V[PO'O,F*_14Y8VYH9
M%[P9/Q?3V59P^12^,R.[3[0+W;O"\>\R8K]%3EC;FAD7O!D_%]/95G#Y%+XS
M([M/M`O=N\+Q[S)BOT5.6-N:&1>\&3\7T]E6</D4OC,CNT^T"]V[PO'O,F*_
M14Y8VYH9%[P9/Q?3V59P^12^,R.[3[0+W;O"\>\R8K]%5H@Q4MR9-8OCC'^+
M\M2^=S9Q4M$2BC%C:5KGJ0.:-G=)`K1-B,INN-0>G9&56J';H;4E.,5^A:M1
M2\S^>*V;J*6333)L"8"ID$P&D_A%M.-_K(/=5RW0'$\=Q3&:6@#VLOS,%Q4-
MO.[%L>*:3`P^)9<?($U]^8QJV\ADVXOK<O81SE>!RO&)'=KAOVL/N1^LF(>:
M,4^BI\@37WYC&K;R&3;B^GL(YRO`Y7C$CNT^UA]R/UDQ#S1BGT5/D":^_,8U
M;>0R;<7T]A'.5X'*\8D=VGVL/N1^LF(>:,4^BI\@37WYC&K;R&3;B^GL(YRO
M`Y7C$CNT^UA]R/UDQ#S1BGT5;$G\W5TZZC-/N5-84GSMI^S+A]HF./M/S%%3
MLAP%ZC2B0.4:D>;%[\4UH5Q(%JDIL2R-%<PVQ>Y;)]@V%<5A6MZ1YD\FX_DS
M!*VBS!*9*J)U4U[`'L?%HEAI,6$@6[!M7Q2_6?>\GS1^\QSHY9S-S05\_$,'
MPW`)U+4/F4M12EDY]6Z:UH94RY;G`L,;S06C1&-BVI.42?@U_P"X+GVO7<\%
M\SH_&G*)/P:_]P7/M>D$C\:<HD_!K_W!<^UZ02/QIRB3\&O_`'!<^UZ02/QJ
M"C[Z04C5ANWO@ML]R$S9+9'$=K6,>UX[!O<!%[6&&PM@0?1"*U[7Z-J$*`_M
MJ=Y1)^#7_N"Y]KT@K'XTY1)^#7_N"Y]KT@D?C3E$GX-?^X+GVO2"1^-0DD?B
M#6%W+LWOH;C0*`V$8R.)8`[(+]$0QD!"$-OLWO>D%";%-\HD_!K_`-P7/M>D
M%8_&G*)/P:_]P7/M>D$C\:<HD_!K_P!P7/M>D$C\:<HD_!K_`-P7/M>D$C\:
M@W)](&Z1T=F]\M8I:N%>PF1Q"(6V:%P-@L(B+",%:XMF]K6OL6V;^A:D%";=
ME3G*)/P:_P#<%S[7I!6/QIRB3\&O_<%S[7I!(_&G*)/P:_\`<%S[7I!(_&G*
M)/P:_P#<%S[7I!(_&H!"^D!D#\;O>^7L:F9;6"%E<1&!W,"_9N,NQ%Q@L+;=
M"][6V=B^QZ%(+"#:=*G^42?@U_[@N?:](+%'XTY1)^#7_N"Y]KT@D?C3E$GX
M-?\`N"Y]KT@D?C3E$GX-?^X+GVO2"1^-5V*OI!#$D+N@?!W":X7VQ3*XF@OM
MG)6.VP,!`@WO:PMB_1Z%^A5(M4!LV58N42?@U_[@N?:]2"L?C3E$GX-?^X+G
MVO2"1^-.42?@U_[@N?:]()'XTY1)^#7_`+@N?:]()'XTY1)^#7_N"Y]KT@D?
MC3E$GX-?^X+GVO2"1^-.42?@U_[@N?:]()'XTY1)^#7_`+@N?:]()'XTY1)^
M#7_N"Y]KT@D?C6IKU<5^`7_TK3?'\GJ_VG67[U^5O^K?OE153&@I>@3Z(])A
M*A>A3G%Z=L<KC"5"U,0<6A(CR2QZX91IH#`(B+_MSKVL6#[(K5WQ@Q`PBFB1
M_-V?>A>+<VM><TXB0"1QZ:-!TWS9\?066)+PS*"PG)WEG4$F*RT!9R=U;SR3
M'`T&ZE("S2E(RQKC2ON@DVO<P0>C8.Q6Y7F[!$([:X\9<P&!:X&$=!T;?Q=%
M?0M[9#EREK*>F@QS1+2FU6V@<T(G!*Y'MZ9V(;CT5C^J2EYS4M)5!)N&Q@DQ
MQ9MK;08177VDW8B\#"$=G3#XX6_$AES`T/+77"(@P,"(D1CHA$$1VP1I4I_^
M6L2P+@3J4RPK=D:E,K)W501NR0\E23NZ0\Q*K(W4@9A>[I%1(RC0;.V+-`(`
MK6$&]K0$&T6A4@M,'`@]'HVCJBT=!=1:\L[:H3)')W:FY4L2N*Y(G<'%&B.4
MH6<*4;NM(+5'%#-1M05Q%U)H;7`18\O;W#MP[,+FM,'$`GH[6GJ;*Q-ES'@N
M8UQ:"`8`F!,8"S9,#`;,#!2`1!&$(P"",`PV$`8!6$`816L((@"#>X1!$&^S
M:]NA>U8E@7`I6(T02AK5B1$`XVR<D:Q40E`<HN4:?9.2)086$T^Y!!@]H'9%
MM"Q"V-@-[VA(&DP6(-<[L03#:M7(2<2I))4ICB5*9044H3J4YI9Z=0G.`$TA
M0G/*$,H\@XH5A`&&]PC#>U[7O:]`01$:%""TW7"#@N6JHE$7`J]B+/::O^3&
MT&E1W8E:0./?@'#/S78O>U/7SXQ7\:5/](F??E?I1R/^A.#?DJD_J\M7"M`N
M3I1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%GM]%
M-_O/M"'^F68_[/&;JY;DK\>#^!?_`-BZ#]Y3_#)WY0I_VWK^C=7;J^?241*(
ME$4`5\*%ON`U^^+O1394_15*(E$2B*OQKV"L]WI)[_.-4J#1TRK!452B)1%`
M2GX./7N<I_%WHH=!4_15*(E$2B*`=?RO&/;[A[RN%4:"H=(4_452B)1$HBKC
M?\))'[58?Q;C5V%A'9%6.HL241*(E$59AWP>1?PSE[Z+:KM*@T*S5%4HB41*
M(E$2B)1$HB41:D?];$HBQ-T4Z7B<APS2?F2;[RC@C!I<TGA8FN\=CCN]RI[A
MT?S.CDT<>7MR*5/#-CU4V9(3;Y-!)=DTB^Y*4"N42,LSN;"*`3J>FJ9L-2VF
MDP$`22&OB"3:&P<(C0[9L"\F9IQHTE=B.'TU[C3L0J[QO.#6A[Y1:X`6&8#+
M-UQMEZ1:01Z/CO2VZXDOB!6[:><?9+C<=QSD".2"%,AV/FTN"9#><U'3E'E=
M&@>D2=KDK@[X[(0MABUO"?($&]*9*F*,*.'8O4R:!U/JBZ2Q[&L<"T71=<7W
MK]MA);`1&Z$`!I6WU>-LK^,-95S9,Y\Z6YKSK#?EB3<,HD&+0)EYP:Z#'7G.
M)!%M=G>E#*66VK%V153,V)Y@O)RUF?),;?[,*)^5S?).6M/LZC>+4,@=T:M[
MQR],^*L97C1<C:C4R]G4-A0-UL4<8&^";A]14-ESB!K3?>X&$;SGRW!D3:TA
MC;MX0(AT5FTN.45`^=2-<XTXU4F6YMXM#)<J>QTTM!#9@,V9K-6X%KPXV1`5
MU*Q]K0N-4J?'G(3JV#DD:.R2QL.:XTRR/(YB>7926/3]@E_NH0)L,1`R/.L3
M`:S'*&DY00VGIPEA-"8<NS=3B>EQ>6WA>`>`7;IT3+/W#8%FYLT$=$Z<U>78
M!LILD/N.U;G27%LO<2P&SFP.N=>$V#P'`%P,80#8*^!-6T-9%R''LODZ=FD<
MD?I5,HOXQTB]P)L\ZC\CS%6V8V46?((1%G)VQI*&XYP,2.[.!><0>48H"I'8
M0L'%,1EM(DN==<XDB];;,<=S:V!+2(P(C;;%9GE3`:B8'U<MFL8QK6.U9`LI
MY;`9EC[P$QK@V+'W000(*T2_"4_RJQ2>^1V&?3F0XY@F$,80A<49C)ADTGF#
M&OC&7LI91WLG0W'$$I;7*;HH^VN+8MNI9GD$<6$!N8$0!5F3*6=4,=KP][V,
M8QO8@DB#WO@[<$%UT$&(==(633XE2T,UG%'RI4J=-G3'CYQS6L<'2I<N+(36
MD,+W-<(/9K&FQ0+E@[6>ZLP7&V1G>%RD$->T">'XKR45$<3,3ZSZ:(,AQZW1
M2*V1&$-#`1J6:W$]27MKV&VBN4:(;:;=./`ZEQ-S8WRV9=-C'08")3;L!L#6
M@QZ'^S8LUF)9=9,N:ELR3K&F_-EWIKFFH>9A<Z,2[BY:!_M6B#Q%2CMB35;-
M\I21PEJ=,5C@B=(I#&V-7D`I]:2CVM'F6/IY''$:][=%3'9UBLO9PJD)*)D2
MD*-T(`E/ZEZN4XG4^(3:ASIGX"]$"]$67Q$6F$01$0:!H@81."77X'343&R"
M>.&46N<&73:93KKB&B,',?!Q+R1`Q%ZZ,Y\51]RB.*\71)Y+))>(IC6`QAW)
M3'`4IB76/1)G9W(E.I+V"U"<I:B&$!@?N1AM:]NA>MUIV.E4\N6[LFL:#\8`
M!7&:Z:R?73Y\O\&^<]P^)SB1^P5?:SEI4HBX%7L19[35_P`F-H-*CNQ*T@<>
M_`.&?FNQ>]J>OGQBOXTJ?Z1,^_*_2CD?]"<&_)5)_5Y:N%:!<G2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+/;Z*;_>?:$/],LQ
M_P!GC-U<MR5^/!_`O_[%T'[RG^&3ORA3_MO7]&ZNW5\^DHB41*(H`KX4+?<!
MK]\7>BFRI^BJ41*(E$5?C7L%9[O23W^<:I4&CIE6"HJE$2B*`E/P<>O<Y3^+
MO10Z"I^BJ41*(E$4`Z_E>,>WW#WE<*HT%0Z0I^HJE$2B)1%7&_X22/VJP_BW
M&KL+".R*L=18DHB41*(JS#O@\B_AG+WT6U7:5!H5FJ*I1$HB41*(E$2B)1$H
MBU(_ZV)1%B1I2U=I\4X,T]XJD,,L<RM>A3#4[A,F2/(]\IOEI_12%(R84*9A
MH-P1NDI01O=6I4$\T:@TM4`1-K$A$+N;#,1%/12*=[=R*.6YIC:YY!@R&V86
M&-MMEB\F9BP$UV,5M=*F?..Q6>Q[2+&2FN;&=&-H:70<(61;;:O<HYKY0R?#
M#+."<>.S3-GF+F[@$^Y;EBE7E2,MD+?,G8R8Y22XHI8XJ(6SR^QH%REI0(EU
MTQP"3AF$F%UK68N)E*)H81-+?C9?`!<T&,3=!TD`&!AH6TSLK.D8BZF,YKJ9
MK_BFB4XO$N86P+1?+(70]Q$02`""O7$^M#%#N]R2/11@R1+GAJG16.XP@8V!
MD'?(LG,F$MA"A!%'!PDS>T(#6UZ@SJ-0!\4,QO4":RLL!A!I0AZ@8G3N<YDL
M/<X/NB`&Z,2V`MAI:>RNV".B"T!R[72Y;)L]TF7+=*UCBYQ^;;<:^+@&DF+7
MMA<#Q>-TD$$+NR35+'4JV*L4>9GCE'(<B)X<H1R=NWO2-J!@U`XZP+D<X]0A
M<5.U=V5XR`68A+MNA1^XB$.]@AVHJ_$&`M8P&^7W;=B$QLMVSI!=8L,G!)SF
MOFS7-U+)1?%IB272)D^7I&@AENR(V*WX)U&8^U$MSZ[8]3R<#8RV859"]_:4
MZ!&_L<I3+UD<?V)6A<71,<E<4S::(Q(H$G<T/[GU6E(W4K;YM)6R:UI=)O71
M#2-(.@BT]32-D"*T^)X15X2]LNK++[KP@TDEKFP#FN!`-D1:(M-MUQ@5[U6K
M6UI1$HB41*(E$7`J]B+/::O^3&T&E1W8E:0./?@'#/S78O>U/7SXQ7\:5/\`
M2)GWY7Z4<C_H3@WY*I/ZO+5PK0+DZ41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB419[?13?[S[0A_IEF/^SQFZN6Y*_'@_@7_]BZ#]
MY3_#)WY0I_VWK^C=7;J^?241*(E$4`5\*%ON`U^^+O1394_15*(E$2B*OQKV
M"L]WI)[_`#C5*@T=,JP5%4HB410$I^#CU[G*?Q=Z*'05/T52B)1$HB@'7\KQ
MCV^X>\KA5&@J'2%/U%4HB41*(JXW_"21^U6'\6XU=A81V15CJ+$E$2B)1%68
M=\'D7\,Y>^BVJ[2H-"LU15*(E$2B)1$HB41*(E$6I'_6Q*(L6]'>%LN2O2OI
M/E]@Z37`UOQ5@B4Q)QF>&<G/TL9UV.&9Z.QHZJW9'F)K;CI'#+3!SNF5)DB8
M`#%Y]P@#8=K6[HPJEJ)F&TTS^3F$J61>8XD%H-TQOPBV)@0!I*\DYFQ&@D9A
MQ&G/'P#4U#7!DV6UI$QPU@`,HFZ^XV()/8BU>WM>DR>LARPYH8M%;?=P9PL*
MHA/A3-ED%VNQ3&G,*3M8\_#:T*Q8FC#:4J6)R2EJPE`G+4'&@*`&VL;ATYL2
MT4HB(=A,T6;&LAL")%I@(E;2_':6:`)CL2,'7A\])C'=;.HB0"YQ`)(!<2`(
MJ3<=-&6W9')6YP'I,/;Y=(B)<^(08SU"I4=Y4G>%<A+DC&F1:C$Y,.>QOS@H
M6FJ66S>:>I4&F&W&(TRXL3J&H<'-=Q>#G1.YF:8QB/G-R8VQ;"W2L#,9H);F
M/9Q\/ELN-.LD$W8!MUT:?=BZ``'W@``!H"XV[3#D]IE"R:-R#1HDE2Y6WKU+
MV##&;3%/5K4_QZ5HE*8D_/QJ)`:&4Q-M<S;IRBNJ7!&!0?NAVV&(*">V89K1
M2B82+;DS8(/?++0#9I(B57XU13)(IWG$3(`(`UTF$"US3^\1.Y<YHB3!I($!
M8KA",1ZBL;(5C7!)#I6C36N5=6&M:/%N=U+8G,MNFT(:&YRU`KD4?;"=V'N2
M)O`E1$[:^T*#69*IJV0"V4ZG:T[%R9#I#66#H"`Z"T]37X16/$RJ97/>!")F
MR0>F1(!<>BZ).R5=MZ=8/Q@Z7/(]E_\`3A6;=Q+Y=/VC^[6FUF7^\UV_2N!3
M>G6#\8.ESR/9?_3A2[B7RZ?M']VFLR_WFNWZ5P*;TZP?C!TN>1[+_P"G"EW$
MOET_:/[M-9E_O-=OTK@4WIU@_&#I<\CV7_TX4NXE\NG[1_=IK,O]YKM^E<"F
M].L'XP=+GD>R_P#IPI=Q+Y=/VC^[369?[S7;]*X%-Z=8/Q@Z7/(]E_\`3A2[
MB7RZ?M']VFLR_P!YKM^E<"N%2T:P>I56SD'2[L=2*MG8P]E^U]KU.9MMB_CP
MO:U]CT*H;B4>SI^T?W:P3)N7VRR[4UU@C^&E<"M+^$J\F%PV)@3N<!L0&-LN
MXV.C4C,.L5=N3W+L:,$O*`,RP;VM>]@AM>_H6MZ%?+;,/.KAE%C]=1OP^H<^
M563F%PGL`);,<TD#4&`,(PB8;97[+N:+]7YGC-/-/E?,U-F_"9%-B&7<-J62
MG8343'2VSZ.3-:QSQB;`]S`\-+@Q@<1$-:#`6CJ[*7">/>]>2^&=;1[7L)Y.
MJ/&&<`NP_LWL_P#KK@_F:H_.R=792X3Q[WKR7PSI[7L)Y.J/&&<`GV;V?_77
M!_,U1^=DZNREPGCWO7DOAG3VO83R=4>,,X!/LWL_^NN#^9JC\[)U=E+A/'O>
MO)?#.GM>PGDZH\89P"?9O9_]=<'\S5'YV3J[*7">/>]>2^&=/:]A/)U1XPS@
M$^S>S_ZZX/YFJ/SLG5V4N$\>]Z\E\,Z>U[">3JCQAG`)]F]G_P!=<'\S5'YV
M3J[*7">/>]>2^&=/:]A/)U1XPS@$^S>S_P"NN#^9JC\[)U=E+A/'O>O)?#.G
MM>PGDZH\89P"?9O9_P#77!_,U1^=DZNREPGCWO7DOAG3VO83R=4>,,X!/LWL
M_P#KK@_F:H_.R=792X3Q[WKR7PSI[7L)Y.J/&&<`GV;V?_77!_,U1^=DZNRE
MPGCWO7DOAG3VO83R=4>,,X!/LWL_^NN#^9JC\[)U=E+A/'O>O)?#.GM>PGDZ
MH\89P"?9O9_]=<'\S5'YV3J[*7">/>]>2^&=/:]A/)U1XPS@$^S>S_ZZX/YF
MJ/SLG5V4N$\>]Z\E\,Z>U[">3JCQAG`)]F]G_P!=<'\S5'YV3J[*7">/>]>2
M^&=/:]A/)U1XPS@$^S>S_P"NN#^9JC\[)U=E+A/'O>O)?#.GM>PGDZH\89P"
M?9O9_P#77!_,U1^=DZNREPGCWO7DOAG3VO83R=4>,,X!/LWL_P#KK@_F:H_.
MR=792X3Q[WKR7PSI[7L)Y.J/&&<`GV;V?_77!_,U1^=E^H'T9'T;N:_I)G7.
M[8T9UQ3B+Q'HL5*U!KCB*8304D\9YN22R@$EILL1D+79E\78KBO<1]S^J[;%
M@;G?;]R\W/DWG!PB=BK&SZ42:C572]DR.X:Z]&XR'90A#8TKYI>^A2YS]S_G
M$PW(%1485C[\1P@5VN;3U%)JP9\V1JM6:JHO?@KU^^.RA=LBOUC_`.&.U"^>
M]A?YLTY_]0M=@^@=!W^=U&]9>/OK4YLY*PWMI_=I_P`,=J%\]["_S9IS_P"H
M6GH'0=_G=1O63ZU.;.2L-[:?W:?\,=J%\]["_P`V:<_^H6GH'0=_G=1O63ZU
M.;.2L-[:?W:?\,=J%\]["_S9IS_ZA:>@=!W^=U&]9/K4YLY*PWMI_=I_PQVH
M7SWL+_-FG/\`ZA:>@=!W^=U&]9/K4YLY*PWMI_=I_P`,=J%\]["_S9IS_P"H
M6GH'0=_G=1O63ZU.;.2L-[:?W:?\,=J%\]["_P`V:<_^H6GH'0=_G=1O63ZU
M.;.2L-[:?W:R'T@_0&9@TKZL=/.HN5:LL:3IMQ).'Q^*B$?P/*HJN?5SQC.?
M0U.F&^N.9I,G0I4P).-0.]D9@QW)""UP[:]ZW3",K4F$5G'),V8]X:6P<&PM
M^(+A6?N?/'N<#+YR[B%#14],9[)M^49I=&7&`@]Q$#&W96S=N4MZ^CO<ERXY
MKD^YZ*Z2M3<I;U]'>Y+EQS3<]%+4W*6]?1WN2Y<<TW/12U-REO7T=[DN7'--
MST4M4*65)^42RUEK!N^\K=MA7;''<MRZN=-I8(-]]M8=A[;9OMKVO;8Z%MB^
MRLZ*EL5-;E+>OH[W)<N.:;GHJVIN4MZ^CO<ERXYIN>BEJ;E+>OH[W)<N.:;G
MHI:FY2WKZ.]R7+CFFYZ*6J#CY<GNC5[BM8`AW[D%A6,;'$8KFV>U]C16N%V!
M:Q8C-FX;;%[V#L6O>]]F]Z8*",%.;E+>OH[W)<N.:FYZ*MJ;E+>OH[W)<N.:
M;GHI:FY2WKZ.]R7+CFFYZ*6J%D94GLPN^[K6`1/4"C=+%-CB`RX=SOLV`(3N
M8$(OM7N&]J6=%0Q@5-;E+>OH[W)<N.:;GHJVIN4MZ^CO<ERXYIN>BEJ;E+>O
MH[W)<N.:;GHI:FY2WKZ.]R7+CFFYZ*6J$<BI/OI'=NM8+F76KMQN%L<;`"+>
MA=M[F!N["N,-R]FUK6N&]A;%_0Z%[9T5#&(4WN4MZ^CO<ERXYJ;GHJVIN4MZ
M^CO<ERXYIN>BEJ;E+>OH[W)<N.:;GHI:FY2WKZ.]R7+CFFYZ*6J!0ER??]^L
M!:PV.LF9=V$)L<;EB#M%^Y;F"SL$0+VML[;9$+9Z&QL?96*",2I[<I;U]'>Y
M+EQS3<]%6U-REO7T=[DN7'--ST4M3<I;U]'>Y+EQS3<]%+4W*6=?1WN4Y<<T
MLZ*6JO14J378DG4ZUA"5NKAM;'-C@89L[Y*]OLB`[%!O:X]G8^YML6Z'1]&J
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MD+*G_@7_`+D_M+17A'P,B/YLL/O6EKX?9R_2_%?RE4_QSU_2.]VW_3MD+^Y>
M"?V;3*T5QM=TI1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6U-_-;OA9KZ
M]Q=)_P#*M2M>TO=N_0^L_*!_BI:_,?\`KK/]1V6O[GL_K]6MO"O0R^.:41*(
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M&9\'JJG',3KY186"MJ-Q$WR);V7R!=NP&L987`F)@#!9EDZD<"*+M@$^68><
MH>4DG7-B`I6J&[*4D*.+3RTZ[+9'OPFM'E)Y12D)Q!8@&GD@M:XSR0CW7CM(
M80F-B8PV]SILTV;/2VPN-'",4%XF1,`:6@F`@"_L;8P-X1(@=`)V#",2:IM/
MBYQ=VU+E%@-&R1F)2Y8L"4Z";#F6</+S'8W9L7`0"*=7A6^L*E(8VI]NX$*`
M;F,FP[#L#"*^C+BT3!8T'9A!Q($-LQ$(:>@L3L$Q5K&O=(?!SW,`LC%@#G1$
M;`&N!O'<D6QT*<8\]8M?I5(HHGE;02H8F5HE*-Q&Z-RENE,0<H&UY%63",C1
M*E!RV,L,;>4PUBP82R`#.!8(A;H#;8V5=.^8Z6'"(`,8B!%T.B.@`1$K+FX7
M6RI#)YEN+7N+2(&+7AYEACHBQSG`P%ILZ!7F,-U;1V1N)*.2XTR3C-MMBZ)Y
MC<IA-#8`5#6B"3Y0[(X,N5*VZ;*I2:YR9Q9S$1*`#/U:!<(!(R[6&`P>GE8B
MQ[H/8]C=6'DNNW0UT;NAT8DB$+L8V+6U&`S9+"Z3.DSGZ]TH,9?OE[(%X`+`
MV#08EU^%VV.D"WJ-5>G9&N=42W+$91%,T.B,]7.ZL2XF/6C4ZDSG#8N<G?!(
M][U+FY2IJ,;[-X!W7`6"+)$58T6TMFG$*($@S&B#0Z.Q!Q+1;HB2(0TQL@M.
M,#Q9S6N;(>2Z8]@`A>O,:'NW,8@!IO7NQA$Q@IY9J&P:WENAJ_*<21;RNS2P
MN9*I8H(6IW=^"[C9D13<8E"X+[N)<?<1%F)BCB=JW*[W':R4^Y>,UE((QF-$
M"`?C,8=6!T;1VBLIN$XFXM#9$PWFEP@+(-A$QC`0O-TD'=-^4(]@_/N#TR=D
M5GY8@H4TD+C)["<4^$*]]T\R*>E$75(2D=E!YZ5Y2QMQ.+,L':`(0GFF7`66
M(5AK*4`$S&0="%NF]&'5@>H5!A>)$N:)$V\R]>LA"Y=O`QV07-!Z+@!I5+:=
M5F&#X6CGLKDZ'&\?7-L*7D'39S9DQXE$ZBSM,VEGLD:7%U76=B(^Q+%!I0R2
M]L2F--)N:26,P.4W$*4RA.F.#&$-[(C[H%P%A-L`>I$6+4S,#Q$5)I9##.F@
MO&X!/8.#"8D`0O.`!CI(!@2`O5F;)^.9')E4,C\XC3U*D386\J&-L<R%BNS6
M8F9UO5I`R;B2K"R44B;SCK$&&#3DN"49H0!4$W'J&SY#WZICVF8!&`.Q9UQU
M1MA:&915DF2*B;*>V070O$0$;1#;%K7`1TEK@(P,+U6<M*N!3[%5^TU?\G-J
MMTA94_\``O\`W)_:6BO"/@9$?S98?>M+7P^SE^E^*_E*I_CGK^D=[MO^G;(7
M]R\$_LVF5HKC:[I2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(MJ;^:W?"
MS7U[BZ3_`.5:E:]I>[=^A]9^4#_%2U^8_P#76?ZCLM?W/9_7ZM;>%>AE\<TH
MB41*(E$2B)1%7GWV5&?SA+]Z'BJ%#L?&K#452B)1$HB@"OA0M]P&OWQ=Z*;*
MGZ*I1$HB415^->P5GN])/?YQJE0:.F58*BJ41*(H"4_!QZ]SE/XN]%#H*GZ*
MI1$HB410#K^5XQ[?</>5PJC05#I"GZBJ41*(E$5<;_A)(_:K#^+<:NPL([(J
MQU%B2B)1$HBK,.^#R+^&<O?1;5=I4&A6:HJE$2B)1$HB41*(E$2B+4C_`*V)
M1%AIHYBLC6Z<<*3U/I+G\AE,ITC8JQ*V909\M:>6)]8XHS1B8HDLBQBXO,G3
M3.`O+N1/UAIA@A%GV$6GVQ0;EBL/N3"I;SA\F:*=[ICJ5C`X/E@@!IM:28M)
MO']A>4,S3Y+<<JZ4U\IDAF(SIIEF5/<"XO:2V8`VX\"X+-&FVU>CQ3!$UAT8
MFL>9].VHQ.OGD<D$=>I6ES_I6:7\DN22*'R9Q6-V\KZW-R<TU=!T9)A0R3"5
M20:@I0$VYPAUJ)=+-E2WL;)GWGM()UDH&T@F$"-EH^,1CI6WS\3IJB=+FS*N
MC+93VN#3(J2W<M>T`Q:3H>3&((,"(041\FZ4`C[;&TVF_/Y*!IO%W%(4;F?1
MXM2<K8;D+)F1&"6G-2I:-I&I3JLP2%N-0!)`UG-JT%MPLH3DJ`X>)3`P,$B=
M`0/9R=(<YP,-'W;A#1`Z(@%9GEB29IG&LI;SKP/S-6#=?+ERW-B!']ZENO1O
M!PTP)"[;_@.;GFR1SAFEW+<(?9OCB'82FY[5F#2VD8Y%A>.HHVQN,('&665L
MS8V74L+,JNW'HK)0M;@YJ!E`NE,,2"KZ2:2YTJGF,>Y@8Z#Y4"P0!;`$`6`P
MA"!)V+%AE8I3`,945M/,E2ISYS(RJDN;.<7.#[Q:2=T1>!C>:T`[H!R]2RG#
M)IEHV9'O^D++3<;,8?C2'C"S9PTR%I&(C$.1G/*<"=&=O<)8X(1KFR6N6V.)
M5EJ42E*0`@9.UN.XM142YM07%]-,%YK18^59<<7M(MV"=F((L@M#15%/0"6)
M5?(.KF3'VR:C=:V6)3P2&`P+181`@DF*A&S&^0&E;&U*/2YF)*C846,BU3"V
M9:T@L<<?7C$F77?-40D:MH975"0UN5I?(W(*T#?=*G6IUH[F@$I"%1;`V3.:
M6D4\V`#;`^2`2QY>#`&PQ)C"$0=NU9KZRDF->'5M.7.,R#C*JBYHFRA)>T$@
MQ%UK;MZ)!%AA8JBVX,R.R3YPRHR80U.MN23Y4&3M,S'GO2([O#``8LJDJF0D
M;ZN<R7QO4M&9'EO":Z!6JDJ0M$!.85U(#;9;:6<V<:ADJ>)]Z(=K))([.RW3
M8]PMB0(0-BSWXE23:44,RIHC27+I9J*H!WX*!W($"#*8[<P!-Z(-XKZP##>7
M(*[N4J:=.N9(O,?'ME+*L;?(?FS2^=9AA61$8H^'$EDDPD3^@%&$L:V1;!2<
MLU$XJ#C$9I9=]@2335$IQF-D36S=<YX(?*L:ZRY:2(0ZA)@K58C05,MLA]73
MOI^*RY3FODU.Z?+-[6Q8UIO%VV8.:`'`E6UBQ7*X\D:$:#2?F[<F5''T2(1V
M?=,XS=QC>'I[A!!<P8)6#9,'$,BKS316V-LN`29;8+"(H>8R1,8`&T\V``_?
M)6PQS-O:<>G!9$VND3G.<ZNIHN+B?F*C[J:R<?N?ERV@="(TVAAW%LKPA*U<
MKAVD3*:@Y0SA;"$K[EK22X*6Y2H8(;'7MS02@M\2S!/RB205":J167[WW47,
M$$FP=Q+)4TB92S-9*IID80M?*LL:"8QO6W1$1A'8VF(5TC$I`D5%?(`#HQ$J
MJ`.Z>X`MNW-R7N`-V]"%NDG)OQN9T\SV?^6K3O\`I`K7<9J_!G]O+[I;+Q##
M>4)6\U'<+A4Y<SIU,JV='T_M;J15LW\=6G>^UMU.9LBV+9`V;[%NCL6Z-45-
M7'^;/[>7W2P3,.PUTMS?*$FT']YJ.#6EW"G*:WAT4W#'#J>3:.,@2CK2:%@L
M:`+:F"$RP#7XLT%AVMLVL(-A6M?HVM>OE%F3FHKJ[,5?6MKZ-K9U;/?=+9\1
M>FN=`PE$1$8&!(VBOVV\S'ZPG*65>9W*>6)^4LR3YV'9:PRF=,ES<+#)AD44
MB47L#Z]CPQY9>:'M:X`B\T&(5FWQG7Q9NW?3!_"&MF]CU?RC1=K4<"NR_M)\
MF^IF:-^PC\XIOC.OBS=N^F#^$-/8]7\HT7:U'`I]I/DWU,S1OV$?G%-\9U\6
M;MWTP?PAI['J_E&B[6HX%/M)\F^IF:-^PC\XIOC.OBS=N^F#^$-/8]7\HT7:
MU'`I]I/DWU,S1OV$?G%-\9U\6;MWTP?PAI['J_E&B[6HX%/M)\F^IF:-^PC\
MXIOC.OBS=N^F#^$-/8]7\HT7:U'`I]I/DWU,S1OV$?G%-\9U\6;MWTP?PAI[
M'J_E&B[6HX%/M)\F^IF:-^PC\XIOC.OBS=N^F#^$-/8]7\HT7:U'`I]I/DWU
M,S1OV$?G%-\9U\6;MWTP?PAI['J_E&B[6HX%/M)\F^IF:-^PC\XIOC.OBS=N
M^F#^$-/8]7\HT7:U'`I]I/DWU,S1OV$?G%-\9U\6;MWTP?PAI['J_E&B[6HX
M%/M)\F^IF:-^PC\XIOC.OBS=N^F#^$-/8]7\HT7:U'`I]I/DWU,S1OV$?G%-
M\9U\6;MWTP?PAI['J_E&B[6HX%/M)\F^IF:-^PC\XIOC.OBS=N^F#^$-/8]7
M\HT7:U'`I]I/DWU,S1OV$?G%-\9U\6;MWTP?PAI['J_E&B[6HX%/M)\F^IF:
M-^PC\XIOC.OBS=N^F#^$-/8]7\HT7:U'`I]I/DWU,S1OV$?G%-\9U\6;MWTP
M?PAI['J_E&B[6HX%/M)\F^IF:-^PC\XIOC.OBS=N^F#^$-/8]7\HT7:U'`I]
MI/DWU,S1OV$?G%;6'\UI<I#:3Z^[K8:X(%(6G2@"Z4;S'%0KE[MJ0,`=8U&Z
M'D6"9NE[;&VVUK@OLVM:]MGTOS+99G97R[4T4^?*GN?6%]Z6'@#YM@@;[6F-
MD;!!?$3]9ESY87S]\\F"9IPG"\0PJ32Y<;3&55OIGS'N%743+[32SI[`R#PV
M#G!T03"$%MY;ZN_-A?W09>,*[A@-M?..)VDWU=^;"_N@R\84@-M(G:3?5WYL
M+^Z#+QA2`VTB=I-]7?FPO[H,O&%(#;2)VDWU=^;"_N@R\84@-M(G:3?5WYL+
M^Z#+QA2`VTB=I-]7?FPO[H,O&%(#;2)VE`O3DZ"4QZXXZM+N!]`,%A+FB^ZC
MWJ=;;F&X%PK!%M17%LBV+;`=C9V;VJA0DV6*>WU=^;"_N@R\85(#;5B=I-]7
M?FPO[H,O&%(#;2)VDWU=^;"_N@R\84@-M(G:3?5WYL+^Z#+QA2`VTB=I0A;D
MZ\HU@^3JVYEV1N#<KJ]HVP067NMPF7OU=M+A'<5[;%K[-MKT;>A2Q2)CH4WO
MJ[\V%_=!EXPI`;:L3M)OJ[\V%_=!EXPI`;:1.TF^KOS87]T&7C"D!MI$[2;Z
MN_-A?W09>,*0&VD3M*"C[DZ`1J[`CJTVUWN0BN(*]HM8(Q/:\0R[V&N#>XBA
M7N&][="][;-KWML7H5!']E3N^KOS87]T&7C"D!MJQ.TF^KOS87]T&7C"D!MI
M$[2;ZN_-A?W09>,*0&VD3M*$DCDZC87<!D<6E`$@46$:)>T7""UP7V17L!<,
M=[6_8M>](!0DPT*;WT=^;"_N@R\84@-M6)VDWU=^;"_N@R\84@-M(G:3?5WY
ML+^Z#+QA2`VTB=I-]7?FPO[H,O&%(#;2)VE!N3DZB=(Z(4=6@$!:NN`%U[1>
MYM[M"X-PAN%=<-KA#>XONKVML6^W10DQT*<WU=^;"_N@R\84@-M6)VDWU=^;
M"_N@R\84@-M(G:3?5WYL+^Z#+QA2`VTB=I-]7?FPO[H,O&%(#;2)VE`(7)TM
M('X=HZM$,:9EL,JR]HL(JP0+]I<0KK;`O8S9OL;%[WML='8Z%%A!,38I_?5W
MYL+^Z#+QA2`VUBB=I-]7?FPO[H,O&%(#;2)VDWU=^;"_N@R\84@-M(G:3?1W
MYL+^Z#+QA2`VTB=I5V*N+H6Q)`%QY:>"QKAL&`7M`0BO=R5B%:UC%H!_<BO>
MWH>C;H="J=*@)AH5BWU=^;"_N@R\85(#;5B=I-]7?FPO[H,O&%(#;2)VDWU=
M^;"_N@R\84@-M(G:3?5WYL+^Z#+QA2`VTB=I-]7?FPO[H,O&%(#;2)VDWU=^
M;"_N@R\84@-M(G:3?5WYL+^Z#+QA2`VTB=I-]7?FPO[H,O&%(#;2)VDWT=^;
M*_N@R\84@-M(G:6IKU2IX-4_TK3JK]_0^SN"/9/[]_A_8_[-156+0)_J/Z2O
M_+_C3_NZEKOG!?Q12_P#/O0O%>;OTJQ'^FS?ORLN*W-<=2B)1$HB41*(E$2B
M)1$HBX%7L19[35_R8V@TJ.[$K2!Q[\`X9^:[%[VIZ^?&*_C2I_I$S[\K]*.1
M_P!"<&_)5)_5Y:N%:!<G2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(MH3
M^;`?#;7][BZ2O_CU(UVID7\63?X?_=:O"OO1_IK0?DP?QTQ;<%<V7FA*(E$2
MB)1$HB415Y]]E1G\X2_>AXJA0['QJPU%4HB41*(H`KX4+?<!K]\7>BFRI^BJ
M41*(E$5?C7L%9[O23W^<:I4&CIE6"HJE$2B*`E/P<>O<Y3^+O10Z"I^BJ41*
M(E$4`Z_E>,>WW#WE<*HT%0Z0I^HJE$2B)1%7&_X22/VJP_BW&KL+".R*L=18
MDHB41*(JS#O@\B_AG+WT6U7:5!H5FJ*I1$HB41*(E$2B)1$HBU(_ZV)1%@#A
M35#E;"NG?3:U(4L=48MOIGT21%J<C6(]8\1/+V:)NX,;<ID"HM98I=#YQ%8^
MM9DMKE%W;9!U`+=!A6""#M^BKZBEH*=K;NHXM(`,+0]Y@(]!P!:-IT-M>6,7
MP2AQ''*Y[B\5O'ZUY%Z`=*DMB;MECV.<'G3>9>LW*]3F.MO.<+2.\I6$0]7!
M@,31%]\B(P<)9$LJS+5CG7$F.W=YW)P$4LA<HBF)RH^<`0`72R):C47,VBDT
M`-5-Q6JE`S#=,J`&CL7&;,8TFWL2&7>@X@[*VZGRWAE0YLAIF"IOET+UCI3*
M63-F`66/:Z:7C;EAPA%HC<7G4QG*[S+&*$9,P_)9"Z3K4_'"(B^%0B)+\)LN
M#<])(#%%SG*')_*CV^&0HE<UK;`S`M(D5RM4A'8_J/JDFV:ZNJ[SF2IDISR^
M:(&Z"P2YET$F,-T+!?@"\BV$0M/+P;#=7+FU,FH9*;*IG7FWW"<9T@O<`T-O
M0EO@YVJB1*#A"]`JZ%:FY9,T&-YEC22JED-;673:VSA=)HBS-"V43'4CJ"@V
M/2T3LQ-JQQ;F5UBV-VMZ7A"UKCD%SY`A5$&*$O4XA9G'IDUK)LAQU0$N]$`1
M,R8UMH$0"&@FPPW0(B(+3'!I%.Z=3UC`*@NJ"P-<2&LIY#YD02`2'3"QNZ`=
M!CFD!T5#+M>4F%"U"TW&4,ATGD4=C<EA2Z39?+1P5NC<TQGF_(#,X3*6K8$2
M4SRPH.#ER9,U%I%B5<L7I"[*K6L?M<+L6?JB;C6S'-!;%^Y`<U[@7&[8?FR`
M($$D6Z5F-RO)%2&B=,F26/<UX;*B\N9,DL(8P/M;\\"71!`:XW="CV7Z0)P;
M("D?)!"6!^5M&-#%[PIOD-MCDE4S.(8TQ%,Y9))K$N3)J'&^+I2HR=8+2\]4
M*B[B)!<28)2DG:868P6R0Y[6DAENZ@8AK"2X0W+3>L=;\5JQS,JL?5&5*F.8
MUTZ`&K+FW'S)K&M8Z]&9,;J]TR`TFV+2KK;6Y(1%R<TO&,(4((-=,SRF6)LQ
M7.@9TF?-0C]IVC#G&),"!")=,6"?&43NZR%0!)O:W`/+`F4'D[`LWRH^#B);
M;K+";^YB9AE@@W>PB(EQA`1L)6F]&Y6X!G3`^;$M;JMW=;(;/<'-OV3+IN-E
MB-YT#>`*HMM:>0@2F33)9&6:^/(]#<:1)NB;#*`/#*ZY4R%J6RC@E7D%3,2L
M>&.SEBM/?&=UC4O1&$6.0*`;="<H5!$DRO*D[6.FEHU+6M``,07NFOEWKUV)
M9N8@C2#HB;-5Z.TFH93M>[C;YDQQ<YL")4NGES@P,UD!,^<@X$&#@8.`;NO;
MX;JODLGGN/HLZ8B(C#),5./(XZN2K(*-UD,?FV1L4Y%RJW-Z=A:XZ<SO,;;F
M_&RA.:X6=2#S+KTXP);;0\`-5*Q!\R<R6Z7=:ZZ";T2'.8YX$`($"[",=D6:
M5MM1@<F32S9S)Y?,EB8X#5D-<R7-ERB;Q=$.)F`AMTC<D7M"S2K=%QQ*(N!5
M[$6>TU?\F-H-*CNQ*T@<>_`.&?FNQ>]J>OGQBOXTJ?Z1,^_*_2CD?]"<&_)5
M)_5Y:N%:!<G2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(MH3^;`?#;7][
MBZ2O_CU(UVID7\63?X?_`'6KPK[T?Z:T'Y,'\=,6W!7-EYH2B)1$HB41*(E$
M5>??949_.$OWH>*H4.Q\:L-15*(E$2B*`*^%"WW`:_?%WHILJ?HJE$2B)1%7
MXU[!6>[TD]_G&J5!HZ95@J*I1$HB@)3\''KW.4_B[T4.@J?HJE$2B)1%`.OY
M7C'M]P]Y7"J-!4.D*?J*I1$HB415QO\`A)(_:K#^+<:NPL([(JQU%B2B)1$H
MBK,.^#R+^&<O?1;5=I4&A6:HJE$2B)1$HB41*(E$2B+4C_K8E$7B>B/"\]>M
M&^F%S3:F\NL*)UP;C563'VZ%:<%[6U)RF=,K;FQ&ID6#WI[5HV8V^RE&M5JE
M!8K;>YEQ[(K]VX12SG853.$^8`9++`V7`6"`M839L1)7D#-.(TLO,V(,-'3N
M<VKFB\7U`)W1!)#9P:"=F``Z$%D_X@\A;0PKY5^:-R.L"QQ7B_TK[D=8I28M
M*L<7\GS:&V*6G#/#85K[4X8C+;`Q7%?<.*3M'&)L/W,K@UL/E2ET\1IHC_;J
M=J'?]JSXK%T3--TN.*=R#M3>5CB)"*PY"0;B_2883(1VO<5AOQ0].PBWH=A"
MO>UU5C;[:][^C4XE,((,^9!VG<R;?C^;MZ:Q#&)`+2**1%G8_.56Y_<_/V=*
M"XFO33+60UZ.:-469&\R1NZ-^?+IH#I="%S>6UH9F%M<%!8L`B*">V,L=0)4
MU@!`!.2C*L78.UM>C:&8R);/FB\8G<RK2``/WO8``'Q*OQF1,#1,HJ<AC2UN
M[J;`27$?A]DN<3MDF*[:G3O-UJ>Z-;JDR\M1WNCO=&LQMI15)+W;C1*&V]TI
M^GDPB]VY0*YB?[G]P'>X@;6][WJFCFD0,^81^YE;&C][V-A86XM3--YM%3AU
MMHF50-NFW7[.SM[*A)+I4?9>TOC)(M3&7G!NDK:WLS^"V/\`2XC5.S.U+$R]
ML:5KDWX`2N1K:@5I"QE$;MN0-KL6#8.S:^"9A[YC2U\^80X0.YE6@:!'5Q@L
MV3CDJGF-F2J.G#V$EN[J3`D$$@&>1$@F)A%3UM/4Y"B,;`:ILO%M9J$368U%
M8UTH%-8VH=SKB:A-I>G@*&[5>Z@S_%MSW#]T%]S]U?9Q\3FPN\8F780A=E0A
MM0U>CH+*\JTUZ_Q*GOQC'6548[<=?&/1TKZCT\3@Q`8TF:I<OC:36\EH-:AX
MVTHB:S6A.$04S0:W"T\W1F-28([V+3"!<@NPK[4-MF].)S87=?,NPA"[*A#:
MAJ]'03RM3!^L%%3ZP&,=94QCMQU\8]'2N8C`.04H""TNJ[,Z4M+8@*4M-C[2
MNG+2A2$#2I`I@$Z?`!3V2)#!%%6!8.YE"N`.P&][7"CG#143;/\`9E<&H<4I
M7$EU#3DG;F5.S:?W_9-IVRN[XE,J>>#GGO-TQ?H"J\5G^$SNI*X-8?*5%R?2
M]O4\.GB4RIYX.>>\W3%^@*G%9_A,[J2N#3RE1<GTO;U/#KB4X4RGU,JV=8&>
M+VZD5;-KPW3'L7MU.9LVOL8"M?8O;[6Q>J*2?'^<SNI*X-8)N)T39;G##Z6(
M!^[J>'6ES"F64<CHI<G)4L3E7CC((L@MK@(BR0C;4PK%%B.AAIP@%[.Q:XQ"
M%L6Z-[WZ-?)S,O.KC%%F/$*.71T#F2JV>P%PGQ(;-<T$PG@1,(F``CH`7[@^
M93]7[S:9IYFLI9FJ\Q9LE56(Y9PNI>R5-PP2V/GT,B:YDL/PQ[PQI>0R^][K
MH%YSC$FS[RRSXT)?W*QYX$5LGM?QKP+#^UG\.NS?LW^:SUFSCON%?FE-Y99\
M:$O[E8\\"*>U_&O`L/[6?PZ?9O\`-9ZS9QWW"OS2F\LL^-"7]RL>>!%/:_C7
M@6']K/X=/LW^:SUFSCON%?FE-Y99\:$O[E8\\"*>U_&O`L/[6?PZ?9O\UGK-
MG'?<*_-*;RRSXT)?W*QYX$4]K^->!8?VL_AT^S?YK/6;..^X5^:4WEEGQH2_
MN5CSP(I[7\:\"P_M9_#I]F_S6>LV<=]PK\TIO++/C0E_<K'G@13VOXUX%A_:
MS^'3[-_FL]9LX[[A7YI3>66?&A+^Y6//`BGM?QKP+#^UG\.GV;_-9ZS9QWW"
MOS2F\LL^-"7]RL>>!%/:_C7@6']K/X=/LW^:SUFSCON%?FE-Y99\:$O[E8\\
M"*>U_&O`L/[6?PZ?9O\`-9ZS9QWW"OS2F\LL^-"7]RL>>!%/:_C7@6']K/X=
M/LW^:SUFSCON%?FE-Y99\:$O[E8\\"*>U_&O`L/[6?PZ?9O\UGK-G'?<*_-*
M;RRSXT)?W*QYX$4]K^->!8?VL_AT^S?YK/6;..^X5^:4WEEGQH2_N5CSP(I[
M7\:\"P_M9_#I]F_S6>LV<=]PK\TIO++/C0E_<K'G@13VOXUX%A_:S^'3[-_F
ML]9LX[[A7YI3>66?&A+^Y6//`BGM?QKP+#^UG\.GV;_-9ZS9QWW"OS2F\LL^
M-"7]RL>>!%/:_C7@6']K/X=/LW^:SUFSCON%?FE-Y99\:$O[E8\\"*>U_&O`
ML/[6?PZ?9O\`-9ZS9QWW"OS2MK'^:T-+R"3Z^PJID_.)XFG2@.ZM6ABQ9VTW
M;4@6$FP$,>1IMS+W*][7W/;WN.^R*]MBUO3G,GF6JS/ERIK:N5(E3&5A8!*#
MPTC5L,3?>\QMV#"&POAK^L\YC\O\P_/1@>5\N5^)XA1U66VU+GUSJ=TQKS5U
M$NZTTU/3,N08#NF%T2=U"`&WGO4Y\YG7L-@XGKN2*^;2;U.?.9U[#8.)Z11-
MZG/G,Z]AL'$](HF]3GSF=>PV#B>D43>ISYS.O8;!Q/2*)O4Y\YG7L-@XGI%$
MWJ<^<SKV&P<3TBB@7IM<`J8[84B<S+C?@!!<25DM<H6]3L+=`;1J!80M@-P[
M`ML'8%?H;.Q>U"AV/C4]O4Y\YG7L-@XGJ153>ISYS.O8;!Q/2*)O4Y\YG7L-
M@XGI%$WJ<^<SKV&P<3TBBA"VQQY2+`<HG.P[,C:*YO4K)MQ!$O=;6+N&[5N=
M@@N&][7L';7N*^S?8V+6*;*F]ZG/G,Z]AL'$](JIO4Y\YG7L-@XGI%$WJ<^<
MSKV&P<3TBB;U.?.9U[#8.)Z1104>;'`:)7<$B<RK6>Y"&X0I&2]A"`]KPB,O
MNC4.]A&BMMKVM?:VO?H6M;8M0J#0IW>ISYS.O8;!Q/2*J;U.?.9U[#8.)Z11
M-ZG/G,Z]AL'$](HH22-CB!@=QCD3F<`*!1<10TK($!EK`O\`<BN6U%F6M?\`
M8%:]%#H*F]ZG/G,Z]AL'$](JIO4Y\YG7L-@XGI%$WJ<^<SKV&P<3TBB;U.?.
M9U[#8.)Z110;DV.`76.A%(G,8AK5U@#NE9+"*O9H7"N(%@M00BN(-MK?;6%;
M8OT-B^Q>J#8H=(4YO4Y\YG7L-@XGJ153>ISYS.O8;!Q/2*)O4Y\YG7L-@XGI
M%$WJ<^<SKV&P<3TBB@$+:X7D#^"TA<PC`F9+C-LE9+C-L("_:A$$35<NUB]C
MH;4(;WV>CL]"ED%!V14_O4Y\YG7L-@XGI%5-ZG/G,Z]AL'$](HF]3GSF=>PV
M#B>D43>ISYS.O8;!Q/2**NQ1M<#&%((N0N1`;FN&P46E9!!#L.2P-[VN:U&&
M?=7MLWV;WZ-^AT.A5=I4&A6+>ISYS.O8;!Q/4BJF]3GSF=>PV#B>D43>ISYS
M.O8;!Q/2*)O4Y\YG7L-@XGI%$WJ<^<SKV&P<3TBB;U.?.9U[#8.)Z11-ZG/G
M,Z]AL'$](HF]3GSF=>PV#B>D43>ISYS.O8;!Q/2*+4SZF4\)*/Z5IU%['0^R
M>%O8WL_^\]C?X*EBJQ4TLZCGR$:<M.4=NX1^+07&.GW1Z9+U*V#/N0)5)_'F
M:LC[<XHDC1,XE>'P5H5M9;5OR%,]C&^K-H-.`E.,)W<N&UKI6'T[(M;*ER)%
M[<EQ.LL!$'"#1"%Z#MT=$!;Y-S#A$JIQRNFP>^JG5M9<`>UC6ZG=$$ECK[R"
M77(LW`B"2;,B4NO`EU@2*?,N`<DJ4+TG>)#&T[P[M$32OT!9</RK-J^5H7N3
M-[:D5+442AZE,H;DI:L);H<G*`J-)-$I*UPQ8.E"<V2^!B1$@1:&%\8F&P#8
M(VP$86K9'98+*HTLRJDAS2&N@"XM>9K9(:0TD@%SP0XPW()N@B!L,GUM1R&C
MF+P_XZD`<;Q5TCD=2Y(:9(PNS>\2^98N?<GQ.#G,@"4J]EF#P%`ULHDHC%):
M=ZDC8F&;NAI@"\R9BC)5YSV'4-(%X$$$N:7!L-()L;#Y3FB*RI&7)U1JY<J:
MWCCVN<99:X$,9,;+<^-H+!%SXV19+>80`CTUNM@QIEZB./&#)<W-""2.3$Z2
MB\Z@ZD*!+',W0S3[+':\>(-$[*!-&1L@-@$Z0%]U7(;*C]L3<@HI5A.*79EQ
MTIP:'$$WF[#VRR8:;'.$!LB)LA;B;ER_(ULNIEF86!P;<?:727SVB]HMEL=$
M_<NNBV)+>5CU8.F7L9'N^-X/*8%))[+<5P/"[[-V<U0S24>7W%4%%,DB=:W-
MB=<.`Q%F=7QY;@]5)DQ2(`.JCPFBN"MQ!U1(O26.8][F-87"PWSIT#L0"XBT
M"&DJ3<"905NKK)C)LF5+F/G-8;6ZH"+#`F%]Y:QCK"2>Q$+:8NU.YU.Q!%,T
MPUHQ9,3,CY4;XW%,($-S\DGS1%6J<S1HE,=<I-:8GI7G)[A&86:G(#O.W(V^
M3G@2F@.(M<591KZOBS:J6);K\P`,@;P`<X$$QM?!L-``=9:%J&X-A@KWX=4.
MGRQ)D%SIT6EA<6,+7!MR(EASXG=N+I8+A`KO8HU>27)TFQ%)`BB2+`N7)=D2
M"PF;,T=<9$=+)BU94RY%(/%'Q27,TCCBQ>]P:"-[@D6J6=T;G1S$XHC#6\TA
M.`RT^(OGS);]R*28YS6N`C$A[PT'=;F+6@@D$$WA80%AKL`DT4FHD_.'%)$N
M6]["X-NL,J4Y[@+A$P![W-(#VN:VXX!X)AU9!K54P5PD\OFUF\$%1S_-6,8M
MCN,P5[>9FX23$,A4Q8E-),BVF-FR,RJ5*4-WD#69&S$Y,<6)C0JC3K[)A^)F
M473)L-5?>T-#23%AA:Z,`3"]"[V)%I*LK+K:EC)%-'C1E29CICG@,#9K;VYE
MW(N:T&Y>$R)F`BZ!HO9NLPEN<(RED6%<@1I$N+BMYJO>%[:W+(.;-<JS?#\8
M$EB[PD:93,$+Q(X2-:2<6D0#$SK"3[E!.VR:LWRF&N:'RGM!A>C#<WGN8+#`
MF);'0+"#IL6F&7B]CW2JF4]PO7``2'W)3)KMT"6L(:^!$7;L$1ANEZUIYSN5
MJ"AZB9I<?S&`MPK1U<Q\K$J@HF31V61ALEC&^,BM0VM/580('0*=<66480E7
M%#+*4*BMH>/44=7QR7K0QS&V0CL@@$$:-N!VCH)TK08MAAPJH%.Z;+FOW0-T
M]BYKBT@B)A:(MMB08D--B]\K6+:UP*?8JOVFK_DYM5ND+*G_`(%_[D_M+17A
M'P,B/YLL/O6EKX?9R_2_%?RE4_QSU_2.]VW_`$[9"_N7@G]FTRM%<;7=*41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%M3?S6[X6:^O<72?_*M2M>TO=N_
M0^L_*!_BI:_,?^NL_P!1V6O[GL_K]6MO"O0R^.:41*(E$2B)1$HBKS[[*C/Y
MPE^]#Q5"AV/C5AJ*I1$HB410!7PH6^X#7[XN]%-E3]%4HB41*(J_&O8*SW>D
MGO\`.-4J#1TRK!452B)1%`2GX./7N<I_%WHH=!4_15*(E$2B*`=?RO&/;[A[
MRN%4:"H=(4_452B)1$HBKC?\))'[58?Q;C5V%A'9%6.HL241*(E$59AWP>1?
MPSE[Z+:KM*@T*S5%4HB41*(E$2B)1$HB41:D?];$HB\$TIY#TFMFEW1BWY@?
M<*VRA!].&.93'$\X;6!SG$6;$L:;GLU]CXG!M6O+8D27`4JN<E$&Q1VYCV;&
M7!>NZ\,G8>,-I!4F5KV4["+T"X"Z#$61Z-B\A9BI,=F9@Q-^'MJ>)3:Z:UUP
MN#'&^1==`@$FT0.D1V%^BC;BG'3"2XIF?&D(9DS@M=71U3-L,86].M<)`VJF
MI\7KB$K:24>J>V98>E5&#M<2A*<84.XBQB#??&T\E@(:Q@!B3!HV1`[&R+#T
M%P]]=5S2#,G37.``!+W&`:8@")T`@$;1`(M5?>L!8G>BU0%.-HVW[XS"!SI]
M-8X^VL*B2R/&TE;9?"E,H4MJ%.>_IV>1M252`I2(81"*#:_W/0O@=1T[@8L:
M(N:XP`$2T@MC#3`@&U9LO%:Z61"<\PEO8V\XN#6S&EK[L3N8M)$1MJ['PB+G
M'&&JH='C5)YRD\TT^.MAAYRA<_))4L.,&8CN88<LE#4G<S17O<1C@F+4BV3B
MPC#FF5+V6MC\0VX_MB/QB.E:85,\"`F/@/\`:.PTM&SL-);^Y)&@JKH,0XO:
M'QJD;)`HO'W=GD#[+4:B.LZ)@*,E4E9%\<>9(Y(V<I$C>'U2QNJM,%4J`<<2
M!6?N8@W-'>^6VFIVO$QC&AP)-@A:1`FS28$B)VSMK/?7ULR4Z3,FO?+<QK3>
M)=N6D.#03$AH(!@(`P$=`4BWXVQRTOSI*FK'T&:Y0^.J1^>I*W1*/H7]W?$(
MCAHGIS>$K>4XKG9*8H,&6I,,$<$9@A6%MA7O?$)$AKS,:Q@F$Q)@(D[9.F/1
M6!U95OE-D/FS726M+0TN<6@'2`"8`':%BX$6+,7MKVT29NQKCYND<?*=2&!_
M00N-HWIC*?5SBZ/9;.YIFTI:V!=W-X6*5.X#!NYZP\P>R(XRXH*>0UP>UC`\
M1@;HB(VF!A9$DD_&575M:^6Z2^=-,E\+S2]Q#KH`$1&!@``(Z``!H"^J[%.+
M'20/$L=,98[<I3(6=1'I!)7"$QE:_OK"K1@;U;*\O"EL-<'1K5-Y84YI!Y@R
MS$X;%BM<%K!L-/3N>9CF,,QP@26B)&B!,(D0L1M=6LE-D,G31(8Z\UH>X-:X
M&(($8`@V@C9MTJ0;,?P)E1M[>SP>'M2!H`U%M2)NC+*C2MI;$[*7]C`A(3HB
MRTEF9^6G+DNTL'J=8<8>7M31B%?$V3*8`UK&@"$(`60,1U"8CHVK"^JJICB^
M9-F.>Z,27$DW@&NC;;%H#3M@`&Q=B+0J&P9&K;H3$8Q#FY>X'NRY!%6!JCR)
M8Z*;!"H<521H2(TYZTX``A$8(-QW"&UMG8M:U)<J5*!;*:UH)C8`+=NQ89]3
M45+@^IF/F/`@"YQ<0-J))L5FK,62N!3[%5^TU?\`)S:K=(65/_`O_<G]I:*\
M(^!D1_-EA]ZTM?#[.7Z7XK^4JG^.>OZ1WNV_Z=LA?W+P3^S:96BN-KNE*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBVIOYK=\+-?7N+I/_E6I6O:7NW?H
M?6?E`_Q4M?F/_76?ZCLM?W/9_7ZM;>%>AE\<THB41*(E$2B)1%7GWV5&?SA+
M]Z'BJ%#L?&K#452B)1$HB@"OA0M]P&OWQ=Z*;*GZ*I1$HB415^->P5GN])/?
MYQJE0:.F58*BJ41*(H"4_!QZ]SE/XN]%#H*GZ*I1$HB410#K^5XQ[?</>5PJ
MC05#I"GZBJ41*(E$5<;_`(22/VJP_BW&KL+".R*L=18DHB41*(JS#O@\B_AG
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MPAN#M$$1;$61@2%HB<2F4,R3,HW&MF26M=,.J=K");I9O`3&6"(<UQ#R"(W8
MAI5$D:#&3*P8X*@FHG'Q!F.,=R4U]4MD=R\DG\[R6\QW)B&4FD25TA*YR<$,
M_'*&DHHM0[M2="8WCNH+5A&ENBRGB0QC!)G,W##&`?><XAT;2V.ZB-D0A;&R
M&JDNK)DV<:FDFPG3FW072C+9+#I9;N0\`%EUT8,<7!UA;;>XH\X0!E28B3VS
ME&HTED^2F0C,\/@96:EL/C>$RL7XZ<IVVE.DG94KX9-LB9=PBV'JU"<H\)9L
ME<@6&;8U0M-C#):)8UK6ATP7VMOW0RZTNM(C><]@B?\`:=IB24UE5,=4'BSW
MN9).I>_4A[IVLF!A@TD7)<J<X`$BR6PP$`T?J:/69IB,&,P67FG;#$(8MB,3
MZUMD5[WOL6M$=BUMF];_`.4Z#O@ZCNLN$C+V,BSB[NV9W2^GRR=,'QO-7>S/
M_!&GE*@[X.H[K*^C^->#N[9G=)\LG3!\;S5WLS_P1IY2H.^#J.ZR>C^->#N[
M9G=)\LG3!\;S5WLS_P`$:>4J#O@ZCNLGH_C7@[NV9W2?+)TP?&\U=[,_\$:>
M4J#O@ZCNLGH_C7@[NV9W2?+)TP?&\U=[,_\`!&GE*@[X.H[K)Z/XUX.[MF=T
MGRR=,'QO-7>S/_!&GE*@[X.H[K)Z/XUX.[MF=TN)1K(TPW3*K6R\U;-TJH-O
M^S,^MLWN09:UNC$MCHWO5&)T$?PHZCNLLN=E[&S*<!3NB6G[IFU^Z6EM#<DP
MDB(Q8DQ\+"83'&0HP/4+G?:F%MJ8`P[-D5[7VH@WMT*^/.:LAYPJLT8E4T^'
MU#Y$ROJ'-<&B!:Z:\@BW008K]]G,)[VGNVX%S%Y+P3%\XX+(Q6CRGA$B=*=-
M<'2YLK#Z>7,EN%RQS'M+3T059/&;!N'0=@.G:-;#[/,[<FU/:CKKMGZY/NN^
MN^![Z[N$\9L&X=!V`Z=HT]GF=N3:GM1UT^N3[KOKO@>^N[A/&;!N'0=@.G:-
M/9YG;DVI[4==/KD^Z[Z[X'OKNX3QFP;AT'8#IVC3V>9VY-J>U'73ZY/NN^N^
M![Z[N$\9L&X=!V`Z=HT]GF=N3:GM1UT^N3[KOKO@>^N[A/&;!N'0=@.G:-/9
MYG;DVI[4==/KD^Z[Z[X'OKNX3QFP;AT'8#IVC3V>9VY-J>U'73ZY/NN^N^![
MZ[N$\9L&X=!V`Z=HT]GF=N3:GM1UT^N3[KOKO@>^N[A/&;!N'0=@.G:-/9YG
M;DVI[4==/KD^Z[Z[X'OKNX3QFP;AT'8#IVC3V>9VY-J>U'73ZY/NN^N^![Z[
MN$\9L&X=!V`Z=HT]GF=N3:GM1UT^N3[KOKO@>^N[A/&;!N'0=@.G:-/9YG;D
MVI[4==/KD^Z[Z[X'OKNX3QFP;AT'8#IVC3V>9VY-J>U'73ZY/NN^N^![Z[N$
M\9L&X=!V`Z=HT]GF=N3:GM1UT^N3[KOKO@>^N[A/&;!N'0=@.G:-/9YG;DVI
M[4==/KD^Z[Z[X'OKNX3QFP;AT'8#IVC3V>9VY-J>U'73ZY/NN^N^![Z[N$\9
ML&X=!V`Z=HT]GF=N3:GM1UT^N3[KOKO@>^N[A/&;!N'0=@.G:-/9YG;DVI[4
M==/KD^Z[Z[X'OKNX6US_`#62:Q=9)-?2I,[`-(WJTI$7'9*O#L&EJ-2)@P7"
M-*$5KV`<"_VM@5OV=CUGS!X+BV"96JZ7%I$RGGNKBX->($MU;!$6Z(@A?GL_
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MZ4B%"%RE@M(E9]W`.Y"96XH(NIU?1,`N=!BML=3[/0"9;_GJW2I$14WROCO"
M0>QEG:]2Z58A.5\=X2#V,L[7I=*1"<KX[PD'L99VO2Z4B$Y7QWA(/8RSM>ET
MI$*#8)2PD(U0#'`(1">I`;:W4ZN^R6<]KS2Q=!/L?=%BM?\`8V?MU2"H"(*<
MY7QWA(/8RSM>I=*L0G*^.\)![&6=KTNE(A.5\=X2#V,L[7I=*1"A)'*6`]A=
MB2G`(C#$"@``]3J[;85P7V+;-T]K6V;U;I4)$"IOE?'>$@]C+.UZETJQ"<KX
M[PD'L99VO2Z4B$Y7QWA(/8RSM>ETI$)ROCO"0>QEG:]+I2(4(Y2E@,=(\8%P
M#<!"U<(V_4ZNVU"-I7%AOL73]'9&*UNA]NK`J$B(4WROCO"0>QEG:]2Z58A.
M5\=X2#V,L[7I=*1"<KX[PD'L99VO2Z4B$Y7QWA(/8RSM>ETI$*!0REA`_OQP
MG`-BSDS*$L74ZN^VN4!?8=MBQ&S;:[>WH_;JP*@(B5/<KX[PD'L99VO4NE6(
M3E?'>$@]C+.UZ72D0G*^.\)![&6=KTNE(A.5\=X2#V,L[7I=*7@J]%90PIV)
M(2<X!`8$UPO<.X*Q;%AN2L8>B$B]NB$5KU2"2H"(*P\KX[PD'L99VO4NE6(3
ME?'>$@]C+.UZ72D0G*^.\)![&6=KTNE(A.5\=X2#V,L[7I=*1"<KX[PD'L99
MVO2Z4B$Y7QWA(/8RSM>ETI$)ROCO"0>QEG:]+I2(3E?'>$@]C+.UZ72D0G*^
M.\)![&6=KTNE(A:F^^S;UX5_2L=^?0,_)O7'[3]M_@OW[^\I`I$*W:`EJP&A
MW20$"M2$(=/V-+!"$\T(0VM'4EK6M:P[6M:UJ[XP4GR12_P#/O0O%6;VM]*L
M2L'\]F_?E9<]7KNO5?9!WW];G$KCMQFT.HG5Z[KU7V0=]_2)2XS:'43J]=UZ
MK[(.^_I$I<9M#J)U>NZ]5]D'??TB4N,VAU$ZO7=>J^R#OOZ1*7&;0ZB=7KNO
M5?9!WW](E+C-H=1.KUW7JOL@[[^D2EQFT.HG5Z[KU7V0=]_2)2XS:'43J]=U
MZK[(.^_I$I<9M#J)U>NZ]5]D'??TB4N,VAU%P*EZ[J19_CJOV&K_`/O!W6QO
M]_5!,5',9=T#J+1[QX<=:!0S]U,^"[%_TQ<&I_V:^>V*@>5*G^D3/OROTJY'
M>_T)P:T_BJDV?_R\M7#=COPIGK@O3K0P"Y1??MGJINQWX4SUP7IT@$OOVSU4
MW8[\*9ZX+TZ0"7W[9ZJ;L=^%,]<%Z=(!+[]L]5-V._"F>N"].D`E]^V>JF['
M?A3/7!>G2`2^_;/53=COPIGK@O3I`)??MGJINQWX4SUP7IT@$OOVSU4W8[\*
M9ZX+TZ0"7W[9ZJ;L=^%,]<%Z=(!+[]L]5-V._"F>N"].D`E]^V>JF['?A3/7
M!>G2`2^_;/53=COPIGK@O3I`)??MGJINQWX4SUP7IT@$OOVSU4W8[\*9ZX+T
MZ0"7W[9ZJ;L=^%,]<%Z=(!+[]L]5-V._"F>N"].D`E]^V>JF['?A3/7!>G2`
M2^_;/56T%_-@1C'-]?VV$(7^1-)7[85[_P#3U(_;O?[==J9$_%DW^'_W6KPG
M[TA)SM01,?\`E@_CIBVWJYLO,Z41*(E$2B)1$HBKS[?851K8YPEV_P#V0\50
MH=CXU8:BJ41*(E$4"5?_`+3K;?8WA:[['_ZP=Z*;*GJ*I1$HB415^-WO="LV
M;[/^7I)Z/N\XU2H-'3*L%15*(E$4#*+[$=>MCH?Y.4_B[T4.@J>HJE$2B)1%
M`.E_\KQFWV+KW#WE<*HT%0Z0I^HJE$2B)1%7&^__`&DD7["5AV/V/W-QIL*#
MLBK'15*(E$2B*LP_X/(OX9R]]%M5VE0:%9JBJ41*(E$2B)1$HB41*(M239O]
MN_\`2Q=GT;^C]O\`LT12F@3_`%'])7_E_P`:?]W4M=\X+^**7^`9]Z%XKS=^
ME6(_TV;]^5EQ6YKCJ41*(E$2B)1$HB41*(E$7`J]B+/::O\`DQM!I4=V)6D#
MCWX!PS\UV+WM3U\^,5_&E3_2)GWY7Z4<C_H3@WY*I/ZO+5PK0+DZ41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1%M"?S8#X;:_O<725_P#'J1KM3(OXLF_P
M_P#NM7A7WH_TUH/R8/XZ8MN"N;+S0E$2B)1$HB41*(J\^^RHS^<)?O0\50H=
MCXU8:BJ41*(E$4`5\*%ON`U^^+O1394_15*(E$2B*OQKV"L]WI)[_.-4J#1T
MRK!452B)1%`2GX./7N<I_%WHH=!4_15*(E$2B*`=?RO&/;[A[RN%4:"H=(4_
M452B)1$HBKC?\))'[58?Q;C5V%A'9%6.HL241*(E$59AWP>1?PSE[Z+:KM*@
MT*S5%4HB41*(E$2B)1$HB41:D?\`6Q*(L",(ZJ<GX5T[Z;&%&VQ0_&H],NBR
M+,3ZL:EZASC68\SS)P8FXF4G%.1:=5#YM$8\O;F^X2B1H9"4D",PT*VP`=P4
M6(3Z6@IV`-U'%Y`!A:'O,!&WL7`$#:=#;7E?&,#HL1QROFN<\5G'ZUSF@B#I
M4EMXW;+'L>YKG:;TLNL%V*RZ6?2"1AE;W:5R/'YC;C]O2H9";(FJ<MDB<HY$
M7N99*QG';Y$8"&-$.%SIWR3`T;8%DNH5W"%]*'U3<Q*I(MN9QAC09CV0D@1B
M'`D`ES1>$-RXN:!=M[(6V$+CC<J3YCVR)4V]5$EMTL+0YP9+F.U;B3?8);RZ
M_`=@1"#@5WCM;KF+)9.(FO$C<[3Q<Z0N,)FX.33F]O9IH\R:)1&;Q69/"_'1
M2=M6X\>9<78\QI"^%J0I32_W)1M2;WRH[7\6$L&=%HA>@`XD-<";METG8O1A
ML&Q09;9Q,U[YY;2AKW1U<26!KG,<P"9:)@99>N0B#:+5#MFLN<)(DY2^406+
M+G!GBT\>G2+0N9&KF)J0PW4:KPXOD;V^*8J;,4RJ-1]"<XN;4@:G-680G$8F
M3F&F!(*PMQ.:)9F3&-+@UQ@TV`-F7(DPO6"T@`G:$;%C?EZF,\4\F:\,<]@#
MGL@XE].)H:!>N0<XAK7%S1$P)`$3V,J:C,CH4<\RKC^31M)A>"O4+C+VM+11
M20OBIF9L:/V4\PSO&S)+Y#`DV0G)B42:.-9K8%>4K$V-+L8A2FN&YE5:BMGM
M#ZB2YHI6%H.@F`:7O<T$MO$1:(1C`.@+UBE#A-&YTJAJF/.(S6O<!%S6@F8V
M7*9,+&OU8==F.#KI%YTL.<&1*D%6MUT32PQ`'#I*F"AD+BA(FP<EITKJJC#)
MGR#Z=W636A"J&`4I%Y\MR,VK4;8<O"(3<4KZH4)E!9!*BG%7"9#5_-7B+UZV
M`F-EDW;NVX$".B,2#`'`W+;#(O\`&"*FX#<U<0'&0^>&WP^T79;FEP;V1;`$
M$D>7O^NV12UOE*K'*9BCX(C&\FN874A49,6&6I4L+QC,\=2=G52&*PYT3)^H
M9:JLI(&AZG/V2S"CCR;@'60_%GS&N,F#;K7&.D'<M<TB(:=DQ$.F0M;*RS)D
M/8VK+GF8^6(=@YI+YC)C2&N>#:T0-Z(M!`,0O6\YZIYIAK4D\8Z&RLCSCYWQ
M3!VC'J4I"L#*%FJ#*,JRHV8JB3DZ@6#3F12?I\<G("P63%FIEQ-A[L*QVU#J
M*K$)M-6F3`&29;0W;UKR\,!.TZ[#18=FU:##<$I\0P=M6'.;5MGO,PQ%T4TM
MLHS7@0[)FL#M,"#HL7@L?U_3YXP>A7+V*)`R1>*K(\Z3-C>$0`!RS',8,>6'
M^0I\-+TK@X->'G-A=+HT#J>[*![Z"`2(C<C"SQ:1F+SG4H)#=?=A>!^[#0\F
MYL,@8`Q-MD-E;I-RM2R\2+6.F<3U@<&.!_!.F.E-;K1`&:'"+FA@W,3&((60
M;AK5$&09%:6S$;@6V1C*EL.Q:4R:8D1:+N4S!F0O"ZD$Z=%T;47@C-OP(;FF
M5)@/ECVP`;&!)5'$D#UCL4W;VMEFZV9<!+H`NOW-T8;D1M!%ZS:)@MJ9ET:J
M3,?/%]\C6N:UEYP9J==N`';LPW)!N0=HBT$KHR#6,%R/1PV*HV)IG8Y>:TNH
MTTL8IDB9FZ(ZD]/F&W\0DR=&F.5MLY:,QFGM+@(H@-B4]C2[#N,%P87XF'$2
MY8`FWH&T.@!-EL/2<'Q!Z$5CE9?N`U$\N=3:N(W)8274\^<W9,"PR@'-MM,#
M""]7T_ZC!:A4,X<DN.7Z%QYI3=41EY=G"RNTB;ECG,&(Q(N1&M;4I9).T'Q7
M=5J0OJY&46M)`!88<6H+*U5#6\<O.#"U@T$[(B1M"!$+1:+1;&,-MQC"!A08
MQTYLR:Z-X`0ND!KH@Q(+3>@#83`Q:`03J,X]^`<,_-=B][4]>!L5_&E3_2)G
MWY7Z.<C_`*$X-^2J3^KRU<*T"Y.E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41;0G\V`^&VO[W%TE?_'J1KM3(OXLF_P`/_NM7A7WH_P!-:#\F#^.F+;@K
MFR\T)1$HB41*(E$2B*O/OLJ,_G"7[T/%4*'8^-6&HJE$2B)1%`%?"A;[@-?O
MB[T4V5/T52B)1$HBK\:]@K/=Z2>_SC5*@T=,JP5%4HB410$I^#CU[G*?Q=Z*
M'05/T52B)1$HB@'7\KQCV^X>\KA5&@J'2%/U%4HB41*(JXW_``DD?M5A_%N-
M786$=D58ZBQ)1$HB415F'?!Y%_#.7OHMJNTJ#0K-452B)1$HB41*(E$2B)1%
MJ1_UL2B+'O13B+-#_H^TTJ6W5&6S-KC@W%BXB+&Z=,'R@;,VIFPI=&V]4Z/:
M,YX=RF126(2)4LV3;'%B-!>QEA7MW5A--5/PNG+:B#3)99JV&`A8(D1,-@E>
M1,TU^'2LRU[7T1<\5<X7N,3FQ-XAQ`!@+VR!L6&Q9"J<)939!.1*W5U&644O
M6'/CT4LTM::6N\M<6PQ(<H>W@M0A3\HE[:::G&-4HL>:0,10KC#>X+UKC2U#
M(QJ6B\8GYJ4(D;)LMA9:>@ME&)4,R!;0/=JQ=$*FH-T&-@MW(-M@@#:I0&GS
M.!3LM?"]4Z,I_<#TZIR?`:2]/);XX*D02P(U+@[!:PN2Q4C"0"Q1AI@AE6`&
MP;VVMMC%Q.KO%_&-V=)U4N/5A%8/*N&E@E<2.J`@&\:GW0#I`$8".S#2NDJT
MWY=5IG%,OU,L*M$[*C7)Y3+M(&FY2B=EQBHEP/<7<A4S&)W)88N2EJ##E`1C
M$<4$P0KC#85H:*I((,\$'3\S*M^.Q8AB]`TAS:-X<T0$*JH!`A"`@;!`P@-@
MP48CTS9,LT$QPG5$R.C*6^.$[3M#CI8T]21*"121\<I&NF!!#ND<MJY.;\Y*
ME(%P?NMT,%8H=@AL&V$4-1=N<8!;$NAJI9M))O6@Z23;U%C=C-'K-<:)S9ET
M,B*F>W<M:&AEA%@:`+O55C!A7.BTQ2,K5^F6FD+%!"T96E[3VJ-(<+K4KTL(
M6"`B,&4ONYED+30&;!MU(2SQ6W2P!UCXK5F,*F)CWJ7IT[6W;\=JR3B.&-`C
M0$`BS^4SQ9"`A;HA$#8A$:(KJHM.>96TH].VZGFEN(5FK%*I.WZ1-.:$A4H<
MA6&XJ%)*5H*+4'.(PVNH&.PA'7M:X[BV+4%%5-L;/`'\#+ZRQ.Q;#WD%]&XD
M0A&JGF$-&D[&QM*0,PYGQ0Y!L?K&"H>@E(G,-C],FG\YX"0UJE&]CD&QB4:\
M)38N5F]3'V^Y3G'#W,01C%LWBU876U.ZT_@I<;-!T;&PL`Q#"PRS#X2[1_.)
M\+1:-,+0!$;(`C8J^YX+RC'$[K+'C5C&F),WQTQ"^29PTGZ;&T".(MPKKS&]
MU>3FLFY4:0F`W;J<TSJ4L5MOM;7Z-8'4E0P&8ZH:`&VG52A8-@F&CH:%FLQ.
MBG%LB70O<XOBUHJ:@Q<;(@1[(Z(BTIX@,GOQ\M%;57%'Y4^&`9<@"#I/TS/"
ME[.0!*N6S3F]FU2<ZG(0!!>R5RW01-K!O8-MBU.)U#R[^4-)-COFI1CT'66_
M$5?*E%*$O^0S&M;:S^4U`A'99;9';;I7?)T[YE0J5CFGU1-"%:J)1!<'-/I'
MTY)%BI,T`2;V@7KRFDM0H3M);:GZGL8,04UDQ6TVNY`VM%%5`EPG@$Z3JI>Q
MHC9L0Z4%@.+8>X!AHG%HC`<:GD",8P$=F)C#3$QTKJ,N'<NA!(W"(:Q&4"AZ
M`6\R-=%-,>G$E0]JG5IWS;G9^6LB,)SDJ=6M8%00J4B,,/3G6-`(0!V%>RJ:
MIO$RZD1)!)$J7;&T$P%L1:(["PU6(T#97\HP]Q#&D-#JFH@+MA`!-@!$"!H(
MAI"T[(6W9#M#HI9/DLP@CDXRW))Y%Q0W<2Q-R80"MT,2B,,W.U]C;"O>]]CH
MU\K<Q\[$ZAS#7T7DVG?J:V>R\9LX%UV8YL2`Z`)A&`LVE^U3F:_5YX5FKF@R
MIF=^=,:IW8CEO#*HRF46'.;*U]%(FZMKGR2YS67[H<XEQ`!<28JS;WY)^-`S
MO'B/:=;-[8IW)=-OL_NUV1]FIA'KUCOB.&<`F]^2?C0,[QXCVG3VQ3N2Z;?9
M_=I]FIA'KUCOB.&<`F]^2?C0,[QXCVG3VQ3N2Z;?9_=I]FIA'KUCOB.&<`F]
M^2?C0,[QXCVG3VQ3N2Z;?9_=I]FIA'KUCOB.&<`F]^2?C0,[QXCVG3VQ3N2Z
M;?9_=I]FIA'KUCOB.&<`F]^2?C0,[QXCVG3VQ3N2Z;?9_=I]FIA'KUCOB.&<
M`F]^2?C0,[QXCVG3VQ3N2Z;?9_=I]FIA'KUCOB.&<`F]^2?C0,[QXCVG3VQ3
MN2Z;?9_=I]FIA'KUCOB.&<`F]^2?C0,[QXCVG3VQ3N2Z;?9_=I]FIA'KUCOB
M.&<`F]^2?C0,[QXCVG3VQ3N2Z;?9_=I]FIA'KUCOB.&<`F]^2?C0,[QXCVG3
MVQ3N2Z;?9_=I]FIA'KUCOB.&<`F]^2?C0,[QXCVG3VQ3N2Z;?9_=I]FIA'KU
MCOB.&<`F]^2?C0,[QXCVG3VQ3N2Z;?9_=I]FIA'KUCOB.&<`LB-'N`YIJ9U<
MZ<--S]FYVBC%F_(#S#G:3LN/8,N>6-,V8RR!.RE;8E<$G4!J@]=#B4XMVL,(
M23ABL&XK!KL3FPS=)SYF4X'74,N1(%+,FWI<V:7186`#=$B!O6V17C3WZO=N
MK?=.YDI?.EE7-%=BN*/QVDH=3645"V3<J65#G/C(ERWWVZD7=U=M,1HAM+_\
M+U$?/VS;Y',(\2UZ"]"\"^3-WP]9?(#ZR7.EWZ@\59W2?\+U$?/VS;Y',(\2
MT]"\"^3-WP]9/K)<Z7?J#Q5G=)_PO41\_;-OD<PCQ+3T+P+Y,W?#UD^LESI=
M^H/%6=TG_"]1'S]LV^1S"/$M/0O`ODS=\/63ZR7.EWZ@\59W2_2WZ-3Z+-E^
MCD>,\!BVH&>Y:>,QH\5&OCE,H9!&$EI0P(>1BF5$TH(J@1%"&>9+58U!IPAB
M'L%V#8-@WVV]X;A5'A,@R*,.$MSKQO&-L`-*ZTSIGG,.?L2EXIF)TEU7)DB4
MTRY8EBY><ZT`F)B3:OU6WKD/.@7<5O\`3K<%Q"!VTWKD/.@7<5O].B0.VF]<
MAYT"[BM_IT2!VTWKD/.@7<5O].B0.VF]<AYT"[BM_IT2!VTWKD/.@7<5O].B
M0.VF]<AYT"[BM_IT2!VU!O+<^A41^QDD$9<;X`!5]YT`=R,NUNHK&[%K[`_N
M`W#L7Z'W6SZ-K50H8V*<WKD/.@7<5O\`3J*P.VF]<AYT"[BM_IT2!VTWKD/.
M@7<5O].B0.VF]<AYT"[BM_IT2!VU"EMS[RB6`M)!6-LRMPKF[SH+[8NZYTL$
MO:[.Q;:"M>^SZ-]M^Q5V%+8J:WKD/.@7<5O].HK`[:;UR'G0+N*W^G1(';3>
MN0\Z!=Q6_P!.B0.VF]<AYT"[BM_IT2!VU",#<^C1JKE2010;/4@"(.\Z`6V,
M`]KPF&;-[[/[J.UQ;'H!V=BW0M5*@C!3>]<AYT"[BM_IU%8';3>N0\Z!=Q6_
MTZ)`[:;UR'G0+N*W^G1(';4+(VY]`PNPS9((TL*!1<96\Z`.Z!W.^R';6OLA
MV?MVZ-JHTJ&,"IK>N0\Z!=Q6_P!.HK`[:;UR'G0+N*W^G1(';3>N0\Z!=Q6_
MTZ)`[:;UR'G0+N*W^G1(';4*Y-SZ%TCP1200QC6K;%#WG06W(5FE<(0MBU]@
M>V!:X=B_0Z.S]BJ-!4MBIK>N0\Z!=Q6_TZBL#MIO7(>=`NXK?Z=$@=M-ZY#S
MH%W%;_3HD#MIO7(>=`NXK?Z=$@=M02)N?;O[\`,D$$P"9EN8;O0@ONMA`7[F
M':;.P'<]B_1MZ.S^Q5V%!&)4[O7(>=`NXK?Z=16!VTWKD/.@7<5O].B0.VF]
M<AYT"[BM_IT2!VTWKD/.@7<5O].B0.VJ_%6Y\,8T@R9&(@NYKAM2MZ$)FUO9
MQ5V%?;"OLWVXK7O^QL[%8G:5`##2K!O7(>=`NXK?Z=858';3>N0\Z!=Q6_TZ
M)`[:;UR'G0+N*W^G1(';3>N0\Z!=Q6_TZ)`[:;UR'G0+N*W^G1(';3>N0\Z!
M=Q6_TZ)`[:;UR'G0+N*W^G1(';3>N0\Z!=Q6_P!.B0.VOG>N0\Z!=Q6_TZ)`
M[:U->IG+A:W]*UZF_)R;V=PK^W_;_P"`_>?V*MB6K%+2W@K*DRT^:<Y/%I*[
MQ.)RO3/I<:7=?#\@.L%E+BD@&)]2Q1S6<XL-TSPG;0S[(\54V"2H+NH`0:*]
M]J0(!G<F&TE1-H*>9+<6RW4\D&#BTFZR99$6]DYA_P"Y>3\PXG14^-UTF<QL
MR?+KZH@/8'M!?.I[8.B(W)<T:+(C;LNZS3GJUD\I;)#-'+?J4LT#EC."9+LL
M$+HD-1,(9@)O(8HUB\QNNU1MV:))!I,8ZO`4Y.^MUI)NV/L:$"//-%B+Y@?-
M,7AA$;UD2V6(!L(`@M=$PMCLQLT3<7P&3)=)IQ=D.FM-P2H.@Q\\Q=,C%P+7
MR[K(F[`BR&ZN*K"NKN73'(YK],Y%#(/(9DZO+0UP_.<M3GA*21/4FW,9[(\;
M^N<E8F%V?9'CM4K;B3&A/8]L/VJ`DE->ZK,-+B4R:\O<6RG.)`;,.U,`@8D@
M$F62++0;("W3MQ'`:>GDB5+9,J62P"7R6[+J<NB+H:YP:V>`XWS!PW9)W/H6
M*,>:HKY-EZ_+;RG(A#_A-3"%):2>.4J9G?(!K/CM&@FB2*+750FCJ\HTJ3!<
M`MK>R(QW/*L`"S;!4`SZ>37Z]SJD_-&5=[(D%T&P="-A[*,`T:-.E:2NJ\%X
ME+;0-)J65-\18&D2XS"6%P$7#\'=O.>;#V.A>2L&F[40Y%P0IR&KQ.1#,+X?
MP0^W@.8U#>^39%B''.>R"Y2@D<03MCFT1%XR5-XT>F;C3"',12,XQ464`JQ9
MVF915I#`8R[LIDLW7VNN-F6Q$"&ESFD"PV&,-G7S<8PAFM+(3S,J9L]M^5%K
M#-F2#=+7Q!>);)@+A%L2`"8Q%Y8</:MTQ^/C%N0DB"\AG@?'N>BDX2Q$PY.Q
MX:E7*R*)FYL3$KYD\SG'3Y&EA=MP&)AE)Q^Z;!!9=LYE-B(N1>!%_P`Y;]S!
MAB(#27-<T_[+B=B"TLW$,!<)H;*)N2OF8M^[C-;==$V,#)C)@T[N6!"TE=7%
MF#]4-F"(-V6\HY#4KT^4X])LCB:LH;VD/S9'\7S]O>3H:\LKP\R%)#9UE)>Q
M+SF%1=K3DDH]J!O3$6/(.E/2U]QK:B8^.L!=!\(P:Z-T@DW7/NF[9H[$"(.*
MMQ+!=;,?0290:9#FRXRXW2Z8PB^"`TO9+#VAXO$D]F3`BH6T^ZF'R$@138QU
MD"^/"A:AK3FYG<FG(<VM#-1\$R6:;)YLTR)8B89'((,T.A5R&]T)C@%5T^XI
MF^QFX)<OB=<^5";%SFW8;LASKLQKK7`P!+0=!NQA8-`S_*N#2JB]3!K&OOQ^
M9!ELOT[Y>Y86@N:UY:8N:9D(Q<^$76:-PC/,LDTDQ]D%7+9#B^^HMKAK6YOI
MC@I1K<`X=<WO/)\BE.^!1(G%]R%.)&R8\LJMNX'-GC1IP1B+,'>L;)57,F.D
MSBXT^N#03'\&PF9$QTESBV7'9#8K)G5.%R)+*NE$ME;Q0O(;`$3YH$BZV&AL
MMC7SX677S`(1"IR73/J+0,,XB6/5;IAR%6=,DR+'Z!GR@P-F1S9<\8PR-:+C
MF62,=,[0LG>/VW-#TRN#.5(1+'Q,D)4%NABA*$M/?*XC6ACI<F,J7%Q;!P#H
MEKH7G-`O-#RTMO1<!&]$6+4G&<(=-E3ZL"HJ(2VO)EN,NX)DN]<ES"0QYDA[
M7F7!A)!8`Z)5BDF&=8"=7&H_%I8YN49:LJ*Y""3/F9I&ND!4$7K\2G/45E2-
MQ>4J&6,;RW$3,LDE:D>CD9BI.G3%H4P@'$YCZ;$@0R6XE@F1B7DFZ2R(,3:"
M+^D.A$`0%HR9.(9?+7S9[&B<Z0&W1):&WP)L'-($6N!U42"P&!)+C8<@]..)
M99B=AE*.5%-11KA!\#,J6S6X!7ANLQGI[AF-Y*$P022=H25(X^H"F%T=W3V`
M9:P;"VMM;A]/,IP1,A$B6+/]F6UI_9%G06QX_7R*YEZ1>@'5!,1"R9.?,;_^
M%PCM&Q:>4(^!D1_-EA]ZTM?$W.7Z7XK^4JG^.>OZ.ONV_P"G;(7]R\$_LVF5
MHKC:[I2B)1$HB41*(E$2B)1$HB41*(E$6>?T4O\`O2=`/^G*5?[/6;Z[W]W;
M_$!_Y.G_`'TM?)W]<O\`Z0Z?^^6%_P`56K^E'7N%?EE2B)1$HBKZ7X3O7N/'
M_P"52"KL*;/2ZZL%15*(E$2B)1$HB415Y]]E1G\X2_>AXJA0['QJPU%4HB41
M*(H`KX4+?<!K]\7>BFRI^BJ41*(E$5?C7L%9[O23W^<:I4&CIE6"HJE$2B*`
ME/P<>O<Y3^+O10Z"I^BJ41*(E$4`Z_E>,>WW#WE<*HT%0Z0I^HJE$2B)1%7&
M_P"$DC]JL/XMQJ["PCLBK'46)*(E$2B*LP[X/(OX9R]]%M5VE0:%9JBJ41*(
ME$2B)1$HB41*(M2/^MB418?Z5]79F)\(Z>,6/L-2*8\BT,84EL`D"5U4!>9K
MFR3HY*EC>%A-@TMT251,&^,7,:E)9@SC3B%81%[!8+W[EPW$>+T5/3O;%@HY
M9:8VN>08,AT86'XUY.S#@`KL7KJZ5,(G'%9[7M(L9):6ETZ,8FX7;H0A`MMM
M*]PC6OF\HPHQS8&.UK3-WN,J4Z=8,2=RQ,MRW$6J$/\`E#';(Y`>TLY4)XJS
M3#=$S@L;4:1<),:`LT0R[!,UC,7UE*)MR$TM^-E\!I<T6WK`=)`!@MIG96U&
M).IC-#J9K]&B:)3B]LN81"YNBRUH<2(@D0-GL2?6=CIY=W]DB,,R=+'))D`&
M-(:0UL["G39&E7+*8P96W,#T[R-L8F90V.L!=%!Q;TH;#A-I`%118PF@#6I&
M)R7.+);9CG!]UL`-T;Q;`$D`0+3V1%EJVXY>JY<MLV?,DRV&5K'Q+B9;;C'@
MN`:7&(>T"X'"\2TFQ=B2:J&1.OBD?CS$[$2.09&*B"LB4(4Y*%N;8WJ(QO@+
M)(C#VIX4WWX;G/((36[:7.(,W`0C.@&Q8Z_$&AS6,:;[GW;=B$QLMV@Z076;
M"DG`YA9,FS7-U3)-\73:2Z1,GR](%A$N#M!$;-M7?`NHJ%:B6IY?(.T2YO9V
MP#`N;W.2-*=$@DS!*DJY;'WUB6(5[BE,LJ3-Q@E*$X93BW[8KJD@O=B]MFTE
M;*K6E\H.#1"!(T@Z"-.U:-(V1:M-BF$U.$O;+J72S,=>!#226N;`.:X$`V$V
M$1:ZVZ3`KWRM8MK2B)1$V;W]'^Q_R41*(E$7`I]BJ_::O^3FU6Z0LJ?^!?\`
MN3^TM%>$?`R(_FRP^]:6OA]G+]+\5_*53_'/7]([W;?].V0O[EX)_9M,K17&
MUW2E$2B)1$HB41*(E$2B)1$HB41*(L\_HI?]Z3H!_P!.4J_V>LWUWO[NW^(#
M_P`G3_OI:^3OZY?_`$AT_P#?+"_XJM7]*.O<*_+*E$2B)1%7TOPG>O<>/_RJ
M05=A39Z775@J*I1$HB41*(E$2B*O/OLJ,_G"7[T/%4*'8^-6&HJE$2B)1%`%
M?"A;[@-?OB[T4V5/T52B)1$HBK\:]@K/=Z2>_P`XU2H-'3*L%15*(E$4!*?@
MX]>YRG\7>BAT%3]%4HB41*(H!U_*\8]ON'O*X51H*ATA3]15*(E$2B*N-_PD
MD?M5A_%N-786$=D58ZBQ)1$HB415F'?!Y%_#.7OHMJNTJ#0K-452B)1$HB41
M*(E$2B)1%J1_UL2B+%;1UB+/$ETK:5)4DOHW7!18HP?)(DXS?">4I!,FA3`&
M5V-QPYKGM%EQN0&R:&`E3E=(K2IDP23%Z@10`6,O:NY\*IZM^&TTP<6,)4LB
M\QQ(NC<DF^+6Q,"`-)@O)69L0PR3F'$)!\H`FIGM<&3I36&^X:P`&43=?=;$
M$F-T1T+W%MTN9>9E"Y4TQ_0.W'.3,5'EMDF`,S%$'LQ1;*39%9';.'49&[$1
MMN+..++`>I*0)@'#&`DL(=:V@J&DEHI`2(?@WZ+/_$Z`^.`VEM#\;H9@#7NQ
M0@.O",^3IMMCJ8_=.@-`O$@")7<<]-V<GE+*4+HFT0+44U>T\EDZ,W#&>@I'
M&1I790_DOY"8G/A9+*]6?5ART:EO"D.-5G&&C$(9@Q"KJ*J<'-=Q4M<8G<3+
M3&,?PEAC;$0MM6%F,8;+<QS/*0=+;=:==(B&PNW?P-HN@"#H@``"P!?#=ILS
M6TR5;,FQKT'H96XJ6Q8L?T^!,T`<353.\,,B;%`#/'C<"8Q+(8LW.&R4$&Z+
MD12@S;&AV]PH:EKS-:*03#"W5OC801^^;8!^,11^,8<^2*=YQ0R&@@-U\F$"
M'-/[SLM<YOQ$@6*U0S$VJ''25P0P5ZT915`Z+;N"Q`TX=SL4@NIN(X5NI$1N
M=SDK6D+$H'<"9*`A,7M[[0L.S>LR53U\D$2C3-!.PQ_"6?$+%D5%=@M60ZJ;
MB+W-$`3-DQAT3J8D]$Q/15RWIUL_&#I%\CV;OTWUF7<4^73]H_NUI[^7.]5^
M^R>!3>G6S\8.D7R/9N_3?2[BGRZ?M']VE_+G>J_?9/`IO3K9^,'2+Y'LW?IO
MI=Q3Y=/VC^[2_ESO5?OLG@4WIUL_&#I%\CV;OTWTNXI\NG[1_=I?RYWJOWV3
MP*;TZV?C!TB^1[-WZ;Z7<4^73]H_NTOY<[U7[[)X%-Z=;/Q@Z1?(]F[]-]+N
M*?+I^T?W:7\N=ZK]]D\"N%2TZV+)E5[Y`TC;6R15<5K8?S;:]PV3F;-K7OF^
M]K7O;T*H;BD>SI^T?W:P3'9;<PM,K$($0_"R>!6F7"6+*9T-BAJ>0X[*3CCC
M+<@LZ+R<PX!.]R>Q833"Y26`9E@6MMKV#:U[^A:U?,?'N;'+%9CM;5SIU>)T
MVKG/<&NDW;SICB81EDPB;(DF&E?K_P":GW\.?3+/-;EK+F&87E%^'4&`8?3R
MG39>(F:Z7(I),IAF%E6UI>6M!>6M:V]&``@%9^3N6><N-N]25>%E;3[*,I]_
MQ'MI/!KGWVA?O!<DY,WK$_IB<G<L\Y<;=ZDJ\+*>RC*??\1[:3P:?:%^\%R3
MDS>L3^F)R=RSSEQMWJ2KPLI[*,I]_P`1[:3P:?:%^\%R3DS>L3^F)R=RSSEQ
MMWJ2KPLI[*,I]_Q'MI/!I]H7[P7).3-ZQ/Z8G)W+/.7&W>I*O"RGLHRGW_$>
MVD\&GVA?O!<DY,WK$_IB<G<L\Y<;=ZDJ\+*>RC*??\1[:3P:?:%^\%R3DS>L
M3^F)R=RSSEQMWJ2KPLI[*,I]_P`1[:3P:?:%^\%R3DS>L3^F)R=RSSEQMWJ2
MKPLI[*,I]_Q'MI/!I]H7[P7).3-ZQ/Z8G)W+/.7&W>I*O"RGLHRGW_$>VD\&
MGVA?O!<DY,WK$_IB<G<L\Y<;=ZDJ\+*>RC*??\1[:3P:?:%^\%R3DS>L3^F)
MR=RSSEQMWJ2KPLI[*,I]_P`1[:3P:?:%^\%R3DS>L3^F)R=RSSEQMWJ2KPLI
M[*,I]_Q'MI/!I]H7[P7).3-ZQ/Z8G)W+/.7&W>I*O"RGLHRGW_$>VD\&GVA?
MO!<DY,WK$_IBS_\`HFV?("/Z4G0,<^/4+6)KYME91!30P/R)0%8/3WFX11IQ
MBV0+2AI@@+'80`A".][VO85K6O:_9'-9D?`LN9G.(8=,JWU!I9C(3#++8.+(
M]BQIC8(6P7BWW\?>NYU>>OF-EY/SG0Y>IL(;CU'4!]$RL;.UDIE0&@F?4367
M"'NO"[>C"!%J_I/[E+>OX[W)<^.J]$V+XYV]#X=--REO7\=[DN?'5+$MZ'PZ
M:;E+>OX[W)<^.J6);T/ATTW*6]?QWN2Y\=4L2WH?#IJ"3%2CE$[V"M8+';TL
M6Z"NV.-R[EW4ONY6`"SO801AO86VO<5[7M>VQ:VQ?9MD%+8J=W*6]?QWN2Y\
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M^.J6);T/ATU!1\J471JMQ6L`0[]R"PK&-CB.]S;/:^QPK7"[@M8L1FS<-MB]
M[!V+7O>^S>],%!&"G=REO7\=[DN?'52Q6WH?#IIN4MZ_CO<ESXZI8EO0^'33
M<I;U_'>Y+GQU2Q+>A\.FH22%2BS"[W/6L`B>H%&Z!*;'$!EP[2^S8`Q.Y@0B
M^U>X;V_8H(*&,"IO<I;U_'>Y+GQU2Q6WH?#IIN4MZ_CO<ESXZI8EO0^'33<I
M;U_'>Y+GQU2Q+>A\.FFY2WK^.]R7/CJEB6]#X=-0;D5*-]([MUK!<RZU=N-P
MMCB$(1;T+MO<P-W<5QAN7LVM:UPWL+8OL['0O1""AC$*<W*6]?QWN2Y\=5+%
M;>A\.FFY2WK^.]R7/CJEB6]#X=--REO7\=[DN?'5+$MZ'PZ:;E+>OX[W)<^.
MJ6);T/ATU`(2I/O^_6`M8+'63,N["$V.-RQ6VB_<MS!9V"(%[6V=MLB%L]#8
MV/LK%!&)4_N4MZ_CO<ESXZI8K;T/ATTW*6]?QWN2Y\=4L2WH?#IIN4MZ_CO<
MESXZI8EO0^'33<I;U]'>Y+GQU2Q+>@J[%2Y/=B273K6$).ZN&U"<V.)AEK[Y
M*]OLB`[%!O:X]G8^YZ%MBW1]&J814$8*Q;E+>OX[W)<^.JEBMO0^'33<I;U_
M'>Y+GQU2Q+>A\.FFY2WK^.]R7/CJEB6]#X=--REO7\=[DN?'5+$MZ'PZ:;E+
M>OX[W)<^.J6);T/ATTW*6]?QWN2Y\=4L2WH?#IIN4MZ_CO<ESXZI8EO0^'33
M<I;U_'>Y+GQU2Q+>A\.FFY2WKZ.]R7/CJEB6]!:FFU>/PS7_`$K7:>Q5GY4Z
MX]F_D_\`P/[[_A*EB6JS:!/]1_25_P"7_&G_`'=2UWS@OXHI?X!GWH7BS-WZ
M58C_`$V;]^5EQ6YKCJ41*(E$2B)1$HB41*(E$7`J]B+/::O^3&T&E1W8E:0.
M/?@'#/S78O>U/7SXQ7\:5/\`2)GWY7Z4<C_H3@WY*I/ZO+5PK0+DZ41*(E$2
MB)1$HB41*(E$2B)1$HBSD^BY_P!Y[H!_T]27_9WSK7+\D?CH_P``_P#;:O/?
MO,_X:M_*E/\`>SE_2`KMM>`DHB41*(J^E^$[U[CQ_P#E4@J["FSTNNK!452B
M)1$HB41*(E$5>??949_.$OWH>*H4.Q\:L-15*(E$2B*`*^%"WW`:_?%WHILJ
M?HJE$2B)1%7XU[!6>[TD]_G&J5!HZ95@J*I1$HB@)3\''KW.4_B[T4.@J?HJ
ME$2B)1%`.OY7C'M]P]Y7"J-!4.D*?J*I1$HB415QO^$DC]JL/XMQJ["PCLBK
M'46)*(E$2B*LP[X/(OX9R]]%M5VE0:%9JBJ41*(E$2B)1$HB41*(M2/^MB41
M4K0IEB*(=,NC[%1"66OLO-TYX5<7@,8A[](6.%-TK:E#=%ET]D+<D-:HFGD2
MME5V2]4&;>Y28PXP)9%MUOWE@]1+&'4M.`XS.+RR8`D-B("\18(P,([4="\;
MYLH9[L?Q*N)EMI^/3P+SVM+RUT7!C28N+01&&R0!$V+)6!:B<1Y-3Q!7"I(I
M=T\[R--\41H8F1V0W637'K2_2"1(SP+DI!B-M,CT=/<$"XRP4CDA.3'IQF%J
M21"U\FMIYX:93HA[W,%A[)H)/2@(@Z"($:5L=5A-?1&8*A@:94EDUUH,&3"U
MK38;3><&N;I:X$&!!5,)UB8)/7,:0#Q*NI)#%VV6(7^\$D]XT0A>T&17-B;G
M1Y`A&0UO[XWXG?S4J,ZP1&60;%[A$:4$>7Y2I(@1=!S08W3"V]`$[!-QT!T.
MBM0<OXF&.<6LBQY:6WVWH@RPX@1M:TS6`D?*Z!7?;=5>)GB"7G[>.6%("IK#
M($M8'V*.<8ES:^3IC8)BS'+F!\`D/`U!QS(B9,:I+$:"S(6:<';&%W*K$VOI
MW2M<+T+S6P((,7`.%AV+IO1^3;T%A?@==+JN*OU=[5O>'-<'-(87,,'-C;K&
MF7`PW<!H,5:(_J%Q"^1.)35?,&^`L4^)`L@U\JJ4.-7"8M2A,WK4#Y&6Z5KD
M"AY9'1$[)C4Z@C;AO8\(1V`9L@MC964[Y;9I<&,?V-_<WAIB(PB#$6K(FX37
MRI\RF;+,V;*L?JHS`PV@M<6@P<"""#M;5J[4ASYAV.QM;)C,BPYY2IH#(,G(
M&V-2>//K])83&&]P<W=\B;0C=+J)$C)3-2BUC$^V*N,D=KCMM!W#7U=,QAF7
MVD7"Z`()+1:2!&W05).%XA.G"0),QKC-;+)<US6M>X@!KB1N3:--MH4++-2F
M)()!GC)$Q>G-@AS#EI/A1T=3V)P6733=5+D<)(N8F:RUR@N/6>UP!'.(PA3I
MD@1J#KEE%BO;#,KJ>5*,Z:2)8F7"8?=1N[&Q'9V!:5F2,'KJJI;1T[6NJ'2-
M<!>`BP-+])@+T!8W23`")*[RC47A-!-LDX_><B1V-2#$BF"H)T=*UQ$7CK<Z
M9'0NSG%&9#*7TU`PO3TJ1,B@9Z5(>:<DVMK'!#>^Q:FMI1-?)<\-?+NAT;`"
MZ)`B;";#8-"PC",2?32:N7)>^5/#RRZ+SB)9`<2UL7``N`!(`.PK"UY=QVY'
MC1FRAH8UP\B2S%K6WR5T:V)PDDRA;F%I>F^+HUJX"A_#U6,%B;IPC&:$P'W%
MKC#:^-M1)<87@#?+0"0(N:8$#;Z2R7X?5L%X,<YNI;-):"X-8\1!<0-S9ICH
M4DDR=C->:]$(<CP%8=&E+@CDA:691Q0./*FA0@1NZ=\"2Y#NTG-2MT3%*0G[
MG<@U06`>U$,-KXA/D.)`>R+3;NA9"$8VV0B(_&L#J*L8&ETF:`\`MBQVZ!B1
M=LMB`2(:0"1H4;&LNX\E.\I"23M+:[R1VF[-'HR_N38SRI]5X\E;]#).8SQY
M2NWR<TB1YC:K:F$@'81`;#O8/1"'#+J9,R`#@'.+@`2`3=):8#2;05CG4%7(
MO%S'.EL:PN<T$M:)C6O;%P$`2'#3LKT-5[$6>TU?\F-K/&E:)W8E:0./?@'#
M/S78O>U/7SXQ7\:5/](F??E?I1R/^A.#?DJD_J\M7"M`N3I1$HB41*(E$2B)
M1$HB41*(E$2B+.3Z+G_>>Z`?]/4E_P!G?.M<OR1^.C_`/_;:O/?O,_X:M_*E
M/][.7]("NVUX"2B)1$HBKZ7X3O7N/'_Y5(*NPIL]+KJP5%4HB41*(E$2B)1%
M7GWV5&?SA+]Z'BJ%#L?&K#452B)1$HB@"OA0M]P&OWQ=Z*;*GZ*I1$HB415^
M->P5GN])/?YQJE0:.F58*BJ41*(H"4_!QZ]SE/XN]%#H*GZ*I1$HB410#K^5
MXQ[?</>5PJC05#I"GZBJ41*(E$5<;_A)(_:K#^+<:NPL([(JQU%B2B)1$HBK
M,.^#R+^&<O?1;5=I4&A6:HJE$2B)1$HB41*(E$2B+4C_`*V)1%@II/*R!;39
MAM^Q["M5\0MD32UB"!3Y=#<8X*ES+*N1</?6.)SF!O4NRPU/,6<B&N3FE"-&
MD&%600G%N"8\L1HNX<,$[R?)?)94-OTTMKH-ED&ZT@.:2\$6':M$+`5Y5S$:
M3R[5RJN90S-3B$Y[`^9.8YM]X<YCPR40X1:#"-A)M<#!>L1[%ZS'+S&'C#V(
M];$'M$9=#YHR-4GB.)<LMJ9VC&&G[`R^UAS'/X'8*>1X[<&Y.,L*H)2,YE3C
M(!:PS07U3*=TA[7TTNJ9=<'`$,>(AAE_=3(VM(V;+H@MLFUK:N6^7B$_#9NL
MEN8XM=-E&#IS9X["1#<S`XZ(D/,=A4P[3JV&N427>)/5^7R2@T5A*1P!B?3W
MRUL3$!96NB.:)X+,PG6--#^5EM:0^M:4K<'A(F+(,,`68=8>7Q(%S3JJG<L#
M8W)=ZR_H=?B`;YO`:0(;:U`Q=X9,9QF@^<FN>1K9]S=:J,6:F#BW5`L<3%A)
M(!("]`QI!5V(Y'$D\(TZ:HFW&,+)D\KCL-#`,+%B9,RR+&L/Q*;.6\@K+V]A
MJ`R.M+VZ&I%%C`A>Y"HN78)&P&V=(DNIGM$J1/$AL2!=98\M#+PW<-`<8?*<
M=A:6LJ6U\F8:FKHG5LPM:Y]^=;*;,?-N'YJ,;Q8T$?<2Q&U59!@QM"TR!O>\
M!:JW(R27DHU*1FPYIYBL,812F;X0G+J3!8"ES.XLT*;ESG@Q&8L2I3+D+%KL
MX+!!"88``,L4@NEKI-0;T=#)8:(N8XW6WR&B,L1`TDD[*SW8F_6,?+JJ$!EV
MTS9[GNNLG,%]YD@O($XP)M`:QN@1/7E&"SY4Y&&*\8ZWR(W8[+C@@B1<%P@-
MM9'C,1F>.4+@R[7.!"!,`I+GM86*QJ,]2?=I1?XP45<\@V3*0S'6RZJYN[+L
MN`+]9$CYS_Q#L;`MA$*R<3$AD&SL-,Z$H%U^=$B5J+H/S,=,@:"`+SK"8$>U
M2)H12R$NF/Y%IFU<.D:?<XJLVOB)1#\,7"YGN#^:^.4*/#;,FQ:/K@'C2C.M
ML*K$BVUK[?8O6J>P3)1DOD5!EF;?-C+;8EO9Z-C;6W2ICI%2VKDUM`V<VFU(
M-^=9!L`_\#V0TPT17@"/3L8TDM*QJQQK>/F*6`NF/I#-9=C/3M-'";(Y8ART
MU3Z2R5M<<O)&X^9R=KRV>4G6@L$#99M3!`2<0,].9HQ1%L"UE5K;A:7%LMQ=
M&^'$B_"\0_3L0%A$0MU=BXF%S9D[#>+F:)C6-F5#`PM,HL:TB43<:90)'W5X
MV@P(N@<.LJ:1PA^2:=]7BI)#'5[/O'Y-"<42!J=V)TR%#LEM[2;9+J!8!$N\
M?DD'1"3N:BRZQMK;<U*,XLDPO-XLT/8\2*F#2;"UA!!<'0_""T%H@;?BT+3>
M4)ADS)3JN@#IC1NFOFM(<);Y9-LAUCFO,6B[T'0)!B'/#TD<(BSP8K'VL5!'
M6)CF<"0!3X3TVC=C<5366Q&;KH@ZNQN9KFNLC3O\*1[$A&`*@Q*,\%TUCC>J
M`X74TQTH2@RI#`'-&XE1N.(=`F_:8M&ZTPC9&U9C,0DMGNJ3-P\S7.8\_/5$
M-:QCF!X&IL;=>?F]$86P$%;FS'"1KRK'\J`T\:M'-4T.AKRL8WZ!8F<$:ET2
M95RMER,.3&<DU!-::.N<<?LON)%CS4CE=0G)($$)!UC##,QLB[4-J-34$@Q@
M6L^6]XA\X($%YV#L:"M.^K+Z%]#QN@:US8`M?-!AJI4IP=&02X.;*:8`M@2=
M(@!ETIS])Q)E0?DJZI;;9(JMLWC.)=BVRG,MLW_SR[.Q;[-;F*N9'^;U'49W
M:X\_"Y`:2:ZA@!\J;P2TRH-D$Q-"XDG%`I\;<F-LI>ZDH8W<DS:MR>UC"KF2
MDLRY8[=&VV"&^Q?HVM7SGQG->5).,5<F?B5,R<RIFAS2V?%K@]P(,))$0;#`
MD;1*_4QS<^[S[PF*<WF`XGA>2<:J,,J,%H9LF:R=A@9-E3*:4Z7,:'X@QX:]
MA#FA[6N@1>:#$"U>,@?Q?9#[`C'A96V^E^3^5*7M9_`KF7U:O>3]0\=W["?S
MDGC('\7V0^P(QX64]+\G\J4O:S^!3ZM7O)^H>.[]A/YR3QD#^+[(?8$8\+*>
ME^3^5*7M9_`I]6KWD_4/'=^PG\Y)XR!_%]D/L",>%E/2_)_*E+VL_@4^K5[R
M?J'CN_83^<D\9`_B^R'V!&/"RGI?D_E2E[6?P*?5J]Y/U#QW?L)_.2>,@?Q?
M9#[`C'A93TOR?RI2]K/X%/JU>\GZAX[OV$_G)/&0/XOLA]@1CPLIZ7Y/Y4I>
MUG\"GU:O>3]0\=W["?SDGC('\7V0^P(QX64]+\G\J4O:S^!3ZM7O)^H>.[]A
M/YR3QD#^+[(?8$8\+*>E^3^5*7M9_`I]6KWD_4/'=^PG\Y)XR!_%]D/L",>%
ME/2_)_*E+VL_@4^K5[R?J'CN_83^<D\9`_B^R'V!&/"RGI?D_E2E[6?P*?5J
M]Y/U#QW?L)_.2>,@?Q?9#[`C'A93TOR?RI2]K/X%/JU>\GZAX[OV$_G)/&0/
MXOLA]@1CPLIZ7Y/Y4I>UG\"GU:O>3]0\=W["?SDL^/HH9H-W^E&T#)K0^8MM
MRLWRI58YT2L11!NY:>LWE]3E"22!:9=2/=ML&P@A!M0BV16OL6OSKF[Q_`,3
MS`:;#*V145/%YANL$T&Z"V)W<MH@+-F/07E;WP^9_G@R'S1,QO/>6,3P?!#C
M%++$^?,H7RS->R>62X4U9/F7G`.(-R[88N%D?Z2F_P`JYLR+UMHXXKO!?+Z)
MVBF_RKFS(O6VCCBB1.T4W^5<V9%ZVT<<42)VBF_RKFS(O6VCCBB1.T5!IGI1
M:1.YG)U^O<;2Q!N58MKW0NP%+[>PQ[+K8&T,V][!V+WOLAOLVMT-F["D;="G
M-_E7-F1>MM''%16)VBF_RKFS(O6VCCBB1.T4W^5<V9%ZVT<<42)VBF_RKFS(
MO6VCCBB1.T4W^5<V9%ZVT<<42)VBF_RKFS(O6VCCBB1.T4W^5<V9%ZVT<<42
M)VBH)Z>E`U,>O>//Q>YOH#+6&6U[)M[-3J'<R]JZBM<S8%MONMK;:AOT=G8M
M>A0G18IW?Y5S9D7K;1QQ45B=HIO\JYLR+UMHXXHD3M%-_E7-F1>MM''%$B=H
MIO\`*N;,B];:..*)$[14*6]*>4:PWDZ_7O=D;B]RL6U[H&P5SJ+=!?Y5VFT%
MMMBVP*]]FU]FUNALW84C;H4UO\JYLR+UMHXXJ*Q.T4W^5<V9%ZVT<<42)VBF
M_P`JYLR+UMHXXHD3M%-_E7-F1>MM''%$B=HJ#C[TH+1J@VCK\;LO<@'MBRVO
M8#<Q[7CN7?;NH+[H5>^U%L6O;;6OL7O;HWITJ`]!3F_RKFS(O6VCCBHK$[13
M?Y5S9D7K;1QQ1(G:*;_*N;,B];:..*)$[14+)'I2:PNY=XZ_%6&@4!N886U[
MF#9+O]T/:.HQ[6WV=BU[_L51I4)L-BFM_E7-F1>MM''%16)VBF_RKFS(O6VC
MCBB1.T4W^5<V9%ZVT<<42)VBF_RKFS(O6VCCBB1.T5".3TI$Z1T=XZ_`N6M7
M7L`1;7MC=LT+@7"7M740=L&U]M?;7#;8M?[/0O1H4C;H4WO\JYLR+UMHXXJ*
MQ.T4W^5<V9%ZVT<<42)VBF_RKFS(O6VCCBB1.T4W^5<V9%ZVT<<42)VBH%"\
MJ`R!^,Y//PKF)F6UR@EM>Z%;0"^UKF;+K8&P9MON=@5_0OL['0V:H#:;%/;_
M`"KFS(O6VCCBHK$[13?Y5S9D7K;1QQ1(G:*;_*N;,B];:..*)$[13?Y5S9D7
MK;1QQ1(G:*KT5>5)+$D+M'GTZP37"^Z%%M=RQ;9R5BO:VZ.I8]D-[[%^AZ-K
M[&S;HUB=I4!LT*P[_*N;,B];:..*PJQ.T4W^5<V9%ZVT<<42)VBF_P`JYLR+
MUMHXXHD3M%-_E7-F1>MM''%$B=HIO\JYLR+UMHXXHD3M%-_E7-F1>MM''%$B
M=HIO\JYLR+UMHXXHD3M%-_E7-F1>MM''%$B=HIOZJYLR+UMHXXHD3M+4TZO,
MX+=/Z5KU;^])/W[@SV;^4/XG_"418ZZ7-1TB@&C[#V\,#9)#"=/VEG37+\SO
M#M+%[%([-626M6(E+CED31MV;7QRC<99CG)1OBM;R5A@@(DXMVN,P'=&&UKY
M.%2;C`Z5)II1>28&#A]R($$@")B1'0+5Y)S!A$FJS+5ZV:YE35XA4LD@-#FQ
MENTS#>!`<XAHNAQ%KC98LK,=ZFGN69`CF-Y1!&Z'S!^S'*<9.\(.=Y("=X\:
MF:`Y+G<>D,Q9GV'L*)Q!-4..KF-BQE4N#&N2*QC3KC#$AI=]RD5SIDYLB8P-
MFF86EL3>:`US@7`@1O7;"TEI!L-BX]5X-+D4KZR3-,RG93MF!\&W)A+Y;'-8
M6O<1<,R#@\->"+6@.!57C&KUUEM\0NC7!VX+%.&S!*>:$"=U1ZZ*R[45DA3$
M84SMSB!*4F<=XXO&W5W7%&)BS#PJ$`0B)",0A8)>(NF:MS6"X\2[UN@S'0:`
M=F`!)^,:%GSL`9(XPQ\TZV69URP0<V1+#GDC2+SG-8V!L@ZPP5?(UYM:'*4Y
M@4MQZ:QL47B^45C'*DDAWP42K(&/,M9:QTT8P(9#&E)U(_Y!9<3*W)K%90;<
MQ38Y)N8KEA-,P>5FBH?)F,@QK7P,=+FO>T-A#2X,)%O06:<KO=12JJ1-O3'O
MEAS2V%UDR5*F&9&)BV69H:ZS1!VS`5AXUY3!MQ;#\JI<-)'0OD)AA]RE!FZ4
MJ%;M%I=F;(2Q@+B\:D06D"60*(=!(=('H90T!)KH,;84`28*@0[Y;L6FMIVU
M`E`[AA<V-H+W0@#"V#0YVBW<Z(K/EY8IWUTRA=4%OSLYLIY:`',E2PZ\YL8M
MOO>QD;Q#=V3&"]`(UWP8W)V3X4EATHE4:B+2TO<`E&/"R)6YY29&]ER$[Y8E
M+:PGF,J%LB.,AX\5IKJM\%!SFI"(I.2(VY19F<,6E:^9*#7.8T`M+;2X`.+S
M"R`;=(C$Q.@+2'+%3Q*34NF,9.F.(>V9N1*)=+$II=:2^9K`870&BTF$2+<X
M:UL4(T+F](XMF&01MM/G-RY/'X"4L9'=EQ?'6R69(ES,8I?D*]5%(;'7A.>H
M4F)R3%(S-P2%*5`1%6S#BE.`7!LPL%ZT-L(8`7$6Z&@@QV=`B5D-RY7.<V6Y
M].R<0S<N?`@S'%LMI@T@.>X$`1,(1<0+5U&#65$%+K)HY(8C-T\B2Y`E\-QV
MDC\?`XH<P$LV8$>(&$&/UZUW1EK'M6\/K7=?9?O8A3=5C,`>,@@X9<9B<HN<
MQ[77P\AL!&_!]P7;=,2(Q@!'3`%6;EZH;+9.E3)1DF4Q\PN=`RHRC-=?`!@T
M!KKMV\XP@1$B/&T:QXH[JWAU*;3TD%;%S<G"L7M[N1,2PI,09>R;/&MQCQ12
ME.CDT0<<0KVVZ<1UDYHRS+!.&.Y.Z&XE+<2Z'S0(TQCV#W.!&V+A$/V="Q3,
MOSY;6L)!J2#8"+ELV5+80[9:\36NC"(B+-,.[;6UB,*%:K51W+*!0PD+WB<,
MZZ"DE/6.86WH<=.IV0ILC*?CRD<0&U9885(+HS5SCN:LS;)`C2*@DWRI3722
MV8"+7"[:UNY-YUNB#VFR)MT6%8/1ROO!K7R"'$!A#[)CR9@U;#=M?&4\6@-L
M&ZW38Y@C!<L8P"V-L`0@"V+VO;9#>]K[%[="]MFU;DM@%HBNLI]BJ_::O^3F
MU6Z0LJ?^!?\`N3^TM%>$?`R(_FRP^]:6OA]G+]+\5_*53_'/7]([W;?].V0O
M[EX)_9M,K17&UW2E$2B)1$HB41*(E$2B)1$HB41*(L\_HI?]Z3H!_P!.4J_V
M>LWUWO[NW^(#_P`G3_OI:^3OZY?_`$AT_P#?+"_XJM7]*.O<*_+*E$2B)1%7
MTOPG>O<>/_RJ05=A39Z775@J*I1$HB41*(E$2B*O/OLJ,_G"7[T/%4*'8^-6
M&HJE$2B)1%`%?"A;[@-?OB[T4V5/T52B)1$HBK\:]@K/=Z2>_P`XU2H-'3*L
M%15*(E$4!*?@X]>YRG\7>BAT%3]%4HB41*(H!U_*\8]ON'O*X51H*ATA3]15
M*(E$2B*N-_PDD?M5A_%N-786$=D58ZBQ)1$HB415F'?!Y%_#.7OHMJNTJ#0K
M-452B)1$HB41*(E$2B)1%J1_UL2B+SO1EA7$$YTH:,I?,(>T/,O2:>,/$)3E
M+FZI`OJ*()DLCCZ:0QQ"[(V6=H(@_K+KD)3JC<"FY2=<PJQ=S+[;O#":6FFX
M923)K09@IY>W;``B(C!T#:(@P*\<YGQ&OILQ8G(IYCFTYKIT8`&Z7DM==<02
MPO:($M+2X"!C!>_+<%:936A^5N#7'>HE\N;'!WEJG)TF+>VR7L1+XTL[>W9$
M,FP9+$CV9+*'1&G:D+BC(()<U9`4]@*3@CUQI*&Z2X"!<(F\8@B(`#KT1")$
M`1I(A:MG;B>,B8UK'/O"60&B6VZ6.NDDR[EUT2UI+G-)):TQL$+*VZ<\0M<3
ME<$#$B3HG+9&P254RB4*&\MD50UFB;!`TD26,8VETBZ2`-D(;;,PTAY:M$:1
M<X)]S1C'?&VBIFRW2KOS;G`PT0N@!L(0(NAHNPM$(Q62_%Z]\]E3K(3Y;'-!
MTQ#RYSRX.B'%Y>Z_$0(,(0"^4>F[`Z$$="1BR+#O$WF$R./'+25SFJ;Y)CF3
M2R:0N2"6N:U8L7R%DE\[>G.RY2,Y4I6N:@U0,X0[WJBBI!=A+;N2TB-MK27-
M-NR"YQB;228H[&,4=?C/?\XU[70@`6S&M8]L```TL8QMT0`#0`!!<D.T^8F@
MS2N8F6*IQLRO(S-E%*VN!IBQ,S2B+H61MB%F@-[EC):HBCCR8*!,:(X(+V&(
MRYES!WNE4=/*:6,;N2\/@=@B%V'0;`0"E1BM=4S!-F/^<$DRR19%KBXNCT7%
MQO$0V(0@J[?21IKLQ,,938?C#6QQ>/((C'4+$>_1Z[/%&X,Q**C*)8Q/#<O`
MP*T^0GPI:DN;<AQ)=#RU03@""$.#R=0W`P2VAK1`0B(`1LL(LW3HC9B8Q6=Y
M>QC6NG&H>Z:]Y<XNNNBXW-T0X$7AJV$&$6EH+8+FF>EO"L\51/?^)%;PQ-RR
M0\!B#8K<&:./KGE-"SMTK-?4[0L0J52!8C9PE&-P3`MJD@XPD].:3>Q=DV@I
M9Q;?;N&EQ@(@$O@#&&Q9HT'01!2GQO$:5LS53/G9@EB^0"YHE$EMV((!!,;T
M+P(!!!M5F>\!8;D03;.\`:#C353VO+6)5+NTN:!RD4X9\EN[JS.K0Y(')B=E
M$_CZ)V+5(C4ZA.L3`$2,L.R&^8^CIG]DP;.V#$N#B00;#>`,1H(L63+Q3$)/
MX.:X"`$#`@AK#+`(((<+CBR!B"#;%?5)I^PJ@;`,R+&\=3-9:4I'9&6%?N8B
M"H=)\?[)PQ+A'*%!T.FKNA..,$,Y0%Q/--&,\>ZT%'2AMT,;=_X2W]IQ'3.R
MCL5Q%S]8Z<\OC&-GRVOVOEL80-`N@"RQ=)YTW8+D+B6[/&-6-8XA6DKCU`5+
MTDWSN2UPIE"@?B$+JF3R-@&VXW8`&-B\"EM.$T)C#"!&%[>^%U%2/-YS`3&.
MS;8T6VVB#6V&(L%BQ2\7Q.4S5RYS@R$(0!A:\Q;$;ET9C]TV#A?<`8%>WB$(
M8A"%>XA"O<0A7OLW$(5]F][W^S>][UJUMJZZGV*K]IJ_Y.;5;I"RI_X%_P"Y
M/[2T5X1\#(C^;+#[UI:^'V<OTOQ7\I5/\<]?TCO=M_T[9"_N7@G]FTRM%<;7
M=*41*(E$2B)1$HB41*(E$2B)1$HBSS^BE_WI.@'_`$Y2K_9ZS?7>_N[?X@/_
M`"=/^^EKY._KE_\`2'3_`-\L+_BJU?THZ]PK\LJ41*(E$5?2_"=Z]QX__*I!
M5V%-GI==6"HJE$2B)1$HB41*(J\^^RHS^<)?O0\50H=CXU8:BJ41*(E$4`5\
M*%ON`U^^+O1394_15*(E$2B*OQKV"L]WI)[_`#C5*@T=,JP5%4HB410$I^#C
MU[G*?Q=Z*'05/T52B)1$HB@'7\KQCV^X>\KA5&@J'2%/U%4HB41*(JXW_"21
M^U6'\6XU=A81V15CJ+$E$2B)1%68=\'D7\,Y>^BVJ[2H-"LU15*(E$2B)1$H
MB41*(E$6I'_6Q*(OSJTXB`\8^T-Y?;\ZZ962V!L&8$BT;@LLRQ%VB9.S#*6M
MR;M3*)6XBFS>G@:UYC3XB3%I%K8M4*%482B"--<=KV[=P\WJ:CJ1-D#4R)8#
M2\!Q!$)MM[<Q!`@0;6C0O+>._-XABM`^FK'<:K*ASGME.+`YK@:<@7#?`<TF
M(<`!,.E7N$,L5A1T.&O/TJ9(Q/CE9DQ@@V`YOJ*TPGRDAEG$#QZQM$NFDT2`
M38^R$Y11SB[LRHE[D29*;19ZN-2>J6@,),SY39<HMB:>93L+@V6Z9*C!S6@$
MN[%Q!!:"=W==:25H:F9/J1,N\>DUTX2W/GLD5%V\Q[R6,88OEAP<UY:TB7K&
M0`:T@C/G!F1L-XPPMB;'$DU)8(?I!!,>Q2*/+NGS-`U"18XLC0F1*.H5#A)`
MKU+<E$5N"8P^P3C""@"'8(KWM;=Z2?2R*67(?/DE[&`$WV[`Z)ZBXOB=)B%;
MB,^LDT=4V5-FN<!J7Q`))M@V$3I,+(FQ>J>/_`/Q]X-\L&./"6M1QRC[]*[=
MO76A\EXIX+4[U,[E/'_@'X^\&^6#''A+3CE'WZ5V[>NGDO%/!:G>IG<IX_\`
M`/Q]X-\L&./"6G'*/OTKMV]=/)>*>"U.]3.Y3Q_X!^/O!OE@QQX2TXY1]^E=
MNWKIY+Q3P6IWJ9W*>/\`P#\?>#?+!CCPEIQRC[]*[=O73R7BG@M3O4SN4\?^
M`?C[P;Y8,<>$M..4??I7;MZZ>2\4\%J=ZF=RGC_P#\?>#?+!CCPEIQRC[]*[
M=O73R7BG@M3O4SN4\?\`@'X^\&^6#''A+3CE'WZ5V[>NGDO%/!:G>IG<KA4Y
M_P``W3*K6SU@Z][I%5K6MF#'-[WO=.9:UK6Y2]&][U6UE'$?/2NW;UUESL+Q
M4R70I:F-T_O4S:_<K2+ADSAQ4/BA1LLC)9A<;8RS"QOS4$8!@;$H1@&&ZNUP
MB"*VQ>U^C:]?%O-V!XU-S9B<R71U3I;L0J2")4P@@SGD$$-M!&@K^B)[N_.E
MS8T/,!D:BK<QX#)K).3\&9,8_$*1KV/;AU,US'M=.!:YK@0YI`((((BK+RWA
M?.^+]WVGMNN.^0,=\"J]YF=RNXO:YS4>L^7O.-'PR<MX7SOB_=]I[;IY`QWP
M*KWF9W*>USFH]9\O><:/ADY;POG?%^[[3VW3R!CO@57O,SN4]KG-1ZSY>\XT
M?#)RWA?.^+]WVGMNGD#'?`JO>9G<I[7.:CUGR]YQH^&3EO"^=\7[OM/;=/(&
M.^!5>\S.Y3VN<U'K/E[SC1\,G+>%\[XOW?:>VZ>0,=\"J]YF=RGM<YJ/6?+W
MG&CX9?%YS"@^C,(M;9]#9D#3;9_YU=49?QXZ*&LWF9W*PNYW^:9G99HRZ([>
M)4?#+XY=0CGE%>^%H[<J^CV/^`UF\S.Y6'VQ<T?K3ESSE1<,G+J$<\HKWPM'
M;E/1['_`:S>9G<I[8N:/UIRYYRHN&3EU".>45[X6CMRGH]C_`(#6;S,[E/;%
MS1^M.7/.5%PR<NH1SRBO?"T=N4]'L?\``:S>9G<I[8N:/UIRYYRHN&3EU".>
M45[X6CMRGH]C_@-9O,SN4]L7-'ZTY<\Y47#)RZA'/**]\+1VY3T>Q_P&LWF9
MW*>V+FC]:<N><J+AE^@/T2\HC3I]*;H%);)$Q.)Q.:Y:J.*0.[>L-*2E:>\V
M6-4F%IU!@P$%7';;#O:P0[-MF_1KN_W?\)Q2BSVZ=64U1*E>3YPO/EO:(ETN
M`BX`1,-"^6OZWOG`R'F?W3Y&&Y:QO",0Q$9NPUYE4U93SY@8V56!S[DJ8]UU
MI(!="`B(FU?TK-^V;A=L[/2]-KVBOS)1";]LW"[9V>EZ;1(A-^V;A=L[/2]-
MHD0F_;-PNV=GI>FT2(4"E=VFTD>#+NC;8L;0PA`.ZY+M1"`J?KC"&^Z[%Q`L
M.VS;[&S;[=JNPI$1Z2GM^V;A=L[/2]-J*Q";]LW"[9V>EZ;1(A-^V;A=L[/2
M]-HD0F_;-PNV=GI>FT2(3?MFX7;.STO3:)$)OVS<+MG9Z7IM$B$W[9N%VSL]
M+TVB1"@'MW:1J8Y<#HW"L6_@,,N%<EO8`+-+L';BO8W[D.V%:VS?[-[6JA0D
M6?&I_?MFX7;.STO3:BL0F_;-PNV=GI>FT2(3?MFX7;.STO3:)$)OVS<+MG9Z
M7IM$B%!EN[3RE6&;Z-NYW8VT%A]7)=K<85[L(0;7W78N*P16O>WV-FU5(B*G
M-^V;A=L[/2]-J)$)OVS<+MG9Z7IM$B$W[9N%VSL]+TVB1";]LW"[9V>EZ;1(
MA0,==VDM$KL8Z-H+W?)$.UA+DMKW`8^.`P"M:YO[48+VO:_V;7V:I4!$.FI[
M?MFX7;.STO3:BL0F_;-PNV=GI>FT2(3?MFX7;.STO3:)$*#DSNTF1]X++=&T
M8Q-ZFP0!7)1"%?<[[%@VL;LWO>J$)$"IS?MFX7;.STO3:B1";]LW"[9V>EZ;
M1(A-^V;A=L[/2]-HD0F_;-PNV=GI>FT2(4$YN[2)UC8PNC:():Y?<P5ER6]@
M6$SKPAN*]C?N;7%>UO[-ZHT%"1$*=W[9N%VSL]+TVHD0F_;-PNV=GI>FT2(3
M?MFX7;.STO3:)$)OVS<+MG9Z7IM$B%7T#NTAD,@,$Z-U@&)6.P!W7);!'<`'
M"P[!%NNQ>X=M;9^ULU=A0$1*L&_;-PNV=GI>FU%8A-^V;A=L[/2]-HD0F_;-
MPNV=GI>FT2(3?MFX7;.STO3:)$*MQ)W:2F!&`UT;BQV.<;W`-:F"*VV<U@@[
M-KFVO;9#>U[?L7K$[2H"(*R;]LW"[9V>EZ;6%6(3?MFX7;.STO3:)$)OVS<+
MMG9Z7IM$B$W[9N%VSL]+TVB1";]LW"[9V>EZ;1(A-^V;A=L[/2]-HD0F_;-P
MNV=GI>FT2(3?MFX7;.STO3:)$)OVS<+MG9Z7IM$B%J6]6(^O$G]*[ZM]DD>P
MNO?WSV'_`(7][_9I:K8H/0CBW%CEHJTIN#EB[&CDX+<#8Y5+7!QQ_$%R]:J.
MCZ49RE8M5LQRE4I.'>]QF&#$,5[[-[WO7>>#4].[":9SI;"XR&?<CY(Z"\:9
MLK:UF:,18R?.#!630`'O``OFP`&Q97>)_#_Q0XG\FD(XBK<N+4W>Y?:CK+C_
M`)0Q#PB?OC^Z3Q/X?^*'$_DTA'$5.+4W>Y?:CK)Y0Q#PB?OC^Z3Q/X?^*'$_
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M7%*JJ;B=2!-F`"HF?=.^6>BOT8Y+P/`YN3,(F3:*C=,=A=(23(E$DF1+)))9
M$DFTDVDJW<EXMS7C7>^S]I5H>-U??9O;NZZY-Z/X!X!0^+R>X3DO%N:\:[WV
M?M*G&ZOOLWMW==/1_`/`*'Q>3W"<EXMS7C7>^S]I4XW5]]F]N[KIZ/X!X!0^
M+R>X3DO%N:\:[WV?M*G&ZOOLWMW==/1_`/`*'Q>3W"<EXMS7C7>^S]I4XW5]
M]F]N[KIZ/X!X!0^+R>X3DO%N:\:[WV?M*G&ZOOLWMW==/1_`/`*'Q>3W"V?O
MYM%AS$,U)UVBF&*<:2H39,]/Y;<*10.*O0D!:J!RXQ26BNXM*FZ4M086$0P@
MVMA"MLWZ-=KY*G3GX,2][R=>_22=ANV5X,]Y3#,-I^<9DNGIZ>7+\F4Y@R6Q
MHC>FVP:T"/16TG\F33;YO>#_`"3P+B"N7:R9\H]4KS]Q.D[U+[5O63Y,FFWS
M>\'^2>!<04UDSY1ZI3B=)WJ7VK>LGR9--OF]X/\`)/`N(*:R9\H]4IQ.D[U+
M[5O63Y,FFWS>\'^2>!<04UDSY1ZI3B=)WJ7VK>LGR9--OF]X/\D\"X@IK)GR
MCU2G$Z3O4OM6]9/DR:;?-[P?Y)X%Q!363/E'JE.)TG>I?:MZR^A.#\*PQ\C#
MU#\/8LBKS9[ZD"[QS'L19'0"90U.G5!!;@VLZ9664?8%K#"$=K"M;8OLVJ%[
MW"!)(^-8FT\B6X.EL8UVV`!^T%[%O.T<%MW8*;I585G0";SM'!;=V"FZ51(!
M-YVC@MN[!3=*HD`F\[1P6W=@INE42`4"E:FN\D>"[MK?<`&AA$$'42;:A$-4
M_6$*UMRV+"%8-MF_V=BWVJNPI`1Z2GMYVC@MN[!3=*J*P";SM'!;=V"FZ51(
M!-YVC@MN[!3=*HD`F\[1P6W=@INE42`3>=HX+;NP4W2J)`)O.T<%MW8*;I5$
M@$WG:."V[L%-TJB0"@'MJ:P*8Y8#:WAL-_``=K(TUK#!=I=Q7"*VY]$.V#:^
MQ]NU4*$"SXU/[SM'!;=V"FZ545@$WG:."V[L%-TJB0";SM'!;=V"FZ51(!-Y
MVC@MN[!3=*HD`H(MJ:^4JPO>UOVEF-M'8'42;:V&)>[!$*UMRV+7O8-K7^WL
M6J["0$5.[SM'!;=V"FZ542`3>=HX+;NP4W2J)`)O.T<%MW8*;I5$@$WG:."V
M[L%-TJB0"@8ZU-9B)7<;:WCO9\D0+7$B37O8('UP"`.S<K]J`-K6M;[%K;%4
MJ`"'34]O.T<%MW8*;I516`3>=HX+;NP4W2J)`)O.T<%MW8*;I5$@%!29J:RX
M^\#`VMX!A;U-PB"B36$&]B[[%[7L5LVO:J-*$"!4[O.T<%MW8*;I51(!-YVC
M@MN[!3=*HD`F\[1P6W=@INE42`3>=HX+;NP4W2J)`*"<VIK"[1L(6UOL$Q<O
ML,-D2:UAV"SKQ6L*VY=&UA6M?^S:J-!4($0IW>=HX+;NP4W2JBL`F\[1P6W=
M@INE42`3>=HX+;NP4W2J)`)O.T<%MW8*;I5$@%7D#4UBD4@!=M07`!*QW`"Z
M--<(;C`X;>X;;GL6N+8ML_;V*NPH`(E6'>=HX+;NP4W2JBL`F\[1P6W=@INE
M42`3>=HX+;NP4W2J)`)O.T<%MW8*;I5$@%6XDUMAK`C&8VH!CN<XVN(:-.(5
M[!<U@0[-[EWOT`VM:W[%8G:5`!!63>=HX+;NP4W2JPJP";SM'!;=V"FZ51(!
M-YVC@MN[!3=*HD`F\[1P6W=@INE42`3>=HX+;NP4W2J)`)O.T<%MW8*;I5$@
M$WG:."V[L%-TJB0";SM'!;=V"FZ51(!-YVG@MN["3=*HD`M2OJ)%UFD_I7W4
MWL8CV-UM^]^Q_P#!_M/V**K$K3-JGD&,-->G7'Z.`.;XC9]/F@HQ'*TK*N61
MEF!GG(;GC>4#GCX6[(R6$+6T-(5#1<)0K&JQ"L=<1>Q:W<N'5[Y&'4\D,)`D
M4]L+!K'73>,;(`1'1TKR=C^"2JW':ZK=-#7.K:Z+20''4,$QMP0-Z),']#1:
MLEB->D==2GCDKAZ>S-7'PS=Y>"(U((4H1!@<%Q[!LH+INR.R]S;B)8E=8G/D
MEV]*VEJ!K50!A(,,($4I'N`Q=CHZN4]Q;>)@6]BUK77@8B,0X0`C$Z++5L3L
MKSI9;KZB5+:^X!>:^-][WRPP@`W2',-XNA`:0#%JEW;7?BYN''UR!B?)%%92
MIF@6&2L3HP*Q.C+%S<AI&*9)&4"H2HN%9"<L7NQ#,O4F)K*=SL,H!P`GW(Q.
MQ:G;`@$RW7H$$6@7H.A\EUPP)A'JPRY>6*U]]KG-9/8&7FN#A`NU9<PG1?EB
M8TO:(PT&%D8^^LEP4S7%K.KQHY8_BCC)$Z7+\@E\BA;J*'-SEIGR%J0;F)"D
MCTB4*U#R3#6)H<%C@06J;4]CU"';".+N<&>4W&;+:999++MV26FZ#*=,`L.F
M`!)M`M&E8O1]HIY\QLYLV>&$RFL:\7R*B73EQ+FPA?<]H:8.,`[08*LCU993
MQHCCTKSG$4K9#I5BH_(D01,$74*G^;RUT:9AD;Q-)I0*7-\9Q]/H#CU"W`LC
M?6^Q,C+(7*R7`HPH28&6<1J)`$RK;"4Z7>;`6N)!=<C$!KFMA8X;J!((T+/&
M!45:Y\C#)A=4,GZMY<[<L:"R7K2VX7/8^876L=&7%K2P@Q-Y3ZU6P!TK;9#B
M64P]_CATJ:FYK?IG`CT\LE,$RXU86E\98W%@='HP:U),GU&%N_Q89[R4:+J8
MBXR]H+-&*-!<U\MS7MB(%S;2UX80""?NB(6;K8"TIRZ^$M\J>R9*?=)+6/W+
M7RC.8XAP%A8TWK8,(W1@N?"NJ%SS/DF%H&="C0X]GI[^X,Q3@W"(EB-A)T_Z
M>\LLJ=R-)<U2`+N0\Y8<"5=RPC*&242`&Q<%S#+2U[JJ<P-`$E\8;<-7+>(V
MZ8O,>DF(X*S#Z.8Z82:N5=!@=R7:^?*)%D80E-(V8Q^(8Z%_2+2=+&4EWJ$Q
M!)-VG/2E!/&U(>_JVMHTG>-A)CMKS"V)@*;N:F5O*MW(9DZ<0Q(S)"@<+!#<
MHG<[:+RU,#!>:W6B;NM,!*OW0\;,3&[#1>!V`MW.49+IQ$N9,-,ZEBPFZ":K
M5&891L@&@`O)TZMS-DQ7KKMKK;&=4G=7V"2"*,#!C^0Y"F3`J.C\IDCFPO4$
MQM.<.JHNZQ=Z6,9*J2)9S<AQ2'B$8@/#;;BW&P#SM2[%FM-Y["UC6%SA8206
MM<R!!A;>M&Q\5IV^7EE\QI9*FLF37S6RV.%YK0X/F,FAP<`Z#;D6D=D.C$"]
MK-82!$UNCB?A_(J<V(XVG.5LCH'93'XRJA\/A<HD\.(<F\B5*F-?,R)<]1)4
M-M&C3E[+?<I0;8NY@";YIQ(!I<93]RQSW1@+H:2-F%Z)!A`:+3M+3-R^]SPP
M5$DB9.9*ED7G![WM:^!NAP9=#A>B3NH@1@2HF9ZRF2(S*4)AL3@NBT)#,H<Y
MH4A!*J02'*+=DW3OCV*)V18C5*TZ*-N"W.A92H1Q`CR1$B,VG[G8LV3<2;+F
M.$"9;;P.V7ATMHAT#K+=E8Z?+TR?3L=>`GS+CP38ULLRY\QT081<!)B(&!C#
M9B,H8',[9#QZTS2T<D<0$_-+H<=&9:WFM<A9U")0Y-:I,O2'`*'<L:A"(Q,=
MM0A4I#"C@A"$RUK:^1-UTILVZYL=@B!%L/\`NVQ:MBK:?BD]]/?9,#3V33%I
MB`1`].T;!B-A:6V/?@'#/S78O>U/7S]Q7\:5/](F??E?I)R/^A.#?DJD_J\M
M7"M`N3I1$HB41*(E$6U1_-?/WC7W^>VG?_N!,:[:R1^)3_#O_::O`?O-?XDL
M_)E/]]-6UY7,%YZ2B)1$HB41*(JX_P#LF,_G&3[U.]583L?&K'46)*(E$2B*
MOI?A.]>X\?\`Y5(*NPIL]+KJP5%4HB41*(E$2B)1%7GWV5&?SA+]Z'BJ%#L?
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MNG<)DFZ9,O3*),`(MB=8(PV+!;:`O(^9Z["I69*YCY-69C:N?:VI#6Q<2UY:
MW4&Z'BPB)B+"2L@XMIUSI![W%"\BZ3HF(0G$8A1W14O9QB$[I4"!TV1H=2!(
MKA<$#2D3FAV=J-.E)*O;<RBPAUTNBJY7X)].WXI$-.G]]Z`Z@6RS\6PRILJ)
M5>\6=E5@Z"2--/L$DCHDG22H_P"2]E[_`+-6M,='E@PM@+BD/`'0Z>`N+1<D
ME:G(CL?*!J,"4T,J=.Y*2RDQ%@%%%J3@@M8)QMASB%3N=U3;D0;\QH&T/G+!
M:;.B=M8_+6'[OYO$/G'WG_RSLG6;IW\GM-@B3:8#:"CYEI-RW/QK%,JGVE5P
M=5T;*AQTB*T</2&4E10I(I;;1Y%)D6I8A[;VD;,M4(!DDGEA$WJ3DU_W`T8+
MX9N'U,Z)F/IRXMNQU)C#:CK8PA$?$2-"QT^.T%+`2)5<&!]^[QL%MZ,;Q::>
MZ3$!T2.R`=I$587C3OG20R93,W[(NDUZEJQE''%4D=-%*Y<]'Q\P(BQLIC@I
MU(&*!-HB17+W+9VNXWN7^TO<-8W456]YFO?3F81")D6PVOPFA9,O%L,E213R
MI5>V0'7@T5@`O;<!3Z>CMVZ4>M.V=9&0M2R#(VD]Z3N1[BJ7E.FBMP6!6*G>
M0I):ZJC[GZD1B,4N4J;R'(\R]]N:O)`>*]S0V%8ZBJW@A[Z<@QTR-LQ/[[LF
MT]&U)>+89)(=*DUS2T`"%6!`!I8!_-]`:2T;321H4DQX0U&1@QO.C>6=+D>-
M:2Q$M1C)HT=&H;82-G:(\(ENNAU)D=1%"8(\@0[4O:AZC0IR=C<R2PAQ-I:U
MD+DRG$-$))$+`+/G=H`?$`%@FXEA$X$3I%:\.TQJP8VEUL:>W=.<?C).DE=0
MO`&?23+'%9+TH%G6(;4FZ@T5+0FW2,TK6SMH2W,MJ/VXDK7.'%0\IR[WVA+H
M>8J#:QXQ#O.)UGRZ?>-HWA^^;#B7#HVZ5B.*841`R:Z$2?YV-):&$_S?26`,
M)V6@-T*,:=,N9&%G41YDF^D%I851;\2J94&B!2F:E)$I0HFN2)U"`O4;9,<F
M?&ML3)518@W+-2IBB;VW,H`0X6T-4QMQCZ8,ML$BRVP_OFR``>@`-A8YF,X=
M-F"=,EX@Z:+L":RW<DEMO%_N221M$DZ25QBTP9A&5&R#9MI$/*AR-[;HJ!5H
ME6J[1]ODMC`R)"UW4ZD#1)D;]NP[K"[7VB@0KB'80KWO3B-3N074VYC#YC1'
M3#YS9V5?+6'Q>1+KP9A!=_+`+Q;V),*>TMV#L;"^$&E_+[5'E$2;)GI`;XNK
M0.;6KCR/1`I3,ZIO>E34N>$BA`5J."G.*=%["A4*-M:]S5"(@T5[F$EB"%!4
MM9JVNIA+((AJ+(&$?WS9@">B!M([&L/?-$]\O$#.!!#C6",1$`QXOL!S@-H$
MC02KJW8QU61Q@)86'.^GAF8VEK/1MK0UZ2Y(B0(48"3A63)$Q.IH)1`-D8K]
M`/[85Q7V;WOLYTN1B#`&,FR0P:`))L__`*JT5178',OSYM+5OF&))-4V)/1/
M%UIN0H.4`0Z*!33*'%I[1QEN06;CQQ/-+*$W)A%@,.#/B`FC`&]K7%8`+"O;
M9V+>A7RUS#SL4E#F"NHG86Y[I-9.87<:NWKLQS8PXN81A&$3#1$K]G/,_P#J
M\\=S5S296S/*SU)II6(Y<PVJ$DX%K3*$^CDS1+,SRM+UA8'W;]QE^%ZZV,!9
MO\ZW/6%>3AR_2'6S^V*CY)=XW_Z==B_9J9@_S`D?]/\`_O*?YUN>L*\G#E^D
M.GMBH^27>-_^G3[-3,'^8$C_`*?_`/>4_P`ZW/6%>3AR_2'3VQ4?)+O&_P#T
MZ?9J9@_S`D?]/_\`O*?YUN>L*\G#E^D.GMBH^27>-_\`IT^S4S!_F!(_Z?\`
M_>4_SK<]85Y.'+](=/;%1\DN\;_].GV:F8/\P)'_`$__`.\I_G6YZPKR<.7Z
M0Z>V*CY)=XW_`.G3[-3,'^8$C_I__P!Y6VW_`#6A/+3&#7@)PD#(H=!SW`8S
MEB2,*42,28,(FI"<@MO,DBPPLTO<;B&9=0*P]M:U@AV.CZ9YI<P2LRY4.)RY
M!IV\;F,N&9K.Q##&]<9ICHNV0TE?#[]8/S/5G,=[P#<CUF+,QF=Y`HJCC#:3
MB8A-F5+1+U/&:FUNKC?UNZO0NB%NV/U')^'FKO=/X_KLZQ>';>A\.FG4<GX>
M:N]T_C^EB6]#X=-.HY/P\U=[I_']+$MZ'PZ:=1R?AYJ[W3^/Z6);T/ATTZCD
M_#S5WNG\?TL2WH?#IIU')^'FKO=/X_I8EO0^'34`]I)$%1'=T>FP=Q/Y02KA
M83B[%F[V.E[&#M=[,W0%@6%;:VVM]F]K[/0V+K%#&SXU/]1R?AYJ[W3^/Z6*
MV]#X=-.HY/P\U=[I_']+$MZ'PZ:=1R?AYJ[W3^/Z6);T/ATTZCD_#S5WNG\?
MTL2WH?#IJ"3))'>1.X;/398VS2QW,,NPG7`,%U+YN0`E[]VN`0!6%>]]M?;;
M:W0ML=&V04MBIWJ.3\/-7>Z?Q_4L5MZ'PZ:=1R?AYJ[W3^/Z6);T/ATTZCD_
M#S5WNG\?TL2WH?#IIU')^'FKO=/X_I8EO0^'33J.3\/-7>Z?Q_2Q+>A\.FG4
M<GX>:N]T_C^EB6]#X=-.HY/P\U=[I_']+$MZ'PZ:@7I)([*8]NCTV#N)]`$J
MX6$X%BS-ZG6^W':[V/=`[2PK;6VUOLWM?9Z&Q>B"AC8I[J.3\/-7>Z?Q_4L5
MMZ'PZ:=1R?AYJ[W3^/Z6);T/ATTZCD_#S5WNG\?TL2WH?#IIU')^'FKO=/X_
MI8EO0^'34(6DD?*-8&SVV;KO(W7$9O"=<%R[KW2P`6*W\V0B"*PKW%MK[-KV
MML6V-FZQ2V*F^HY/P\U=[I_']+%;>A\.FG4<GX>:N]T_C^EB6]#X=-.HY/P\
MU=[I_']+$MZ'PZ:=1R?AYJ[W3^/Z6);T/ATU!1])(Q(U=RGIL+#9[D%A!&PG
M&7N99[7V-'85GLO8"89:XK!V+[6U]C9OL;-Z8*"/[*G>HY/P\U=[I_']2Q6W
MH?#IIU')^'FKO=/X_I8EO0^'33J.3\/-7>Z?Q_2Q+>A\.FH22))&%A=Q'/;8
M859`HN86!A.*&,.TOLA"9=\-L"][?9VM]C[5+%#&!4WU')^'FKO=/X_I8K;T
M/ATTZCD_#S5WNG\?TL2WH?#IIU')^'FKO=/X_I8EO0^'33J.3\/-7>Z?Q_2Q
M+>A\.FH-R22.SK';#>VP0Q+5UBA!83@A+%9H77$(8+O8KFV$7:]K6M<.Q>^S
MLWV-B]$(*&,0ISJ.3\/-7>Z?Q_4L5MZ'PZ:=1R?AYJ[W3^/Z6);T/ATTZCD_
M#S5WNG\?TL2WH?#IIU')^'FKO=/X_I8EO0^'34`A22*\@?PA>FP)H4S+NIEV
M$X0#`W`OW.P2[/8;EW!L7V;W$+;;/V-CHK%!&)4_U')^'FKO=/X_I8K;T/AT
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MY:89("!*5!ER`=V835W,-D2VL)9+II;GNCV(+8V"!+C`$D"%D(1-B\@YGPO6
MYAK9SYH;.J,1GLDLNDWW-F`&\Z(;+!<X-!,;8DP`BLG7'5WAIND[HP"5RE<T
M,<2D\L>)^T1)[=H$CM%G>',:I@)>D"4\QV?W)UG;:D0DHBE`%2\\*,`KJA!*
MON#L1IFS"S=%H:27`$ML+1".R27`"&DV:5L3,!Q!\ELV#!,=,:T,+P'F\'N#
MH'0T!CBXDB#1>[&U0=]9.,#)@[P],%S`YH,<2>:IVEX:9(S2TA[@3QD-JR/&
M)=$#8\I?(2CQ_:!A&ZNJLD:4@3DE`$)@U"4*G#Y2D:PRQ&\&%T""#%I<'`B$
M6W;MI-EHVQ',]'JT4[:@W;AG-9$%I;=>)9EN:^]=>9E_<M!B;KM`#H3QVKS!
M;::_)I!)7)@-BT?5OC\O71*7EQ;JAJ8X&_O<?CLM4,*1GE<B:V_)K$.Z)&(2
MH=G(FUB[#W0LO$<2I&Q#W$76Q,086!I(!A`D7FV"VU90P#$WAIE,:\/>&M`<
MR]:Y[0YS;Q+6DRWVFS<FV$"8M-K!QD^.)#?$4$I?25$?CK_RD5,#PT1!$:]9
MN'@5=%'=["V.9[7-66;)CRAHC$VY'&%A!8\(!W.!!B4A[H2PXBZ#&!`M?JR"
M8&#@[8AT]E9AR_62V%\\L:0]S;H<"\W9.O#@(B+"R!C&(VHV*[1O4IB>7RB)
M1".K96N=9\X2=)!SS8%+F]FEK=#E*5%(99'GMQ:DK8[0M"X+2D^^9!AB<9AE
MA!O<K]UK,EUU/,F-EL+BYY-W<F!`TD&$"W8CH6FG8/74\F9430P2Y0:7[MI+
M2^):UP!)#R`3=-O3L7C2C5G,0.+*K08?8G/'LP3:@9/#YX?E43&)1CO3VK`F
MD$J=(SR`?ENQ(4E[+VL*4\ZRI$:"^P$7[?3'$9EX$2P9+M80Z_#<R])(NG3I
M$-(6X#`J>XX/J'-JY9D->S57OG)XBUH=?:-R=RZ($".IZ,YZM<-L+1)7Q\6R
MU&S0AUCT?FLB3P":K8C'GY_C+=+Q(N56\2=L=4[*P.Z52N/37'9*6I*L8$)H
MKE!SW8C3,:Y[RX-80'&ZZ`)`.F$#`$$PT1"TC,!Q";,9*EB69DQKG,:7L#W-
M:XLC=O1$7`AH.F!A8(K@?-8^GF--HGE\FJMN:;2^;0L#@?&G^R<]?C582WY#
M=T^PAN:;%84O4%DN+AM;%$&##:UA;<%Q1^)4<MMY[H-O.;H.EMCC\3=DJRLO
MXM.?JY4L&9JV/A>;HF",L:>R>+6MTE=A5JZP<BFRJ`J7:9EOB.4*(BH5AQ?D
M,V,!=4.0&_%+H>5+2HX..J&9IR4\M[&I7`4"3`<')*788K&7$&G$:43=22Z^
M'0[%T(AUPVPA`.(:3HB0HW`<2=3"J#9>J++\-9+O0+#-&YO7@3+#G@0C=:X[
M"BX7J^QA+&^+O;FGD&/F:8QN//K/R]9G=D>DQTB<,G)$2=^;MZSFUF;%1&*G
M$:-P$O,*5G;4BP`#$3<_#*Q*GF-:\WF-<T$7@0;;VFR`&X,#&W1M1QU&`5LA
M[Y;"R;,EO<TW""-R)9-TQB2-:V+;L0+;;89&,S\VRJ*-<I9AJ#6:3QA'(V<U
M6C5-RHYI?&<MT;3E#>N*(7(3CD2LL0B3@`-*O?:C#85KVMKY3VS&MF-[%P!'
MQ&T+8JR4^0)LB9#6,O-,""(MB#:+#:-(L6C?"/@9$?S98?>M+7Q`SE^E^*_E
M*I_CGK^D5[MO^G;(7]R\$_LVF5HKC:[I2B)1$HB41*(ML[^:V?DC7A^>F`?^
MZ$]KW-[O7^'W_P#?SOO92_*M^N*_U@C^Z6&?QU<MLBN\E\K$HB41*(E$2B*N
M/_LF,_G&3[U.]583L?&K'46)*(E$2B*OI?A.]>X\?_E4@J["FSTNNK!452B)
M1$HB41*(E$5>??949_.$OWH>*H4.Q\:L-15*(E$2B*`*^%"WW`:_?%WHILJ?
MHJE$2B)1%7XU[!6>[TD]_G&J5!HZ95@J*I1$HB@)3\''KW.4_B[T4.@J?HJE
M$2B)1%`.OY7C'M]P]Y7"J-!4.D*?J*I1$HB415QO^$DC]JL/XMQJ["PCLBK'
M46)*(E$2B*LP[X/(OX9R]]%M5VE0:%9JBJ41*(E$2B)1$HB41*(M2/\`K8E$
M6!FDM^?4^.])Z=EQ5%W>9E::\%E/SNPZ@-14<C#ACX"9_#BE=J9CL!TT2G&S
M0C4*K.XD25X=%Q9*>ZH)B@U!;;W[?PM\P4U*&RVF;Q>7$B9,`NP-S6ALHM&S
M"\3LVP7EC,<F0<0Q$S*B8VFX_470ZGIW.$R(UHIW/J6S"87;Q:T1,(`.4)BV
M0PLK31@@L_$4$70P&!LH@2+`ZC-036]*H:')T>M-5$\;8'I:>$Z&2GYRLSBC
M)/5:EP*?KH@M9I@K6%=(?+XC*C*896I=^^S`;MX1O!LDVW[MVTF]"ZE;)G'&
M:HBIG"HXU*B.+2"`_5NN7"^J$6ZF_K#`-++U\!7P,DQWOJEWTPQB[QD[SY$W
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MPXH)8Q3R6!P0>BU*ZG%,)*R==-(;10W"Z6::4$D$4$!DG5EXH6`XMF$ML*Q@
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M0V=NR"X7621GQFO?5N%XIX[O&J[V>=QU-ZE_&-OCR;CF_`C[VTD;IXKN2V]&
MWL+]PW+J/:WW7<*.F-UYC*9QK6&/SLV]&`C^\]C"[T-'06)DB9Q)MVIF>3=0
M(?R:FU<+SH?^;_"7K_1[+8BO47F2-^_J_?3#."=]^44HZKVFIG/>TW\^5_CS
ME!N>X:2NI]I\J/>*X=K^Y[ELV+_R?NUZSW3-WNI4F_$_OLS3KFQ_>>^W?^Y:
M*7(.J%RIJ]7<;_Y:1V/%9EW_`,WX-?\`^W=P7E+_`"3&GB4GW++#&*/%)R/A
M6_?*/4UJ=ZKOCSQ]S3Q;\C;WTDVD]HOXU=][M6]NR+>G9M?_`"=M;UIWS)/%
M7ZR5+XO=;&,V;V.L==N_,QA?C"&Q_LK6RI%5Y1E<7J:CC^L?"[34T-9J&:R_
M_*[M[57;U[[K_;7Z/FR/4[U&=N6&]/-DW4)VXW2:EL@B363=2CW*Z0).DX)`
MD]B=C<[`O8%P[&Q>UMBM\;,Q"(A*D0_A7<"N%SY&!:I]ZIK(W3'^32X_UO2M
M*R'*YF&(Q8*=@C!I`8ZR6(-.ESJ0<839M36+,-(!"5("#!@V+B!8PRP;WV+"
M%L;-_C/FVGRT<U8F9U77-G'$*B\&TDIP!USX@.-:TN`.@EK21;=&A?T(O=[Q
M?GNE\P>2&8;E[*LW#FY0P<2GS<PU\J8^6,.IKCYDIN6)S9;W-@72VSIK6.):
M)CP+QL?5DYYNQ/OS>/`.N/\`%LJ^&XAXG)^GKN#RUS]^K64/^I<1_P#B:=63
MGF[$^_-X\`Z<6RKX;B'B<GZ>GEKG[]6LH?\`4N(__$TZLG/-V)]^;QX!TXME
M7PW$/$Y/T]/+7/WZM90_ZEQ'_P")IU9.>;L3[\WCP#IQ;*OAN(>)R?IZ>6N?
MOU:RA_U+B/\`\33JR<\W8GWYO'@'3BV5?#<0\3D_3T\M<_?JUE#_`*EQ'_XF
MG5DYYNQ/OS>/`.G%LJ^&XAXG)^GIY:Y^_5K*'_4N(_\`Q-;0O\VPD&IIL:M:
M]L38CP3-0'R_!PI`+(FHK(&+QMB@N*SBS<6S@C6ES+P7TE40(P1PSA-PDXPA
M"$!UA7$#VAS#,H69$+</F39M/QZ=NIDMLIT;LN(NMFSA#1`WXG:$+?S*_K9J
MG--5[UXFYOH\/H<7]%L.&JHZR=72;FMK+KM?/H<.??)O7F<7@T`$3'1(;L_<
MM=?7FTZ0/GPYG_5[5W0OF6G+77UYM.D#Y\.9_P!7M1$Y:Z^O-IT@?/AS/^KV
MHB<M=?7FTZ0/GPYG_5[41.6NOKS:=('SX<S_`*O:B)RUU]>;3I`^?#F?]7M1
M%!/,SUY7/8-WTVZ12Q!?2KIK%:VLRFA-4;W.=K%G"%]'Z3<@K<KCOM[6,OM@
MVMM=@5Q!*'8^-3O+77UYM.D#Y\.9_P!7M15.6NOKS:=('SX<S_J]J(G+77UY
MM.D#Y\.9_P!7M1$Y:Z^O-IT@?/AS/^KVHBA4TSUY<H'80=-ND6ZF[6R6.*OK
M;S*$D!5E+YN(RS[?1^B$:88*X]L&Y8+`L$.P(6VO8-V%-GI*:Y:Z^O-IT@?/
MAS/^KVJ*IRUU]>;3I`^?#F?]7M1$Y:Z^O-IT@?/AS/\`J]J(G+77UYM.D#Y\
M.9_U>U$3EKKZ\VG2!\^',_ZO:B)RUU]>;3I`^?#F?]7M1$Y:Z^O-IT@?/AS/
M^KVHBA'B9Z\KJ&#=]-ND4`@O@+I[%ZV\RFA-/WL=+6+.$+Z/TFY!6Y7%?;VL
M9?;6M;:[%[B#0H=CXU-\M=?7FTZ0/GPYG_5[5%4Y:Z^O-IT@?/AS/^KVHB<M
M=?7FTZ0/GPYG_5[41.6NOKS:=('SX<S_`*O:B*&+F>O+E`J%;3;I%NJNS-]A
ME7UMYEL0%/9:Y7*,`H^K]N,9HS+CL(%R@V#8(;V$+;7L$ILJ9Y:Z^O-IT@?/
MAS/^KVHJG+77UYM.D#Y\.9_U>U$3EKKZ\VG2!\^',_ZO:B)RUU]>;3I`^?#F
M?]7M1%"L4SUXA2*K)M-ND4TO?E^N(1VMK,I`K'B>5UU!80`^C^4V$44?<00#
MVUKF`M85P@O>X;4J#1TU-<M=?7FTZ0/GPYG_`%>U15.6NOKS:=('SX<S_J]J
M(G+77UYM.D#Y\.9_U>U$4/(9GKR$QNH56FW2*2GNA46.-(UM9E4G`+W.^V$6
M0/Z/Y*`T=OL6N8"U_MT4.@J8Y:Z^O-IT@?/AS/\`J]J*IRUU]>;3I`^?#F?]
M7M1$Y:Z^O-IT@?/AS/\`J]J(G+77UYM.D#Y\.9_U>U$4,XS/7E=R8+FZ;=(H
M#@K5ETP`:VLRF%FCNU+;&V.-%]'\4).$!-Q"M<(#;B%:P=@-K[:U&A0Z0IGE
MKKZ\VG2!\^',_P"KVJ*IRUU]>;3I`^?#F?\`5[41.6NOKS:=('SX<S_J]J(G
M+77UYM.D#Y\.9_U>U$4$BF>O*S\^7+TVZ11*+IF;J@L6MO,H"B[6"OW"Y1UO
MH_1B.N8&]]M:Y9>TO:VQ<6SLV*#25.\M=?7FTZ0/GPYG_5[453EKKZ\VG2!\
M^',_ZO:B)RUU]>;3I`^?#F?]7M1$Y:Z^O-IT@?/AS/\`J]J(J_%YGKQ"R);)
M--ND8Y/8U?M##];694QHKW<5=Q[8D'T?RH(+!,V;6V#!;-K6OT-G8M7:5!H5
M@Y:Z^O-IT@?/AS/^KVJ*IRUU]>;3I`^?#F?]7M1$Y:Z^O-IT@?/AS/\`J]J(
MG+77UYM.D#Y\.9_U>U$3EKKZ\VG2!\^',_ZO:B)RUU]>;3I`^?#F?]7M1$Y:
MZ^O-IT@?/AS/^KVHB<M=?7FTZ0/GPYG_`%>U$3EKKZ\VG2!\^',_ZO:B+5[W
G]U$?%;A3^DX;\?\`CU.__&_XN_\`5O\`_"?_`/&?Y9__``O1%__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>v371611_tpg69a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v371611_tpg69a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!-`#V`P$1``(1`0,1`?_$`.H```$$`P$!`0``````
M```````%!@<(`0,)!`(*`0$``04!`0``````````````!`(#!08'"`$0```'
M``$"`@4#"1$,!P<%``$"`P0%!@<(`!$2$R$Q%!4)(A8705%Q(QAXN!DYL=$R
MDM255I;6-Y?7J&EYN2IAD=)3)#57IUB8V%F!0C.35"<H4D,TE"4F1W)$1L=(
M$0`"`@$#`@,"!0H2"`8#`0$!`@,$$0`2!2$3,2(&011183(C%7&QT4)2TE-S
M-1:!D:%BDK+",Y.SPR14A'4V1@=RHF/3E-15-\&"0Z,T%X,E1?!$_]H`#`,!
M``(1`Q$`/P#]/W)+DOS:K/+68PGCQ$<3",:_QPRS7K)/[@3:7#QX[ONG[52V
MD-`M<^=IMD6T<EF_GJJ.`\PYG0%*/8O6:XCA9>8,@A=4[>,Y!/RL_!]3]76*
MY+E(^,V-*C/OSX$#&,?#]73$^GSXM/UOAK?K;RL_5W6;_,FW^'B_8M]G6*_.
MJO\`@9/TQH^GSXM/UOAK?K;RL_5W3\R;?X>+]BWV=/SJK_@9/TQH^GSXM/UO
MAK?K;RL_5W3\R;?X>+]BWV=/SJK_`(&3],:/I\^+3];X:WZV\K/U=T_,FW^'
MB_8M]G3\ZJ_X&3],:/I\^+3];X:WZV\K/U=T_,FW^'B_8M]G3\ZJ_P"!D_3&
MCZ?/BT_6^&M^MO*S]7=/S)M_AXOV+?9T_.JO^!D_3&CZ?/BT_6^&M^MO*S]7
M=/S)M_AXOV+?9T_.JO\`@9/TQH^GSXM/UOAK?K;RL_5W3\R;?X>+]BWV=/SJ
MK_@9/TQH^GSXM/UOAK?K;RL_5W3\R;?X>+]BWV=/SJK_`(&3],:/I\^+3];X
M:WZV\K/U=T_,FW^'B_8M]G3\ZJ_X&3],:/I\^+3];X:WZV\K/U=T_,FW^'B_
M8M]G3\ZJ_P"!D_3&CZ?/BT_6^&M^MO*S]7=/S)M_AXOV+?9T_.JO^!D_3&CZ
M?/BT_6^&M^MO*S]7=/S)M_AXOV+?9T_.JO\`@9/TQH^GSXM/UOAK?K;RL_5W
M3\R;?X>+]BWV=/SJK_@9/TQI(9<M_B&U3;>*U1VZ%X12]`VWD$RR%\MDB7(%
MC=()Z^RG5[VRFV8W1X:`<M4C4$S=5)0!,(.0,7TE[]8WE?3ECB:WO4LB.A8+
M@`CQS\)^+4[C^;BY&?W>.-E8*3DD$=,?!]75Y>87-,>'E<R65F,4TC79K6];
M;8]6JOF#[.FDE)6!7/K_`*"H_0=:'?:7#,(E"'SYX<3.G9%1'PD`@F,';4[M
MVKQU5[EMMM=,9."<9(`Z`$^)UGHXY)I!'&,N=51_&W6[_ER\OOVZ\.O^)SK7
M?SV]-?AS_!O][J9]&W/N?U1]G1^-NMW_`"Y>7W[=>'7_`!.=/SV]-?AS_!O]
M[I]&W/N?U1]G1^-NMW_+EY??MUX=?\3G3\]O37X<_P`&_P![I]&W/N?U1]G1
M^-NMW_+EY??MUX=?\3G3\]O37X<_P;_>Z?1MS[G]4?9T?C;K=_RY>7W[=>'7
M_$YT_/;TU^'/\&_WNGT;<^Y_5'V='XVZW?\`+EY??MUX=?\`$YT_/;TU^'/\
M&_WNGT;<^Y_5'V='XVZW?\N7E]^W7AU_Q.=/SV]-?AS_``;_`'NGT;<^Y_5'
MV='XVZW?\N7E]^W7AU_Q.=/SV]-?AS_!O][I]&W/N?U1]G1^-NMW_+EY??MU
MX=?\3G3\]O37X<_P;_>Z?1MS[G]4?9T?C;K=_P`N7E]^W7AU_P`3G3\]O37X
M<_P;_>Z?1MS[G]4?9T?C;K=_RY>7W[=>'7_$YT_/;TU^'/\`!O\`>Z?1MS[G
M]4?9T?C;K=_RY>7W[=>'7_$YT_/;TU^'/\&_WNGT;<^Y_5'V=9_&W6[_`)<O
M+[]NO#K_`(G.GY[>FOPY_@W^]T^C;GW/ZH^SJ1HCXG\/,<.;3R\;\<]J!O5=
MY1X^O\>.]R(NDFOJ_(^L\:TXE)W]*!L\4`URLZ1_:O?@-`;$,IX_0!1SWTC2
M^COI7?\`S'M]S=@_)QG.,9_0QG43M2][L8^=SC]'4?[#^4QU;[PWB_\`A"\O
M.ND^A_E6?J)^ZUIWJOY,'_G_`'.I$ZW_`%INCIIHZ::.FFCIIHZ::.FFCIIH
MZ::.FFCIIHZ::.FFCIIJL^W_`+^WPX_O]:S^#1R@ZU7UC^2!^.7ZS:V'TS^4
M3^*;ZXU+/Q<0`ROP]2CZC<ZT0'M]8>)G*H.N"^M25],6V'B%4_ZZZZ9Q_P#\
MQ/T?K'7Y\J1SYO#&V;+,7*<I^IT?,7?(`+9G&6YW)P.@8\TRO17=3H:=FMLE
M;I>"MLAHL8U#RDC-HLY5E/&0#)D/VY96X:*U0HK%'(;-V'CS'9W`0O9N-&K5
M1'MR#'O>3>)&(2!P5\P(V?E4-3FWHUG01Q*"T+_OAA]P2V]KN9`$:RGW<(4P
M6F0[P5PUI+-S!?59Q)I/./6H/&]#@:Y9-Q>1UBSERGB\=;7CI*`2DT2V/VB^
M2CF-9G>KM*\5\LT0^2L!3_)Z@1<9`V)K%N"'CVM>[),P?8\ZA.ZG0%E2%Y8X
MVF8"-F=2C%3G5F.9K`6.FAEOO"9UAR$?W?S&*9]Y"Q]]$=XHW(D(1P5!4C4<
M:%\0B@8]%3TE:TU[4]D-RT/+Z'")N*CFC=Q&T"(@)B5>.;=;;2M7%V[=I/(&
M07=*1[I^902$:E%,W>^G!6I/=J^W;:-'WB;KN*@S20J!&!N+;XV4K&9,8W$@
M'&KTCP]IKL;CW(UZ,D?0Y<W(FD&#@$85=S[E`C&!N8L#J0:=S.0U=M37&(XE
MH.JEL-$87^S'9V.@4UIGD;+NY!A$Q\T]NT[#(3LH_=1:PE3B_:>S<"+#]K4(
M(V>0X>3C?>I+4L:UJV`KD-\[(T`L*@C`,B$QLA+.H"E\'JK8B0W$E2N`/YW-
M*ZM&"&[:1S"&28N#L:,/O"E"3(8G"9.-1I7/B!R[ZDX?+V3C?9H"];N>T*U2
ME+:UD,9$*Q%5&-!Y+(WZSV.%JRCAU[S`48M59&4,FBH?R?``",Y/3R3\B*-:
MRK1)4@GF?MR$Q=\ML41*#),,*69HE8("BOAW5=536'KBV\\;*E;D9JBGH0YB
M;:6=AE8B6RBJY'<*2-&62,MJV&O[U6,3+`+W&*F/8+%"W229R+$[!1JG)TJK
MN[<YK:HG<%.:4EXF.<>R'*`H&42\)C`)B]]>BAEGDL15U+O7K][`Z%QWXH-J
M`]2^91(1[$1O:,:GTX9+@K8`0V+*0G)!$32([(TCC*A&D58%8$[I9(P.ASJ'
M7_+R%G*9)V.J1<]`G@`Q%S/+2T-#SZD:ZUQV[35I+N))9(86]EK@1ZR$BH*X
MD:J@`ID6]!1S*<'(.3IU2\<M:URK5$920)@D2RF16P2B,LL15BI;SCR>.,&.
M7BEX6SR4:LL\'&26V0X+P[9NR@=<@.9&64IA@K"-_."`#%]JYI["R>3;>.XX
M3$5\U^7<!QV0:FMU*MC_`$V+?QMD=/2UQ&.G685"PBI'-5?:9(?=[=NH83',
M)3^!P_%5N0AI3R2YDN4;DW:`*]IJYC"L\K?-]L;G##(9F"JOB"<Q?Q3FY6O_
M`.G0XVO92;J59IY(U"&,?.$%6.TX&/%]N,:L('()W8^.6N:_`5=Y3KCF</K<
M=*TJW+14\O6-$RUM*MY."EW58DG$-/-6LO'@45&+L47"8_(4#OW#$<M6;CZ]
M>Q7D66"W6@GB=4?K'/@CYMMK;@#@J<=?#4KAX/?><3B+\;PN+,<;KN7)23#)
M(K+N7;)&P=#UP#U&JG-.1'*EQ@=2T1.0DQ7F;RT;W[09_A)HM1'*:&I359LT
MZWQ-[J3JP:'5U+!Y#9:QH2C1HR;+*+&1."!@-LG)<=PU'F$IS.L-(13$NUA&
M$DBN%2*9@@%`;.Y*9)!("8TCP#,K#7Z%J[>X][4$9FN-V=L4:D[4<N))(6R?
M?'4B-%@0(Q#F7=A<:=T#S)LK?D7$U2R3V8V#C[(<>\_N!-'IS5^FC(:G:HZ]
MV#VJ.G7LB9L%,L$/0'*$<U4;%<E>+)D%4XCX>HTW%PQ\5R%F:.6#DHK<XKQ.
MP_>H(ZSO$WE'<DV6>]W1M40Q.Q3KTG.2*_$35Y4FCMV;,-APN`HCDBAAE"Y.
MPF9^U)%E]KMM#D)EH\BN:VYR.!W&SJI9/';%-\DYO+<>92S1S#U%*ADKT)H$
M0]MB,I86JS^<9TJ4(1ZHFX;%]K<$,5(`()37;G#U:%KB8+'<RW&R6^17/G`J
M,XNQ5P`V)%VE(00X=D;KYABXKI-)<DKL#2DKU!18993/?DEAJ/,PZ&O*\?>,
M@"A(7`)SU/2G*K_%:KF]$TB$.B>-NM9BIY$K9P1V@@X=(%+(LDG27=-R6/DT
MED/,+Z#^7W#U]8KF./;BN3GX]MV(W\NX88HP#QEA[&,;*2/821[-0^+N"_0C
MM`J6.Y6*_)+QLT;E?;M+J2N>NTC/7210OR46U_TNL7_6]9%UUL_W!']G_N=8
MK_\`J?\`Y?\`QU>?8?RF.K?>&\7_`,(7EYUW'T/\JS]1/W6M`]5_)@_\_P"Y
MU(G6_P"M-T=--'331TTT=--'331TTT=--'331TTT=--'331TTT=--5GV_P#?
MV^'']_K6?P:.4'6J^L?R0/QR_6;6P^F?RB?Q3?7&I8^+D(E4^'L8/67G4B(?
M9#B7RJ'K@WK0!O3-I3X$*/\`7773./\`_F)^C]8ZY[+<>L\7R2Z8FI\X1H]\
MF[Q8)X@3/:8"0T*VR-UL0L)+V3LT0&;E%?9R>4?R4?"3N;MW'BB\C96Y0OC;
M[QQONO9Z=/YHJK#O&?-T0;_#=U\-;7+(TTUF=_EVTV28\,=A*_E^`]M%Z]?-
MD^W&FMI7%+/-0NCZY2]DTZ`3L<;78?1*;3;@G`T;6(NI.E'==8Z+##$/7LFE
M&&643`S-VP5414,10QP[=OM#D[''*4C2&:,3FQ&DR[TBG*[3*B],%L*6#;E)
M1&VY4:L/&&BBBC9X9(H&@$L>!*86QE&<@[@H!"9&4#N%(#'3`KW$19Y'V"3N
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M+T0J2-SX8%B=1W+\(*/,4`F3+:_R%;95[5+"YSA"[U%Q4I&%E7S>0)4I!C+9
MW)N'%8AEF_9@D"Q7+8IS#YYC^$Y:HN4D66">Q%#/-7ABC5I`VX]DMMD+(Z,)
MB"%9T*':B8"D$F]*)'EM6())*]BW9FG9HR`5><#N*FX,H0L&<(P8;I),Y5@H
MFG5L#SO9*E5*5<&TPG!TNRUBT0(0<PO&/T7=44(+./<2!R.W#N%DFI!:OVYQ
M'VMJ<Z9C!XA'JU6Y*U6YN+U`I5N1BDD<;@"C&165]Z#`(PQ('0!L$=0-6#3K
M?0LW`*NWC9H$BPI(9%C96C,;>*NC(I5O$$::\5Q4R.$H]MSZ.:6!"OW74GFP
M3AO?7CDCVYY-H6`R35\9F)F\"A(H=T6GA,"29SE`WRNJH^3MQ3\=84J9>,*&
M'(\60,JM*!C>VPK&6Z$I'&#\C)JM5H[:WUFR1R,'9EQTVQ#&$BZ>10P9Q\H[
MY)&).[IM6XQ9^XN\I>%IJ^J*2>MU_<2U8;(U^9L7I5?CI2,"=B8H(<'K8LTU
MEE/;T3NE4US$3$@)^$0%0Y*QQU9*U<(1''8C1F&76*UL,D8.0-@*!DZ94D]2
M#@7[0]\DL22DCWJE%6D"]`R0NKQMCKB0;0I8'!3(VY.=.QIB%&94?4\^0":^
M;VQ3^EV6Y`>4`S\9/6'+QU;?=#OV8`CFPJOU/92>!3V<.P=S=NHD\[V:U6K+
MCM4Z\4,>.AV0XV;C[3T\QZ9U*CMRQ<K],ICWWYCV>7^;HL<?3_14;NO4Y/37
MDO>(QMUJU1J\;H6LYD:DD0;0MERRX-:W9SQR46>(5BI-W)0<_%R<>[:B4RA5
M&8J`JF4Z9R"`][[79).3EY298Y)9D=9$89C82,CME<Y!#(NU@00,C.&(./J5
MX:7'IQD(^8BV%&/RT9`0K*PQUVLRD,"I#9*[@I$13_!+CU:*K*4R<B+0\@9F
M%R.%D40L[AL[7)BTY.V2IR0/VK9%TE,2$U9'B\JL4P`_%40$I"^@9D/-W*\U
M>:NL2)4MM/$@7,:AH8JW8*L6#5A!#'$(GW>0=6).=5=LFH*CN[-VK2&0D=QF
MN2)-/.6P`+!E02I(JKVW+%`,C#O5XB8-(6QU;+)2F-W%S<+??"5:]LH:W45E
M:;M"P-=F91C4IJ(=1J*J,-7&Z#03`<6Q/'X1[F[A97EKR1"(/YA4%??_`.IV
MQ8:UG?G<':5VWL"-R>4_#KY-!%+V%`*15XXXU1"50I%$\,:NN<.$5V*ALX?#
M#!&I/R3)Z?B=,:9[06[QA48Z4F9*&AW3E-PV@49N04DEH2$31;M4H^OL'*QP
M:-2E\+<AA*`B'4>U=LW1";3&26&ND6]B2[K'D*TC$DO(0<,YZD`?!I'!%%/8
MGC`4V;#S,``%5G"@A%``5/*,+["2<]=>2A?DHMK_`*76+_K>LBZ[$?[@C^S_
M`-SK`_\`]3_\O_CJZV\RK&"^(UMDY)KD:QL+\/KC=+/W"I@(F@SCM[Y@O'*I
MS#Z"E(DB(B/79?3-Z#BZ'(\E:.VM7@[C'X%0.Q/Z0UH_J"M+<LTZD`+32R%%
M`\26*@8US[9\^-?=<9;OK$KD=:H^C5C1<]B5V%B;7B:I%/R#7"UZ?I6SW>&K
M@*7U]"PE-L7_`-:;1H>:62CW9$>R9``-PO7[M#C:`N^[U.;]Z:GR8DWR5Z%^
M)!*]7='AI.^LE9*TO[VKVX7F(19,:TE6I+R%X46:[Q2UO>J!A9!+=J-+)`D_
MG`6/#P6)FCQO>O$"@WR*!)J/(_D/H4MFV38DUXS3^O3652VP7O09*<N]DP%"
MKMK1\T:TVI:-4EFUR<RMRD5TE03=NS&B$RK)NBF53$.IDK\I-<MQ\=#&*O'Q
M5^\)&W/-/9$IBBKM&1'VW2O-*+!+QA`B#<S;C$B;C8$A%^21Y+<DO9,2[=L$
M(B,LTZ2>=61IXX.SY9&<F7RQ^42[EO*BO3?'!KOFS,D\D)!O9NMZ2P12F[?'
M5ZUU>?=5B8]S#7(J6FY:#D)%GY[,Q6RBQ&ZQ"J]S%,83\SP[\10]0P2.O$<E
M"DD&]27!9Y(C$X0$;TEAEC+`!&VAQ@,!KZO'<@.5O<*RI)<H3NC,A`5D5(Y5
MD7>01F.5"5)+!LCKC4JY=N^1;33Y/0,RNB-FID,N^;2L\I!6JLHL5HUJ+U\"
MS2XP->DO+;-2B<RA4!2[!Z#>@>KUNW!1XEN<LG;Q:PRRE_UD()D.WQ&W!\0,
M^S(ZZLQ12V+WT9`I:_O1-@\=TF-@!\"6R,8)Q[<:IYD_/UN[QS5->Y"4*2S-
MI0K-1UX2%JD7,66<L^:[*]A6N-SS6"<J$D'$],.I]&/D$DC`BG()+`F`$+VZ
MC1WI(.+J+RD;+ZL:P:=NI#\[V>0[7O,=:)^@D[]5H98F)"DS(KLO4B<U!+/-
MSU.)FBFX(UY;56R6VB6E7[J3V)1CYM4EKV-HQEHD#@9;&G'+_$&I;-QF3*)P
M3D[.3-\VISAMDJ`YHQB;UE-J1J`7ANK?*T[LBH-D)6LN&T@T(@Y4%:.6,X[E
M\H4S7Z=Q;G)\;Q\2/VN2CM,LOVD1J2213)-[497B<MC(6,&3S#H8]BH];B[_
M`"<A`-%*S]O[:>.S(D<<D'L="S;`W3=.!#@$[@XYOFO0Z+&>.U1]KO-FFMMN
M6,4BDX]1GDC;K%.55D25<QS*&M=GB4)>18Q9A.NJW=D(X,'9N@(AVZ@T^72S
M4X]D22:W>BM2XB3RI%6NSTVE96;>D8>)8V/G+2$N%6)AMNS43%:NI(\<->G)
M"A,C8\TU6&R%W*I4G;(7R=BA`$+&0$-JU?X@G'O%;I"4#0OGW$65]!TRP6IH
M:"KR/T3L;\L5O6DM3;REPC)."?N%?&"J+!M*&0%(X&'N``,Q.0IR<J>*CD0X
MLBOW@08#,V,1AQEB?,@SVP/.O7J<4_1]T<:G)F-@DJ3.D9&)62`XED"GR[%\
M02X)&2!I?BN;N,3.L/LE9Q6J`M&Z5)XX\TIQGKI#'$]4C(I2</1$[V:2$SF>
M?1"1W#4B3,Z2Q""'C*8/#U;J<I5M!Y&WP0)4LV-\RE%:.F0+03Q+/7)Q(NT=
M0=A;&EBA8@BBE7;*)HZ\F(SN*16__C2R9P$CEZ88GIN7=C.D>N\]\/L&67_<
M5(75JSC="*T*AI]MIL5$4S0WLA/FJT=$9E,(VM^E89A[83(M`;NPC3)*ND?.
M\H#&$A^2CAXZ&_:BFAEL2*D4#A5L2%UW@JF_85VAB6$A'D<=2N-7(.,GM<F>
M+IO'-*J2N[J6[<2PH7<RDJ'3"`L`4RP!P/#,F\=.4&6\H(*SS6;&L+%S29]*
MM6ZL6]G"Q]HKLHYC6LPP+(M*_8;3%`A)13U)=`Z;U03)F^4!3`(!/KNEJDG(
M0,&KO(\9QXI)&1NC?V!PK*^`2-CHV>N!CY0T%DU905D[:R+GP>-RRK(GMV[T
M=,D*=Z,,8`)L1U5KYHZ::.FFJS[?^_M\./[_`%K/X-'*#K5?6/Y('XY?K-K8
M?3/Y1/XIOKC4K_%S_1?#X]`C_P"NA/T%#N8>W$KE6/8H>CN8?4`?5'K@_K+^
M[5GZB?MUUTSCO_F)^C]8ZY$89RVG=,OEFK]XS><SF#E=KLV+8T23K4@TG+%*
MT6MV*R6R2M4D>Q2D*1H+2MK&;BS12\H3II*`<Q_&7C,5"&?T]7Y6.16O/4L6
MIHPPQ'!%:%91C;N[NXXD!8KO615Z)EMBNN]7E+U95)XZ@:B-(1U>2V(=FS!P
M4#2@]1N[31R>+%56[#S?R:#)`A'538KN\GX?2;(E%T2@)S<C&5?([LZH%^LT
MX1S/1C:-A82<9G/XQ5,HLU`%"$,(^#JE>*L$L9&BCA1*C.[MA$%V,25]QP>K
M@A2`"5<X(VY829XY('DB*EITL^[A%ZM)-V%L[(Q]L1"P;J5&<J,GQ:FY\[:?
MFL`]=T"F773I%M'Y#*NK'$UETZRRJ--CL%<9U1&_6MK)-Y"#?RU=FCOFR:#5
MT!1*F"YDP,(=9#B_3EF[S4?%VW2")K\U0NS8,DL$<CRK7Z$2,C(%;=M7J<$G
M&K,<T#0I._<*O3FL%4&Z2%(U?:TZ9W1JTBA,`,Y!+*I4%A(UJY55//SW`MFC
M++9743M;#$JQ6\UITE-6N=MDQ7'EEB(8C&0EVS21?N64<OXG*2K9F40`#>$.
MY@Q52C-=AKM7&Z:=;C^("]NG8$$C=?D[`0S;CA@K%/M5-N*4N;#2E4BK5*<\
MA.?+[W%$ZC(^5N>5$0`9&X!SG+:9MLY[Y#4J;#W)6D;A/@^CKQ*V"J5C/6,G
M=,Z8YM86-2O"NB0R]I8-8,:[9Y%)BL5!T\$5Q'P^(H>+J9!P5RS=CI5VA<3+
M2*2AOFG/([O<D5B,[Y]C[05`&QMQ&!FU8O04Z\L]W=!)"MEFC<8D[=1$DLS!
M1D&**.2*0MG)6:,J&W'%TV3GVUFS>^SN6@/&K=T#5ZF5%XV!PD18$':)%%2I
M.4@/X3E`Q@*8!#N/KZQ4\78F>'<K[&*[E.5.#C*G`R#[#@9'LU?AE[T*3;63
M>H;:PPPR,X89."/:,GK[=>GJWJ[HZ::.FFCIIHZ::.FFLAZP^R'YO3345T+\
ME%M?]+K%_P!;UD77;#_<$?V?^YUK?_\`4_\`R_\`CJR_,K-$]EYN<D,I<3[V
MM1V@_#MXU52<EHYL5T^+79CD+RZ:6)@U*9RS%!:7A5%V@+E4*HW\[S2=S$`!
MZ_Z>XN#F:T]&WAJ1L5'E0C*S113B66N^""$L1HT+D'*JY(!(P=,YR]/QLT%R
MJ2EU(YNU(,;H9FCVQ3KD$%H)"LJJP*LR!6Z$Z@:N?#^AL.G+=8>&NH2_&-]<
M:O28.5C7$+,;A6'TI1IA^YCIJ7B=+OJT@_9N:]-/HU2.0?,VX`LFL4P&1\L_
M0/=+D0GBIV2M.:T)^U(@E0,U>:O.#N8.YG#UY-S/E)*<)`92RZTSO59I:\MZ
M'N/!6EBW(W:<[Y()82&52JK`\4F$"8=+$RY0D-I*KO`FXYDE4[7AO(M#+-N9
M1M[A-`T$F&UBPT.^P^@VI.[2K6/Q8+;!P5$7BK(U07C5&DBX*U*50IB*"L<W
M5FMQ1XVLO%\//)!PON<4#Q-B1SV9;$R212^4PO&;=F*(!&2*N\<(4B)6-UKL
M5R:6]S$*6>4>T\Z2`F/87CBA>-U&[NQR100F4,RL]A._N!8IJS%:XPYK%8(S
MX]64L[=Z>HFZ<VB0D+!/UR?MM@E99Q8)V?>S--EH&8C5I.<>*JE2:NDRHI"1
M'Q'*3N,VWQ_&VJM?CEA[?&4Q&L$:NP[8CW%<LI0NQ9G>0GRO([,5ZX$:O<OP
MV['(R2]SD;;NTSE%\Q<*I`4A@JA$1%`ZJJ@;LY)\B7%G-ZQANAX/D_OC,ZUH
MT5,Q,I(?..Y:!)M$;(U"+GU6;S0+7.RJ:K^%46;D`CQ--`ROF$+XB^F-R_&1
M\MPR\%(VWCA(A*D;@\0G2:>%CD,R6$5H7)8E4D;;X8-VA<>AR1Y>,?S_``2K
M`X*2B-DAE48*AH'*RJ-N&9`&R"=5G;?"]P^FO7X8I+3^15RQ1.,,;C647MFO
M[6RR>&ZW`:K3IP']\N4N]@W/CBG4:J@S%-MY#[S0)XD2E-.I1"AR;7(2?<A<
MCLQP$Y6*58+5:1A(<NW>AFA1MQ.U:D87Y38^I>E`C>4*]I*'(5&?`4NEZ!8>
MH4!0('[LZ*!AGF?)7Q,LW+B$_FKK:='I^MN*;=)WDE4>1D6^?4.-MT5!/*[C
M]=Q:4IZL,ZGXDLPRGZQ"K*E>'6159.G8&*FH"(`>Q2JM1L<9-&^4X^Q==U(_
M?XKS3-+#G/S17O864!R-GR/-TKOWS>XJ3C&0*6XFO35P<[6K7WY".<KC#?..
M$:+(!49W9/1I:EPEL=WS^VYY5=?IU=BKWJ-ZTJR.;[Q]K^M/&I[NP;,!94IV
M[O-3DZ%/0A$!,VG(YRG(%$_R?!V].(/`,>-X_B>_BG1BLIN5-L[-9O6+N])U
M<-"8_>&B"J&5]JR,/%-28>7['(W.52,^^6Y8'P6S$!!5AKA)(64I,K-`LI#]
M`25`\&TWI;X?)V]ZIMYI.EY][9%4;*J/>3[EQES[D=/V]#)F9HR&EZU<+K/Q
M<[G$G(Q2ZR;D[<S\3JBFN(F42[GS$51(N:DY+RFE+<]Y*;%$QE*1H[&RNTDR
M=J-V^:`67>R*@<J,>+`/#Q<=*'-J&*9!('81E9I#+@P'<I6-V81C?TB/:8L`
M&U,"O$9@!2"RO\BS7;<PY3E^Q/\`-QBNBTG)"'EHI"C>S>\DB*0S$TIYH.^Y
M53^4!/**!A$/L%>2O!32*3,]/CK=56==^XVNO==2?,8SUV9Q)U!89SJ7+R0L
MI:CL1`Q6^*J47"G;A*K1-O7`.#)VL;?!-W0G'6`FWPWU)R)W)KINP5FQ2&P1
M=*:,&V>8!6<DSJMR^?6\;S6K)/Y&TN=KI%[EC3R2)9(YD8PTLR*HBZ,H97S2
M8R'A?=Z*0Q2*;T=N*PC/&)*Z/%$\)V57)5.[')(D@60(1VF5%DC+O>;F7DY1
M;LRLU05[,3)O*S.MK`<R65Q(Y3:C0EU8Q.&.61M@MMQMQ2PX=4IJOV>R93:I
M.5G32I)3)>.=)XU0Q&?L39LFRD:C1YJ=CYJ13724/[>JL542*`GX`*0!'.0(
MD%**H@(9"Q8@G:S,?E+'U"$*%0X)+;02?8,-+Y[1G7.PQJH#>9_*3U,AP6!S
MT7&%.2/E'5B>ONOFCIIHZ::K/M_[^WPX_O\`6L_@T<H.M5]8_D@?CE^LVMA]
M,_E$_BF^N-2Q\7(?"I\/8WUN=2(_WN)?*H>N#^LO[MV?J)^W773./_\`F)^C
M]8ZY?SW%MHZAFJ5.T^W9_<8?8[9M-8OT;!U*PR=<G[NTDXNR1+>"LL8^KTA$
MO8.9<LRBY1.LD57S"F\PH#UPVE9:G%#6P'JI5L5Y$)([T5BQ+997(ZJ4ED#(
M4P1VTS[<[19_G1NE^C79*KG'VCTUKK$5'@P/NR%U;(.YAX8TF4+A[4J'&L6*
M5[N\^X;8]KF//)6:"'._EV>S7E;0;5:7QF[-)()Y"=<J`V3(`-2I'[&(/8.I
MU_EWO0351$D=>62BP52QV+0C[,*`DDME,!V;+,1NSDG55>6:&>.U*YELIR/O
MI9L#=+[NM<K@8"QD+N55QLZ(N$4#3)F."$*_C5JM$;;IU7H$Y7\<AK[28F.I
MZK:]/\/1@F].GG<Z]B5IVOK.F]?0+(M(Y5%H\'N)R=P#J=%ZEG3D1R4L$4DD
M5ZQ;@4[@L$UK=W\8(,JL6)"R9"G&/#5@Q;9'L5R8K<T$L,TBXWRQ2&78"3\A
MH5E:..1,/V_(20S9F9SQMK#JWI7(UCL1'R6^1O(,&A$XP&@V2-I,[1DX`1%M
MYWN%6/GE%C&\7M'G$*`'\/<!QE'DI:%9:T:JR+6NPY.<E;UE+,A./:C(%3V;
M2=V3UU3V%V6TR<7*M*!OUJTE@6-E^-Q`N_/3S-MQTU0CDIP,UZ:O-#M&%GHM
MI1@[9K-^.KJBE,`U4NNHZ4AHKEXSC+%GEV:S,"P=_:B(LQC7QR-B>:X.82"G
ME_3/.1<=R&_D"T=5*7&UD:/>7V4A81RVQXV#NDJD%7`#`]!@'5?J)?IBD<+N
MG8R"2+(5)%-6K6C&YU=1@5CN#QN#W3@;05/7MJ5P5LV*\.BJ[*W0*Z4;IF20
M4<E2*"YT$CF.=-$RH")2B(B!>P=^M:E,9E8P@B(L=H)R0,],GVG'CJF!9E@1
M;!5IP@#$#`+8ZD#V`GP'LUOZHU>T=--'331TTT=--'3360]8?9#\WIIJ*Z%^
M2BVO^EUB_P"MZR+KMA_N"/[/_<ZUO_\`J?\`Y?\`QU;WDU=JQFW/_?M`NDHE
M"5*F_#PXXV.PRJQ%52,HJ*WSF`[=JE00(HX<K>6F()I)E,HJ<0*4!,(!UV7T
MO?@XVM;MV`Y0=I0J*7=W=BD<<:+EGDD=E1$`)9F`'4ZTCU!5FNS5JT&.XV_J
M2%50`"S,QPJHB@L[,0JJ"20!J%:MS?J\G(3T-?L6W/$9MEE<WM-0B=0AJ41?
M3\[K9D"V"4IKFG7>VQ[25AP?-#+Q4RM%2I".R']G\)%A3W>YRL7'<=?N7T>*
M[QL*S6*V4:=(F;MB12CM#*G=^:9HI7".4#E1+$7U2&@UJQ22C(DU&_8:&&PN
M\1&41F4(ZNJRQEXE:2/?&NY4<#S*1J=(_<Z,X;#+2[QK4*PCE%?V-_:[=8J;
M"1$/4;`DFN56<07L9IB%+%HK%%T\<MDHLHCX2.CG`2AE>4[?#7>2I\E)%$.,
MLI!+(SJ(R\G>`(8GRC,+`=T1L^X&(.%<IC>/9^5KT9Z"22-R$#2Q(%)?"]OI
MM'RFQ*,]O>%P0Y4E`R.ERLXN+T!SK"')+!5LL93*5<>:4EKM!4H+2PKE\:,"
MYMY)\8!"95)Z2M3.`6$/2!>HLUVG7BBGGEB2"PSK$S,H60QXWB,DX<ID;PN2
MN1G&=2XJMF>62O!&[SPJK2*JDM&K?)9P!E0WVI;`/LTNV?D+@-(1JSFZ;CD%
M1;WEO&NZ4O9])IT$C<&DRO[+$.JNK)S#4D^VE7/VML=J*I5E/DD$1]'5V6:&
M"\G%SNJ<F[[%A8@2LY"ML6,^8MM=&V@9PZG&&&;44<D])N1A4OQZ`EI5&8U`
MSG+CRC&#G)Z8/P:>;N^T5A[Y]ONE39?-R4@(.P^UV*(;>X9NU^[OFM#S/G.R
M>[)2R^^&GN]NMX%7GM2/E%/YA.]P>9E1>K/(\:@>+21[NY&OPNFUMZCS+M;(
M&#JH0S$!@C%6@:8'!P85W;I1\,:['W./*-C9/E.(EN_*G":2GH#0NC5"WV[+
M?=`W[-J1;*K/Z/5$YN6CH9DM/U!*:3E(1'VN50\1G9$`\)P[=Q$`&%'R%6<P
MFJPFBFY2MQ^^,ATCLVK`K1K*P)";9-V\?+`1\*2I&JY*TL"R&P#&\=">X%<%
M6D@KP]]VC!^5E-NTCRDNF6`8'3XD]LQB$T2(R":US,8C6K`U;OH'+I.]UAAH
MDTS=`N9LZBJ6ZDTK%((.`:J^`Z3<Y3>4?L(^$>TBO/!;M24JCI+<AW%T0AG0
M*N]BRC+*`GF.0,+U/35N:*6O62[85HZDK!4=@51F)"@*QP"2Q"X!)ST\=-V7
MY-<<X)]H\1*;MD2$[C\!)6G4ZVGH55=6?/J_$-B.Y&4MM;;2BTW!MFZ*A/2X
M0()C*$*4!,<H##?E^,2A/RG?B;CZV.[(K!UC)?M@,5S@F3R`>)?R@;NFI4?&
M7Y+M?CEAD%ZV<0HP*M)TW93=C("^8MX!06)"@G7QG?(S)M="FR>66VOZ!3+W
M4)6Y0%^K%JJ#^NK,89PDWD&)V03Y;0,@S\T!<^"/.W9C\ARJDI\CJ;)((99D
ML8CA@I16S(S+L,,SNBN""2JCMLQD<+$>JH[2(Z+#4=P1]G+RR6I:^P`[A+$J
MEEP0-S'>`%3<_4,5",C,VJ=S`XYZ#;KQ6*/K%"MT7F^=,--NVB5J\4V=S6M0
MCRPV:NN&$W;8J>=LXB:AUZJY7>I.@1(W:F(<3^D0+9CNU)..FY9I$3C(9TB[
MK,!&Y=$<%'SM9?.$)S^^97&I3T;2O7A1"]NQ/-$(E!,JO!'#*P=,;EW).A0=
M2<,<`8)E[.]1S/7JZ6WY-HM&U"IG=N(\MHSRV05SKQG[00*Z9%F:Z^D8X7;8
M1`%$_,\9._I`.I8!,*6`,P2@E&^U<!BI*GP8!E*DC.&!'B#J&2!*\)/ST9`9
M?:I(#`,/$$J0P!\00?`Z?77S31TTT=--5GV_]_;X<?W^M9_!HY0=:KZQ_)`_
M'+]9M;#Z9_*)_%-]<:ECXN8=S_#W#Z_.E(/[_$OE5_=#K@_K+^[=GZB?MUUT
MSC__`)B?H_6.N:$URGS*DQ4A*Z!*^[_#J=AR>`C:7!7S1)VPV6!B3SQHAG78
M"F#/.K$I#HJ+':,VSQ$/!X4UU3#V#AM>M+9A@DA!:2:O+,1TP(HK+UGDR3^]
MHR@R,P01^=C\VO<.T.-D]J)B!'4>%6)(!!GBADC4@]-SF95C56<OE/!V**M,
MN4&&/X!>S(7<$XAM36=_7.]@;%'ODJP\L!:F#DT2]BD)3W@RLYPCWC'R?;63
MO[4NDF?T=7I.,O1S-`R9=9J\7E(92]J%K$`5E)5A)"C2!E)4*#DC5F*Q%*44
M':[QSR`,"A"5G6.<N&P4V.RC#8+;@5!!SI+A>6&*VBP3M1J]@EI&QQ49;G\6
M$C3;K7*K<UZ2T5<V*/HM]G*\RIUV=1!T_`[)$/'IVOI$Y0\(]6;=&_5XFQR_
M;#15ZYF9=ZB3M^;:_;SW!&Y7I)LV8(;.""9-416.1K\>[%#8GBBW;2RH\VW:
MCL/*DI#9$3LKD@KC(.-E.Y/9I/T:+MMADR5.06K%`LTW75D921<1"&F2Q8&I
M)M'*,8E[]2DIHX-@5:IF*FJ!@4`G@-VG<AQ,E+D):,3=Q8K7N^\C:#+[LMME
MZG`"P-W&8G:%!)(P0,70Y!;E&.Y(O;,E22SMSNQ#'-)`6R,9)DB957&]F*A5
M.Y<H<3S7XU32UQ39Z`\2;4>K6*[2TO)TJ\0]=E:C4Q3^<5AI-BE*ZTA=!BXH
MBR9U%81=^7RU"'#N4Y1&V>(Y!8%L.@4&2)"K,JR*TS;(]\9(>-6?"[G554E0
MQ&X9R/7Z07B\$W7D,8`!*]T#)BWCR"4`,>V6W^23IY'QX:YSEXT6JU15+BKC
M9TK'+V>,IR+*;RO4JVBPGY\J!JJVGI"?I\='UMK=@<%]Q.GZK=M-B4X,E%Q(
M?PWH^`Y61"ZQ@`122$%T!'90R3(5+`B:%!OE@([T:%6=`'4F)->JP1]UVS%M
M5PR@L#&S%!,"H(,&X;3./FE/BXTY(WEWQ_EKM-T!E=7PSD"WM3AR_<4VYLJ=
M)?,AJY>6UK6;\[@4:7;9&`09+^T-HU\Z7(9NJ7P>),X%A^X6O<#R;*%JA%<[
MF57".P59.V2).V2RG?MVA"')V'.I4V:]U..E!][>1(P`"P$D@#)&S#*I(X(V
MHQ#,2%`)(&F!*\_>.+'.K=IT9(:-9J_3F%6F'C.$Q_3"SDU`W*61A8*S5&+E
MJQ&*VRJKOUO+/)L!78IJ%\H5?-,1,U]N&Y".:&"9`CRVQ6PS*#'*5WA95SNC
MRGF7<`7!!3=D:1/'--)`C`O%!+-GQ5EAR)!&XRDC*RE65"2O5GVJ&86ZKTZQ
ML\##62,3DDHZ=C6DJQ2F8B3K\LFU>I%61))0<TT8R\0]*0WVQNY1263'T&*`
M]1+E66C;DISE#-$Y5BK*ZY'W+J2K#XP2-1Z=J.]4CN0AA%*@8!E*M@C(RK`$
M'ZH^/PTL=1]2='331TTUD/6'V0_-Z::BNA?DHMK_`*76+_K>LBZ[8?[@C^S_
M`-SK6_\`^I_^7_QU/?/#)%]VY>\ILC:2Z-?D;S\.'C?$P\VZ;*/&<7.%Y"<N
MG4*]?,TE457<>A*MDA72*<IE$@,4!`1ZZ[Z?K6[$$DO'[#?J7*-N(/D(\E.T
MEI$<CJ%=H@C,/D@Y]FM,YV:M$Z175=J-BO9KRA"`_:LPM!(4)R`ZI(2F01N`
MR"-0*[R?E3O4A)V?:LSS;'']+P'2<IH5<K6LI:C\^[GI3*)9/[;)SS2KUIO2
MZY&-8,$DV"B#UP<[SQBMV1\)MN]0</)S%+E[U=!%S%_C'H00LX98H);,%N4R
MS`!9'>6M`J;47MK'(3N[JA=;X^Y!Q=OCJ/<,_&4N16W)8"&-I7CKSU8U2`L2
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M^U%8YGPU8"U)8[N#O,J6G=TE`,;F+"@*%4'Z[5[5GDH;5J9)GY6&VS1+F*<F
M%8F@E'EVM55$E@P719F+%GR0)GJG`F]0=3LK"6BLWE[%(<&]$Q*MKE73]WU#
M6M!ON@752#K8OF3MQ%4V(+9&*)),IO&91`3%3*`%`+:<2*/$R<57E>S.DG$(
MEF7`FL0\<8V9YB/DN'#]M1GRA,G/76:@YR&QS-3E;Z&.$^HKEZQ"/.JU[,-:
M$1`]%E)6%PXPHPWQZTZ%Q>Y2KS%JI5,I^<3M$V*\<.-)OFF3^FA%3%'?<=$\
MGCK95XJBDKSAY;'4VVS/VEE)^WMT2F<>6=$1`#=3ZYL?3:-,JIQ-/E[ER*0'
M,DR78I@8S'@=IXY;#-O)8-''MVAGW#'P7TK<575,OR*>G[O'%2,(C3O>=)"V
M<R(4L)'L7:48[R61"C.F%X[\A4<:V7CL\R7+XV,=WRR6^C;DPTV/7FM21L6S
MJZ&8UWI@5%.;J\^6'?J"\<*R;U%R]1'RTTRJ%`F,XZK<^BN`JVT6&QPG(<(&
M"N'%BOQD\1FMY`79+-'`)A`P9NY,R&3*EFL\A-"]_EIZ[O-%RG'7U#.-KP36
MJG:BK>)WP0NYACD7:$KPQ90D]&?8.$5Z7Y=6W0IC.K=IN;:#MU)V1&]0W,^Z
M9'&9J[@(&J0J*,AQU;1$G!:))55_4ROT5B.V2<@1<B!R`*0G-9XCB9*X%6R7
MCD@DN/%9,K3*6G:62)A6.!&5,IB9=S(0HDQU(U-YCDTMT8S`0[?1T=5ZYC$8
M94=R\?O"]>U,'R<KO5C)YB&7'U4N'N\/CUK+[?GF1U2C8^?DO(5S<(6WMK#<
M=M?[C'7!E#(6"BEK["0I0-!M@&F%'LC*%=^R`"!4?$7PVY.-N7^-$LR)4O5O
M3S\;'7C8-#99H5@$LS[1M0&,6XU*LR6Y7<L0,&\.2K5.19X9K%JO8YRG>DFE
MZ2QQUIEL&+;U[A\:L94HJUHX@RD@Y>$7Q7W.U4"B0%BKM'RF9KO$77..C]*"
MNC>WLD[#8F2416;"BXB(*N^T1%B;(><^2*4BS0BIDA.H;Y?4SE*=CD)>0O;$
M$EWA^&C$);*]_C[[V[%5GQ@PR1@1";;M;N-F/"D'&\=/#3GHQLT@AJ\SR<_=
M0;9%AN0K'!9B!SML0OF14).UHD.XYP(<LG"GD+L-;U]Q9,HRG`I2P8'QTRVN
M5',==<.'EPF./NM/]#7/,:+4Z_5%Z@C<XLJ+-@\1;J.(8RA3*BX\DP'JN06K
M!FY3MGWNQSL?(-628Q81:9I&$V5&"Z@]U75`A5%B9/$F7QMZ"DM"@S_-5*O)
M5S9,8=R+L,2I(L39\F]9.]$S%R7E='7>H6ZW"?$IG'JOH;JTY19<GMEZN+29
MFH^T<J;#RS?V$D97XR'CYL;O8(6"5@O+;-?9?=Z:`AX4"JB<1/V#*TXHZG%Q
MU(^A::69T/F*R/M4_.GJX9(T;&`%8M@9))PMEFFO"5CO1*T<2L!L&U7D?8(O
M!0&D9MV26W8/R1JZ_56J='331TTU6?;_`-_;X<?W^M:_!GY0=:KZQ_)`_'+]
M9M;#Z9_*)_%-]<:7OC1ZAG.>0O!&TWJ[5RI5NM<Z&I[!.3TDDPC8<JW%CE%&
MHC(.5/DMP4D':2(=_6HH4/J]<-]5P36/3]B&NC/,VS``R3AU/3]#72^/(]\0
M>WK\?L.N*D1L?"&)NM4N1>:^,KJ5;>M`W--@,Y%IE>.+WGDK0#5L7(2!C-TH
MHDG[45V!#&5,3RQ3*`^(.05N/YJMQQX\4YB#QD]/=M(Z3WVNF3&/M=W:VYZC
MS9'R=;-:'O)ODAA[]8I2_))V>YK54`=/-W/=0<]-N_P.WK%KM_P+?'Q477.;
M(S(9=H&A6BTM4IB&31U&GWO09W32YQ.",B=2,AHBV2;9QYZ8JF<&8E$2$\?R
M9D<7,K:>=Z,[1-Q4-14\P"3P0I#%=7ICO(@=5!!PLC*&QG/WD6EOK9"EX_>+
MRV.BDX7W>.O)$<CS+(L88-T*/@X8#!5J=H/$^#DJQ'V7XA&&6?-LN;:<ECM0
M:-(B`G:ZOIJ3YNY<W:WA9Y,EV-7&S]0C$K:/AP-W[N/.'MVCWJ/*7Z,XFH3?
M3=CC?<C.`VQ8C&L3E8<8WR1QQ*Y+L!LRBH6)T@"U+<7NB%.)CY2.]V<,6[D3
MM*J"4]1'W9)7(*LWGV[MJ@:UN+%P1=SO&Z57YRY(##"JT%7M,&A-0R337H^)
M]X.Z62=6%^=6%1I\_,.Y!!-/V@%%U2]Q+X`$9-N+E[EOE+,U"?9R-8(J^;^;
MR]LP-8C.,&1Z[/`V5&4(&<*!K'U:3U>(J<4CO_-9V?=L.)$>2.9HV4@X^=@@
M=&!\NQP0W<\L7YU7>`V=UV\4R,Y8<'&\'8<VMV;5ZY0&/U2L[G&,;-X$4I&W
M:JPNJB5U<),P$KTA8J-"16`BAA3\/A-.:WS\KPV9JEP7([-65EC=DKN*\B2%
M.QM;:)&1"/.1&1D*W3$MX8QRGTA$GD]XDF`=6D=3('R$E.&&W>0K$,VPE222
M6U8&U:KP?M%AL$^?FUC+,T]IO'G1U&I9F*6*W-@,@1^VA?.]XI&62LW@\!EN
MQ19@/<I%/5UC:5?F:BA&I3NHGY&0]""?I"I%58>!_>A'O!^W)VD+C)H6N52=
M5+9FX5./SM/E"-882XQU),_R/#R#S=>D,T=KP%H5GNSZ)Y3\'%(.TL]91C9\
M^355#?85WJR4\=V[>;>UN2)YLL2_L*W8!A4%7+,A&YU0$!5&MH^=EXF/CGJW
M4EBA@B!C9DA9(&3`>#:P)>.,*^'"ELR;?%3)D*MS:<P$W$7([!616D.]-I(C
M<X*99=R$[S&6(&1@"1;5>.$=DKI(-+G3C4<NUXV4KCXP?>\HITF@O1;A&W2+
MN:[()=MYZ;F1BTTUHTJJ8"D)O"X*80$%E.>ELV;<5*59K'+QWQE2P4QIL[9'
M0L",^;((..AQI5"5X(*TBNT4+WR<`@L+T3Q,!T.WMA]P.#N(P0-6T@.=?$)G
M!P[2Q\N\#FI]K&M&\S,1=A:P4=)R**)4W+YC"K2,RM%-G!R^(J!G;D4P]`J&
M]?6.N<1R4UN6:K2LQUW<LJMYV4$YP6"KN/Q[5^IJ-3BEKU(J\Q,DL<:J6",H
M;:,`[?-CH!TR>NE;[O/A3_M3XE^W9A^=U'^@^9_HL_[$ZDY^)OV)^QH^[SX4
M_P"U/B7[=F'YW3Z#YG^BS_L3IGXF_8G[&C[O/A3_`+4^)?MV8?G=/H/F?Z+/
M^Q.F?B;]B?L:R'//A3W#_P!5&(^L/_YLP_.Z?0?,_P!%G_8G3/Q-^Q/V-+-$
MU_*R?!LV?23:#52Y\K\5&-N*5S&51"O*50GQ;,CE#6(LA_V8Q)8X!7%;]#Y7
MRO5UU\U;/YDBIL;WGW';MQYMVWPQ\.M;R/I3'M[OZ/C\'CJ_^\RE,S'X@V]6
MRP2<;4*;5_A\<<;1:K!+O%48F#A8;>.8#R6FI-XY46]E81T>V,HJ?]"5,@CV
MZ[%Z3NU:,-JU>D6*LO:!9C@`LQ51GXV(`^,C6D>H*EB[/4ITHVEMRNRHBC+,
MQV@*![23X#2FMR!PUO$5>?7UFBI0=WII=$J$L><;@PLE$.]@HTMNB7/84W,#
M[PL\<B*_H*"CU(!_1==)E5H+1HS#;<$\$.P_*[MES'73XVG<%8L?*(Z:T>,&
M:BW)Q>;CD+AI!\@&..260$^PI%%*[#V+&Q/AI9D=FRN`>:$UD]'JL5(9#%P<
M]IR#B730=9_#V8CQ6NREG*'RXMI-)QZYFQS?]H"1NWJZB-=JQUGNM(HJ1V?=
MF?/1;&(SV3C_`-3$L1V^.'7X=7Q4LO9AI"-C:LP&:),>:2)25:1![4#*P)^$
M'4BE>!()HO2N3.TW2**Z#D5#J><W63*J@H4Y_E"0Z9P$/[@]3989*\KP3*5F
M1BK`^(93@@_&",'42*6.>)9X6#0NH92/`JPR"/B(.1I@:+J^9Y#%PLYJ=[K.
M?0]CM<#1("3M4DE%LI>YVE=1K6ZPQ75`2+3$VY2,1NEZ!4,40ZCB:(W(..#+
M[_9+"*//FD*+N8*/:57J?LZD+!,\$]I%8UJT1EE8#I'&"JEW/L4,R@GV$C3C
MA[/7;#.6JLP,U'S%AHSZ.C+E#1ZWM,C69"7B&D_%LYAN0HF:+R$(_0=I`/Z)
M!4IOJ]7(_G818B\T!=TW#PWQL4D7ZJ,"K#V$8U3+&\/:[H*]Z+NQY^WCWLF]
M?A7>C+GX5(]FEI91-N8Y%U$T5"(N'!DE#E(O[.S*4[M8J!A!8Z34I@%0P%$"
M>(._;N'5+.B*SL0$52Q/P*/$GXA\/Z&O@5F(`'5F`'QD^`^J<$@?`"?`'255
M[!"W:$862HR2%A@91)1>/E8P%E6CM%)91LHJD)DDU/`1=$Q!$2AZ2CU]C998
M8[$9S!+%'*C#P:.5!)&X^)T96'Q$:I/E=XFZ21R.C#VAXV*.I^-64J?C!TNE
M16,4QRI*F(7OXCE3,)2]O7XC`'8.WU>OOLS[-/;CVZ^?+4_]@_H$H#\DWH$_
MZ`/5ZS?4^OTP?#3X_9I!962`DK#-5-A*M7=FKB$6YGH1'S3/XI";2,O$JNDQ
M3`@%D$2"9/PF,(@'I[=6X98[!E$!#F"41R8^TD:-90A^,QNC_P"BPU5(K1%!
M*-IDC+KG[9`[1EA\6]67ZH.L0]FKUAF;378*982T]1Y5G!W&'8JBO(5F9D(6
M/L;&,F&Q2^-H\=P,LV>$(/I,W7(;U#U7&1-"+,7F@9G4,/`M&Q209^%'!5O@
M((U5-%)7:-9U*-+$)4STW1EG0./A4O&Z@_"K#V:7C%,0PE.4Q#%'L8I@$I@'
MZP@/80'K[JC7STU\T=--5@WAL@\V_P"'.V<I@J@KSUJ_C3$QR@;P<:^3RA?E
M$,4P=CD`?7]3ZW6J^L?R0/QR_6;6P^F?RB?Q3?7&GU\91%-G7.`#=L44D6_.
M-@BB0#''P)I\4>4I2%`QS&.;L7T=Q$1ZXMZ@Z\1-_P"7]L->@O\`*GIZ^X_'
MPR_Q,FJ%^:K_`(P_Z8WY_7,\#7M#<WPZ/-5_QA_TQOS^F!IN;X='FJ_XP_Z8
MWY_3`TW-\.CS5?\`&'_3&_/Z8&FYOAT>:K_C#_IC?G],#3<WPZ/-5_QA_P!,
M;\_I@:;F^'1YJO\`C#_IC?G],#3<WPZ/-5_QA_TQOS^F!IN;X='FJ_XP_P"F
M-^?TP--S?#H\U7_&'_3&_/Z8&FYOAT>:K_C#_IC?G],#3<WPZ/-5_P`8?],;
M\_I@:;F^'6055[A]L/ZP_P"L;Z_V>F!IN;X=?5#,;\3?M1O$/?\`&MQ8]^X]
M^_XW3(_3W^OUT3_#7]5_<Z\B#_O.3[?IO^4&K"_$B@I:T<@N=-:@8=_89N?^
M$YED/$P,6R7DI*:D)'5^:+1K%L(YLFJX?.WRRH)II$*8ZAC`4`$1ZZ5Z;@%A
M3$R;XOI#CRXQD;%MQERWZT("6)Z!02>@UQR*Q'4]4<1:F=8XH[:L78@!0&4Y
M)/0`?"=<_F7&"_M]XLG&]SFUC'CTEPEWSZ)[X5@Y<5>#?:Y;LFL*N-KOA$?=
M5FJ=PK;]S&M3&2\,6X030#LV/X=PDBY->"YZG"63E^+>@G'3>5FEAJ269Z,L
M0(V%Z*E:8C.]ME>"64L\^M$XBY5H<9PMC:&-_EH[%N$CI%(*-NO<[R-X0VFG
MCFZC8TDEA,*JJ#&%.SKD=H<YF6B77(M'@GG/2Q0]3Y(P$G5G;5UE,!ELY17"
M3R\B93PP\4[A:%-$CSN"E17/-%\DOVWPGR'%;/SDJUXHC!QEEOSA>3S!!:IV
M;;5*$BL!LEM<?9JK,'(E$M40LI9?+"NI[IQ,Z),T][B4;@*LL;;&>G-`@:^@
MZ.W;Y%9'[J%=M1_DM\O75;F#0N5E];4T.,%]<T5TQ<RREL,TUV$R@'R+@B7N
MX@JS'&/D>67!`X&[%33B_*[^DRO?L6+>K\Q+?26G(5IB`AAW`N9-^0VTP2$^
M7IN[@^#8?E:OTI.+AIF&:,=X2#;B/($87&T$2H`,X\NP_#N'AJ,>6.&6+9,A
MXE93I,-+WM8_(#.":Y(1BZEI5C&B&=:>RD[L\L,95ZDB1.&G'K19*5]U1::3
MP43@BB82EZG<K0K<MZA05R8*XH7##+LQV+*BJ]:50S.!(D\?<C5G8.4((*EE
MU]X&[-QGI[E_>"LEN3C.V8RV>^KW*XDA!"H6WP;U;:H8)N(ZKNUSKG*QR,EL
M_P"3L-KN9:95957E/C]-F=7K]<Y!6<7%0S?CY#U!KN=-HG&NYT'4=9K-NDHA
M%@=@SEB(,'#XSAX`F:&)U@;$\W*<'Q5R_')0O36>4FGC59YS%9><GW?;"T?S
M<YWS17)%[(6,!5!F36;<U>.G/&\=(MJ*EPD4,+,T*K)%+R4M@9DE5]LU>!U$
ML2`2[_*"8]Q+ZP;)K0YLG`K4=]K?(2;MU.KW)O+X6T$C.1$`I%.&^F(+8<IH
M5)C[58WE<@96GQYU`=W!R_3<)$0))/7*I43=9:-)$YGWYD>/G;?HJ-7.X.@N
M1PQ>\1,R`5EGP\NT*%,DH#0AI40K@)Y8).'>JK*_$IZMKSQC:5<U9H9R)`C$
MS]L3=@.&ZP(SQR)%$\T9<UXB[@M1<(:<D(#ES.T8N1[,,&QQPN^J7%MR2-H#
MOY@KZ2KCCE"^HLCU`Z@1:DTJ%8(';VOT^3VQ,D4DE"*,BS^<WYM\**3`R"-;
M(I1K?]X.>R+`M]@RFWU[:V?%]VI]-BLTI#51PK>H>0]Z#!3,:WO4S5C#D%O<
M^P'!%?$ID:ML/:W:]=AQSD/,L-&U*_.-^D-LQ[%^&3W*F%?NE]CZNXTH57!M
M7<GJ%$DXZDZ38T&ARM[`BNWD8X#@8_E`'@4ZV&O6,7-5>7LD/RI]0I'8*EO=
MNQ[M"+9AA;$8I36^])$[H61=BQM&NY-6JHH7:=+B)2(^&GJ\N[>"RIMLL>-#
MRGYU)5K"-%1GW/YMX9\G21J;;F'5-0U6'IL+MUAK5#N=DSF@.&9K6[@YRH<L
M'JJ#>YEE$W#A2T)X'$D(J9<HE4AEQ$"J$#U:UQ%>\U*#CR)8PLAX5A*S_.K6
MGBO1\B9?,T:SPO;K>\9`9UAB=QY-?9[%1HX+YVI<$,7-,P4,OO!K&O-QG84#
M"^^+!*M<A@(6E<D#<VK`\@Z]MD"PY$5^`^F:8IC&A\4JX^>TAQ<']DDZ4PGF
MC#>'F8+QZR\PYN+JJ$=*/#PPGG#D./D"+OR1#(3O!/?OR\LMD>FW]61NZQB7
MN>Y#AX.R(A#\]V/I$0K/V.F>^7P.XVK%)9X8Z@H&L.97TW-M[Q4P^]M?LF02
M%CL[_NC/[J9#@2>[;B8P`:(V+*=(:9AMC?#4.3&8\=KIS*I5@F)K0,\Y*:9K
M<GB;;C=6H>/D0I\+>J%RMG:RAJL<S;B1O+HS;,J(>UE,T2<IC%GAMMQ_$T^2
M=HJD?THV%CDD8226C+1[GNKHRAJK28>7>`Q1;*]_++FDLTB\K4562\O"5HU+
MR(B*_P!(V7N+`9U=>X%<LZ':K*TC4R$:OGLAP<KTY5^--#AYW2+=JIV[BR&B
M[3>LOTG'K0G!J6*2&,@9"B[#-6+3V*-?1_R5LXFWSIZ\:IIK&54`X'-N$G<6
MI4BG(>TE1%>0%,R^)C9E0`(RQ&.-U.7W(6D/<9M:9A!=M=H;*YGRJ#<5CS&F
M\*[%C('DWRE@=BM(8T"J@46VZL:N:.FFJS[?^_M\./[_`%K/X-'*#K5?6/Y(
M'XY?K-K8?3/Y1/XIOKC3W^,[_F/@/]_0S_!3Y2]<6Y_\D3?47]L->@?\JO[_
M`''_`.E+_$R:H'US/7L_1TTT=--'331TTT=--'331TTT=--'331TTT=--9#U
MA]D/S>FFMM#_`"-VU?TK47_6Z9'UT3_#7]5_<Z\C#_O.?[:_E!KHGL'?\9EJ
MO;OW^X.XO=NWK[_=#<O.W;^[UUWT/\JSCX$_=:\\^J_DP?\`G_<ZDQ1NZ1[E
M50<)=B@J)5$U"=BB/A!00,4/DB8>P#]?K?OB^#6F]#U'MUK`%3%,<`4,7N4I
MS!XA+W']"4P^KN/;T`/7WK^AG]7[.G_@-?(D.!_`)#`?N!?`)1`_B'U!X>W?
MN/?KYXZ>&L?**(E'N40[E,'I`?0/82B'K]`AZNFFL@<X"`@<P"`=@$#"`@'U
M@]/H#IIKZ[J^$Q^ZGA$0(<_RO"(B`B!3&]7<0#T`/UNGUM-8*=0!^28X&-V#
MY)A[F^H`>@>X].OAIK/A5+XNY5"^4/R_08/+$1[?*_\`8$1]'I^KTTU\^(P>
M@#&]'<`](^@!]?\`?Z::P!C!V[&$.WI#L(AV'ZX?6Z::^^ZW;S>ZG8#>'S>Y
MNP&$._A\?_M=OJ=^GA^CIKX$PF$1,(F$?6(B(B/V1'T]--9$IB@4QBB!3`(E
M$0$`,`>@1*(^@0`>FF@Q#$'L<IB#V`>Q@$H]A#N`]A`!["'3P.#XZ:K+M_[^
MWPX_O]:S^#1R@ZU7UC^2!^.7ZS:V'TS^43^*;ZXT^/C.!WA.`P!ZQYTL@#_I
MXI\I>N+<_P#DB;ZB_MAKT#_E5_?[C_JR_P`3)KCI4^3M+MVA$SY"I:;"&?6F
MYTFNW2Q5F,94*W6V@IO7%F@:[,,[%(R:KYFTC'2Q/:F+1-9-N<2&$?"4W/:M
M22W1-Y&10*WO&QCB0P"40&4#!7:)"`1NW`$-C&<>M9N<K5^3^C)(K'2RE<S!
M`81,\(G2,L&W`LA`#%`AD(CW;B`9,B=;R>>5LJ$%J.<S2],.=.XHQ%WK,DK4
ME$W(LE"6=-G)K'@3IO"BB8'0)""H"3]%Z.K0AF,"6@C&K(0$?!V,2I8!6\&)
M4%@`22H)\!J>G(4)+<E".>%K\0R\0=3(@!"DN@.Y0&(4D@=2!XG7K@M-S6TM
M/>%8T2B61A[_`"U3VV`M]?F&GSI,"HEK7M,=(.$?G`8K=009>+VD0(;Y'R1[
M??=[&V-NV^V6-G0[3AT7&YT./,JY&YAD#(R>NJ8>2XZP)37L0.(&"R[9%;ML
M>@63!.QB>@#8).MS_1,]BE6R,I?*7&K/)EQ7&:,A:8)FJ[L31RDR=0#5-P^3
M.XFVKQ<B*C0@"N14Y2&*!A`!H5'<`HI(9`XP,Y0AF#CX5*HY#>&$8YPIQ<GN
M4ZN1:FBC*^.]U7&2H&<D8ZN@_P#.GW0SH@M.S2T2LK!5C1:'9)R"9(R<W#0%
MPKTQ+0T:X("C>0EHZ.D7#R.8KIF`Q%EB$3,`]P'MU]>*6.N]N166K&Y1W((1
M6&<JS'RJPVMD$@C:WP'2.]2FN_1L4T3<CLW]H.IDV^7S=L'=M\R]<8\R_"-)
ML?M&-RU8F;M%:WF$G3*XO[+8;?'WZJ/:O`NODC[--6!M+*1,6X^67Y"ZJ9O2
M'H]/2:*6ND<DZLD<K;4+`@.QP`J$XW,20,#)ZCX1JW#R7'6!,:]B!Q7!,NV1
M&[0&<F3!.P#!ZMCP/P'6'^TXU%5N!N4IKF7QE/M3@S2KVR0O]495JRNB&4*=
MM7YUS+)Q<RX(9$X"1LJH8!((=O0/5PU;2VA1:.07BH81[3W"IQA@F-V#D8.,
M'(QXZH/+\2M+Z2:U6'&AMO=[J=K<!DKW-VS<!UQG.-(^H;]D6/LD%[Q>*\QD
MWZ4.XAJFA.0BMSL;2;G(VOLGM;J[B3:R<XR!_*I"HJW(<A$@,?N/A[#53IV;
MU\<=61FM=S8PP?FCM9OG<`]L84]6`ZX'MU]M\IQM&));4\*":-GB!=0TRHI8
M]D$@RG`.`F<XU\ZMM47E,I38!2C:5H=COAYX("NYE!0LY+&0K39DZEWCPL[9
M:PR;-6Z4@EV'SS'.8W8"^CJQ"C33R0+T[4)E=C\E45@AR1DDDL,``YZZIO<G
M#1IPW#'+*+$R11I&`79Y$>11AF4`;8V))88Z#7U3=^R.ZUBMVEG=(:`0M+]]
M"QT)='["HVE*RQ4@:'F:H\K\R[;O262&F"BU<-DP5$JW8"F.!BF&18IRUY0B
ME)8VB65'C.Y'B=&D253@'8T:._F"D!'W!2C`6*7.\?<JBS(QK.':-XY\12QR
M*ZQM&ZDXW!WC4%69',D9C=UD0L^UKQ26[%&4<7*J(1CB`<6MO(K6*'28+U5G
M[/[79D7AWA6ZM>:^V(^8]*86Q/-)W.'B+WC2J\&\S@H(BH?<,;"V=H;/R2V#
MM!P3@X\-9598GV[64[F91@CJRYW`?"5VMN`ZK@YQ@Z9GT_X*-9^>H;ACPTT)
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M3(OX:Q1'PSN/+IO.Q2)G$K7V`;_R[)-V&*1(50YY*"A3.'2'8IA\U(O8!ZWS
MC6B''RQ6I6AXV:]QT-F0,4,=2:Y'%;?>.L>RN\C=S[3&[V:X;R:.]J(P1">\
ME:T]>(C<);*0,]:(K]OW)Q&FS(WYV^W5*K5F&5TZV<.:7P2U^`H;^^[JL\L<
M]"69?9JW&K.N,NR*%MKNIR]@DX64M$^T8'74:O%RMUG+1!15%/RRF'J,L5V'
MF;5+C'2MQE?C^2?:$$BQ,DM$FO`&)0)D1AO,QB2:5XVWL!K4JMA)O3/*\KRP
M:WR#P<6&=SVY')Y2#YU]H!#DR/G"J'QL;R@ZE7+]RN>F27'>0N0UR5M<I2.9
M]/LUK9PI8=])O\9LMSHB<["LF#[W?7"60U4(]=-4B*D145%-,Q2E#K%<I(DT
M/)SQJ(C)_EXESRDEA++/3$@#'KV][LZ#`*ML\WEP;\E*3BN8I\7,_>:+U9##
MDJ`#'+QOOJ>7V.B2K$QZA@K''FSJM5HVS5B<8('.JOR`IN$,(C@YK.N2]DOL
M#$6R9UN6/.VNJM:5`RMCD6SZ'&/;"*AW<69:7(Y42\!?++WZIYRS/)69S(@@
MITO3J+7ZA[!M4JDLD^]?G0J;>WY`0TC9D/7J]+UHQR7'KVY#+:YZ^38Z-%"M
M>](!`4;R%V_?"'(`K*P0%P!I^*\G>2E&QC;KO4IZMS4'@61<3ZG1L_>5R%![
M(V?9,\SE>4O]RT2P.?.;I5)>?7<(HN0"/6\(&?'*D!S!E>;M<@LLLJ,G<N>I
M;E")OFHUKQ5YI`)&+D1,[A5APY$8RK+\XPU#X"G0MSUH9=[1FA9NR[-S&9@T
MY6"(#SB+*"0L!W0FY5&%4:4:ONO/-[5LWIUGOF3UVVZMRDK^1UK6FA\'UY^V
MH<AD%^O=B6DJCC$W(YPQL\5-5(A8Y-9<#N6QBF7*`&,/5JK])<B]>B9!4G->
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M8KV(S(P:-S+%XAXC@Q,JO&0%)5D99%;S$"U0BD@]5UZ4X0?.U)`BL)4V2RD*
M>X/E%PIWQL`T1&UAUZTGRW1N75)I?#*^::WPRQ4V"X[[=<,]B<SF-@=W^WR-
M<P!6;B$-0+;"^XWY!:MRJ+FCQ66*X\9DOJ#U58N<AQZ<C9O=H<FGI[CRI3)@
M023U8VF8-YOFU?N,?:JMN/75^&K4N36JU`2M3;U!,KA]O>8"]9Q%!M\@:1U[
M48;"X9!TU(<1R3Y2K0-FA:/ON$[U<;5QSI^VUZR#%YEF-<QFSV:VH1+S/Y"=
M7F#4:0*6$.N,8>T+MGBKUL)7!`(8!ZIY"2_5DO\`$PR=R*G:J!>0`B`F24R+
M+!#$Q[#V`L<=I0"?YM8R/.JYM0)3E6GR,T+U_>WN(:C=Q^S[O'&Z/*R#W@>=
MVKR878)HQ@[=VD]CR[TVU)<=*)"<LJ]0'>AJ\GHW2=HV3#<SJTU&6K$W%%5C
M:M7:82<-F#Q,H3SM%.13>';2K(GM*8^9X"C3/?\`>HY;%*W#7I0\0+2-(A#S
M2QV)J\RRQR8,*J5'?C3=)&RKVMR-(PN1T!!6MO8@::_'RE"J(XY-\<27*\\^
M])H\B8D1)@G"J796P5`UY+#O>U:)CTC?H:R0^9:U-?#QN&H-]-JM33D)1"=K
M]K3!O-5>,G'16;.`L+0IW+8AT!4;"X*H0PB0I>HG-V+@XWF.1K++Q-Q*'IRQ
M)"^&FK&T>3>Q4L,W3=`4,>_H4/<)SGI+X6K3/JKB>(L;;U$\MS-0.V`LJUY*
M$4,X5/+\YO$C("4?"*"%\6OO7,'DCC),_6H6X1&N,Z)E63W#8'DU6^.%*J]^
M5O5CDF35Y7WTK8!NUG>2;)@NU>MJ:FY-&*-$U#B"SKL&?LVF3UU]'8!X1N9K
MT"N%4[Y1$'>-$S+VV$J31R$=C+M&C%(7(U_BH$G]&5KDI/TO/1M60^68JL(4
MK'(6`B[B,6CP3WI=K,RAL#72;`GKIUR`YA-EGKI=!EHN9)LVRKM==&/37H?F
MJ),T55#ILR**#XC%(4H&-Z1`1ZL^FP6XJV&))'JCDTS[=JQ<;A1\`&20/`$G
M`ZG5OD9>Y>KR@!=_I_CWP/#+-=)/U3@`GQ.!GPU3.M:IO%C=XKDF,WJBXNXU
M;=N8D39+<&;QU[6C87(VD--12D'6[')*1CB=D'TH;VM1=0$CE$1`I1`H=:WQ
MUGDYO1M&[3EC@BK^DOI`J$#;I1>NQ+$H8D)`XC'<.3(A&8SYB!L%R"C6M<_<
MM1O,:WJ"I47SE3LLQQ[Y&(^5(H7"`@*<^8=-2Y0=3G=MB?A#ZI:",BV.X\RZ
MN]G#1J!&K!>39\>>5\2[>-&B9CIM$7JC#S02*(E2$XE#T`'67_S#BAAHK[NI
M2%S`X4DMMWQ;B,GJ<$G!^#5?!59N-]1W>'LN)9Z-B>N7`VA^VRX;;]KD$=/B
MU;SXS8]H7@*(^H.=+(?[W%3E+UP?U!^1YOJ#]L-=]_RJ_O\`<?\`5E_B9-<!
M*KQ+N-=NYKI\Z#.SSE\WJ0FX.8M<]/URK06H-9]&LV_-H)\G[OJ-\CBOTT)`
M&1&Y'C1RY(=0QA*;KG*O_P#HVX;)4/Q9@[@`[BS"R)PHD^6:SJ-K1Y"J^R4*
M3&`?5,O!S'U%]/QMN(Y2*;M.[&%H13CK,XB^0EN-P9(Y<,Q13$2!*2*LO>'=
M_P`XX_[%$NLN5F+>PQ%#-ZO:F'(72-='0SDLU8\XBF/2M3CD:@TG$HWVU8B#
M^269%`Z)#F+W4ZS[\G#=Y"K/'LB>;DZTDD+QJT:+&6<YL9!PCX4,4&006S@J
MV'X[TQ8HVIGLHTJI!<V6#9D9G,R2`,U3:$WN'\P$F`^2F,C%A/N=MJ?J2VF%
MH&/4V^Q>A8E<:GDU5N;U"D3S?(8.;@UE[!=B4=H>%EK$E8%#I&3AG)F:2!45
M#N#&%4(T7(1T;(GB>:?OV+;3*Y&V".Q&L>*Y&=[917E)"+(^654&!JW2X3EK
M7",DL%:K87AZU:%%8D321S13M).=BF(X4QJI$K(.C,VG'D_&S1HW0*UI6IQ6
M<GD6EJY-7>3AH*0>6)O`R>S3=8EJRV@G,I#,QDW<2A#+)N'8IMC`H)3)D^5V
M+!Y&U6K^G+?&4C+),.$JU$?9M9V@:RTIV!F**XE0*H9B<$$X\<FG$\KR/-0<
MQRT=:-??3.T2N9!&/=H847>442NC(Q+[(U.0P13T%<,9XK;+?L4HT)9*5GV)
M$@\!T6DPE@B'DN-_N<WI810I):36UZ[`OJNQBB17=^W.^D5G3A4#I&;%()#Y
MKE+L-;DY[\16>=/<D6KD&G*M6>*=F=AGY0A6*)=K&*.Q85WE)!UCH."Y#D9)
MJ#@4*/TER4HNPG%Q>^MF"/M(R>4I[P9UD,C([PPLL:@X$O3'&[4KA&7"R6G#
M,EAYR4C,NKL#E.;;E-T:%16SJ3?S2.ANM-B,O042ET'STI&L9[D4**"9R.'"
MQ50`F/>W%#*9:D]AY9KC3%I%4K7'9DBPD9++,TXD(L%MB$)$50%#NK'`\C;J
MHM^C2C%:D(5AAF9$GD,T$O>:41AX?=S`#`,2/EW!<9SIN7KB5N5SB<CG[I'P
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MP7YG-5RY:"[SE)9M;X^";M';"::4R[`NJT6B3>8D9LGXBG`0.'JZPE*98+EA
MI<BO/4:+<.I5NZC@[>F00ISYA@_#K9.5IWI..I)12.2Y4N0S%7<QJRI!-$P#
M[7P<R`CR'(!\-1;G'%ZV1>A5G1]!4I<Q-.Z_O$E;2L$3.6U:O.Q6>I34<QIZ
M+QB`OHRM1L&HU-)*&0<N%"`KY915,!:V]SK\+=X*DTACEK5HHY2-K2,LEV:U
M(R[F[22S6@T<09PB?-[B%RT"OQ')6^4I\YS"UQ:]YFGGB0ETBS!6KUDC9E'=
M:.*N!)*5C#R9D6-`0JU4U#C_`,CH+&G;6;IU26@L=XS3&#T]+.[+-7:\WA)>
MW41^UNB\&7/UBP`!#4TJJL6C'V)1-902@F[*'@')2\U&_(1\L^Y>2N<SQD\J
MA0T5?W<R=X[F#]U"TI(+1`*B>8,6RN+YCA>9N<-R7%O#"W&I#RC1;97[UGWI
M9^TH51'V&4.H8+)(SLV490FV3T9UD^C:7@\%*T_#W$?IT3J>E64ETOFAK8\[
M):+)%14>O?V]%?\`&RO0-PKLDW23;F@I6G1D<`-C&(103BIU(O/[G9I+5F2*
MJG&+"``)]BBP\NR2,S2!BSLTO<[R3+T4+&`C:P_"\?/R7&W+!HM-R3\N]EFD
ME:GNE>M'$SQ,*<)4!$2)H_=C`PRP>0F11UMJ+.=CZM66%H>,)&R,H.*:S[^*
M9)QT:[ET&:*;]PP8(E(@T:J."F$A$RD3`/T)"%[%#"7I*\MR22H&6LSDJ&))
MQ\9))ZGJ`69@,`LQ!8](XF&[7XR"#DG1[ZQ@2,BA5+>)PJA5P/#*JH8C<%4'
M:'-0_P`C=M7]*U%_UNF1];U_AK^J_N=>5A_WG/\`;7\H-=$-E335^)=K22I"
M*I*\">,*2J2A"J)*I*<@^7I%$E$S@)%$U""(&*("`@/8>NL^C(XYDMPS*KPN
MJ!E8`JP.X$$'(((Z$'H1XZ\]>J69#7="0X+$$'!!&W!!'@1\.M=-Q;&<Y;MF
MF>9!E=!:LIUS:&3:D9W3JDW9V=['*0[VR-4*_#1R3>P/(A8[15Z0"N5&IS)&
M.*8B7KH$:)#$L$("0(C(JJ,*J.070`=`K%5+*!AB`2"0-:A+-+.\DL[,\DVW
MN%B6,FQMZ;R<E]C^==V=K^88/73F9TNFQQF9H^H55@:/]]^[S,J[#M#,!LSE
MP\L@LA;LDQ:#8GCM55_Y?A]L55.=;QF,81^&.,@J54JT`@(P.L(((A/PQ`JI
M$9\@*@[<@:/-+)()I&9I1()`Q)+=Q4$:R9/7>L8$8?Y00!`=HQIM6'%\;MR%
M9;6S(<LM+:E'<*TQO9,[I\\A3U7@&!VI5496&=IUU1V!A!468(BIW'Q=^OG9
MA]ZCO;$]]BC$:28'<2,``1H^-RH```BD*```,#02R+"U9685WD[C("=K29W;
MRO@7W>;<1NW=<YZZ<WS-IP,YR.^:-7]WVABE&69A\WH?V&R1B$;[F0CI]I['
M[/-,$(?_`"0B+DJJ9&OVH"@G\GJF:O7L5VISHCU&8LR,H9"S$,S%2"I9F`8D
MC)8`GJ-(YI895L0NR3I\EE)#+U)\K#!'4D]#XDGQ)TTJ7AV)9LR0C<YQG)<^
MC6L^6UMH^BYM2Z@P;6DL<O#ELS=G7H2.;HV(L.Y4:`^*4'0-5#)>/RS"4;R?
M-JB1^5(U95`Z!5<AG50.BJ[`%P,!B`6!(&OCN\A=I"6:555R23O56#JK9^4J
MN`Z@Y`8!@`>NG')9]0)BLS-*EZ+2Y:F61:4<6*GR=5@9"JV!Q-O5I.;7G*X[
MCUH:76F9)PHX=G<(J&<KJ&44$QS"(V)ZM6U76I9CCDJILVHZJR+VR#'M4@J-
MA`*8`V$`KC`U<2U9CG-J.21;3+M+AB'*A!&`6!W$","/!.-@"?)`&M-,S;.<
MXK1J7G6>T7/Z:=1ZJ>H4>GUVHU8RLD0$I%4U=KT;'0YE)!,`*N84>ZQ0['[A
MU><"6!:TGFK(FQ4/553);8%/0+N9CM`QEB<9)U93YN5K$?EG9PY8=&+@`!BP
MZE@%4!B<@*!G`&EE"LUIJ2#2:UR`;)5ALNSK*3>&C4$ZXS=-/=[EI`)I-B$A
MFKA@'D*)M@2(='Y`@)?1U\=5D#"0!@\7;;(SNC'01MGQ3`'D.5Z>&OJNZ$E"
M03)O.#C+[B^__3WDMN^5N);.3G4;-N.?'AG6[-3&>`X@TIUVDDYFZ5%KDF?-
MZO<)A$_F)2]KKR-=)$6.424^45P\166*;T@;OU':A1>I'0>"$T87WQQE%,:.
M!M#HF-J.%Z!E`..F<:O"U:6RUQ99!<="C2;FWLA.XHSYW%"WF*DD9ZXSIF63
MAWQIMC[-!F\9S=U5,EA;Y!4W+!H-&-D#5KHKBM.Y]RYS9>M+5I211=51LHT6
M221%!0RIA`XG[A7)5K32M-:C29C%#&O<4.(EKF4Q&(,#VV432("N,(=@P"<U
MQ7;,''R\;68Q5YK<=B0H2K/)&LJC<5(W*W=9G#`[F"L3E>L[FJ54.``>KULX
M!`GJH`:"BC`%65`H*UD`%H(!75`*`&8__"F[!W)Z.KME$NB<7%$PM*!-O`?O
M!=^T2[L]P#N28#[@-[X^4V8L!-7L^[$Q^[DF+9Y>T3MR8\8V$[$SMQG8N?DC
M$=+<<N.S@M2(XP##G!:`R6C:$5?(\^6+1XYPY,]<1]-*I73!5V*[PYECHL?(
M3.J83B`F$1Z^".,7!R(4#D!&D8EP.X(XP5C02?+"1J2J+G:BDA0`=?0S"`5@
M2*PE,H3/E$K,':0+X"1G`<OC<6`8G/74K-(J*CW<C(,(R.8OYA9!S+OF3%JU
M>RSAJC[.U<2;I!)->07;(?(3.L8YB$^240#T=5(JQJ5C`53(SD#H"[;0SD#Q
M=@JAF^4P5<DX&*3U()ZD(J#XD7.U!\"KN.U?`9.`,G28TI]18.F#UC5*PR>Q
M3N8?Q;QG7XEJ[C'UB(FG87L<Y09IK,7D^FB0KY5(Q#NP(4%1.`!U0L,*0^[H
MBBOV>UM``7M;BW:V^';W,S;,;=S,<9))K:21]X=F/=D61\DG?(O17;/RG4=%
M8Y9?81JN^L0T/7MD^&Q"U^)BX&&C^>-;181$+'LXJ*8I&XU\HU3),HY@BW9M
M4S*J&,)4R%`3&$?6(]:UZS9FX@%B21*@ZG/0!@!]0#H![!K8/3C-)RKS2$M,
MZLS,>K,Q*Y9B>K,?:3DGVZDGXSO^8^`WW]#/\%/E+UQ7G_R1-_Y?VPUW_P#R
MJ_O]Q_U9?XF37+*H;+GMZF;["5R7=+GS680K]KF7T1)1%43F5DS'/'PULDV[
M:OV%PQ.7RW0,G"WLRWVM3PG]'7.(X7DX^'E$V^YV'D6/J-S&)S&Y"?*V[U8*
MV-K8)4D#7L!>3IOR=CB%9C<J!#+Y3VTWHDBJ9<;-^QU)3=N&<$`@ZD@'S(/9
MQ!^R`78%%F(/6W=V!P[D%G]M_P`J`X>KR_%W^IU1M;)7!W#Q&.H]O7]#K]3K
MJ:)(\!@R[3X'(P>N.GP]>G3V]/'43.MYS=IJ),>%[8G5S!6*:OU8VFVB3J4#
M(SK)>1A(>S7AE%K52NS4PQ:J*MFCQTDNL0O<I1ZJBB>:K->7`J0B3+,0H<Q`
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MUXES+Q\:/8`(\B22&)6'W0[B[3MSMRI.`RYMMS_%(G&N\N%Y=Y%JY5OG&CB$
MSJ>GD(C.X!]N<$#)!&I3ZBZS&CIIHZ::.FFCIIK("("`@(@(>H0'L(?8$.FF
M@QC&'N8PF'ZYA$1_OCTU]))\=`>L/LA^;TU\UMH?Y&[:OZ5J+_K=,CZZ)_AK
M^J_N=>1A_P!YS_;7\H-6FYX:5,X_R^Y1Z17&+&1L58^'-QI<U]K*"J$2$X[Y
M$<MXZ)<S`H&*L$0Q?.R+.O"(&\A,W80ZZ-P,UQ('K<<XCO7+M"G'(5WB)[MI
M*JRE,C>(C+W-F1NVXR,ZX-SJ5BRV+NXTJU6W9D52`SI6@:PR*QR%+B,H&((4
MG.#C&H\7LW(/CFRI-&=764YEZYN=D;1N9Q.C&S_$&%<=0E1D[1H2D_>,WS?W
M8SHK&-BO,C"C79*6]K/Y*RZB:H*(=+EEL)=;@N,B]YM0QV+32RR"-A3C>"!!
M)L0H]@V9EC7MQQ(PE7<%[;,VDI[K+`>9Y)UIP2=J)(84:16M.)93'#W'WA!`
MK2,996*QP,07=@C-:/YA6RQS^83Y:\O48UO1N4KK6,M5>Q<SXKU@,;)BO%Q-
MU]TH.G4.I(Q)CL7R;=I[2U7346;$-XD2XVOS->=IN5J,;'"OZ96["I';9;"\
MS!QDX;Q.89!:KD99&V=Q1DJ1+EXR5+57AY2D?)-ZACI2NI+H8IN--R+&0N>D
MD$C=`P<-&&91N9S7'G$%7I,/;662R=@>3G%.G<G(^OM;6R:.%SW*[U&DLZ`1
MZYB/9_:&SFVD7-(F`J9B(B7R`$P"&7Y!IZ?(V>+K1F>U!R-6FH!"[VM1RNKG
M.=B1]OS_`"CM)902H1JJ?&QV!$\TPBADY&]5+%2=HI1RR-)@'S&41;53IAF&
M6QDZ:%0YR:Z[U..SG2N+S*@1Q-U:\=+5;X?:F=U;1>AV&HSEXI[NLQ/T?UUS
M::L[@8)5.3=+J1BT=(""*:#M/[>.&BY.:_QEFQ$.PZU.5[3_`"\VN**1V5VD
M+\R9)`:\S#=*JGN019QJ/;J""&6>NPF%>I3N2KC:4JW"@C)\09U,B%X@2H0[
MA*2-NHEQGG_M4%@5'OV_XR@^2LO'K6-;IN@16@0Y973)?&8D)R?C+11HZD1D
M9F:5G8+D-$KM7<L11-(YED4#`!#96:^B<D.+LP^[<E+7K3PP[]Y:"2Q5JSL[
M8`CGK/<K-)"-Z'N[8YFV$ZSEKT_#-ZML<7Q\H'%?G(W&!F4[H7D:8P!5R3-$
MJ5Y@TC.CY5/*=YVV;VKF8^RD-#;0V/S=ZE:1F6$:*BA'R4V=FY)N-PN-222G
M$ZK2;M9X>O4L:B9W(R3.*E5`;+";V4I4C&&-R-Z:GW4A1&DBY8TBTC-'"`M>
M.RTTDBI)V@5<QQAEV-+L626)',B8/BJB\EQE#DBQ47X+4@C4*SCW;W7*KO>-
M9,^\[F&Y7"1MVTED*QFR.&Z$]UO,:G?I!//4'EC2=J+)Y9I2&O41(S:3=L`)
M"Z$WKU43GA(#;LX`8]L=LY!1`Q?$F(CFI(51XU4DJ\<;9P-IWJ&RC`LLD9SF
M.13MD3#CH=8T2'N2HRE3&Y7#`JXP`<21L`T4@S@QL-R],]3@<Z[=K')6V53D
M=R:HVX.J#7N.VT2^?UKCX>DY_+Y]>ZUGDA4FMF/IT_+UAYJ#:RW'YRK>RGA9
MR);LR)MQ!%03'\6GU>3NT^`XWU?;)M0\C85FJA0HCJR7Y./5(64=QK2&-K!D
MD9XFR%[(`.=A-:G:Y>]Z6B0Q3TX746029'L"F+F]D;,?N^&6)4"B0XD8RDE=
MKOQ_F#L;C4K)7]%SAC(Y%8.95QXZTK3C7&.CK)791S"(V"FU`F;1U.)[\KD6
MV8NV[N;<S*#[V@0`6ZI>QPV/BN_8FJ\==7;-)4N.DV03.U*<QLSQKA84E4@P
ME7<LJDNB$@&#RD"1TUY.@,I'PG&7+,?4"(6H@99(W)8R8D>/,9"[=V%)`.G-
M6^6.E2M<SVKY9F:VTZY>9C;7Q&&E:5`9E"Q-)R"TH0,Q,3-QJ>7RK0'3AY*M
M6\4Q;P!U%B`H+AR!DP.KA>-Y&_=X'C[].$V"?3M'D+#/(J2?SP2B%`%3MR3R
MM!-NV+!"O;R%4,!JY;K4JO)WZMR;M21\S:IUXU0MW/=F4S,N6RD$"O%DN\DN
M94`[GG9;@8EJL;MV4TG4XJ(D:^VN$.G(*P$N9NI)0;]-0[:2B':S4YVSA6/?
M(J)>8F/A4`H&``[]NM@$E.Q7K\AQLO?XJY5ALUY=I7N06(UEA<J<E2R,"5).
M#TR=8UXYJ]JQ0M!5N5+4U>4*VY!+!(T4FQB%+)N4[6*J2,$J/#4I]?-?-'33
M1TTU6?;_`-_;X<?W^M9_!HY0=:KZQ_)`_'+]9M;#Z9_*)_%-]<:?7QFDS*0O
M`4@)F4\7.AF`D*03^(H\4N4WB#P@`^(!+W]'U0ZXMS^/HB;=X>7]L->@O\J<
M_G]Q^WQS+_$R:_.F\XARE4B%%X[C=3-%K;KDAH.BWK%(WY@U]EJ-3GHV:8TB
M7ESV)2,ILR]ITK)DD$H^76`J8D,8@><!`'G?$66JT*5&X25@X^Y#'URM6:6\
M\T4J#V;Z:I5+1`O$C@`?-X'IODO3DAM\ER%*M&PM<M5GEC4(K7ZR4XXGAE=L
M!>U;:2XJR$"62,JWEG8EY8;Q7M==T7.+AH.?0B,-3<[OQ*G7U'K.Q-LCL=FT
M^/LM7JM;1`RS8B]6JB:C=-\Q)[*T-XF[53R?+$V46^M>E9@]X>?DG6G&;&"K
M3I'%868DGS*H$D4`W8>:*-6<=6`M5?3LTG)5K,].*'B8Y;<J5O(5K;S7["!4
MRA(:*2?"92.20E3NZZ=E^S/77&_QEKS+,[-27SRPU`]MVB"T6N$HEVH<8U6)
M*5W2<FEWBD[+3K)$?9V3R.C`=)B8!!^"(&3'$4RON4U>PZBDS6>Y68%EE#Q,
ML3UW`/8G:0H[DF*,[6[O=)4B=ZBX_DK%Y;7$5W7E6C@1+B2*G;59%,L=N%S_
M`#B$1ADBVI+*@9>V8L,#4I'A%R(;YXIF[.#AF=*L6.7.=N5<&?9'<O>0S2!M
ME/HL8D8`4CE:W+PTZ@\>NO-(DD^;$.81,`CUG_I2F>3]ZD8O%5LUY*GEZ)W7
MKFXP\&1XC#/(I.[NBXZ+M"XU&DX#DSSYM0!4XJ[R#2W1D9ECK2.]3<.I;NAX
M%*J%,7N2,6^<*ZE2T\8N4LI>#[%"RU082=.L>*!3\U?U)G)V.;J>4QWN^6;,
M=7^>;&-IWSJ3MEE*+=2+<#Y+P"G4*)P\%FAR-."VCV@[P6.3N238;8(HK2^Y
M*Q`#&PD5:*"ZL)*XL@@891K"W/37JB7CI/='2*U5XVG%7C($G?EJ2+?(#F14
MJM/;+4II,-W*T4;,P&T)TY]D>#V$6;DHB`")?)4'PB(=Q+W`O8?"/HZP/0=`
M>FNG!7(R0<Z/8WG_`(5S_P!PK_@],C7W:WP'1[&\_P#"N?\`N%?\'ID:;6^`
MZ/8WG_A7/_<*_P"#TR--K?`='L;S_P`*Y_[A7_!Z9&FUO@.CV-Y_X5S_`-PK
M_@],C3:WP'1[&\_\*Y_[A7_!Z9&FUO@.L@S>=P_R5SZP_P#<*_7_`/T],C3:
MWP'6*&FI^)PVI/RS^9^-;BR^#PF\?B_&ZY&'A\/;Q>+O]3KHG^&OZK^YUY$`
M/_W01[?IO^4&KO[]!5S3?B!;Y3K?6UW]5M7P]N.58L4#8&?D)2\-+[QS`9R+
M4Z7F'$S=PV<&)X@$#%-ZO2'?KJ'ICCZO*5;E&X"8'$?@2K*0S,KHPZJZ,`R,
M.JL`1U&N`\]<GHV*ERJ=MB)V921D9&WH0>A!\"IZ$9!Z:AHG`7&@IK2HKWWD
MP_?P]CB+-4].DN0][>[-0G,'$OX&/B:'IJRPSM7K1(26>-%&"'VE5!ZN4_?S
M/1O]BF++)+)+.+:M.7F60K-.+*JLRV)!UE1PD9V-T#1HP\R@ZU&*ZT(FBBC@
M%.=(E,/;7LIV9.[&T49Z1NK@>9>I4;#Y<@RK5.+6+TQC08^&K\DHWSFMWJKP
MPRL\_E5Y=GIQ'?T@R-R7=F,I;+#;G$@X</7SH165<N%%/0)NW5RQ4K6'F8QH
MB3\6O'E$&Q%JK+'.J1H.B,)8D?>/-G<3DL3JTMFP)8[#2.]J/D/?0['<YL=H
MP!F8]6583VU0]%54`^2-194/A_<>Z:%J!%SK]H-;*=$9VLI?=>M=Q4KN?5^W
M,+O!4BE&E%!"J5>'GXQ`S=JV`")H)@E^@Z4JR4!&8B[3QSPS&1V+RRR5XVBA
M:9SUD,<;,HW>QCGJ=7);L\UA;#;5V2SR(BC;&CV59;!1!T7N[RS?"^&]FIB?
M\;\IDK(K;'<9,GFEMFAM\.L2P/TVXZ7`5J6J,9(@U*/E!%)PDVX(=C_V"BAB
MG'Y10ZM0\=5KU33B!$!^D/:2?_V;*]SK^O9%V?@_!?'5LV92EF,D;;=*M4DZ
M>,%3MF%1]RP[2;F'5L'/CJ(<U^'_`,<,L4DTX-EH]@A'M&MF;Q-.T#3;)>*3
M1Z=?3$/>8G/*Q-**1]."X'23&04;!XG'E$`>P%[=6SQE9J%OCI#*T-N*.(LS
MDRQ0Q%S%#7D^5!%$7RB(<`I$>IC7$^;F^0GY6+F695N173<PJA4>T?\`_HE0
M=))?E>=NHWR?=G6FL\",EIT5<6E;U#E9%V*^,:9#V/3DN2=^/K2M?S]>97J=
M88Z`H<TO'5N,+8':7L:8`FH@IX#=P#JY/12Q![NTLZJUDV)2LA5K$S1]HO8;
M_P!8]L(N&Z8BB^X&H4=GM&,".%HX(GCA5D!2".1H69(5\(QNA5ACJ&>4_P#J
M'3]Q[C6TPZP5YG0[G:FF352CV"#8T"3GI&;=VF]7"VIVFR:;H4N]*4+%:4_(
M%LR7`I#$3=./&`B)1"537W1)8$5!2$5>.M&HPE=(S,\Y1?`/8ED61V'B=_@&
MP+5A^^JL2S7'LRSV)7.Z69BBQ0IO\>U''D;#GJD&#\WU0[5PCPVWZ/*:/)*Z
M<R2LEGB+M=\L@-/LL'A6BW2$!H#.VZ%DC)0M;M5@4]W-?:'"X`+@6B(G`?+#
MJ)QO&U.*F22J"8XIWGAC<EXH)G.6E@C/EC?=EP1\ER7`R3J3;OV;M7W:8J&,
M`A:10%F>$$D0R2CS/&`2H4_:$KG!U(1>-N3D71<%BYD%6_(-URA2'YP/_"&P
MO&CUBO+"7OX1@A;/U0"-_P#ABB("`>@.I=2-:)J&OD&E6E@BSUQ'.09`V?E,
M2.C'J/9JFQ=GM1V89=O;M4(:<@``_F]<H8E7'R6&Q<L.IQU\=1[;.$N*6JMU
M2NM9+7*`O29R\SM;N.5:Q9\]T)B.ENP?7J"-<H4X2;BK65TFD=Q'G[H&%NCV
M[>6'6,CX6E%6J4HC*M2GQL=!4#L%EJ18[<5@?^N$ZE2W4%WQ\LZOCE+/=M3,
M(GEN7S=<LBMMLDN3)%G][^6PPO0C`.=HQ9"CTFKYM3JU0:3$-X"I5"&8P->A
MVOB%%A&1Z)4&R('.(J+*>$O<ZAA$ZAQ$QA$1ZSEB=[,QFD"@G&`H"JH`P%51
MT55``50``!@:Q4<?;#$L[R.[.[N2SN[DL[NQZL[L2S,>I))TZ>K.J]'331TT
MU6#>%_9MO^'.OY+AQX.>M7^TM4_.7/XN-?)XGR$_$7Q>'Q=S>GT%`1^IUJOK
M'\D#\<OUFUL/IK\HG\4WUQK/QP<^J%_H7!J%LT7+K1%FYQ1AI5BE9+96WXE)
MQ>Y.R)$ROJY.Q4K%*D=-4Q,#5PD(@`D$1(8Q3<9YR1XN+E=,;@%]@/VP]A!&
MN\_Y9U8+OK>C6L@F%S)D!F4](G/RD*L.H]A'P>&N3GW%_'+]B-R_AVY!_P`:
MO7//?[7W2_L$^]UZW_-7@OP4O_$6?]]H^XOXY?L1N7\.W(/^-7I[_:^Z7]@G
MWNGYJ\%^"E_XBS_OM'W%_'+]B-R_AVY!_P`:O3W^U]TO[!/O=/S5X+\%+_Q%
MG_?:/N+^.7[$;E_#MR#_`(U>GO\`:^Z7]@GWNGYJ\%^"E_XBS_OM'W%_'+]B
M-R_AVY!_QJ]/?[7W2_L$^]T_-7@OP4O_`!%G_?:/N+^.7[$;E_#MR#_C5Z>_
MVONE_8)][I^:O!?@I?\`B+/^^T?<7\<OV(W+^';D'_&KT]_M?=+^P3[W3\U>
M"_!2_P#$6?\`?:/N+^.7[$;E_#MR#_C5Z>_VONE_8)][I^:O!?@I?^(L_P"^
MT?<7\<OV(W+^';D'_&KT]_M?=+^P3[W3\U>"_!2_\19_WVC[B_CE^Q&Y?P[<
M@_XU>GO]K[I?V"?>Z?FKP7X*7_B+/^^T?<7\<OV(W+^';D'_`!J]/?[7W2_L
M$^]T_-7@OP4O_$6?]]H^XOXY?L1N7\.W(/\`C5Z>_P!K[I?V"?>Z?FKP7X*7
M_B+/^^UD.%_'+N'_`-H7+UA_^=N0?\:O3W^U]TO[!/O=/S5X+\%+_P`19_WV
MIHHN64<WP/MFH9HV5^:R7Q.8VJD8A;[H#X(,WQ9LDC3-AL06$+,=T+,?#[8+
MT7H&^6"OF?*ZWSNO^;W=R.Y[MGP'CCX,8_0QC7EL4:O_`-MFAM/NOTOLQN?.
MW?C&_=OS^NW;OCUT,Y@:9#XWSCY&ZA/,W\E&TKX=O&R:/%1295I29=(\@N79
M(Z&C4SF(0SZ6D%$FZ7B$"^-0.X]NNC^G;TM"K8DK1]Z]+-6@@CW!1)8LS"""
M,N>B*\LB*SGHH)8^&N'\]66U+"DCB*O''/+(YR0D4,?=E?`R6V1HS;0"6Q@#
M)U5/2.6G+7&ZQ02ZKB_&:EW#4+_'5BJVJ4VZ_(8)"1K^J2MA2C+_`'-3.BVV
MO7]Y*1A(IDW+%JQ3QZ]0`CL0\P2;[8M6H>4J\)FJO(RR3AB[NL4XB[0CCHL5
MW2693([B&=82(*UB0GH@;4!'2DI6.7A]Z/%HL)4%%,T0E9]TEM%8K'!$BH'D
MB:3YV5$`(R=3$YW_`)`V;3"4;),:SBQ,,\@LYDN0;RV:5*0TC$S6@(*2!ZEC
M+F%@)BK7:5KL0S<.7*\H^BV9RF;E(J851[2:-AKW(SR(A3TW#R'N?<8CWCN+
M$DTS&(>3976>N),.6D:4]@2!"=1[$:5:2Q2MGU!)6,Z(HS7[7<>*(M*<2!K#
MQ2M$O;RD:'O=MR%,QZ?R=XY8I88NIZ[N&:9M99Q!-W"05RLS*$E)9HLX!JBY
M8M'0@JNDJY,!"B'K,/;JE>0HO=/&K+&>0!0&//G!D^0,>/G^U^'5;4[2U??C
M&XIX8[\>7"?+.?UOM^#3.W;:]+K%GS?*\`I%&T+6M*BK);V'TF6BQ4[,X&AU
M%NR/*3,[8ZG7K5/%D9=Y*MT(M!!BJ1<P*F4.F4@"-J>;D_I.;CZ4"/[G4]XL
MEWV,H>5H8(HQ@[I9I8Y5&XK'&(\R.NY<W($X]:D=R_+(L=F;LP"-0Y=PBRR.
M^2`L,43*S$9=BZ!%;S;4I[S'SRF7ND9+KE:TW.]'MB549NW:N:W&6QR+M%K0
M1!C7TMO:1AJ`\.O*K%8HG!U\MZ<C<>RQO`$Z&S2O<Q)Q''-(TBNZH94,/=[:
M&1MF[HS=M68!2=RJQ7(&=1GJW*W$)RUT1;"FYQ&XD,8[G;)91YE`;!)8#"$.
M?+UU\L.3SATZF47T+78)*(Y1J<=DQ?/;/(.)IN5BT<H2L6A"P+[RK(]7=@1-
MLY%)@`%'Q.`$0`8'%WSR,/$2E0K<G-RZ%!N9P.+DY-`8NFUFD7CQ*ZN4PKND
M9>01J]V]`*<W)1`Y2BO'$.<!3[^E!O/UR`K7>VA4-DJK/L0NRP7E_P`1J$M#
M/7;7H.:7VI4ZN;8_Q;&:W6\IVNS[EK,K7D)$UJ=M<P/1&CB8&)&,4<J!7E95
M)DQ*91Z9`P>'K'\+ZAAY/TQ0Y^>.5;7(&Y(L,<;R-'6J3O#WIAM#Q_((E+*(
MXYB:^\S1R*L_D.(EJ\W=XNN\9J\?'!WII'2-#+82)D2-LE'W%RJ+N$CKVY`I
MCE1C.27.CCBZ/44XZPW"85N%&L>DH)0N;W.55J]+I[Y]%6V8T0C.*4-GQ:O,
M1B[)^G*^SJ-7B8HG`#^CK+37Z<'=>21?=8:\4[S#K`L4Z;XG,P\F'`*CKGN*
MT?RU(U"6A=8JAB=;#V176)@5E:8E1VUB/G+;724X'2%UE^00=(L%SKQO1,\T
M>ZYB[L":U!I,/H:0:SG6E9Q#6.E3SU)G%W6MG>5E:;MU*>+>8B21B&KQ(71/
M+$>X&[6;-YXN,;DD0Q]OD*U1TG5XI$DLRPHFZ+:9`)(Y@\+E1&Y*%F5"S"L4
MREXT93N/N]F0/&5>-C525I%$@.QFC:,B5`Q=5R0I;:"\+9S$QZ@Z95LGNK;3
MH*>MI:FG%V]7)+Z..JOKFU:JP+,VMGB"4YNJ^>NTV9"*N"G*^4(W.`+#X.IT
M,T5GF9>"A$BWHYI8P)%[>]HE=V",?*YV(SC82&"L5)`SJ,T$L?#Q<VY1JDD*
MR'ML'95+!"70>=`&(/F`(0AR`-,WDWR;T#&]5QG**'4\G>2.IL[/)#8-MT*;
MS6LR"U9?037Z/*',Q->GV4KJT\VEU7+%E(G8,3(-%#*."@`]08;LLWJ!>(40
MB%:XF92Y%F==S=SW.,@1R^[(A:R9)$V--6`R)&*R'KPQ\2.0=GW/8[08+N@A
M;:"C6F7,B+,[!8>VCE]DO0%0#\-^?>*)3'(2)LU=V6E(\<;1$4VT35ER>VMH
M6YV2?;02D)`Y<^18J)7JR3CVP((1T8S$[Z0`2KH)G052.:W6YFI;XUN4C6<(
M+\E18C&PG=XP2S)#C>T:J"[L!\TFUY-JNA-T\3=6]!QY$??FXL7V8.IBBAR^
M[NS`]M2FPY.[:Q#HI+12!1;XA?&A&BPU]!]J;E&>M%II3&DL,7T60UE*TTNN
MEMMCAI'+64*O<8QVQK!@?`"S8H*-A`Y>X#WZKGY?CZ\<4KONCEA:;*`OVXHY
M.W,\NW/:6N2'L%\=F(B23"$'5-;B[MJ2:-%"M`80=Y";C8;97[9;'<[[Y2+9
MG>ZLJY*G3_P;F%@_)68E(/)9VS2;N.JT5>&KBPT6U4^+M%-F'JD4VM-'E+%'
M,6=R@6TV@K'NG+`RR;5^BHW4$JA#%#)5C[W5DN0@]F*5(VW#:WSD?=B<*>IB
MFB(DBE`V2(0RD@C4*PCU94AG!5W,B@^*B2(XEA9O`3Q=#)$3O12&(`.MNW_O
M[?#C^_UK/X-'*#K5O6/Y('XY?K-K/>F?RB?Q3?7&GO\`&=_S'P'^_H9_@I\I
M>N+<_P#DB;ZB_MAKT#_E5_?[C_\`2E_B9-4#ZYGKV?HZ::.FFCIIHZ::.FFC
MIIHZ::.FFCIIHZ::.FFLAZP^R'YO336VA_D;MJ_I6HO^MTR/KHG^&OZK^YUY
M&'_><_VU_*#5S.7^:Q6Q<XN1^7S3Y]$L+M\.KC?!C,Q?D>](-VYY`<O1CIV,
M!TDNU&1AI`B3E$%"'3%1(/$`AW#KI?IRC+R%:>.M*8+L4]6>&3:'[<]:83P.
M4;HX66-"RG&X`C(SG7!.>LQUI8&GC$U1TFBEC)*B2&5.U-&64AE[D;LNY2&7
M.5((U$,IA_,^?H+FMV+D[@MDF9!L>K3<;/<5I61R6R4%Q`/(E^A/T53;@LSN
M]2+QT599^G8$H<R20)!%AW,<V^<K1FY>.6"V8&J6H["6(C$6BQ,T10UPSEHS
M"J2*.\U@-WW+#*Q[-4H6ZW&S++6%@20/$\$G<`E#QE@1.P0))&ZE3B)('$B!
MA)L+1E"S?AOJ&$2%;:83O5?J5'?4C.*AK5=M&4'M4I,N\\]M;H6;)I5I=8",
MS:1DXB358"WD6%C8MFB+4B2)?($3S:4<U.TT+RO/P9L0S;9.MIGCJ04Y#+9&
M%D][2K6ELMV0YF1VB:)9"H@2=F2J)#&J<WME4R)D0%9+$MI4$'5E2O)/.L`6
M4'M2;93*R*PL1J_&?+]HLD3:[H]UII*PC=-HP2H.^;9EL**"3D':?O"O9Q?*
MO!2ZP*E`#*NFZRAR?(,82^CJRM"!+QY$&3WDE#^^2%/F_D_-;NV/UP"^?[?.
MK[6YFJ>Y$)V,./D)O\_C\X!O_P!$[O+]KC3>V[$-%M]LS'4,0T^NY=J&91ME
MJR+R_421U*CVND6UM'IRD':*Y&7.@V)>08/8I%TP>MYE`R2QEO.(N"@`6F6"
M^.4GY&I,D:W*@KV$,8.0DK30R1$%1%+#))+MR'B8/AHCM7")Z)HI2N12.U>;
MNP.LFUHV9!',K;@PD2:-45]PWJ8U9'7+[JDZ7\-V;T[9:]K%EU',;-),+=B]
M[DK?>L$;6K;HJ:R1W`.W5>RG3/GQ'1669U<5X0Z[J*9PJRA';Q97V@_F'*:K
MCJ47&^HUYJ!46O%:L3H%7%B3WB"6#LVK)),\4(F/954BV)'#'DA"6N7[\O(\
M.G%S_*-+W9_P(`D:42P0G(CF9]O<>1I2R[P-I9&CLN?BH8[UR\^?)0]HY7M>
M3OE_-XP^`K9)DG\RO%[W^48_LG?V_L`!XO\`L/1U1Q%'Z*;A6W[_`*(GY>3P
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MLDFYCC>UB>>64GRJA?:J[`JBJ+EISSM;U!:57MP\BUMU7*H^5@C2-`2Q0+%7
MC4L2Y9LMTS@*4]PO/-QSF/\`I&*V]HX>T?BB"OS7,J"9J;:3V4;T"?OQ,!)(
M^/R?=W<!2_1>T&_0]2>9K_2_OW7M^^<M1N_=;/<I89.W[-W<[.-W39NSM;&#
M;K7_`'>C#3V9[-CE)<YQGZ2K/7VXQT[._?G)[F,87.=0]L_PX%-;VV+U5:[Y
M:=HRLV(VM*2N^'C?-FI[C&#UT2U;(-5>WM@TS.@7`:^+A_'MX==87SQ=;V@W
MF&(-%&JU3U.?4)[>!?M6EV)ML2&U%-&8;-C+=Z"$3D0(J1E(XXDR0I+6[-OW
MG@H>$(;8G'K4;)!CVJYD$T46`$G9]O<D<R[EWA0I*,EFN5&&ZMOL$[I%2TC+
MJ[G%OKTK6-,I6L8JKKS&8:/G39=E.T]9G>Z*-:M<4F54$EWQ9=F"ODJ`V*9(
MWF8_D^&;F!+2O2__`*B98>B*%L020N[]ZK,<K'*28V5Y(I>U)!$Z`><-(X[D
MOHM4M5$(Y:(OL8M\RZNFTI8BP'D08QMCEBW))*C[]R&.!=)^'TKH->V"AN]!
MILQG6@V/'-'K5:TC+#Z&>.TW&HFG0<:?2#/[@RA=*S2R1E):ED88K",?J'66
M,22)XB`21>HR7[4M^P*KVOINQ?A5X=\"+<A$5F&6,OF1O%J\J/$8>F5D(W:M
M\==3C8JU2'O"G%P`XR0K)LF81RS20SQR!<1LG?;>C)(DA5<X7<I>N3<+_H]B
M\_0.7CQ27U)GM<F'<;QIX^*870K"73LW5S]LX=5%70;LNE8(0%S.%GIGJOMB
M12(@FCX?&-5KC4L<7:XV-NVMOB)J9`'S:/-+O::./I@$*BLFXEBNXOC"A5Y#
MW:\;A3?_`#JG-U/SA%67N;'?'F#>"':.WDG#9T_<3XMFQZXT2V#=R6`*5QQ:
MX![O+7QC/>`M]+E]#&U%<>]GH-"G]Z^R>Q^`_82>9YWI\`9>.78MA<9[Z4%_
MT?<J4=3/Q]SM]SV;,[?-C=J$SYXJOQOMK\I=N;ONO?`1V\>SMY^5D[ON5TO;
M?^_M\./[_6L_@T<H.M0]8_D@?CE^LVL[Z9_*)_%-]<:>WQGA`(+@0(B``7G.
MT,(B/8`*7BERF$1$1]```!Z>N*^H"!Q$Q/AA?VPUZ"_RI&?7_'@>.Z7^)DUS
MC3MU268Q4HC::XK&3LBE#P<BE-QJC":EUW!VB$5$NRN1;R,DL[2,D5!$QU3*
M%$H%[@(=<W6.1V5$4EWC[B@#):/9W>XH]J=KYS</+V_/G;UU[&:Y46(S-+&(
M1,(BQ9=HE,G:$1.<=PR_-!/E=SR8W=-+#YXTBVCF0DW3:.8,T3N'CY^NDT9M
M&Z8=U%W+EP9-%!%,/28QC`4/JCU;9E098@#('7X2<`?HD@#X2<:D^`)/@`2?
MB`&23\0`))]@&3K:@JDZ01=-54W+9PBFX;N$#E607;K$*HBNBLF)DU454S`8
MIBB)3%$!`>W5QT>)VCE!612001@@@X((/4$'H0>H.K<4D<\:S0LKPNH964@J
MRD9#`CH01U!'0CJ-;?";T>@?3ZO0/I^Q]?JC5S2<ZEHID_CHI[)Q[.4F!=!$
M1KIXW;OY4620+O0CF:JA7#T6:`@=7RRF\L@]S=@Z^J"[%$ZNJ%R!U(0,JEB/
M8H9T4MX!F49RPU;DDCBV"5E4R/L7)`W/M9]JY\6VH[;1UVJQQ@'2B("';N`A
MW]7<!]/V/K]?-5Z1XJP0$ZK*HP<Y#S*T#)JPDZC$R;*15A9I!)%=>(EDVBRQ
MXZ410<)G.W6`BI2'*(E["'56Q^TD^#V)02C8\KA258J?!@&!4X)P00>NK2SP
M//)61T-F$@2(""T98;E#KXJ67S*&`RO4=->A25BT91M!K23!*:>-%Y!G#JO&
MY)1VP:G*FZ>MF!E`=+M&RAP*HH4@D((@`B'?KXH+[MG78`6QUVAB54M\`9@0
M"?$@@=1JIY8XW2*1E623=L!(!;8`6VCQ;:""V,X!!/CKZ]Y1OO,\($@Q&928
M)2JD1[6A[T3BUW"S1"248>9[42/7=ME$B+"3RS*)F*`B)1``5F0R*"8U;:3[
M`Q`8*3X`[2#CQP0?`Z^LZ*ZQL0)'!*@GJ0N-Q`]H&1G'AD9\=>WKYJK1TTT=
M--9#UA]D/S>FFMM#_(W;5_2M1?\`6Z9'UT3_``U_5?W.O(P_[SG^VOY0:OER
M.ME<H?Q"=WNMOEVD#5JG\/3C?8+#-/CB1I&1$5OG,!X^=K"4#'$J2"0B!2@)
MC#V``$1`.NH>F+];BZEV];+=F-8^B@LS$E@J(HZN[L0J(.K,0HZG7`/4-:>Y
M-5JUQNF=F`Z@#V9))P%4#)9B0%`))`&FMG?*+.KS5+'=++$7O`H&KJPHR+KD
MM`Q>-(K1EE3$]<GV,E-V%W`KPLX<IDFYSO$U_.+X#HD,8GBZ/)+%7@$UQDKR
M=]X#'*RI(DL:J[1LI."=KAAL9@1G!RK`:8(6DLFO2/O2"(2K)"&DB>,EP'1M
MH)'D).Y5PI4GY0T]GVVYRTL%(KK:<).K:+5K7<ZA,5@S2PUB6KU,CC2DR^0L
M,8\7CUB&:%$6XI&4(N;T`8.K%B[%5DMPSAUDH\8>0E!4C^;"6.+<N?E,6E0J
MOVR'<#CQ^Q0/.M9XBK);O>YQD$'Y_MO)AL>"@1L&;V,-I&=.3.K]7=2H];T*
MI'?*5NUL#R,0>29FCWYFQ';ED87+(RBIFZGGM#_)$P^CL/U>IS(R+&Y^3+!#
M,O\`H3Q)-'GX#LD7</8<CV:BQR+)OVY\DLD9_P!**1HGQ\6]&P?:,'VZ7+!8
MZ[4H9_8[;88&J5R*2*XE;#9YF-KT#%H&4(B5>2F9ATRC6")EE"D`ZJI"B8P!
MW[B`=1YIX*ZA[#I&A8*"S!06/@H)(!)P<#Q..FI$4,T[]N!'=\$X4%C@=2<`
M$X`ZD^S34D=>R*'KD7<9?6<NB:?.M_:X.W2FB4V.JLVT\:*7M4-8WDTC#2K8
M%7"9?,;KJ$\2A0[]S!W33PUB@LND9DV[=[!=V\,R;=Q&[>J.R8SN56*Y"DCY
M#%+8#M75I%C)#%06VD'!#8SM(/0@XP>AZZ=4K8ZY!03JTSMA@(2KL6/O-]9I
MF:C(JN,HSP`H$D\G7[IO%-8\4S`;SSK%2\(]_%VZJM21T03=980K!3W"$PQ(
M4*=V,,6(4*>I8@`9.-4UT:WCW0&7<NX;!ORH&2PVYR`.I(Z8Z^&HL'D'F+B4
MEXFOS!KHK$YG]+9)"E*P]BK\W3AEC0A5J[9&TP2!E7YY$AB`F#@B8`41%0.P
M]1YKB0079V20B@:O=7&&/OBRO`4#%0P9(78G(`&W&=PU<CB[DM:%63-L6"AS
MD?S5HTF#$`[2K2JH&"<[LXVG3N7U3-&#VMQ$UH%'KEBMR$6M7:I9+G58:U2Z
MDPU*\CV4=`/)DLA)OW"(CX4VI5_,$IO`)P#OU,E[<?(-Q0DC>^KNNQ6RS=MM
MKE4Z.0#C/E!&1N`)QJQ&6>BO(E72DRJ=[#"C<`0"W5`>HZ;C\1.M2VITF-;7
M>1M$TPH<'G\VG!6&RWV8KM5K1'"R""Z+M&:D9LK-"/7]H*0AW@M%#J>@$^W8
M1AK>J^["W,ZPPFS)`.XRKNDB;:=N3@A^I0`[R`257&-2#6G,YK1JTDHA24[`
M6PD@W#.!D;?!NFT$C#'QUJ:[-C;ZPQ-08[!D[VW6!HT?P%3::32G-HG6#]F,
MBP?0M>0G%)B69/HX!<(JMT5$U4`\P@B3Y74I");#U(R&MQ$AT'5T(\=ZCS+C
M/7<!CVZLL"M9+K`BE(/)(1\V_FV^5_DMYO+T)\WE\>FOJJ:I4;HEHBT&I)G)
MEMHFZ?;/:XXS4R<U7HY"4DB1I15/[P:E:N2^6J'@`YNX=@[=03R-8<)^</F^
MC2;0\//_`#2Q+5F\OXV%]G7S+ANF<:O/!(G)-Q38][3L9Z^7^<PQSQ=?Q<J;
MON6R/9I$R+?<AW.FQ5WS:]UJ;C9*IUZZ/8KW]`_.FIP=HAT9Z(->ZXUE7DA3
M7BL6N"ATGP)"4`-Z1`!'K(V0E7O-))$8:[E))%=3&CKG<K2`[5(VL"&((*L"
M/*<+%:>KR$O%SHRWXIY82F#N9H93"Y08RZ;QY7`PP92/E#6F9Y"8[&45728R
M^UN]TQ"SPE/7F\RGH'06:%AL$BVBV$>NZK4J]9HK$<O$Q6*94%$DS>(2]NW>
M/[Q&9J4*G=](78ZL##JC329V@L.@48\S#.W(R.NJ'B>..W)(-II5GGF4]'6-
M,9\IZ[C]J#C.#CPUF^\@L@S>XU#.['>(`^@7>\UG/H>BP\U"2MS;3-M0E'$)
M(S541E"3\165DHA83R"C?R"_)]?BZ5)X;UWZ/J,)+`25FVD$1B)0SB0C.QL,
M-JM@L>FKK5)TK3VY!LBKUFG.[H7C5T1C$#^^8+KG;TQDYZ:9NW_O[?#D^_UK
M7X-'*#K6_6/Y('XY?K-K,^FACDB/]FWUQI\?&<]$'P&[@`A]W0S[@/I`0^Y3
MY2]P$/J@(=<5]0`-P\RM\D@`_4W#7H'_`"I)'K_CR.A#2_Q,FOSJTW.;Q$;U
M/Y<>B3;O*,:LVH<B,ZFSMW<9!6&QZE"&0K]'B9]5O[O)*P=JL=B>?Y.H92-\
MIF<2E\9.^@03/^;<O(.V>7I4FXJ-,[9'C=^XEB%@0PBBH*O'MTRY+#=\/IR6
M@_YXKPHB8<#;N1\O)((P85=%,;5G<]!8?D%3D@0`2#)W#M_?(&QM#<Y1EOM>
MD_IEG:M9./,R^7JUVJG(M5.K:J,_'H%HL%:=ZM=L>7J2C(ITY0,]KB,?$R14
MO/(B8!3\$SF(Z;^EY4B,<TJ<C1[$H$:/-#G=-)V`._$H949EL,S(3@8(<ZPW
M"3<Q)ZELF06DJOQ_(B:)ULF.&9A(*T:S32&"=F7<`]-!%X+D!HPRY=[#=%=-
MN5%C9?DRE?JGG_%-/&*YFI=`3SB"MDM68@]R2T8E=2^9[%LLR;+'>H6HR<>*
M!3B@!G/8.LJV;'*37J1K//)ZCO!GL;37:DLQ+X8Y4C87[97-@2F+9\R<ZBL&
MJ<+Q?'W?I*-U],PM''7$P87D58XQ*(?.H#!!(LVVOL#[_/N&I+GX74XRHV2U
MW:<Y&+0=@Y.V>%U1"AR>E.[;#8=%/Y].L*9/5ZB52SQ$$YFSL?/?5QM[T<QX
MA\LR!5.V'KMQJCC*[C^;OQ;29;)<WRJ"%+3#+*@B$NY&(C,^PR99LG,V8N<$
M/)77:?N)R$<<BJS]*)ZV'HHGRYS.T>QE!*5N^(BNR-0X:)].`Q>2+P(:DYA!
MN6^J4Q33$K$K:29\-7E_HI^E5:P)&L2*ZSXJ0M??PEE#`*0.@!QXBA'NBXD5
MA916^FE]-SCYK9VO>??J7NX!3YHVO=-W>[>5,@G*%ERVI%+N^\4/=/?3P(]3
M1;3-WC*:@XN[WVE[OSP@-_';[H&`80``4&I&XP6%I$8Q9K*FGR1GM(BJ^TEM
M'B=KC->6F%]%0AW2\A&4&*O3-*"5B%YL%"`E4P4B`+Y?ECX/+ZN>J9(8:+2<
M$L;</F3W3;@V"A"!#/G-G<JE6/?&[<),>;?J]Z*+O+,>8-S\X!M-Q9.^*PD#
M3%EI;\0=IB'5/=SDQ]GN8\FJ55BI\LLA@-#4=Y:O57VVY6A<[)/XW:[)HMS^
M?$5<33MC7=H.<_J:-.T!2AVQ\Q9-T5I%1=5BFFBN=5)(!R$GT3$D?I^Y,QXG
MCKM0MVE*P^[D&O?-9XV,TC6K@BN,JJ"D1D8="Y.M5$]5Q69/4-:K$G*<Q0N>
M9\F8V.EBB;J",1PFI1#T8U+NIL$8<LQW6F*O:46U>=\=_ISE8!#$-W/`+;"V
MU0]G5T(B+,U41L2FUMFMH]XB\`1C$Y'PH''N"?=/Q=8^Z)=O(#D>RH-3C`IK
M]O(B]]D%HQ=G.;`K;BP`,W2/<,[=9KC"W=XAO3QO.@EY8O[\+&#8%.`U%LF<
M!A6:SA1M^9P9NR>APA\18`";=:K;#)\CY"MO^/\`G$'*V'D.TTA)^;165ON$
MA;86N*ZDV:V))@V4?E6,@W(6+**H&:=TQ`>LK<DC3B;<">[K7?E=]<)MWM7%
M>-`\F/.3O5A\_P#.@@]-FW4'TY%(_)T9_P#]FTZU)Q;-D2]M+3=G*Q=[Y(*C
MRBO_`#8J`03/W==(^M9UT?1TTT=--9#UA]D/S>FFMM#_`"-VU?TK47_6Z9'U
MT3_#7]5_<Z\C#_O.?[:_E!JTW/',I;8N7O*7-8!U',[#:/AR<:VU=6F?-]RF
ML#3D/RXD(5O.`BFJL,*[DVB23OPE,;V<Y^P#ZNNC<##<D@>QQR))>IWJ%R.-
MFV+(U.TEH1%_M>Z8MF[P7=D]!K@_-R5UD2"XSQT[-:U6D=`&>..S`T#R(I(#
M-&LA=5)`8@`GKJG?)[)N4?+C-,M4NG'ZXYN3)=*C9Z<QBB\B,42O.H,'-"LE
M8E).`N<JG;,<CX:%G9IF[:,9\I72R+5<?`FN#41WCEJ+W>3CY81SO`T=J(0!
MX@\(D:%X)I2^8I&RDL;K`^Y%=65CYUUK?$VX^/XZYQ'=A662*OMG[<ABD[4R
MO)$JC;-&&5`RLR@%MJ.-F_$@XIQ8M>>M..2-?I5YJ-;H6?\`(J,L=<UK5:'I
M%[K-@T].4&&C5[+1"MJG,Q[^0=><D6*3*TCFZQ4A`O@$`N7:%AH^0KQ%9(I?
M1K<;"W4,UAKL-D1RER2=B!T[I/;VHB*<!=0XK,?O52Q)D/'ZE2[+@`+V5HM7
MWQJH&W+;1V\;RV^0YW$FQ65X?:&O%.C8E;+;><MM4;6_=DO9L@M\?#7&!=%G
M9*1`:[;`C)V/2%9NX(!S@W5`2F$OH'K*<C7%ZM3A6:>%H*=!&,3;&+UZ<,,D
M9)!W1F1&!Q\L`$'&H''2-2DL.\<4G=LVV`<;@%FLRRHX`(P^QE(^Y)((SIL\
MJ,=N=KSK&V=3IX\AD<CT^HV^V9/H-HK3%QME;AH6;A7+2>G[:6-I,E86CR41
MDBDEBI1SE5`PF*"@)!U$O]Q^=K<N:D=BJD-F)H5V*(GGCC6.U&LIV%H3&RXS
MOQ.[)U&IE'$?%6N/6W+7LNL967S,90DFYZLK(-RQ3!@S.@W`P1H?*S:JWF_!
M^?E[]E5LUK$LT94%D;F);7&+2+NHW*JXY*;7,YNYS>GQ\*@5Y4)AVRC8&1%T
MK%)*Q$<Y,/LP@0R1NL:W!=KT[<XN9EN<F>',$$K`_-O+9MV/=HB_F2*FDL5:
MO,V)#$N`R@N#D;/+K(+$E+?`9.6XR0*,*7@I4;%:>9]GE)GF:.8QG+,6W."Z
MDB1[%Q[V9?@AQORJ4I$-J&E9`C@,GI&.S5M@$H'4DLX?0JULI+FUS;DM2?`H
MFS.LU%^I[L=N&Z:;@11.;K/^IYC<]2U>>B@-ZI#:E>6%BBF7OU)JRRGO>0M6
MFF6V`WF)A^;S)MU8A:C'-S=.A*:-*W+;%21%;$<!M&:&':GGCBL5U%63;YHX
MY6]JZ6IO#M&N1M*G(7&H/'HZ[\/Y#)8#+TK%GQD*I=W%L<R:=9,:C.%*>C'&
M9F!87;,PL@,H)>_C\76!YOC+=OA_4%*%A+8Y$\,8,D@$5([8G1BWR>R9HXUS
MY7`)CRHU:XRW#7Y3B+<B]J&FO)K+@`];$E<Q.`ORNZ(GD;[92</YB=1=?N%-
MPM*&ZV;Z.:-*Z9,8MPWI6,VJ3>UUQ.URR8X@G](80$T^\U:EJ,G`#Y3U`R!W
MQ1[$.8H]NMDMI6;U+-S=50))?64_(&7&)#3?HAS\H9!.Z$$9/5E)P=4\'-7K
M\/PG$\GDU*G!VZUF+!:/ORK'V?*/+)ADZ2`'9CQ`TN;)QOUJ0LETO#+(*WN,
M"?EK6=C/B<Q:Z7$L=2HS3/%JLNY=*W1PA34IVN32H.&K&;,5LN'C,(>,J?6K
M4:5CCA6EGJK;C2_SQ,.Z+"#DI8'J6QW2$+0K"X*K\\G>.W[;544W?J6*[V6K
M6I>)XB/NX8]R2C&5LU9"GG6*5F#=Q>C&)/M2=0-N_$;D/JN^T?18'%WU-C82
MV<>+#2U*7H_'NCTS*J/2I.MO=$H.C0L5$NM$T2XM3LWQ(]W`/T(08TZ+0@B4
MABGR?#U;-'UG'RUAR\,=VS)-.3F*Q!)5FB@6&$8F29#)&MAK.5DD225>G;RO
MVX+7IE.+KH(M]`Q=K[:*QWVF,COUB,3``(D`+*S*6Q\X1TGR/,KA4$.3:<XR
M9MC:=K=^MU.!"2:.@>P4_6X^-BW#L43F"-75=MS%,DKV.F`=Q#L/4!N.M-Z`
M_-_`^DL\ME<C&+?)7+,/G\/-#-&6Z^0DJ<$'5IYXV]2R<F"?=&''8/M_F]&K
M!+T\>DD3@?=`!AT(USSAN`>FU;'LVI-`I=%S^P)_#^G,7UA6"EX:*+<MP]_Y
M9,1\-:YN&$LI9V$FT@)MG[Z,HNFS0<B0AR)J`7K,\Q%#[S>DX^NDW%F[Q$\=
M7HB68Z#S&:!P<*IEC<(7E_?-Q,C,=QUF9>0J6K=BT\\L/(3>H>2FBMJI>:M3
MN+=,<T>[.6262K((#\ED'0;-/QAQGU>V1&JV2(XXT[C`E<I[CJTA,&@K?FCQ
MB9#*K">7MV@2SW-'2N>MGS]JZ!LS(B<9%RBW'VKY7E!U'IU):W)T+[N6JCU7
M3Y!X2`!5KUHY(Y63'E:6T762:.+*`Q1A,G=C`W)1/QDU!!BP/3URIOZD3V+,
ML,D8#-\YVX5B9%>;S><XZ$Z1I3BCK[_D3`3CCC[0I,T#SO\`NFG7+![<Z4%K
ME\G=1#]@UH+*#%Q])24O`E<%;J,7*1(8$0`S41,)NHOI*I-Q<O'FU$L#<?QU
MVM-(K!FO3669A:PA/0@J)/>`)5V#8/@RG.78+5;EHX97LKR%.%*\;KM6EVFB
M)K`^.U-CF%DRKEV%@]$U>S</3N_PY/O]:U^#1R@ZQ_K#\CC\<GUFU>]-G/)D
M_P"S;ZXU\?'+J$W9:1P@B8K2;O17LISFCRL['5$:<I-5X4^,')UT8T.6S52Q
M1!C*HH&;F]K:N@\E8_8`4\)R\:YMU3BY6958#;T.<'S#QP0?TCKO'^6D$ECU
MO1ABFD@=C)ATV;E^:<]-ZNO7PZJ>A/MZZY)_<[ZAV[?=M<H^P>D`]@XW]N_V
M/H`ZYY[U#_1X?_<^_P!>M?H3D/\`JW(_I5?^6UD>/&I#V[\W.4@]O5W8\;Q[
M?8_\@/1T]ZA_H\/_`+GW^GT)R'_5N1_2J_\`+:36O%^],I*5F&?,?DHTEYTK
M$LW*-H7C.A(3!8M`S6,+*/$^/A7#XL<V.*:`*F-Y1!$I>P#U5[Y&(A`((NR&
M9@N9,!F^4P&_&6P-Q\3CKJGZ!N]SO?2O(=W;MW8JYVYSMS[MG&>N/#/72D''
MC40$!#FWRD`0]`"#'C>`@']P?H`ZI]ZA_H\/_N??ZJ^@^0_ZMR/Z57_EM`\=
M]0'OWYM\I![^ONPXW^G[/_D!Z>GO,/\`1X?]?[_3Z$Y#_JW(_I5?^6T#QXU$
M>PCS;Y2"(>KNQXWCV^Q_Y`>CI[U#_1X?_<^_T^A.0_ZMR/Z57_EM'W.^H!ZN
M;?*0/J__``'&_P!?U_W@.GO4/]'A_P#<^_T^@^0_ZMR/Z57_`);0/'C41](\
MV^4@C_=8\;Q__H#I[S#_`$>'_7^_T^A.0_ZMR/Z57_EM`\>-1-^BYM\I#?98
M\;Q_-P#I[S#_`$>'_7^_T^A.0_ZMR/Z57_EM8^YVT_\`VVN4?_R'&[^(#I[U
M#_1X?_<^_P!/H/D/^K<C^E5_Y;1]SMI_^VURC_\`D.-W\0'3WJ'^CP_^Y]_I
M]!\A_P!6Y']*K_RVC[G;3_\`;:Y1_P#R'&[^(#I[U#_1X?\`W/O]/H/D/^K<
MC^E5_P"6T!QVT_N'_K:Y1^L/_P!AQN_X?^GO4/\`1X?_`'/O]/H/D/\`JW(_
MI5?^6U-E%I$^;X'FS5<-7T`DN3XG$;"&T`J%%^>"K\WQ9LD9A:U$S4P:K\X"
M+_Y2`%C08>?ZVWE_:^M][B_F]W-B[?=L[>N/#P\<X_1S\>O+@K2__;9J]^7O
M?2^WN^3N9W_+^1LW>WY&W/VN-=,]M=UNC?$3V^=FI=I7ZU"<`.-<[/SUCFSH
MQ4-%QV]\OG$A*2<M-/#(1L8Q9H&46444(BF0HF,(!W'KJ7I"U7JI:L6Y$B@'
M;!9B%49+`9)P.I(`^$D#7"?4E>:S)6K5D>2Q(S!54%F9CM`"@9))]@&GDCI6
M<N&D2_;WZF+L9ZI.K]!/$;-#*-9FBL08"^ND4X(\%)_5682K7S9!(3-4_:4O
M$</,+WZ'99:7?-PB(5@#-O\`+V@V0IDSC8&*L!NQG!QX'6F0(]J-):P,D4DO
M;4J"P:3:S=M2,@OM1VVCS85CC"G&I'4,T<S+^N-]#I"]ABZ:ST:3@4;3"J3$
M=GLAYHL+T^C2/1>-:>]!`_E21R%:*>`WA4'L/21EB-@2D*:DHBGST[,IZB.7
M\&Y'@K8;XM?(T>5:[Q`LEO/8(ZB;&W/:(_?,;USMSC<OPC3'GN3W&NJV*LU"
MS\@\4KMLNC"&E:=69S3J;%S]JB[&!#5Z2KL2]F$7TPPG2J%%FLW(HFY`P>6)
MN_5N.:&;D6XB%U;ED;:T((,JL06`,8\P)4$@$9P,ZKFAFKTSR%A&2@&=3(P(
M3=&VR0;SY<H_D<9\K>4X.G<]U[)XW1H_'I#3L_8ZU+1XRT7F#NWP+?0)&+`A
ME!DF-05?%GG3'RR";S2("3P@(]^P=?*]BO;LS4JKI)<KH'E12&>)2`0TBCJB
MD,I!8`88'VC7R:*6O#'9L*T=:9BL;L"%=AD%48]&(((P,GH?@U(G5[5O36D[
MS2H2T5BD3-PK$1=+NG++4RHR<[&,;-;D8!!-S.JUF#<N4Y*<3A6RQ%'0MDU`
M;D.`G\("'5"21R3/71@T\47==0<LD6[;W&'BJ;CMW'R[NF<ZK9'2O[VX(J]Q
M8]Y'E[C!F5-WAO8*Q5<Y(5B!T.E.#GX*SL!E*U,Q5AC"O9*--(PC]K*,2R,-
M(.8F78"Z9*K(`\BI5DLV<I>+QHN$CIG`#%$`K'5%D'[VZ!E/L96&593[58$$
M$=".HTD1XI6KR@K.F-RD89=RJZY!ZC*,K#/BK`CH1K9,S,/78I_.V"5CH.$B
M6QGDI+RSUO'QD:T()2F=/WKI1)NT;E,8`$ZABE[CZ^K4T\->,S6'5(@0"S$`
M99@JC)Z99B%`]I(`ZG2..25MD2EGP3@#)PH+,?J``D_``2=>Y!5)R@BZ;*$<
M-G"*3ANX1,"J"[==,JJ*Z2I!$BB2R1P,4P"(&*("'HZD21O$[12J5D4D$$8(
M(.""/80>A'L.K2.DB"2,AHV`((Z@@C((/M!'4'6WL/;OV'M]?MZ/[_5&JM>5
M^\9Q;)W)2;IO'1S!LL\?/WRR;5FS9MDS*N'3IRN8B+=N@D43'.80*4H=Q'MU
M:GG@JPM9LNL==%+,S$*JJ/$L3@`#VD]!JY%%+/(L,*L\K$!54$DD^``'4D^P
M#6&+YC*,6<G&/&LC&R+5N^CY!BNDZ9/F3M(J[5XS=(&.BY:N4#E.FH01*<H@
M("(#U)EBE@E:"=629&*LK`AE(.""#U!!Z$'J-6(Y(YHUFA8/$Z@JP.00>H((
MZ$$=01XZ]75O5>CIIJL.[MTW6X?#F06\SRS\]:OXO*660/\`(XU\GE"^%5`Z
M:I/E%#OV,'</0/H$0ZU7UC^2!^.7ZS:V'TS^43^*;ZXT^/C+(IMJYP!;I>/R
MT><C!)/S%5%E/`3BERE*7QK+'455-V#TF,83#]4>N+>H/R3-_P"7]L->@?\`
M*G^_W'_5E_B9-4(ZYGKV?HZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFLA
MZP^R'YO336VA_D;MJ_I6HO\`K=,CZZ)_AK^J_N=>1A_WG/\`;7\H-3W\3&,=
M3>Z\](9C&NIEY+?"3S*-;1#%FO(/)19[J?--N2/:L&J:SEZN[%3RRI)D,<XF
M[``B/72/3T$=J,UYD[D#<AQP=<9!3WR/?G]:%R6/@!DGH-<>KS+7]5\-.S!%
M2XK;B0`N&4Y)/0`?'KG6SS:^Y;MEDP1O0;<OEU!X!<C9/%K<A$2,C`C6M2L^
M12:.2$?)HK^SV6D6&(D4&D<804&',T!(I@3/X=CYM;DGHOU9Q=E7>Y1KTZ<+
M8RUJI&UIJ<D84>8P0,*3CS2,U83RL6L#6E>G)*U>IP$ZL%'(\Y'<D3..Q.E"
MY'<W@_(266:.PA.%+3R1+M$0!\FK9??(*1V'D=1,^M<YH>2<&N,58/7XV)D4
M)/1LXL>3Z]`ZGG46BJBFE-3\(+YO(-V(>-5O)((^(I3B4!S?K</2YCG^8IH9
M:UWU1=JVP@#%Z<KU&AM#H2RT[*K8';PTRH\._8S#5CTBJ6O3_HWC)F6.U3JR
MVH2QV=NQ"]#,,A.-@LP"6'YSHI.X#<N01UUR*C0%]S/:J#:;%8]CX$\4:=FU
M#^AO0+&_NMK;Y#(PR=:8S\?3W]>J,W%6AVT!89*0CC1ZI`4.)13Z@^J8VY"[
MZGX#C8VE]1S<Q&U;8,8D$.(K"S-LC*02XF.).JQLN,G!OT;D2'AO4EANWZ?C
MEY=Y]XR1%+RAE,3P#<Y:>`L@780^_&X*21(55%QC?(/+*I#/9VU\@;@KA,;O
M&':/D%BL<&+JLYN$$7;<JY!,((8FO3=5KQ1:NTWLX=BZ$#@$>#E3S.LI0MI8
M]3R4:1-CA)>3MO9=H^S)2E$1,]Z)CM[U6];`81MWW"6$$`@5'76#NP20^GA<
MMKV^0-*.&N%8/%;B]Z':J2Q`L89:<`(RHB3?">X\PV,;5<EJWS]D]PK+[CI9
M)&.Q=%"NELC)MH/'FMHKKI28FL!CPND\<],NSD58[T"+6<:E4]2((G^7U&H)
MRP]0&6Z2>"]XA(7=&1V@J=X;%C67JV_H9BY^T=`5"S+C<>W#[*H__;]F49PX
M/<);MG<SM'X;>O;VC[96P<LOF1C5BU#E-QZLM2B7QKWD&`[UH^8V5-L[)'Q6
MGUW0,'DX:O/IE%,K1JE>8QF^C'#8ZA3.V"[@"E$H&[1KB6:<_*^HN,B,O*T8
M*;Q1C`:S"WO\=RFI<%1[S6D>'?AC"SI*N)%0ZR$7NUSTB.!O.$JW><K([>+1
M%:=UH;(`P<5[(BD/@K$"-O*^#S(L.BZP/%K$YE@CLO&B>L\CR\T:-4D%.5K-
MRO>Y+D!<YBO8U)9MQMGZO[==9%-_[:SEK.=:`%HW.F!3D<`(V.7EEJS\<G%3
M2231\)QG8C"RDV043<P1F]VA,(VI/'84R,TJC&V-R)]B:M/?Y.Q?2/8>4@AL
M/\V5@['%5X7=90#/+$\\;+&8,*0H<X;`U;1%O8HN];SH4Q8][9[WJ?`S#KK6
MX0LOJZU-D;6VHZA-(6B:BS;N<W@K)7YQ8OE1Y@;O6JRR@MD1\1QZE\S&G'MZ
MKI<*TA8<_1D499\59+,2!H&;IL.&1A%DI%N#A(SUP5,O/%Z=;DPB]KC>6A;Y
M*GO1AS&LV"26*`N&D)$DBHP=Y`NE#;[U>&^FRD+)Z%R9KN_!7>.1N(=#SH^G
MH99=V<G'UQ329&_1\`Q-E=DD0E1E23);DLDHQ;I_Y*41*B`S+#6F]4V8^'Q)
MZ@3U-.K0S%A27BUF&QL'YG8U$S2!X\S>]+$O0:MT1"/3]23E5C7@SP9D,BDB
MT][LL-LI3YY&6V(5BC&(W@+/)U9M/&HL]QAM4A=>?W7D!8YNR?$`W3&)//9"
MU7(V4QN"QL+J3JO(Q%`4\%48QWOBKQHQMC5;^80%RIIN/+4*08O'0-5J02QF
MU;>YZ;NRR+)(0[3(\'NJID[:UA8\QAD"R2$O)+OD+-K(<E#!8CM12&*!J'&\
M-/&R!1NGG6HEU9-O6==UB:1XSN[9C4`*J8%9N-5YV2S7?>:TXMNDV2G6GBYM
M<M;<OM`\J[J\R/3XN4AF5?SN5O/(.<G*W8+@SC)I\B<]);LXJ0\`G`JI2(@G
M@.15K?\`EIZD@CD-Z,<?7]WF5)5[KR16N^L23[K9P%@+JYVC<A4;BVLDSQQ>
MO.-E15KF/EY5D7,:@0%AV)6$.VNBR&-R@4,T>&4LJE=_<7!&SAEA>+LWC9=F
M[:91GK9TT=(*-G35PA5(I)9LY;+$(LW704*)3D.4#%,`@(`(==9]6.DOJGDI
M(V#1M?G(((((,C8((Z$'V$>.N9^FD>/TY0C<%76E""",$$1KD$'J"/:-2SU@
M-9K1TTU6?;_W]OAQ_?ZUG\&CE!UJOK'\D#\<OUFUL/IG\HG\4WUQI[_&=_S'
MP'^_H9_@I\I>N+<_^2)OJ+^V&O0/^57]_N/_`-*7^)DU0/KF>O9^CIIHZ::.
MFFCIIHZ::.FFCIIHZ::.FFCIIHZ::R'K#[(?F]--;:'^1NVK^E:B_P"MTR/K
MHG^&OZK^YUY&'_><_P!M?R@UT4U\3!\3/5!()@.'`[B\)1+W`P&^Z&Y>=O"(
M>GOWZZ[Z'SNLX^!/W6O/'JS&V#/AY_W.I'\:I0$GC4*`'\8D\1@`%"]P`PE[
M_HP[^OU];]GPQK3C\>L>8IW*/F'[E,)RCXC=RG$0$3E]/H,(@'<?7T'3PT/7
MQ]NMQ7#LJ9P(NY!(QA\P"JJ@F8Q_2/C[&\(F/]7OZ^GLQ]KI[<^W6L%UP2%`
M%E01$>XH@H<$A'OW[BGW\'?O_<Z'KXZ#IX:U=--?0&,!1*!C`41`PE`1\(F+
MW`!$/4(@`CV^STTUN(Y=`<137<`=0"D,)%5`.H`=BE*(E-W,``'8`Z^C)Z#V
MZ=!U^#6#*.4A,D<ZZ8@?QG3,90@@IZ_&8@B'R_3ZQ#OU\S^IIKY*NN4ATBK*
ME34'NHF50X$.(^L3D`?"81_N]/9CV:>W/MU\^8IZ?EG])`3'Y1O2F';L0?3^
M@#L'8/5Z.FFOL[EPH!2G76.4G;P%.J<P$\/Z'P@)A`OA^IV]77W)SGVZ>S'L
MUJ$1$1$1$1$1$1$>XB(^L1'ZHCU\U]UCIKYHZ::K/M_[^WPX_O\`6L_@T<H.
MM5]8_D@?CE^LVMA],_E$_BF^N-/?XSO^8^`_W]#/\%/E+UQ;G_R1-]1?VPUZ
M!_RJ_O\`<?\`Z4O\3)J@?7,]>S]'331TTT=--'331TTT=--'331TTT=--'33
M1TTUD/6'V0_-Z::VT/\`(W;5_2M1?];ID?71/\-?U7]SKR,/^\Y_MK^4&KD<
MR'3ECS0Y6O63E=F\9_#%Q1TT>-5E&SIJY0V/F8J@Y;.$3$50714*!B'*(&*8
M`$!`>MT[LL'H[GIX&9)DXZ0JRDJRD1R$$$8((\01U&N*2QQR^HN)BE4-&UQ0
M00"""Z9!!Z$'X#J@$_R2Y/5&G*2.?VS,V-"X]<-N/F_:`UO5'F[U>]3<W`MR
M;3]6C[(6Y5]O4U7L;3/,)+K(R:J3E3Y3=4#")>W\T]K\]+KR=E>#C]4Q\?V4
M3#O'.:Q9Q)G;$81*P11&XEW]3%VAW.=>E>+7DO3?`TXF?Z;Y6K9VS.VY(WK)
M6V;TQND$C6,NV]2H3H&W=)%T3>N4D)MFKTF>N%5Q.ES%0T,O&0KO"QTUGH\K
M7\L<6I"R+Z_7]80:U&<@9E%8RE<LE?AU9$K<I6*SHICG)IEFYRL?%\I#/,D'
MJ)(K,E:'M@;(JS9:2.3>\=OYE#*Z?,SPAV9X#%!W),CQ:\=='$<E'$S\-8FH
MK.W<RVZVZ*(9(MJO$79]BR1]Z``*3,))>VC'K>F<C%<LPZ5LFKT^R;?<.&&Y
MZ4AK;*@R\/&14U"U1A883VG,F6BN*G-R+)0#E<.5_EG6$ITB-R`9$\WU%+:J
MKRQXQUAO5?2U"QW,%PTDEU!(1&S;4!1L`C+AP27:,]H4<-'!-RG&P7U[U"?U
M5=J]O.PK%&C(BEP-S89<D'IVR%`$@[Q<U5Y3;EG>2R;S7-"S.ZV"N_#W><G4
M;^:EEH,9-:064M+2.BG\5\\)=FLQ;-8MD1VB@X34<.%1.4$04*F7*\K<2HMU
M5V+8J6^*A'P.MP0++*%))`>21DCZL%<8RQZ:>G>-CY.7B5G+F._SEZO(!C,=
M:OVV&#CY2*SLTA&-@&5\I8QI9.5'+C-VG+735KE2]1AZ\AQCA,=Q^/S2%K3Z
MI6C?X+.$T9@]NGM,B8NP1,&^N2BBC*26C&\DZ*4II!@D<13Q+S<K6]YXM3[Q
MRDOJ:2C`X1!V8HX&L%6C>6-)"ZJL:YEC8/N=>X76(7:$''<B_&W7S%QI].6;
MLZJ68S20V+,:LKJCLB_,%G98W"0'.TF(O)<7BWJ?*R0R/4[)RPRU2MVZBO9A
M_43LV&;UY[H%78UA":!4]1S#9-Z@ZV\:RY7#(`-/KJN$R%7\I/Q>`)?(<C)Q
MWI67F)XL<K76?='G.]4PT<O0%8PP8QM&'D(,3.2`X40*]5+?-QT8)`:,PB(<
MC`1W9E>,$G=)M"K()&2,$R]L+\V6:DEWY(<L;%B5H06V/$EY#>>(%PY"9Y+9
MSG$LWE,%C6KFNI'K$ZY)I"ZVA`[C;6#!.P%&NJMI)N!B-#"IX4]=]?)R?'<#
MSO!/8[EVA4JSF[`ACAEC>W#7EK)B0F*:RDAL5)A(Q-:*9^WTZ9_T_P"XR\IQ
M_+1UIH:ECD)ZBU;&#-')'5L3K+/E<!X6@[5BKL(663;WCL\_4KC-07.8<?L@
MHCV;/97T#180K^?46M"YI=[(M_>[EZ*ETMM\M'VQ5^(=G<N^.`A\DY2>%,G4
MO4T<<'J"Y4A4+%7G>$`#`Q">UD#Q`)0D!BS`$!GD8%VY]P<DECB8+L[%I[,2
MS,3\,BA@/@R%VJVT*K,"X1-VT3EU@]9;1TTT=--'331TTT=--5GV_P#?V^''
M]_K6?P:.4'6J^L?R0/QR_6;6P^F?RB?Q3?7&GO\`&=_S'P'^_H9_@I\I>N+<
M_P#DB;ZB_MAKT#_E5_?[C_\`2E_B9-4#ZYGKV?HZ::.FFCIIHZ::.FFCIIHZ
M::.FFCIIHZ::.FFLAZP^R'YO336VA_D;MJ_I6HO^MTR/KHG^&OZK^YUY&'_>
M<_VU_*#70C<&#*4^)'L49)M&TA&R/`/C,QD&#Q$CAH]9.N0'+Y!TT=-U0,FN
MW<(G$AR&`2F*(@/75_1]>"W#<JVD62M(BJZ,`593N!5@>A!'0@^(UY]]32RU
MWK3P,R3(S,K*<%2-I!!'4$>PZ4E<LS)=C,1B^?4U:-L-4B:)/,%:[&'9S5)@
M`?!!U&4;F;BD]KD.$HY]F9J`9!'VA3PE#QCWZ-(S2RM-*2TSV189CU)G7;B8
MGVRC8N'^4-J]>@UIM>66F(%JL8UJAA#M..T'V[Q'CY`;8F[;C.U<^`TT87C9
MQZK>B3.NU_$,LA=5L23]&>T:-I4&UN<RC*M08R:<C8$V@2#HD@R*"2P&./F)
M_)'N'HZAUZ5.I!/6JQ1QU[(82JJ@+('<NX<#Y0=R6;/RF))\=?9)I96@>5F9
MJVWLDG]ZV*$3M_<[$`5<>"@`:7*CB6.4!HP847*Z!3V,62QI1K.N56(B6T>E
M<5/.MB3-%HV3(W2LJH>)\4H`5R(?+`>K@K5UK>YA$%3W-:FS`V^ZHQ9*^/#L
MJQ++'\D$D@9U\,LIL>]EF]Y]Y:QOSYN^RA6FSX]UE4*7^40`"=,20X@\4I:#
MJ=8E.-V)2-<H;J:?4B!>YQ67,34GED5!>P.*\P6CSMXM2:7#QNO**4%C>DW<
M>OBU:R3PV4C06:U=8(FP-T<"9V1(?%8TW':HZ+DXU5[Q8VNF]]DMCWAQDX:?
M*GO'X9,JI+^)*CKTT]97"L4G):=GIK),ZEINT4DN:V26D:E#.W\_GA"@5.D2
M[E9J91_5TRE`"LU!,B4`#L4.P=42T:4R68I8HVCN2123@J")I(1B%Y/NVB'1
M&/51X'2&Q8KR5Y8'9):BNL!4X,*RG=(L9'R!(WF<#`8]3K?EF*X]AL`]JF,9
M?1,JK$E)JS,C7J#6HRL0[Z77:MV2\F[CXM!!NN]69M$DC*&*)C)IE*/H`.I7
MC62F?_B1JRJGVJJQ+,`/`!BQ)'M))]NK3,7G-IB39(4%_ML*25&?'RDDCX,G
M2%4>-G'C/R7I*BX;E-/3U`ZQ](3KE&K\22]F<+N'2_SK(S9)%FBKN7:JABK^
M(ICJ&$0[CU$7CZ*<8>$6&,<.2I,&T=HE0`N4^2=H`"].@`QJ_);M2WAR<DCM
MR(W8E))D&\Y?#>/F/5NO7VZF9!!!J@@U;(IMVS5!%LV;HD*FBW;MTRHH((IE
M`"II(I$`I2@'8"@`!U/FEEL2O/.S//(Q9F8Y+,QRS$GJ22223XDZB11QPQK#
M"H6%%"JH&`%`P`![``,`>P:V]6]5Z.FFCIIHZ::.FFCIIJL^W_O[?#C^_P!:
MS^#1R@ZU7UC^2!^.7ZS:V'TS^43^*;ZXT]_C._YCX#_?T,_P4^4O7%N?_)$W
MU%_;#7H'_*K^_P!Q_P#I2_Q,FJ!]<SU[/T=--'331TTT=--'331TTT=--'33
M1TTT=--'3360]8?9#\WIIK;0_P`C=M7]*U%_UNF1]=$_PU_5?W.O(P_[SG^V
MOY0:L]\0&\6G,^3_`#2T6C/&4==*-\*W(;74I"18(2L>QLD%KO,Z1A7;Z,<@
M+>0:-Y%NF=1%3Y"I`$H^@>NC\`]Y*TT?&NL=V:U3A5F4,!WK"Q$D'H>CGZGC
MKBST:G)>H>*X^^&:C-:"2!258H64,`1U!QX$:J!3N?-TIJD&'()Y%LG..\9-
MZNW)R'KL`U,^D-$R6PY"E7+364FJ9W,9!7JG7DTHU8HE,B!)$A1[F;]@Z)-S
M-)>.N<QVRB(*420EB.U>EGLU+-=G(+=L681V99!EJS16,;91G1.'XBSR=&M$
M&47;',Q1I*<!'H3TKEN*4KT`8"%!(1U66*:+V'3PPOXHM'VJ*<N2Y=*0<PVU
M_%<I/'PMX87:$,7;I]6N0ED3N"57KD8JI`/FYS2$6FF=V1,2"!OEAU+XF8<L
MT,<0*R23S1-GJJ&*NUE2K=.ZLBQR+E0!&RC=\H:CRU.V;)#9B@XN>\N1AWCK
ME0Z,G4PN=Z;-Y.[+8^0=3+*<TE1TA#*Z=BMFN-I5VW5,>6.>Y5JL0S!GCU9J
MMMM]^D)26;*I-H<D-:2F;LQ`72RC<Q`'N8O4*#DXI*\=Z56CXWZ.:[/(>H@K
MI8DKN2HZR.&CW*BX+`^(VG4F]Q4M(A`PEL20U3$B@[I9;@D,,(^#K&P>0^5,
M@D==(%<YN35O62.KAUISVAZ94=5F^.6O35KJ]@:Z2OF\4[>JKSN>QR"=ASDC
M]-,KADG***^V)E,4.P@/6,YCE;U#A>2%A!1]3P<'8Y"O"Y$N^."(2.V5&P/`
MLM>22)L^68#.0VK_`!]"C9Y*F8)DN<(_*UJ4TL9*CN3NRA8L]949HIH^\F`K
M1YQU&D1'FO?XG/J#(1&&SN[6&,P6M;GR"G*W;ZCG3#/*G-$DC%DHJ(GVRYKM
M8'[>OR+E*$C!37!)NF'B[KD[9WU#R5+AN1ORR(T7ICC9HH[-DMN$!>"*Q*>W
M^^2)!7E2>5E.%1@HZZP_`4Y^7H4D[L9]07]Q@@QM[B]UH4=Y/D0QR3*849L[
MG24XPASMA_B"-KCR*B<+HF.O;#69F5D(`VKAJ]!C9*%?,,F::T[E)#&'B*M]
M3KR,/)MFR$@H)&CMZH"9#?4&S#/:FM7JDT78BJ5N0F[H=)<K0M>X/NC7K%))
M<PD4<G5X?YQ@Q9U4YK+5I6H7:62W9J0]LHT8#6X#<3;(?+(BU`7D=.BRYK_O
MHTLT#EO>+6TQJIT#([/N=UNE:FKK?9E_;<^RAG0J/%WYS1R6.7\YFM!S$L\>
M)B9K$1I2.%VZ!U/$!@-W^<=9FNK5VIFF.)XNQ9L%E';DY&DMF$&(=6:54FDD
M[9$414JOE*Z^W(TJP6)2X-WZ2OP5ZX!W2)2L/%(^\]$B1NU$KR99C(F[S%CI
MGT/XC=?OW('1^,ZU%C*M=ZU`:H_JM@@M3KFI1\R[S6,>23HTS&0%?CV]7\QB
MB1<$U7KL2K>)J?LH4W;#+SDO(>D^7YJD!%>X[C)+(!Q(F1OC7SX56VRJ.F"K
MKU!QK-3\/'QW.\?Q]IC+4M7X*[]#$ZF4(^-A)895B,Y!'1L8(U<3CA=[#I6#
MY7?K8X;.K+:ZFWEIIRS9HQ[59\H[>(G.@R;@"#9,2(E^27T!UN=V&.&2-8^@
M:K6D/M\TM:&5_P!`N[$#V#H/#6ITIGG@9Y/E">=?T(YY(U_250"?:>OMU-?4
M34O1TTT=--'331TTU6?;_P!_;X<?W^M9_!HY0=:KZQ_)`_'+]9M;#Z9_*)_%
M-]<:>_QG?\Q\!_OZ&?X*?*7KBW/_`)(F^HO[8:]`_P"57]_N/_TI?XF35`^N
M9Z]GZ.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIK(>L/LA^;TTUMH?Y&[:
MOZ5J+_K=,CZZ)_AK^J_N=>1A_P!YS_;7\H-7=Y54"`U;G?R.S&U#(!6=!^'%
MQ\IM@&*=%8R80]BW3F)%R(Q[TZ+@K1X#5R;RU!3.!#]A\(^KKJ_HZ!)VEWY^
M:FK2C'W<,O=3/PC<@R/:,C(\=<&YJ_8XJ]2Y*KM]Y@D+KN&1N4J1D=,C]'3`
MMG!_CY=M4LVQ6"`G%[A<^/[WC5;$VU@<LX2?SAY)1DHFY?1C=(@EN,<XB$2M
MY1)1-8B)?`8#@4G@W9N/K_\`[)H2T,O*6ZUJ5D.UDM501#8B.#LE`V!B=P80
MQ`KY>NF5+UBG5XRG&08.)D9H`P!W!D>/MS>R6,+)+M0@;3+(0?.1K>KQ,;2^
M<3>;7GD3R?T]N^G:E:*K<;_?*7)7O++)1W7M];G<VF8G-H2/BY%B^(183/V4
MD4ZB11$O;Q`;[/26=(6$DD=Z"R9UG3:LQ9AAD8A.V8G&0R=L`AF&<8Q37LK5
M,D=>*):$M.2JT&&,1BD`4C!8ON51M5M^0/')ZZ^LEX;97C\Y7K1#SFDVNTP-
MRU'0'%DT"UMK'+6>V[%"0\!>)6TG2A(UJ_%Y'P3<$$44FR#<P#X2"4?"%Z&K
M5@JM1BC44&H>Y]LY*]@S-89>I+$O*[EF+'(8J,#&*+5FS=D[]F1FL[H&WYPV
M:ZNL1&W`7:KXPH4>53\K)9'H/![*<^G5)1I;M?LT+&0=\K><4"Y75C,T3%X?
M2_&%R:Y9%-Z['248:32."9%)-Y+*-4B`5$4P$WBA/Q,$_%6>+NO+8:U0-)YY
M"K6%JE2AB20*`H*E0QVEG$<8=F"*-37Y:PW(1WXDAA$=]+O:C0)"]F/JDC(#
M]H2Q54*H"[G;EM>2W\%<KM;6K1S.][;0XJ$S.+QJTQ>?7J,@FFMY;#O'3MC3
M-3%Y5I5S+L$_>3Q+VB.4BGWD/EB`N`>7Y<ZS7BN\G/R%P=R"U+#+/6;!K32P
M*J1O)&1DDHJ1R#>$E1%2164$&'1M2\92KU*.$FJ=WL3X!GB[V"P5STPK#?&&
M5A'(6=0&9B:^YUPCW#.N:EGW"#N>?1&-VB;GEI>-C%HX]QEZ1)4Q&"B<\5KZ
M^,IS$8TA)EHU7(]"_.D!*S*8K`GC!%/%^G:%VA5NT^8E$T5M^09MGC*UR]-:
MB9CMC9&@2<H2QL[BNU=B..W(Y6Q5G6I]%H8WK+35`V=L(JP1PN$!:02";MG(
M`K[3,SDNR'NV63X7Y_$2683-%T;;<OF,NA)JJ-).@W*#8.+I3;!;27:2J&A)
M3=0GV4_"&GB`=(4$F;M%,3$(N4#&[S8*$5>2(*SM12A4IR5V(,-F*E`*U8V%
MP':1(=Z;DDCR)9.F2-L>:R\]66LP4227K%M)0/G89K3O)-V6\%1G?=L977*1
MG!*YUX:7P;RVC7B+N,;>-FD8RKMM299]F<U<XAQEV9L]E))!?V])KK*J1\BV
M"4<3#E<AWSY^JDLJ(@?P_)ZC1\/7''W./GDFG]]XX4))9&!E%1<=N%&5551&
M%148HS[8T!9L',F;D[$W()R(5$D2[';VJ#L:S'MQ,X)+,S*H5P6V8)VJIP19
MK.J'!9?1:MGE8%^->J$4G#Q`RCHKV1%FDJLL7VQV1%N5PMXUS=S`0OH[>CK-
MS3/.RL^,K%%&,?<Q1I$GZ.Q%R?:<GVZQ,,*0(8X\[2[OU^&1VD;]#<YQ\`P-
M//JUJ[HZ::.FFCIIHZ::K/M_[^WPX_O]:S^#1R@ZU7UC^2!^.7ZS:V'TS^43
M^*;ZXT^?C-``PO`0!]0\ZF(#_NJ<I>N*^H/R/-]0?MAKT#_E5_?[C_JR_P`3
M)K\V>.ZGI$UR+>1+C0=O>).M&Y#1<[7-%)"L,4?T*D$F6]=1PYTE"-I"1NE:
MF$H\'I`<K&39BY.<ABE$2Z)16$^F);,JH\B\0T^3GWH3>]]M90!T%8QYC+E2
M`[1#Y1&?3$]RZ?6Z489;:*>6BA"L%]Q:`T8Y98=Q`)M;F:=$5BQ5&.!&&(EV
M!VNX&98=8TWTLXCY7)=]M\Y7Y653E3V&1S]I,+P@2\P2+8N5E"J1@`!TD4O`
M4_;PF\(=X[@0/8+`,J\!QEA1X;9+,M$._P`;;)G#,>C=6VKG`E4^1LVFX@*[
MJMCGN5K29.XO'66ZL:DX'E5HE=5&"H`3<P&2ORW)VVGA(U:!@\XBYN1XOU?D
M0<UWGK,G!,'D]-HQ:E573KD8^GET5P4\M@HFB*SEV8B?A`![]2>0H&G)>2ON
MF]RY.*J%`\\PEC+KLQD"1FVA0?)L)=B`,ZG)S+25ZKGLPR6HK;[I&(CC6JV&
MD?`+F+:&WE06#`*H).-(LIR(Y$LH-H0<IR2$O5-P]KNNWUZV76W,8N'A'KJ7
M(WK&>OFD(HZ?3OLD"X.JYEB-6#=51(BAP$%.WV_%Q=![MTRS2\'1M1UV:-`T
M[R&))I2B9VE560+&,[YI`44:@<;R_J/DHZ/'BK5K^H[E5[165Y17CK]UX8B7
M5-YE=D+R)M^:B*N^`ZZ2;7RCL],3VF_1T#/W)FTJW'$^;YM[,=PJVL^P/7,(
MBBJWBT@E7*:LF_;'=)H&475(CX4"^88H#=;C)(F/$KMDOMZAMU1)@D"&#CZ=
MHC`ZX&9F7ID/)YCM'2'#ZI[TTW-8D'%+Z7I75@Z;N]-<Y"(X_7/VX$8YP$0-
MTP29^XYZ;K.FU6:?;'CTWC]GB)Y2.;,I*$LE?CK)%':-W+>:A(ZX)H61)!-5
M4[=;VE,@"JD(D[D$!ZM7:M.&&*6I,'9]P=,J60J1@^7(V.I&W/FR'!&`,Y?T
M_P`IS'(F9.7IO5>,H4;9(B2*X.0!+ABZ%?.0-F'3!)W8L)UC=;'HZ::.FFCI
MIHZ::.FFLAZP^R'YO336VA_D;MJ_I6HO^MTR/KHG^&OZK^YUY&'_`'G/]M?R
M@U='EW>_HMYO<G=+]U#.CG_PU<&N00@/0C1F!KFV\QY4L9[P,W=@Q]N,U\OS
MA25\OQ>+P&[=AZ3P/(OQ7&W^0CC$LD:1X0ML#$L0`6PVT9/4[3CX-<+Y/CQR
MW*<?Q9?MBQ/V]V-VW<5&[;D9QXXR,_#J%*=RYTEM(/JWO>(U?(++*XS,[?F4
MA`:X^TK.+C6JT5B-GAIVX$S*J3-1L\`$NS66;%AI`BC-8RJ*BADCI]=!Y*_]
M%U^4CM]M.8XJ+NR1LY$;P%Q%WXI0K.T<<Q6*?YD&)I8,!Q*=FB<=!])^XVJN
M]N)ORB%'`7N+,8WF6)XBP`+PH\D3"1E;M2AS&53N3*CRHQPMOH.<NIV8>:!H
M$'3IJ/B*?0-0O5?CB7AF#N`"P7FN49U5JBVDR$4.V4G7$4HHW(*IDTR]^V4G
M[,?-W.#C+&S2EE20NNQ%,62ZM*28.ZB@-)$LKNFY,_+0M"A9GXB'F9-@K30)
M*`KAFV./*ZQ])C&QR$<QJ'VMMZJP5*C.:/&27M5HIS+46_O>H,;9(RKQ[5KO
M&5-ZTHB"CFZFJ5\DZTTH]]7JC=(YY!&#D9!9J5,_F%+X#=L7#RU">C+R*28I
MPQ)(S,K)\T\HA655=59XC(0O<0,@R&+!3G64L<5R-6RM.:)O>F<)M7SE79-Z
M1OLW".1UP4C?:[DA44L0-1IJ7Q&.,.:Y8KIH6Z9GR25#NM\I,$AG>K-'5HBZ
M>S<')(OUOF"Z5I5/G95,C)G899%K#N5%!%!=8"&`%KD8ZTR5`K&VYKY5@R!!
M9F$*=UG`6&0G<R0RE)9`!M7SJ3>X[B9;UN*%F"59+HK&1<2`.`C2%`A)E6%'
M#RM'N6-<EV7:V),=<P<)A9NEU&U6E_"7"X1%)?JQ[*FWZSUJJR%^8,'M<@[I
MHU=JDA0*7)RGO)$&J4S(QRKDBR*A">!9(39!Y*_TM)Q$3EK$<SQ`E61'=`2R
M)(X$;.-I';5V??\`-X[F%UB84L2<5%S#IBI-&TBX(=C&CE&E"+E^T"K%I=O;
M4*[%MJ.0FR?./C!%M9]X?0IB42K=Q>Y]()U?+M;N+UW<XI:9;S<!6XZJ469?
MW!W75:\]"3-$IO4HT$!%T9(!*(XU.7H2UZ]J)I'@M#,16*1MR=N.3NX"$K!B
M6-#.X6$3.*Y?O_-ZG/QUN*=JTH5)T`R&=%P26"IYF'SC!6D6+]\:$=]4,.)-
M3!:-EH=.S1IKLXK;0I#UE"2#96'S;2+-:C-K%Y'NKQYW6JG+:&@X/[23ST5(
MLJS/T^T%2\)NT[D)X^+E$%O=W#)L&Q6E&X#/C$'&,?;9V^S.=1Z,$G(EA5VY
M57)WLL?2/.['<*Y/0[0,E_M`V1J(YCF_QA@*14]!EM&?MH&\3\_5*LP+G.HN
MKS)VJK,0E+#6!S%I2U])86.)C#%<JL7,2BZ!N<J@$$ABF&+<Y2A16-YY`5EK
M>\)L#29@WM&TWS8;$<;JPF8X$."9=@&=7JW'W+33K$G6LZ))N(0*\F.VN7*A
MC*2!'MSW#T3<0=-K:>??&W%\R;:,_NIK$%BRVT:M0H2`K5ZF%K+7ZZP?*HNY
MQU7ZE.CG,+(S3(8T9*>28M4'OC2./F)'3#[R-Y..NGC7&Z^#6R,_-JMJ1$B+
M3=85+A]Z(SAI.@498:O\1QDG*M7ERT="Q=]V[A4EE=2O=^:Z2MV482287")Y
MV(7KKV;]RN=8WE^+7B*IE7EIK<+#3JU`H:'IC;*\TK$C;JN[LS;Y[:HXK=F;
M0:*PM/8&(A'*C(2"R2)`(*@=7.5EL4>?@]/55B>W-),JF63LAS%M':A\KF6W
M*SJ8:P`:2-)W#?,D-`XXU[G"S<[.SK3AVY[:=T@,[+W7PRA*R!"TLY)6,M&"
M#O!'G<<Y\<JEZD\KUQM<\KT2I8W%[1HB,M2;E,4"F0#MM(N9)FXT^'KJ]3>K
MQ"<4J850532<`)2)"9P"B*=I>6XN::\D#R+%1F@B<RQF)B]EE2)0/,"Y=T0J
MK-U)*EE21DOMQ_(114FD17DO/86(0MW0WNP!=Q@!^VZY:,LBMM`WJADB#KDU
MSDXP5T:B$YH4O&_/6,3G8LSG+]:`L17UYEQ7V=COIRT8Q<OK<C*,UBM9"RC$
MLG:2*BR*IT2&4"_%:@EOQ\:"1;D:!0&5E57LC=#%([`)%,P(S#(R2H3AT4]-
M?/<[+56N1KW*XDE0%"',AAQW3"J%FG1-RYDA#H=RX8[AGV47EKFEKTC2\KF'
MS*K6ZA7^]U6/8J/7,N2>J>>4VHW&PZ7)O&486,I5501MA6X+R3A-L=='P)KJ
M**`F'RM:BGXP<B^4*P/+,I!^95;,E90S8`,DC1DI$/G6&=J$*6U?O\=-3>F8
M_G:]Z&JT+KU[DMKO;8D4$E]JP[C(/)AAN*^UW9+R9Q;<9B9@,UM$M*2\''HS
M#AE/4+0Z&:2@G+D[1M8ZNK?JK64+G67+@GA3DH@[UB<!*(*B4Q1&]5D6Y7:S
M#NV1LJNK`I(A897?$X65`?`,R!=V5SN!&H=J&2E8]UL`"0LZ@@AT+(<.@D0M
M&73[9`Q=1U(`ZZ0-O_?V^'']_K6?P:.4'6L>L?R0/QR_6;6<],_E$_BF^N-?
M?QQ9J\15+X//:G0FEQFV?.>/&%@G%VCJFE-F'B_R>24*K-OXF1;0_ELSJ+]U
M$E?$*0)^LX&#C/.+&W%2K(VU"%R<9^V'LR,Z[S_EG)9B]<47JQ":<&3"%PF[
MYI\^8@@8'7P.<8UQC0#9&QXU5OP7HB*L/99ZXQ2I.35+!6/M-H1?M['.M5/F
M()TG\VWE')'`@/A4*L8!+Z>N?*M54$:V&$8KM!CMG'9<[FC\>J%O-@_;8(Z@
M$>KW?EY',C\3"9#82QDVH\]^-56.4?-]'55501CRC:<@D'[CE-GB?F^$;P:H
MK,*I'S436RI<FJ4)(:,L9E33S%F12B'*#:7,N?SRF`P'\0_4Z^/'4<.KSL1)
M6CKM\V?-!%L[<1Z_(3MIM'B-HZZ^1'EH&A:'B85:O8EGBQ:3R33%S+*OS?RI
M#(^X^!WGIJ*$L/=HQ=GA$_AP9F$7<V[1G:&IN5$,H:69,);W\P8'=*5D[UG'
ML)G_`"E!NV41116`#$*7L'4@SJ8X8O>GV5Y%>/"$%71#&KY!RS*A*`L6(4E?
M#6.'%2`SM]!U\V0XES;4[A(0SCJAVJ[`,RIM!8;L9ZZ4Y?*K'8&-1C9SX>E!
MEV5#;*L:HE(\L(IT>-CUW:;]:,<N5:V9W.Q:SQ(%#-9%1VW,81[D^4;O7%;,
M-OWZ*VRV]L8W"+V19[9Q\G<F3M;&X?#T&OLG%S2TH^.DX6)J43R,BF[\EI@H
MEPVW=B0*H9=VT@`8T_)Q#7[*UM;*>X*4*4:WF+BH6W(N>3-+`L[%P15"0C1T
M*-%2.B$,"QA:G0%)5N<0,0Q3`40BE*Q79[P^T638^0P(G*QH900V=Y6*-2<]
M50`],YGCZ4$C2CAX-[U5K-_.8\&NID982.WCM@S2D#'C(VOK/";3E$(M7,\X
M35RLPCA^K)K,$^6T++%._72105<>TV"J2STHG2;D#P@J"8>'N!0$1$;UB9+0
M06++,(UPOS6,`DMCIC/4D]<G]#5JA#R/%AEH<1'&'(+?ST-G'0?*5L8^+&GY
M])G*7_9'@/\`>CI'[@.H_9I_AS_!G[.LA[_ZB_Z;'_Q<?^[T?29RE_V1X#_>
MCI'[@.G9I_AS_!G[.GO_`*B_Z;'_`,7'_N]'TF<I?]D>`_WHZ1^X#IV:?X<_
MP9^SI[_ZB_Z;'_Q<?^[T?29RE_V1X#_>CI'[@.G9I_AS_!G[.GO_`*B_Z;'_
M`,7'_N]'TF<I?]D>`_WHZ1^X#IV:?X<_P9^SI[_ZB_Z;'_Q<?^[T?29RE_V1
MX#_>CI'[@.G9I_AS_!G[.GO_`*B_Z;'_`,7'_N]`:9RF[A_Z1X#UA_\`ZCI'
M[@.G:I_AS_!G[.GO_J+_`*:G_%Q_[O4QT6>T$/@@[-+%S=F:X&^)W&OU*3](
M$45LE80^+/DBY:V%Q&&&.41.^_R?W@#8$@#[;Y?A^3UOFV/\WMN[YOW;Y6/9
MCQQG/Z&O+0EM_P#VX9>R/?/I?/;[@QNWCR]S&/BW;<?%KH!S`IZFM<T>5&<P
M<U&,'U]^&?AE+93+@#R,;%/[%M/,B,;/7Z#!4'"[9HJZ*HHFF8JADP'PB`B`
M]="X7C['*<7?HU61+,B1[6<$H&#%AN"X8CIUP<ZXQ?Y"+BN7X[DY59XJ]@2,
MJD!B%*D@$]`3[,]-0#`<5N0-U2D)7D5H^.N['7<)MN%Y+$8K7;]$T:(;WAG&
MMK#>KLE>Y65GYBT'3A&S=NFU53:H-3+]B^-3OUO?/<7)SM3EYYF1>?Y:H:N_
M:3%7KF9;#I$/WP]^=(7FW$C^;0;,'N9T?AK2<,_'4X07X7C["6`#CO2SI#+7
M5G<>55CAED"JH`9I69\[(\)LUP^V=SL.,W*K6W&,]@<\K645&[:+2&^MU[D-
MI5/SV,(TELZLSUA/DS2SYS..?,,C'R;%46X*B?Q>8`#UD.1KMROJ?E>6G(@X
M?DK=F5X(<YG2=&0+:#YC:5=Q`GB"R1A4:(AQG46FYX[TS2X:OB3D:E6*-990
M"()$*[YJFW#H2JC".61MS+("C$:;C+@UM4A",LNN6IY2ZQG+87=&>#I5VGVA
MGHQY39V$Y'I.-?D7SY:N/6552GUNQ8-!JK(>$OM(G]/6*FXJUR,,5GEGB;FZ
MM".E`T0981"#`DKR1DY:22M6CC4#YM)2\J@$ZRJWZ=*PZ<5'*G&3\E'<E$C[
MY0\9>54C?VJ;$LCEGRZQE8U("C3LV'B)N-A:.8S(M,R6O,+]Q/B^*>L*:+3;
M-87;2$A(V19L;7EZ4*]:LFD@X4E5BKM)8KAH"8$.0H+`)NI_(U)[_*7W#*G#
M<CR=>_(,9G6>ML"1J3\V876)-^1W%8NR$=-6>&NP<2>+N;&?E>+9U3S8A>&2
M;O'<ORA*CLY5@<2+MCE#1@C4:6+X;8*[RTU5I2>)&JPTXKC3VZ/.0%%TJ8TF
MN2.4UNM5+SLIDZ98HFM)(+L*NA(L2S39T+25$1[^24I0IIT%@YF6\Z0K6;D)
M[B/&#[RLL[&8;F?,9[,_6-P`XBZ$E@"+#VF?@*_&,\K6X:+56!(]WD0O(P)0
M`.H=92DJ*0K`9`RS9?\`H'#'29##H;*Z8KQWL-ABMMV'7XJXZQ"ZLS>Y])Z/
M=+E:J_9\JELRGX.PUC3*FA:_("2,J=(3IF,4G80#J'/QM]J_$P5)4AGX[B(J
M9L*72P'CBBC9X'4X2.0HSNC@EFV9\&S.BY&LMSD+<R.\=VPCF%@CP/&J@&.=
M6!+C*(!M(PFY?@U+NL\<=)T?BK5L.<ZBTM=^@F>?C:;/I)K.\J.Q+U%=BYL%
M;U<M;?Q]QFJ7>_9CH2@(N4W[M$XF44%0QA'(<]4/)V()JJP/'#("8YTQ%+\W
MV^\\<.U5F1_YS"B#L1S@#88@%U`X:R:$-F.TT@ELPS('B(+P&5BP6%I=Q"(#
MVE9LR=H#KOZZAOC+P.L&%2>,S$C/90S+F>W;_L3RI9A5;'"4QH3:<X@Z.PK5
M&0L;^2E(Y"LNX@S@R[Q555=-7L!O'W'KXE$Q<7]'"1I''I^7CA(X&[=+:ELE
M_*`!&!+V@@ZE5!8DDZ^V+?O56_&R*D]ZWQ\YVYV)[B^<=?,3(@4[B?+(6^TV
M@,4_`??JK1%J3E^P8ZV"]<>+OQRUB2OM'MDTHA7K)=+[;HNRYFA&R"*3>::I
MW@S5TWEP<,C^0"J9`4]/5%NI9ML](O&O#3R<?/)A<S]^A#%"H0G,?8D6%"0R
M]Q&9RI!QK,R<U3_.8>K(89!R45^26-"_S78E:)]CJ,?/)(KL'7"R*4BD!C!&
MKDZKE>O2&,TG.<FDL-DY"`A(2IVN%Y!4B?MV:7.ML*R6">><RJSMC98N6(X1
M(LU406(0"G.53T^`0N>H(;/-77DVUFXV=9Q+#*K-YI=NR2-U(96C7NI@G#+*
M2?,H.L!P'9XFF(IGG%R(JT<D)5<D.S%'1@5[;Y#':-RNB!?*6!JE]P3J,30_
MHTK.FYS\UK1Q:5X^W[YP05S=O(V59S5FL=<D,V2;2@-&E,CI"U+-3,90'#DD
M>W1*D8#^,1ICHO'9"23//0B/".LDN#9EEXB5=TE@KB(FU""6**"+!W?O>1J1
M#>,9KV2BI<2WRLTBQY$*KR:1DI`#YU$$L2;-Y(,1(/G`(E+;N,&WW*[:(ME>
MB956\XY!YQ1<RWAE?:I:)Z\1T32%9MJC*Y"]AWS:O-W\C`V-RB=M.(NF23A-
M)4A`[J=[$W%"_P"^<5R;;_3-[DA=E5"RV>XT<,<T8DSM"2+5K[7`[L1[Q1@7
MU5Q]R/BXZ-VJA//4:35D+'^;L@+-`2@PRM&\LY?:1WE:-7R(EPV:GP)D:7J7
M(6YP&AQ[2J\H%+M6]6KJD9(/));.Y++Z]1L^&%>NE3MVM\IDM$N%UW!@%B_8
MNA2.F*@>+I:XZ:]Q5WB;;H:M])II%5<*.0DMO86POM$3Q,()X?!]JR+AE4ZO
M17X*L_#W*RR>]<+1IU(B6\LD4+N9]X'@[AD:&5</&RE6)C;&MW"/A*YXL3$F
MZE<YXAPYV=(B:)6[]A-(TNM:I8HB)7(3Q:4]N=CF*Z<)%J@FX70B$&R'O`QS
ME*"8@4,G0#5Z]EI%BAN6I$,BUP5@*KE@N'S(=DA)C!8A5.#D]=0.2:.S:B>!
MI9*\4DS*9R&D7NG[4IA<X\CL1N=0,G.=6`W-1-+<_ARJ*J$23+SUK'B.H<J9
M"]^-/)\H=S'$"AXC"`!]<1[=:SZQ_)`_')]9M9KTS^43^*;ZXT^/C-'(K`<!
M%$SD434YS,CIJ)F*<AR&XI<I1*8ARB)3%$/4(#V'KBW/_DB;_P`O[8:]`_Y5
M?W^X_P"K+_$R:H+US/7L_1TTT=--'331TTT=--'331TTT=--'331TTT=--9#
MUA]D/S>FFMM#_(W;5_2M1?\`6Z9'UT3_``U_5?W.O(P_[SG^VOY0:OGO$I6*
M-\1#<;),NHBL5FO_``^^-T]/RKCV:-C(V,C-[Y@.G\B^6`$DDTFS5`3&.;U%
M+VZZCZ7OU>,J7N0NMLJQ(C,<$G`W=`!U+$]%49+$@`9.O/\`ZBK36YJM6JI>
MQ([*JCQ).W'_`/O`>.J_)_$5XQ(Q]+D;&_U//4]!U&L9%5&NG8OHF?24A:;G
M$24Y5Y-2.LT*Q<LZ+-1L.Z.C/*`6,$R!RBJ`E'KHD$\<]^MQ?F3DK4DL212`
MHZS1=K=#(K8,4S&:)8HWPTK2(J`DXUJ4M.6*M>O*8Y:''5H[$TL3"2+L23=A
M98W7*RIO^44)"IYSY>NGU?N:&%9T\F8B4<Z#9+'!:5-9.]J&=Y?<]"N*MMK5
M,A-"LJD?6*O&/Y:2K=<IU@;/G\HBF9DU2,?QG`4S=HJ\G6?W;M"61;22.I1&
M81Q0S&N\TY`Q!")U[0EDPK.54'+#5Z7B[<"!Y^VF^&&2,%U!E[[2K%'$,_.3
M-V)3VERX5=Q&#G5G(22:6.)BIN'.H\CIJ-8R\<L"*I%%6$BV2=M53H'*"J)S
M(+%$Q#`!B#Z!`!#K*21F.1HR5;:<94AE/P%6'1E/BK#H001TUBHY4E02+D`Y
MZ$8((.&5@>H92"K*>H8$'J--_0KY5<JIMCOU\E"P-7JL>>1EWJJ2JRX$`Y$&
MK)BR2*9U(R\H]63;,VB)3+NG2R:293'.4!QU_D*W&P"Q:+;6D2-552[O)(P1
M$1%!9W9B`%4$_I'4ZG4FO6!7@V[R"26(555069W8X5$106=V(55!).!IC97O
MN=ZY4G=RAC6FEL(Z:/7Y6'V2H3F.6Z'E@;D>(-9:J:`WA9A@,BP5(Y:B=,`<
MMCE4)W*/?J:=H@BLLRB.;>%!(#!HG,<B,N<J\;J5=2,J1UU&P>_)74%FBV$E
M02A#J'1D<>5E96!#`XR<>.I6<3,*T4:I.YJ&:*OA2*Q2=RT<V5?&<=P;@R37
M<IG>"X$!\ORP-X^WR>_0D"3LGI,21M^VR,9&WQR,C(QTR,^(U\'6/NC]Z^Z^
MU_3\-(4;H5`F7]FBHF\T^1DZ5(DB+A'M+)#K.ZM**-6[TD?8$"O/,BG9VCM)
M0"+`0?"H7Z_5J*>&>$V(75ZXD9-P(*[TQN3/AN7(R/$:N212PRK!*K+,\:R*
MI!!9&+*K@>)5BK`'P)!TMMIV`>/RQ32?@74H8H'",;3<6XDO+,0JH*^P(NSO
M/*%(X'\7@\/@$#=^P]^KJ?.,43JP."![.N.OP8/0Y\-6V\JAVZ(W@?8?J'P.
M?9C4=QNVYS+9Q==88R[U6CY\6]FM4D:'D4W;(,V0>.+=[/%G1!\_%@DQ5%/R
MB&]H$`!/N(AUC9>6I0\%!ZD8N>*LUTGC*JS.T;R&)"(P-VXN"NW&[VXZZFU^
M/M6>9;@(0#RB6Q6*D@`3'9A=Q\N/.OFSMZ^/0Z:68\IL1V*.Q65SVU.IMER"
MI5KT#,%#P4JP/)5RD?-[YT&FDGC=-2LRT2>TLB*,GH).?&<Q?#W(;MEC'YW1
M61ECJPV=ZL#&T%@L(I4<>5U?8W52<`9/340(QJS7""(H+XI2`]&6R>[\V5^5
M_P"A)DXP,#[H:F]O8*\[;N';2PU]VT:*>4[=M)R*<M&BHAW!)VY0=J(-E1#_
M`*JABC_<ZL[TV"3([9S@Y&#@9.#X=!U/P#J>FFUM_;P>YTZ8.>IP.GCU/0?"
M>GCKU)2,:NBDX0DHU=LX$P-W*,@S5;KF(0RARH+IK&26,1,HF,!1$0*`B/H#
MOU]+*HRQ`'7Q_6YW?L2"&^`@@XP=?`"WR>N,?JXQ^GD8^'(QXC6IG,PLB@#N
M.FH:1:&<%9E=Q\M'OFIGANWA9E<M7*J(NS=P[)`;S![^@.OH(8`KU#9QCVX\
M<?#CVX\/;H002I&&7Q'M'U?@_1UA[-0D:B9Q)3<+&MRN#-#.)&7CF#<CLH`)
MFAEW;E%(KLI1`12$?,`![B'5.]`5!(R_R>H\W^C\/Z&=5!'.<*W0`GH>@/@3
M\`/L/M]FJY[D1N[W#X<93E0=-EN>57-V,";ANL0>-')Y1,X=_&DH0>P&*(=P
M]0AUJ_K($<2`>A[R_6;6=],$-R!(P1VF^N-/KXS*::-?X!I(ID223YRL2)I)
M$*FFF0O%+E*!2)D(`%(0H>H```#KBW/_`)(F_P#+^V&O07^57]_N/^K+_$R:
MH-US/7L_1TTT=--'331TTT=--'331TTT=--'331TTT=--9#UA]D/S>FFMM#_
M`"-VU?TK47_6Z9'UT3_#7]5_<Z\C#_O.?[:_E!JSW/S-YO7N6G*O.:T,>:QV
M;X<'&UO`-I=4R$/(S+3D-RXD8V(F5B(N3)1$N[:$;.3`FIV05,/A-ZAZ+P45
MIH&M4H^]:IW^/N+%N"=WW.W':,08@A3*(B@)&T%AGIG7".:>$2)7L2&&"S5M
MUFD"[C$+,#0&4+E2YB[F_:&4MMP&&<ZKQH%-U7F0IQZCM/XLW;&J13=$MK70
M(;1K-F4O,)0]@X[ZA3%K1%M:+;K3'J5QC;9^-;QRI7(22JQSG49MTT@4/T>U
M1CY6U:M.TD"S\?:CA).R>&7WBG-6D9HRW:FW1R.#%(_;$8(E#,`-6X^XO#\/
M?XU>W+,RT``@)@F2.]`]B)=ZJ6001NS"6-%92%`8Y758Z[@W)6`S?2E-RXVZ
MIJNNK\I+]:LQU#C=J](I^G5Q&.Q[.L]H&X-E;3=:5!NH*\$J9O?T/(KO$C.3
M*IKQ+MJ8O?%2OS%GB>,F6%J?JY>/ML\T!0007YKTDC120L622A)N-J%'CM=I
M>VAB$Z]Q9D[\5[\:2R1V/2U2I1@6.4/OG@ADM2@0NH[D=N!9TKO()(.X%>03
M%7,1O=KG';<>07&'+\\LNJ1=,V".;UV8OEO=EUANA(S"#`Q9%LJ3CWM/'>9"
M1.=4H.!1E/=9G!#F3:>`2>')>H>,;D;U6:E)'"E=?G`GO';>1H$24Q8FB/:[
MPD:+OK(W;*](WR=8;@[YI4YTN(\DL[$KN[.Y$[KO&KYB<;Q$41^T5&\-YG7&
M4*Y<9M.K_#&"R2)D8C8-+S.TU'0X]HJ]O;&*T9S2[FQM*E6*^V#2-@MK9[(Q
MS=1-D>5L+U`L@1`3*((]S$N\E/8@O<)S%2!K#<1:A>2)617E45[%61HR0JEE
M%GO*LKEG[>UILD,**,$4]?D^*M3B"'DXI$$I5G$6989T#*"259H1$YC"JJR%
MUB.W8U9^9&9;?R\1QK0[7QHY&5[/ZB[TR&G^/M:=\.+QK[J4L;6I#5]!GZCN
MGTE<>'$7$K0TFU060E%)QH@\240%/VATB3#<AQ@FO"U:2>:.>EL18EKM[LZ3
MR9[IF&Y'L0M&Q:LY"M&4<N`CC-\?R"P\58XZ*2&&<7()&9NZ%GC6*0%(FB(;
M;%(XS',BI+\K`:--WBL/!&1GZ??7R>0VNX6>J<%L9S_C5*[K(YQ8=9I>R5:<
MUF<=-AD(!Z-,K6FUDTM"E--18-VI![$:.A2*<.LV]-8N1/)?-R<M'Z@X^1;(
M+-(U6M%126822?.*9FBD:T!M:RZ*9$8+$%HXJWQY/&<?R&5X,V^6:["5`A[=
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M^^DHK=/G&OWU>)FAY`6F?8(I99U^8:JL/GD0G:TC729!+W7'VFKWJ.:K9X9>
M+X\JT"UJH@4%B8GA=GF$AD\D1;.(%K*%&<,ZY)%SZECVD1G#SDCF#RMJ(7J]
M(\GRU."]X19U)8V@1L^A3P(]3>FCVOOA9ZD!?.53\KQ=U/``#VCP4K2>A."X
M=EQR5.E3CF3(\CQ7C,XSG:=L9#94D'P&3TU-XZ]4@_S#GYN5L<4_/+8#X.#"
M.QE]N-WVC=,;NGAX:IO,\,>2D+JK"&R^/9UG*+!PYW]I'6-E8&4-(9%R<URC
MYC69V`1(T,X>(Q=LG:DK,I2+%%R1F]47[@!2I`>NY2N"#U#QT)W<<TM5Z&S&
M^2J;LMNW2/=#(-A:2.LCHM9*TL4!4A'U3Q/)5*E;C+,Z@WWYFO-=##<%]S2V
MD5P@$"7N)8B69-PDDEB:1B>YY8SR/@K.$SJRUM#".2]3<3^C\6C7^G;>CPOJ
M^=W2LT34V%@O4]7(7BLPK#6?6:0J3KWDYL:(R,G'J(H`5;Y:99M&A3%RD[Q$
M\..2FF>&PJ9B4<;;AC80Q9K!)I)HHI44-O,:;QVUR8$]JS$LY,RORGT=/&DT
M)<AI'E@8$S3#W@NNQI*SDCLEI&4I(^3,>O<,-LDM#W"C9=5XZO\`'Z*I]HU[
M"&L),QU7C3;+H%/B,QLF0PD;%*-G=1A&U4@I!VDZ*DFV2=V#NF</+/X</6I7
M8X)YN3A]Z@X^_P!NO6R-UWC[5Z/E;^YV;;WWL&[5;N&-9(+2H00K,<@+-025
MDXZ5:5BW'&;-@(7$-FI#+7K3-"05=0#0EC1/+OH.SJ'<&3QL>/V@DB+'J>3<
M-+!QTJE6U[B_HT!Q(B7..P5NO#_%)>4D[U982'I5W<8[#6"Q,I1%HT<.9E!Q
M*>RB=\='RTO%EZ;V^&MIRJ1O9IOR4KQU8PBM3AFJO6FE`++$#.YCGDKQOLC$
M*A"6<@1$FBL5IN/=UCLR>G;=62=RS+-8GEADA5I=K32B%(W02RJ&S*<#!8ZC
MK3N/^UWJBV*Y6;A[J=BTZR<H>0&V9UESZ/XO;-D\#':!$U*)K"').B:EH4+$
M3;%P6&.<35.12F(\WC%%]X>Q%,2*-RE]#QUH8Y^8I<=VFDD"-21VMR3860XM
MPRA77=8@CZ`8>.PL:Q-E;'*4KMB2>62:+BO=J406)FCN-[O#(KD*-U9LLP`B
MG:1!T:-X7=Y%Z:7I&8;Z)\+9O8HR&A9]#F?GJ$U#5THDK\3*(\5>2Z;V-A$Q
M*7R8IDN4R:"8=P33*!0,8``PR/7S1-3=H6=XC94AF.6/1LDG`+=<X8A2PPQ5
M2=HQ7HM)8YD2=4240ME4&U1E@0`N3CIC(!(#9P2.NI?^,T`&A>`A1]0\ZF(#
M_P!/%3E*'7"O41V\-.P\0H/^L->C/\JO[_<?_I2_Q,FOS,J\W=<:H;S*QTQE
MEY#-HOD(Y/3:]1K(TF\H<9-<W,!2#Z%-A<9-G9B7V/:CX$$T(E<5U`,D!B%/
MVTNC3@FK49)DE>*RE!VG3Y#26I8XY*D<>TGNJCO(K[VPL#[DPV1ZC;FK8]5R
M\0DL#P))(C0"-N_%&M,65MO)O(,1EQ7V=H$M-&0^5PUDYWFW4*/3+Q9=-SZZ
M9U.TF1H<;\R[+)TA*3L0Z<F^/1)!G,L[([J\`QG@BW'C][/&:D>*7A=E2,(`
M-J7CGW0K69)))K-B`J&&8WK*KS!F.$<*K@JT1<28.S.K?'^K%?B6Y'EX):HC
MH0V@S;=LZ2X`,0#,R$R%5[<NUTWJ'`ZZ2ZUSMJUYKU(?9]DNC7RVWNSWBI1E
M#K,OGCITVE*!%QTS-KN;FM:T,^7B%(Z33.B\0DE6YC]TQ,!^P#]M<9+51IV8
M&I'4]Y=R&4+&KM&^5<!BZ,!A0"90V8M^UL54?6%7D*S2UX)6LBW'6$2O$^9)
ME+Q?.HYA5756+,S@1;<2[2R@OV*Y>YY,1$;*M8.U`K/5_.[!6XE1*++)6%'1
M;2XIK9E%E"0%%5[7)Y@Y)(@)@*FDV.J03D$IAJEXFQ'R#\<K(TBW!7#9.ULU
M/?>]@C<(NT&&2`QD1D`)QJ2OJ>JM7WBU#/"PJF5D8+N61;/NAJY!*FP)6BRH
M)54FB<L%;.HG9<L=3"1R)LTRESICJ_1'(5]*UB@%B(>;24R6[U.`AG;68N=J
MB:U%1Q(:8<G>^U.!,Z<@D1OV.8$SVJU>"7C_`'N4L`.(XNXSCY"FY#(\W3!9
MQO5!#$FZ7:68AE1F6.W/7UC8QP=ZQ^<5Z@D2@!FCK/96/S,PC23;"I>1V6,G
M<J@,R#4K-.7^=OZ?>;JR@;>M%T')*7K\NV.TCVTBM$71S8&2$"W;.7R8I6&&
M>5MPD\(L*:)3=O`<WI[7SQ,AD@$,L4D%J_'6BD4DH_=CAEBG4XSV7CF1A]O@
M]5UE:/,PW>VG;DCL-#9=T;:3&]240SPL5)!=)<IE"R':2&(P2R]`YD3U>4FP
MHG'70]$8UO9*[B\M._.C.JI$+V2:]U*N$X4E@LS25?&:M9A(Q%#MTVAC@8IU
M2=NXT4.--N>A'/(L,5]G"$Y+!4:5&<J`>@>(CJ1N!RN<'&$O>KV@XZ[>H49[
M+4J\<K`/$B_.K$\:;F<>8I+DA0=A7#8W+EW2O+JJQL:\.G2+4XLT0KI#>QT]
MW-4:`>5=;+O=/SA^<%@L%DCJG'M'0RY"LW)GOL[DR9P*81[=X:P%ZR74934>
MM#/NS\E9YI((T(/F,A>,DQ@%E!&X`G67/.Q)8:E+#,G(+8FB[3;02((%L23!
MMVSL!&&)=VUSDJ2H)TRJ5SRH^A5..G*?G5UL=DDM2:9$A1*_/YU.O0M,C5WU
MR8*#;XRUN*">,7K[`ZJBQ9(0;G$$U0*?N`9*3A+*35XPRF*Q6GGWD,@5*TT<
M$VX.H;RM("I`(<`A"6*@X:IZXH7*D]F&&1IH+$$/;5X9&9[$3R0[61RGFV["
M"P*$[G`168(CCGLSJ=$M-VU?&;-G*D=L4YCE-A9"^9>M\^IR#5F#OSIV`]J0
MKE7-&1T(LJY-)N6S8ZGA2;*KF.7O#BJ)/#2->17M6X)9F0`@Q11.$+Y(&\%V
M"!4S)G)V[,,9<OJ9ZAY.3DZDE>IQ\M>-7:2(]^2=%<1KM<[&4,')<A.V0=VY
M75;4X=LE:WO-X72ZHU?,(R67DF2L=(K1[MU'240^7CI!H,C$.GT+*HIKH"*;
MIDNNU73,!TU#%'OU5?H2<?(BN0R2Q+(IPRY5LCJK`,I5@RD,!U7(RI!.0X'G
M*W/TVMUU*&.5HW4LC[64!NCQEHW!5E;*,0,[3AE8"6^H&LUK(>L/LA^;TTUM
MH?Y&[:OZ5J+_`*W3(^NB?X:_JO[G7D8?]YS_`&U_*#70O:W35C\2C7WSYTV9
M,67`7C*[>/7BZ35FS:-N0/+Y9PZ=NESIH-FS=$@G44.8I"%`1$0`._76/1LT
M->.Y8L.L=>-%9F8A555WDLS$@*H'4DD`#J=>>_4\<DK5HHE9I69@J@$DD[0`
M`.I)/0`=2=.:I76EW^&3L=!N-3O==677;(V"E66$MD$JY;&\#ELE,5]](QRC
MAN?T*$!03$'T"`==$`)C24?O4B[E;V,,D94^##((R,C((\0=:62`[1G]\1L,
M/:IP#AAXJ<$'!P<$'P.G,`"(@`!W$?0`!ZQ'ZP=?--9$!*(E,`E$!["`@("`
MA]00'T@/336.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIJL^W_`+^WPX_O
M]:S^#1R@ZU7UC^2!^.7ZS:V'TS^43^*;ZXU\_')OS:G4GA!/+U30[$G!<YXX
MZD52:5*VNP2?F<8.3K(`@H6.#VJ8$AW(*F!+]"W(HI^A(/7&.=B[W%31Y4;@
M!DG`^4/$^S7>/\M+*U/6]&PR2R!3)Y8T+N<Q./*HZGX3CP&3KA0M>LG7R:]8
MPI@G.KYFZ&_O4C8#%XXWH)DKC1+'(6FP^[G_`+`*35,LI)J@V`R2GE)>$HB8
M0[CHX%@34;'<K=SCQ7$7G&/YMM$>_P"Z^2-WAGXM>KXN=K0RV)DI<MOLN6?^
M:R8R8UB\OP#:H^'KDZ2[K9<DO,C;9M]A_/F&L5K)FZJ5BKO'B[L)>J2^4#+C
M2['4E7$6];,9I@:;7%0SE)VW7[@!DNP=A1>]P!.Q/`C):FG!#KDM854F1LY!
MB=%"E<9\<-G6.DGXJ6JE.6CR[0QTA57-:3(0,C*X..DJ-&I5QX'/3KI4KND5
M2)E<\L5BH/Q&-*L^9.;NO7;+H''>?>RRR=^CXZ,EV4M\W:K6X]XS9-8M/V,I
M$$CI&,83&4[AV3Q]Z&S704XHK51:\FQ\;D5F<-YF;#DL03X8`\NJH;\21I'9
MCYZR8[23J9:Q)5T#`*-B(-GF)((R3[=101'.8Z_<99R$P_FDE4N-\7?DHZ.D
M^-.D/)VPREG*W+`#)KHMFT:\CZ\=Q(+$\P@'(LY**8?HAZFPV)EN<CR,[UC;
MNT(*JX=0%$;LS.<Y(<*0J%?'?+NP"-0.2:I>M495I\H(JW(V+DA-:;<6F5,Q
M*H&UHI)%5Y`_5#!"8\DOI6G4<FE&M-+"9Q\2:@2]#)HJ%=L]$PJUQE@29ZI+
ML)FYL'BLI69F-?-'SB-333*HU$4$^XD$%`*H7'1P2Q0BL)*YK>XU:C*9!B2"
MFC)$K8(.>H9W0JY95P54NK2I9Z#JQBK<Y%,>2L7U=*SAH[-EY'D9,JR[?G9$
M5'5U"MX%@K!*MU;PJU14;7FV0_$9IE70HL#G%CK5*PFY1<;H-3K#I1]`LKTX
M?P$K,R:\>[<.%`6;.F:BQG2WFBIX_1/BMVXN0;D0U(M[Q'/'&640P2PKMB>"
M-2`FQ=JA#N3;'&"I"ZC2)QKU:U6.'GXE@CF1V2!P]E++K)86PY4ENZZ[F:/M
M."[E67/209RS93-5.WU1/%N?L$6X:8WUU:?@N.UQ0L<#>6:<0DSDJXZ?0TA'
MM$6Q(5+PHKMG).YC]^_<.T5?>5DHR++7#<>3V_.OF!DDD99/NE8RNK8VG;@`
M@C.KV[B1Q]WC5I\R(;\2QR'W:3<H2..)6C.,*RB-2"0PW9)&#C4;N&><V+1.
M0-RN>)<U'[+9Z[FE:CTXOC1H2$U7QH)4Y)Q;//=,5(E"WR]M;(2!U46QVZAT
M2^8F8/D=55EDI\6E2G+##<7EI[P>.1`(S)Y4CCW;CMV%PX?."QVG/F%J62I:
MYJQR-VGRDL$W%0TCNK3;Y=BD/+*`%19!A40Q@!T7,@^UT\*>_P`MJDNA9'V8
M_$9O=L)I<;K#VU7O`;5)3,O;8FEO*"Q&1]TUN#C0BD:Z^,7V9NW0+YI2G[AV
M$!N+--&B1U_<HH4KV80JOT*VYDL3L<L27:6,$'.%!("X/2FO'QT6Y[$//V;+
MV()3)+78MFJC1P)Y$1!''&VP`*"0`69FR3KE7N8R`V%9CG7Q(*T^E=&6U>M2
M5=P&QM7V97B0;2+.P2N>J/:K(),TK2UEW2;]"3)*(G*N;RBI"!1+%K1SU88(
M89:X["31[MZEI()V#M7D]C1(X#Q@!75@"7.!J;9M4K5FY9DK\V#<-=]HK,%A
MFK*$2>#REDF9%59"S.C`8V`%@TZ4[DE&U.MQM??Y=SXOKN/(L16UWKC3:GUI
ME?-<*KE/*.H.$K\6J=N50$D_*:(@"1"@/<W<PK$/?D[B>Z1#:!M1\+T`&?,S
M'+8RW7&2<`#IJ;1YI:<'9DAYNPVXG?+58OU]F45!@>SIGX].?[K2!_V?^97^
MZ]H'YW5CW)OPD'\(NI?YR0_T+E?^$DT!RU@>X?\`I_YE^L/_`/+V@?X/3W)O
MPL'\(NGYR0_T+E?^$DU-E%TAH7X'FS77YF:>9LI\3B-L@5DM`F37PB)?BS9(
M_P#<RM0`/>2=H,4/*"/'[<+G[5^BZWWMG\WNUN7/NV,Y\OAXY\,?'KRX+B__
M`&V;O;GV_2^[9VSW?E_)[?RM_P"M\<ZO#S^AJ98N5G+F!T69L-<HDQ\,_C_&
MVVQU9DYDINNP3O>.8",A/MV#4IE7;>&1,+ERGV\!FZ9P/\CQ=;WQ2U6XZP+<
MHA3WBGMD9!+&DOO"]IIXV\LE82[391_FV@[@D\A;7&N1:PMZL*L?>F:.=>V&
MV.X:(JR1,/,L[*2L#+YQ*4*>;&N7T3R5M6+Y')ZGD[C-[KDE!UTN1/+KQUHZ
ME"H>_2.LY\TJF;V]QG#6-:PM=TBGZJX@F,E[H,I&%155-XU%14$-S]ZYBS-5
MJQQ/#R'+O<XNF@;^:>\@5;5;DXMP#"*<16:)`&R*U)8";HE#G4J]+C1))$TK
M21<;!4N3.5!G$"R6([E*QM/5:E>1;YDZRR1I#W-H)552(M6B$W:_X/=.6.N[
MC>)K)+Q46,9A6R+PHY).5_$`"<D-AR20I*94[+)7))PO%3\%(.DDEG*7M1$S
M%*`Q[4D/(\;SM;C9[,\7:N/'91R\21UI,1(.@>I8:.,1.,/%8G[HC823A1(J
MM)5L\/>Y"&"O8DNTS)59`LFZQ())`C9*V*D"N6;?LF2$(-I2+<8"MFH:_7<4
MXEU7.N:[O-<U/BLZ^F]MW;9]4KLC)\@(F7C(F7S&9O5%RZUO9XM%9>)0*U(M
MFI12\9O:CB(]I=ZY>L\I&U2Q`D'T?Q[T=S,!;26/,L[1@;+.V8"%B61PN%*8
MRVOE*I6CH6Q+7EFM?3UV.SMV[J\:LYAC0DAH!*F)1*JNID;`QD#5N-6)R:GK
M!/V)IRGUZM/JO<.'E"8L,?,DSR>>B]7SA@;5K6SA9>#6D)DTTX>G>QSQ95(T
M,[$BXD,8OECD7JS6>?HQ=ZS%2Y'U%>HRQG:K0588;,X[9&1'+WX`J3G=M@80
M`'Y1QZ6H*_I-K/:KS7:_$26%D&XF2Q](Q01ER<%T2!\/%@=UE9R0&.+Z\,)&
M[KYA=Z]?+?<[](9UO^[YC!7#0UROKO/4NBZ)+P52>627(RCDYZ2&&;I@=\5!
M(KGMXP+Z>LE3E:UP'$W9E47)^,@>7`QNDVX9BOL9L9;X6R<#5GEJD?'\]9HU
MV9JG:JS+DYVM9JQSR(I^X21V5%\47"$G&K;]5:B:.FFCIIHZ::.FFCIIHZ::
M.FFCIIJL^W_O[?#C^_UK/X-'*#K5?6/Y('XY?K-K8?3/Y1/XIOKC3W^,[_F/
M@/\`?T,_P4^4O7%N?_)$WU%_;#7H'_*K^_W'_P"E+_$R:H'US/7M#)T=-,G1
MTTR='33)T=-,G1TTR='33)T=-,G1TTR='33)T=-,G1TTR=9#UA]D/S>FF3K;
M0_R-VU?TK47_`%NF1]=$_P`-?U7]SKR*/^\Y_MK^4&N@VHIR2/Q+=8]XO6SQ
M?[A'B^9-5HQ/'D(G]T)RZ[$,D=Z]$YP/W'Q>(/0/;MZ._77?1'RK./@3]UKS
MQZK^3!G]=^YTY+O0:EHS&(C+S!(6..@[17+G%L7ZCHK5"SU&5;SE:E3HH+HD
M=J1$NT2<))K`HCYI"B8@]NM\5$6Y#?4?SRN7,;>U&DC>%F`\,]MV`)!*D[EV
MN`PU'>_8EK`D03*%<`D;DW!BA(P=C$`.N=LB91PR,REXF.J(>$QC]@]/8>_8
M/3Z![?9ZJU1H%90O<XJ"3N'RC&/X0[!]43"(``=,Z:^?$<>W81'N`]NP]^X&
M](B';U@/3XM.F@?$/;OW'T``=^_J]0=O[G337SZO7TTT=--9$HAZP$._UP'I
MIK'331TTUGL(AW[#V#UCV]`=--8Z::.FFCIIJL&[E<'W#X<Y6JR2#@>>M8\M
M59`7*9/_`$U<GA/XD2K-S'\1.X!\LO81[^GMV'5?6/Y('XY?K-K8?37Y1/XI
MOKC3Y^,L58M=X!%<*)K."\Y&`+*I)"@FHJ'%+E+XSIHBHL*1#&](%$YNWUQZ
MXMS_`.2)O_+^V&O0/^57]_N/^K+_`!,FJ$=<SU[/T=--'331TTT=--'331TT
MT=--'331TTT=--'3360]8?9#\WIIK;0_R-VU?TK47_6Z9'UT3_#7]5_<Z\C#
M_O.?[:_E!JP_Q&]&M.1\E^8>DTE1)M::C\,[CS*P\DX;INV\&N7D!R[14L:[
M58IT'"-=;JG>F(H`IF!#L8!+WZZ%PLTD=9H8YC76UR''57F&T&&*U<CKRS*7
MR@:*.1G4L"H*@L"!KA?+Q"6=&[1L20U;<R0C/S\D$#2Q0>7S?/2(L>%\YW87
MS8U4C0,WU'*;C&9-@G*/4'LOR`XN:)./G.X;'/WIM&WJ"?U!O3M*J%GMDE*/
MLH1LKVT.(KPP_E1H*.T5$6YE6J(%WGD(+R<GR/I2G&YXV&K#,J-8DCL"<<A7
MK?1HNMOL1OR59[':D;N2Q2U3)"-QE#ZA5MU9N+X_U'=:,6WN21-+'"A@:*2A
M8G-IJ@VPO'3GBA<J`B;)3%(P5UUZLLTN>JVI\6\?=R.]4*9B>16KT'7L]V36
M)77E_?4MQYE[)3JO&ZW*.EI;5:.^G$$W\$O*$;O0>'$A6R(%1*.5]/\`(5.5
MY)DKR%ZJ\?<@2.1525+5.6K/91P&82215Y^\DV]W>I(CMM`[<=NU6:CP/(M=
M$:\B!PTJNC%HVCM7VA[D18*8S.L3130JJQHZ,JABS.ZI8;O<-"J>]8T-IFI>
M2V+X@-DPRINE9-=X-9RV%CJ'8[@C7U14.1O`5Y@T<)*(HB":0O5`]`B/4+CD
MAYFKZ7H6\2PV!/=M$G]]K4)YI&&\>+%UA$9)P>V5ZXQK(<JXXFS=Y"F$62OP
M5"%%P"HOW1/%MD7[5WC9B^[#+\VS#JNM=EU2Z1W&CF(M#WZRL;+GO/#Z-*JJ
MA.O49VI4QQO>51==I,.H*I7C&%<TIXY1:M$OD*QZBH$`4Q-U+XJX_(0>E+<[
M]RQ=N/'9.<F6>-;AGCD'BSHZ@NA&5V@D=-74I\=3]0V*06->.K>EJ\@#8V([
M<5*4E.>@=YNV0QP6E*8RQ&H#@N0VKU&P\NLBL&IWB4M/)KD9M5*XJ.W<\Y>3
M.?&JVG2N97ZOYX9VJ(PC'+*.W0L[5!'Y"1S&$H!VZU*2>]8]&0<)'/(G,O7@
MN"P"=YI2P6+<X>4'<)`]"Y720X6#WBDNXF15TY%:W%\Q#S/9!XVOP=`21;-R
M&^U:IV7E4^7;9FO5^ZI(:18;4FUMC#5L*-R8N6(_#7XU[?.1[O;+F[R3($+`
MZN=MNC"6M,K-P<>C(V.;LM3S+8;*\E72XF75.,.J"RAA$ZJ??Q=;SZWY1.)Y
MI5JP)V+%DH%!9!&.RTF0$BD!^3MPVP=2=V0%:!!PRGE^9H=QQ%1Y*\B9VMY8
M[KPJF6=,!5(QC<0%`V@9(]=OY?7RY\`M!Y&UJO,,KMI2+P+<[*5LEJ:4IFZG
MX^O/KF5[?,RRF475AF#\[HH.(1-%)0@"!U`#OUC>64R5^'K]]JT/+\A3KRR*
M55H(K%HP2,CL>C!5\KNJ%2W1>BL8G'DB?D72`6;''UK$L474^\2PP":-"H&2
M&8X*(S[@N-W4J*\<EF>B<47&KT?%-YVBX-+%Q?8:0HPU/7K7HL_6[Y#[%3*O
M`WJO7.R24K9*7!7MC*+,G;!FJG%*$4$Z"("4!"+%8Y%/4,G`U(E]R@L\>\7=
M9V,4\]IX):,\C$RS1M7!L[)6,A,+!74.QUFN(CI7Y.(Y2WLDDL2<A'+VU1([
M$*<;)92=(0.U&R3JH1XT"+O"$'"C5A+'R`V:+C=!I.M-J`]T/*]\XZ5U:6R%
MUI.?U.3KFQ,6L^P;KH.+I+6-U(0#=P=N]34?&C),Y0,9J4GVL,A3D-OD>!BE
M/SUCU+9HRE<K&P@KVF618BS95P@)AF:9%.#U9$8:PT3U?3DU_):&7TZER'=U
MD!6W6K2+(XQA][$K)%L8KD'HS`JK#E;MSS0H:TJ0V/\`W/MGY36SBK$4])M;
M$]Z:SU65LT>O?']B-93TI9HM(51992NIP*;YLQ7*<SP?(.92)P-^>ZW"GD0O
M:]04Y)Z_:!S6Q#)9B%HL6#)VH7BGD41B*S)!%U+X.4Y:K6JQ<FU,RB3ANR)S
M(!MG9YX:[BN!M*1[["O!,QD6Q%&[JJAUV)?)8-`I/(N%V>P6/597`:JTS2NG
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MRRW>44D=QX\2F=YE:,\@M`SZ_?,(*)%^?.F3=MZ:JNXW#75KVO[D=)+IR[9M
M!MU>QN[4GB`A<M26P([=7E1V^2JR(`<;!+DE9%6'=*R-&PWEFF*E"%`)&[6-
MOFLEJ,\8W=I/+.A&=S1B)B$D>3;&#W""AB$0:-P<N0,:G[;_`-_;X<?W^M9_
M!HY0=:QZQ_)`_'+]9M9STS^43^*;ZXT]_C._YCX#_?T,_P`%/E+UQ;G_`,D3
M?47]L->@?\JO[_<?_I2_Q,FJ!]<SU[/T=--'331TTT=--'331TTT=--'331T
MTT=--'3360]8?9#\WIIK;0_R-VU?TK47_6Z9'UT3_#7]5_<Z\C#_`+SG^VOY
M0:Z$[<Q92?Q)-BC9)FUD(Z1X!\9V,@P?-TG;)\R=\@.7Z#IH[:KE.BX;.$%#
M$.0X"4Q1$!#KJOI&K7NP7*EM%DK2(BLK#(8'=D'_`/V1[.NO/GJ:62%ZTT+%
M)D9F5@<$$;2""/`@ZBRE\*.)N=5B_P!,I6#TF!J^IQ/N'08E(T_($LL)X5BA
M$+O9>;D9*-CB>T&$J+%9J0A^QR@!RD,7>I./IS4/HN6,-0[RR[23^^H04D+Y
MWET*@HQ8E3DK@ELZN>1NGE!S1D/THN[$F%Z!CE@$QL`8_*&W##`((`&O0APS
MXKMLD=X.EAU.#(G\^2U.Z4HK8%VZUF3.W.E/^^UYM6TI2R(M$P(N1^4Y"D`I
M1`OHZ^6^.HWH*]>W$CPU6+1#Y/;8YW,"N&+,&(<DDNOE8E0`+5:W9IV)K59R
ML]@8D/0[Q@+@AL@``#:`!M/F7#$DK=4XUY?0[%E\E2(-E5:MC=4M5<SR@Q+/
MM"0#^YN$?G!9R/W;IU+/)A]&)>R',X.L8Q#>,3^(`ZFQETN376;=++3CJ@8`
M6.&.3N@(``%+-@,0!E>ASDG5A]C5%J(-J^^M9D())F=H]B]S/CL/SBGQ#?$-
M?4QQ8XZ6#8(_D!-8_4)'9HL[%5E?UTY,),CB,:J,8UXXCDI).O2$@P:*F31<
MN&:KA,!]!^X`(1J5.KQMN:]0C6*W.6,C+XL7`#M@Y"LX`#.@5FZY)R<W;4\U
MZFG'VV,E*/&U#C'1MP!/BP5NJJQ(4@8`P-.1#!\8;3<)94<QJ!;#6[3?+O7Y
MHT;YLC"V_414'1;'&N5E5#M)6YBJ;V]0G;S0,(``!U3[C3VJG;7:E"2D!\%2
M5HWDK_BG:&)B#GJ@P1US78MVK6[WF1G#25Y&!/0O5C:&LQ'@3!$[)'GP#'V]
M=/JF5:NYW6*]2Z)#LZI4ZG$,H"M0$,"K:/A(2-0(U81C`@JJ*)M&K=,"$*)C
M"!0]?60EGFGD,TS%I6\2?$ZL2NT\\MF8[K$TSRR,?%I)&+R.?USNQ8_&3I0G
M(R.L\7*0=C8M9Z&G(]U$S$7+(D?L9.,?(';/&+UNX`Y%VSA!0Q3%'Z@^CL/8
M>H5NI5O5WJ7(UDK2##*W@?\`QR/$$8(/4'5R">:M,EBNS)/&P96!P5(Z@C__
M`'U=5XH7#CBWE]3M]%H.(4RNU*_FC#72&3&<E$[&6%<MWL2W?O9V8E90K&.>
M-$E4FR2Z;<JA`-X.X=^KL2+#%%#$,1P3B=/:5F'02;CEF<#H"Q;`)QC)S6;=
MEKYY0N??S&R;Q@$(X8.J@`*JL&8$*!G/Q#$GRV0Y?/2$_+35&@)*3M4U4+'9
M'SINJ9>:G:`V*RI4J^,5<H*.ZRT(";40`H$*'I`W7R.*.*2&:,!9:]M[,1'B
MEB161YE^!V5W4GPPQZ:CLQ>H*+'-,5?=@GVHKF19NU_H=U5DQX[E!SIGQ_&#
MCW%;-)<AX[)*FTVR8]I-):(FG)#+N5WC9%D\?^PJ2)X!"6=M$"IJO4F9':A>
M_B4'Q'\5OCZM?B1,O&H(5L;NYM^VWOW''7.U6<!F5=JD@9'0:OW;=GD5C2\[
M2I$(PH;V")=D8.,;A&OE0-D*/#P&OF[<7^/>CZ;6-FO>3UBSZC3"QA:S<I`\
MR1_&>Y'RTE#F.Q9RK6%DSQC]P=5`SQJX,F8?0/8``/E6G5I7WY2K&J7Y#EG`
MR2VP1[L'*[Q&`H<`.`JX(*J1\L6)[5!>+L,7H*VX(?`$E6(R,-M+*"4SL/7*
M^9LMZS\,^+%S972.L^(5"69:)=&NC71!1>Q-`G;TT04:HV<ZD=.,UHZ2.W6.
M1;V,S9)P!S><0_B-WB_0O%>ZPTNPGNE>>::-?-A)+)S.PZY(E/5D)*9ZA0>N
MKS<A=>>:RTC&Q8ABAD;IEXX!B%3T_P#3``5AA@`!N(`TX&'%WCO%AEQ8W(*>
MP)BA9A/*4VB$@BC24+"HY6G6D:B20!)VQEUGBIW"#TKI%0Z@F$O?T]3IH(;%
MQ^0G56N24FILQ'C58`-`1\G9A5`Z97`VD:C++(E9::L166S'8"Y\)X@%CE!^
M5O50!NSU^VSUUKR#BSQYP&<LUEQC*H'/)NY)`A9GD(_LJZ<F@5\K)$0"/EYR
M3BX]`CU8RA2-$$"E[^$``H`4/M2*.A3^CZ@V4]P;;DGJJ[5.6);HO0=?#55R
M>;D+(N76[EE2Q#$`'+_+/E`!+>TD>/7Q.D3;_P!_;X<?W^M9_!HY0=:SZQ_)
M`_'+]9M9OTS^43^*;ZXT]_C._P"8^`_W]#/\%/E+UQ;G_P`D3?47]L->@?\`
M*K^_W'_Z4O\`$R:H'US/7L_1TTT=--'331TTT=--'331TTT=--'331TTT=--
M9#UA]D/S>FFMM#_(W;5_2M1?];ID?71/\-?U7]SKR,/^\Y_MK^4&K5\[]`G<
MGY8<PM0JY(Y2R9Y\+O%[G`IR[91Y%'EZYLG,N5CR2+1)=JJY9&<MB@JF55,Q
MB=P`P>OKJ/I2=X&;9CYV[2A.?N)K*Q/CX#M<[3[#@X/AKB5GCX.5YSC.-M;A
M7GL;&VG#88J#@X.#^@=,O9N5K[$+O6W%FC2R6:M>)&P\AKLS@8KVNXNY?.)_
M*V#)A6#KR+=GY+IC<WA1;*`(JK>4/FE`H@;H=JU%3M<C%(DCI6GHQ1*BEG+V
MYIXNH'5NJ)C:,CS'!]FA\!QT_.\!QMN$J.4O<I#6.3B,))2M6&..I!WP+@Y/
MEW#!)!'D6YC*R5/O;R4SC1<(NN?63'TY:JZ!%4"ZSKRG:[*JMJG9&K*H:(XA
M6C*Q(1[Q(Z;J01E(M1`PKLQ.!4S6HIIYI.-CD7L6;/J&+C)H6*2&.4F+>C2Q
MLT6QA*`+$#3J-K,J/TS$;MBA/R$/SE'Z'GO5Y@"JRI$!N*HP#EXRR;HI!%GN
M("R]<9T;XA&(Y9!V*=N<9<(E*G3^M5ZYL5$80750=9&2$&1=3R@RY6K6+LCB
MRL$8YSXQ2\3CQ+BB1-0Q,<G/5WXZMR!1E-JFLX1WC0H7M24XX9&9Q&DLDL3$
M9?8J%2[*6`UEHN#M3<D_&*RB5;"QH2&VRH8/>6L1=,O!'$&);&79&6,,1C49
M9W\4G)M3KWME%S*]VVZ*:M5<@9YU2;MB&@.WMDNE<E;5`O$M`I&ESN4I12D5
M".?:3*39%62I`(N0AA`!R%.Z.0>O%1C>269K"MC`6+W;LM(7D8B-E[4PE5HV
M<$*8\]TJC0)*O86:6RZQUXH$FW-G<T<CM$N(@#*K&91'L=%?S=W':5G66*9S
M.8ZE+[W`T[-+C"Q>%,K[%V;2I6QX[,,HJ]4EEYCRM.LKC]++JS=_YHG4;C(Q
M<?'O44/$5T5-5)0^*M\V/S.O^K*^8J4%::2!RJS&58UD(<1K(-C`*KM7LO!,
MN\1R*CAPLZOQ;CG:7"SC=;L30J\9+1[%E/1NXRD/&3Y5F@$T;_OD1=/-J/R<
M])V#L[F.L6`:%,YC7^.>8;W8=QB)G,H]HG%7M63;OW;S.%;XYL\='11HM45"
M-@>K)G16#L9$$%EL_9E>#G^2X:>!H%I\O2HHQ=71VNS+"LC-Y2L<>6D9F53V
MHI20',2OB*L3V^%XKDZ;&S8Y&I<F[2H5D!J11R=M$ZAY9>XB*B,WGFA"LP$Q
MBM[4MQI]MC]<GV+>21K>-62=KDY8'GL98F?<5BL1MHG'M;6;NEE',8Q2D@:&
M45*D87B*I``0+WZ@S\BD/`-Z@"X@VV#&K="_N\LE?/3P#V(GB4'#94D@`J3(
MBJ^\<G%Q<+JTLB0$LO4(;"AU5OA986CF;&5V2(02=P%84]IU^D<$93D1,R;2
M:T69:H:-`M[)'D7B8>JWW1HII38$6#(8M4[5CG\PU4`#J>:5TJ83',`>'J:8
M9^/DX7A[9+W99:D%MV&)#)8#33J0/*LD#/[L,#&(`2"229G%05.9YZX$#)QA
MEMF%5.=J58712K==R2RP-.#URDN`?##@W7ELMQ_UG0&-I@GMAS&B<:J;K:L3
M48DC[0):X6[<7.3,XV)4=231@Z9K@NT`C<Q2&!43G\P>X%ZCFWVS:C[4DMD<
MG7J0)&!EFGK-*`V2`,NNW>2J1@[I"$5F%OB^-?E>%XF[&RI:NR6^\S9V+%5H
M17&90`6R,R'`W%@%51N\?DO+Q29A7'MU#O>*WFI;KF>27S.[M&4&\6)D.D1C
M2?K9O;:9H;NJ-F%CK\JV<E>(2#MTP`PD5:"J!B%^P3FQ8X<+Y1R'(7:SQD`L
MLE*O=DDC:0$JOGJ[TEB[RR#:@PLAD2'/&:]&W;8'LQT:]J&7[62*:W7K=Q$.
M"VUY6B=).V48,W4H%=NZ'\2/"<RIY[C:(FW,6[5I>PF8YTO5(M2KV*D:C$8W
M\TK3,2]@8UZ`?V+0)DK5H]<NDXQ)!NNY<N$$$CJ!C5YZNU*M;V$-:HT;"HSQ
M(5-^.66*N[.XC69(Z]DR#=L#0-&&,C1JV4BX2S)=FHDA)(;%E#E7.Z&K%WI+
M:*%+O`T;0-#A>Y*+4!1"&.$#,?B99AL413U,WR_0;K;[AJTSD*-'IUKQNXC%
MST#21T20E7>@UC1)3+'T"2H%,X\UE,N%`6(+82`X#R^LA6O17#":RNT#P3S2
M/C"P)6FABGWYZR%%GBE40B3NJW;BWS?-Z@2TY*ZSM89$[/9P"PS)[QW%@``R
M4,DL3Q$2A.U@32[(")-.NK\WX_5*)R!N='H%MK%2Q9G<F9-.E9C'KBUDK/2I
M@8:8A2Y9!:B31(26;*)'6!I8FD&"B'A-YA1.0#8Z;EG;TN/4:J8(I7@[6>W/
MOCFF1`X,4AC'1U#QO(LL3/M:/N1N@E#C^WS"\0^7L!)&D4AXC'MA>09$B!F5
MBA[;(K)*`'5NTZR:\B7..7A]*T"I7'`+\PS7/X7"7[C<&=BS9:&>_3:QB_=4
MG*TI&YKVR$C/>DJDF`)MW1D2F'S?!V*)LRD[R<S:XF:!J\L?J$\9'EU="=DL
M@E9QC"`18R5!;>@"ARR+CC$?HNAR%9_>6M<+)?951E<")T1HU3KN8!B[;20@
M1SN,:[].&?U&#UK8>!$Y6V,HVAZ]\3)U049"1*T*WL+JF<>^443(3T$9HY<^
M?7GSLAO955/+.H4HCX0#K4_4DXN^E:G*Q@K7N!)HP?E=IMX1CC(&\#<!G<!T
M8`]-;#P2"OS\]'<KR0(%=EZJ'*HS1Y\=T>0K],;ODDCKJP7QG`[PG`8/K\Z6
M0?W^*?*7KCGJ#\D3'XE_;#7??\JO[_<?]67^)DUQU1Y09HK&'>B[22D$]@#&
ME*RI.5L+,6:^>/S,/.##!*B^]PIN>[H1\OSO9`\7@[^CKGU6I);6O)&1VK%6
M:?=@E42!)7<.1D`XB8#V9(SCKKUQ8YNE6EM02$=^K/'$5W*&=I4B==BD@D?/
M*OADL#C/33VG=VQBL02%GL.GTV'KSJ!<VAK+O)=,C1S76<BC#NI=L)"G57:(
M2RY&P^`IC^>8"`43>CJPJ.S*J@EG$)`P>HG4/"1^-0AD^%3GPU*?DN/CKM;>
M:,55[V6W#:/=RRSY/^R9663[E@0>NH]IG+S!+I&+3;>^P<3#.='L&9U.2E'Z
M`(7Z9KIHQ-T\J2;7SW3Q@LI+(E*"B::I!'[84H=NI[<3?4UX^V3:L5UF$?VZ
M(S.%W^P9[;$$$K@>.>FL7'ZJX"1))Q9B%%`F)2?(^X`D+]MN3(#*0#DC`(ZZ
M=;;DIQ^>R]P@6NPT1>8S])RXNC`DP4%*XW9NB,GKA\J9(K<Z#)VH5-8Z)U2I
M"(>,0#T]1(JUB>LEV%&:K(\2*P'0M,_;A`]OSC^5,]">F=3I>:XF"Y+QTUB)
M;T$;O(A/F18UWR$]/M$\S#Y0'LTY$MER99S9V:.C5%5S2F#Z4MJ1)=`PU^-C
M"H&DGTD</M:36/!RF"YP$P)&.`&["/;JV8I!$TQ5NTI4$X/0O)+$@^J\D$R+
M]TT3XSC5Z/DN/EM>XQS1M<VEM@8;MJQP3,WU%BLUY&/@%FC)^5KU--7S-]'1
M,NSO=9<Q<])V*%A7Z4DF+:3EZBC)N+1&LU!``5=P"$*\.Z)Z!2*V4$?T(]5S
MP35BPL*4*0"9L^R)BH$A_6$NH!^%A\.JHK]*>+OPRHT)9%R#TW2!61?JNK*5
M'M!&F(]Y3<<8ZMQ=P>[/14:M-RCJ%AYT)%PNPDI-BB@N\;LSMFBRBI&R+E,Q
MU@+Y``</E]Q[=731N"PM0Q.++KN52,$KO,>>OAYU*]<$D''3KJ$WJ'@UIOR#
M6H?<DD",^25#E!(%Z`Y/;(;IGIXZ6I7D%B$'<87/IC4*G&W2QH13J"K[IVX(
MZE6\XB#B&6:.2M31QB2:!@,CW6+X^X!ZQ`.OD%&Y:DDAKQL\L+,KJ!U5DR74
MCQRH!)QGH,ZKL\[PU-87M68D2PH:,D]'5B%4@@8P20.N.O34PB`@/8?0(>@0
MZBZRNCIIHZ::.FFLAZP^R'YO336VA_D;MJ_I6HO^MTR/KHG^&OZK^YUY&'_>
M<_VU_*#5[N2E0KV@_$"W^AVV/)+5:Z?#LX[U:QQBAU$R/X2>W;F'&230RB1B
M*I^<T<F*!BB!BB/<![]=/],T(.4I7N/L[A%*B#*DJZG+%71AU5T8!D8=58`C
MJ-<#YV[8XVW2Y"HVVU!(70^.&4J1T]OU-5RB>`]?4JEYK&D;QM>S+6C()+!Z
MM8[X&=M)W+,LF5XYU+5ZGGJ-*KK&4=R;F$CSN)&;1DY%86*7C6$!.!NCHDQ)
ML6Y7GY.2[5LS3L%5YGINTD*LD:K$B!WD9A$B%^YYB0D>S4Z%_P"BK]2SQD:P
M\?19FAJAG:%7*[-[%V:5W6/,:,[L41G"D=R3=,%XXMT:^SNC3\K.VIH[TUCB
MK";28+196[)+#)6?EZP>,!Q&KJ$4E'%B6*_\TR@&(0GE`F/<1I6NJSP3@G=7
MYU.57X#/&(P(S_LCVUR!Y^I\WAJ"C&/A8>"'_P`6#B[5`-]L8K?9[CGV=Q>P
MNPXV]6RIZ89-RX,8Y>M#W_2)Q];QE.0U&K=+L$6UDVS>&J#FM2B,ZC<J0@5I
MY\=;96;9,W+Y991=%T+)(ATQ2\9#8VKPL-&I9KT9)(;%CE1R"S+M,D,X55(C
MRI4QL5#LDBN"_764^EI6MU+<T<<AJUVA*-DI+&RM&!(N?%(G>)63:=K9)+!6
M"S5N+DNS+1E=.Y$:SN,IG.K1.L529NE<QRJNV4A$UN:K9:ZX0RW.*.P?P+Q*
M<5<*G62.]\\I?"N4G<@Y>NH@M17SY[L5>U"6.!O6T8BQ95P@,?:41[`HP3NW
M=,8R5@]:6E$!'3E6(;02VTPL64AG+,2<[6W$@@9QNR=-Q#A8PD=ALNSZ%N&F
MZ=8)6@7_`#*KL)VL8Y6V^?4[15459J'A9N@YS5K78F+7V9/V9"=?2:)%"^:8
MIE1$XX$^GH)>(Y#B[<TTT_)434FG.Q)#"V<_-QJD#2`G,<CQ,\/G$1199@^4
M;F)A?IVZZ)'4HW1;C@&YH^^HVJVYRTJ@)N4JKJKAAW`Q2,JK/^)$.R<-92M7
M:VF1C^."G'64H$F%4-3M,KT3&32%.>W617K#VQQ,E`R,VNL"L0X9HJBJ/G)*
ME*0H2O5=*?U#7]0'RM-SU8*T3';%',IDVS(P!D#;)&C(9G3;@A`_FU"X21.)
M7AJR,R0\/.[I(`&D=)5A62-P<*03!&X*A6#+\K:2I8N?<3;AG?!6D\48VR-G
MMK=5Z#KFJ7=S*NA<OC6:;3E]<L,9)KLW#J6EE?;'9&(+D3]I+X`.9,!]&7]0
M15N8M5:V-_!Q6*W>5AM,\$#*\P*J<));D#2R8)"22,WF]M'%V6H26N1B01<@
M\4[5TR9$AD,9BJ0LYP9(ZT(C@[A4%DB#;03C5M-#RBDZ9EEEQJQ1IBT2S5;Y
MH+1\>J=DM'13=!!*)/%+I"!FCN#59MUFIP]!%4""("`"`QN:@?G%E:U+(ER2
M83"9#B1)Q)W5F0X(#K)YNH((RK`J2#3P\GT&8!2'S4$7:"G.&C[9B9&(P<-&
M2I((89R"#@ZJXRX*P4A6+U$:EN>R;3:KQ#9U4ATN\)9W&VZN4+,+O#Z%6Z3!
M-*32ZS5QC5;/#@N\=N6*\D[,NH*C@QA*);T`:&6*T[&2\O(+=ED(`,\ZPO`N
M]5`1$6-R`D*QKGS$$]=2:MUJ-A'J*$HPU)Z\,&6,42V(GAD==Q+M*8V"]R1F
M;:B*3M&-2C8N+-&LMNOUS>SUK0DM$UC(]AEV[9:*!FSL.-52(J%=CHXJL:HL
M6'DH^&34>E4.HL98QA3.F7L4+-:NE6>A/&26X[D+=R//@TER&S#(K_K%6TY3
M&&W*FXD9!L6;#VN*7B9`!`O&)1R/E=J.\M\-\&\RJ$)QM[>0%W>;4<SW`K(Y
MR?Y#VHEAO<18.0E@H-O/(QS^).&46W-I%.QUR?S)D^BG3!JJK=R#./FTBF^9
MOWZAP7240.9(<=1X6/C..2AQLLD,L7)SWHY@$:1'L&0R1892C0GO6`$=&Q[S
M-@Y(Q/DY5Y[RW+44<J^XFK)&V[9*C1K"7;#!DE[,5>,/&4P*T+C$@+%\U#C-
M(Q,AF=@T+>M0V>VY1;[E;:Q:;C7\EK#TWSSHSZB.(*0C,QS^E03F*BFDDN[;
M']F!T+I3LJJHD!4PRL40AE-F,D6VX^2HS^UEDGCL=TK\@2(T2(N%"%!YE+'.
ML?++W8FKE0*K3PR[.N`T.[H"?-APV'R2>@V[3G,<Q_!6&=7#6+]HVX:CJ]MU
M7,I/(#S<_6L;J3^J4&3FO?GN2,<YIG%.5LB<<Z[`T-/#*&;@`F((',8PXA."
M@^B[''SR2R3VS6,TQVJTGNLBRQEHT"P;RZC,HB$HC+1*ZQL5U-EY.:2Y7L(J
MI5JFPT4(R41K,30R,&8M+^]L5";]A(#LI=0P4M2XC*3L3M#VC7NR)2VG<<FN
M*_,&:4K;:@R=FJ-65K^::-*3:59=W2(L567*@M_D+Q-D<Z(',V,<`,%7J3C9
MN=J\Q"'VMS-^O:/L%6:.='DF@(&XL57(24NNY%"[,EM4</9@XV3B1,ADJ\55
MFK[0<-9KRJ=T$I\$#G*=R-0R"0L0P4+IN0^2M<'/\(S'FSP\F;/>7N>5U_+*
MG.LO,3+3BWR<&:EW"ZOVURM(RAU5!4/\L_<!-Z>OG^8UJ&[7>>L@CJ=]!&@&
M`J*&```Z+GJQ4=`6(&I'H^.6.ZS6#NM2*[N<YRS,#U/VVT83<<%@N<#.-6!^
M-A:*Q7ZQP2DY^RUV"C8SG0P-)2,W.Q4/'QQ3<6N4+<HOWTD[;-&0'<*D3`53
ME[J'*7UF`!X/SR._$S*@)8@8P,GY0^#7H;_*^:&#UU0EG=$B!ERS,%4?,R#J
M20!UZ=?;K\^S#*^,+1,DZII?$)33"<CD=J^DCW_E@VSYOIZ.%P-7!M!GWSC]
MX'@P]A[^?[/W^3_V?6D\;+9H)4@6.858:5F"5%#*LIGCG3)`P",R@MNZG:?;
MC7IR_2]/7K-Z[+/QK7;%F&6*1FA9XA%%`@`<DL"&B9E*D8W#VYU"<!0X!W:-
M5M4?N_'N)>43?X2>XV0VBZ73OFLI0("6-?IV-F@A+"^ED("UWVPNE4'3=,RZ
M0M"B5,`*'4GC;-OC>+XZ81O)RSPSQVLAP>T$EIU,$+Y)Z]5BJ#Y.SM%FSK#7
MJ''\IR_*,+M:*G'8BDHYDC6/O%X;5I&4/\]3FGC4NV`9'>PI4[<F9,JJ5"JV
M@0.C7?DAQ;>2R>@[_H,\PIFA5./8M'FV0]9C46-7<2$TDY(:#/!J"JZ7*FLX
M!0INWB[AU'FV-PTW"016A`_#Q4%<KA\)/-,[D+T4,)<!%)&5!/CK+0;&YR#U
M!>N\5[TG(+:>-)%,>Y*XA498AI6!&XR2`,02OL&65%4-L%=K]%F>3/#(E6RB
MD:51\DDHV\0;V>FT-*23BG<MJ$7)3",*DI%P93&.SC5%T))V("N8I"`/7V\_
MTH9;MZ&PO)6JT-698MR0K`'B-@PG&\3%(E]U)`6LY9ESN.K="*/BC!1I7^.?
MB:%Z2Y6:6</8DF"3"NMML[74-.QG=27E4*,=-1\ZQZ@46M<>\GJ?(7'++5Z]
MK%JK-JLYM/HRTHXXT6\"7^WP>D23NRIC(629N=48,"O$P5]I37+X@*8ZG;(P
M<E9N<]'R%Z)T@BXSYQ0I"26J,J#BI$&,F6)6+2*<*0UM@2-NM>GX*AQWIM.!
MH<A7EW<D%23NH\RU;E9TY..:0N#%`QWM`4)"-#Q\!&1E)4)38P+)'P8<F^)#
M?'ZI>-ROM731TR)7T.4D=K@+FR7CK*5:83K<?'5N5NS@R1F:BIW#9(@'`I^X
M=89A-8XN2&W'*>3;C$HC:I[7;CFC=)&R-YD[<*(RXVEF=L]`#M<TB#EG-2]Q
MB<&UV"SUE7O[H8H8S%@-VU0LC2*X._HB%<%B$C1\?RR?B\*6A=GXE7"7RO#F
M^'S=;ON_V"@TR0C`3@UWD["26/W*.L1E5WT,*9F#Y,[-5NL)C`"A0ZR$]Q['
M-\G=>"84>2L)*?+NDC[9<*@5@8F4HY!SU5E7:=N1K'2<=0'"<71CN\>][C@X
MPU@QPOW!YGW0N)1('P5/@5+!O'.D[6<?I]]FZZW@^17%:.H\.TR5.&B)3D#8
M2#E26=2,7)3-=SFL0]P0J5GA;.X8"?VJR%</4CB7L``'HN\9R$M3FOI6U'8D
MD2W)-W.VIEG1H7BCBF##MQ"$,`K0`$@>;J=0.:X:KR/&0<53N<5!2%18&C]Y
MDV5R)A,\M<+(#8>4C#>]'`W';X#72L^Z8:<YC?3?C`>(PCV^EC/OJCW_`&1=
M:_[M8_!R?L6^QKH2\OQ`4`VZF0`/WZ/V#_2U\?3EAO\`IOQC^%C/_P!T73W:
MQ^#D_8M]C57TOQ']+J_PT?WVCZ<L-_TWXQ_"QG_[HNGNUC\')^Q;[&GTOQ']
M+J_PT?WVCZ<L-_TWXQ_"QG_[HNGNUC\')^Q;[&GTOQ']+J_PT?WVLAN>&]P_
M\[\8]8?_`)8S_P#=%T]VL?@Y/V+?8T^E^(_I=7^&C^^T]:);JD'P5]HL`VRK
MA7C_`!28R7)8!L4,$":(#XMN2.AERS0O?=AHH&H>:+D%?)\KY?B\/IZZ#L?\
MW-F#O]VQC!SG;X8\=>4!8K__`'";'<C]W^F<[]PV8[@Z[L[<?'G&ND^YR4?#
M?$@V67EWS2,BHK@!QIDI.2?KIM64?'L=_P"7[EX]>.53%20;-6Z1CG.80`I2
MB(]=2](V:]*"Y;MN(ZT:(S,?``;NOP_H#)/@`3K@GJ2":U+5K5U9[$CE54#)
M9B5``'M)/0:J;IOQ,>*-+P6\;Q2-%@]:BZ;-P523K\$I8*X\E+G:ER-ZU!N'
M<_507A(^5.<3!*JLU6!$TU!`YS$$G6U<CSE>C7HSQ*9OI#E(J$77:.](4+[R
M0=@AB?O.&`+(,)N8@:UVKQ,T\]J"<]HTZ<MF0XW^2,'`7!PY=P(QM8A692^%
M.=/'9N9L-AL5Q1E+?GLN[2Y/7.#J#M6#LD8\CLI3E*<>WR%EG9-2/0+9:_"H
MD\DZC9)L94!!0`*`^#K-S$0^K8_2F&+R[U$I&!W>X(88BF2P,TI"!@2J'JV1
MUUCJT3VO2]_U2F/=J$44I0'+2133+$KH>G4*RR;"-Q!VXR"=$]S.@8?=MSPY
M&AR*JF&XY&ZQ*:#+6J'KU(G';BQ(U^9I*+QTR=+P\G6#N45GCM8%$`!8A`)X
MC`/6%BYI)^+Y'EHT"UZ')PTO.X3NR2E`S*2#M6,R*JY![K'"'QQD9^*D@-%2
MVY[J3.0JDF)8X)+$1;KYQ-'$Y!7]["DMGPU*SGE#@<?I56QB5TVOLM<M\9$R
M</1$D)^3=JI3$0:<9E6FHZ$<5MCYL:F=8@NW;8QT2^/P@!@[YCO5GY*YQ4$@
M>U1:3O`@IL$?RBQ;"@J""ZAF*$[6P01K&".<<=#RDJ;:DZ(RD$-GN$!<!<L0
MS$!#M`<>9<CKI&K?,?B[;XS3)NN;559*%QQB62TV9]CLS")JC!1=XU1=+2,I
M`,6<PFY=1ZR2(1IWIEU"@5,#"<@&A)RW'/Q*\XLH^BFD6-9"K#+OMVJ$*B0L
MVY<#9[?B.)GT;>^D$XH1D\A(KLJ`JV5C&9&W*2FU!U8E@`,G.`<+V>\G^/>K
MQ-1F\ZUJK6J-OEMDJ%4%&GO9DZG+K$0DC9I*L(Q4Q%QLNSEFM=B'+[RW2"`'
M:I"H03%$HFGQL)8TEC.Z.6"6=2.N8H9.S*_Q".7R.#A@Q'3!!U%:.14GD92(
MZO;[I(P$[SI'$2?:'>1$5ER"S;<Y#8\KSE5QX:R-:@D]:J+JQW=[:HFDP*"\
MFJ]LTS2YYY4[+'M1;Q;@C-.%MC!2.=N7'EMF[@H^(XAV$8DEZ`(YA*O,M/WD
M+G`,)@DL(Y8C:B/%$[AF]BGH3A3*?C[4$S16T:()+%&Y(R5:7M;!M!RS,L\3
M!5R2K@G`R1)&:7=MI-"J][9HL&[:RQYWR:$7.-;+'HBF\=,E4FL^R;M&DHF1
M5H8!532(7Q=P[>COU-`/9AE(QWJT$V/@$\$<P`/VR@2`*XP)%PX`#`#'JP9Y
M%'_ISRQ_HQ2O$<_`<H<KU*'*DDC.GSU\U5HZ::.FFCIIHZ::.FFJS[?^_M\.
M/[_6L_@T<H.M5]8_D@?CE^LVMA],_E$_BF^N-+/QM*I5;#5>"L98:O6I^+D^
M<[$).-GH")F8V1*GQ9Y0NBA(L))FZ:/2D<HD5`%2'[*$*;]$4!#B_/2&/B)G
M#%<`'()&/,/@UWW_`"NKPV?7="":-)(V:3*LH8'YJ3&0P(/7X?;KB31Y/B/?
M'UK]CXXT2O5*J#9P/J=RP?*Z[EDZ6ES:M=MJD#;EVBI!1K\P@HDX,^18%^UF
M,3QE*(]:`3<2C'>GF,0F6-TC>0B5HIANAE"Y(,<JE&3S;B)$RH)('JFL?3EO
MDIN.K<?&Z032PO,*T78[\!*S0;\;NY$RNKY0)F-P'/EW.64:\+V5)7T2*SCC
MG=JBVFXRO+2^>YUD-U:IR\J];L&[0SF#C7#,JJ2SI,52BJ!TR&\0E]75:1\F
M]ZIQ[&=+%V=8HMY=5+-NP<G[7RD%AG!Z:JL2>D(.*M\RD5">E1A,DIAC@D*K
ME1C"@^8EA@$C(R?9KZK#'AE;+98Z''YKQU9W:LW"PTES4)G.,BC+1*2U7!L,
MN[KU>6C#3$U"I`[+X722'@'L/<`[=6U-YZ4=^-Y&K25Q,2&8]N,D@-+C][\"
M?,<8P<ZD2P>EX.2/$V(*$=_*!4:.%3(74L!$"`9"`#N"@X(QIP6&G\/*I6G%
MQLE#XPPU5;0\I85)][0LF3C#PD(5,TO*-7)80Y7[.-\T@+&0\SP'4(4?E'*`
MVI+%N'(E>92-N02^1O.$R/$;ST7[H^&=2_HO@,$FM1"ABI)CA`#*"6!)7`*@
M$L">@!)P`=(+)+@C(DJYV4;PY7^>[9L\IJ7N7#$W-K;/')V356O,UF2;N7!=
M\D=`H($.;SR&3[>,HE"6\',)9>F5L^]QXW(-Y8`KN!(&>A7S`^!7S`D==8N&
M;T38I1<C%]%&A.6$<A6`*Y0[752P&61O*Z_*5NC`'2Y,U3AG7)-Q"6*H\3J_
M-,V;R1=P\Y5\4B)5I'Q[4CV0?N8Z0CVSQNR8,E2K+JG(":21@.80*(#U$2>W
M(K/&\K(H4DAF(`9BBY(/3<X*+GY3@J,L"-3Y:/IJO(L4\''QROG:K1PJ6VC+
M8!`)P""<>`()UF5J7#6"A8*RSE0XGPM<M"B2-8L,O5L4C(*R++D%1!*OS#V.
M0CII5=,!,0K9143`'<.X=7"W(BU[D3/[[C/;R_<QTZ[/E8ZCKCVCX1JV:_I1
M:0Y)H^,'&L<"8K!VB>HP),;">A\#[#\!UZ&.=\9)&\S>>M<)QPU@@*Y"VI^8
M<8SD(TT3/N%VT<=J^"`,#A<RC<PF*!``I>P@(]^J4EN20S3"20+7LK`X+,")
M&B[H&,^`7Q/3#=,:^FGZ>%^+CA4J&>:F;*D0Q%3$)3#G<%\2XR`,Y7#9T\?H
M"P/_`$#XA_!#G7[F^J/>;/X23]DWV=2_H;AOZ'4_@8_O='T!8'_H'Q#^"'.O
MW-]/>;/X23]DWV=/H;AOZ'4_@8_O='T!8'_H'Q#^"'.OW-]/>;/X23]DWV=/
MH;AOZ'4_@8_O='T!8'_H'Q#^"'.OW-]/>;/X23]DWV=/H;AOZ'4_@8_O=9#`
ML"[A_P"0V(>L/_Q#G7[F^GO-G\))^R;[.GT-PW]#J?P,7WNGU1*;33?!5VBN
M#3ZH-<)\4B,A25P:U"#7R0P_%LR1H,.6#%C[K+$BT'RA;`EY`I?(\/A]'70-
M[_FYOW'?[MG.3G./'/CG7E(5Z_\`]PFMVX_=OIG;LVKLV[QY=N-N/BQC5SN<
M=+A]7YE\H<H?6Z&J:VB?#9X_UAA+RCU@1LT>2&[\P$&SEPR=.FP2<>@Y.3VI
MN`_;4!,0>P&ZZ/Z<K3V8935,8N5[-2S&)/WMI*LZV(TD`R3$[QA),`G83@'P
MUPWF9X(+-=K0E--TFCD[3;91'*G;=H7_`/3F56)B?Q20*P\-5G>81L&I)7.W
M;)H?&:JZ/,Q."4>`B,GN\[-4IM2\:OXWR0DYB;LL'69]:?GW+E5%HP38F91I
M4P\*Y_/4\&^34>[=CY4/B[+ZDXCDK"EBT:P\39,R10DX9YY%EG[DSJG</81L
M+"&.DF0+QXXI%/NT/"\I3C;&TM-R4,<3.T8RL<<?8BPJ%R07^(&=>4F,P'(N
M6R<XW_.V<'1E]A6GFTO8F*CQZIH.26.B5QS$@V762%Q!V64;/EO-.G]H1-X!
M$_8!M<AQ\EH7'KR)'8FXPPPMD_-V%LPV(I"5((0&+:Q0A\$@>.LEQ_)1U*%B
ME*CL+%FFS8Q^]0V%DF7K]L\6Y8\@@/M+=!JK%$X7VNNT:9CK9R`RF[:1=>-%
MQR_1KXYF?80MFN6[2HFW.+N=GYSH[:O%KT(V:&(!A<>>GX@3\)A$')\<;O"6
M.*@9$::7C9`6.?/6G-JWN(`R'FDE6OTRL(B1\;3JU4O15V0E)-D=^Y*HSNV5
MY>-/'58@3U+1@))+T5-S2E!ENLA2&*:BSY$U_2\[MO'S-*R6.I<5J=J@-PNS
MJV;O7J71C5MC2](QZ4J+K+AB@?\`@\F382;251;D\2AG`_:.KTT$MGDN4F=8
M!PMVS>F-0NTD5DV=^PS;@#5E+.&EEK&0='7M2]S>D)3''P]&@ID/(5H*T0L[
M0DM;ME#*U<J?GP0ICC2QC"L-KP[-K117>)^O-J#H5*1T/CKEU0:3697?#\*K
M6V7[7\8@[]G.C):(YDIB0TJJP5UJ,+<UF2+1ZQ8FF&K4WA<M$4A0(@>W5CY2
MH:?(M+%8Y2A<CD@CE9C'''[M/5G06,&9]Z6&DA$D;-!/$L@E82%8I5J:E=LS
MQ21R0T+56=)Y(`(II9':.2!FB7$*)"\*K(L11;%>6:!T`.]GX]PK;9"=^Z%<
M7GBP');[H.)VA.C(Z%9D<.2BHG&9'"$J^ZO!:P-_EI8:Q*K28OE(-,1=@DS\
M(()`N-%:A-Q(+\6\<DMQ[K7!*Q"J;D5>(>ZA0VT1>Y5&*MM$TALRML:;`NSW
MX[U:S1M*Z53QU*I#LPS$5.1/(EI-VT)W9))8\)N[:;""QR`O<;.-4_DL[`6J
M_P"L8M/6%#)N1%-GUZK,%;(?.?=-V7V`JL(,GY2Z=:B6CHS-;S#$754(4P)B
M41[3)*B+PG(</"X+6>+HTTD.%S[G6LP%Y%!.T2-*DHC4N$(89.U2:;?)RW^:
MAY>="JIR26C&,D*JU*U8(I.-S*(&42$*70AB%+,HMCQ[@8G'\6SW,IR^425E
MJ?$.XY](Q%DC0C7:KB:E9,JC0'KENZ\LJ+\I1\9"CXBC]3L/61,B&O5AR-U?
MCZ5=NHZM6IP5G8?K6:(LN>NTC(!R-82.)D>=SX2W+4P^)9[,LZ@_&JR`-[-P
M.,C!U,?SJJG[+*K^V6$_5_5&Y?A'Z8U>VM\!T?.JJ?LLJO[983]7]-R_"/TQ
MIM;X#H^=54_995?VRPGZOZ;E^$?IC3:WP'1\ZJI^RRJ_MEA/U?TW+\(_3&FU
MO@.CYU53]EE5_;+"?J_IN7X1^F--K?`='SJJG[+*K^V6$_5_3<OPC],:;6^`
MZKALL]`/][^'&@PGX)^O]WG6S^0PF8QZOX"\:.3X&/Y+5TJKX"B(=Q[=@[A]
M?K5?6!4\0`",]Y?K-K8/30(Y$D^';;ZXU)?QG1`8+@,)3%]/.=GX#=P$O<>*
M7*;L/H$`,'V!](=<6]09^AYL>.!^V&O0/^5/]_\`C_@W2_Q,FOSZOL`W=]9M
M1DZ=!9MAP6FHZ!&.W-3OTI:Z=K=MGG!25FWVG)9:IM8&GV!HU\:KA^*THX\Q
M02?*((B/.X&@CXQ:]C?+#M@W5<[0DBRI)8>M:ZM`)562(!8R<21N6S"`WJA^
M-Y,^H3R%2.O6\T[-95F;WD-"\=:.S4VA9&A=TE,IEZM$X5`)SM9&;<.]2KE/
MV>&5CX:K$T*U8S-UNN2VT6#75HM'/W+U6RKR5RE*C73`M*`N0S=!!B5,/#X3
M"'KZSPY:JL_#.S%UH<U);D*Q"/$+JH6-1N8R.I4DEBH.[V8.=2K^C>9^BN:K
M.J1V.0XB*I&&LO/NEC<.TSOVT$:29($:H2FWJS!AM>@<9=-6UVT/EJ=D#:I6
M/E,/(-+86L\Y-J\5`-&8)-J8A`FK('%^_6^UBX)+IM$6QC%.@L<P&+B*$T,?
M'4:EAY(GHTK$96,92R\ZR+LER1B+$FZ7.\R/'&4$8!!V3G.%Y#D.1O25X:QB
MOFH!.S8FK+692SHNQM[OMVIL>+8KN&WZ;$9Q4VR2C:OG-FALJ8Y_F>/<A<NK
MEA+:GEEE[L[UHD22NSLE5%ZI&L:HTB_=8&<MA<OU`4$#$4]`!U?N<BESCKL[
M@CF;=6FG;'[VDE5F8GO'J5DW`+A`4P2=V0!,BH<G].!9(X!P*<U+<,A8M))%
M*)5"=G:%1D#^?=(ZR!L#9M.YG;-Q"WC4ZE48)M4J%7#1&515+B(>J[2\H\'G
M%OC)5\K)VE\K6,R:O-:C+,Q%HHC'K#&)Q:Z:W851<*''*U>7HP>I_IEFD*&_
M6L%V3?\`,Q]MGJK"7VJR,LBK9W'>KQ@QJL04Z=<])<[:])U.`$->-H:=FNR1
MV#$HDE8*EQI$A#2@Q@.U7$9#AU,S&3>MBK%Q/:V>Y_.J<JN<3;E?D=1-4>OY
MAJW?2;JEUBAU>L/HQ=9S%K*+.57L0X[,#'%JNB8HJ&$1$H86M;2LM9(\K''6
MY57`\#+<6T(&_7;#+"23^]E2R`D`G8.0],SWJ9BD6%[)GXKS-U/9ISI)83."
M1O0.`H_?-VUR`>D9)\6=5J$=6RPM#QG4DVU'VO.3T^[V<\+6Z"VT34)>Z5RZ
M5(RU+L;5VYCH-ZFS=1Z35BN4`\"#LA"^FN>W%=AGI3/)%[S6X]394;IHVJ5^
MQ(BC<I9&)[R-O7YV.,LI'02)>$LU.33E*4$%BM%;M,*3L(Z[)8$+K/\`O<BK
M822-X=NPKV)I<$.V=6:QW&+#FEO-)2,O'S,2WQ?.,Y0?D<K^\GDU45G:LFZ5
M9KD.+>,.#@"MA,NJIX"@!O2'<5J]'8/(-ALVN1AF3."2D5-:Y:0C`[KNN]L#
M!+$Y'AJOB."N<=9HRRNKI7XF2NY&<]V2]):PH/\`Z:(X122#Y0-N-63_`.DO
MZ8OY_6,UM6#H_P"DOZ8OY_33!T?])?TQ?S^FF#H_Z2_IB_G]-,'60]8>DOK#
M_K%^O]GII@ZV4,0_$V[5Z0_*MQ8=^X=N_P"-UR,/7ZO7UT3_``U_5?W.O(H_
M[SG^VOY0:ZO<H/Q2/TJ1WW:7XOSY]?1["_-/[I3Z`_G7\T?G):^WN#Z2/_JG
MS>]\>T_]A]H]I\S_`*_CZV'K\>=<E&,],8QJOO\`9R/YG#^1]T\WQZJZ?%^I
MH_LY'\SA_(^Z>;X].GQ?J:/[.1_,X?R/NGF^/3I\7ZFC^SD?S.'\C[IYOCTZ
M?%^IH_LY'\SA_(^Z>;X].GQ?J:/[.1_,X?R/NGF^/3I\7ZFC^SD?S.'\C[IY
MOCTZ?%^IH_LY'\SA_(^Z>;X].GQ?J:/[.1_,X?R/NGF^/3I\7ZFC^SD?S.'\
MC[IYOCTZ?%^IH_LY'\SA_(^Z>;X].GQ?J:/[.1_,X?R/NGF^/3I\7ZFC^SD?
MS.'\C[IYOCTZ?%^IH_LY'\SA_(^Z>;X].GQ?J:?>3_B//I=R[[FO\6#]-?SM
M4^8_T+_<R_27[9\V[#[?\U_F;_\`<OM/NKS_`#?9?E>S^9XOD]^G7X]?#CXM
M6&YG?B\OF)1?NU_N8/HH^DMI[F^GWYE?,WY\?-&W>Z_=7SJ_^F_./W1[=Y/E
M_;?9_.[?(\?0^!W>'QZ^Q[MX[.[N?K<Y_4ZZH%_9IOYJ?_41U:^9_6?J:E?S
M_P#V_P#KZ/[--_-3_P"HCI\S^L_4T_G_`/M_]?1_9IOYJ?\`U$=/F?UGZFG\
M_P#]O_KZ/[--_-3_`.HCI\S^L_4T_G_^W_U]']FF_FI_]1'3YG]9^II_/_\`
M;_Z^C^S3?S4_^HCI\S^L_4T_G_\`M_\`7T?V:;^:G_U$=/F?UGZFG\__`-O_
M`*^C^S3?S4_^HCI\S^L_4T_G_P#M_P#7T?V:;^:G_P!1'3YG]9^II_/_`/;_
M`.OH_LTW\U/_`*B.GS/ZS]33^?\`^W_U]']FF_FI_P#41T^9_6?J:?S_`/V_
M^OH_LTW\U/\`ZB.GS/ZS]33^?_[?_7T?V:;^:G_U$=/F?UGZFG\__P!O_KZL
MY&?BG/N);![%]Q;]PE]))/>WL_T<?<Z^]?INKWA]N\O_`.SO>GTF^Q]O'\OW
?SY7_`+WP]7.FWV;<?H:C?.=S[;O[OCW9S^GG]77_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>v371611_tlogo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v371611_tlogo1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`<`!B`P$1``(1`0,1`?_$`,<``0`"`@,!`0$`````
M```````&!P@)!`4*`@,!`0$``@(#`0$`````````````!@<("0($!0H#$```
M!@$#`@(#!Q`%#0`````!`@,$!08'`!$($A,A%#%!46$B,D(5%@EQ4B,S-#65
MU5:VUA<W5W<88H)#8U2!D7*B4Y.SM'5FEB<X$0`!!``#`@D'"04)`0``````
M`0(#!!$%!A('(3%!46%Q$P@)@9&A,D(S%")28G*2(U-C-(*BLD,UHT14U!55
M%M87&?_:``P#`0`"$0,1`#\`]_&@&@&@&@&@&@&@&@&@.#(RD;$-C/)5^SCF
MI-^IP]<HM40V#?;K6.0HF$/0`>(ZB^KM;:.T#D[]0:XS7+\HR./':GN6(JT2
M8)CAMRN8U7<S457+Q(BJ=JG1NYA,E>A%)-.OLL:KE\R(OG*1LG(6GQ/<1A$7
M=C=%W`#H%%C'`8/KG;E/O'`!]::)RCZAUK5WQ^+3W?-!]KEV[>O?UAGC,41\
M*+2H(Y/G6K#%F>B+RPU)6.3BDXE+/R7=!J/,,),S='2@7D=\N3[#5P3]IZ*G
M,4!9,YWR?[B39ZE`,C[AY>'(*2XD]&RD@J*CSJV](IF2`?9K5)OB\3CO1;U.
MUH9/F4.E=.R8IV&4L6*96KP(C[TBR6]K#C6"2NUWX:<1;62[K=*93A)-$ZW9
M3VIEQ;CT1I@S#ZR.7I(#\I2/^/>_>SSOW6X^[/\`%?;/NG^G\+W=8N?\QU=_
MNN9?TGXO]3-^J_Q/K_J/SO>?2)9\%3_"B]_L>HWU/F\7J_1XN@V<Z^U`P@&@
M&@&@&@&@/A11-%,ZJRA$DDRB9110Q2)D*'B)CG,(%*4`]8ZZURY4R^K)>ORQ
MP4HFJY\DCFL8QJ<;G/<J-:U.555$0Y,8^1Z1QHKGJN"(B8JJ]")QE363-M"K
MO<23DAG'I.H/*PA2NR`8/#91\8Z;`H;^`[*&,'UNL#M\?B4=UK=)VM&MG#M3
M:BCQ3X;)VMM,1R<&#[JN92:F/`[8GDD;P_=KQ+8&2[L=5YQA(^%*M9?:F^0N
M'0S!9/.U$Z2@+)R)M<GW$8!HSKK8VX%6V"1DA*/AOWW"96B0B'UJ(B`^@VM4
MF^/Q=-^VM.UR[=71R_263.Q1)<$OY@K5X,>VG8VM'BG#@RIML5?DRK@BEM9+
MN>R"CA+FTDER=.3W<?V6KMKY7X+S%'2DQ*S;D7<O)/9-R;?[,^<JN3@`_%(*
MIC`F3V`78`]FM9>M=X6N]Y&;NS_7^<9EG.<NQ^^N6);#T1>'98LCG;#.9C-E
MJ)P(B(6C1RZAED*5\NAB@@3D8U&IY<$X5Z5Q4ZW4..Z-`=Q^(M6-_P!=/._S
M1M&U]NA@L-`-`-`0.R9,I55ZR2LXU%V3?>/8CY]_U!\0[=MW.P8?[T2![NL7
M=\7?.[MVXU):VN-3T79]$BXT*2_&W=I/8?!7V^P<O(MET#/I(2O)=$ZFS[!U
M"K)\.O\`,?\`=Q]:.=AM?L[2]!0%DY)O5NXA5(1)H0=RED)@P.'&WJ.FP;'*
M@D</5U*JA[0UJDWQ^,CJ*_VN6;B]-PT*ZXHV]FSNWGP^<RE7>V")R<:=I8LM
MYV%MY+N6K1X2Y_:=([ECA39;U*]R;2IU-:O24'8+G:;2H)YZ;?/R"83%;'5[
M3),=]_L3%`$FB8A[0)O[NM5N]?O&;[]]]IUC>AJ7,\U@5VTVNZ7LJ;%QQQCI
MPI'5C5.=L2.7!,54MC*--Y%D3-G*JL4+L/61,7KUO=B]?/@1C5*'N'8,8F5D
MS`2-C)"0.([`5DR<NAW]FR"2FI;IG06NM:3)7T=DN;9M.JX;-.I8LNQYL(8W
MJ=.UF%"BW:NSPPM^F]K?XE0G<;A_(\GT]JL/&Q!^/)*-HX"A[3$=KI+?YB".
MLH-(>'QWP-:*QU'1684Z[O;OR5Z"-3G5EN:*;R)&J]!%;N\71E''M+T;W)R1
MHZ3TL:K?23V-XW6YQTFDI:$C2CZ2I'=/UR_5(1!NCO\`44'65&C_``=-_N;;
M,NL<^TUD\"\;8WV;LS>MC88(57JL*G21.[OHT]#BE*O:F=SJC8V^=7.=^Z3Z
M-XT0*72,M8Y5Z(;"8C%LTCR#[0W6^4#[?Y0'65&C_!DW74=B37>L,\S)Z8*Y
MM*O6H,7G3&;X]V'2BM7J(G=WV9K)BE"E7B3D5[G2+Z.S0EWZ@Z!]9,_<?DOO
MG_9_[3[1]M_U?<U?W_RP[J_X>H?Z?\)_4$]3\3W'O?[/\LC_`/ZSJWGK>\V_
M=\O-ZW%Z>DNK6Q\K,CT[:ZW64>]/3+",+MU%3<+E\RJ']PT3ZW2X_P"@0VJF
MWH;]MSVY>A_J&]#465Y,Q6[38YYFK8D3\FK'MV9N+^5$\]?*L@SG.Y.SRJM+
M.N/"K6_)3ZSUP:WRJA14]R+8=9FE.@7LVY'<J;IZ11NV$WJ,FR;@J^<%'V&%
M$=:PMZ7B\:6;:?I_N]:6S'4><KBUEFXU\%=5Y'1TX$DN3M7@^3(ZF\M3*MSE
MO92QJ.W%6AY6L5'.ZE>[!C5ZMM"L9-YG:_=1#1]A;L%O`&;-H>OQPD'XIU'!
MFIW)/'^U54UA7K/4'B@=ZAKJ\^4ZLJZ7L8HE2K5?D>7N8OLNDG=6=8CX?[S8
MGZR;TJ^ZO2>#FS4WVV^V]Z6),>=$:CD:OU6M/RCN/-_>"47GR-$E-XF\W("X
M5#?^@P1=D,/]<->?I#PD^]7J)S9-0KI_(H7<+OBKRSR)U-HQ6F*O0LK>L_2Y
MO?TE6Q2O\385.+8CV4\\CF+Z">QO&5,.DTO:U##X=2,;&E)]4`<.G"F_^ZUE
M-H_P6Z;=F77^NI7\6U%E^7M9UX6+-A_D5:R=1%+N^Y_"F74$3F6215_=:U/X
MB?1O'['C'I%RWE)8Q=A'S\DHF0PAZ?L<>1B'2/L'?65&C_"@[I6FMA^<U<[S
MZ9N"K\;F#XVN5/H4&4N!>957RD3N[W-86L4@?!7:OS(T5?/(KR?1N/J1$;"P
MJL(B<NW2J=@@Y7#;T#YAT59;?^MK*G1_=/[M6@U:_2VA]-06&882OI0V)DPX
ML)[+9IL>G;Q(E=U=J?,,4MW[3FKR)(YK?LM5&^@EJ:::1`32(1,A0V*1,I2$
M*'L`I0``#5]U:E6C`VK2BCAK,3!K&-1C43F1K41$\B$?>]\CE>]5<Y>55Q4^
M]=@XC0#0#0$?E(->6ZDUIV89-##]S0ZR,:8Q?6"CY-!21`1#TBFLEJJ-;;M,
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M#0#0#0#0#0#0#0%.R/(;`\0_>Q4KF7&,=)QKMPQD(][>*XU>,7K54R+EH[;+
M2)%F[ENL02G(8`,4P"`AOH#A_P`RW'C]^.)__/ZQ^,]`2BI9@Q3?9)6'I&2:
M-;I9!H=^M&5NTPLR_28I*)(J.SM(]XX7*V357(4Q^GI`QP`1W$-`1D_)/CVD
MHHDKF[%2:J2ATE4U+Y62*)*IF$BB:A#20&(HF<H@8H@`@(;#H";T[)&/LADD
M%*%=ZI<TXH[=.3/5Y^,G"QYW953M2/1C7+CRQG)4#BF!]NL"&VWV'0$HD9*/
MAX]]+2SYI&1<8T</Y&1?N$FC%BR:)&7=.W;I<Z:+=LW1(8YSG,!2E`1$=M`4
M\')?CN/B&<L3[#_W_6/QGH"RJK<:G>HD)ZEV6#M<(9RNS++UZ49S$:9TU$I7
M+<KU@LNW,LW,8`.4#;E'P'8=`230#0#0#0#0'D+Y!%*.>,SB)2B/ZTKWZ@_*
M62T!%JKC+(5Z;/'E)H%PN#2/<)M'[JL5B7G6[)TJEWTFSM:,9N4VZZB/ORD.
M(&$OB`;:`O;#=0Y,X2R94LG5C"F61D:Q)$7<L0H%K22FH5P'EYN"="6*#=O*
MQQSI;C\!02*![X@"`%P?2!8+;4^Z0><JC!OXG'^<6Z<^O&2$4O$O:M>W;4DC
M,P\I&.4TUXMQ+IJ&>`BH4@E=%=$`-B!H"L>$>>AP!G2"EI)T+>CW+LTZ\D,8
M"MV\=(.2?)<^J`@)2FKLJ8BQS@'4#0ZY0^%H#9C]*/G\M8H4/@RN/@";R.D2
M8MIVR@"=I163G9NR.8H"!?G1+(='@/OFK58HATJ!H#2=B_&MAR[D&J8WJ;8%
M9RV2R,<@J*0J(1S0`,O)S#P"%$2L8>.25<*CZRI[!XB`"!ZV,7XYK>)*!5<<
MU)L#:"J<0VBVFY0!9VJ0!4>R;P0\%'\J^44<KF^,JJ8?1H">Z`:`:`:`:`\A
MO(+]N^9_XI7O\Y9+0&7'"3F92.+U5O<#:ZG;;&YM=F83;-:N?(H-VS=I#I1R
MB+H9238J=\RJ74'04Q>D?$0'PT!FV'TMN'1$`_5AD_Q$`^%4O6(!^4'NZ`SX
MSGB*O\@,1V7'<Z4J"5BC".8:1.F51:!L+<@.X*91\#""C!\!14`NPJHBHGOT
MG'0'DUMM4G*19K%2[2P-'6&L2S^"FF*FX@B]8+&06[9AV!5LN``HD</>J)'*
M8/`0T!]VBVV2ZRB<U:YE[.RJ45#0B;^04!5<L57XUO$Q#/J`"AVV;!J0@#\(
MYMSF$3F,80-Y7T7_`!S^:-->Y[M+`"6*_-#1U(2<I!WHJCIKE.O*)@?<R*]K
M?-RG*.P"+)!(0'I6,`@;9-`-`-`-`-`-`>0WD%^W?,_\4KW^<LEH#(GB5PJ<
M<J*Y<;`AD9*D?-*P,H(6BM6/8//^<BTY(70+EGX?RW;[@$Z.@_5Z>H/1H#+4
M/H@Y`!`?U^-/`P#^S=7U"`_EK[F@-UK9'R[9NWZNOL()(]6W3U=I,I.K;<=M
M^G?;?0&BGZ67&M=@;MC7)T6CY6=OK&<@K,FF0I4)!2I)0YHF64V]\+\&,J+5
M0?09%!(/27Q`URX&HL5D[-6+<?3JBZ4);KI#Q$P9J8".#QAU3.'K=$X_:CNV
M[<R77Z2`?J#Q`-`>NN/8,HI@QBXUJ@QCHUFV81[)LF5)LS9,T2-VK5ND0`*D
M@W03*0A0\"E``T!S-`-`-`-`-`-`>0WD%^W?,_\`%*]_G+):`_;&'(/,^&(^
M5B\77Z2IT?./D9*6;,&$$[*]?-VP-$7!SRT5(*D,1L4";$,4H@&X@(^.@+._
MGJY;_ONL7X&IOZ-:`V!?1R\D,X9BS%<*[DW(DK;H2.QRZF&4>^80+5)O)IV2
M`9D>%/%1$>N90K5VH38QQ)L<?#?80`_OTOOWLP)_U/(?_)5+0&MGA]_]2X&_
MB+$_\!YH#U@Z`:`:`:`:`:`:`Q6G>$G%BS3<O8YW#T%(S<])/9B7?JREF34>
MR4BX4=O72A$)Q)$AUW"IC"!"E*`CX``:`ZK^0CB'^Y*O_A:U_I!H!_(1Q#_<
ME7_PM:_T@T!9.+^,^#,+SCZR8PQY%U&;DHL\*^D&+Z:<JN(M1TV>G:&))2;U
M$I#.F:9]RE`VY/3MN&@.YRK@?$F;TX-+*E*C[BG6U'ZL(5\[E6H1ZDH1HF_,
MD,8_8B<7)&*0#U]0!T!MMX[@5[5.&7&.CV6$N%4Q+"0UDKC]*4A)5"3LBJS!
M^B!BI.4DW4TNW.<@''P.0Q?'T:`R>T`T`T`T`T`T`T!J/:\F\\H7\';BX3)Z
MLGRA<8D>,)G#T8QQ,QIA[N-;`SW,;06[EC8V[-4A4DSE.8[L2)GZNH1T!E'+
M<L(Y]2X62C:Y8(5Y>#\BH.)?IKPSQU7)#!D3<'#F7.T=E,R?FE%:N8[5$X"0
MICE*MN4#:`K*H\L[;'2<DQDHJ8R9)6%MQGKN+JHS3J]8F):R9+Q$_P`@VF1G
M9=0[6$C^LC%=RN;K\LAVRI($`HB.@(?4N9%QA(4;SD-.P2XQN-LUW64H,7'5
M%@V,-4Y#-,;PK$9=,IGR<]!1CPC3I34.R<E(=4YC*B4V@+R/S$=-S/ZN_P`+
MVUEE]'(E6QY&8M/9:BJO*NKC4WEYAI<+:D_-764<2LQKE5SW#B9!9,$O?";J
M`"PH'DC&36`)/.[FLJ5UO%N+(Q<5>R6>N0ZJ,E6[6]J*[%W9'CI*OM3N)%B/
M0;N&`PF`A.LXE`P$1B>4!<A\=<X95IL8E`67%D3D-B+9X^86B$)9:K5/G!'O
MV,I%G3:3T(N1XW/N`(G$0.F<A1#<0*\B.<J%>I'_`+.H$W`9$90F(G$=$R$_
M4&<;>4\J,G98:T$L2+\M<J429U"O5GY7ATQCTB!N!C#T`!QX7F#>\A9'P\SQ
MOC)Y+5&V5O*Y[)%_..E@]<VR@R4?$OVD98%908Y>&KRRR2I72`]N52E$#HB)
M4EB@!':7SKGH;#>/;/E&C$<7J_R>0%8)`EMI%1@INLTI\Y4EII*0EI4C&&-&
MJ+)0[1@Y.+Z3>HB<@"10%-`9`XXY1'RUD!O5J'BZSRE1)7*):)W(CJ8K\9'U
MV.R'3UK7`(/(%TZ";=R('1,S72;$5!)4.L3=&PB!EAH!H#!YOQYX['E%K"YR
MY8Y>JOKC8,TK49YER--C!W.0=B+,3MF7@F0-$'D36;&"9W(J+J-FRZ9"KCN&
MP@?*''/C?\^I9=OE*:/(-V&2[2GCL,I0Z\#4(O,,!)M+Q88>K*)*O(:-EV,Z
MJ\(Y.8R*1S%.4W;]Z($*EL?\5UIRGT^#OMB=REK<5Q["W^AY"KZPXY><:<5B
MQCI=S9F)E$*^Z<T>2$CD%4EB.RKF4,1,A0,`!K@SC,9M9Z5*V6RQM4A,=MZL
MGD">R93QB+3!YIO*V8%UXZ:.X6>.)@]@KO6FZ=(I$7;*&!'O^_4*!-LNXOP;
M88.SY9C\A1+.RWB>IEJH]O3S!$4B&&\XYK<C5*XG4[LV8S"4<1]$.G+9^":,
MAW"F,/:`2AT@<S'V!*4WXQT?"N2[Q%RIK+-GLD79JQ:TVZK^Y2-N?Y,AG5$G
MW_4XGY"*=;+(+F26.\*@=8Z728Q0`D]<QO@JN8VRE3C93//5_,+"U7"]6>R9
M#KLC,OXR>C&='L-G1FB)M636+2,T(@+CM"U0=#T>'@F`%;)\>>*\-51++Y>D
M'QKJ%'=4W(EDS##*6>-:XS<G:TDN.+(<[9J1A77LN=,A4TW)%#NNA;KZBE`#
MJV\GQ^1H&/LX2^1,FQ!\'2V8FE8D++>8IC?LE%K5A=?/JMOVCM5,MQ8SLC6"
M]AB@+<XM^TG]B(82`!-JOQ)Q3-T.F.Z]9<O5M!->4N]$DV-W\K9*%$Y)C47D
M_2Z^Z!@Z:,JO(@Z[BS4Y'!@<AW"K=0`;0&15)Q36J%8K;:(=S..I:ZQU'C)Q
M:9DS27=1Q_`'KD&LF=5$KCSB[`XF=JJ**&76'K\/1H"S-`-`:C+SP3RC-Y!N
MDG!3,8QI<CDE**K4223*@@TP;E)W(6+.\6=D#<>T]<6%\0&J&XBJFD(@8NX!
MH"3O>).4S7J<;L:O1FD2SR)FC)L;E]"=(%VMT1D2D3]=KV)Y.+&)2>LF,8O,
M(M72RSM1CY%DD*2?6&P@?-^X.V2UXIX[8^KC&N4![3,;7!EDR0K2D9'EE+T^
MQW7XJ)3EP;QX#;H>;L\0*$H=0.XLQ$P"(@;;0$EF.-F5+Y:"6.XTVE(,Y^U<
M/IVU5HDI'O(9-MB-C;$<D1K=D#/RKJ,:+RZ16*`E`KE`W3L7I$-`5!F#!-EQ
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M"!M`5-.\0LVH5QRBE0,>Y!?V"A\B,?%B[+:6;1&@/LDY5G+S5LAPCIW"R:#E
M^>*?))+IH%0=)+$(`*@4!,`&U&A1#VOT6EP,F5,LE"5.N1$@5)0%DBO8V'9L
8G94U0``53!=$VQ@`.H/'0$LT`T`T!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
